The None None O
design None None O
, None None O
synthesis None None O
, None None O
and None None O
biological None None O
evaluation None None O
of None None O
several None None O
unsaturated None None O
acyclonucleosides None None O
related None None O
to None None O
augustmycin None None O
A None None O
are None None O
described None None O
. None None O

The None None O
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
acyclonucleoside None None I-IUPAC
analogues None None I-MODIFIER
of None None O
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
, None None O
adenine None None I-IUPAC
, None None O
6 None None I-IUPAC
- None None I-IUPAC
methoxypurine None None I-IUPAC
, None None O
hypoxanthine None None I-IUPAC
, None None O
6 None None I-IUPAC
- None None I-IUPAC
mercaptopurine None None I-IUPAC
, None None O
and None None O
azathioprine None None I-IUPAC
have None None O
been None None O
prepared None None O
. None None O

The None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
adenine None None I-IUPAC
( None None O
5 None None O
) None None O
and None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
hypoxanthine None None I-IUPAC
( None None O
12 None None O
) None None O
analogues None None I-MODIFIER
were None None O
converted None None O
to None None O
the None None O
corresponding None None O
5' None None I-IUPAC
- None None I-IUPAC
tributylstannyl None None I-IUPAC
intermediates None None I-MODIFIER
( None None O
9 None None O
and None None O
13 None None O
) None None O
, None None O
respectively None None O
, None None O
which None None O
gave None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
adenine None None I-IUPAC
( None None O
10 None None O
) None None O
and None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
hypoxanthine None None I-IUPAC
( None None O
14 None None O
) None None O
, None None O
respectively None None O
, None None O
after None None O
iododestannylation None None O
. None None O

The None None O
[ None None O
125I None None O
] None None O
- None None O
radiolabeled None None O
congeners None None O
of None None O
10 None None O
and None None O
14 None None O
were None None O
prepared None None O
as None None O
potential None None O
metabolic None None O
markers None None O
. None None O

Among None None O
the None None O
unsaturated None None O
acyclonucleosides None None O
tested None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
mercaptopurine None None I-IUPAC
( None None O
15 None None O
) None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
azathioprine None None I-IUPAC
( None None O
17 None None O
) None None O
, None None O
and None None O
angustmycin None None O
A None None O
analogue None None O
10 None None O
showed None None O
inhibition None None O
of None None O
cancer None None O
cell None None O
growth None None O
, None None O
but None None O
only None None O
at None None O
a None None O
minimal None None O
level None None O
, None None O
and None None O
17 None None O
also None None O
showed None None O
14% None None O
cancer None None O
cell None None O
death None None O
in None None O
vitro None None O
. None None O

Compound None None O
10 None None O
provided None None O
approximately None None O
50% None None O
protection None None O
against None None O
HIV None None O
at None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
concentrations None None O
. None None O

Biodistribution None None O
results None None O
of None None O
[ None None O
125I None None O
] None None O
- None None O
10 None None O
in None None O
mice None None O
indicate None None O
that None None O
compound None None O
10 None None O
is None None O
readily None None O
metabolized None None O
via None None O
deiodination None None O
in None None O
vivo None None O
, None None O
possibly None None O
by None None O
serving None None O
as None None O
a None None O
substrate None None O
for None None O
the None None O
enzyme None None O
S None None I-IUPAC
- None None I-IUPAC
adenosyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
homocysteine None None I-IUPAC
hydrolase None None O
. None None O


Sulfur None None O
- None None O
bridged None None O
pregnanes None None O
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
, None None O
21 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
, None None O
and None None O
the None None O
corresponding None None O
sulfoxides None None O
and None None O
sulfones None None O
were None None O
synthesized None None O
and None None O
tested None None O
as None None O
blockers None None O
of None None O
the None None O
immunosuppresive None None O
activity None None O
of None None O
dexamethasone None None O
in None None O
rat None None O
thymocytes None None O
. None None O

A None None O
new None None O
one None None O
- None None O
pot None None O
procedure None None O
is None None O
described None None O
for None None O
the None None O
preparation None None O
of None None O
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
and None None O
related None None O
compounds None None O
by None None O
iodocyclization None None O
of None None O
a None None O
19 None None I-IUPAC
- None None I-IUPAC
sulfanylpregn None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ene None None I-IUPAC
. None None O

Antiimmunosuppresive None None O
activity None None O
was None None O
evaluated None None O
by None None O
the None None O
ability None None O
of None None O
the None None O
different None None O
steroids None None O
to None None O
block None None O
dexamethasone None None O
- None None O
mediated None None O
apoptosis None None O
in None None O
thymocytes None None O
and None None O
dexamethasone None None O
- None None O
mediated None None O
inhibition None None O
of None None O
the None None O
NFkappa None None O
- None None O
B None None O
transcription None None O
factor None None O
activity None None O
. None None O

DNA None None O
fragmentation None None O
and None None O
annexin None None O
V None None O
- None None O
FITC None None O
positive None None O
cells None None O
were None None O
taken None None O
as None None O
parameters None None O
of None None O
apoptosis None None O
whereas None None O
NFkappa None None O
- None None O
B None None O
activity None None O
was None None O
tested None None O
by None None O
the None None O
expression None None O
of None None O
the None None O
reporter None None O
vector None None O
kappaB None None O
- None None O
luciferase None None O
by None None O
TNF None None O
- None None O
alpha None None O
in None None O
Hela None None O
cells None None O
. None None O

21 None None I-IUPAC
- None None I-IUPAC
Hydroxy None None I-IUPAC
- None None I-IUPAC
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
S None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
had None None O
improved None None O
activity None None O
in None None O
both None None O
parameters None None O
, None None O
while None None O
21 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
had None None O
improved None None O
activity None None O
only None None O
in None None O
blocking None None O
dexamethasone None None O
- None None O
induced None None O
programmed None None O
cell None None O
death None None O
. None None O


A None None O
new None None O
procedure None None O
for None None O
the None None O
preparation None None O
of None None O
the None None O
antiviral None None O
and None None O
antitumor None None O
agent None None O
3 None None I-IUPAC
- None None I-IUPAC
deazaguanine None None I-IUPAC
( None None O
1 None None O
) None None O
and None None O
its None None O
metabolite None None O
3 None None I-IUPAC
- None None I-IUPAC
deazaguanosine None None I-IUPAC
( None None O
2 None None O
) None None O
has None None O
been None None O
developed None None O
by None None O
reacting None None O
methyl None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
cyanomethyl None None I-IUPAC
) None None I-IUPAC
imidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
4 None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
cyanomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
) None None I-IUPAC
imidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
6 None None O
) None None O
, None None O
respectively None None O
, None None O
with None None O
hydrazine None None O
. None None O

The None None O
3 None None I-IUPAC
- None None I-IUPAC
deazaguanosine None None I-IUPAC
3' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
cyclic None None I-IUPAC
phosphate None None I-IUPAC
( None None O
13 None None O
) None None O
was None None O
prepared None None O
from None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
cyanomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
- None None I-IUPAC
imidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
phosphate None None I-IUPAC
. None None O

Glycosylation None None O
of None None O
the None None O
trimethylsilyl None None O
4 None None O
with None None O
1 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranose None None I-IUPAC
in None None O
the None None O
presence None None O
of None None O
trimethylsilyl None None I-IUPAC
trifluoromethanesulfonate None None I-IUPAC
gave None None O
the None None O
corresponding None None O
N None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
glycosyl None None I-IUPAC
derivatives None None I-MODIFIER
with None None O
alpha None None O
- None None O
configuration None None O
( None None O
18 None None O
and None None O
20 None None O
) None None O
as None None O
the None None O
major None None O
products None None O
, None None O
along None None O
with None None O
minor None None O
amounts None None O
of None None O
the None None O
beta None None O
- None None O
anomers None None O
( None None O
19 None None O
and None None O
21 None None O
) None None O
. None None O

However None None O
, None None O
glycosylation None None O
of None None O
the None None O
sodium None None O
salt None None O
of None None O
4 None None O
with None None O
1 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoyl None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofurano None None I-IUPAC
se None None I-IUPAC
( None None O
17 None None O
) None None O
gave None None O
exclusively None None O
the None None O
beta None None O
- None None O
anomers None None O
( None None O
19 None None O
and None None O
21 None None O
) None None O
in None None O
good None None O
yield None None O
. None None O

Base None None O
- None None O
catalyzed None None O
ring None None O
closure None None O
of None None O
these None None O
imidazole None None O
nucleosides None None O
gave None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
deazaguanosine None None I-IUPAC
( None None O
29 None None O
) None None O
, None None O
the None None O
alpha None None O
- None None O
anomer None None O
28 None None O
, None None O
and None None O
the None None O
corresponding None None O
N None None O
- None None O
3 None None O
positional None None O
isomers None None O
27 None None O
and None None O
26 None None O
. None None O

The None None O
site None None O
of None None O
glycosylation None None O
and None None O
the None None O
anomeric None None O
configuration None None O
of None None O
these None None O
nucleosides None None O
have None None O
been None None O
assigned None None O
on None None O
the None None O
basis None None O
of None None O
1' None None O
NMR None None O
and None None O
UV None None O
spectral None None O
characteristics None None O
and None None O
by None None O
single None None O
- None None O
crystal None None O
X None None O
- None None O
ray None None O
analysis None None O
for None None O
27-29 None None O
. None None O

In None None O
a None None O
preliminary None None O
screening None None O
, None None O
several None None O
of None None O
these None None O
compounds None None O
have None None O
demonstrated None None O
significant None None O
broad None None O
- None None O
spectrum None None O
antiviral None None O
activity None None O
against None None O
certain None None O
DNA None None O
and None None O
RNA None None O
viruses None None O
in None None O
vitro None None O
, None None O
as None None O
well None None O
as None None O
moderate None None O
activity None None O
against None None O
L1210 None None O
and None None O
P388 None None O
leukemia None None O
in None None O
cell None None O
culture None None O
. None None O


To None None O
synthesize None None O
potent None None O
antagonists None None O
of None None O
the None None O
mu None None O
- None None O
opioid None None O
receptor None None O
, None None O
we None None O
prepared None None O
a None None O
series None None O
of None None O
endomorphin None None O
- None None O
1 None None O
and None None O
endomorphin None None O
- None None O
2 None None O
analogues None None O
with None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
- None None I-IUPAC
alanine None None I-IUPAC
( None None O
d None None O
- None None O
1 None None O
- None None O
Nal None None O
) None None O
or None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
- None None I-IUPAC
alanine None None I-IUPAC
( None None O
d None None O
- None None O
2 None None O
- None None O
Nal None None O
) None None O
in None None O
position None None O
4 None None O
. None None O

Some None None O
of None None O
these None None O
analogues None None O
displayed None None O
weak None None O
antagonist None None O
properties None None O
. None None O

We None None O
tried None None O
to None None O
strengthen None None O
these None None O
properties None None O
by None None O
introducing None None O
the None None O
structurally None None O
modified None None O
tyrosine None None O
residue None None O
2,6 None None I-IUPAC
- None None I-IUPAC
dimethyltyrosine None None I-IUPAC
( None None O
Dmt None None O
) None None O
in None None O
place None None O
of None None O
Tyr1 None None O
. None None O

Among None None O
the None None O
synthesized None None O
compounds None None O
, None None O
[ None None O
Dmt1 None None O
, None None O
d None None O
- None None O
2 None None O
- None None O
Nal4 None None O
] None None O
endomorphin None None O
- None None O
1 None None O
, None None O
designated None None O
antanal None None O
- None None O
1 None None O
, None None O
and None None O
[ None None O
Dmt1 None None O
, None None O
d None None O
- None None O
2 None None O
- None None O
Nal4 None None O
] None None O
endomorphin None None O
- None None O
2 None None O
, None None O
designated None None O
antanal None None O
- None None O
2 None None O
, None None O
turned None None O
out None None O
to None None O
be None None O
highly None None O
potent None None O
and None None O
selective None None O
mu None None O
- None None O
opioid None None O
receptor None None O
antagonists None None O
, None None O
as None None O
judged None None O
on None None O
the None None O
basis None None O
of None None O
two None None O
functional None None O
assays None None O
, None None O
the None None O
receptor None None O
binding None None O
assay None None O
and None None O
the None None O
hot None None O
plate None None O
test None None O
of None None O
analgesia None None O
. None None O

Interestingly None None O
, None None O
another None None O
analogue None None O
of None None O
this None None O
series None None O
, None None O
[ None None O
Dmt1 None None O
, None None O
d None None O
- None None O
1 None None O
- None None O
Nal4 None None O
] None None O
endomorphin None None O
- None None O
1 None None O
, None None O
turned None None O
out None None O
to None None O
be None None O
a None None O
moderately None None O
potent None None O
mixed None None O
mu None None O
- None None O
agonist None None O
/ None None O
delta None None O
- None None O
antagonist None None O
. None None O


A None None O
family None None O
of None None O
analogues None None O
of None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
DTrp None None O
( None None O
8 None None O
) None None O
/ None None O
D2Nal None None O
( None None O
8 None None O
) None None O
] None None O
- None None O
SRIF None None O
that None None O
contain None None O
a None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aminomethylphenylalanine None None I-IUPAC
( None None O
IAmp None None O
) None None O
at None None O
position None None O
9 None None O
was None None O
identified None None O
that None None O
has None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
human None None O
somatostatin None None O
receptor None None O
subtype None None O
1 None None O
( None None O
sst1 None None O
) None None O
. None None O

The None None O
binding None None O
affinities None None O
of None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
c None None O
[ None None O
H None None O
- None None O
Cys None None O
- None None O
Lys None None O
- None None O
Phe None None O
- None None O
Phe None None O
- None None O
DTrp None None O
- None None O
IAmp None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Thr None None O
- None None O
Ser None None O
- None None O
Cys None None O
- None None O
OH None None O
] None None O
, None None O
CH None None O
- None None O
275 None None O
) None None O
( None None O
7 None None O
) None None O
, None None O
des None None O
- None None O
AA None None O
( None None O
1,5 None None O
) None None O
- None None O
[ None None O
Tyr None None O
( None None O
2 None None O
) None None O
, None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
CH None None O
- None None O
288 None None O
) None None O
( None None O
16 None None O
) None None O
, None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
Tyr None None O
( None None O
7 None None O
) None None O
, None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
23 None None O
) None None O
, None None O
and None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
, None None O
Tyr None None O
( None None O
11 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
25 None None O
) None None O
are None None O
about None None O
( None None O
1 None None O
) None None O
/ None None O
( None None O
7 None None O
) None None O
, None None O
( None None O
1 None None O
) None None O
/ None None O
( None None O
4 None None O
) None None O
, None None O
( None None O
1 None None O
) None None O
/ None None O
( None None O
125 None None O
) None None O
, None None O
and None None O
( None None O
1 None None O
) None None O
/ None None O
( None None O
4 None None O
) None None O
that None None O
of None None O
SRIF None None O
- None None O
28 None None O
( None None O
1 None None O
) None None O
to None None O
sst1 None None O
, None None O
respectively None None O
, None None O
about None None O
( None None O
1 None None O
) None None O
/ None None O
( None None O
65 None None O
) None None O
, None None O
( None None O
1 None None O
) None None O
/ None None O
( None None O
130 None None O
) None None O
, None None O
& None None O
lt None None O
; None None O
( None None O
1 None None O
) None None O
/ None None O
( None None O
1000 None None O
) None None O
, None None O
and None None O
& None None O
lt None None O
; None None O
( None None O
1 None None O
) None None O
/ None None O
( None None O
150 None None O
) None None O
that None None O
of None None O
1 None None O
to None None O
sst3 None None O
, None None O
respectively None None O
, None None O
and None None O
about None None O
or None None O
less None None O
than None None O
( None None O
1 None None O
) None None O
/ None None O
( None None O
1000 None None O
) None None O
that None None O
of None None O
1 None None O
to None None O
the None None O
other None None O
three None None O
human None None O
SRIF None None O
receptor None None O
subtypes None None O
. None None O

A None None O
substitution None None O
of None None O
DTrp None None O
( None None O
8 None None O
) None None O
by None None O
D2Nal None None O
( None None O
8 None None O
) None None O
in None None O
7 None None O
to None None O
yield None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
D2Nal None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
13 None None O
) None None O
and None None O
in None None O
16 None None O
to None None O
yield None None O
des None None O
- None None O
AA None None O
( None None O
1,5 None None O
) None None O
- None None O
[ None None O
Tyr None None O
( None None O
2 None None O
) None None O
, None None O
D2Nal None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
17 None None O
) None None O
was None None O
intended None None O
to None None O
increase None None O
chemical None None O
stability None None O
, None None O
selectivity None None O
, None None O
and None None O
affinity None None O
and None None O
resulted None None O
in None None O
two None None O
analogues None None O
that None None O
were None None O
less None None O
potent None None O
or None None O
equipotent None None O
with None None O
similar None None O
selectivity None None O
, None None O
respectively None None O
. None None O

Carbamoylation None None O
of None None O
the None None O
N None None O
- None None O
terminus None None O
as None None O
in None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
, None None O
Tyr None None O
( None None O
11 None None O
) None None O
] None None O
- None None O
Cbm None None O
- None None O
SRIF None None O
( None None O
27 None None O
) None None O
increased None None O
affinity None None O
slightly None None O
as None None O
well None None O
as None None O
improved None None O
selectivity None None O
. None None O

Monoiodination None None O
of None None O
25 None None O
to None None O
yield None None O
26 None None O
and None None O
of None None O
27 None None O
to None None O
yield None None O
28 None None O
resulted None None O
in None None O
an None None O
additional None None O
4 None None O
- None None O
fold None None O
increase None None O
in None None O
affinity None None O
at None None O
sst1 None None O
. None None O

Desamination None None O
of None None O
the None None O
N None None O
- None None O
terminus None None O
of None None O
17 None None O
to None None O
yield None None O
18 None None O
, None None O
on None None O
the None None O
other None None O
hand None None O
, None None O
resulted None None O
in None None O
significant None None O
loss None None O
of None None O
affinity None None O
. None None O

Attempts None None O
at None None O
reducing None None O
the None None O
size None None O
of None None O
the None None O
ring None None O
with None None O
maintenance None None O
of None None O
selectivity None None O
failed None None O
in None None O
that None None O
des None None O
- None None O
AA None None O
( None None O
1,4,5,13 None None O
) None None O
- None None O
[ None None O
Tyr None None O
( None None O
2 None None O
) None None O
, None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
33 None None O
) None None O
and None None O
des None None O
- None None O
AA None None O
( None None O
1,4,5,6,12,13 None None O
) None None O
- None None O
[ None None O
Tyr None None O
( None None O
2 None None O
) None None O
, None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
34 None None O
) None None O
progressively None None O
lost None None O
affinity None None O
for None None O
all None None O
receptors None None O
. None None O

Both None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
, None None O
Tyr None None O
( None None O
11 None None O
) None None O
] None None O
- None None O
Cbm None None O
- None None O
SRIF None None O
( None None O
27 None None O
) None None O
and None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
DCys None None O
( None None O
3 None None O
) None None O
, None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
, None None O
Tyr None None O
( None None O
11 None None O
) None None O
] None None O
- None None O
Cbm None None O
- None None O
SRIF None None O
( None None O
29 None None O
) None None O
show None None O
agonistic None None O
activity None None O
in None None O
a None None O
cAMP None None O
assay None None O
; None None O
therefore None None O
, None None O
the None None O
structural None None O
basis None None O
for None None O
the None None O
agonist None None O
property None None O
of None None O
this None None O
family None None O
of None None O
analogues None None O
is None None O
not None None O
contingent None None O
upon None None O
the None None O
chirality None None O
of None None O
the None None O
Cys None None O
residue None None O
at None None O
position None None O
3 None None O
as None None O
shown None None O
to None None O
be None None O
the None None O
case None None O
in None None O
18 None None O
- None None O
membered None None O
ring None None O
SRIF None None O
octapeptides None None O
. None None O

None None None O
of None None O
the None None O
high None None O
affinity None None O
structures None None O
described None None O
here None None O
showed None None O
receptor None None O
antagonism None None O
. None None O

We None None O
have None None O
prepared None None O
the None None O
radiolabeled None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
, None None O
( None None O
125 None None O
) None None O
ITyr None None O
( None None O
11 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
( None None O
125 None None O
) None None O
I None None O
- None None O
25 None None O
) None None O
and None None O
des None None O
- None None O
AA None None O
( None None O
1,2,5 None None O
) None None O
- None None O
[ None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
, None None O
( None None O
125 None None O
) None None O
ITyr None None O
( None None O
11 None None O
) None None O
] None None O
- None None O
Cbm None None O
- None None O
SRIF None None O
( None None O
( None None O
125 None None O
) None None O
I None None O
- None None O
27 None None O
) None None O
, None None O
used None None O
them None None O
as None None O
in None None O
vitro None None O
tracers None None O
, None None O
and None None O
found None None O
them None None O
to None None O
be None None O
superior None None O
to None None O
des None None O
- None None O
AA None None O
( None None O
1,5 None None O
) None None O
- None None O
[ None None O
( None None O
125 None None O
) None None O
ITyr None None O
( None None O
2 None None O
) None None O
, None None O
DTrp None None O
( None None O
8 None None O
) None None O
, None None O
IAmp None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
SRIF None None O
( None None O
( None None O
125 None None O
) None None O
I None None O
- None None O
16 None None O
) None None O
for None None O
the None None O
detection None None O
of None None O
sst1 None None O
tumors None None O
in None None O
receptor None None O
autoradiography None None O
studies None None O
. None None O


2 None None I-PARTIUPAC
- None None I-PARTIUPAC
Fluoro None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
fluoro None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
6 None None I-IUPAC
- None None I-IUPAC
fluorodimethoxybenzaldehydes None None I-IUPAC
were None None O
prepared None None O
by None None O
photochemical None None O
decomposition None None O
of None None O
the None None O
corresponding None None O
diazonium None None O
fluoroborates None None O
. None None O

The None None O
aldehydes None None O
were None None O
converted None None O
to None None O
the None None O
cyanohydrin None None I-IUPAC
trimethylsilyl None None I-IUPAC
ethers None None I-IUPAC
, None None O
which None None O
, None None O
in None None O
turn None None O
, None None O
were None None O
reduced None None O
to None None O
the None None O
dimethoxyphenethanolamines None None I-IUPAC
. None None O

Boron None None O
tribromide None None O
demethylation None None O
afforded None None O
the None None O
racemic None None O
ring None None O
- None None O
fluorinated None None O
norepinephrines None None O
. None None O

An None None O
alternate None None O
route None None O
, None None O
using None None O
the None None O
dibenzyloxyfluoroaldehyde None None I-IUPAC
, None None O
was None None O
also None None O
used None None O
to None None O
prepare None None O
6 None None I-IUPAC
- None None I-IUPAC
fluoronorepinephrine None None I-IUPAC
. None None O

The None None O
fluorine None None O
substituent None None O
markedly None None O
increases None None O
the None None O
phenolic None None O
acidities None None O
of None None O
these None None O
analogues None None O
. None None O

The None None O
biological None None O
properties None None O
conferred None None O
upon None None O
norepinephrine None None O
by None None O
the None None O
fluorine None None O
substituents None None O
in None None O
peripheral None None O
and None None O
central None None O
adrenergically None None O
responsive None None O
systems None None O
clearly None None O
demonstrate None None O
that None None O
2 None None I-IUPAC
- None None I-IUPAC
fluoronorepinephrine None None I-IUPAC
is None None O
a None None O
nearly None None O
a None None O
pure None None O
beta None None O
- None None O
adrenergic None None O
agonist None None O
, None None O
while None None O
6 None None I-IUPAC
- None None I-IUPAC
fluoronorepinephrine None None I-IUPAC
is None None O
an None None O
alpha None None O
- None None O
adrenergic None None O
agonist None None O
. None None O

5 None None I-IUPAC
- None None I-IUPAC
Fluoronorepinephrine None None I-IUPAC
retains None None O
both None None O
beta None None O
- None None O
and None None O
alpha None None O
- None None O
adrenergic None None O
agonist None None O
properties None None O
. None None O

Receptor None None O
- None None O
binding None None O
studies None None O
with None None O
specific None None O
radiolabeled None None O
ligands None None O
indicate None None O
that None None O
the None None O
specificity None None O
conferred None None O
by None None O
the None None O
site None None O
of None None O
fluorine None None O
substituents None None O
results None None O
from None None O
a None None O
change None None O
in None None O
the None None O
affinity None None O
of None None O
these None None O
analogues None None O
for None None O
the None None O
alpha None None O
- None None O
and None None O
beta None None O
- None None O
adrenergic None None O
receptors None None O
. None None O


Three None None O
N None None I-IUPAC
- None None I-IUPAC
fluoroethyl None None I-IUPAC
- None None I-IUPAC
substituted None None I-MODIFIER
( None None B-IUPAC
imidazolylphenyl None None I-IUPAC
) None None I-IUPAC
formamidine None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
namely None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
fluoroethyl None None I-IUPAC
( None None O
3b None None O
) None None O
, None None O
2,2 None None I-IUPAC
- None None I-IUPAC
difluoroethyl None None I-IUPAC
( None None O
3c None None O
) None None O
, None None O
and None None O
2,2,2 None None I-IUPAC
- None None I-IUPAC
trifluoroethyl None None I-IUPAC
( None None O
3d None None O
) None None O
, None None O
were None None O
prepared None None O
to None None O
test None None O
the None None O
effect None None O
of None None O
fluorine None None O
substitution None None O
on None None O
basicity None None O
and None None O
, None None O
then None None O
, None None O
on None None O
H2 None None O
- None None O
antagonist None None O
affinity None None O
in None None O
comparison None None O
with None None O
the None None O
unsubstituted None None I-MODIFIER
N None None B-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
derivative None None I-MODIFIER
( None None O
3a None None O
) None None O
, None None O
taken None None O
as None None O
a None None O
model None None O
of None None O
mifentidine None None O
. None None O

Imidazolylphenyl None None O
isothiocyanate None None O
( None None O
1 None None O
) None None O
, None None O
obtained None None O
by None None O
reaction None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
imidazole None None I-IUPAC
with None None O
carbon None None O
disulfide None None O
and None None O
ethyl None None I-IUPAC
chloroformate None None I-IUPAC
, None None O
was None None O
condensed None None O
with None None O
the None None O
requisite None None O
2 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None O
substituted None None I-MODIFIER
ethylamines None None B-IUPAC
to None None O
give None None O
the None None O
intermediate None None O
thioureas None None O
( None None O
2b None None O
- None None O
d None None O
) None None O
. None None O

Desulfurization None None O
of None None O
these None None O
thioureas None None O
by None None O
Raney None None O
nickel None None O
furnished None None O
the None None O
desired None None O
formamidines None None O
( None None O
3b None None O
- None None O
d None None O
) None None O
. None None O

Increasing None None O
fluorine None None O
substitution None None O
was None None O
found None None O
to None None O
decrease None None O
basicity None None O
of None None O
the None None O
formamidino None None O
group None None O
substantially None None O
( None None O
3a None None O
, None None O
pKa None None O
= None None O
8.65 None None O
; None None O
3b None None O
, None None O
pKa None None O
= None None O
8.12 None None O
; None None O
3c None None O
, None None O
pKa None None O
= None None O
6.60 None None O
; None None O
3d None None O
, None None O
pKa None None O
= None None O
6.14 None None O
) None None O
, None None O
while None None O
having None None O
a None None O
modest None None O
effect None None O
on None None O
the None None O
imidazole None None O
portion None None O
. None None O

Affinity None None O
at None None O
the None None O
H2 None None O
receptors None None O
, None None O
evaluated None None O
from None None O
antagonism None None O
of None None O
histamine None None O
- None None O
stimulated None None O
chronotropic None None O
response None None O
on None None O
guinea None None O
pig None None O
atria None None O
, None None O
increased None None O
following None None O
fluorine None None O
substitution None None O
( None None O
3a None None O
, None None O
KB None None O
= None None O
177 None None O
; None None O
3b None None O
, None None O
KB None None O
= None None O
61 None None O
; None None O
3c None None O
, None None O
KB None None O
= None None O
21 None None O
; None None O
3d None None O
, None None O
KB None None O
= None None O
7.6 None None O
) None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
H2 None None O
- None None O
receptor None None O
antagonist None None O
affinity None None O
in None None O
the None None O
mifentidine None None O
series None None O
is None None O
mostly None None O
dependent None None O
on None None O
the None None O
availability None None O
of None None O
the None None O
neutral None None O
species None None O
. None None O

These None None O
data None None O
support None None O
the None None O
hypothesis None None O
that None None O
mifentidine None None O
, None None O
like None None O
cimetidine None None O
, None None O
acts None None O
through None None O
the None None O
neutral None None O
species None None O
. None None O


Glycosylation None None O
of None None O
ethyl None None I-IUPAC
3 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
pyrazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
3 None None O
) None None O
and None None O
3 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
pyrazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
4 None None O
) None None O
with None None O
poly None None O
- None None O
O None None O
- None None O
acetylated None None O
sugars None None O
via None None O
an None None O
acid None None O
- None None O
catalyzed None None O
fusion None None O
method None None O
afforded None None O
the None None O
corresponding None None O
ethyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
pyrazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
pyrazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
substituted None None I-MODIFIER
nucleosides None None I-MODIFIER
5 None None I-MODIFIER
and None None O
7 None None I-MODIFIER
, None None O
respectively None None O
. None None O

In None None O
some None None O
cases None None O
, None None O
the None None O
positional None None O
isomers None None O
6 None None O
and None None O
8 None None O
were None None O
also None None O
obtained None None O
. None None O

Treatment None None O
of None None O
5 None None O
and None None O
7 None None O
with None None O
methanolic None None O
ammonia None None O
gave None None O
the None None O
deprotected None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
pyrazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
nucleosides None None I-MODIFIER
9 None None O
. None None O

Reaction None None O
of None None O
3 None None O
- None None O
- None None O
5 None None O
and None None O
7 None None O
with None None O
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
amine None None I-IUPAC
led None None O
to None None O
the None None O
corresponding None None O
pyrazole None None O
nitrogen None None O
mustards None None O
10 None None O
- None None O
- None None O
13 None None O
. None None O

All None None O
the None None O
bromomethylpyrazole None None O
nucleosides None None O
described None None O
showed None None O
significant None None O
cytostatic None None O
activity None None O
against None None O
HeLa None None O
cell None None O
cultures None None O
. None None O


2beta None None O
- None None O
( None None O
R None None O
) None None O
- None None O
Carbo None None O
- None None O
1 None None O
- None None O
fluoro None None O
- None None O
2 None None O
- None None O
propoxy None None O
- None None O
3beta None None O
- None None O
( None None O
4 None None O
- None None O
chlorophenyl None None O
) None None O
tro None None O
pane None None O
( None None O
( None None O
R None None O
) None None O
- None None O
FIPCT None None O
, None None O
R None None O
- None None O
6 None None O
) None None O
and None None O
2beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
carbo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
tro None None I-IUPAC
pane None None I-IUPAC
( None None O
( None None O
S None None O
) None None O
- None None O
FIPCT None None O
, None None O
S None None O
- None None O
6 None None O
) None None O
were None None O
prepared None None O
and None None O
evaluated None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
for None None O
dopamine None None O
transporter None None O
( None None O
DAT None None O
) None None O
selectivity None None O
and None None O
specificity None None O
. None None O

High None None O
specific None None O
activity None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
R None None O
) None None O
- None None O
FIPCT None None O
and None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
S None None O
) None None O
- None None O
FIPCT None None O
were None None O
synthesized None None O
in None None O
5% None None O
radiochemical None None O
yield None None O
( None None O
decay None None O
- None None O
corrected None None O
to None None O
end None None O
of None None O
bombardment None None O
( None None O
EOB None None O
) None None O
) None None O
by None None O
preparation None None O
of None None O
the None None O
precursors None None O
2beta None None I-IUPAC
- None None I-IUPAC
carbo None None I-IUPAC
- None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
mesyloxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorop None None I-IUPAC
hen None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
tropane None None I-IUPAC
( None None O
R None None O
- None None O
12 None None O
) None None O
and None None O
2beta None None I-IUPAC
- None None I-IUPAC
carbo None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
mesyloxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorop None None I-IUPAC
hen None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
tropane None None I-IUPAC
( None None O
S None None O
- None None O
12 None None O
) None None O
followed None None O
by None None O
treatment None None O
with None None O
no None None O
carrier None None O
- None None O
added None None O
potassium None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
fluoride None None O
and None None O
kyrptofix None None O
K222 None None O
in None None O
acetonitrile None None O
. None None O

Competition None None O
binding None None O
in None None O
cells None None O
stably None None O
expressing None None O
the None None O
transfected None None O
human None None O
DAT None None O
and None None O
serotonin None None O
transporter None None O
( None None O
SERT None None O
) None None O
labeled None None O
by None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
WIN None None O
35428 None None O
and None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
citalopram None None O
, None None O
respectively None None O
, None None O
demonstrated None None O
the None None O
following None None O
order None None O
of None None O
DAT None None O
affinity None None O
( None None O
K None None O
( None None O
i None None O
) None None O
in None None O
nM None None O
) None None O
: None None O
GBR None None O
12909 None None O
( None None O
0.36 None None O
) None None O
& None None O
gt None None O
; None None O
CIT None None O
( None None O
0.48 None None O
) None None O
& None None O
gt None None O
; None None O
( None None O
S None None O
) None None O
- None None O
FIPCT None None O
( None None O
0.67 None None O
) None None O
& None None O
gt None None O
; None None O
& None None O
gt None None O
; None None O
( None None O
R None None O
) None None O
- None None O
FIPCT None None O
( None None O
3.2 None None O
) None None O
. None None O

The None None O
affinity None None O
of None None O
( None None O
S None None O
) None None O
- None None O
FIPCT None None O
and None None O
( None None O
R None None O
) None None O
- None None O
FIPCT None None O
for None None O
SERT None None O
was None None O
127 None None O
- None None O
and None None O
20 None None O
- None None O
fold None None O
lower None None O
, None None O
respectively None None O
, None None O
than None None O
for None None O
DAT None None O
. None None O

In None None O
vivo None None O
biodistribution None None O
studies None None O
were None None O
performed None None O
in None None O
male None None O
rats None None O
and None None O
demonstrated None None O
that None None O
the None None O
brain None None O
uptake None None O
of None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
R None None O
) None None O
- None None O
FIPCT None None O
and None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
S None None O
) None None O
- None None O
FIPCT None None O
were None None O
selective None None O
and None None O
specific None None O
for None None O
DAT None None O
rich None None O
regions None None O
( None None O
caudate None None O
and None None O
putamen None None O
) None None O
. None None O

PET None None O
brain None None O
imaging None None O
studies None None O
in None None O
monkeys None None O
demonstrated None None O
high None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
R None None O
) None None O
- None None O
FIPCT None None O
and None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
S None None O
) None None O
- None None O
FIPCT None None O
uptake None None O
in None None O
the None None O
caudate None None O
and None None O
putamen None None O
which None None O
resulted None None O
in None None O
caudate None None O
- None None O
to None None O
- None None O
cerebellum None None O
and None None O
putamen None None O
- None None O
to None None O
- None None O
cerebellum None None O
ratios None None O
of None None O
2.5-3.5 None None O
at None None O
115 None None O
min None None O
. None None O

[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
R None None O
) None None O
- None None O
FIPCT None None O
uptake None None O
in None None O
the None None O
caudate None None O
/ None None O
putamen None None O
achieved None None O
transient None None O
equilibrium None None O
at None None O
75 None None O
min None None O
. None None O

In None None O
an None None O
imaging None None O
experiment None None O
with None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
S None None O
) None None O
- None None O
FIPCT None None O
in None None O
a None None O
rhesus None None O
monkey None None O
with None None O
its None None O
left None None O
hemisphere None None O
lesioned None None O
with None None O
MPTP None None O
, None None O
radioactivity None None O
was None None O
reduced None None O
to None None O
background None None O
in None None O
the None None O
caudate None None O
and None None O
putamen None None O
of None None O
the None None O
lesioned None None O
hemisphere None None O
. None None O

The None None O
high None None O
specific None None O
activity None None O
one None None O
- None None O
step None None O
radiolabeling None None O
preparation None None O
and None None O
high None None O
specificity None None O
and None None O
selectivity None None O
of None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
R None None O
) None None O
- None None O
FIPCT None None O
and None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
S None None O
) None None O
- None None O
FIPCT None None O
for None None O
DAT None None O
indicate None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
R None None O
) None None O
- None None O
FIPCT None None O
and None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
( None None O
S None None O
) None None O
- None None O
FIPCT None None O
are None None O
potential None None O
radioligands None None O
for None None O
mapping None None O
brain None None O
DAT None None O
in None None O
humans None None O
using None None O
PET None None O
. None None O


Steric None None O
and None None O
electrostatic None None O
requirements None None O
at None None O
position None None O
6 None None O
of None None O
[ None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
, None None O
a None None O
full None None O
agonist None None O
of None None O
NK None None O
- None None O
2 None None O
receptors None None O
, None None O
for None None O
molecular None None O
recognition None None O
by None None O
the None None O
receptor None None O
were None None O
studied None None O
. None None O

Two None None O
series None None O
of None None O
peptide None None O
analogues None None O
, None None O
( None None O
a None None O
) None None O
p None None O
- None None O
substituted None None O
analogues None None O
, None None O
[ None None O
p None None O
- None None O
X None None O
- None None O
Phe None None O
( None None O
6 None None O
) None None O
, None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
, None None O
where None None O
X None None O
= None None O
F None None O
, None None O
Cl None None O
, None None O
Br None None O
, None None O
I None None O
, None None O
NH None None O
( None None O
2 None None O
) None None O
, None None O
NO None None O
( None None O
2 None None O
) None None O
, None None O
and None None O
( None None O
b None None O
) None None O
[ None None O
D None None O
- None None O
Phe None None O
( None None O
6 None None O
) None None O
, None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
, None None O
[ None None O
Trp None None O
( None None O
6 None None O
) None None O
, None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
, None None O
and None None O
[ None None O
Chex None None O
- None None O
Ala None None O
( None None O
6 None None O
) None None O
, None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
, None None O
were None None O
synthesized None None O
, None None O
and None None O
their None None O
biological None None O
activity None None O
was None None O
examined None None O
. None None O

Competition None None O
binding None None O
experiments None None O
with None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
NKA None None O
were None None O
performed None None O
using None None O
cloned None None O
human None None O
NK None None O
- None None O
2 None None O
receptors None None O
expressed None None O
in None None O
CHO None None O
cells None None O
. None None O

Antagonistic None None O
and None None O
agonistic None None O
properties None None O
of None None O
the None None O
analogues None None O
were None None O
studied None None O
using None None O
an None None O
in None None O
vitro None None O
functional None None O
assay None None O
with None None O
hamster None None O
tracheal None None O
rings None None O
. None None O

The None None O
rank None None O
order None None O
of None None O
potency None None O
of None None O
agonists None None O
was None None O
[ None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
approximately None None O
[ None None O
p None None O
- None None O
F None None O
- None None O
Phe None None O
( None None O
6 None None O
) None None O
, None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
& None None O
gt None None O
; None None O
[ None None O
p None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
- None None O
Phe None None O
( None None O
6 None None O
) None None O
, None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
& None None O
gt None None O
; None None O
[ None None O
p None None O
- None None O
Cl None None O
- None None O
Phe None None O
( None None O
6 None None O
) None None O
, None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
& None None O
gt None None O
; None None O
[ None None O
p None None O
- None None O
NO None None O
( None None O
2 None None O
) None None O
- None None O
Phe None None O
( None None O
6 None None O
) None None O
, None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
& None None O
gt None None O
; None None O
[ None None O
Trp None None O
( None None O
6 None None O
) None None O
, None None O
Nle None None O
( None None O
10 None None O
) None None O
] None None O
NKA None None O
( None None O
4-10 None None O
) None None O
. None None O

Size None None O
and None None O
planarity None None O
of None None O
the None None O
aromatic None None O
side None None O
chain None None O
were None None O
crucially None None O
important None None O
for None None O
the None None O
biological None None O
activity None None O
, None None O
whereas None None O
electron None None O
- None None O
donating None None O
and None None O
electron None None O
- None None O
withdrawing None None O
properties None None O
of None None O
the None None O
para None None O
- None None O
substituent None None O
were None None O
less None None O
important None None O
. None None O

The None None O
results None None O
favor None None O
the None None O
hypothesis None None O
that None None O
weakly None None O
polar None None O
pi None None O
- None None O
pi None None O
interactions None None O
exist None None O
between None None O
the None None O
aromatic None None O
group None None O
and None None O
the None None O
receptor None None O
. None None O


We None None O
have None None O
previously None None O
described None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
6H None None I-IUPAC
- None None I-IUPAC
cyclohepta None None I-IUPAC
[ None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
isoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None O
- None None O
AHCP None None O
) None None O
as None None O
a None None O
highly None None O
effective None None O
agonist None None O
at None None O
non None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
- None None I-IUPAC
aspartate None None I-IUPAC
( None None O
non None None O
- None None O
NMDA None None O
) None None O
glutamate None None O
( None None O
Glu None None O
) None None O
receptors None None O
in None None O
vivo None None O
, None None O
which None None O
is None None O
more None None O
potent None None O
than None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
) None None O
but None None O
inactive None None O
at None None O
NMDA None None O
receptors None None O
. None None O

However None None O
, None None O
4 None None O
- None None O
AHCP None None O
was None None O
found None None O
to None None O
be None None O
much None None O
weaker None None O
than None None O
AMPA None None O
as None None O
an None None O
inhibitor None None O
of None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
AMPA None None O
binding None None O
and None None O
to None None O
have None None O
limited None None O
effect None None O
in None None O
a None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
kainic None None O
acid None None O
binding None None O
assay None None O
using None None O
rat None None O
cortical None None O
membranes None None O
. None None O

To None None O
shed None None O
light None None O
on None None O
the None None O
mechanism None None O
( None None O
s None None O
) None None O
underlying None None O
this None None O
quite None None O
enigmatic None None O
pharmacological None None O
profile None None O
of None None O
4 None None O
- None None O
AHCP None None O
, None None O
we None None O
have None None O
now None None O
developed None None O
a None None O
synthesis None None O
of None None O
( None None O
S None None O
) None None O
- None None O
4 None None O
- None None O
AHCP None None O
( None None O
6 None None O
) None None O
and None None O
( None None O
R None None O
) None None O
- None None O
4 None None O
- None None O
AHCP None None O
( None None O
7 None None O
) None None O
. None None O

At None None O
cloned None None O
metabotropic None None O
Glu None None O
receptors None None O
mGluR1alpha None None O
( None None O
group None None O
I None None O
) None None O
, None None O
mGluR2 None None O
( None None O
group None None O
II None None O
) None None O
, None None O
and None None O
mGluR4a None None O
( None None O
group None None O
III None None O
) None None O
, None None O
neither None None O
6 None None O
nor None None O
7 None None O
showed None None O
significant None None O
agonist None None O
or None None O
antagonist None None O
effects None None O
. None None O

The None None O
stereoisomer None None O
6 None None O
, None None O
but None None O
not None None O
7 None None O
, None None O
activated None None O
cloned None None O
AMPA None None O
receptor None None O
subunits None None O
GluR1o None None O
, None None O
GluR3o None None O
, None None O
and None None O
GluR4o None None O
with None None O
EC None None O
( None None O
50 None None O
) None None O
values None None O
in None None O
the None None O
range None None O
4.5-15 None None O
microM None None O
and None None O
the None None O
coexpressed None None O
kainate None None O
- None None O
preferring None None O
subunits None None O
GluR6 None None O
+ None None O
KA2 None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
6.4 None None O
microM None None O
) None None O
. None None O

Compound None None O
6 None None O
, None None O
but None None O
not None None O
7 None None O
, None None O
proved None None O
to None None O
be None None O
a None None O
very None None O
potent None None O
agonist None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
0.13 None None O
microM None None O
) None None O
at None None O
the None None O
kainate None None O
- None None O
preferring None None O
GluR5 None None O
subunit None None O
, None None O
equipotent None None O
with None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyisothiazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
[ None None O
( None None O
S None None O
) None None O
- None None O
Thio None None O
- None None O
ATPA None None O
, None None O
4 None None O
] None None O
and None None O
almost None None O
4 None None O
times None None O
more None None O
potent None None O
than None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
[ None None O
( None None O
S None None O
) None None O
- None None O
ATPA None None O
, None None O
3 None None O
] None None O
. None None O

Compound None None O
6 None None O
thus None None O
represents None None O
a None None O
new None None O
structural None None O
class None None O
of None None O
GluR5 None None O
agonists None None O
. None None O

Molecular None None O
modeling None None O
and None None O
docking None None O
to None None O
a None None O
crystal None None O
structure None None O
of None None O
the None None O
extracellular None None O
binding None None O
domain None None O
of None None O
the None None O
AMPA None None O
subunit None None O
GluR2 None None O
has None None O
enabled None None O
identification None None O
of None None O
the None None O
probable None None O
active None None O
conformation None None O
and None None O
binding None None O
mode None None O
of None None O
6 None None O
. None None O

We None None O
are None None O
able None None O
to None None O
rationalize None None O
the None None O
observed None None O
selectivities None None O
by None None O
comparing None None O
the None None O
docking None None O
of None None O
4 None None O
and None None O
6 None None O
to None None O
subtype None None O
constructs None None O
, None None O
i.e. None None O
, None None O
a None None O
crystal None None O
structure None None O
of None None O
the None None O
extracellular None None O
binding None None O
domain None None O
of None None O
GluR2 None None O
and None None O
a None None O
homology None None O
model None None O
of None None O
GluR5 None None O
. None None O


N None None O
- None None O
Methylacetazolamide None None O
was None None O
shown None None O
to None None O
be None None O
active None None O
topically None None O
in None None O
reducing None None O
intraocular None None O
pressure None None O
( None None O
IOP None None O
) None None O
to None None O
a None None O
small None None O
but None None O
statistically None None O
significant None None O
level None None O
in None None O
the None None O
normotensive None None O
rabbit None None O
eye None None O
. None None O

In None None O
vivo None None O
experiments None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
methylacetazolamide None None I-IUPAC
suggest None None O
that None None O
ocular None None O
metabolism None None O
to None None O
acetazolamide None None O
was None None O
responsible None None O
for None None O
the None None O
observed None None O
topical None None O
activity None None O
. None None O

Examination None None O
of None None O
initial None None O
rate None None O
kinetics None None O
of None None O
carbonic None None O
anhydrase None None O
catalyzed None None O
p None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
acetate None None I-IUPAC
hydrolysis None None O
showed None None O
that None None O
N None None I-IUPAC
- None None I-IUPAC
methylacetazolamide None None I-IUPAC
was None None O
a None None O
competitive None None O
inhibitor None None O
, None None O
in None None O
contrast None None O
to None None O
noncompetitive None None O
inhibition None None O
seen None None O
with None None O
acetazolamide None None O
and None None O
other None None O
primary None None O
sulfonamide None None O
inhibitors None None O
. None None O

N None None I-MODIFIER
- None None I-MODIFIER
Substituted None None I-MODIFIER
and None None O
unsubstituted None None I-MODIFIER
4 None None B-PARTIUPAC
- None None I-PARTIUPAC
chlorobenzene None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
nitrobenzenesulfonamides None None I-IUPAC
were None None O
also None None O
synthesized None None O
, None None O
and None None O
their None None O
biochemical None None O
characteristics None None O
and None None O
in None None O
vivo None None O
ability None None O
to None None O
lower None None O
IOP None None O
when None None O
applied None None O
topically None None O
were None None O
determined None None O
. None None O

The None None O
primary None None O
sulfonamides None None O
were None None O
reversible None None O
noncompetitive None None O
inhibitors None None O
of None None O
carbonic None None O
anhydrase None None O
, None None O
with None None O
no None None O
effect None None O
on None None O
IOP None None O
after None None O
topical None None O
administration None None O
. None None O

4 None None I-PARTIUPAC
- None None I-PARTIUPAC
Nitrobenzene None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
chlorobenzenesulfonamides None None I-IUPAC
containing None None O
both None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
substituents None None I-MODIFIER
were None None O
model None None O
irreversible None None O
inhibitors None None O
of None None O
carbonic None None O
anhydrase None None O
and None None O
exhibited None None O
a None None O
trend None None O
toward None None O
topical None None O
activity None None O
in None None O
reducing None None O
IOP None None O
in None None O
normotensive None None O
rabbit None None O
eyes None None O
. None None O

Therefore None None O
, None None O
this None None O
paper None None O
describes None None O
the None None O
synthesis None None O
and None None O
characterization None None O
of None None O
two None None O
types None None O
of None None O
carbonic None None O
anhydrase None None O
inhibitors None None O
; None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
sulfonamides None None B-IUPAC
are None None O
reversible None None O
competitive None None O
inhibitors None None O
of None None O
carbonic None None O
anhydrase None None O
, None None O
while None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
sulfonamides None None B-IUPAC
are None None O
irreversible None None O
inhibitors None None O
. None None O


The None None O
synthesis None None O
and None None O
pharmacological None None O
profile None None O
of None None O
a None None O
series None None O
of None None O
neuroprotective None None O
adenosine None None O
agonists None None O
are None None O
described None None O
. None None O

Novel None None O
A None None O
( None None O
1 None None O
) None None O
agonists None None O
with None None O
potent None None O
central None None O
nervous None None O
system None None O
effects None None O
and None None O
diminished None None O
influence None None O
on None None O
the None None O
cardiovascular None None O
system None None O
are None None O
reported None None O
and None None O
compared None None O
to None None O
selected None None O
reference None None O
adenosine None None O
agonists None None O
. None None O

The None None O
novel None None O
compounds None None O
featured None None O
are None None O
derived None None O
structurally None None O
from None None O
two None None O
key None None O
lead None None O
structures None None O
: None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
( None None O
NNC None None O
21-0041 None None O
, None None O
9 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
( None None O
NNC None None O
90-1515 None None O
, None None O
4 None None O
) None None O
. None None O

The None None O
agonists None None O
are None None O
characterized None None O
in None None O
terms None None O
of None None O
their None None O
in None None O
vitro None None O
profiles None None O
, None None O
both None None O
binding None None O
and None None O
functional None None O
, None None O
and None None O
in None None O
vivo None None O
activity None None O
in None None O
relevant None None O
animal None None O
models None None O
. None None O

Neuroprotective None None O
properties None None O
assessed None None O
after None None O
postischemic None None O
dosing None None O
in None None O
a None None O
Mongolian None None O
gerbil None None O
severe None None O
temporary None None O
forebrain None None O
ischemia None None O
paradigm None None O
, None None O
using None None O
hippocampal None None O
CA1 None None O
damage None None O
endpoints None None O
, None None O
and None None O
the None None O
efficacy None None O
of None None O
these None None O
agonists None None O
in None None O
an None None O
A None None O
( None None O
1 None None O
) None None O
functional None None O
assay None None O
show None None O
similarities None None O
to None None O
some None None O
reference None None O
adenosine None None O
agonists None None O
. None None O

However None None O
, None None O
the None None O
new None None O
compounds None None O
we None None O
describe None None O
exhibit None None O
diminished None None O
cardiovascular None None O
effects None None O
in None None O
both None None O
anesthetized None None O
and None None O
awake None None O
rats None None O
when None None O
compared None None O
to None None O
reference None None O
A None None O
( None None O
1 None None O
) None None O
agonists None None O
such None None O
as None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
phenylisopropyladenosine None None I-IUPAC
( None None O
R None None O
- None None O
PIA None None O
, None None O
5 None None O
) None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
cyclopentyladenosine None None I-IUPAC
( None None O
CPA None None O
, None None O
2 None None O
) None None O
, None None O
4 None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
trans None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxycyclopentyl None None I-IUPAC
] None None I-IUPAC
adenosine None None I-IUPAC
( None None O
GR None None O
79236 None None O
, None None O
26 None None O
) None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
cyclohexyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyladenosine None None I-IUPAC
( None None O
SDZ None None O
WAG None None O
994 None None O
, None None O
27 None None O
) None None O
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
adenosine None None I-IUPAC
( None None O
Metrifudil None None O
, None None O
28 None None O
) None None O
. None None O

In None None O
mouse None None O
permanent None None O
middle None None O
cerebral None None O
artery None None O
occlusion None None O
focal None None O
ischemia None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzothiazolyl None None I-IUPAC
) None None I-IUPAC
thio None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
adenosine None None I-IUPAC
( None None O
NNC None None O
21-0136 None None O
, None None O
12 None None O
) None None O
exhibited None None O
significant None None O
neuroprotection None None O
at None None O
the None None O
remarkably None None O
low None None O
total None None O
intraperitoneal None None O
dose None None O
of None None O
0.1 None None O
mg None None O
/ None None O
kg None None O
, None None O
a None None O
dose None None O
at None None O
which None None O
no None None O
cardiovascular None None O
effects None None O
are None None O
observed None None O
in None None O
conscious None None O
rats None None O
. None None O

The None None O
novel None None O
agonists None None O
described None None O
inhibit None None O
6 None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
carboline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
- None None O
induced None None I-MODIFIER
seizures None None I-MODIFIER
, None None O
and None None O
in None None O
mouse None None O
locomotor None None O
activity None None O
higher None None O
doses None None O
are None None O
required None None O
to None None O
reach None None O
ED None None O
( None None O
50 None None O
) None None O
values None None O
than None None O
for None None O
reference None None O
A None None O
( None None O
1 None None O
) None None O
agonists None None O
. None None O

We None None O
conclude None None O
that None None O
two None None O
of None None O
the None None O
novel None None O
adenosine None None O
derivatives None None O
revealed None None O
herein None None O
, None None O
12 None None I-PARTIUPAC
and None None O
5' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
] None None I-IUPAC
adenosine None None I-IUPAC
( None None O
NNC None None O
21-0147 None None O
, None None O
13 None None O
) None None O
, None None O
representatives None None O
of None None O
a None None O
new None None O
series None None O
of None None O
P None None O
( None None O
1 None None O
) None None O
ligands None None O
, None None O
reinforce None None O
the None None O
fact None None O
that None None O
novel None None O
selective None None O
adenosine None None O
A None None O
( None None O
1 None None O
) None None O
agonists None None O
have None None O
potential None None O
in None None O
the None None O
treatment None None O
of None None O
cerebral None None O
ischemia None None O
in None None O
humans None None O
. None None O


Conversion None None O
of None None O
the None None O
8 None None I-IUPAC
- None None I-IUPAC
phenolic None None I-IUPAC
1,2,3,4,5,6 None None I-IUPAC
- None None I-IUPAC
hexahydro None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
methano None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzazocines None None I-IUPAC
to None None O
the None None O
corresponding None None O
8 None None I-IUPAC
- None None I-IUPAC
thiophenolic None None I-IUPAC
analogues None None I-MODIFIER
was None None O
achieved None None O
by None None O
three None None O
different None None O
routes None None O
. None None O

Diazotization None None O
of None None O
8 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
methano None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzazocine None None I-IUPAC
( None None O
2 None None O
) None None O
followed None None O
by None None O
the None None O
reaction None None O
with None None O
CH3SNa None None O
afforded None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4,5,6 None None I-IUPAC
- None None I-IUPAC
hexahydro None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
methano None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzazocine None None I-IUPAC
( None None O
3 None None O
) None None O
. None None O

Another None None O
route None None O
using None None O
Grewe None None O
cyclization None None O
was None None O
also None None O
examined None None O
for None None O
the None None O
synthesis None None O
of None None O
3 None None O
. None None O

As None None O
the None None O
most None None O
effective None None O
route None None O
, None None O
Newman None None O
- None None O
Kwart None None O
rearrangement None None O
of None None O
benzazocines None None O
was None None O
selected None None O
and None None O
closely None None O
investigated None None O
. None None O

8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
Dimethylthiocarbamoyl None None I-IUPAC
) None None I-IUPAC
oxy None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
6a None None O
- None None O
e None None O
) None None O
rearranged None None O
to None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylcarbamoyl None None I-IUPAC
) None None I-IUPAC
thio None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
7a None None O
- None None O
e None None O
) None None O
in None None O
good None None O
yields None None O
. None None O

Reductive None None O
cleavage None None O
of None None O
7a None None O
- None None O
e None None O
and None None O
subsequent None None O
methylation None None O
or None None O
acylations None None O
gave None None O
the None None O
title None None O
compounds None None O
( None None O
3 None None O
, None None O
8-24 None None O
) None None O
. None None O

Although None None O
analgesic None None O
activities None None O
of None None O
sulfur None None O
- None None O
containing None None O
benzazocines None None O
decreased None None O
compared None None O
to None None O
the None None O
corresponding None None O
hydroxy None None O
compounds None None O
, None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
derivative None None I-MODIFIER
( None None O
S None None O
- None None O
metazocine None None O
, None None O
8 None None O
) None None O
showed None None O
potent None None O
analgesic None None O
activity None None O
. None None O


Two None None O
alkylating None None O
glucocorticoids None None O
have None None O
been None None O
synthesized None None O
in None None O
order None None O
to None None O
test None None O
the None None O
possibility None None O
of None None O
alkylating None None O
glucocorticoid None None O
receptors None None O
. None None O

The None None O
title None None O
compounds None None O
are None None O
9alpha None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
11beta None None I-IUPAC
, None None I-IUPAC
16alpha None None I-IUPAC
, None None I-IUPAC
17alpha None None I-IUPAC
, None None I-IUPAC
21 None None I-IUPAC
- None None I-IUPAC
tetrahydroxypregna None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
diene None None I-IUPAC
- None None I-IUPAC
3,20 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
21 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
carbamate None None I-IUPAC
] None None I-IUPAC
16,17 None None I-IUPAC
- None None I-IUPAC
acetonide None None I-IUPAC
( None None O
I None None O
) None None O
and None None O
11beta None None I-IUPAC
, None None I-IUPAC
17alpha None None I-IUPAC
, None None I-IUPAC
21 None None I-IUPAC
- None None I-IUPAC
trihydroxypregn None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ene None None I-IUPAC
- None None I-IUPAC
3,20 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
21 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
carbamate None None I-IUPAC
] None None I-IUPAC
( None None O
II None None O
) None None O
, None None O
prepared None None O
from None None O
triamcinolone None None O
acetonide None None O
and None None O
cortisol None None O
, None None O
respectively None None O
, None None O
through None None O
the None None O
reaction None None O
of None None O
the None None O
C None None O
- None None O
21 None None O
hydroxyl None None I-IUPAC
group None None B-MODIFIER
with None None O
phosgene None None O
and None None O
di None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethylamine None None I-IUPAC
in None None O
the None None O
presence None None O
of None None O
triethylamine None None O
. None None O

Both None None O
compounds None None O
are None None O
biologically None None O
active None None O
as None None O
inhibitors None None O
of None None O
the None None O
growth None None O
of None None O
cultured None None O
mouse None None O
fibroblasts None None O
and None None O
are None None O
able None None O
to None None O
compete None None O
for None None O
the None None O
specific None None O
binding None None O
of None None O
radiolabeled None None O
triamcinolone None None O
acetonide None None O
to None None O
the None None O
L929 None None O
cell None None O
receptor None None O
. None None O

The None None O
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
carbamate None None I-IUPAC
moiety None None I-MODIFIER
is None None O
capable None None O
of None None O
reacting None None O
with None None O
nucleophilic None None O
groups None None O
as None None O
evidenced None None O
by None None O
the None None O
colorimetric None None O
reaction None None O
with None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
nitrobenzyl None None I-IUPAC
) None None I-IUPAC
pyridine None None I-IUPAC
. None None O

Both None None O
the None None O
interaction None None O
with None None O
the None None O
receptor None None O
and None None O
inhibition None None O
of None None O
cell None None O
growth None None O
by None None O
these None None O
two None None O
glucocorticoids None None O
are None None O
reversible None None O
. None None O


Syntheses None None O
of None None O
the None None O
enantiomers None None O
of None None O
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
1,3,4 None None I-IUPAC
- None None I-IUPAC
trisphosphate None None I-IUPAC
are None None O
described None None O
. None None O

1,4 None None I-IUPAC
- None None I-IUPAC
Di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
was None None O
regioselectively None None O
p None None O
- None None O
methoxybenzylated None None O
at None None O
the None None O
3 None None O
- None None O
position None None O
to None None O
give None None O
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
followed None None O
by None None O
benzylation None None O
of None None O
the None None O
remaining None None O
free None None O
hydroxyl None None I-IUPAC
groups None None B-MODIFIER
to None None O
give None None O
the None None O
key None None O
intermediate None None O
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
- None None I-IUPAC
2,5,6 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
. None None O

Removal None None O
of None None O
the None None O
p None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
and None None O
allyl None None I-IUPAC
groups None None B-MODIFIER
gave None None O
2,4,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
which None None O
was None None O
phosphitylated None None O
with None None O
bis None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
( None None I-IUPAC
diisopropylamino None None I-IUPAC
) None None I-IUPAC
phosphine None None I-IUPAC
to None None O
give None None O
the None None O
fully None None O
protected None None O
trisphosphite None None O
triester None None O
. None None O

Oxidation None None O
using None None O
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
hydroperoxide None None I-IUPAC
gave None None O
2,5,6 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
1,3,4 None None I-IUPAC
- None None I-IUPAC
tris None None I-IUPAC
( None None I-IUPAC
dibenzylphospho None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
, None None O
and None None O
deprotection None None O
using None None O
sodium None None O
in None None O
liquid None None O
ammonia None None O
gave None None O
racemic None None I-MODIFIER
myo None None B-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
1,3,4 None None I-IUPAC
- None None I-IUPAC
trisphosphate None None I-IUPAC
. None None O

Deprotection None None O
of None None O
the None None O
key None None O
intermediate None None O
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
- None None I-IUPAC
2,5,6 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
by None None O
isomerization None None O
of None None O
allyl None None O
groups None None O
followed None None O
by None None O
mild None None O
acid None None O
hydrolysis None None O
gave None None O
2,4,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
, None None O
which None None O
was None None O
converted None None O
to None None O
the None None O
diastereoisomeric None None O
( None None O
bis None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
camphanates None None I-IUPAC
. None None O

The None None O
diastereoisomers None None O
were None None O
separated None None O
by None None O
column None None O
chromatography None None O
and None None O
the None None O
camphanates None None O
and None None O
the None None O
p None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
group None None I-MODIFIER
removed None None O
by None None O
saponification None None O
and None None O
acid None None O
hydrolysis None None O
, None None O
respectively None None O
, None None O
for None None O
each None None O
diastereoisomer None None O
to None None O
give None None O
the None None O
enantiomers None None O
of None None O
2,4,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
. None None O

The None None O
absolute None None O
configurations None None O
of None None O
the None None O
latter None None O
were None None O
established None None O
by None None O
conversion None None O
of None None O
1L None None I-IUPAC
- None None I-IUPAC
2,5,6 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
methoxybenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
to None None O
the None None O
known None None O
1L None None I-IUPAC
- None None I-IUPAC
1,2,4,5,6 None None I-IUPAC
- None None I-IUPAC
penta None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
. None None O

Phosphorylation None None O
and None None O
deblocking None None O
gave None None O
the None None O
D None None O
- None None O
and None None O
L None None O
- None None O
enantiomers None None O
of None None O
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
1,3,4 None None I-IUPAC
- None None I-IUPAC
trisphosphate None None I-IUPAC
. None None O

Biological None None O
evaluation None None O
in None None O
Limulus None None O
photoreceptors None None O
showed None None O
that None None O
1L None None I-IUPAC
- None None I-IUPAC
myo None None I-IUPAC
- None None I-IUPAC
inositol None None I-IUPAC
1,3,4 None None I-IUPAC
- None None I-IUPAC
trisphosphate None None I-IUPAC
was None None O
much None None O
more None None O
active None None O
than None None O
the None None O
D None None O
- None None O
enantiomer None None O
, None None O
producing None None O
repetitive None None O
bursts None None O
of None None O
depolarization None None O
due None None O
to None None O
mobilization None None O
of None None O
intracellular None None O
calcium None None O
. None None O


The None None O
formation None None O
of None None O
nitric None None O
oxide None None O
( None None O
NO None None O
) None None O
was None None O
followed None None O
during None None O
the None None O
oxidation None None O
of None None O
37 None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxyguanidines None None I-IUPAC
or None None O
related None None O
derivatives None None O
, None None O
including None None O
18 None None O
new None None O
N None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
hydroxyguanidines None None I-IUPAC
, None None O
by None None O
recombinant None None O
inducible None None O
nitric None None O
oxide None None O
synthase None None O
( None None O
NOS None None O
II None None O
) None None O
. None None O

Several None None O
N None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
hydroxyguanidines None None I-IUPAC
bearing None None O
a None None O
relatively None None O
small None None O
, None None O
electron None None O
- None None O
donating None None O
para None None O
subtituent None None O
, None None O
such None None O
as None None O
H None None O
, None None O
F None None O
, None None O
Cl None None O
, None None O
CH None None O
( None None O
3 None None O
) None None O
, None None O
OH None None O
, None None O
OCH None None O
( None None O
3 None None O
) None None O
, None None O
and None None O
NH None None O
( None None O
2 None None O
) None None O
, None None O
led None None O
to None None O
NO None None O
formation None None O
rates None None O
between None None O
8 None None O
and None None O
41% None None O
of None None O
that None None O
of None None O
NO None None O
formation None None O
from None None O
the None None O
natural None None O
NOS None None O
substrate None None O
, None None O
N None None I-IUPAC
( None None I-IUPAC
omega None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
arginine None None I-IUPAC
( None None O
NOHA None None O
) None None O
. None None O

The None None O
characteristics None None O
of None None O
these None None O
reactions None None O
were None None O
very None None O
similar None None O
to None None O
those None None O
previously None None O
reported None None O
for None None O
the None None O
oxidation None None O
of None None O
NOHA None None O
by None None O
NOS None None O
: None None O
( None None O
i None None O
) None None O
the None None O
strict None None O
requirement None None O
of None None O
NOS None None O
containing None None O
( None None I-IUPAC
6R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
biopterin None None I-IUPAC
, None None O
reduced None None O
nicotinamide None None O
adenine None None O
dinucleotide None None O
phosphate None None O
, None None O
and None None O
O None None O
( None None O
2 None None O
) None None O
for None None O
the None None O
oxidation None None O
to None None O
occur None None O
, None None O
( None None O
ii None None O
) None None O
the None None O
formation None None O
of None None O
NO None None O
and None None O
the None None O
corresponding None None O
urea None None O
in None None O
a None None O
1 None None O
: None None O
1 None None O
molar None None O
ratio None None O
, None None O
and None None O
( None None O
iii None None O
) None None O
a None None O
strong None None O
inhibitory None None O
effect None None O
of None None O
the None None O
classical None None O
NOS None None O
inhibitors None None O
such None None O
as None None O
N None None I-IUPAC
( None None I-IUPAC
omega None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
arginine None None I-IUPAC
and None None O
S None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
iso None None I-IUPAC
- None None I-IUPAC
thiourea None None I-IUPAC
. None None O

Structure None None O
- None None O
activity None None O
relationship None None O
studies None None O
showed None None O
that None None O
two None None O
structural None None O
factors None None O
are None None O
crucial None None O
for None None O
NO None None O
formation None None O
from None None O
compounds None None O
containing None None O
a None None O
C None None O
( None None O
triple None None O
bond None None O
) None None O
NOH None None O
function None None O
. None None O

The None None O
first None None O
one None None O
is None None O
the None None O
presence None None O
of None None O
a None None O
monosubstituted None None I-MODIFIER
N None None B-IUPAC
- None None I-IUPAC
hydroxyguanidine None None I-IUPAC
function None None O
, None None O
since None None O
disubstituted None None I-MODIFIER
N None None B-IUPAC
- None None I-IUPAC
hydroxyguanidines None None I-IUPAC
, None None O
amidoximes None None O
, None None O
ketoximes None None O
, None None O
and None None O
aldoximes None None O
failed None None O
to None None O
produce None None O
NO None None O
. None None O

The None None O
second None None O
one None None O
is None None O
the None None O
presence None None O
of None None O
a None None O
N None None O
- None None O
phenyl None None O
ring None None O
bearing None None O
a None None O
relatively None None O
small None None O
, None None O
not None None O
electron None None O
- None None O
withdrawing None None O
para None None O
substituent None None O
that None None O
could None None O
favorably None None O
interact None None O
with None None O
a None None O
hydrophobic None None O
cavity None None O
close None None O
to None None O
the None None O
NOS None None O
catalytic None None O
site None None O
. None None O

The None None O
k None None O
( None None O
cat None None O
) None None O
value None None O
for None None O
NOS None None O
II None None O
- None None O
catalyzed None None O
oxidation None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
para None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
hydroxyguanidine None None I-IUPAC
was None None O
80% None None O
of None None O
that None None O
found None None O
for None None O
NOHA None None O
, None None O
and None None O
its None None O
k None None O
( None None O
cat None None O
) None None O
/ None None O
K None None O
( None None O
m None None O
) None None O
value None None O
was None None O
only None None O
9 None None O
- None None O
fold None None O
lower None None O
than None None O
that None None O
of None None O
NOHA None None O
. None None O

Interestingly None None O
, None None O
the None None O
K None None O
( None None O
m None None O
) None None O
value None None O
found None None O
for None None O
NOS None None O
II None None O
- None None O
catalyzed None None O
oxidation None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
hydroxyguanidine None None I-IUPAC
was None None O
25 None None O
microM None None O
, None None O
almost None None O
identical None None O
to None None O
that None None O
of None None O
NOHA None None O
. None None O

Recombinant None None O
NOS None None O
I None None O
and None None O
NOS None None O
III None None O
also None None O
oxidize None None O
several None None O
N None None I-MODIFIER
- None None I-MODIFIER
aryl None None I-MODIFIER
N' None None I-IUPAC
- None None I-IUPAC
hydroxyguanidines None None I-IUPAC
with None None O
the None None O
formation None None O
of None None O
NO None None O
, None None O
with None None O
a None None O
clearly None None O
different None None O
substrate None None O
specificity None None O
. None None O

The None None O
best None None O
substrates None None O
of None None O
the None None O
studied None None O
series None None O
for None None O
NOS None None O
I None None O
and None None O
NOS None None O
III None None O
were None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
para None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxyphenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
meta None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
hydroxyguanidine None None I-IUPAC
, None None O
respectively None None O
. None None O

Among None None O
the None None O
studied None None O
compounds None None O
, None None O
the None None O
para None None O
- None None O
chlorophenyl None None O
and None None O
para None None O
- None None O
methylphenyl None None O
derivatives None None O
were None None O
selective None None O
substrates None None O
of None None O
NOS None None O
II None None O
. None None O

These None None O
results None None O
open None None O
the None None O
way None None O
toward None None O
a None None O
new None None O
class None None O
of None None O
selective None None O
NO None None O
donors None None O
after None None O
in None None O
situ None None O
oxidation None None O
by None None O
each None None O
NOS None None O
family None None O
. None None O


Several None None O
novel None None O
substituted None None I-MODIFIER
tetrahydro None None B-PARTIUPAC
- None None I-PARTIUPAC
and None None O
hexahydro None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
benzisothiazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxides None None I-IUPAC
and None None O
thiadiazinones None None I-IUPAC
were None None O
prepared None None O
and None None O
examined None None O
in None None O
a None None O
series None None O
of None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
tests None None O
to None None O
determine None None O
their None None O
pharmacological None None O
profile None None O
. None None O

Most None None O
compounds None None O
were None None O
orally None None O
active None None O
in None None O
blocking None None O
the None None O
conditioned None None O
avoidance None None O
response None None O
( None None O
CAR None None O
) None None O
but None None O
did None None O
not None None O
antagonize None None O
apomorphine None None O
- None None O
induced None None O
stereotyped None None O
behavior None None O
. None None O

Several None None O
compounds None None O
demonstrated None None O
moderate None None O
to None None O
high None None O
affinity None None O
for None None O
the None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
binding None None O
site None None O
, None None O
with None None O
compounds None None O
37 None None O
and None None O
38 None None O
containing None None O
2 None None I-IUPAC
- None None I-IUPAC
pyrimidinylpiperazinyl None None I-IUPAC
and None None O
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
piperazinyl None None I-IUPAC
moieties None None I-MODIFIER
and None None O
compound None None O
47 None None O
containing None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
pyrazinylpiperazinyl None None I-IUPAC
moiety None None I-MODIFIER
displaying None None O
the None None O
highest None None O
affinity None None O
( None None O
Ki None None O
values None None O
of None None O
10 None None O
, None None O
4 None None O
, None None O
and None None O
9 None None O
nM None None O
, None None O
respectively None None O
) None None O
. None None O

Compound None None O
37 None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyrimidinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperazinyl None None I-IUPAC
] None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
hexahydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
etheno None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
cyclobut None None I-IUPAC
[ None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
benzisothiazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
( None None I-IUPAC
2H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
, None None O
buspirone None None O
, None None O
and None None O
ipsapirone None None O
showed None None O
similarities None None O
in None None O
their None None O
neurochemical None None O
and None None O
behavioral None None O
profiles None None O
. None None O

They None None O
were None None O
similar None None O
in None None O
potency None None O
in None None O
blocking None None O
CAR None None O
with None None O
AB50 None None O
values None None O
of None None O
39 None None O
, None None O
32 None None O
, None None O
and None None O
42 None None O
mg None None O
/ None None O
kg None None O
, None None O
respectively None None O
. None None O

They None None O
also None None O
demonstrated None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
the None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
site None None O
( None None O
Ki None None O
= None None O
10 None None O
nM None None O
) None None O
and None None O
exhibited None None O
partial None None O
agonist None None O
/ None None O
antagonist None None O
activity None None O
in None None O
the None None O
serotonin None None O
syndrome None None O
test None None O
. None None O

In None None O
addition None None O
, None None O
compound None None O
37 None None O
inhibited None None O
apomorphine None None O
- None None O
induced None None O
climbing None None O
behavior None None O
much None None O
more None None O
potently None None O
( None None O
ED50 None None O
of None None O
3.4 None None O
mg None None O
/ None None O
kg None None O
) None None O
than None None O
stereotyped None None O
behavior None None O
( None None O
ED50 None None O
of None None O
32.2 None None O
mg None None O
/ None None O
kg None None O
) None None O
and None None O
will None None O
be None None O
evaluated None None O
further None None O
. None None O

Structure None None O
- None None O
activity None None O
relationships None None O
within None None O
this None None O
series None None O
of None None O
compounds None None O
are None None O
discussed None None O
. None None O


The None None O
synthesis None None O
of None None O
various None None O
substituted None None I-MODIFIER
5 None None B-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylic None None I-IUPAC
acids None None I-IUPAC
and None None O
their None None O
derivatives None None O
is None None O
described None None O
by None None O
three None None O
general None None O
methods None None O
: None None O
( None None O
1 None None O
) None None O
reductive None None O
alkylation None None O
of None None O
methyl None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylates None None I-IUPAC
( None None O
2 None None O
) None None O
and None None O
subsequent None None O
hydrolysis None None O
; None None O
( None None O
2 None None O
) None None O
alkylation None None O
of None None O
the None None O
urethane None None O
( None None O
9 None None O
) None None O
, None None O
followed None None O
by None None O
hydrolysis None None O
; None None O
and None None O
( None None O
3 None None O
) None None O
selective None None O
NaBH4 None None O
reduction None None O
of None None O
the None None O
appropriate None None O
amide None None O
of None None O
( None None O
2 None None O
) None None O
, None None O
followed None None O
by None None O
hydrolysis None None O
. None None O

A None None O
more None None O
specific None None O
process None None O
was None None O
used None None O
for None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylamino None None I-IUPAC
) None None I-IUPAC
compound None None I-MODIFIER
, None None O
i.e. None None O
, None None O
nucleophilic None None O
displacement None None O
of None None O
nitrite None None O
from None None O
methyl None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylate None None I-IUPAC
by None None O
sodioformanilide None None O
and None None O
subsequent None None O
hydrolysis None None O
. None None O

Many None None O
of None None O
these None None O
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylic None None I-IUPAC
acid None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
potent None None O
antihypertensive None None O
agents None None O
in None None O
the None None O
spontaneously None None O
hypertensive None None O
rat None None O
( None None O
SHR None None O
) None None O
. None None O

Optimization None None O
of None None O
structural None None O
parameters None None O
for None None O
this None None O
activity None None O
yielded None None O
compounds None None O
54 None None O
, None None O
55 None None O
, None None O
34 None None O
, None None O
65 None None O
, None None O
and None None O
22 None None O
, None None O
which None None O
were None None O
selected None None O
for None None O
further None None O
study None None O
in None None O
the None None O
renal None None O
hypertensive None None O
dog None None O
( None None O
RHD None None O
) None None O
. None None O

Based None None O
on None None O
these None None O
studies None None O
, None None O
one None None O
compound None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorobenzyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
65 None None O
) None None O
, None None O
was None None O
selected None None O
for None None O
preclinical None None O
toxicity None None O
evaluation None None O
. None None O

Based None None O
on None None O
the None None O
toxicological None None O
findings None None O
, None None O
it None None O
was None None O
decided None None O
not None None O
to None None O
pursue None None O
compound None None O
65 None None O
clinically None None O
. None None O


The None None O
synthesis None None O
and None None O
structure None None O
- None None O
activity None None O
relationships None None O
( None None O
SAR None None O
) None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethylamine None None I-IUPAC
derivatives None None I-MODIFIER
5-8 None None O
designed None None O
from None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dipropyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethoxy None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
ethylamine None None I-IUPAC
hydrochloride None None I-IUPAC
( None None O
1 None None O
, None None O
NE None None O
- None None O
100 None None O
) None None O
are None None O
presented None None O
. None None O

The None None O
SAR None None O
between None None O
compound None None O
1 None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethylamine None None I-IUPAC
derivatives None None I-MODIFIER
suggested None None O
that None None O
the None None O
alkyl None None O
group None None O
on None None O
the None None O
1 None None O
- None None O
position None None O
carbon None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
ethylamine None None I-IUPAC
derivatives None None I-MODIFIER
played None None O
the None None O
role None None O
of None None O
one None None O
of None None O
the None None O
propyl None None O
groups None None O
on None None O
the None None O
aminic None None O
nitrogen None None O
of None None O
compound None None O
1 None None O
. None None O

( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
Propyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethoxy None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
ethylam None None I-IUPAC
ine None None I-IUPAC
hydrochloride None None I-IUPAC
( None None O
( None None O
- None None O
) None None O
- None None O
6d None None O
, None None O
NE None None O
- None None O
537 None None O
) None None O
and None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methybutyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethoxy None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
e None None I-IUPAC
thylamine None None I-IUPAC
hydrochloride None None I-IUPAC
( None None O
( None None O
- None None O
) None None O
- None None O
6i None None O
, None None O
NE None None O
- None None O
535 None None O
) None None O
, None None O
typical None None O
compounds None None O
in None None O
this None None O
series None None O
, None None O
have None None O
potent None None O
and None None O
selective None None O
sigma None None O
( None None O
1 None None O
) None None O
affinity None None O
. None None O


We None None O
have None None O
previously None None O
shown None None O
that None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
[ None None O
( None None O
S None None O
) None None O
- None None O
APPA None None O
, None None O
2 None None O
] None None O
is None None O
a None None O
weak None None O
agonist None None O
at None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
) None None O
receptors None None O
, None None O
specifically None None O
activated None None O
by None None O
( None None O
S None None O
) None None O
- None None O
AMPA None None O
( None None O
1 None None O
) None None O
, None None O
whereas None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
] None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
[ None None O
( None None O
S None None O
) None None O
- None None O
2 None None O
- None None O
Py None None O
- None None O
AMPA None None O
, None None O
5 None None O
] None None O
and None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thiazolyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
] None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None O
) None None O
are None None O
potent None None O
AMPA None None O
agonists None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
( None None O
R None None O
) None None O
- None None O
APPA None None O
( None None O
3 None None O
) None None O
and None None O
( None None O
R None None O
) None None O
- None None O
2 None None O
- None None O
Py None None O
- None None O
AMPA None None O
( None None O
6 None None O
) None None O
have None None O
been None None O
shown None None O
to None None O
be None None O
weak None None O
AMPA None None O
antagonists None None O
. None None O

We None None O
now None None O
report None None O
the None None O
synthesis None None O
of None None O
2 None None O
- None None O
Py None None O
- None None O
AMPA None None O
( None None O
7a None None O
) None None O
and None None O
the None None O
isomeric None None O
compounds None None O
3 None None O
- None None O
Py None None O
- None None O
AMPA None None O
( None None O
7b None None O
) None None O
and None None O
4 None None O
- None None O
Py None None O
- None None O
AMPA None None O
( None None O
7c None None O
) None None O
as None None O
well None None O
as None None O
the None None O
7a None None O
analogues None None O
, None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
] None None I-IUPAC
p None None I-IUPAC
ropion None None I-IUPAC
ic None None I-IUPAC
acid None None I-IUPAC
( None None O
7d None None O
) None None O
and None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
quinolinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
] None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
7e None None O
) None None O
. None None O

Furthermore None None O
, None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
] None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
2 None None O
- None None O
Fu None None O
- None None O
AMPA None None O
, None None O
7f None None O
) None None O
and None None O
its None None O
5 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furyl None None I-IUPAC
derivative None None I-MODIFIER
( None None O
7g None None O
) None None O
were None None O
synthesized None None O
, None None O
and None None O
( None None O
S None None O
) None None O
- None None O
2 None None O
- None None O
Fu None None O
- None None O
AMPA None None O
( None None O
8 None None O
) None None O
and None None O
( None None O
R None None O
) None None O
- None None O
2 None None O
- None None O
Fu None None O
- None None O
AMPA None None O
( None None O
9 None None O
) None None O
were None None O
prepared None None O
by None None O
semipreparative None None O
chiral None None O
HPLC None None O
resolution None None O
of None None O
7f None None O
. None None O

HPLC None None O
analyses None None O
and None None O
circular None None O
dichroism None None O
spectroscopy None None O
indicated None None O
the None None O
absolute None None O
stereochemistry None None O
of None None O
8 None None O
and None None O
9 None None O
to None None O
be None None O
S None None O
and None None O
R None None O
, None None O
respectively None None O
. None None O

This None None O
was None None O
confirmed None None O
by None None O
an None None O
X None None O
- None None O
ray None None O
crystallographic None None O
analysis None None O
of None None O
9 None None O
. None None O

HCl None None O
. None None O

In None None O
receptor None None O
binding None None O
( None None O
IC50 None None O
values None None O
) None None O
and None None O
rat None None O
cortical None None O
wedge None None O
electrophysiological None None O
( None None O
EC50 None None O
values None None O
) None None O
studies None None O
, None None O
7c None None O
( None None O
IC50 None None O
= None None O
5.5 None None O
+ None None O
/ None None O
- None None O
0.6 None None O
microM None None O
; None None O
EC50 None None O
= None None O
96 None None O
+ None None O
/ None None O
- None None O
5 None None O
microM None None O
) None None O
was None None O
shown None None O
to None None O
be None None O
markedly None None O
weaker None None O
than None None O
7a None None O
( None None O
IC50 None None O
= None None O
0.57 None None O
+ None None O
/ None None O
- None None O
0.16 None None O
microM None None O
; None None O
EC50 None None O
= None None O
7.4 None None O
+ None None O
/ None None O
- None None O
0.2 None None O
microM None None O
) None None O
as None None O
an None None O
AMPA None None O
agonist None None O
, None None O
whereas None None O
7b None None O
, None None O
d None None O
, None None O
e None None O
were None None O
inactive None None O
. None None O

The None None O
very None None O
potent None None O
AMPA None None O
agonist None None O
effect None None O
of None None O
7f None None O
( None None O
IC50 None None O
= None None O
0.15 None None O
+ None None O
/ None None O
- None None O
0.03 None None O
microM None None O
; None None O
EC50 None None O
= None None O
1.7 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O

2 None None O
microM None None O
) None None O
was None None O
shown None None O
to None None O
reside None None O
exclusively None None O
in None None O
8 None None O
( None None O
IC50 None None O
= None None O
0.11 None None O
+ None None O
/ None None O
- None None O
0.01 None None O
microM None None O
; None None O
EC50 None None O
= None None O
0.71 None None O
+ None None O
/ None None O
- None None O
0.11 None None O
microM None None O
) None None O
, None None O
whereas None None O
9 None None O
did None None O
not None None O
interact None None O
significantly None None O
with None None O
AMPA None None O
receptors None None O
, None None O
either None None O
as None None O
an None None O
agonist None None O
or None None O
as None None O
an None None O
antagonist None None O
. None None O

8 None None O
was None None O
shown None None O
to None None O
be None None O
photochemically None None O
active None None O
and None None O
is None None O
a None None O
potential None None O
photoaffinity None None O
label None None O
for None None O
the None None O
recognition None None O
site None None O
of None None O
the None None O
AMPA None None O
receptors None None O
. None None O

Compound None None O
7g None None O
turned None None O
out None None O
to None None O
be None None O
a None None O
very None None O
weak None None O
AMPA None None O
receptor None None O
agonist None None O
( None None O
IC50 None None O
= None None O
12 None None O
+ None None O
/ None None O
- None None O
0.7 None None O
microM None None O
; None None O
EC50 None None O
= None None O
160 None None O
+ None None O
/ None None O
- None None O
15 None None O
microM None None O
) None None O
. None None O

None None None O
of None None O
these None None O
new None None O
compounds None None O
showed None None O
detectable None None O
effects None None O
at None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
- None None I-IUPAC
aspartic None None I-IUPAC
acid None None I-IUPAC
( None None O
NMDA None None O
) None None O
or None None O
kainic None None O
acid None None O
receptors None None O
in None None O
vitro None None O
. None None O

The None None O
present None None O
studies None None O
have None None O
emphasized None None O
that None None O
the None None O
presence None None O
of None None O
a None None O
heteroatom None None O
in None None O
the None None O
2 None None O
- None None O
position None None O
of None None O
the None None O
heteroaryl None None O
5 None None O
- None None O
substituent None None O
greatly None None O
facilitates None None O
AMPA None None O
receptor None None O
agonist None None O
activity None None O
. None None O


Biological None None O
tests None None O
indicate None None O
hexahydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indeno None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridines None None I-IUPAC
to None None O
be None None O
potential None None O
human None None O
antidepressants None None O
with None None O
additional None None O
stimulating None None O
properties None None O
. None None O

Two None None O
diastereomeric None None O
series None None O
with None None O
H4a None None O
, None None O
H5 None None O
- None None O
trans None None O
, None None O
H4a None None O
, None None O
H9b None None O
- None None O
cis None None O
and None None O
H4a None None O
, None None O
H5 None None O
- None None O
cis None None O
, None None O
H4a None None O
, None None O
H9b None None O
- None None O
cis None None O
configurations None None O
have None None O
been None None O
tested None None O
biologically None None O
. None None O

The None None O
results None None O
revealed None None O
that None None O
the None None O
H4a None None O
, None None O
H5 None None O
- None None O
cis None None O
, None None O
H4a None None O
, None None O
H9b None None O
- None None O
cis None None O
series None None O
and None None O
the None None O
ortho None None O
- None None O
substituted None None O
5 None None O
- None None O
phenyl None None O
H4a None None O
, None None O
H5 None None O
- None None O
trans None None O
, None None O
H4a None None O
, None None O
H9b None None O
- None None O
cis None None O
compounds None None O
lack None None O
activity None None O
. None None O

Neither None None O
the None None O
conformation None None O
with None None O
lowest None None O
potential None None O
energy None None O
nor None None O
any None None O
other None None O
electron None None O
- None None O
derived None None O
parameter None None O
correlate None None O
with None None O
these None None O
data None None O
. None None O

The None None O
only None None O
relevant None None O
difference None None O
between None None O
the None None O
active None None O
and None None O
the None None O
inactive None None O
compounds None None O
detected None None O
thus None None O
far None None O
is None None O
the None None O
rotational None None O
barrier None None O
of None None O
the None None O
phenyl None None O
in None None O
the None None O
5 None None O
- None None O
position None None O
. None None O

The None None O
conclusion None None O
was None None O
reached None None O
that None None O
certain None None O
conformations None None O
, None None O
which None None O
do None None O
not None None O
resemble None None O
those None None O
of None None O
lowest None None O
potential None None O
energy None None O
, None None O
cannot None None O
be None None O
adopted None None O
by None None O
the None None O
inactive None None O
compounds None None O
. None None O

Therefore None None O
, None None O
the None None O
interaction None None O
of None None O
the None None O
drug None None O
with None None O
the None None O
binding None None O
site None None O
, None None O
responsible None None O
for None None O
its None None O
biological None None O
activity None None O
, None None O
appears None None O
to None None O
be None None O
governed None None O
by None None O
a None None O
dynamic None None O
process None None O
. None None O

This None None O
process None None O
is None None O
characterized None None O
by None None O
a None None O
transformation None None O
of None None O
the None None O
conformation None None O
of None None O
lowest None None O
potential None None O
energy None None O
to None None O
one None None O
with None None O
an None None O
energy None None O
content None None O
above None None O
the None None O
minimum None None O
. None None O


A None None O
number None None O
of None None O
4,7 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
benzopyran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
crude None None O
rat None None O
lens None None O
aldose None None O
reductase None None O
inhibitory None None O
activity None None O
. None None O

Substituents None None O
on None None O
position None None O
4 None None O
included None None O
CH3 None None O
, None None O
CO2H None None O
, None None O
CH2CO2H None None O
, None None O
CH None None O
= None None O
CHCO2H None None O
, None None O
and None None O
CH2CH2CO2H None None O
. None None O

The None None O
aromatic None None O
substituents None None O
included None None O
OH None None O
, None None O
OCH3 None None O
, None None O
OCOCH3 None None O
, None None O
CH2CH3 None None O
, None None O
and None None O
Cl None None O
. None None O

Also None None O
included None None O
in None None O
the None None O
study None None O
were None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
oxo None None I-PARTIUPAC
- None None I-PARTIUPAC
3H None None I-PARTIUPAC
- None None I-PARTIUPAC
naphtho None None I-PARTIUPAC
[ None None I-PARTIUPAC
2,1 None None I-PARTIUPAC
- None None I-PARTIUPAC
b None None I-PARTIUPAC
] None None I-PARTIUPAC
pyran None None I-PARTIUPAC
- None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
acetic None None I-PARTIUPAC
, None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
oxo None None I-PARTIUPAC
- None None I-PARTIUPAC
2H None None I-PARTIUPAC
- None None I-PARTIUPAC
naphtho None None I-PARTIUPAC
[ None None I-PARTIUPAC
1,2 None None I-PARTIUPAC
- None None I-PARTIUPAC
b None None I-PARTIUPAC
] None None I-PARTIUPAC
pyran None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
acetic None None I-PARTIUPAC
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
naphthylacetic None None I-IUPAC
acids None None I-IUPAC
. None None O

The None None O
benzopyran None None O
and None None O
naphthopyran None None O
derivatives None None O
were None None O
prepared None None O
by None None O
the None None O
classical None None O
von None None O
Pechmann None None O
reaction None None O
. None None O

General None None O
structure None None O
- None None O
activity None None O
relationships None None O
reveal None None O
that None None O
optimal None None O
enzyme None None O
inhibitory None None O
activity None None O
is None None O
displayed None None O
by None None O
those None None O
compounds None None O
possessing None None O
the None None O
acetic None None I-IUPAC
acid None None I-IUPAC
moiety None None I-MODIFIER
. None None O

For None None O
example None None O
, None None O
the None None O
most None None O
potent None None O
derivative None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
naphtho None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
acetic None None I-IUPAC
acid None None I-IUPAC
with None None O
an None None O
IC50 None None O
of None None O
0.020 None None O
microM None None O
, None None O
is None None O
as None None O
potent None None O
as None None O
sorbinil None None O
( None None O
IC50 None None O
= None None O
0.017 None None O
microM None None O
) None None O
in None None O
the None None O
crude None None O
rat None None O
lens None None O
aldose None None O
reductase None None O
assay None None O
. None None O


Modification None None O
of None None O
the None None O
benzodiazepine None None O
( None None O
BZ None None O
) None None O
receptor None None O
binding None None O
template None None O
2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
quinazolin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
6H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
by None None O
replacement None None O
of None None O
the None None O
annelated None None O
benzene None None O
ring None None O
with None None O
various None None O
alicyclic None None O
and None None O
heterocyclic None None O
moieties None None O
led None None O
to None None O
novel None None O
structures None None O
with None None O
potent None None O
BZ None None O
receptor None None O
binding None None O
affinity None None O
. None None O

High None None O
affinity None None O
was None None O
found None None O
in None None O
some None None O
cycloalkyl None None I-MODIFIER
- None None I-MODIFIER
annelated None None I-MODIFIER
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
6H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
and None None O
in None None O
some None None O
7,8,9,10 None None I-IUPAC
- None None I-IUPAC
tetrahydropyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
6H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
in None None O
which None None O
the None None O
degree None None O
of None None O
activity None None O
was None None O
strongly None None O
dependent None None O
on None None O
the None None O
N None None O
- None None O
substituent None None O
in None None O
the None None O
9 None None O
- None None O
position None None O
. None None O

Nine None None O
compounds None None O
with None None O
BZ None None O
receptor None None O
IC50 None None O
binding None None O
affinity None None O
values None None O
equal None None O
or None None O
superior None None O
to None None O
diazepam None None O
were None None O
evaluated None None O
in None None O
secondary None None O
screening None None O
. None None O

One None None O
of None None O
these None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
7,8,9,10 None None I-IUPAC
- None None I-IUPAC
tetrahydropyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
6H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
, None None O
showed None None O
good None None O
activity None None O
in None None O
rats None None O
as None None O
a None None O
potential None None O
anxiolytic None None O
agent None None O
without None None O
sedative None None O
liability None None O
. None None O

However None None O
, None None O
it None None O
increased None None O
the None None O
rotorod None None O
deficit None None O
produced None None O
by None None O
ethanol None None O
at None None O
anxiolytic None None O
doses None None O
, None None O
an None None O
indication None None O
of None None O
alcohol None None O
interaction None None O
. None None O

Thus None None O
, None None O
none None None O
of None None O
the None None O
compounds None None O
showed None None O
an None None O
advantage None None O
over None None O
CGS None None O
9896 None None O
( None None O
Yokoyama None None O
et None None O
al. None None O
J None None O
. None None O

Med. None None O
Chem. None None O
1982 None None O
, None None O
25 None None O
, None None O
337-339 None None O
) None None O
, None None O
which None None O
is None None O
free None None O
of None None O
sedative None None O
and None None O
alcohol None None O
interaction None None O
potential None None O
as None None O
measured None None O
by None None O
the None None O
test None None O
procedures None None O
described None None O
. None None O


Appropriately None None O
substituted None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
7H None None I-IUPAC
- None None I-IUPAC
thiazolo None None I-IUPAC
[ None None I-IUPAC
3,2 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
9-12 None None O
and None None O
18 None None O
were None None O
considered None None O
as None None O
annulated None None O
analogues None None O
of None None O
HEPT None None O
( None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
thymine None None I-IUPAC
) None None O
, None None O
and None None O
some None None O
of None None O
these None None O
compounds None None O
were None None O
also None None O
found None None O
active None None O
against None None O
HIV None None O
- None None O
1 None None O
, None None O
the None None O
most None None O
active None None O
one None None O
being None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dimethylphenyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
7H None None I-IUPAC
- None None I-IUPAC
thiazolo None None I-IUPAC
[ None None I-IUPAC
3,2 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
10b None None O
) None None O
. None None O

S None None O
- None None O
Alkylation None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thiouracils None None I-IUPAC
1-4 None None O
was None None O
performed None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
bromoacetaldehyde None None I-IUPAC
acetals None None I-IUPAC
to None None O
furnish None None O
the None None O
S None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
alkoxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
derivatives None None I-MODIFIER
5-8 None None O
and None None O
with None None O
allyl None None O
bromide None None O
to None None O
furnish None None O
S None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
derivatives None None I-MODIFIER
17 None None O
. None None O

The None None O
target None None O
compounds None None O
9-12 None None O
were None None O
obtained None None O
by None None O
an None None O
N1 None None O
regioselective None None O
intramolecular None None O
cyclization None None O
reaction None None O
of None None O
silylated None None O
5-8 None None O
using None None O
trimethylsilyl None None O
trifluoromethanesulfonate None None O
( None None O
TMS None None O
triflate None None O
) None None O
as None None O
the None None O
catalyst None None O
. None None O

Treatment None None O
of None None O
the None None O
S None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
derivatives None None I-MODIFIER
17 None None O
with None None O
bromine None None O
in None None O
dry None None O
methylene None None O
chloride None None O
afforded None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
18 None None O
. None None O


A None None O
novel None None O
series None None O
of None None O
nonpeptide None None O
CCK None None O
( None None O
2 None None O
) None None O
receptor None None O
antagonists None None O
has None None O
been None None O
prepared None None O
, None None O
in None None O
which None None O
2,7 None None I-IUPAC
- None None I-IUPAC
dioxo None None I-IUPAC
- None None I-IUPAC
2,3,4,5,6,7 None None I-IUPAC
- None None I-IUPAC
hexahydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
h None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
] None None I-IUPAC
diazonine None None I-IUPAC
( None None O
5 None None O
) None None O
was None None O
used None None O
as None None O
a None None O
chemical None None O
template None None O
. None None O

This None None O
uncommon None None O
ring None None O
system None None O
was None None O
obtained None None O
in None None O
a None None O
highly None None O
substituted None None O
form None None O
and None None O
in None None O
high None None O
yield None None O
by None None O
ozonolysis None None O
of None None O
the None None O
enamine None None O
bond None None O
of None None O
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
9H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
4 None None O
) None None O
, None None O
in None None O
which None None O
the None None O
configuration None None O
of None None O
the None None O
substituents None None O
was None None O
established None None O
stereoselectively None None O
via None None O
the None None O
Pictet None None O
- None None O
Spengler None None O
reaction None None O
. None None O

Further None None O
structural None None O
manipulation None None O
was None None O
guided None None O
by None None O
molecular None None O
modeling None None O
through None None O
comparison None None O
of None None O
fieldpoint None None O
- None None O
based None None O
structures None None O
of None None O
candidate None None O
compounds None None O
with None None O
a None None O
selected None None O
low None None O
- None None O
energy None None O
conformation None None O
of None None O
the None None O
representative None None O
CCK None None O
( None None O
2 None None O
) None None O
receptor None None O
antagonist None None O
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
dicarboxyphenyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
adamantylmethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
( None None O
JB93182 None None O
( None None O
3 None None O
) None None O
) None None O
. None None O

By None None O
this None None O
approach None None O
compounds None None O
such None None O
as None None O
( None None I-IUPAC
3R None None I-IUPAC
, None None I-IUPAC
5S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
adamantyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chlorobenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxymet None None I-IUPAC
hyl None None I-IUPAC
aminocarbonyl None None I-IUPAC
- None None I-IUPAC
2,7 None None I-IUPAC
- None None I-IUPAC
dioxo None None I-IUPAC
- None None I-IUPAC
2,3,4,5,6,7 None None I-IUPAC
- None None I-IUPAC
hexahydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
h None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
] None None I-IUPAC
diazonine None None I-IUPAC
( None None O
32 None None O
) None None O
were None None O
prepared None None O
. None None O

Compound None None O
32 None None O
behaved None None O
as None None O
a None None O
competitive None None O
CCK None None O
( None None O
2 None None O
) None None O
receptor None None O
antagonist None None O
in None None O
vitro None None O
as None None O
judged None None O
by None None O
its None None O
inhibition None None O
of None None O
pentagastrin None None O
- None None O
stimulated None None O
acid None None O
secretion None None O
in None None O
an None None O
isolated None None O
, None None O
lumen None None O
- None None O
perfused None None O
, None None O
immature None None O
rat None None O
stomach None None O
assay None None O
( None None O
pK None None O
( None None O
B None None O
) None None O
= None None O
6.74 None None O
+ None None O
/ None None O
- None None O
0.27 None None O
) None None O
and None None O
by None None O
its None None O
displacement None None O
of None None O
[ None None O
( None None O
125 None None O
) None None O
I None None O
] None None O
CCK None None O
- None None O
8S None None O
from None None O
CCK None None O
( None None O
2 None None O
) None None O
sites None None O
in None None O
mouse None None O
cortical None None O
homogenates None None O
( None None O
pK None None O
( None None O
i None None O
) None None O
= None None O
6.99 None None O
+ None None O
/ None None O
- None None O
0.05 None None O
) None None O
. None None O

Compound None None O
32 None None O
was None None O
100 None None O
- None None O
fold None None O
selective None None O
for None None O
CCK None None O
( None None O
2 None None O
) None None O
over None None O
CCK None None O
( None None O
1 None None O
) None None O
receptors None None O
based None None O
on None None O
the None None O
affinity None None O
estimate None None O
obtained None None O
in None None O
a None None O
guinea None None O
pig None None O
pancreas None None O
radioligand None None O
binding None None O
assay None None O
( None None O
pK None None O
( None None O
i None None O
) None None O
= None None O
5.0 None None O
) None None O
. None None O


A None None O
group None None O
of None None O
racemic None None I-MODIFIER
alkyl None None B-IUPAC
and None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
phenethyl None None I-PARTIUPAC
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
dihydro None None I-PARTIUPAC
- None None I-PARTIUPAC
2,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
dimethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
nitro None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-MODIFIER
- None None I-MODIFIER
or None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
pyridyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
pyridinecarboxylates None None I-PARTIUPAC
( None None O
13a None None O
- None None O
q None None O
) None None O
was None None O
prepared None None O
using None None O
a None None O
modified None None O
Hantzsch None None O
reaction None None O
that None None O
involved None None O
the None None O
condensation None None O
of None None O
a None None O
3 None None I-MODIFIER
- None None I-MODIFIER
or None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxaldehyde None None I-IUPAC
( None None O
7a None None O
- None None O
j None None O
) None None O
with None None O
an None None O
alkyl None None I-IUPAC
or None None O
2 None None I-IUPAC
- None None I-IUPAC
phenethyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminocrotonate None None I-IUPAC
( None None O
11a None None O
- None None O
d None None O
) None None O
and None None O
nitroacetone None None O
( None None O
12 None None O
) None None O
. None None O

Nuclear None None O
Overhauser None None O
( None None O
NOE None None O
) None None O
studies None None O
indicated None None O
there None None O
is None None O
a None None O
significant None None O
rotamer None None O
fraction None None O
in None None O
solution None None O
where None None O
the None None O
pyridyl None None O
nitrogen None None O
is None None O
oriented None None O
above None None O
the None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyridine None None I-IUPAC
ring None None I-MODIFIER
, None None O
irrespective None None O
of None None O
whether None None O
a None None O
substituent None None O
is None None O
located None None O
at None None O
the None None O
3 None None O
- None None O
or None None O
6 None None O
- None None O
position None None O
. None None O

A None None O
potential None None O
H None None O
- None None O
bonding None None O
interaction None None O
between None None O
the None None O
pyridyl None None O
nitrogen None None O
free None None O
electron None None O
pair None None O
and None None O
the None None O
suitably None None O
positioned None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyridine None None I-IUPAC
NH None None I-MODIFIER
moiety None None I-MODIFIER
may None None O
stablize None None O
this None None O
rotamer None None O
orientation None None O
. None None O

In None None O
vitro None None O
calcium None None O
channel None None O
antagonist None None O
and None None O
agonist None None O
activities None None O
were None None O
determined None None O
using None None O
guinea None None O
pig None None O
ileum None None O
longitudinal None None O
smooth None None O
muscle None None O
( None None O
GPILSM None None O
) None None O
and None None O
guinea None None O
pig None None O
left None None O
atrium None None O
( None None O
GPLA None None O
) None None O
assays None None O
, None None O
respectively None None O
. None None O

Compounds None None O
having None None O
an None None O
i None None O
- None None O
Pr None None O
ester None None O
substituent None None O
acted None None O
as None None O
dual None None O
cardioselective None None O
calcium None None O
channel None None O
agonists None None O
( None None O
GPLA None None O
) None None O
/ None None O
smooth None None O
muscle None None O
- None None O
selective None None O
calcium None None O
channel None None O
antagonists None None O
( None None O
GPILSM None None O
) None None O
, None None O
except None None O
for None None O
the None None O
C None None O
- None None O
4 None None O
3 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
compound None None I-MODIFIER
which None None O
exhibited None None O
an None None O
antagonist None None O
effect None None O
on None None O
both None None O
GPLA None None O
and None None O
GPILSM None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
compounds None None O
with None None O
a None None O
phenethyl None None O
ester None None O
group None None O
, None None O
which None None O
exhibited None None O
antagonist None None O
activity None None O
( None None O
IC50 None None O
= None None O
10 None None O
( None None O
- None None O
5 None None O
) None None O
- None None O
10 None None O
( None None O
- None None O
7 None None O
) None None O
M None None O
range None None O
) None None O
on None None O
GPILSM None None O
, None None O
were None None O
devoid None None O
of None None O
cardiac None None O
agonist None None O
activity None None O
on None None O
GPLA None None O
. None None O

Structure None None O
- None None O
activity None None O
relationships None None O
showing None None O
the None None O
effect None None O
of None None O
a None None O
substituent None None O
( None None O
Me None None O
, None None O
CF3 None None O
, None None O
Cl None None O
, None None O
NO2 None None O
, None None O
Ph None None O
) None None O
at None None O
the None None O
3 None None O
- None None O
or None None O
6 None None O
- None None O
position None None O
of None None O
a None None O
C None None O
- None None O
4 None None O
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
moiety None None I-MODIFIER
and None None O
a None None O
variety None None O
of None None O
ester None None O
substituents None None O
( None None O
Me None None O
, None None O
Et None None O
, None None O
i None None O
- None None O
Pr None None O
, None None O
PhCH2CH2 None None O
- None None O
) None None O
upon None None O
calcium None None O
channel None None O
modulation None None O
are None None O
described None None O
. None None O

Compounds None None O
possessing None None O
a None None O
3 None None I-MODIFIER
- None None I-MODIFIER
or None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
moiety None None I-MODIFIER
, None None O
in None None O
conjuction None None O
with None None O
an None None O
i None None O
- None None O
Pr None None O
ester None None O
substituent None None O
, None None O
are None None O
novel None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyridine None None I-IUPAC
calcium None None O
channel None None O
modulators None None O
that None None O
offer None None O
a None None O
new None None O
drug None None O
design None None O
approach None None O
directed None None O
to None None O
the None None O
treatment None None O
of None None O
congestive None None O
heart None None O
failure None None O
and None None O
may None None O
also None None O
be None None O
useful None None O
as None None O
probes None None O
to None None O
study None None O
the None None O
structure None None O
- None None O
function None None O
relationships None None O
of None None O
calcium None None O
channels None None O
. None None O


A None None O
series None None O
of None None O
4' None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
spiro None None I-IUPAC
[ None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
3,1 None None I-IUPAC
- None None I-IUPAC
benzoxazine None None I-IUPAC
- None None I-IUPAC
4,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
piperidin None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
was None None O
prepared None None O
and None None O
evaluated None None O
for None None O
antihypertensive None None O
activity None None O
in None None O
the None None O
spontaneously None None O
hypertensive None None O
rat None None O
( None None O
SHR None None O
) None None O
. None None O

The None None O
basic None None O
ring None None O
system None None O
was None None O
prepared None None O
in None None O
one None None O
step None None O
by None None O
condensation None None O
of None None O
dilithiated None None I-MODIFIER
( None None B-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
aniline None None I-IUPAC
( None None O
3 None None O
) None None O
with None None O
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
piperidinone None None I-IUPAC
. None None O

Deprotection None None O
afforded None None O
6 None None O
, None None O
which None None O
was None None O
condensed None None O
with None None O
expoxides None None O
or None None O
alkyl None None O
halides None None O
to None None O
furnish None None O
the None None O
title None None O
compounds None None O
. None None O

The None None O
most None None O
active None None O
compound None None O
was None None O
dl None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
benzodioxan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
] None None I-IUPAC
spiro None None I-IUPAC
[ None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
3,1 None None I-IUPAC
- None None I-IUPAC
benzoxazine None None I-IUPAC
- None None I-IUPAC
4,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
piperidin None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
9 None None O
) None None O
, None None O
and None None O
various None None O
modifications None None O
of None None O
this None None O
compound None None O
were None None O
made None None O
in None None O
order None None O
to None None O
elucidate None None O
the None None O
structure None None O
- None None O
activity None None O
relationships None None O
in None None O
the None None O
series None None O
. None None O

Preliminary None None O
indications None None O
are None None O
that None None O
9 None None O
may None None O
act None None O
by None None O
both None None O
central None None O
and None None O
peripheral None None O
mechanisms None None O
. None None O


A None None O
number None None O
of None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
: None None I-IUPAC
N' None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
: None None I-IUPAC
N None None I-IUPAC
" None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
" None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
ethanediylphosphoric None None I-IUPAC
triamide None None I-IUPAC
( None None O
TEPA None None O
) None None O
and None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
: None None I-IUPAC
N' None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
: None None I-IUPAC
N None None I-IUPAC
" None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
" None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
ethanediylphosphorothioic None None I-IUPAC
triamide None None I-IUPAC
( None None O
thio None None O
- None None O
TEPA None None O
) None None O
derivatives None None O
containing None None O
either None None O
two None None O
aziridine None None I-IUPAC
moieties None None B-MODIFIER
( None None O
1a None None O
) None None O
or None None O
two None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
functions None None I-MODIFIER
( None None O
1b None None O
) None None O
and None None O
either None None O
a None None O
2,2,6,6 None None I-IUPAC
- None None I-IUPAC
tetramethylpiperidine None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
oxy None None I-IUPAC
- None None I-IUPAC
2,2,6,6 None None I-IUPAC
- None None I-IUPAC
tetramethylpiperidine None None I-IUPAC
or None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2,2,6,6 None None I-IUPAC
- None None I-IUPAC
tetramethylpiperidine None None I-IUPAC
component None None I-MODIFIER
were None None O
synthesized None None O
and None None O
tested None None O
against None None O
lymphocytic None None O
leukemia None None O
P388 None None O
in None None O
mice None None O
. None None O

In None None O
a None None O
structure None None O
- None None O
activity None None O
comparison None None O
it None None O
was None None O
found None None O
that None None O
at None None O
optimum None None O
dose None None O
all None None O
compounds None None O
containing None None O
the None None O
nitroxyl None None O
radical None None O
were None None O
more None None O
active None None O
than None None O
the None None O
corresponding None None O
hydroxylamine None None O
derivatives None None O
. None None O

The None None O
open None None O
- None None O
chain None None O
compounds None None O
( None None O
1b None None O
) None None O
were None None O
less None None O
active None None O
than None None O
the None None O
corresponding None None O
aziridine None None O
ring None None O
compounds None None O
( None None O
1a None None O
) None None O
. None None O

The None None O
replacement None None O
of None None O
the None None O
X None None O
= None None O
bridge None None O
in None None O
1a None None O
with None None O
the None None O
X None None O
= None None O
N None None O
( None None O
CH3 None None O
) None None O
group None None O
resulted None None O
in None None O
lowering None None O
of None None O
the None None O
anticancer None None O
activity None None O
. None None O


A None None O
series None None O
of None None O
esters None None O
of None None O
6beta None None I-IUPAC
- None None I-IUPAC
hydroxynortropane None None I-IUPAC
and None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
analogue None None I-MODIFIER
6beta None None B-IUPAC
- None None I-IUPAC
tropanol None None I-IUPAC
were None None O
synthesized None None O
and None None O
screened None None O
versus None None O
binding None None O
of None None O
an None None O
antagonist None None O
( None None O
quinuclidinyl None None I-IUPAC
benzilate None None I-IUPAC
) None None O
and None None O
an None None O
agonist None None O
( None None O
oxotremorine None None O
- None None O
M None None O
) None None O
at None None O
sites None None O
on None None O
human None None O
m None None O
( None None O
1 None None O
) None None O
- None None O
, None None O
m None None O
( None None O
2 None None O
) None None O
- None None O
, None None O
m None None O
( None None O
3 None None O
) None None O
- None None O
, None None O
and None None O
m None None O
( None None O
4 None None O
) None None O
- None None O
muscarinic None None O
receptors None None O
in None None O
transfected None None O
cell None None O
membranes None None O
and None None O
on None None O
native None None O
M None None O
( None None O
1 None None O
) None None O
- None None O
muscarinic None None O
receptors None None O
in None None O
rat None None O
brain None None O
membranes None None O
and None None O
native None None O
M None None O
( None None O
2 None None O
) None None O
- None None O
muscarinic None None O
receptors None None O
in None None O
rat None None O
heart None None O
membranes None None O
. None None O

Most None None O
6beta None None I-IUPAC
- None None I-IUPAC
acyloxy None None I-IUPAC
( None None I-IUPAC
nor None None I-IUPAC
) None None I-IUPAC
tropanes None None I-IUPAC
had None None O
higher None None O
affinity None None O
versus None None O
oxotremorine None None O
- None None O
M None None O
binding None None O
compared None None O
to None None O
quinuclidinyl None None O
benzilate None None O
binding None None O
at None None O
transfected None None O
m None None O
( None None O
1 None None O
) None None O
- None None O
and None None O
native None None O
M None None O
( None None O
1 None None O
) None None O
- None None O
receptors None None O
, None None O
indicative None None O
of None None O
agonist None None O
activity None None O
. None None O

6beta None None I-IUPAC
- None None I-IUPAC
Acetoxynortropane None None I-IUPAC
had None None O
K None None O
( None None O
i None None O
) None None O
values None None O
versus None None O
oxotremorine None None O
- None None O
M None None O
binding None None O
at None None O
m None None O
( None None O
1 None None O
) None None O
- None None O
, None None O
m None None O
( None None O
2 None None O
) None None O
- None None O
, None None O
and None None O
m None None O
( None None O
4 None None O
) None None O
- None None O
receptors None None O
ranging None None O
from None None O
4 None None O
to None None O
7 None None O
nM None None O
. None None O

N None None O
- None None O
Methylation None None O
reduced None None O
affinity None None O
greatly None None O
as None None O
did None None O
increasing None None O
the None None O
size None None O
of None None O
the None None O
acyl None None O
moiety None None O
. None None O

The None None O
affinity None None O
of None None O
6beta None None I-IUPAC
- None None I-IUPAC
benzoyloxynortropane None None I-IUPAC
and None None O
other None None O
analogues None None O
with None None O
larger None None O
acyl None None O
moieties None None O
was None None O
little None None O
affected None None O
by None None O
N None None O
- None None O
methylation None None O
or None None O
in None None O
some None None O
cases None None O
was None None O
increased None None O
. None None O

6beta None None I-IUPAC
- None None I-IUPAC
Acyloxy None None I-IUPAC
( None None I-IUPAC
nor None None I-IUPAC
) None None I-IUPAC
tropanes None None I-IUPAC
and None None O
classical None None O
muscarinic None None O
agonists None None O
, None None O
such None None O
as None None O
muscarine None None O
and None None O
oxotremorine None None O
, None None O
had None None O
higher None None O
affinity None None O
versus None None O
oxotremorine None None O
- None None O
M None None O
binding None None O
compared None None O
to None None O
quinuclidinyl None None O
benzilate None None O
binding None None O
at None None O
native None None O
M None None O
( None None O
2 None None O
) None None O
- None None O
muscarinic None None O
receptors None None O
of None None O
heart None None O
, None None O
but None None O
not None None O
at None None O
transfected None None O
m None None O
( None None O
2 None None O
) None None O
- None None O
muscarinic None None O
receptors None None O
. None None O

Antagonist None None O
/ None None O
agonist None None O
binding None None O
ratios None None O
were None None O
not None None O
obtained None None O
for None None O
transfected None None O
m None None O
( None None O
3 None None O
) None None O
- None None O
receptors None None O
, None None O
since None None O
significant None None O
oxotremorine None None O
- None None O
M None None O
binding None None O
could None None O
not None None O
be None None O
detected None None O
. None None O

6beta None None I-IUPAC
- None None I-IUPAC
Acyloxy None None I-IUPAC
( None None I-IUPAC
nor None None I-IUPAC
) None None I-IUPAC
tropane None None I-IUPAC
, None None O
two None None O
other None None O
( None None O
nor None None O
) None None O
tropanes None None O
, None None O
and None None O
the None None O
classical None None O
muscarinic None None O
agonists None None O
had None None O
higher None None O
affinity None None O
versus None None O
agonist None None O
binding None None O
compared None None O
to None None O
antagonist None None O
binding None None O
for None None O
transfected None None O
m None None O
( None None O
4 None None O
) None None O
- None None O
receptors None None O
. None None O

The None None O
antagonist None None O
/ None None O
agonist None None O
binding None None O
ratio None None O
method None None O
is None None O
clearly None None O
not None None O
always None None O
reliable None None O
for None None O
predicting None None O
agonist None None O
activity None None O
at None None O
muscarinic None None O
receptors None None O
. None None O


New None None O
histamine None None O
derivatives None None O
characterized None None O
by None None O
a None None O
( None None O
substituted None None O
) None None O
aryl None None O
, None None O
heteroaryl None None O
, None None O
benzyl None None O
, None None O
or None None O
heteroarylmethyl None None O
substituent None None O
in None None O
the None None O
C2 None None O
position None None O
of None None O
the None None O
imidazole None None O
ring None None O
have None None O
been None None O
prepared None None O
from None None O
appropriate None None O
imidates None None O
or None None O
amidines None None O
, None None O
respectively None None O
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phthalimido None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
acetate None None I-IUPAC
( None None O
1 None None O
) None None O
. None None O

The None None O
compounds None None O
were None None O
screened None None O
as None None O
potential None None O
H1 None None O
receptor None None O
agonists None None O
on None None O
the None None O
isolated None None O
guinea None None O
pig None None O
ileum None None O
. None None O

The None None O
3 None None I-IUPAC
- None None I-IUPAC
halogenated None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylhistamines None None I-IUPAC
( None None O
halogen None None O
= None None O
Br None None O
( None None O
35 None None O
) None None O
and None None O
I None None O
( None None O
36 None None O
) None None O
) None None O
were None None O
equipotent None None O
with None None O
histamine None None O
, None None O
while None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
histamine None None I-IUPAC
( None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
ethanamine None None I-IUPAC
( None None O
39 None None O
) None None O
) None None O
was None None O
significantly None None O
more None None O
potent None None O
than None None O
histamine None None O
( None None O
39 None None O
: None None O
pD2 None None O
= None None O
6.81 None None O
, None None O
relative None None O
activity None None O
= None None O
128% None None O
) None None O
. None None O

The None None O
2 None None O
- None None O
substituted None None O
histamine None None O
analogues None None O
were None None O
partial None None O
H1 None None O
receptor None None O
agonists None None O
on None None O
the None None O
endothelium None None O
- None None O
denuded None None O
isolated None None O
guinea None None O
pig None None O
aorta None None O
with None None O
pEC50 None None O
values None None O
generally None None O
smaller None None O
than None None O
observed None None O
on None None O
the None None O
guinea None None O
pig None None O
ileum None None O
, None None O
but None None O
the None None O
rank None None O
order None None O
of None None O
potency None None O
was None None O
found None None O
to None None O
be None None O
similar None None O
. None None O

The None None O
contractile None None O
effects None None O
on None None O
guinea None None O
pig None None O
ileum None None O
and None None O
aorta None None O
, None None O
respectively None None O
, None None O
could None None O
be None None O
blocked None None O
concentration None None O
- None None O
dependently None None O
by None None O
the None None O
H1 None None O
receptor None None O
antagonist None None O
mepyramine None None O
, None None O
yielding None None O
KB None None O
values None None O
for None None O
mepyramine None None O
in None None O
the None None O
nanomolar None None O
range None None O
. None None O

In None None O
vitro None None O
compounds None None O
35 None None O
and None None O
39 None None O
bound None None O
to None None O
[ None None O
3H None None O
] None None O
mepyramine None None O
- None None O
labeled None None O
guinea None None O
pig None None O
cerebellar None None O
membranes None None O
with None None O
a None None O
pKi None None O
of None None O
6.1 None None O
and None None O
5.9 None None O
, None None O
respectively None None O
. None None O

However None None O
, None None O
upon None None O
iv None None O
administration None None O
, None None O
35 None None O
( None None O
3-100 None None O
mg None None O
/ None None O
kg None None O
) None None O
and None None O
39 None None O
( None None O
3-300 None None O
mg None None O
/ None None O
kg None None O
) None None O
failed None None O
to None None O
inhibit None None O
the None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
mepyramine None None O
to None None O
mouse None None O
cerebral None None O
cortex None None O
in None None O
vivo None None O
, None None O
thereby None None O
indicating None None O
that None None O
these None None O
histamine None None O
derivatives None None O
are None None O
not None None O
able None None O
to None None O
penetrate None None O
the None None O
blood None None O
- None None O
brain None None O
barrier None None O
. None None O

In None None O
functional None None O
in None None O
vitro None None O
studies None None O
on None None O
histamine None None O
H2 None None O
, None None O
H3 None None O
, None None O
and None None O
other None None O
neurotransmitter None None O
receptors None None O
the None None O
selectivity None None O
of None None O
39 None None O
was None None O
found None None O
to None None O
be None None O
2138 None None O
( None None O
H1 None None O
: None None O
H2 None None O
) None None O
, None None O
& None None O
gt None None O
; None None O
64 None None O
( None None O
H1 None None O
: None None O
H3 None None O
) None None O
, None None O
1000 None None O
( None None O
H1 None None O
: None None O
M3 None None O
) None None O
, None None O
105 None None O
( None None O
H1 None None O
: None None O
alpha None None O
1 None None O
) None None O
, None None O
708 None None O
( None None O
H1 None None O
: None None O
beta None None O
1 None None O
) None None O
, None None O
and None None O
71 None None O
( None None O
H1 None None O
: None None O
5HT2A None None O
) None None O
. None None O

Thus None None O
compound None None O
39 None None O
is None None O
the None None O
most None None O
potent None None O
and None None O
selective None None O
H1 None None O
receptor None None O
agonist None None O
reported None None O
so None None O
far None None O
. None None O

These None None O
results None None O
make None None O
meta None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2 None None I-IUPAC
- None None I-IUPAC
phenylhistamines None None I-IUPAC
, None None O
especially None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
trifluoromethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
phenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
bromophenyl None None I-IUPAC
) None None I-IUPAC
histamine None None I-IUPAC
( None None O
39 None None O
and None None O
35 None None O
, None None O
respectively None None O
) None None O
valuable None None O
experimental None None O
tools None None O
for None None O
the None None O
selective None None O
stimulation None None O
of None None O
histamine None None O
H1 None None O
receptors None None O
and None None O
the None None O
study None None O
of None None O
H1 None None O
receptor None None O
- None None O
mediated None None O
functions None None O
. None None O


Substrate None None O
enantioselectivity None None O
in None None O
the None None O
conjugation None None O
of None None O
phenethyl None None O
halides None None O
catalyzed None None O
by None None O
the None None O
glutathione None None O
S None None O
- None None O
transferases None None O
was None None O
studied None None O
with None None O
partially None None O
purified None None O
isozymes None None O
from None None O
rat None None O
liver None None O
. None None O

All None None O
of None None O
the None None O
isozymes None None O
tested None None O
possessed None None O
measurable None None O
activity None None O
with None None O
phenethyl None None O
chloride None None O
. None None O

Tranferase None None O
A None None O
was None None O
the None None O
most None None O
active None None O
isozyme None None O
tested None None O
. None None O

Each None None O
of None None O
the None None O
isozymes None None O
demonstrated None None O
a None None O
high None None O
degree None None O
of None None O
substrate None None O
enantioselectivity None None O
, None None O
with None None O
transferase None None O
A None None O
being None None O
the None None O
most None None O
enantioselective None None O
isozyme None None O
. None None O

The None None O
enantioselectivity None None O
was None None O
determined None None O
by None None O
high None None O
- None None O
pressure None None O
liquid None None O
chromatographic None None O
analysis None None O
of None None O
the None None O
enzymatically None None O
formed None None O
diastereomeric None None O
products None None O
. None None O

The None None O
effect None None O
of None None O
limiting None None O
glutathione None None O
concentrations None None O
on None None O
the None None O
stereochemical None None O
outcome None None O
of None None O
the None None O
transferase None None O
A None None O
catalyzed None None O
conjugation None None O
of None None O
the None None O
chiral None None O
substrate None None O
, None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
phenethyl None None I-IUPAC
chloride None None I-IUPAC
( None None O
4 None None O
mM None None O
) None None O
, None None O
was None None O
investigated None None O
. None None O

The None None O
stereochemical None None O
course None None O
of None None O
the None None O
enzymatic None None O
reaction None None O
was None None O
not None None O
significantly None None O
altered None None O
at None None O
glutathione None None O
concentrations None None O
as None None O
low None None O
as None None O
25 None None O
microM None None O
. None None O

The None None O
major None None O
product None None O
of None None O
conjugation None None O
had None None O
the None None O
opposite None None O
stereochemistry None None O
at None None O
the None None O
benzylic None None O
carbon None None O
, None None O
indicating None None O
that None None O
the None None O
reaction None None O
proceeded None None O
primarily None None O
with None None O
inversion None None O
of None None O
configuration None None O
. None None O

The None None O
glutathione None None O
conjugates None None O
, None None O
S None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
] None None I-IUPAC
glutathione None None I-IUPAC
, None None O
S None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
] None None I-IUPAC
glutathione None None I-IUPAC
, None None O
S None None I-IUPAC
- None None I-IUPAC
benzylglutathione None None I-IUPAC
, None None O
and None None O
S None None I-IUPAC
- None None I-IUPAC
methylglutathione None None I-IUPAC
were None None O
studied None None O
as None None O
inhibitors None None O
of None None O
the None None O
transferase None None O
A None None O
catalyzed None None O
conjugation None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dinitrobenzene None None I-IUPAC
. None None O

The None None O
order None None O
of None None O
the None None O
inhibitory None None O
potency None None O
was None None O
S None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
] None None I-IUPAC
glutathione None None I-IUPAC
= None None O
S None None I-IUPAC
- None None I-IUPAC
benzylglutathione None None I-IUPAC
greater None None O
than None None O
S None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
] None None I-IUPAC
glutathione None None I-IUPAC
greater None None O
than None None O
S None None I-IUPAC
- None None I-IUPAC
methylglutathione None None I-IUPAC
. None None O

This None None O
represented None None O
the None None O
first None None O
demonstration None None O
of None None O
the None None O
stereoselective None None O
product None None O
inhibition None None O
of None None O
the None None O
glutathione None None O
S None None O
- None None O
transferases None None O
. None None O


Due None None O
to None None O
the None None O
antiviral None None O
activity None None O
of None None O
certain None None O
5 None None O
- None None O
substituted None None O
imidazole None None O
nucleosides None None O
related None None O
to None None O
ribavirin None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
methylimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
nucleosides None None I-MODIFIER
having None None O
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
, None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
deoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
alpha None None I-PARTIUPAC
- None None I-PARTIUPAC
D None None I-PARTIUPAC
- None None I-PARTIUPAC
ribofuranosyl None None I-PARTIUPAC
, None None O
and None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
moieties None None I-MODIFIER
have None None O
been None None O
prepared None None O
and None None O
tested None None O
as None None O
antiviral None None O
agents None None O
. None None O

1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
Ribofuranosyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
was None None O
obtained None None O
by None None O
deacetylation None None O
of None None O
the None None O
corresponding None None O
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
nucleoside None None I-IUPAC
11 None None O
or None None O
by None None O
deacetylation None None O
and None None O
ammonolysis None None O
of None None O
the None None O
blocked None None O
ethyl None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
nucleoside None None I-IUPAC
10 None None O
, None None O
which None None O
was None None O
prepared None None O
from None None O
the None None O
stannic None None O
chloride None None O
catalyzed None None O
condensation None None O
of None None O
the None None O
trimethylsilyl None None I-IUPAC
derivative None None B-MODIFIER
of None None O
ethyl None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methylimidazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
. None None O

Glycosylation None None O
of None None O
4 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methylimidazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
with None None O
3,5 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
chloride None None I-IUPAC
via None None O
mercuric None None O
cyanide None None O
method None None O
provided None None O
an None None O
anomeric None None O
mixture None None O
of None None O
the None None O
blocked None None O
5 None None I-IUPAC
- None None I-IUPAC
methylimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
deoxynucleoside None None I-IUPAC
14 None None O
along None None O
with None None O
an None None O
anomeric None None O
mixture None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
isomer None None I-MODIFIER
15 None None O
. None None O

Separation None None O
of None None O
compound None None O
14 None None O
into None None O
the None None O
corresponding None None O
beta None None O
and None None O
alpha None None O
anomers None None O
was None None O
achieved None None O
by None None O
conversion None None O
to None None O
the None None O
3' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
derivatives None None I-MODIFIER
17 None None O
and None None O
18 None None O
, None None O
which None None O
after None None O
chromatographic None None O
separation None None O
were None None O
deacetylated None None O
to None None O
give None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxa None None I-IUPAC
mid None None I-IUPAC
e None None I-IUPAC
and None None O
its None None O
alpha None None O
anomer None None O
20 None None O
. None None O

1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
Hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
was None None O
prepared None None O
by None None O
alkylation None None O
of None None O
the None None O
imidazole None None O
13 None None O
with None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acetoxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
bromide None None I-IUPAC
followed None None O
by None None O
treatment None None O
with None None O
methanolic None None O
ammonia None None O
. None None O

All None None O
these None None O
imidazole None None O
nucleosides None None O
were None None O
tested None None O
in None None O
HeLa None None O
cell None None O
cultures None None O
against None None O
type None None O
1 None None O
herpes None None O
simplex None None O
and None None O
vesicular None None O
stomatitis None None O
viruses None None O
. None None O

The None None O
ribofuranosyl None None I-IUPAC
derivative None None B-MODIFIER
12 None None O
showed None None O
a None None O
significant None None O
activity None None O
against None None O
type None None O
1 None None O
herpes None None O
simplex None None O
virus None None O
. None None O


A None None O
series None None O
of None None O
thymidylate None None O
synthetase None None O
inhibitors None None O
was None None O
synthesized None None O
, None None O
some None None O
of None None O
which None None O
were None None O
potential None None O
irreversible None None O
inhibitors None None O
. None None O

5 None None I-IUPAC
- None None I-IUPAC
Formyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
9 None None O
) None None O
and None None O
its None None O
dithiolane None None I-IUPAC
derivative None None B-MODIFIER
11 None None O
were None None O
prepared None None O
by None None O
condensation None None O
of None None O
the None None O
bis None None I-IUPAC
( None None I-IUPAC
trimethylsilyl None None I-IUPAC
) None None I-IUPAC
derivative None None I-MODIFIER
of None None O
5 None None I-IUPAC
- None None I-IUPAC
formyluracil None None I-IUPAC
dimethyl None None I-IUPAC
acetal None None I-IUPAC
and None None O
the None None O
protected None None O
chloro None None O
sugar None None O
followed None None O
by None None O
saponification None None O
of None None O
the None None O
protective None None O
groups None None O
. None None O

5 None None I-IUPAC
- None None I-IUPAC
Acetyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
15 None None O
) None None O
was None None O
prepared None None O
in None None O
the None None O
same None None O
way None None O
from None None O
5 None None I-IUPAC
- None None I-IUPAC
acetyluracil None None I-IUPAC
. None None O

Treatment None None O
of None None O
the None None O
diester None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
17 None None O
or None None O
22 None None O
) None None O
with None None O
m None None I-IUPAC
- None None I-IUPAC
chloroperbenzoic None None I-IUPAC
acid None None I-IUPAC
gave None None O
the None None O
corresponding None None O
epoxide None None O
. None None O

Dimethylamine None None O
removed None None O
the None None O
ester None None O
groups None None O
and None None O
opened None None O
the None None O
epoxide None None O
to None None O
give None None O
the None None O
amino None None O
alcohol None None O
24 None None O
. None None O

The None None O
diester None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
chloromethyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
27 None None O
) None None O
treated None None O
with None None O
methanol None None I-IUPAC
or None None O
sodium None None O
azide None None O
gave None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxymethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
29 None None O
) None None O
and None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
azidomethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
31 None None O
) None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridines None None I-IUPAC
. None None O

Compound None None O
27 None None O
also None None O
was None None O
converted None None O
to None None O
5 None None I-IUPAC
- None None I-IUPAC
iodoacetamidomethyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
by None None O
treatment None None O
with None None O
ammonia None None O
, None None O
chloroacetyl None None O
chloride None None O
, None None O
base None None O
saponification None None O
, None None O
and None None O
finally None None O
sodium None None O
iodide None None O
. None None O


Reaction None None O
of None None O
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydrofolic None None I-IUPAC
acid None None I-IUPAC
( None None O
THF None None O
, None None O
7 None None O
) None None O
with None None O
phosgene None None O
, None None O
thiophosgene None None O
, None None O
and None None O
cyanogen None None O
bromide None None O
gave None None O
the None None O
bridged None None O
derivatives None None O
, None None O
5,10 None None O
- None None O
( None None O
CO None None O
) None None O
- None None O
THF None None O
( None None O
8 None None O
) None None O
, None None O
5,10 None None O
- None None O
( None None O
CS None None O
) None None O
- None None O
THF None None O
( None None O
9 None None O
) None None O
, None None O
and None None O
5,10 None None O
- None None O
( None None O
C None None O
= None None O
NH None None O
) None None O
- None None O
THF None None O
( None None O
11 None None O
) None None O
, None None O
respectively None None O
. None None O

Catalytic None None O
hydrogenation None None O
of None None O
10 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloroacetyl None None I-IUPAC
) None None I-IUPAC
folic None None I-IUPAC
acid None None I-IUPAC
( None None O
2 None None O
) None None O
gave None None O
5,10 None None O
- None None O
( None None O
CH2CO None None O
) None None O
- None None O
THF None None O
( None None O
12 None None O
) None None O
. None None O

A None None O
similar None None O
reaction None None O
with None None O
10 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chloropropionyl None None I-IUPAC
) None None I-IUPAC
folic None None I-IUPAC
acid None None I-IUPAC
( None None O
3 None None O
) None None O
gave None None O
10 None None O
- None None O
( None None O
ClCH2CH2CO None None O
) None None O
- None None O
THF None None O
( None None O
14 None None O
) None None O
rather None None O
than None None O
5,10 None None O
- None None O
( None None O
CH2CH2CO None None O
) None None O
- None None O
THF None None O
( None None O
13 None None O
) None None O
. None None O

In None None O
the None None O
catalytic None None O
hydrogenation None None O
of None None O
10 None None I-IUPAC
- None None I-IUPAC
ethoxalylfolic None None I-IUPAC
acid None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
the None None O
initial None None O
product None None O
10 None None O
- None None O
( None None O
EtO2CCO None None O
) None None O
- None None O
THF None None O
( None None O
22 None None O
) None None O
rearranged None None O
readily None None O
to None None O
give None None O
5 None None O
- None None O
( None None O
EtO2CCO None None O
) None None O
- None None O
THF None None O
( None None O
21 None None O
) None None O
. None None O

Acylation None None O
of None None O
THF None None O
with None None O
chloroacetyl None None O
chloride None None O
gave None None O
a None None O
N5 None None O
, None None O
N10 None None O
- None None O
diacylated None None O
product None None O
( None None O
18 None None O
or None None O
19 None None O
) None None O
, None None O
which None None O
could None None O
not None None O
be None None O
converted None None O
to None None O
5,10 None None O
- None None O
COCH2 None None O
) None None O
- None None O
THF None None O
( None None O
17 None None O
) None None O
. None None O

Reductive None None O
alkylation None None O
of None None O
THF None None O
with None None O
glyoxylic None None O
acid None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
hydroxypentanal None None I-IUPAC
, None None O
respectively None None O
, None None O
gave None None O
5 None None O
- None None O
( None None O
HO2CCH2 None None O
) None None O
- None None O
THF None None O
( None None O
24 None None O
) None None O
and None None O
5 None None O
- None None O
[ None None O
HO None None O
( None None O
CH2 None None O
) None None O
5 None None O
] None None O
- None None O
THF None None O
( None None O
25 None None O
) None None O
. None None O

Reductive None None O
dialkylation None None O
of None None O
THF None None O
with None None O
formaldehyde None None O
gave None None O
5,10 None None O
- None None O
( None None O
CH3 None None O
) None None O
2 None None O
- None None O
THF None None O
( None None O
27 None None O
) None None O
, None None O
whereas None None O
glyoxal None None O
gave None None O
5,10 None None O
- None None O
CH2CH2 None None O
) None None O
- None None O
THF None None O
( None None O
10 None None O
) None None O
. None None O

Also None None O
, None None O
both None None O
folic None None O
acid None None O
and None None O
5 None None O
- None None O
( None None O
CHO None None O
) None None O
- None None O
THF None None O
were None None O
reductively None None O
alkylated None None O
with None None O
formaldehyde None None O
to None None O
give None None O
10 None None I-IUPAC
- None None I-IUPAC
methylfolic None None I-IUPAC
acid None None I-IUPAC
( None None O
6 None None O
) None None O
and None None O
5 None None O
- None None O
( None None O
CHO None None O
) None None O
- None None O
10 None None O
- None None O
( None None O
CH3 None None O
) None None O
- None None O
THF None None O
( None None O
28 None None O
) None None O
, None None O
respectively None None O
. None None O

These None None O
compounds None None O
were None None O
tested None None O
as None None O
inhibitors None None O
of None None O
the None None O
enzymes None None O
involved None None O
in None None O
folate None None O
metabolism None None O
and None None O
for None None O
activity None None O
against None None O
lymphocytic None None O
leukemia None None O
P388 None None O
in None None O
mice None None O
. None None O


A None None O
broad None None O
screening None None O
of None None O
phytochemicals None None O
has None None O
demonstrated None None O
that None None O
certain None None O
flavone None None O
and None None O
flavonol None None O
derivatives None None O
have None None O
a None None O
relatively None None O
high None None O
affinity None None O
at None None O
A3 None None O
adenosine None None O
receptors None None O
, None None O
with None None O
Ki None None O
values None None O
of None None O
& None None O
gt None None O
; None None O
or None None O
= None None O
1 None None O
microM None None O
( None None O
Ji None None O
et None None O
al. None None O
J None None O
. None None O

Med. None None O
Chem. None None O
1996 None None O
, None None O
39 None None O
, None None O
781-788 None None O
) None None O
. None None O

We None None O
have None None O
further None None O
modified None None O
the None None O
flavone None None O
structure None None O
to None None O
achieve None None O
a None None O
degree None None O
of None None O
selectivity None None O
for None None O
cloned None None O
human None None O
brain None None O
A3 None None O
receptors None None O
, None None O
determined None None O
in None None O
competitive None None O
binding None None O
assays None None O
versus None None O
[ None None O
125I None None O
] None None O
AB None None O
- None None O
MECA None None O
[ None None O
N6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
iodobenzyl None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylur None None I-IUPAC
onamide None None I-IUPAC
) None None I-IUPAC
] None None O
. None None O

Affinity None None O
was None None O
determined None None O
in None None O
radioligand None None O
binding None None O
assays None None O
at None None O
rat None None O
brain None None O
A1 None None O
and None None O
A2a None None O
receptors None None O
using None None O
[ None None O
3H None None O
] None None O
- None None O
N6 None None O
- None None O
PIA None None O
( None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N6 None None I-IUPAC
- None None I-IUPAC
phenylisopropyladenosine None None I-IUPAC
) None None O
and None None O
[ None None O
3H None None O
] None None O
CGS21680 None None O
[ None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxyethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
ethylamino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
ethylcarbamoyl+ None None I-IUPAC
+ None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
] None None O
, None None O
respectively None None O
. None None O

The None None O
triethyl None None O
and None None O
tripropyl None None O
ether None None O
derivatives None None O
of None None O
the None None O
flavonol None None O
galangin None None O
, None None O
4 None None O
, None None O
had None None O
Ki None None O
values None None O
of None None O
0.3 None None O
- None None O
0.4 None None O
microM None None O
at None None O
human None None O
A3 None None O
receptors None None O
. None None O

The None None O
presence None None O
of None None O
a None None O
5 None None I-IUPAC
- None None I-IUPAC
hydroxyl None None I-IUPAC
group None None I-MODIFIER
increased None None O
selectivity None None O
of None None O
flavonols None None O
for None None O
human None None O
A3 None None O
receptors None None O
. None None O

The None None O
2' None None I-IUPAC
, None None I-IUPAC
3,4 None None I-IUPAC
' None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
tetraethyl None None I-IUPAC
ether None None I-IUPAC
derivative None None I-MODIFIER
of None None O
the None None O
flavonol None None O
morin None None O
, None None O
7 None None O
, None None O
displayed None None O
a None None O
Ki None None O
value None None O
of None None O
4.8 None None O
microM None None O
at None None O
human None None O
A3 None None O
receptors None None O
and None None O
was None None O
inactive None None O
at None None O
rat None None O
A1 None None O
/ None None O
A2a None None O
receptors None None O
. None None O

3,6 None None I-IUPAC
- None None I-IUPAC
Dichloro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
isopropyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
methylflavone None None I-IUPAC
, None None O
11e None None O
, None None O
was None None O
both None None O
potent None None O
and None None O
highly None None O
selective None None O
( None None O
approximately None None O
200 None None O
- None None O
fold None None O
) None None O
for None None O
human None None O
A3 None None O
receptors None None O
( None None O
Ki None None O
= None None O
0.56 None None O
microM None None O
) None None O
. None None O

Among None None O
dihydroflavonol None None O
analogues None None O
, None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
styryl None None I-IUPAC
instead None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
substituent None None I-MODIFIER
, None None O
in None None O
15 None None O
, None None O
afforded None None O
selectivity None None O
for None None O
human None None O
A3 None None O
vs None None O
rat None None O
A1 None None O
or None None O
A2A None None O
receptors None None O
. None None O

The None None O
2 None None I-IUPAC
- None None I-IUPAC
styryl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
propoxy None None I-IUPAC
derivative None None I-MODIFIER
, None None O
20 None None O
, None None O
of None None O
the None None O
furanochromone None None O
visnagin None None O
was None None O
30 None None O
- None None O
fold None None O
selective None None O
for None None O
human None None O
A3 None None O
receptors None None O
vs None None O
either None None O
rat None None O
A1 None None O
or None None O
A2A None None O
receptors None None O
. None None O

Several None None O
of None None O
the None None O
more None None O
potent None None O
derivatives None None O
effectively None None O
antagonized None None O
the None None O
effects None None O
of None None O
an None None O
agonist None None O
in None None O
a None None O
functional None None O
A3 None None O
receptor None None O
assay None None O
, None None O
i.e. None None O
inhibition None None O
of None None O
adenylyl None None I-IUPAC
cyclase None None I-IUPAC
in None None O
CHO None None O
cells None None O
expressing None None O
cloned None None O
rat None None O
A3 None None O
receptors None None O
. None None O

In None None O
conclusion None None O
, None None O
these None None O
series None None O
of None None O
flavonoids None None O
provide None None O
leads None None O
for None None O
the None None O
development None None O
of None None O
novel None None O
potent None None O
and None None O
subtype None None O
selective None None O
A3 None None O
antagonists None None O
. None None O


A None None O
number None None O
of None None O
novel None None O
dihydropyridine None None O
derivatives None None O
based None None O
upon None None O
1 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
diphenylpiperidin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
aminocarbonyl None None I-IUPAC
) None None I-IUPAC
pyridine None None I-IUPAC
( None None O
4 None None O
) None None O
have None None O
been None None O
synthesized None None O
and None None O
tested None None O
at None None O
cloned None None O
human None None O
alpha None None O
adrenoceptors None None O
as None None O
well None None O
as None None O
the None None O
rat None None O
L None None O
- None None O
type None None O
calcium None None O
channel None None O
. None None O

Within None None O
this None None O
compound None None O
series None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminocarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
diphenylpiperidin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
aminocarbonyl None None I-IUPAC
) None None I-IUPAC
pyridine None None I-IUPAC
( None None O
19 None None O
) None None O
displayed None None O
good None None O
binding None None O
affinity None None O
and None None O
selectivity None None O
for None None O
the None None O
alpha1a None None O
adrenoceptor None None O
( None None O
pKi None None O
= None None O
8.73 None None O
) None None O
and None None O
potently None None O
inhibited None None O
( None None O
pA2 None None O
= None None O
9.23 None None O
) None None O
phenylephrine None None O
- None None O
induced None None O
contraction None None O
of None None O
the None None O
human None None O
prostate None None O
. None None O


The None None O
synthesis None None O
of None None O
several None None O
analogues None None O
of None None O
( None None I-IUPAC
8R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydroimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
diazepin None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
( None None O
pentostatin None None O
, None None O
1a None None O
) None None O
is None None O
described None None O
. None None O

Ring None None O
closure None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
ethanone None None I-IUPAC
dihydrochloride None None I-IUPAC
( None None O
3 None None O
) None None O
with None None O
triethyl None None I-IUPAC
orthoacetate None None I-IUPAC
or None None O
triethyl None None I-IUPAC
orthopropionate None None I-IUPAC
gave None None O
the None None O
C None None I-MODIFIER
- None None I-MODIFIER
5 None None I-MODIFIER
methyl None None I-IUPAC
and None None O
ethyl None None I-IUPAC
ketoaglycons None None I-IUPAC
, None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
diazepin None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
4b None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
dihydroimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
diazepin None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
4c None None O
) None None O
, None None O
respectively None None O
. None None O

Stannic None None O
chloride None None O
catalyzed None None O
condensation None None O
of None None O
the None None O
pertrimethylsilyl None None O
derivatives None None O
of None None O
4b None None O
and None None O
4c None None O
with None None O
a None None O
protected None None O
glycosyl None None O
halide None None O
afforded None None O
anomeric None None O
mixtures None None O
of None None O
ketonucleosides None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
deoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
3,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
di None None I-PARTIUPAC
- None None I-PARTIUPAC
O None None I-PARTIUPAC
- None None I-PARTIUPAC
p None None I-PARTIUPAC
- None None I-PARTIUPAC
toluoyl None None I-PARTIUPAC
- None None I-PARTIUPAC
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
alpha None None I-PARTIUPAC
- None None I-PARTIUPAC
D None None I-PARTIUPAC
- None None I-PARTIUPAC
erythro None None I-PARTIUPAC
- None None I-PARTIUPAC
pentofuranosyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
6,7 None None I-PARTIUPAC
- None None I-PARTIUPAC
dihydro None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
methylimidazo None None I-PARTIUPAC
[ None None I-PARTIUPAC
4,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
d None None I-PARTIUPAC
] None None I-PARTIUPAC
[ None None I-PARTIUPAC
1,3 None None I-PARTIUPAC
] None None I-PARTIUPAC
diazepin None None I-PARTIUPAC
- None None I-PARTIUPAC
8 None None I-PARTIUPAC
( None None I-PARTIUPAC
3H None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
one None None I-PARTIUPAC
( None None O
5b None None O
and None None O
6b None None O
) None None O
and None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
deoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
3,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
di None None I-PARTIUPAC
- None None I-PARTIUPAC
O None None I-PARTIUPAC
- None None I-PARTIUPAC
p None None I-PARTIUPAC
- None None I-PARTIUPAC
toluoyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
alpha None None I-PARTIUPAC
- None None I-PARTIUPAC
D None None I-PARTIUPAC
- None None I-PARTIUPAC
erythro None None I-PARTIUPAC
- None None I-PARTIUPAC
pentofuranosyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
ethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
6,7 None None I-PARTIUPAC
- None None I-PARTIUPAC
dihydroimidazo None None I-PARTIUPAC
[ None None I-PARTIUPAC
4,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
d None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
1,3 None None I-PARTIUPAC
] None None I-PARTIUPAC
diazepin None None I-PARTIUPAC
- None None I-PARTIUPAC
8 None None I-PARTIUPAC
( None None I-PARTIUPAC
3H None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
one None None I-PARTIUPAC
( None None O
5c None None O
and None None O
6c None None O
) None None O
, None None O
respectively None None O
. None None O

Subsequent None None O
separation None None O
of None None O
the None None O
anomers None None O
, None None O
followed None None O
by None None O
deprotection None None O
and None None O
reduction None None O
of None None O
5b None None O
, None None O
6b None None O
, None None O
and None None O
5c None None O
, None None O
afforded None None O
the None None O
respective None None O
8R None None O
and None None O
8S None None O
isomers None None O
. None None O

Stannic None None O
chloride None None O
catalyzed None None O
condensation None None O
of None None O
pertrimethylsilyl None None O
ketoaglycon None None O
4a None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloromethoxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoyloxy None None I-IUPAC
) None None I-IUPAC
ethane None None I-IUPAC
to None None O
give None None O
ketonucleoside None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoyloxy None None I-IUPAC
) None None I-IUPAC
ethoxy None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
diazepin None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
9a None None O
) None None O
was None None O
followed None None O
by None None O
deprotection None None O
to None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
diazepin None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
9b None None O
) None None O
and None None O
then None None O
reduction None None O
to None None O
the None None O
racemic None None O
acyclic None None O
pentostatin None None O
analogue None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
diazepin None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
( None None O
2 None None O
) None None O
. None None O

Ki None None O
values None None O
for None None O
the None None O
in None None O
vitro None None O
adenosine None None O
deaminase None None O
( None None O
EC None None O
3.5.4.4 None None O
; None None O
type None None O
I None None O
; None None O
calf None None O
intestinal None None O
mucosa None None O
) None None O
inhibitory None None O
activities None None O
of None None O
1b None None O
, None None O
1c None None O
, None None O
and None None O
2 None None O
were None None O
determined None None O
to None None O
be None None O
1.6 None None O
X None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
, None None O
1.5 None None O
X None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
, None None O
and None None O
9.8 None None O
X None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
, None None O
respectively None None O
. None None O

When None None O
compounds None None O
2 None None O
and None None O
9b None None O
were None None O
tested None None O
in None None O
combination None None O
with None None O
vidarabine None None O
against None None O
herpes None None O
simplex None None O
virus None None O
, None None O
type None None O
1 None None O
, None None O
in None None O
an None None O
HEp None None O
- None None O
2 None None O
plaque None None O
reduction None None O
assay None None O
, None None O
only None None O
compound None None O
2 None None O
was None None O
able None None O
to None None O
potentiate None None O
the None None O
antiviral None None O
activity None None O
of None None O
vidarabine None None O
. None None O


A None None O
series None None O
of None None O
2 None None I-MODIFIER
- None None I-MODIFIER
( None None I-MODIFIER
4 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
homo None None I-IUPAC
) None None I-IUPAC
piperazinyl None None I-IUPAC
) None None I-IUPAC
benzimidazoles None None I-IUPAC
was None None O
prepared None None O
and None None O
tested None None O
for None None O
H1 None None O
- None None O
antihistaminic None None O
activity None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

Most None None O
of None None O
the None None O
compounds None None O
showed None None O
antihistaminic None None O
activity None None O
and None None O
some None None O
of None None O
the None None O
1 None None I-MODIFIER
- None None I-MODIFIER
[ None None I-MODIFIER
2 None None I-MODIFIER
- None None I-MODIFIER
( None None I-MODIFIER
substituted None None I-MODIFIER
- None None I-MODIFIER
oxy None None I-MODIFIER
) None None I-MODIFIER
ethyl None None I-MODIFIER
] None None I-MODIFIER
derivatives None None B-MODIFIER
exhibited None None O
potent None None O
activity None None O
. None None O

In None None O
a None None O
structure None None O
- None None O
activity None None O
comparison None None O
it None None O
was None None O
found None None O
that None None O
the None None O
oxygen None None O
atom None None O
in None None O
the None None O
2 None None I-MODIFIER
- None None I-MODIFIER
( None None I-MODIFIER
substituted None None I-MODIFIER
- None None I-MODIFIER
oxy None None I-MODIFIER
) None None I-MODIFIER
ethyl None None I-MODIFIER
group None None B-MODIFIER
at None None O
the None None O
1 None None O
- None None O
position None None O
of None None O
the None None O
benzimidazole None None O
nucleus None None O
played None None O
an None None O
important None None O
role None None O
for None None O
potent None None O
antihistaminic None None O
activity None None O
, None None O
especially None None O
in None None O
vivo None None O
. None None O

One None None O
of None None O
the None None O
most None None O
potent None None O
compounds None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ethoxyethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
homopiperazinyl None None I-IUPAC
) None None I-IUPAC
benzimidazole None None I-IUPAC
( None None O
69 None None O
) None None O
, None None O
was None None O
39 None None O
times None None O
more None None O
potent None None O
than None None O
chlorpheniramine None None O
maleate None None O
in None None O
H1 None None O
- None None O
antihistaminic None None O
activity None None O
in None None O
vivo None None O
and None None O
was None None O
selected None None O
for None None O
clinical None None O
evaluation None None O
. None None O

The None None O
structure None None O
of None None O
compound None None O
69 None None O
is None None O
of None None O
interest None None O
because None None O
it None None O
provides None None O
only None None O
a None None O
single None None O
aromatic None None O
unit None None O
linked None None O
through None None O
a None None O
chain None None O
to None None O
a None None O
basic None None O
nitrogen None None O
, None None O
while None None O
most None None O
H1 None None O
- None None O
antihistaminic None None O
agents None None O
have None None O
structures None None O
that None None O
comprise None None O
a None None O
double None None O
- None None O
aromatic None None O
unit None None O
linked None None O
through None None O
a None None O
chain None None O
to None None O
a None None O
basic None None O
tertiary None None O
amino None None O
group None None O
. None None O


( None None O
E None None O
) None None O
- None None O
4 None None O
- None None O
[ None None O
4 None None O
- None None O
( None None O
Methylthio None None O
) None None O
phenyl None None O
] None None O
- None None O
1 None None O
- None None O
( None None O
2 None None O
- None None O
piperidinyl None None O
) None None O
- None None O
3 None None O
- None None O
buten None None O
- None None O
2 None None O
- None None O
one None None O
hydrochloride None None O
( None None O
44 None None O
, None None O
RMI None None O
14 None None O
133A None None O
) None None O
was None None O
found None None O
to None None O
inhibit None None O
ADP None None O
- None None O
induced None None O
aggregation None None O
of None None O
blood None None O
platelets None None O
. None None O

It None None O
was None None O
selected None None O
from None None O
a None None O
large None None O
series None None O
of None None O
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
piperidinyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
ethanones None None I-IUPAC
synthesized None None O
by None None O
a None None O
modified None None O
Schopf None None O
reaction None None O
from None None O
enolate None None O
magnesium None None O
salts None None O
of None None O
beta None None O
- None None O
keto None None O
acids None None O
and None None O
2,3,4,5 None None I-IUPAC
- None None I-IUPAC
tetrahydropyridine None None I-IUPAC
trimer None None I-MODIFIER
or None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
pyrrole None None I-IUPAC
trimer None None I-MODIFIER
, None None O
respectively None None O
. None None O

Evaluation None None O
of None None O
the None None O
compounds None None O
was None None O
carried None None O
out None None O
in None None O
vitro None None O
on None None O
human None None O
blood None None O
platelets None None O
. None None O

Structure None None O
- None None O
activity None None O
relationships None None O
are None None O
discussed None None O
. None None O

44 None None O
also None None O
inhibited None None O
platelet None None O
aggregation None None O
ex None None O
vivo None None O
in None None O
guinea None None O
pigs None None O
. None None O

Subacute None None O
toxicity None None O
evaluation None None O
in None None O
dogs None None O
and None None O
guinea None None O
pigs None None O
showed None None O
it None None O
to None None O
have None None O
an None None O
unfavorable None None O
therapeutic None None O
ratio None None O
. None None O

1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
Chloro None None I-IUPAC
( None None I-IUPAC
1,1 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
biphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
a1 None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
piperdinyl None None I-IUPAC
) None None I-IUPAC
ethanone None None I-IUPAC
hydrochloride None None I-IUPAC
( None None O
18 None None O
, None None O
RMI None None O
12436A None None O
) None None O
was None None O
found None None O
to None None O
lower None None O
serum None None O
cholesterol None None O
levles None None O
in None None O
rats None None O
with None None O
concurrent None None O
accumulation None None O
of None None O
( None None I-IUPAC
3beta None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cholesta None None I-IUPAC
- None None I-IUPAC
5,7 None None I-IUPAC
- None None I-IUPAC
dien None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
, None None O
suggesting None None O
inhibition None None O
of None None O
7 None None I-IUPAC
- None None I-IUPAC
dehydrocholesterol None None I-IUPAC
delta7 None None O
- None None O
reductase None None O
. None None O


A None None O
new None None O
class None None O
of None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
halo None None I-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkoxy None None I-PARTIUPAC
( None None O
or None None O
azido None None I-PARTIUPAC
) None None O
- None None I-PARTIUPAC
5,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
dihydro None None I-PARTIUPAC
- None None I-PARTIUPAC
3' None None I-PARTIUPAC
- None None I-PARTIUPAC
azido None None I-PARTIUPAC
- None None I-PARTIUPAC
3' None None I-PARTIUPAC
- None None I-PARTIUPAC
deoxythymidines None None I-PARTIUPAC
was None None O
investigated None None O
as None None O
potential None None O
anti None None O
- None None O
AIDS None None O
drugs None None O
. None None O

These None None O
5,6 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
which None None O
are None None O
also None None O
potential None None O
prodrugs None None O
to None None O
3' None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
deoxythymidine None None I-IUPAC
( None None O
AZT None None O
) None None O
, None None O
were None None O
designed None None O
in None None O
an None None O
effort None None O
to None None O
enhance None None O
the None None O
duration None None O
of None None O
action None None O
, None None O
lipophilicity None None O
, None None O
and None None O
cephalic None None O
delivery None None O
to None None O
the None None O
central None None O
nervous None None O
system None None O
. None None O

The None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
halo None None I-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkoxy None None I-PARTIUPAC
( None None O
or None None O
azido None None I-PARTIUPAC
) None None O
- None None I-PARTIUPAC
5,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
dihydro None None I-PARTIUPAC
- None None I-PARTIUPAC
3' None None I-PARTIUPAC
- None None I-PARTIUPAC
azido None None I-PARTIUPAC
- None None I-PARTIUPAC
3' None None I-PARTIUPAC
- None None I-PARTIUPAC
deoxythymidines None None I-PARTIUPAC
, None None O
which None None O
differ None None O
in None None O
configuration None None O
at None None O
the None None O
C None None O
- None None O
5 None None O
and None None O
C None None O
- None None O
6 None None O
positions None None O
, None None O
were None None O
synthesized None None O
by None None O
the None None O
regiospecific None None O
addition None None O
of None None O
XR None None O
( None None O
X None None O
= None None O
Br None None O
, None None O
Cl None None O
, None None O
I None None O
; None None O
R None None O
= None None O
alkoxy None None O
, None None O
azido None None O
) None None O
to None None O
the None None O
5,6 None None O
- None None O
olefinic None None O
bond None None O
of None None O
AZT None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
halo None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
5,6 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
AZT None None O
are None None O
more None None O
lipophilic None None O
( None None O
P None None O
= None None O
3.3-18.8 None None O
range None None O
) None None O
than None None O
the None None O
parent None None O
compound None None O
AZT None None O
( None None O
P None None O
= None None O
1.29 None None O
) None None O
. None None O

These None None O
5 None None I-IUPAC
- None None I-IUPAC
halo None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
5,6 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
compounds None None I-MODIFIER
, None None O
like None None O
AZT None None O
, None None O
did None None O
not None None O
undergo None None O
glycosidic None None O
bond None None O
cleavage None None O
upon None None O
incubation None None O
with None None O
Escherichia None None O
coli None None O
thymidine None None O
phosphorylase None None O
. None None O

Regeneration None None O
of None None O
the None None O
5,6 None None O
- None None O
olefinic None None O
bond None None O
to None None O
give None None O
AZT None None O
, None None O
upon None None O
incubation None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
halo None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
5,6 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
compounds None None I-MODIFIER
with None None O
glutathione None None O
, None None O
mouse None None O
blood None None O
, None None O
or None None O
mouse None None O
liver None None O
homogenate None None O
, None None O
was None None O
dependent None None O
upon None None O
the None None O
nature None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
halo None None I-IUPAC
substituent None None I-MODIFIER
( None None O
I None None O
& None None O
gt None None O
; None None O
Br None None O
) None None O
. None None O

No None None O
5,6 None None O
- None None O
olefinic None None O
bond None None O
regeneration None None O
was None None O
observed None None O
for None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
analogs None None I-MODIFIER
. None None O

The None None O
ability None None O
of None None O
these None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
halo None None I-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkoxy None None I-PARTIUPAC
( None None O
or None None O
azido None None I-PARTIUPAC
) None None O
- None None I-PARTIUPAC
5,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
dihydro None None I-PARTIUPAC
- None None I-PARTIUPAC
3' None None I-PARTIUPAC
- None None I-PARTIUPAC
azido None None I-PARTIUPAC
- None None I-PARTIUPAC
3' None None I-PARTIUPAC
- None None I-PARTIUPAC
deoxythymidines None None I-PARTIUPAC
to None None O
protect None None O
CEM None None O
cells None None O
against None None O
HIV None None O
- None None O
induced None None O
cytopathogenicity None None O
was None None O
evaluated None None O
. None None O

Structure None None O
- None None O
activity None None O
studies None None O
showed None None O
that None None O
the None None O
C None None O
- None None O
5 None None O
substituent None None O
( None None O
I None None O
, None None O
Br None None O
, None None O
Cl None None O
) None None O
was None None O
a None None O
determinant None None O
of None None O
anti None None O
- None None O
HIV None None O
- None None O
1 None None O
activity None None O
where None None O
the None None O
potency None None O
order None None O
was None None O
I None None O
& None None O
gt None None O
; None None O
or None None O
= None None O
Br None None O
& None None O
gt None None O
; None None O
Cl None None O
. None None O

In None None O
the None None O
5 None None O
- None None O
bromo None None O
series None None O
of None None O
compounds None None O
, None None O
the None None O
C None None O
- None None O
6 None None O
substituent None None O
was None None O
also None None O
a None None O
determinant None None O
of None None O
activity None None O
where None None O
6 None None O
- None None O
OMe None None O
and None None O
6 None None O
- None None O
OEt None None O
substituents None None O
exhibited None None O
a None None O
greater None None O
potency None None O
than None None O
the None None O
corresponding None None O
6 None None O
- None None O
i None None O
- None None O
PrO None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
octyloxy None None I-IUPAC
) None None I-IUPAC
, None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hexadecyloxy None None I-IUPAC
) None None I-IUPAC
, None None O
and None None O
6 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
analogs None None I-MODIFIER
. None None O

All None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None O
substituted None None I-MODIFIER
- None None O
5,6 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
compounds None None I-MODIFIER
were None None O
inactive None None O
, None None O
except None None O
for None None O
the None None O
approximately None None O
equipotent None None O
6 None None O
- None None O
OMe None None O
and None None O
6 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
diastereomeric None None I-IUPAC
mixtures None None I-MODIFIER
which None None O
were None None O
2-3 None None O
log None None O
units None None O
less None None O
active None None O
than None None O
the None None O
reference None None O
drug None None O
AZT None None O
. None None O

The None None O
configuration None None O
at None None O
the None None O
C None None O
- None None O
5 None None O
and None None O
C None None O
- None None O
6 None None O
positions None None O
also None None O
influenced None None O
potency None None O
where None None O
the None None O
activity None None O
of None None O
the None None O
5R None None O
, None None O
6R None None O
- None None O
diastereomer None None O
was None None O
generally None None O
greater None None O
than None None O
that None None O
of None None O
the None None O
corresponding None None O
5S None None O
, None None O
6S None None O
- None None O
diastereomer None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

The None None O
synthesis None None O
of None None O
certain None None O
heteroarotinoids None None O
has None None O
been None None O
achieved None None O
, None None O
namely None None O
the None None O
systems None None O
( None None I-IUPAC
2E None None I-IUPAC
, None None I-IUPAC
4E None None I-IUPAC
, None None I-IUPAC
6E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
thiochromanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4,6 None None I-IUPAC
- None None I-IUPAC
heptatrienoic None None I-IUPAC
acid None None I-IUPAC
( None None O
1a None None O
) None None O
, None None O
ethyl None None I-IUPAC
( None None I-IUPAC
2E None None I-IUPAC
, None None I-IUPAC
4E None None I-IUPAC
, None None I-IUPAC
6E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
teterahydro None None I-IUPAC
- None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
thiochromanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4,6 None None I-IUPAC
- None None I-IUPAC
heptatrienoate None None I-IUPAC
( None None O
1b None None O
) None None O
, None None O
( None None I-IUPAC
2E None None I-IUPAC
, None None I-IUPAC
4E None None I-IUPAC
, None None I-IUPAC
6E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chromanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4,6 None None I-IUPAC
- None None I-IUPAC
heptatrienoic None None I-IUPAC
acid None None I-IUPAC
( None None O
1c None None O
) None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
phthalimidoethyl None None I-IUPAC
3,7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
thiochromanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4,6 None None I-IUPAC
- None None I-IUPAC
heptatrienoate None None I-IUPAC
( None None O
1d None None O
) None None O
, None None O
methyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chromanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
2a None None O
) None None O
, None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chromanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzyl None None I-IUPAC
alcohol None None I-IUPAC
( None None O
2b None None O
) None None O
, None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chromanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzonitrile None None I-IUPAC
( None None O
2c None None O
) None None O
, None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chromanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzaldehyde None None I-IUPAC
( None None O
2d None None O
) None None O
, None None O
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
benzofuranyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
3a None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
benzofuranyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
3b None None O
) None None O
. None None O

Characterization None None O
via None None O
elemental None None O
, None None O
IR None None O
, None None O
1H None None O
NMR None None O
, None None O
and None None O
13C None None O
NMR None None O
analyses None None O
was None None O
completed None None O
for None None O
these None None O
heterocycles None None O
. None None O

The None None O
biological None None O
activity None None O
of None None O
these None None O
heteroarotinoids None None O
was None None O
assayed None None O
by None None O
either None None O
the None None O
suppression None None O
of None None O
the None None O
12 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
tetradecanoylphorbol None None I-IUPAC
13 None None I-IUPAC
- None None I-IUPAC
acetate None None I-IUPAC
( None None O
TPA None None O
) None None O
induced None None O
synthesis None None O
of None None O
ornithine None None O
decarboxylase None None O
( None None O
ODC None None O
) None None O
in None None O
mouse None None O
skin None None O
or None None O
the None None O
induction None None O
of None None O
differentiation None None O
of None None O
human None None O
( None None O
HL None None O
- None None O
60 None None O
) None None O
promyelocytic None None O
cells None None O
. None None O

In None None O
the None None O
ODC None None O
assay None None O
, None None O
systems None None O
1a None None O
- None None O
c None None O
exhibited None None O
strong None None O
activity None None O
( None None O
within None None O
10% None None O
of None None O
or None None O
less None None O
than None None O
the None None O
control None None O
) None None O
whereas None None O
alcohols None None O
2b None None O
and None None O
3a None None O
showed None None O
good None None O
activity None None O
( None None O
within None None O
50% None None O
of None None O
the None None O
control None None O
) None None O
as None None O
compared None None O
to None None O
either None None O
13 None None I-IUPAC
- None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
retinoic None None I-IUPAC
acid None None I-IUPAC
or None None O
trans None None I-IUPAC
- None None I-IUPAC
retinoic None None I-IUPAC
acid None None I-IUPAC
. None None O

Moderate None None O
activity None None O
was None None O
observed None None O
with None None O
2a None None O
and None None O
2b None None O
while None None O
1d None None O
and None None O
2c None None O
were None None O
essentially None None O
inactive None None O
. None None O

With None None O
the None None O
HL None None O
- None None O
60 None None O
assay None None O
, None None O
1a None None O
and None None O
1c None None O
were None None O
approximately None None O
2 None None O
- None None O
and None None O
5 None None O
- None None O
fold None None O
less None None O
active None None O
, None None O
respectively None None O
, None None O
than None None O
trans None None O
- None None O
retinoic None None O
acid None None O
. None None O

In None None O
contrast None None O
, None None O
2a None None O
, None None O
3a None None O
, None None O
and None None O
3b None None O
induced None None O
differentiation None None O
of None None O
only None None O
a None None O
very None None O
small None None O
percentage None None O
of None None O
the None None O
cells None None O
. None None O

Acids None None O
1a None None O
and None None O
1c None None O
were None None O
the None None O
most None None O
active None None O
heteroarotinoids None None O
in None None O
the None None O
two None None O
biological None None O
assays None None O
. None None O

Consequently None None O
, None None O
the None None O
presence None None O
of None None O
the None None O
heteroatom None None O
does None None O
not None None O
eradicate None None O
the None None O
activity None None O
of None None O
the None None O
heteroarotinoids None None O
and None None O
thus None None O
they None None O
may None None O
have None None O
potential None None O
as None None O
chemotherapeutic None None O
agents None None O
. None None O


A None None O
number None None O
of None None O
nucleoside None None O
analogues None None O
have None None O
been None None O
either None None O
used None None O
clinically None None O
as None None O
anticancer None None O
drugs None None O
or None None O
evaluated None None O
in None None O
clinical None None O
studies None None O
, None None O
while None None O
new None None O
nucleoside None None O
analogues None None O
continue None None O
to None None O
show None None O
promise None None O
. None None O

In None None O
this None None O
article None None O
, None None O
we None None O
report None None O
synthesis None None O
and None None O
cytotoxicity None None O
of None None O
a None None O
series None None O
of None None O
new None None O
pyrido None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
nucleosides None None I-MODIFIER
. None None O

2 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxypyridine None None I-IUPAC
was None None O
converted None None O
, None None O
in None None O
two None None O
steps None None O
, None None O
to None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
oxopyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
. None None O

A None None O
variety None None O
of None None O
1 None None O
- None None O
O None None O
- None None O
acetylated None None O
pentose None None O
sugar None None O
derivatives None None O
were None None O
condensed None None O
with None None O
silylated None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
oxopyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
, None None O
followed None None O
by None None O
protection None None O
, None None O
to None None O
afford None None O
a None None O
series None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
oxopyrido None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
nucleosides None None I-MODIFIER
. None None O

Further None None O
derivatizations None None O
provided None None O
an None None O
additional None None O
group None None O
of None None O
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
nucleosides None None I-MODIFIER
. None None O

These None None O
nucleosides None None O
were None None O
evaluated None None O
for None None O
in None None O
vitro None None O
cytotoxicity None None O
to None None O
human None None O
prostate None None O
cancer None None O
( None None O
HTB None None O
- None None O
81 None None O
) None None O
and None None O
mouse None None O
melanoma None None O
( None None O
B16 None None O
) None None O
cells None None O
as None None O
well None None O
as None None O
normal None None O
human None None O
fibroblasts None None O
( None None O
NHF None None O
) None None O
. None None O

A None None O
number None None O
of None None O
compounds None None O
( None None O
1a None None O
, None None O
b None None O
, None None O
2a None None O
- None None O
c None None O
, None None O
f None None O
, None None O
3f None None O
+ None None O
4d None None O
) None None O
showed None None O
significant None None O
cytotoxicity None None O
to None None O
cancer None None O
cells None None O
, None None O
with None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
1b None None O
) None None O
being None None O
the None None O
most None None O
potent None None O
proliferation None None O
inhibitor None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
: None None O
0.06-0.08 None None O
microM None None O
) None None O
to None None O
all None None O
types None None O
of None None O
cells None None O
tested None None O
. None None O

However None None O
, None None O
a None None O
selective None None O
inhibition None None O
to None None O
the None None O
cancer None None O
cells None None O
was None None O
observed None None O
for None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
xylofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
2b None None O
) None None O
, None None O
which None None O
is None None O
a None None O
potent None None O
inhibitor None None O
of None None O
HTB None None O
- None None O
81 None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
: None None O
0.73 None None O
microM None None O
) None None O
and None None O
has None None O
a None None O
favorable None None O
in None None O
vitro None None O
selectivity None None O
index None None O
( None None O
28 None None O
) None None O
. None None O


Two None None O
series None None O
of None None O
compounds None None O
that None None O
are None None O
structurally None None O
related None None O
to None None O
benzomorphans None None O
, None None O
derived None None O
by None None O
structural None None O
modification None None O
of None None O
arylpiperazines None None O
with None None O
high None None O
5 None None O
- None None O
HT1A None None O
affinity None None O
and None None O
moderate None None O
sigma None None O
affinity None None O
, None None O
were None None O
prepared None None O
in None None O
order None None O
to None None O
increase None None O
sigma None None O
affinity None None O
and None None O
selectivity None None O
. None None O

All None None O
new None None O
compounds None None O
are None None O
N None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
omega None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
1,2,3,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
tetrahydronaphthalen None None I-PARTIUPAC
- None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
yl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
- None None I-PARTIUPAC
omega None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
1,2 None None I-PARTIUPAC
- None None I-PARTIUPAC
dihydronaphthalen None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
yl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
n None None I-PARTIUPAC
- None None I-PARTIUPAC
alkylamines None None I-PARTIUPAC
with None None O
, None None O
in None None O
some None None O
cases None None O
, None None O
a None None O
methoxy None None I-IUPAC
group None None B-MODIFIER
on None None O
the None None O
tetralin None None O
moiety None None O
. None None O

They None None O
were None None O
tested None None O
in None None O
radioligand None None O
binding None None O
assays None None O
on None None O
sigma None None O
( None None O
[ None None O
3H None None O
] None None O
DTG None None O
and None None O
[ None None O
3H None None O
] None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
pentazocine None None O
) None None O
, None None O
D None None O
- None None O
2 None None O
dopaminergic None None O
, None None O
5 None None O
- None None O
HT1A None None O
and None None O
5 None None O
- None None O
HT2 None None O
serotonergic None None O
, None None O
and None None O
PCP None None O
( None None O
phencyclidine None None O
) None None O
receptors None None O
. None None O

A None None O
first None None O
set None None O
of None None O
compounds None None O
bearing None None O
a None None O
4 None None I-MODIFIER
- None None I-MODIFIER
( None None I-MODIFIER
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
) None None I-MODIFIER
piperazine None None O
moiety None None I-MODIFIER
as None None O
terminal None None O
fragment None None O
on None None O
the None None O
alkyl None None I-IUPAC
chain None None B-MODIFIER
showed None None O
moderate None None O
to None None O
high None None O
sigma None None O
affinity None None O
( None None O
Ki None None O
= None None O
5.3-139 None None O
nM None None O
) None None O
, None None O
the None None O
most None None O
active None None O
and None None O
selective None None O
being None None O
1 None None I-IUPAC
- None None I-IUPAC
cyclohexyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydronaphthalen None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
piperazine None None I-IUPAC
( None None O
14 None None O
) None None O
, None None O
with None None O
probable None None O
pronounced None None O
sigma None None O
2 None None O
affinity None None O
( None None O
Ki None None O
= None None O
5.3 None None O
nM None None O
on None None O
[ None None O
3H None None O
] None None O
DTG None None O
and None None O
Ki None None O
= None None O
71 None None O
nM None None O
on None None O
[ None None O
3H None None O
] None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
pentazocine None None O
) None None O
. None None O

Moreover None None O
, None None O
compound None None O
13 None None O
, None None O
a None None O
1 None None I-IUPAC
- None None I-IUPAC
benzylpiperazine None None I-IUPAC
analogue None None I-MODIFIER
of None None O
14 None None O
, None None O
preserved None None O
a None None O
dual None None O
high None None O
5 None None O
- None None O
HT1A None None O
and None None O
sigma None None O
affinity None None O
( None None O
Ki None None O
= None None O
3.6 None None O
nM None None O
on None None O
[ None None O
3H None None O
] None None O
- None None O
5 None None O
- None None O
HT None None O
and None None O
Ki None None O
= None None O
7.0 None None O
nM None None O
on None None O
[ None None O
3H None None O
] None None O
DTG None None O
) None None O
. None None O

The None None O
second None None O
set None None O
of None None O
compounds None None O
includes None None O
some None None O
N None None I-IUPAC
- None None I-IUPAC
phenylalkyl None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydronaphthalen None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylamine None None I-IUPAC
that None None O
can None None O
be None None O
considered None None O
to None None O
be None None O
open None None O
- None None O
chain None None O
derivatives None None O
of None None O
4 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
1 None None I-IUPAC
- None None I-IUPAC
arylpiperazines None None I-IUPAC
. None None O

Among None None O
these None None O
compounds None None O
that None None O
had None None O
a None None O
lower None None O
activity None None O
toward None None O
sigma None None O
binding None None O
sites None None O
, None None O
a None None O
high None None O
5 None None O
- None None O
HT1A None None O
affinity None None O
was None None O
found None None O
for None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylpropyl None None I-IUPAC
) None None I-IUPAC
derivative None None I-MODIFIER
21 None None O
( None None O
Ki None None O
= None None O
4.4 None None O
nM None None O
) None None O
which None None O
demonstrated None None O
very None None O
good None None O
selectivity None None O
. None None O


A None None O
series None None O
of None None O
complexes None None O
of None None O
the None None O
general None None O
formula None None O
trans None None O
- None None O
[ None None O
PtCl2 None None O
( None None O
Am None None O
) None None O
( None None O
pip None None O
- None None O
pip None None O
) None None O
] None None O
x None None O
HCl None None O
where None None O
pip None None O
- None None O
pip None None O
is None None O
4 None None I-IUPAC
- None None I-IUPAC
piperidinopiperidine None None I-IUPAC
and None None O
Am None None O
is None None O
NH3 None None O
, None None O
methylamine None None O
( None None O
MA None None O
) None None O
, None None O
dimethylamine None None I-IUPAC
( None None O
DMA None None O
) None None O
, None None O
n None None I-IUPAC
- None None I-IUPAC
propylamine None None I-IUPAC
( None None O
NPA None None O
) None None O
, None None O
isopropylamine None None O
( None None O
IPA None None O
) None None O
, None None O
n None None I-IUPAC
- None None I-IUPAC
butylamine None None I-IUPAC
( None None O
NBA None None O
) None None O
, None None O
or None None O
cyclohexylamine None None I-IUPAC
( None None O
CHA None None O
) None None O
were None None O
prepared None None O
and None None O
characterized None None O
, None None O
and None None O
their None None O
cytotoxic None None O
properties None None O
against None None O
ovarian None None O
and None None O
colon None None O
cancer None None O
cells None None O
were None None O
evaluated None None O
. None None O

The None None O
trans None None O
- None None O
[ None None O
PtCl2 None None O
( None None O
NH3 None None O
) None None O
( None None O
pip None None O
- None None O
pip None None O
) None None O
] None None O
x None None O
HCl None None O
was None None O
significantly None None O
more None None O
potent None None O
than None None O
cisplatin None None O
in None None O
all None None O
the None None O
cisplatin None None O
- None None O
resistant None None O
ovarian None None O
cancer None None O
cell None None O
lines None None O
and None None O
was None None O
nearly None None O
as None None O
cytotoxic None None O
as None None O
cisplatin None None O
against None None O
colon None None O
cancer None None O
cells None None O
. None None O

In None None O
vivo None None O
studies None None O
in None None O
mice None None O
showed None None O
that None None O
the None None O
pip None None O
- None None O
pip None None O
complexes None None O
are None None O
significantly None None O
less None None O
toxic None None O
than None None O
cisplatin None None O
. None None O

Cisplatin None None O
was None None O
more None None O
efficacious None None O
than None None O
both None None O
trans None None O
- None None O
[ None None O
PtCl2 None None O
( None None O
NH3 None None O
) None None O
( None None O
pip None None O
- None None O
pip None None O
) None None O
] None None O
x None None O
HCl None None O
and None None O
trans None None O
- None None O
[ None None O
PtCl2 None None O
( None None O
NBA None None O
) None None O
( None None O
pip None None O
- None None O
pip None None O
) None None O
] None None O
x None None O
HCl None None O
in None None O
the None None O
A2780 None None O
and None None O
A2780cisR None None O
tumor None None O
xenograft None None O
models None None O
, None None O
consistent None None O
with None None O
its None None O
lower None None O
IC50 None None O
values None None O
in None None O
A2780 None None O
cells None None O
but None None O
contrary None None O
to None None O
the None None O
higher None None O
IC50 None None O
values None None O
in None None O
A2780cisR None None O
cells None None O
. None None O

In None None O
the None None O
colon None None O
cancer None None O
cell None None O
studies None None O
, None None O
trans None None O
- None None O
[ None None O
PtCl2 None None O
( None None O
NH3 None None O
) None None O
( None None O
pip None None O
- None None O
pip None None O
) None None O
] None None O
x None None O
HCl None None O
was None None O
slightly None None O
less None None O
potent None None O
than None None O
cisplatin None None O
in None None O
the None None O
in None None O
vitro None None O
studies None None O
but None None O
had None None O
efficacy None None O
comparable None None O
to None None O
that None None O
of None None O
cisplatin None None O
in None None O
the None None O
in None None O
vivo None None O
xenograft None None O
model None None O
. None None O


Palladium None None O
( None None O
0 None None O
) None None O
- None None O
mediated None None O
Suzuki None None O
- None None O
Miyaura None None O
and None None O
Heck None None O
transformations None None O
have None None O
been None None O
exploited None None O
to None None O
provide None None O
examples None None O
of None None O
8 None None I-IUPAC
- None None I-IUPAC
methylquino None None I-IUPAC
[ None None I-IUPAC
4,3,2 None None I-IUPAC
- None None I-IUPAC
kl None None I-IUPAC
] None None I-IUPAC
acridines None None I-IUPAC
and None None O
8,13 None None I-IUPAC
- None None I-IUPAC
dimethylquino None None I-IUPAC
[ None None I-IUPAC
4,3,2 None None I-IUPAC
- None None I-IUPAC
kl None None I-IUPAC
] None None I-IUPAC
acridinium None None I-IUPAC
iodides None None I-IUPAC
bearing None None O
bulky None None O
saturated None None O
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
acetoxy None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
or None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
morpholin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxopropenyl None None I-IUPAC
substituents None None I-MODIFIER
variously None None O
in None None O
the None None O
3 None None O
- None None O
, None None O
6 None None O
- None None O
, None None O
or None None O
10 None None O
- None None O
positions None None O
of None None O
the None None O
pentacyclic None None O
nucleus None None O
. None None O

The None None O
pharmacological None None O
/ None None O
pharmaceutical None None O
properties None None O
of None None O
four None None O
compounds None None O
( None None O
4 None None O
, None None O
RHPS4 None None O
) None None O
, None None O
( None None O
5 None None O
, None None O
IH383 None None O
) None None O
, None None O
( None None O
6 None None O
, None None O
RHPS16 None None O
) None None O
, None None O
and None None O
( None None O
17 None None O
, None None O
RHPS19 None None O
) None None O
were None None O
measured None None O
to None None O
assess None None O
their None None O
clinical None None O
potential None None O
as None None O
DNA None None O
G None None O
- None None O
quadruplex None None O
- None None O
stabilizing None None O
/ None None O
telomerase None None O
inhibitory None None O
agents None None O
. None None O

The None None O
following None None O
properties None None O
were None None O
measured None None O
: None None O
stability None None O
in None None O
tissue None None O
culture None None O
media None None O
in None None O
the None None O
presence None None O
of None None O
A549 None None O
lung None None O
and None None O
MCF None None O
- None None O
7 None None O
breast None None O
tumor None None O
cells None None O
, None None O
metabolic None None O
stability None None O
when None None O
incubated None None O
with None None O
rat None None O
liver None None O
microsomes None None O
, None None O
and None None O
rate None None O
of None None O
uptake None None O
and None None O
subcellular None None O
location None None O
in None None O
A549 None None O
and None None O
MCF None None O
- None None O
7 None None O
cells None None O
. None None O

Compound None None O
17 None None O
was None None O
unstable None None O
in None None O
tissue None None O
culture None None O
media None None O
, None None O
failed None None O
to None None O
achieve None None O
nuclear None None O
access None None O
, None None O
and None None O
was None None O
excluded None None O
from None None O
further None None O
consideration None None O
. None None O

Of None None O
the None None O
other None None O
agents None None O
, None None O
4 None None O
exhibited None None O
the None None O
most None None O
favorable None None O
pharmaceutical None None O
profile None None O
: None None O
the None None O
agent None None O
has None None O
appropriate None None O
stability None None O
in None None O
the None None O
presence None None O
of None None O
tumor None None O
cells None None O
and None None O
rat None None O
liver None None O
microsomes None None O
and None None O
achieves None None O
rapid None None O
ingress None None O
into None None O
cell None None O
nuclei None None O
where None None O
the None None O
putative None None O
molecular None None O
target None None O
is None None O
located None None O
. None None O


N None None O
- None None O
( None None O
2 None None O
- None None O
Naphthyl None None O
) None None O
glycine None None O
hydrazide None None O
analogues None None I-MODIFIER
were None None O
synthesized None None O
and None None O
tested None None O
for None None O
possible None None O
in None None O
vitro None None O
antitubercular None None O
activity None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
Naphthyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
hydrazide None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
) None None I-IUPAC
glycine None None I-IUPAC
hydrazide None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
) None None I-IUPAC
glycine None None I-IUPAC
hydrazide None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthylamino None None I-IUPAC
) None None I-IUPAC
butyric None None I-IUPAC
acid None None I-IUPAC
hydrazide None None I-IUPAC
( None None O
23 None None O
) None None O
showed None None O
potent None None O
inhibitory None None O
action None None O
against None None O
Mycobacterium None None O
tuberculosis None None O
H37Rv None None O
in None None O
Youman None None O
's None None O
medium None None O
at None None O
concentrations None None O
ranging None None O
from None None O
0.5 None None O
to None None O
10.0 None None O
micrograms None None O
/ None None O
mL None None O
. None None O

These None None O
compounds None None O
showed None None O
significant None None O
inhibitory None None O
action None None O
against None None O
isonicotinic None None O
acid None None O
hydrazide None None O
and None None O
streptomycin None None O
- None None O
resistant None None O
strains None None O
of None None O
M None None O
. None None O

tuberculosis None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
Quinolyl None None I-IUPAC
) None None I-IUPAC
glycine None None I-IUPAC
hydrazide None None I-IUPAC
( None None O
18 None None O
) None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
quinolylamino None None I-IUPAC
) None None I-IUPAC
butyric None None I-IUPAC
acid None None I-IUPAC
hydrazide None None I-IUPAC
( None None O
24 None None O
) None None O
, None None O
which None None O
are None None O
bioisosteres None None O
of None None O
compounds None None O
1 None None O
and None None O
23 None None O
, None None O
showed None None O
loss None None O
of None None O
antitubercular None None O
activity None None O
at None None O
low None None O
concentrations None None O
. None None O


The None None O
pyrimidine None None O
acyclonucleoside None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
uracil None None I-IUPAC
( None None O
3 None None O
) None None O
was None None O
synthesized None None O
as None None O
part None None O
of None None O
a None None O
program None None O
aimed None None O
at None None O
the None None O
development None None O
of None None O
new None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorouracil None None I-IUPAC
derivatives None None I-MODIFIER
with None None O
fewer None None O
side None None O
effects None None O
and None None O
a None None O
broader None None O
margin None None O
of None None O
safety None None O
. None None O

Condensation None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
trimethylsilyl None None I-IUPAC
) None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
with None None O
2 None None I-IUPAC
- None None I-IUPAC
acetoxyethyl None None I-IUPAC
acetoxymethyl None None I-IUPAC
ether None None I-IUPAC
( None None O
6 None None O
) None None O
in None None O
the None None O
presence None None O
of None None O
SnCl4 None None O
afforded None None O
the None None O
acetate None None O
ester None None O
7 None None O
, None None O
which None None O
on None None O
deprotection None None O
with None None O
NaOMe None None O
gave None None O
3 None None O
in None None O
50-60% None None O
overall None None O
yield None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
analogues None None I-MODIFIER
10 None None O
and None None O
11 None None O
, None None O
respectively None None O
, None None O
were None None O
obtained None None O
similarly None None O
. None None O

Reaction None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
trimethylsilyl None None I-IUPAC
) None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
with None None O
2 None None I-IUPAC
- None None I-IUPAC
acetoxyethyl None None I-IUPAC
acetoxymethyl None None I-IUPAC
ether None None I-IUPAC
and None None O
SnCl4 None None O
, None None O
followed None None O
by None None O
ammonolysis None None O
, None None O
yielded None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
cytosine None None I-IUPAC
( None None O
12 None None O
) None None O
. None None O

Deamination None None O
of None None O
12 None None O
with None None O
nitrous None None O
acid None None O
produced None None O
3 None None O
, None None O
thereby None None O
confirming None None O
that None None O
alkylation None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
trimethylsilyl None None I-IUPAC
) None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
had None None O
occurred None None O
at None None O
N1 None None O
. None None O

The None None O
ID50 None None O
of None None O
3 None None O
against None None O
L1210 None None O
mouse None None O
leukemia None None O
cells None None O
in None None O
culture None None O
was None None O
1.7 None None O
x None None O
10 None None O
( None None O
- None None O
5 None None O
) None None O
M None None O
, None None O
as None None O
compared None None O
with None None O
1 None None O
x None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
M None None O
for None None O
FU None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
analogue None None I-MODIFIER
12 None None O
was None None O
inactive None None O
at None None O
up None None O
to None None O
1 None None O
x None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
, None None O
and None None O
the None None O
other None None O
halogenated None None O
derivatives None None O
10 None None O
and None None O
11 None None O
had None None O
no None None O
effect None None O
even None None O
at None None O
1 None None O
x None None O
10 None None O
( None None O
- None None O
3 None None O
) None None O
M None None O
. None None O

When None None O
3 None None O
was None None O
given None None O
ip None None O
in None None O
water None None O
to None None O
P388 None None O
leukemic None None O
mice None None O
at None None O
400 None None O
mg None None O
/ None None O
kg None None O
( None None O
b None None O
. None None O

i None None O
. None None O

d None None O
. None None O

x None None O
4 None None O
) None None O
or None None O
240 None None O
mg None None O
/ None None O
kg None None O
( None None O
q None None O
. None None O

d None None O
. None None O

1-9 None None O
) None None O
, None None O
a None None O
75% None None O
increase None None O
in None None O
survival None None O
was None None O
observed None None O
relative None None O
to None None O
untreated None None O
controls None None O
, None None O
and None None O
there None None O
was None None O
no None None O
evidence None None O
of None None O
any None None O
host None None O
toxicity None None O
. None None O


A None None O
series None None O
of None None O
21 None None O
1,3 None None I-IUPAC
- None None I-IUPAC
dialkylpyrazolo None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
substituted None None O
in None None O
the None None O
5 None None O
- None None O
position None None O
with None None O
various None None O
phenyl None None I-IUPAC
substituents None None B-MODIFIER
has None None O
been None None O
synthesized None None O
and None None O
found None None O
to None None O
have None None O
affinity None None O
for None None O
the None None O
adenosine None None O
A1 None None O
receptor None None O
. None None O

The None None O
potency None None O
pattern None None O
due None None O
to None None O
substituents None None O
of None None O
the None None O
phenyl None None I-IUPAC
ring None None B-MODIFIER
was None None O
found None None O
to None None O
parallel None None O
that None None O
found None None O
in None None O
a None None O
previously None None O
reported None None O
1,3 None None I-IUPAC
- None None I-IUPAC
dialkyl None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
phenylxanthine None None I-IUPAC
series None None I-MODIFIER
. None None O

A None None O
quantitative None None O
structure None None O
- None None O
activity None None O
relationship None None O
was None None O
developed None None O
between None None O
these None None O
two None None O
series None None O
that None None O
correctly None None O
predicted None None O
the None None O
potencies None None O
of None None O
six None None O
additional None None O
5 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
pyrazolo None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
that None None O
were None None O
synthesized None None O
during None None O
the None None O
course None None O
of None None O
the None None O
analysis None None O
. None None O

With None None O
use None None O
of None None O
the None None O
correlation None None O
as None None O
a None None O
guide None None O
, None None O
one None None O
additional None None O
5 None None I-IUPAC
- None None I-IUPAC
phenylpyrazolo None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
containing None None O
a None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
sulfonyl None None I-IUPAC
substituent None None I-MODIFIER
to None None O
improve None None O
aqueous None None O
solubility None None O
was None None O
prepared None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
the None None O
high None None O
correlation None None O
between None None O
adenosine None None O
binding None None O
affinities None None O
of None None O
analogously None None O
substituted None None O
xanthines None None O
and None None O
pyrazolo None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
and None None O
the None None O
close None None O
superposition None None O
of None None O
the None None O
heterocyclic None None O
rings None None O
and None None O
substituents None None O
that None None O
is None None O
apparent None None O
from None None O
molecular None None O
models None None O
of None None O
these None None O
two None None O
series None None O
, None None O
it None None O
is None None O
hypothesized None None O
they None None O
fit None None O
the None None O
receptor None None O
in None None O
an None None O
analogous None None O
fashion None None O
. None None O


The None None O
previously None None O
reported None None O
diphenyl None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
prolylpyrrolidine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
phosphonate None None I-IUPAC
( None None O
5 None None O
) None None O
was None None O
used None None O
as None None O
a None None O
lead None None O
compound None None O
for None None O
the None None O
development None None O
of None None O
potent None None O
and None None O
irreversible None None O
inhibitors None None O
of None None O
dipeptidyl None None I-IUPAC
peptidase None None I-IUPAC
IV None None I-IUPAC
( None None O
DPP None None O
IV None None O
, None None O
EC None None O
3.4.14.5 None None O
) None None O
. None None O

The None None O
synthesis None None O
of None None O
a None None O
series None None O
of None None O
diaryl None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
prolylpyrrolidine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
phosphonates None None I-IUPAC
with None None O
different None None O
substituents None None O
on None None O
the None None O
aryl None None O
rings None None O
( None None O
hydroxyl None None I-IUPAC
, None None O
methoxy None None I-IUPAC
, None None O
acylamino None None I-IUPAC
, None None O
sulfonylamino None None I-IUPAC
, None None O
ureyl None None I-IUPAC
, None None O
methoxycarbonyl None None I-IUPAC
, None None O
and None None O
alkylaminocarbonyl None None I-IUPAC
) None None O
started None None O
from None None O
the None None O
corresponding None None O
phosphites None None O
. None None O

A None None O
good None None O
correlation None None O
was None None O
found None None O
between None None O
the None None O
electronic None None O
properties None None O
of None None O
the None None O
substituent None None O
and None None O
the None None O
inhibitory None None O
activity None None O
and None None O
stability None None O
. None None O

The None None O
most None None O
striking None None O
divergence None None O
of None None O
this None None O
correlation None None O
was None None O
the None None O
high None None O
potency None None O
combined None None O
with None None O
a None None O
high None None O
stability None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
acetylamino None None I-IUPAC
- None None O
substituted None None I-MODIFIER
derivative None None I-MODIFIER
11e None None O
. None None O

This None None O
compound None None O
shows None None O
low None None O
cytotoxicity None None O
in None None O
human None None O
peripheral None None O
blood None None O
mononuclear None None O
cells None None O
and None None O
also None None O
has None None O
favorable None None O
properties None None O
in None None O
vivo None None O
. None None O

Therefore None None O
bis None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
acetamidophenyl None None I-IUPAC
) None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
prolylpyrrolidine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
phosphonate None None I-IUPAC
( None None O
11e None None O
) None None O
is None None O
considered None None O
as None None O
a None None O
major None None O
improvement None None O
and None None O
will None None O
be None None O
a None None O
highly None None O
valuable None None O
DPP None None O
IV None None O
inhibitor None None O
for None None O
further None None O
studies None None O
on None None O
the None None O
biological None None O
function None None O
of None None O
the None None O
enzyme None None O
and None None O
the None None O
therapeutic None None O
value None None O
of None None O
its None None O
inhibition None None O
. None None O


A None None O
number None None O
of None None O
nitrogen None None O
analogues None None O
of None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
guanine None None I-IUPAC
[ None None O
acylovir None None O
, None None O
Zovirax None None O
] None None O
containing None None O
amine None None O
functions None None O
in None None O
the None None O
side None None O
chain None None O
were None None O
synthesized None None O
and None None O
tested None None O
for None None O
antiviral None None O
activity None None O
. None None O

These None None O
purine None None O
acyclic None None O
nucleosides None None O
were None None O
prepared None None O
by None None O
reaction None None O
of None None O
tris None None I-PARTIUPAC
( None None I-PARTIUPAC
trimethylsilyl None None I-PARTIUPAC
) None None I-PARTIUPAC
guanine None None I-PARTIUPAC
or None None O
2,6 None None I-IUPAC
- None None I-IUPAC
diaminopurine None None I-IUPAC
sodium None None I-IUPAC
salt None None I-IUPAC
with None None O
the None None O
chloromethyl None None O
ethers None None O
prepared None None O
from None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
) None None I-IUPAC
phthalimide None None I-IUPAC
, None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
phthalimide None None I-IUPAC
, None None O
or None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
) None None I-IUPAC
oxazolidin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
to None None O
give None None O
the None None O
N None None O
- None None O
blocked None None O
intermediates None None O
5-8 None None O
. None None O

Deprotection None None O
with None None O
hydrazine None None O
or None None O
by None None O
alkaline None None O
hydrolysis None None O
gave None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
guanine None None I-IUPAC
( None None O
9 None None O
) None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
diaminopurine None None I-IUPAC
( None None O
10 None None O
) None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoethoxy None None I-IUPAC
] None None I-IUPAC
ethoxymethyl None None I-IUPAC
] None None I-IUPAC
guanine None None I-IUPAC
( None None O
11 None None O
) None None O
, None None O
and None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
ethoxy None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
guanine None None I-IUPAC
( None None O
12 None None O
) None None O
. None None O

When None None O
tested None None O
against None None O
herpes None None O
simplex None None O
virus None None O
type None None O
1 None None O
, None None O
only None None O
9 None None O
was None None O
active None None O
with None None O
an None None O
IC50 None None O
= None None O
8 None None O
microM None None O
. None None O

Little None None O
or None None O
no None None O
activity None None O
was None None O
observed None None O
against None None O
a None None O
range None None O
of None None O
other None None O
DNA None None O
and None None O
RNA None None O
viruses None None O
. None None O


Seven None None O
1,2 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
dihydroacronycine None None I-IUPAC
and None None O
1,2 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
demethoxyacronycine None None I-IUPAC
esters None None I-IUPAC
and None None O
diesters None None O
were None None O
synthesized None None O
via None None O
osmic None None O
oxidation None None O
of None None O
acronycine None None O
or None None O
6 None None I-IUPAC
- None None I-IUPAC
demethoxyacronycine None None I-IUPAC
followed None None O
by None None O
acylation None None O
. None None O

The None None O
6 None None I-IUPAC
- None None I-IUPAC
demethoxyacronycine None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
found None None O
to None None O
be None None O
inactive None None O
, None None O
whereas None None O
in None None O
contrast None None O
, None None O
all None None O
of None None O
the None None O
acronycine None None O
derivatives None None O
were None None O
more None None O
potent None None O
than None None O
acronycine None None O
itself None None O
when None None O
tested None None O
against None None O
L1210 None None O
cells None None O
in None None O
vitro None None O
. None None O

Four None None O
selected None None O
acronycine None None O
derivatives None None O
( None None O
17,19 None None O
, None None O
21 None None O
, None None O
and None None O
22 None None O
) None None O
were None None O
evaluated None None O
in None None O
vivo None None O
against None None O
murine None None O
P388 None None O
leukemia None None O
and None None O
colon None None O
38 None None O
adenocarcinoma None None O
implanted None None O
in None None O
mice None None O
. None None O

All None None O
compounds None None O
were None None O
markedly None None O
active None None O
against None None O
P388 None None O
at None None O
doses None None O
4-16 None None O
- None None O
fold None None O
lower None None O
than None None O
acronycine None None O
itself None None O
. None None O

Against None None O
the None None O
colon None None O
38 None None O
adenocarcinoma None None O
, None None O
the None None O
three None None O
compounds None None O
17 None None O
, None None O
21 None None O
, None None O
and None None O
22 None None O
were None None O
highly None None O
efficient None None O
. None None O

1,2 None None I-IUPAC
- None None I-IUPAC
Diacetoxy None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
dihydroacronycine None None I-IUPAC
( None None O
17 None None O
) None None O
was None None O
the None None O
most None None O
active None None O
, None None O
all None None O
the None None O
treated None None O
mice None None O
being None None O
tumor None None O
- None None O
free None None O
on None None O
day None None O
23 None None O
. None None O


3,4 None None O
- None None O
Dihydro None None O
- None None O
2 None None O
( None None O
1H None None O
) None None O
- None None O
quinolones None None O
, None None O
evolved None None O
from None None O
2 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
, None None I-IUPAC
- None None I-IUPAC
tetrahydroquinolines None None I-IUPAC
and None None O
3 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
quinolones None None I-IUPAC
, None None O
have None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
in None None O
vitro None None O
for None None O
antagonist None None O
activity None None O
at None None O
the None None O
glycine None None O
site None None O
on None None O
the None None O
NMDA None None O
receptor None None O
and None None O
for None None O
AMPA None None O
[ None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolepropionic None None I-IUPAC
acid None None I-IUPAC
] None None O
antagonist None None O
activity None None O
. None None O

Generally None None O
poor None None O
potency None None O
at None None O
the None None O
glycine None None O
site None None O
is None None O
observed None None O
when None None O
a None None O
variety None None O
of None None O
electron None None O
- None None O
withdrawing None None O
substituents None None O
are None None O
attached None None O
to None None O
the None None O
3 None None O
- None None O
position None None O
of None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
quinolones None None I-IUPAC
. None None O

The None None O
analogues None None O
5-9 None None O
( None None O
IC50 None None O
values None None O
& None None O
gt None None O
; None None O
100 None None O
microM None None O
, None None O
Table None None O
I None None O
) None None O
exist None None O
largely None None O
in None None O
the None None O
3,4 None None O
- None None O
dipseudoaxial None None O
conformation None None O
( None None O
as None None O
evidenced None None O
by None None O
1H None None O
NMR None None O
spectra None None O
) None None O
, None None O
whereas None None O
the None None O
3 None None O
- None None O
cyano None None O
derivative None None O
( None None O
10 None None O
, None None O
IC50 None None O
= None None O
12.0 None None O
microM None None O
) None None O
has None None O
a None None O
relatively None None O
high None None O
population None None O
of None None O
the None None O
3 None None O
- None None O
pseudoequatorial None None O
conformer None None O
. None None O

The None None O
3 None None O
- None None O
nitro None None O
analogue None None O
( None None O
4 None None O
, None None O
IC50 None None O
= None None O
1.32 None None O
microM None None O
) None None O
has None None O
a None None O
pKa None None O
approximately None None O
5 None None O
and None None O
thus None None O
exists None None O
at None None O
physiological None None O
pH None None O
as None None O
an None None O
anion None None O
with None None O
the None None O
nitro None None O
group None None O
planar None None O
to None None O
the None None O
quinolone None None O
ring None None O
. None None O

The None None O
general None None O
requirement None None O
of None None O
acidity None None O
for None None O
high None None O
affinity None None O
binding None None O
at None None O
the None None O
glycine None None O
/ None None O
NMDA None None O
site None None O
is None None O
supported None None O
with None None O
the None None O
good None None O
activity None None O
of None None O
the None None O
other None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
nitro None None I-PARTIUPAC
derivatives None None I-MODIFIER
( None None O
13-21 None None O
) None None O
, None None O
all None None O
of None None O
which None None O
are None None O
deprotonated None None O
at None None O
physiological None None O
pH None None O
. None None O

The None None O
3 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
quinolones None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroquinolines None None I-IUPAC
show None None O
quite None None O
different None None O
structure None None O
- None None O
activity None None O
relationships None None O
at None None O
the None None O
4 None None O
- None None O
position None None O
. None None O

The None None O
unselective None None O
excitatory None None O
amino None None O
acid None None O
activity None None O
of None None O
21 None None O
is None None O
comparable None None O
with None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
quinoxaline None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
and None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dichloroquinoxalic None None I-IUPAC
acid None None I-IUPAC
and None None O
this None None O
suggests None None O
similarities None None O
in None None O
their None None O
modes None None O
of None None O
binding None None O
to None None O
excitatory None None O
amino None None O
acid None None O
receptors None None O
. None None O

The None None O
broad None None O
spectrum None None O
excitatory None None O
amino None None O
acid None None O
antagonist None None O
activity None None O
of None None O
the None None O
4 None None O
- None None O
unsubstituted None None O
analogue None None O
21 None None O
( None None O
KbNMDA None None O
= None None O
6.7 None None O
microM None None O
, None None O
KbAMPA None None O
= None None O
9.2 None None O
microM None None O
) None None O
and None None O
the None None O
glycine None None O
/ None None O
NMDA None None O
selectivity None None O
of None None O
the None None O
other None None O
3 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
derivatives None None I-MODIFIER
allows None None O
the None None O
proposal None None O
of None None O
a None None O
model None None O
for None None O
AMPA None None O
receptor None None O
binding None None O
which None None O
differs None None O
from None None O
the None None O
glycine None None O
binding None None O
pharmacophore None None O
in None None O
that None None O
there None None O
is None None O
bulk None None O
intolerance None None O
adjacent None None O
to None None O
the None None O
4 None None O
- None None O
position None None O
. None None O

Compound None None O
21 None None O
( None None O
L None None O
- None None O
698,544 None None O
) None None O
is None None O
active None None O
( None None O
ED50 None None O
= None None O
13.2 None None O
mg None None O
/ None None O
kg None None O
) None None O
in None None O
the None None O
DBA None None O
/ None None O
2 None None O
mouse None None O
anticonvulsant None None O
model None None O
and None None O
is None None O
the None None O
most None None O
potent None None O
combined None None O
glycine None None O
/ None None O
NMDA None None O
- None None O
AMPA None None O
antagonist None None O
yet None None O
reported None None O
, None None O
in None None O
vivo None None O
, None None O
and None None O
may None None O
prove None None O
to None None O
be None None O
a None None O
useful None None O
pharmacological None None O
tool None None O
. None None O


Antagonists None None O
at None None O
the None None O
1A None None O
/ None None O
2B None None O
subtype None None O
of None None O
the None None O
NMDA None None O
receptor None None O
( None None O
NR1A None None O
/ None None O
2B None None O
) None None O
are None None O
typically None None O
small None None O
molecules None None O
that None None O
consist None None O
of None None O
a None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
benzyl None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
a None None O
4 None None I-IUPAC
- None None I-IUPAC
phenylpiperidine None None I-IUPAC
with None None O
an None None O
omega None None I-IUPAC
- None None I-IUPAC
phenylalkyl None None I-IUPAC
substituent None None I-MODIFIER
on None None O
the None None O
heterocyclic None None O
nitrogen None None O
. None None O

Many None None O
of None None O
these None None O
antagonists None None O
, None None O
for None None O
example None None O
ifenprodil None None O
( None None O
1 None None O
) None None O
, None None O
incorporate None None O
a None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
substituent None None I-MODIFIER
on None None O
the None None O
omega None None O
- None None O
phenyl None None O
group None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
position None None O
of None None O
this None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
substituent None None I-MODIFIER
was None None O
transferred None None O
from None None O
the None None O
omega None None O
- None None O
phenyl None None O
group None None O
to None None O
the None None O
benzyl None None O
or None None O
phenyl None None O
group None None O
located None None O
on None None O
the None None O
4 None None O
- None None O
position None None O
of None None O
the None None O
piperidine None None O
ring None None O
. None None O

Analogues None None O
incorporating None None O
pyrrolidine None None O
in None None O
lieu None None O
of None None O
piperidine None None O
were None None O
also None None O
prepared None None O
. None None O

Electrical None None O
recordings None None O
using None None O
cloned None None O
receptors None None O
expressed None None O
in None None O
Xenopus None None O
oocytes None None O
show None None O
that None None O
high None None O
- None None O
potency None None O
antagonists None None O
at None None O
the None None O
NR1A None None O
/ None None O
2B None None O
subtype None None O
are None None O
obtained None None O
employing None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
omega None None I-IUPAC
- None None I-IUPAC
phenylalkyl None None I-IUPAC
) None None I-IUPAC
- None None O
substituted None None I-MODIFIER
4 None None B-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
piperidine None None I-IUPAC
, None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxybenzyl None None I-IUPAC
) None None I-IUPAC
piperidine None None I-IUPAC
, None None O
and None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
pyrrolidine None None I-IUPAC
as None None O
exemplified None None O
by None None O
21 None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.022 None None O
microM None None O
) None None O
, None None O
33 None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.059 None None O
microM None None O
) None None O
, None None O
and None None O
40 None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.017 None None O
microM None None O
) None None O
, None None O
respectively None None O
. None None O

These None None O
high None None O
- None None O
potency None None O
antagonists None None O
are None None O
& None None O
gt None None O
; None None O
1000 None None O
times None None O
more None None O
potent None None O
at None None O
the None None O
NR1A None None O
/ None None O
2B None None O
subtype None None O
than None None O
at None None O
either None None O
the None None O
NR1A None None O
/ None None O
2A None None O
or None None O
NR1A None None O
/ None None O
2C None None O
subtypes None None O
. None None O

The None None O
binding None None O
affinities None None O
of None None O
21 None None O
at None None O
alpha None None O
( None None O
1 None None O
) None None O
- None None O
adrenergic None None O
receptors None None O
( None None O
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
) None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
prazosin None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.54 None None O
microM None None O
) None None O
and None None O
dopamine None None O
D2 None None O
receptors None None O
( None None O
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
) None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
raclopride None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.2 None None O
microM None None O
) None None O
are None None O
reduced None None O
by None None O
incorporating None None O
a None None O
hydroxy None None O
group None None O
onto None None O
the None None O
4 None None O
- None None O
position None None O
of None None O
the None None O
piperidine None None O
ring None None O
and None None O
the None None O
beta None None O
- None None O
carbon None None O
of None None O
the None None O
N None None O
- None None O
alkyl None None O
spacer None None O
to None None O
give None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
27 None None O
: None None O
IC None None O
( None None O
50 None None O
) None None O
NR1A None None O
/ None None O
2B None None O
, None None O
0.026 None None O
; None None O
alpha None None O
( None None O
1 None None O
) None None O
, None None O
14 None None O
; None None O
D2 None None O
, None None O
105 None None O
microM None None O
. None None O

The None None O
high None None O
- None None O
potency None None O
phenolic None None O
antagonist None None O
21 None None O
and None None O
its None None O
low None None O
- None None O
potency None None O
O None None O
- None None O
methylated None None O
analogue None None O
18 None None O
are None None O
both None None O
potent None None O
anticonvulsants None None O
in None None O
a None None O
mouse None None O
maximal None None O
electroshock None None O
- None None O
induced None None O
seizure None None O
( None None O
MES None None O
) None None O
study None None O
( None None O
ED None None O
( None None O
50 None None O
) None None O
( None None O
iv None None O
) None None O
= None None O
0.23 None None O
and None None O
0.56 None None O
mg None None O
/ None None O
kg None None O
, None None O
respectively None None O
) None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
such None None O
compounds None None O
penetrate None None O
the None None O
blood None None O
- None None O
brain None None O
barrier None None O
but None None O
their None None O
MES None None O
activity None None O
may None None O
not None None O
be None None O
related None None O
to None None O
NMDA None None O
receptor None None O
antagonism None None O
. None None O


8 None None O
- None None O
Carbamoyl None None O
- None None O
3 None None O
- None None O
methylimidazo None None O
[ None None O
5,1 None None O
- None None O
d None None O
] None None O
- None None O
1,2,3,5 None None O
- None None O
tetrazin None None O
- None None O
4 None None O
( None None O
3H None None O
) None None O
- None None O
one None None O
( None None O
temozolomide None None O
, None None O
1 None None O
) None None O
is None None O
an None None O
anticancer None None O
prodrug None None O
. None None O

As None None O
part None None O
of None None O
investigations None None O
to None None O
probe None None O
its None None O
postulated None None O
mode None None O
of None None O
action None None O
using None None O
PET None None O
we None None O
have None None O
developed None None O
two None None O
rapid None None O
radiosynthetic None None O
routes None None O
for None None O
the None None O
preparation None None O
of None None O
temozolomide None None O
labeled None None O
with None None O
the None None O
short None None O
- None None O
lived None None O
positron None None O
emitter None None O
, None None O
carbon None None O
- None None O
11 None None O
( None None O
t None None O
( None None O
1/2 None None O
) None None O
= None None O
20.4 None None O
min None None O
) None None O
. None None O

Reaction None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
diazoimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
7 None None O
) None None O
with None None O
the None None O
novel None None O
labeling None None O
agent None None O
[ None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
isocyanate None None I-IUPAC
( None None O
8 None None O
) None None O
gave None None O
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
temozolomide None None I-IUPAC
( None None O
9 None None O
) None None O
in None None O
14-20% None None O
radiochemical None None O
yield None None O
from None None O
[ None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
isocyanate None None I-IUPAC
( None None O
8 None None O
) None None O
( None None O
decay None None O
corrected None None O
) None None O
. None None O

The None None O
position None None O
of None None O
radiolabeling None None O
in None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
was None None O
confirmed None None O
by None None O
[ None None O
( None None O
11/13 None None O
) None None O
C None None O
] None None O
colabeling None None O
and None None O
subsequent None None O
carbon None None O
- None None O
13 None None O
NMR None None O
spectroscopy None None O
. None None O

Similarly None None O
, None None O
the None None O
reaction None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
diazoimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
7 None None O
) None None O
with None None O
[ None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
isocyanate None None I-IUPAC
( None None O
10 None None O
) None None O
gave None None O
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
temozolomide None None I-IUPAC
( None None O
11 None None O
) None None O
in None None O
10-15% None None O
radiochemical None None O
yield None None O
from None None O
[ None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
isocyanate None None I-IUPAC
( None None O
10 None None O
) None None O
( None None O
decay None None O
corrected None None O
) None None O
. None None O

Apyrogenic None None O
samples None None O
of None None O
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
temozolomide None None I-IUPAC
( None None O
9 None None O
) None None O
and None None O
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
temozolomide None None I-IUPAC
( None None O
11 None None O
) None None O
, None None O
with None None O
good None None O
chemical None None O
and None None O
radiochemical None None O
purities None None O
, None None O
have None None O
been None None O
prepared None None O
and None None O
used None None O
in None None O
human None None O
PET None None O
studies None None O
. None None O


Alkoxymethyl None None O
, None None O
acyloxymethyl None None O
, None None O
and None None O
mixed None None O
alkylalkoxymethyl None None O
or None None O
alkylacyloxymethyl None None O
derivatives None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenylhydantoin None None I-IUPAC
exhibit None None O
anticonvulsant None None O
activity None None O
. None None O

Also None None O
effective None None O
are None None O
bis None None O
( None None O
alkoxymethyl None None O
) None None O
and None None O
mixed None None O
alkylalkoxymethyl None None O
derivatives None None O
of None None O
5,5 None None I-IUPAC
- None None I-IUPAC
diphenylhydantoin None None I-IUPAC
. None None O

Of None None O
particular None None O
interest None None O
are None None O
1,3 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
methoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5,5 None None I-IUPAC
- None None I-IUPAC
diphenylhydantoin None None I-IUPAC
and None None O
3 None None I-IUPAC
- None None I-IUPAC
acetoxymethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenylhydantoin None None I-IUPAC
, None None O
which None None O
show None None O
good None None O
activity None None O
against None None O
maximal None None O
electroshock None None O
seizures None None O
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
methoxymethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenylhydantoin None None I-IUPAC
, None None O
which None None O
is None None O
effective None None O
against None None O
both None None O
maximal None None O
electroshock None None O
and None None O
pentylenetetrazole None None I-IUPAC
. None None O

None None None O
of None None O
the None None O
above None None O
compounds None None O
show None None O
greater None None O
activity None None O
against None None O
maximal None None O
electroshock None None O
seizures None None O
than None None O
the None None O
parent None None O
compounds None None O
, None None O
however None None O
. None None O


By None None O
a None None O
variety None None O
of None None O
synthetic None None O
routes None None O
, None None O
we None None O
have None None O
synthesized None None O
a None None O
series None None O
of None None O
3,4,5 None None I-MODIFIER
- None None I-MODIFIER
trisubstituted None None I-MODIFIER
4H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazoles None None I-IUPAC
and None None O
a None None O
related None None O
series None None O
of None None O
3H None None I-IUPAC
- None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazoles None None I-IUPAC
and None None O
evaluated None None O
them None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
as None None O
angiotensin None None O
II None None O
( None None O
AII None None O
) None None O
antagonists None None O
. None None O

Principal None None O
efforts None None O
focused None None O
on None None O
triazoles None None O
bearing None None O
an None None O
n None None O
- None None O
alkyl None None O
substitutent None None O
at None None O
C3 None None O
and None None O
a None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxybenzoyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
benzyl None None I-IUPAC
, None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
carboxybiphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
, None None O
or None None O
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
side None None I-MODIFIER
chain None None I-MODIFIER
at None None O
N4 None None O
. None None O

Among None None O
numerous None None O
variations None None O
at None None O
C5 None None O
, None None O
benzylthio None None O
groups None None O
gave None None O
the None None O
best None None O
potency None None O
. None None O

Particularly None None O
noteworthy None None O
was None None O
3 None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxybenzyl None None I-IUPAC
) None None I-IUPAC
thio None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazole None None I-IUPAC
( None None O
71 None None O
, None None O
IC50 None None O
1.4 None None O
nM None None O
) None None O
, None None O
which None None O
blocked None None O
the None None O
AII None None O
pressor None None O
response None None O
in None None O
conscious None None O
rats None None O
at None None O
0.3 None None O
mg None None O
/ None None O
kg None None O
iv None None O
with None None O
a None None O
duration None None O
of None None O
action None None O
of None None O
approximately None None O
6 None None O
h None None O
, None None O
similar None None O
to None None O
that None None O
of None None O
DuP None None O
753 None None O
. None None O

Although None None O
71 None None O
was None None O
active None None O
orally None None O
only None None O
at None None O
a None None O
10 None None O
- None None O
fold None None O
higher None None O
dose None None O
level None None O
, None None O
good None None O
oral None None O
bioavailability None None O
was None None O
demonstrated None None O
for None None O
a None None O
monoacidic None None O
analogue None None O
62 None None O
. None None O

Most None None O
potent None None O
among None None O
the None None O
bicyclic None None O
derivatives None None O
was None None O
2 None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
5,6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
meth None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazole None None I-IUPAC
( None None O
93 None None O
, None None O
IC50 None None O
7.8 None None O
nM None None O
) None None O
. None None O

The None None O
effects None None O
of None None O
hydrophobic None None O
, None None O
hydrogen None None O
- None None O
bonding None None O
, None None O
and None None O
ionic None None O
interactions None None O
with None None O
the None None O
AT1 None None O
receptor None None O
are None None O
considered None None O
. None None O


A None None O
still None None O
unknown None None O
tricyclic None None O
heterocyclic None None O
system None None O
( None None O
5 None None O
) None None O
was None None O
synthesized None None O
from None None O
6 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylpyridazin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
and None None O
its None None O
structure None None O
identified None None O
as None None O
2,8 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methylpyrrolo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
: None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d' None None I-IUPAC
] None None I-IUPAC
dipyridazin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
6H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
by None None O
spectroscopic None None O
investigations None None O
. None None O

Selective None None O
condensation None None O
of None None O
5 None None O
with None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
substituted None None I-MODIFIER
- None None O
phenyl None None I-IUPAC
) None None I-IUPAC
piperazin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
ethylamine None None I-IUPAC
gave None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
arylpiperazinylethylamino None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
derivatives None None I-MODIFIER
6a None None O
- None None O
c None None O
, None None O
which None None O
were None None O
investigated None None O
in None None O
binding None None O
studies None None O
toward None None O
the None None O
three None None O
alpha1 None None O
- None None O
adrenergic None None O
and None None O
5 None None O
- None None O
HT1A None None O
- None None O
serotonergic None None O
receptor None None O
subtypes None None O
. None None O

They None None O
displayed None None O
high None None O
potency None None O
on None None O
all None None O
the None None O
assays None None O
and None None O
some None None O
selectivity None None O
for None None O
alpha1a None None O
and None None O
alpha1d None None O
subtypes None None O
. None None O


Five None None O
1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabinofuranosylcytosine None None I-IUPAC
conjugates None None I-MODIFIER
and None None O
two None None O
cytidine None None O
conjugates None None O
of None None O
thioether None None O
lipids None None O
( None None O
1 None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
alkylthioglycerols None None I-IUPAC
) None None O
linked None None O
by None None O
a None None O
pyrophosphate None None O
diester None None O
bond None None O
have None None O
been None None O
prepared None None O
and None None O
their None None O
antitumor None None O
activity None None O
against None None O
an None None O
ara None None O
- None None O
C2 None None O
sensitive None None O
( None None O
L1210/0 None None O
) None None O
and None None O
two None None O
ara None None O
- None None O
C None None O
resistant None None O
L1210 None None O
lymphoid None None O
leukemia None None O
sublines None None O
in None None O
mice None None O
were None None O
evaluated None None O
. None None O

These None None O
prodrugs None None O
of None None O
ara None None O
- None None O
C None None O
include None None O
ara None None I-IUPAC
- None None I-IUPAC
CDP None None I-IUPAC
- None None I-IUPAC
rac None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
hexadecyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
palmitoyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
thioglycerol None None I-IUPAC
( None None O
8a None None O
) None None O
, None None O
ara None None I-IUPAC
- None None I-IUPAC
CDP None None I-IUPAC
- None None I-IUPAC
rac None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
octadecyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
palmitoylthioglycerol None None I-IUPAC
( None None O
8b None None O
) None None O
, None None O
and None None O
ara None None I-IUPAC
- None None I-IUPAC
CDP None None I-IUPAC
- None None I-IUPAC
rac None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
octadecyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
( None None O
or None None O
- None None I-PARTIUPAC
ethyl None None I-PARTIUPAC
, None None O
- None None I-PARTIUPAC
hexadecyl None None I-PARTIUPAC
) None None O
thioglycerols None None I-PARTIUPAC
( None None O
8c None None O
- None None O
e None None O
) None None O
. None None O

The None None O
cytidine None None O
conjugates None None O
include None None O
CDP None None I-IUPAC
- None None I-IUPAC
rac None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
octadecyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
palmitoyl None None I-IUPAC
( None None O
or None None O
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
) None None O
- None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
thioglycerols None None I-PARTIUPAC
( None None O
9a None None O
and None None O
9b None None O
) None None O
. None None O

Sonicated None None O
solutions None None O
of None None O
the None None O
conjugates None None O
existed None None O
in None None O
the None None O
form None None O
of None None O
micellar None None O
disks None None O
( None None O
size None None O
0.01-0.04 None None O
microns None None O
) None None O
. None None O

Single None None O
doses None None O
( None None O
200-400 None None O
mg None None O
/ None None O
kg None None O
) None None O
of None None O
8a None None O
and None None O
8b None None O
produced None None O
significant None None O
increase None None O
in None None O
life None None O
span None None O
( None None O
257-371% None None O
) None None O
in None None O
mice None None O
bearing None None O
ip None None O
implanted None None O
L1210/0 None None O
leukemia None None O
. None None O

In None None O
contrast None None O
, None None O
conjugates None None O
8c None None O
- None None O
e None None O
were None None O
less None None O
effective None None O
( None None O
ILS None None O
19-75% None None O
) None None O
and None None O
cytidine None None O
conjugates None None O
( None None O
9a None None O
and None None O
9b None None O
) None None O
were None None O
ineffective None None O
. None None O

Even None None O
though None None O
8a None None O
and None None O
8b None None O
were None None O
found None None O
to None None O
be None None O
curative None None O
in None None O
a None None O
high None None O
percentage None None O
of None None O
mice None None O
bearing None None O
ip None None O
implanted None None O
partially None None O
ara None None O
- None None O
C None None O
resistant None None O
L1210 None None O
subline None None O
[ None None O
L1210 None None O
/ None None O
ara None None O
- None None O
C None None O
( None None O
I None None O
) None None O
] None None O
, None None O
they None None O
were None None O
completely None None O
ineffective None None O
against None None O
deoxycytidine None None O
kinase None None O
deficient None None O
ara None None O
- None None O
C None None O
resistant None None O
L1210 None None O
subline None None O
[ None None O
L1210 None None O
/ None None O
ara None None O
- None None O
C None None O
( None None O
II None None O
) None None O
] None None O
. None None O

However None None O
, None None O
the None None O
present None None O
results None None O
, None None O
together None None O
with None None O
the None None O
previous None None O
, None None O
demonstrate None None O
that None None O
8a None None O
and None None O
8b None None O
are None None O
promising None None O
new None None O
prodrugs None None O
of None None O
ara None None O
- None None O
C None None O
with None None O
improved None None O
efficacy None None O
. None None O


Pyrazolo None None O
[ None None O
3,4 None None O
- None None O
d None None O
] None None O
pyrimidines None None O
are None None O
pyrazolo None None O
analogues None None O
of None None O
purines None None O
. None None O

They None None O
have None None O
been None None O
shown None None O
to None None O
be None None O
a None None O
general None None O
class None None O
of None None O
compounds None None O
which None None O
exhibit None None O
A1 None None O
adenosine None None O
receptor None None O
affinity None None O
. None None O

Two None None O
series None None O
of None None O
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
analogues None None I-MODIFIER
of None None O
1 None None I-IUPAC
- None None I-IUPAC
methylisoguanosine None None I-IUPAC
have None None O
been None None O
synthesized None None O
. None None O

The None None O
first None None O
involved None None O
substitution None None O
of None None O
the None None O
N1 None None O
- None None O
position None None O
while None None O
the None None O
second None None O
involved None None O
substitution None None O
of None None O
the None None O
N5 None None O
- None None O
position None None O
. None None O

Both None None O
alkyl None None O
and None None O
aryl None None O
substituents None None O
were None None O
examined None None O
. None None O

All None None O
compounds None None O
were None None O
tested None None O
for None None O
A1 None None O
adenosine None None O
receptor None None O
affinity None None O
by None None O
using None None O
a None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylisopropyl None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
binding None None O
assay None None O
. None None O

The None None O
3 None None O
- None None O
chlorophenyl None None O
group None None O
showed None None O
the None None O
greatest None None O
activity None None O
in None None O
the None None O
N1 None None O
- None None O
position None None O
and None None O
the None None O
butyl None None O
group None None O
produced None None O
the None None O
greatest None None O
activity None None O
in None None O
the None None O
N5 None None O
- None None O
position None None O
. None None O

Combination None None O
of None None O
the None None O
best None None O
substituent None None O
in None None O
each None None O
of None None O
these None None O
positions None None O
enhanced None None O
the None None O
overall None None O
activity None None O
. None None O

The None None O
most None None O
potent None None O
compound None None O
was None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
( None None I-IUPAC
5H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
with None None O
an None None O
IC50 None None O
of None None O
6.4 None None O
x None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
M None None O
. None None O

Selectivity None None O
at None None O
the None None O
receptor None None O
subclasses None None O
was None None O
examined None None O
by None None O
performing None None O
an None None O
A2 None None O
adenosine None None O
receptor None None O
affinity None None O
assay None None O
with None None O
[ None None O
3H None None O
] None None O
CGS None None O
21680 None None O
. None None O

This None None O
series None None O
of None None O
compounds None None O
were None None O
slightly None None O
less None None O
potent None None O
at None None O
A2 None None O
receptors None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
( None None I-IUPAC
5H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
was None None O
the None None O
most None None O
potent None None O
compound None None O
with None None O
an None None O
IC50 None None O
of None None O
19.2 None None O
x None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
M None None O
. None None O


Several None None O
new None None O
analogues None None O
of None None O
L None None I-IUPAC
- None None I-IUPAC
fucose None None I-IUPAC
modified None None O
in None None O
the None None O
2 None None O
position None None O
and None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
have None None O
been None None O
synthesized None None O
as None None O
potential None None O
plasma None None O
- None None O
membrane None None O
glycoconjugate None None O
inhibitors None None O
or None None O
modifiers None None O
, None None O
and None None O
their None None O
biological None None O
effects None None O
have None None O
been None None O
studied None None O
. None None O

2 None None I-PARTIUPAC
- None None I-PARTIUPAC
Chloro None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
bromo None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
fucose None None I-IUPAC
( None None O
9a None None O
, None None O
9b None None O
, None None O
and None None O
13 None None O
, None None O
respectively None None O
) None None O
have None None O
been None None O
prepared None None O
by None None O
addition None None O
of None None O
the None None O
appropriate None None O
halogen None None O
to None None O
3,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
fucal None None I-IUPAC
, None None O
followed None None O
by None None O
hydrolysis None None O
of None None O
the None None O
anomeric None None O
halogen None None O
and None None O
the None None O
acetyl None None O
groups None None O
. None None O

A None None O
series None None O
of None None O
four None None O
halogenated None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
analogues None None I-MODIFIER
of None None O
L None None I-IUPAC
- None None I-IUPAC
fucose None None I-IUPAC
( None None O
4 None None O
, None None O
X None None O
= None None O
F None None O
, None None O
Cl None None O
, None None O
Br None None O
, None None O
and None None O
I None None O
) None None O
have None None O
been None None O
obtained None None O
starting None None O
from None None O
1,2 None None I-IUPAC
: None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
isopropylidene None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
galactose None None I-IUPAC
. None None O

The None None O
synthesis None None O
of None None O
this None None O
latter None None O
compound None None O
has None None O
been None None O
improved None None O
. None None O

A None None O
corresponding None None O
series None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
halo None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
galactose None None I-IUPAC
analogues None None I-MODIFIER
, None None O
which None None O
are None None O
enantiomers None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
halomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
fucose None None I-IUPAC
analogues None None I-MODIFIER
, None None O
has None None O
also None None O
been None None O
synthesized None None O
. None None O

Analogues None None O
4b None None O
, None None O
4c None None O
, None None O
and None None O
9b None None O
at None None O
1 None None O
x None None O
10 None None O
( None None O
- None None O
3 None None O
) None None O
M None None O
specifically None None O
inhibited None None O
the None None O
incorporation None None O
of None None O
L None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
fucose None None I-IUPAC
into None None O
macromolecular None None O
components None None O
of None None O
SW613 None None O
human None None O
mammary None None O
tumor None None O
cells None None O
. None None O

Analogue None None O
13 None None O
inhibited None None O
the None None O
growth None None O
of None None O
L1210 None None O
murine None None O
leukemic None None O
cells None None O
with None None O
an None None O
IC50 None None O
of None None O
6 None None O
x None None O
10 None None O
( None None O
5 None None O
) None None O
M None None O
in None None O
culture None None O
. None None O

6 None None I-IUPAC
- None None I-IUPAC
Deoxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
galactose None None I-IUPAC
and None None O
its None None O
enantiomer None None O
4a None None O
were None None O
found None None O
to None None O
be None None O
effective None None O
inhibitors None None O
of None None O
D None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
galactose None None I-IUPAC
and None None O
L None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
fucose None None I-IUPAC
incorporation None None O
, None None O
respectively None None O
, None None O
into None None O
macromolecular None None O
components None None O
of None None O
human None None O
mammary None None O
tumor None None O
cells None None O
. None None O

The None None O
effectiveness None None O
of None None O
inhibition None None O
was None None O
reduced None None O
with None None O
an None None O
increase None None O
in None None O
size None None O
of None None O
the None None O
halogen None None O
atom None None O
. None None O

Analogue None None O
4a None None O
and None None O
its None None O
enantiomer None None O
have None None O
been None None O
tritiated None None O
at None None O
C None None O
- None None O
1 None None O
and None None O
both None None O
were None None O
found None None O
to None None O
be None None O
activated None None O
to None None O
a None None O
nucleotide None None O
sugar None None O
, None None O
which None None O
was None None O
followed None None O
by None None O
incorporation None None O
into None None O
the None None O
macromolecular None None O
fraction None None O
of None None O
SW613 None None O
human None None O
mammary None None O
tumor None None O
cells None None O
in None None O
vitro None None O
. None None O


The None None O
transition None None O
metal None None O
complexes None None O
[ None None I-IUPAC
eta None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2beta None None I-IUPAC
- None None I-IUPAC
carbomethoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
phenyltropane None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
tricarbonylchromium None None I-IUPAC
( None None O
3 None None O
) None None O
and None None O
[ None None I-IUPAC
eta None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2beta None None I-IUPAC
- None None I-IUPAC
carbomethoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
phenyltropane None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
eta None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
pentamethylcyclopentadienyl None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
ruthenium None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
triflate None None I-IUPAC
( None None O
4 None None O
) None None O
were None None O
synthesized None None O
from None None O
2beta None None I-IUPAC
- None None I-IUPAC
carbomethoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
phenyltropane None None I-IUPAC
( None None O
2 None None O
, None None O
WIN None None O
35,065 None None O
) None None O
to None None O
further None None O
elucidate None None O
the None None O
influence None None O
of None None O
substituents None None O
on None None O
the None None O
3beta None None O
- None None O
aryl None None O
on None None O
the None None O
affinity None None O
of None None O
the None None O
ligand None None O
for None None O
cocaine None None O
- None None O
binding None None O
sites None None O
at None None O
the None None O
dopamine None None O
transporter None None O
. None None O

The None None O
compounds None None O
were None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
displace None None O
bound None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
WIN None None O
35,428 None None O
( None None O
5 None None O
) None None O
from None None O
rat None None O
caudate None None O
putamen None None O
tissue None None O
and None None O
for None None O
their None None O
ability None None O
to None None O
inhibit None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
dopamine None None O
uptake None None O
. None None O

The None None O
binding None None O
affinity None None O
for None None O
3 None None O
was None None O
2 None None O
- None None O
fold None None O
greater None None O
than None None O
those None None O
observed None None O
for None None O
cocaine None None O
( None None O
1 None None O
) None None O
and None None O
2 None None O
, None None O
while None None O
the None None O
binding None None O
affinity None None O
for None None O
4 None None O
was None None O
found None None O
to None None O
be None None O
100 None None O
- None None O
fold None None O
less None None O
than None None O
those None None O
of None None O
1 None None O
and None None O
2 None None O
. None None O

In None None O
addition None None O
, None None O
3 None None O
was None None O
equipotent None None O
with None None O
1 None None O
and None None O
2 None None O
in None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
dopamine None None O
uptake None None O
inhibition None None O
studies None None O
, None None O
while None None O
4 None None O
was None None O
10 None None O
- None None O
fold None None O
less None None O
potent None None O
. None None O

The None None O
potencies None None O
of None None O
the None None O
complexes None None O
3 None None O
and None None O
4 None None O
correlated None None O
well None None O
with None None O
the None None O
structure None None O
- None None O
activity None None O
relationships None None O
of None None O
other None None O
2beta None None I-IUPAC
- None None I-IUPAC
carbomethoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
aryltropane None None I-IUPAC
derivatives None None I-MODIFIER
. None None O

These None None O
data None None O
further None None O
support None None O
a None None O
pharmacophore None None O
model None None O
in None None O
which None None O
the None None O
region None None O
occupied None None O
by None None O
the None None O
aryl None None O
ring None None O
is None None O
a None None O
lipophilic None None O
pocket None None O
with None None O
electropositive None None O
character None None O
. None None O


A None None O
variety None None O
of None None O
mesoionic None None O
xanthines None None O
including None None O
mesoionic None None I-MODIFIER
thiazolo None None B-IUPAC
[ None None I-IUPAC
3,2 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
, None None O
benzothiazolopyrimidines None None I-IUPAC
, None None O
and None None O
1,3,4 None None I-IUPAC
- None None I-IUPAC
thiadiazolo None None I-IUPAC
[ None None I-IUPAC
3,2 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
were None None O
antagonists None None O
of None None O
A1 None None O
- None None O
adenosine None None O
receptors None None O
( None None O
inhibition None None O
of None None O
binding None None O
of None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
cyclohexyladenosine None None I-IUPAC
) None None O
and None None O
A2 None None O
- None None O
adenosine None None O
receptors None None O
( None None O
inhibition None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
chloroadenosine None None I-IUPAC
- None None O
elicited None None O
accumulations None None O
of None None O
cyclic None None O
AMP None None O
) None None O
in None None O
brain None None O
tissue None None O
. None None O

Most None None O
of None None O
the None None O
compounds None None O
were None None O
less None None O
potent None None O
than None None O
theophylline None None O
and None None O
none None None O
were None None O
remarkably None None O
selective None None O
for None None O
A1 None None O
- None None O
or None None O
A2 None None O
- None None O
adenosine None None O
receptors None None O
. None None O

However None None O
, None None O
members None None O
of None None O
the None None O
thiadiazolopyrimidine None None I-IUPAC
class None None O
of None None O
mesoionics None None O
exhibited None None O
very None None O
low None None O
or None None O
no None None O
activity None None O
as None None O
antagonists None None O
of None None O
A2 None None O
- None None O
adenosine None None O
receptors None None O
while None None O
exhibiting None None O
activity None None O
only None None O
2-4 None None O
- None None O
fold None None O
lower None None O
than None None O
that None None O
of None None O
theophylline None None O
at None None O
A1 None None O
- None None O
adenosine None None O
receptors None None O
. None None O

Unlike None None O
the None None O
case None None O
for None None O
theophylline None None O
, None None O
the None None O
presence None None O
of None None O
a None None O
phenyl None None O
substituent None None O
in None None O
the None None O
five None None O
- None None O
membered None None O
ring None None O
did None None O
not None None O
enhance None None O
the None None O
potency None None O
of None None O
a None None O
mesoionic None None O
thiadiazolopyrimidine None None O
. None None O

The None None O
nature None None O
of None None O
the None None O
substituents None None O
on None None O
the None None O
mesoionic None None O
ring None None O
did None None O
not None None O
appear None None O
to None None O
have None None O
marked None None O
effects None None O
on None None O
potency None None O
unlike None None O
the None None O
marked None None O
effect None None O
of None None O
the None None O
nature None None O
of None None O
1,3 None None O
- None None O
substituents None None O
on None None O
activity None None O
of None None O
nonmesoionic None None O
xanthines None None O
. None None O

The None None O
benzothiazolo None None I-IUPAC
[ None None I-IUPAC
3,2 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
were None None O
the None None O
most None None O
potent None None O
antagonists None None O
, None None O
being None None O
nearly None None O
as None None O
potent None None O
as None None O
theophylline None None O
at None None O
A1 None None O
- None None O
adenosine None None O
receptors None None O
and None None O
somewhat None None O
more None None O
potent None None O
than None None O
theophylline None None O
at None None O
A2 None None O
- None None O
adenosine None None O
receptors None None O
. None None O


The None None O
conformational None None O
characteristics None None O
of None None O
two None None O
series None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
hydroxytryptamine None None I-IUPAC
( None None O
5 None None O
- None None O
HT None None O
) None None O
receptor None None O
agonists None None O
, None None O
monophenolic None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dialkylated None None I-MODIFIER
2 None None B-IUPAC
- None None I-IUPAC
aminotetralins None None I-IUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylcyclopropylamines None None I-IUPAC
, None None O
have None None O
been None None O
studied None None O
by None None O
a None None O
combination None None O
of None None O
experimental None None O
( None None O
NMR None None O
spectroscopy None None O
) None None O
and None None O
theoretical None None O
( None None O
molecular None None O
mechanics None None O
and None None O
MNDO None None O
calculations None None O
) None None O
methods None None O
. None None O

In None None O
addition None None O
, None None O
molecular None None O
electrostatic None None O
potentials None None O
have None None O
been None None O
calculated None None O
for None None O
selected None None O
conformations None None O
and None None O
the None None O
absolute None None O
configuration None None O
of None None O
the None None O
potent None None O
5 None None O
- None None O
HT None None O
- None None O
receptor None None O
agonist None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylamino None None I-IUPAC
) None None I-IUPAC
tetralin None None I-IUPAC
has None None O
been None None O
determined None None O
, None None O
by None None O
X None None O
- None None O
ray None None O
crystallography None None O
of None None O
the None None O
synthetic None None O
precursor None None O
, None None O
to None None O
be None None O
1S None None O
, None None O
2R None None O
. None None O

Results None None O
obtained None None O
are None None O
discussed None None O
in None None O
terms None None O
of None None O
conformational None None O
, None None O
steric None None O
, None None O
and None None O
electronic None None O
requirements None None O
for None None O
5 None None O
- None None O
HT None None O
- None None O
receptor None None O
activation None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
different None None O
conformations None None O
of None None O
the None None O
5 None None O
- None None O
HT None None O
- None None O
receptor None None O
agonists None None O
( None None I-IUPAC
1R None None I-IUPAC
, None None I-IUPAC
2S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylcyclopropylamine None None I-IUPAC
[ None None O
( None None O
1R None None O
, None None O
2S None None O
) None None O
- None None O
4 None None O
] None None O
and None None O
its None None O
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
isomer None None I-MODIFIER
( None None O
1R None None O
, None None O
2S None None O
) None None O
- None None O
5 None None O
are None None O
able None None O
to None None O
activate None None O
5 None None O
- None None O
HT None None O
receptors None None O
. None None O

The None None O
strongly None None O
increased None None O
stereoselectivity None None O
of None None O
2 None None O
, None None O
4 None None O
, None None O
and None None O
5 None None O
as None None O
compared None None O
to None None O
that None None O
of None None O
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylamino None None I-IUPAC
) None None I-IUPAC
tetralin None None I-IUPAC
( None None O
8 None None O
- None None O
OH None None O
- None None O
DPAT None None O
; None None O
1 None None O
) None None O
is None None O
rationalized None None O
on None None O
the None None O
basis None None O
of None None O
steric None None O
factors None None O
. None None O

Conformational None None O
factors None None O
appear None None O
to None None O
be None None O
responsible None None O
for None None O
the None None O
inability None None O
of None None O
the None None O
trans None None O
- None None O
C1 None None O
- None None O
methyl None None O
- None None O
substituted None None O
derivative None None O
of None None O
1 None None O
to None None O
activate None None O
5 None None O
- None None O
HT None None O
receptors None None O
. None None O


A None None O
series None None O
of None None O
osteotropic None None O
( None None O
bone None None O
- None None O
seeking None None O
) None None O
[ None None I-IUPAC
( None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
phosphonomethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
kappaN None None I-IUPAC
) None None I-IUPAC
acetato None None I-IUPAC
- None None I-IUPAC
kappaO None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
platinum None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
complexes None None I-MODIFIER
attached None None O
to None None O
diammine None None I-IUPAC
, None None O
ethane None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
diamine None None I-IUPAC
, None None O
cis None None I-IUPAC
- None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
cyclohexane None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
diamine None None I-IUPAC
, None None O
trans None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
cyclohexane None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
diamine None None I-IUPAC
, None None O
or None None O
trans None None I-IUPAC
- None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
cyclohexane None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
diamine None None I-IUPAC
has None None O
been None None O
synthesized None None O
in None None O
accord None None O
with None None O
the None None O
concept None None O
of None None O
drug None None O
targeting None None O
and None None O
characterized None None O
by None None O
elemental None None O
analysis None None O
, None None O
( None None O
1 None None O
) None None O
H None None O
, None None O
( None None O
13 None None O
) None None O
C None None O
, None None O
and None None O
( None None O
31 None None O
) None None O
P None None O
NMR None None O
spectroscopy None None O
. None None O

The None None O
in None None O
vitro None None O
antitumor None None O
activity None None O
in None None O
ovarian None None O
cancer None None O
cells None None O
( None None O
CH1 None None O
) None None O
has None None O
been None None O
determined None None O
by None None O
means None None O
of None None O
the None None O
MTT None None O
assay None None O
. None None O

In None None O
this None None O
cisplatin None None O
- None None O
sensitive None None O
cell None None O
line None None O
the None None O
complexes None None O
containing None None O
cyclohexane None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
diamine None None I-IUPAC
( None None O
chxn None None O
) None None O
displayed None None O
a None None O
high None None O
activity None None O
in None None O
comparison None None O
to None None O
the None None O
diammine None None I-IUPAC
and None None O
ethane None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
diamine None None I-IUPAC
counterparts None None O
. None None O

In None None O
agreement None None O
with None None O
structure None None O
- None None O
activity None None O
relationships None None O
of None None O
other None None O
chxn None None O
- None None O
containing None None O
platinum None None O
( None None O
II None None O
) None None O
complexes None None O
both None None O
[ None None I-IUPAC
( None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
phosphonomethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
kappaN None None I-IUPAC
) None None I-IUPAC
acetato None None I-IUPAC
- None None I-IUPAC
kappaO None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
( None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
cyclohexane None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
diamine None None I-IUPAC
) None None I-IUPAC
platinum None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
complexes None None I-MODIFIER
show None None O
superior None None O
potency None None O
than None None O
the None None O
corresponding None None O
cis None None O
- None None O
congener None None O
whereas None None O
the None None O
trans None None O
- None None O
R None None O
, None None O
R None None O
isomer None None O
displays None None O
the None None O
highest None None O
activity None None O
. None None O

Within None None O
the None None O
series None None O
of None None O
complexes None None O
under None None O
investigation None None O
, None None O
potency None None O
decreases None None O
depending None None O
on None None O
the None None O
coordinated None None O
amine None None O
ligand None None O
in None None O
the None None O
following None None O
order None None O
: None None O
trans None None O
- None None O
R None None O
, None None O
R None None O
- None None O
chxn None None O
& None None O
gt None None O
; None None O
trans None None O
- None None O
S None None O
, None None O
S None None O
- None None O
chxn None None O
& None None O
gt None None O
; None None O
NH None None O
( None None O
3 None None O
) None None O
& None None O
gt None None O
; None None O
or None None O
= None None O
cis None None O
- None None O
R None None O
, None None O
S None None O
- None None O
chxn None None O
& None None O
gt None None O
; None None O
en None None O
. None None O


Rotationally None None O
restricted None None O
analogues None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
deazapteroyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
and None None O
( None None I-IUPAC
6R None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
- None None I-IUPAC
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydropteroyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
with None None O
a None None O
one None None O
- None None O
carbon None None O
bridge None None O
between None None O
the None None O
amide None None O
nitrogen None None O
and None None O
the None None O
6' None None O
- None None O
position None None O
of None None O
the None None O
p None None I-IUPAC
- None None I-IUPAC
aminobenzoyl None None I-IUPAC
moiety None None I-MODIFIER
were None None O
synthesized None None O
and None None O
tested None None O
as None None O
substrates None None O
for None None O
folylpolyglutamate None None O
synthetase None None O
( None None O
FPGS None None O
) None None O
, None None O
a None None O
key None None O
enzyme None None O
in None None O
folate None None O
metabolism None None O
and None None O
an None None O
important None None O
determinant None None O
of None None O
the None None O
therapeutic None None O
potency None None O
and None None O
selectivity None None O
of None None O
classical None None O
antifolates None None O
. None None O

The None None O
corresponding None None O
bridged None None O
analogues None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
deazapteroyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
ornithine None None I-IUPAC
and None None O
( None None I-IUPAC
6R None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
- None None I-IUPAC
5,6,7 None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
tetrahydropteroyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
ornithine None None I-IUPAC
were None None O
also None None O
synthesized None None O
as None None O
potential None None O
inhibitors None None O
. None None O

Condensation None None O
of None None O
diethyl None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
with None None O
methyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromomethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitrobenzoate None None I-IUPAC
followed None None O
by None None O
catalytic None None O
reduction None None O
of None None O
the None None O
nitro None None O
group None None O
, None None O
reductive None None O
coupling None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
acetamido None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
formylpyrido None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
in None None O
the None None O
presence None None O
of None None O
dimethylaminoborane None None O
, None None O
and None None O
acidolysis None None O
with None None O
HBr None None O
/ None None O
AcOH None None O
yielded None None O
2 None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acetamido None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
oxopyrido None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methylamino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
isoindolyl None None I-IUPAC
] None None I-IUPAC
glutaric None None I-IUPAC
acid None None I-IUPAC
( None None O
1 None None O
) None None O
. None None O

When None None O
acidolysis None None O
was None None O
preceded None None O
by None None O
catalytic None None O
hydrogenation None None O
, None None O
the None None O
final None None O
product None None O
was None None O
the None None O
corresponding None None O
( None None O
6R None None O
, None None O
6S None None O
) None None O
- None None O
tetrahydro None None O
derivative None None O
2 None None O
. None None O

A None None O
similar None None O
sequence None None O
starting None None O
from None None O
methyl None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
delta None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzyloxycarbonyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
ornithine None None I-IUPAC
led None None O
to None None O
2 None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
oxopyrido None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methylamino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
isoindolyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
aminopentanoic None None I-IUPAC
acid None None I-IUPAC
( None None O
3 None None O
) None None O
and None None O
the None None O
( None None I-IUPAC
6R None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
derivative None None I-MODIFIER
4 None None O
. None None O

Compounds None None O
3 None None O
and None None O
4 None None O
were None None O
powerful None None O
inhibitors None None O
of None None O
recombinant None None O
human None None O
FPGS None None O
, None None O
whereas None None O
1 None None O
and None None O
2 None None O
were None None O
exceptionally None None O
efficient None None O
FPGS None None O
substrates None None O
, None None O
with None None O
the None None O
reduced None None O
compound None None O
2 None None O
giving None None O
a None None O
K None None O
( None None O
m None None O
) None None O
( None None O
0.018 None None O
microM None None O
) None None O
lower None None O
than None None O
that None None O
of None None O
any None None O
other None None O
substrate None None O
identified None None O
to None None O
date None None O
. None None O

( None None I-IUPAC
6R None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
Deazatetrahydrofolate None None I-IUPAC
, None None O
in None None O
which None None O
the None None O
side None None O
chain None None O
is None None O
free None None O
to None None O
rotate None None O
, None None O
was None None O
rapidly None None O
converted None None O
to None None O
long None None O
- None None O
chain None None O
polyglutamates None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
reaction None None O
of None None O
1 None None O
and None None O
2 None None O
was None None O
limited None None O
to None None O
the None None O
addition None None O
of None None O
a None None O
single None None O
molecule None None O
of None None O
glutamic None None O
acid None None O
. None None O

Hence None None O
rotational None None O
restriction None None O
of None None O
the None None O
side None None O
chain None None O
did None None O
not None None O
interfere None None O
with None None O
the None None O
initial None None O
FPGS None None O
- None None O
catalyzed None None O
reaction None None O
and None None O
indeed None None O
seemed None None O
to None None O
facilitate None None O
it None None O
, None None O
but None None O
the None None O
ensuing None None O
gamma None None O
- None None O
glutamyl None None O
adduct None None O
was None None O
no None None O
longer None None O
an None None O
efficient None None O
substrate None None O
for None None O
the None None O
enzyme None None O
. None None O


[ None None I-IUPAC
1 None None I-IUPAC
] None None I-IUPAC
Benzothieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridines None None I-IUPAC
( None None O
10a None None O
- None None O
c None None O
, None None O
11 None None O
, None None O
12a None None O
- None None O
t None None O
, None None O
and None None O
13a None None O
, None None O
b None None O
) None None O
and None None O
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
] None None I-IUPAC
benzothieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridines None None I-IUPAC
( None None O
3a None None O
- None None O
c None None O
, None None O
7 None None O
, None None O
8a None None O
- None None O
c None None O
, None None O
and None None O
9 None None O
) None None O
were None None O
synthesized None None O
. None None O

The None None O
compounds None None O
are None None O
bioisosteres None None O
of None None O
beta None None O
- None None O
carbolines None None O
and None None O
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
carbolines None None I-IUPAC
where None None O
the None None O
indole None None O
nitrogen None None O
is None None O
replaced None None O
by None None O
sulfur None None O
. None None O

Their None None O
pharmacological None None O
activity None None O
was None None O
evaluated None None O
in None None O
a None None O
water None None O
lick None None O
conflict None None O
test None None O
in None None O
rats None None O
and None None O
a None None O
passive None None O
avoidance None None O
test None None O
in None None O
mice None None O
. None None O

In None None O
the None None O
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
] None None I-IUPAC
benzothieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
series None None I-MODIFIER
, None None O
the None None O
presence None None O
of None None O
ethyl None None O
ester None None O
( None None O
3b None None O
) None None O
or None None O
cyclohexyl None None O
carboxamide None None O
( None None O
7 None None O
) None None O
groups None None O
at None None O
C None None O
- None None O
3 None None O
conferred None None O
good None None O
anticonflict None None O
activity None None O
and None None O
lessening None None O
of None None O
memory None None O
impairment None None O
, None None O
while None None O
N None None O
- None None O
acylation None None O
of None None O
3b None None O
abolished None None O
activity None None O
. None None O

In None None O
the None None O
[ None None I-IUPAC
1 None None I-IUPAC
] None None I-IUPAC
benzothieno None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
series None None I-MODIFIER
, None None O
the None None O
aminoethyl None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
12a None None O
) None None O
group None None I-MODIFIER
at None None O
C None None O
- None None O
3 None None O
also None None O
conferred None None O
activity None None O
, None None O
but None None O
other None None O
amides None None O
studied None None O
were None None O
not None None O
active None None O
. None None O

The None None O
most None None O
potent None None O
compounds None None O
( None None O
3b None None O
, None None O
7 None None O
, None None O
and None None O
12a None None O
) None None O
were None None O
also None None O
administered None None O
orally None None O
and None None O
had None None O
potent None None O
anticonflict None None O
and None None O
antiscopolamine None None O
amnesia None None O
- None None O
reversal None None O
activity None None O
. None None O

These None None O
compounds None None O
did None None O
not None None O
bind None None O
to None None O
the None None O
BZP None None O
receptor None None O
in None None O
spite None None O
of None None O
having None None O
structures None None O
similar None None O
to None None O
those None None O
of None None O
beta None None O
- None None O
carbolines None None O
. None None O

Compound None None O
7 None None O
bound None None O
strongly None None O
to None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
and None None O
would None None O
be None None O
expected None None O
to None None O
be None None O
a None None O
novel None None O
anxiolytic None None O
. None None O


A None None O
series None None O
of None None O
new None None O
dipeptidyl None None O
alpha None None O
- None None O
keto None None O
amides None None O
of None None O
the None None O
general None None O
structure None None O
R1 None None O
- None None O
L None None O
- None None O
Leu None None O
- None None O
D None None O
, None None O
L None None O
- None None O
AA None None O
- None None O
CONH None None O
- None None O
R2 None None O
were None None O
synthesized None None O
and None None O
evaluated None None O
as None None O
inhibitors None None O
for None None O
the None None O
cysteine None None O
proteases None None O
calpain None None O
I None None O
, None None O
calpain None None O
II None None O
, None None O
and None None O
cathepsin None None O
B None None O
. None None O

They None None O
combine None None O
10 None None O
different None None O
N None None O
- None None O
protecting None None O
groups None None O
( None None O
R1 None None O
) None None O
, None None O
3 None None O
amino None None O
acids None None O
residues None None O
in None None O
P1 None None O
( None None O
AA None None O
) None None O
, None None O
and None None O
44 None None O
distinct None None O
substituents None None O
on None None O
the None None O
alpha None None O
- None None O
keto None None O
amide None None O
nitrogen None None O
( None None O
R2 None None O
) None None O
. None None O

In None None O
general None None O
, None None O
calpain None None O
II None None O
was None None O
more None None O
sensitive None None O
to None None O
these None None O
inhibitors None None O
than None None O
calpain None None O
I None None O
, None None O
with None None O
a None None O
large None None O
number None None O
of None None O
inhibitors None None O
displaying None None O
dissociation None None O
constants None None O
( None None O
Ki None None O
) None None O
in None None O
the None None O
10-100 None None O
nM None None O
range None None O
. None None O

Calpain None None O
I None None O
was None None O
also None None O
effectively None None O
inhibited None None O
, None None O
but None None O
very None None O
low None None O
Ki None None O
values None None O
were None None O
observed None None O
with None None O
a None None O
smaller None None O
number None None O
of None None O
inhibitors None None O
than None None O
with None None O
calpain None None O
II None None O
. None None O

Cathepsin None None O
B None None O
was None None O
weakly None None O
inhibited None None O
by None None O
most None None O
compounds None None O
in None None O
this None None O
study None None O
. None None O

The None None O
best None None O
inhibitors None None O
for None None O
calpain None None O
II None None O
were None None O
Z None None O
- None None O
Leu None None O
- None None O
Abu None None O
- None None O
CONH None None O
- None None O
CH2 None None O
- None None O
CHOH None None O
- None None O
C6H5 None None O
( None None O
Ki None None O
= None None O
15 None None O
nM None None O
) None None O
, None None O
Z None None O
- None None O
Leu None None O
- None None O
Abu None None O
- None None O
CONH None None O
- None None O
CH2 None None O
- None None O
2 None None O
- None None O
pyridyl None None O
( None None O
Ki None None O
= None None O
17 None None O
nM None None O
) None None O
, None None O
and None None O
Z None None O
- None None O
Leu None None O
- None None O
Abu None None O
- None None O
CONH None None O
- None None O
CH2 None None O
- None None O
C6H3 None None O
( None None O
3,5 None None O
( None None O
OMe None None O
) None None O
2 None None O
) None None O
( None None O
Ki None None O
= None None O
22 None None O
nM None None O
) None None O
. None None O

The None None O
best None None O
calpain None None O
I None None O
inhibitor None None O
in None None O
this None None O
study None None O
was None None O
Z None None O
- None None O
Leu None None O
- None None O
Nva None None O
- None None O
CONH None None O
- None None O
CH2 None None O
- None None O
2 None None O
- None None O
pyridyl None None O
( None None O
Ki None None O
= None None O
19 None None O
nM None None O
) None None O
. None None O

The None None O
peptide None None O
alpha None None O
- None None O
keto None None O
amide None None O
Z None None O
- None None O
Leu None None O
- None None O
Abu None None O
- None None O
CONH None None O
- None None O
( None None O
CH2 None None O
) None None O
2-3 None None O
- None None O
indolyl None None O
was None None O
the None None O
best None None O
inhibitor None None O
for None None O
cathepsin None None O
B None None O
( None None O
Ki None None O
= None None O
31 None None O
nM None None O
) None None O
. None None O

Some None None O
compounds None None O
acted None None O
as None None O
specific None None O
calpain None None O
inhibitors None None O
, None None O
with None None O
comparable None None O
activity None None O
on None None O
both None None O
calpains None None O
I None None O
and None None O
II None None O
and None None O
a None None O
lack None None O
of None None O
activity None None O
on None None O
cathepsin None None O
B None None O
( None None O
e.g. None None O
, None None O
40 None None O
, None None O
42 None None O
, None None O
48 None None O
, None None O
70 None None O
) None None O
. None None O

Others None None O
were None None O
specific None None O
inhibitors None None O
for None None O
calpain None None O
I None None O
( None None O
e.g. None None O
, None None O
73 None None O
) None None O
or None None O
calpain None None O
II None None O
( None None O
e.g. None None O
, None None O
18 None None O
, None None O
19 None None O
, None None O
33 None None O
, None None O
35 None None O
, None None O
56 None None O
) None None O
. None None O

Such None None O
inhibitors None None O
may None None O
be None None O
useful None None O
in None None O
elucidating None None O
the None None O
physiological None None O
and None None O
pathological None None O
events None None O
involving None None O
these None None O
proteases None None O
and None None O
may None None O
become None None O
possible None None O
therapeutic None None O
agents None None O
. None None O


Lipophilic None None O
methotrexate None None O
( None None O
MTX None None O
) None None O
and None None O
3' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
dichloromethotrexate None None I-IUPAC
( None None O
DCM None None O
) None None O
diesters None None I-MODIFIER
were None None O
prepared None None O
by None None O
HCl None None O
- None None O
catalyzed None None O
esterification None None O
or None None O
by None None O
neutral None None O
esterification None None O
using None None O
cesium None None O
carbonate None None O
and None None O
an None None O
alkyl None None O
or None None O
aralkyl None None O
halide None None O
in None None O
Me2SO None None O
. None None O

The None None O
products None None O
were None None O
tested None None O
for None None O
in None None O
vivo None None O
antitumor None None O
activity None None O
against None None O
L1210 None None O
leukemia None None O
in None None O
mice None None O
to None None O
test None None O
whether None None O
all None None O
MTX None None O
and None None O
DCM None None O
diesters None None O
are None None O
therapeutically None None O
equivalent None None O
in None None O
this None None O
species None None O
. None None O

Contrary None None O
to None None O
what None None O
has None None O
been None None O
found None None O
with None None O
simple None None O
primary None None O
dialkyl None None O
esters None None O
, None None O
ortho None None O
- None None O
substituted None None O
dibenzyl None None O
esters None None O
of None None O
MTX None None O
produce None None O
longer None None O
survival None None O
on None None O
a None None O
q3dX3 None None O
schedule None None O
than None None O
does None None O
MTX None None O
itself None None O
and None None O
show None None O
a None None O
dose None None O
- None None O
sparing None None O
effect None None O
comparable None None O
to None None O
that None None O
of None None O
MTX None None O
at None None O
shorter None None O
treatment None None O
intervals None None O
. None None O

Thus None None O
, None None O
MTX None None O
bis None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropiperonyl None None I-IUPAC
) None None I-IUPAC
ester None None I-IUPAC
at None None O
an None None O
MTX None None O
- None None O
equivalent None None O
dose None None O
of None None O
5.5 None None O
mg None None O
/ None None O
kg None None O
gave None None O
a None None O
+ None None O
88% None None O
increase None None O
in None None O
median None None O
life None None O
span None None O
( None None O
ILS None None O
) None None O
, None None O
whereas None None O
for None None O
MTX None None O
a None None O
+ None None O
88% None None O
ILS None None O
required None None O
30 None None O
mg None None O
/ None None O
kg None None O
. None None O

When None None O
the None None O
MTX None None O
- None None O
equivalent None None O
dose None None O
of None None O
MTX None None O
bis None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropiperonyl None None I-IUPAC
) None None I-IUPAC
ester None None I-IUPAC
was None None O
increased None None O
to None None O
40 None None O
mg None None O
/ None None O
kg None None O
, None None O
a None None O
+ None None O
167% None None O
ILS None None O
was None None O
observed None None O
, None None O
as None None O
compared None None O
with None None O
a None None O
+ None None O
100% None None O
ILS None None O
with None None O
60 None None O
mg None None O
/ None None O
kg None None O
of None None O
the None None O
parent None None O
drug None None O
. None None O

High None None O
activity None None O
( None None O
greater None None O
than None None O
100% None None O
ILS None None O
) None None O
was None None O
likewise None None O
shown None None O
by None None O
the None None O
bis None None I-PARTIUPAC
( None None I-PARTIUPAC
2,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
dimethylbenzyl None None I-PARTIUPAC
) None None I-PARTIUPAC
, None None O
bis None None I-PARTIUPAC
( None None I-PARTIUPAC
2,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
dichlorobenzyl None None I-PARTIUPAC
) None None I-PARTIUPAC
, None None O
and None None O
di None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
picolyl None None I-IUPAC
esters None None I-IUPAC
of None None O
MTX None None O
and None None O
by None None O
the None None O
bis None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methylbutyl None None I-IUPAC
) None None I-IUPAC
ester None None I-IUPAC
of None None O
DCM None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
indicate None None O
that None None O
MTX None None O
and None None O
DCM None None O
esters None None O
are None None O
not None None O
therapeutically None None O
equivalent None None O
in None None O
mice None None O
, None None O
despite None None O
the None None O
high None None O
serum None None O
esterase None None O
activity None None O
in None None O
this None None O
species None None O
, None None O
and None None O
that None None O
an None None O
up None None O
to None None O
10 None None O
- None None O
fold None None O
reduction None None O
in None None O
total None None O
administered None None O
dose None None O
on None None O
the None None O
q3dX3 None None O
schedule None None O
is None None O
feasible None None O
by None None O
this None None O
approach None None O
. None None O


The None None O
higher None None O
toxicity None None O
of None None O
neonicotinoid None None O
insecticides None None O
such None None O
as None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropyridin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
nitroiminoimidazolidine None None I-IUPAC
( None None O
imidacloprid None None O
) None None O
to None None O
insects None None O
than None None O
mammals None None O
is None None O
due None None O
in None None O
large None None O
part None None O
to None None O
target None None O
site None None O
specificity None None O
at None None O
the None None O
corresponding None None O
nicotinic None None O
acetylcholine None None O
receptors None None O
( None None O
nAChRs None None O
) None None O
. None None O

We None None O
propose None None O
that None None O
neonicotinoids None None O
with None None O
a None None O
protonated None None O
N None None O
- None None O
unsubstituted None None O
imine None None O
or None None O
equivalent None None O
substituent None None O
recognize None None O
the None None O
anionic None None O
subsite None None O
of None None O
the None None O
mammalian None None O
alpha4beta2 None None O
nAChR None None O
whereas None None O
the None None O
negatively None None O
charged None None O
( None None O
delta None None O
( None None O
- None None O
) None None O
) None None O
tip None None O
of None None O
the None None O
neonicotinoid None None O
insecticides None None O
interacts None None O
with None None O
a None None O
putative None None O
cationic None None O
subsite None None O
of None None O
the None None O
insect None None O
nAChR None None O
. None None O

This None None O
hypothesis None None O
can None None O
be None None O
tested None None O
by None None O
using None None O
two None None O
photoaffinity None None O
probes None None O
that None None O
differ None None O
only None None O
in None None O
the None None O
N None None O
- None None O
unsubstituted None None O
imine None None O
vs None None O
negatively None None O
charged None None O
( None None O
delta None None O
( None None O
- None None O
) None None O
) None None O
tip None None O
. None None O

Synthesis None None O
methodology None None O
was None None O
developed None None O
for None None O
compounds None None O
combining None None O
three None None O
moieties None None O
: None None O
pyridin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
or None None O
6 None None I-IUPAC
- None None I-IUPAC
chloropyridin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
and None None O
their None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
analogues None None I-MODIFIER
; None None O
imidazolidine None None I-IUPAC
, None None O
4 None None I-IUPAC
- None None I-IUPAC
imidazoline None None I-IUPAC
or None None O
4 None None I-IUPAC
- None None I-IUPAC
thiazoline None None I-IUPAC
; None None O
and None None O
N None None I-MODIFIER
- None None I-MODIFIER
unsubstituted None None I-MODIFIER
imine None None I-IUPAC
, None None O
nitroimine None None O
, None None O
cyanoimine None None O
, None None O
or None None O
nitromethylene None None O
. None None O

Structure None None O
- None None O
activity None None O
studies None None O
compared None None O
displacement None None O
of None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
nicotine None None O
binding None None O
in None None O
mammalian None None O
alpha4beta2 None None O
nAChR None None O
and None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
imidacloprid None None O
binding None None O
in None None O
Drosophila None None O
nAChR None None O
. None None O

Preferred None None O
compounds None None O
are None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropyridin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
with None None O
2 None None I-IUPAC
- None None I-IUPAC
iminothiazoline None None I-IUPAC
for None None O
alpha4beta2 None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
0.47 None None O
nM None None O
) None None O
and None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
nitroiminothiazoline None None I-IUPAC
or None None O
2 None None I-IUPAC
- None None I-IUPAC
nitromethyleneimidazolidine None None I-IUPAC
for None None O
Drosophila None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
0.72-3.9 None None O
nM None None O
) None None O
. None None O


Improved None None O
rationally None None O
designed None None O
lead None None O
drug None None O
structures None None O
against None None O
African None None O
trypanosomiasis None None O
, None None O
Chagas None None O
disease None None O
, None None O
and None None O
leishmaniasis None None O
were None None O
obtained None None O
against None None O
trypanothione None None O
reductase None None O
from None None O
Trypanosoma None None O
cruzi None None O
. None None O

Substituted None None I-MODIFIER
- None None I-MODIFIER
benzyl None None I-MODIFIER
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4a None None I-IUPAC
, None None I-IUPAC
10a None None I-IUPAC
- None None I-IUPAC
dihydrophenothiazin None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
dimethylammonium None None I-IUPAC
salts None None I-IUPAC
, None None O
synthesized None None O
by None None O
Menschutkin None None O
quaternization None None O
of None None O
the None None O
tertiary None None O
alkylamine None None O
omega None None O
- None None O
nitrogen None None O
atom None None O
of None None O
chlorpromazine None None O
, None None O
were None None O
linear None None O
, None None O
competitive None None O
inhibitors None None O
of None None O
recombinant None None O
trypanothione None None O
reductase None None O
from None None O
T None None O
. None None O

cruzi None None O
, None None O
with None None O
either None None O
trypanothione None None O
disulfide None None O
or None None O
N None None I-IUPAC
- None None I-IUPAC
benzyloxycarbonyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
cysteinylglycyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
dimethylaminopropylamide None None I-IUPAC
disulfide None None I-IUPAC
as None None O
substrate None None O
. None None O

The None None O
permanent None None O
positive None None O
charge None None O
on None None O
the None None O
distal None None O
nitrogen None None O
atom None None O
of None None O
the None None O
tricyclic None None O
side None None O
chain None None O
contribution None None O
to None None O
binding None None O
was None None O
estimated None None O
as None None O
& None None O
gt None None O
; None None O
/ None None O
= None None O
5.6 None None O
kcal None None O
. None None O

mol None None O
( None None O
- None None O
1 None None O
) None None O
by None None O
comparison None None O
with None None O
the None None O
analogue None None O
with None None O
the None None O
cationic None None O
nitrogen None None O
atom None None O
of None None O
the None None O
quaternary None None O
replaced None None O
by None None O
an None None O
ether None None O
oxygen None None O
atom None None O
. None None O

A None None O
further None None O
major None None O
contribution None None O
to None None O
improving None None O
K None None O
( None None O
i None None O
) None None O
values None None O
and None None O
inhibition None None O
strength None None O
was None None O
the None None O
hydrophobic None None O
natures None None O
and None None O
structures None None O
of None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
substituents None None I-MODIFIER
. None None O

The None None O
strongest None None O
inhibitor None None O
, None None O
the None None O
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4a None None I-IUPAC
, None None I-IUPAC
10a None None I-IUPAC
- None None I-IUPAC
dihydrophenothiazin None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
dichlorobenzyl None None I-IUPAC
) None None I-IUPAC
dimethylammonium None None I-IUPAC
derivative None None I-MODIFIER
( None None O
K None None O
( None None O
i None None O
) None None O
0.12 None None O
microM None None O
) None None O
, None None O
was None None O
approximately None None O
2 None None O
orders None None O
of None None O
magnitude None None O
more None None O
inhibitory None None O
than None None O
the None None O
parent None None O
chlorpromazine None None O
. None None O

Several None None O
of None None O
these None None O
quaternary None None O
phenothiazines None None O
completely None None O
inhibited None None O
T None None O
. None None O

brucei None None O
parasite None None O
growth None None O
in None None O
vitro None None O
at None None O
& None None O
lt None None O
; None None O
1 None None O
microM None None O
. None None O

Antiparasite None None O
activity None None O
was None None O
not None None O
solely None None O
determined None None O
by None None O
inhibition None None O
strength None None O
against None None O
trypanothione None None O
reductase None None O
, None None O
there None None O
being None None O
a None None O
strong None None O
contribution None None O
from None None O
hydrophobicity None None O
( None None O
for None None O
example None None O
, None None O
benzhydryl None None I-IUPAC
- None None O
quaternized None None I-MODIFIER
chlorpromazime None None B-IUPAC
had None None O
ED None None O
( None None O
50 None None O
) None None O
& None None O
lt None None O
; None None O
1 None None O
microM None None O
) None None O
. None None O

Although None None O
active None None O
against None None O
Leishmania None None O
donovani None None O
, None None O
none None None O
of None None O
the None None O
analogues None None O
showed None None O
major None None O
improvement None None O
in None None O
this None None O
activity None None O
relative None None O
to None None O
chlorpromazine None None O
or None None O
other None None O
nonquaternized None None O
phenothiazines None None O
. None None O

The None None O
p None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butylbenzyl None None I-IUPAC
- None None O
quaternized None None I-MODIFIER
analogue None None I-MODIFIER
very None None O
strongly None None O
inhibited None None O
( None None O
ED None None O
( None None O
50 None None O
) None None O
& None None O
lt None None O
; None None O
1 None None O
microM None None O
) None None O
growth None None O
of None None O
the None None O
amastigote None None O
stage None None O
of None None O
T None None O
. None None O

cruzi None None O
. None None O


After None None O
our None None O
discovery None None O
that None None O
H None None O
- None None O
c None None O
[ None None O
Cys None None O
- None None O
Phe None None O
- None None O
Phe None None O
- None None O
DNal None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Cys None None O
] None None O
- None None O
OH None None O
( None None O
ODN None None O
- None None O
8 None None O
) None None O
had None None O
high None None O
affinity None None O
and None None O
marginal None None O
selectivity None None O
for None None O
human None None O
sst None None O
( None None O
3 None None O
) None None O
( None None O
part None None O
2 None None O
of None None O
this None None O
series None None O
: None None O
Erchegyi None None O
et None None O
al. None None O
J None None O
. None None O

Med. None None O
Chem. None None O
, None None O
preceding None None O
paper None None O
in None None O
this None None O
issue None None O
) None None O
( None None O
11 None None O
) None None O
and None None O
that None None O
H None None O
- None None O
c None None O
[ None None O
Cys None None O
- None None O
Phe None None O
- None None O
Phe None None O
- None None O
DTrp None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Cys None None O
] None None O
- None None O
OH None None O
( None None O
ODT None None O
- None None O
8 None None O
, None None O
3 None None O
) None None O
had None None O
high None None O
affinity None None O
and None None O
marginal None None O
selectivity None None O
for None None O
human None None O
sst None None O
( None None O
4 None None O
) None None O
, None None O
that None None O
H None None O
- None None O
c None None O
[ None None O
Cys None None O
- None None O
Phe None None O
- None None O
Tyr None None O
- None None O
D None None O
- None None O
threo None None O
- None None O
beta None None O
- None None O
Me2Nal None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Cys None None O
] None None O
- None None O
OH None None O
had None None O
high None None O
affinity None None O
for None None O
all None None O
sst None None O
's None None O
except None None O
for None None O
sst None None O
( None None O
1 None None O
) None None O
, None None O
and None None O
that None None O
H None None O
- None None O
c None None O
[ None None O
Cys None None O
- None None O
Phe None None O
- None None O
Tyr None None O
- None None O
L None None O
- None None O
threo None None O
- None None O
beta None None O
- None None O
Me2Nal None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Cys None None O
] None None O
- None None O
OH None None O
had None None O
high None None O
affinity None None O
for None None O
sst None None O
( None None O
4 None None O
) None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
2.1 None None O
nM None None O
) None None O
, None None O
with None None O
more None None O
than None None O
50 None None O
- None None O
fold None None O
selectivity None None O
toward None None O
the None None O
other None None O
receptors None None O
( None None O
parts None None O
1 None None O
and None None O
2 None None O
of None None O
this None None O
series None None O
: None None O
Rivier None None O
et None None O
al. None None O
and None None O
Erchegyi None None O
et None None O
al. None None O
J None None O
. None None O

Med. None None O
Chem. None None O
, None None O
preceding None None O
papers None None O
in None None O
this None None O
issue None None O
) None None O
, None None O
we None None O
found None None O
H None None O
- None None O
c None None O
[ None None O
Cys None None O
- None None O
Phe None None O
- None None O
Phe None None O
- None None O
Trp None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Cys None None O
] None None O
- None None O
OH None None O
( None None O
OLT None None O
- None None O
8 None None O
, None None O
2 None None O
) None None O
, None None O
H None None O
- None None O
c None None O
[ None None O
Cys None None O
- None None O
Phe None None O
- None None O
Phe None None O
- None None O
L None None O
- None None O
threo None None O
- None None O
beta None None O
- None None O
MeTrp None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Cys None None O
] None None O
- None None O
OH None None O
( None None O
4 None None O
) None None O
and None None O
H None None O
- None None O
c None None O
[ None None O
Cys None None O
- None None O
Phe None None O
- None None O
Phe None None O
- None None O
D None None O
- None None O
threo None None O
- None None O
beta None None O
- None None O
MeTrp None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Cys None None O
] None None O
- None None O
OH None None O
( None None O
5 None None O
) None None O
to None None O
have None None O
very None None O
high None None O
affinity None None O
for None None O
sst None None O
( None None O
4 None None O
) None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.7 None None O
, None None O
1.8 None None O
, None None O
and None None O
4.0 None None O
nM None None O
, None None O
respectively None None O
) None None O
and None None O
5 None None O
- None None O
to None None O
10 None None O
- None None O
fold None None O
selectivity None None O
versus None None O
the None None O
other None None O
sst None None O
's None None O
. None None O

From None None O
earlier None None O
work None None O
, None None O
we None None O
concluded None None O
that None None O
an None None O
l None None O
- None None O
amino None None O
acid None None O
at None None O
position None None O
8 None None O
and None None O
a None None O
tyrosine None None I-IUPAC
or None None O
4 None None I-IUPAC
- None None I-IUPAC
aminophenylalanine None None I-IUPAC
substitution None None I-MODIFIER
at None None O
position None None O
7 None None O
may None None O
lead None None O
to None None O
high None None O
sst None None O
( None None O
4 None None O
) None None O
selectivity None None O
. None None O

In None None O
fact None None O
, None None O
[ None None O
Tyr None None O
( None None O
7 None None O
) None None O
] None None O
- None None O
2 None None O
( None None O
6 None None O
) None None O
and None None O
[ None None O
Tyr None None O
( None None O
7 None None O
) None None O
] None None O
- None None O
3 None None O
( None None O
7 None None O
) None None O
show None None O
ca. None None O
5 None None O
- None None O
fold None None O
selectivity None None O
for None None O
sst None None O
( None None O
4 None None O
) None None O
, None None O
and None None O
[ None None O
Aph None None O
( None None O
7 None None O
) None None O
] None None O
- None None O
2 None None O
( None None O
8 None None O
) None None O
and None None O
[ None None O
Aph None None O
( None None O
7 None None O
) None None O
] None None O
- None None O
3 None None O
( None None O
9 None None O
) None None O
have None None O
high None None O
sst None None O
( None None O
4 None None O
) None None O
affinity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.2 None None O
and None None O
0.88 None None O
nM None None O
, None None O
respectively None None O
) None None O
and None None O
selectivity None None O
, None None O
suggesting None None O
that None None O
indeed None None O
an None None O
l None None O
- None None O
residue None None O
at None None O
position None None O
8 None None O
will None None O
direct None None O
selectivity None None O
toward None None O
sst None None O
( None None O
4 None None O
) None None O
. None None O

Unexpectedly None None O
, None None O
[ None None O
Ala None None O
( None None O
7 None None O
) None None O
] None None O
- None None O
2 None None O
( None None O
10 None None O
) None None O
and None None O
[ None None O
Ala None None O
( None None O
7 None None O
) None None O
] None None O
- None None O
3 None None O
( None None O
11 None None O
) None None O
have None None O
very None None O
high None None O
sst None None O
( None None O
4 None None O
) None None O
affinity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.84 None None O
and None None O
0.98 None None O
nM None None O
, None None O
respectively None None O
) None None O
and None None O
selectivity None None O
( None None O
& None None O
gt None None O
; None None O
600 None None O
- None None O
and None None O
200 None None O
- None None O
fold None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
combination None None O
of None None O
Tyr None None O
( None None O
2 None None O
) None None O
and None None O
dTrp None None O
( None None O
8 None None O
) None None O
in None None O
analogues None None O
14 None None O
and None None O
22 None None O
did None None O
not None None O
affect None None O
the None None O
affinity None None O
of None None O
the None None O
analogues None None O
for None None O
sst None None O
( None None O
4 None None O
) None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.2 None None O
and None None O
1.1 None None O
nM None None O
, None None O
respectively None None O
) None None O
but None None O
resulted None None O
in None None O
loss None None O
of None None O
selectivity None None O
, None None O
whereas None None O
the None None O
combination None None O
of None None O
Tyr None None O
( None None O
2 None None O
) None None O
and None None O
LTrp None None O
( None None O
8 None None O
) None None O
in None None O
H None None O
- None None O
Tyr None None O
- None None O
c None None O
[ None None O
Cys None None O
- None None O
Phe None None O
- None None O
Aph None None O
- None None O
Trp None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Cys None None O
] None None O
- None None O
OH None None O
( None None O
13 None None O
) None None O
and None None O
H None None O
- None None O
Tyr None None O
- None None O
c None None O
[ None None O
Cys None None O
- None None O
Phe None None O
- None None O
Ala None None O
- None None O
Trp None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Phe None None O
- None None O
Cys None None O
] None None O
- None None O
OH None None O
( None None O
19 None None O
) None None O
retained None None O
high None None O
affinity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.9 None None O
and None None O
1.98 None None O
nM None None O
, None None O
respectively None None O
) None None O
and None None O
sst None None O
( None None O
4 None None O
) None None O
selectivity None None O
( None None O
& None None O
gt None None O
; None None O
50 None None O
and None None O
& None None O
gt None None O
; None None O
250 None None O
, None None O
respectively None None O
) None None O
. None None O

Interestingly None None O
, None None O
the None None O
same None None O
substitutions None None O
at None None O
positions None None O
2 None None O
and None None O
7 None None O
, None None O
with None None O
l None None O
- None None O
threo None None O
- None None O
beta None None O
- None None O
MeTrp None None O
at None None O
position None None O
8 None None O
, None None O
yielded None None O
a None None O
much None None O
less None None O
selective None None O
analogue None None O
( None None O
20 None None O
) None None O
. None None O

Carbamoylation None None O
of None None O
the None None O
N None None O
- None None O
terminus None None O
of None None O
most None None O
of None None O
these None None O
analogues None None O
resulted None None O
in None None O
slightly None None O
improved None None O
affinity None None O
, None None O
selectivity None None O
, None None O
or None None O
both None None O
. None None O

Other None None O
amino None None O
acid None None O
substitutions None None O
in None None O
this None None O
series None None O
, None None O
such None None O
as None None O
those None None O
with None None O
Amp None None O
( None None O
25 None None O
, None None O
26 None None O
) None None O
, None None O
Orn None None O
( None None O
27 None None O
) None None O
, None None O
or None None O
IAmp None None O
( None None O
29 None None O
) None None O
at None None O
position None None O
7 None None O
, None None O
were None None O
also None None O
tolerated None None O
but None None O
with None None O
a None None O
2 None None O
- None None O
to None None O
3 None None O
- None None O
fold None None O
loss None None O
of None None O
affinity None None O
and None None O
concomitant None None O
loss None None O
of None None O
selectivity None None O
. None None O

Analogous None None O
peptides None None O
with None None O
a None None O
tyrosine None None O
at None None O
position None None O
11 None None O
( None None O
31-36 None None O
) None None O
were None None O
less None None O
selective None None O
than None None O
the None None O
corresponding None None O
peptides None None O
with None None O
a None None O
tyrosine None None O
at None None O
position None None O
2 None None O
. None None O

Several None None O
analogues None None O
in None None O
this None None O
series None None O
compared None None O
favorably None None O
with None None O
the None None O
non None None O
- None None O
peptide None None O
L None None O
- None None O
803,087 None None O
( None None O
37 None None O
) None None O
in None None O
terms None None O
of None None O
affinity None None O
and None None O
selectivity None None O
. None None O

Analogues None None O
8 None None O
, None None O
10 None None O
, None None O
and None None O
21 None None O
potently None None O
inhibited None None O
the None None O
forskolin None None O
- None None O
stimulated None None O
cAMP None None O
production None None O
in None None O
sst None None O
( None None O
4 None None O
) None None O
- None None O
transfected None None O
cells None None O
, None None O
therefore None None O
acting None None O
as None None O
full None None O
agonists None None O
. None None O

Cold None None O
monoiodination None None O
of None None O
19 None None O
yielded None None O
21 None None O
, None None O
with None None O
retention None None O
of None None O
high None None O
sst None None O
( None None O
4 None None O
) None None O
selectivity None None O
and None None O
affinity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
3.5 None None O
nM None None O
) None None O
. None None O

( None None O
125 None None O
) None None O
Iodinated None None O
19 None None O
selectively None None O
binds None None O
to None None O
sst None None O
( None None O
4 None None O
) None None O
- None None O
transfected None None O
cells None None O
but None None O
not None None O
to None None O
sst None None O
( None None O
1-3 None None O
) None None O
- None None O
or None None O
sst None None O
( None None O
5 None None O
) None None O
- None None O
transfected None None O
cells None None O
. None None O

Binding None None O
in None None O
sst None None O
( None None O
4 None None O
) None None O
- None None O
transfected None None O
cells None None O
was None None O
completely None None O
displaced None None O
by None None O
SRIF None None O
- None None O
28 None None O
or None None O
the None None O
sst None None O
( None None O
4 None None O
) None None O
- None None O
selective None None O
L None None O
- None None O
803,087 None None O
. None None O


Nineteen None None O
previously None None O
undescribed None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5,6,7 None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
tetrahydroquinazolines None None I-IUPAC
( None None O
5a None None O
- None None O
m None None O
, None None O
10-12 None None O
) None None O
were None None O
synthesized None None O
as None None O
part None None O
of None None O
a None None O
larger None None O
effort None None O
to None None O
assess None None O
the None None O
therapeutic None None O
potential None None O
of None None O
lipophilic None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
inhibitors None None O
against None None O
opportunistic None None O
infections None None O
of None None O
AIDS None None O
. None None O

Condensation None None O
of None None O
appropriately None None O
substituted None None O
( None None O
arylmethyl None None O
) None None O
triphenylphosphoranes None None O
with None None O
4 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ethylenedioxycyclohexanone None None I-IUPAC
, None None O
followed None None O
by None None O
hydrogenation None None O
( None None O
H2 None None O
/ None None O
Pd None None O
- None None O
C None None O
) None None O
and None None O
acidolysis None None O
, None None O
yielded None None O
the None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylmethyl None None I-IUPAC
) None None I-IUPAC
cyclohexanones None None I-IUPAC
, None None O
which None None O
were None None O
then None None O
condensed None None O
with None None O
cyanoguanidine None None O
to None None O
form None None O
the None None O
tetrahydroquinazolines None None O
. None None O

Three None None O
simple None None O
2 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydroquinazoline None None I-IUPAC
model None None I-MODIFIER
compounds None None I-MODIFIER
( None None O
9a None None O
- None None O
c None None O
) None None O
were None None O
also None None O
prepared None None O
in None None O
one None None O
step None None O
from None None O
commercially None None O
available None None O
4 None None I-IUPAC
- None None I-IUPAC
alkylcyclohexanones None None I-IUPAC
by None None O
this None None O
method None None O
. None None O

Enzyme None None O
inhibition None None O
assays None None O
against None None O
rat None None O
liver None None O
DHFR None None O
, None None O
Pneumocystis None None O
carinii None None O
DHFR None None O
, None None O
and None None O
the None None O
bifunctional None None O
DHFR None None O
- None None O
TS None None O
enzyme None None O
from None None O
Toxoplasma None None O
gondii None None O
were None None O
carried None None O
out None None O
, None None O
and None None O
the None None O
selectivity None None O
ratios None None O
IC50 None None O
( None None O
rat None None O
) None None O
/ None None O
IC50 None None O
( None None O
P None None O
. None None O

carinii None None O
) None None O
and None None O
IC50 None None O
( None None O
rat None None O
) None None O
/ None None O
IC50 None None O
( None None O
T None None O
. None None O

gondii None None O
) None None O
were None None O
compared None None O
. None None O

The None None O
three None None O
most None None O
potent None None O
inhibitors None None O
of None None O
P None None O
. None None O

carinii None None O
DHFR None None O
were None None O
the None None O
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzyl None None I-IUPAC
( None None O
5j None None O
) None None O
, None None O
3 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzyl None None I-IUPAC
( None None O
5k None None O
) None None O
, None None O
and None None O
3,4,5 None None I-IUPAC
- None None I-IUPAC
trimethoxybenzyl None None I-IUPAC
( None None O
5l None None O
) None None O
analogues None None I-MODIFIER
, None None O
with None None O
IC50 None None O
values None None O
of None None O
0.057 None None O
, None None O
0.10 None None O
, None None O
and None None O
0.091 None None O
microM None None O
, None None O
respectively None None O
. None None O

The None None O
remaining None None O
compounds None None O
generally None None O
had None None O
IC50 None None O
values None None O
in None None O
the None None O
0.1-1.0 None None O
microM None None O
range None None O
. None None O

However None None O
all None None O
the None None O
compounds None None O
were None None O
more None None O
potent None None O
against None None O
the None None O
rat None None O
liver None None O
enzyme None None O
than None None O
the None None O
P None None O
. None None O

carinii None None O
enzyme None None O
and None None O
thus None None O
were None None O
nonselective None None O
. None None O

The None None O
T None None O
. None None O

gondii None None O
enzyme None None O
was None None O
always None None O
more None None O
sensitive None None O
than None None O
the None None O
P None None O
. None None O

carinii None None O
enzyme None None O
, None None O
with None None O
most None None O
of None None O
the None None O
analogues None None O
giving None None O
IC50 None None O
values None None O
of None None O
0.01-0.1 None None O
microM None None O
. None None O

Moderate None None O
5-10 None None O
- None None O
fold None None O
selectivity None None O
for None None O
T None None O
. None None O

gondii None None O
versus None None O
rat None None O
liver None None O
DHFR None None O
was None None O
observed None None O
with None None O
five None None O
compounds None None O
, None None O
the None None O
best None None O
combination None None O
of None None O
potency None None O
and None None O
selectivity None None O
being None None O
achieved None None O
with None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
analogue None None I-MODIFIER
5d None None O
, None None O
which None None O
had None None O
an None None O
IC50 None None O
of None None O
0.014 None None O
microM None None O
and None None O
a None None O
selectivity None None O
ratio None None O
of None None O
8.6 None None O
. None None O

One None None O
compound None None O
( None None O
5l None None O
) None None O
was None None O
tested None None O
for None None O
antiproliferative None None O
activity None None O
against None None O
P None None O
. None None O

carinii None None O
trophozoites None None O
in None None O
culture None None O
at None None O
a None None O
concentration None None O
of None None O
10 None None O
microgram None None O
/ None None O
mL None None O
and None None O
was None None O
found None None O
to None None O
completely None None O
suppress None None O
growth None None O
over None None O
7 None None O
days None None O
. None None O

The None None O
suppressive None None O
effect None None O
of None None O
5l None None O
was None None O
the None None O
same None None O
as None None O
that None None O
of None None O
trimethoprim None None O
( None None O
10 None None O
microgram None None O
/ None None O
mL None None O
) None None O
+ None None O
sulfamethoxazole None None O
( None None O
250 None None O
microgram None None O
/ None None O
mL None None O
) None None O
, None None O
a None None O
standard None None O
clinical None None O
combination None None O
for None None O
the None None O
treatment None None O
of None None O
P None None O
. None None O

carinii None None O
pneumonia None None O
in None None O
AIDS None None O
patients None None O
. None None O

Four None None O
compounds None None O
( None None O
5a None None O
, None None O
h None None O
, None None O
k None None O
, None None O
l None None O
) None None O
were None None O
tested None None O
against None None O
T None None O
. None None O

gondii None None O
tachyzoites None None O
in None None O
culture None None O
and None None O
were None None O
found None None O
to None None O
have None None O
a None None O
potency None None O
( None None O
IC50 None None O
= None None O
0.1-0.5 None None O
microM None None O
) None None O
similar None None O
to None None O
that None None O
of None None O
pyrimethamine None None O
( None None O
IC50 None None O
= None None O
0.69 None None O
microM None None O
) None None O
, None None O
a None None O
standard None None O
clinical None None O
agent None None O
for None None O
the None None O
treatment None None O
of None None O
cerebral None None O
toxoplasmosis None None O
in None None O
AIDS None None O
patients None None O
. None None O

Compound None None O
5h None None O
was None None O
also None None O
active None None O
against None None O
T None None O
. None None O

gondii None None O
infection None None O
in None None O
mice None None O
when None None O
given None None O
qdx8 None None O
by None None O
peritoneal None None O
injection None None O
at None None O
doses None None O
ranging None None O
from None None O
62.5 None None O
( None None O
initial None None O
dose None None O
) None None O
to None None O
25 None None O
mg None None O
/ None None O
kg None None O
. None None O

Survival None None O
was None None O
prolonged None None O
to None None O
the None None O
same None None O
degree None None O
as None None O
with None None O
25 None None O
mg None None O
/ None None O
kg None None O
clindamycin None None O
, None None O
another None None O
widely None None O
used None None O
drug None None O
against None None O
toxoplasmosis None None O
. None None O

Three None None O
compounds None None O
( None None O
5j None None O
- None None O
l None None O
) None None O
were None None O
tested None None O
for None None O
antiproliferative None None O
activity None None O
against None None O
human None None O
tumor None None O
cells None None O
in None None O
culture None None O
. None None O

Among None None O
the None None O
25 None None O
cell None None O
lines None None O
in None None O
the None None O
National None None O
Cancer None None O
Institute None None O
panel None None O
for None None O
which None None O
data None None O
were None None O
confirmed None None O
in None None O
two None None O
independent None None O
experiments None None O
, None None O
the None None O
IC50 None None O
for None None O
at None None O
least None None O
two None None O
of None None O
these None None O
compounds None None O
was None None O
& None None O
lt None None O
; None None O
10 None None O
microM None None O
against None None O
17 None None O
cell None None O
lines None None O
( None None O
68% None None O
) None None O
and None None O
in None None O
the None None O
0 None None O
. None None O

1-1 None None O
microM None None O
range None None O
against None None O
13 None None O
cell None None O
lines None None O
( None None O
52% None None O
) None None O
. None None O

One None None O
compound None None O
( None None O
5j None None O
) None None O
had None None O
an None None O
IC50 None None O
of None None O
& None None O
lt None None O
; None None O
0.01 None None O
microM None None O
against None None O
four None None O
of None None O
the None None O
cell None None O
lines None None O
. None None O

The None None O
activity None None O
profiles None None O
of None None O
5k None None O
, None None O
l None None O
were None None O
generally None None O
similar None None O
to None None O
that None None O
of None None O
5j None None O
except None None O
that None None O
there None None O
were None None O
no None None O
cells None None O
against None None O
which None None O
the None None O
IC50 None None O
was None None O
& None None O
lt None None O
; None None O
0.01 None None O
microM None None O
. None None O


A None None O
series None None O
of None None O
novel None None O
( None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dialkyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
arylmethanones None None I-IUPAC
was None None O
synthesized None None O
. None None O

Pharmacological None None O
evaluation None None O
of None None O
these None None O
compounds None None O
demonstrated None None O
central None None O
nervous None None O
system None None O
depressant None None O
activity None None O
, None None O
potential None None O
anticonvulsant None None O
properties None None O
, None None O
and None None O
a None None O
low None None O
order None None O
of None None O
acute None None O
toxicity None None O
. None None O

In None None O
addition None None O
, None None O
selected None None O
compounds None None O
showed None None O
potential None None O
antipsychotic None None O
effects None None O
. None None O

This None None O
report None None O
focuses None None O
on None None O
the None None O
synthesis None None O
and None None O
structure None None O
- None None O
activity None None O
relationships None None O
of None None O
these None None O
compounds None None O
. None None O

( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
methanone None None I-IUPAC
( None None O
21 None None O
) None None O
was None None O
the None None O
most None None O
active None None O
compound None None O
against None None O
pentylenetetrazole None None O
- None None O
induced None None O
convulsions None None O
. None None O

( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
methanone None None I-IUPAC
( None None O
4 None None O
) None None O
also None None O
has None None O
a None None O
favorable None None O
anticonvulsant None None O
depression None None O
ratio None None O
. None None O

( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
trifluoromethylphenyl None None I-IUPAC
) None None I-IUPAC
methan None None I-IUPAC
one None None I-IUPAC
( None None O
8 None None O
) None None O
, None None O
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
methanone None None I-IUPAC
( None None O
13 None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
phenylmethanone None None I-IUPAC
( None None O
14 None None O
) None None O
are None None O
very None None O
potent None None O
depressants None None O
. None None O

( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
methanone None None I-IUPAC
( None None O
12 None None O
) None None O
possessed None None O
marked None None O
central None None O
depressant None None O
activity None None O
without None None O
anticonvulsant None None O
activity None None O
and None None O
without None None O
impairment None None O
of None None O
motor None None O
functioning None None O
. None None O

( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyrazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
methanone None None I-IUPAC
( None None O
2 None None O
) None None O
has None None O
a None None O
behavioral None None O
profile None None O
suggestive None None O
of None None O
antipsychotic None None O
activity None None O
and None None O
gave None None O
a None None O
positive None None O
Ames None None O
test None None O
result None None O
. None None O


A None None O
series None None O
of None None O
2,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
diamino None None I-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
aralkyl None None I-PARTIUPAC
and None None O
alicyclic None None I-PARTIUPAC
) None None I-PARTIUPAC
thio None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
sulfinyl None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
sulfonyl None None I-PARTIUPAC
] None None I-PARTIUPAC
quinazolines None None I-PARTIUPAC
was None None O
prepared None None O
via None None O
condensation None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
nitrobenzonitrile None None I-IUPAC
or None None O
5,6 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
nitrobenzonitrile None None I-IUPAC
with None None O
the None None O
appropriate None None O
aralkyl None None O
or None None O
alicyclic None None O
thiopseudourea None None O
, None None O
reduction None None O
of None None O
the None None O
resulting None None O
2 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
aralkyl None None I-IUPAC
or None None I-IUPAC
alicyclic None None I-IUPAC
) None None I-IUPAC
thio None None I-IUPAC
] None None I-IUPAC
benzonitrile None None I-IUPAC
with None None O
stannous None None O
chloride None None O
to None None O
the None None O
amine None None O
, None None O
and None None O
cyclization None None O
with None None O
chloroformamidine None None I-IUPAC
hydrochloride None None I-IUPAC
. None None O

Oxidation None None O
was None None O
effected None None O
with None None O
hydrogen None None O
peroxide None None O
or None None O
the None None O
bromine None None O
complex None None O
of None None O
1,4 None None I-IUPAC
- None None I-IUPAC
diazabicyclo None None I-IUPAC
[ None None I-IUPAC
2.2.2 None None I-IUPAC
] None None I-IUPAC
octane None None I-IUPAC
. None None O

These None None O
analogues None None O
when None None O
examined None None O
for None None O
suppressive None None O
activity None None O
against None None O
drug None None O
- None None O
sensitive None None O
lines None None O
of None None O
Plasmodium None None O
berghei None None O
in None None O
mice None None O
were None None O
not None None O
as None None O
active None None O
as None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorobenzyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
quinazoline None None I-IUPAC
( None None O
Ia None None O
) None None O
. None None O


We None None O
describe None None O
the None None O
synthesis None None O
and None None O
some None None O
pharmacological None None O
properties None None O
of None None O
16 None None O
new None None O
in None None O
vivo None None O
antagonists None None O
of None None O
oxytocin None None O
. None None O

These None None O
are None None O
based None None O
on None None O
modifications None None O
of None None O
three None None O
peptides None None O
: None None O
A None None O
, None None O
B None None O
, None None O
and None None O
C None None O
. None None O

A None None O
is None None O
our None None O
previously None None O
reported None None O
potent None None O
and None None O
selective None None O
antagonist None None O
of None None O
the None None O
vasopressor None None O
( None None O
V1 None None O
receptor None None O
) None None O
responses None None O
to None None O
arginine None None O
- None None O
vasopressin None None O
( None None O
AVP None None O
) None None O
/ None None O
weak None None O
oxytocin None None O
antagonist None None O
, None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
mercapto None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
, None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
pentamethylenepropionic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyltyrosine None None I-IUPAC
] None None I-IUPAC
arginine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
( None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
] None None O
AVP None None O
. None None O

B None None O
reported None None O
here None None O
, None None O
the None None O
Ile3 None None O
analogue None None O
of None None O
A None None O
, None None O
is None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
] None None O
AVT None None O
( None None O
5 None None O
below None None O
) None None O
and None None O
C None None O
is None None O
our None None O
previously None None O
reported None None O
potent None None O
nonselective None None O
oxytocin None None O
antagonist None None O
/ None None O
AVP None None O
V1 None None O
antagonist None None O
, None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
mercapto None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
, None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
pentamethylenepropionic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyltyrosine None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
ornithine None None I-IUPAC
] None None I-IUPAC
vasotocin None None I-IUPAC
( None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
] None None O
OVT None None O
) None None O
. None None O

The None None O
following None None O
substitutions None None O
and None None O
deletions None None O
, None None O
alone None None O
or None None O
in None None O
combination None None O
, None None O
were None None O
employed None None O
in None None O
A None None O
, None None O
B None None O
, None None O
and None None O
C None None O
: None None O
1 None None I-IUPAC
- None None I-IUPAC
deaminopenicillamine None None I-IUPAC
( None None O
dP None None O
) None None O
; None None O
D None None O
- None None O
Tyr None None O
( None None O
Alk None None O
) None None O
2 None None O
( None None O
where None None O
Alk None None O
= None None O
Me None None O
or None None O
Et None None O
) None None O
, None None O
D None None O
- None None O
Phe2 None None O
; None None O
Val4 None None O
, None None O
Thr4 None None O
; None None O
delta None None O
3 None None O
- None None O
Pro7 None None O
; None None O
Lys8 None None O
, None None O
Cit8 None None O
; None None O
desGly9 None None O
, None None O
desGly None None O
- None None O
NH2 None None O
( None None O
9 None None O
) None None O
, None None O
Ala None None O
- None None O
NH2 None None O
( None None O
9 None None O
) None None O
; None None O
Leu None None O
- None None O
NH2 None None O
( None None O
9 None None O
) None None O
; None None O
Arg None None O
- None None O
NH2 None None O
( None None O
9 None None O
) None None O
. None None O

The None None O
16 None None O
new None None O
analogues None None O
are None None O
( None None O
1 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
D None None O
- None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
] None None O
AVP None None O
, None None O
( None None O
2 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
D None None O
- None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Val4 None None O
, None None O
delta None None O
3 None None O
- None None O
Pro7 None None O
] None None O
AVP None None O
, None None O
( None None O
3 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
D None None O
- None None O
Tyr None None O
- None None O
( None None O
Et None None O
) None None O
2 None None O
, None None O
Val4 None None O
, None None O
Lys8 None None O
] None None O
VP None None O
, None None O
( None None O
4 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
D None None O
- None None O
Tyr None None O
( None None O
Et None None O
) None None O
2 None None O
, None None O
Val4 None None O
, None None O
Cit8 None None O
] None None O
VP None None O
, None None O
( None None O
5 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
] None None O
AVT None None O
, None None O
( None None O
6 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Lys8 None None O
] None None O
VT None None O
, None None O
( None None O
7 None None O
) None None O
dP None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
] None None O
AVT None None O
, None None O
( None None O
8 None None O
) None None O
dP None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Val4 None None O
] None None O
AVT None None O
, None None O
( None None O
9 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
D None None O
- None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Val4 None None O
] None None O
AVT None None O
, None None O
( None None O
10 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
D None None O
- None None O
Phe2 None None O
, None None O
Val4 None None O
] None None O
AVT None None O
, None None O
( None None O
11 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Thr4 None None O
] None None O
OVT None None O
, None None O
( None None O
12 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Thr4 None None O
, None None O
Ala None None O
- None None O
NH2 None None O
( None None O
9 None None O
) None None O
] None None O
OVT None None O
, None None O
( None None O
13 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Thr4 None None O
, None None O
Leu None None O
- None None O
NH2 None None O
( None None O
9 None None O
) None None O
] None None O
OVT None None O
, None None O
( None None O
14 None None O
) None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Thr4 None None O
, None None O
Arg None None O
- None None O
NH2 None None O
( None None O
9 None None O
) None None O
] None None O
OVT None None O
, None None O
( None None O
15 None None O
) None None O
desGly None None O
- None None O
NH2 None None O
( None None O
9 None None O
) None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Thr4 None None O
] None None O
OVT None None O
, None None O
( None None O
16 None None O
) None None O
desGly9 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
, None None O
Thr4 None None O
] None None O
OVT None None O
. None None O

1-4 None None O
are None None O
analogues None None O
of None None O
A None None O
, None None O
5-10 None None O
are None None O
analogues None None O
of None None O
B None None O
, None None O
and None None O
11-16 None None O
are None None O
analogues None None O
of None None O
C None None O
. None None O

Their None None O
protected None None O
precursors None None O
were None None O
synthesized None None O
either None None O
entirely None None O
by None None O
the None None O
solid None None O
- None None O
phase None None O
method None None O
or None None O
by None None O
a None None O
combination None None O
of None None O
solid None None O
- None None O
phase None None O
and None None O
solution None None O
methods None None O
( None None O
1 None None O
+ None None O
8 None None O
or None None O
8 None None O
+ None None O
1 None None O
couplings None None O
) None None O
. None None O

All None None O
analogues None None O
were None None O
tested None None O
in None None O
rats None None O
for None None O
agonistic None None O
and None None O
antagonistic None None O
activities None None O
in None None O
oxytocic None None O
( None None O
in None None O
vitro None None O
, None None O
without None None O
and None None O
with None None O
Mg2+ None None O
, None None O
and None None O
in None None O
vivo None None O
) None None O
assays None None O
as None None O
well None None O
as None None O
by None None O
antidiuretic None None O
and None None O
vasopressor None None O
assays None None O
. None None O

All None None O
analogues None None O
exhibit None None O
potent None None O
oxytocic None None O
antagonism None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

With None None O
an None None O
in None None O
vitro None None O
pA2 None None O
( None None O
in None None O
the None None O
absence None None O
of None None O
Mg2+ None None O
) None None O
= None None O
9.12 None None O
+ None None O
/ None None O
- None None O
0.09 None None O
, None None O
dP None None O
[ None None O
Tyr None None O
( None None O
Me None None O
) None None O
2 None None O
] None None O
AVT None None O
is None None O
( None None O
7 None None O
) None None O
one None None O
of None None O
the None None O
most None None O
potent None None O
in None None O
vitro None None O
oxytocin None None O
antagonists None None O
reported None None O
to None None O
date None None O
. None None O

Fifteen None None O
of None None O
these None None O
analogues None None O
( None None O
all None None O
but None None O
6 None None O
) None None O
appear None None O
as None None O
potent None None O
or None None O
more None None O
potent None None O
in None None O
vivo None None O
oxytocin None None O
antagonists None None O
than None None O
C None None O
( None None O
pA2 None None O
= None None O
7.37 None None O
+ None None O
/ None None O
- None None O
0.17 None None O
) None None O
. None None O

Analogues None None O
1-9 None None O
and None None O
14 None None O
are None None O
potent None None O
AVP None None O
V1 None None O
antagonists None None O
. None None O

Their None None O
anti None None O
- None None O
V1 None None O
pA2 None None O
values None None O
range None None O
from None None O
7.92 None None O
to None None O
8.45 None None O
. None None O

They None None O
are None None O
thus None None O
nonselective None None O
oxytocin None None O
antagonists None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

A None None O
series None None O
of None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
decahydroisoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acids None None I-IUPAC
were None None O
prepared None None O
as None None O
excitatory None None O
amino None None O
acid None None O
( None None O
EAA None None O
) None None O
receptor None None O
antagonists None None O
. None None O

These None None O
compounds None None O
are None None O
antagonists None None O
at None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
aspartate None None I-IUPAC
( None None O
NMDA None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propanoic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
) None None O
subclasses None None O
of None None O
ligand None None O
gated None None O
ion None None O
channel None None O
( None None O
ionotropic None None O
) None None O
EAA None None O
receptors None None O
. None None O

( None None I-IUPAC
3S None None I-IUPAC
, None None I-IUPAC
4aR None None I-IUPAC
, None None I-IUPAC
6R None None I-IUPAC
, None None I-IUPAC
8aR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4,4 None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
5,6,7,8,8 None None I-IUPAC
a None None I-IUPAC
- None None I-IUPAC
decahydroisoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
9 None None O
) None None O
is None None O
a None None O
potent None None O
, None None O
selective None None O
and None None O
systemically None None O
active None None O
AMPA None None O
antagonist None None O
. None None O

Other None None O
analogs None None O
from None None O
this None None O
series None None O
, None None O
including None None O
( None None I-IUPAC
3S None None I-IUPAC
, None None I-IUPAC
4aR None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
, None None I-IUPAC
8aR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4,4 None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
5,6,7,8,8 None None I-IUPAC
a None None I-IUPAC
- None None I-IUPAC
decahydroisoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
32 None None O
) None None O
and None None O
( None None I-IUPAC
3S None None I-IUPAC
, None None I-IUPAC
4aR None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
, None None I-IUPAC
8aR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4,4 None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
5,6,7,8,8 None None I-IUPAC
a None None I-IUPAC
- None None I-IUPAC
decahydroisoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ca None None I-IUPAC
rboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
61 None None O
) None None O
are None None O
potent None None O
, None None O
selective None None O
, None None O
and None None O
systemically None None O
active None None O
NMDA None None O
antagonists None None O
. None None O

This None None O
and None None O
the None None O
subsequent None None O
publication None None O
look None None O
at None None O
the None None O
AMPA None None O
antagonist None None O
aspects None None O
of None None O
this None None O
SAR None None O
. None None O

Herein None None O
we None None O
report None None O
the None None O
effects None None O
of None None O
varying None None O
stereochemistry None None O
around None None O
the None None O
hydroisoquinoline None None O
ring None None O
; None None O
of None None O
tetrahydro None None O
- None None O
versus None None O
decahydroisoquinoline None None O
; None None O
of None None O
having None None O
the None None O
carboxylic None None O
acid None None O
at None None O
C None None O
- None None O
1 None None O
versus None None O
C None None O
- None None O
3 None None O
; None None O
of None None O
varying None None O
the None None O
length None None O
of None None O
the None None O
carbon None None O
chain None None O
connecting None None O
a None None O
tetrazole None None O
to None None O
the None None O
bicyclic None None O
nucleus None None O
; None None O
and None None O
of None None O
holding None None O
the None None O
connecting None None O
chain None None O
constant None None O
at None None O
two None None O
atoms None None O
, None None O
the None None O
effect None None O
of None None O
heteroatom None None O
substitution None None O
in None None O
the None None O
position None None O
adjacent None None O
to None None O
the None None O
bicyclic None None O
nucleus None None O
and None None O
substitution None None O
with None None O
methyl None None O
or None None O
phenyl None None O
on None None O
the None None O
chain None None O
. None None O

Compounds None None O
were None None O
evaluated None None O
on None None O
rat None None O
cortical None None O
tissue None None O
for None None O
their None None O
ability None None O
to None None O
inhibit None None O
the None None O
binding None None O
of None None O
radioligands None None O
selective None None O
for None None O
AMPA None None O
( None None O
[ None None O
3H None None O
] None None O
AMPA None None O
) None None O
, None None O
NMDA None None O
( None None O
[ None None O
3H None None O
] None None O
CGS None None O
19755 None None O
) None None O
, None None O
and None None O
kainic None None O
acid None None O
( None None O
[ None None O
3H None None O
] None None O
- None None O
kainic None None O
acid None None O
) None None O
receptors None None O
and None None O
for None None O
their None None O
ability None None O
to None None O
inhibit None None O
depolarizations None None O
induced None None O
by None None O
AMPA None None O
( None None O
40 None None O
microM None None O
) None None O
, None None O
NMDA None None O
( None None O
40 None None O
microM None None O
) None None O
, None None O
and None None O
kainic None None O
acid None None O
( None None O
10 None None O
microM None None O
) None None O
. None None O

Our None None O
findings None None O
revealed None None O
that None None O
the None None O
optimal None None O
stereochemical None None O
array None None O
was None None O
the None None O
same None None O
for None None O
both None None O
NMDA None None O
( None None O
32 None None O
and None None O
61 None None O
) None None O
and None None O
AMPA None None O
( None None O
9 None None O
) None None O
antagonists None None O
identified None None O
in None None O
this None None O
series None None O
and None None O
that None None O
the None None O
tetrahydroisoquinoline None None O
( None None O
25 None None O
) None None O
and None None O
the None None O
C None None I-MODIFIER
- None None I-MODIFIER
1 None None I-MODIFIER
carboxy None None I-IUPAC
( None None O
30 None None O
) None None O
analogs None None I-MODIFIER
of None None O
9 None None O
are None None O
inactive None None O
. None None O

With None None O
a None None O
tetrazole None None O
in None None O
the None None O
distal None None O
acid None None O
position None None O
, None None O
an None None O
ethylene None None O
spacer None None O
( None None O
9 None None O
) None None O
is None None O
optimal None None O
; None None O
substitution None None O
with None None O
oxygen None None O
or None None O
nitrogen None None O
on None None O
the None None O
chain None None O
in None None O
the None None O
position None None O
adjacent None None O
to None None O
the None None O
bicyclic None None O
nucleus None None O
significantly None None O
reduced None None O
activity None None O
, None None O
while None None O
substitution None None O
with None None O
a None None O
methyl None None O
or None None O
phenyl None None O
group None None O
on None None O
the None None O
chain None None O
was None None O
well None None O
tolerated None None O
. None None O


As None None O
part None None O
of None None O
a None None O
program None None O
in None None O
which None None O
we None None O
are None None O
attempting None None O
( None None O
a None None O
) None None O
to None None O
delineate None None O
the None None O
structural None None O
features None None O
at None None O
positions None None O
1-9 None None O
in None None O
our None None O
previously None None O
reported None None O
antidiuretic None None O
antagonists None None O
required None None O
for None None O
antidiuretic None None O
antagonism None None O
and None None O
( None None O
b None None O
) None None O
to None None O
obtain None None O
analogues None None O
with None None O
enhanced None None O
antiantidiuretic None None O
potency None None O
and None None O
/ None None O
or None None O
selectivity None None O
, None None O
we None None O
have None None O
synthesized None None O
14 None None O
new None None O
analogues None None O
of None None O
the None None O
antidiuretic None None O
antagonist None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
mercapto None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
, None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
cyclopentamethylenepropionic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
phenylalanine None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
valine None None I-IUPAC
] None None I-IUPAC
arginine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
[ None None O
d None None O
- None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2VAVP None None O
) None None O
, None None O
in None None O
which None None O
the None None O
valine None None O
residue None None O
at None None O
position None None O
4 None None O
was None None O
replaced None None O
by None None O
the None None O
following None None O
L None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
acids None None I-IUPAC
and None None O
glycine None None I-PARTIUPAC
: None None O
Ile None None O
, None None O
Abu None None O
, None None O
Thr None None O
, None None O
Ala None None O
, None None O
Gln None None O
, None None O
Lys None None O
, None None O
Cha None None O
, None None O
Nle None None O
, None None O
Nva None None O
, None None O
Phe None None O
, None None O
Leu None None O
, None None O
Gly None None O
, None None O
Tyr None None O
, None None O
and None None O
Pro None None O
. None None O

These None None O
analogues None None O
are None None O
1 None None O
, None None O
d None None O
- None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Ile4AVP None None O
; None None O
2 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Abu4AVP None None O
; None None O
3 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Thr4AVP None None O
; None None O
4 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Ala4AVP None None O
; None None O
5 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2AVP None None O
; None None O
6 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Lys4AVP None None O
; None None O
7 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Cha4AVP None None O
; None None O
8 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Nle4AVP None None O
; None None O
9 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Nva4AVP None None O
; None None O
10 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Phe4AVP None None O
; None None O
11 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Leu4AVP None None O
; None None O
12 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Gly4AVP None None O
; None None O
13 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Tyr4AVP None None O
; None None O
14 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Pro4AVP None None O
. None None O

The None None O
protected None None O
intermediates None None O
required None None O
for None None O
the None None O
synthesis None None O
of None None O
all None None O
of None None O
these None None O
peptides None None O
were None None O
prepared None None O
by None None O
the None None O
solid None None O
- None None O
phase None None O
method None None O
and None None O
cleaved None None O
from None None O
the None None O
resin None None O
by None None O
ammonolysis None None O
. None None O

Following None None O
deblocking None None O
with None None O
Na None None O
in None None O
NH3 None None O
and None None O
oxidizing None None O
with None None O
K3 None None O
[ None None O
Fe None None O
( None None O
CN None None O
) None None O
6 None None O
] None None O
, None None O
each None None O
peptide None None O
was None None O
purified None None O
on None None O
Sephadex None None O
G None None O
- None None O
15 None None O
in None None O
a None None O
two None None O
- None None O
step None None O
procedure None None O
using None None O
50% None None O
HOAc None None O
and None None O
0.2 None None O
M None None O
HOAc None None O
as None None O
eluants None None O
. None None O

Analogues None None O
1-14 None None O
were None None O
tested None None O
for None None O
agonistic None None O
and None None O
antagonistic None None O
activities None None O
by None None O
antidiuretic None None O
, None None O
vasopressor None None O
, None None O
and None None O
oxytocic None None O
assays None None O
in None None O
rats None None O
. None None O

Analogues None None O
1 None None O
, None None O
2 None None O
, None None O
and None None O
4-6 None None O
exhibit None None O
no None None O
detectable None None O
antidiuretic None None O
agonistic None None O
activity None None O
. None None O

All None None O
analogues None None O
, None None O
with None None O
the None None O
exception None None O
of None None O
the None None O
Pro4 None None O
- None None O
containing None None O
analogue None None O
, None None O
are None None O
antidiuretic None None O
antagonists None None O
. None None O

Their None None O
antiantidiuretic None None O
pA2 None None O
values None None O
are None None O
as None None O
follows None None O
: None None O
1 None None O
, None None O
8.24 None None O
+ None None O
/ None None O
- None None O
0.08 None None O
; None None O
2 None None O
, None None O
7.96 None None O
+ None None O
/ None None O
- None None O
0.07 None None O
; None None O
3 None None O
, None None O
7.62 None None O
+ None None O
/ None None O
- None None O
0.09 None None O
; None None O
4 None None O
, None None O
7.52 None None O
+ None None O
/ None None O
- None None O
0.03 None None O
; None None O
5 None None O
, None None O
7.21 None None O
+ None None O
/ None None O
- None None O
0.07 None None O
; None None O
6 None None O
, None None O
7.22 None None O
+ None None O
/ None None O
- None None O
0.12 None None O
; None None O
7 None None O
, None None O
7.19 None None O
+ None None O
/ None None O
- None None O
0.08 None None O
; None None O
8 None None O
, None None O
7.12 None None O
+ None None O
/ None None O
- None None O
0.09 None None O
; None None O
9 None None O
, None None O
6.99 None None O
+ None None O
/ None None O
- None None O
0.06 None None O
; None None O
10 None None O
, None None O
6.07 None None O
+ None None O
/ None None O
- None None O
0.11 None None O
; None None O
11 None None O
, None None O
6.07 None None O
+ None None O
/ None None O
- None None O
0.11 None None O
; None None O
12 None None O
, None None O
5.85 None None O
+ None None O
/ None None O
- None None O
0.05 None None O
; None None O
13 None None O
, None None O
approximately None None O
5.57 None None O
; None None O
14 None None O
, None None O
a None None O
weak None None O
agonist None None O
( None None O
0.004 None None O
U None None O
/ None None O
mg None None O
) None None O
. None None O

Analogues None None O
1-14 None None O
also None None O
antagonize None None O
the None None O
vascular None None O
responses None None O
to None None O
arginine None None O
- None None O
vasopressin None None O
( None None O
AVP None None O
) None None O
and None None O
the None None O
in None None O
vitro None None O
oxytocic None None O
responses None None O
to None None O
oxytocin None None O
. None None O

Analogues None None O
1 None None O
, None None O
2 None None O
, None None O
3 None None O
, None None O
and None None O
5 None None O
have None None O
also None None O
been None None O
shown None None O
to None None O
antagonize None None O
the None None O
in None None O
vivo None None O
oxytocic None None O
responses None None O
to None None O
oxytocin None None O
. None None O

Five None None O
of None None O
these None None O
analogues None None O
( None None O
1 None None O
, None None O
2 None None O
, None None O
3 None None O
, None None O
6 None None O
, None None O
and None None O
7 None None O
) None None O
exhibit None None O
enhanced None None O
antiantidiuretic None None O
/ None None O
antivasopressor None None O
selectivity None None O
. None None O

d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Lys4AVP None None O
and None None O
other None None O
position None None O
- None None O
4 None None O
analogues None None O
with None None O
side None None O
- None None O
chain None None O
functional None None O
groups None None O
may None None O
be None None O
useful None None O
covalent None None O
ligands None None O
with None None O
which None None O
to None None O
probe None None O
the None None O
structural None None O
characteristics None None O
of None None O
AVP None None O
renal None None O
and None None O
vascular None None O
receptors None None O
. None None O

With None None O
an None None O
antiantidiuretic None None O
" None None O
effective None None O
dose None None O
" None None O
of None None O
0.46 None None O
+ None None O
/ None None O
- None None O
0.07 None None O
nmol None None O
/ None None O
kg None None O
and None None O
a None None O
pA2 None None O
value None None O
of None None O
8.24 None None O
+ None None O
/ None None O
- None None O
0.08 None None O
, None None O
d None None O
( None None O
CH2 None None O
) None None O
5 None None O
- None None O
D None None O
- None None O
Phe2 None None O
, None None O
Ile4AVP None None O
( None None O
1 None None O
) None None O
appears None None O
to None None O
be None None O
the None None O
most None None O
potent None None O
antidiuretic None None O
antagonist None None O
reported None None O
to None None O
date None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

The None None O
synthesis None None O
and None None O
alpha None None O
2 None None O
- None None O
adrenergic None None O
activity None None O
of None None O
a None None O
series None None O
of None None O
indolin None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
yl None None I-PARTIUPAC
and None None O
tetrahydroquinolin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
imidazolines None None I-IUPAC
are None None O
described None None O
. None None O

The None None O
indolin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
imidazoline None None I-IUPAC
4b None None O
was None None O
found None None O
to None None O
possess None None O
potent None None O
alpha None None O
2 None None O
- None None O
adrenergic None None O
agonist None None O
and None None O
antagonist None None O
activity None None O
. None None O

The None None O
modification None None O
of None None O
the None None O
substituents None None O
on None None O
the None None O
indoline None None O
ring None None O
of None None O
4b None None O
has None None O
led None None O
to None None O
the None None O
separation None None O
of None None O
these None None O
activities None None O
. None None O

Substitution None None O
on None None O
the None None O
aromatic None None O
ring None None O
of None None O
4b None None O
with None None O
halogen None None O
or None None O
increasing None None O
the None None O
size None None O
of None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
substituent None None I-MODIFIER
of None None O
4b None None O
gave None None O
alpha None None O
2 None None O
- None None O
adrenergic None None O
antagonists None None O
without None None O
agonist None None O
activity None None O
. None None O

The None None O
N None None I-IUPAC
- None None I-IUPAC
allylindoline None None I-IUPAC
4d None None O
is None None O
more None None O
potent None None O
than None None O
idazoxan None None O
in None None O
vitro None None O
and None None O
is None None O
equipotent None None O
in None None O
vivo None None O
, None None O
but None None O
is None None O
less None None O
receptor None None O
selective None None O
( None None O
alpha None None O
2 None None O
vs. None None O
alpha None None O
1 None None O
) None None O
than None None O
idazoxan None None O
. None None O

The None None O
cis None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dimethylindolin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
imidazoline None None I-IUPAC
6a None None O
is None None O
an None None O
alpha None None O
2 None None O
- None None O
adrenergic None None O
agonist None None O
equal None None O
in None None O
potency None None O
to None None O
clonidine None None O
in None None O
vitro None None O
, None None O
while None None O
the None None O
trans None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dimethylindolin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
imidazoline None None I-IUPAC
6b None None O
is None None O
a None None O
moderately None None O
potent None None O
alpha None None O
2 None None O
- None None O
adrenergic None None O
antagonist None None O
. None None O


2 None None O
- None None O
Amino None None O
- None None O
3 None None O
- None None O
aroylthiophenes None None O
are None None O
agonist None None O
allosteric None None O
enhancers None None O
( None None O
AE None None O
) None None O
at None None O
the None None O
A None None O
( None None O
1 None None O
) None None O
adenosine None None O
receptor None None O
( None None O
A None None O
( None None O
1 None None O
) None None O
AR None None O
) None None O
. None None O

Here None None O
we None None O
report None None O
the None None O
syntheses None None O
of None None O
three None None O
kinds None None O
of None None O
novel None None O
2 None None I-IUPAC
- None None I-IUPAC
aminothiophenes None None I-IUPAC
and None None O
assays None None O
of None None O
their None None O
AE None None O
activity None None O
at None None O
the None None O
human None None O
A None None O
( None None O
1 None None O
) None None O
AR None None O
( None None O
hA None None O
( None None O
1 None None O
) None None O
AR None None O
) None None O
, None None O
namely None None O
, None None O
( None None O
1 None None O
) None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
diphenylthiophene None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylates None None I-IUPAC
, None None O
3a None None O
- None None O
h None None O
, None None O
( None None O
2 None None O
) None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
diphenylthiophenes None None I-IUPAC
, None None O
7a None None O
- None None O
p None None O
, None None O
and None None O
( None None O
3 None None O
) None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenylthiophenes None None I-IUPAC
, None None O
10a None None O
- None None O
h None None O
. None None O

An None None O
in None None O
vitro None None O
assay None None O
employing None None O
the None None O
A None None O
( None None O
1 None None O
) None None O
AR None None O
agonist None None O
[ None None O
( None None O
125 None None O
) None None O
I None None O
] None None O
ABA None None O
and None None O
membranes None None O
from None None O
CHO None None O
- None None O
K1 None None O
cells None None O
stably None None O
expressing None None O
the None None O
hA None None O
( None None O
1 None None O
) None None O
AR None None O
measured None None O
an None None O
index None None O
of None None O
AE None None O
activity None None O
, None None O
the None None O
ability None None O
of None None O
a None None O
candidate None None O
AE None None O
to None None O
stabilize None None O
the None None O
agonist None None O
- None None O
A None None O
( None None O
1 None None O
) None None O
AR None None O
- None None O
G None None O
protein None None O
ternary None None O
complex None None O
, None None O
scored None None O
as None None O
the None None O
percentage None None O
of None None O
ternary None None O
complex None None O
remaining None None O
after None None O
10 None None O
min None None O
of None None O
dissociation None None O
initiated None None O
by None None O
CPX None None O
and None None O
GTPgammaS None None O
. None None O

The None None O
AE None None O
activity None None O
score None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
trifluoromethylbenzoyl None None I-IUPAC
) None None I-IUPAC
thiophene None None I-IUPAC
( None None O
PD None None O
81,723 None None O
) None None O
, None None O
which None None O
was None None O
19% None None O
, None None O
served None None O
as None None O
a None None O
standard None None O
for None None O
comparison None None O
. None None O

Two None None O
3 None None I-IUPAC
- None None I-IUPAC
carboxythiophene None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
trifluoromethylbenzyl None None I-IUPAC
esters None None I-IUPAC
, None None O
3d None None O
( None None O
49% None None O
) None None O
and None None O
3f None None O
( None None O
63% None None O
) None None O
, None None O
had None None O
substantial None None O
AE None None O
activity None None O
. None None O

The None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthoyl None None I-IUPAC
) None None I-IUPAC
substituent None None I-MODIFIER
of None None O
7e None None O
( None None O
52% None None O
) None None O
also None None O
supported None None O
AE None None O
activity None None O
. None None O

Compounds None None O
in None None O
series None None O
3 None None O
tended None None O
to None None O
be None None O
more None None O
potent None None O
, None None O
10a None None O
and None None O
10c None None O
having None None O
scores None None O
of None None O
91 None None O
and None None O
80% None None O
, None None O
respectively None None O
. None None O

The None None O
activity None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
thiophene None None I-IUPAC
, None None O
10h None None O
( None None O
26% None None O
) None None O
, None None O
is None None O
an None None O
exception None None O
to None None O
the None None O
rule None None O
that None None O
a None None O
3 None None I-IUPAC
- None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
substituent None None I-MODIFIER
cannot None None O
support None None O
AE None None O
activity None None O
. None None O


The None None O
novel None None O
acidic None None O
amino None None O
acids None None O
6a None None O
- None None O
c None None O
, None None O
7 None None O
, None None O
and None None O
8 None None O
have None None O
been None None O
synthesized None None O
via None None O
1,3 None None O
- None None O
dipolar None None O
cycloadditions None None O
, None None O
using None None O
nitrile None None O
oxides None None O
and None None O
alkynes None None O
. None None O

The None None O
prepared None None O
compounds None None O
are None None O
heterocyclic None None O
analogues None None O
of None None O
glutamic None None O
acid None None O
with None None O
differing None None O
chain None None O
lengths None None O
. None None O

One None None O
of None None O
these None None O
compounds None None O
, None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
ACPA None None O
, None None O
8 None None O
) None None O
, None None O
was None None O
shown None None O
in None None O
[ None None O
3H None None O
] None None O
AMPA None None O
binding None None O
studies None None O
to None None O
be None None O
more None None O
active None None O
than None None O
AMPA None None O
itself None None O
( None None O
IC50 None None O
= None None O
20 None None O
nM None None O
compared None None O
to None None O
IC50 None None O
= None None O
79 None None O
nM None None O
for None None O
AMPA None None O
) None None O
. None None O

No None None O
affinity None None O
for None None O
NMDA None None O
receptors None None O
( None None O
NMDA None None O
- None None O
sensitive None None O
[ None None O
3H None None O
] None None O
glutamic None None O
acid None None O
binding None None O
) None None O
was None None O
found None None O
, None None O
and None None O
only None None O
weak None None O
affinity None None O
in None None O
[ None None O
3H None None O
] None None O
kainic None None O
acid None None O
binding None None O
( None None O
IC50 None None O
= None None O
6.3 None None O
microM None None O
) None None O
was None None O
detected None None O
. None None O

The None None O
excitatory None None O
activity None None O
in None None O
rat None None O
cortical None None O
wedge None None O
also None None O
showed None None O
that None None O
ACPA None None O
was None None O
more None None O
potent None None O
than None None O
AMPA None None O
( None None O
EC50 None None O
= None None O
1.0 None None O
microM None None O
compared None None O
to None None O
EC50 None None O
= None None O
3.5 None None O
microM None None O
for None None O
AMPA None None O
) None None O
. None None O

The None None O
depolarizing None None O
effect None None O
of None None O
ACPA None None O
could None None O
be None None O
fully None None O
antagonized None None O
by None None O
the None None O
selective None None O
non None None O
- None None O
NMDA None None O
antagonist None None O
6 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
quinoxazoline None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
( None None O
CNQX None None O
) None None O
, None None O
but None None O
was None None O
unaffected None None O
by None None O
the None None O
selective None None O
NMDA None None O
antagonist None None O
D None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phosphonovaleric None None I-IUPAC
acid None None I-IUPAC
( None None O
AP5 None None O
) None None O
. None None O


A None None O
series None None O
of None None O
C11 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aporphines None None I-IUPAC
and None None O
C11 None None I-MODIFIER
- None None I-MODIFIER
oxygenated None None I-MODIFIER
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
noraporphines None None I-IUPAC
has None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
central None None O
serotonergic None None O
and None None O
dopaminergic None None O
effects None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

The None None O
various None None O
C11 None None O
- None None O
substituents None None O
were None None O
introduced None None O
using None None O
efficient None None O
nickel None None O
- None None O
and None None O
palladium None None O
- None None O
catalyzed None None O
reactions None None O
of None None O
the None None O
corresponding None None O
triflate None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
sulfonyl None None I-IUPAC
] None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
aporphine None None I-IUPAC
( None None O
6 None None O
) None None O
. None None O

Several None None O
compounds None None O
display None None O
high None None O
affinity None None O
to None None O
serotonin None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
in None None O
spite None None O
of None None O
major None None O
differences None None O
in None None O
steric None None O
bulk None None O
and None None O
electronic None None O
properties None None O
of None None O
the None None O
various None None O
C11 None None O
- None None O
substituents None None O
. None None O

A None None O
change None None O
of None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
of None None O
the None None O
nonselective None None O
3 None None O
to None None O
H None None O
[ None None O
23 None None O
, None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
hydroxynoraporphine None None I-IUPAC
] None None O
or None None O
propyl None None O
[ None None O
2 None None O
, None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
propylnoraporphine None None I-IUPAC
] None None O
increases None None O
the None None O
selectivity None None O
for None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
( None None O
100 None None O
- None None O
fold None None O
) None None O
and None None O
dopamine None None O
D2A None None O
receptors None None O
( None None O
3 None None O
- None None O
fold None None O
) None None O
, None None O
respectively None None O
. None None O

Compounds None None O
3 None None O
and None None O
23 None None O
have None None O
similar None None O
affinities None None O
to None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
, None None O
whereas None None O
the None None O
propyl None None I-IUPAC
substituent None None B-MODIFIER
of None None O
2 None None O
not None None O
only None None O
enhances None None O
the None None O
selectivity None None O
for None None O
D2A None None O
receptors None None O
but None None O
also None None O
increases None None O
the None None O
D2A None None O
affinity None None O
. None None O

Modeling None None O
of None None O
ligand None None O
- None None O
receptor None None O
binding None None O
site None None O
interactions None None O
yielded None None O
an None None O
interaction None None O
site None None O
model None None O
for None None O
the None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
that None None O
describes None None O
a None None O
gradual None None O
change None None O
in None None O
binding None None O
mode None None O
for None None O
C11 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxy None None I-PARTIUPAC
, None None O
- None None I-PARTIUPAC
methoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
- None None I-PARTIUPAC
phenyl None None I-PARTIUPAC
- None None O
substituted None None I-MODIFIER
derivatives None None I-MODIFIER
. None None O

Hydrogen None None O
bonding None None O
is None None O
hereby None None O
gradually None None O
replaced None None O
by None None O
van None None O
der None None O
Waals None None O
interactions None None O
involving None None O
a None None O
relatively None None O
large None None O
lipophilic None None O
pocket None None O
. None None O

The None None O
derived None None O
D2A None None O
receptor None None O
model None None O
can None None O
accommodate None None O
both None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
substituent None None I-MODIFIER
of None None O
2 None None O
and None None O
the None None O
C11 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
substituent None None I-MODIFIER
of None None O
11 None None O
[ None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
ethylaporphine None None I-IUPAC
] None None O
. None None O


Methotrexate None None O
poly None None O
( None None O
gamma None None O
- None None O
L None None O
- None None O
glutamate None None O
) None None O
s None None O
bearing None None O
two None None O
and None None O
three None None O
glutamate None None O
units None None O
above None None O
that None None O
present None None O
in None None O
methotrexate None None O
have None None O
been None None O
synthesized None None O
by None None O
extension None None O
of None None O
a None None O
previously None None O
described None None O
route None None O
used None None O
to None None O
synthesize None None O
the None None O
lower None None O
conjugate None None O
bearing None None O
one None None O
added None None O
glutamate None None O
unit None None O
. None None O

Key None None O
steps None None O
in None None O
the None None O
sequence None None O
are None None O
the None None O
peptide None None O
coupling None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
] None None I-IUPAC
benzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
ester None None I-IUPAC
( None None O
5 None None O
) None None O
with None None O
oligo None None I-IUPAC
( None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
) None None I-IUPAC
benzyl None None I-IUPAC
esters None None I-IUPAC
, None None O
removal None None O
of None None O
blocking None None O
groups None None O
by None None O
catalytic None None O
hydrogenolysis None None O
, None None O
and None None O
introduction None None O
of None None O
the None None O
( None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
pteridinyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
grouping None None I-MODIFIER
by None None O
alkylation None None O
with None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
pteridinediamine None None I-IUPAC
hydrobromide None None I-IUPAC
. None None O

Elaboration None None O
of None None O
the None None O
required None None O
oligo None None I-IUPAC
( None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
) None None I-IUPAC
chain None None O
was None None O
achieved None None O
one None None O
unit None None O
at None None O
a None None O
time None None O
, None None O
beginning None None O
with None None O
the None None O
coupling None None O
of None None O
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
dibenzyl None None I-IUPAC
ester None None I-IUPAC
with None None O
[ None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyloxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
ester None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
followed None None O
by None None O
selective None None O
removal None None O
of None None O
the None None O
tert None None O
- None None O
butyloxycarbonyl None None O
grouping None None O
and None None O
another None None O
coupling None None O
step None None O
with None None O
5 None None O
or None None O
7 None None O
as None None O
required None None O
. None None O

Diphenylphosphoryl None None O
azide None None O
was None None O
used None None O
as None None O
the None None O
coupling None None O
reagent None None O
in None None O
each None None O
conversion None None O
producing None None O
a None None O
peptide None None O
linkage None None O
. None None O


The None None O
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
triazine None None I-IUPAC
derivative None None I-MODIFIER
3 None None O
, None None O
more None None O
commonly None None O
known None None O
in None None O
the None None O
field None None O
of None None O
adenosine None None O
research None None O
as None None O
ZM None None O
- None None O
241385 None None O
, None None O
has None None O
previously None None O
been None None O
demonstrated None None O
to None None O
be None None O
a None None O
potent None None O
and None None O
selective None None O
adenosine None None O
A2a None None O
receptor None None O
antagonist None None O
, None None O
although None None O
with None None O
limited None None O
oral None None O
bioavailability None None O
. None None O

This None None O
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
triazine None None I-IUPAC
core None None I-MODIFIER
structure None None I-MODIFIER
has None None O
now None None O
been None None O
improved None None O
by None None O
incorporating None None O
various None None O
piperazine None None O
derivatives None None O
. None None O

With None None O
some None None O
preliminary None None O
optimization None None O
, None None O
the None None O
A2a None None O
binding None None O
affinity None None O
of None None O
some None None O
of None None O
the None None O
best None None O
piperazine None None O
derivatives None None O
is None None O
almost None None O
as None None O
good None None O
as None None O
that None None O
of None None O
compound None None O
3 None None O
. None None O

The None None O
selectivity None None O
level None None O
over None None O
the None None O
adenosine None None O
A1 None None O
receptor None None O
subtype None None O
for None None O
some None None O
of None None O
the None None O
more None None O
active None None O
analogues None None O
is None None O
also None None O
fairly None None O
high None None O
, None None O
& None None O
gt None None O
; None None O
400 None None O
- None None O
fold None None O
in None None O
some None None O
cases None None O
. None None O

Many None None O
compounds None None O
within None None O
this None None O
piperazine None None O
series None None O
of None None O
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
triazine None None I-IUPAC
have None None O
now None None O
been None None O
shown None None O
to None None O
have None None O
good None None O
oral None None O
bioavailability None None O
in None None O
the None None O
rat None None O
, None None O
with None None O
some None None O
as None None O
high None None O
as None None O
89% None None O
( None None O
compound None None O
35 None None O
) None None O
. None None O

More None None O
significantly None None O
, None None O
some None None O
piperazines None None O
derivatives None None O
of None None O
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
triazine None None I-IUPAC
also None None O
possessed None None O
good None None O
oral None None O
efficacy None None O
in None None O
rodent None None O
models None None O
of None None O
Parkinson None None O
's None None O
disease None None O
. None None O

For None None O
instance None None O
, None None O
compound None None O
34 None None O
was None None O
orally None None O
active None None O
in None None O
the None None O
rat None None O
catalepsy None None O
model None None O
at None None O
3 None None O
mg None None O
/ None None O
kg None None O
. None None O

In None None O
the None None O
6 None None I-IUPAC
- None None I-IUPAC
hydroxydopamine None None I-IUPAC
- None None O
lesioned None None O
rat None None O
model None None O
, None None O
this None None O
compound None None O
was None None O
also None None O
quite None None O
effective None None O
, None None O
with None None O
a None None O
minimum None None O
effective None None O
dose None None O
of None None O
3 None None O
mg None None O
/ None None O
kg None None O
po None None O
. None None O


The None None O
racemate None None O
and None None O
the None None O
enantiomers None None I-MODIFIER
of None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminopropane None None I-IUPAC
( None None O
6 None None O
) None None O
and None None O
racemic None None I-MODIFIER
5 None None B-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoindan None None I-IUPAC
( None None O
11 None None O
) None None O
were None None O
tested None None O
for None None O
stimulus None None O
generalization None None O
in None None O
the None None O
two None None O
- None None O
lever None None O
drug None None O
- None None O
discrimination None None O
paradigm None None O
. None None O

Both None None O
6 None None O
and None None O
11 None None O
were None None O
found None None O
to None None O
substitute None None O
with None None O
high None None O
potency None None O
in None None O
3,4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylenedioxy None None I-IUPAC
) None None I-IUPAC
methamphetamine None None I-IUPAC
( None None O
1 None None O
) None None O
and None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
benzodioxol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylamino None None I-IUPAC
) None None I-IUPAC
butane None None I-IUPAC
( None None O
2 None None O
) None None O
trained None None O
rats None None O
. None None O

In None None O
the None None O
latter None None O
assay None None O
, None None O
both None None O
enantiomers None None O
of None None O
6 None None O
had None None O
identical None None O
potencies None None O
, None None O
but None None O
their None None O
dose None None O
- None None O
response None None O
curves None None O
were None None O
not None None O
parallel None None O
. None None O

Racemic None None O
6 None None O
, None None O
but None None O
not None None O
11 None None O
, None None O
partially None None O
substituted None None O
for None None O
LSD None None O
. None None O

Racemic None None O
6 None None O
and None None O
11 None None O
did None None O
not None None O
substitute None None O
in None None O
( None None O
S None None O
) None None O
- None None O
amphetamine None None O
- None None O
trained None None O
rats None None O
. None None O

All None None O
of None None O
the None None O
test None None O
compounds None None O
were None None O
potent None None O
inhibitors None None O
of None None O
[ None None O
3H None None O
] None None O
- None None O
5 None None O
- None None O
HT None None O
uptake None None O
into None None O
synaptosomes None None O
in None None O
vitro None None O
, None None O
with None None O
the None None O
S None None O
enantiomer None None O
of None None O
6 None None O
being None None O
most None None O
active None None O
. None None O

Rat None None O
brain None None O
monoamine None None O
levels None None O
were None None O
unaltered None None O
1 None None O
week None None O
following None None O
a None None O
single None None O
high None None O
dose None None O
( None None O
10 None None O
or None None O
20 None None O
mg None None O
/ None None O
kg None None O
, None None O
sc None None O
) None None O
of None None O
6 None None O
or None None O
11 None None O
, None None O
or None None O
two None None O
weeks None None O
following None None O
a None None O
subacute None None O
dosing None None O
regimen None None O
( None None O
20 None None O
mg None None O
/ None None O
kg None None O
, None None O
sc None None O
, None None O
twice None None O
a None None O
day None None O
for None None O
4 None None O
days None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
radioligand None None O
- None None O
binding None None O
parameters None None O
in None None O
rat None None O
brain None None O
homogenate None None O
with None None O
the None None O
5 None None O
- None None O
HT None None O
uptake None None O
inhibitor None None O
[ None None O
3H None None O
] None None O
paroxetine None None O
were None None O
unchanged None None O
after None None O
subacute None None O
dosing None None O
with None None O
either None None O
racemic None None O
6 None None O
or None None O
11 None None O
. None None O

The None None O
results None None O
indicate None None O
that None None O
compounds None None O
6 None None O
and None None O
11 None None O
have None None O
animal None None O
behavioral None None O
pharmacology None None O
similar None None O
to None None O
the None None O
methylenedioxy None None O
compounds None None O
1 None None O
and None None O
2 None None O
, None None O
but None None O
that None None O
they None None O
do None None O
not None None O
induce None None O
the None None O
serotonin None None O
neurotoxicity None None O
that None None O
has None None O
been None None O
observed None None O
for None None O
the None None O
latter None None O
two None None O
drugs None None O
. None None O


The None None O
development None None O
of None None O
a None None O
prostaglandin None None O
PGF2 None None O
alpha None None O
photoaffinity None None O
probe None None O
led None None O
to None None O
the None None O
synthesis None None O
and None None O
biological None None O
evaluation None None O
of None None O
azide None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
17 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
18,19,20 None None I-IUPAC
- None None I-IUPAC
trinorprostaglandin None None I-IUPAC
F2 None None I-IUPAC
alpha None None I-IUPAC
and None None O
16 None None I-IUPAC
- None None I-IUPAC
phenoxy None None I-IUPAC
- None None I-IUPAC
17,18,19,20 None None I-IUPAC
- None None I-IUPAC
tetranorprostaglandin None None I-IUPAC
F2 None None I-IUPAC
alpha None None I-IUPAC
derivatives None None O
. None None O

Two None None O
approaches None None O
for None None O
the None None O
preparation None None O
of None None O
iodinated None None O
versions None None O
of None None O
these None None O
prostaglandins None None O
were None None O
evaluated None None O
: None None O
( None None O
1 None None O
) None None O
iodination None None O
of None None O
a None None O
phenyl None None O
azide None None O
bearing None None O
an None None O
activating None None O
hydroxyl None None O
group None None O
and None None O
( None None O
2 None None O
) None None O
iodination None None O
of None None O
an None None O
aniline None None O
precursor None None O
to None None O
the None None O
phenyl None None O
azide None None O
group None None O
and None None O
subsequent None None O
conversion None None O
of None None O
the None None O
aniline None None O
to None None O
the None None O
phenyl None None O
azide None None O
. None None O

In None None O
the None None O
first None None O
approach None None O
, None None O
17 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
18,19,20 None None I-IUPAC
- None None I-IUPAC
trinorprostaglandin None None I-IUPAC
F2 None None I-IUPAC
alpha None None I-IUPAC
, None None O
16 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenoxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
17,18,19,20 None None I-IUPAC
- None None I-IUPAC
tetranorprostaglandin None None I-IUPAC
F2 None None I-IUPAC
alpha None None I-IUPAC
, None None O
and None None O
16 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyphenoxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
17,18,19,20 None None I-IUPAC
- None None I-IUPAC
tetranorprostaglandin None None I-IUPAC
F2 None None I-IUPAC
alpha None None I-IUPAC
were None None O
prepared None None O
by None None O
using None None O
the None None O
Corey None None O
synthesis None None O
, None None O
but None None O
were None None O
biologically None None O
inactive None None O
presumably None None O
as None None O
a None None O
result None None O
of None None O
the None None O
hydrophilic None None O
phenolic None None O
hydroxyl None None O
group None None O
. None None O

In None None O
the None None O
second None None O
approach None None O
, None None O
the None None O
iodination None None O
of None None O
a None None O
17 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
18,19,20 None None I-IUPAC
- None None I-IUPAC
trinorprostaglandin None None I-IUPAC
F2 None None I-IUPAC
alpha None None I-IUPAC
derivative None None I-MODIFIER
delivered None None O
17 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
iodophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
18,19,20 None None I-IUPAC
- None None I-IUPAC
trinorprostaglandin None None I-IUPAC
F2 None None I-IUPAC
alpha None None I-IUPAC
, None None O
which None None O
exhibited None None O
competitive None None O
binding None None O
with None None O
natural None None O
[ None None O
3H None None O
] None None O
PGF2 None None O
alpha None None O
to None None O
ovine None None O
luteal None None O
cells None None O
and None None O
to None None O
plasma None None O
membranes None None O
of None None O
bovine None None O
corpora None None O
lutea None None O
. None None O

[ None None I-IUPAC
125I None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
Azido None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
iodophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
18,19,20 None None I-IUPAC
- None None I-IUPAC
trinorprostaglandin None None I-IUPAC
F2 None None I-IUPAC
alpha None None I-IUPAC
was None None O
utilized None None O
in None None O
a None None O
preliminary None None O
photoaffinity None None O
cross None None O
- None None O
linking None None O
experiment None None O
. None None O


We None None O
have None None O
synthesized None None O
five None None O
fluorinated None None O
derivatives None None O
of None None O
WAY None None O
100635 None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
{ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
) None None I-IUPAC
piperazino None None I-IUPAC
] None None I-IUPAC
ethyl None None I-IUPAC
} None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
cyclohe None None I-IUPAC
xaneca None None I-IUPAC
rboxamide None None I-IUPAC
( None None O
4a None None O
) None None O
, None None O
using None None O
various None None O
acids None None O
in None None O
place None None O
of None None O
the None None O
cyclohexanecarboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
CHCA None None O
, None None O
2a None None O
) None None O
in None None O
the None None O
reaction None None O
scheme None None O
. None None O

The None None O
five None None O
acids None None O
are None None O
4 None None I-IUPAC
- None None I-IUPAC
fluorobenzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
FB None None O
, None None O
2b None None O
) None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylbenzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
MeFB None None O
, None None O
2c None None O
) None None O
, None None O
trans None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorocyclohexanecarboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
FC None None O
, None None O
2d None None O
) None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoromethyl None None I-IUPAC
) None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
FMeB None None O
, None None O
2e None None O
) None None O
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoromethyl None None I-IUPAC
) None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
NFMeB None None O
, None None O
2f None None O
) None None O
( None None O
see None None O
Scheme None None O
1 None None O
) None None O
. None None O

These None None O
compounds None None O
were None None O
radiolabeled None None O
with None None O
fluorine None None O
- None None O
18 None None O
, None None O
and None None O
their None None O
biological None None O
properties None None O
were None None O
evaluated None None O
in None None O
rats None None O
and None None O
compared None None O
with None None O
those None None O
of None None O
[ None None O
11C None None O
] None None O
carbonyl None None O
WAY None None O
100635 None None O
( None None O
[ None None O
carbonyl None None O
- None None O
11C None None O
] None None O
4a None None O
) None None O
. None None O

[ None None O
Carbonyl None None O
- None None O
11C None None O
] None None O
4a None None O
cleared None None O
the None None O
brain None None O
with None None O
a None None O
biological None None O
half None None O
- None None O
life None None O
averaging None None O
41 None None O
min None None O
. None None O

The None None O
metabolite None None O
- None None O
corrected None None O
blood None None O
radioactivity None None O
had None None O
a None None O
half None None O
- None None O
life None None O
of None None O
29 None None O
min None None O
. None None O

[ None None O
18F None None O
] None None O
FCWAY None None O
( None None O
[ None None O
18F None None O
] None None O
4d None None O
) None None O
gave None None O
half None None O
- None None O
lives None None O
and None None O
intercepts None None O
comparable None None O
to None None O
[ None None O
carbonyl None None O
- None None O
11C None None O
] None None O
4a None None O
in None None O
the None None O
brain None None O
, None None O
but None None O
the None None O
blood None None O
clearance None None O
was None None O
faster None None O
. None None O

[ None None O
18F None None O
] None None O
FBWAY None None O
( None None O
[ None None O
18F None None O
] None None O
4b None None O
) None None O
showed None None O
an None None O
early None None O
rapid None None O
net None None O
efflux None None O
from None None O
the None None O
whole None None O
brain None None O
, None None O
clearing None None O
with None None O
a None None O
biological None None O
half None None O
- None None O
life None None O
of None None O
35 None None O
min None None O
. None None O

The None None O
metabolite None None O
- None None O
corrected None None O
blood None None O
half None None O
- None None O
life None None O
was None None O
41 None None O
min None None O
. None None O

The None None O
comparable None None O
whole None None O
brain None None O
and None None O
blood None None O
half None None O
- None None O
lives None None O
for None None O
Me None None O
[ None None O
18F None None O
] None None O
FBWAY None None O
( None None O
[ None None O
18F None None O
] None None O
4c None None O
) None None O
were None None O
16 None None O
and None None O
18 None None O
min None None O
, None None O
respectively None None O
. None None O

For None None O
each None None O
compound None None O
, None None O
the None None O
corresponding None None O
carboxylic None None O
acid None None O
was None None O
identified None None O
as None None O
a None None O
major None None O
metabolite None None O
in None None O
blood None None O
. None None O

Fluoride None None O
was None None O
also None None O
found None None O
after None None O
injection None None O
of None None O
[ None None O
18F None None O
] None None O
4d None None O
. None None O

However None None O
, None None O
for None None O
all None None O
compounds None None O
there None None O
was None None O
a None None O
good None None O
correlation None None O
( None None O
R None None O
& None None O
gt None None O
; None None O
0.97 None None O
) None None O
between None None O
the None None O
differential None None O
uptake None None O
ratio None None O
( None None O
DUR None None O
, None None O
( None None O
% None None O
ID None None O
/ None None O
g None None O
) None None O
x None None O
body None None O
weight None None O
( None None O
g None None O
) None None O
/ None None O
100 None None O
) None None O
in None None O
individual None None O
rat None None O
brain None None O
regions None None O
at None None O
30 None None O
min None None O
after None None O
injection None None O
and None None O
the None None O
concentration None None O
of None None O
receptors None None O
as None None O
determined None None O
by None None O
in None None O
vitro None None O
quantitative None None O
autoradiography None None O
in None None O
rat None None O
. None None O

Specific None None O
binding None None O
ratios None None O
[ None None O
region None None O
of None None O
interest None None O
( None None O
ROI None None O
) None None O
/ None None O
cerebellum None None O
- None None O
1 None None O
] None None O
in None None O
control None None O
studies None None O
for None None O
cortex None None O
( None None O
Ctx None None O
) None None O
and None None O
hippocampus None None O
( None None O
H None None O
) None None O
were None None O
higher None None O
for None None O
[ None None O
carbonyl None None O
- None None O
11C None None O
] None None O
4a None None O
and None None O
[ None None O
18F None None O
] None None O
4d None None O
compared None None O
to None None O
[ None None O
18F None None O
] None None O
4b None None O
and None None O
[ None None O
18F None None O
] None None O
4c None None O
. None None O

[ None None O
18F None None O
] None None O
4d None None O
has None None O
similar None None O
pharmacokinetic None None O
properties None None O
and None None O
comparable None None O
specific None None O
binding None None O
ratios None None O
to None None O
[ None None O
carbonyl None None O
- None None O
11C None None O
] None None O
4a None None O
. None None O

Fifty None None O
nanomoles None None O
of None None O
4a None None O
blocked None None O
only None None O
30% None None O
of None None O
the None None O
specific None None O
binding None None O
of None None O
[ None None O
18F None None O
] None None O
4d None None O
, None None O
while None None O
complete None None O
blockade None None O
was None None O
obtained None None O
from None None O
co None None O
- None None O
injection None None O
of None None O
200 None None O
nmol None None O
of None None O
4a None None O
( None None O
H None None O
/ None None O
Cb None None O
- None None O
1 None None O
from None None O
17.2 None None O
to None None O
0.6 None None O
) None None O
. None None O

[ None None O
18F None None O
] None None O
4b None None O
and None None O
[ None None O
18F None None O
] None None O
4c None None O
showed None None O
lower None None O
specific None None O
binding None None O
ratios None None O
than None None O
[ None None O
carbonyl None None O
- None None O
11C None None O
] None None O
4a None None O
and None None O
[ None None O
18F None None O
] None None O
4d None None O
. None None O

[ None None O
18F None None O
] None None O
4c None None O
was None None O
superior None None O
to None None O
[ None None O
18F None None O
] None None O
4b None None O
since None None O
its None None O
specific None None O
binding None None O
was None None O
more None None O
readily None None O
blocked None None O
by None None O
4a None None O
. None None O

These None None O
studies None None O
suggest None None O
that None None O
[ None None O
18F None None O
] None None O
4c None None O
should None None O
be None None O
a None None O
useful None None O
compound None None O
to None None O
assess None None O
dynamic None None O
changes None None O
in None None O
serotonin None None O
levels None None O
while None None O
[ None None O
18F None None O
] None None O
4d None None O
, None None O
with None None O
its None None O
high None None O
contrast None None O
and None None O
F None None O
- None None O
18 None None O
label None None O
, None None O
should None None O
provide None None O
better None None O
statistics None None O
and None None O
quantification None None O
for None None O
static None None O
measurement None None O
of None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
distribution None None O
. None None O


A None None O
conformationally None None O
defined None None O
retinoic None None O
acid None None O
analog None None O
( None None O
1 None None O
) None None O
which None None O
contains None None O
a None None O
dimethylene None None O
bridge None None O
to None None O
maintain None None O
the None None O
6 None None O
- None None O
s None None O
- None None O
trans None None O
orientation None None O
for None None O
two None None O
terminal None None O
double None None O
bonds None None O
in None None O
the None None O
polyene None None O
chain None None O
was None None O
synthesized None None O
. None None O

A None None O
Reformatsky None None O
reaction None None O
was None None O
utilized None None O
to None None O
extend None None O
the None None O
polyene None None O
chain None None O
of None None O
the None None O
starting None None O
enone None None O
, None None O
which None None O
provided None None O
exclusively None None O
the None None O
9Z None None O
- None None O
configuration None None O
for None None O
the None None O
intermediate None None O
aldehyde None None O
. None None O

A None None O
Horners None None O
- None None O
Emmons None None O
condensation None None O
with None None O
this None None O
aldehyde None None O
then None None O
produced None None O
retinoic None None O
acid None None O
analogs None None O
with None None O
both None None O
9Z None None O
- None None O
and None None O
9Z None None O
, None None O
13Z None None O
- None None O
configurations None None O
. None None O

An None None O
I2 None None O
- None None O
catalyzed None None O
isomerization None None O
of None None O
the None None O
intermediate None None O
9Z None None I-IUPAC
- None None I-IUPAC
aldehyde None None I-IUPAC
yielded None None O
the None None O
all None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
- None None I-IUPAC
aldehyde None None I-IUPAC
, None None O
which None None O
was None None O
olefinated None None O
as None None O
above None None O
to None None O
yield None None O
the None None O
( None None I-PARTIUPAC
all None None I-PARTIUPAC
- None None I-PARTIUPAC
E None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
13Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
retinoic None None I-IUPAC
acid None None I-IUPAC
analogs None None I-MODIFIER
of None None O
1 None None O
. None None O

Each None None O
configurational None None O
isomer None None O
of None None O
1 None None O
was None None O
evaluated None None O
for None None O
its None None O
ability None None O
to None None O
inhibit None None O
the None None O
binding None None O
of None None O
retinoic None None O
acid None None O
to None None O
CRABP None None O
( None None O
chick None None O
skin None None O
) None None O
and None None O
to None None O
inhibit None None O
the None None O
chemical None None O
induction None None O
of None None O
ornithine None None O
decarboxylase None None O
in None None O
mouse None None O
skin None None O
. None None O

In None None O
each None None O
assay None None O
( None None O
all None None O
- None None O
E None None O
) None None O
- None None O
1 None None O
was None None O
the None None O
most None None O
active None None O
isomer None None O
, None None O
and None None O
this None None O
activity None None O
was None None O
comparable None None O
to None None O
or None None O
better None None O
than None None O
that None None O
for None None O
( None None I-IUPAC
all None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
retinoic None None I-IUPAC
acid None None I-IUPAC
. None None O

( None None O
all None None O
- None None O
E None None O
) None None O
- None None O
1 None None O
and None None O
( None None O
13Z None None O
) None None O
- None None O
1 None None O
were None None O
both None None O
shown None None O
to None None O
be None None O
equally None None O
effective None None O
as None None O
( None None I-IUPAC
13Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
retinoic None None I-IUPAC
acid None None I-IUPAC
in None None O
suppressing None None O
the None None O
proliferation None None O
of None None O
human None None O
sebaceous None None O
cells None None O
in None None O
vitro None None O
. None None O

( None None O
all None None O
- None None O
E None None O
) None None O
- None None O
1 None None O
was None None O
further None None O
evaluated None None O
for None None O
its None None O
ability None None O
to None None O
prevent None None O
the None None O
induction None None O
of None None O
mouse None None O
skin None None O
papillomas None None O
and None None O
to None None O
induce None None O
signs None None O
of None None O
vitamin None None O
A None None O
toxicity None None O
in None None O
mice None None O
. None None O

The None None O
cancer None None O
chemopreventive None None O
activity None None O
of None None O
( None None O
all None None O
- None None O
E None None O
) None None O
- None None O
1 None None O
was None None O
comparable None None O
to None None O
that None None O
of None None O
( None None I-IUPAC
all None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
retinoic None None I-IUPAC
acid None None I-IUPAC
, None None O
and None None O
the None None O
toxicity None None O
was None None O
comparable None None O
to None None O
or None None O
slightly None None O
better None None O
than None None O
that None None O
of None None O
the None None O
natural None None O
vitamin None None O
. None None O


A None None O
number None None O
of None None O
3,4 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
ribonucleosides None None I-MODIFIER
were None None O
synthesized None None O
and None None O
tested None None O
for None None O
their None None O
biological None None O
activity None None O
. None None O

Glycosylation None None O
of None None O
persilylated None None O
as None None O
well None None O
as None None O
nonsilylated None None O
3 None None I-IUPAC
- None None I-IUPAC
bromoallopurinol None None I-IUPAC
with None None O
1 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
2,3,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranose None None I-IUPAC
( None None O
4 None None O
) None None O
provided None None O
the None None O
key None None O
intermediate None None O
3 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
5H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
5a None None O
) None None O
. None None O

Similar None None O
glycosylations None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
cyanoallopurinol None None I-IUPAC
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
allopurinol None None I-IUPAC
furnished None None O
the None None O
corresponding None None O
protected None None O
N None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
glycosyl None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
5b None None O
and None None O
5c None None O
) None None O
. None None O

Debenzoylation None None O
of None None O
these None None O
nucleosides None None O
( None None O
5a None None O
- None None O
c None None O
) None None O
gave None None O
the None None O
corresponding None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
bromo None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
cyano None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
allopurinol None None I-IUPAC
nucleosides None None I-MODIFIER
( None None O
6a None None O
- None None O
c None None O
) None None O
. None None O

The None None O
site None None O
of None None O
glycosylation None None O
and None None O
anomeric None None O
configuration None None O
of None None O
6a None None O
and None None O
6c None None O
were None None O
assigned None None O
on None None O
the None None O
basis None None O
of None None O
spectral None None O
studies None None O
as None None O
well None None O
as None None O
conversion None None O
to None None O
allopurinol None None O
ribonucleoside None None O
, None None O
whereas None None O
the None None O
structural None None O
assignment None None O
of None None O
6b None None O
was None None O
made None None O
by None None O
single None None O
- None None O
crystal None None O
X None None O
- None None O
ray None None O
analysis None None O
. None None O

Conventional None None O
functional None None O
group None None O
transformation None None O
of None None O
5a None None O
and None None O
5b None None O
provided None None O
a None None O
number None None O
of None None O
novel None None O
3 None None O
- None None O
substituted None None O
allopurinol None None O
nucleosides None None O
, None None O
which None None O
included None None O
10a None None O
and None None O
18a None None O
- None None O
d None None O
. None None O

Glycosylation None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
bromopyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
14 None None O
) None None O
with None None O
4 None None O
and None None O
subsequent None None O
debenzoylation None None O
gave None None O
3 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminopyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
ribonucleoside None None I-MODIFIER
( None None O
13a None None O
) None None O
from None None O
which None None O
3,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosylpyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
13b None None O
) None None O
was None None O
obtained None None O
by None None O
amination None None O
. None None O

Thiation None None O
of None None O
5b None None O
, None None O
followed None None O
by None None O
deblocking None None O
, None None O
gave None None O
3 None None I-IUPAC
- None None I-IUPAC
cyanothiopurinol None None I-IUPAC
ribonucleoside None None I-MODIFIER
( None None O
20 None None O
) None None O
. None None O

All None None O
of None None O
these None None O
compounds None None O
were None None O
tested None None O
in None None O
vitro None None O
against None None O
certain None None O
viruses None None O
, None None O
tumor None None O
cells None None O
, None None O
and None None O
the None None O
parasite None None O
Leishmania None None O
tropica None None O
. None None O

Among None None O
the None None O
3 None None O
- None None O
substituted None None O
allopurinol None None O
nucleosides None None O
, None None O
18b None None O
and None None O
18c None None O
showed None None O
significant None None O
activity None None O
against None None O
Para None None O
3 None None O
virus None None O
and None None O
were None None O
found None None O
to None None O
be None None O
potent None None O
inhibitors None None O
of None None O
growth None None O
of None None O
L1210 None None O
and None None O
P388 None None O
leukemia None None O
. None None O

Compound None None O
20 None None O
exhibited None None O
the None None O
most None None O
significant None None O
broad None None O
- None None O
spectrum None None O
in None None O
vitro None None O
antiviral None None O
and None None O
antitumor None None O
activity None None O
. None None O

3 None None I-IUPAC
- None None I-IUPAC
Bromoallopurinol None None I-IUPAC
ribonucleoside None None I-MODIFIER
( None None O
6a None None O
) None None O
was None None O
found None None O
to None None O
be None None O
more None None O
active None None O
than None None O
allopurinol None None O
ribonucleoside None None O
against None None O
Leishmania None None O
tropica None None O
within None None O
human None None O
macrophages None None O
in None None O
vitro None None O
. None None O


The None None O
synthesis None None O
of None None O
10 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
analogues None None I-MODIFIER
of None None O
the None None O
potent None None O
antitumor None None O
agent None None O
8,10 None None I-IUPAC
- None None I-IUPAC
dideazaminopterin None None I-IUPAC
is None None O
described None None O
. None None O

Alkylation None None O
of None None O
appropriate None None O
alpha None None O
- None None O
alkyl None None O
homoterephthalate None None O
esters None None O
with None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
deazapteridine None None I-IUPAC
afforded None None O
10 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
8,10 None None I-IUPAC
- None None I-IUPAC
dideazapteroic None None I-IUPAC
acid None None I-IUPAC
diesters None None I-IUPAC
. None None O

Ester None None O
cleavage None None O
and None None O
decarboxylation None None O
at None None O
C None None O
- None None O
10 None None O
were None None O
accomplished None None O
by None None O
heating None None O
with None None O
sodium None None O
cyanide None None O
in None None O
Me2SO None None O
at None None O
170-180 None None O
degrees None None O
C None None O
to None None O
afford None None O
the None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
8,10 None None I-IUPAC
- None None I-IUPAC
dideazapteroic None None I-IUPAC
acids None None I-IUPAC
. None None O

The None None O
acids None None O
were None None O
coupled None None O
with None None O
diethyl None None O
glutamate None None O
, None None O
followed None None O
by None None O
saponification None None O
, None None O
to None None O
give None None O
the None None O
10 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
8,10 None None I-IUPAC
- None None I-IUPAC
dideazaminopterins None None I-IUPAC
. None None O

The None None O
compounds None None O
were None None O
potent None None O
inhibitors None None O
of None None O
growth None None O
in None None O
folate None None O
- None None O
dependent None None O
bacteria None None O
, None None O
Streptococcus None None O
faecium None None O
and None None O
Lactobacillus None None O
casei None None O
. None None O

The None None O
10 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
and None None O
10 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
analogues None None I-MODIFIER
gave None None O
the None None O
highest None None O
percent None None O
increases None None O
in None None O
life None None O
span None None O
for None None O
mice None None O
infected None None O
with None None O
L1210 None None O
leukemia None None O
with None None O
ILS None None O
values None None O
of None None O
+ None None O
203 None None O
and None None O
+ None None O
235% None None O
, None None O
respectively None None O
. None None O


Of None None O
a None None O
series None None O
of None None O
58 None None O
aliphatic None None O
nucleoside None None O
analogues None None O
, None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydroxypropyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
[ None None O
( None None O
S None None O
) None None O
- None None O
DHPA None None O
] None None O
proved None None O
to None None O
be None None O
the None None O
most None None O
active None None O
congener None None O
, None None O
when None None O
assayed None None O
for None None O
antiviral None None O
activity None None O
in None None O
primary None None O
rabbit None None O
kidney None None O
cell None None O
cultures None None O
challenged None None O
with None None O
either None None O
vaccinia None None O
or None None O
vesicular None None O
stomatitis None None O
virus None None O
. None None O

Whereas None None O
most None None O
analogues None None O
derived None None O
from None None O
substituted None None O
purine None None O
and None None O
pyrimidine None None O
bases None None O
and None None O
bearing None None O
various None None O
hydroxy None None I-MODIFIER
- None None I-MODIFIER
or None None O
amino None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
alkyl None None I-IUPAC
chains None None B-MODIFIER
did None None O
not None None O
show None None O
evidence None None O
of None None O
antiviral None None O
activity None None O
at None None O
a None None O
concentration None None O
of None None O
2 None None O
mM None None O
, None None O
( None None O
S None None O
) None None O
- None None O
DHPA None None O
inhibited None None O
both None None O
vaccinia None None O
and None None O
vesicular None None O
stomatitis None None O
virus None None O
replication None None O
at None None O
0.05-0.1 None None O
mM None None O
. None None O

For None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
diazidopropyl None None I-IUPAC
] None None I-IUPAC
adenine None None I-IUPAC
and None None O
some None None O
di None None I-MODIFIER
- None None I-MODIFIER
and None None O
trihydroxybutyl None None I-MODIFIER
analogues None None I-MODIFIER
of None None O
DHPA None None O
, None None O
viz None None O
. None None O

, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2RS None None I-IUPAC
, None None I-IUPAC
3SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydroxybutylladenine None None I-IUPAC
, None None O
9 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
RS None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydroxybutyl None None I-IUPAC
] None None I-IUPAC
adenine None None I-IUPAC
, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2S None None I-IUPAC
, None None I-IUPAC
3R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,3,4 None None I-IUPAC
- None None I-IUPAC
trihydroxybutyl None None I-IUPAC
] None None I-IUPAC
adenine None None I-IUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
adenin None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alanine None None I-IUPAC
, None None O
an None None O
antiviral None None O
effect None None O
was None None O
noted None None O
at None None O
a None None O
concentration None None O
of None None O
0.5-1 None None O
mM None None O
. None None O


Several None None O
N None None O
( None None O
1 None None O
) None None O
- None None O
substituted None None O
polyamines None None O
containing None None O
various None None O
spacer None None O
units None None O
between None None O
nitrogen None None O
centers None None O
were None None O
synthesized None None O
as None None O
their None None O
respective None None O
HCl None None O
salts None None O
. None None O

The None None O
N None None O
( None None O
1 None None O
) None None O
- None None O
substituents None None O
included None None O
benzyl None None I-IUPAC
, None None O
naphthalen None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
, None None O
anthracen None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
, None None O
and None None O
pyren None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
. None None O

The None None O
polyamine None None O
spacer None None O
units None None O
ranged None None O
from None None O
generic None None O
( None None O
4,4 None None I-IUPAC
- None None I-IUPAC
triamine None None I-IUPAC
, None None O
4,3 None None I-IUPAC
- None None I-IUPAC
triamine None None I-IUPAC
, None None O
and None None O
diaminooctane None None O
) None None O
spacers None None O
to None None O
more None None O
exotic None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxy None None I-IUPAC
) None None I-IUPAC
ethanoxy None None I-IUPAC
- None None I-IUPAC
containing None None I-MODIFIER
diamine None None B-IUPAC
, None None O
hydroxylated None None I-MODIFIER
4,3 None None B-IUPAC
- None None I-IUPAC
triamine None None I-IUPAC
, None None O
and None None O
cyclohexylene None None O
- None None O
containing None None O
triamine None None O
] None None O
spacers None None O
. None None O

Two None None O
control None None O
compounds None None O
were None None O
also None None O
evaluated None None O
: None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
anthracen None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
butylamine None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
anthracen None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
butanediamine None None I-IUPAC
. None None O

Biological None None O
activities None None O
in None None O
L1210 None None O
( None None O
murine None None O
leukemia None None O
) None None O
, None None O
alpha None None I-IUPAC
- None None I-IUPAC
difluoromethylornithine None None I-IUPAC
( None None O
DFMO None None O
) None None O
- None None O
treated None None O
L1210 None None O
, None None O
and None None O
Chinese None None O
hamster None None O
ovary None None O
( None None O
CHO None None O
) None None O
and None None O
its None None O
polyamine None None O
transport None None O
- None None O
deficient None None O
mutant None None O
( None None O
CHO None None O
- None None O
MG None None O
) None None O
cell None None O
lines None None O
were None None O
investigated None None O
via None None O
IC None None O
( None None O
50 None None O
) None None O
cytotoxicity None None O
determinations None None O
. None None O

K None None O
( None None O
i None None O
) None None O
values None None O
for None None O
spermidine None None O
uptake None None O
were None None O
also None None O
determined None None O
in None None O
L1210 None None O
cells None None O
. None None O

Of None None O
the None None O
series None None O
studied None None O
, None None O
the None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
triamine None None I-IUPAC
system None None I-MODIFIER
6 None None O
had None None O
significantly None None O
higher None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
( None None O
lower None None O
cytotoxicity None None O
) None None O
in None None O
the None None O
L1210 None None O
, None None O
CHO None None O
, None None O
and None None O
CHO None None O
- None None O
MG None None O
cell None None O
lines None None O
. None None O

A None None O
cellular None None O
debenzylation None None O
process None None O
was None None O
observed None None O
in None None O
L1210 None None O
cells None None O
with None None O
6 None None O
and None None O
generated None None O
" None None O
free None None O
" None None O
homospermidine None None O
. None None O

The None None O
size None None O
of None None O
the None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
arylmethyl None None I-IUPAC
substituent None None I-MODIFIER
had None None O
direct None None O
bearing None None O
on None None O
the None None O
observed None None O
cytotoxicity None None O
in None None O
CHO None None O
- None None O
MG None None O
cells None None O
. None None O

The None None O
N None None I-PARTIUPAC
( None None I-PARTIUPAC
1 None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
naphthalenylmethyl None None I-PARTIUPAC
, None None O
N None None I-PARTIUPAC
( None None I-PARTIUPAC
1 None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
anthracenylmethyl None None I-PARTIUPAC
, None None O
and None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyrenylmethyl None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
triamines None None I-IUPAC
had None None O
similar None None O
toxicity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
s None None O
: None None O
approximately None None O
0.5 None None O
microM None None O
) None None O
in None None O
CHO None None O
cells None None O
, None None O
which None None O
have None None O
an None None O
active None None O
polyamine None None O
transporter None None O
( None None O
PAT None None O
) None None O
. None None O

However None None O
, None None O
this None None O
series None None O
had None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
of None None O
& None None O
gt None None O
; None None O
100 None None O
microM None None O
, None None O
66.7 None None O
microM None None O
, None None O
and None None O
15.5 None None O
microM None None O
, None None O
respectively None None O
, None None O
in None None O
CHO None None O
- None None O
MG None None O
cells None None O
, None None O
which None None O
are None None O
PAT None None O
- None None O
deficient None None O
. None None O

The None None O
observed None None O
lower None None O
cytotoxicity None None O
in None None O
the None None O
PAT None None O
- None None O
deficient None None O
CHO None None O
- None None O
MG None None O
cell None None O
line None None O
supported None None O
the None None O
premise None None O
that None None O
the None None O
conjugates None None O
use None None O
PAT None None O
for None None O
cellular None None O
entry None None O
. None None O

In None None O
general None None O
, None None O
moderate None None O
affinities None None O
for None None O
the None None O
polyamine None None O
transporter None None O
were None None O
observed None None O
for None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
arylmethyl None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
triamine None None I-IUPAC
series None None I-MODIFIER
with None None O
their None None O
L1210 None None O
K None None O
( None None O
i None None O
) None None O
values None None O
all None None O
near None None O
3 None None O
microM None None O
. None None O

In None None O
summary None None O
, None None O
the None None O
4,4 None None I-IUPAC
- None None I-IUPAC
triamine None None I-IUPAC
motif None None I-MODIFIER
was None None O
shown None None O
to None None O
facilitate None None O
entry None None O
of None None O
polyamine None None O
conjugates None None O
into None None O
cells None None O
containing None None O
active None None O
polyamine None None O
transporters None None O
. None None O


The None None O
utility None None O
of None None O
polyamines None None O
as None None O
vectors None None O
for None None O
the None None O
intracellular None None O
transport None None O
of None None O
iron None None O
chelators None None O
is None None O
further None None O
described None None O
. None None O

Consistent None None O
with None None O
earlier None None O
results None None O
with None None O
polyamine None None O
analogues None None O
, None None O
these None None O
studies None None O
underscore None None O
the None None O
importance None None O
of None None O
charge None None O
in None None O
the None None O
design None None O
of None None O
polyamine None None O
- None None O
vectored None None O
chelators None None O
. None None O

Four None None O
polyamine None None O
conjugates None None O
are None None O
synthesized None None O
, None None O
two None None O
of None None O
terephthalic None None O
acid None None O
[ None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
) None None I-IUPAC
benzoylspermine None None I-IUPAC
( None None O
7 None None O
) None None O
and None None O
its None None O
methyl None None O
ester None None O
( None None O
6 None None O
) None None O
] None None O
and None None O
two None None O
of None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dihydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
thiazolecarboxylic None None I-IUPAC
acid None None I-IUPAC
[ None None O
( None None O
S None None O
) None None O
- None None O
4' None None O
- None None O
( None None O
HO None None O
) None None O
- None None O
DADFT None None O
] None None O
[ None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5,9 None None I-IUPAC
- None None I-IUPAC
diazadodecyl None None I-IUPAC
- None None I-IUPAC
oxy None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
thiazolecarboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
10 None None O
) None None O
and None None O
its None None O
ethyl None None O
ester None None O
( None None O
9 None None O
) None None O
] None None O
. None None O

These None None O
four None None O
molecules None None O
were None None O
evaluated None None O
in None None O
murine None None O
leukemia None None O
L1210 None None O
cells None None O
for None None O
their None None O
impact None None O
on None None O
cell None None O
proliferation None None O
( None None O
48 None None O
- None None O
and None None O
96 None None O
- None None O
h None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
) None None O
, None None O
their None None O
ability None None O
to None None O
compete None None O
with None None O
spermidine None None O
for None None O
the None None O
polyamine None None O
transport None None O
apparatus None None O
( None None O
K None None O
( None None O
i None None O
) None None O
) None None O
, None None O
and None None O
their None None O
intracellular None None O
accumulation None None O
. None None O

The None None O
data None None O
revealed None None O
that None None O
when None None O
neutral None None O
molecules None None O
( None None O
cargo None None O
fragments None None O
) None None O
were None None O
fixed None None O
to None None O
the None None O
polyamine None None O
vector None None O
, None None O
the None None O
conjugates None None O
competed None None O
well None None O
with None None O
spermidine None None O
for None None O
transport None None O
and None None O
were None None O
accumulated None None O
intracellularly None None O
to None None O
millimolar None None O
levels None None O
. None None O

However None None O
, None None O
this None None O
was None None O
not None None O
the None None O
case None None O
when None None O
the None None O
cargo None None O
fragments None None O
were None None O
negatively None None O
charged None None O
. None None O

Metabolic None None O
studies None None O
of None None O
the None None O
polyamine None None O
- None None O
vectored None None O
( None None O
S None None O
) None None O
- None None O
4' None None O
- None None O
( None None O
HO None None O
) None None O
- None None O
DADFTs None None O
in None None O
rodents None None O
indicated None None O
that None None O
not None None O
only None None O
did None None O
the None None O
expected None None O
deaminopropylation None None O
step None None O
occur None None O
, None None O
but None None O
also None None O
a None None O
surprisingly None None O
high None None O
level None None O
of None None O
oxidative None None O
deamination None None O
at None None O
the None None O
terminal None None O
primary None None O
nitrogens None None O
took None None O
place None None O
. None None O

Finally None None O
, None None O
the None None O
iron None None O
- None None O
clearing None None O
efficiency None None O
of None None O
the None None O
( None None O
S None None O
) None None O
- None None O
4' None None O
- None None O
( None None O
HO None None O
) None None O
- None None O
DADFT None None O
conjugates None None O
was None None O
determined None None O
in None None O
a None None O
bile None None O
- None None O
duct None None O
- None None O
cannulated None None O
rodent None None O
model None None O
. None None O

Attaching None None O
the None None O
ligand None None O
to None None O
a None None O
polyamine None None O
vector None None O
had None None O
a None None O
profound None None O
effect None None O
on None None O
increasing None None O
the None None O
iron None None O
- None None O
clearing None None O
efficiency None None O
of None None O
this None None O
chelator None None O
relative None None O
to None None O
its None None O
parent None None O
drug None None O
. None None O


This None None O
publication None None O
describes None None O
the None None O
synthesis None None O
and None None O
optimization None None O
of None None O
a None None O
novel None None O
series None None O
of None None O
stilbene None None O
endothelin None None O
antagonists None None O
. None None O

Analysis None None O
of None None O
the None None O
SAR None None O
established None None O
for None None O
previous None None O
papers None None O
in None None O
this None None O
series None None O
prompted None None O
the None None O
design None None O
and None None O
synthesis None None O
of None None O
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzyloxyphenyl None None I-IUPAC
) None None I-IUPAC
pent None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
enoic None None I-IUPAC
acid None None I-IUPAC
3 None None O
which None None O
was None None O
found None None O
to None None O
be None None O
a None None O
moderately None None O
active None None O
inhibitor None None O
of None None O
the None None O
binding None None O
of None None O
[ None None O
125I None None O
] None None O
ET None None O
- None None O
1 None None O
to None None O
ETA None None O
receptors None None O
with None None O
an None None O
IC50 None None O
of None None O
6 None None O
microM None None O
. None None O

More None None O
interestingly None None O
, None None O
the None None O
intermediate None None O
compound None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzyloxyphenyl None None I-IUPAC
) None None I-IUPAC
propenoic None None I-IUPAC
acid None None I-IUPAC
5 None None O
was None None O
equiactive None None O
with None None O
3 None None O
. None None O

Optimization None None O
of None None O
5 None None O
resulted None None O
in None None O
the None None O
preparation None None O
of None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
thien None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylmethoxy None None I-IUPAC
) None None I-IUPAC
) None None I-IUPAC
phenylprope None None I-IUPAC
noic None None I-IUPAC
acid None None I-IUPAC
18 None None O
( None None O
RPR111723 None None O
) None None O
which None None O
had None None O
an None None O
IC50 None None O
in None None O
the None None O
binding None None O
assay None None O
of None None O
80 None None O
nM None None O
on None None O
the None None O
ETA None None O
receptor None None O
and None None O
a None None O
pKB None None O
of None None O
6.5 None None O
in None None O
the None None O
functional None None O
assay None None O
, None None O
measured None None O
on None None O
rat None None O
aortic None None O
strips None None O
. None None O

Reduction None None O
of None None O
the None None O
acid None None O
group None None O
of None None O
5 None None O
gave None None O
the None None O
first None None O
nonacidic None None O
ETA None None O
antagonist None None O
in None None O
our None None O
series None None O
, None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzyloxyphenoxy None None I-IUPAC
) None None I-IUPAC
prop2 None None I-IUPAC
- None None I-IUPAC
enol None None I-IUPAC
6 None None O
with None None O
an None None O
IC50 None None O
of None None O
20 None None O
microM None None O
. None None O

Optimization None None O
of None None O
6 None None O
resulted None None O
in None None O
the None None O
preparation None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
thien None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
pro None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
enol None None I-IUPAC
33 None None O
with None None O
an None None O
IC50 None None O
of None None O
300 None None O
nM None None O
on None None O
the None None O
ETA None None O
receptor None None O
. None None O


Several None None O
potentially None None O
bis None None O
( None None O
alkylating None None O
) None None O
bis None None O
( None None O
quinones None None O
) None None O
( None None O
3-5 None None O
) None None O
and None None O
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
1,3 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
alkylating None None I-IUPAC
) None None I-IUPAC
monoquinones None None I-IUPAC
( None None O
6-13 None None O
) None None O
belonging None None O
to None None O
general None None O
structure None None O
2,2 None None I-PARTIUPAC
' None None I-PARTIUPAC
- None None I-PARTIUPAC
ethylenebis None None I-PARTIUPAC
[ None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None O
leaving None None O
group None None O
) None None O
methyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
benzoquinone None None I-PARTIUPAC
] None None I-PARTIUPAC
( None None O
3-5 None None O
) None None O
and None None O
2,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
bis None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None O
leaving None None O
group None None O
) None None O
methyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
benzoquinone None None I-PARTIUPAC
water None None O
- None None O
soluble None None O
and None None O
- None None O
insoluble None None O
classes None None O
were None None O
prepared None None O
by None None O
oxidative None None O
demethylation None None O
of None None O
the None None O
corresponding None None O
tetramethoxydiphenylethanes None None O
( None None O
17-19 None None O
) None None O
and None None O
dimethoxybenzenes None None O
( None None O
24 None None O
, None None O
27 None None O
, None None O
36-39 None None O
) None None O
, None None O
respectively None None O
. None None O

Methods None None O
employed None None O
for None None O
the None None O
preparation None None O
of None None O
tetramethoxydiphenylethane None None I-IUPAC
intermediates None None O
involved None None O
( None None O
1 None None O
) None None O
arylmethyl None None O
bromide None None O
coupling None None O
and None None O
( None None O
2 None None O
) None None O
catalytic None None O
hydrogenation None None O
of None None O
stilbene None None O
intermediates None None O
derived None None O
via None None O
Wittig None None O
reaction None None O
of None None O
( None None O
arylmethyl None None O
) None None O
phosphonium None None O
salts None None O
with None None O
aryl None None O
aldehydes None None O
. None None O

However None None O
, None None O
in None None O
biological None None O
investigations None None O
using None None O
a None None O
subcutaneous None None O
B16 None None O
( None None O
hypoxic None None O
) None None O
melanoma None None O
tumor None None O
in None None O
BDF1 None None O
hybrid None None O
mice None None O
with None None O
cyclophosphamide None None O
as None None O
positive None None O
control None None O
the None None O
most None None O
interesting None None O
series None None O
of None None O
structurally None None O
related None None O
analogues None None O
were None None O
the None None O
potentially None None O
monoalkylating None None O
monoquinones None None O
of None None O
the None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None O
leaving None None O
group None None O
) None None O
methyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
benzoquinone None None I-PARTIUPAC
type None None I-MODIFIER
( None None O
i.e. None None O
, None None O
14 None None O
and None None O
15 None None O
) None None O
having None None O
water None None O
- None None O
insoluble None None O
( None None O
acetoxy None None O
) None None O
and None None O
water None None O
- None None O
solubilizing None None O
( None None O
succinate None None O
) None None O
groups None None O
. None None O

Serial None None O
measurements None None O
of None None O
tumor None None O
size None None O
, None None O
and None None O
evaluation None None O
of None None O
increased None None O
life None None O
span None None O
, None None O
in None None O
response None None O
to None None O
drug None None O
treatment None None O
also None None O
revealed None None O
potentially None None O
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
bis None None I-PARTIUPAC
( None None O
alkylating None None O
) None None O
( None None I-PARTIUPAC
bromomethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
quinone None None I-PARTIUPAC
7 None None O
and None None O
1,3 None None I-PARTIUPAC
- None None I-PARTIUPAC
bis None None I-PARTIUPAC
( None None O
alkylating None None O
) None None O
( None None I-PARTIUPAC
hydroxymethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
quinone None None I-PARTIUPAC
10 None None O
to None None O
have None None O
variable None None O
activity None None O
, None None O
but None None O
none None None O
of None None O
the None None O
potentially None None O
bis None None O
( None None O
alkylating None None O
) None None O
bis None None O
( None None O
quinones None None O
) None None O
showed None None O
antitumor None None O
properties None None O
in None None O
this None None O
model None None O
. None None O


The None None O
homologous None None O
series None None O
of None None O
acidic None None O
amino None None O
acids None None O
, None None O
ranging None None O
from None None O
aspartic None None O
acid None None O
( None None O
1 None None O
) None None O
to None None O
2 None None I-IUPAC
- None None I-IUPAC
aminosuberic None None I-IUPAC
acid None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
and None None O
the None None O
corresponding None None O
series None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
isoxazolol None None I-IUPAC
bioisosteres None None I-MODIFIER
of None None O
these None None O
amino None None O
acids None None O
, None None O
ranging None None O
from None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
acetic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMAA None None O
, None None O
6 None None O
) None None O
to None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
hexanoic None None I-IUPAC
acid None None I-IUPAC
( None None O
10 None None O
) None None O
, None None O
were None None O
tested None None O
as None None O
ligands None None O
for None None O
metabotropic None None O
excitatory None None O
amino None None O
acid None None O
receptors None None O
( None None O
mGlu1 None None O
alpha None None O
, None None O
mGlu2 None None O
, None None O
mGlu4a None None O
, None None O
and None None O
mGlu6 None None O
) None None O
. None None O

Whereas None None O
AMAA None None O
( None None O
6 None None O
) None None O
and None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propinoic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
, None None O
7 None None O
) None None O
are None None O
potent None None O
and None None O
highly None None O
selective None None O
agonists None None O
at None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
aspartic None None I-IUPAC
acid None None I-IUPAC
( None None O
NMDA None None O
) None None O
and None None O
AMPA None None O
receptors None None O
, None None O
respectively None None O
, None None O
the None None O
higher None None O
homologue None None O
of None None O
AMPA None None O
( None None O
7 None None O
) None None O
, None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
butyric None None I-IUPAC
acid None None I-IUPAC
( None None O
homo None None O
- None None O
AMPA None None O
, None None O
8 None None O
) None None O
, None None O
is None None O
inactive None None O
at None None O
ionotropic None None O
excitatory None None O
amino None None O
acid None None O
receptors None None O
. None None O

Homo None None O
- None None O
AMPA None None O
( None None O
8 None None O
) None None O
, None None O
which None None O
is None None O
a None None O
3 None None I-IUPAC
- None None I-IUPAC
isoxazolol None None I-IUPAC
bioisostere None None I-MODIFIER
of None None O
2 None None I-IUPAC
- None None I-IUPAC
aminoadipic None None I-IUPAC
acid None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
was None None O
, None None O
however None None O
, None None O
shown None None O
to None None O
be None None O
a None None O
specific None None O
and None None O
rather None None O
potent None None O
agonist None None O
at None None O
mGlu6 None None O
, None None O
approximately None None O
4 None None O
times None None O
weaker None None O
than None None O
the None None O
nonselective None None O
excitatory None None O
amino None None O
acid None None O
receptor None None O
agonist None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
. None None O

2 None None I-IUPAC
- None None I-IUPAC
Aminoadipic None None I-IUPAC
acid None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
which None None O
shows None None O
a None None O
complex None None O
excitatory None None O
amino None None O
acid None None O
synaptic None None O
pharmacology None None O
, None None O
was None None O
an None None O
agonist None None O
at None None O
mGlu6 None None O
as None None O
well None None O
as None None O
mGlu2 None None O
. None None O

AMPA None None O
( None None O
7 None None O
) None None O
and None None O
the None None O
higher None None O
homologue None None O
of None None O
homo None None O
- None None O
AMPA None None O
( None None O
8 None None O
) None None O
, None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
pentanoic None None I-IUPAC
acid None None I-IUPAC
( None None O
9 None None O
) None None O
, None None O
showed None None O
relatively None None O
weak None None O
agonist None None O
effects None None O
at None None O
mGlu6 None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
homo None None O
- None None O
AMPA None None O
( None None O
8 None None O
) None None O
is None None O
likely None None O
to None None O
be None None O
a None None O
useful None None O
tool None None O
for None None O
studies None None O
of None None O
the None None O
pharmacology None None O
and None None O
physiological None None O
role None None O
of None None O
mGlu6 None None O
. None None O

We None None O
describe None None O
a None None O
new None None O
versatile None None O
synthesis None None O
of None None O
this None None O
homologue None None O
of None None O
AMPA None None O
and None None O
the None None O
synthesis None None O
of None None O
compound None None O
10 None None O
. None None O


A None None O
novel None None O
series None None O
of None None O
( None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
difluorocyclopentyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylacetamides None None I-IUPAC
was None None O
designed None None O
and None None O
synthesized None None O
based None None O
on None None O
the None None O
structure None None O
and None None O
biological None None O
profiles None None O
of None None O
an None None O
active None None O
metabolite None None O
2 None None O
of None None O
our None None O
prototype None None O
muscarinic None None O
M None None O
( None None O
3 None None O
) None None O
receptor None None O
selective None None O
antagonist None None O
1 None None O
, None None O
to None None O
develop None None O
a None None O
potent None None O
, None None O
long None None O
- None None O
acting None None O
, None None O
orally None None O
active None None O
M None None O
( None None O
3 None None O
) None None O
antagonist None None O
for None None O
the None None O
treatment None None O
of None None O
urinary None None O
tract None None O
disorders None None O
, None None O
irritable None None O
bowel None None O
syndrome None None O
, None None O
and None None O
respiratory None None O
disorders None None O
. None None O

Investigation None None O
of None None O
( None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
difluorocyclopentyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylacetamides None None I-IUPAC
containing None None O
a None None O
phenyl None None I-IUPAC
or None None O
heterocyclic None None I-IUPAC
ring None None B-MODIFIER
as None None O
the None None O
piperidinyl None None I-IUPAC
side None None B-MODIFIER
chain None None I-MODIFIER
in None None O
place None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pentenyl None None I-IUPAC
moiety None None I-MODIFIER
of None None O
15a None None O
revealed None None O
that None None O
this None None O
acid None None O
moiety None None O
was None None O
a None None O
versatile None None O
template None None O
for None None O
improving None None O
the None None O
selectivity None None O
for None None O
M None None O
( None None O
3 None None O
) None None O
over None None O
M None None O
( None None O
2 None None O
) None None O
receptors None None O
in None None O
comparison None None O
with None None O
the None None O
corresponding None None O
cyclopentylphenylacetic None None O
acid None None O
group None None O
. None None O

However None None O
, None None O
since None None O
the None None O
in None None O
vitro None None O
metabolic None None O
stability None None O
of None None O
these None None O
analogues None None O
was None None O
insufficient None None O
compared None None O
with None None O
that None None O
of None None O
2 None None O
, None None O
further None None O
derivatization None None O
was None None O
performed None None O
by None None O
introducing None None O
an None None O
appropriate None None O
hydrophilic None None O
group None None O
into None None O
the None None O
phenyl None None I-IUPAC
or None None O
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
ring None None I-MODIFIER
. None None O

Thus None None O
, None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
aminopyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
piperidine None None I-IUPAC
analogue None None I-MODIFIER
15y None None O
exhibiting None None O
190 None None O
- None None O
fold None None O
selectivity None None O
for None None O
M None None O
( None None O
3 None None O
) None None O
receptors None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
2.8 None None O
nM None None O
) None None O
over None None O
M None None O
( None None O
2 None None O
) None None O
receptors None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
530 None None O
nM None None O
) None None O
in None None O
a None None O
human None None O
binding None None O
assay None None O
and None None O
good None None O
in None None O
vitro None None O
metabolic None None O
stability None None O
in None None O
dog None None O
and None None O
human None None O
hepatic None None O
microsomes None None O
was None None O
identified None None O
. None None O

This None None O
compound None None O
has None None O
excellent None None O
oral None None O
activity None None O
at None None O
4 None None O
h None None O
after None None O
oral None None O
dosing None None O
( None None O
1 None None O
mg None None O
/ None None O
kg None None O
) None None O
, None None O
inhibiting None None O
methacholine None None O
- None None O
induced None None O
bronchoconstriction None None O
in None None O
dogs None None O
, None None O
and None None O
may None None O
be None None O
useful None None O
in None None O
clinical None None O
situations None None O
in None None O
which None None O
M None None O
( None None O
3 None None O
) None None O
over None None O
M None None O
( None None O
2 None None O
) None None O
selectivity None None O
is None None O
desirable None None O
. None None O


3 None None I-IUPAC
- None None I-IUPAC
Methoxy None None I-IUPAC
- None None I-IUPAC
4,5,6,7 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
benzisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
20a None None O
) None None O
, None None O
or None None O
the None None O
corresponding None None O
3 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
analogue None None I-MODIFIER
( None None O
20b None None O
) None None O
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4,5,6 None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
benzisothiazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
51 None None O
) None None O
were None None O
synthesized None None O
by None None O
regioselective None None O
chromic None None O
acid None None O
oxidation None None O
of None None O
the None None O
respective None None O
bicyclic None None O
tetrahydrobenzenes None None O
19a None None O
, None None O
b None None O
and None None O
50 None None O
, None None O
and None None O
they None None O
were None None O
used None None O
as None None O
key None None O
intermediates None None O
for None None O
the None None O
syntheses None None O
of None None O
the None None O
target None None O
zwitterionic None None O
3 None None I-IUPAC
- None None I-IUPAC
isoxazolols None None I-IUPAC
8-15 None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
isothiazolols None None I-IUPAC
16 None None O
and None None O
17 None None O
, None None O
respectively None None O
. None None O

These None None O
reaction None None O
sequences None None O
involved None None O
different None None O
reductive None None O
processes None None O
. None None O

Whereas None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4,5,6,7 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
benzisoxazole None None I-IUPAC
( None None O
8 None None O
, None None O
exo None None O
- None None O
THPO None None O
) None None O
was None None O
synthesized None None O
via None None O
aluminum None None O
amalgam None None O
reduction None None O
of None None O
oxime None None O
22a None None O
or None None O
22b None None O
, None None O
compounds None None O
9 None None O
, None None O
11-13 None None O
, None None O
and None None O
15-17 None None O
were None None O
obtained None None O
via None None O
reductive None None O
aminations None None O
. None None O

Compound None None O
10 None None O
was None None O
synthesized None None O
via None None O
N None None O
- None None O
ethylation None None O
of None None O
the None None O
N None None O
- None None O
Boc None None O
- None None O
protected None None O
primary None None O
amine None None O
25 None None O
. None None O

The None None O
enantiomers None None O
of None None O
8 None None O
were None None O
obtained None None O
in None None O
high None None O
enantiomeric None None O
purities None None O
( None None O
ee None None O
& None None O
gt None None O
; None None O
/ None None O
= None None O
99.1% None None O
) None None O
via None None O
the None None O
diastereomeric None None O
amides None None O
32 None None O
and None None O
33 None None O
, None None O
synthesized None None O
from None None O
the None None O
primary None None O
amine None None O
23b None None O
and None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
methoxyphenylacetyl None None I-IUPAC
chloride None None I-IUPAC
and None None O
subsequent None None O
separation None None O
by None None O
preparative None None O
HPLC None None O
. None None O

The None None O
enantiomers None None O
of None None O
9 None None O
were None None O
prepared None None O
analogously None None O
from None None O
the None None O
secondary None None O
amine None None O
27 None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
X None None O
- None None O
ray None None O
crystallographic None None O
analyses None None O
, None None O
the None None O
configuration None None O
of None None O
oxime None None O
22a None None O
was None None O
shown None None O
to None None O
be None None O
E None None O
and None None O
the None None O
absolute None None O
configurations None None O
of None None O
( None None O
- None None O
) None None O
- None None O
8 None None O
x None None O
HCl None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
9 None None O
x None None O
HBr None None O
were None None O
established None None O
to None None O
be None None O
R None None O
. None None O

The None None O
effects None None O
of None None O
the None None O
target None None O
compounds None None O
on None None O
GABA None None O
uptake None None O
mechanisms None None O
in None None O
vitro None None O
were None None O
measured None None O
using None None O
a None None O
rat None None O
brain None None O
synaptosomal None None O
preparation None None O
and None None O
primary None None O
cultures None None O
of None None O
mouse None None O
cortical None None O
neurons None None O
and None None O
glia None None O
cells None None O
( None None O
astrocytes None None O
) None None O
. None None O

Whereas None None O
the None None O
classical None None O
GABA None None O
uptake None None O
inhibitor None None O
, None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nipecotic None None I-IUPAC
acid None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
nonselectively None None O
inhibits None None O
neuronal None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
12 None None O
microM None None O
) None None O
and None None O
glial None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
16 None None O
microM None None O
) None None O
GABA None None O
uptake None None O
and None None O
4,5,6,7 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoxazolo None None I-IUPAC
 None None I-IUPAC
 None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
cpyridin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
( None None O
1 None None O
, None None O
THPO None None O
) None None O
shows None None O
some None None O
selectivity None None O
for None None O
glial None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
268 None None O
microM None None O
) None None O
versus None None O
neuronal None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
530 None None O
microM None None O
) None None O
GABA None None O
uptake None None O
, None None O
exo None None O
- None None O
THPO None None O
( None None O
8 None None O
) None None O
was None None O
shown None None O
to None None O
be None None O
more None None O
potent None None O
as None None O
an None None O
inhibitor None None O
of None None O
glial None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
200 None None O
microM None None O
) None None O
rather None None O
than None None O
neuronal None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
900 None None O
microM None None O
) None None O
GABA None None O
uptake None None O
. None None O

This None None O
selectivity None None O
was None None O
more None None O
pronounced None None O
for None None O
9 None None O
, None None O
which None None O
showed None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
of None None O
40 None None O
and None None O
500 None None O
microM None None O
as None None O
an None None O
inhibitor None None O
of None None O
glial None None O
and None None O
neuronal None None O
GABA None None O
uptake None None O
, None None O
respectively None None O
. None None O

These None None O
effects None None O
of None None O
8 None None O
and None None O
9 None None O
proved None None O
to None None O
be None None O
enantioselective None None O
, None None O
( None None O
R None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
8 None None O
and None None O
( None None O
R None None O
) None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
9 None None O
being None None O
the None None O
active None None O
inhibitors None None O
of None None O
both None None O
uptake None None O
systems None None O
. None None O

The None None O
selectivity None None O
of None None O
9 None None O
as None None O
a None None O
glial None None O
GABA None None O
uptake None None O
inhibitor None None O
was None None O
largely None None O
lost None None O
by None None O
replacing None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
of None None O
9 None None O
by None None O
an None None O
ethyl None None I-IUPAC
group None None B-MODIFIER
, None None O
compound None None O
10 None None O
being None None O
an None None O
almost None None O
equipotent None None O
inhibitor None None O
of None None O
glial None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
280 None None O
microM None None O
) None None O
and None None O
neuronal None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
400 None None O
microM None None O
) None None O
GABA None None O
uptake None None O
. None None O

The None None O
remaining None None O
target None None O
compounds None None O
, None None O
11-17 None None O
, None None O
were None None O
very None None O
weak None None O
or None None O
inactive None None O
as None None O
inhibitors None None O
of None None O
both None None O
uptake None None O
systems None None O
. None None O

Compounds None None O
9-13 None None O
and None None O
15 None None O
were None None O
shown None None O
to None None O
be None None O
essentially None None O
inactive None None O
against None None O
isoniazide None None O
- None None O
induced None None O
convulsions None None O
in None None O
mice None None O
after None None O
subcutaneous None None O
administration None None O
. None None O

The None None O
isomeric None None I-MODIFIER
pivaloyloxymethyl None None B-IUPAC
derivatives None None B-MODIFIER
of None None O
9 None None O
, None None O
compounds None None O
43 None None O
and None None O
44 None None O
, None None O
were None None O
synthesized None None O
and None None O
tested None None O
as None None O
potential None None O
prodrugs None None O
in None None O
the None None O
isoniazide None None O
animal None None O
model None None O
. None None O

Both None None O
43 None None O
( None None O
ED None None O
( None None O
50 None None O
) None None O
= None None O
150 None None O
micromol None None O
/ None None O
kg None None O
) None None O
and None None O
44 None None O
( None None O
ED None None O
( None None O
50 None None O
) None None O
= None None O
220 None None O
micromol None None O
/ None None O
kg None None O
) None None O
showed None None O
anticonvulsant None None O
effects None None O
, None None O
and None None O
this None None O
effect None None O
of None None O
43 None None O
was None None O
shown None None O
to None None O
reside None None O
in None None O
the None None O
( None None O
R None None O
) None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
enantiomer None None O
, None None O
45 None None O
( None None O
ED None None O
( None None O
50 None None O
) None None O
= None None O
44 None None O
micromol None None O
/ None None O
kg None None O
) None None O
. None None O

Compound None None O
9 None None O
also None None O
showed None None O
anticonvulsant None None O
activity None None O
when None None O
administered None None O
intracerebroventricularly None None O
( None None O
ED None None O
( None None O
50 None None O
) None None O
= None None O
59 None None O
nmol None None O
) None None O
. None None O


A None None O
series None None O
of None None O
substituted None None O
racemic None None O
naphthofurans None None O
were None None O
synthesized None None O
as None None O
" None None O
hybrid None None O
" None None O
molecules None None O
of None None O
the None None O
two None None O
major None None O
prototypical None None O
hallucinogenic None None O
drug None None O
classes None None O
, None None O
the None None O
phenethylamines None None O
and None None O
the None None O
tryptamines None None O
/ None None O
ergolines None None O
. None None O

Although None None O
it None None O
was None None O
hypothesized None None O
that None None O
these None None O
new None None O
agents None None O
might None None O
possess None None O
high None None O
affinity None None O
for None None O
the None None O
serotonin None None O
5 None None O
- None None O
HT2A None None O
/ None None O
2C None None O
receptor None None O
subtypes None None O
, None None O
unexpected None None O
affinity None None O
for None None O
muscarinic None None O
receptors None None O
was None None O
observed None None O
. None None O

The None None O
compounds None None O
initially None None O
synthesized None None O
for None None O
this None None O
study None None O
were None None O
( None None I-PARTIUPAC
+ None None I-PARTIUPAC
/ None None I-PARTIUPAC
- None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
anti None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
syn None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2a None None I-IUPAC
, None None I-IUPAC
3,4,5 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
naphtho None None I-IUPAC
[ None None I-IUPAC
1,8 None None I-IUPAC
- None None I-IUPAC
bc None None I-IUPAC
] None None I-IUPAC
furan None None I-IUPAC
( None None O
4a None None O
, None None O
b None None O
) None None O
, None None O
respectively None None O
, None None O
and None None O
their None None O
8 None None O
- None None O
bromo None None O
derivatives None None O
4c None None O
, None None O
d None None O
, None None O
respectively None None O
. None None O

The None None O
brominated None None O
primary None None O
amines None None O
4c None None O
, None None O
d None None O
were None None O
assayed None None O
initially None None O
for None None O
activity None None O
in None None O
the None None O
two None None O
- None None O
lever None None O
drug None None O
discrimination None None O
( None None O
DD None None O
) None None O
paradigm None None O
in None None O
rats None None O
trained None None O
to None None O
discriminate None None O
saline None None O
from None None O
LSD None None O
tartrate None None O
( None None O
0 None None O
. None None O

08 None None O
mg None None O
/ None None O
kg None None O
) None None O
. None None O

Also None None O
, None None O
4c None None O
, None None O
d None None O
were None None O
evaluated None None O
for None None O
their None None O
ability None None O
to None None O
compete None None O
against None None O
agonist None None O
and None None O
antagonist None None O
radioligands None None O
at None None O
cloned None None O
human None None O
5 None None O
- None None O
HT2A None None O
, None None O
5 None None O
- None None O
HT2B None None O
, None None O
and None None O
5 None None O
- None None O
HT2C None None O
receptors None None O
. None None O

After None None O
the None None O
syn None None O
diastereomers None None O
were None None O
found None None O
to None None O
have None None O
the None None O
highest None None O
activity None None O
in None None O
these None None O
preliminary None None O
assays None None O
, None None O
the None None O
N None None O
- None None O
alkylated None None O
analogues None None O
syn None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2a None None I-IUPAC
, None None I-IUPAC
3,4 None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
naphtho None None I-IUPAC
[ None None I-IUPAC
1,8 None None I-IUPAC
- None None I-IUPAC
bc None None I-IUPAC
] None None I-IUPAC
furan None None I-IUPAC
( None None O
4e None None O
) None None O
and None None O
syn None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dipropyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2a None None I-IUPAC
, None None I-IUPAC
3,4,5 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
naphtho None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
bc None None I-IUPAC
] None None I-IUPAC
furan None None I-IUPAC
( None None O
4f None None O
) None None O
were None None O
prepared None None O
and None None O
assayed None None O
for None None O
their None None O
affinities None None O
at None None O
[ None None O
3H None None O
] None None O
ketanserin None None O
- None None O
labeled None None O
5 None None O
- None None O
HT2A None None O
and None None O
[ None None O
3H None None O
] None None O
- None None O
8 None None O
- None None O
OH None None O
- None None O
DPAT None None O
- None None O
labeled None None O
5 None None O
- None None O
HT1A None None O
sites None None O
. None None O

All None None O
of None None O
the None None O
molecules None None O
tested None None O
had None None O
relatively None None O
low None None O
affinity None None O
for None None O
serotonin None None O
receptors None None O
, None None O
yet None None O
a None None O
preliminary None None O
screen None None O
indicated None None O
that None None O
compound None None O
4d None None O
had None None O
affinity None None O
for None None O
muscarinic None None O
receptors None None O
. None None O

Thus None None O
, None None O
4b None None O
, None None O
d None None O
, None None O
e None None O
were None None O
evaluated None None O
for None None O
their None None O
affinity None None O
at None None O
muscarinic None None O
M1 None None O
- None None O
M5 None None O
receptors None None O
and None None O
also None None O
assessed None None O
for None None O
their None None O
functional None None O
characteristics None None O
at None None O
the None None O
M1 None None O
and None None O
M2 None None O
isoforms None None O
. None None O

Compound None None O
4d None None O
had None None O
affinities None None O
of None None O
12-33 None None O
nM None None O
at None None O
all None None O
of None None O
the None None O
muscarinic None None O
sites None None O
, None None O
with None None O
4b None None O
, None None O
e None None O
having None None O
much None None O
lower None None O
affinity None None O
. None None O

All None None O
three None None O
compounds None None O
fully None None O
antagonized None None O
the None None O
effects None None O
of None None O
carbachol None None O
at None None O
the None None O
M1 None None O
receptor None None O
, None None O
while None None O
only None None O
4d None None O
completely None None O
antagonized None None O
carbachol None None O
at None None O
the None None O
M2 None None O
receptor None None O
. None None O

The None None O
fact None None O
that None None O
the None None O
naphthofurans None None O
lack None None O
LSD None None O
- None None O
like None None O
activity None None O
suggests None None O
that None None O
they None None O
do None None O
not None None O
bind None None O
to None None O
the None None O
serotonin None None O
receptor None None O
in None None O
a None None O
way None None O
such None None O
that None None O
the None None O
tricyclic None None O
naphthofuran None None O
nucleus None None O
is None None O
bioisosteric None None O
with None None O
, None None O
and None None O
directly None None O
superimposable None None O
upon None None O
, None None O
the None None O
A None None O
, None None O
B None None O
, None None O
and None None O
C None None O
rings None None O
of None None O
LSD None None O
. None None O

This None None O
also None None O
implies None None O
, None None O
therefore None None O
, None None O
that None None O
the None None O
hallucinogenic None None O
phenethylamines None None O
cannot None None O
be None None O
directly None None O
superimposed None None O
on None None O
LSD None None O
in None None O
a None None O
common None None O
binding None None O
orientation None None O
for None None O
these None None O
two None None O
chemical None None O
classes None None O
, None None O
contrary None None O
to None None O
previous None None O
hypotheses None None O
. None None O


A None None O
Langendorff None None O
guinea None None O
pig None None O
heart None None O
preparation None None O
served None None O
for None None O
the None None O
assay None None O
of None None O
agonist None None O
potency None None O
of None None O
a None None O
series None None O
of None None O
26 None None O
2 None None I-IUPAC
- None None I-IUPAC
aralkoxyadenosines None None I-IUPAC
at None None O
the None None O
A1 None None O
and None None O
A2 None None O
receptors None None O
of None None O
, None None O
respectively None None O
, None None O
the None None O
atrioventricular None None O
node None None O
( None None O
conduction None None O
block None None O
) None None O
and None None O
coronary None None O
arteries None None O
( None None O
vasodilation None None O
) None None O
. None None O

All None None O
of None None O
the None None O
analogues None None O
are None None O
weak None None O
agonists None None O
at None None O
the None None O
A1 None None O
receptor None None O
, None None O
requiring None None O
concentrations None None O
greater None None O
than None None O
9 None None O
microM None None O
to None None O
cause None None O
second None None O
degree None None O
heart None None O
block None None O
. None None O

At None None O
the None None O
A2 None None O
receptor None None O
2 None None I-IUPAC
- None None I-IUPAC
phenethoxyadenosine None None I-IUPAC
is None None O
the None None O
most None None O
potent None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
phenylalkyladenosines None None I-IUPAC
. None None O

The None None O
activity None None O
of None None O
ring None None O
- None None O
substituted None None O
( None None O
F None None O
, None None O
Cl None None O
, None None O
CH3 None None O
, None None O
and None None O
OCH3 None None O
) None None O
2 None None I-IUPAC
- None None I-IUPAC
phenethoxyadenosines None None I-IUPAC
increases None None O
ortho None None O
less None None O
than None None O
meta None None O
less None None O
than None None O
para None None O
. None None O

The None None O
EC50s None None O
of None None O
coronary None None O
vasoactivity None None O
of None None O
several None None O
para None None O
- None None O
substituted None None O
analogues None None O
are None None O
in None None O
the None None O
subnanomolar None None O
range None None O
. None None O

The None None O
most None None O
potent None None O
analogue None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
ethoxy None None I-IUPAC
] None None I-IUPAC
adenosine None None I-IUPAC
19 None None O
, None None O
has None None O
an None None O
EC50 None None O
for None None O
coronary None None O
vasodilation None None O
of None None O
190 None None O
pM None None O
and None None O
an None None O
A1 None None O
/ None None O
A2 None None O
selectivity None None O
ratio None None O
of None None O
44,000 None None O
. None None O

Aryl None None O
groups None None O
such None None O
as None None O
thienyl None None O
, None None O
indoloyl None None O
, None None O
or None None O
naphthyl None None O
also None None O
support None None O
A2 None None O
agonist None None O
activity None None O
. None None O

Although None None O
2 None None I-IUPAC
- None None I-IUPAC
oxoadenosine None None I-IUPAC
is None None O
3 None None O
times None None O
more None None O
vasoactive None None O
than None None O
2 None None I-IUPAC
- None None I-IUPAC
aminoadenosine None None I-IUPAC
, None None O
the None None O
activities None None O
of None None O
the None None O
phenyl None None I-IUPAC
derivatives None None B-MODIFIER
are None None O
markedly None None O
different None None O
; None None O
2 None None I-IUPAC
- None None I-IUPAC
phenoxyadenosine None None I-IUPAC
is None None O
23 None None O
times None None O
weaker None None O
than None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylamino None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
( None None O
CV None None O
- None None O
1808 None None O
) None None O
. None None O


In None None O
an None None O
attempt None None O
to None None O
increase None None O
the None None O
combined None None O
toxicity None None O
of None None O
the None None O
metabolic None None O
end None None O
- None None O
products None None O
[ None None O
acrolein None None O
( None None O
4 None None O
) None None O
and None None O
phosphoramide None None O
mustard None None O
( None None O
3 None None O
) None None O
] None None O
from None None O
cyclophosphamide None None O
( None None O
1 None None O
) None None O
, None None O
the None None O
analog None None I-MODIFIER
2 None None B-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
trifluoromethyl None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
oxazaphosphorine None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
2 None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
trifluoromethylcyclophosphamide None None I-IUPAC
) None None O
was None None O
synthesized None None O
and None None O
its None None O
metabolism None None O
and None None O
antitumor None None O
activity None None O
studied None None O
. None None O

Following None None O
metabolism None None O
of None None O
2 None None O
by None None O
rat None None O
liver None None O
microsomes None None O
the None None O
predicted None None O
formation None None O
of None None O
4,4,4 None None I-IUPAC
- None None I-IUPAC
trifluorocrotonaldehyde None None I-IUPAC
( None None O
5 None None O
) None None O
was None None O
confirmed None None O
by None None O
isolation None None O
and None None O
identification None None O
, None None O
by None None O
mass None None O
spectrometry None None O
, None None O
of None None O
its None None O
dinitrophenylhydrazone None None O
. None None O

The None None O
therapeutic None None O
indices None None O
( None None O
LD50 None None O
- None None O
/ None None O
ID90 None None O
) None None O
for None None O
2 None None O
against None None O
the None None O
ADJ None None O
/ None None O
PC6 None None O
mouse None None O
tumor None None O
and None None O
the None None O
Walker None None O
256 None None O
tumor None None O
in None None O
the None None O
rat None None O
were None None O
28.6 None None O
and None None O
7.7 None None O
, None None O
respectively None None O
, None None O
and None None O
were None None O
lower None None O
than None None O
the None None O
corresponding None None O
values None None O
for None None O
1 None None O
( None None O
91.8 None None O
and None None O
33.2 None None O
, None None O
respectively None None O
) None None O
although None None O
the None None O
toxicities None None O
toward None None O
Walker None None O
cells None None O
in None None O
a None None O
bioassay None None O
system None None O
of None None O
1 None None O
and None None O
2 None None O
following None None O
microsomal None None O
metabolism None None O
were None None O
similar None None O
. None None O

In None None O
order None None O
to None None O
study None None O
the None None O
toxicities None None O
of None None O
4 None None O
and None None O
5 None None O
released None None O
under None None O
drug None None O
metabolizing None None O
conditions None None O
independently None None O
of None None O
the None None O
production None None O
of None None O
a None None O
toxic None None O
mustard None None O
the None None O
analogs None None I-MODIFIER
18 None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
oxazaphosphorine None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
] None None O
and None None O
6 None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
trifluoromethyl None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
oxazaphosphorine None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
] None None O
were None None O
also None None O
synthesized None None O
. None None O

The None None O
release None None O
of None None O
5 None None O
from None None O
6 None None O
following None None O
metabolism None None O
was None None O
confirmed None None O
and None None O
shown None None O
by None None O
use None None O
of None None O
the None None O
bioassay None None O
system None None O
to None None O
be None None O
an None None O
event None None O
of None None O
similar None None O
toxicity None None O
to None None O
release None None O
of None None O
4 None None O
from None None O
18 None None O
; None None O
in None None O
vivo None None O
, None None O
however None None O
, None None O
6 None None O
( None None O
LD50 None None O
330 None None O
mg None None O
/ None None O
kg None None O
) None None O
was None None O
more None None O
toxic None None O
to None None O
mice None None O
than None None O
18 None None O
( None None O
LD50 None None O
greater None None O
than None None O
500 None None O
mg None None O
/ None None O
kg None None O
) None None O
. None None O


There None None O
is None None O
reported None None O
the None None O
first None None O
four None None O
members None None O
of None None O
heteroarotinoids None None O
, None None O
the None None O
names None None O
of None None O
which None None O
are None None O
ethyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylthiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
1b None None O
) None None O
, None None O
ethyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylchroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
1c None None O
) None None O
, None None O
ethyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxothiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
1d None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylchroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
1e None None O
) None None O
. None None O

IR None None O
, None None O
1H None None O
NMR None None O
and None None O
13C None None O
NMR None None O
data None None O
have None None O
been None None O
recorded None None O
for None None O
each None None O
compound None None O
and None None O
support None None O
the None None O
structural None None O
assignments None None O
. None None O

To None None O
provide None None O
a None None O
firm None None O
basis None None O
for None None O
comparison None None O
purposes None None O
of None None O
future None None O
analogues None None O
, None None O
an None None O
X None None O
- None None O
ray None None O
analysis None None O
was None None O
performed None None O
on None None O
a None None O
single None None O
crystal None None O
of None None O
ethyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylthiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
1b None None O
) None None O
and None None O
a None None O
precursor None None O
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylthiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
methyl None None I-IUPAC
ketone None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
( None None O
18 None None O
) None None O
. None None O

These None None O
data None None O
for None None O
the None None O
heteroarotinoid None None O
1b None None O
revealed None None O
that None None O
the None None O
two None None O
aryl None None O
ring None None O
systems None None O
were None None O
nearly None None O
perpendicular None None O
in None None O
each None None O
of None None O
the None None O
two None None O
molecules None None O
present None None O
in None None O
the None None O
unit None None O
cell None None O
( None None O
86.37 None None O
degrees None None O
and None None O
84.17 None None O
degrees None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
space None None O
group None None O
for None None O
both None None O
molecules None None O
was None None O
P1 None None O
in None None O
triclinic None None O
systems None None O
. None None O

Unit None None O
cell None None O
dimensions None None O
( None None O
at None None O
15 None None O
degrees None None O
C None None O
) None None O
are None None O
as None None O
follows None None O
: None None O
for None None O
1b None None O
, None None O
a None None O
= None None O
20.568 None None O
( None None O
6 None None O
) None None O
A None None O
, None None O
b None None O
= None None O
14.760 None None O
( None None O
3 None None O
) None None O
A None None O
, None None O
c None None O
= None None O
7.679 None None O
( None None O
2 None None O
) None None O
A None None O
, None None O
alpha None None O
= None None O
113.33 None None O
( None None O
2 None None O
) None None O
degrees None None O
, None None O
beta None None O
= None None O
79.45 None None O
( None None O
2 None None O
) None None O
degrees None None O
, None None O
gamma None None O
= None None O
79.98 None None O
( None None O
2 None None O
) None None O
degrees None None O
, None None O
Z None None O
= None None O
4 None None O
; None None O
for None None O
18 None None O
, None None O
a None None O
= None None O
9.292 None None O
( None None O
5 None None O
) None None O
A None None O
, None None O
b None None O
= None None O
9.291 None None O
( None None O
5 None None O
) None None O
A None None O
, None None O
c None None O
= None None O
7.951 None None O
( None None O
3 None None O
) None None O
A None None O
, None None O
alpha None None O
= None None O
102.16 None None O
( None None O
3 None None O
) None None O
degrees None None O
, None None O
beta None None O
= None None O
77.49 None None O
( None None O
3 None None O
) None None O
degrees None None O
, None None O
gamma None None O
= None None O
79.60 None None O
( None None O
4 None None O
) None None O
degrees None None O
, None None O
Z None None O
= None None O
2 None None O
. None None O

The None None O
sulfur None None O
- None None O
containing None None O
ring None None O
is None None O
in None None O
a None None O
distorted None None O
half None None O
- None None O
chair None None O
in None None O
1b None None O
and None None O
the None None O
methyl None None O
carbon None None O
C None None O
( None None O
12 None None O
) None None O
is None None O
shown None None O
to None None O
be None None O
trans None None O
to None None O
H None None O
( None None O
13 None None O
) None None O
at None None O
the None None O
C None None O
( None None O
11 None None O
) None None O
- None None O
C None None O
( None None O
13 None None O
) None None O
bond None None O
. None None O

The None None O
biological None None O
activity None None O
of None None O
these None None O
arotinoids None None O
was None None O
determined None None O
in None None O
the None None O
tracheal None None O
organ None None O
culture None None O
assay None None O
and None None O
compared None None O
with None None O
trans None None O
- None None O
retinoic None None O
acid None None O
for None None O
ability None None O
to None None O
reverse None None O
keratinization None None O
in None None O
vitamin None None O
A None None O
deficient None None O
hamsters None None O
. None None O

The None None O
ester None None O
1b None None O
displayed None None O
activity None None O
about None None O
one None None O
- None None O
half None None O
log None None O
unit None None O
less None None O
than None None O
that None None O
of None None O
the None None O
reference None None O
while None None O
1c None None O
and None None O
1e None None O
had None None O
activity None None O
nearly None None O
one None None O
log None None O
until None None O
less None None O
than None None O
trans None None O
- None None O
retinoic None None O
acid None None O
. None None O

The None None O
sulfoxide None None O
was None None O
the None None O
least None None O
active None None O
of None None O
the None None O
heteroretinoids None None O
. None None O


A None None O
series None None O
of None None O
new None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
and None None O
uridine None None I-IUPAC
compounds None None B-MODIFIER
( None None O
11 None None O
, None None O
16 None None O
) None None O
was None None O
synthesized None None O
by None None O
the None None O
regiospecific None None O
addition None None O
of None None O
HOI None None O
to None None O
the None None O
vinyl None None O
substituent None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
10a None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
10b None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyluridine None None I-IUPAC
( None None O
10c None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodovinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
4b None None O
) None None O
. None None O

Treatment None None O
of None None O
the None None O
iodohydrins None None O
11a None None O
- None None O
c None None O
with None None O
methanolic None None O
sulfuric None None O
acid None None O
afforded None None O
the None None O
corresponding None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
12a None None O
- None None O
c None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
reaction None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
11a None None O
) None None O
with None None O
sodium None None O
carbonate None None O
in None None O
methanol None None O
afforded None None O
a None None O
mixture None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxyethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
13 None None O
) None None O
and None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
furano None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
( None None I-IUPAC
5H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
14 None None O
) None None O
. None None O

The None None O
most None None O
active None None O
compound None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
12a None None O
, None None O
ID50 None None O
= None None O
0.1 None None O
micrograms None None O
/ None None O
mL None None O
) None None O
, None None O
which None None O
exhibited None None O
antiviral None None O
activity None None O
( None None O
HSV None None O
- None None O
1 None None O
) None None O
100 None None O
- None None O
fold None None O
higher None None O
than None None O
that None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
analogue None None I-MODIFIER
( None None O
11a None None O
) None None O
, None None O
was None None O
less None None O
active None None O
than None None O
IVDU None None O
or None None O
acyclovir None None O
( None None O
ID50 None None O
= None None O
0.01-0.1 None None O
micrograms None None O
/ None None O
mL None None O
range None None O
) None None O
. None None O

The None None O
C None None O
- None None O
5 None None O
substituent None None O
in None None O
the None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
series None None I-MODIFIER
was None None O
a None None O
determinant None None O
of None None O
cytotoxic None None O
activity None None O
, None None O
as None None O
determined None None O
in None None O
the None None O
in None None O
vitro None None O
L1210 None None O
screen None None O
, None None O
where None None O
the None None O
relative None None O
activity None None O
order None None O
was None None O
CH None None O
( None None O
OH None None O
) None None O
CHI2 None None O
( None None O
16 None None O
) None None O
greater None None O
than None None O
CH None None O
( None None O
OMe None None O
) None None O
CH2I None None O
( None None O
12a None None O
) None None O
greater None None O
than None None O
CH None None O
( None None O
OH None None O
) None None O
CH2I None None O
( None None O
11a None None O
) None None O
congruent None None O
to None None O
CH None None O
( None None O
OH None None O
) None None O
CH2OMe None None O
( None None O
13 None None O
) None None O
. None None O

The None None O
2' None None O
- None None O
substituent None None O
was None None O
also None None O
a None None O
determinant None None O
of None None O
cytotoxic None None O
activity None None O
in None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
( None None O
11a None None O
- None None O
c None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
series None None I-MODIFIER
of None None O
compounds None None O
, None None O
where None None O
the None None O
relative None None O
activity None None O
profile None None O
was None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
greater None None O
than None None O
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
greater None None O
than None None O
uridine None None I-IUPAC
( None None O
11a None None O
greater None None O
than None None O
11b None None O
greater None None O
than None None O
or None None O
equal None None O
to None None O
11c None None O
; None None O
12a None None O
greater None None O
than None None O
12b None None O
greater None None O
than None None O
12c None None O
) None None O
. None None O

The None None O
most None None O
active None None O
cytotoxic None None O
agent None None O
( None None O
16 None None O
) None None O
, None None O
possessing None None O
a None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
diiodoethyl None None I-IUPAC
) None None I-IUPAC
substituent None None I-MODIFIER
( None None O
ED50 None None O
= None None O
0.77 None None O
micrograms None None O
/ None None O
mL None None O
) None None O
, None None O
exhibited None None O
an None None O
activity None None O
approaching None None O
that None None O
of None None O
melphalan None None O
( None None O
ED50 None None O
= None None O
0.15 None None O
micrograms None None O
/ None None O
mL None None O
) None None O
. None None O

All None None O
compounds None None O
tested None None O
, None None O
except None None O
for None None O
13 None None O
and None None O
14 None None O
, None None O
exhibited None None O
high None None O
affinity None None O
( None None O
Ki None None O
= None None O
0.035-0.22 None None O
mM None None O
range None None O
relative None None O
to None None O
deoxyuridine None None O
, None None O
Ki None None O
= None None O
0.125 None None O
) None None O
for None None O
the None None O
murine None None O
NBMPR None None O
- None None O
sensitive None None O
erythrocyte None None O
nucleoside None None O
transport None None O
system None None O
, None None O
suggesting None None O
that None None O
these None None O
iodohydrins None None O
are None None O
good None None O
permeants None None O
of None None O
cell None None O
membranes None None O
. None None O


A None None O
number None None O
of None None O
derivatives None None O
structurally None None O
related None None O
to None None O
cirazoline None None O
( None None O
1 None None O
) None None O
were None None O
synthesized None None O
and None None O
studied None None O
with None None O
the None None O
purpose None None O
of None None O
modulating None None O
alpha2 None None O
- None None O
adrenoreceptors None None O
selectivity None None O
versus None None O
both None None O
alpha1 None None O
- None None O
adrenoreceptors None None O
and None None O
I2 None None O
imidazoline None None O
binding None None O
sites None None O
. None None O

The None None O
most None None O
potent None None O
alpha2 None None O
- None None O
agonist None None O
was None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yloxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazole None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
whose None None O
key None None O
pharmacophoric None None O
features None None O
closely None None O
matched None None O
those None None O
found None None O
in None None O
the None None O
alpha2 None None O
- None None O
agonist None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
exo None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylprop None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
exo None None I-IUPAC
- None None I-IUPAC
norbornyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxazoline None None I-IUPAC
( None None O
15 None None O
) None None O
. None None O

( None None O
S None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
7 None None O
was None None O
the None None O
most None None O
potent None None O
of None None O
the None None O
two None None O
enantiomers None None O
, None None O
confirming None None O
the None None O
stereospecificity None None O
of None None O
the None None O
interaction None None O
with None None O
alpha2 None None O
- None None O
adrenoreceptors None None O
. None None O

This None None O
eutomer None None O
was None None O
tested None None O
on None None O
two None None O
algesiometric None None O
paradigms None None O
and None None O
, None None O
because None None O
of None None O
the None None O
interaction None None O
with None None O
alpha2 None None O
- None None O
adrenoreceptors None None O
, None None O
showed None None O
a None None O
potent None None O
and None None O
long None None O
- None None O
lasting None None O
antinociceptive None None O
activity None None O
, None None O
since None None O
it None None O
was None None O
abolished None None O
by None None O
the None None O
selective None None O
alpha2 None None O
- None None O
antagonist None None O
RX821002 None None O
. None None O


A None None O
series None None O
of None None O
substituted None None I-MODIFIER
1,4 None None B-IUPAC
- None None I-IUPAC
dihydronaphthoquinones None None I-IUPAC
, None None O
hydroindoloquinones None None O
, None None O
benzofuran None None I-IUPAC
- None None I-IUPAC
4,7 None None I-IUPAC
- None None I-IUPAC
dihydroquinones None None I-IUPAC
, None None O
and None None O
benzothiophene None None I-IUPAC
- None None I-IUPAC
4,7 None None I-IUPAC
- None None I-IUPAC
dihydroquinones None None I-IUPAC
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
inhibitory None None O
activity None None O
against None None O
5 None None O
- None None O
lipoxygenase None None O
. None None O

These None None O
compounds None None O
were None None O
found None None O
to None None O
be None None O
active None None O
in None None O
vitro None None O
for None None O
LTC4 None None O
/ None None O
D4 None None O
inhibition None None O
with None None O
the None None O
potencies None None O
( None None O
IC50 None None O
's None None O
) None None O
ranging None None O
from None None O
0.2 None None O
to None None O
85 None None O
microM None None O
. None None O

Active None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydronaphthoquinone None None I-IUPAC
acetates None None I-IUPAC
( None None O
IC50 None None O
less None None O
than None None O
20 None None O
microM None None O
) None None O
were None None O
evaluated None None O
in None None O
an None None O
ex None None O
vivo None None O
LTB4 None None O
inhibition None None O
assay None None O
. None None O

The None None O
acetates None None O
of None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydronaphthoquinones None None I-IUPAC
containing None None O
the None None O
alkyl None None O
substituent None None O
( None None O
s None None O
) None None O
( None None O
2 None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
, None None O
11 None None O
, None None O
and None None O
2,3 None None I-IUPAC
- None None I-IUPAC
diethyl None None I-IUPAC
, None None O
15 None None O
) None None O
exhibited None None O
the None None O
best None None O
activity None None O
in None None O
LTC4 None None O
/ None None O
D4 None None O
inhibition None None O
( None None O
IC50 None None O
= None None O
0.2-0.4 None None O
microM None None O
, None None O
in None None O
vitro None None O
) None None O
as None None O
well None None O
as None None O
in None None O
LTB4 None None O
inhibition None None O
( None None O
60-75% None None O
inhibition None None O
) None None O
. None None O


In None None O
the None None O
present None None O
investigation None None O
, None None O
the None None O
last None None O
two None None O
possible None None O
modes None None O
of None None O
generating None None O
conformationally None None O
semirigid None None O
diacylglycerol None None O
( None None O
DAG None None O
) None None O
analogues None None O
embedded None None O
into None None O
five None None O
- None None O
membered None None O
ring None None O
lactones None None O
as None None O
templates None None O
III None None O
and None None O
IV None None O
are None None O
investigated None None O
. None None O

The None None O
first None None O
two None None O
templates None None O
studied None None O
in None None O
previous None None O
investigations None None O
corresponded None None O
to None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxyribonolactone None None I-IUPAC
( None None O
template None None O
I None None O
) None None O
and None None O
4,4 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
gamma None None I-IUPAC
- None None I-IUPAC
butyrolactone None None I-IUPAC
( None None O
template None None O
II None None O
) None None O
, None None O
with None None O
the None None O
latter None None O
producing None None O
potent None None O
protein None None O
kinase None None O
C None None O
( None None O
PK None None O
- None None O
C None None O
) None None O
ligands None None O
with None None O
low None None O
nanomolar None None O
binding None None O
affinities None None O
. None None O

The None None O
templates None None O
reported None None O
in None None O
this None None O
work None None O
correspond None None O
to None None O
2,3 None None I-PARTIUPAC
- None None I-PARTIUPAC
dideoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
L None None I-PARTIUPAC
- None None I-PARTIUPAC
erythro None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
- None None I-PARTIUPAC
threo None None I-PARTIUPAC
- None None I-PARTIUPAC
hexono None None I-PARTIUPAC
- None None I-PARTIUPAC
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
lactone None None I-PARTIUPAC
( None None O
template None None O
III None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxyapiolactone None None I-IUPAC
( None None O
template None None O
IV None None O
) None None O
. None None O

Compounds None None O
constructed None None O
with None None O
the None None O
dideoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
L None None I-PARTIUPAC
- None None I-PARTIUPAC
erythro None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
- None None I-PARTIUPAC
threo None None I-PARTIUPAC
- None None I-PARTIUPAC
hexono None None I-PARTIUPAC
- None None I-PARTIUPAC
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
lactone None None I-PARTIUPAC
template None None O
were None None O
synthesized None None O
stereospecifically None None O
from None None O
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glucal None None I-IUPAC
and None None O
L None None I-IUPAC
- None None I-IUPAC
galactono None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
lactone None None I-IUPAC
, None None O
respectively None None O
. None None O

Compounds None None O
constructed None None O
with None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxyapiolactone None None I-IUPAC
template None None O
were None None O
synthesized None None O
stereoselectively None None O
from None None O
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
isopropylidene None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
apiose None None I-IUPAC
. None None O

Inhibition None None O
of None None O
the None None O
binding None None O
of None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
phorbol None None I-IUPAC
- None None I-IUPAC
12,13 None None I-IUPAC
- None None I-IUPAC
dibutyrate None None I-IUPAC
to None None O
PK None None O
- None None O
C None None O
alpha None None O
showed None None O
that None None O
only None None O
the None None O
threo None None O
- None None O
isomer None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
tetradecanoyl None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
threo None None I-IUPAC
- None None I-IUPAC
hexono None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
lactone None None I-IUPAC
( None None O
2 None None O
) None None O
was None None O
a None None O
good None None O
PK None None O
- None None O
C None None O
ligand None None O
( None None O
Ki None None O
= None None O
1 None None O
microM None None O
) None None O
. None None O

The None None O
rest None None O
of None None O
the None None O
ligands None None O
had None None O
poorer None None O
affinities None None O
with None None O
Ki None None O
values None None O
between None None O
10 None None O
and None None O
28 None None O
microM None None O
. None None O

With None None O
these None None O
results None None O
, None None O
the None None O
order None None O
of None None O
importance None None O
of None None O
five None None O
- None None O
membered None None O
ring None None O
lactones None None O
as None None O
competent None None O
templates None None O
for None None O
the None None O
construction None None O
of None None O
semirigid None None O
DAG None None O
surrogates None None O
with None None O
effective None None O
PK None None O
- None None O
C None None O
binding None None O
affinity None None O
can None None O
be None None O
established None None O
as None None O
II None None O
& None None O
gt None None O
; None None O
& None None O
gt None None O
; None None O
I None None O
approximately None None O
III None None O
& None None O
gt None None O
; None None O
IV None None O
. None None O


Structure None None O
- None None O
activity None None O
relationships None None O
have None None O
been None None O
investigated None None O
for None None O
inhibition None None O
of None None O
DNA None None O
- None None O
dependent None None O
protein None None O
kinase None None O
( None None O
DNA None None O
- None None O
PK None None O
) None None O
and None None O
ATM None None O
kinase None None O
by None None O
a None None O
series None None O
of None None O
pyran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
pyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
thiopyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
and None None O
pyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
. None None O

A None None O
wide None None O
range None None O
of None None O
IC50 None None O
values None None O
were None None O
observed None None O
for None None O
pyranones None None O
and None None O
thiopyranones None None O
substituted None None O
at None None O
the None None O
6 None None O
- None None O
position None None O
, None None O
with None None O
the None None O
3 None None O
- None None O
and None None O
5 None None O
- None None O
positions None None O
proving None None O
intolerant None None O
to None None O
substitution None None O
. None None O

Related None None O
pyran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
pyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
and None None O
thiopyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
showed None None O
similar None None O
IC50 None None O
values None None O
against None None O
DNA None None O
- None None O
PK None None O
, None None O
whereas None None O
the None None O
pyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
system None None I-MODIFIER
proved None None O
, None None O
in None None O
general None None O
, None None O
ineffective None None O
at None None O
inhibiting None None O
DNA None None O
- None None O
PK None None O
. None None O

Extended None None O
libraries None None O
exploring None None O
the None None O
6 None None O
- None None O
position None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
morpholino None None I-IUPAC
- None None I-IUPAC
pyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
morpholino None None I-IUPAC
- None None I-IUPAC
thiopyrano None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
identified None None O
the None None O
first None None O
highly None None O
potent None None O
and None None O
selective None None O
ATM None None O
inhibitor None None O
2 None None I-IUPAC
- None None I-IUPAC
morpholin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
thianthren None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
pyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
151C None None O
; None None O
ATM None None O
; None None O
IC50 None None O
= None None O
13 None None O
nM None None O
) None None O
and None None O
revealed None None O
constrained None None O
SARs None None O
for None None O
ATM None None O
inhibition None None O
compared None None O
with None None O
DNA None None O
- None None O
PK None None O
. None None O

One None None O
of None None O
the None None O
most None None O
potent None None O
DNA None None O
- None None O
PK None None O
inhibitors None None O
identified None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
morpholin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
pyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
16 None None O
; None None O
DNA None None O
- None None O
PK None None O
; None None O
IC50 None None O
= None None O
220 None None O
nM None None O
) None None O
effectively None None O
sensitized None None O
HeLa None None O
cells None None O
to None None O
the None None O
topoisomerase None None O
II None None O
inhibitor None None O
etoposide None None O
in None None O
vitro None None O
. None None O


Radiolabeled None None O
m None None I-IUPAC
- None None I-IUPAC
iodobenzylguanidine None None I-IUPAC
( None None O
MIBG None None O
) None None O
is None None O
a None None O
tumor None None O
- None None O
seeking None None O
radioactive None None O
drug None None O
used None None O
in None None O
the None None O
diagnosis None None O
and None None O
treatment None None O
of None None O
pheochromocytomas None None O
and None None O
neuroblastomas None None O
. None None O

It None None O
is None None O
transported None None O
into None None O
the None None O
tumor None None O
cells None None O
by None None O
the None None O
neuronal None None O
norepinephrine None None O
( None None O
NE None None O
) None None O
transporter None None O
( None None O
NET None None O
) None None O
which None None O
is None None O
expressed None None O
in None None O
almost None None O
all None None O
neuroblastoma None None O
cells None None O
. None None O

Here None None O
, None None O
we None None O
describe None None O
the None None O
synthesis None None O
and None None O
some None None O
pharmacological None None O
properties None None O
of None None O
a None None O
series None None O
of None None O
fluorescent None None O
compounds None None O
structurally None None O
related None None O
to None None O
the None None O
NET None None O
substrate None None O
, None None O
MIBG None None O
, None None O
or None None O
to None None O
the None None O
NET None None O
inhibitors None None O
, None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2R None None I-IUPAC
, None None I-IUPAC
3S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cocaine None None I-IUPAC
and None None O
nisoxetine None None O
. None None O

Three None None O
of None None O
10 None None O
synthesized None None O
fluorescent None None O
compounds None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthylmethyl None None I-IUPAC
) None None I-IUPAC
guanidinium None None I-IUPAC
sulfate None None I-IUPAC
( None None O
1 None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dibenz None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
, None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
azepin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
guanidinium None None I-IUPAC
sulfate None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
2R None None I-IUPAC
, None None I-IUPAC
3S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2beta None None I-IUPAC
- None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
tropanyl None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
naphthalene None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
sulfonate None None I-IUPAC
( None None O
6 None None O
) None None O
, None None O
exhibited None None O
high None None O
affinity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
about None None O
50 None None O
nM None None O
) None None O
for None None O
the None None O
NET None None O
. None None O

The None None O
nisoxetine None None O
derivatives None None O
8 None None O
( None None O
rac None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthale None None I-IUPAC
nesulfonamide None None I-IUPAC
) None None O
and None None O
9 None None O
( None None O
rac None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
2,1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzoxadiazole None None I-IUPAC
) None None O
and None None O
especially None None O
the None None O
guanidine None None O
derivative None None O
4 None None O
( None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
butadienyl None None I-IUPAC
) None None I-IUPAC
benzyl None None I-IUPAC
] None None I-IUPAC
guanidinium None None I-IUPAC
sulfate None None I-IUPAC
) None None O
which None None O
are None None O
characterized None None O
by None None O
intermediate None None O
affinity None None O
for None None O
the None None O
NET None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
370-850 None None O
nM None None O
) None None O
caused None None O
significant None None O
and None None O
nisoxetine None None O
- None None O
sensitive None None O
cell None None O
fluorescence None None O
. None None O

At None None O
least None None O
the None None O
guanidine None None O
derivative None None O
4 None None O
might None None O
represent None None O
a None None O
potentially None None O
useful None None O
agent None None O
for None None O
imaging None None O
of None None O
neuroblastoma None None O
cells None None O
. None None O


Selective None None O
protection None None O
of None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxoerythromycin None None I-IUPAC
A None None I-IUPAC
allowed None None O
for None None O
elimination None None O
of None None O
the None None O
12 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxyl None None I-PARTIUPAC
group None None I-MODIFIER
to None None O
afford None None O
a None None O
versatile None None O
12,21 None None O
- None None O
olefin None None O
intermediate None None O
. None None O

Further None None O
modifications None None O
of None None O
the None None O
intermediate None None O
led None None O
to None None O
the None None O
syntheses None None O
of None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxo None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
12,21 None None I-IUPAC
- None None I-IUPAC
epoxyerythromycin None None I-IUPAC
B None None I-IUPAC
, None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxo None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
21 None None I-IUPAC
- None None I-IUPAC
hydroxyerythromycin None None I-IUPAC
A None None I-IUPAC
, None None O
and None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxo None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
21 None None I-IUPAC
- None None I-IUPAC
hydroxyerythromycin None None I-IUPAC
B None None I-IUPAC
. None None O

All None None O
three None None O
compounds None None O
retained None None O
antibacterial None None O
activity None None O
against None None O
several None None O
organisms None None O
normally None None O
susceptible None None O
to None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxo None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
erythromycin None None I-IUPAC
A None None I-IUPAC
. None None O

However None None O
, None None O
the None None O
21 None None O
- None None O
hydroxylated None None O
erythromycin None None O
A None None O
analogue None None O
was None None O
weaker None None O
in None None O
potency None None O
than None None O
the None None O
corresponding None None O
erythromycin None None O
B None None O
congener None None O
and None None O
much None None O
weaker None None O
than None None O
the None None O
epoxy None None O
derivative None None O
. None None O

This None None O
suggests None None O
that None None O
while None None O
substitution None None O
of None None O
a None None O
polar None None O
functionality None None O
at None None O
C None None O
- None None O
21 None None O
does None None O
not None None O
abolish None None O
antibacterial None None O
activity None None O
, None None O
introduction None None O
of None None O
vicinal None None O
polar None None O
groups None None O
at None None O
both None None O
C None None O
- None None O
12 None None O
and None None O
C None None O
- None None O
21 None None O
may None None O
lead None None O
to None None O
reduction None None O
in None None O
potency None None O
. None None O

Nevertheless None None O
, None None O
these None None O
21 None None O
- None None O
functionalized None None O
derivatives None None O
of None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
erythromycylamine None None I-IUPAC
provide None None O
an None None O
entry None None O
into None None O
novel None None O
analogues None None O
of None None O
the None None O
important None None O
macrolide None None O
antibiotic None None O
erythromycin None None O
. None None O


The None None O
syntheses None None O
of None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
5SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
20 None None O
) None None O
, None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
acetamidopiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
10 None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
5SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
acetamidopiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
18 None None O
) None None O
, None None O
related None None O
to None None O
the None None O
specific None None O
gamma None None I-IUPAC
- None None I-IUPAC
aminobutyric None None I-IUPAC
acid None None I-IUPAC
( None None O
GABA None None O
) None None O
uptake None None O
inhibitors None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
nipecotic None None O
acid None None O
) None None O
and None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
21 None None O
) None None O
, None None O
are None None O
described None None O
. None None O

Furthermore None None O
, None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
14 None None O
) None None O
, None None O
related None None O
to None None O
the None None O
specific None None O
GABA None None O
agonist None None O
piperidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
isonipecotic None None O
acid None None O
) None None O
, None None O
has None None O
been None None O
synthesized None None O
. None None O

The None None O
structures None None O
of None None O
4 None None O
, None None O
10 None None O
, None None O
14 None None O
, None None O
18 None None O
, None None O
and None None O
20 None None O
have None None O
been None None O
established None None O
by None None O
270 None None O
- None None O
MHz None None O
1H None None O
NMR None None O
spectroscopic None None O
analyses None None O
. None None O

The None None O
affinity None None O
of None None O
the None None O
compounds None None O
for None None O
the None None O
GABA None None O
receptors None None O
and None None O
for None None O
the None None O
neuronal None None O
( None None O
synaptosomal None None O
) None None O
GABA None None O
uptake None None O
system None None O
in None None O
vitro None None O
has None None O
been None None O
measured None None O
. None None O

Compound None None O
14 None None O
interacts None None O
selectively None None O
with None None O
the None None O
GABA None None O
receptors None None O
but None None O
less None None O
effectively None None O
than None None O
isonipecotic None None O
acid None None O
and None None O
the None None O
cis None None O
- None None O
isomer None None O
22 None None O
. None None O

Compounds None None O
4 None None O
, None None O
18 None None O
, None None O
and None None O
20 None None O
are None None O
inhibitors None None O
of None None O
the None None O
GABA None None O
uptake None None O
system None None O
, None None O
although None None O
much None None O
weaker None None O
than None None O
nipecotic None None O
acid None None O
and None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
21 None None O
) None None O
. None None O

Compound None None O
10 None None O
is None None O
inactive None None O
in None None O
both None None O
test None None O
systems None None O
. None None O


This None None O
study None None O
emphasizes None None O
the None None O
importance None None O
of None None O
the None None O
metabolic None None O
conversion None None O
of None None O
the None None O
enantiomers None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylpiperidine None None I-IUPAC
( None None O
3 None None O
- None None O
PPP None None O
) None None O
into None None O
their None None O
catechol None None O
analogues None None O
, None None O
the None None O
enantiomers None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylpiperidine None None I-IUPAC
. None None O

These None None O
isomers None None O
are None None O
both None None O
shown None None O
to None None O
be None None O
excellent None None O
substrates None None O
for None None O
COMT None None O
, None None O
with None None O
a None None O
slight None None O
preference None None O
for None None O
the None None O
S None None O
- None None O
( None None O
- None None O
) None None O
enantiomer None None O
. None None O

Assessment None None O
of None None O
the None None O
dopaminergic None None O
activity None None O
of None None O
these None None O
catechols None None O
and None None O
the None None O
results None None O
from None None O
the None None O
determination None None O
of None None O
brain None None O
levels None None O
of None None O
the None None O
enantiomers None None O
of None None O
3 None None O
- None None O
PPP None None O
and None None O
their None None O
metabolites None None O
indicate None None O
that None None O
the None None O
metabolites None None O
probably None None O
do None None O
not None None O
alter None None O
the None None O
pharmacological None None O
profiles None None O
established None None O
for None None O
( None None O
R None None O
) None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
and None None O
( None None O
S None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
3 None None O
- None None O
PPP None None O
. None None O

The None None O
conversion None None O
of None None O
the None None O
monophenols None None O
into None None O
catecholic None None O
metabolites None None O
is None None O
only None None O
1-5% None None O
, None None O
and None None O
the None None O
further None None O
conversion None None O
of None None O
these None None O
catecholic None None O
metabolites None None O
into None None O
methoxylated None None O
analogues None None O
is None None O
very None None O
rapid None None O
. None None O

However None None O
, None None O
the None None O
very None None O
interesting None None O
observation None None O
was None None O
made None None O
that None None O
, None None O
when None None O
inhibiting None None O
COMT None None O
by None None O
means None None O
of None None O
tropolone None None O
and None None O
subsequently None None O
treating None None O
the None None O
rats None None O
with None None O
high None None O
doses None None O
of None None O
( None None O
S None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
3 None None O
- None None O
PPP None None O
( None None O
ip None None O
) None None O
, None None O
postsynaptic None None O
dopaminergic None None O
activity None None O
was None None O
elicited None None O
. None None O

This None None O
has None None O
never None None O
been None None O
seen None None O
for None None O
( None None O
S None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
3 None None O
- None None O
PPP None None O
without None None O
tropolone None None O
pretreatment None None O
and None None O
might None None O
indicate None None O
that None None O
, None None O
in None None O
this None None O
special None None O
case None None O
, None None O
the None None O
catecholic None None O
metabolite None None O
affects None None O
the None None O
in None None O
vivo None None O
pharmacological None None O
profile None None O
of None None O
( None None O
S None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
3 None None O
- None None O
PPP None None O
. None None O


The None None O
synthesis None None O
of None None O
a None None O
range None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinones None None I-IUPAC
with None None O
potential None None O
for None None O
the None None O
chelation None None O
of None None O
iron None None O
( None None O
III None None O
) None None O
is None None O
described None None O
. None None O

The None None O
pKa None None O
values None None O
of None None O
respective None None O
ligands None None O
and None None O
the None None O
stability None None O
constants None None O
of None None O
their None None O
iron None None O
( None None O
III None None O
) None None O
complexes None None O
are None None O
presented None None O
. None None O

The None None O
distribution None None O
coefficient None None O
values None None O
of None None O
a None None O
range None None O
of None None O
48 None None O
hydroxypyridinones None None O
and None None O
their None None O
corresponding None None O
iron None None O
( None None O
III None None O
) None None O
complexes None None O
between None None O
1 None None O
- None None O
octanol None None O
and None None O
MOPS None None O
buffer None None O
( None None O
pH None None O
7.4 None None O
) None None O
are None None O
reported None None O
. None None O

The None None O
range None None O
of None None O
log None None O
Dcomplex None None O
values None None O
covers None None O
7 None None O
orders None None O
of None None O
magnitude None None O
. None None O

The None None O
results None None O
suggest None None O
the None None O
existence None None O
of None None O
a None None O
biphasic None None O
relationship None None O
between None None O
the None None O
distribution None None O
coefficient None None O
values None None O
of None None O
the None None O
chelator None None O
and None None O
the None None O
corresponding None None O
iron None None O
( None None O
III None None O
) None None O
complexes None None O
. None None O

For None None O
ligands None None O
with None None O
a None None O
log None None O
Dligand None None O
= None None O
- None None O
1 None None O
, None None O
a None None O
linear None None O
relationship None None O
exists None None O
with None None O
a None None O
value None None O
of None None O
the None None O
slope None None O
2.53 None None O
, None None O
whereas None None O
with None None O
ligands None None O
with None None O
a None None O
log None None O
Dligand None None O
& None None O
lt None None O
; None None O
- None None O
1 None None O
, None None O
a None None O
linear None None O
relationship None None O
exists None None O
with None None O
a None None O
slope None None O
of None None O
0.49 None None O
. None None O

The None None O
reduced None None O
slope None None O
for None None O
the None None O
more None None O
hydrophilic None None O
molecules None None O
of None None O
the None None O
series None None O
offers None None O
some None None O
advantage None None O
for None None O
this None None O
type None None O
of None None O
hydroxypyridinone None None O
as None None O
the None None O
distribution None None O
coefficients None None O
for None None O
such None None O
complexes None None O
do None None O
not None None O
change None None O
so None None O
rapidly None None O
with None None O
increasing None None O
ligand None None O
hydrophilicity None None O
. None None O

The None None O
ability None None O
of None None O
selected None None O
3 None None I-IUPAC
- None None I-IUPAC
hydroxypyridinones None None I-IUPAC
to None None O
facilitate None None O
the None None O
excretion None None O
of None None O
iron None None O
in None None O
bile None None O
was None None O
investigated None None O
in None None O
non None None O
- None None O
iron None None O
- None None O
overloaded None None O
, None None O
bile None None O
duct None None O
- None None O
cannulated None None O
rats None None O
and None None O
in None None O
a None None O
[ None None O
59Fe None None O
] None None O
ferritin None None O
- None None O
loaded None None O
rat None None O
model None None O
. None None O

Both None None O
systems None None O
compare None None O
the None None O
ability None None O
of None None O
chelators None None O
to None None O
remove None None O
iron None None O
from None None O
the None None O
liver None None O
, None None O
the None None O
prime None None O
target None None O
organ None None O
in None None O
thalassemia None None O
. None None O

The None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyalkyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
are None None O
demonstrated None None O
to None None O
be None None O
orally None None O
active None None O
under None None O
the None None O
in None None O
vivo None None O
conditions None None O
adopted None None O
. None None O

Thus None None O
both None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
hydroxyalkyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carboxyalkyl None None I-IUPAC
) None None I-IUPAC
pyridinones None None I-IUPAC
are None None O
able None None O
to None None O
remove None None O
iron None None O
from None None O
the None None O
liver None None O
. None None O

Although None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carboxyalkyl None None I-IUPAC
) None None I-IUPAC
hydroxypyridinones None None I-IUPAC
are None None O
active None None O
, None None O
they None None O
do None None O
not None None O
demonstrate None None O
any None None O
clear None None O
advantage None None O
over None None O
Deferiprone None None O
( None None O
1,2 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
) None None O
. None None O

Indeed None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyalkyl None None I-IUPAC
) None None I-IUPAC
hydroxypyridinones None None I-IUPAC
which None None O
are None None O
known None None O
to None None O
be None None O
rapidly None None O
converted None None O
to None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carboxyalkyl None None I-IUPAC
) None None I-IUPAC
hydroxypyridinones None None I-IUPAC
are None None O
also None None O
marginally None None O
superior None None O
to None None O
Deferiprone None None O
. None None O

In None None O
contrast None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
, None None O
which None None O
is None None O
not None None O
metabolized None None O
to None None O
the None None O
corresponding None None O
( None None O
carboxyalkyl None None O
) None None O
hydroxypyridinone None None O
, None None O
was None None O
found None None O
to None None O
be None None O
superior None None O
to None None O
Deferiprone None None O
and None None O
therefore None None O
deserves None None O
further None None O
consideration None None O
as None None O
an None None O
orally None None O
active None None O
iron None None O
chelator None None O
with None None O
potential None None O
for None None O
the None None O
treatment None None O
of None None O
iron None None O
overload None None O
associated None None O
with None None O
transfusion None None O
- None None O
dependent None None O
thalassemia None None O
. None None O


Degarelix None None O
( None None O
FE200486 None None O
, None None O
Ac None None O
- None None O
d None None O
- None None O
2Nal None None O
( None None O
1 None None O
) None None O
- None None O
d None None O
- None None O
4Cpa None None O
( None None O
2 None None O
) None None O
- None None O
d None None O
- None None O
3Pal None None O
( None None O
3 None None O
) None None O
- None None O
Ser None None O
( None None O
4 None None O
) None None O
- None None O
4Aph None None O
( None None O
l None None O
- None None O
Hor None None O
) None None O
( None None O
5 None None O
) None None O
- None None O
d None None O
- None None O
4Aph None None O
( None None O
Cbm None None O
) None None O
( None None O
6 None None O
) None None O
- None None O
Leu None None O
( None None O
7 None None O
) None None O
- None None O
ILys None None O
( None None O
8 None None O
) None None O
- None None O
Pro None None O
( None None O
9 None None O
) None None O
- None None O
d None None O
- None None O
Ala None None O
( None None O
10 None None O
) None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
) None None O
is None None O
a None None O
potent None None O
and None None O
very None None O
long None None O
acting None None O
antagonist None None O
of None None O
gonadotropin None None O
- None None O
releasing None None O
hormone None None O
( None None O
GnRH None None O
) None None O
after None None O
subcutaneous None None O
administration None None O
in None None O
mammals None None O
including None None O
humans None None O
. None None O

Analogues None None O
of None None O
degarelix None None O
were None None O
synthesized None None O
, None None O
characterized None None O
, None None O
and None None O
screened None None O
for None None O
the None None O
antagonism None None O
of None None O
GnRH None None O
- None None O
induced None None O
response None None O
in None None O
a None None O
reporter None None O
gene None None O
assay None None O
in None None O
HEK None None O
- None None O
293 None None O
cells None None O
expressing None None O
the None None O
human None None O
GnRH None None O
receptor None None O
. None None O

The None None O
duration None None O
of None None O
action None None O
was None None O
also None None O
determined None None O
in None None O
the None None O
castrated None None O
male None None O
rat None None O
assay None None O
to None None O
measure None None O
the None None O
extent None None O
( None None O
efficacy None None O
and None None O
duration None None O
of None None O
action None None O
) None None O
of None None O
inhibition None None O
of None None O
luteinizing None None O
hormone None None O
( None None O
LH None None O
) None None O
release None None O
. None None O

Structurally None None O
, None None O
this None None O
series None None O
of None None O
analogues None None O
has None None O
novel None None O
substitutions None None O
at None None O
positions None None O
3 None None O
, None None O
7 None None O
, None None O
and None None O
8 None None O
and None None O
N None None O
( None None O
alpha None None O
) None None O
- None None O
methylation None None O
at None None O
positions None None O
6 None None O
, None None O
7 None None O
, None None O
and None None O
8 None None O
in None None O
the None None O
structure None None O
of None None O
degarelix None None O
. None None O

These None None O
substitutions None None O
were None None O
designed None None O
to None None O
probe None None O
the None None O
spatial None None O
limitations None None O
of None None O
the None None O
receptor None None O
's None None O
cavity None None O
and None None O
to None None O
map None None O
the None None O
steric None None O
and None None O
ionic None None O
boundaries None None O
. None None O

Some None None O
functional None None O
groups None None O
were None None O
introduced None None O
that None None O
were None None O
hypothesized None None O
to None None O
influence None None O
the None None O
phamacokinetic None None O
properties None None O
of None None O
the None None O
analogues None None O
such None None O
as None None O
bioavailability None None O
, None None O
solubility None None O
, None None O
intra None None O
- None None O
or None None O
intermolecular None None O
hydrogen None None O
bond None None O
forming None None O
capacity None None O
, None None O
and None None O
ability None None O
to None None O
bind None None O
carrier None None O
proteins None None O
. None None O

Substitutions None None O
at None None O
positions None None O
3 None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
) None None I-IUPAC
d None None I-IUPAC
- None None I-IUPAC
Dap None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
2.71 None None O
nM None None O
) None None O
( None None O
5 None None O
) None None O
, None None O
7 None None O
( None None O
[ None None I-IUPAC
Pra None None I-IUPAC
( None None I-IUPAC
7 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
2.11 None None O
nM None None O
) None None O
( None None O
16 None None O
) None None O
, None None O
and None None O
8 None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
delta None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
IGly None None I-IUPAC
) None None I-IUPAC
Orn None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.38 None None O
nM None None O
) None None O
( None None O
20 None None O
) None None O
and None None O
N None None O
- None None O
methylation None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
alpha None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
Leu None None I-IUPAC
( None None I-IUPAC
7 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.47 None None O
nM None None O
) None None O
( None None O
32 None None O
) None None O
yielded None None O
analogues None None O
that None None O
were None None O
equipotent None None O
to None None O
degarelix None None O
( None None O
2 None None O
) None None O
in None None O
vitro None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.64 None None O
nM None None O
) None None O
but None None O
shorter None None O
acting None None O
in None None O
vivo None None O
. None None O

Out None None O
of None None O
the None None O
33 None None O
novel None None O
analogues None None O
tested None None O
for None None O
the None None O
duration None None O
of None None O
action None None O
in None None O
this None None O
series None None O
, None None O
two None None O
analogues None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
epsilon None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyclohexyl None None I-IUPAC
- None None I-IUPAC
Lys None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.50 None None O
nM None None O
) None None O
( None None O
23 None None O
) None None O
and None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
IbetaAla None None I-IUPAC
) None None I-IUPAC
Dap None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.98 None None O
nM None None O
) None None O
( None None O
26 None None O
) None None O
had None None O
antagonist None None O
potencies None None O
and None None O
duration None None O
of None None O
action None None O
similar None None O
to None None O
that None None O
of None None O
azaline None None O
B None None O
{ None None O
inhibited None None O
LH None None O
( None None O
& None None O
gt None None O
; None None O
80% None None O
) None None O
release None None O
for None None O
& None None O
gt None None O
; None None O
72 None None O
h None None O
after None None O
sc None None O
injection None None O
to None None O
castrated None None O
male None None O
rats None None O
at None None O
a None None O
standard None None O
dose None None O
of None None O
50 None None O
mug None None O
/ None None O
rat None None O
in None None O
5% None None O
mannitol None None O
} None None O
. None None O

Under None None O
similar None None O
conditions None None O
analogues None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
gamma None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
IGly None None I-IUPAC
) None None I-IUPAC
Dab None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.56 None None O
nM None None O
) None None O
( None None O
21 None None O
) None None O
and None None O
( None None O
[ None None O
IOrn None None O
( None None O
8 None None O
) None None O
] None None O
degarelix None None O
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.72 None None O
nM None None O
) None None O
( None None O
18 None None O
) None None O
had None None O
a None None O
longer None None O
duration None None O
of None None O
action None None O
{ None None O
inhibited None None O
LH None None O
( None None O
& None None O
gt None None O
; None None O
96 None None O
h None None O
) None None O
release None None O
} None None O
than None None O
azaline None None O
B None None O
; None None O
however None None O
they None None O
were None None O
shorter None None O
acting None None O
than None None O
degarelix None None O
. None None O

Hydrophilicity None None O
of None None O
these None None O
analogues None None O
, None None O
a None None O
potential None None O
measure None None O
of None None O
their None None O
ability None None O
to None None O
be None None O
formulated None None O
for None None O
sustained None None O
release None None O
, None None O
was None None O
determined None None O
using None None O
RP None None O
- None None O
HPLC None None O
at None None O
neutral None None O
pH None None O
yielding None None O
analogues None None O
with None None O
shorter None None O
as None None O
well None None O
as None None O
longer None None O
retention None None O
times None None O
. None None O

No None None O
correlation None None O
was None None O
found None None O
between None None O
retention None None O
times None None O
and None None O
antagonist None None O
potency None None O
or None None O
duration None None O
of None None O
action None None O
. None None O


At None None O
physiological None None O
pH None None O
, None None O
the None None O
spatial None None O
arrangement None None O
of None None O
the None None O
three None None O
charges None None O
of None None O
DL None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylglycine None None I-IUPAC
( None None O
5 None None O
) None None O
could None None O
be None None O
viewed None None O
as None None O
similar None None O
to None None O
those None None O
found None None O
in None None O
certain None None O
conformations None None O
of None None O
the None None O
two None None O
excitatory None None O
amino None None O
acids None None O
( None None O
EAAs None None O
) None None O
- None None O
- None None O
aspartic None None O
and None None O
glutamic None None O
acids None None O
. None None O

Given None None O
significant None None O
binding None None O
to None None O
one None None O
or None None O
more None None O
EAA None None O
receptors None None O
, None None O
5 None None O
would None None O
offer None None O
unique None None O
modeling None None O
and None None O
perhaps None None O
biological None None O
opportunities None None O
. None None O

We None None O
have None None O
previously None None O
shown None None O
it None None O
to None None O
be None None O
the None None O
most None None O
potent None None O
NMDA None None O
agonist None None O
known None None O
, None None O
with None None O
a None None O
unique None None O
and None None O
marked None None O
in None None O
vitro None None O
neutrotoxicity None None O
at None None O
depolarizing None None O
concentrations None None O
. None None O

Now None None O
we None None O
report None None O
the None None O
details None None O
required None None O
for None None O
its None None O
synthesis None None O
, None None O
together None None O
with None None O
its None None O
potency None None O
and None None O
efficacy None None O
in None None O
two None None O
assays None None O
of None None O
functional None None O
activation None None O
of None None O
the None None O
NMDA None None O
receptor None None O
, None None O
namely None None O
agonist None None O
- None None O
influenced None None O
[ None None O
3H None None O
] None None O
MK801 None None O
binding None None O
and None None O
agonist None None O
- None None O
induced None None O
release None None O
of None None O
the None None O
neurotransmitter None None O
[ None None O
3H None None O
] None None O
- None None O
norepinephrine None None O
from None None O
brain None None O
slices None None O
. None None O

In None None O
both None None O
these None None O
assays None None O
DL None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylglycine None None I-IUPAC
proved None None O
to None None O
be None None O
more None None O
potent None None O
and None None O
efficacious None None O
than None None O
NMDA None None O
and None None O
cis None None O
- None None O
methanoglutamate None None O
. None None O

It None None O
was None None O
more None None O
potent None None O
than None None O
, None None O
and None None O
equally None None O
efficacious None None O
to None None O
, None None O
L None None O
- None None O
glutamate None None O
in None None O
[ None None O
3H None None O
] None None O
MK801 None None O
binding None None O
. None None O

The None None O
structural None None O
features None None O
of None None O
5 None None O
may None None O
well None None O
reflect None None O
optimal None None O
agonist None None O
interaction None None O
at None None O
the None None O
NMDA None None O
receptor None None O
site None None O
. None None O

( None None O
We None None O
considered None None O
the None None O
possibility None None O
that None None O
some None None O
decarboxylation None None O
of None None O
DL None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylglycine None None I-IUPAC
may None None O
have None None O
occurred None None O
during None None O
testing None None O
. None None O

This None None O
would None None O
give None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
tetrazole None None I-IUPAC
( None None O
13 None None O
) None None O
, None None O
the None None O
tetrazole None None O
acid None None O
analog None None O
of None None O
glycine None None O
; None None O
and None None O
glycine None None O
is None None O
involved None None O
in None None O
NMDA None None O
receptor None None O
activation None None O
. None None O

Compound None None O
13 None None O
does None None O
not None None O
affect None None O
[ None None O
3H None None O
] None None O
glycine None None O
binding None None O
at None None O
the None None O
strychnine None None O
- None None O
insensitive None None O
glycine None None O
binding None None O
site None None O
, None None O
and None None O
[ None None O
3H None None O
] None None O
MK801 None None O
binding None None O
studies None None O
showed None None O
that None None O
the None None O
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
tetrazole None None I-IUPAC
, None None O
even None None O
if None None O
is None None O
formed None None O
, None None O
would None None O
probably None None O
have None None O
no None None O
effect None None O
on None None O
the None None O
activity None None O
of None None O
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylglycine None None I-IUPAC
at None None O
the None None O
NMDA None None O
receptor None None O
. None None O


The None None O
thermal None None O
Fischer None None O
indolization None None O
of None None O
hydrazones None None O
resulting None None O
from None None O
4 None None I-IUPAC
- None None I-IUPAC
hydrazino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
and None None O
various None None O
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
alpha None None I-IUPAC
- None None I-IUPAC
tetralones None None I-IUPAC
led None None O
to None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
, None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
, None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
g None None I-IUPAC
] None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
respectively None None O
. None None O

After None None O
aromatization None None O
, None None O
these None None O
compounds None None O
were None None O
transformed None None O
by None None O
phosphorus None None O
oxychloride None None O
, None None O
giving None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloro None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
- None None I-PARTIUPAC
5H None None I-PARTIUPAC
- None None I-PARTIUPAC
pyrido None None I-PARTIUPAC
[ None None I-PARTIUPAC
4,3 None None I-PARTIUPAC
- None None I-PARTIUPAC
b None None I-PARTIUPAC
] None None I-PARTIUPAC
benzo None None I-PARTIUPAC
[ None None I-PARTIUPAC
e None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
benzo None None I-PARTIUPAC
[ None None I-PARTIUPAC
g None None I-PARTIUPAC
] None None I-PARTIUPAC
indoles None None I-PARTIUPAC
which None None O
were None None O
substituted None None O
by None None O
[ None None I-IUPAC
( None None I-IUPAC
dialkylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
] None None I-IUPAC
amines None None I-IUPAC
. None None O

The None None O
resulting None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
dialkylamino None None I-PARTIUPAC
) None None I-PARTIUPAC
alkyl None None I-PARTIUPAC
] None None I-PARTIUPAC
amino None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
- None None I-PARTIUPAC
5H None None I-PARTIUPAC
- None None I-PARTIUPAC
pyrido None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
4,3 None None I-PARTIUPAC
- None None I-PARTIUPAC
b None None I-PARTIUPAC
] None None I-PARTIUPAC
benzo None None I-PARTIUPAC
[ None None I-PARTIUPAC
e None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
benzo None None I-PARTIUPAC
[ None None I-PARTIUPAC
g None None I-PARTIUPAC
] None None I-PARTIUPAC
indoles None None I-PARTIUPAC
, None None O
as None None O
well None None O
as None None O
hydroxy None None O
derivatives None None O
obtained None None O
by None None O
demethylation None None O
of None None O
methoxylated None None O
compounds None None O
with None None O
hydrobromic None None O
acid None None O
, None None O
were None None O
tested None None O
for None None O
antitumor None None O
activity None None O
in None None O
vitro None None O
( None None O
leukemic None None O
and None None O
solid None None O
tumor None None O
cells None None O
) None None O
and None None O
in None None O
vivo None None O
on None None O
various None None O
experimental None None O
tumor None None O
models None None O
using None None O
the None None O
standard None None O
NCI None None O
protocols None None O
. None None O

1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Dialkylamino None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
indoles None None I-IUPAC
appeared None None O
as None None O
a None None O
promising None None O
new None None O
class None None O
of None None O
antineoplastic None None O
agents None None O
. None None O


The None None O
determination None None O
of None None O
the None None O
structure None None O
and None None O
function None None O
of None None O
the None None O
sigma None None O
receptor None None O
subtypes None None O
and None None O
their None None O
physiological None None O
role None None O
( None None O
s None None O
) None None O
has None None O
been None None O
impeded None None O
by None None O
the None None O
unavailability None None O
of None None O
selective None None O
ligands None None O
. None None O

We None None O
have None None O
developed None None O
a None None O
new None None O
class None None O
of None None O
sigma None None O
subtype None None O
selective None None O
receptor None None O
ligands None None O
that None None O
are None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
benzylidene None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
the None None O
synthetic None None O
opioid None None O
( None None I-PARTIUPAC
+ None None I-PARTIUPAC
/ None None I-PARTIUPAC
- None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
( None None I-PARTIUPAC
+ None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
morphan None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
1 None None O
) None None O
. None None O

The None None O
derivatives None None O
can None None O
be None None O
prepared None None O
by None None O
reaction None None O
of None None O
1 None None O
, None None O
( None None O
+ None None O
) None None O
- None None O
1 None None O
, None None O
and None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
with None None O
the None None O
appropriate None None O
benzaldehyde None None O
under None None O
Claisen None None O
- None None O
Schmidt None None O
conditions None None O
. None None O

Incorporation None None O
of None None O
substituted None None I-MODIFIER
( None None B-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
benzylidene None None I-IUPAC
moieties None None I-MODIFIER
onto None None O
the None None O
7 None None O
- None None O
keto None None O
precursor None None O
of None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
morphan None None I-IUPAC
, None None O
( None None O
+ None None O
) None None O
- None None O
1 None None O
, None None O
produces None None O
compounds None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
through None None O
( None None O
- None None O
) None None O
- None None O
7 None None O
( None None O
5.8-32.0 None None O
nM None None O
, None None O
sigma None None O
1 None None O
) None None O
, None None O
which None None O
have None None O
between None None O
a None None O
25 None None O
- None None O
and None None O
131 None None O
- None None O
fold None None O
increase None None O
in None None O
affinity None None O
for None None O
the None None O
sigma None None O
1 None None O
receptor None None O
subtype None None O
relative None None O
to None None O
the None None O
keto None None O
precursor None None O
( None None O
+ None None O
) None None O
- None None O
1 None None O
( None None O
Ki None None O
= None None O
762 None None O
nM None None O
, None None O
sigma None None O
1 None None O
) None None O
. None None O

Compound None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
is None None O
the None None O
most None None O
selective None None O
of None None O
this None None O
group None None O
( None None O
16 None None O
- None None O
fold None None O
) None None O
for None None O
the None None O
sigma None None O
1 None None O
subtype None None O
versus None None O
sigma None None O
2 None None O
. None None O

Substitution None None O
of None None O
an None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
benzylidene None None I-IUPAC
moiety None None I-MODIFIER
onto None None O
the None None O
7 None None I-MODIFIER
- None None I-MODIFIER
keto None None I-MODIFIER
precursor None None I-MODIFIER
of None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
morphan None None I-IUPAC
, None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
, None None O
produces None None O
compounds None None O
( None None O
+ None None O
) None None O
- None None O
2 None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
9 None None O
( None None O
6.4-52.6 None None O
nM None None O
, None None O
sigma None None O
2 None None O
) None None O
, None None O
which None None O
have None None O
at None None O
least None None O
a None None O
475-3906 None None O
- None None O
fold None None O
increase None None O
in None None O
affinity None None O
for None None O
the None None O
sigma None None O
2 None None O
receptor None None O
subtype None None O
relative None None O
to None None O
the None None O
keto None None O
precursor None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
( None None O
Ki None None O
= None None O
25 None None O
x None None O
10 None None O
( None None O
3 None None O
) None None O
nM None None O
) None None O
. None None O

This None None O
enhancement None None O
of None None O
sigma None None O
2 None None O
receptor None None O
affinity None None O
is None None O
accompanied None None O
by None None O
substantial None None O
selectivity None None O
of None None O
all None None O
of None None O
these None None O
dextrorotatory None None O
products None None O
for None None O
the None None O
sigma None None O
2 None None O
relative None None O
to None None O
the None None O
sigma None None O
1 None None O
subtype None None O
( None None O
32-238 None None O
- None None O
fold None None O
) None None O
, None None O
and None None O
thus None None O
, None None O
they None None O
are None None O
among None None O
the None None O
most None None O
sigma None None O
2 None None O
selective None None O
compounds None None O
currently None None O
known None None O
. None None O

Furthermore None None O
, None None O
the None None O
sigma None None O
1 None None O
subtype None None O
is None None O
highly None None O
enantioselective None None O
for None None O
the None None O
levorotatory None None O
isomers None None O
, None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
- None None O
( None None O
- None None O
) None None O
- None None O
7 None None O
( None None O
41-1034 None None O
- None None O
fold None None O
) None None O
, None None O
whereas None None O
the None None O
sigma None None O
2 None None O
subtype None None O
is None None O
only None None O
somewhat None None O
enantioselective None None O
for None None O
the None None O
dextrorotatory None None O
isomers None None O
, None None O
( None None O
+ None None O
) None None O
- None None O
2 None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
7 None None O
( None None O
2.6-9.3 None None O
- None None O
fold None None O
) None None O
. None None O

All None None O
of None None O
these None None O
derivatives None None O
retain None None O
substantial None None O
affinity None None O
for None None O
the None None O
mu None None O
opioid None None O
receptor None None O
. None None O

Despite None None O
the None None O
high None None O
affinity None None O
of None None O
the None None O
dextrorotatory None None O
derivatives None None O
for None None O
the None None O
mu None None O
opioid None None O
receptor None None O
, None None O
the None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
sigma None None O
2 None None O
over None None O
sigma None None O
1 None None O
sites None None O
will None None O
surely None None O
prove None None O
beneficial None None O
as None None O
tools None None O
for None None O
the None None O
delineation None None O
of None None O
the None None O
function None None O
and None None O
physiological None None O
role None None O
of None None O
sigma None None O
2 None None O
receptors None None O
. None None O


Some None None O
novel None None O
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None O
substituted None None I-MODIFIER
- None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acids None None I-IUPAC
have None None O
been None None O
prepared None None O
. None None O

At None None O
the None None O
N None None O
- None None O
1 None None O
position None None O
" None None O
standard None None O
" None None O
substitution None None O
was None None O
employed None None O
with None None O
the None None O
ethyl None None I-IUPAC
, None None O
cyclopropyl None None I-IUPAC
, None None O
and None None O
p None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
groups None None I-MODIFIER
being None None O
used None None O
. None None O

At None None O
C None None O
- None None O
7 None None O
the None None O
introduction None None O
of None None O
some None None O
novel None None O
piperazines None None O
was None None O
made None None O
. None None O

Most None None O
notably None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoromethyl None None I-IUPAC
) None None I-IUPAC
piperazine None None I-IUPAC
( None None O
10 None None O
) None None O
and None None O
hexahydro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
diazepine None None I-IUPAC
( None None O
16 None None O
, None None O
fluorohomopiperazine None None O
) None None O
at None None O
the None None O
quinolone None None O
C None None O
- None None O
7 None None O
position None None O
produced None None O
products None None O
with None None O
similar None None O
in None None O
vitro None None O
antibacterial None None O
activity None None O
as None None O
the None None O
ciprofloxacin None None O
reference None None O
. None None O

The None None O
in None None O
vivo None None O
efficacy None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
cyclopropyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoromethyl None None I-IUPAC
) None None I-IUPAC
piperazinyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
20 None None O
) None None O
was None None O
excellent None None O
with None None O
better None None O
oral None None O
absorption None None O
than None None O
ciprofloxacin None None O
( None None O
2 None None O
) None None O
. None None O


In None None O
a None None O
continuing None None O
effort None None O
to None None O
design None None O
small None None O
- None None O
molecule None None O
inhibitors None None O
of None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
that None None O
combine None None O
the None None O
enzyme None None O
- None None O
binding None None O
selectivity None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
trimethoxybenzyl None None I-IUPAC
) None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
trimethoprim None None O
, None None O
TMP None None O
) None None O
with None None O
the None None O
potency None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
dimethoxybenzyl None None I-IUPAC
) None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
piritrexim None None O
, None None O
PTX None None O
) None None O
, None None O
seven None None O
previously None None O
undescribed None None O
2,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
diamino None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
2' None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
5' None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
substituted None None I-MODIFIER
benzyl None None B-PARTIUPAC
) None None O
] None None I-PARTIUPAC
pyrimidines None None I-PARTIUPAC
were None None O
synthesized None None O
in None None O
which None None O
the None None O
substituent None None O
at None None O
the None None O
5' None None O
- None None O
position None None O
was None None O
a None None O
carboxyphenyl None None I-IUPAC
group None None B-MODIFIER
linked None None O
to None None O
the None None O
benzyl None None I-IUPAC
moiety None None B-MODIFIER
by None None O
a None None O
bridge None None O
of None None O
two None None O
or None None O
four None None O
atoms None None O
in None None O
length None None O
. None None O

The None None O
new None None O
analogues None None O
were None None O
all None None O
obtained None None O
from None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
) None None I-IUPAC
pyrimidine None None I-IUPAC
via None None O
a None None O
Sonogashira None None O
reaction None None O
, None None O
followed None None O
, None None O
where None None O
appropriate None None O
, None None O
by None None O
catalytic None None O
hydrogenation None None O
. None None O

The None None O
new None None O
analogues None None O
were None None O
tested None None O
as None None O
inhibitors None None O
of None None O
DHFR None None O
from None None O
Pneumocystis None None O
carinii None None O
( None None O
Pc None None O
) None None O
, None None O
Toxoplasma None None O
gondii None None O
( None None O
Tg None None O
) None None O
, None None O
and None None O
Mycobacterium None None O
avium None None O
( None None O
Ma None None O
) None None O
, None None O
three None None O
life None None O
- None None O
threatening None None O
pathogens None None O
often None None O
found None None O
in None None O
AIDS None None O
patients None None O
and None None O
individuals None None O
whose None None O
immune None None O
system None None O
is None None O
impaired None None O
as None None O
a None None O
result None None O
of None None O
treatment None None O
with None None O
immunosuppressive None None O
chemotherapy None None O
or None None O
radiation None None O
. None None O

The None None O
selectivity None None O
index None None O
( None None O
SI None None O
) None None O
of None None O
each None None O
compound None None O
was None None O
obtained None None O
by None None O
dividing None None O
its None None O
50% None None O
inhibitory None None O
concentration None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
) None None O
against None None O
Pc None None O
, None None O
Tg None None O
, None None O
or None None O
Ma None None O
DHFR None None O
by None None O
its None None O
IC None None O
( None None O
50 None None O
) None None O
against None None O
rat None None O
DHFR None None O
. None None O

2,4 None None I-IUPAC
- None None I-IUPAC
Diamino None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxyphenyl None None I-IUPAC
) None None I-IUPAC
ethynylbenzyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
28 None None O
) None None O
, None None O
with None None O
an None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
23 None None O
nM None None O
and None None O
an None None O
SI None None O
of None None O
28 None None O
in None None O
the None None O
Pc None None O
DHFR None None O
assay None None O
, None None O
had None None O
about None None O
the None None O
same None None O
potency None None O
as None None O
PTX None None O
and None None O
was None None O
520 None None O
times None None O
more None None O
potent None None O
than None None O
TMP None None O
. None None O

As None None O
an None None O
inhibitor None None O
of None None O
Tg None None O
DHFR None None O
, None None O
28 None None O
had None None O
an None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
5.5 None None O
nM None None O
( None None O
510 None None O
- None None O
fold None None O
lower None None O
than None None O
that None None O
of None None O
TMP None None O
and None None O
similar None None O
to None None O
that None None O
of None None O
PTX None None O
) None None O
and None None O
an None None O
SI None None O
value None None O
of None None O
120 None None O
( None None O
2 None None O
- None None O
fold None None O
better None None O
than None None O
TMP None None O
and None None O
vastly None None O
superior None None O
to None None O
PTX None None O
) None None O
. None None O

Against None None O
Ma None None O
DHFR None None O
, None None O
28 None None O
had None None O
IC None None O
( None None O
50 None None O
) None None O
and None None O
SI None None O
values None None O
of None None O
1.5 None None O
nM None None O
and None None O
430 None None O
, None None O
respectively None None O
, None None O
compared None None O
with None None O
300 None None O
nM None None O
and None None O
610 None None O
for None None O
TMP None None O
. None None O

Although None None O
it None None O
had None None O
2.5 None None O
- None None O
fold None None O
lower None None O
potency None None O
than None None O
28 None None O
against None None O
Ma None None O
DHFR None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
3.7 None None O
nM None None O
) None None O
and None None O
was None None O
substantially None None O
weaker None None O
against None None O
Pc None None O
and None None O
Tg None None O
DHFR None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxyphenyl None None I-IUPAC
) None None I-IUPAC
ethynylbenzyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
29 None None O
) None None O
, None None O
with None None O
the None None O
carboxy None None I-IUPAC
group None None B-MODIFIER
at None None O
the None None O
para None None O
rather None None O
than None None O
the None None O
meta None None O
position None None O
, None None O
displayed None None O
2200 None None O
- None None O
fold None None O
selectivity None None O
against None None O
the None None O
Ma None None O
enzyme None None O
and None None O
was None None O
the None None O
most None None O
selective None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None O
5' None None I-MODIFIER
- None None O
substituted None None I-MODIFIER
benzyl None None I-PARTIUPAC
) None None O
pyrimidine None None I-PARTIUPAC
inhibitor None None O
of None None O
this None None O
enzyme None None O
we None None O
have None None O
encountered None None O
to None None O
date None None O
. None None O

Additional None None O
bioassay None None O
data None None O
for None None O
these None None O
compounds None None O
are None None O
also None None O
reported None None O
. None None O


A None None O
series None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
thieno1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
 None None I-IUPAC
 None None I-IUPAC
xazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
was None None O
synthesized None None O
and None None O
evaluated None None O
in None None O
vitro None None O
for None None O
inhibitory None None O
activity None None O
toward None None O
human None None O
leukocyte None None O
elastase None None O
( None None O
HLE None None O
) None None O
. None None O

The None None O
Gewald None None O
thiophene None None O
synthesis None None O
was None None O
utilized None None O
to None None O
obtain None None O
several None None O
ethyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminothiophene None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylates None None I-IUPAC
. None None O

These None None O
precursors None None O
were None None O
subjected None None O
to None None O
a None None O
five None None O
- None None O
step None None O
route None None O
to None None O
obtain None None O
thieno2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
 None None I-IUPAC
 None None I-IUPAC
xazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
bearing None None O
various None None O
substituents None None O
at None None O
positions None None O
5 None None O
and None None O
6 None None O
. None None O

Both None None O
thieno2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
and None None O
thieno3 None None I-IUPAC
, None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
fused None None O
oxazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
possess None None O
extraordinary None None O
chemical None None O
stability None None O
, None None O
which None None O
was None None O
expressed None None O
as None None O
rate None None O
constants None None O
of None None O
the None None O
alkaline None None O
hydrolysis None None O
. None None O

The None None O
kinetic None None O
parameters None None O
of None None O
the None None O
HLE None None O
inhibition None None O
were None None O
determined None None O
. None None O

The None None O
most None None O
potent None None O
compound None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
1benzothieno2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
 None None I-IUPAC
 None None I-IUPAC
xazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
, None None O
exhibited None None O
a None None O
K None None O
( None None O
i None None O
) None None O
value None None O
of None None O
5.8 None None O
nM None None O
. None None O

2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Diethylamino None None I-IUPAC
) None None I-IUPAC
thieno1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
 None None I-IUPAC
 None None I-IUPAC
xazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
act None None O
as None None O
acyl None None O
- None None O
enzyme None None O
inhibitors None None O
of None None O
HLE None None O
, None None O
similar None None O
to None None O
the None None O
inhibition None None O
of None None O
serine None None O
proteases None None O
by None None O
4H None None I-IUPAC
- None None I-IUPAC
3,1 None None I-IUPAC
- None None I-IUPAC
benzoxazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
. None None O

The None None O
isosteric None None O
benzene None None O
- None None O
thiophene None None O
replacement None None O
accounts None None O
for None None O
an None None O
enhanced None None O
stability None None O
of None None O
the None None O
acyl None None O
- None None O
enzyme None None O
intermediates None None O
. None None O


In None None O
order None None O
to None None O
develop None None O
tracers None None O
with None None O
higher None None O
specific None None O
activity None None O
to None None O
supplant None None O
the None None O
currently None None O
used None None O
[ None None O
3H None None O
] None None O
- None None O
8 None None O
- None None O
OH None None O
- None None O
DPAT None None O
[ None None O
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylamino None None I-IUPAC
) None None I-IUPAC
tetralin None None I-IUPAC
] None None O
for None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
evaluation None None O
of None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
, None None O
a None None O
new None None O
radioiodinated None None O
ligand None None O
was None None O
prepared None None O
. None None O

( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
Hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
tetralin None None I-IUPAC
( None None O
trans None None O
- None None O
8 None None O
- None None O
OH None None O
- None None O
PIPAT None None O
) None None O
, None None O
8 None None O
, None None O
was None None O
synthesized None None O
by None None O
a None None O
10 None None O
- None None O
step None None O
reaction None None O
. None None O

Binding None None O
studies None None O
with None None O
rat None None O
hippocampal None None O
membrane None None O
homogenates None None O
showed None None O
that None None O
8 None None O
exhibited None None O
a None None O
Ki None None O
value None None O
of None None O
0.92 None None O
nM None None O
against None None O
( None None O
R None None O
, None None O
S None None O
) None None O
- None None O
[ None None O
3H None None O
] None None O
- None None O
8 None None O
- None None O
OH None None O
- None None O
DPAT None None O
. None None O

Radiolabeled None None O
[ None None O
125I None None O
] None None O
- None None O
8 None None O
was None None O
prepared None None O
from None None O
the None None O
corresponding None None O
tri None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butyltin None None I-IUPAC
precursor None None O
via None None O
an None None O
oxidative None None O
iododestannylation None None O
reaction None None O
with None None O
sodium None None O
[ None None O
125I None None O
] None None O
iodide None None O
. None None O

Binding None None O
studies None None O
in None None O
the None None O
hippocampal None None O
homogenates None None O
revealed None None O
that None None O
[ None None O
125I None None O
] None None O
- None None O
8 None None O
bound None None O
to None None O
a None None O
single None None O
high None None O
- None None O
affinity None None O
site None None O
( None None O
Kd None None O
= None None O
0.38 None None O
+ None None O
/ None None O
- None None O
0.03 None None O
nM None None O
, None None O
Bmax None None O
= None None O
310 None None O
+ None None O
/ None None O
- None None O
20 None None O
fmol None None O
/ None None O
mg None None O
of None None O
protein None None O
) None None O
. None None O

Competition None None O
binding None None O
experiments None None O
clearly None None O
indicated None None O
that None None O
the None None O
new None None O
ligand None None O
displayed None None O
the None None O
expected None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
binding None None O
profile None None O
. None None O

The None None O
rank None None O
order None None O
of None None O
potency None None O
was None None O
( None None O
R None None O
, None None O
S None None O
) None None O
- None None O
trans None None O
- None None O
8 None None O
- None None O
OH None None O
- None None O
PIPAT None None O
& None None O
gt None None O
; None None O
( None None O
R None None O
, None None O
S None None O
) None None O
- None None O
8 None None O
- None None O
OH None None O
- None None O
DPAT None None O
& None None O
gt None None O
; None None O
WB4101 None None O
& None None O
gt None None O
; None None O
5 None None O
- None None O
HT None None O
& None None O
gt None None O
; None None O
( None None O
R None None O
, None None O
S None None O
) None None O
- None None O
trans None None O
- None None O
7 None None O
- None None O
OH None None O
- None None O
PIPAT None None O
& None None O
gt None None O
; None None O
( None None O
R None None O
, None None O
S None None O
) None None O
- None None O
7 None None O
- None None O
OH None None O
- None None O
DPAT None None O
& None None O
gt None None O
; None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
propranolol None None I-IUPAC
& None None O
gt None None O
; None None O
spiperone None None O
& None None O
gt None None O
; None None O
& None None O
gt None None O
; None None O
ketanserin None None O
& None None O
gt None None O
; None None O
& None None O
gt None None O
; None None O
dopamine None None O
& None None O
gt None None O
; None None O
atropine None None O
. None None O

This None None O
new None None O
ligand None None O
offers None None O
several None None O
unique None None O
advantages None None O
, None None O
including None None O
high None None O
specific None None O
activity None None O
, None None O
high None None O
binding None None O
affinity None None O
, None None O
and None None O
low None None O
nonspecific None None O
binding None None O
, None None O
all None None O
of None None O
which None None O
make None None O
it None None O
an None None O
excellent None None O
probe None None O
for None None O
the None None O
investigation None None O
and None None O
characterization None None O
of None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
. None None O


Two None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydrobenzofuran None None I-IUPAC
analogues None None I-MODIFIER
of None None O
hallucinogenic None None O
amphetamines None None O
were None None O
prepared None None O
and None None O
evaluated None None O
for None None O
activity None None O
in None None O
the None None O
two None None O
- None None O
lever None None O
drug None None O
- None None O
discrimination None None O
paradigm None None O
in None None O
rats None None O
trained None None O
to None None O
discriminate None None O
saline None None O
from None None O
LSD None None O
tartrate None None O
( None None O
0.08 None None O
mg None None O
/ None None O
kg None None O
) None None O
and None None O
for None None O
the None None O
ability None None O
to None None O
displace None None O
[ None None O
125I None None O
] None None O
- None None O
( None None O
R None None O
) None None O
- None None O
DOI None None O
[ None None I-IUPAC
( None None I-IUPAC
125I None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
iodophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminopropane None None I-IUPAC
) None None I-IUPAC
from None None O
rat None None O
cortical None None O
homogenate None None O
5 None None O
- None None O
HT2 None None O
receptors None None O
. None None O

The None None O
compounds None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydrobenzofuran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminopropane None None I-IUPAC
( None None O
6a None None O
) None None O
and None None O
its None None O
7 None None O
- None None O
brominated None None O
analogue None None O
6b None None O
, None None O
possessed None None O
activity None None O
comparable None None O
to None None O
their None None O
conformationally None None O
flexible None None O
counterparts None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminopropane None None I-IUPAC
( None None O
3 None None O
) None None O
and None None O
its None None O
4 None None O
- None None O
bromo None None O
derivative None None O
DOB None None O
( None None O
5 None None O
) None None O
, None None O
respectively None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
the None None O
dihydrofuran None None O
ring None None O
in None None O
6a None None O
and None None O
6b None None O
models None None O
the None None O
active None None O
conformation None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
groups None None I-MODIFIER
in None None O
3 None None O
and None None O
5 None None O
. None None O

Free None None O
energy None None O
of None None O
binding None None O
, None None O
derived None None O
from None None O
radioligand None None O
displacement None None O
KA None None O
values None None O
, None None O
indicated None None O
that None None O
addition None None O
of None None O
the None None O
bromine None None O
in None None O
either None None O
series None None O
contributes None None O
2.4-3.2 None None O
kcal None None O
/ None None O
mol None None O
of None None O
binding None None O
energy None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
surface None None O
area None None O
of None None O
the None None O
bromine None None O
atom None None O
, None None O
this None None O
value None None O
is None None O
2-3 None None O
times None None O
higher None None O
than None None O
would None None O
be None None O
expected None None O
on None None O
the None None O
basis None None O
of None None O
hydrophobic None None O
binding None None O
. None None O

Thus None None O
, None None O
hydrophobicity None None O
of None None O
the None None O
para None None O
substituent None None O
alone None None O
cannot None None O
account None None O
for None None O
the None None O
dramatic None None O
enhancement None None O
of None None O
hallucinogenic None None O
activity None None O
. None None O

Although None None O
this None None O
substituent None None O
may None None O
play None None O
a None None O
minor None None O
role None None O
in None None O
orienting None None O
the None None O
conformation None None O
of None None O
the None None O
5 None None O
- None None O
methoxy None None O
group None None O
in None None O
derivatives None None O
such None None O
as None None O
4 None None O
and None None O
5 None None O
, None None O
there None None O
appears None None O
to None None O
be None None O
some None None O
other None None O
, None None O
as None None O
yet None None O
unknown None None O
, None None O
critical None None O
receptor None None O
interaction None None O
. None None O


N None None O
, None None O
O None None O
- None None O
Dicarbethoxy None None O
- None None O
4 None None O
- None None O
chlorobenzenesulfohydroxamate None None O
( None None O
1c None None O
) None None O
and None None O
O None None I-IUPAC
- None None I-IUPAC
carbethoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
hydroxysaccharin None None I-IUPAC
( None None O
6 None None O
) None None O
, None None O
both None None O
potential None None O
carbethoxylating None None O
agents None None O
, None None O
inhibited None None O
yeast None None O
aldehyde None None O
dehydrogenase None None O
( None None O
AlDH None None O
) None None O
with None None O
IC50 None None O
's None None O
of None None O
24 None None O
and None None O
56 None None O
microM None None O
, None None O
respectively None None O
. None None O

The None None O
esterase None None O
activity None None O
of None None O
the None None O
enzyme None None O
was None None O
commensurably None None O
inhibited None None O
. None None O

AlDH None None O
activity None None O
was None None O
only None None O
partially None None O
restored None None O
on None None O
incubation None None O
with None None O
mercaptoethanol None None O
( None None O
20 None None O
mM None None O
) None None O
for None None O
1 None None O
h None None O
. None None O

On None None O
incubation None None O
with None None O
rat None None O
plasma None None O
, None None O
1c None None O
liberated None None O
nitroxyl None None I-IUPAC
, None None O
a None None O
potent None None O
inhibitor None None O
of None None O
AlDH None None O
. None None O

Under None None O
the None None O
same None None O
conditions None None O
, None None O
nitroxyl None None I-IUPAC
generation None None O
from None None O
6 None None O
was None None O
minimal None None O
, None None O
a None None O
result None None O
compatible None None O
with None None O
a None None O
previous None None O
observation None None O
that None None O
nitroxyl None None O
generation None None O
from None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxysaccharin None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
the None None O
product None None O
of None None O
the None None O
hydrolysis None None O
of None None O
the None None O
carbethoxy None None I-IUPAC
group None None B-MODIFIER
of None None O
6 None None O
, None None O
was None None O
minimal None None O
at None None O
physiological None None O
pH None None O
. None None O

Since None None O
chemical None None O
carbethoxylating None None O
agents None None O
represented None None O
by None None O
the None None O
O None None I-MODIFIER
- None None I-MODIFIER
carbethoxylated None None I-MODIFIER
N None None I-IUPAC
- None None I-IUPAC
hydroxyphthalimide None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxybenzotriazole None None I-IUPAC
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxysuccinimide None None I-IUPAC
( None None O
8 None None O
, None None O
9 None None O
, None None O
and None None O
10 None None O
, None None O
respectively None None O
) None None O
likewise None None O
inhibited None None O
yeast None None O
AlDH None None O
, None None O
albeit None None O
with None None O
IC50 None None O
's None None O
1 None None O
order None None O
of None None O
magnitude None None O
higher None None O
, None None O
we None None O
postulate None None O
that None None O
1c None None O
and None None O
6 None None O
act None None O
as None None O
irreversible None None O
inhibitors None None O
of None None O
AlDH None None O
by None None O
carbethoxylating None None O
the None None O
active None None O
site None None O
of None None O
the None None O
enzyme None None O
. None None O


The None None O
synthesis None None O
of None None O
aminoaceto None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidides None None I-IUPAC
substituted None None I-MODIFIER
on None None O
the None None O
amide None None O
nitrogen None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
ethoxyethyl None None I-IUPAC
groups None None I-MODIFIER
is None None O
described None None O
. None None O

The None None O
2 None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
prepared None None O
by None None O
treatment None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phthalimidoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidine None None I-IUPAC
with None None O
chloroacetyl None None O
chloride None None O
, None None O
followed None None O
by None None O
treatment None None O
with None None O
either None None O
potassium None None O
phthalmide None None O
or None None O
diethylamine None None O
. None None O

Hydrazinolysis None None O
of None None O
the None None O
phthalimides None None O
liberated None None O
the None None O
free None None O
amines None None O
. None None O

The None None O
remaining None None O
target None None O
compounds None None O
were None None O
produced None None O
by None None O
alkylation None None O
of None None O
lidocaine None None O
or None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
phthalimidoaceto None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidide None None I-IUPAC
with None None O
the None None O
appropriate None None O
halide None None O
and None None O
sodium None None O
hydride None None O
, None None O
followed None None O
by None None O
hydrazinolysis None None O
where None None O
necessary None None O
. None None O

All None None O
target None None O
compounds None None O
were None None O
evaluated None None O
for None None O
antiarrhythmic None None O
efficacy None None O
against None None O
chloroform None None O
- None None O
induced None None O
ventricular None None O
tachycardia None None O
, None None O
as None None O
well None None O
as None None O
for None None O
acute None None O
CNS None None O
toxicity None None O
in None None O
mice None None O
. None None O

Most None None O
of None None O
the None None O
target None None O
compounds None None O
were None None O
more None None O
potent None None O
than None None O
the None None O
corresponding None None O
secondary None None O
amides None None O
and None None O
had None None O
improved None None O
therapeutic None None O
margins None None O
toward None None O
CNS None None O
toxicity None None O
. None None O

The None None O
diamines None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoaceto None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidide None None I-IUPAC
( None None O
13 None None O
) None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
aceto None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidide None None I-IUPAC
( None None O
29 None None O
) None None O
are None None O
especially None None O
promising None None O
in None None O
this None None O
respect None None O
. None None O

Several None None O
compounds None None O
were None None O
tested None None O
as None None O
spinal None None O
anesthetics None None O
. None None O


A None None O
series None None O
of None None O
analogues None None O
of None None O
the None None O
analgesic None None O
dipeptide None None O
derivative None None O
H None None O
- None None O
Lys None None O
- None None O
Trp None None O
( None None O
NPS None None O
) None None O
- None None O
OMe None None O
has None None O
been None None O
designed None None O
to None None O
determine None None O
the None None O
influence None None O
of None None O
the None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
sulfenyl None None I-IUPAC
( None None O
NPS None None O
) None None O
moiety None None I-MODIFIER
on None None O
the None None O
activity None None O
. None None O

The None None O
syntheses None None O
and None None O
antinociceptive None None O
effects None None O
of None None O
these None None O
analogues None None O
of None None O
general None None O
formula None None O
H None None O
- None None O
Lys None None O
- None None O
Trp None None O
( None None O
R None None O
) None None O
- None None O
OMe None None O
[ None None O
R None None O
= None None O
phenylsulfenyl None None I-IUPAC
( None None O
PS None None O
) None None O
( None None O
9 None None O
) None None O
; None None O
R None None O
= None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbomethyoxyphenyl None None I-IUPAC
) None None I-IUPAC
sulfenyl None None I-IUPAC
( None None O
CmPS None None O
) None None O
( None None O
10 None None O
) None None O
; None None O
R None None O
= None None O
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
sulfenyl None None I-IUPAC
( None None O
pNPS None None O
) None None O
( None None O
11 None None O
) None None O
; None None O
R None None O
= None None O
( None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dinitrophenyl None None I-IUPAC
) None None I-IUPAC
sulfenyl None None I-IUPAC
( None None O
DNPS None None O
) None None O
( None None O
12 None None O
) None None O
; None None O
R None None O
= None None O
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
acetylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbomethoxyethyl None None I-IUPAC
] None None I-IUPAC
sulfenyl None None I-IUPAC
( None None O
AacCmES None None O
) None None O
( None None O
13 None None O
) None None O
; None None O
R None None O
= None None O
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
acetylamino None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
sulfenyl None None I-IUPAC
( None None O
AacPS None None O
) None None O
( None None O
17 None None O
) None None O
; None None O
R None None O
= None None O
tert None None I-IUPAC
- None None I-IUPAC
butylsulfenyl None None I-IUPAC
( None None O
t None None O
- None None O
BuS None None O
) None None O
( None None O
23 None None O
) None None O
; None None O
R None None O
= None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbomethoxyethyl None None I-IUPAC
) None None I-IUPAC
sulfenyl None None I-IUPAC
( None None O
CmES None None O
) None None O
( None None O
24 None None O
) None None O
] None None O
are None None O
described None None O
. None None O

Reaction None None O
of None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
Trp None None O
- None None O
OMe None None O
( None None O
3 None None O
) None None O
with None None O
PS None None O
- None None O
, None None O
CmPS None None O
- None None O
, None None O
pNPS None None O
- None None O
, None None O
DNPS None None O
- None None O
, None None O
and None None O
AacCmES None None O
- None None O
Cl None None O
afforded None None O
the None None O
corresponding None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
sulfenyl None None I-IUPAC
) None None I-IUPAC
tryptophan None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
which None None O
on None None O
treatment None None O
with None None O
boron None None I-IUPAC
- None None I-IUPAC
tris None None I-IUPAC
( None None I-IUPAC
trifluoroacetate None None I-IUPAC
) None None I-IUPAC
/ None None O
trifluoroacetic None None O
acid None None O
or None None O
trimethylsilyl None None O
iodide None None O
in None None O
acetonitrile None None O
( None None O
Me3SiI None None O
/ None None O
CH3CN None None O
) None None O
provided None None O
9-13 None None O
, None None O
respectively None None O
. None None O

Sulfenylation None None O
of None None O
3 None None O
with None None O
NPS None None O
- None None O
Cl None None O
gave None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
Trp None None O
( None None O
NPS None None O
) None None O
- None None O
OMe None None O
, None None O
which None None O
, None None O
on None None O
catalytic None None O
hydrogenation None None O
of None None O
the None None O
nitro None None O
group None None O
using None None O
10% None None O
Pd None None O
/ None None O
C None None O
followed None None O
by None None O
acetylation None None O
of None None O
the None None O
resulting None None O
amino None None O
function None None O
and None None O
removal None None O
of None None O
the None None O
protecting None None O
Z None None O
groups None None O
, None None O
gave None None O
17 None None O
. None None O

Condensation None None O
of None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
tert None None I-PARTIUPAC
- None None I-PARTIUPAC
butylsulfenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbomethoxyethyl None None I-IUPAC
) None None I-IUPAC
sulfenyl None None I-IUPAC
] None None I-IUPAC
tryptophan None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
, None None O
obtained None None O
by None None O
reaction None None O
of None None O
methyl None None I-IUPAC
3a None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1,2,3,3 None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
8,8 None None I-IUPAC
a None None I-IUPAC
- None None I-IUPAC
hexahydropyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxyla None None I-IUPAC
te None None I-IUPAC
with None None O
the None None O
corresponding None None O
thiol None None O
, None None O
with None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
OSu None None O
afforded None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
Trp None None O
( None None O
t None None O
- None None O
BuS None None O
) None None O
- None None O
OMe None None O
and None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
Trp None None O
( None None O
CmES None None O
) None None O
- None None O
OMe None None O
, None None O
which None None O
on None None O
treatment None None O
with None None O
Me3SiI None None O
/ None None O
CH3CN None None O
provided None None O
23 None None O
and None None O
24 None None O
, None None O
respectively None None O
. None None O

Intracerebroventricular None None O
administration None None O
of None None O
10 None None O
elicited None None O
a None None O
naloxone None None O
- None None O
reversible None None O
antinociceptive None None O
effect None None O
in None None O
mice None None O
similar None None O
to None None O
that None None O
of None None O
H None None O
- None None O
Lys None None O
- None None O
Trp None None O
( None None O
NPS None None O
) None None O
- None None O
OMe None None O
. None None O

No None None O
analgesia None None O
was None None O
however None None O
found None None O
with None None O
the None None O
phenylsulfenyl None None O
or None None O
acyclic None None O
sulfenyl None None O
substituted None None O
dipeptides None None O
9 None None O
, None None O
11 None None O
, None None O
and None None O
17 None None O
or None None O
13 None None O
, None None O
23 None None O
, None None O
and None None O
24 None None O
. None None O

The None None O
Trp None None O
( None None O
DNPS None None O
) None None O
- None None O
containing None None O
analogue None None O
was None None O
neurotoxic None None O
. None None O

Structure None None O
- None None O
activity None None O
studies None None O
indicate None None O
that None None O
the None None O
role None None O
of None None O
the None None O
NPS None None O
and None None O
CmPS None None O
moieties None None O
could None None O
be None None O
related None None O
to None None O
the None None O
adoption None None O
of None None O
a None None O
preferential None None O
active None None O
conformation None None O
. None None O


Adenosine None None O
5' None None O
- None None O
triphosphate None None O
( None None O
ATP None None O
) None None O
derivatives None None I-MODIFIER
of None None O
the None None O
types None None O
N6 None None O
- None None O
R None None O
- None None O
ATP None None O
[ None None O
R None None O
= None None O
( None None O
CH2 None None O
) None None O
nNHCOCH2I None None O
, None None O
( None None O
CH2 None None O
) None None O
nNHCO None None O
- None None O
( None None O
CH2 None None O
) None None O
mNHCOCH2I None None O
, None None O
or None None O
( None None O
CH2 None None O
) None None O
nCON None None O
( None None O
Me None None O
) None None O
( None None O
CH2 None None O
) None None O
mN None None O
( None None O
Me None None O
) None None O
CO None None O
( None None O
CH2 None None O
) None None O
nNHCOCH2I None None O
] None None O
, None None O
N6 None None O
- None None O
Me None None O
- None None O
N6 None None O
- None None O
R None None O
- None None O
ATP None None O
[ None None O
R None None O
= None None O
( None None O
CH2 None None O
) None None O
nN None None O
- None None O
( None None O
Me None None O
) None None O
CO None None O
( None None O
CH2 None None O
) None None O
mNHCOCH2I None None O
] None None O
, None None O
and None None O
8 None None O
- None None O
R None None O
- None None O
ATP None None O
[ None None O
R None None O
= None None O
NM None None O
( None None O
CH2 None None O
) None None O
nNHCOCH2I None None O
] None None O
with None None O
5 None None O
- None None O
- None None O
19 None None O
spacer None None O
atoms None None O
between None None O
N6 None None O
or None None O
C None None O
- None None O
8 None None O
and None None O
iodine None None O
have None None O
been None None O
evaluated None None O
as None None O
potential None None O
exo None None O
- None None O
ATP None None O
- None None O
site None None O
- None None O
directed None None O
reagents None None O
for None None O
phosphokinases None None O
. None None O

Substrate None None O
and None None O
inhibitor None None O
properties None None O
indicated None None O
that None None O
the None None O
compounds None None O
possessed None None O
affinity None None O
for None None O
the None None O
ATP None None O
sites None None O
of None None O
the None None O
muscle None None O
( None None O
M None None O
) None None O
, None None O
kidney None None O
( None None O
K None None O
) None None O
, None None O
and None None O
liver None None O
( None None O
L None None O
) None None O
isozymes None None O
of None None O
rat None None O
pyruvate None None O
kinase None None O
( None None O
PK None None O
) None None O
, None None O
of None None O
E None None O
. None None O

coli None None O
thymidine None None O
kinase None None O
( None None O
TK None None O
) None None O
, None None O
and None None O
of None None O
yeast None None O
hexokinase None None O
( None None O
HK None None O
) None None O
and None None O
rat None None O
KH None None O
I None None O
, None None O
II None None O
, None None O
and None None O
III None None O
isozymes None None O
. None None O

Tests None None O
for None None O
time None None O
- None None O
dependent None None O
loss None None O
of None None O
enzyme None None O
activity None None O
( None None O
inactivation None None O
) None None O
were None None O
performed None None O
under None None O
conditions None None O
in None None O
which None None O
a None None O
large None None O
proportion None None O
of None None O
each None None O
phosphokinase None None O
was None None O
present None None O
as None None O
an None None O
enzyme None None O
- None None O
inhibitor None None O
complex None None O
. None None O

No None None O
ATP None None O
- None None O
site None None O
- None None O
directed None None O
inactivations None None O
resulted None None O
when None None O
the None None O
M None None O
, None None O
L None None O
, None None O
or None None O
K None None O
isozymes None None O
of None None O
PK None None O
were None None O
exposed None None O
for None None O
8 None None O
h None None O
, None None O
22 None None O
degrees None None O
C None None O
, None None O
to None None O
5 None None O
mM None None O
levels None None O
of None None O
18 None None O
ATP None None O
derivatives None None O
or None None O
6 None None O
analogous None None O
ADP None None O
derivatives None None O
or None None O
when None None O
yeast None None O
HK None None O
or None None O
rat None None O
KH None None O
I None None O
, None None O
II None None O
, None None O
or None None O
III None None O
was None None O
exposed None None O
for None None O
6 None None O
h None None O
, None None O
22 None None O
degrees None None O
C None None O
, None None O
to None None O
5 None None O
mM None None O
levels None None O
of None None O
28 None None O
ATP None None O
derivatives None None O
. None None O

Escherichia None None O
coli None None O
TK None None O
was None None O
inactivated None None O
by None None O
6 None None O
of None None O
25 None None O
ATP None None O
derivatives None None O
tested None None O
at None None O
10 None None O
mM None None O
, None None O
6 None None O
h None None O
, None None O
0 None None O
degrees None None O
C None None O
; None None O
inactivation None None O
was None None O
slowed None None O
by None None O
MgATP None None O
in None None O
the None None O
case None None O
of None None O
N6 None None O
- None None O
CH3 None None O
- None None O
N6 None None O
- None None O
R None None O
- None None O
ATP None None O
[ None None O
R None None O
= None None O
( None None O
CH2 None None O
) None None O
4N None None O
( None None O
CH3 None None O
) None None O
CO None None O
( None None O
CH2 None None O
) None None O
5NHCOCH2I None None O
] None None O
. None None O

Only None None O
1% None None O
of None None O
298 None None O
enzyme None None O
- None None O
inhibitor None None O
combinations None None O
exhibited None None O
ATP None None O
- None None O
site None None O
- None None O
directed None None O
inactivation None None O
, None None O
signifying None None O
that None None O
few None None O
suitably None None O
positioned None None O
and None None O
sufficiently None None O
reactive None None O
nucleophilic None None O
groups None None O
were None None O
present None None O
near None None O
the None None O
enzymic None None O
ATP None None O
sites None None O
. None None O

Studies None None O
have None None O
now None None O
shown None None O
that None None O
exo None None O
- None None O
active None None O
- None None O
site None None O
- None None O
directed None None O
reagents None None O
can None None O
act None None O
as None None O
isozyme None None O
- None None O
or None None O
species None None O
- None None O
selective None None O
enzyme None None O
inhibitors None None O
. None None O

The None None O
present None None O
survey None None O
indicates None None O
that None None O
in None None O
many None None O
cases None None O
such None None O
reagents None None O
may None None O
be None None O
difficult None None O
of None None O
access None None O
when None None O
data None None O
are None None O
not None None O
available None None O
regarding None None O
structural None None O
or None None O
physicochemical None None O
features None None O
of None None O
the None None O
target None None O
enzyme None None O
adjacent None None O
to None None O
its None None O
catalytic None None O
site None None O
. None None O


The None None O
synthesis None None O
of None None O
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
propargyl None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dideazafolic None None I-IUPAC
acid None None I-IUPAC
and None None O
its None None O
2 None None I-IUPAC
- None None I-IUPAC
desamino None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
desamino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxymethyl None None I-IUPAC
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
desamino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
analogues None None I-MODIFIER
is None None O
described None None O
. None None O

In None None O
general None None O
the None None O
synthetic None None O
route None None O
involved None None O
the None None O
coupling None None O
of None None O
diethyl None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
prop None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ynylamino None None I-IUPAC
) None None I-IUPAC
benzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
with None None O
the None None O
appropriate None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
quinazoline None None I-IUPAC
followed None None O
by None None O
deprotection None None O
with None None O
mild None None O
alkali None None O
. None None O

These None None O
four None None O
compounds None None O
together None None O
with None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
desamino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
analogue None None I-MODIFIER
were None None O
tested None None O
for None None O
their None None O
activity None None O
against None None O
L1210 None None O
thymidylate None None O
synthase None None O
( None None O
TS None None O
) None None O
. None None O

They None None O
were None None O
also None None O
examined None None O
for None None O
their None None O
inhibition None None O
of None None O
the None None O
growth None None O
of None None O
the None None O
L1210 None None O
cell None None O
line None None O
and None None O
of None None O
two None None O
mutant None None O
L1210 None None O
cell None None O
lines None None O
, None None O
the None None O
L1210 None None O
: None None O
R7A None None O
that None None O
overproduces None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
and None None O
the None None O
L1210 None None O
: None None O
1565 None None O
that None None O
has None None O
impaired None None O
uptake None None O
of None None O
reduced None None O
folates None None O
. None None O

Compared None None O
with None None O
their None None O
non None None O
- None None O
fluorinated None None O
parent None None O
compounds None None O
, None None O
the None None O
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
analogues None None I-MODIFIER
were None None O
all None None O
approximately None None O
2 None None O
- None None O
fold None None O
more None None O
potent None None O
as None None O
TS None None O
inhibitors None None O
. None None O

Similarly None None O
, None None O
they None None O
also None None O
showed None None O
improved None None O
inhibition None None O
of None None O
L1210 None None O
cell None None O
growth None None O
( None None O
1.5-5 None None O
- None None O
fold None None O
) None None O
, None None O
and None None O
this None None O
activity None None O
was None None O
prevented None None O
by None None O
co None None O
- None None O
incubation None None O
with None None O
thymidine None None O
. None None O

All None None O
had None None O
retained None None O
or None None O
improved None None O
activity None None O
against None None O
both None None O
the None None O
L1210 None None O
: None None O
R7A None None O
and None None O
L1210 None None O
: None None O
1565 None None O
cell None None O
lines None None O
. None None O


A None None O
series None None O
of None None O
8 None None O
- None None O
( None None O
trifluoromethyl None None O
) None None O
- None None O
substituted None None O
quinolones None None O
has None None O
been None None O
prepared None None O
and None None O
evaluated None None O
for None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
antibacterial None None O
activity None None O
, None None O
and None None O
phototolerance None None O
in None None O
a None None O
mouse None None O
phototolerance None None O
assay None None O
. None None O

These None None O
analogues None None O
were None None O
compared None None O
to None None O
the None None O
corresponding None None O
series None None O
of None None O
6,8 None None I-PARTIUPAC
- None None I-PARTIUPAC
difluoro None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
8H None None I-IUPAC
- None None I-IUPAC
quinolones None None I-IUPAC
( None None O
ciprofloxacin None None O
type None None O
) None None O
. None None O

Although None None O
their None None O
in None None O
vitro None None O
antibacterial None None O
activities None None O
are None None O
less None None O
than None None O
the None None O
6,8 None None I-IUPAC
- None None I-IUPAC
difluoro None None I-IUPAC
analogues None None I-MODIFIER
, None None O
the None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
quinolones None None I-IUPAC
are None None O
generally None None O
equivalent None None O
to None None O
their None None O
8H None None O
analogues None None O
. None None O

In None None O
vivo None None O
, None None O
they None None O
are None None O
comparable None None O
to None None O
the None None O
6,8 None None I-IUPAC
- None None I-IUPAC
difluoro None None I-IUPAC
series None None I-MODIFIER
and None None O
show None None O
up None None O
to None None O
10 None None O
- None None O
fold None None O
improvement None None O
in None None O
efficacy None None O
when None None O
compared None None O
to None None O
their None None O
ciprofloxacin None None O
counterparts None None O
vs None None O
Streptococcus None None O
pyogenes None None O
and None None O
Streptococcus None None O
pneumonia None None O
. None None O

In None None O
the None None O
phototolerance None None O
model None None O
, None None O
the None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
quinolones None None I-IUPAC
are None None O
comparable None None O
to None None O
the None None O
8H None None I-IUPAC
- None None I-IUPAC
quinolones None None I-IUPAC
. None None O

Both None None O
of None None O
these None None O
series None None O
display None None O
much None None O
higher None None O
no None None O
effect None None O
doses None None O
( None None O
greater None None O
tolerance None None O
) None None O
than None None O
the None None O
corresponding None None O
6,8 None None I-IUPAC
- None None I-IUPAC
difluoroquinolones None None I-IUPAC
. None None O


The None None O
syntheses None None O
and None None O
anthelmintic None None O
activities None None O
of None None O
31 None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazoles None None I-IUPAC
are None None O
reported None None O
. None None O

In None None O
the None None O
primary None None O
anthelmintic None None O
screen None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
( None None O
39 None None O
) None None O
showed None None O
100% None None O
nematocidal None None O
activity None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
( None None O
63 None None O
) None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
( None None O
64 None None O
) None None O
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
( None None O
66 None None O
) None None O
showed None None O
100% None None O
taeniacidal None None O
activity None None O
when None None O
administered None None O
orally None None O
to None None O
mice None None O
. None None O

The None None O
two None None O
most None None O
active None None O
members None None O
of None None O
this None None O
series None None O
, None None O
39 None None O
and None None O
63 None None O
, None None O
were None None O
active None None O
against None None O
the None None O
gastrointestinal None None O
nematodes None None O
of None None O
sheep None None O
at None None O
100 None None O
mg None None O
/ None None O
kg None None O
. None None O

In None None O
addition None None O
, None None O
39 None None O
was None None O
also None None O
found None None O
to None None O
be None None O
active None None O
against None None O
hookworms None None O
in None None O
dogs None None O
at None None O
a None None O
single None None O
, None None O
oral None None O
dose None None O
of None None O
200 None None O
mg None None O
/ None None O
kg None None O
. None None O


A None None O
novel None None O
class None None O
of None None O
5 None None O
- None None O
substituted None None O
acyclic None None O
pyrimidine None None O
nucleosides None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azidovinyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
9a None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
ethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azidovinyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
9b None None O
) None None O
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azidovinyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
9c None None O
) None None O
, None None O
were None None O
synthesized None None O
by None None O
regiospecific None None O
addition None None O
of None None O
bromine None None O
azide None None O
to None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyl None None I-IUPAC
substituent None None I-MODIFIER
of None None O
the None None O
respective None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyluracils None None I-IUPAC
( None None O
2a None None O
- None None O
c None None O
) None None O
followed None None O
by None None O
treatment None None O
of None None O
the None None O
obtained None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromoethyl None None I-IUPAC
) None None I-IUPAC
compounds None None I-MODIFIER
( None None O
3a None None O
- None None O
c None None O
) None None O
with None None O
t None None O
- None None O
BuOK None None O
, None None O
to None None O
affect None None O
the None None O
base None None O
- None None O
catalyzed None None O
elimination None None O
of None None O
HBr None None O
. None None O

Thermal None None O
decomposition None None O
of None None O
9b None None O
and None None O
9c None None O
at None None O
110 None None O
degrees None None O
C None None O
in None None O
dioxane None None O
yielded None None O
corresponding None None O
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azirinyl None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
uracil None None I-IUPAC
analogues None None I-MODIFIER
( None None O
10b None None O
, None None O
c None None O
) None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azidovinyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
derivatives None None I-MODIFIER
9a None None O
- None None O
c None None O
were None None O
found None None O
to None None O
exhibit None None O
potent None None O
and None None O
selective None None O
in None None O
vitro None None O
anti None None O
- None None O
HBV None None O
activity None None O
against None None O
duck None None O
hepatitis None None O
B None None O
virus None None O
( None None O
DHBV None None O
) None None O
infected None None O
primary None None O
duck None None O
hepatocytes None None O
at None None O
low None None O
concentrations None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
0.01-0.1 None None O
microg None None O
/ None None O
mL None None O
range None None O
) None None O
. None None O

The None None O
most None None O
active None None O
anti None None O
- None None O
DHBV None None O
agent None None O
( None None O
9c None None O
) None None O
, None None O
possessing None None O
a None None O
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
substituent None None I-MODIFIER
at None None O
N None None O
- None None O
1 None None O
, None None O
exhibited None None O
an None None O
activity None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
of None None O
0.01-0.05 None None O
microg None None O
/ None None O
mL None None O
) None None O
comparable None None O
to None None O
that None None O
of None None O
reference None None O
compound None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
thiacytidine None None I-IUPAC
( None None O
3 None None O
- None None O
TC None None O
) None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
0.01-0.05 None None O
microg None None O
/ None None O
mL None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
related None None O
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azirinyl None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
uracil None None I-IUPAC
analogues None None I-MODIFIER
( None None O
10b None None O
, None None O
c None None O
) None None O
were None None O
devoid None None O
of None None O
anti None None O
- None None O
DHBV None None O
activity None None O
, None None O
indicating None None O
that None None O
an None None O
acyclic None None O
side None None O
chain None None O
at None None O
C None None O
- None None O
5 None None O
position None None O
of None None O
the None None O
pyrimidine None None O
ring None None O
is None None O
essential None None O
for None None O
anti None None O
- None None O
HBV None None O
activity None None O
. None None O

The None None O
pyrimidine None None O
nucleosides None None O
( None None O
9a None None O
- None None O
c None None O
, None None O
10b None None O
, None None O
c None None O
) None None O
exhibited None None O
no None None O
cytotoxic None None O
activity None None O
against None None O
a None None O
panel None None O
of None None O
60 None None O
human None None O
cancer None None O
cell None None O
lines None None O
. None None O

All None None O
of None None O
the None None O
compounds None None O
investigated None None O
did None None O
not None None O
show None None O
any None None O
detectable None None O
toxicity None None O
to None None O
several None None O
stationary None None O
and None None O
proliferating None None O
host None None O
cell None None O
lines None None O
or None None O
to None None O
mitogen None None O
stimulated None None O
proliferating None None O
human None None O
T None None O
lymphocytes None None O
, None None O
up None None O
to None None O
the None None O
highest None None O
concentration None None O
tested None None O
. None None O


The None None O
isomeric None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloro None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxyphenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinolines None None I-IUPAC
, None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
derivative None None I-MODIFIER
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
isomer None None I-MODIFIER
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
dopamine None None O
D None None O
- None None O
1 None None O
antagonist None None O
activity None None O
. None None O

The None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
and None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
isomer None None I-MODIFIER
possessed None None O
similar None None O
potencies None None O
as None None O
D None None O
- None None O
1 None None O
antagonists None None O
. None None O

Introduction None None O
of None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
enhanced None None O
potency None None O
about None None O
twofold None None O
. None None O

The None None O
" None None O
pharmacophore None None O
" None None O
for None None O
selective None None O
dopamine None None O
D None None O
- None None O
1 None None O
antagonist None None O
activity None None O
appears None None O
to None None O
be None None O
a None None O
tertiary None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenethylamine None None I-IUPAC
. None None O


Spiro None None O
[ None None O
isobenzofuran None None O
- None None O
1 None None O
( None None O
3H None None O
) None None O
, None None O
4' None None O
- None None O
piperidines None None O
] None None O
and None None O
the None None O
corresponding None None O
benzofuran None None O
and None None O
benzopyran None None O
derivatives None None O
have None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
as None None O
sigma None None O
ligands None None O
. None None O

The None None O
compounds None None O
are None None O
related None None O
to None None O
Lu None None O
28-179 None None O
( None None O
1' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
spiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
) None None O
that None None O
has None None O
been None None O
demonstrated None None O
to None None O
be None None O
a None None O
selective None None O
sigma None None O
2 None None O
ligand None None O
with None None O
affinity None None O
in None None O
the None None O
subnanomolar None None O
range None None O
. None None O

The None None O
object None None O
of None None O
the None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
structural None None O
factors None None O
governing None None O
sigma None None O
1 None None O
/ None None O
sigma None None O
2 None None O
affinity None None O
and None None O
selectivity None None O
within None None O
this None None O
class None None O
of None None O
compounds None None O
. None None O

The None None O
N None None O
- None None O
substituent None None O
in None None O
spiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidines None None I-IUPAC
] None None I-IUPAC
is None None O
highly None None O
important None None O
, None None O
both None None O
for None None O
affinity None None O
and None None O
selectivity None None O
. None None O

Spiropiperidines None None O
with None None O
no None None O
or None None O
small None None O
N None None O
- None None O
substituents None None O
( None None O
H None None O
, None None O
Me None None O
, None None O
Et None None O
) None None O
exert None None O
very None None O
low None None O
affinity None None O
for None None O
both None None O
sigma None None O
1 None None O
and None None O
sigma None None O
2 None None O
binding None None O
sites None None O
( None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
, None None O
sigma None None O
2 None None O
) None None O
& None None O
gt None None O
; None None O
100 None None O
nM None None O
) None None O
, None None O
whereas None None O
medium None None O
- None None O
sized None None O
substituents None None O
( None None O
e.g. None None O
, None None O
Pr None None O
, None None O
Bu None None O
, None None O
Ph None None O
( None None O
CH2 None None O
) None None O
2 None None O
) None None O
result None None O
in None None O
potent None None O
, None None O
but None None O
unselective None None O
compounds None None O
( None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
, None None O
sigma None None O
2 None None O
) None None O
= None None O
2-5 None None O
nM None None O
) None None O
. None None O

Increasing None None O
the None None O
chain None None O
length None None O
and None None O
the None None O
lipophilicity None None O
of None None O
the None None O
N None None O
- None None O
substituent None None O
result None None O
in None None O
compounds None None O
in None None O
which None None O
high None None O
affinity None None O
for None None O
sigma None None O
2 None None O
binding None None O
sites None None O
is None None O
retained None None O
and None None O
with None None O
selectivity None None O
for None None O
sigma None None O
2 None None O
vs None None O
sigma None None O
1 None None O
binding None None O
sites None None O
( None None O
e.g. None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
cyclohexyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
: None None O
IC50 None None O
- None None O
( None None O
sigma None None O
1 None None O
) None None O
= None None O
1.5 None None O
nM None None O
, None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.07 None None O
nM None None O
) None None O
. None None O

Introduction None None O
of None None O
substituents None None O
in None None O
the None None O
benzene None None O
ring None None O
of None None O
the None None O
spiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
ring None None O
system None None O
of None None O
Lu None None O
28-179 None None O
mainly None None O
affects None None O
affinity None None O
for None None O
sigma None None O
1 None None O
binding None None O
sites None None O
. None None O

Compounds None None O
with None None O
substituents None None O
( None None O
F None None O
, None None O
CF3 None None O
) None None O
in None None O
the None None O
4 None None O
- None None O
or None None O
7 None None O
- None None O
position None None O
of None None O
the None None O
isobenzofuran None None O
display None None O
high None None O
affinity None None O
for None None O
sigma None None O
2 None None O
binding None None O
sites None None O
( None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.5-2 None None O
nM None None O
) None None O
and None None O
very None None O
low None None O
affinity None None O
for None None O
sigma None None O
1 None None O
binding None None O
sites None None O
( None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
) None None O
& None None O
gt None None O
; None None O
100 None None O
nM None None O
) None None O
. None None O

Compounds None None O
with None None O
substituents None None O
( None None O
F None None O
, None None O
CF3 None None O
, None None O
Me None None O
) None None O
in None None O
the None None O
5 None None O
- None None O
or None None O
6 None None O
- None None O
position None None O
of None None O
the None None O
isobenzofuran None None O
exert None None O
increased None None O
affinity None None O
for None None O
sigma None None O
1 None None O
binding None None O
sites None None O
( None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
) None None O
= None None O
5-30 None None O
nM None None O
, None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.3-7 None None O
nM None None O
) None None O
, None None O
thus None None O
rendering None None O
unselective None None O
compounds None None O
. None None O

Exchanging None None O
the None None O
isobenzofuran None None O
moiety None None O
of None None O
Lu None None O
28-179 None None O
with None None O
thioisobenzofuran None None O
, None None O
benzofuran None None O
, None None O
or None None O
benzopyran None None O
also None None O
has None None O
a None None O
pronounced None None O
effect None None O
on None None O
both None None O
affinity None None O
and None None O
selectivity None None O
for None None O
sigma None None O
binding None None O
sites None None O
. None None O

The None None O
position None None O
of None None O
the None None O
oxygen None None O
atom None None O
and None None O
the None None O
position None None O
of None None O
the None None O
spiroconnection None None O
with None None O
the None None O
4 None None O
- None None O
position None None O
of None None O
the None None O
piperidine None None O
ring None None O
were None None O
varied None None O
, None None O
and None None O
only None None O
compounds None None O
in None None O
which None None O
both None None O
the None None O
benzene None None O
ring None None O
and None None O
the None None O
heteroatom None None O
are None None O
attached None None O
directly None None O
to None None O
the None None O
piperidine None None O
ring None None O
retain None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
sigma None None O
2 None None O
binding None None O
sites None None O
( None None O
e.g. None None O
, None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
spiro None None I-IUPAC
[ None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
: None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
) None None O
= None None O
53 None None O
nM None None O
, None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.9 None None O
nM None None O
) None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

A None None O
series None None O
of None None O
22 None None I-IUPAC
- None None I-IUPAC
hydroxycholesterol None None I-IUPAC
derivatives None None I-MODIFIER
with None None O
a None None O
modified None None O
side None None O
chain None None O
terminus None None O
was None None O
prepared None None O
. None None O

These None None O
agents None None O
were None None O
evaluated None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
for None None O
their None None O
ability None None O
to None None O
suppress None None O
HMG None None O
CoA None None O
reductase None None O
, None None O
the None None O
rate None None O
- None None O
limiting None None O
enzyme None None O
of None None O
cholesterol None None O
biosynthesis None None O
. None None O

In None None O
tissue None None O
culture None None O
assays None None O
, None None O
22 None None I-IUPAC
- None None I-IUPAC
hydroxycholesterol None None I-IUPAC
as None None O
well None None O
as None None O
the None None O
side None None O
chain None None O
modified None None O
analogues None None O
were None None O
potent None None O
inhibitors None None O
of None None O
HMG None None O
CoA None None O
reductase None None O
. None None O

However None None O
, None None O
only None None O
those None None O
sterols None None O
with None None O
a None None O
modified None None O
side None None O
chain None None O
terminus None None O
were None None O
effective None None O
suppressors None None O
of None None O
liver None None O
reductase None None O
when None None O
administered None None O
ig None None O
to None None O
rats None None O
. None None O

22 None None I-IUPAC
- None None I-IUPAC
Hydroxy None None I-IUPAC
- None None I-IUPAC
25 None None I-IUPAC
- None None I-IUPAC
methylcholesterol None None I-IUPAC
( None None O
4a None None O
) None None O
and None None O
25 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
22 None None I-IUPAC
- None None I-IUPAC
hydroxycholesterol None None I-IUPAC
( None None O
15a None None O
) None None O
significantly None None O
lowered None None O
serum None None O
cholesterol None None O
levels None None O
when None None O
administered None None O
ig None None O
to None None O
primates None None O
; None None O
25 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
22 None None I-IUPAC
- None None I-IUPAC
hydroxycholesterol None None I-IUPAC
( None None O
15b None None O
) None None O
and None None O
the None None O
analogue None None O
with None None O
a None None O
cyclopropyl None None I-IUPAC
terminus None None B-MODIFIER
, None None O
20b None None O
, None None O
were None None O
ineffective None None O
. None None O

The None None O
cholesterol None None O
- None None O
lowering None None O
sterols None None O
did None None O
not None None O
significantly None None O
alter None None O
lipoprotein None None O
levels None None O
; None None O
however None None O
, None None O
the None None O
two None None O
compounds None None O
have None None O
been None None O
shown None None O
to None None O
inhibit None None O
acyl None None O
- None None O
coenzyme None None O
A None None O
: None None O
cholesterol None None O
acyl None None O
- None None O
transferase None None O
( None None O
ACAT None None O
) None None O
in None None O
tissue None None O
culture None None O
studies None None O
. None None O


Hypoxic None None O
cells None None O
are None None O
an None None O
important None None O
target None None O
for None None O
antitumor None None O
therapy None None O
because None None O
tumors None None O
are None None O
typically None None O
characterized None None O
by None None O
such None None O
cells None None O
. None None O

Virtually None None O
all None None O
tumors None None O
which None None O
are None None O
present None None O
as None None O
solid None None O
masses None None O
contain None None O
hypoxic None None O
cells None None O
, None None O
while None None O
normal None None O
cells None None O
generally None None O
have None None O
an None None O
adequate None None O
supply None None O
of None None O
oxygen None None O
. None None O

Accordingly None None O
, None None O
antitumor None None O
agents None None O
can None None O
be None None O
made None None O
selective None None O
for None None O
tumors None None O
by None None O
virtue None None O
of None None O
high None None O
activity None None O
under None None O
hypoxic None None O
conditions None None O
. None None O

The None None O
initial None None O
purpose None None O
of None None O
this None None O
work None None O
was None None O
to None None O
determine None None O
the None None O
influence None None O
of None None O
different None None O
groups None None O
in None None O
position None None O
3 None None O
. None None O

Thus None None O
, None None O
the None None O
synthesis None None O
of None None O
some None None O
3 None None O
- None None O
NH None None O
- None None O
substituted None None O
derivatives None None O
( None None O
2a None None O
, None None O
3a None None O
, None None O
4a None None O
) None None O
starting None None O
from None None O
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
quinoxalinecarbonitrile None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
1a None None O
) None None O
is None None O
described None None O
. None None O

Reductive None None O
deamination None None O
of None None O
compounds None None O
1a None None O
- None None O
k None None O
provides None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
quinoxalinecarbonitriles None None I-IUPAC
5a None None O
- None None O
k None None O
, None None O
which None None O
are None None O
more None None O
potent None None O
, None None O
while None None O
selectivity None None O
is None None O
maintained None None O
or None None O
increased None None O
in None None O
some None None O
derivatives None None O
. None None O

The None None O
compound None None O
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
quinoxalinecarbonitrile None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
5k None None O
) None None O
is None None O
150 None None O
- None None O
fold None None O
more None None O
potent None None O
than None None O
tirapazamine None None O
( None None O
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
benzotriazine None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
) None None O
, None None O
which None None O
has None None O
been None None O
used None None O
as None None O
a None None O
standard None None O
. None None O

Three None None O
derivatives None None O
( None None O
5g None None O
, None None O
i None None O
, None None O
k None None O
) None None O
show None None O
a None None O
hypoxic None None O
cytotoxicity None None O
ratio None None O
( None None O
HCR None None O
) None None O
& None None O
gt None None O
; None None O
or None None O
= None None O
200 None None O
, None None O
better None None O
than None None O
that None None O
of None None O
tirapazamine None None O
( None None O
HCR None None O
= None None O
75 None None O
) None None O
in None None O
V79 None None O
cells None None O
. None None O

Replacement None None O
of None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
group None None I-MODIFIER
by None None O
chlorine None None O
affords None None O
the None None O
potent None None O
but None None O
nonselective None None O
3 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
derivatives None None I-MODIFIER
6a None None O
- None None O
k None None O
showing None None O
similar None None O
toxicities None None O
under None None O
both None None O
aerobic None None O
and None None O
hypoxic None None O
conditions None None O
. None None O

These None None O
compounds None None O
were None None O
used None None O
as None None O
intermediates None None O
for None None O
the None None O
synthesis None None O
of None None O
a None None O
new None None O
series None None O
of None None O
water None None O
- None None O
soluble None None O
compounds None None O
derived None None O
from None None O
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dialkylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
[ None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
quinoxalinecarbonitrile None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxides None None I-IUPAC
10a None None O
- None None O
i None None O
and None None O
11a None None O
- None None O
i None None O
. None None O

The None None O
7 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
and None None O
the None None O
7 None None I-IUPAC
- None None I-IUPAC
trifluoromethyl None None I-IUPAC
derivatives None None I-MODIFIER
10b None None O
, None None O
f None None O
have None None O
demonstrated None None O
high None None O
potency None None O
( None None O
0.4 None None O
and None None O
0.3 None None O
microM None None O
) None None O
and None None O
excellent None None O
selectivity None None O
( None None O
HCR None None O
= None None O
250 None None O
and None None O
340 None None O
) None None O
. None None O

Several None None O
7 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
analogues None None I-MODIFIER
, None None O
12b None None O
, None None O
13b None None O
.1 None None O
, None None O
b None None O
.2 None None O
, None None O
and None None O
14b None None O
, None None O
and None None O
the None None O
dimer None None O
16b None None O
have None None O
been None None O
prepared None None O
and None None O
evaluated None None O
in None None O
order None None O
to None None O
determine None None O
the None None O
optimum None None O
lateral None None O
chain None None O
in None None O
position None None O
3 None None O
, None None O
which None None O
appears None None O
to None None O
be None None O
the None None O
[ None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
moiety None None I-MODIFIER
. None None O


Condensation None None O
of None None O
14 None None I-IUPAC
- None None I-IUPAC
bromodaunorubicin None None I-IUPAC
with None None O
thiols None None O
in None None O
methanol None None O
, None None O
in None None O
the None None O
presence None None O
of None None O
potassium None None O
carbonate None None O
, None None O
resulted None None O
in None None O
the None None O
formation None None O
of None None O
14 None None O
- None None O
thia None None O
analogues None None O
of None None O
the None None O
antitumor None None O
antibiotic None None O
adriamycin None None O
. None None O

However None None O
, None None O
similar None None O
condensation None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
iododaunorubicin None None I-IUPAC
with None None O
thiols None None O
invariably None None O
led None None O
to None None O
a None None O
redox None None O
reaction None None O
, None None O
with None None O
the None None O
formation None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
daunorubicin None None I-IUPAC
and None None O
disulfides None None O
. None None O

Accordingly None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
bromodaunorubicin None None I-IUPAC
was None None O
used None None O
for None None O
reaction None None O
with None None O
thiols None None O
to None None O
yield None None O
thia None None O
analogues None None O
of None None O
the None None O
clinically None None O
active None None O
but None None O
non None None O
- None None O
DNA None None O
- None None O
binding None None O
adriamycin None None O
analogue None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
adriamycin None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
valerate None None I-IUPAC
( None None O
AD None None O
32 None None O
) None None O
. None None O

Reaction None None O
of None None O
14 None None I-IUPAC
- None None I-IUPAC
bromoadunorubicin None None I-IUPAC
with None None O
alpha None None O
, None None O
omega None None O
- None None O
alkanedithiols None None O
gave None None O
bis None None O
( None None O
thiaadriamycin None None O
) None None O
analogues None None O
as None None O
potential None None O
difunctional None None O
intercalating None None O
agents None None O
. None None O

The None None O
aforementioned None None O
products None None O
, None None O
plus None None O
two None None O
related None None O
phenylselena None None O
derivatives None None O
, None None O
were None None O
examined None None O
for None None O
in None None O
vitro None None O
growth None None O
inhibition None None O
, None None O
in None None O
vivo None None O
antitumor None None O
activity None None O
, None None O
and None None O
, None None O
where None None O
appropriate None None O
, None None O
DNA None None O
binding None None O
. None None O

A None None O
number None None O
of None None O
agents None None O
, None None O
most None None O
notably None None O
14 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carbethoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
thiaadriamycin None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
selenaadriamycin None None I-IUPAC
, None None O
were None None O
active None None O
against None None O
murine None None O
L1210 None None O
leukemia None None O
in None None O
vivo None None O
. None None O

Several None None O
of None None O
the None None O
amino None None O
glycoside None None O
unsubstituted None None O
14 None None I-IUPAC
- None None I-IUPAC
thiaadriamycin None None I-IUPAC
analogues None None I-MODIFIER
exhibited None None O
DNA None None O
- None None O
binding None None O
properties None None O
equivalent None None O
to None None O
those None None O
of None None O
adriamycin None None O
. None None O


Three None None O
electrophilic None None O
amide None None O
analogues None None O
of None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
diaminopropionic None None I-IUPAC
acid None None I-IUPAC
( None None O
1 None None O
, None None O
DAP None None O
) None None O
have None None O
been None None O
prepared None None O
as None None O
potential None None O
inhibitors None None O
of None None O
L None None O
- None None O
asparagine None None O
synthetase None None O
( None None O
ASase None None O
, None None O
from None None O
Novikoff None None O
hepatoma None None O
, None None O
EC None None O
6.3.5.4 None None O
) None None O
. None None O

DAP None None O
was None None O
selectively None None O
blocked None None O
by None None O
the None None O
carbobenzoxy None None O
( None None O
Cbz None None O
) None None O
group None None O
to None None O
give None None O
3 None None O
- None None O
N None None O
- None None O
Cbz None None O
- None None O
DAP None None O
( None None O
2a None None O
) None None O
. None None O

Esterification None None O
of None None O
2a None None O
with None None O
isobutylene None None O
afforded None None O
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
carbobenzoxy None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
diaminopropionate None None I-IUPAC
( None None O
3a None None O
) None None O
, None None O
which None None O
was None None O
then None None O
blocked None None O
at None None O
the None None O
2 None None O
position None None O
with None None O
the None None O
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
( None None O
Boc None None O
) None None O
group None None I-MODIFIER
to None None O
give None None O
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
carbobenzoxy None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
propionate None None I-IUPAC
( None None O
4 None None O
) None None O
. None None O

Selective None None O
cleavage None None O
of None None O
the None None O
Cbz None None O
group None None O
by None None O
H2 None None O
/ None None O
Pd None None O
gave None None O
the None None O
key None None O
intermediate None None O
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
diaminopropionate None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
which None None O
was None None O
acylated None None O
, None None O
via None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxysuccinimide None None I-IUPAC
esters None None I-IUPAC
, None None O
with None None O
bromoacetic None None I-IUPAC
acid None None I-IUPAC
, None None O
dichloroacetic None None O
acid None None O
, None None O
and None None O
fumaric None None I-IUPAC
acid None None I-IUPAC
monoethyl None None I-IUPAC
ester None None I-IUPAC
to None None O
give None None O
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromoacetamido None None I-IUPAC
) None None I-IUPAC
propionate None None I-IUPAC
( None None O
6a None None O
) None None O
, None None O
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
dichloroacetamido None None I-IUPAC
) None None I-IUPAC
propionate None None I-IUPAC
( None None O
6b None None O
) None None O
, None None O
and None None O
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
) None None I-IUPAC
acrylamido None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
propionate None None I-IUPAC
( None None O
6c None None O
) None None O
, None None O
respectively None None O
. None None O

Deblocking None None O
of None None O
6a None None O
- None None O
c None None O
gave None None O
the None None O
corresponding None None O
amino None None I-IUPAC
acids None None I-IUPAC
( None None B-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromoacetamido None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
hydrobromide None None I-IUPAC
( None None O
7a None None O
) None None O
, None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
dichloroacetamido None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
7b None None O
) None None O
, None None O
and None None O
ethyl None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxyethyl None None I-IUPAC
] None None I-IUPAC
fumarate None None I-IUPAC
( None None O
7c None None O
) None None O
. None None O

By None None O
a None None O
slightly None None O
different None None O
procedure None None O
, None None O
5 None None O
was None None O
converted None None O
in None None O
two None None O
steps None None O
to None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
acetamidopropionic None None I-IUPAC
acid None None I-IUPAC
hydrobromide None None I-IUPAC
( None None O
7d None None O
) None None O
. None None O

The None None O
inhibition None None O
of None None O
ASase None None O
by None None O
7a None None O
- None None O
c None None O
at None None O
1 None None O
mM None None O
was None None O
93 None None O
, None None O
19 None None O
, None None O
and None None O
37% None None O
, None None O
respectively None None O
, None None O
while None None O
7d None None O
was None None O
without None None O
inhibition None None O
at None None O
2 None None O
mM None None O
. None None O

Compounds None None O
7a None None O
- None None O
c None None O
failed None None O
to None None O
increase None None O
the None None O
life None None O
span None None O
of None None O
mice None None O
infected None None O
with None None O
B16 None None O
melanoma None None O
. None None O


4 None None O
- None None O
( None None O
Dimethylamino None None O
) None None O
- None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
arylspiro None None I-IUPAC
[ None None I-IUPAC
cyclohexane None None I-IUPAC
- None None I-IUPAC
1,1 None None I-IUPAC
' None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
isobenzofuran None None I-IUPAC
] None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
prepared None None O
as None None O
analogues None None O
of None None O
previously None None O
reported None None O
3 None None I-IUPAC
- None None I-IUPAC
arylspiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidines None None I-IUPAC
] None None I-IUPAC
. None None O

Metalation None None O
of None None O
benzanilide None None O
with None None O
n None None I-IUPAC
- None None I-IUPAC
butyllithium None None I-IUPAC
, None None O
addition None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
cyclohexanone None None I-IUPAC
, None None O
and None None O
acidification None None O
afforded None None O
a None None O
mixture None None O
of None None O
cis None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
spiro None None I-IUPAC
[ None None I-IUPAC
cyclohexane None None I-IUPAC
- None None I-IUPAC
1,1 None None I-IUPAC
' None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
isobenzofuran None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
( None None O
1a None None O
, None None O
b None None O
) None None O
, None None O
which None None O
were None None O
separated None None O
by None None O
fractional None None O
crystallization None None O
. None None O

Addition None None O
of None None O
aryllithium None None O
or None None O
aryl None None O
Grignard None None O
reagents None None O
to None None O
1a None None O
, None None O
b None None O
and None None O
formic None None O
acid None None O
reduction None None O
afforded None None O
cis None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
arylspiro None None I-IUPAC
[ None None I-IUPAC
cyclohexane None None I-IUPAC
- None None I-IUPAC
1,1 None None I-IUPAC
' None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
isobenzofurans None None I-IUPAC
] None None I-IUPAC
3a None None O
- None None O
f None None O
, None None O
which None None O
were None None O
converted None None O
to None None O
secondary None None O
amine None None O
analogues None None O
5a None None O
- None None O
e None None O
. None None O

Tentative None None O
stereochemical None None O
assignments None None O
are None None O
based None None O
on None None O
chemical None None O
arguments None None O
and None None O
are None None O
supported None None O
by None None O
13C None None O
NMR None None O
chemical None None O
shift None None O
data None None O
. None None O

Marked None None O
inhibition None None O
of None None O
tetrabenazine None None O
- None None O
induced None None O
ptosis None None O
is None None O
a None None O
property None None O
of None None O
most None None O
antidepressants None None O
, None None O
and None None O
significant None None O
antitetrabenazine None None O
activity None None O
is None None O
observed None None O
for None None O
several None None O
of None None O
these None None O
compounds None None O
. None None O

Optimal None None O
antitetrabenazine None None O
activity None None O
is None None O
associated None None O
with None None O
the None None O
cis None None I-PARTIUPAC
- None None I-PARTIUPAC
3' None None I-PARTIUPAC
- None None I-PARTIUPAC
phenyl None None I-PARTIUPAC
series None None I-MODIFIER
, None None O
and None None O
the None None O
cis None None O
secondary None None O
amine None None O
5a None None O
is None None O
approximately None None O
twice None None O
as None None O
potent None None O
as None None O
the None None O
cis None None O
tertiary None None O
amine None None O
3a None None O
. None None O

The None None O
various None None O
compounds None None O
are None None O
relatively None None O
weak None None O
with None None O
respect None None O
to None None O
potentiation None None O
of None None O
L None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxytryptophan None None I-IUPAC
- None None O
induced None None O
seizures None None O
. None None O


Several None None O
series None None O
of None None O
N6 None None O
- None None O
or None None O
8 None None O
- None None O
substituted None None O
derivatives None None O
of None None O
adenosine None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
triphosphate None None I-IUPAC
( None None O
ATP None None O
) None None O
were None None O
synthesized None None O
. None None O

N6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
omega None None I-IUPAC
- None None I-IUPAC
Aminoalkyl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
adenosine None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
monophosphate None None I-IUPAC
( None None O
AMP None None O
) None None O
were None None O
converted None None O
into None None O
their None None O
omega None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
carbobenzyloxy None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
and None None O
these None None O
were None None O
converted None None O
, None None O
via None None O
the None None O
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
their None None O
5' None None I-IUPAC
- None None I-IUPAC
phosphorimidazolidates None None I-IUPAC
, None None O
into None None O
the None None O
corresponding None None O
ATP None None O
derivatives None None O
. None None O

Hydrogenolytic None None O
removal None None O
of None None O
the None None O
carbobenzyloxy None None O
groups None None O
, None None O
followed None None O
by None None O
iodoacetylation None None O
of None None O
the None None O
omega None None O
- None None O
amino None None O
groups None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
iodoacetoxy None None I-IUPAC
) None None I-IUPAC
succinimide None None I-IUPAC
, None None O
gave None None O
N6 None None O
- None None O
R None None O
- None None O
ATP None None O
, None None O
where None None O
R None None O
= None None O
( None None O
CH2 None None O
) None None O
nNHCOCH2I None None O
( None None O
n None None O
= None None O
2 None None O
- None None O
- None None O
8 None None O
) None None O
or None None O
( None None O
CH2 None None O
) None None O
nCON None None O
) None None O
CH3 None None O
) None None O
( None None O
CH2 None None O
) None None O
mN None None O
( None None O
CH3 None None O
) None None O
CO None None O
( None None O
CH2 None None O
) None None O
nNHCOCH2I None None O
( None None O
n None None O
= None None O
m None None O
= None None O
3 None None O
; None None O
n None None O
= None None O
3 None None O
, None None O
m None None O
= None None O
4 None None O
; None None O
n None None O
= None None O
4 None None O
, None None O
m None None O
= None None O
3 None None O
; None None O
n None None O
= None None O
m None None O
= None None O
4 None None O
) None None O
. None None O

Condensation None None O
of None None O
N6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
omega None None I-IUPAC
- None None I-IUPAC
aminoalkyl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
AMP None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxysuccinimide None None I-IUPAC
esters None None I-IUPAC
of None None O
omega None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carbobenzyloxy None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
carboxylic None None I-IUPAC
acids None None I-IUPAC
gave None None O
N6 None None O
- None None O
( None None O
CH2 None None O
) None None O
nNHCO None None O
( None None O
CH2 None None O
) None None O
mNH None None O
- None None O
Cbz None None O
derivatives None None O
of None None O
AMP None None O
which None None O
, None None O
upon None None O
conversion None None O
to None None O
the None None O
corresponding None None O
derivatives None None O
of None None O
ATP None None O
, None None O
followed None None O
by None None O
removal None None O
of None None O
the None None O
carbobenzyloxy None None I-IUPAC
group None None B-MODIFIER
and None None O
iodoacetylation None None O
, None None O
as None None O
described None None O
above None None O
, None None O
gave None None O
N6 None None O
- None None O
( None None O
CH2 None None O
) None None O
nNHCO None None O
( None None O
CH2 None None O
) None None O
mNHCOCH2I None None O
- None None O
ATP None None O
derivatives None None O
( None None O
n None None O
= None None O
3 None None O
, None None O
m None None O
= None None O
5 None None O
or None None O
6 None None O
; None None O
n None None O
= None None O
4 None None O
, None None O
m None None O
= None None O
5 None None O
; None None O
n None None O
= None None O
6 None None O
, None None O
m None None O
= None None O
1 None None O
- None None O
- None None O
6 None None O
) None None O
. None None O

The None None O
same None None O
sequence None None O
of None None O
reactions None None O
starting None None O
with None None O
N6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
omega None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
] None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
N6 None None O
- None None O
CH3 None None O
- None None O
AMP None None O
gave None None O
N6 None None O
- None None O
CH3 None None O
, None None O
N6 None None O
- None None O
( None None O
CH2 None None O
) None None O
nH None None O
( None None O
CH3 None None O
) None None O
CO None None O
( None None O
CH2 None None O
) None None O
mNHCOCH2I None None O
derivatives None None O
of None None O
ATP None None O
( None None O
n None None O
= None None O
4 None None O
, None None O
m None None O
= None None O
3 None None O
, None None O
5 None None O
or None None O
6 None None O
; None None O
n None None O
= None None O
6 None None O
, None None O
m None None O
= None None O
5 None None O
or None None O
6 None None O
) None None O
. None None O

Reaction None None O
of None None O
alpha None None O
, None None O
omega None None O
- None None O
diaminoalkanes None None O
with None None O
8 None None O
- None None O
Br None None O
- None None O
ATP None None O
gave None None O
8 None None O
- None None O
NH None None O
( None None O
CH2 None None O
) None None O
nNH2 None None O
derivatives None None O
of None None O
ATP None None O
, None None O
which None None O
upon None None O
iodoacetylation None None O
gave None None O
8 None None O
- None None O
NH None None O
( None None O
CH2 None None O
) None None O
nNHCOCH2I None None O
derivatives None None O
of None None O
ATP None None O
( None None O
n None None O
= None None O
2 None None O
, None None O
4 None None O
, None None O
6 None None O
, None None O
or None None O
8 None None O
) None None O
. None None O

Substrate None None O
and None None O
inhibitor None None O
properties None None O
indicated None None O
that None None O
the None None O
ATP None None O
derivatives None None O
are None None O
potential None None O
exco None None O
- None None O
ATP None None O
- None None O
site None None O
- None None O
directed None None O
inactivators None None O
of None None O
hexokinases None None O
, None None O
adenylate None None O
kinases None None O
, None None O
and None None O
pyruvate None None O
kinases None None O
. None None O


Several None None O
7 None None I-IUPAC
- None None I-IUPAC
hydroxypyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
( None None O
1-21 None None O
) None None O
, None None O
7 None None I-IUPAC
- None None I-IUPAC
mercaptopyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
( None None O
37-49 None None O
) None None O
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
alkylpyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
( None None O
50-55 None None O
) None None O
and None None O
the None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
alkylpyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
thiones None None I-IUPAC
( None None O
56-60 None None O
) None None O
were None None O
synthesized None None O
and None None O
tested None None O
for None None O
antischistosomal None None O
activity None None O
against None None O
Schistosoma None None O
mansoni None None O
. None None O

Of None None O
the None None O
compounds None None O
examined None None O
, None None O
the None None O
greatest None None O
degree None None O
of None None O
activity None None O
in None None O
vitro None None O
was None None O
found None None O
with None None O
the None None O
7 None None I-IUPAC
- None None I-IUPAC
mercaptopyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
. None None O

In None None O
particular None None O
, None None O
compounds None None O
37 None None O
and None None O
47 None None O
proved None None O
lethal None None O
at None None O
100 None None O
micrograms None None O
/ None None O
mL None None O
after None None O
an None None O
exposure None None O
of None None O
only None None O
1 None None O
h None None O
. None None O

The None None O
7 None None I-IUPAC
- None None I-IUPAC
hydroxypyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
pyrimidines None None I-IUPAC
were None None O
not None None O
as None None O
active None None O
. None None O

None None None O
of None None O
the None None O
compounds None None O
exhibiting None None O
in None None O
vitro None None O
activity None None O
were None None O
active None None O
against None None O
S None None O
. None None O

mansoni None None O
in None None O
vivo None None O
. None None O


The None None O
metabolic None None O
fate None None O
of None None O
tolazamide None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hexahydroazepin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
tolylsulfonylurea None None I-IUPAC
( None None O
1 None None O
) None None O
, None None O
was None None O
studied None None O
in None None O
man None None O
and None None O
in None None O
the None None O
rat None None O
using None None O
tritium None None O
- None None O
labeled None None O
1 None None O
. None None O

The None None O
metabolites None None O
were None None O
isolated None None O
in None None O
crystalline None None O
form None None O
from None None O
urine None None O
for None None O
structure None None O
determination None None O
. None None O

The None None O
crystal None None O
structure None None O
and None None O
final None None O
molecular None None O
structure None None O
of None None O
one None None O
of None None O
these None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyhexahydroazepin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
tolylsulfonylurea None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
were None None O
determined None None O
using None None O
single None None O
- None None O
crystal None None O
X None None O
- None None O
ray None None O
techniques None None O
. None None O

Following None None O
oral None None O
administration None None O
of None None O
tritiated None None O
tolazamide None None O
to None None O
male None None O
humans None None O
, None None O
85% None None O
of None None O
the None None O
radioactivity None None O
was None None O
excreted None None O
in None None O
urine None None O
during None None O
a None None O
5 None None O
- None None O
day None None O
period None None O
. None None O

In None None O
addition None None O
to None None O
being None None O
excreted None None O
in None None O
urine None None O
unchanged None None O
, None None O
tolazamide None None O
was None None O
metabolized None None O
to None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hexahydroazepin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carboxyphenyl None None I-IUPAC
) None None I-IUPAC
sulfonylurea None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
p None None I-IUPAC
- None None I-IUPAC
toluenesulfonamide None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hexahydroazepin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethylphenyl None None I-IUPAC
) None None I-IUPAC
sulfonylurea None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyhexahydroazepin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
tolylsulfonylurea None None I-IUPAC
( None None O
5 None None O
) None None O
and None None O
a None None O
labile None None O
, None None O
unidentified None None O
metabolite None None O
6 None None O
by None None O
man None None O
. None None O

The None None O
relative None None O
amounts None None O
of None None O
these None None O
materials None None O
excreted None None O
in None None O
0-24 None None O
- None None O
h None None O
urine None None O
collections None None O
from None None O
eight None None O
subjects None None O
averaged None None O
7 None None O
, None None O
17 None None O
, None None O
26 None None O
, None None O
10 None None O
, None None O
25 None None O
, None None O
and None None O
15% None None O
for None None O
1-6 None None O
, None None O
respectively None None O
. None None O

In None None O
the None None O
female None None O
rat None None O
, None None O
79% None None O
of None None O
an None None O
orally None None O
administered None None O
dose None None O
of None None O
tritiated None None O
tolazamide None None O
was None None O
excreted None None O
in None None O
urine None None O
during None None O
a None None O
5 None None O
- None None O
day None None O
period None None O
as None None O
1-4 None None O
. None None O

The None None O
relative None None O
amounts None None O
of None None O
these None None O
materials None None O
excreted None None O
during None None O
the None None O
24 None None O
- None None O
h None None O
period None None O
following None None O
administration None None O
of None None O
tolazamide None None O
were None None O
10 None None O
, None None O
5 None None O
, None None O
5 None None O
, None None O
and None None O
80% None None O
for None None O
1-4 None None O
, None None O
respectively None None O
. None None O


Incubation None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
hydroxytryptamine None None I-IUPAC
( None None O
1 None None O
) None None O
with None None O
L None None O
- None None O
cysteine None None O
and None None O
pig None None O
or None None O
bovine None None O
brain None None O
microsomes None None O
and None None O
an None None O
NADPH None None O
- None None O
generating None None O
system None None O
or None None O
with None None O
synaptosomes None None O
results None None O
in None None O
the None None O
rapid None None O
formation None None O
of None None O
the None None O
( None None I-MODIFIER
2R None None I-MODIFIER
, None None I-MODIFIER
4R None None I-MODIFIER
) None None I-MODIFIER
- None None I-MODIFIER
and None None O
( None None I-MODIFIER
2S None None I-MODIFIER
, None None I-MODIFIER
4R None None I-MODIFIER
) None None I-MODIFIER
- None None I-MODIFIER
epimers None None I-MODIFIER
of None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
thiazolidine None None I-IUPAC
. None None O

Incubation None None O
of None None O
1 None None O
and None None O
glutathione None None O
under None None O
the None None O
same None None O
experimental None None O
conditions None None O
yields None None O
the None None O
( None None I-MODIFIER
2R None None I-MODIFIER
, None None I-MODIFIER
4R None None I-MODIFIER
) None None I-MODIFIER
- None None I-MODIFIER
and None None O
( None None I-MODIFIER
2S None None I-MODIFIER
, None None I-MODIFIER
4R None None I-MODIFIER
) None None I-MODIFIER
- None None I-MODIFIER
epimers None None I-MODIFIER
of None None O
alpha None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
carboxymethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
delta None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
thiazolidinepentanoic None None I-IUPAC
acid None None I-IUPAC
. None None O

These None None O
various None None O
thiazolidine None None O
derivatives None None O
are None None O
formed None None O
by None None O
nucleophilic None None O
addition None None O
of None None O
the None None O
thiol None None O
residues None None O
of None None O
cysteine None None O
or None None O
glutathione None None O
to None None O
the None None O
aldehyde None None I-IUPAC
group None None B-MODIFIER
of None None O
5 None None I-IUPAC
- None None I-IUPAC
hydroxyindole None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
acetaldehyde None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
the None None O
primary None None O
product None None O
of None None O
the None None O
monoamine None None O
oxidase None None O
- None None O
mediated None None O
oxidative None None O
deamination None None O
of None None O
1 None None O
. None None O

The None None O
facile None None O
reaction None None O
of None None O
cysteine None None O
and None None O
glutathione None None O
with None None O
2 None None O
might None None O
represent None None O
a None None O
mechanism None None O
designed None None O
to None None O
scavenge None None O
the None None O
biogenic None None O
aldehyde None None O
and None None O
therefore None None O
to None None O
prevent None None O
its None None O
alkylation None None O
of None None O
key None None O
intraneuronal None None O
protein None None O
nucleophiles None None O
. None None O


We None None O
have None None O
found None None O
that None None O
alpha None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
halo None None B-IUPAC
enol None None I-IUPAC
lactones None None I-IUPAC
( None None O
I None None O
and None None O
II None None O
) None None O
are None None O
effective None None O
mechanism None None O
- None None O
based None None O
inactivators None None O
for None None O
chymotrypsin None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
investigated None None O
, None None O
for None None O
comparative None None O
purposes None None O
, None None O
halo None None I-IUPAC
enol None None I-IUPAC
lactones None None I-IUPAC
with None None O
aryl None None O
functions None None O
situated None None O
beta None None O
and None None O
gamma None None O
to None None O
the None None O
lactone None None O
carbonyl None None O
group None None O
. None None O

We None None O
synthesized None None O
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
iodomethylidene None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanone None None I-IUPAC
( None None O
1 None None O
) None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
iodomethylidene None None I-IUPAC
) None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanone None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
iodomethylidene None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyranone None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
iodomethylidene None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyranone None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
using None None O
a None None O
halolactonization None None O
reaction None None O
to None None O
convert None None O
the None None O
appropriate None None O
phenyl None None O
- None None O
substituted None None O
acetylenic None None O
acid None None O
precursor None None O
into None None O
the None None O
corresponding None None O
5 None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
halomethylidene None None I-IUPAC
) None None I-IUPAC
furanone None None I-IUPAC
and None None O
6 None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
halomethylidene None None I-IUPAC
) None None I-IUPAC
pyranone None None I-IUPAC
system None None I-MODIFIER
. None None O

The None None O
4 None None I-IUPAC
- None None I-IUPAC
phenylfuranone None None I-IUPAC
( None None O
1 None None O
and None None O
2 None None O
) None None O
and None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
phenylpyranone None None I-IUPAC
( None None O
4 None None O
) None None O
proved None None O
to None None O
be None None O
only None None O
reversible None None O
, None None O
competitive None None O
inhibitors None None O
. None None O

By None None O
contrast None None O
, None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
phenyltetrahydropyranone None None I-IUPAC
( None None O
3 None None O
) None None O
inactivated None None O
alpha None None O
- None None O
chymotrypsin None None O
in None None O
a None None O
time None None O
- None None O
dependent None None O
manner None None O
. None None O

This None None O
inactivation None None O
was None None O
very None None O
rapid None None O
but None None O
reversible None None O
, None None O
with None None O
regeneration None None O
of None None O
enzyme None None O
activity None None O
being None None O
spontaneous None None O
and None None O
hydrazine None None O
- None None O
accelerated None None O
, None None O
suggestive None None O
of None None O
the None None O
intermediacy None None O
of None None O
a None None O
stable None None O
acyl None None O
enzyme None None O
. None None O

Kinetic None None O
comparison None None O
of None None O
the None None O
iodomethylene None None O
lactone None None O
3 None None O
with None None O
the None None O
corresponding None None O
protio None None O
lactone None None O
25 None None O
indicates None None O
that None None O
the None None O
iodine None None O
accelerates None None O
the None None O
rate None None O
of None None O
chymotrypsin None None O
acylation None None O
but None None O
produces None None O
an None None O
acyl None None O
enzyme None None O
that None None O
is None None O
more None None O
hydrolytically None None O
labile None None O
than None None O
that None None O
formed None None O
from None None O
lactone None None O
25 None None O
. None None O

From None None O
the None None O
results None None O
of None None O
this None None O
study None None O
, None None O
we None None O
conclude None None O
that None None O
a None None O
phenyl None None O
group None None O
situated None None O
at None None O
C None None O
- None None O
3 None None O
( None None O
alpha None None O
to None None O
the None None O
lactone None None O
carbonyl None None O
group None None O
) None None O
in None None O
both None None O
the None None O
5 None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
iodomethylidene None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanone None None I-IUPAC
( None None O
I None None O
) None None O
and None None O
6 None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
iodomethylidene None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyranone None None I-IUPAC
( None None O
II None None O
) None None O
series None None O
is None None O
essential None None O
for None None O
their None None O
activity None None O
as None None O
mechanism None None O
- None None O
based None None O
irreversible None None O
inactivators None None O
of None None O
chymotrypsin None None O
. None None O

The None None O
corresponding None None O
beta None None O
- None None O
aryl None None O
- None None O
substituted None None O
lactones None None O
, None None O
by None None O
contrast None None O
, None None O
are None None O
potent None None O
acylating None None O
agents None None O
that None None O
lead None None O
to None None O
acyl None None O
enzymes None None O
of None None O
high None None O
stability None None O
. None None O


A None None O
series None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
naphthalenylsulfonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
thiazolidinediones None None I-IUPAC
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
antihyperglycemic None None O
activity None None O
in None None O
an None None O
insulin None None O
- None None O
resistant None None O
, None None O
genetically None None O
diabetic None None O
db None None O
/ None None O
db None None O
mouse None None O
model None None O
of None None O
non None None O
- None None O
insulin None None O
- None None O
dependent None None O
diabetes None None O
mellitus None None O
( None None O
NIDDM None None O
) None None O
. None None O

The None None O
sulfones None None O
could None None O
be None None O
synthesized None None O
by None None O
a None None O
novel None None O
, None None O
selective None None O
C None None O
- None None O
5 None None O
sulfonylation None None O
of None None O
dilithio None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
thiazolidinedione None None I-IUPAC
with None None O
appropriate None None O
sulfonyl None None O
chlorides None None O
. None None O

Within None None O
this None None O
series None None O
, None None O
naphthalene None None O
was None None O
found None None O
to None None O
be None None O
superior None None O
to None None O
other None None O
groups None None O
for None None O
eliciting None None O
antihyperglycemic None None O
activity None None O
, None None O
including None None O
the None None O
p None None I-IUPAC
- None None I-IUPAC
alkoxyphenyl None None I-IUPAC
group None None I-MODIFIER
found None None O
in None None O
ciglitazone None None O
, None None O
a None None O
prototypical None None O
agent None None O
for None None O
this None None O
activity None None O
. None None O

Attachment None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
sulfonyl None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
thiazolidinedione None None I-IUPAC
moiety None None I-MODIFIER
to None None O
the None None O
2 None None O
- None None O
naphthalene None None O
position None None O
led None None O
to None None O
optimum None None O
activity None None O
. None None O

Other None None O
linkers None None O
between None None O
the None None O
naphthalene None None O
and None None O
2,4 None None I-IUPAC
- None None I-IUPAC
thiazolidinedione None None I-IUPAC
rings None None I-MODIFIER
, None None O
such None None O
as None None O
thio None None O
, None None O
methylene None None O
, None None O
oxy None None O
, None None O
and None None O
sulfinyl None None O
led None None O
to None None O
decreased None None O
antihyperglycemic None None O
activity None None O
. None None O

The None None O
best None None O
analogue None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthalenylsulfonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
thiazolidinedione None None I-IUPAC
( None None O
AY None None O
- None None O
31,637 None None O
) None None O
was None None O
equipotent None None O
to None None O
ciglitazone None None O
in None None O
two None None O
animal None None O
models None None O
of None None O
NIDDM None None O
. None None O


The None None O
reduction None None O
of None None O
acetylcholinesterase None None O
( None None O
AChE None None O
) None None O
activity None None O
in None None O
the None None O
brain None None O
has None None O
been None None O
measured None None O
in None None O
dementia None None O
disorders None None O
such None None O
as None None O
Alzheimer None None O
's None None O
disease None None O
and None None O
dementia None None O
with None None O
Lewy None None O
bodies None None O
using None None O
( None None O
11 None None O
) None None O
C None None O
- None None O
labeled None None O
acetylcholine None None O
analogues None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
] None None I-IUPAC
methylpiperidin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
acetate None None I-IUPAC
and None None O
propionate None None O
, None None O
and None None O
positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
. None None O

Our None None O
aim None None O
was None None O
to None None O
develop None None O
an None None O
( None None O
18 None None O
) None None O
F None None O
- None None O
labeled None None O
acetylcholine None None O
analogue None None O
useful None None O
for None None O
brain None None O
AChE None None O
mapping None None O
with None None O
PET None None O
, None None O
since None None O
( None None O
18 None None O
) None None O
F None None O
, None None O
with None None O
a None None O
longer None None O
half None None O
- None None O
life None None O
, None None O
has None None O
advantages None None O
over None None O
( None None O
11 None None O
) None None O
C None None O
. None None O

In None None O
a None None O
preliminary None None O
study None None O
, None None O
a None None O
series None None O
of None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
14 None None I-PARTIUPAC
) None None I-PARTIUPAC
C None None I-PARTIUPAC
] None None I-PARTIUPAC
ethylpiperidin None None I-PARTIUPAC
- None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
yl None None I-PARTIUPAC
or None None O
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
ylmethanol None None I-PARTIUPAC
esters None None I-PARTIUPAC
( None None O
acetyl None None O
and None None O
propionyl None None O
esters None None O
) None None O
were None None O
newly None None O
designed None None O
and None None O
evaluated None None O
in None None O
vitro None None O
regarding None None O
the None None O
reactivity None None O
with None None O
and None None O
specificity None None O
to None None O
AChE None None O
using None None O
purified None None O
human None None O
enzymes None None O
, None None O
leading None None O
to None None O
a None None O
novel None None O
( None None O
18 None None O
) None None O
F None None O
- None None O
labeled None None O
acetylcholine None None O
analogue None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
18 None None I-IUPAC
) None None I-IUPAC
F None None I-IUPAC
] None None I-IUPAC
fluoroethylpiperidin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
acetate None None I-IUPAC
. None None O

In None None O
rat None None O
experiments None None O
, None None O
the None None O
( None None O
18 None None O
) None None O
F None None O
- None None O
labeled None None O
candidate None None O
showed None None O
desirable None None O
properties None None O
for None None O
PET None None O
AChE None None O
measurement None None O
: None None O
high None None O
brain None None O
uptake None None O
of None None O
the None None O
authentic None None O
ester None None O
, None None O
high None None O
AChE None None O
specificity None None O
, None None O
a None None O
moderate None None O
hydrolysis None None O
rate None None O
, None None O
and None None O
low None None O
membrane None None O
permeability None None O
( None None O
metabolic None None O
trapping None None O
) None None O
of None None O
the None None O
metabolite None None O
. None None O


A None None O
potent None None O
and None None O
orally None None O
active None None O
NK1 None None O
antagonist None None O
, None None O
trans None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
benzyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1,7 None None I-IUPAC
- None None I-IUPAC
naphthyridine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
1t None None O
) None None O
, None None O
was None None O
shown None None O
to None None O
exist None None O
as None None O
a None None O
mixture None None O
of None None O
separable None None O
and None None O
stable None None O
( None None O
R None None O
) None None O
- None None O
and None None O
( None None O
S None None O
) None None O
- None None O
atropisomers None None O
( None None O
1t None None O
- None None O
A None None O
and None None O
1t None None O
- None None O
B None None O
) None None O
originating None None O
from None None O
the None None O
restricted None None O
rotation None None O
around None None O
the None None O
- None None O
C None None O
( None None O
6 None None O
) None None O
- None None O
C None None O
( None None O
= None None O
O None None O
) None None O
- None None O
bond None None O
; None None O
the None None O
antagonistic None None O
activities None None O
of None None O
1t None None O
- None None O
A None None O
were None None O
ca. None None O
6-13 None None O
- None None O
fold None None O
higher None None O
than None None O
those None None O
of None None O
1t None None O
- None None O
B None None O
. None None O

Analogues None None O
of None None O
1t None None O
( None None O
3 None None O
) None None O
, None None O
which None None O
have None None O
( None None I-PARTIUPAC
S None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
groups None None I-MODIFIER
at None None O
the None None O
benzylic None None O
methylene None None O
portion None None O
of None None O
1t None None O
, None None O
were None None O
prepared None None O
and None None O
separated None None O
into None None O
the None None O
diastereomeric None None O
atropisomers None None O
, None None O
3a None None O
- None None O
A None None O
, None None O
3a None None O
- None None O
B None None O
and None None O
3b None None O
- None None O
A None None O
, None None O
3b None None O
- None None O
B None None O
, None None O
in None None O
enantiomerically None None O
pure None None O
forms None None O
. None None O

Among None None O
the None None O
four None None O
isomers None None O
of None None O
3 None None O
, None None O
the None None O
( None None O
aR None None O
, None None O
S None None O
) None None O
- None None O
enantiomer None None O
( None None O
3a None None O
- None None O
A None None O
) None None O
exhibited None None O
the None None O
most None None O
potent None None O
antagonistic None None O
activities None None O
with None None O
an None None O
IC50 None None O
value None None O
of None None O
0.80 None None O
nM None None O
( None None O
in None None O
vitro None None O
inhibition None None O
of None None O
[ None None O
125I None None O
] None None O
BH None None O
- None None O
SP None None O
binding None None O
in None None O
human None None O
IM None None O
- None None O
9 None None O
cells None None O
) None None O
and None None O
ED50 None None O
values None None O
of None None O
9.3 None None O
micrograms None None O
/ None None O
kg None None O
( None None O
iv None None O
) None None O
and None None O
67.7 None None O
micrograms None None O
/ None None O
kg None None O
( None None O
po None None O
) None None O
( None None O
in None None O
vivo None None O
inhibition None None O
of None None O
capsaicin None None O
- None None O
induced None None O
plasma None None O
extravasation None None O
in None None O
guinea None None O
pig None None O
trachea None None O
) None None O
, None None O
while None None O
the None None O
activity None None O
of None None O
the None None O
( None None O
aS None None O
, None None O
R None None O
) None None O
- None None O
enantiomer None None O
( None None O
3b None None O
- None None O
B None None O
) None None O
was None None O
the None None O
weakest None None O
with None None O
an None None O
IC50 None None O
value None None O
of None None O
620 None None O
nM None None O
. None None O

The None None O
structure None None O
- None None O
activity None None O
relationships None None O
in None None O
this None None O
series None None O
of None None O
antagonists None None O
indicate None None O
that None None O
the None None O
( None None O
R None None O
) None None O
- None None O
configuration None None O
at None None O
the None None O
axial None None O
bond None None O
and None None O
the None None O
stacking None None O
( None None O
or None None O
stacking None None O
- None None O
like None None O
) None None O
conformation None None O
between None None O
the None None O
two None None O
phenyl None None I-IUPAC
rings None None B-MODIFIER
as None None O
shown None None O
in None None O
1t None None O
- None None O
A None None O
and None None O
3a None None O
- None None O
A None None O
are None None O
essential None None O
for None None O
high None None O
- None None O
affinity None None O
binding None None O
and None None O
suggest None None O
that None None O
the None None O
amide None None I-IUPAC
moiety None None B-MODIFIER
functions None None O
as None None O
a None None O
hydrogen None None O
bond None None O
acceptor None None O
in None None O
the None None O
interaction None None O
with None None O
the None None O
receptor None None O
. None None O


Nonclassical None None O
antifolates None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
- None None I-IUPAC
furo None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
3-12 None None O
with None None O
bridge None None O
region None None O
variations None None O
of None None O
C8 None None O
- None None O
S9 None None O
, None None O
C8 None None O
- None None O
N9 None None O
, None None O
and None None O
C8 None None O
- None None O
O9 None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
phenoxyphenyl None None I-IUPAC
, None None O
4 None None I-IUPAC
- None None I-IUPAC
phenoxyphenyl None None I-IUPAC
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
biphenyl None None I-IUPAC
side None None I-MODIFIER
chains None None I-MODIFIER
were None None O
synthesized None None O
as None None O
phenyl None None O
ring None None O
appended None None O
analogues None None O
of None None O
previously None None O
reported None None O
2 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
anilinomethyl None None I-IUPAC
) None None I-IUPAC
furo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
. None None O

The None None O
phenyl None None O
ring None None O
appended None None O
analogues None None O
were None None O
designed None None O
to None None O
specifically None None O
interact None None O
with None None O
Phe69 None None O
of None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
from None None O
Pneumocystis None None O
carinii None None O
( None None O
pc None None O
) None None O
to None None O
afford None None O
selective None None O
inhibitors None None O
of None None O
pcDHFR None None O
. None None O

Additional None None O
substituted None None O
phenyl None None O
side None None O
chains None None O
which None None O
include None None O
2,5 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
, None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
, None None O
3,4,5 None None I-IUPAC
- None None I-IUPAC
trichloro None None I-IUPAC
, None None O
3 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
, None None O
and None None O
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
analogues None None I-MODIFIER
13-17 None None O
were None None O
also None None O
synthesized None None O
. None None O

The None None O
compounds None None O
were None None O
prepared None None O
by None None O
nucleophilic None None O
displacement None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloromethyl None None I-IUPAC
) None None I-IUPAC
furo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
2 None None O
) None None O
with None None O
the None None O
appropriate None None O
thiol None None O
, None None O
amine None None O
, None None O
or None None O
naphthol None None O
. None None O

Compound None None O
2 None None O
was None None O
obtained None None O
from None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hydroxypyrimidine None None I-IUPAC
and None None O
1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
dichloroacetone None None I-IUPAC
. None None O

The None None O
compounds None None O
were None None O
evaluated None None O
as None None O
inhibitors None None O
against None None O
DHFR None None O
from None None O
P None None O
. None None O

carinii None None O
, None None O
Toxoplasma None None O
gondii None None O
, None None O
and None None O
rat None None O
liver None None O
. None None O

Two None None O
analogues None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
naphthylthio None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
furo None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
5 None None O
) None None O
and None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
phenylanilino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
furo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
11 None None O
) None None O
showed None None O
significant None None O
selectivity None None O
and None None O
potency None None O
for None None O
pcDHFR None None O
compared None None O
to None None O
trimethoprim None None O
. None None O

The None None O
X None None O
- None None O
ray None None O
crystal None None O
structure None None O
of None None O
5 None None O
with None None O
pcDHFR None None O
was None None O
also None None O
carried None None O
out None None O
, None None O
which None None O
corroborated None None O
the None None O
design None None O
rationale None None O
and None None O
indicated None None O
a None None O
hydrophobic None None O
interaction None None O
of None None O
the None None O
naphthalene None None O
ring None None O
of None None O
5 None None O
and None None O
Phe69 None None O
of None None O
pcDHFR None None O
which None None O
is None None O
responsible None None O
, None None O
in None None O
part None None O
, None None O
for None None O
the None None O
more None None O
than None None O
18 None None O
- None None O
fold None None O
selectivity None None O
of None None O
5 None None O
for None None O
pcDHFR None None O
as None None O
compared None None O
with None None O
rat None None O
liver None None O
DHFR None None O
. None None O


New None None O
compounds None None O
of None None O
the None None O
nitroimidazole None None O
series None None O
have None None O
been None None O
synthesized None None O
as None None O
radiosensitizers None None O
which None None O
selectively None None O
sensitize None None O
hypoxic None None O
cells None None O
to None None O
the None None O
lethal None None O
effect None None O
of None None O
radiation None None O
. None None O

The None None O
reaction None None O
of None None O
2,4 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dinitroimidazole None None I-IUPAC
( None None O
2 None None O
) None None O
with None None O
chloroethanol None None O
or None None O
hydrochloric None None O
acid None None O
yielded None None O
4 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
chloroimidazole None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
which None None O
upon None None O
reaction None None O
with None None O
ethylene None None O
oxide None None O
yielded None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
chloroimidazole None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ethanol None None I-IUPAC
( None None O
6 None None O
) None None O
. None None O

Reaction None None O
of None None O
2 None None O
with None None O
ethylene None None O
oxide None None O
resulted None None O
in None None O
a None None O
mixture None None O
of None None O
two None None O
compounds None None O
, None None O
the None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dinitroimidazole None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ethanol None None I-IUPAC
( None None O
4 None None O
) None None O
and None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
nitroimidazo None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
oxazole None None I-IUPAC
( None None O
5 None None O
) None None O
. None None O

The None None O
structure None None O
of None None O
the None None O
new None None O
heterocyclic None None O
compound None None O
5 None None O
was None None O
confirmed None None O
by None None O
1H None None O
NMR None None O
, None None O
mass None None O
spectrum None None O
, None None O
and None None O
X None None O
- None None O
ray None None O
crystallography None None O
. None None O

These None None O
agents None None O
were None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
sensitize None None O
hypoxic None None O
Escherichia None None O
coli None None O
cells None None O
to None None O
killing None None O
by None None O
ionizing None None O
radiation None None O
. None None O

Compound None None O
4 None None O
was None None O
found None None O
to None None O
be None None O
the None None O
most None None O
active None None O
agent None None O
of None None O
this None None O
series None None O
of None None O
compounds None None O
. None None O


The None None O
synthesis None None O
of None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
thienylvinyl None None I-IUPAC
) None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiazoles None None I-IUPAC
and None None O
6 None None I-IUPAC
- None None I-IUPAC
thienylimidazo None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiazoles None None I-IUPAC
is None None O
reported None None O
. None None O

These None None O
compounds None None O
were None None O
tested None None O
as None None O
specific None None O
inhibitors None None O
of None None O
the None None O
NADH None None O
: None None O
ubiquinone None None O
( None None O
UBQ None None O
) None None O
reductase None None O
activity None None O
of None None O
NADH None None O
dehydrogenase None None O
in None None O
mitochondrial None None O
membranes None None O
. None None O

The None None O
6 None None I-IUPAC
- None None I-IUPAC
thienylimidazo None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiazoles None None I-IUPAC
were None None O
more None None O
potent None None O
in None None O
mammalian None None O
than None None O
in None None O
nematode None None O
mitochondria None None O
and None None O
had None None O
an None None O
average None None O
titer None None O
of None None O
0.11 None None O
mM None None O
for None None O
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiazole None None I-IUPAC
( None None O
10 None None O
) None None O
. None None O

This None None O
compound None None O
is None None O
noncompetitive None None O
with None None O
the None None O
ubiquinone None None O
substrate None None O
and None None O
interacts None None O
with None None O
a None None O
site None None O
which None None O
is None None O
mutually None None O
exclusive None None O
with None None O
that None None O
of None None O
rotenone None None O
but None None O
nonexclusive None None O
with None None O
that None None O
of None None O
piericidin None None O
and None None O
several None None O
other None None O
inhibitors None None O
of None None O
NADH None None O
dehydrogenase None None O
. None None O

In None None O
the None None O
series None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
thienylvinyl None None I-IUPAC
) None None I-IUPAC
imidazothiazoles None None I-IUPAC
, None None O
the None None O
hydrobromide None None I-MODIFIER
of None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thienylvinyl None None I-IUPAC
) None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiazole None None I-IUPAC
( None None O
E None None O
- None None O
5 None None O
. None None O

HBr None None O
) None None O
was None None O
found None None O
to None None O
be None None O
more None None O
potent None None O
as None None O
an None None O
inhibitor None None O
of None None O
the None None O
NADH None None O
: None None O
UBQ None None O
activity None None O
( None None O
IC50 None None O
= None None O
15-17 None None O
microM None None O
) None None O
than None None O
the None None O
6 None None I-IUPAC
- None None I-IUPAC
thienylimidazoles None None I-IUPAC
such None None O
as None None O
10 None None O
. None None O

The None None O
inhibitory None None O
action None None O
of None None O
E None None O
- None None O
5 None None O
. None None O

HBr None None O
and None None O
its None None O
analogs None None O
is None None O
different None None O
from None None O
that None None O
of None None O
compound None None O
10 None None O
as None None O
indicated None None O
by None None O
the None None O
mutual None None O
exclusivity None None O
with None None O
other None None O
inhibitors None None O
and None None O
the None None O
relative None None O
inhibition None None O
of None None O
the None None O
activity None None O
with None None O
various None None O
electron None None O
acceptors None None O
. None None O


The None None O
transformation None None O
of None None O
milrinone None None O
to None None O
1,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
13a None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
thiazolo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
51 None None O
) None None O
, None None O
and None None O
7 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,8 None None I-IUPAC
- None None I-IUPAC
naphthyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
22 None None O
) None None O
resulted None None O
in None None O
very None None O
potent None None O
cAMP None None O
PDE None None O
III None None O
inhibitors None None O
with None None O
in None None O
vitro None None O
activity None None O
in None None O
the None None O
nanomolar None None O
range None None O
. None None O

1,3 None None I-IUPAC
- None None I-IUPAC
Dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
13 None None O
were None None O
prepared None None O
from None None O
2 None None I-IUPAC
- None None I-IUPAC
aminopyridine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acids None None I-IUPAC
( None None O
7 None None O
, None None O
10 None None O
) None None O
via None None O
Curtius None None O
rearrangement None None O
. None None O

1,8 None None I-IUPAC
- None None I-IUPAC
Naphthyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
22 None None O
and None None O
the None None O
corresponding None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
derivative None None I-MODIFIER
28 None None O
were None None O
prepared None None O
from None None O
5 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
bipyridin None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
amine None None I-IUPAC
( None None O
21 None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
bipyridin None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
24 None None O
) None None O
, None None O
respectively None None O
, None None O
via None None O
Heck None None O
reaction None None O
. None None O

Thiazolo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
35 None None O
were None None O
prepared None None O
from None None O
6 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
bipyridin None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
amines None None I-IUPAC
30 None None O
and None None O
32 None None O
via None None O
a None None O
four None None O
- None None O
step None None O
sequence None None O
. None None O

Treatment None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
bipyridine None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
thiol None None I-IUPAC
( None None O
59 None None O
) None None O
with None None O
ethyl None None I-IUPAC
bromoacetate None None B-IUPAC
and None None O
ethyl None None I-IUPAC
bromodifluoroacetate None None B-IUPAC
gave None None O
pyridothiazinones None None O
60 None None O
and None None O
61 None None O
, None None O
respectively None None O
. None None O


Several None None O
3beta None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
substituted None None I-MODIFIER
phenyl None None B-PARTIUPAC
) None None O
- None None I-PARTIUPAC
2beta None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
isoxazol None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
yl None None I-PARTIUPAC
) None None I-PARTIUPAC
tropanes None None I-PARTIUPAC
( None None O
3a None None O
- None None O
t None None O
) None None O
were None None O
evaluated None None O
for None None O
their None None O
ability None None O
to None None O
inhibit None None O
radioligand None None O
binding None None O
at None None O
the None None O
DAT None None O
, None None O
5 None None O
- None None O
HTT None None O
, None None O
and None None O
NET None None O
as None None O
well None None O
as None None O
in None None O
gross None None O
observation None None O
and None None O
locomotor None None O
activity None None O
in None None O
mice None None O
and None None O
in None None O
rats None None O
trained None None O
to None None O
discriminate None None O
cocaine None None O
. None None O

All None None O
compounds None None O
showed None None O
high None None O
affinity None None O
for None None O
the None None O
DAT None None O
. None None O

The None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
ranged None None O
from None None O
0.5 None None O
to None None O
26 None None O
nM None None O
. None None O

With None None O
the None None O
exception None None O
of None None O
3e None None O
and None None O
3f None None O
, None None O
which None None O
have None None O
no None None O
substituent None None O
on None None O
the None None O
2beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
isoxazole None None I-IUPAC
) None None I-IUPAC
ring None None I-MODIFIER
, None None O
all None None O
compounds None None O
were None None O
selective None None O
for None None O
the None None O
DAT None None O
relative None None O
to None None O
the None None O
5 None None O
- None None O
HTT None None O
and None None O
NET None None O
. None None O

No None None O
compound None None O
showed None None O
death None None O
when None None O
dosed None None O
at None None O
100 None None O
mg None None O
/ None None O
kg None None O
; None None O
however None None O
, None None O
most None None O
compounds None None O
did None None O
show None None O
signs None None O
typical None None O
of None None O
dopamine None None O
activity None None O
. None None O

The None None O
ED None None O
( None None O
50 None None O
) None None O
values None None O
for None None O
2beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
isoxazoles None None I-IUPAC
) None None I-IUPAC
that None None O
caused None None O
locomotor None None O
stimulation None None O
ranged None None O
from None None O
0.2 None None O
to None None O
12.8 None None O
mg None None O
/ None None O
kg None None O
. None None O

Most None None O
compounds None None O
showed None None O
slower None None O
on None None O
- None None O
set None None O
and None None O
longer None None O
duration None None O
of None None O
action None None O
relative None None O
to None None O
cocaine None None O
. None None O

Surprisingly None None O
, None None O
3beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2beta None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
isoxazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
tropane None None I-IUPAC
( None None O
3p None None O
) None None O
and None None O
3beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2beta None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
isoxazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
tropane None None I-IUPAC
( None None O
3r None None O
) None None O
did None None O
not None None O
produce None None O
significant None None O
increases None None O
in None None O
locomotor None None O
activity None None O
. None None O

In None None O
the None None O
cocaine None None O
discrimination None None O
test None None O
, None None O
all None None O
analogues None None O
showed None None O
full None None O
or None None O
at None None O
least None None O
50% None None O
generalization None None O
with None None O
the None None O
exception None None O
of None None O
3p None None O
, None None O
which None None O
did None None O
not None None O
show None None O
generalization None None O
. None None O

Importantly None None O
, None None O
both None None O
the None None O
locomotor None None O
activity None None O
and None None O
the None None O
cocaine None None O
discrimination None None O
ED None None O
( None None O
50 None None O
) None None O
values None None O
were None None O
correlated None None O
with None None O
the None None O
DAT None None O
binding None None O
but None None O
not None None O
5 None None O
- None None O
HTT None None O
and None None O
NET None None O
binding None None O
. None None O

This None None O
provides None None O
further None None O
support None None O
for None None O
the None None O
dopamine None None O
hypothesis None None O
of None None O
cocaine None None O
abuse None None O
. None None O

High None None O
DAT None None O
affinity None None O
and None None O
selectivity None None O
, None None O
increased None None O
locomotor None None O
activity None None O
with None None O
slow None None O
onset None None O
and None None O
long None None O
duration None None O
of None None O
action None None O
, None None O
and None None O
generalization None None O
to None None O
cocaine None None O
shown None None O
by None None O
the None None O
3beta None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
substituted None None I-MODIFIER
phenyl None None B-PARTIUPAC
) None None O
- None None I-PARTIUPAC
2beta None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
isoxazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
tropanes None None I-IUPAC
are None None O
properties None None O
thought None None O
necessary None None O
for None None O
a None None O
pharmacotherapy None None O
for None None O
treating None None O
cocaine None None O
abuse None None O
. None None O


Tomaymycin None None O
is None None O
a None None O
member None None O
of None None O
the None None O
pyrrolo None None I-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
benzodiazepine None None I-IUPAC
antitumor None None O
- None None O
antibiotic None None O
group None None O
that None None O
binds None None O
covalently None None O
to None None O
the None None O
exocyclic None None I-MODIFIER
2 None None B-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
group None None I-MODIFIER
of None None O
guanine None None O
in None None O
DNA None None O
. None None O

Previous None None O
correlation None None O
of None None O
fluorescence None None O
and None None O
NMR None None O
data None None O
suggested None None O
that None None O
the None None O
11R None None O
, None None O
11aS None None O
and None None O
the None None O
11S None None O
, None None O
11aS None None O
diastereomers None None O
of None None O
tomaymycin None None O
could None None O
bind None None O
to None None O
DNA None None O
in None None O
two None None O
orientations None None O
relative None None O
to None None O
the None None O
covalently None None O
modified None None O
guanine None None O
( None None O
Barkley None None O
, None None O
M None None O
. None None O

D None None O
. None None O

; None None O
Cheatham None None O
, None None O
S None None O
. None None O

; None None O
Thurston None None O
, None None O
D None None O
. None None O

E None None O
. None None O

; None None O
Hurley None None O
, None None O
L None None O
. None None O

H None None O
. None None O

Biochemistry None None O
1986 None None O
, None None O
25 None None O
, None None O
3021-3031 None None O
) None None O
. None None O

We None None O
now None None O
report None None O
on None None O
fluorescence None None O
, None None O
one None None O
- None None O
and None None O
two None None O
- None None O
dimensional None None O
proton None None O
NMR None None O
, None None O
and None None O
molecular None None O
modeling None None O
studies None None O
of None None O
the None None O
tomaymycin None None O
- None None O
d None None O
( None None O
ATGCAT None None O
) None None O
2 None None O
adduct None None O
, None None O
which None None O
corroborate None None O
these None None O
earlier None None O
observations None None O
. None None O

Fluorescence None None O
measurements None None O
show None None O
that None None O
there None None O
are None None O
two None None O
species None None O
of None None O
tomaymycin None None O
bound None None O
to None None O
d None None O
( None None O
ATGCAT None None O
) None None O
2 None None O
, None None O
which None None O
are None None O
tentatively None None O
identified None None O
as None None O
the None None O
11R None None O
, None None O
11aS None None O
and None None O
11S None None O
, None None O
11aS None None O
diastereomers None None O
. None None O

Two None None O
distinct None None O
sets None None O
of None None O
signals None None O
for None None O
the None None O
tomaymycin None None O
molecule None None O
are None None O
present None None O
in None None O
the None None O
proton None None O
NMR None None O
spectrum None None O
of None None O
the None None O
tomaymycin None None O
- None None O
d None None O
( None None O
ATGCAT None None O
) None None O
2 None None O
duplex None None O
adduct None None O
. None None O

Two None None O
- None None O
dimensional None None O
correlation None None O
spectroscopy None None O
( None None O
2D None None O
- None None O
COSY None None O
) None None O
studies None None O
also None None O
show None None O
connectivities None None O
for None None O
four None None O
cytosine None None O
H5 None None O
- None None O
H6 None None O
and None None O
eight None None O
thymine None None O
methyl None None O
- None None O
H6 None None O
protons None None O
and None None O
thus None None O
clearly None None O
establish None None O
the None None O
presence None None O
of None None O
two None None O
distinct None None O
species None None O
of None None O
tomaymycin None None O
- None None O
d None None O
( None None O
ATGCAT None None O
) None None O
2 None None O
adducts None None O
in None None O
solution None None O
. None None O

A None None O
single None None O
scalar None None O
11-11 None None O
a None None O
1H None None O
NMR None None O
coupling None None O
in None None O
the None None O
2D None None O
- None None O
COSY None None O
spectrum None None O
is None None O
indicative None None O
of None None O
an None None O
adduct None None O
species None None O
that None None O
has None None O
an None None O
S None None O
configuration None None O
at None None O
the None None O
C None None O
- None None O
11 None None O
position None None O
. None None O

Two None None O
- None None O
dimensional None None O
nuclear None None O
Overhauser None None O
effect None None O
( None None O
NOESY None None O
) None None O
spectra None None O
of None None O
the None None O
tomaymycin None None O
- None None O
d None None O
( None None O
ATGCAT None None O
) None None O
2 None None O
duplex None None O
adduct None None O
show None None O
that None None O
the None None O
adducts None None O
are None None O
relatively None None O
nondistortive None None O
. None None O

In None None O
a None None O
NOESY None None O
experiment None None O
, None None O
cross None None O
- None None O
peaks None None O
were None None O
identified None None O
between None None O
both None None O
the None None O
aromatic None None O
H9 None None O
proton None None O
and None None O
the None None O
ethylidine None None O
methyl None None O
protons None None O
of None None O
tomaymycin None None O
and None None O
two None None O
different None None O
adenine None None O
H2 None None O
protons None None O
of None None O
d None None O
( None None O
ATGCAT None None O
) None None O
2 None None O
. None None O

Molecular None None O
mechanics None None O
calculations None None O
with None None O
AMBER None None O
show None None O
that None None O
the None None O
two None None O
species None None O
with None None O
the None None O
thermodynamically None None O
most None None O
favorable None None O
binding None None O
energies None None O
are None None O
the None None O
11R None None O
, None None O
11aS None None O
and None None O
11S None None O
, None None O
11aS None None O
isomers None None O
with None None O
their None None O
aromatic None None O
rings None None O
to None None O
the None None O
5' None None O
and None None O
3' None None O
sides None None O
of None None O
the None None O
covalently None None O
bound None None O
guanine None None O
, None None O
respectively None None O
. None None O

The None None O
NOEs None None O
observed None None O
between None None O
tomaymycin None None O
protons None None O
and None None O
adenine None None O
H2 None None O
protons None None O
are None None O
in None None O
accord None None O
with None None O
molecular None None O
modeling None None O
studies None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
results None None O
strongly None None O
suggest None None O
that None None O
the None None O
two None None O
forms None None O
of None None O
tomaymycin None None O
bound None None O
to None None O
d None None O
( None None O
ATGCAT None None O
) None None O
2 None None O
are None None O
the None None O
11S None None O
, None None O
11aS None None O
and None None O
11R None None O
, None None O
11aS None None O
species None None O
, None None O
oriented None None O
with None None O
their None None O
aromatic None None O
rings None None O
to None None O
the None None O
3' None None O
and None None O
5' None None O
sides None None O
, None None O
respectively None None O
, None None O
of None None O
the None None O
covalently None None O
modified None None O
guanines None None O
. None None O


A None None O
series None None O
of None None O
28 None None O
4 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
and None None O
4,5 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
2 None None I-IUPAC
- None None I-IUPAC
pyridylimidazoles None None I-IUPAC
was None None O
synthesized None None O
and None None O
evaluated None None O
in None None O
vitro None None O
for None None O
inhibition None None O
of None None O
xanthine None None O
oxidase None None O
. None None O

Included None None O
within None None O
this None None O
group None None O
are None None O
examples None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
pyridylimidazopyridines None None I-IUPAC
and None None O
halo None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2 None None I-IUPAC
- None None I-IUPAC
pyridylbenzimidazoles None None I-IUPAC
. None None O

Five None None O
compounds None None O
exhibited None None O
inhibitory None None O
activity None None O
in None None O
the None None O
same None None O
range None None O
as None None O
the None None O
standards None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxypyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
trifluoromethylimidazole None None I-IUPAC
( None None O
22 None None O
) None None O
. None None O

Two None None O
examples None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dicyanoimidazole None None I-IUPAC
( None None O
16 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitroimidazole None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
were None None O
at None None O
least None None O
an None None O
order None None O
of None None O
magnitude None None O
more None None O
active None None O
than None None O
the None None O
standards None None O
and None None O
therefore None None O
rank None None O
among None None O
the None None O
most None None O
potent None None O
known None None O
inhibitors None None O
of None None O
the None None O
enzyme None None O
. None None O


A None None O
series None None O
of None None O
N2 None None I-PARTIUPAC
( None None O
and None None O
N4 None None I-PARTIUPAC
) None None O
- None None I-PARTIUPAC
aryl None None B-PARTIUPAC
- None None B-PARTIUPAC
N4 None None B-PARTIUPAC
( None None O
and None None O
N2 None None I-PARTIUPAC
) None None O
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
dialkylamino None None I-PARTIUPAC
) None None I-PARTIUPAC
alkyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
2,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
quinazolinediamines None None I-PARTIUPAC
has None None O
been None None O
synthesized None None O
for None None O
antimalarial None None O
evaluation None None O
. None None O

Condensation None None O
of None None O
the None None O
appropriate None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dichloroquinazoline None None I-IUPAC
( None None O
IV None None O
) None None O
with None None O
the None None O
requisite None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dialkylalkylenediamine None None I-IUPAC
afforded None None O
a None None O
series None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
dialkylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
quinazolinamines None None I-IUPAC
( None None O
V None None O
) None None O
which None None O
were None None O
condensed None None O
with None None O
the None None O
appropriate None None O
arylamine None None O
to None None O
provide None None O
the None None O
corresponding None None O
N2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
N4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
dialkylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
quinazolinediamines None None I-IUPAC
( None None O
VI None None O
) None None O
. None None O

Hydrolysis None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dichloroquinazoline None None I-IUPAC
to None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
quinazolinol None None I-IUPAC
was None None O
followed None None O
by None None O
condensation None None O
with None None O
the None None O
appropriate None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dialkylalkylenediamine None None I-IUPAC
to None None O
give None None O
an None None O
array None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
dialkylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
quinazolinols None None I-IUPAC
( None None O
IXa None None O
) None None O
. None None O

Chlorination None None O
with None None O
phosphorus None None O
oxychloride None None O
and None None O
condensation None None O
with None None O
a None None O
requisite None None O
arylamine None None O
provided None None O
the None None O
N2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
dialkylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
quinazolinediamines None None I-IUPAC
( None None O
X None None O
) None None O
. None None O

Antimalarial None None O
activity None None O
was None None O
general None None O
among None None O
the None None O
N2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
N4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
dialkylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
quinazolinediamines None None I-IUPAC
( None None O
VI None None O
) None None O
, None None O
while None None O
the None None O
reverse None None O
isomers None None O
were None None O
of None None O
lower None None O
activity None None O
. None None O

Phototoxic None None O
liability None None O
precluded None None O
clinical None None O
evaluation None None O
of None None O
a None None O
member None None O
of None None O
the None None O
series None None O
. None None O


Careful None None O
analysis None None O
of None None O
the None None O
NMR None None O
structures None None O
of None None O
cyclo None None O
( None None O
4-10 None None O
) None None O
[ None None O
Ac None None O
- None None O
Delta None None O
( None None O
3 None None O
) None None O
Pro None None O
( None None O
1 None None O
) None None O
, None None O
DFpa None None O
( None None O
2 None None O
) None None O
, None None O
DTrp None None O
( None None O
3 None None O
) None None O
, None None O
Asp None None O
( None None O
4 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
Dpr None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
, None None O
dicyclo None None O
( None None O
4-10/5-8 None None O
) None None O
[ None None O
Ac None None O
- None None O
DNal None None O
( None None O
1 None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DTrp None None O
( None None O
3 None None O
) None None O
, None None O
Asp None None O
( None None O
4 None None O
) None None O
, None None O
Glu None None O
( None None O
5 None None O
) None None O
, None None O
DArg None None O
( None None O
6 None None O
) None None O
, None None O
Lys None None O
( None None O
8 None None O
) None None O
, None None O
Dpr None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
, None None O
and None None O
dicyclo None None O
( None None O
4-10/5 None None O
, None None O
5' None None O
- None None O
8 None None O
) None None O
[ None None O
Ac None None O
- None None O
DNal None None O
( None None O
1 None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DPal None None O
( None None O
3 None None O
) None None O
, None None O
Asp None None O
( None None O
4 None None O
) None None O
, None None O
Glu None None O
( None None O
5 None None O
) None None O
( None None O
Gly None None O
) None None O
, None None O
DArg None None O
( None None O
6 None None O
) None None O
, None None O
Dbu None None O
( None None O
8 None None O
) None None O
, None None O
Dpr None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
showed None None O
that None None O
, None None O
in None None O
the None None O
N None None O
- None None O
terminal None None O
tripeptide None None O
, None None O
a None None O
type None None O
II None None O
beta None None O
- None None O
turn None None O
around None None O
residues None None O
1 None None O
and None None O
2 None None O
was None None O
probable None None O
along None None O
with None None O
a None None O
gamma None None O
- None None O
turn None None O
around None None O
DTrp None None O
( None None O
3 None None O
) None None O
/ None None O
DPal None None O
( None None O
3 None None O
) None None O
. None None O

This None None O
suggested None None O
the None None O
possibility None None O
of None None O
constraining None None O
the None None O
N None None O
- None None O
terminus None None O
by None None O
the None None O
introduction None None O
of None None O
a None None O
cyclo None None O
( None None O
1-3 None None O
) None None O
scaffold None None O
. None None O

Optimization None None O
of None None O
ring None None O
size None None O
and None None O
composition None None O
led None None O
to None None O
the None None O
discovery None None O
of None None O
cyclo None None O
( None None O
1-3 None None O
) None None O
[ None None O
Ac None None O
- None None O
DAsp None None O
( None None O
1 None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DLys None None O
( None None O
3 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
DAla None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
5 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
0.82 None None O
nM None None O
) None None O
, None None O
cyclo None None O
( None None O
1,1 None None O
' None None O
- None None O
3 None None O
) None None O
[ None None O
Ac None None O
- None None O
DAsp None None O
( None None O
1 None None O
) None None O
( None None O
Gly None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DOrn None None O
( None None O
3 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
DAla None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
13 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
0.34 None None O
nM None None O
) None None O
, None None O
cyclo None None O
( None None O
1 None None O
, None None O
1' None None O
- None None O
3 None None O
) None None O
[ None None O
Ac None None O
- None None O
DAsp None None O
( None None O
1 None None O
) None None O
( None None O
Gly None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DLys None None O
( None None O
3 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
DA None None O
la None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
20 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
0.14 None None O
nM None None O
) None None O
, None None O
and None None O
cyclo None None O
( None None O
1,1 None None O
' None None O
- None None O
3 None None O
) None None O
[ None None O
Ac None None O
- None None O
DAsp None None O
( None None O
1 None None O
) None None O
( None None O
betaAla None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DOrn None None O
( None None O
3 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
DAla None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
21 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
0.17 None None O
nM None None O
) None None O
, None None O
which None None O
inhibited None None O
ovulation None None O
significantly None None O
at None None O
doses None None O
equal None None O
to None None O
or None None O
lower None None O
than None None O
25 None None O
microgram None None O
/ None None O
rat None None O
. None None O

These None None O
results None None O
were None None O
particularly None None O
unexpected None None O
in None None O
view None None O
of None None O
the None None O
critical None None O
role None None O
( None None O
s None None O
) None None O
originally None None O
ascribed None None O
to None None O
the None None O
side None None O
chains None None O
of None None O
residues None None O
1 None None O
and None None O
3 None None O
. None None O

( None None O
1 None None O
) None None O
Other None None O
closely None None O
related None None O
analogues None None O
, None None O
such None None O
as None None O
those None None O
where None None O
the None None O
[ None None O
DAsp None None O
( None None O
1 None None O
) None None O
( None None O
betaAla None None O
) None None O
, None None O
DOrn None None O
( None None O
3 None None O
) None None O
] None None O
cycle None None O
of None None O
21 None None O
was None None O
changed None None O
to None None O
[ None None O
DOrn None None O
( None None O
1 None None O
) None None O
( None None O
betaAla None None O
) None None O
, None None O
DAsp None None O
( None None O
3 None None O
) None None O
] None None O
of None None O
cyclo None None O
( None None O
1,1 None None O
' None None O
- None None O
3 None None O
) None None O
[ None None O
Ac None None O
- None None O
DOrn None None O
( None None O
1 None None O
) None None O
( None None O
betaAla None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DAsp None None O
( None None O
3 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
DAla None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
22 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
2.2 None None O
nM None None O
) None None O
or None None O
where None None O
the None None O
size None None O
of None None O
the None None O
cycle None None O
was None None O
conserved None None O
and None None O
[ None None O
DAsp None None O
( None None O
1 None None O
) None None O
( None None O
betaAla None None O
) None None O
, None None O
DOrn None None O
( None None O
3 None None O
) None None O
] None None O
was None None O
replaced None None O
by None None O
[ None None O
DGlu None None O
( None None O
1 None None O
) None None O
( None None O
Gly None None O
) None None O
, None None O
DOrn None None O
( None None O
3 None None O
) None None O
] None None O
as None None O
in None None O
cyclo None None O
( None None O
1 None None O
, None None O
1' None None O
- None None O
3 None None O
) None None O
[ None None O
Ac None None O
- None None O
DGlu None None O
( None None O
1 None None O
) None None O
( None None O
Gly None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DOrn None None O
( None None O
3 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
DA None None O
la None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
23 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
4.2 None None O
nM None None O
) None None O
, None None O
were None None O
approximately None None O
100 None None O
and None None O
25 None None O
times None None O
less None None O
potent None None O
in None None O
vivo None None O
, None None O
respectively None None O
. None None O

Analogues None None O
with None None O
ring None None O
sizes None None O
of None None O
18 None None O
 None None O
 None None O
cyclo None None O
( None None O
1 None None O
, None None O
1' None None O
- None None O
3 None None O
) None None O
[ None None O
Ac None None O
- None None O
DGlu None None O
( None None O
1 None None O
) None None O
( None None O
Gly None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DLys None None O
( None None O
3 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
DA None None O
la None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
24 None None O
) None None O
 None None O
 None None O
and None None O
19 None None O
 None None O
 None None O
cyclo None None O
( None None O
1,1 None None O
' None None O
- None None O
3 None None O
) None None O
[ None None O
Ac None None O
- None None O
DGlu None None O
( None None O
1 None None O
) None None O
( None None O
betaAla None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DLys None None O
( None None O
3 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
DAla None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
25 None None O
) None None O
 None None O
 None None O
atoms None None O
were None None O
also None None O
less None None O
potent None None O
than None None O
21 None None O
with None None O
slightly None None O
higher None None O
K None None O
( None None O
i None None O
) None None O
values None None O
( None None O
1.5 None None O
and None None O
2.2 None None O
nM None None O
, None None O
respectively None None O
) None None O
. None None O

These None None O
results None None O
suggested None None O
that None None O
the None None O
N None None O
- None None O
terminal None None O
tripeptide None None O
was None None O
likely None None O
to None None O
assume None None O
a None None O
folded None None O
conformation None None O
favoring None None O
the None None O
close None None O
proximity None None O
of None None O
the None None O
side None None O
chains None None O
of None None O
residues None None O
1 None None O
and None None O
3 None None O
. None None O

The None None O
dicyclic None None O
analogue None None O
dicyclo None None O
( None None O
1-3/4-10 None None O
) None None O
[ None None O
Ac None None O
- None None O
DAsp None None O
( None None O
1 None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DLys None None O
( None None O
3 None None O
) None None O
, None None O
Asp None None O
( None None O
4 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
Dpr None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
26 None None O
) None None O
was None None O
fully None None O
active None None O
at None None O
500 None None O
microgram None None O
, None None O
with None None O
a None None O
K None None O
( None None O
i None None O
) None None O
value None None O
of None None O
1 None None O
nM None None O
. None None O

The None None O
in None None O
vivo None None O
potency None None O
of None None O
26 None None O
was None None O
at None None O
least None None O
10 None None O
- None None O
fold None None O
less None None O
than None None O
that None None O
of None None O
monocyclic None None O
cyclo None None O
( None None O
1-3 None None O
) None None O
[ None None O
Ac None None O
- None None O
DAsp None None O
( None None O
1 None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DLys None None O
( None None O
3 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
DAla None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
5 None None O
) None None O
; None None O
this None None O
suggested None None O
the None None O
existence None None O
of None None O
unfavorable None None O
interactions None None O
between None None O
the None None O
now None None O
optimized None None O
and None None O
constrained None None O
( None None O
1-3 None None O
) None None O
and None None O
( None None O
4-10 None None O
) None None O
cyclic None None O
moieties None None O
that None None O
must None None O
interact None None O
as None None O
originally None None O
hypothesized None None O
. None None O

Tricyclo None None O
( None None O
1-3/4-10/5-8 None None O
) None None O
[ None None O
Ac None None O
- None None O
DGlu None None O
( None None O
1 None None O
) None None O
, None None O
DCpa None None O
( None None O
2 None None O
) None None O
, None None O
DLys None None O
( None None O
3 None None O
) None None O
, None None O
Asp None None O
( None None O
4 None None O
) None None O
, None None O
Glu None None O
( None None O
5 None None O
) None None O
, None None O
DNal None None O
( None None O
6 None None O
) None None O
, None None O
Lys None None O
( None None O
8 None None O
) None None O
, None None O
Dpr None None O
( None None O
10 None None O
) None None O
] None None O
GnRH None None O
( None None O
27 None None O
) None None O
was None None O
inactive None None O
at None None O
500 None None O
microgram None None O
/ None None O
rat None None O
with None None O
a None None O
corresponding None None O
low None None O
affinity None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
4.6 None None O
nM None None O
) None None O
when None None O
compared None None O
to None None O
those None None O
of None None O
the None None O
most None None O
potent None None O
analogues None None O
( None None O
K None None O
( None None O
i None None O
) None None O
& None None O
lt None None O
; None None O
0.5 None None O
nM None None O
) None None O
. None None O


Molecular None None O
interactions None None O
between None None O
RGD None None O
peptides None None O
and None None O
integrins None None O
are None None O
known None None O
to None None O
mediate None None O
many None None O
biological None None O
and None None O
pathological None None O
processes None None O
. None None O

This None None O
has None None O
led None None O
to None None O
an None None O
increased None None O
interest None None O
in None None O
the None None O
development None None O
of None None O
RGD None None O
compounds None None O
with None None O
high None None O
affinity None None O
and None None O
improved None None O
selectivity None None O
for None None O
integrin None None O
receptors None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
synthesized None None O
and None None O
evaluated None None O
a None None O
series None None O
of None None O
multimeric None None O
RGD None None O
compounds None None O
constructed None None O
on None None O
a None None O
dicarboxylic None None O
acid None None O
- None None O
containing None None O
near None None O
- None None O
infrared None None O
( None None O
NIR None None O
) None None O
fluorescent None None O
dye None None O
( None None O
cypate None None O
) None None O
for None None O
tumor None None O
targeting None None O
. None None O

An None None O
array None None O
of None None O
NIR None None O
fluorescent None None O
RGD None None O
compounds None None O
was None None O
prepared None None O
efficiently None None O
, None None O
including None None O
one None None O
RGD None None O
monomer None None O
( None None O
cypate None None O
- None None O
( None None O
RGD None None O
) None None O
( None None O
2 None None O
) None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
) None None O
, None None O
two None None O
RGD None None O
dimers None None O
( None None O
cypate None None O
- None None O
( None None O
RGD None None O
) None None O
( None None O
2 None None O
) None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
and None None O
cypate None None O
- None None O
( None None O
RGD None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
2 None None O
) None None O
) None None O
, None None O
one None None O
trimer None None O
( None None O
cypate None None O
- None None O
( None None O
RGD None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
) None None O
, None None O
two None None O
tetramers None None O
( None None O
cypate None None O
- None None O
( None None O
RGD None None O
) None None O
( None None O
4 None None O
) None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
and None None O
cypate None None O
- None None O
[ None None O
( None None O
RGD None None O
) None None O
( None None O
2 None None O
) None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
] None None O
( None None O
2 None None O
) None None O
) None None O
, None None O
one None None O
hexamer None None O
( None None O
cypate None None O
- None None O
[ None None O
( None None O
RGD None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
] None None O
( None None O
2 None None O
) None None O
) None None O
, None None O
and None None O
one None None O
octamer None None O
( None None O
cypate None None O
- None None O
[ None None O
( None None O
RGD None None O
) None None O
( None None O
4 None None O
) None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
] None None O
( None None O
2 None None O
) None None O
) None None O
. None None O

The None None O
binding None None O
affinity None None O
of None None O
the None None O
multimeric None None O
RGD None None O
compounds None None O
for None None O
alpha None None O
( None None O
v None None O
) None None O
beta None None O
( None None O
3 None None O
) None None O
integrin None None O
receptor None None O
( None None O
ABIR None None O
) None None O
showed None None O
a None None O
remarkable None None O
increase None None O
relative None None O
to None None O
the None None O
monomer None None O
cypate None None O
- None None O
RGD None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
. None None O

Generally None None O
, None None O
the None None O
divalent None None O
linear None None O
arrays None None O
of None None O
the None None O
multimeric None None O
RGD None None O
units None None O
bound None None O
the None None O
ABIR None None O
with None None O
slightly None None O
higher None None O
affinity None None O
than None None O
their None None O
monovalent None None O
analogues None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
receptor None None O
binding None None O
affinity None None O
was None None O
not None None O
only None None O
dependent None None O
on None None O
the None None O
number None None O
of None None O
RGD None None O
moieties None None O
but None None O
also None None O
on None None O
the None None O
spatial None None O
alignments None None O
of None None O
the None None O
pendant None None O
peptides None None O
. None None O

Internalization None None O
of None None O
the None None O
compounds None None O
by None None O
ABIR None None O
- None None O
positive None None O
tumor None None O
cells None None O
( None None O
A549 None None O
) None None O
was None None O
monitored None None O
by None None O
NIR None None O
fluorescence None None O
microscopy None None O
. None None O

The None None O
data None None O
showed None None O
that None None O
endocytosis None None O
of None None O
the None None O
octameric None None O
RGD None None O
derivative None None O
was None None O
significantly None None O
higher None None O
by None None O
comparison None None O
to None None O
other None None O
compounds None None O
in None None O
this None None O
study None None O
. None None O

In None None O
vivo None None O
noninvasive None None O
optical None None O
imaging None None O
and None None O
biodistribution None None O
data None None O
showed None None O
that None None O
the None None O
compounds None None O
were None None O
retained None None O
in None None O
A549 None None O
tumor None None O
tissue None None O
. None None O

These None None O
results None None O
clearly None None O
demonstrated None None O
that None None O
an None None O
array None None O
of None None O
simple None None O
RGD None None O
tripeptides None None O
on None None O
a None None O
NIR None None O
fluorescent None None O
dye None None O
core None None O
can None None O
be None None O
recognized None None O
by None None O
ABIR None None O
. None None O

Optimization None None O
of None None O
the None None O
spatial None None O
alignment None None O
of None None O
the None None O
RGD None None O
moieties None None O
through None None O
careful None None O
molecular None None O
design None None O
and None None O
library None None O
construction None None O
could None None O
induce None None O
multivalent None None O
ligand None None O
- None None O
receptor None None O
interactions None None O
useful None None O
for None None O
in None None O
vivo None None O
tumor None None O
imaging None None O
and None None O
tumor None None O
- None None O
targeted None None O
therapy None None O
. None None O


Syntheses None None O
of None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxyapomorphine None None I-IUPAC
( None None O
R None None O
- None None O
8 None None O
) None None O
, None None O
its None None O
antipode None None O
S None None O
- None None O
8 None None O
, None None O
and None None O
its None None O
( None None I-PARTIUPAC
R None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
- None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
n None None I-PARTIUPAC
- None None I-PARTIUPAC
propyl None None I-PARTIUPAC
R None None O
- None None O
9 None None O
derivatives None None I-MODIFIER
are None None O
described None None O
. None None O

The None None O
dopaminergic None None O
receptor None None O
affinities None None O
of None None O
these None None O
compounds None None O
and None None O
their None None O
2 None None I-MODIFIER
- None None I-MODIFIER
unsubstituted None None I-MODIFIER
counterparts None None I-MODIFIER
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
apomorphine None None I-IUPAC
( None None O
R None None O
( None None O
- None None O
) None None O
- None None O
APO None None O
, None None O
R None None O
- None None O
1 None None O
) None None O
, None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
apomorphine None None I-IUPAC
( None None O
S None None O
( None None O
+ None None O
) None None O
- None None O
APO None None O
, None None O
S None None O
- None None O
1 None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylnorapomorphine None None I-IUPAC
( None None O
R None None O
( None None O
- None None O
) None None O
- None None O
NPA None None O
, None None O
R None None O
- None None O
2 None None O
) None None O
, None None O
as None None O
well None None O
as None None O
those None None O
of None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroapomorphine None None I-IUPAC
( None None O
R None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
- None None O
Cl None None O
- None None O
APO None None O
, None None O
R None None O
- None None O
6 None None O
) None None O
, None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromoapomorphine None None I-IUPAC
( None None O
R None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
- None None O
Br None None O
- None None O
APO None None O
, None None O
R None None O
- None None O
6 None None O
) None None O
, None None O
were None None O
determined None None O
with None None O
tissue None None O
membrane None None O
preparations None None O
of None None O
corpus None None O
striatum None None O
from None None O
rat None None O
brain None None O
. None None O

Contribution None None O
of None None O
both None None O
an None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
n None None I-PARTIUPAC
- None None I-PARTIUPAC
propyl None None I-PARTIUPAC
and None None O
a None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxy None None I-PARTIUPAC
in None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylnorapomorphine None None I-IUPAC
( None None O
R None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
- None None O
OH None None O
- None None O
NPA None None O
, None None O
R None None O
- None None O
7 None None O
) None None O
or None None O
a None None O
methoxy None None O
group None None O
in None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylnorapomorphine None None I-IUPAC
( None None O
R None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
- None None O
OCH3 None None O
- None None O
NPA None None O
, None None O
R None None O
- None None O
9 None None O
) None None O
produced None None O
the None None O
highest None None O
D2 None None O
affinity None None O
( None None O
0.053 None None O
and None None O
0.17 None None O
nM None None O
) None None O
and None None O
D2 None None O
over None None O
D1 None None O
selectivity None None O
( None None O
17,300 None None O
and None None O
10,500 None None O
times None None O
) None None O
of None None O
the None None O
compounds None None O
evaluated None None O
. None None O

The None None O
structure None None O
- None None O
affinity None None O
relationships None None O
of None None O
these None None O
2 None None O
- None None O
substituted None None O
aporphines None None O
suggest None None O
that None None O
secondary None None O
binding None None O
sites None None O
of None None O
D2 None None O
receptors None None O
interact None None O
with None None O
2 None None O
- None None O
substituents None None O
on None None O
the None None O
A None None O
ring None None O
of None None O
aporphines None None O
through None None O
H None None O
- None None O
bonding None None O
. None None O


On None None O
the None None O
basis None None O
of None None O
our None None O
previous None None O
observation None None O
that None None O
N1 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
substituted None None I-MODIFIER
chlorpropamide None None B-IUPAC
derivatives None None B-MODIFIER
when None None O
administered None None O
to None None O
rats None None O
nonenzymatically None None O
eliminated None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
isocyanate None None I-IUPAC
, None None O
a None None O
known None None O
inhibitor None None O
of None None O
aldehyde None None O
dehydrogenase None None O
( None None O
AlDH None None O
) None None O
, None None O
we None None O
have None None O
synthesized None None O
other None None O
latentiated None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
isocyanates None None I-IUPAC
as None None O
in None None O
vivo None None O
inhibitors None None O
of None None O
AlDH None None O
. None None O

N1 None None I-IUPAC
- None None I-IUPAC
Allylchlorpropamide None None I-IUPAC
3 None None O
was None None O
, None None O
as None None O
expected None None O
, None None O
a None None O
potent None None O
inhibitor None None O
of None None O
hepatic None None O
AlDH None None O
in None None O
rats None None O
, None None O
as None None O
indicated None None O
by None None O
the None None O
4 None None O
- None None O
fold None None O
increase None None O
in None None O
the None None O
levels None None O
of None None O
ethanol None None O
- None None O
derived None None O
blood None None O
acetaldehyde None None O
relative None None O
to None None O
that None None O
elicited None None O
by None None O
chlorpropamide None None O
itself None None O
. None None O

Closely None None O
following None None O
in None None O
activity None None O
in None None O
decreasing None None O
order None None O
were None None O
N3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylcarbamoyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylcarbamoyl None None I-IUPAC
) None None I-IUPAC
saccharin None None I-IUPAC
( None None O
6 None None O
) None None O
, None None O
and None None O
the None None O
S None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylcarbamoyl None None I-IUPAC
) None None I-IUPAC
derivative None None I-MODIFIER
( None None O
9 None None O
) None None O
of None None O
benzyl None None I-IUPAC
mercaptan None None I-IUPAC
. None None O

However None None O
, None None O
two None None O
hydantoin None None O
derivatives None None O
, None None O
5 None None O
and None None O
8 None None O
, None None O
were None None O
totally None None O
inactive None None O
in None None O
inhibiting None None O
AlDH None None O
in None None O
vivo None None O
. None None O

A None None O
prodrug None None O
of None None O
N1 None None I-IUPAC
- None None I-IUPAC
ethylchlorpropamide None None I-IUPAC
, None None O
viz None None O
. None None O

, None None O
its None None O
N3 None None I-IUPAC
- None None I-IUPAC
trifluoroacetyl None None I-IUPAC
derivative None None I-MODIFIER
( None None O
4b None None O
) None None O
, None None O
was None None O
a None None O
good None None O
in None None O
vivo None None O
inhibitor None None O
of None None O
AlDH None None O
, None None O
mimicking None None O
the None None O
activity None None O
of None None O
the None None O
parent None None O
N1 None None I-IUPAC
- None None I-IUPAC
ethylchlorpropamide None None I-IUPAC
. None None O

These None None O
results None None O
suggest None None O
that None None O
latent None None O
alkyl None None I-IUPAC
isocyanates None None I-IUPAC
are None None O
inhibitors None None O
of None None O
AlDH None None O
, None None O
giving None None O
further None None O
support None None O
to None None O
the None None O
hypothesis None None O
that None None O
the None None O
inhibition None None O
of None None O
AlDH None None O
in None None O
vivo None None O
by None None O
the None None O
hypoglycemic None None O
agent None None O
chlorpropamide None None O
may None None O
be None None O
due None None O
to None None O
the None None O
release None None O
of None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
isocyanate None None I-IUPAC
following None None O
metabolic None None O
bioactivation None None O
. None None O


A None None O
series None None O
of None None O
polyamines None None O
based None None O
on None None O
the None None O
high None None O
affinity None None O
sigma None None O
receptor None None O
ligand None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
ethylamine None None I-IUPAC
( None None O
3 None None O
) None None O
were None None O
developed None None O
and None None O
evaluated None None O
for None None O
their None None O
binding None None O
characteristics None None O
at None None O
sigma None None O
- None None O
1 None None O
and None None O
sigma None None O
- None None O
2 None None O
receptor None None O
subtypes None None O
. None None O

The None None O
data None None O
indicated None None O
that None None O
a None None O
considerable None None O
degree None None O
of None None O
structural None None O
variation None None O
is None None O
possible None None O
while None None O
still None None O
retaining None None O
nanomolar None None O
affinity None None O
at None None O
sigma None None O
receptors None None O
. None None O

As None None O
the None None O
structure None None O
of None None O
the None None O
polyamines None None O
was None None O
varied None None O
, None None O
their None None O
binding None None O
at None None O
sigma None None O
- None None O
1 None None O
and None None O
sigma None None O
- None None O
2 None None O
subtypes None None O
showed None None O
quite None None O
different None None O
and None None O
in None None O
some None None O
cases None None O
opposite None None O
trends None None O
, None None O
supporting None None O
the None None O
belief None None O
that None None O
these None None O
are None None O
pharmacologically None None O
distinct None None O
entities None None O
. None None O

Polyamines None None O
containing None None O
two None None O
nitrogen None None O
atoms None None O
showed None None O
optimal None None O
binding None None O
at None None O
both None None O
sigma None None O
- None None O
1 None None O
and None None O
sigma None None O
- None None O
2 None None O
receptor None None O
subtypes None None O
. None None O

Although None None O
additional None None O
nitrogen None None O
atoms None None O
resulted None None O
in None None O
decreased None None O
affinity None None O
at None None O
sigma None None O
- None None O
1 None None O
and None None O
sigma None None O
- None None O
2 None None O
subtypes None None O
, None None O
an None None O
increase None None O
in None None O
selectivity None None O
for None None O
sigma None None O
- None None O
2 None None O
subtypes None None O
was None None O
evident None None O
; None None O
the None None O
parent None None O
3 None None O
showed None None O
greater None None O
selectivity None None O
for None None O
sigma None None O
- None None O
1 None None O
subtypes None None O
. None None O

Internitrogen None None O
spacings None None O
had None None O
a None None O
large None None O
effect None None O
on None None O
binding None None O
affinity None None O
and None None O
subtype None None O
selectivity None None O
. None None O

For None None O
example None None O
, None None O
the None None O
difference None None O
between None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorobenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
dimethylethylenediamine None None I-IUPAC
( None None O
8 None None O
) None None O
[ None None O
K None None O
( None None O
i None None O
) None None O
= None None O
29.9 None None O
nM None None O
at None None O
sigma None None O
- None None O
1 None None O
receptor None None O
and None None O
18.3 None None O
nM None None O
at None None O
sigma None None O
- None None O
2 None None O
receptor None None O
] None None O
to None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorobenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
dimethylethylenediamine None None I-IUPAC
( None None O
10 None None O
) None None O
[ None None O
K None None O
( None None O
i None None O
) None None O
= None None O
1.49 None None O
nM None None O
at None None O
sigma None None O
- None None O
1 None None O
receptor None None O
and None None O
12.1 None None O
nM None None O
at None None O
sigma None None O
- None None O
2 None None O
receptor None None O
] None None O
illustrates None None O
the None None O
importance None None O
of None None O
internitrogen None None O
spacing None None O
. None None O

Triamines None None O
11 None None O
and None None O
13 None None O
[ None None O
Ki None None O
( None None O
sigma None None O
- None None O
2 None None O
) None None O
/ None None O
K None None O
( None None O
i None None O
) None None O
( None None O
sigma None None O
- None None O
1 None None O
) None None O
= None None O
0.19 None None O
and None None O
0.10 None None O
, None None O
respectively None None O
] None None O
containing None None O
the None None O
N None None O
- None None O
N None None O
- None None O
N None None O
- None None O
Ar None None O
spacings None None O
3-3-2 None None O
and None None O
4-4-2 None None O
, None None O
proved None None O
to None None O
be None None O
the None None O
most None None O
sigma None None O
- None None O
2 None None O
subtype None None O
selective None None O
of None None O
the None None O
15 None None O
polyamines None None O
examined None None O
in None None O
this None None O
study None None O
. None None O

The None None O
N None None O
- None None O
N None None O
- None None O
N None None O
spacings None None O
appear None None O
to None None O
be None None O
an None None O
important None None O
factor None None O
in None None O
their None None O
sigma None None O
- None None O
2 None None O
subtype None None O
selectivity None None O
. None None O

These None None O
compounds None None O
will None None O
serve None None O
as None None O
templates None None O
in None None O
the None None O
design None None O
of None None O
still None None O
further None None O
sigma None None O
- None None O
2 None None O
subtype None None O
selective None None O
ligands None None O
. None None O

The None None O
pyrrolidine None None O
ring None None O
( None None O
present None None O
in None None O
most None None O
of None None O
the None None O
polyamines None None O
tested None None O
in None None O
this None None O
series None None O
) None None O
proved None None O
to None None O
be None None O
an None None O
important None None O
recognition None None O
site None None O
for None None O
sigma None None O
receptor None None O
binding None None O
activity None None O
. None None O

Furthermore None None O
, None None O
alkyl None None O
substitution None None O
also None None O
appears None None O
to None None O
be None None O
important None None O
since None None O
the None None O
stripped None None O
down None None O
polyamines None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
ethylenediamine None None I-IUPAC
( None None O
15 None None O
) None None O
and None None O
N1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
diethylenetriamine None None I-IUPAC
( None None O
16 None None O
) None None O
exhibited None None O
relatively None None O
low None None O
binding None None O
affinity None None O
. None None O


Substituted None None O
indole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxamides None None I-IUPAC
and None None O
indole None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxamides None None I-IUPAC
have None None O
been None None O
found None None O
to None None O
be None None O
potent None None O
and None None O
selective None None O
antagonists None None O
of None None O
the None None O
peptidoleukotrienes None None O
. None None O

Initial None None O
derivatives None None O
of None None O
these None None O
series None None O
( None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
cyclopentylmethyl None None I-IUPAC
) None None I-IUPAC
carbamoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methylindol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
sulfonyl None None I-IUPAC
] None None I-IUPAC
benzamide None None I-IUPAC
( None None O
5a None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
cyclopentylmethyl None None I-IUPAC
) None None I-IUPAC
carbamoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylindol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
sulfonyl None None I-IUPAC
] None None I-IUPAC
benzamide None None I-IUPAC
( None None O
6a None None O
) None None O
, None None O
respectively None None O
) None None O
, None None O
when None None O
compared None None O
to None None O
the None None O
corresponding None None O
indole None None O
amides None None O
( None None O
e.g. None None O
28 None None O
and None None O
29 None None O
) None None O
, None None O
were None None O
found None None O
to None None O
be None None O
approximately None None O
10 None None O
- None None O
fold None None O
less None None O
potent None None O
in None None O
vitro None None O
and None None O
substantially None None O
less None None O
active None None O
when None None O
administered None None O
orally None None O
to None None O
guinea None None O
pigs None None O
. None None O

Efforts None None O
to None None O
improve None None O
the None None O
potency None None O
of None None O
the None None O
title None None O
series None None O
by None None O
variation None None O
of None None O
the None None O
amide None None O
, None None O
indole None None O
, None None O
or None None O
sulfonamide None None O
substituents None None O
led None None O
to None None O
compounds None None O
of None None O
comparable None None O
in None None O
vitro None None O
potency None None O
to None None O
ICI None None O
204,219 None None O
, None None O
but None None O
of None None O
somewhat None None O
lower None None O
oral None None O
activity None None O
. None None O

A None None O
trend None None O
which None None O
suggested None None O
that None None O
more None None O
lipophilic None None O
transposed None None O
amides None None O
were None None O
needed None None O
to None None O
increase None None O
oral None None O
activity None None O
was None None O
exploited None None O
with None None O
some None None O
success None None O
and None None O
has None None O
led None None O
to None None O
the None None O
discovery None None O
of None None O
5q None None O
( None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ethylbutyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
carbamoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ethylindol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
sulfonyl None None I-IUPAC
] None None I-IUPAC
benzamide None None I-IUPAC
) None None O
, None None O
a None None O
transposed None None O
amide None None O
with None None O
subnanomolar None None O
affinity None None O
for None None O
the None None O
leukotriene None None O
receptor None None O
and None None O
an None None O
oral None None O
ED50 None None O
of None None O
5 None None O
mg None None O
/ None None O
kg None None O
in None None O
a None None O
model None None O
of None None O
asthma None None O
in None None O
guinea None None O
pigs None None O
. None None O

In None None O
this None None O
model None None O
, None None O
ICI None None O
204,219 None None O
was None None O
active None None O
at None None O
0.4 None None O
mg None None O
/ None None O
kg None None O
. None None O

The None None O
absolute None None O
bioavailability None None O
of None None O
5q None None O
has None None O
been None None O
found None None O
to None None O
be None None O
28% None None O
in None None O
the None None O
rat None None O
, None None O
as None None O
compared None None O
to None None O
68% None None O
for None None O
ICI None None O
204,219 None None O
, None None O
with None None O
significant None None O
levels None None O
of None None O
5q None None O
observed None None O
in None None O
the None None O
blood None None O
of None None O
rats None None O
up None None O
to None None O
24 None None O
h None None O
postdose None None O
. None None O


Variable None None O
- None None O
temperature None None O
proton None None O
nuclear None None O
magnetic None None O
resonance None None O
studies None None O
have None None O
shown None None O
that None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propylidene None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylpiperazino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
dibenzo None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
cycloheptene None None I-IUPAC
, None None O
a None None O
5,11 None None I-IUPAC
- None None I-IUPAC
dicarbo None None I-IUPAC
analogue None None I-MODIFIER
of None None O
the None None O
atypical None None O
neuroleptic None None O
agent None None O
clozapine None None I-IUPAC
[ None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylpiperazino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
dibenzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
, None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
diazepine None None I-IUPAC
] None None I-IUPAC
, None None O
exists None None O
as None None O
thermally None None O
stable None None O
configurational None None O
isomers None None O
. None None O

The None None O
presence None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
propylidene None None I-IUPAC
group None None I-MODIFIER
at None None O
C None None O
- None None O
5 None None O
on None None O
the None None O
5H None None I-IUPAC
- None None I-IUPAC
dibenzo None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
cycloheptene None None I-IUPAC
moiety None None I-MODIFIER
did None None O
not None None O
interfere None None O
greatly None None O
, None None O
as None None O
compared None None O
to None None O
clozapine None None O
, None None O
with None None O
the None None O
in None None O
vitro None None O
affinity None None O
of None None O
this None None O
5,11 None None I-IUPAC
- None None I-IUPAC
dicarbo None None I-IUPAC
analogue None None I-MODIFIER
of None None O
clozapine None None O
for None None O
muscarinic None None O
and None None O
dopamine None None O
D None None O
- None None O
1 None None O
and None None O
D None None O
- None None O
2 None None O
binding None None O
sites None None O
in None None O
rat None None O
brain None None O
. None None O

Since None None O
the None None O
presence None None O
and None None O
position None None O
of None None O
a None None O
chloro None None O
substituent None None O
on None None O
the None None O
5H None None I-IUPAC
- None None I-IUPAC
dibenzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
, None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
diazepine None None I-IUPAC
moiety None None I-MODIFIER
have None None O
a None None O
marked None None O
influence None None O
on None None O
the None None O
respective None None O
binding None None O
affinities None None O
of None None O
1,4 None None I-IUPAC
- None None I-IUPAC
diazepines None None I-IUPAC
related None None O
to None None O
clozapine None None O
, None None O
chloro None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
5,11 None None I-IUPAC
- None None I-IUPAC
dicarbo None None I-IUPAC
analogues None None I-MODIFIER
of None None O
clozapine None None O
were None None O
prepared None None O
in None None O
order None None O
to None None O
further None None O
examine None None O
structure None None O
- None None O
activity None None O
relationships None None O
. None None O

Evaluation None None O
of None None O
these None None O
analogues None None O
for None None O
binding None None O
to None None O
muscarinic None None O
and None None O
dopamine None None O
binding None None O
sites None None O
in None None O
comparison None None O
with None None O
clozapine None None O
and None None O
other None None O
5H None None I-IUPAC
- None None I-IUPAC
dibenzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
, None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
diazepine None None I-IUPAC
analogues None None I-MODIFIER
of None None O
clozapine None None O
shows None None O
that None None O
the None None O
dopamine None None O
D None None O
- None None O
1 None None O
and None None O
D None None O
- None None O
2 None None O
receptor None None O
affinities None None O
of None None O
both None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propylidene None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5,11 None None I-IUPAC
- None None I-IUPAC
dicarbo None None I-IUPAC
analogue None None I-MODIFIER
and None None O
its None None O
corresponding None None O
distal None None O
- None None O
chloro None None O
derivative None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propylidene None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylpiperazino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
dibenzo None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
cycloheptene None None I-IUPAC
, None None O
are None None O
retained None None O
. None None O

Because None None O
of None None O
the None None O
susceptibility None None O
to None None O
acid None None O
- None None O
catalyzed None None O
hydrolysis None None O
of None None O
these None None O
tertiary None None O
enamines None None O
, None None O
however None None O
, None None O
these None None O
compounds None None O
serve None None O
only None None O
as None None O
model None None O
compounds None None O
for None None O
their None None O
structure None None O
- None None O
activity None None O
evaluation None None O
. None None O

Since None None O
the None None O
proximal None None O
nitrogen None None O
atom None None O
of None None O
the None None O
piperazine None None O
ring None None O
is None None O
redundant None None O
for None None O
biological None None O
activity None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propylidene None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
dibenzo None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
cycloh None None I-IUPAC
eptene None None I-IUPAC
and None None O
its None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
derivative None None I-MODIFIER
are None None O
excellent None None O
candidates None None O
for None None O
resolution None None O
into None None O
enantiomers None None O
as None None O
a None None O
means None None O
to None None O
separate None None O
antimuscarinic None None O
and None None O
antidopaminergic None None O
activity None None O
, None None O
respectively None None O
, None None O
associated None None O
with None None O
only None None O
a None None O
single None None O
stereoisomer None None O
. None None O


The None None O
9 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
analogue None None I-MODIFIER
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
demethoxydaunomycin None None I-IUPAC
has None None O
been None None O
synthesized None None O
from None None O
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzaldehyde None None I-IUPAC
. None None O

Pomeranz None None O
- None None O
Fritsch None None O
condensation None None O
followed None None O
by None None O
borohydride None None O
reduction None None O
and None None O
acid None None O
- None None O
catalyzed None None O
cyclization None None O
led None None O
smoothly None None O
to None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
. None None O

Selective None None O
N None None O
- None None O
acetylation None None O
and None None O
subsequent None None O
Friedel None None O
- None None O
Crafts None None O
acylation None None O
with None None O
phthalic None None O
anhydride None None O
produced None None O
2 None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
5,12 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
azanaphthacene None None I-IUPAC
- None None I-IUPAC
6,11 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
, None None O
which None None O
was None None O
protected None None O
as None None O
its None None O
dimethyl None None O
ether None None O
and None None O
epoxidized None None O
to None None O
an None None O
acylated None None O
aza None None O
Brigl None None O
's None None O
anhydride None None O
. None None O

This None None O
was None None O
converted None None O
to None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5,12 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
azanaphthacene None None I-IUPAC
- None None I-IUPAC
6,11 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
by None None O
dehydration None None O
to None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
keto None None I-IUPAC
analogue None None I-MODIFIER
followed None None O
by None None O
cyanoborohydride None None O
reduction None None O
either None None O
stepwise None None O
or None None O
in None None O
situ None None O
. None None O

The None None O
protecting None None O
groups None None O
were None None O
removed None None O
with None None O
boron None None O
trichloride None None O
and None None O
the None None O
resulting None None O
aglycone None None O
glycosidated None None O
with None None O
optically None None O
active None None O
N None None I-IUPAC
, None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
daunosamine None None I-IUPAC
bromide None None I-IUPAC
and None None O
silver None None O
trifluoromethanesulfonate None None O
. None None O

The None None O
resulting None None O
diastereoisomers None None O
were None None O
separated None None O
by None None O
column None None O
chromatography None None O
and None None O
their None None O
structures None None O
established None None O
by None None O
CD None None O
and None None O
NMR None None O
spectroscopy None None O
. None None O

Unexpectedly None None O
it None None O
was None None O
not None None O
possible None None O
to None None O
remove None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
trifluoroacetyl None None I-IUPAC
blocking None None I-MODIFIER
group None None I-MODIFIER
without None None O
aromatization None None O
to None None O
the None None O
azanaphthaquinone None None O
. None None O

Both None None O
( None None I-PARTIUPAC
R None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
daunosaminyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5,12 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
azanaphthacene None None I-IUPAC
- None None I-IUPAC
6,11 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
were None None O
inactive None None O
ip None None O
in None None O
mice None None O
carrying None None O
the None None O
P388 None None O
tumor None None O
. None None O

Drugs None None O
were None None O
given None None O
at None None O
various None None O
concentrations None None O
on None None O
days None None O
0 None None O
, None None O
5 None None O
, None None O
and None None O
9 None None O
. None None O


Novel None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxochroman None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
amide None None I-IUPAC
derivatives None None I-MODIFIER
1 None None O
were None None O
synthesized None None O
and None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
inhibit None None O
rabbit None None O
small None None O
intestinal None None O
ACAT None None O
( None None O
acyl None None O
- None None O
CoA None None O
: None None O
cholesterol None None O
acyltransferase None None O
) None None O
in None None O
vitro None None O
and None None O
to None None O
lower None None O
serum None None O
total None None O
cholesterol None None O
in None None O
cholesterol None None O
- None None O
fed None None O
rats None None O
in None None O
vivo None None O
. None None O

Among None None O
the None None O
synthesized None None O
compounds None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
alkoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxochroman None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
amide None None I-IUPAC
derivatives None None I-MODIFIER
showed None None O
potent None None O
ACAT None None O
inhibitory None None O
activity None None O
both None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

The None None O
structure None None O
- None None O
activity None None O
relationships None None O
of None None O
these None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxochroman None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
amides None None I-IUPAC
and None None O
related None None O
compounds None None O
are None None O
discussed None None O
on None None O
the None None O
basis None None O
of None None O
these None None O
two None None O
assays None None O
. None None O

The None None O
carbonyl None None I-IUPAC
group None None B-MODIFIER
at None None O
position None None O
4 None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
chromanone None None I-IUPAC
was None None O
essential None None O
for None None O
potent None None O
ACAT None None O
inhibitory None None O
activity None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Chromon None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
less None None O
potent None None O
than None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxochroman None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
. None None O

An None None O
alkoxy None None O
group None None O
at None None O
position None None O
7 None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
chromanone None None I-IUPAC
moiety None None I-MODIFIER
was None None O
important None None O
for None None O
potent None None O
ACAT None None O
inhibitory None None O
activity None None O
. None None O

In None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
alkoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxochroman None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
amide None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
another None None O
necessary None None O
factor None None O
to None None O
elicit None None O
the None None O
potent None None O
ACAT None None O
inhibitory None None O
activity None None O
was None None O
lipophilicity None None O
of None None O
the None None O
molecules None None O
. None None O

The None None O
highly None None O
lipophilic None None O
acid None None O
amides None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxochroman None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
dimethyldodecanamide None None I-IUPAC
( None None O
35 None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorophenoxy None None I-IUPAC
) None None I-IUPAC
hexyl None None I-IUPAC
] None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxochroman None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
benzamide None None I-IUPAC
( None None O
63 None None O
) None None O
showed None None O
potent None None O
activity None None O
. None None O

Introduction None None O
of None None O
a None None O
highly None None O
lipophilic None None O
alkoxy None None O
group None None O
at None None O
position None None O
7 None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
chromanone None None I-IUPAC
moiety None None I-MODIFIER
instead None None O
of None None O
methoxy None None O
group None None O
also None None O
resulted None None O
in None None O
potent None None O
activity None None O
. None None O

In None None O
this None None O
case None None O
, None None O
highest None None O
inhibitory None None O
activity None None O
was None None O
obtained None None O
by None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
decyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxochroman None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
dimethylpropanamid None None I-IUPAC
e None None I-IUPAC
( None None O
65 None None O
) None None O
. None None O

The None None O
most None None O
potent None None O
compound None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxochroman None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
dimethyldodecanamide None None I-IUPAC
( None None O
35 None None O
, None None O
TEI None None O
- None None O
6522 None None O
) None None O
, None None O
showed None None O
significant None None O
ACAT None None O
inhibitory None None O
activity None None O
( None None O
rabbit None None O
small None None O
intestine None None O
IC50 None None O
= None None O
13 None None O
nM None None O
, None None O
rabbit None None O
liver None None O
IC50 None None O
= None None O
16 None None O
nM None None O
) None None O
, None None O
foam None None O
cell None None O
formation None None O
inhibitory None None O
activity None None O
( None None O
rat None None O
peritoneal None None O
macrophage None None O
IC50 None None O
= None None O
160 None None O
nM None None O
) None None O
, None None O
and None None O
extremely None None O
potent None None O
serum None None O
cholesterol None None O
- None None O
lowering None None O
activity None None O
in None None O
cholesterol None None O
- None None O
fed None None O
rats None None O
( None None O
61% None None O
at None None O
a None None O
dose None None O
of None None O
0.1 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
po None None O
) None None O
. None None O


An None None O
enantiospecific None None O
method None None O
was None None O
developed None None O
for None None O
the None None O
synthesis None None O
of None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
fluoromethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxymethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
chloromethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None O
substituted None None I-MODIFIER
- None None O
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinolines None None I-IUPAC
( None None O
THIQs None None O
) None None O
from None None O
phenylalanine None None O
. None None O

Biochemical None None O
evaluation None None O
of None None O
the None None O
enantiomers None None O
of None None O
these None None O
compounds None None O
at None None O
both None None O
PNMT None None O
and None None O
the None None O
alpha None None O
( None None O
2 None None O
) None None O
- None None O
adrenoceptor None None O
indicates None None O
that None None O
both None None O
sites None None O
display None None O
similar None None O
stereoselectivity None None O
. None None O

Overall None None O
the None None O
R None None O
- None None O
enantiomer None None O
was None None O
usually None None O
the None None O
more None None O
potent None None O
enantiomer None None O
at None None O
both None None O
PNMT None None O
and None None O
the None None O
alpha None None O
( None None O
2 None None O
) None None O
- None None O
adrenoceptor None None O
for None None O
these None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
fluoromethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxymethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
chloromethyl None None I-IUPAC
- None None I-IUPAC
THIQs None None I-IUPAC
. None None O

The None None O
one None None O
exception None None O
is None None O
3 None None I-IUPAC
- None None I-IUPAC
hydroxymethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
THIQ None None I-IUPAC
( None None O
9 None None O
) None None O
, None None O
which None None O
was None None O
found None None O
to None None O
display None None O
the None None O
opposite None None O
stereoselectivity None None O
at None None O
the None None O
alpha None None O
( None None O
2 None None O
) None None O
- None None O
adrenoceptor None None O
. None None O

A None None O
comparison None None O
of None None O
the None None O
PNMT None None O
inhibitory None None O
potency None None O
of None None O
the None None O
enantiomers None None O
of None None O
these None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
fluoromethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxymethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
chloromethyl None None I-IUPAC
- None None I-IUPAC
THIQs None None I-IUPAC
indicates None None O
that None None O
all None None O
of None None O
the None None O
3 None None O
- None None O
substituted None None O
- None None O
THIQs None None O
displayed None None O
similar None None O
inhibitory None None O
potency None None O
for None None O
PNMT None None O
. None None O

However None None O
, None None O
the None None O
nature None None O
of None None O
the None None O
3 None None O
- None None O
substituent None None O
was None None O
found None None O
to None None O
have None None O
a None None O
major None None O
effect None None O
on None None O
the None None O
alpha None None O
( None None O
2 None None O
) None None O
- None None O
adrenoceptor None None O
affinity None None O
of None None O
these None None O
compounds None None O
with None None O
the None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxymethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
3 None None I-IUPAC
- None None I-IUPAC
fluoromethyl None None I-IUPAC
- None None I-IUPAC
THIQs None None I-IUPAC
having None None O
the None None O
highest None None O
affinity None None O
and None None O
THIQs None None O
containing None None O
the None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloromethyl None None I-PARTIUPAC
moiety None None I-MODIFIER
the None None O
least None None O
. None None O

Compounds None None O
R None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
fluoromethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
THIQ None None I-IUPAC
( None None O
R None None O
- None None O
12 None None O
) None None O
and None None O
R None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
fluoromethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
aminosulfonyl None None I-IUPAC
- None None I-IUPAC
THIQ None None I-IUPAC
( None None O
R None None O
- None None O
13 None None O
) None None O
and None None O
both None None O
enantiomers None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
chloromethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
THIQ None None I-IUPAC
( None None O
R None None O
- None None O
and None None O
S None None O
- None None O
30 None None O
) None None O
are None None O
the None None O
most None None O
selective None None O
inhibitors None None O
in None None O
this None None O
study None None O
and None None O
display None None O
selectivities None None O
( None None O
alpha None None O
( None None O
2 None None O
) None None O
- None None O
adrenoceptor None None O
K None None O
( None None O
i None None O
) None None O
/ None None O
PNMT None None O
K None None O
( None None O
i None None O
) None None O
) None None O
greater None None O
than None None O
200 None None O
. None None O

These None None O
compounds None None O
give None None O
important None None O
insight None None O
into None None O
the None None O
steric None None O
and None None O
stereochemical None None O
preferences None None O
of None None O
both None None O
PNMT None None O
and None None O
the None None O
alpha None None O
( None None O
2 None None O
) None None O
- None None O
adrenoceptor None None O
, None None O
which None None O
should None None O
assist None None O
in None None O
the None None O
development None None O
of None None O
new None None O
PNMT None None O
inhibitors None None O
. None None O


We None None O
have None None O
previously None None O
shown None None O
that None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
) None None O
receptor None None O
agonist None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
ACPA None None O
, None None O
2 None None O
) None None O
, None None O
binds None None O
to None None O
AMPA None None O
receptors None None O
in None None O
a None None O
manner None None O
different None None O
from None None O
that None None O
of None None O
AMPA None None O
( None None O
1 None None O
) None None O
itself None None O
and None None O
that None None O
2 None None O
, None None O
in None None O
contrast None None O
to None None O
1 None None O
, None None O
also None None O
binds None None O
to None None O
kainic None None O
acid None None O
receptor None None O
sites None None O
. None None O

To None None O
elucidate None None O
the None None O
structural None None O
requirements None None O
for None None O
selective None None O
activation None None O
of None None O
the None None O
site None None O
/ None None O
conformation None None O
of None None O
AMPA None None O
receptors None None O
recognized None None O
by None None O
2 None None O
, None None O
a None None O
number None None O
of None None O
isosteric None None O
analogues None None O
of None None O
2 None None O
have None None O
now None None O
been None None O
synthesized None None O
and None None O
pharmacologically None None O
characterized None None O
. None None O

The None None O
compound None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
3a None None O
) None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.11 None None O
microM None None O
; None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
1.2 None None O
microM None None O
) None None O
, None None O
which None None O
is None None O
a None None O
regioisostere None None O
of None None O
2 None None O
with None None O
a None None O
methoxy None None O
group None None O
substituted None None O
for None None O
the None None O
methyl None None I-IUPAC
group None None B-MODIFIER
, None None O
was None None O
approximately None None O
equipotent None None O
with None None O
2 None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.020 None None O
microM None None O
; None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
1.0 None None O
microM None None O
) None None O
as None None O
an None None O
inhibitor None None O
of None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
AMPA None None O
binding None None O
and None None O
as None None O
an None None O
AMPA None None O
agonist None None O
, None None O
respectively None None O
, None None O
whereas None None O
the None None O
corresponding None None O
3 None None O
- None None O
ethoxy None None O
analogue None None O
3b None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.0 None None O
microM None None O
; None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
4.8 None None O
microM None None O
) None None O
was None None O
slightly None None O
weaker None None O
. None None O

The None None O
analogues None None O
3c None None O
- None None O
e None None O
, None None O
containing None None O
C3 None None O
alkoxy None None O
groups None None O
, None None O
were None None O
an None None O
order None None O
of None None O
magnitude None None O
weaker None None O
than None None O
3b None None O
, None None O
whereas None None O
the None None O
additional None None O
steric None None O
bulk None None O
of None None O
the None None O
alkoxy None None O
groups None None O
of None None O
3f None None O
- None None O
i None None O
or None None O
the None None O
presence None None O
of None None O
an None None O
acidic None None O
hydroxyl None None O
group None None O
at None None O
the None None O
3 None None O
- None None O
position None None O
of None None O
the None None O
isoxazole None None O
ring None None O
of None None O
3j None None O
prevented None None O
interaction None None O
with None None O
AMPA None None O
receptor None None O
sites None None O
. None None O

The None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acids None None I-IUPAC
4a None None O
, None None O
b None None O
, None None O
i None None O
, None None O
which None None O
are None None O
regioisosteric None None O
analogues None None O
of None None O
3a None None O
, None None O
b None None O
, None None O
i None None O
, None None O
showed None None O
negligible None None O
interaction None None O
with None None O
AMPA None None O
recognition None None O
sites None None O
. None None O

Similarly None None O
, None None O
replacement None None O
of None None O
the None None O
carboxyl None None I-IUPAC
group None None B-MODIFIER
of None None O
3b None None O
by None None O
isosteric None None O
tetrazolyl None None I-IUPAC
or None None O
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazolyl None None I-IUPAC
groups None None I-MODIFIER
to None None O
give None None O
5 None None O
and None None O
6 None None O
, None None O
respectively None None O
, None None O
or None None O
conversion None None O
of None None O
3b None None O
into None None O
analogue None None O
7 None None O
, None None O
in None None O
which None None O
the None None O
diaminosquaric None None O
acid None None O
group None None O
has None None O
been None None O
bioisosterically None None O
substituted None None O
for None None O
the None None O
alpha None None I-IUPAC
- None None I-IUPAC
aminocarboxylic None None I-IUPAC
acid None None I-IUPAC
unit None None O
, None None O
provided None None O
compounds None None O
completely None None O
devoid None None O
of None None O
effect None None O
at None None O
AMPA None None O
receptors None None O
. None None O

In None None O
contrast None None O
to None None O
the None None O
parent None None O
compound None None O
ACPA None None O
( None None O
2 None None O
) None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
6.3 None None O
microM None None O
) None None O
, None None O
none None None O
of None None O
the None None O
analogues None None O
described None None O
showed None None O
detectable None None O
inhibitory None None O
effect None None O
on None None O
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
) None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
kainic None None I-IUPAC
acid None None I-IUPAC
receptor None None O
binding None None O
. None None O


A None None O
series None None O
of None None O
4 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None O
substituted None None I-MODIFIER
- None None O
imidazoles None None I-IUPAC
has None None O
been None None O
synthesized None None O
and None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
selectively None None O
radiosensitize None None O
hypoxic None None O
Chinese None None O
hamster None None O
cells None None O
( None None O
V None None O
- None None O
79 None None O
) None None O
to None None O
the None None O
lethal None None O
effect None None O
of None None O
radiation None None O
. None None O

The None None O
reaction None None O
of None None O
4 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nitroimidazole None None I-IUPAC
with None None O
1,2 None None I-IUPAC
- None None I-IUPAC
epoxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxypropane None None I-IUPAC
and None None O
ethyl None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
chloroacetate None None I-IUPAC
produced None None O
two None None O
isomeric None None O
products None None O
in None None O
each None None O
case None None O
, None None O
which None None O
were None None O
identified None None O
by None None O
their None None O
NMR None None O
spectra None None O
. None None O

The None None O
ethyl None None O
esters None None O
were None None O
further None None O
reacted None None O
with None None O
3 None None I-IUPAC
- None None I-IUPAC
picolylamine None None I-IUPAC
to None None O
produce None None O
corresponding None None O
amides None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitroimidazole None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
picolyl None None I-IUPAC
) None None I-IUPAC
acetamide None None I-IUPAC
on None None O
further None None O
reaction None None O
with None None O
m None None I-IUPAC
- None None I-IUPAC
chloroperbenzoic None None I-IUPAC
acid None None I-IUPAC
produced None None O
the None None O
corresponding None None O
N None None O
- None None O
oxide None None O
. None None O

These None None O
compounds None None O
were None None O
generally None None O
more None None O
toxic None None O
to None None O
V None None O
- None None O
79 None None O
cells None None O
than None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
nitroimidazole None None I-IUPAC
derivatives None None I-MODIFIER
and None None O
were None None O
found None None O
to None None O
be None None O
more None None O
effective None None O
radiosensitizers None None O
in None None O
vitro None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitroimidazole None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
more None None O
efficient None None O
as None None O
sensitizers None None O
than None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
nitroimidazole None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
and None None O
the None None O
sensitizing None None O
efficiency None None O
of None None O
this None None O
class None None O
of None None O
agents None None O
was None None O
found None None O
to None None O
have None None O
significant None None O
correlation None None O
with None None O
their None None O
partition None None O
coefficients None None O
. None None O


A None None O
series None None O
of None None O
PGE2 None None O
, None None O
16,16 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
PGE2 None None I-IUPAC
, None None O
and None None O
PGF2 None None O
alpha None None O
analogues None None O
modified None None O
at None None O
the None None O
carboxyl None None O
terminus None None O
with None None O
tetrazole None None O
, None None O
amide None None O
, None None O
acylurea None None O
, None None O
imide None None O
, None None O
and None None O
sulfonimide None None O
functionalities None None O
was None None O
evaluated None None O
for None None O
uterine None None O
stimulant None None O
, None None O
bronchodilator None None O
, None None O
hypotensive None None O
, None None O
gastric None None O
antisecretory None None O
, None None O
and None None O
diarrheal None None O
activity None None O
. None None O

These None None O
compounds None None O
were None None O
prepared None None O
by None None O
modification None None O
of None None O
the None None O
Corey None None O
prostaglandin None None O
synthesis None None O
utilizing None None O
as None None O
a None None O
key None None O
step None None O
condensation None None O
of None None O
known None None O
hemiacetals None None O
with None None O
the None None O
ylide None None O
derived None None O
from None None O
the None None O
requisite None None O
substituted None None O
phosphonium None None O
salts None None O
. None None O

Structure None None O
- None None O
- None None O
activity None None O
relationships None None O
suggest None None O
that None None O
a None None O
proton None None O
at None None O
the None None O
C None None O
- None None O
1 None None O
position None None O
appears None None O
necessary None None O
for None None O
agonist None None O
activity None None O
and None None O
the None None O
acidity None None O
of None None O
this None None O
proton None None O
has None None O
a None None O
relatively None None O
greater None None O
influence None None O
on None None O
activity None None O
than None None O
pendant None None O
steric None None O
bulk None None O
. None None O

Noteworthy None None O
are None None O
the None None O
tissue None None O
- None None O
selective None None O
bronchodilator None None O
activity None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
PGE2 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
and None None O
the None None O
selectivity None None O
for None None O
uterine None None O
tissue None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
methanesulfonyl None None I-IUPAC
- None None I-IUPAC
PGE2 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
decarboxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
16,16 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
PGE2 None None I-IUPAC
, None None O
N None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
16,16 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
PGE2 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
methanesulfonyl None None I-IUPAC
- None None I-IUPAC
16,16 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
PGE2 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
. None None O


The None None O
retinoic None None O
acid None None O
receptors None None O
( None None O
RARs None None O
) None None O
transduce None None O
retinoid None None O
dependant None None O
gene None None O
regulation None None O
, None None O
and None None O
many None None O
biological None None O
effects None None O
of None None O
retinoids None None O
are None None O
mediated None None O
through None None O
binding None None O
and None None O
activation None None O
of None None O
three None None O
closely None None O
related None None O
receptor None None O
subtypes None None O
( None None O
RAR None None O
alpha None None O
, None None O
RAR None None O
beta None None O
, None None O
and None None O
RAR None None O
gamma None None O
) None None O
. None None O

In None None O
order None None O
to None None O
investigate None None O
the None None O
role None None O
of None None O
receptor None None O
subtypes None None O
, None None O
we None None O
have None None O
carried None None O
out None None O
a None None O
chemical None None O
synthesis None None O
program None None O
to None None O
seek None None O
selective None None O
retinoids None None O
for None None O
these None None O
receptors None None O
. None None O

We None None O
measured None None O
receptor None None O
binding None None O
affinity None None O
using None None O
recombinant None None O
RAR None None O
alpha None None O
, None None O
- None None O
beta None None O
, None None O
and None None O
- None None O
gamma None None O
proteins None None O
and None None O
assessed None None O
cellular None None O
differentiating None None O
activity None None O
in None None O
F9 None None O
murine None None O
teratocarcinoma None None O
cells None None O
( None None O
F9 None None O
cells None None O
) None None O
. None None O

This None None O
research None None O
has None None O
identified None None O
the None None O
4 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
adamantyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
moiety None None I-MODIFIER
as None None O
a None None O
new None None O
pharmacophore None None O
which None None O
can None None O
replace None None O
the None None O
beta None None I-IUPAC
- None None I-IUPAC
cyclogeranylidene None None I-IUPAC
ring None None I-MODIFIER
of None None O
the None None O
naturally None None O
occurring None None O
all None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
retinoic None None I-IUPAC
acid None None I-IUPAC
. None None O

Two None None O
chemical None None O
series None None O
derived None None O
from None None O
the None None O
general None None O
structures None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
tertioalkylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
( None None O
series None None O
I None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
tertioalkylphenyl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
series None None O
II None None O
) None None O
were None None O
developed None None O
. None None O

In None None O
particular None None O
, None None O
we None None O
have None None O
obtained None None O
the None None O
RAR None None O
gamma None None O
selective None None O
derivatives None None O
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
adamantyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
( None None O
7 None None O
) None None O
[ None None O
Ki None None O
( None None O
RAR None None O
alpha None None O
) None None O
= None None O
6500 None None O
nM None None O
, None None O
Ki None None O
( None None O
RAR None None O
beta None None O
) None None O
= None None O
2480 None None O
nM None None O
, None None O
Ki None None O
( None None O
RAR None None O
gamma None None O
) None None O
= None None O
77 None None O
nM None None O
] None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
adamantyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
] None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
19 None None O
) None None O
[ None None O
Ki None None O
( None None O
RAR None None O
alpha None None O
) None None O
= None None O
1,144 None None O
nM None None O
, None None O
Ki None None O
( None None O
RAR None None O
beta None None O
) None None O
= None None O
1245 None None O
nM None None O
, None None O
Ki None None O
( None None O
RAR None None O
gamma None None O
) None None O
= None None O
53 None None O
nM None None O
] None None O
. None None O

In None None O
series None None O
I None None O
, None None O
the None None O
presence None None O
of None None O
a None None O
phenol None None I-PARTIUPAC
group None None B-MODIFIER
, None None O
irrespective None None O
of None None O
the None None O
nature None None O
of None None O
tertioalkyl None None I-PARTIUPAC
group None None B-MODIFIER
, None None O
imparted None None O
at None None O
least None None O
partial None None O
RAR None None O
gamma None None O
selectivity None None O
, None None O
whereas None None O
in None None O
series None None O
II None None O
, None None O
the None None O
presence None None O
of None None O
both None None O
adamantyl None None I-PARTIUPAC
and None None O
phenol None None I-PARTIUPAC
groups None None B-MODIFIER
is None None O
needed None None O
to None None O
confer None None O
RAR None None O
gamma None None O
selectivity None None O
. None None O

The None None O
RAR None None O
gamma None None O
selective None None O
ligands None None O
induce None None O
differentiation None None O
in None None O
F9 None None O
cells None None O
( None None O
7 None None O
, None None O
AC50 None None O
= None None O
33 None None O
nM None None O
; None None O
19 None None O
, None None O
AC50 None None O
= None None O
66 None None O
nM None None O
) None None O
. None None O

From None None O
series None None O
I None None O
, None None O
a None None O
mixed None None O
RAR None None O
beta None None O
- None None O
gamma None None O
agonist None None O
with None None O
potent None None O
cellular None None O
differentiating None None O
activity None None O
was None None O
selected None None O
for None None O
development None None O
as None None O
a None None O
topical None None O
antiacne None None O
agent None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
adamantyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
( None None O
5 None None O
, None None O
CD None None O
271 None None O
) None None O
[ None None O
Ki None None O
( None None O
RAR None None O
alpha None None O
) None None O
= None None O
1100 None None O
nM None None O
, None None O
Ki None None O
- None None O
( None None O
RAR None None O
beta None None O
) None None O
= None None O
34 None None O
nM None None O
, None None O
Ki None None O
( None None O
RAR None None O
gamma None None O
) None None O
= None None O
130 None None O
nM None None O
, None None O
AC50 None None O
( None None O
F9 None None O
) None None O
= None None O
37 None None O
nM None None O
] None None O
. None None O

Finally None None O
, None None O
from None None O
series None None O
II None None O
, None None O
we None None O
have None None O
obtained None None O
a None None O
weak None None O
antagonist None None O
in None None O
the None None O
F9 None None O
cellular None None O
differentiation None None O
assay None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
15 None None O
, None None O
IC50 None None O
= None None O
700 None None O
nM None None O
) None None O
. None None O


In None None O
an None None O
attempt None None O
to None None O
determine None None O
some None None O
of None None O
the None None O
structural None None O
features None None O
in None None O
position None None O
1 None None O
that None None O
account None None O
for None None O
antivasopressor None None O
activity None None O
, None None O
eight None None O
new None None O
1 None None O
- None None O
( None None O
beta None None O
, None None O
beta None None O
- None None O
dialkyl None None O
- None None O
substituted None None O
) None None O
analogues None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
mercaptopropanoic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
arginine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
and None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
mercaptopropanoic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyltyrosine None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
arginine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
have None None O
been None None O
designed None None O
and None None O
synthesized None None O
. None None O

The None None O
protected None None O
precursors None None O
required None None O
for None None O
these None None O
peptides None None O
were None None O
obtained None None O
by None None O
a None None O
combination None None O
of None None O
solid None None O
- None None O
phase None None O
and None None O
solutions None None O
methods None None O
. None None O

Some None None O
of None None O
the None None O
reported None None O
analogues None None O
, None None O
namely None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
mercapto None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylcyclohexaneacetic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
arginine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
mercapto None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylcyclohexaneacetic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyltryosine None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
arginine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
mercaptocyclohexaneacetic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyltyrosine None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
arginine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
mercapto None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenylcyclohexaneacetic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
arginine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
and None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
mercapto None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenylcyclohexaneacetic None None I-IUPAC
acid None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyltyrosine None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
arginine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
, None None O
are None None O
among None None O
the None None O
most None None O
potent None None O
and None None O
selective None None O
antagonists None None O
of None None O
the None None O
vasopressor None None O
response None None O
to None None O
arginine None None O
- None None O
vasopressin None None O
reported None None O
to None None O
date None None O
. None None O


Glycosylated None None O
antitumor None None O
ether None None O
lipids None None O
( None None O
GAELs None None O
) None None O
, None None O
analogs None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
octadecyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
sn None None I-IUPAC
- None None I-IUPAC
glycero None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phosphocholine None None I-IUPAC
( None None O
1 None None O
, None None O
ET None None O
- None None O
18 None None O
- None None O
OCH3 None None O
, None None O
edelfosine None None O
) None None O
, None None O
were None None O
synthesized None None O
in None None O
good None None O
overall None None O
yields None None O
by None None O
glycosylation None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
sn None None I-IUPAC
- None None I-IUPAC
glycerol None None I-IUPAC
and None None O
tested None None O
for None None O
in None None O
vitro None None O
antineoplastic None None O
activity None None O
against None None O
a None None O
variety None None O
of None None O
murine None None O
and None None O
human None None O
tumor None None O
cell None None O
lines None None O
. None None O

Stereospecific None None O
glycosylation None None O
was None None O
achieved None None O
by None None O
the None None O
use None None O
of None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
O None None I-PARTIUPAC
- None None I-PARTIUPAC
acetyl None None I-PARTIUPAC
- None None I-PARTIUPAC
3,4,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
tri None None I-PARTIUPAC
- None None I-PARTIUPAC
O None None I-PARTIUPAC
- None None I-PARTIUPAC
benzylglucopyranosyl None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
mannopyranosyl None None I-PARTIUPAC
trichloroacetimidates None None I-PARTIUPAC
as None None O
donors None None O
, None None O
with None None O
trimethylsilyl None None I-IUPAC
trifluoromethanesulfonate None None I-IUPAC
as None None O
catalyst None None O
in None None O
the None None O
presence None None O
of None None O
molecular None None O
sieves None None O
at None None O
- None None O
78 None None O
degrees None None O
C None None O
. None None O

The None None O
GAELs None None O
differ None None O
from None None O
1 None None O
in None None O
having None None O
the None None O
sn None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phosphocholine None None I-IUPAC
residue None None O
replaced None None O
by None None O
one None None O
of None None O
the None None O
following None None O
monosaccharide None None O
residues None None O
: None None O
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
alpha None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabino None None I-IUPAC
- None None I-IUPAC
hexopyranosyl None None I-IUPAC
, None None O
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
mannopyranosyl None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
glucopyranosyl None None I-IUPAC
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
mannopyranosyl None None I-IUPAC
. None None O

1 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
Hexadecyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabino None None I-IUPAC
- None None I-IUPAC
hexopyranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
sn None None I-IUPAC
- None None I-IUPAC
glycerol None None I-IUPAC
( None None O
2 None None O
) None None O
was None None O
more None None O
effective None None O
than None None O
1 None None O
in None None O
inhibiting None None O
the None None O
growth None None O
of None None O
MCF None None O
- None None O
7 None None O
( None None O
human None None O
breast None None O
cancer None None O
) None None O
and None None O
its None None O
adriamycin None None O
- None None O
resistant None None O
form None None O
MCF None None O
- None None O
7 None None O
/ None None O
adriamycin None None O
, None None O
and None None O
murine None None O
Lewis None None O
lung None None O
cancer None None O
cells None None O
. None None O

2 None None I-IUPAC
- None None I-IUPAC
Deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabino None None I-IUPAC
- None None I-IUPAC
hexopyranoside None None I-IUPAC
2 None None O
was None None O
also None None O
an None None O
effective None None O
growth None None O
inhibitor None None O
of None None O
two None None O
drug None None O
- None None O
resistant None None O
leukemic None None O
cell None None O
lines None None O
, None None O
P388 None None O
/ None None O
Adr None None O
and None None O
L1210 None None O
/ None None O
vmdr None None O
. None None O


A None None O
series None None O
of None None O
sulfonyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
hydroxyguanidine None None I-IUPAC
derivatives None None I-MODIFIER
was None None O
designed None None O
and None None O
synthesized None None O
for None None O
cytotoxic None None O
evaluation None None O
as None None O
potential None None O
anticancer None None O
agents None None O
on None None O
the None None O
basis None None O
of None None O
the None None O
lead None None O
compound None None O
LY None None O
- None None O
181984 None None O
. None None O

Replacement None None O
of None None O
the None None O
ureido None None O
moiety None None O
of None None O
the None None O
lead None None O
compound None None O
with None None O
hydroxyguanidine None None O
provided None None O
a None None O
stable None None O
cytotoxic None None O
agent None None O
. None None O

The None None O
conformation None None O
of None None O
sulfonyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
hydroxyguanidine None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
such None None O
as None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
2,1,3 None None I-IUPAC
] None None I-IUPAC
thiadiazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
sulfonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
" None None I-IUPAC
- None None I-IUPAC
hydroxyguanidine None None I-IUPAC
( None None O
4g None None O
) None None O
, None None O
investigated None None O
utilizing None None O
HMBC None None O
NMR None None O
, None None O
theoretical None None O
calculations None None O
, None None O
and None None O
X None None O
- None None O
ray None None O
crystallography None None O
, None None O
indicated None None O
stacking None None O
of None None O
the None None O
two None None O
aromatic None None O
rings None None O
. None None O

The None None O
derivatives None None O
were None None O
evaluated None None O
for None None O
in None None O
vitro None None O
cytoxicity None None O
against None None O
five None None O
human None None O
tumor None None O
cell None None O
lines None None O
, None None O
including None None O
HepG2 None None O
, None None O
TSGH None None O
8302 None None O
, None None O
COLO None None O
205 None None O
, None None O
KB None None O
, None None O
and None None O
MOLT None None O
- None None O
4 None None O
. None None O

The None None O
cytotoxic None None O
activities None None O
of None None O
the None None O
derived None None O
compounds None None O
against None None O
the None None O
human None None O
tumor None None O
cell None None O
lines None None O
were None None O
equal None None O
to None None O
or None None O
greater None None O
than None None O
that None None O
of None None O
the None None O
lead None None O
compound None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
Chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitrophenoxy None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
sulfonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
" None None I-IUPAC
- None None I-IUPAC
hydroxyguanidine None None I-IUPAC
( None None O
4n None None O
) None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitrophenoxy None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
sulfonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
" None None I-IUPAC
- None None I-IUPAC
hydroxyguanidine None None I-IUPAC
( None None O
4o None None O
) None None O
exhibited None None O
the None None O
greatest None None O
growth None None O
inhibition None None O
of None None O
solid None None O
tumor None None O
cell None None O
lines None None O
. None None O

Compound None None O
4o None None O
was None None O
found None None O
to None None O
possess None None O
antitumor None None O
activity None None O
against None None O
murine None None O
K1735 None None O
/ None None O
M2 None None O
melanoma None None O
xenografts None None O
. None None O


A None None O
study None None O
of None None O
ring None None O
- None None O
expanded None None O
analogues None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
propananilido None None I-IUPAC
) None None I-IUPAC
piperidine None None I-IUPAC
analgesics None None O
has None None O
been None None O
undertaken None None O
in None None O
order None None O
to None None O
evaluate None None O
the None None O
influence None None O
of None None O
this None None O
structural None None O
modification None None O
on None None O
both None None O
analgesic None None O
activity None None O
and None None O
physical None None O
- None None O
dependence None None O
capacity None None O
. None None O

Thus None None O
, None None O
a None None O
series None None O
of None None O
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
propananilido None None I-IUPAC
) None None I-IUPAC
perhydroazepine None None I-IUPAC
derivatives None None I-MODIFIER
was None None O
synthesized None None O
and None None O
pharmacologically None None O
evaluated None None O
in None None O
mice None None O
for None None O
analgesic None None O
activity None None O
and None None O
physical None None O
- None None O
dependence None None O
capacity None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
indicate None None O
that None None O
the None None O
ring None None O
- None None O
expanded None None O
analogues None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
propananilido None None I-IUPAC
) None None I-IUPAC
piperidines None None I-IUPAC
retain None None O
a None None O
relatively None None O
high None None O
degree None None O
of None None O
analgesic None None O
potency None None O
, None None O
except None None O
in None None O
the None None O
case None None O
of None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
phenylethylated None None I-IUPAC
analogue None None I-MODIFIER
which None None O
is None None O
approximately None None O
150 None None O
- None None O
fold None None O
less None None O
potent None None O
than None None O
the None None O
correspondingly None None O
1 None None O
- None None O
substituted None None O
piperidine None None O
analgesic None None O
. None None O

Evaluation None None O
of None None O
physical None None O
- None None O
dependence None None O
capacity None None O
of None None O
the None None O
most None None O
potent None None O
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
propananilido None None I-IUPAC
) None None I-IUPAC
perhydroazepines None None I-IUPAC
reveals None None O
no None None O
significant None None O
difference None None O
for None None O
these None None O
compounds None None O
as None None O
compared None None O
with None None O
morphine None None O
. None None O

The None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
propananilido None None I-IUPAC
) None None I-IUPAC
perhydroazepines None None I-IUPAC
having None None O
1 None None O
- None None O
substitutents None None O
in None None O
common None None O
with None None O
known None None O
opiate None None O
antagonists None None O
failed None None O
to None None O
exhibit None None O
antagonism None None O
of None None O
morphine None None O
analgesia None None O
. None None O


A None None O
series None None O
of None None O
compounds None None O
related None None O
to None None O
ethyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
benzyloxybenzoate None None I-IUPAC
was None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
potential None None O
hypolipidemic None None O
activity None None O
in None None O
rats None None O
. None None O

Structure None None O
- None None O
- None None O
activity None None O
relationships None None O
are None None O
discussed None None O
in None None O
terms None None O
of None None O
cholesterol None None O
- None None O
lowering None None O
activity None None O
together None None O
with None None O
effects None None O
on None None O
weight None None O
gain None None O
and None None O
liver None None O
lipids None None O
. None None O

A None None O
number None None O
of None None O
the None None O
compounds None None O
inhibited None None O
cholesterol None None O
and None None O
free None None O
fatty None None O
acid None None O
biosynthesis None None O
from None None O
[ None None O
1-14 None None O
C None None O
] None None O
acetate None None O
in None None O
rat None None O
liver None None O
slices None None O
in None None O
vitro None None O
. None None O

Ethyl None None O
4 None None I-IUPAC
- None None I-IUPAC
benzyloxybenzoate None None I-IUPAC
, None None O
ethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
benzyloxybenzoic None None I-IUPAC
acid None None I-IUPAC
, None None O
ethyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
bromobenzyloxybenzoates None None I-IUPAC
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
o None None I-IUPAC
- None None I-IUPAC
methoxybenzyloxyphenyl None None I-IUPAC
acetate None None I-IUPAC
exhibited None None O
the None None O
most None None O
favorable None None O
spectrum None None O
of None None O
activity None None O
. None None O


In None None O
this None None O
paper None None O
we None None O
describe None None O
the None None O
synthesis None None O
of None None O
a None None O
series None None O
of None None O
novel None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
alkylsemicarbazono None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
methylenedioxyphenylacetic None None I-IUPAC
acid None None I-IUPAC
alkyl None None I-IUPAC
esters None None I-IUPAC
( None None O
10-19 None None O
) None None O
carrying None None O
an None None O
alkylsemicarbazono None None O
moiety None None O
at None None O
a None None O
benzylic None None O
site None None O
. None None O

The None None O
influence None None O
of None None O
this None None O
group None None O
on None None O
the None None O
biological None None O
activity None None O
was None None O
evaluated None None O
by None None O
testing None None O
the None None O
corresponding None None O
derivatives None None O
20-22 None None O
in None None O
which None None O
the None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkylsemicarbazono None None I-PARTIUPAC
moiety None None I-MODIFIER
was None None O
removed None None O
( None None O
compound None None O
20 None None O
) None None O
or None None O
its None None O
alkylureido None None O
portion None None O
shifted None None O
at None None O
position None None O
1 None None O
( None None O
compounds None None O
21-22 None None O
) None None O
. None None O

Furthermore None None O
, None None O
the None None O
involvement None None O
of None None O
the None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
aminobenzyl None None I-PARTIUPAC
moiety None None I-MODIFIER
in None None O
the None None O
anticonvulsant None None O
activity None None O
was None None O
evaluated None None O
by None None O
testing None None O
derivative None None O
23 None None O
. None None O

The None None O
anticonvulsant None None O
activity None None O
of None None O
all None None O
compounds None None O
was None None O
assayed None None O
against None None O
audiogenic None None O
seizures None None O
induced None None O
in None None O
DBA None None O
/ None None O
2 None None O
mice None None O
. None None O

Within None None O
this None None O
series None None O
of None None O
derivatives None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylsemicarbazono None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
methylenedioxyphenylacetic None None I-IUPAC
acid None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
( None None O
10 None None O
) None None O
proved None None O
to None None O
be None None O
the None None O
most None None O
active None None O
compound None None O
. None None O

It None None O
displayed None None O
a None None O
potency None None O
5 None None O
- None None O
fold None None O
higher None None O
than None None O
that None None O
shown None None O
by None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
methylenedioxy None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
benzodiazepine None None I-IUPAC
( None None O
1 None None O
, None None O
GYKI None None O
52466 None None O
) None None O
, None None O
a None None O
well None None O
- None None O
known None None O
noncompetitive None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
) None None O
receptor None None O
antagonist None None O
. None None O

Compound None None O
10 None None O
was None None O
also None None O
effective None None O
in None None O
suppressing None None O
seizures None None O
induced None None O
in None None O
Swiss None None O
mice None None O
by None None O
maximal None None O
electroshock None None O
( None None O
MES None None O
) None None O
or None None O
pentylenetetrazole None None O
( None None O
PTZ None None O
) None None O
. None None O

Furthermore None None O
, None None O
it None None O
antagonized None None O
in None None O
vivo None None O
seizures None None O
induced None None O
by None None O
icv None None O
administration None None O
of None None O
AMPA None None O
or None None O
kainate None None O
( None None O
KA None None O
) None None O
. None None O

Using None None O
the None None O
patch None None O
- None None O
clamp None None O
technique None None O
in None None O
primary None None O
cultures None None O
of None None O
granule None None O
neurons None None O
we None None O
tested None None O
compounds None None O
10 None None O
and None None O
21 None None O
for None None O
their None None O
ability None None O
to None None O
modulate None None O
currents None None O
evoked None None O
by None None O
KA None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
ATPA None None O
) None None O
. None None O

These None None O
two None None O
derivatives None None O
reduced None None O
KA None None O
and None None O
ATPA None None O
currents None None O
to None None O
a None None O
larger None None O
extent None None O
than None None O
that None None O
shown None None O
by None None O
reference None None O
compound None None O
1 None None O
. None None O

Compounds None None O
10 None None O
and None None O
21 None None O
were None None O
also None None O
able None None O
to None None O
reduce None None O
neuronal None None O
cell None None O
death None None O
induced None None O
by None None O
the None None O
application None None O
of None None O
KA None None O
( None None O
100 None None O
microM None None O
) None None O
. None None O


Novel None None O
3 None None O
- None None O
substituted None None O
analogues None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
3 None None I-IUPAC
- None None I-IUPAC
deazacytidine None None I-IUPAC
, None None O
3 None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
3 None None I-IUPAC
- None None I-IUPAC
deazauridine None None I-IUPAC
, None None O
4 None None O
) None None O
have None None O
been None None O
synthesized None None O
and None None O
tested None None O
for None None O
antitumor None None O
and None None O
antiviral None None O
activity None None O
. None None O

Thus None None O
the None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloro None None I-PARTIUPAC
( None None O
9a None None O
) None None O
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
bromo None None I-PARTIUPAC
( None None O
9b None None O
) None None O
, None None O
and None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
nitro None None I-PARTIUPAC
( None None O
9c None None O
) None None O
analogues None None I-MODIFIER
of None None O
3 None None O
and None None O
the None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloro None None I-PARTIUPAC
( None None O
9d None None O
) None None O
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
bromo None None I-PARTIUPAC
( None None O
9e None None O
) None None O
, None None O
and None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
nitro None None I-PARTIUPAC
( None None O
9f None None O
) None None O
analogues None None I-MODIFIER
of None None O
4 None None O
were None None O
prepared None None O
by None None O
standard None None O
glycosylating None None O
procedures None None O
. None None O

Novel None None O
requisite None None O
heterocycles None None I-MODIFIER
4 None None B-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
7a None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
7b None None O
) None None O
were None None O
prepared None None O
by None None O
halogenating None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
5 None None O
) None None O
. None None O

Requisite None None O
heterocycles None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
7c None None O
) None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
7d None None O
) None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
7e None None O
) None None O
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
7f None None O
) None None O
were None None O
synthesized None None O
by None None O
known None None O
procedures None None O
from None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
6 None None O
) None None O
. None None O

Structure None None O
proof None None O
of None None O
target None None O
nucleosides None None O
was None None O
provided None None O
by None None O
independent None None O
synthesis None None O
, None None O
1H None None O
NMR None None O
, None None O
and None None O
UV None None O
. None None O

Compounds None None O
9a None None O
- None None O
f None None O
were None None O
devoid None None O
of None None O
activity None None O
against None None O
intraperitoneally None None O
implanted None None O
L1210 None None O
leukemia None None O
in None None O
mice None None O
. None None O

Compound None None O
9f None None O
displayed None None O
significant None None O
activity None None O
against None None O
rhinovirus None None O
type None None O
34 None None O
grown None None O
in None None O
WISH None None O
cells None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
1 None None O
) None None O
displayed None None O
good None None O
activity None None O
against None None O
intraperitoneally None None O
implanted None None O
P388 None None O
leukemia None None O
in None None O
mice None None O
, None None O
but None None O
it None None O
was None None O
devoid None None O
of None None O
activity None None O
against None None O
M5076 None None O
sarcoma None None O
, None None O
amelanotic None None O
( None None O
LOX None None O
) None None O
melanoma None None O
xenograft None None O
, None None O
and None None O
subrenal None None O
capsule None None O
human None None O
mammary None None O
carcinoma None None O
MX None None O
- None None O
1 None None O
xenograft None None O
in None None O
mice None None O
. None None O

Compound None None O
1 None None O
also None None O
displayed None None O
significant None None O
activity None None O
against None None O
rhinovirus None None O
type None None O
34 None None O
. None None O


The None None O
in None None O
vitro None None O
screening None None O
for None None O
trypanocidal None None O
activity None None O
against None None O
Trypanosoma None None O
brucei None None O
rhodesiense None None O
of None None O
an None None O
in None None O
- None None O
house None None O
library None None O
of None None O
62 None None O
compounds None None O
[ None None O
i.e. None None O
alkane None None O
, None None O
diphenyl None None O
, None None O
and None None O
azaalkane None None O
bisguanidines None None O
and None None O
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoimidazolines None None I-IUPAC
) None None I-IUPAC
] None None O
, None None O
which None None O
were None None O
chosen None None O
for None None O
their None None O
structural None None O
similarity None None O
to None None O
the None None O
trypanocidal None None O
agents None None O
synthalin None None O
( None None O
1,10 None None I-IUPAC
- None None I-IUPAC
decanediguanidine None None I-IUPAC
) None None O
and None None O
4,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
diguanidinodiphenylmethane None None I-IUPAC
and None None O
the None None O
polyamine None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
propane None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
diamine None None I-IUPAC
, None None O
respectively None None O
, None None O
is None None O
reported None None O
. None None O

The None None O
original None None O
synthetic None None O
procedure None None O
for None None O
the None None O
preparation None None O
of None None O
21 None None O
of None None O
these None None O
compounds None None O
is None None O
also None None O
reported None None O
. None None O

Most None None O
compounds None None O
displayed None None O
low None None O
micromolar None None O
antitrypanosomal None None O
activity None None O
, None None O
with None None O
five None None O
of None None O
them None None O
presenting None None O
a None None O
nanomolar None None O
inhibitory None None O
action None None O
on None None O
the None None O
parasite None None O
: None None O
1,9 None None I-IUPAC
- None None I-IUPAC
nonanediguanidine None None I-IUPAC
( None None O
1c None None O
) None None O
, None None O
1,12 None None I-IUPAC
- None None I-IUPAC
dodecanediguanidine None None I-IUPAC
( None None O
1d None None O
) None None O
, None None O
4,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
imidazolidinylimino None None I-IUPAC
] None None I-IUPAC
diphenylamine None None I-IUPAC
( None None O
28a None None O
) None None O
, None None O
4,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
imidazolylamino None None I-IUPAC
) None None I-IUPAC
diphenylamine None None I-IUPAC
( None None O
28b None None O
) None None O
, None None O
and None None O
4,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
diguanidinodiphenylamine None None I-IUPAC
( None None O
32b None None O
) None None O
. None None O

Those None None O
molecules None None O
that None None O
showed None None O
an None None O
excellent None None O
in None None O
vitro None None O
activity None None O
as None None O
well None None O
as None None O
high None None O
selectivity None None O
for None None O
the None None O
parasite None None O
[ None None O
e.g. None None O
1c None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
49 None None O
nM None None O
; None None O
SI None None O
& None None O
gt None None O
; None None O
5294 None None O
) None None O
, None None O
28b None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
69 None None O
nM None None O
; None None O
SI None None O
= None None O
3072 None None O
) None None O
, None None O
32b None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
22 None None O
nM None None O
; None None O
SI None None O
= None None O
29.5 None None O
) None None O
, None None O
41b None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
118 None None O
nM None None O
; None None O
SI None None O
= None None O
881 None None O
) None None O
] None None O
represent None None O
new None None O
antitrypanosomal None None O
lead None None O
compounds None None O
. None None O


In None None O
earlier None None O
reports None None O
we None None O
identified None None O
specific None None O
point None None O
substitutions None None O
( None None O
DPhe12 None None O
, None None O
Nle21 None None O
, None None O
38 None None O
) None None O
, None None O
cyclization None None O
strategies None None O
[ None None O
in None None O
particular None None O
, None None O
introduction None None O
of None None O
lactam None None O
rings None None O
such None None O
as None None O
that None None O
of None None O
cyclo None None O
( None None O
Glu30 None None O
, None None O
Lys33 None None O
) None None O
] None None O
, None None O
and None None O
deletions None None O
( None None O
residues None None O
1-7 None None O
) None None O
in None None O
the None None O
CRF None None O
molecule None None O
that None None O
led None None O
to None None O
agonists None None O
. None None O

We None None O
also None None O
noted None None O
that None None O
further None None O
deletions None None O
( None None O
residues None None O
8-14 None None O
) None None O
produced None None O
antagonists None None O
such None None O
as None None O
astressin None None O
 None None O
 None None O
cyclo None None O
( None None O
30-33 None None O
) None None O
[ None None O
DPhe12 None None O
, None None O
Nle21 None None O
, None None O
38 None None O
, None None O
Glu30 None None O
, None None O
Lys33 None None O
] None None O
hCRF None None O
( None None O
12-41 None None O
) None None O
 None None O
 None None O
( None None O
1 None None O
) None None O
. None None O

We None None O
hypothesized None None O
that None None O
the None None O
lactam None None O
ring None None O
promoted None None O
conformational None None O
stability None None O
to None None O
yield None None O
analogues None None O
with None None O
increased None None O
potency None None O
both None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
as None None O
compared None None O
to None None O
that None None O
of None None O
their None None O
linear None None O
counterparts None None O
. None None O

Additionally None None O
, None None O
we None None O
reported None None O
that None None O
cyclo None None O
( None None O
30-33 None None O
) None None O
[ None None O
DPhe12 None None O
, None None O
Nle21 None None O
, None None O
38 None None O
, None None O
Glu30 None None O
, None None O
DHis32 None None O
, None None O
Lys33 None None O
] None None O
hCRF None None O
( None None O
12-41 None None O
) None None O
( None None O
3 None None O
) None None O
and None None O
dicyclo None None O
( None None O
26-36,30-33 None None O
) None None O
[ None None O
Ac None None O
- None None O
Asp9 None None O
, None None O
DPhe12 None None O
, None None O
Nle21 None None O
, None None O
38 None None O
, None None O
Cys26 None None O
, None None O
Glu30 None None O
, None None O
Lys33 None None O
, None None O
Cys36 None None O
] None None O
hCRF None None O
( None None O
9-41 None None O
) None None O
were None None O
ca. None None O
twice None None O
and None None O
1/100 None None O
as None None O
potent None None O
as None None O
astressin None None O
, None None O
respectively None None O
, None None O
suggesting None None O
a None None O
putative None None O
turn None None O
that None None O
encompasses None None O
residues None None O
30-33 None None O
( None None O
previous None None O
paper None None O
: None None O
Koerber None None O
et None None O
al. None None O
J None None O
. None None O

Med. None None O
Chem. None None O
1998 None None O
, None None O
41 None None O
) None None O
. None None O

To None None O
increase None None O
the None None O
potency None None O
of None None O
1 None None O
and None None O
/ None None O
or None None O
3 None None O
in None None O
vivo None None O
, None None O
we None None O
extended None None O
their None None O
chain None None O
length None None O
by None None O
one None None O
( None None O
5-8 None None O
) None None O
, None None O
two None None O
( None None O
9 None None O
, None None O
10 None None O
) None None O
, None None O
and None None O
three None None O
( None None O
11 None None O
, None None O
12 None None O
) None None O
residues None None O
at None None O
the None None O
N None None O
- None None O
terminus None None O
and None None O
acetylated None None O
( None None O
6 None None O
, None None O
8 None None O
, None None O
10 None None O
, None None O
12 None None O
) None None O
. None None O

Of None None O
the None None O
compounds None None O
tested None None O
for None None O
duration None None O
of None None O
action None None O
( None None O
1 None None O
, None None O
3-6 None None O
, None None O
8 None None O
) None None O
, None None O
we None None O
found None None O
6 None None O
and None None O
8 None None O
to None None O
be None None O
slightly None None O
longer None None O
- None None O
acting None None O
than None None O
astressin None None O
or None None O
[ None None O
DHis32 None None O
] None None O
astressin None None O
, None None O
while None None O
their None None O
potencies None None O
in None None O
vitro None None O
were None None O
not None None O
significantly None None O
different None None O
from None None O
that None None O
of None None O
3 None None O
. None None O

Additionally None None O
, None None O
we None None O
introduced None None O
CalphaMe None None O
- None None O
leucine None None O
residues None None O
in None None O
lieu None None O
of None None O
leucine None None O
at None None O
positions None None O
14 None None O
, None None O
15 None None O
, None None O
19 None None O
, None None O
27 None None O
, None None O
and None None O
37 None None O
in None None O
[ None None O
DHis32 None None O
] None None O
astressin None None O
. None None O

The None None O
analogue None None O
[ None None O
CalphaMe None None O
- None None O
Leu27 None None O
, None None O
DHis32 None None O
] None None O
astressin None None O
( None None O
16 None None O
) None None O
was None None O
more None None O
potent None None O
( None None O
although None None O
not None None O
statistically None None O
in None None O
all None None O
cases None None O
) None None O
than None None O
the None None O
other None None O
four None None O
analogues None None O
in None None O
vitro None None O
. None None O

While None None O
acetylation None None O
of None None O
the None None O
N None None O
- None None O
terminus None None O
of None None O
16 None None O
( None None O
i.e. None None O
, None None O
18 None None O
) None None O
or None None O
of None None O
[ None None O
CalphaMe None None O
- None None O
Leu27 None None O
] None None O
astressin None None O
( None None O
i.e. None None O
, None None O
19 None None O
) None None O
did None None O
not None None O
have None None O
a None None O
significant None None O
effect None None O
on None None O
in None None O
vitro None None O
potency None None O
, None None O
elongation None None O
of None None O
the None None O
N None None O
- None None O
terminus None None O
by None None O
one None None O
or None None O
three None None O
residues None None O
in None None O
addition None None O
to None None O
acetylation None None O
resulted None None O
in None None O
cyclo None None O
( None None O
30-33 None None O
) None None O
[ None None O
DPhe12 None None O
, None None O
Nle21 None None O
, None None O
CalphaMe None None O
- None None O
Leu27 None None O
, None None O
Glu3 None None O
0 None None O
, None None O
DHis32 None None O
, None None O
Lys33 None None O
, None None O
Nle38 None None O
] None None O
Ac None None O
- None None O
hCRF None None O
( None None O
11-41 None None O
) None None O
( None None O
21 None None O
) None None O
, None None O
cyclo None None O
( None None O
30-33 None None O
) None None O
[ None None O
DPhe12 None None O
, None None O
Nle21 None None O
, None None O
CalphaMe None None O
- None None O
Leu27 None None O
, None None O
Glu30 None None O
, None None O
Lys33 None None O
, None None O
Nle38 None None O
] None None O
Ac None None O
- None None O
hCRF None None O
( None None O
9-41 None None O
) None None O
( None None O
22 None None O
) None None O
, None None O
and None None O
cyclo None None O
( None None O
30-33 None None O
) None None O
[ None None O
DPhe12 None None O
, None None O
Nle21 None None O
, None None O
CalphaMe None None O
- None None O
Leu27 None None O
, None None O
Glu30 None None O
, None None O
DHis32 None None O
, None None O
Lys33 None None O
, None None O
Nle38 None None O
] None None O
Ac None None O
- None None O
hCRF None None O
( None None O
9-41 None None O
) None None O
( None None O
23 None None O
) None None O
that None None O
were None None O
longer None None O
- None None O
acting None None O
than None None O
6 None None O
and None None O
8 None None O
( None None O
ca. None None O
2 None None O
h None None O
inhibition None None O
of None None O
ACTH None None O
secretion None None O
at None None O
25 None None O
micrograms None None O
/ None None O
adrenalectomized None None O
rat None None O
) None None O
. None None O

Analogues None None O
22 None None O
and None None O
23 None None O
were None None O
also None None O
more None None O
potent None None O
than None None O
astressin None None O
at None None O
reversing None None O
intracisternal None None O
CRF None None O
- None None O
and None None O
abdominal None None O
surgery None None O
- None None O
induced None None O
delay None None O
of None None O
gastric None None O
emptying None None O
in None None O
conscious None None O
rats None None O
. None None O


A None None O
new None None O
means None None O
of None None O
accessing None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyclopropylmethyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ethylnorspermine None None I-IUPAC
( None None O
CPMENSPM None None O
) None None O
and None None O
the None None O
first None None O
synthesis None None O
of None None O
( None None I-IUPAC
2R None None I-IUPAC
, None None I-IUPAC
10S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyclopropylmethyl None None I-IUPAC
- None None I-IUPAC
2,10 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ethylnorspermine None None I-IUPAC
[ None None O
( None None O
2R None None O
, None None O
10S None None O
) None None O
- None None O
( None None O
HO None None O
) None None O
( None None O
2 None None O
) None None O
CPMENSPM None None O
] None None O
are None None O
described None None O
. None None O

Both None None O
of None None O
these None None O
polyamine None None O
analogues None None O
are None None O
shown None None O
to None None O
be None None O
more None None O
active None None O
against None None O
L1210 None None O
murine None None O
leukemia None None O
cell None None O
growth None None O
than None None O
either None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
diethylnorspermine None None I-IUPAC
( None None O
DENSPM None None O
) None None O
or None None O
( None None I-IUPAC
2R None None I-IUPAC
, None None I-IUPAC
10R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
diethyl None None I-IUPAC
- None None I-IUPAC
2,10 None None I-IUPAC
- None None I-IUPAC
dihydroxynorspermine None None I-IUPAC
[ None None O
( None None O
2R None None O
, None None O
10R None None O
) None None O
- None None O
( None None O
HO None None O
) None None O
( None None O
2 None None O
) None None O
DENSPM None None O
] None None O
after None None O
96 None None O
h None None O
of None None O
treatment None None O
; None None O
the None None O
activity None None O
was None None O
comparable None None O
to None None O
that None None O
of None None O
( None None I-IUPAC
2S None None I-IUPAC
, None None I-IUPAC
10S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
diethyl None None I-IUPAC
- None None I-IUPAC
2,10 None None I-IUPAC
- None None I-IUPAC
dihydroxynorspermine None None I-IUPAC
[ None None O
( None None O
2S None None O
, None None O
10S None None O
) None None O
- None None O
( None None O
HO None None O
) None None O
( None None O
2 None None O
) None None O
DENSPM None None O
] None None O
at None None O
96 None None O
h None None O
. None None O

Both None None O
cyclopropyl None None I-PARTIUPAC
compounds None None B-MODIFIER
reduced None None O
putrescine None None O
and None None O
spermidine None None O
pools None None O
, None None O
but None None O
less None None O
effectively None None O
than None None O
did None None O
DENSPM None None O
and None None O
its None None O
derivatives None None O
. None None O

Only None None O
CPMENSPM None None O
, None None O
and None None O
not None None O
( None None O
2R None None O
, None None O
10S None None O
) None None O
- None None O
( None None O
HO None None O
) None None O
( None None O
2 None None O
) None None O
CPMENSPM None None O
, None None O
lowered None None O
spermine None None O
pools None None O
. None None O

As None None O
with None None O
DENSPM None None O
and None None O
( None None O
2R None None O
, None None O
10R None None O
) None None O
- None None O
( None None O
HO None None O
) None None O
( None None O
2 None None O
) None None O
DENSPM None None O
, None None O
both None None O
cyclopropyl None None I-PARTIUPAC
analogues None None B-MODIFIER
diminished None None O
ornithine None None O
decarboxylase None None O
and None None O
S None None I-IUPAC
- None None I-IUPAC
adenosylmethionine None None I-IUPAC
decarboxylase None None O
activity None None O
. None None O

Unlike None None O
the None None O
hydroxylated None None O
DENSPM None None O
compounds None None O
, None None O
both None None O
cyclopropyl None None O
norspermines None None O
substantially None None O
upregulated None None O
spermidine None None O
/ None None O
spermine None None O
N None None O
( None None O
1 None None O
) None None O
- None None O
acetyltransferase None None O
. None None O

The None None O
most None None O
interesting None None O
effect None None O
of None None O
hydroxylating None None O
CPMENSPM None None O
is None None O
the None None O
profound None None O
reduction None None O
in None None O
toxicity None None O
compared None None O
with None None O
that None None O
of None None O
the None None O
parent None None O
drug None None O
. None None O

The None None O
same None None O
phenomenon None None O
had None None O
been None None O
observed None None O
for None None O
the None None O
DENSPM None None O
/ None None O
( None None O
2R None None O
, None None O
10R None None O
) None None O
- None None O
( None None O
HO None None O
) None None O
( None None O
2 None None O
) None None O
DENSPM None None O
pair None None O
. None None O

Thus None None O
, None None O
hydroxylation None None O
of None None O
norspermine None None O
analogues None None O
appears None None O
to None None O
be None None O
a None None O
way None None O
to None None O
maintain None None O
the None None O
compounds None None O
' None None O
antiproliferative None None O
activity None None O
while None None O
reducing None None O
their None None O
toxicity None None O
. None None O


Three None None O
series None None O
of None None O
benzamides None None O
of None None O
N None None I-MODIFIER
, None None I-MODIFIER
N None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
ethylenediamines None None I-IUPAC
( None None O
linear None None I-MODIFIER
alkane None None B-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
diamines None None I-IUPAC
) None None O
, None None O
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
pyrrolidines None None I-IUPAC
, None None O
and None None O
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
3 None None I-IUPAC
- None None I-IUPAC
aminopyrrolidines None None I-IUPAC
( None None O
cyclic None None I-MODIFIER
alkane None None B-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
diamines None None I-IUPAC
) None None O
were None None O
designed None None O
and None None O
synthesized None None O
as None None O
potential None None O
neuroleptics None None O
. None None O

All None None O
target None None O
compounds None None O
were None None O
evaluated None None O
for None None O
their None None O
inhibitory None None O
effects None None O
on None None O
apomorphine None None O
- None None O
induced None None O
stereotyped None None O
behavior None None O
in None None O
rats None None O
, None None O
and None None O
a None None O
good None None O
correlation None None O
between None None O
structure None None O
and None None O
activity None None O
was None None O
found None None O
throughout None None O
the None None O
series None None O
. None None O

In None None O
the None None O
linear None None O
series None None O
( None None O
analogues None None O
of None None O
metoclopramide None None O
) None None O
, None None O
introduction None None O
of None None O
a None None O
benzyl None None I-IUPAC
group None None B-MODIFIER
on None None O
the None None O
terminal None None O
nitrogen None None O
, None None O
rather None None O
than None None O
an None None O
ethyl None None I-IUPAC
group None None B-MODIFIER
, None None O
and None None O
a None None O
methyl None None I-IUPAC
group None None B-MODIFIER
on None None O
the None None O
p None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
group None None I-MODIFIER
of None None O
metoclopramide None None O
both None None O
enhanced None None O
the None None O
activity None None O
. None None O

The None None O
resulting None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylamino None None I-IUPAC
) None None I-IUPAC
benzamide None None I-IUPAC
( None None O
23 None None O
) None None O
was None None O
about None None O
15 None None O
times None None O
more None None O
active None None O
than None None O
metoclopramide None None O
. None None O

In None None O
the None None O
cyclic None None O
series None None O
, None None O
particularly None None O
among None None O
the None None O
benzamides None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminopyrrolidine None None I-IUPAC
, None None O
most None None O
of None None O
the None None O
compounds None None O
tested None None O
were None None O
more None None O
active None None O
than None None O
the None None O
corresponding None None O
linear None None O
benzamides None None O
. None None O

cis None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
Benzyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylpyrrolidin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylamino None None I-IUPAC
) None None I-IUPAC
benzamide None None I-IUPAC
( None None O
YM None None O
- None None O
09151-2 None None O
, None None O
55 None None O
) None None O
was None None O
the None None O
most None None O
active None None O
among None None O
all None None O
of None None O
the None None O
compounds None None O
tested None None O
, None None O
being None None O
13 None None O
and None None O
408 None None O
times None None O
more None None O
potent None None O
than None None O
haloperidol None None O
and None None O
metoclopramide None None O
, None None O
respectively None None O
. None None O

Moreover None None O
, None None O
compound None None O
55 None None O
exhibited None None O
a None None O
fairly None None O
high None None O
ratio None None O
of None None O
antistereotypic None None O
activity None None O
to None None O
cataleptogenicity None None O
compared None None O
with None None O
haloperidol None None O
and None None O
metoclopramide None None O
. None None O

It None None O
is None None O
expected None None O
that None None O
compound None None O
55 None None O
may None None O
be None None O
used None None O
as None None O
a None None O
potent None None O
drug None None O
with None None O
few None None O
side None None O
effects None None O
in None None O
the None None O
treatment None None O
of None None O
psychosis None None O
. None None O


A None None O
series None None O
of None None O
monoamidic None None I-MODIFIER
derivatives None None I-MODIFIER
of None None I-MODIFIER
cis None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
trans None None I-PARTIUPAC
- None None I-PARTIUPAC
1,2 None None I-PARTIUPAC
- None None I-PARTIUPAC
cyclohexanedicarboxylic None None I-PARTIUPAC
and None None O
1,2 None None I-IUPAC
- None None I-IUPAC
cyclopentanedicarboxylic None None I-IUPAC
acids None None I-IUPAC
bearing None None O
either None None O
a None None O
carboxylic None None O
, None None O
sulfhydrylic None None O
, None None O
or None None O
hydroxamic None None O
group None None O
in None None O
the None None O
side None None O
chain None None O
were None None O
synthesized None None O
and None None O
evaluated None None O
in None None O
vitro None None O
for None None O
their None None O
inhibitory None None O
activity None None O
against None None O
angiotensin None None O
converting None None O
enzyme None None O
. None None O

The None None O
compounds None None O
were None None O
designed None None O
as None None O
potential None None O
ACE None None O
inhibitors None None O
of None None O
novel None None O
structure None None O
, None None O
assuming None None O
that None None O
a None None O
monoamidic None None O
residue None None O
of None None O
an None None O
1,2 None None I-IUPAC
- None None I-IUPAC
cyclomethylenedicarboxylic None None I-IUPAC
acid None None I-IUPAC
could None None O
be None None O
an None None O
alternative None None O
structure None None O
to None None O
the None None O
acylproline None None O
moiety None None O
, None None O
the None None O
carboxyl None None O
- None None O
terminal None None O
portion None None O
common None None O
to None None O
various None None O
ACE None None O
inhibitors None None O
. None None O

The None None O
most None None O
active None None O
compounds None None O
were None None O
found None None O
in None None O
the None None O
hydroxamic None None O
derivatives None None O
of None None O
cyclohexane None None O
series None None O
; None None O
within None None O
this None None O
series None None O
of None None O
derivatives None None O
a None None O
marked None None O
increase None None O
of None None O
potency None None O
was None None O
caused None None O
by None None O
alkylation None None O
of None None O
the None None O
amidic None None O
nitrogen None None O
with None None O
a None None O
methyl None None I-IUPAC
or None None O
ethyl None None I-IUPAC
group None None B-MODIFIER
. None None O

Therefore None None O
enantiomers None None O
of None None O
the None None O
selected None None O
hydroxamic None None O
derivatives None None O
of None None O
cis None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
cyclohexanedicarboxylic None None I-IUPAC
acid None None I-IUPAC
were None None O
prepared None None O
by None None O
two None None O
different None None O
chiral None None O
synthetic None None O
routes None None O
and None None O
evaluated None None O
in None None O
vitro None None O
for None None O
their None None O
ACE None None O
inhibitor None None O
potencies None None O
. None None O

The None None O
active None None O
enantiomers None None O
both None None O
of None None O
the None None O
cis None None O
series None None O
( None None O
21a None None O
, None None O
21c None None O
) None None O
and None None O
trans None None O
series None None O
( None None O
16b None None O
, None None O
16d None None O
) None None O
were None None O
found None None O
to None None O
have None None O
all None None O
R None None O
configuration None None O
at None None O
the None None O
C None None O
- None None O
2 None None O
and None None O
R None None O
or None None O
S None None O
configuration None None O
at None None O
the None None O
C None None O
- None None O
1 None None O
, None None O
while None None O
in None None O
the None None O
classical None None O
ACE None None O
inhibitors None None O
S None None O
configuration None None O
at None None O
the None None O
terminal None None O
carboxylate None None O
( None None O
corresponding None None O
to None None O
the None None O
C None None O
- None None O
1 None None O
of None None O
our None None O
compounds None None O
) None None O
is None None O
strictly None None O
required None None O
for None None O
activity None None O
. None None O

The None None O
most None None O
potent None None O
compound None None O
of None None O
the None None O
series None None O
was None None O
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoethyl None None I-IUPAC
] None None I-IUPAC
methylamino None None I-IUPAC
] None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
cyclohexanecarboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
21a None None O
) None None O
with None None O
an None None O
IC50 None None O
value None None O
of None None O
7.0 None None O
nM None None O
compared None None O
with None None O
the None None O
value None None O
of None None O
3.0 None None O
nM None None O
for None None O
captopril None None O
. None None O

Further None None O
21a None None O
was None None O
shown None None O
to None None O
be None None O
highly None None O
selective None None O
and None None O
competitive None None O
ACE None None O
inhibitor None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
this None None O
non None None O
- None None O
amino None None O
acid None None O
structure None None O
of None None O
inhibitors None None O
meets None None O
the None None O
ACE None None O
active None None O
site None None O
requirements None None O
for None None O
the None None O
binding None None O
. None None O

The None None O
binding None None O
compatibility None None O
of None None O
the None None O
most None None O
active None None O
compounds None None O
with None None O
a None None O
model None None O
of None None O
ACE None None O
active None None O
site None None O
was None None O
evaluated None None O
by None None O
molecular None None O
modeling None None O
techniques None None O
. None None O


The None None O
nigrostriatal None None O
toxin None None O
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydropyridine None None I-IUPAC
( None None O
MPTP None None O
) None None O
is None None O
biotransformed None None O
by None None O
brain None None O
monoamine None None O
oxidase None None O
( None None O
MAO None None O
) None None O
to None None O
an None None O
unstable None None O
dihydropyridinium None None O
intermediate None None O
that None None O
reacts None None O
with None None O
cyanide None None O
ion None None O
to None None O
form None None O
an None None O
alpha None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
tetrahydropyridine None None I-IUPAC
adduct None None O
and None None O
, None None O
in None None O
the None None O
absence None None O
of None None O
cyanide None None O
ion None None O
, None None O
undergoes None None O
disproportionation None None O
to None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenylpyridinium None None I-IUPAC
species None None O
MPP+ None None O
and None None O
MPTP None None O
. None None O

Comparison None None O
of None None O
the None None O
HPLC None None O
retention None None O
times None None O
, None None O
diode None None O
array None None O
UV None None O
, None None O
and None None O
chemical None None O
ion None None O
mass None None O
spectral None None O
characteristics None None O
of None None O
these None None O
products None None O
with None None O
those None None O
of None None O
synthetic None None O
standards None None O
led None None O
us None None O
to None None O
propose None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydropyridinium None None I-IUPAC
species None None O
2,3 None None O
- None None O
MPDP+ None None O
and None None O
6 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydropyridine None None I-IUPAC
as None None O
tentative None None O
structure None None O
assignments None None O
for None None O
the None None O
dihydropyridinium None None O
metabolite None None O
and None None O
the None None O
cyano None None O
adduct None None O
, None None O
respectively None None O
. None None O

Results None None O
presented None None O
in None None O
this None None O
paper None None O
confirm None None O
the None None O
first None None O
assignment None None O
and None None O
establish None None O
that None None O
, None None O
although None None O
the None None O
proposed None None O
6 None None O
- None None O
cyano None None O
adduct None None O
is None None O
initially None None O
formed None None O
, None None O
the None None O
product None None O
that None None O
was None None O
isolated None None O
from None None O
the None None O
mitochondrial None None O
incubation None None O
mixtures None None O
of None None O
MPTP None None O
and None None O
sodium None None O
cyanide None None O
actually None None O
is None None O
the None None O
isomeric None None O
2 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydropyridine None None I-IUPAC
. None None O

On None None O
the None None O
basis None None O
of None None O
the None None O
selective None None O
incorporation None None O
of None None O
deuterium None None O
into None None O
these None None O
products None None O
, None None O
we None None O
provide None None O
rational None None O
mechanistic None None O
interpretations None None O
of None None O
the None None O
disproportionation None None O
reaction None None O
and None None O
the None None O
rearrangement None None O
of None None O
the None None O
cyano None None O
adducts None None O
. None None O

These None None O
results None None O
establish None None O
that None None O
the None None O
MAO None None O
- None None O
catalyzed None None O
bioactivation None None O
of None None O
MPTP None None O
leads None None O
to None None O
the None None O
formation None None O
of None None O
a None None O
variety None None O
of None None O
reactive None None O
molecules None None O
that None None O
are None None O
potentially None None O
cytotoxic None None O
to None None O
nigrostriatal None None O
cells None None O
. None None O


A None None O
novel None None O
class None None O
of None None O
tricyclic None None O
tropane None None O
analogues None None O
has None None O
been None None O
synthesized None None O
by None None O
making None None O
use None None O
of None None O
radical None None O
cyclization None None O
technology None None O
in None None O
combination None None O
with None None O
the None None O
Stille None None O
coupling None None O
reaction None None O
. None None O

As None None O
hybrids None None O
between None None O
tropanes None None O
and None None O
quinuclidines None None O
, None None O
these None None O
tropaquinuclidines None None O
represent None None O
a None None O
significant None None O
structural None None O
departure None None O
from None None O
many None None O
of None None O
the None None O
other None None O
classes None None O
of None None O
tropane None None O
ligands None None O
synthesized None None O
to None None O
date None None O
. None None O

This None None O
structure None None O
class None None O
is None None O
characterized None None O
by None None O
the None None O
boat None None O
conformation None None O
of None None O
the None None O
tropane None None O
ring None None O
and None None O
the None None O
orientation None None O
of None None O
the None None O
additional None None O
bridge None None O
( None None O
and None None O
therefore None None O
of None None O
the None None O
nitrogen None None O
lone None None O
pair None None O
) None None O
together None None O
with None None O
the None None O
unusual None None O
placement None None O
of None None O
the None None O
aromatic None None O
moiety None None O
. None None O

All None None O
compounds None None O
were None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
inhibit None None O
monoamine None None O
reuptake None None O
under None None O
identical None None O
conditions None None O
. None None O

The None None O
ability None None O
to None None O
inhibit None None O
reuptake None None O
of None None O
dopamine None None O
in None None O
comparison None None O
to None None O
cocaine None None O
is None None O
generally None None O
decreased None None O
in None None O
this None None O
series None None O
but None None O
for None None O
one None None O
compound None None O
. None None O

( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
3R None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
thienylmethylene None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
azatricyclo None None I-IUPAC
[ None None I-IUPAC
4.3.1.0 None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
decane None None I-IUPAC
- None None I-IUPAC
2beta None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
( None None O
5h None None O
) None None O
exhibits None None O
reasonable None None O
activity None None O
at None None O
the None None O
dopamine None None O
transporter None None O
( None None O
DAT None None O
) None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
268 None None O
nM None None O
) None None O
and None None O
good None None O
activity None None O
at None None O
the None None O
norepinephrine None None O
transporter None None O
( None None O
NET None None O
) None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
26 None None O
nM None None O
) None None O
. None None O

The None None O
potency None None O
and None None O
selectivity None None O
shown None None O
by None None O
some None None O
of None None O
these None None O
ligands None None O
for None None O
the None None O
NET None None O
, None None O
serotonine None None O
transporter None None O
( None None O
SERT None None O
) None None O
, None None O
or None None O
NET None None O
/ None None O
SERT None None O
is None None O
striking None None O
, None None O
particularly None None O
in None None O
view None None O
of None None O
the None None O
displacement None None O
of None None O
the None None O
aromatic None None O
ring None None O
in None None O
this None None O
series None None O
from None None O
its None None O
usual None None O
position None None O
at None None O
C None None O
- None None O
3 None None O
in None None O
the None None O
WIN None None O
analogues None None O
. None None O

Thus None None O
, None None O
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
3R None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
biphenylylmethylene None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
azatricyclo None None I-IUPAC
[ None None I-IUPAC
4.3.1 None None I-IUPAC
. None None I-IUPAC

0 None None I-IUPAC
( None None I-IUPAC
3,7 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
decane None None I-IUPAC
- None None I-IUPAC
2beta None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
( None None O
5a None None O
) None None O
is None None O
a None None O
selective None None O
inhibitor None None O
of None None O
norepinephrine None None O
reuptake None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
12 None None O
nM None None O
) None None O
. None None O

Its None None O
p None None O
- None None O
methoxy None None O
analogue None None O
5c None None O
is None None O
a None None O
mixed None None O
inhibitor None None O
of None None O
norepinephrine None None O
and None None O
serotonin None None O
reuptake None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
187 None None O
nM None None O
at None None O
the None None O
NET None None O
and None None O
56 None None O
nM None None O
at None None O
the None None O
SERT None None O
) None None O
. None None O

The None None O
most None None O
active None None O
and None None O
selective None None O
compound None None O
we None None O
found None None O
in None None O
the None None O
present None None O
series None None O
is None None O
compound None None O
8b None None O
[ None None O
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
3R None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
acetoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
dichlorophenylmethylene None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
azatricyclo None None I-IUPAC
[ None None I-IUPAC
4.3.1.0 None None I-IUPAC
( None None I-IUPAC
3,7 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
decane None None I-IUPAC
] None None O
. None None O

This None None O
compound None None O
is None None O
a None None O
potent None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
1.6 None None O
nM None None O
) None None O
and None None O
selective None None O
inhibitor None None O
of None None O
serotonin None None O
reuptake None None O
into None None O
rat None None O
midbrain None None O
synaptosomes None None O
. None None O

Its None None O
selectivity None None O
is None None O
about None None O
400 None None O
- None None O
fold None None O
over None None O
the None None O
NET None None O
and None None O
about None None O
1000 None None O
- None None O
fold None None O
over None None O
the None None O
DAT None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
further None None O
demonstrate None None O
the None None O
possibility None None O
of None None O
tuning None None O
the None None O
selectivity None None O
of None None O
tropane None None O
analogues None None O
toward None None O
the None None O
SERT None None O
or None None O
NET None None O
binding None None O
site None None O
. None None O

The None None O
ligands None None O
disclosed None None O
herein None None O
provide None None O
additional None None O
pharmacological None None O
tools None None O
of None None O
use None None O
in None None O
attempting None None O
to None None O
correlate None None O
structure None None O
and None None O
transporter None None O
selectivity None None O
with None None O
in None None O
vivo None None O
studies None None O
of None None O
behavioral None None O
outcomes None None O
. None None O


Recently None None O
, None None O
we None None O
reported None None O
the None None O
first None None O
human None None O
study None None O
of None None O
[ None None O
99mTc None None O
] None None O
TRODAT None None O
- None None O
1 None None O
, None None O
technetium None None O
, None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
[ None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
[ None None I-PARTIUPAC
[ None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
chlorophenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
- None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
azabicyclo None None I-PARTIUPAC
[ None None O
3.2.1 None None O
] None None O
oct None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
yl None None I-PARTIUPAC
] None None I-PARTIUPAC
methyl None None I-PARTIUPAC
] None None I-PARTIUPAC
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
mercaptoethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
amino None None I-PARTIUPAC
] None None I-PARTIUPAC
ethyl None None I-PARTIUPAC
] None None I-PARTIUPAC
amino None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
ethanethiolato None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
o None None I-PARTIUPAC
xo None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
1R None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
exo None None I-PARTIUPAC
- None None I-PARTIUPAC
exo None None I-PARTIUPAC
) None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
as None None O
an None None O
imaging None None O
agent None None O
of None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
dopamine None None O
transporters None None O
. None None O

Due None None O
to None None O
the None None O
existence None None O
of None None O
several None None O
chiral None None O
centers None None O
on None None O
this None None O
molecule None None O
, None None O
upon None None O
the None None O
formation None None O
of None None O
[ None None O
99mTc None None O
] None None O
TRODAT None None O
- None None O
1 None None O
complex None None O
( None None O
2 None None O
) None None O
several None None O
diastereomers None None O
could None None O
be None None O
created None None O
. None None O

Two None None O
major None None O
diastereomers None None O
of None None O
[ None None O
99mTc None None O
] None None O
TRODAT None None O
- None None O
1 None None O
( None None O
2 None None O
) None None O
, None None O
designated None None O
as None None O
peak None None O
A None None O
( None None O
2A None None O
) None None O
and None None O
peak None None O
B None None O
( None None O
2B None None O
) None None O
, None None O
were None None O
separated None None O
by None None O
HPLC None None O
. None None O

Biodistribution None None O
of None None O
the None None O
purified None None O
diastereomers None None O
2A None None O
, None None O
B None None O
was None None O
evaluated None None O
in None None O
rats None None O
. None None O

It None None O
appears None None O
that None None O
2A None None O
displayed None None O
a None None O
higher None None O
lipophilicity None None O
than None None O
2B None None O
( None None O
PC None None O
= None None O
305 None None O
and None None O
229 None None O
, None None O
respectively None None O
) None None O
, None None O
and None None O
a None None O
similar None None O
trend None None O
was None None O
observed None None O
for None None O
the None None O
initial None None O
brain None None O
uptake None None O
at None None O
2 None None O
min None None O
postinjection None None O
( None None O
0.50% None None O
and None None O
0.28% None None O
dose None None O
/ None None O
organ None None O
for None None O
2A None None O
, None None O
B None None O
, None None O
respectively None None O
) None None O
. None None O

At None None O
60 None None O
min None None O
post None None O
- None None O
iv None None O
- None None O
injection None None O
, None None O
the None None O
specific None None O
uptakes None None O
, None None O
as None None O
measured None None O
by None None O
[ None None O
striatum None None O
- None None O
cerebellum None None O
] None None O
/ None None O
cerebellum None None O
( None None O
[ None None O
ST None None O
- None None O
CB None None O
] None None O
/ None None O
CB None None O
) None None O
ratio None None O
, None None O
were None None O
1.72 None None O
and None None O
2.79 None None O
for None None O
2A None None O
, None None O
B None None O
, None None O
respectively None None O
. None None O

The None None O
higher None None O
[ None None O
ST None None O
- None None O
CB None None O
] None None O
/ None None O
CB None None O
ratio None None O
observed None None O
for None None O
2B None None O
was None None O
corroborated None None O
by None None O
the None None O
results None None O
of None None O
an None None O
in None None O
vitro None None O
binding None None O
assay None None O
. None None O

Higher None None O
binding None None O
affinity None None O
for None None O
dopamine None None O
transporters None None O
was None None O
observed None None O
for None None O
3B None None O
( None None O
Ki None None O
= None None O
13.87 None None O
and None None O
8.42 None None O
nM None None O
for None None O
the None None O
analogous None None O
rhenium None None O
complexes None None O
3A None None O
, None None O
B None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
structure None None O
of None None O
the None None O
[ None None O
99mTc None None O
] None None O
TRODAT None None O
- None None O
1 None None O
complexes None None O
was None None O
deduced None None O
using None None O
nonradioactive None None O
rhenium None None O
as None None O
a None None O
surrogate None None O
for None None O
radioactive None None O
technetium None None O
complex None None O
. None None O

Reacting None None O
free None None O
TRODAT None None O
- None None O
1 None None O
ligand None None O
with None None O
[ None None O
Bu4N None None O
] None None O
[ None None O
ReOCl4 None None O
] None None O
yielded None None O
two None None O
major None None O
complexes None None O
: None None O
Re None None O
- None None O
TRODAT None None O
- None None O
1A None None O
( None None O
3A None None O
) None None O
and None None O
Re None None O
- None None O
TRODAT None None O
- None None O
1B None None O
( None None O
3B None None O
) None None O
( None None O
corresponding None None O
with None None O
peaks None None O
A None None O
and None None O
B None None O
of None None O
[ None None O
99mTc None None O
] None None O
TRODAT None None O
- None None O
1 None None O
, None None O
respectively None None O
) None None O
, None None O
whose None None O
structures None None O
were None None O
determined None None O
by None None O
X None None O
- None None O
ray None None O
analysis None None O
. None None O

The None None O
X None None O
- None None O
ray None None O
structures None None O
show None None O
that None None O
both None None O
complexes None None O
have None None O
a None None O
pseudo None None O
- None None O
square None None O
- None None O
pyramidal None None O
structure None None O
of None None O
[ None None O
RevO None None O
] None None O
3+ None None O
N2S2 None None O
core None None O
with None None O
oxygen None None O
occupying None None O
the None None O
apical None None O
position None None O
and None None O
the None None O
N None None O
- None None O
alkyl None None O
substitution None None O
in None None O
syn None None O
- None None O
configuration None None O
to None None O
the None None O
oxo None None O
- None None O
rhenium None None O
bond None None O
. None None O

In None None O
conclusion None None O
, None None O
TRODAT None None O
- None None O
1 None None O
formed None None O
at None None O
least None None O
two None None O
diastereomers None None O
after None None O
complexing None None O
with None None O
a None None O
metal None None O
( None None O
V None None O
) None None O
- None None O
oxo None None O
( None None O
M None None O
= None None O
99mTc None None O
, None None O
Re None None O
) None None O
center None None O
core None None O
. None None O

The None None O
two None None O
isomers None None O
display None None O
different None None O
binding None None O
affinities None None O
toward None None O
dopamine None None O
transporters None None O
and None None O
distinct None None O
properties None None O
of None None O
localization None None O
in None None O
the None None O
striatum None None O
area None None O
of None None O
the None None O
brain None None O
where None None O
the None None O
transporters None None O
are None None O
located None None O
. None None O


The None None O
novel None None O
calcium None None O
antagonists None None O
3 None None I-MODIFIER
- None None I-MODIFIER
N None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dihydropyrimidines None None I-IUPAC
1 None None O
and None None O
9 None None O
and None None O
3 None None I-MODIFIER
- None None I-MODIFIER
N None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
dihydro None None I-IUPAC
- None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
8 None None O
were None None O
regioselectively None None O
synthesized None None O
in None None O
good None None O
yields None None O
. None None O

Compounds None None O
1 None None O
[ None None O
especially None None O
1s None None O
[ None None O
R1 None None O
= None None O
( None None I-PARTIUPAC
CH2 None None I-PARTIUPAC
) None None I-PARTIUPAC
2N None None I-PARTIUPAC
( None None I-PARTIUPAC
benzyl None None I-PARTIUPAC
) None None I-PARTIUPAC
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
naphthylmethyl None None I-PARTIUPAC
) None None O
, None None O
R2 None None O
= None None O
i None None O
- None None O
Pr None None O
, None None O
X None None O
= None None O
0 None None O
- None None O
NO2 None None O
] None None O
and None None O
1t None None O
[ None None O
R1 None None O
= None None O
( None None I-PARTIUPAC
CH2 None None I-PARTIUPAC
) None None I-PARTIUPAC
2N None None I-PARTIUPAC
( None None I-PARTIUPAC
benzyl None None I-PARTIUPAC
) None None I-PARTIUPAC
( None None I-PARTIUPAC
3,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
dichlorobenzyl None None I-PARTIUPAC
) None None O
, None None O
R2 None None O
= None None O
i None None O
- None None O
Pr None None O
, None None O
X None None O
= None None O
0 None None O
- None None O
NO2 None None O
] None None O
] None None O
exhibited None None O
not None None O
only None None O
more None None O
potent None None O
and None None O
longer None None O
lasting None None O
vasodilative None None O
action None None O
but None None O
also None None O
a None None O
hypotensive None None O
activity None None O
with None None O
slow None None O
onset None None O
as None None O
compared None None O
with None None O
dihydropyridines None None O
. None None O

Moreover None None O
, None None O
some None None O
dihydropyrimidines None None O
[ None None O
1q None None O
[ None None O
R1 None None O
= None None O
( None None I-PARTIUPAC
CH2 None None I-PARTIUPAC
) None None I-PARTIUPAC
2N None None I-PARTIUPAC
( None None I-PARTIUPAC
benzyl None None I-PARTIUPAC
) None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
phenylpropyl None None I-PARTIUPAC
) None None O
, None None O
R2 None None O
= None None O
CH2 None None I-IUPAC
( None None I-IUPAC
cyclopropyl None None I-IUPAC
) None None I-IUPAC
, None None O
X None None O
= None None O
0 None None O
- None None O
NO2 None None O
] None None O
, None None O
1s None None O
, None None O
and None None O
1t None None O
] None None O
were None None O
weaker None None O
in None None O
blocking None None O
atrioventricular None None O
conduction None None O
in None None O
anesthetized None None O
open None None O
- None None O
chest None None O
dogs None None O
and None None O
less None None O
toxic None None O
than None None O
the None None O
dihydropyridines None None O
. None None O


A None None O
new None None O
series None None O
of None None O
thyrotropin None None O
- None None O
releasing None None O
hormone None None O
( None None O
TRH None None O
) None None O
analogues None None O
, None None O
obtained None None O
by None None O
further None None O
modifications None None O
of None None O
our None None O
most None None O
potent None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
stimulating None None O
neutral None None O
tripeptides None None O
at None None O
both None None O
termini None None O
, None None O
were None None O
synthesized None None O
by None None O
the None None O
pentafluorophenyl None None O
ester None None O
method None None O
and None None O
tested None None O
for None None O
CNS None None O
and None None O
thyrotropin None None O
( None None O
TSH None None O
) None None O
releasing None None O
activity None None O
. None None O

Replacement None None O
of None None O
pyroglutamic None None O
acid None None O
by None None O
pyro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoadipic None None I-IUPAC
acid None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
oxoimidazolidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
or None None O
gamma None None I-IUPAC
- None None I-IUPAC
butyrolactone None None I-IUPAC
- None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
and None None O
that None None O
of None None O
proline None None O
by None None O
pipecolic None None O
acid None None O
, None None O
thiazolidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
, None None O
or None None O
homoproline None None O
in None None O
[ None None O
Leu2 None None O
] None None O
- None None O
and None None O
[ None None O
Nva2 None None O
] None None O
TRH None None O
led None None O
to None None O
tripeptides None None O
structurally None None O
widely None None O
different None None O
from None None O
TRH None None O
. None None O

In None None O
spite None None O
of None None O
this None None O
fact None None O
, None None O
7 None None O
of None None O
the None None O
17 None None O
analogues None None O
( None None O
1 None None O
, None None O
2 None None O
, None None O
8-10 None None O
, None None O
16 None None O
, None None O
and None None O
17 None None O
) None None O
have None None O
stronger None None O
anticataleptic None None O
effect None None O
than None None O
TRH None None O
, None None O
with None None O
negligible None None O
or None None O
no None None O
hormonal None None O
potency None None O
. None None O

The None None O
highest None None O
CNS None None O
activity None None O
was None None O
achieved None None O
when None None O
pyroglutamic None None O
acid None None O
was None None O
replaced None None O
by None None O
pyro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoadipic None None I-IUPAC
acid None None I-IUPAC
at None None O
the None None O
N None None O
- None None O
terminus None None O
[ None None O
pAad None None O
- None None O
Leu None None O
- None None O
Pro None None O
- None None O
NH2 None None O
, None None O
1 None None O
( None None O
RGH None None O
2202 None None O
) None None O
, None None O
and None None O
pAad None None O
- None None O
Nva None None O
- None None O
Pro None None O
- None None O
NH2 None None O
, None None O
2 None None O
] None None O
. None None O

A None None O
novel None None O
synthesis None None O
of None None O
L None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoadipic None None I-IUPAC
acid None None I-IUPAC
suitable None None O
for None None O
large None None O
- None None O
scale None None O
preparation None None O
is None None O
also None None O
described None None O
. None None O


Novel None None O
arylpiperazines None None O
were None None O
identified None None O
as None None O
alpha None None O
1 None None O
- None None O
adrenoceptor None None O
( None None O
AR None None O
) None None O
subtype None None O
- None None O
selective None None O
antagonists None None O
by None None O
functional None None O
in None None O
vitro None None O
screening None None O
. None None O

3 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
ortho None None I-IUPAC
- None None O
Substituted None None I-MODIFIER
phenyl None None B-IUPAC
) None None O
piperazin None None I-PARTIUPAC
- None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
yl None None I-PARTIUPAC
] None None I-PARTIUPAC
propylamines None None I-PARTIUPAC
were None None O
derivatized None None O
with None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
anthranilamides None None I-IUPAC
, None None O
nicotinamides None None O
, None None O
as None None O
well None None O
as None None O
carboxamides None None O
of None None O
quinoline None None O
, None None O
1,8 None None I-IUPAC
- None None I-IUPAC
naphthyridine None None I-IUPAC
, None None O
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
, None None O
isoxazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
, None None O
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
, None None O
and None None O
pyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
. None None O

Strips None None O
of None None O
rabbit None None O
bladder None None O
neck None None O
were None None O
employed None None O
as None None O
a None None O
predictive None None O
assay None None O
for None None O
antagonism None None O
in None None O
the None None O
human None None O
lower None None O
tract None None O
. None None O

Rings None None O
of None None O
rat None None O
aorta None None O
were None None O
used None None O
as None None O
a None None O
" None None O
negative None None O
screen None None O
" None None O
for None None O
the None None O
test None None O
antagonists None None O
. None None O

Binding None None O
to None None O
alpha None None O
1 None None O
- None None O
ARs None None O
was None None O
relatively None None O
sensitive None None O
to None None O
size None None O
and None None O
electronic None None O
features None None O
of None None O
the None None O
arylpiperazine None None I-IUPAC
portion None None O
of None None O
the None None O
antagonists None None O
and None None O
permissive None None O
to None None O
these None None O
features None None O
on None None O
the None None O
heteroaryl None None O
carboxamide None None O
side None None O
. None None O

These None None O
structure None None O
- None None O
affinity None None O
findings None None O
were None None O
exploited None None O
to None None O
produce None None O
nicotinamides None None O
( None None O
e.g. None None O
13ii None None O
and None None O
25x None None O
) None None O
and None None O
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridines None None I-IUPAC
( None None O
e.g. None None O
37f None None O
and None None O
37y None None O
) None None O
ligands None None O
with None None O
nanomolar None None O
affinity None None O
at None None O
the None None O
alpha None None O
1 None None O
- None None O
AR None None O
subtype None None O
prevalent None None O
in None None O
the None None O
human None None O
lower None None O
urinary None None O
tract None None O
( None None O
pA2 None None O
values None None O
: None None O
8.8 None None O
, None None O
10.7 None None O
, None None O
9.3 None None O
, None None O
and None None O
9.9 None None O
, None None O
respectively None None O
) None None O
and None None O
displaying None None O
2-3 None None O
orders None None O
of None None O
magnitude None None O
selectivity None None O
over None None O
the None None O
alpha None None O
1D None None O
- None None O
AR None None O
. None None O


A None None O
series None None O
of None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
pyridinyl None None I-PARTIUPAC
) None None I-PARTIUPAC
butyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
5,5 None None I-PARTIUPAC
- None None O
disubstituted None None I-MODIFIER
- None None O
pentadienamides None None I-PARTIUPAC
was None None O
prepared None None O
and None None O
evaluated None None O
for None None O
PAF None None O
- None None O
antagonist None None O
activity None None O
. None None O

Compounds None None O
were None None O
assayed None None O
in None None O
vitro None None O
in None None O
a None None O
PAF None None O
- None None O
binding None None O
assay None None O
employing None None O
washed None None O
, None None O
whole None None O
dog None None O
platelets None None O
as None None O
the None None O
receptor None None O
source None None O
and None None O
in None None O
vivo None None O
after None None O
intravenous None None O
or None None O
oral None None O
administration None None O
for None None O
their None None O
ability None None O
to None None O
prevent None None O
PAF None None O
- None None O
induced None None O
bronchoconstriction None None O
in None None O
guinea None None O
pigs None None O
. None None O

Criteria None None O
required None None O
for None None O
good None None O
oral None None O
activity None None O
in None None O
the None None O
latter None None O
model None None O
include None None O
an None None O
( None None I-IUPAC
E None None I-IUPAC
, None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
pentadienamide None None I-IUPAC
, None None O
a None None O
second None None O
phenyl None None I-PARTIUPAC
or None None O
a None None O
four None None O
- None None O
or None None O
five None None O
- None None O
carbon None None O
alkyl None None I-PARTIUPAC
moiety None None B-MODIFIER
in None None O
the None None O
5 None None O
- None None O
position None None O
of None None O
the None None O
diene None None O
, None None O
and None None O
an None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
substituent None None I-MODIFIER
on None None O
the None None O
carboxamide None None O
nitrogen None None O
atom None None O
. None None O

The None None O
alkyl None None I-PARTIUPAC
substituent None None B-MODIFIER
on None None O
this None None O
side None None O
chain None None O
can None None O
be None None O
methyl None None I-PARTIUPAC
, None None O
ethyl None None I-PARTIUPAC
, None None O
or None None O
cyclopropyl None None I-PARTIUPAC
. None None O

Two None None O
members None None O
of None None O
this None None O
series None None O
, None None O
[ None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5,5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
pentadienamide None None I-IUPAC
( None None O
31 None None O
) None None O
and None None O
[ None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
, None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
decadienamide None None I-IUPAC
( None None O
58 None None O
) None None O
, None None O
were None None O
selected None None O
for None None O
further None None O
pharmacological None None O
evaluation None None O
. None None O

Both None None O
were None None O
found None None O
to None None O
be None None O
substantially None None O
longer None None O
acting None None O
after None None O
oral None None O
administration None None O
than None None O
the None None O
corresponding None None O
S None None O
enantiomers None None O
in None None O
the None None O
guinea None None O
pig None None O
bronchoconstriction None None O
assay None None O
. None None O

A None None O
second None None O
in None None O
vivo None None O
model None None O
used None None O
to None None O
evaluate None None O
PAF None None O
antagonists None None O
determines None None O
the None None O
ability None None O
of None None O
test None None O
compounds None None O
to None None O
decrease None None O
the None None O
area None None O
of None None O
skin None None O
wheals None None O
induced None None O
by None None O
an None None O
intradermal None None O
injection None None O
of None None O
PAF None None O
. None None O

In None None O
this None None O
model None None O
, None None O
using None None O
both None None O
rats None None O
and None None O
guinea None None O
pigs None None O
, None None O
compounds None None O
31 None None O
and None None O
58 None None O
were None None O
found None None O
to None None O
be None None O
as None None O
active None None O
as None None O
the None None O
reference None None O
PAF None None O
antagonist None None O
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
morpholinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propanone None None I-IUPAC
( None None O
45 None None O
) None None O
. None None O


Convenient None None O
procedures None None O
are None None O
described None None O
for None None O
the None None O
synthesis None None O
of None None O
5 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
N None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxycytidines None None I-IUPAC
5a None None O
, None None O
b None None O
, None None O
d None None O
- None None O
h None None O
via None None O
transformation None None O
of None None O
the None None O
respective None None O
5 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
3' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridines None None I-IUPAC
1a None None O
- None None O
c None None O
, None None O
e None None O
- None None O
h None None O
. None None O

These None None O
procedures None None O
involved None None O
site None None O
- None None O
specific None None O
triazolation None None O
or None None O
N None None O
- None None O
methylimidazolation None None O
at None None O
position None None O
C None None O
( None None O
4 None None O
) None None O
, None None O
followed None None O
by None None O
hydroxylamination None None O
and None None O
deblocking None None O
with None None O
MeOH None None O
- None None O
NH None None O
( None None O
3 None None O
) None None O
. None None O

Nucleosides None None O
5a None None O
, None None O
b None None O
, None None O
d None None O
- None None O
h None None O
were None None O
selectively None None O
converted None None O
to None None O
the None None O
corresponding None None O
5' None None O
- None None O
monophosphates None None O
6a None None O
, None None O
b None None O
, None None O
d None None O
- None None O
h None None O
with None None O
the None None O
aid None None O
of None None O
the None None O
wheat None None O
shoot None None O
phosphotransferase None None O
system None None O
. None None O

Conformation None None O
of None None O
each None None O
nucleoside None None O
in None None O
D None None O
( None None O
2 None None O
) None None O
O None None O
solution None None O
, None None O
deduced None None O
from None None O
( None None O
1 None None O
) None None O
H None None O
NMR None None O
spectra None None O
and None None O
confirmed None None O
by None None O
molecular None None O
mechanics None None O
calculations None None O
, None None O
showed None None O
the None None O
pentose None None O
ring None None O
to None None O
exist None None O
predominantly None None O
in None None O
the None None O
conformation None None O
S None None O
( None None O
C None None O
- None None O
2' None None O
- None None O
endo None None O
) None None O
and None None O
the None None O
N None None O
( None None O
4 None None O
) None None O
- None None O
OH None None O
group None None O
as None None O
the None None O
cis None None O
rotamer None None O
. None None O

Cell None None O
growth None None O
inhibition None None O
was None None O
studied None None O
with None None O
two None None O
L5178Y None None O
murine None None O
leukemia None None O
cell None None O
lines None None O
, None None O
parental None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
FdUrd None None O
) None None O
- None None O
resistant None None O
, None None O
the None None O
latter None None O
70 None None O
- None None O
fold None None O
less None None O
sensitive None None O
toward None None O
FdUrd None None O
than None None O
the None None O
former None None O
. None None O

With None None O
FdUrd None None O
- None None O
resistant None None O
L5178Y None None O
cells None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxycytidine None None I-IUPAC
( None None O
5e None None O
) None None O
caused None None O
almost None None O
3 None None O
- None None O
fold None None O
stronger None None O
growth None None O
inhibition None None O
than None None O
FdUrd None None O
; None None O
5e None None O
was None None O
only None None O
some None None O
3 None None O
- None None O
fold None None O
weaker None None O
growth None None O
inhibitor None None O
of None None O
the None None O
resistant None None O
cells None None O
than None None O
of None None O
the None None O
parental None None O
cells None None O
. None None O

Thymidylate None None O
synthase None None O
inhibition None None O
was None None O
studied None None O
with None None O
two None None O
forms None None O
of None None O
the None None O
enzyme None None O
differing None None O
in None None O
sensitivities None None O
toward None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
monophosphate None None I-IUPAC
( None None O
FdUMP None None O
) None None O
, None None O
isolated None None O
from None None O
parental None None O
and None None O
FdUrd None None O
- None None O
resistant None None O
L1210 None None O
cell None None O
lines None None O
. None None O

All None None O
N None None O
( None None O
4 None None O
) None None O
- None None O
hydroxy None None O
- None None O
dCMP None None O
( None None O
6a None None O
, None None O
b None None O
, None None O
d None None O
- None None O
h None None O
) None None O
and None None O
dUMP None None O
analogues None None O
studied None None O
were None None O
competitive None None O
vs None None O
dUMP None None O
inhibitors None None O
of None None O
the None None O
enzyme None None O
. None None O

Analogues None None O
6b None None O
, None None O
d None None O
- None None O
h None None O
and None None O
5 None None O
- None None O
hydroxymethyl None None O
- None None O
dUMP None None O
, None None O
similar None None O
to None None O
N None None O
( None None O
4 None None O
) None None O
- None None O
hydroxy None None O
- None None O
dCMP None None O
( None None O
6a None None O
) None None O
and None None O
FdUMP None None O
, None None O
were None None O
also None None O
N None None O
( None None O
5 None None O
) None None O
, None None O
N None None I-IUPAC
( None None I-IUPAC
10 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methylenetetrahydrofolate None None I-IUPAC
- None None O
dependent None None O
, None None O
hence None None O
mechanism None None O
- None None O
based None None O
, None None O
slow None None O
- None None O
binding None None O
inhibitors None None O
. None None O

5 None None O
- None None O
Chloro None None O
- None None O
dUMP None None O
, None None O
5 None None O
- None None O
bromo None None O
- None None O
dUMP None None O
, None None O
and None None O
5 None None O
- None None O
iodo None None O
- None None O
dUMP None None O
, None None O
similar None None O
to None None O
dTMP None None O
, None None O
did None None O
not None None O
cause None None O
a None None O
time None None O
- None None O
dependent None None O
inactivation None None O
of None None O
the None None O
enzyme None None O
. None None O

Instead None None O
, None None O
they None None O
behaved None None O
as None None O
classic None None O
inhibitors None None O
of None None O
tritium None None O
release None None O
from None None O
[ None None O
5 None None O
- None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
dUMP None None O
. None None O

5 None None O
- None None O
Bromo None None O
- None None O
dUMP None None O
and None None O
5 None None O
- None None O
iodo None None O
- None None O
dUMP None None O
showed None None O
substrate None None O
activity None None O
independent None None O
of None None O
N None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
10 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methylenetetrahydrofolate None None I-IUPAC
in None None O
the None None O
thymidylate None None O
synthase None None O
- None None O
catalyzed None None O
dehalogenation None None O
reaction None None O
. None None O

The None None O
= None None O
N None None O
- None None O
OH None None O
substituent None None O
of None None O
the None None O
pyrimidine None None O
C None None O
( None None O
4 None None O
) None None O
prevented None None O
the None None O
enzyme None None O
- None None O
catalyzed None None O
release None None O
from None None O
the None None O
C None None O
( None None O
5 None None O
) None None O
of None None O
Br None None O
( None None O
- None None O
) None None O
and None None O
I None None O
( None None O
- None None O
) None None O
( None None O
the None None O
same None None O
shown None None O
previously None None O
for None None O
H None None O
( None None O
+ None None O
) None None O
) None None O
. None None O

While None None O
FdUMP None None O
and None None O
6a None None O
showed None None O
a None None O
higher None None O
affinity None None O
and None None O
greater None None O
inactivation None None O
power None None O
with None None O
the None None O
parental None None O
cell None None O
than None None O
FdUrd None None O
- None None O
resistant None None O
cell None None O
enzyme None None O
, None None O
an None None O
opposite None None O
relationship None None O
could None None O
be None None O
seen None None O
with None None O
5 None None O
- None None O
hydroxymethyl None None O
- None None O
dUMP None None O
. None None O


The None None O
palladium None None O
- None None O
catalyzed None None O
coupling None None O
of None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trialkylstannyl None None I-IUPAC
) None None I-IUPAC
pyridines None None I-IUPAC
with None None O
7 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
or None None O
7 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
1,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
quinolinecarboxylates None None I-IUPAC
has None None O
provided None None O
access None None O
to None None O
the None None O
corresponding None None O
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
1,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
quinolinecarboxylic None None I-IUPAC
acids None None I-IUPAC
. None None O

The None None O
antibacterial None None O
activity None None O
of None None O
these None None O
derivatives None None O
was None None O
studied None None O
with None None O
the None None O
finding None None O
that None None O
the None None O
optimal None None O
1 None None O
- None None O
and None None O
7 None None O
- None None O
position None None O
substituents None None O
for None None O
Gram None None O
positive None None O
activity None None O
are None None O
cyclopropyl None None O
and None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
dimethylpyridinyl None None I-PARTIUPAC
) None None I-PARTIUPAC
, None None O
respectively None None O
. None None O

We None None O
find None None O
that None None O
for None None O
the None None O
fluorine None None O
- None None O
substituted None None O
derivatives None None O
studied None None O
, None None O
the None None O
position None None O
of None None O
the None None O
fluorine None None O
on None None O
the None None O
quinolone None None O
nucleus None None O
or None None O
the None None O
number None None O
of None None O
fluorine None None O
atoms None None O
does None None O
not None None O
seem None None O
to None None O
be None None O
important None None O
for None None O
good None None O
Gram None None O
positive None None O
activity None None O
. None None O

For None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
cyclopropyl None None I-PARTIUPAC
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
dimethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
pyridinyl None None I-PARTIUPAC
) None None I-PARTIUPAC
derivatives None None I-MODIFIER
, None None O
the None None O
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
fluoro None None I-PARTIUPAC
4a None None O
, None None O
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
fluoro None None I-PARTIUPAC
10d None None O
, None None O
6,8 None None I-PARTIUPAC
- None None I-PARTIUPAC
difluoro None None I-PARTIUPAC
10b None None O
, None None O
and None None O
5,6,8 None None I-PARTIUPAC
- None None I-PARTIUPAC
trifluoro None None I-PARTIUPAC
8 None None O
, None None O
all None None O
provided None None O
equal None None O
antibacterial None None O
activity None None O
against None None O
Staphylococcus None None O
aureus None None O
ATCC None None O
29213 None None O
. None None O

There None None O
is None None O
also None None O
a None None O
correlation None None O
between None None O
the None None O
substitution None None O
on None None O
the None None O
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
pyridinyl None None I-PARTIUPAC
) None None I-PARTIUPAC
group None None I-MODIFIER
and None None O
the None None O
Gram None None O
positive None None O
activity None None O
, None None O
particularly None None O
for None None O
S None None O
. None None O

aureus None None O
, None None O
clearly None None O
indicating None None O
that None None O
the None None O
2,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
dimethylpyridinyl None None I-PARTIUPAC
group None None I-MODIFIER
is None None O
optimal None None O
. None None O

The None None O
MIC50 None None O
value None None O
for None None O
the None None O
most None None O
potent None None O
agents None None O
in None None O
this None None O
study None None O
against None None O
S None None O
. None None O

aureus None None O
ATCC None None O
29213 None None O
is None None O
0.008 None None O
microgram None None O
/ None None O
mL None None O
. None None O

By None None O
comparison None None O
, None None O
ciprofloxacin None None O
and None None O
aminopyrrolidine None None O
28 None None O
gave None None O
values None None O
of None None O
0.25 None None O
and None None O
0.015 None None O
microgram None None O
/ None None O
mL None None O
, None None O
respectively None None O
, None None O
against None None O
this None None O
organism None None O
. None None O


In None None O
an None None O
effort None None O
to None None O
develop None None O
selective None None O
inhibitors None None O
of None None O
vesicular None None O
acetylcholine None None O
storage None None O
, None None O
we None None O
have None None O
synthesized None None O
a None None O
series None None O
of None None O
semirigid None None O
vesamicol None None O
receptor None None O
ligands None None O
based None None O
on None None O
the None None O
structure None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenylpiperidino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyclohexanol None None I-IUPAC
( None None O
vesamicol None None O
, None None O
AH5183 None None O
, None None O
1 None None O
) None None O
. None None O

In None None O
these None None O
compounds None None O
, None None O
the None None O
planes None None O
of None None O
the None None O
phenyl None None O
and None None O
piperidyl None None O
moieties None None O
of None None O
the None None O
parent None None O
ligand None None O
1 None None O
are None None O
held None None O
at None None O
right None None O
angles None None O
by None None O
vinyl None None O
, None None O
ethylene None None O
, None None O
and None None O
propylene None None O
bridges None None O
to None None O
form None None O
N None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
derivatives None None B-MODIFIER
of None None O
spiro None None I-IUPAC
[ None None I-IUPAC
indene None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
, None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydrospiro None None I-IUPAC
[ None None I-IUPAC
indene None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
, None None O
and None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dihydrospiro None None I-IUPAC
[ None None I-IUPAC
naphthalene None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
2H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
, None None O
respectively None None O
. None None O

Preliminary None None O
evaluation None None O
of None None O
these None None O
compounds None None O
in None None O
electric None None O
organ None None O
synaptic None None O
vesicles None None O
revealed None None O
several None None O
potent None None O
vesamicol None None O
receptor None None O
ligands None None O
, None None O
such None None O
as None None O
1' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydronaphth None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
spiro None None I-IUPAC
[ None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indene None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
iperidine None None I-IUPAC
( None None O
11b None None O
) None None O
and None None O
1' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydronaphth None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
spiro None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
in None None I-IUPAC
den None None I-IUPAC
e None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
( None None O
14 None None O
) None None O
, None None O
which None None O
display None None O
subnanomolar None None O
affinity None None O
for None None O
this None None O
receptor None None O
. None None O

In None None O
general None None O
, None None O
the None None O
vinyl None None O
and None None O
ethylene None None O
bridges None None O
yielded None None O
the None None O
most None None O
potent None None O
analogs None None O
while None None O
the None None O
propylene None None O
- None None O
bridged None None O
analogs None None O
were None None O
among None None O
the None None O
least None None O
potent None None O
compounds None None O
. None None O

The None None O
increased None None O
rigidity None None O
of None None O
these None None O
spiro None None O
- None None O
fused None None O
compounds None None O
, None None O
relative None None O
to None None O
the None None O
corresponding None None O
simple None None O
4 None None I-IUPAC
- None None I-IUPAC
phenylpiperidine None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
vesamicol None None O
, None None O
is None None O
expected None None O
to None None O
confer None None O
greater None None O
selectivity None None O
for None None O
the None None O
vesamicol None None O
receptor None None O
. None None O


Analogues None None O
of None None O
methotrexate None None O
( None None O
MTX None None O
) None None O
and None None O
aminopterin None None O
( None None O
AMT None None O
) None None O
modified None None O
at None None O
the None None O
gamma None None O
- None None O
position None None O
of None None O
the None None O
glutamate None None O
side None None O
chain None None O
were None None O
synthesized None None O
and None None O
evaluated None None O
as None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
inhibitors None None O
and None None O
tumor None None O
cell None None O
growth None None O
inhibitors None None O
. None None O

Condesations None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
N10 None None I-IUPAC
- None None I-IUPAC
methylpteroic None None I-IUPAC
acid None None I-IUPAC
( None None O
mAPA None None O
) None None O
with None None O
dimethyl None None I-IUPAC
DL None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyleneglutamate None None I-IUPAC
in None None O
the None None O
presence None None O
of None None O
diethyl None None O
phosphorocyanidate None None O
( None None O
DEPC None None O
) None None O
followed None None O
by None None O
alkaline None None O
hydrolysis None None O
yielded None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
N10 None None I-IUPAC
- None None I-IUPAC
methylpteroyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
DL None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyleneglutamic None None I-IUPAC
acid None None I-IUPAC
( None None O
gamma None None O
- None None O
methyleneMTX None None O
) None None O
. None None O

Condensation None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
N10 None None I-IUPAC
- None None I-IUPAC
formylpteroic None None I-IUPAC
acid None None I-IUPAC
( None None O
fAPA None None O
) None None O
with None None O
dimethyl None None I-IUPAC
- None None I-IUPAC
DL None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyleneglutamate None None I-IUPAC
by None None O
the None None O
mixed None None O
carboxylic None None O
- None None O
carbonic None None O
anhydride None None O
method None None O
yielded None None O
N None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxypteroyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
DL None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyleneglutamic None None I-IUPAC
acid None None I-IUPAC
( None None O
gamma None None O
- None None O
methyleneAMT None None O
) None None O
. None None O

Also None None O
prepared None None O
via None None O
DEPC None None O
coupling None None O
was None None O
a None None O
mixture None None O
of None None O
the None None O
four None None O
possible None None O
diastereomers None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
N10 None None I-IUPAC
- None None I-IUPAC
methylpteroyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
cyanoglutamic None None I-IUPAC
acid None None I-IUPAC
( None None O
gamma None None O
- None None O
cyanoMTX None None O
) None None O
. None None O

The None None O
requisite None None O
intermediate None None O
gamma None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
cyanoglutamate None None I-IUPAC
, None None O
as None None O
a None None O
DL None None O
- None None O
threo None None O
/ None None O
DL None None O
- None None O
erythro None None O
mixture None None O
, None None O
was None None O
prepared None None O
from None None O
methyl None None I-IUPAC
N None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
Boc None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
tosyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
serinate None None I-IUPAC
by None None O
reaction None None O
with None None O
sodium None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
cyanoacetate None None I-IUPAC
followed None None O
by None None O
mild None None O
trifluoroacetic None None O
treatment None None O
to None None O
selectively None None O
remove None None O
the None None O
Boc None None O
group None None O
. None None O

The None None O
gamma None None I-PARTIUPAC
- None None I-PARTIUPAC
methylene None None I-PARTIUPAC
derivatives None None I-MODIFIER
of None None O
MTX None None O
and None None O
AMT None None O
are None None O
attractive None None O
because None None O
of None None O
their None None O
potential None None O
to None None O
act None None O
as None None O
Michael None None O
acceptors None None O
within None None O
the None None O
DHFR None None O
active None None O
site None None O
. None None O

gamma None None O
- None None O
CyanoMTX None None O
may None None O
be None None O
viewed None None O
as None None O
a None None O
congener None None O
of None None O
the None None O
nonpolyglutamated None None O
MTX None None O
analogue None None O
gamma None None O
- None None O
fluoroMTX None None O
. None None O

In None None O
vitro None None O
bioassay None None O
data None None O
for None None O
the None None O
gamma None None I-IUPAC
- None None I-IUPAC
methylene None None I-IUPAC
and None None O
gamma None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
compounds None None I-MODIFIER
support None None O
the None None O
idea None None O
that None None O
the None None O
active None None O
site None None O
of None None O
DHFR None None O
, None None O
already None None O
known None None O
for None None O
its None None O
ability None None O
to None None O
tolerate None None O
modification None None O
of None None O
the None None O
gamma None None I-IUPAC
- None None I-IUPAC
carboxyl None None I-IUPAC
group None None I-MODIFIER
of None None O
MTX None None O
and None None O
AMT None None O
, None None O
can None None O
likewise None None O
accommodate None None O
substitution None None O
on None None O
the None None O
gamma None None O
- None None O
carbon None None O
itself None None O
. None None O


Analogues None None O
of None None O
the None None O
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tyrosine None None I-IUPAC
( None None I-IUPAC
Dmt None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
Tic None None O
) None None O
pharmacophore None None O
were None None O
prepared None None O
to None None O
test None None O
the None None O
hypothesis None None O
that None None O
a None None O
" None None O
spacer None None O
" None None O
and None None O
a None None O
third None None O
aromatic None None O
center None None O
in None None O
opioid None None O
peptides None None O
are None None O
required None None O
to None None O
convert None None O
a None None O
delta None None O
- None None O
antagonist None None O
into None None O
ligands None None O
with None None O
delta None None O
- None None O
agonist None None O
or None None O
with None None O
mixed None None O
delta None None O
- None None O
antagonist None None O
/ None None O
mu None None O
- None None O
agonist None None O
properties None None O
. None None O

Potent None None O
delta None None O
- None None O
agonists None None O
and None None O
bifunctional None None O
compounds None None O
with None None O
high None None O
delta None None O
- None None O
and None None O
mu None None O
- None None O
opioid None None O
receptor None None O
affinities None None O
were None None O
obtained None None O
by None None O
varying None None O
the None None O
spacer None None O
length None None O
[ None None O
none None None O
, None None O
NH None None O
- None None O
CH None None O
( None None O
2 None None O
) None None O
, None None O
NH None None O
- None None O
CH None None O
( None None O
2 None None O
) None None O
- None None O
CH None None O
( None None O
2 None None O
) None None O
, None None O
Gly None None O
- None None O
NH None None O
- None None O
CH None None O
( None None O
2 None None O
) None None O
] None None O
and None None O
C None None O
- None None O
terminal None None O
aromatic None None O
nucleus None None O
[ None None O
1H None None I-PARTIUPAC
- None None I-PARTIUPAC
benzimidazole None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
yl None None I-PARTIUPAC
, None None O
phenyl None None I-PARTIUPAC
( None None O
Ph None None O
) None None O
and None None O
benzyl None None I-IUPAC
groups None None B-MODIFIER
] None None O
. None None O

C None None O
- None None O
terminal None None O
modification None None O
primarily None None O
affected None None O
mu None None O
- None None O
opioid None None O
receptor None None O
affinities None None O
, None None O
which None None O
increased None None O
maximally None None O
1700 None None O
- None None O
fold None None O
relative None None O
to None None O
the None None O
prototype None None O
delta None None O
- None None O
antagonist None None O
H None None O
- None None O
Dmt None None O
- None None O
Tic None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
and None None O
differentially None None O
modified None None O
bioactivity None None O
. None None O

In None None O
the None None O
absence None None O
of None None O
a None None O
spacer None None O
( None None O
1 None None O
) None None O
, None None O
the None None O
analogue None None O
exhibited None None O
dual None None O
delta None None O
- None None O
agonism None None O
( None None O
pEC None None O
( None None O
50 None None O
) None None O
, None None O
7.28 None None O
) None None O
and None None O
delta None None O
- None None O
antagonism None None O
( None None O
pA None None O
( None None O
2 None None O
) None None O
, None None O
7.90 None None O
) None None O
. None None O

H None None O
- None None O
Dmt None None O
- None None O
Tic None None O
- None None O
NH None None O
- None None O
CH None None O
( None None O
2 None None O
) None None O
- None None O
1H None None O
- None None O
benzimidazole None None O
- None None O
2 None None O
- None None O
yl None None O
( None None O
Bid None None O
) None None O
( None None O
2 None None O
) None None O
became None None O
a None None O
highly None None O
potent None None O
delta None None O
- None None O
agonist None None O
( None None O
pEC None None O
( None None O
50 None None O
) None None O
, None None O
9.90 None None O
) None None O
, None None O
slightly None None O
greater None None O
than None None O
deltorphin None None O
C None None O
( None None O
pEC None None O
( None None O
50 None None O
) None None O
, None None O
9.56 None None O
) None None O
, None None O
with None None O
mu None None O
- None None O
agonism None None O
( None None O
pE None None O
( None None O
50 None None O
) None None O
, None None O
7.57 None None O
) None None O
, None None O
while None None O
H None None O
- None None O
Dmt None None O
- None None O
Tic None None O
- None None O
Gly None None O
- None None O
NH None None O
- None None O
CH None None O
( None None O
2 None None O
) None None O
- None None O
Bid None None O
( None None O
4 None None O
) None None O
retained None None O
potent None None O
delta None None O
- None None O
antagonism None None O
( None None O
pA None None O
( None None O
2 None None O
) None None O
, None None O
9.0 None None O
) None None O
but None None O
with None None O
an None None O
order None None O
of None None O
magnitude None None O
less None None O
mu None None O
- None None O
agonism None None O
. None None O

Similarly None None O
, None None O
H None None O
- None None O
Dmt None None O
- None None O
Tic None None O
- None None O
Gly None None O
- None None O
NH None None O
- None None O
Ph None None O
( None None O
5 None None O
) None None O
had None None O
nearly None None O
equivalent None None O
high None None O
delta None None O
- None None O
agonism None None O
( None None O
pEC None None O
( None None O
50 None None O
) None None O
, None None O
8.52 None None O
) None None O
and None None O
mu None None O
- None None O
agonism None None O
( None None O
pEC None None O
( None None O
50 None None O
) None None O
, None None O
8.59 None None O
) None None O
, None None O
while None None O
H None None O
- None None O
Dmt None None O
- None None O
Tic None None O
- None None O
Gly None None O
- None None O
NH None None O
- None None O
CH None None O
( None None O
2 None None O
) None None O
- None None O
Ph None None O
( None None O
6 None None O
) None None O
whose None None O
spacer None None O
was None None O
longer None None O
by None None O
a None None O
single None None O
methylene None None O
group None None O
exhibited None None O
potent None None O
delta None None O
- None None O
antagonism None None O
( None None O
pA None None O
( None None O
2 None None O
) None None O
, None None O
9.25 None None O
) None None O
and None None O
very None None O
high None None O
mu None None O
- None None O
agonism None None O
( None None O
pEC None None O
( None None O
50 None None O
) None None O
, None None O
8.57 None None O
) None None O
. None None O

These None None O
data None None O
confirm None None O
that None None O
the None None O
distance None None O
between None None O
the None None O
Dmt None None O
- None None O
Tic None None O
pharmacophore None None O
and None None O
a None None O
third None None O
aromatic None None O
nucleus None None O
is None None O
an None None O
important None None O
criterion None None O
in None None O
converting None None O
Dmt None None O
- None None O
Tic None None O
from None None O
a None None O
highly None None O
potent None None O
delta None None O
- None None O
antagonist None None O
into None None O
a None None O
potent None None O
delta None None O
- None None O
agonist None None O
or None None O
into None None O
ligands None None O
with None None O
mixed None None O
delta None None O
- None None O
and None None O
mu None None O
- None None O
opioid None None O
properties None None O
. None None O


Ring None None O
closure None None O
of None None O
ethyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminopyrazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
with None None O
sulfamoyl None None O
chloride None None O
gave None None O
1,7 None None I-IUPAC
- None None I-IUPAC
dihydropyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,2,6 None None I-IUPAC
] None None I-IUPAC
thiadiazine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
. None None O

The None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
analogue None None I-MODIFIER
of None None O
this None None O
new None None O
heterocyclic None None O
ring None None O
system None None O
was None None O
similarly None None O
prepared None None O
from None None O
3 None None I-IUPAC
- None None I-IUPAC
aminopyrazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carbonitrile None None I-IUPAC
. None None O

Treatment None None O
of None None O
4,5,6 None None I-IUPAC
- None None I-IUPAC
triamino None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1,2,6 None None I-IUPAC
- None None I-IUPAC
thiadiazine None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
with None None O
N None None I-IUPAC
- None None I-IUPAC
thionylaniline None None I-IUPAC
gave None None O
a None None O
derivative None None O
of None None O
another None None O
new None None O
ring None None O
system None None O
, None None O
7 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1,2,5 None None I-IUPAC
] None None I-IUPAC
thiadiazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,2,6 None None I-IUPAC
] None None I-IUPAC
thiadiazine None None I-IUPAC
5,5 None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
. None None O

These None None O
compounds None None O
and None None O
the None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxyimidazol None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,2,6 None None I-IUPAC
] None None I-IUPAC
thiadiazine None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
dioxides None None I-IUPAC
were None None O
examined None None O
as None None O
potential None None O
transition None None O
- None None O
state None None O
analogue None None O
inhibitors None None O
of None None O
xanthine None None O
oxidase None None O
and None None O
guanine None None O
aminohydrolase None None O
. None None O

Two None None O
of None None O
the None None O
compounds None None O
possessed None None O
Ki None None O
values None None O
of None None O
about None None O
2x None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
with None None O
guanine None None O
aminohydrolase None None O
, None None O
but None None O
no None None O
inhibition None None O
of None None O
xanthine None None O
oxidase None None O
was None None O
observed None None O
by None None O
any None None O
at None None O
5 None None O
x None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
. None None O


[ None None O
3 None None O
- None None O
( None None O
1,4 None None O
- None None O
Cyclohexadienyl None None O
) None None O
- None None O
L None None O
- None None O
alanine None None O
, None None O
8 None None O
- None None O
lysine None None O
] None None O
vasopressin None None O
, None None O
otherwise None None O
known None None O
as None None O
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,5 None None I-IUPAC
- None None I-IUPAC
dihydrophenylalanine None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
lysine None None I-IUPAC
] None None I-IUPAC
vasopressin None None I-IUPAC
or None None O
[ None None O
DiHPhe3 None None O
] None None O
lysine None None O
- None None O
vasopressin None None O
, None None O
has None None O
been None None O
synthesized None None O
in None None O
an None None O
attempt None None O
to None None O
utilize None None O
2,5 None None I-IUPAC
- None None I-IUPAC
dihydrophenylalanine None None I-IUPAC
( None None O
DiHPhe None None O
) None None O
to None None O
evaluate None None O
the None None O
contribution None None O
of None None O
aromaticity None None O
in None None O
position None None O
3 None None O
to None None O
biological None None O
activity None None O
. None None O

The None None O
analogue None None O
has None None O
the None None O
same None None O
primary None None O
structure None None O
as None None O
lysine None None O
- None None O
vasopressin None None O
, None None O
except None None O
that None None O
two None None O
additional None None O
hydrogen None None O
atoms None None O
are None None O
present None None O
on None None O
the None None O
ring None None O
moiety None None O
of None None O
the None None O
phenylalanine None None O
residue None None O
in None None O
position None None O
3 None None O
. None None O

The None None O
key None None O
intermediate None None O
was None None O
the None None O
protected None None O
nonapeptide None None O
N None None I-IUPAC
- None None I-IUPAC
carbobenzoxy None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
cysteinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tyrosyldihydrophenyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
alanyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutaminyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
asparaginyl None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
cysteinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
prolyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
epsilon None None I-IUPAC
- None None I-IUPAC
tosyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
lysylglycinamide None None I-IUPAC
that None None O
was None None O
synthesized None None O
stepwise None None O
by None None O
the None None O
solid None None O
- None None O
phase None None O
technique None None O
. None None O

Deprotection None None O
with None None O
sodium None None O
in None None O
liquid None None O
ammonia None None O
was None None O
followed None None O
by None None O
sulfhydryl None None O
oxidation None None O
with None None O
I2 None None O
to None None O
give None None O
the None None O
hormone None None O
analogue None None O
. None None O

[ None None O
DiHPhe3 None None O
] None None O
lysine None None O
- None None O
vasopressin None None O
exhibited None None O
125 None None O
- None None O
- None None O
130 None None O
units None None O
/ None None O
mg None None O
of None None O
antidiuretic None None O
, None None O
129 None None O
- None None O
- None None O
132 None None O
units None None O
/ None None O
mg None None O
of None None O
rat None None O
pressor None None O
, None None O
and None None O
6 None None O
units None None O
/ None None O
mg None None O
of None None O
rat None None O
uterus None None O
contracting None None O
activity None None O
. None None O

To None None O
confirm None None O
the None None O
presence None None O
of None None O
DiHPhe None None O
in None None O
the None None O
analogue None None O
, None None O
an None None O
enzymatic None None O
procedure None None O
employing None None O
Aspergillus None None O
oryzae None None O
was None None O
developed None None O
that None None O
liberates None None O
in None None O
high None None O
yield None None O
the None None O
amino None None O
acid None None O
residue None None O
in None None O
position None None O
3 None None O
of None None O
the None None O
posterior None None O
pituitary None None O
hormone None None O
structure None None O
. None None O

This None None O
study None None O
should None None O
be None None O
applicable None None O
to None None O
other None None O
biologically None None O
active None None O
peptides None None O
. None None O


A None None O
series None None O
of None None O
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
alkynyl None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
adenosine None None O
( None None O
Ado None None O
) None None O
have None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
their None None O
affinity None None O
at None None O
human None None O
A None None O
( None None O
1 None None O
) None None O
, None None O
A None None O
( None None O
2A None None O
) None None O
, None None O
and None None O
A None None O
( None None O
3 None None O
) None None O
receptors None None O
and None None O
for None None O
their None None O
potency None None O
at None None O
A None None O
( None None O
2B None None O
) None None O
adenosine None None O
receptor None None O
subtypes None None O
. None None O

The None None O
corresponding None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
alkynyl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
5' None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
ethylcarboxamidoadenosine None None I-IUPAC
( None None O
NECA None None O
) None None O
and None None O
Ado None None O
are None None O
used None None O
as None None O
reference None None O
compounds None None O
. None None O

Binding None None O
studies None None O
demonstrated None None O
that None None O
the None None O
activities None None O
of None None O
2 None None O
- None None O
alkynylAdos None None O
were None None O
slightly None None O
increased None None O
for None None O
the None None O
adenosine None None O
A None None O
( None None O
1 None None O
) None None O
receptor None None O
and None None O
slightly None None O
decreased None None O
for None None O
both None None O
A None None O
( None None O
3 None None O
) None None O
and None None O
A None None O
( None None O
2B None None O
) None None O
subtypes None None O
compared None None O
to None None O
those None None O
of None None O
their None None O
corresponding None None O
NECA None None O
derivatives None None O
, None None O
whereas None None O
the None None O
A None None O
( None None O
2A None None O
) None None O
receptor None None O
affinities None None O
of None None O
the None None O
two None None O
series None None O
of None None O
nucleosides None None O
were None None O
similar None None O
. None None O

The None None O
presence None None O
of None None O
a None None O
methyl None None I-IUPAC
group None None B-MODIFIER
on None None O
N None None O
( None None O
6 None None O
) None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
alkynyladenosines None None I-IUPAC
, None None O
inducing None None O
an None None O
increase None None O
in None None O
affinity None None O
at None None O
the None None O
human None None O
A None None O
( None None O
3 None None O
) None None O
receptor None None O
and None None O
a None None O
decrease None None O
at None None O
the None None O
other None None O
subtypes None None O
, None None O
resulted None None O
in None None O
an None None O
increase None None O
in None None O
A None None O
( None None O
3 None None O
) None None O
selectivity None None O
. None None O

In None None O
particular None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
phenylethynyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
Ado None None O
( None None O
8b None None O
) None None O
showed None None O
an None None O
A None None O
( None None O
3 None None O
) None None O
affinity None None O
in None None O
the None None O
low None None O
nanomolar None None O
range None None O
( None None O
K None None O
( None None O
i None None O
) None None O
( None None O
A None None O
( None None O
3 None None O
) None None O
) None None O
= None None O
3.4 None None O
nM None None O
) None None O
, None None O
with None None O
a None None O
A None None O
( None None O
1 None None O
) None None O
/ None None O
A None None O
( None None O
3 None None O
) None None O
and None None O
A None None O
( None None O
2A None None O
) None None O
/ None None O
A None None O
( None None O
3 None None O
) None None O
selectivity None None O
of None None O
about None None O
500 None None O
and None None O
2500 None None O
, None None O
respectively None None O
. None None O

These None None O
findings None None O
motivated None None O
us None None O
to None None O
search None None O
for None None O
the None None O
preparation None None O
of None None O
new None None O
selective None None O
radioligands None None O
for None None O
the None None O
A None None O
( None None O
3 None None O
) None None O
subtype None None O
; None None O
hence None None O
, None None O
a None None O
procedure None None O
to None None O
introduce None None O
a None None O
tritiated None None O
alkylamino None None O
group None None O
in None None O
these None None O
molecules None None O
was None None O
carried None None O
out None None O
. None None O

As None None O
far None None O
as None None O
the None None O
potency None None O
at None None O
the None None O
A None None O
( None None O
2B None None O
) None None O
receptor None None O
, None None O
the None None O
type None None O
of None None O
2 None None O
- None None O
alkynyl None None O
chain None None O
and None None O
the None None O
presence None None O
of None None O
the None None O
ethylcarboxamido None None O
group None None O
on None None O
the None None O
sugar None None O
seem None None O
to None None O
be None None O
very None None O
important None None O
; None None O
in None None O
fact None None O
, None None O
the None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylhydroxypropynyl None None I-IUPAC
NECA None None O
[ None None O
( None None O
S None None O
) None None O
- None None O
PHPNECA None None O
, None None O
1e None None O
, None None O
EC None None O
( None None O
50 None None O
) None None O
( None None O
A None None O
( None None O
2B None None O
) None None O
) None None O
= None None O
0.22 None None O
microM None None O
] None None O
proved None None O
to None None O
be None None O
one None None O
of None None O
the None None O
most None None O
potent None None O
A None None O
( None None O
2B None None O
) None None O
agonist None None O
reported None None O
so None None O
far None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
the None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylhydroxypropynyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
Ado None None O
( None None O
9e None None O
, None None O
EC None None O
( None None O
50 None None O
) None None O
( None None O
A None None O
( None None O
2B None None O
) None None O
) None None O
= None None O
0.73 None None O
microM None None O
) None None O
showed None None O
a None None O
significantly None None O
increase None None O
of None None O
potency None None O
at None None O
the None None O
A None None O
( None None O
2B None None O
) None None O
subtype None None O
in None None O
comparison None None O
with None None O
the None None O
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
, None None O
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
, None None O
and None None O
the None None O
unsubstituted None None O
adenosine None None O
derivatives None None O
, None None O
although None None O
it None None O
resulted None None O
in None None O
being None None O
less None None O
potent None None O
than None None O
( None None O
S None None O
) None None O
- None None O
PHPNECA None None O
( None None O
1e None None O
, None None O
EC None None O
( None None O
50 None None O
) None None O
( None None O
A None None O
( None None O
2B None None O
) None None O
) None None O
= None None O
0.22 None None O
microM None None O
) None None O
. None None O

These None None O
observations None None O
suggest None None O
that None None O
the None None O
introduction None None O
of None None O
an None None O
ethyl None None O
group None None O
in None None O
the None None O
N None None O
( None None O
6 None None O
) None None O
- None None O
position None None O
and None None O
an None None O
ethylcarboxamido None None O
substituent None None O
in None None O
the None None O
4' None None O
- None None O
position None None O
of None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylhydroxypropynyladenosine None None I-IUPAC
could None None O
lead None None O
to None None O
a None None O
compound None None O
endowed None None O
with None None O
high None None O
potency None None O
at None None O
the None None O
A None None O
( None None O
2B None None O
) None None O
receptor None None O
. None None O


Derivatives None None O
of None None O
the None None O
nonselective None None O
excitatory None None O
amino None None O
acid None None O
antagonist None None O
kynurenic None None O
acid None None O
( None None O
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydroquinoline None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
, None None O
1 None None O
) None None O
have None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
in None None O
vitro None None O
antagonist None None O
activity None None O
at None None O
the None None O
excitatory None None O
amino None None O
acid None None O
receptors None None O
sensitive None None O
to None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
aspartic None None I-IUPAC
acid None None I-IUPAC
( None None O
NMDA None None O
) None None O
, None None O
quisqualic None None O
acid None None O
( None None O
QUIS None None O
or None None O
AMPA None None O
) None None O
, None None O
and None None O
kainic None None O
acid None None O
( None None O
KA None None O
) None None O
. None None O

Introduction None None O
of None None O
substituents None None O
at None None O
the None None O
5 None None O
- None None O
, None None O
7 None None O
- None None O
, None None O
and None None O
5,7 None None O
- None None O
positions None None O
resulted None None O
in None None O
analogues None None O
having None None O
selective None None O
NMDA None None O
antagonist None None O
action None None O
, None None O
as None None O
a None None O
result None None O
of None None O
blockade None None O
of None None O
the None None O
glycine None None O
modulatory None None O
( None None O
or None None O
coagonist None None O
) None None O
site None None O
on None None O
the None None O
NMDA None None O
receptor None None O
. None None O

Regression None None O
analysis None None O
suggested None None O
a None None O
requirement None None O
for None None O
optimally None None O
sized None None O
, None None O
hydrophobic None None O
5 None None O
- None None O
and None None O
7 None None O
- None None O
substituents None None O
, None None O
with None None O
bulk None None O
tolerance None None O
being None None O
greater None None O
at None None O
the None None O
5 None None O
- None None O
position None None O
. None None O

Optimization None None O
led None None O
to None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
derivative None None I-MODIFIER
( None None O
53 None None O
) None None O
, None None O
which None None O
is None None O
the None None O
most None None O
potent None None O
and None None O
selective None None O
glycine None None O
/ None None O
NMDA None None O
antagonist None None O
to None None O
date None None O
( None None O
IC50 None None O
vs None None O
[ None None O
3H None None O
] None None O
glycine None None O
binding None None O
, None None O
32 None None O
nM None None O
; None None O
IC50 None None O
's None None O
for None None O
other None None O
excitatory None None O
amino None None O
acid None None O
receptor None None O
sites None None O
, None None O
greater None None O
than None None O
100 None None O
microM None None O
) None None O
. None None O

Substitution None None O
of None None O
1 None None O
at None None O
the None None O
6 None None O
- None None O
position None None O
resulted None None O
in None None O
compounds None None O
having None None O
selective None None O
non None None O
- None None O
NMDA None None O
antagonism None None O
and None None O
8 None None O
- None None O
substituted None None O
compounds None None O
were None None O
inactive None None O
at None None O
all None None O
receptors None None O
. None None O

The None None O
retention None None O
of None None O
glycine None None O
/ None None O
NMDA None None O
antagonist None None O
activity None None O
in None None O
heterocyclic None None O
ring None None O
modified None None O
analogues None None O
, None None O
such None None O
as None None O
the None None O
oxanilide None None O
69 None None O
and None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
carboxybenzimidazole None None I-IUPAC
70 None None O
, None None O
suggests None None O
that None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
tautomer None None I-MODIFIER
of None None O
1 None None O
and None None O
its None None O
derivatives None None O
is None None O
required None None O
for None None O
activity None None O
. None None O

Structurally None None O
related None None O
quinoxaline None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
diones None None I-IUPAC
are None None O
also None None O
glycine None None O
/ None None O
NMDA None None O
antagonists None None O
, None None O
but None None O
are None None O
not None None O
selective None None O
and None None O
are None None O
less None None O
potent None None O
than None None O
the None None O
1 None None O
derivatives None None O
, None None O
and None None O
additionally None None O
show None None O
different None None O
structure None None O
- None None O
activity None None O
requirements None None O
for None None O
aromatic None None O
ring None None O
substitution None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
these None None O
results None None O
, None None O
a None None O
model None None O
accounting None None O
for None None O
glycine None None O
receptor None None O
binding None None O
of None None O
the None None O
1 None None O
derived None None O
antagonists None None O
is None None O
proposed None None O
, None None O
comprising None None O
( None None O
a None None O
) None None O
size None None O
- None None O
limited None None O
, None None O
hydrophobic None None O
binding None None O
of None None O
the None None O
benzene None None O
ring None None O
, None None O
( None None O
b None None O
) None None O
hydrogen None None O
- None None O
bond None None O
acceptance None None O
by None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
group None None I-MODIFIER
, None None O
( None None O
c None None O
) None None O
hydrogen None None O
- None None O
bond None None O
donation None None O
by None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
group None None I-MODIFIER
, None None O
and None None O
( None None O
d None None O
) None None O
a None None O
Coulombic None None O
attraction None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
. None None O

The None None O
model None None O
can None None O
also None None O
account None None O
for None None O
the None None O
binding None None O
of None None O
quinoxaline None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
diones None None I-IUPAC
, None None O
quinoxalic None None I-IUPAC
acids None None I-IUPAC
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
carboxybenzimidazoles None None I-IUPAC
. None None O


To None None O
enhance None None O
the None None O
intrinsic None None O
potency None None O
of None None O
dihydropyrimidine None None O
calcium None None O
channel None None O
blockers None None O
, None None O
we None None O
have None None O
modified None None O
the None None O
structure None None O
of None None O
previously None None O
described None None O
2 None None I-IUPAC
- None None I-IUPAC
heteroalkyl None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyrimidines None None I-IUPAC
2 None None O
to None None O
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyrimidines None None I-IUPAC
3 None None O
. None None O

Structure None None O
- None None O
activity None None O
studies None None O
using None None O
potassium None None O
- None None O
depolarized None None O
rabbit None None O
aorta None None O
show None None O
that None None O
ortho None None I-IUPAC
, None None O
meta None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
aryl None None I-IUPAC
derivatives None None B-MODIFIER
are None None O
more None None O
potent None None O
than None None O
either None None O
ortho None None O
- None None O
or None None O
meta None None O
- None None O
monosubstituted None None O
compounds None None O
. None None O

While None None O
vasorelaxant None None O
activity None None O
was None None O
critically None None O
dependent None None O
on None None O
the None None O
size None None O
of None None O
the None None O
C5 None None O
ester None None I-IUPAC
group None None B-MODIFIER
, None None O
isopropyl None None O
ester None None O
being None None O
the None None O
best None None O
, None None O
a None None O
variety None None O
of None None O
substituents None None I-MODIFIER
( None None O
carbamate None None I-IUPAC
, None None O
acyl None None I-IUPAC
, None None O
sulfonyl None None I-IUPAC
, None None O
alkyl None None I-IUPAC
) None None O
were None None O
tolerated None None O
at None None O
N3 None None O
. None None O

Our None None O
results None None O
show None None O
dihydropyrimidines None None I-IUPAC
3 None None O
are None None O
significantly None None O
more None None O
potent None None O
than None None O
corresponding None None O
2 None None I-IUPAC
- None None I-IUPAC
heteroalkyl None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyrimidines None None I-IUPAC
2 None None O
and None None O
only None None O
slightly None None O
less None None O
potent None None O
than None None O
similarly None None O
substituted None None I-MODIFIER
2 None None B-IUPAC
- None None I-IUPAC
heteroalkyl None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyridines None None I-IUPAC
4 None None O
and None None O
5 None None O
. None None O

Whereas None None O
dihydropyridine None None O
enantiomers None None O
usually None None O
show None None O
10-15 None None O
- None None O
fold None None O
difference None None O
in None None O
activity None None O
, None None O
the None None O
enantiomers None None O
of None None O
dihydropyrimidine None None O
3j None None O
show None None O
more None None O
than None None O
a None None O
1000 None None O
- None None O
fold None None O
difference None None O
in None None O
activity None None O
. None None O

These None None O
results None None O
strengthen None None O
the None None O
requirement None None O
of None None O
an None None O
enamino None None O
ester None None O
for None None O
binding None None O
to None None O
the None None O
dihydropyridine None None O
receptor None None O
and None None O
indicate None None O
a None None O
nonspecific None None O
role None None O
for None None O
the None None O
N3 None None O
- None None O
substituent None None O
. None None O


A None None O
number None None O
of None None O
N9 None None O
- None None O
alkyl None None O
- None None O
substituted None None O
purines None None O
and None None O
purine None None O
ribonucleosides None None O
have None None O
been None None O
synthesized None None O
as None None O
congeners None None O
of None None O
sulfinosine None None O
and None None O
evaluated None None O
for None None O
their None None O
antileukemic None None O
activity None None O
in None None O
mice None None O
. None None O

NaH None None O
- None None O
mediated None None O
alkylation None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
( None None O
4 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
( None None O
5 None None O
) None None O
with None None O
certain None None O
alkyl None None O
bromides None None O
gave None None O
N7 None None O
- None None O
and None None O
N9 None None O
- None None O
alkylated None None O
derivatives None None O
( None None O
7a None None O
- None None O
d None None O
and None None O
6a None None O
- None None O
d None None O
) None None O
, None None O
the None None O
N9 None None O
- None None O
isomer None None O
being None None O
the None None O
major None None O
product None None O
. None None O

Treatment None None O
of None None O
6a None None O
- None None O
d None None O
and None None O
7a None None O
- None None O
d None None O
with None None O
thiourea None None O
furnished None None O
the None None O
corresponding None None O
6 None None I-IUPAC
- None None I-IUPAC
thio None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
9a None None O
- None None O
d None None O
and None None O
8a None None O
- None None O
d None None O
) None None O
. None None O

Amination None None O
of None None O
9a None None O
- None None O
e None None O
with None None O
aqueous None None O
chloramine None None O
solution None None O
afforded None None O
the None None O
corresponding None None O
purine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
sulfenamides None None I-IUPAC
( None None O
10 None None O
- None None O
a None None O
- None None O
e None None O
) None None O
, None None O
which None None O
on None None O
controlled None None O
oxidation None None O
with None None O
3 None None I-IUPAC
- None None I-IUPAC
chloroperoxbenzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
MCPBA None None O
) None None O
gave None None O
the None None O
respective None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
alkylpurine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
sulfinamides None None I-IUPAC
( None None O
11a None None O
- None None O
e None None O
) None None O
. None None O

A None None O
similar None None O
oxidation None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methyl None None I-IUPAC
/ None None I-IUPAC
benzylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosylpurine None None I-IUPAC
( None None O
12a None None O
and None None O
12b None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
purine None None I-IUPAC
( None None O
12c None None O
) None None O
with None None O
MCPBA None None O
gave None None O
the None None O
corresponding None None O
sulfoxides None None O
( None None O
13a None None O
- None None O
c None None O
) None None O
, None None O
which None None O
on None None O
further None None O
oxidation None None O
furnished None None O
the None None O
respective None None O
sulfones None None O
( None None O
14a None None O
- None None O
c None None O
) None None O
. None None O

Of None None O
the None None O
20 None None O
compounds None None O
evaluated None None O
, None None O
six None None O
exhibited None None O
biologically None None O
significant None None O
anti None None O
- None None O
L1210 None None O
activity None None O
in None None O
BD2F1 None None O
mice None None O
and None None O
reduced None None O
body None None O
burdens None None O
of None None O
viable None None O
L1210 None None O
cells None None O
more None None O
than None None O
90-97% None None O
by None None O
single None None O
treatment None None O
. None None O

Although None None O
compounds None None O
9b None None O
and None None O
9c None None O
at None None O
44 None None O
mg None None O
and None None O
40 None None O
mg None None O
/ None None O
kg None None O
per None None O
day None None O
x None None O
1 None None O
showed None None O
a None None O
T None None O
/ None None O
C None None O
of None None O
147 None None O
and None None O
149 None None O
, None None O
respectively None None O
, None None O
this None None O
group None None O
of None None O
compounds None None O
was None None O
found None None O
to None None O
be None None O
less None None O
effective None None O
than None None O
some None None O
of None None O
the None None O
sulfur None None O
- None None O
containing None None O
drugs None None O
that None None O
we None None O
previously None None O
described None None O
( None None O
e.g. None None O
sulfenosine None None O
and None None O
sulfinosine None None O
) None None O
. None None O


A None None O
series None None O
of None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
anilinopyrimido None None I-IUPAC
[ None None I-IUPAC
5,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
has None None O
been None None O
prepared None None O
and None None O
shown None None O
to None None O
be None None O
potent None None O
inhibitors None None O
of None None O
the None None O
tyrosine None None O
kinase None None O
activity None None O
of None None O
the None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
( None None O
EGFR None None O
) None None O
. None None O

These None None O
compounds None None O
are None None O
structurally None None O
related None None O
to None None O
the None None O
pyrido None None I-PARTIUPAC
[ None None I-PARTIUPAC
3,2 None None I-PARTIUPAC
- None None I-PARTIUPAC
d None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
pyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
pyrimidines None None I-IUPAC
previously None None O
shown None None O
to None None O
be None None O
EGFR None None O
inhibitors None None O
. None None O

Their None None O
structure None None O
- None None O
activity None None O
relationships None None O
( None None O
SAR None None O
) None None O
for None None O
inhibition None None O
of None None O
the None None O
isolated None None O
enzyme None None O
more None None O
closely None None O
resemble None None O
those None None O
of None None O
the None None O
[ None None O
3,2 None None O
- None None O
d None None O
] None None O
than None None O
the None None O
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyridopyrimidine None None I-IUPAC
isomers None None O
. None None O

This None None O
suggests None None O
the None None O
requirement None None O
of None None O
an None None O
aza None None O
atom None None O
in None None O
the None None O
7 None None O
- None None O
but None None O
not None None O
the None None O
5 None None O
- None None O
position None None O
( None None O
i.e. None None O
, None None O
a None None O
carbon None None O
atom None None O
in None None O
the None None O
5 None None O
- None None O
position None None O
) None None O
for None None O
the None None O
enhanced None None O
potency None None O
shown None None O
by None None O
6 None None O
- None None O
N None None O
- None None O
methylated None None O
derivatives None None O
in None None O
each None None O
series None None O
. None None O

X None None O
- None None O
ray None None O
crystal None None O
structures None None O
were None None O
determined None None O
for None None O
the None None O
three None None O
NHMe None None O
derivatives None None O
2 None None O
, None None O
3 None None O
, None None O
and None None O
5c None None O
in None None O
the None None O
pyrido None None I-PARTIUPAC
[ None None I-PARTIUPAC
9,2 None None I-PARTIUPAC
- None None I-PARTIUPAC
d None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None I-PARTIUPAC
pyrido None None I-PARTIUPAC
[ None None I-PARTIUPAC
3,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
d None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
pyrimido None None I-IUPAC
[ None None I-IUPAC
5,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
pyrimidine None None I-IUPAC
series None None I-MODIFIER
, None None O
respectively None None O
. None None O

These None None O
show None None O
that None None O
a None None O
carbon None None O
rather None None O
than None None O
a None None O
nitrogen None None O
atom None None O
at None None O
the None None O
5 None None O
- None None O
position None None O
leads None None O
to None None O
significant None None O
conformational None None O
changes None None O
in None None O
the None None O
molecule None None O
( None None O
a None None O
longer None None O
C5a None None O
- None None O
C4 None None O
bond None None O
and None None O
a None None O
30 None None O
degrees None None O
out None None O
- None None O
of None None O
- None None O
plane None None O
rotation None None O
of None None O
the None None O
phenyl None None O
group None None O
) None None O
, None None O
due None None O
to None None O
the None None O
requirement None None O
to None None O
relieve None None O
nonbonding None None O
interactions None None O
between None None O
the None None O
C5 None None O
and None None O
N9 None None O
protons None None O
. None None O

Pyrimido None None I-IUPAC
[ None None I-IUPAC
5,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
analogues None None I-MODIFIER
bearing None None O
bulky None None O
, None None O
weakly None None O
basic None None O
solubilizing None None O
side None None O
chains None None O
linked None None O
to None None O
the None None O
6 None None O
- None None O
position None None O
through None None O
a None None O
secondary None None O
amine None None O
generally None None O
retained None None O
potency None None O
both None None O
against None None O
the None None O
isolated None None O
enzyme None None O
and None None O
for None None O
inhibition None None O
of None None O
autophosphorylation None None O
of None None O
EGFR None None O
in None None O
intact None None O
A431 None None O
cells None None O
. None None O

This None None O
agrees None None O
with None None O
a None None O
recent None None O
binding None None O
model None None O
that None None O
suggests None None O
this None None O
general None None O
class None None O
of None None O
compounds None None O
binds None None O
to None None O
EGFR None None O
with None None O
the None None O
6 None None O
- None None O
position None None O
located None None O
in None None O
an None None O
area None None O
of None None O
comparative None None O
bulk None None O
tolerance None None O
at None None O
the None None O
entrance None None O
to None None O
the None None O
ATP None None O
- None None O
binding None None O
pocket None None O
. None None O

While None None O
these None None O
solubilized None None O
pyrimido None None I-IUPAC
[ None None I-IUPAC
5,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
analogues None None I-MODIFIER
were None None O
less None None O
potent None None O
than None None O
the None None O
NHMe None None O
derivative None None O
5c None None O
in None None O
the None None O
isolated None None O
enzyme None None O
assay None None O
, None None O
some None None O
were None None O
considerably None None O
superior None None O
to None None O
5c None None O
( None None O
and None None O
among None None O
the None None O
most None None O
potent None None O
ever None None O
reported None None O
) None None O
as None None O
inhibitors None None O
of None None O
EGFR None None O
autophosphorylation None None O
in None None O
cellular None None O
assays None None O
. None None O


The None None O
sodium None None O
salt None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyanopyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
1 None None O
) None None O
was None None O
condensed None None O
with None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acetoxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
bromide None None I-IUPAC
( None None O
2 None None O
) None None O
to None None O
provide None None O
the None None O
corresponding None None O
protected None None O
acyclic None None O
nucleoside None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acetoxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimid None None I-IUPAC
ine None None I-IUPAC
( None None O
3 None None O
) None None O
. None None O

Treatment None None O
of None None O
3 None None O
with None None O
sodium None None O
methoxide None None O
in None None O
methanol None None O
provided None None O
a None None O
good None None O
yield None None O
of None None O
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
formimidate None None I-IUPAC
( None None O
4 None None O
) None None O
. None None O

Treatment None None O
of None None O
the None None O
imidate None None O
( None None O
4 None None O
) None None O
with None None O
sodium None None O
hydrogen None None O
sulfide None None O
gave None None O
the None None O
thiocarboxamide None None I-IUPAC
derivative None None B-MODIFIER
5 None None O
. None None O

Aqueous None None O
base None None O
transformed None None O
4 None None O
into None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
6 None None O
) None None O
in None None O
good None None O
yield None None O
. None None O

Treatment None None O
of None None O
5 None None O
with None None O
mercuric None None O
chloride None None O
furnished None None O
the None None O
toyocamycin None None O
analogue None None O
7 None None O
. None None O

Evaluation None None O
of None None O
compounds None None O
1 None None O
, None None O
3-7 None None O
revealed None None O
that None None O
only None None O
the None None O
heterocycle None None O
( None None O
1 None None O
) None None O
and None None O
the None None O
thiocarboxamide None None O
acyclic None None O
nucleoside None None O
( None None O
5 None None O
) None None O
were None None O
active None None O
. None None O

Compound None None O
5 None None O
was None None O
the None None O
more None None O
potent None None O
with None None O
activity None None O
against None None O
human None None O
cytomegalovirus None None O
and None None O
herpes None None O
simplex None None O
virus None None O
type None None O
1 None None O
. None None O


[ None None O
1 None None O
- None None O
N None None O
- None None O
Methylisoasparagine None None O
, None None O
8 None None O
- None None O
isoleucine None None O
] None None O
- None None O
( None None O
I None None O
) None None O
, None None O
[ None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
sarcosine None None I-PARTIUPAC
, None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
methyltyrosine None None I-PARTIUPAC
, None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
isoleucine None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
II None None O
) None None O
, None None O
[ None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
sarcosine None None I-PARTIUPAC
, None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
methylisoleucine None None I-PARTIUPAC
, None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
isoleucine None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
III None None O
) None None O
, None None O
[ None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
sarcosine None None I-PARTIUPAC
, None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
methylisoleucine None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
IV None None O
) None None O
, None None O
[ None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
sarcosine8k None None I-PARTIUPAC
- None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
methylisoleucine None None I-PARTIUPAC
, None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
methylisoleucine None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
V None None O
) None None O
, None None O
[ None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
sarcosine None None I-PARTIUPAC
, None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
O None None I-PARTIUPAC
- None None I-PARTIUPAC
methylthreonine None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
VI None None O
) None None O
, None None O
[ None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
sarcosine None None I-PARTIUPAC
, None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
methionine None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
VII None None O
) None None O
, None None O
and None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
sarcosine None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
serine None None I-IUPAC
] None None I-IUPAC
angiotensin None None I-IUPAC
II None None I-IUPAC
( None None O
VIII None None O
) None None O
, None None O
synthesized None None O
by None None O
Merrifield None None O
's None None O
solid None None O
- None None O
phase None None O
procedure None None O
, None None O
possess None None O
respectively None None O
0.8 None None O
, None None O
0.3 None None O
, None None O
0.5 None None O
, None None O
1.0 None None O
, None None O
0.0 None None O
, None None O
0.5 None None O
, None None O
3.7 None None O
, None None O
and None None O
0.7% None None O
pressor None None O
activity None None O
of None None O
angiotensin None None O
II None None O
( None None O
vagotomized None None O
, None None O
ganglion None None O
- None None O
blocked None None O
rats None None O
) None None O
. None None O

They None None O
caused None None O
an None None O
initial None None O
rise None None O
in None None O
blood None None O
pressure None None O
( None None O
30 None None O
min None None O
of None None O
infusion None None O
, None None O
250 None None O
ng None None O
/ None None O
kg None None O
/ None None O
min None None O
in None None O
vagotomized None None O
, None None O
ganglion None None O
- None None O
blocked None None O
rats None None O
) None None O
of None None O
16.57 None None O
, None None O
9.80 None None O
, None None O
22.80 None None O
, None None O
32.00 None None O
, None None O
7.00 None None O
, None None O
15.06 None None O
, None None O
32.50 None None O
, None None O
and None None O
11.42 None None O
mmHg None None O
and None None O
showed None None O
secretory None None O
activity None None O
( None None O
isolated None None O
cat None None O
adrenal None None O
medulla None None O
) None None O
of None None O
1.0 None None O
, None None O
0.1 None None O
, None None O
0.01 None None O
, None None O
0.1 None None O
, None None O
less None None O
than None None O
0.01 None None O
, None None O
0.1 None None O
, None None O
less None None O
than None None O
0.01 None None O
, None None O
and None None O
0.05% None None O
of None None O
angiotensin None None O
II None None O
. None None O

On None None O
isolated None None O
organs None None O
pA2 None None O
values None None O
( None None O
rabbit None None O
aortic None None O
strips None None O
) None None O
of None None O
8.74 None None O
, None None O
7.44 None None O
, None None O
7.64 None None O
, None None O
7.85 None None O
, None None O
7.89 None None O
, None None O
8.76 None None O
, None None O
8.63 None None O
, None None O
and None None O
8.08 None None O
, None None O
and None None O
pA2 None None O
values None None O
( None None O
cat None None O
adrenal None None O
medulla None None O
of None None O
8.16 None None O
, None None O
9.16 None None O
, None None O
9.31 None None O
, None None O
8.00 None None O
, None None O
8.00 None None O
, None None O
7.00 None None O
, None None O
9.16 None None O
, None None O
and None None O
9.33 None None O
were None None O
obtained None None O
. None None O

Dose None None O
ratios None None O
( None None O
ratio None None O
of None None O
ED20 None None O
of None None O
angiotensin None None O
II None None O
during None None O
infusion None None O
of None None O
the None None O
antagonist None None O
and None None O
before None None O
infusion None None O
of None None O
the None None O
antagonist None None O
) None None O
in None None O
vagotomized None None O
, None None O
ganglion None None O
- None None O
blocked None None O
rats None None O
, None None O
infused None None O
at None None O
250 None None O
ng None None O
/ None None O
kg None None O
/ None None O
min None None O
, None None O
were None None O
33.43 None None O
, None None O
2.14 None None O
, None None O
3.26 None None O
, None None O
2.99 None None O
, None None O
0.62 None None O
, None None O
62.52 None None O
, None None O
incalculable None None O
, None None O
and None None O
11.15 None None O
, None None O
respectively None None O
. None None O

The None None O
results None None O
obtained None None O
suggest None None O
that None None O
( None None O
a None None O
) None None O
analogs None None O
I None None O
and None None O
VI None None O
are None None O
potent None None O
antagonists None None O
of None None O
the None None O
pressor None None O
response None None O
of None None O
angiotensin None None O
II None None O
in None None O
normal None None O
rat None None O
, None None O
VI None None O
being None None O
the None None O
most None None O
potent None None O
antagonist None None O
thus None None O
far None None O
synthesized None None O
; None None O
( None None O
b None None O
) None None O
replacement None None O
of None None O
position None None O
4 None None O
( None None O
Tyr None None O
) None None O
with None None O
MeTyr None None O
or None None O
position None None O
5 None None O
and None None O
/ None None O
or None None O
8 None None O
( None None O
Ile None None O
) None None O
with None None O
Melle None None O
in None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
sarcosine None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
isoleucine None None I-IUPAC
] None None I-IUPAC
angiotensin None None I-IUPAC
II None None I-IUPAC
reduced None None O
the None None O
antagonist None None O
activity None None O
of None None O
this None None O
peptide None None O
( None None O
rabbit None None O
aortic None None O
strips None None O
and None None O
rats None None O
) None None O
, None None O
indicating None None O
that None None O
steric None None O
hindrance None None O
imposed None None O
due None None O
to None None O
N None None O
- None None O
methylation None None O
in None None O
positions None None O
4 None None O
, None None O
5 None None O
, None None O
or None None O
8 None None O
was None None O
not None None O
favorable None None O
in None None O
eliminating None None O
the None None O
initial None None O
pressor None None O
activity None None O
or None None O
prolonging None None O
the None None O
duration None None O
of None None O
action None None O
of None None O
[ None None O
Sar1 None None O
, None None O
Ile8 None None O
] None None O
angiotensin None None O
II None None O
without None None O
reducing None None O
its None None O
antagonistic None None O
properties None None O
; None None O
( None None O
c None None O
) None None O
except None None O
II None None O
, None None O
none None None O
of None None O
the None None O
analogs None None O
showed None None O
any None None O
enhanced None None O
duration None None O
of None None O
action None None O
, None None O
suggesting None None O
that None None O
N None None O
- None None O
methylation None None O
in None None O
positions None None O
5 None None O
or None None O
8 None None O
did None None O
not None None O
afford None None O
protection None None O
against None None O
proteolytic None None O
enzymes None None O
; None None O
and None None O
( None None O
d None None O
) None None O
perfusion None None O
studies None None O
in None None O
cat None None O
adrenals None None O
indicated None None O
that None None O
all None None O
of None None O
these None None O
analogs None None O
are None None O
only None None O
very None None O
weak None None O
secretagogues None None O
. None None O

With None None O
the None None O
exception None None O
of None None O
[ None None O
Sar1 None None O
, None None O
Thr None None O
( None None O
ObetaMe None None O
) None None O
8 None None O
] None None O
angiotensin None None O
II None None O
, None None O
which None None O
gave None None O
lower None None O
antagonistic None None O
properties None None O
, None None O
all None None O
other None None O
analogs None None O
had None None O
either None None O
similar None None O
antagonistic None None O
properties None None O
or None None O
were None None O
better None None O
antagonists None None O
in None None O
adrenal None None O
medulla None None O
than None None O
in None None O
smooth None None O
muscle None None O
. None None O


Treatment None None O
of None None O
7,12 None None I-IUPAC
- None None I-IUPAC
benz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthraquinone None None I-IUPAC
( None None O
2 None None O
) None None O
with None None O
methylmagnesium None None O
iodide None None O
or None None O
methyllithium None None O
yields None None O
mixtures None None O
of None None O
cis None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
7,12 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
7,12 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
7,12 None None I-IUPAC
- None None I-IUPAC
dimethylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracenes None None I-IUPAC
( None None O
3a None None O
, None None O
b None None O
) None None O
, None None O
in None None O
which None None O
the None None O
ratio None None O
of None None O
cis None None O
to None None O
trans None None O
lies None None O
in None None O
the None None O
3 None None O
- None None O
- None None O
4 None None O
: None None O
1 None None O
region None None O
. None None O

Each None None O
isomer None None O
afforded None None O
high None None O
yields None None O
of None None O
7 None None I-IUPAC
- None None I-IUPAC
chloromethyl None None I-IUPAC
- None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
methylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
( None None O
5 None None O
) None None O
on None None O
treatment None None O
with None None O
hydrogen None None O
chloride None None O
in None None O
ethyl None None O
acetate None None O
. None None O

Similarly None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
7,12 None None I-IUPAC
- None None I-IUPAC
benz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthraquinone None None I-IUPAC
( None None O
8 None None O
) None None O
afforded None None O
a None None O
mixture None None O
of None None O
cis None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
7,12 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
7,12 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
7,12 None None I-IUPAC
- None None I-IUPAC
dimethylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracenes None None I-IUPAC
( None None O
9 None None O
) None None O
which None None O
yielded None None O
7 None None I-IUPAC
- None None I-IUPAC
chloromethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
methylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
( None None O
10 None None O
) None None O
on None None O
treatment None None O
with None None O
HCl None None O
. None None O

The None None O
chloromethyl None None O
compounds None None O
, None None O
5 None None O
and None None O
10 None None O
, None None O
yielded None None O
7 None None I-IUPAC
- None None I-IUPAC
acetoxymethyl None None I-IUPAC
- None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
methylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
( None None O
6 None None O
) None None O
and None None O
7 None None I-IUPAC
- None None I-IUPAC
acetoxymethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
methylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
( None None O
11 None None O
) None None O
on None None O
treatment None None O
with None None O
acetate None None O
ion None None O
. None None O

Hydrolysis None None O
of None None O
6 None None O
and None None O
11 None None O
yielded None None O
7 None None I-IUPAC
- None None I-IUPAC
hydroxymethyl None None I-IUPAC
- None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
methylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
( None None O
7 None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
hydroxymethyl None None I-IUPAC
- None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
methylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
( None None O
12 None None O
) None None O
, None None O
respectively None None O
. None None O

Since None None O
neither None None O
11 None None O
nor None None O
12 None None O
is None None O
appreciably None None O
carcinogenic None None O
, None None O
the None None O
carcinogenic None None O
metabolism None None O
of None None O
7,12 None None I-IUPAC
- None None I-IUPAC
dimethylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
( None None O
DMBA None None O
) None None O
probably None None O
does None None O
not None None O
involve None None O
attack None None O
at None None O
the None None O
7 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
. None None O


The None None O
synthesis None None O
and None None O
in None None O
vitro None None O
sigma None None O
receptor None None O
activity None None O
of None None O
the None None O
two None None O
diastereomers None None O
of None None O
U50 None None O
, None None O
488 None None O
[ None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
2 None None O
] None None O
, None None O
namely None None O
, None None O
( None None I-IUPAC
1R None None I-IUPAC
, None None I-IUPAC
2S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
cyclohexyl None None I-IUPAC
] None None I-IUPAC
benzeneacet None None I-IUPAC
ami None None I-IUPAC
de None None I-IUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
+ None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
1 None None I-PARTIUPAC
] None None I-PARTIUPAC
and None None O
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
cyclohexyl None None I-IUPAC
] None None I-IUPAC
benzeneacetamide None None I-IUPAC
[ None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
] None None O
, None None O
are None None O
described None None O
. None None O

( None None O
+ None None O
) None None O
- None None O
1 None None O
and None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
were None None O
synthesized None None O
from None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminocyclohexanol None None I-IUPAC
[ None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
3 None None O
] None None O
. None None O

Pyridinium None None O
chlorochromate None None O
( None None O
PCC None None O
) None None O
oxidation None None O
of None None O
the None None O
N None None O
- None None O
t None None O
- None None O
Boc None None O
- None None O
protected None None O
derivative None None O
of None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
3 None None O
afforded None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyloxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
] None None I-IUPAC
cyclohexanone None None I-IUPAC
[ None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
5 None None O
] None None O
. None None O

The None None O
sequence None None O
of None None O
enamine None None O
formation None None O
with None None O
pyrrolidine None None O
, None None O
catalytic None None O
reduction None None O
, None None O
N None None O
- None None O
deprotection None None O
, None None O
and None None O
optical None None O
resolution None None O
afforded None None O
( None None I-IUPAC
1R None None I-IUPAC
, None None I-IUPAC
2S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylcyclohexylamine None None I-IUPAC
[ None None O
( None None O
- None None O
) None None O
- None None O
10 None None O
] None None O
and None None O
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylcyclohexylamine None None I-IUPAC
[ None None O
( None None O
+ None None O
) None None O
- None None O
10 None None O
] None None O
. None None O

The None None O
optical None None O
purity None None O
( None None O
greater None None O
than None None O
99.5% None None O
) None None O
of None None O
( None None O
- None None O
) None None O
- None None O
10 None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
10 None None O
was None None O
determined None None O
by None None O
HPLC None None O
analysis None None O
of None None O
the None None O
diastereomeric None None O
ureas None None O
formed None None O
by None None O
reaction None None O
with None None O
optically None None O
pure None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
methylbenzyl None None I-IUPAC
isocyanate None None I-IUPAC
. None None O

The None None O
absolute None None O
configuration None None O
of None None O
( None None O
- None None O
) None None O
- None None O
10 None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
10 None None O
was None None O
determined None None O
by None None O
single None None O
- None None O
crystal None None O
X None None O
- None None O
ray None None O
diffractometry None None O
of None None O
the None None O
bis None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
mandelate None None I-IUPAC
salt None None I-MODIFIER
. None None O

Condensation None None O
of None None O
optically None None O
pure None None O
( None None O
- None None O
) None None O
- None None O
10 None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
10 None None O
with None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenylacetic None None I-IUPAC
acid None None I-IUPAC
furnished None None O
( None None O
+ None None O
) None None O
- None None O
1 None None O
and None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
, None None O
respectively None None O
. None None O

Compounds None None O
( None None O
+ None None O
) None None O
- None None O
1 None None O
, None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
, None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
, None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
2 None None O
were None None O
compared None None O
for None None O
their None None O
binding None None O
affinities None None O
at None None O
kappa None None O
opioid None None O
, None None O
sigma None None O
, None None O
D2 None None I-IUPAC
- None None I-IUPAC
dopamine None None I-IUPAC
, None None O
and None None O
phencyclidine None None O
( None None O
PCP None None O
) None None O
receptors None None O
in None None O
competitive None None O
binding None None O
assays None None O
using None None O
[ None None O
3H None None O
] None None O
bremazocine None None O
( None None O
[ None None O
3H None None O
] None None O
BREM None None O
) None None O
or None None O
[ None None O
3H None None O
] None None O
U69 None None O
, None None O
593 None None O
, None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
piperidine None None I-IUPAC
[ None None O
[ None None O
3H None None O
] None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
3 None None O
- None None O
PPP None None O
] None None O
, None None O
or None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
( None None I-IUPAC
o None None I-IUPAC
- None None I-IUPAC
tolyl None None I-IUPAC
) None None I-IUPAC
guanidine None None I-IUPAC
( None None O
[ None None O
3H None None O
] None None O
DTG None None O
) None None O
, None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
sulpiride None None I-IUPAC
[ None None O
[ None None O
3H None None O
] None None O
- None None O
( None None O
- None None O
) None None O
SULP None None O
] None None O
, None None O
and None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
cyclohexyl None None I-IUPAC
] None None I-IUPAC
piperidine None None I-IUPAC
( None None O
[ None None O
3H None None O
] None None O
TCP None None O
) None None O
, None None O
respectively None None O
. None None O

In None None O
the None None O
systems None None O
examined None None O
, None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
exhibited None None O
the None None O
highest None None O
affinity None None O
for None None O
kappa None None O
receptors None None O
, None None O
with None None O
a None None O
Ki None None O
of None None O
44 None None O
+ None None O
/ None None O
- None None O
8 None None O
nM None None O
. None None O

However None None O
, None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
also None None O
showed None None O
moderate None None O
affinity None None O
for None None O
sigma None None O
receptors None None O
, None None O
with None None O
a None None O
Ki None None O
of None None O
594 None None O
+ None None O
/ None None O
- None None O
3 None None O
nM None None O
[ None None O
[ None None O
3H None None O
] None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
3 None None O
- None None O
PPP None None O
] None None O
. None None O

The None None O
( None None O
1R None None O
, None None O
2R None None O
) None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
enantiomer None None O
, None None O
( None None O
+ None None O
) None None O
- None None O
2 None None O
, None None O
had None None O
low None None O
affinity None None O
for None None O
both None None O
kappa None None O
and None None O
sigma None None O
receptors None None O
, None None O
exhibiting None None O
Ki None None O
values None None O
of None None O
1298 None None O
+ None None O
/ None None O
- None None O
49 None None O
nM None None O
at None None O
kappa None None O
( None None O
[ None None O
3H None None O
] None None O
BREM None None O
) None None O
and None None O
1270 None None O
+ None None O
/ None None O
- None None O
168 None None O
nM None None O
at None None O
sigma None None O
[ None None O
[ None None O
3H None None O
] None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
3 None None O
- None None O
PPP None None O
] None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
chiral None None O
cis None None O
compounds None None O
( None None O
+ None None O
) None None O
- None None O
1 None None O
and None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
showed None None O
high None None O
affinity None None O
for None None O
sigma None None O
receptors None None O
and None None O
negligible None None O
affinity None None O
for None None O
kappa None None O
opioid None None O
receptors None None O
in None None O
the None None O
[ None None O
3H None None O
] None None O
BREM None None O
assay None None O
. None None O

Compound None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
exhibited None None O
a None None O
Ki None None O
of None None O
81 None None O
+ None None O
/ None None O
- None None O
13 None None O
nM None None O
at None None O
sigma None None O
receptors None None O
[ None None O
[ None None O
3H None None O
] None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
3 None None O
- None None O
PPP None None O
] None None O
and None None O
250 None None O
+ None None O
/ None None O
- None None O
8 None None O
nM None None O
( None None O
[ None None O
3H None None O
] None None O
DTG None None O
) None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

Previously None None O
, None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
quinuclidinyl None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
iodobenzilate None None I-IUPAC
( None None O
( None None O
R None None O
, None None O
R None None O
) None None O
- None None O
IQNB None None O
) None None O
, None None O
a None None O
muscarinic None None O
receptor None None O
antagonist None None O
, None None O
has None None O
been None None O
labeled None None O
with None None O
123I None None O
and None None O
125I None None O
for None None O
use None None O
in None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
studies None None O
in None None O
animals None None O
and None None O
humans None None O
. None None O

We None None O
have None None O
prepared None None O
fluoroalkyl None None O
analogs None None O
of None None O
QNB None None O
, None None O
which None None O
are None None O
amenable None None O
to None None O
labeling None None O
with None None O
18F None None O
, None None O
for None None O
potential None None O
imaging None None O
applications None None O
with None None O
positron None None O
emission None None O
tomography None None O
. None None O

The None None O
enantiomers None None O
of None None O
( None None O
fluoroalkyl None None O
) None None O
benzilic None None O
acids None None O
were None None O
prepared None None O
via None None O
an None None O
enantioselective None None O
Grignard None None O
addition None None O
reaction None None O
. None None O

Subsequent None None O
coupling None None O
of None None O
the None None O
enantiomeric None None I-MODIFIER
( None None B-IUPAC
fluoroalkyl None None I-IUPAC
) None None I-IUPAC
benzilic None None I-IUPAC
acid None None I-IUPAC
with None None O
a None None O
selected None None O
enantiomer None None O
of None None O
quinuclidinol None None O
provides None None O
fluorinated None None O
analogs None None O
of None None O
QNB None None O
with None None O
known None None O
stereochemistry None None O
at None None O
each None None O
of None None O
the None None O
stereogenic None None O
centers None None O
. None None O

These None None O
compounds None None O
exhibit None None O
different None None O
affinities None None O
for None None O
the None None O
muscarinic None None O
receptor None None O
tissue None None O
subtypes None None O
in None None O
vitro None None O
. None None O

( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Fluoromethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
QNB None None I-IUPAC
, None None O
and None None O
( None None O
R None None O
, None None O
R None None O
) None None O
- None None O
IQNB None None O
, None None O
and None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoroethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
QNB None None I-IUPAC
exhibit None None O
selectivity None None O
for None None O
the None None O
M1 None None O
subtype None None O
, None None O
and None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoromethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
QNB None None I-IUPAC
exhibits None None O
selectivity None None O
for None None O
the None None O
M2 None None O
subtype None None O
. None None O


Hypoxic None None O
cells None None O
of None None O
solid None None O
tumors None None O
are None None O
an None None O
obstacle None None O
to None None O
effective None None O
cancer None None O
therapy None None O
. None None O

Since None None O
hypoxic None None O
cells None None O
remote None None O
from None None O
the None None O
tumor None None O
blood None None O
supply None None O
may None None O
have None None O
a None None O
greater None None O
capacity None None O
for None None O
reductive None None O
reactions None None O
than None None O
well None None O
- None None O
oxygenated None None O
cells None None O
, None None O
we None None O
have None None O
prepared None None O
a None None O
series None None O
of None None O
anthraquinone None None O
prodrugs None None O
which None None O
may None None O
be None None O
capable None None O
of None None O
generating None None O
a None None O
reactive None None O
quinonemethide None None O
species None None O
following None None O
enzymatic None None O
reduction None None O
to None None O
the None None O
hydroquinone None None O
and None None O
loss None None O
of None None O
the None None O
substituent None None O
on None None O
the None None O
methylene None None O
group None None O
in None None O
the None None O
2 None None O
position None None O
. None None O

The None None O
synthesized None None O
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
anthraquinone None None B-IUPAC
derivatives None None B-MODIFIER
have None None O
first None None O
half None None O
- None None O
wave None None O
reduction None None O
potentials None None O
of None None O
- None None O
0.52 None None O
to None None O
- None None O
0.56 None None O
V None None O
at None None O
pH None None O
7.0 None None O
, None None O
which None None O
are None None O
the None None O
lowest None None O
oxidation None None O
- None None O
reduction None None O
potentials None None O
of None None O
quinone None None O
bioreductive None None O
alkylating None None O
agents None None O
synthesized None None O
by None None O
this None None O
laboratory None None O
to None None O
date None None O
. None None O

Tests None None O
of None None O
the None None O
cytotoxicity None None O
of None None O
these None None O
agents None None O
to None None O
oxygenated None None O
and None None O
chronically None None O
hypoxic None None O
EMT6 None None O
tumor None None O
cells None None O
in None None O
culture None None O
demonstrated None None O
that None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
anthraquinone None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylcarbamyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
anthraquinone None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluenesulfonyl None None I-IUPAC
) None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
anthraquinone None None I-IUPAC
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methoxymethyl None None I-IUPAC
) None None I-IUPAC
anthraquinone None None I-IUPAC
were None None O
significantly None None O
more None None O
toxic None None O
to None None O
hypoxic None None O
cells None None O
than None None O
to None None O
their None None O
normally None None O
aerated None None O
counterparts None None O
. None None O

The None None O
findings None None O
demonstrate None None O
differences None None O
between None None O
various None None O
leaving None None O
groups None None O
in None None O
the None None O
2 None None O
position None None O
for None None O
the None None O
expression None None O
of None None O
differential None None O
cytotoxicity None None O
. None None O


Fourteen None None O
125I None None O
- None None O
labeled None None O
aralkylguanidines None None O
were None None O
synthesized None None O
and None None O
evaluated None None O
as None None O
potential None None O
imaging None None O
agents None None O
for None None O
the None None O
adrenal None None O
medullae None None O
and None None O
tumors None None O
of None None O
adrenomedullary None None O
origin None None O
. None None O

These None None O
guanidines None None O
are None None O
radiotracer None None O
analogues None None O
of None None O
guanethidine None None O
, None None O
an None None O
antihypertensive None None O
agent None None O
thought None None O
to None None O
mediate None None O
neuron None None O
blockade None None O
by None None O
uptake None None O
into None None O
adrenergic None None O
nerves None None O
. None None O

Dog None None O
adrenal None None O
medullae None None O
were None None O
used None None O
as None None O
a None None O
model None None O
to None None O
test None None O
radiotracer None None O
affinity None None O
for None None O
catecholamine None None O
storage None None O
tissue None None O
. None None O

Tissue None None O
distribution None None O
studies None None O
revealed None None O
that None None O
a None None O
number None None O
of None None O
radioiodinated None None O
guanidines None None O
showed None None O
pronounced None None O
localization None None O
in None None O
the None None O
adrenal None None O
medullae None None O
following None None O
intravenous None None O
injection None None O
, None None O
in None None O
certain None None O
cases None None O
exceeding None None O
that None None O
of None None O
either None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
norepinephrine None None I-IUPAC
or None None O
[ None None I-IUPAC
14C None None I-IUPAC
] None None I-IUPAC
guanethidine None None I-IUPAC
. None None O

( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
125I None None I-IUPAC
] None None I-IUPAC
Iodobenzyl None None I-IUPAC
) None None I-IUPAC
guanidine None None I-IUPAC
( None None O
m None None O
- None None O
IBG None None O
, None None O
2b None None O
) None None O
gave None None O
the None None O
best None None O
combination None None O
of None None O
high None None O
concentration None None O
and None None O
selectivity None None O
. None None O

The None None O
low None None O
adrenomedullary None None O
affinity None None O
observed None None O
with None None O
[ None None I-IUPAC
14C None None I-IUPAC
] None None I-IUPAC
guanidine None None I-IUPAC
and None None O
m None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
125I None None I-IUPAC
] None None I-IUPAC
iodobenzylamine None None I-IUPAC
demonstrates None None O
the None None O
uniqueness None None O
of None None O
the None None O
aralkylguanidine None None O
structure None None O
. None None O

Preliminary None None O
evidence None None O
suggests None None O
that None None O
2b None None O
is None None O
a None None O
storage None None O
analogue None None O
of None None O
norepinephrine None None O
. None None O

[ None None O
125I None None O
] None None O
2a None None O
is None None O
now None None O
being None None O
used None None O
clinically None None O
in None None O
imaging None None O
and None None O
radiotherapy None None O
of None None O
catecholamine None None O
tumors None None O
, None None O
such None None O
as None None O
pheochromocytoma None None O
. None None O


The None None O
1,2 None None I-IUPAC
- None None I-IUPAC
dihydropyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyrazines None None I-IUPAC
( None None O
1 None None O
) None None O
are None None O
mitotic None None O
inhibitors None None O
with None None O
significant None None O
antitumor None None O
activity None None O
in None None O
mice None None O
. None None O

Also None None O
, None None O
the None None O
active None None O
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
3 None None O
was None None O
shown None None O
to None None O
cause None None O
the None None O
accumulation None None O
of None None O
cells None None O
at None None O
mitosis None None O
. None None O

Routes None None O
were None None O
developed None None O
for None None O
the None None O
synthesis None None O
of None None O
congeners None None O
of None None O
3 None None O
by None None O
cyclization None None O
of None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
substituted None None I-MODIFIER
amino None None B-IUPAC
) None None O
- None None I-PARTIUPAC
5,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
diaminopyridines None None I-PARTIUPAC
with None None O
ethyl None None O
orthoformate None None O
. None None O

Oxidative None None O
cyclization None None O
of None None O
either None None O
4,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
5,6 None None I-IUPAC
- None None I-IUPAC
diaminopyridines None None I-IUPAC
with None None O
aryl None None O
aldehydes None None O
produced None None O
the None None O
[ None None O
4,5 None None O
- None None O
c None None O
] None None O
and None None O
[ None None O
4,5 None None O
- None None O
b None None O
] None None O
imidazopyridine None None O
ring None None O
systems None None O
, None None O
respectively None None O
. None None O

The None None O
latter None None O
reaction None None O
with None None O
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
substituted None None I-MODIFIER
amino None None B-IUPAC
) None None O
- None None I-PARTIUPAC
4,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
diaminopyridines None None I-PARTIUPAC
gave None None O
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
ring None None I-MODIFIER
analogues None None I-MODIFIER
of None None O
1 None None O
. None None O

Biological None None O
studies None None O
indicated None None O
that None None O
the None None O
target None None O
compounds None None O
were None None O
less None None O
active None None O
than None None O
1 None None O
and None None O
3 None None O
. None None O


The None None O
design None None O
, None None O
synthesis None None O
, None None O
and None None O
pharmacological None None O
properties None None O
of None None O
a None None O
novel None None O
type None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,5,6 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thiazolamine None None I-IUPAC
with None None O
dopaminergic None None O
properties None None O
are None None O
described None None O
. None None O

In None None O
particular None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,5,6 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thiazolamine None None I-IUPAC
( None None O
4c None None O
, None None O
PD None None O
118440 None None O
) None None O
and None None O
its None None O
allyl None None I-IUPAC
analogue None None B-MODIFIER
( None None O
4i None None O
, None None O
PD None None O
120697 None None O
) None None O
have None None O
been None None O
identified None None O
as None None O
orally None None O
active None None O
dopamine None None O
( None None O
DA None None O
) None None O
agonists None None O
with None None O
pronounced None None O
central None None O
nervous None None O
system None None O
effects None None O
in None None O
tests None None O
that None None O
include None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
haloperidol None None I-IUPAC
and None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
propylnorapomorphine None None I-IUPAC
binding None None O
, None None O
inhibition None None O
of None None O
striatal None None O
DA None None O
synthesis None None O
, None None O
inhibition None None O
of None None O
DA None None O
neuronal None None O
firing None None O
, None None O
inhibition None None O
of None None O
spontaneous None None O
locomotor None None O
activity None None O
, None None O
and None None O
reversal None None O
of None None O
reserpine None None O
- None None O
induced None None O
depression None None O
in None None O
rats None None O
. None None O

The None None O
DA None None O
autoreceptor None None O
selectivity None None O
of None None O
these None None O
heterocyclic None None O
analogues None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
) None None I-IUPAC
phenol None None I-IUPAC
( None None O
3 None None O
- None None O
PPP None None O
) None None O
was None None O
also None None O
evaluated None None O
. None None O

In None None O
this None None O
series None None O
, None None O
DA None None O
agonist None None O
activity None None O
was None None O
found None None O
to None None O
be None None O
highly None None O
dependent None None O
on None None O
the None None O
size None None O
of None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
substituent None None I-MODIFIER
, None None O
the None None O
saturation None None O
level None None O
of None None O
the None None O
six None None O
- None None O
membered None None O
ring None None O
, None None O
and None None O
the None None O
mode None None O
of None None O
attachment None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
aminothiazole None None I-IUPAC
ring None None I-MODIFIER
. None None O


Diarylguanidines None None O
, None None O
acting None None O
as None None O
NMDA None None O
receptor None None O
ion None None O
channel None None O
site None None O
ligands None None O
, None None O
represent None None O
a None None O
new None None O
class None None O
of None None O
potential None None O
neuroprotective None None O
drugs None None O
. None None O

Several None None O
diarylguanidines None None O
structurally None None O
related None None O
to None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
o None None I-IUPAC
- None None I-IUPAC
tolylguanidine None None I-IUPAC
( None None O
DTG None None O
) None None O
, None None O
a None None O
known None None O
selective None None O
sigma None None O
receptor None None O
ligand None None O
, None None O
were None None O
synthesized None None O
and None None O
evaluated None None O
in None None O
in None None O
vitro None None O
radioligand None None O
displacement None None O
assays None None O
, None None O
with None None O
rat None None O
or None None O
guinea None None O
pig None None O
brain None None O
membrane None None O
homogenates None None O
, None None O
using None None O
the None None O
NMDA None None O
receptor None None O
ion None None O
channel None None O
site None None O
specific None None O
radioligand None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
dibenzo None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
cyclohepten None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
, None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
imine None None I-IUPAC
( None None O
MK None None O
- None None O
801 None None O
, None None O
3 None None O
) None None O
, None None O
and None None O
the None None O
sigma None None O
receptor None None O
- None None O
specific None None O
radioligand None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
o None None I-IUPAC
- None None I-IUPAC
tolylguanidine None None I-IUPAC
( None None O
DTG None None O
, None None O
5 None None O
) None None O
. None None O

This None None O
paper None None O
presents None None O
the None None O
structure None None O
- None None O
activity None None O
relationships None None O
leading None None O
to None None O
novel None None O
tri None None I-MODIFIER
- None None I-MODIFIER
and None None O
tetrasubstituted None None I-MODIFIER
guanidines None None B-IUPAC
, None None O
which None None O
exhibit None None O
high None None O
selectivity None None O
for None None O
NMDA None None O
receptor None None O
ion None None O
channel None None O
sites None None O
and None None O
weak None None O
or None None O
negligible None None O
affinity None None O
for None None O
sigma None None O
receptors None None O
. None None O

The None None O
in None None O
vitro None None O
binding None None O
results None None O
from None None O
symmetrically None None O
substituted None None O
diphenylguanidines None None O
indicated None None O
that None None O
compounds None None O
having None None O
ortho None None O
or None None O
meta None None O
substituents None None O
( None None O
with None None O
respect None None O
to None None O
the None None O
position None None O
of None None O
the None None O
guanidine None None O
nitrogen None None O
) None None O
on None None O
the None None O
phenyl None None O
rings None None O
showed None None O
greater None None O
affinity None None O
for None None O
the None None O
NMDA None None O
receptor None None O
ion None None O
channel None None O
site None None O
compared None None O
with None None O
para None None O
- None None O
substituted None None O
derivatives None None O
. None None O

Among None None O
the None None O
group None None O
of None None O
ring None None O
substituents None None O
studied None None O
for None None O
symmetrical None None O
diarylguanidines None None O
, None None O
an None None O
isopropyl None None I-IUPAC
group None None B-MODIFIER
was None None O
preferred None None O
at None None O
the None None O
ortho None None O
position None None O
and None None O
an None None O
ethyl None None O
group None None O
was None None O
preferred None None O
at None None O
the None None O
meta None None O
position None None O
. None None O

Several None None O
unsymmetrical None None O
guanidines None None O
containing None None O
a None None O
naphthalene None None O
ring None None O
on None None O
one None None O
nitrogen None None O
atom None None O
and None None O
an None None O
ortho None None O
- None None O
or None None O
a None None O
meta None None O
- None None O
substituted None None O
phenyl None None O
ring None None O
on None None O
the None None O
second None None O
nitrogen None None O
atom None None O
, None None O
e.g. None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethylphenyl None None I-IUPAC
) None None I-IUPAC
guanidine None None I-IUPAC
( None None O
36 None None O
) None None O
, None None O
showed None None O
a None None O
3-5 None None O
- None None O
fold None None O
increase None None O
in None None O
affinity None None O
for None None O
the None None O
NMDA None None O
receptor None None O
ion None None O
channel None None O
site None None O
and None None O
no None None O
change None None O
in None None O
sigma None None O
receptor None None O
affinity None None O
compared None None O
to None None O
the None None O
respective None None O
symmetrical None None O
counterparts None None O
. None None O

Additional None None O
small None None O
substituents None None O
on None None O
the None None O
guanidine None None O
nitrogen None None O
atoms None None O
bearing None None O
the None None O
aryl None None O
rings None None O
resulted None None O
in None None O
tri None None O
- None None O
and None None O
tetrasubstituted None None O
guanidine None None O
derivatives None None O
which None None O
retained None None O
affinity None None O
for None None O
NMDA None None O
receptor None None O
ion None None O
channel None None O
sites None None O
but None None O
exhibited None None O
a None None O
significant None None O
reduction None None O
in None None O
their None None O
affinities None None O
for None None O
sigma None None O
receptors None None O
. None None O

For None None O
example None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
methylguanidine None None I-IUPAC
( None None O
40 None None O
) None None O
showed None None O
high None None O
affinity None None O
for None None O
the None None O
NMDA None None O
receptor None None O
ion None None O
channel None None O
site None None O
( None None O
IC50 None None O
= None None O
36 None None O
nM None None O
vs None None O
[ None None O
3H None None O
] None None O
- None None O
3 None None O
) None None O
and None None O
low None None O
affinity None None O
for None None O
sigma None None O
receptors None None O
( None None O
IC50 None None O
= None None O
2540 None None O
nM None None O
vs None None O
[ None None O
3H None None O
] None None O
- None None O
5 None None O
) None None O
. None None O

Selectivity None None O
for None None O
the None None O
NMDA None None O
receptor None None O
ion None None O
channel None None O
sites None None O
over None None O
sigma None None O
receptors None None O
appears None None O
to None None O
be None None O
dependent None None O
upon None None O
the None None O
structure None None O
of None None O
the None None O
additional None None O
substituents None None O
on None None O
the None None O
guanidine None None O
nitrogen None None O
atoms None None O
bearing None None O
the None None O
aryl None None O
groups None None O
. None None O

Methyl None None O
and None None O
ethyl None None O
substituents None None O
are None None O
most None None O
preferred None None O
in None None O
the None None O
tri None None O
- None None O
and None None O
tetrasubstituted None None O
diarylguanidines None None O
. None None O

The None None O
trisubstituted None None O
guanidine None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
methylguanidine None None I-IUPAC
( None None O
40 None None O
) None None O
and None None O
its None None O
close None None O
analogues None None O
showed None None O
good None None O
in None None O
vivo None None O
neuroprotection None None O
and None None O
are None None O
potential None None O
neuroprotective None None O
drug None None O
candidates None None O
for None None O
the None None O
treatment None None O
of None None O
stroke None None O
and None None O
other None None O
neurodegenerative None None O
disorders None None O
. None None O


Syntheses None None O
of None None O
several None None O
carbamate None None O
analogues None None O
of None None O
2 None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amidinophenyl None None I-IUPAC
) None None I-IUPAC
furan None None I-IUPAC
( None None O
1 None None O
) None None O
under None None O
mild None None O
conditions None None O
and None None O
their None None O
evaluation None None O
as None None O
prodrugs None None O
against None None O
Pneumocystis None None O
carinii None None O
pneumonia None None O
( None None O
PCP None None O
) None None O
in None None O
an None None O
immunosuppressed None None O
rat None None O
model None None O
are None None O
described None None O
. None None O

Thus None None O
, None None O
nine None None O
new None None O
bis None None O
- None None O
carbamates None None O
: None None O
methoxycarbonyl None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
2,2,2 None None I-IUPAC
- None None I-IUPAC
trichloroethoxycarbonyl None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
ethylthiocarbonyl None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
benzyloxycarbonyl None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
dioxol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methoxycarbonyl None None I-IUPAC
( None None O
6 None None O
) None None O
, None None O
phenoxycarbonyl None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
fluorophenoxycarbonyl None None I-IUPAC
( None None O
8 None None O
) None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenoxycarbonyl None None I-IUPAC
( None None O
9 None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
acetoxy None None I-IUPAC
) None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
( None None O
10 None None O
) None None O
and None None O
a None None O
bis None None I-IUPAC
- None None I-IUPAC
carbonate None None I-IUPAC
ethoxycarbonyloxy None None I-IUPAC
( None None O
11 None None O
) None None O
of None None O
the None None O
bis None None O
- None None O
amidine None None O
1 None None O
have None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
. None None O

The None None O
in None None O
vivo None None O
results None None O
show None None O
that None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
carbamate None None I-IUPAC
8 None None O
and None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
carbamate None None I-IUPAC
9 None None O
in None None O
this None None O
series None None O
had None None O
the None None O
best None None O
anti None None O
- None None O
PCP None None O
activity None None O
by None None O
both None None O
intravenous None None O
and None None O
oral None None O
administration None None O
at None None O
a None None O
dosage None None O
level None None O
of None None O
22 None None O
mol None None O
and None None O
33 None None O
micromol None None O
/ None None O
kg None None O
/ None None O
day None None O
, None None O
respectively None None O
. None None O

Compounds None None O
3-7 None None O
were None None O
also None None O
more None None O
active None None O
than None None O
the None None O
parent None None O
drug None None O
( None None O
1 None None O
) None None O
on None None O
oral None None O
administration None None O
. None None O

The None None O
acute None None O
toxicity None None O
usually None None O
exhibited None None O
by None None O
the None None O
parent None None O
amidine None None O
1 None None O
at None None O
a None None O
dosage None None O
level None None O
of None None O
22 None None O
micromol None None O
/ None None O
kg None None O
/ None None O
day None None O
on None None O
intravenous None None O
administration None None O
has None None O
been None None O
significantly None None O
reduced None None O
by None None O
the None None O
prodrug None None O
modifications None None O
, None None O
with None None O
the None None O
exception None None O
of None None O
compound None None O
10 None None O
which None None O
exhibited None None O
some None None O
toxicity None None O
. None None O

This None None O
report None None O
also None None O
describes None None O
the None None O
synthesis None None O
of None None O
several None None O
aryl None None O
- None None O
alkyl None None O
and None None O
aryl None None O
- None None O
aryl None None O
carbonates None None O
( None None O
12-14 None None O
, None None O
16-23 None None O
) None None O
as None None O
efficient None None O
reagents None None O
for None None O
the None None O
preparation None None O
of None None O
carbamate None None O
derivatives None None O
from None None O
bis None None O
- None None O
arylamidines None None O
. None None O


A None None O
series None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydronaphthalenes None None I-IUPAC
( None None O
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminotetralins None None I-IUPAC
, None None O
PATs None None O
) None None O
previously None None O
was None None O
found None None O
to None None O
modulate None None O
tyrosine None None O
hydroxylase None None O
activity None None O
and None None O
dopamine None None O
synthesis None None O
in None None O
rodent None None O
forebrain None None O
through None None O
interaction None None O
with None None O
a None None O
binding None None O
site None None O
labeled None None O
by None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
- None None O
( None None O
- None None O
) None None O
- None None O
( None None O
1R None None O
, None None O
3S None None O
) None None O
- None None O
trans None None O
- None None O
H None None O
( None None O
2 None None O
) None None O
- None None O
PAT None None O
. None None O

Recently None None O
, None None O
we None None O
have None None O
discovered None None O
that None None O
PATs None None O
also None None O
bind None None O
with None None O
high None None O
affinity None None O
to None None O
the None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
mepyramine None None O
- None None O
labeled None None O
H None None O
( None None O
1 None None O
) None None O
receptor None None O
in None None O
rat None None O
and None None O
guinea None None O
pig None None O
brain None None O
. None None O

Here None None O
, None None O
we None None O
report None None O
the None None O
synthesis None None O
and None None O
biological None None O
evaluation None None O
of None None O
additional None None O
PAT None None O
analogues None None O
in None None O
order None None O
to None None O
identify None None O
differences None None O
in None None O
binding None None O
at None None O
these None None O
two None None O
sites None None O
. None None O

Further None None O
molecular None None O
modifications None None O
involve None None O
the None None O
pendant None None O
phenyl None None O
ring None None O
as None None O
well None None O
as None None O
quaternary None None O
amine None None O
compounds None None O
. None None O

Comparison None None O
of None None O
about None None O
38 None None O
PAT None None O
analogues None None O
, None None O
10 None None O
structurally None None O
diverse None None O
H None None O
( None None O
1 None None O
) None None O
ligands None None O
, None None O
and None None O
several None None O
other None None O
CNS None None O
- None None O
active None None O
compounds None None O
revealed None None O
no None None O
significant None None O
differences None None O
in None None O
affinity None None O
at None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
- None None O
( None None O
- None None O
) None None O
- None None O
trans None None O
- None None O
H None None O
( None None O
2 None None O
) None None O
- None None O
PAT None None O
sites None None O
versus None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
mepyramine None None O
- None None O
labeled None None O
H None None O
( None None O
1 None None O
) None None O
receptors None None O
. None None O

These None None O
results None None O
, None None O
together None None O
with None None O
previous None None O
autoradiographic None None O
brain None None O
receptor None None O
- None None O
mapping None None O
studies None None O
that None None O
indicate None None O
similar None None O
distribution None None O
of None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
- None None O
( None None O
- None None O
) None None O
- None None O
trans None None O
- None None O
H None None O
( None None O
2 None None O
) None None O
- None None O
PAT None None O
sites None None O
and None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
mepyramine None None O
- None None O
labeled None None O
H None None O
( None None O
1 None None O
) None None O
receptors None None O
, None None O
suggest None None O
that None None O
both None None O
radioligands None None O
label None None O
the None None O
same None None O
histamine None None O
H None None O
( None None O
1 None None O
) None None O
receptors None None O
in None None O
rodent None None O
brain None None O
. None None O

We None None O
also None None O
report None None O
a None None O
revision None None O
of None None O
our None None O
previous None None O
comparative None None O
molecular None None O
field None None O
analysis None None O
( None None O
CoMFA None None O
) None None O
study None None O
of None None O
the None None O
PAT None None O
ligands None None O
that None None O
yields None None O
a None None O
highly None None O
predictive None None O
model None None O
for None None O
66 None None O
compounds None None O
with None None O
a None None O
cross None None O
- None None O
validated None None O
R None None O
( None None O
2 None None O
) None None O
( None None O
q None None O
( None None O
2 None None O
) None None O
) None None O
value None None O
of None None O
0.67 None None O
. None None O

This None None O
model None None O
will None None O
be None None O
useful None None O
for None None O
the None None O
prediction None None O
of None None O
high None None O
- None None O
affinity None None O
ligands None None O
at None None O
radiolabeled None None O
H None None O
( None None O
1 None None O
) None None O
receptors None None O
in None None O
mammalian None None O
brain None None O
. None None O


A None None O
new None None O
class None None O
of None None O
histamine None None O
analogues None None O
characterized None None O
by None None O
a None None O
3 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
diphenylpropyl None None I-IUPAC
substituent None None I-MODIFIER
at None None O
the None None O
2 None None O
- None None O
position None None O
of None None O
the None None O
imidazole None None O
nucleus None None O
has None None O
been None None O
prepared None None O
outgoing None None O
from None None O
4,4 None None I-IUPAC
- None None I-IUPAC
diphenylbutyronitrile None None I-IUPAC
( None None O
4b None None O
) None None O
via None None O
cyclization None None O
of None None O
the None None O
corresponding None None O
methyl None None O
imidate None None O
5b None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phthalimido None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
acetate None None I-IUPAC
or None None O
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
butandiol None None I-IUPAC
in None None O
liquid None None O
ammonia None None O
, None None O
followed None None O
by None None O
standard None None O
reactions None None O
. None None O

The None None O
title None None O
compounds None None O
displayed None None O
partial None None O
agonism None None O
on None None O
contractile None None O
H None None O
( None None O
1 None None O
) None None O
receptors None None O
of None None O
the None None O
guinea None None O
- None None O
pig None None O
ileum None None O
and None None O
endothelium None None O
- None None O
denuded None None O
aorta None None O
, None None O
respectively None None O
, None None O
except None None O
10 None None O
( None None O
histaprodifen None None O
; None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
diphenylpropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
ethanamine None None I-IUPAC
) None None O
which None None O
was None None O
a None None O
full None None O
agonist None None O
in None None O
the None None O
ileum None None O
assay None None O
. None None O

While None None O
10 None None O
was None None O
equipotent None None O
with None None O
histamine None None O
( None None O
1 None None O
) None None O
, None None O
methylhistaprodifen None None O
( None None O
13 None None O
) None None O
and None None O
dimethylhistaprodifen None None O
( None None O
14 None None O
) None None O
exceeded None None O
the None None O
functional None None O
potency None None O
of None None O
1 None None O
by None None O
a None None O
factor None None O
of None None O
3-5 None None O
( None None O
13 None None O
) None None O
and None None O
2-3 None None O
( None None O
14 None None O
) None None O
. None None O

Compounds None None O
10 None None O
and None None O
13-17 None None O
relaxed None None O
precontracted None None O
rat None None O
aortic None None O
rings None None O
( None None O
intact None None O
endothelium None None O
) None None O
with None None O
relative None None O
potencies None None O
of None None O
3.3 None None O
- None None O
up None None O
to None None O
28 None None O
- None None O
fold None None O
( None None O
compared None None O
with None None O
1 None None O
) None None O
, None None O
displaying None None O
partial None None O
agonism None None O
as None None O
well None None O
. None None O

Agonist None None O
effects None None O
were None None O
sensitive None None O
to None None O
blockade None None O
by None None O
the None None O
selective None None O
H None None O
( None None O
1 None None O
) None None O
- None None O
receptor None None O
antagonist None None O
mepyramine None None O
( None None O
pA None None O
( None None O
2 None None O
) None None O
approximately None None O
9 None None O
( None None O
guinea None None O
- None None O
pig None None O
) None None O
and None None O
pA None None O
( None None O
2 None None O
) None None O
approximately None None O
8 None None O
( None None O
rat None None O
aorta None None O
) None None O
) None None O
. None None O

The None None O
affinity None None O
of None None O
10 None None O
and None None O
13-17 None None O
for None None O
guinea None None O
- None None O
pig None None O
H None None O
( None None O
1 None None O
) None None O
receptors None None O
increased None None O
20 None None O
- None None O
to None None O
100 None None O
- None None O
fold None None O
compared None None O
with None None O
1 None None O
. None None O

Two None None O
lower None None O
homologues None None O
of None None O
10 None None O
were None None O
weak None None O
partial None None O
H None None O
( None None O
1 None None O
) None None O
- None None O
receptor None None O
agonists None None O
while None None O
two None None O
higher None None O
homologues None None O
of None None O
10 None None O
were None None O
silent None None O
antagonists None None O
endowed None None O
with None None O
micromolar None None O
affinity None None O
for None None O
rat None None O
and None None O
guinea None None O
- None None O
pig None None O
H None None O
( None None O
1 None None O
) None None O
receptors None None O
. None None O

In None None O
functional None None O
selectivity None None O
experiments None None O
, None None O
10 None None O
, None None O
13 None None O
, None None O
and None None O
14 None None O
did None None O
not None None O
stimulate None None O
H None None O
( None None O
2 None None O
) None None O
, None None O
H None None O
( None None O
3 None None O
) None None O
, None None O
and None None O
several None None O
other None None O
neurotransmitter None None O
receptors None None O
. None None O

They None None O
displayed None None O
only None None O
low None None O
to None None O
moderate None None O
affinity None None O
for None None O
these None None O
sites None None O
( None None O
pA None None O
( None None O
2 None None O
) None None O
& None None O
lt None None O
; None None O
6 None None O
) None None O
. None None O

For None None O
a None None O
better None None O
understanding None None O
of None None O
structure None None O
- None None O
activity None None O
relationships None None O
, None None O
the None None O
interaction None None O
of None None O
1 None None O
and None None O
10 None None O
, None None O
13 None None O
and None None O
14 None None O
within None None O
the None None O
transmembrane None None O
( None None O
TM None None O
) None None O
domains None None O
of None None O
the None None O
human None None O
histamine None None O
H None None O
( None None O
1 None None O
) None None O
receptor None None O
were None None O
studied None None O
using None None O
molecular None None O
dynamics None None O
simulations None None O
. None None O

Remarkable None None O
differences None None O
were None None O
found None None O
between None None O
the None None O
binding None None O
modes None None O
of None None O
10 None None O
, None None O
13 None None O
, None None O
and None None O
14 None None O
and None None O
that None None O
of None None O
1 None None O
. None None O

The None None O
imidazole None None O
ring None None O
of None None O
10 None None O
, None None O
13 None None O
, None None O
and None None O
14 None None O
was None None O
placed None None O
' None None O
upside None None O
down None None O
' None None O
compared None None O
with None None O
1 None None O
, None None O
making None None O
the None None O
interaction None None O
of None None O
the None None O
N None None O
( None None O
pi None None O
) None None O
- None None O
atom None None O
with None None O
Tyr431 None None O
possible None None O
. None None O

This None None O
new None None O
orientation None None O
was None None O
mainly None None O
caused None None O
by None None O
the None None O
space None None O
filling None None O
substitution None None O
at None None O
the None None O
2 None None O
- None None O
position None None O
of None None O
the None None O
imidazole None None O
ring None None O
and None None O
influenced None None O
the None None O
location None None O
of None None O
the None None O
protonated None None O
N None None O
( None None O
alpha None None O
) None None O
- None None O
atom None None O
which None None O
was None None O
positioned None None O
more None None O
between None None O
TM None None O
III None None O
and None None O
TM None None O
VI None None O
. None None O

This None None O
orientation None None O
can None None O
explain None None O
both None None O
the None None O
increased None None O
relative None None O
potency None None O
and None None O
the None None O
maximum None None O
effect None None O
of None None O
10 None None O
, None None O
13 None None O
, None None O
and None None O
14 None None O
compared None None O
with None None O
1 None None O
. None None O

Compound None None O
13 None None O
( None None O
methylhistaprodifen None None O
; None None O
N None None I-IUPAC
( None None I-IUPAC
alpha None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
diphenylpropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
ethanamine None None I-IUPAC
) None None O
is None None O
the None None O
most None None O
potent None None O
histamine None None O
H None None O
( None None O
1 None None O
) None None O
- None None O
receptor None None O
agonist None None O
reported None None O
so None None O
far None None O
in None None O
the None None O
literature None None O
and None None O
may None None O
become None None O
a None None O
valuable None None O
tool None None O
for None None O
the None None O
study None None O
of None None O
physiological None None O
and None None O
pathophysiological None None O
H None None O
( None None O
1 None None O
) None None O
- None None O
receptor None None O
- None None O
mediated None None O
effects None None O
. None None O


The None None O
ability None None O
of None None O
conjugates None None O
of None None O
peptides None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
or None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoroorotic None None I-IUPAC
acid None None I-IUPAC
to None None O
enter None None O
Candida None None O
albicans None None O
was None None O
investigated None None O
. None None O

A None None O
number None None O
of None None O
conjugates None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoroorotic None None I-IUPAC
acid None None I-IUPAC
and None None O
peptides None None O
were None None O
synthesized None None O
using None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
dihydroquinoline None None I-IUPAC
as None None O
the None None O
coupling None None O
agent None None O
. None None O

Orotyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
leucyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
leucine None None I-IUPAC
, None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
succinamoyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
alanyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
leucine None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyrimidinone None None I-IUPAC
[ None None O
a None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
derivative None None I-MODIFIER
] None None O
, None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoroorotyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
leucyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
leucine None None I-IUPAC
all None None O
inhibited None None O
the None None O
uptake None None O
of None None O
trimethionine None None O
into None None O
C None None O
. None None O

albicans None None O
WD None None O
18-4 None None O
. None None O

Inhibition None None O
by None None O
5 None None I-IUPAC
- None None I-IUPAC
fluoroorotyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
leucyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
leucine None None I-IUPAC
was None None O
competitive None None O
as None None O
judged None None O
using None None O
double None None O
- None None O
reciprocal None None O
plots None None O
. None None O

Evaluation None None O
of None None O
minimum None None O
inhibitory None None O
concentrations None None O
of None None O
peptide None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
conjugates None None I-MODIFIER
suggest None None O
that None None O
these None None O
conjugates None None O
enter None None O
C None None O
. None None O

albicans None None O
in None None O
the None None O
intact None None O
form None None O
. None None O

These None None O
results None None O
provide None None O
the None None O
first None None O
experimental None None O
evidence None None O
that None None O
peptides None None O
can None None O
carry None None O
pyrimidines None None O
into None None O
a None None O
eukaryote None None O
. None None O


In None None O
a None None O
previous None None O
study None None O
, None None O
we None None O
described None None O
affinity None None O
labeling None None O
of None None O
the None None O
lamb None None O
uterine None None O
estrogen None None O
receptor None None O
by None None O
17 None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
bromoacetoxy None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
/ None None I-IUPAC
alkynyl None None I-IUPAC
] None None I-IUPAC
estradiols None None I-IUPAC
. None None O

However None None O
, None None O
the None None O
intrinsic None None O
receptor None None O
- None None O
alkylating None None O
activities None None O
of None None O
these None None O
compounds None None O
were None None O
probably None None O
very None None O
hampered None None O
by None None O
their None None O
poor None None O
hydrolytic None None O
stability None None O
in None None O
estrogen None None O
receptor None None O
- None None O
containing None None O
tissue None None O
extracts None None O
. None None O

Therefore None None O
, None None O
( None None O
i None None O
) None None O
to None None O
develop None None O
affinity None None O
labels None None O
of None None O
the None None O
receptor None None O
not None None O
susceptible None None O
to None None O
hydrolysis None None O
and None None O
( None None O
ii None None O
) None None O
to None None O
specify None None O
the None None O
structural None None O
requirements None None O
for None None O
17 None None O
alpha None None O
- None None O
electrophilic None None O
estradiol None None O
derivatives None None O
to None None O
be None None O
potent None None O
affinity None None O
labels None None O
of None None O
the None None O
receptor None None O
, None None O
we None None O
prepared None None O
four None None O
17 None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
haloacetamido None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
] None None I-IUPAC
estradiols None None I-IUPAC
. None None O

Three None None O
were None None O
bromoacetamides None None O
differing None None O
at None None O
the None None O
alkyl None None O
substituent None None O
( None None O
methyl None None O
, None None O
ethyl None None O
, None None O
or None None O
propyl None None O
) None None O
, None None O
and None None O
the None None O
last None None O
was None None O
an None None O
[ None None I-IUPAC
( None None I-IUPAC
iodoacetamido None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
estradiol None None I-IUPAC
prepared None None O
under None None O
both None None O
nonradioactive None None O
and None None O
3H None None O
- None None O
labeled None None O
forms None None O
. None None O

Although None None O
their None None O
affinities None None O
for None None O
the None None O
estrogen None None O
receptor None None O
were None None O
very None None O
low None None O
( None None O
from None None O
0.008% None None O
to None None O
0.02% None None O
that None None O
of None None O
estradiol None None O
) None None O
, None None O
they None None O
appeared None None O
to None None O
be None None O
efficient None None O
affinity None None O
labels None None O
of None None O
the None None O
receptor None None O
due None None O
to None None O
their None None O
irreversible None None O
inhibition None None O
of None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
estradiol None None I-IUPAC
specific None None O
binding None None O
in None None O
lamb None None O
uterine None None O
cytosol None None O
. None None O

The None None O
effect None None O
of None None O
the None None O
compounds None None O
was None None O
time None None O
- None None O
, None None O
pH None None O
- None None O
, None None O
and None None O
concentration None None O
- None None O
dependent None None O
, None None O
with None None O
& None None O
gt None None O
; None None O
50% None None O
and None None O
& None None O
gt None None O
; None None O
80% None None O
estrogen None None O
- None None O
binding None None O
sites None None O
inactivated None None O
at None None O
0 None None O
degrees None None O
C None None O
and None None O
pH None None O
8.5 None None O
, None None O
for None None O
the None None O
less None None O
active None None O
and None None O
more None None O
active None None O
compounds None None O
, None None O
respectively None None O
; None None O
the None None O
corresponding None None O
IC50 None None O
values None None O
varied None None O
from None None O
approximately None None O
20 None None O
nM None None O
to None None O
approximately None None O
10 None None O
microM None None O
. None None O

The None None O
order None None O
of None None O
efficiency None None O
was None None O
[ None None I-IUPAC
( None None I-IUPAC
bromoacetamido None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
estradiol None None I-IUPAC
& None None O
lt None None O
; None None O
[ None None I-IUPAC
( None None I-IUPAC
bromoacetamido None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
estradiol None None I-IUPAC
& None None O
lt None None O
; None None O
& None None O
lt None None O
; None None O
[ None None I-IUPAC
( None None I-IUPAC
bromoacetamido None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
estradiol None None I-IUPAC
& None None O
lt None None O
; None None O
[ None None I-IUPAC
( None None I-IUPAC
iodoacetamido None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
estradiol None None I-IUPAC
. None None O

Affinity None None O
labeling None None O
was None None O
directly None None O
demonstrated None None O
by None None O
ethanol None None O
- None None O
resistant None None O
binding None None O
of None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
iodoacetamido None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
estradiol None None I-IUPAC
to None None O
the None None O
receptor None None O
. None None O

The None None O
irreversible None None O
inactivation None None O
of None None O
the None None O
hormone None None O
- None None O
binding None None O
site None None O
by None None O
the None None O
four None None O
haloacetamides None None O
was None None O
prevented None None O
by None None O
treatment None None O
of None None O
the None None O
cytosol None None O
with None None O
the None None O
thiol None None O
- None None O
specific None None O
reagent None None O
methyl None None O
methanethiosulfonate None None O
, None None O
suggesting None None O
that None None O
the None None O
target None None O
of None None O
these None None O
compounds None None O
was None None O
probably None None O
the None None O
- None None O
SH None None O
of None None O
cysteines None None O
. None None O

Negative None None O
results None None O
obtained None None O
with None None O
other None None O
17 None None O
alpha None None O
- None None O
electrophilic None None O
estradiol None None O
derivatives None None O
suggested None None O
that None None O
affinity None None O
labeling None None O
of None None O
the None None O
receptor None None O
by None None O
such None None O
derivatives None None O
required None None O
a None None O
minimal None None O
distance None None O
, None None O
including None None O
at None None O
least None None O
four None None O
C None None O
- None None O
C None None O
or None None O
C None None O
- None None O
N None None O
bonds None None O
, None None O
between None None O
the None None O
steroid None None O
and None None O
the None None O
electrophilic None None O
carbon None None O
. None None O

We None None O
therefore None None O
concluded None None O
that None None O
target None None O
cysteines None None O
in None None O
the None None O
hormone None None O
- None None O
binding None None O
site None None O
were None None O
not None None O
in None None O
direct None None O
contact None None O
with None None O
the None None O
steroid None None O
but None None O
probably None None O
in None None O
the None None O
immediate None None O
neighborhood None None O
of None None O
the None None O
D None None O
ring None None O
of None None O
the None None O
bound None None O
steroid None None O
. None None O


Ten None None O
heretofore None None O
undescribed None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
chloroquinazoline None None I-IUPAC
analogues None None I-MODIFIER
of None None O
trimetrexate None None O
( None None O
TMQ None None O
) None None O
and None None O
piritrexim None None O
( None None O
PTX None None O
) None None O
were None None O
synthesized None None O
and None None O
tested None None O
as None None O
inhibitors None None O
of None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
from None None O
rat None None O
liver None None O
, None None O
Pneumocystis None None O
carinii None None O
, None None O
and None None O
Toxoplasma None None O
gondii None None O
. None None O

The None None O
most None None O
active None None O
quinazolines None None O
against None None O
both None None O
the None None O
P None None O
. None None O

carinii None None O
and None None O
the None None O
T None None O
. None None O

gondii None None O
enzyme None None O
were None None O
those None None O
with None None O
an None None O
ArCH2 None None O
- None None O
NH None None O
or None None O
ArNHCH2 None None O
side None None O
chain None None O
. None None O

Among None None O
ArNH None None O
( None None O
CH2 None None O
) None None O
n None None O
compounds None None O
with None None O
n None None O
= None None O
1-3 None None O
and None None O
either None None O
2' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
dimethoxyphenyl None None I-IUPAC
or None None O
3' None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
trimethoxyphenyl None None I-IUPAC
as None None O
the None None O
Ar None None O
moiety None None O
, None None O
activity None None O
decreased None None O
in None None O
the None None O
order None None O
n None None O
= None None O
1 None None O
& None None O
gt None None O
; None None O
n None None O
= None None O
2 None None O
& None None O
gt None None O
; None None O
n None None O
= None None O
3 None None O
. None None O

The None None O
best None None O
inhibitor None None O
of None None O
P None None O
. None None O

carinii None None O
DHFR None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
trimethoxyanilino None None I-IUPAC
) None None I-IUPAC
methy None None I-IUPAC
l None None I-IUPAC
] None None I-IUPAC
quinazoline None None I-IUPAC
( None None O
10 None None O
) None None O
had None None O
an None None O
IC50 None None O
of None None O
0.012 None None O
microM None None O
and None None O
was None None O
slightly None None O
more None None O
potent None None O
than None None O
TMQ None None O
and None None O
PTX None None O
. None None O

Compound None None O
10 None None O
was None None O
also None None O
the None None O
best None None O
inhibitor None None O
of None None O
T None None O
. None None O

gondii None None O
DHFR None None O
, None None O
with None None O
an None None O
IC50 None None O
of None None O
0.0064 None None O
microM None None O
corresponding None None O
again None None O
to None None O
a None None O
minor None None O
increase None None O
in None None O
activity None None O
over None None O
TMQ None None O
and None None O
PTX None None O
. None None O

However None None O
, None None O
as None None O
with None None O
these None None O
standard None None O
agents None None O
, None None O
10 None None O
showed None None O
no None None O
appreciable None None O
selectivity None None O
for None None O
either None None O
the None None O
P None None O
. None None O

carinii None None O
or None None O
T None None O
. None None O

gondii None None O
enzyme None None O
relative None None O
to None None O
the None None O
rat None None O
liver None None O
enzyme None None O
. None None O

The None None O
highest None None O
selectivity None None O
achieved None None O
in None None O
this None None O
limited None None O
series None None O
was None None O
with None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
trimethoxybenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
] None None I-IUPAC
quinazoline None None I-IUPAC
( None None O
17 None None O
) None None O
against None None O
T None None O
. None None O

gondii None None O
DHFR None None O
. None None O

While None None O
17 None None O
( None None O
IC50 None None O
= None None O
0.016 None None O
microM None None O
) None None O
was None None O
somewhat None None O
less None None O
potent None None O
than None None O
10 None None O
, None None O
its None None O
selectivity None None O
, None None O
as None None O
defined None None O
by None None O
the None None O
ratio None None O
IC50 None None O
( None None O
rat None None O
liver None None O
) None None O
/ None None O
IC50 None None O
( None None O
T None None O
. None None O

gondii None None O
) None None O
was None None O
ca. None None O
30 None None O
- None None O
fold None None O
higher None None O
than None None O
that None None O
of None None O
TMQ None None O
or None None O
PTX None None O
. None None O

Two None None O
compounds None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
trimethoxyanilino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
quinazoline None None I-IUPAC
( None None O
9 None None O
) None None O
and None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
trimethoxybenzyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
quinazoline None None I-IUPAC
( None None O
15 None None O
) None None O
, None None O
were None None O
also None None O
tested None None O
against None None O
human None None O
DHFR None None O
and None None O
were None None O
found None None O
to None None O
have None None O
an None None O
IC50 None None O
/ None None O
[ None None O
E None None O
] None None O
of None None O
0.5 None None O
, None None O
indicating None None O
that None None O
their None None O
binding None None O
was None None O
near None None O
- None None O
stoichiometric None None O
. None None O


A None None O
number None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
heteroaromatic None None I-IUPAC
- None None O
substituted None None I-MODIFIER
2' None None B-IUPAC
- None None I-IUPAC
deoxyuridines None None I-IUPAC
were None None O
synthesized None None O
from None None O
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
using None None O
tetraorganotin None None O
reagents None None O
and None None O
palladium None None O
complexes None None O
as None None O
catalyst None None O
. None None O

The None None O
palladium None None O
- None None O
catalyzed None None O
cross None None O
- None None O
coupling None None O
reaction None None O
between None None O
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
and None None O
stannylated None None O
heteroaromatics None None O
was None None O
optimized None None O
for None None O
the None None O
synthesis None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
thien None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
furan None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
. None None O

5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
Iodothien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
was None None O
used None None O
as None None O
starting None None O
material None None O
for None None O
the None None O
synthesis None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylthien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
vinylthien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
, None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ethynylthien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
. None None O

5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
Nitrothien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
was None None O
synthesized None None O
using None None O
ceric None None O
ammonium None None O
nitrate None None O
as None None O
reagent None None O
. None None O

5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Isoxazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
was None None O
synthesized None None O
from None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxopropyn None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
. None None O

Finally None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
chlorothien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabinofuranosyluracil None None I-IUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
bromothien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabinofuranosyluracil None None I-IUPAC
were None None O
obtained None None O
by None None O
halogenation None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
thien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabinofuranosyluracil None None I-IUPAC
. None None O

Introduction None None O
of None None O
an None None O
alkyl None None O
substituent None None O
in None None O
the None None O
5 None None O
- None None O
position None None O
of None None O
the None None O
thienyl None None O
group None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
thien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
or None None O
substitution None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxyribofuranose None None I-IUPAC
ring None None I-MODIFIER
by None None O
an None None O
arabinofuranose None None O
moiety None None O
gave None None O
decreased None None O
activity None None O
against None None O
HSV None None O
- None None O
1 None None O
and None None O
VZV None None O
replication None None O
when None None O
compared None None O
with None None O
the None None O
5 None None I-IUPAC
" None None I-IUPAC
- None None I-IUPAC
halogenated None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
thien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridines None None I-IUPAC
. None None O

5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
Bromothien None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
caused None None O
prompt None None O
healing None None O
of None None O
HSV None None O
- None None O
1 None None O
keratitis None None O
when None None O
administered None None O
as None None O
eye None None O
drops None None O
( None None O
0.2% None None O
) None None O
to None None O
rabbits None None O
. None None O


( None None O
3S None None O
, None None O
4R None None O
) None None O
- None None O
4 None None O
- None None O
( None None O
4 None None O
- None None O
Fluorophenyl None None O
) None None O
- None None O
3 None None O
- None None O
[ None None O
[ None None O
3,4 None None O
- None None O
( None None O
methylenedioxy None None O
) None None O
phenoxy None None O
] None None O
methyl None None O
] None None O
piperidine None None O
[ None None O
( None None O
3S None None O
, None None O
9R None None O
) None None O
- None None O
3 None None O
, None None O
paroxetine None None O
] None None O
is None None O
a None None O
selective None None O
serotonin None None O
reuptake None None O
inhibitor None None O
( None None O
SSRI None None O
) None None O
used None None O
as None None O
an None None O
antidepressant None None O
in None None O
humans None None O
. None None O

In None None O
previous None None O
studies None None O
, None None O
we None None O
reported None None O
that None None O
certain None None O
( None None I-PARTIUPAC
1R None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
3 None None I-PARTIUPAC
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
substituted None None I-MODIFIER
phenyl None None B-IUPAC
) None None O
nortropane None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
carboxylic None None I-PARTIUPAC
acid None None I-PARTIUPAC
methyl None None I-PARTIUPAC
esters None None I-PARTIUPAC
( None None O
2a None None O
) None None O
exhibited None None O
high None None O
affinity None None O
and None None O
reasonable None None O
selectivity None None O
for None None O
the None None O
serotonin None None O
transporter None None O
( None None O
5 None None O
- None None O
HTT None None O
) None None O
. None None O

The None None O
major None None O
structural None None O
differences None None O
between None None O
2a None None O
and None None O
( None None O
3S None None O
, None None O
4R None None O
) None None O
- None None O
3 None None O
are None None O
that None None O
2a None None O
possesses None None O
a None None O
different None None O
absolute None None O
stereochemistry None None O
and None None O
has None None O
an None None O
ethylene None None O
bridge None None O
not None None O
present None None O
in None None O
3 None None O
. None None O

In None None O
addition None None O
, None None O
2a None None O
possesses None None O
a None None O
carbomethoxy None None O
substituent None None O
adjacent None None O
to None None O
the None None O
aryl None None O
ring None None O
, None None O
whereas None None O
( None None O
3S None None O
, None None O
4R None None O
) None None O
- None None O
3 None None O
contains None None O
a None None O
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylenedioxy None None I-IUPAC
) None None I-IUPAC
phenoxy None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
present None None O
the None None O
synthesis None None O
and None None O
biological None None O
evaluations None None O
of None None O
six None None O
of None None O
the None None O
possible None None O
eight None None O
isomers None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylenedioxy None None I-IUPAC
) None None I-IUPAC
phenoxy None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
nortropane None None I-IUPAC
+ None None O
+ None None O
+ None None O
( None None O
4 None None O
) None None O
. None None O

The None None O
data None None O
for None None O
inhibition None None O
of None None O
[ None None O
3H None None O
] None None O
paroxetine None None O
binding None None O
show None None O
that None None O
( None None O
1R None None O
) None None O
- None None O
2 None None O
beta None None O
, None None O
3 None None O
alpha None None O
- None None O
4c None None O
, None None O
which None None O
has None None O
the None None O
same None None O
stereochemistry None None O
as None None O
paroxetine None None O
, None None O
has None None O
the None None O
highest None None O
affinity None None O
at None None O
the None None O
5 None None O
- None None O
HTT None None O
. None None O

Strikingly None None O
, None None O
the None None O
most None None O
potent None None O
compounds None None O
for None None O
inhibition None None O
of None None O
[ None None O
3H None None O
] None None O
WIN None None O
- None None O
35,428 None None O
binding None None O
were None None O
not None None O
the None None O
( None None O
1R None None O
) None None O
- None None O
2 None None O
beta None None O
, None None O
3 None None O
beta None None O
- None None O
isomers None None O
but None None O
rather None None O
( None None O
1R None None O
) None None O
- None None O
2 None None O
beta None None O
, None None O
3 None None O
alpha None None O
- None None O
4c None None O
and None None O
( None None O
1S None None O
) None None O
- None None O
2 None None O
beta None None O
, None None O
3 None None O
alpha None None O
- None None O
4f None None O
. None None O

Conformational None None O
analyses None None O
show None None O
that None None O
these None None O
isomers None None O
exist None None O
in None None O
a None None O
flattened None None O
boat None None O
conformation None None O
with None None O
pseudoequatorial None None O
substituents None None O
. None None O

Thus None None O
, None None O
the None None O
binding None None O
data None None O
show None None O
that None None O
this None None O
conformation None None O
is None None O
recognized None None O
by None None O
the None None O
DAT None None O
- None None O
associated None None O
binding None None O
site None None O
and None None O
also None None O
suggest None None O
that None None O
this None None O
conformation None None O
of None None O
paroxetine None None O
is None None O
recognized None None O
by None None O
the None None O
5 None None O
- None None O
HTT None None O
- None None O
associated None None O
binding None None O
site None None O
. None None O


A None None O
series None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aryloxy None None I-IUPAC
) None None I-IUPAC
propan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ols None None I-IUPAC
was None None O
synthesized None None O
together None None O
with None None O
several None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dimethoxyphenethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aryloxy None None I-IUPAC
) None None I-IUPAC
propan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ols None None I-IUPAC
. None None O

Their None None O
affinity None None O
to None None O
beta None None O
1 None None O
- None None O
and None None O
beta None None O
- None None O
2 None None O
- None None O
adrenoceptors None None O
was None None O
determined None None O
and None None O
compared None None O
with None None O
the None None O
affinity None None O
of None None O
known None None O
beta None None O
- None None O
blockers None None O
. None None O

We None None O
were None None O
able None None O
to None None O
confirm None None O
the None None O
substantial None None O
cardioselectivity None None O
of None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
dimethoxyphenethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
4 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
aryl None None I-IUPAC
) None None B-PARTIUPAC
oxy None None I-PARTIUPAC
] None None I-PARTIUPAC
propan None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
ols None None I-PARTIUPAC
when None None O
compared None None O
to None None O
those None None O
with None None O
a None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenethyl None None I-IUPAC
) None None I-IUPAC
group None None I-MODIFIER
. None None O

An None None O
increase None None O
in None None O
the None None O
size None None O
of None None O
the None None O
4 None None O
substitutent None None O
of None None O
the None None O
3 None None O
- None None O
( None None O
aryloxy None None O
) None None O
moiety None None O
to None None O
caproamido None None O
leads None None O
to None None O
a None None O
substantially None None O
higher None None O
affinity None None O
for None None O
the None None O
beta None None O
1 None None O
- None None O
- None None O
adrenoceptor None None O
of None None O
rat None None O
ventricular None None O
muscle None None O
in None None O
the None None O
presence None None O
of None None O
the None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dimethoxyphenethyl None None I-IUPAC
than None None O
in None None O
the None None O
presence None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenethyl None None I-IUPAC
or None None O
isopropyl None None O
group None None O
; None None O
this None None O
combination None None O
also None None O
gave None None O
the None None O
highest None None O
cardioselectivity None None O
. None None O


A None None O
number None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxyazole None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
synthesized None None O
as None None O
bioisosteres None None O
of None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
( None None O
Glu None None O
) None None O
and None None O
as None None O
analogues None None O
of None None O
the None None O
AMPA None None O
receptor None None O
agonist None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
, None None O
3b None None O
) None None O
. None None O

All None None O
compounds None None O
were None None O
subjected None None O
to None None O
in None None O
vitro None None O
pharmacological None None O
studies None None O
, None None O
including None None O
a None None O
series None None O
of None None O
Glu None None O
receptor None None O
binding None None O
assays None None O
, None None O
uptake None None O
studies None None O
on None None O
native None None O
as None None O
well None None O
as None None O
cloned None None O
Glu None None O
uptake None None O
systems None None O
, None None O
and None None O
the None None O
electrophysiological None None O
rat None None O
cortical None None O
slice None None O
model None None O
. None None O

Compounds None None O
7a None None O
, None None O
b None None O
, None None O
analogues None None O
of None None O
AMPA None None O
bearing None None O
a None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
pyrazolyl None None I-IUPAC
moiety None None I-MODIFIER
as None None O
the None None O
distal None None O
carboxylic None None O
functionality None None O
, None None O
showed None None O
only None None O
moderate None None O
affinity None None O
for None None O
[ None None O
3H None None O
] None None O
AMPA None None O
receptor None None O
binding None None O
sites None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
2.7 None None O
+ None None O
/ None None O
- None None O
0.4 None None O
microM None None O
and None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
2.6 None None O
+ None None O
/ None None O
- None None O
0.6 None None O
microM None None O
, None None O
respectively None None O
) None None O
, None None O
correlating None None O
with None None O
electrophysiological None None O
data None None O
from None None O
the None None O
rat None None O
cortical None None O
wedge None None O
model None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
280 None None O
+ None None O
/ None None O
- None None O
48 None None O
microM None None O
and None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
586 None None O
+ None None O
/ None None O
- None None O
41 None None O
microM None None O
, None None O
respectively None None O
) None None O
. None None O

1 None None I-IUPAC
- None None I-IUPAC
Hydroxy None None I-IUPAC
- None None I-IUPAC
1,2,3 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
analogues None None I-MODIFIER
of None None O
AMPA None None O
, None None O
compounds None None O
8a None None O
, None None O
b None None O
, None None O
showed None None O
high None None O
affinity None None O
for None None O
[ None None O
3H None None O
] None None O
AMPA None None O
receptor None None O
binding None None O
sites None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.15 None None O
+ None None O
/ None None O
- None None O
0.03 None None O
microM None None O
and None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.13 None None O
+ None None O
/ None None O
- None None O
0.02 None None O
microM None None O
, None None O
respectively None None O
) None None O
. None None O

Electrophysiological None None O
data None None O
showed None None O
that None None O
compound None None O
8a None None O
was None None O
devoid None None O
of None None O
activity None None O
in None None O
the None None O
rat None None O
cortical None None O
wedge None None O
model None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
& None None O
gt None None O
; None None O
1000 None None O
microM None None O
) None None O
, None None O
whereas None None O
the None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
analogue None None I-MODIFIER
8b None None O
was None None O
a None None O
potent None None O
AMPA None None O
receptor None None O
agonist None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
15 None None O
+ None None O
/ None None O
- None None O
2 None None O
microM None None O
) None None O
. None None O

In None None O
accordance None None O
with None None O
this None None O
disparity None None O
, None None O
compound None None O
8a None None O
was None None O
found None None O
to None None O
inhibit None None O
synaptosomal None None O
[ None None O
3H None None O
] None None O
D None None O
- None None O
aspartic None None O
acid None None O
uptake None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
93 None None O
+ None None O
/ None None O
- None None O
25 None None O
microM None None O
) None None O
, None None O
as None None O
well None None O
as None None O
excitatory None None O
amino None None O
acid None None O
transporters None None O
( None None O
EAATs None None O
) None None O
EAAT1 None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
100 None None O
+ None None O
/ None None O
- None None O
30 None None O
microM None None O
) None None O
and None None O
EAAT2 None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
300 None None O
+ None None O
/ None None O
- None None O
80 None None O
microM None None O
) None None O
. None None O

By None None O
contrast None None O
, None None O
compound None None O
8b None None O
showed None None O
no None None O
appreciable None None O
affinity None None O
for None None O
Glu None None O
uptake None None O
sites None None O
, None None O
neither None None O
synaptosomal None None O
nor None None O
cloned None None O
. None None O

Compounds None None O
9a None None O
- None None O
c None None O
and None None O
10a None None O
, None None O
b None None O
, None None O
possessing None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxyimidazole None None I-IUPAC
as None None O
the None None O
terminal None None O
acidic None None O
function None None O
, None None O
were None None O
devoid None None O
of None None O
activity None None O
in None None O
all None None O
of None None O
the None None O
systems None None O
tested None None O
. None None O

Protolytic None None O
properties None None O
of None None O
compounds None None O
7a None None O
, None None O
b None None O
, None None O
8b None None O
, None None O
and None None O
9b None None O
were None None O
determined None None O
by None None O
titration None None O
, None None O
and None None O
a None None O
correlation None None O
between None None O
the None None O
pK None None O
( None None O
a None None O
) None None O
values None None O
and None None O
the None None O
activity None None O
at None None O
AMPA None None O
receptors None None O
was None None O
apparent None None O
. None None O

Optimized None None O
structures None None O
of None None O
all None None O
the None None O
synthesized None None O
ligands None None O
were None None O
fitted None None O
to None None O
the None None O
known None None O
crystal None None O
structure None None O
of None None O
an None None O
AMPA None None O
- None None O
GluR2 None None O
construct None None O
. None None O

Where None None O
substantial None None O
reduction None None O
or None None O
abolition None None O
of None None O
affinity None None O
at None None O
AMPA None None O
receptors None None O
was None None O
observed None None O
, None None O
this None None O
could None None O
be None None O
rationalized None None O
on None None O
the None None O
basis None None O
of None None O
the None None O
ability None None O
of None None O
the None None O
ligand None None O
to None None O
fit None None O
the None None O
construct None None O
. None None O

The None None O
results None None O
presented None None O
in None None O
this None None O
article None None O
point None None O
to None None O
the None None O
utility None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxypyrazole None None I-IUPAC
and None None O
1,2,3 None None I-IUPAC
- None None I-IUPAC
hydroxytriazole None None I-IUPAC
as None None O
bioisosteres None None O
of None None O
carboxylic None None O
acids None None O
at None None O
Glu None None O
receptors None None O
and None None O
transporters None None O
. None None O

None None None O
of None None O
the None None O
compounds None None O
showed None None O
significant None None O
activity None None O
at None None O
metabotropic None None O
Glu None None O
receptors None None O
. None None O


Methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
isothiocyanatomethyl None None I-IUPAC
) None None I-IUPAC
thiazole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamate None None I-IUPAC
and None None O
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
isothiocyanatomethyl None None I-IUPAC
) None None I-IUPAC
selenazole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamate None None I-IUPAC
have None None O
been None None O
prepared None None O
via None None O
chemical None None O
transformations None None O
involving None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloromethyl None None I-IUPAC
) None None I-IUPAC
thiazole None None I-IUPAC
( None None O
1 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloromethyl None None I-IUPAC
) None None I-IUPAC
selenazole None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
respectively None None O
, None None O
as None None O
starting None None O
materials None None O
. None None O

The None None O
homoanalog None None O
, None None O
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
isothiocyanatoethyl None None I-IUPAC
) None None I-IUPAC
thiazole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamate None None I-IUPAC
, None None O
was None None O
prepared None None O
from None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminothiazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
acetic None None I-IUPAC
acid None None I-IUPAC
. None None O

All None None O
compounds None None O
prepared None None O
were None None O
evaluated None None O
for None None O
their None None O
ability None None O
to None None O
inhibit None None O
leukemia None None O
L1210 None None O
cell None None O
proliferation None None O
. None None O

Methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
isothiocyanatomethyl None None I-IUPAC
) None None I-IUPAC
thiazole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamate None None I-IUPAC
( None None O
7 None None O
) None None O
was None None O
the None None O
most None None O
active None None O
compound None None O
in None None O
this None None O
screen None None O
, None None O
inhibiting None None O
the None None O
growth None None O
of None None O
L1210 None None O
leukemic None None O
cells None None O
with None None O
an None None O
IC50 None None O
= None None O
3.2 None None O
microM None None O
. None None O

Mitotic None None O
blocking None None O
appears None None O
to None None O
be None None O
its None None O
primary None None O
mechanism None None O
of None None O
cytotoxic None None O
activity None None O
. None None O

Compound None None O
7 None None O
also None None O
was None None O
the None None O
only None None O
compound None None O
which None None O
demonstrated None None O
significant None None O
in None None O
vivo None None O
antifilarial None None O
activity None None O
against None None O
the None None O
adult None None O
worms None None O
of None None O
Acanthocheilonema None None O
viteae None None O
in None None O
experimentally None None O
infected None None O
jirds None None O
. None None O

This None None O
compound None None O
was None None O
inactive None None O
against None None O
Brugia None None O
pahangi None None O
at None None O
a None None O
dosage None None O
of None None O
100 None None O
mg None None O
/ None None O
kg None None O
x None None O
5 None None O
days None None O
. None None O


From None None O
salicyclic None None O
acid None None O
, None None O
the None None O
two None None O
enantiomers None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxybenzamide None None I-IUPAC
( None None O
6b None None O
) None None O
were None None O
prepared None None O
in None None O
a None None O
five None None O
- None None O
step None None O
synthesis None None O
. None None O

With None None O
use None None O
of None None O
Heindel None None O
's None None O
triazene None None O
method None None O
for None None O
introduction None None O
of None None O
the None None O
radionuclide None None O
, None None O
the None None O
iodine None None O
- None None O
125 None None O
- None None O
labeled None None O
substituted None None O
benzamide None None O
was None None O
obtained None None O
with None None O
a None None O
calculated None None O
specific None None O
activity None None O
of None None O
136 None None O
Ci None None O
/ None None O
mmol None None O
and None None O
14% None None O
radiochemical None None O
yield None None O
. None None O

For None None O
the None None O
preparation None None O
of None None O
the None None O
iodine None None O
- None None O
125 None None O
- None None O
labeled None None O
benzamide None None O
with None None O
higher None None O
specific None None O
activity None None O
, None None O
this None None O
method None None O
was None None O
unsuccessful None None O
and None None O
utilization None None O
of None None O
the None None O
corresponding None None O
tri None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butyltin None None I-IUPAC
derivative None None I-MODIFIER
was None None O
required None None O
. None None O

Treatment None None O
of None None O
the None None O
latter None None O
in None None O
dilute None None O
hydrochloric None None O
acid None None O
with None None O
sodium None None O
iodide None None O
- None None O
125 None None O
and None None O
chloramine None None O
- None None O
T None None O
gave None None O
[ None None O
125I None None O
] None None O
( None None O
S None None O
) None None O
- None None O
6b None None O
in None None O
56% None None O
radiochemical None None O
yield None None O
and None None O
at None None O
least None None O
97% None None O
radiochemical None None O
purity None None O
. None None O

The None None O
displacement None None O
of None None O
[ None None I-PARTIUPAC
125I None None I-PARTIUPAC
] None None I-PARTIUPAC
( None None I-PARTIUPAC
S None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
6b None None O
and None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
sulpiride None None I-IUPAC
from None None O
their None None O
respective None None O
binding None None O
sites None None O
in None None O
striatal None None O
rat None None O
brain None None O
homogenates None None O
using None None O
various None None O
neuroleptic None None O
agents None None O
showed None None O
that None None O
( None None O
S None None O
) None None O
- None None O
6b None None O
has None None O
the None None O
same None None O
binding None None O
profile None None O
but None None O
more None None O
potent None None O
binding None None O
for None None O
dopamine None None O
D None None O
- None None O
2 None None O
receptors None None O
than None None O
has None None O
sulpiride None None O
. None None O

These None None O
experiments None None O
also None None O
indicate None None O
that None None O
the None None O
S None None O
enantiomer None None O
of None None O
6b None None O
is None None O
a None None O
specific None None O
ligand None None O
( None None O
KD None None O
= None None O
1.2 None None O
nM None None O
) None None O
for None None O
the None None O
D None None O
- None None O
2 None None O
receptor None None O
. None None O

Further None None O
, None None O
the None None O
octanol None None O
- None None O
water None None O
partition None None O
coefficient None None O
of None None O
( None None O
S None None O
) None None O
- None None O
6b None None O
as None None O
determined None None O
by None None O
reverse None None O
- None None O
phase None None O
high None None O
- None None O
performance None None O
liquid None None O
chromatography None None O
was None None O
found None None O
to None None O
be None None O
40 None None O
times None None O
greater None None O
than None None O
that None None O
for None None O
sulpiride None None O
. None None O

Thus None None O
( None None O
S None None O
) None None O
- None None O
6b None None O
has None None O
a None None O
lipophilicity None None O
that None None O
will None None O
allow None None O
a None None O
relatively None None O
higher None None O
uptake None None O
into None None O
the None None O
brain None None O
compared None None O
to None None O
sulpiride None None O
. None None O

In None None O
vivo None None O
experiments None None O
with None None O
rats None None O
show None None O
that None None O
[ None None O
125I None None O
] None None O
( None None O
S None None O
) None None O
- None None O
6b None None O
penetrates None None O
readily None None O
into None None O
the None None O
brain None None O
and None None O
is None None O
preferentially None None O
localized None None O
in None None O
the None None O
striatum None None O
as None None O
compared None None O
to None None O
the None None O
cerebellum None None O
, None None O
the None None O
ratio None None O
of None None O
uptake None None O
being None None O
7.2 None None O
to None None O
1 None None O
, None None O
60 None None O
min None None O
after None None O
injection None None O
. None None O

These None None O
observations None None O
of None None O
good None None O
brain None None O
penetration None None O
and None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
D None None O
- None None O
2 None None O
receptors None None O
indicate None None O
that None None O
the None None O
corresponding None None O
iodine None None O
- None None O
123 None None O
- None None O
labeled None None O
benzamide None None O
may None None O
be None None O
a None None O
useful None None O
ligand None None O
for None None O
the None None O
noninvasive None None O
visualization None None O
study None None O
of None None O
dopamine None None O
D None None O
- None None O
2 None None O
receptor None None O
sites None None O
in None None O
vivo None None O
by None None O
single None None O
photon None None O
emission None None O
computed None None O
tomography None None O
. None None O


The None None O
inhibitions None None O
of None None O
cytochrome None None O
P None None O
- None None O
450 None None O
dependent None None O
monooxygenase None None O
activity None None O
in None None O
microsomes None None O
from None None O
rat None None O
liver None None O
by None None O
1 None None I-IUPAC
- None None I-IUPAC
phenylpyrrole None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
isopropylphenyl None None I-IUPAC
) None None I-IUPAC
pyrrole None None I-IUPAC
, None None O
4 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
phenylimidazole None None I-IUPAC
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
isopropylphenyl None None I-IUPAC
) None None I-IUPAC
imidazole None None I-IUPAC
have None None O
been None None O
compared None None O
. None None O

The None None O
results None None O
establish None None O
that None None O
the None None O
presence None None O
of None None O
an None None O
imidazole None None O
N None None O
- None None O
3 None None O
nitrogen None None O
substituent None None O
is None None O
not None None O
required None None O
to None None O
inhibit None None O
the None None O
monooxygenase None None O
activity None None O
measured None None O
by None None O
the None None O
deethylation None None O
of None None O
7 None None I-IUPAC
- None None I-IUPAC
ethoxycoumarin None None I-IUPAC
. None None O

The None None O
presence None None O
of None None O
an None None O
appropriately None None O
situated None None O
N None None O
- None None O
3 None None O
atom None None O
, None None O
however None None O
, None None O
as None None O
in None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
isopropylphenyl None None I-IUPAC
) None None I-IUPAC
imidazole None None I-IUPAC
, None None O
significantly None None O
decreases None None O
both None None O
the None None O
Ki None None O
and None None O
alphaKi None None O
of None None O
these None None O
mixed None None O
type None None O
inhibitors None None O
. None None O

The None None O
induction None None O
of None None O
7 None None I-IUPAC
- None None I-IUPAC
ethoxycoumarin None None I-IUPAC
deethylase None None O
activity None None O
in None None O
the None None O
microsomal None None O
fraction None None O
from None None O
rat None None O
liver None None O
by None None O
alpha None None I-IUPAC
- None None I-IUPAC
naphthoflavone None None I-IUPAC
, None None O
beta None None I-IUPAC
- None None I-IUPAC
naphthoflavone None None I-IUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
methylcholanthrene None None I-IUPAC
and None None O
the None None O
inhibition None None O
of None None O
these None None O
activities None None O
by None None O
flavone None None O
and None None O
alpha None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
beta None None I-PARTIUPAC
, None None O
and None None O
gamma None None I-IUPAC
- None None I-IUPAC
naphthoflavone None None I-IUPAC
have None None O
also None None O
been None None O
examined None None O
. None None O

The None None O
results None None O
establish None None O
that None None O
alpha None None I-IUPAC
- None None I-IUPAC
naphthoflavone None None I-IUPAC
is None None O
the None None O
most None None O
effective None None O
in None None O
vitro None None O
inhibitor None None O
. None None O

The None None O
results None None O
also None None O
indicate None None O
that None None O
the None None O
microsomal None None O
monooxygenase None None O
activities None None O
induced None None O
in None None O
rat None None O
liver None None O
by None None O
alpha None None I-IUPAC
- None None I-IUPAC
naphthoflavone None None I-IUPAC
, None None O
beta None None I-IUPAC
- None None I-IUPAC
naphthoflavone None None I-IUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
methylcholanthrene None None I-IUPAC
are None None O
not None None O
equivalent None None O
. None None O

Based None None O
upon None None O
the None None O
observed None None O
results None None O
, None None O
it None None O
is None None O
concluded None None O
that None None O
differential None None O
effects None None O
of None None O
alpha None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
beta None None I-IUPAC
- None None I-IUPAC
naphthoflavone None None I-IUPAC
on None None O
aryl None None O
hydrocarbon None None O
skin None None O
tumorigenesis None None O
may None None O
be None None O
the None None O
result None None O
of None None O
differential None None O
enzyme None None O
induction None None O
rather None None O
than None None O
the None None O
result None None O
of None None O
differential None None O
enzyme None None O
inhibition None None O
. None None O


A None None O
series None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
4 None None B-IUPAC
- None None I-IUPAC
phenylpiperidines None None I-IUPAC
, None None O
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydropyridines None None I-IUPAC
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
phenylpiperazines None None I-IUPAC
was None None O
synthesized None None O
. None None O

The None None O
phenyl None None I-IUPAC
group None None B-MODIFIER
was None None O
optionally None None O
substituted None None O
with None None O
4 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
or None None O
2 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
substituents None None I-MODIFIER
. None None O

High None None O
affinity None None O
for None None O
both None None O
sigma None None O
1 None None O
and None None O
sigma None None O
2 None None O
binding None None O
sites None None O
was None None O
achieved None None O
with None None O
these None None O
compounds None None O
. None None O

Additionally None None O
, None None O
these None None O
compounds None None O
had None None O
relatively None None O
high None None O
affinity None None O
for None None O
serotonin None None O
5 None None O
- None None O
HT1A None None O
and None None O
5 None None O
- None None O
HT2A None None O
, None None O
dopamine None None O
D2 None None O
, None None O
and None None O
adrenergic None None O
alpha None None O
1 None None O
receptors None None O
. None None O

Introduction None None O
of None None O
a None None O
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
substituent None None I-MODIFIER
at None None O
the None None O
indole None None O
nitrogen None None O
atom None None O
rendered None None O
very None None O
selective None None O
sigma None None O
2 None None O
ligands None None O
with None None O
subnanomolar None None O
affinity None None O
for None None O
the None None O
sigma None None O
2 None None O
binding None None O
site None None O
. None None O

The None None O
prototype None None O
of None None O
such None None O
a None None O
compound None None O
was None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indole None None I-IUPAC
, None None O
11a None None O
( None None O
code None None O
no None None O
. None None O

Lu None None O
29-253 None None O
) None None O
. None None O

This None None O
compound None None O
had None None O
the None None O
following None None O
binding None None O
affinities None None O
: None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
) None None O
= None None O
16 None None O
nM None None O
, None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.27 None None O
nM None None O
, None None O
IC50 None None O
( None None O
5 None None O
- None None O
HT1A None None O
) None None O
= None None O
22,000 None None O
nM None None O
, None None O
IC50 None None O
( None None O
5 None None O
- None None O
HT2A None None O
) None None O
= None None O
270 None None O
nM None None O
, None None O
IC50 None None O
( None None O
D2 None None O
) None None O
= None None O
4200 None None O
nM None None O
, None None O
IC50 None None O
( None None O
alpha None None O
1 None None O
) None None O
= None None O
220 None None O
nM None None O
. None None O

Spiro None None O
- None None O
joining None None O
of None None O
the None None O
phenyl None None I-IUPAC
and None None O
the None None O
piperidine None None I-IUPAC
rings None None B-MODIFIER
into None None O
a None None O
spiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperdine None None I-IUPAC
] None None I-IUPAC
ring None None I-MODIFIER
system None None I-MODIFIER
resulted None None O
in None None O
even None None O
more None None O
selective None None O
compounds None None O
. None None O

Variations None None O
of None None O
the None None O
1 None None O
- None None O
substituent None None O
at None None O
the None None O
indole None None O
and None None O
of None None O
the None None O
chain None None O
length None None O
of None None O
the None None O
alkylene None None O
spacer None None O
group None None O
were None None O
studied None None O
. None None O

The None None O
optimal None None O
compound None None O
was None None O
the None None O
spiro None None O
analogue None None O
of None None O
compound None None O
11a None None O
. None None O

This None None O
compound None None O
is None None O
1' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
spiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
, None None O
14f None None O
( None None O
code None None O
no None None O
. None None O

Lu None None O
28-179 None None O
) None None O
, None None O
with None None O
the None None O
binding None None O
affinities None None O
: None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
) None None O
= None None O
17 None None O
nM None None O
, None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.12 None None O
nM None None O
, None None O
IC50 None None O
( None None O
5 None None O
- None None O
HT1A None None O
) None None O
= None None O
21,000 None None O
nM None None O
, None None O
IC50 None None O
( None None O
5 None None O
- None None O
HT2A None None O
) None None O
= None None O
2000 None None O
nM None None O
, None None O
IC50 None None O
( None None O
D2 None None O
) None None O
= None None O
800 None None O
nM None None O
, None None O
IC50 None None O
( None None O
alpha None None O
1 None None O
) None None O
= None None O
330 None None O
nM None None O
. None None O

However None None O
, None None O
the None None O
most None None O
selective None None O
sigma None None O
2 None None O
versus None None O
sigma None None O
1 None None O
ligand None None O
was None None O
the None None O
tropane None None O
derivative None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
azabicyclo None None I-IUPAC
[ None None I-IUPAC
3.2.1 None None I-IUPAC
] None None I-IUPAC
oct None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indole None None I-IUPAC
, None None O
15a None None O
. None None O

This None None O
compound None None O
had None None O
the None None O
following None None O
binding None None O
affinities None None O
: None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
) None None O
= None None O
1200 None None O
nM None None O
, None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
2.5 None None O
nM None None O
. None None O

Potent None None O
anxiolytic None None O
activity None None O
in None None O
the None None O
black None None O
/ None None O
white None None O
box None None O
exploration None None O
test None None O
in None None O
rats None None O
was None None O
found None None O
with None None O
the None None O
two None None O
most None None O
prominent None None O
sigma None None O
2 None None O
ligands None None O
Lu None None O
29-253 None None O
and None None O
Lu None None O
28-179 None None O
. None None O

Good None None O
penetration None None O
into None None O
the None None O
CNS None None O
was None None O
documented None None O
both None None O
after None None O
subcutaneous None None O
and None None O
peroral None None O
administration None None O
of None None O
Lu None None O
28-179 None None O
by None None O
ex None None O
vivo None None O
binding None None O
studies None None O
. None None O

Long None None O
duration None None O
of None None O
action None None O
was None None O
demonstrated None None O
both None None O
in None None O
ex None None O
vivo None None O
binding None None O
( None None O
T1/2 None None O
approximately None None O
20 None None O
h None None O
) None None O
and None None O
in None None O
the None None O
black None None O
/ None None O
white None None O
box None None O
exploration None None O
test None None O
. None None O


2beta None None I-IUPAC
- None None I-IUPAC
Carbomethoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethenyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
nortropane None None I-IUPAC
( None None O
ZIENT None None O
) None None O
( None None O
6 None None O
) None None O
and None None O
2beta None None I-IUPAC
- None None I-IUPAC
carbomethoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethenyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
nortropane None None I-IUPAC
( None None O
EIENT None None O
) None None O
( None None O
10 None None O
) None None O
were None None O
prepared None None O
and None None O
evaluated None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
for None None O
serotonin None None O
transporter None None O
( None None O
SERT None None O
) None None O
selectivity None None O
and None None O
specificity None None O
. None None O

High None None O
specific None None O
activity None None O
[ None None O
( None None O
123 None None O
) None None O
I None None O
] None None O
ZIENT None None O
and None None O
[ None None O
( None None O
123 None None O
) None None O
I None None O
] None None O
EIENT None None O
were None None O
synthesized None None O
in None None O
45% None None O
( None None O
n None None O
= None None O
5 None None O
) None None O
and None None O
42% None None O
( None None O
n None None O
= None None O
4 None None O
) None None O
radiochemical None None O
yield None None O
( None None O
decay None None O
- None None O
corrected None None O
to None None O
end None None O
of None None O
bombardment None None O
( None None O
EOB None None O
) None None O
) None None O
, None None O
respectively None None O
, None None O
by None None O
preparation None None O
of None None O
the None None O
precursor None None O
carbomethoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
trimethylstannylethenyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
nortropane None None I-IUPAC
( None None O
7 None None O
) None None O
and None None O
2beta None None I-IUPAC
- None None I-IUPAC
carbomethoxy None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
tributylstannylethenyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
nortropane None None I-IUPAC
( None None O
9 None None O
) None None O
, None None O
respectively None None O
, None None O
followed None None O
by None None O
treatment None None O
with None None O
no None None O
carrier None None O
- None None O
added None None O
sodium None None O
[ None None O
( None None O
123 None None O
) None None O
I None None O
] None None O
iodide None None O
and None None O
hydrogen None None O
peroxide None None O
in None None O
ethanolic None None O
HCl None None O
. None None O

Competition None None O
binding None None O
in None None O
cells None None O
stably None None O
expressing None None O
the None None O
transfected None None O
human None None O
SERT None None O
, None None O
dopamine None None O
transporter None None O
( None None O
DAT None None O
) None None O
, None None O
and None None O
norepinephrine None None O
transporter None None O
( None None O
NET None None O
) None None O
using None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
citalopram None None O
, None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
WIN None None O
35,428 None None O
, None None O
and None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
nisoxetine None None O
, None None O
respectively None None O
, None None O
demonstrated None None O
the None None O
following None None O
order None None O
of None None O
SERT None None O
affinity None None O
( None None O
K None None O
( None None O
i None None O
) None None O
in None None O
nM None None O
) None None O
: None None O
ZIENT None None O
( None None O
0.05 None None O
) None None O
& None None O
gt None None O
; None None O
nor None None O
- None None O
CIT None None O
( None None O
0.12 None None O
) None None O
& None None O
gt None None O
; None None O
& None None O
gt None None O
; None None O
EIENT None None O
( None None O
1.15 None None O
) None None O
& None None O
gt None None O
; None None O
fluvoxamine None None O
( None None O
1.46 None None O
) None None O
. None None O

The None None O
affinity None None O
of None None O
ZIENT None None O
and None None O
EIENT None None O
for None None O
DAT None None O
was None None O
69 None None O
and None None O
1.6 None None O
- None None O
fold None None O
lower None None O
, None None O
respectively None None O
, None None O
than None None O
for None None O
SERT None None O
. None None O

In None None O
vivo None None O
biodistribution None None O
and None None O
blocking None None O
studies None None O
were None None O
performed None None O
in None None O
male None None O
rats None None O
and None None O
demonstrated None None O
that None None O
the None None O
brain None None O
uptake None None O
of None None O
[ None None O
( None None O
123 None None O
) None None O
I None None O
] None None O
ZIENT None None O
was None None O
selective None None O
and None None O
specific None None O
for None None O
SERT None None O
- None None O
rich None None O
regions None None O
( None None O
hypothalamus None None O
, None None O
striatum None None O
, None None O
pons None None O
, None None O
and None None O
prefrontal None None O
cortex None None O
) None None O
. None None O

SPECT None None O
brain None None O
imaging None None O
studies None None O
in None None O
monkeys None None O
demonstrated None None O
high None None O
[ None None O
( None None O
123 None None O
) None None O
I None None O
] None None O
ZIENT None None O
uptake None None O
in None None O
the None None O
diencephalon None None O
, None None O
which None None O
resulted None None O
in None None O
diencephalon None None O
- None None O
to None None O
- None None O
cerebellum None None O
ratios None None O
of None None O
2.12 None None O
at None None O
190 None None O
min None None O
. None None O

[ None None O
( None None O
123 None None O
) None None O
I None None O
] None None O
ZIENT None None O
uptake None None O
in None None O
the None None O
diencephalon None None O
achieved None None O
transient None None O
equilibrium None None O
at None None O
157 None None O
min None None O
. None None O

In None None O
a None None O
displacement None None O
experiment None None O
of None None O
[ None None O
( None None O
123 None None O
) None None O
I None None O
] None None O
ZIENT None None O
in None None O
a None None O
cynomolgus None None O
monkey None None O
, None None O
radioactivity None None O
was None None O
reduced None None O
by None None O
39% None None O
in None None O
the None None O
diencephalon None None O
at None None O
101 None None O
min None None O
following None None O
injection None None O
of None None O
citalopram None None O
. None None O

The None None O
high None None O
specific None None O
activity None None O
one None None O
- None None O
step None None O
radiolabeling None None O
preparation None None O
and None None O
high None None O
selectivity None None O
of None None O
[ None None O
( None None O
123 None None O
) None None O
I None None O
] None None O
ZIENT None None O
for None None O
SERT None None O
support None None O
its None None O
candidacy None None O
as None None O
a None None O
radioligand None None O
for None None O
mapping None None O
brain None None O
SERT None None O
sites None None O
. None None O


Several None None O
series None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2,4,5 None None I-IUPAC
- None None O
trisubstituted None None I-MODIFIER
- None None O
3H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
with None None O
acidic None None O
sulfonamide None None O
replacements None None O
of None None O
tetrazole None None O
at None None O
the None None O
2' None None O
- None None O
position None None O
of None None O
the None None O
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
side None None I-MODIFIER
chain None None I-MODIFIER
at None None O
N4 None None O
were None None O
prepared None None O
and None None O
tested None None O
as None None O
angiotensin None None O
II None None O
( None None O
AII None None O
) None None O
antagonists None None O
. None None O

Preferred None None O
substituents None None O
on None None O
the None None O
triazolinone None None O
ring None None O
were None None O
n None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
at None None O
C5 None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
at None None O
N2 None None O
. None None O

Subnanomolar None None O
IC50 None None O
values None None O
at None None O
the None None O
AT1 None None O
receptor None None O
subtype None None O
were None None O
observed None None O
for None None O
a None None O
variety None None O
of None None O
acylsulfonamides None None O
, None None O
including None None O
aroyl None None O
, None None O
heteroaroyl None None O
, None None O
and None None O
cycloalkylcarbonyl None None I-IUPAC
derivatives None None B-MODIFIER
. None None O

Certain None None O
other None None O
acidic None None O
sulfonamides None None O
, None None O
such None None O
as None None O
sulfonylcarbamates None None O
and None None O
disulfimides None None O
also None None O
displayed None None O
high None None O
affinity None None O
for None None O
the None None O
AT1 None None O
receptor None None O
. None None O

In None None O
addition None None O
, None None O
AT2 None None O
binding None None O
for None None O
some None None O
of None None O
these None None O
compounds None None O
was None None O
increased None None O
by None None O
as None None O
much None None O
as None None O
1000 None None O
- None None O
fold None None O
over None None O
the None None O
corresponding None None O
tetrazole None None O
( None None O
e.g. None None O
, None None O
AT2 None None O
IC50 None None O
17 None None O
nM None None O
for None None O
the None None O
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
sulfonylcarbamate None None I-IUPAC
92 None None O
) None None O
. None None O

When None None O
evaluated None None O
for None None O
inhibition None None O
of None None O
the None None O
AII None None O
pressor None None O
response None None O
, None None O
the None None O
benchmark None None O
benzoylsulfonamide None None O
9 None None O
( None None O
L None None O
- None None O
159,913 None None O
) None None O
was None None O
efficacious None None O
in None None O
several None None O
species None None O
and None None O
was None None O
superior None None O
to None None O
losartan None None O
( None None O
1a None None O
) None None O
in None None O
conscious None None O
rhesus None None O
monkeys None None O
. None None O

Several None None O
subsequent None None O
analogues None None O
, None None O
including None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
chlorobenzoyl None None I-IUPAC
( None None O
18 None None O
) None None O
, None None O
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chlorothiophene None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
( None None O
51 None None O
) None None O
, None None O
( None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
dimethylcyclopropyl None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
( None None O
80 None None O
) None None O
, None None O
and None None O
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
( None None O
92 None None O
) None None O
derivatives None None I-MODIFIER
, None None O
were None None O
highly None None O
effective None None O
in None None O
rats None None O
, None None O
surpassing None None O
9 None None O
and None None O
losartan None None O
in None None O
duration None None O
of None None O
action None None O
and None None O
/ None None O
or None None O
potency None None O
. None None O

Compound None None O
18 None None O
( None None O
L None None O
- None None O
162,223 None None O
) None None O
displayed None None O
very None None O
prolonged None None O
AII None None O
antagonism None None O
in None None O
the None None O
rat None None O
model None None O
( None None O
& None None O
gt None None O
; None None O
24 None None O
h None None O
at None None O
1 None None O
mg None None O
/ None None O
kg None None O
iv None None O
) None None O
. None None O

At None None O
1 None None O
mg None None O
/ None None O
kg None None O
po None None O
in None None O
rats None None O
, None None O
18 None None O
and None None O
92 None None O
( None None O
L None None O
- None None O
162,234 None None O
) None None O
produced None None O
85-87% None None O
peak None None O
inhibition None None O
of None None O
the None None O
AII None None O
pressor None None O
response None None O
with None None O
duration None None O
exceeding None None O
6 None None O
h None None O
. None None O

The None None O
identification None None O
of None None O
triazolinone None None O
- None None O
based None None O
sulfonamide None None O
derivatives None None O
combining None None O
high None None O
AT1 None None O
affinity None None O
, None None O
considerably None None O
enhanced None None O
AT2 None None O
potency None None O
, None None O
and None None O
favorable None None O
in None None O
vivo None None O
properties None None O
provides None None O
insights None None O
relevant None None O
to None None O
the None None O
design None None O
of None None O
dual None None O
AT1 None None O
/ None None O
AT2 None None O
receptor None None O
antagonists None None O
. None None O


A None None O
series None None I-MODIFIER
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indoles None None I-IUPAC
substituted None None I-MODIFIER
in None None I-MODIFIER
the None None I-MODIFIER
1 None None I-MODIFIER
- None None I-MODIFIER
position None None I-MODIFIER
with None None O
4 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
, None None O
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
piperazinyl None None I-IUPAC
was None None O
synthesized None None O
. None None O

By None None O
variation None None O
of None None O
the None None O
substituents None None O
in None None O
the None None O
benzene None None O
part None None O
of None None O
the None None O
indole None None O
nucleus None None O
in None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3-4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
imidazolidinones None None I-IUPAC
, None None O
the None None O
highest None None O
5 None None O
- None None O
HT2 None None O
receptor None None O
affinity None None O
and None None O
selectivity None None O
with None None O
respect None None O
to None None O
dopamine None None O
D2 None None O
receptors None None O
and None None O
alpha None None O
1 None None O
adrenoceptors None None O
were None None O
obtained None None O
by None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
substitution None None I-MODIFIER
. None None O

Different None None O
substituents None None O
were None None O
introduced None None O
in None None O
the None None O
1 None None O
- None None O
position None None O
of None None O
the None None O
piperidine None None O
ring None None O
in None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
derivative None None I-MODIFIER
. None None O

Thus None None O
replacement None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
imidazolidinon None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
side None None I-MODIFIER
chain None None I-MODIFIER
with None None O
a None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ureido None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
or None None O
methyl None None I-IUPAC
substituent None None B-MODIFIER
resulted None None O
in None None O
unchanged None None O
affinity None None O
and None None O
selectivity None None O
for None None O
5 None None O
- None None O
HT2 None None O
receptors None None O
. None None O

Replacement None None O
with None None O
a None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
imidazolidinon None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
ethyl None None I-IUPAC
side None None I-MODIFIER
chain None None I-MODIFIER
reduced None None O
binding None None O
to None None O
alpha None None O
1 None None O
adrenoceptors None None O
with None None O
a None None O
factor None None O
of None None O
four None None O
, None None O
while None None O
affinities None None O
for None None O
5 None None O
- None None O
HT2 None None O
and None None O
D2 None None O
receptors None None O
were None None O
retained None None O
, None None O
compared None None O
to None None O
the None None O
3 None None I-MODIFIER
- None None I-MODIFIER
unsubstituted None None I-MODIFIER
imidazolidinone None None I-IUPAC
. None None O

Indoles None None O
substituted None None I-MODIFIER
in None None O
the None None O
1 None None O
- None None O
position None None O
with None None O
4 None None I-IUPAC
- None None I-IUPAC
piperazinyl None None I-IUPAC
had None None O
generally None None O
weaker None None O
affinity None None O
for None None O
both None None O
5 None None O
- None None O
HT2 None None O
and None None O
D2 None None O
receptors None None O
compared None None O
to None None O
corresponding None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
piperidinyl None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
indoles None None B-IUPAC
. None None O

Introduction None None O
of None None O
a None None O
methyl None None I-IUPAC
group None None B-MODIFIER
in None None O
the None None O
2 None None O
- None None O
position None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
indole None None O
resulted None None O
in None None O
further None None O
increase None None O
of None None O
selectivity None None O
for None None O
the None None O
5 None None O
- None None O
HT2 None None O
receptor None None O
. None None O

Compounds None None O
with None None O
potent None None O
receptor None None O
binding None None O
also None None O
potently None None O
inhibited None None O
the None None O
quipazine None None O
- None None O
induced None None O
head None None O
twitch None None O
syndrome None None O
in None None O
rats None None O
. None None O

The None None O
compounds None None O
were None None O
equally None None O
active None None O
after None None O
oral None None O
and None None O
subcutaneous None None O
administration None None O
and None None O
showed None None O
a None None O
long None None O
duration None None O
of None None O
action None None O
( None None O
& None None O
gt None None O
; None None O
24 None None O
h None None O
) None None O
. None None O

In None None O
general None None O
, None None O
the None None O
derivatives None None O
were None None O
found None None O
to None None O
be None None O
considerably None None O
more None None O
potent None None O
at None None O
24 None None O
h None None O
than None None O
at None None O
2 None None O
h None None O
after None None O
the None None O
administration None None O
. None None O

The None None O
compounds None None O
within None None O
this None None O
series None None O
were None None O
prepared None None O
as None None O
analogues None None O
of None None O
the None None O
previously None None O
described None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indoles None None I-IUPAC
by None None O
interchange None None O
of None None O
the None None O
C None None O
- None None O
3 None None O
carbon None None O
atom None None O
and None None O
the None None O
nitrogen None None O
atom None None O
in None None O
the None None O
indole None None O
nucleus None None O
. None None O

The None None O
pharmacological None None O
results None None O
indicate None None O
that None None O
this None None O
isosteric None None O
replacement None None O
results None None O
in None None O
higher None None O
selectivity None None O
for None None O
5 None None O
- None None O
HT2 None None O
receptors None None O
compared None None O
to None None O
the None None O
former None None O
series None None O
. None None O

The None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2,5 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
] None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
imidazolidinone None None I-IUPAC
has None None O
high None None O
affinity None None O
for None None O
5 None None O
- None None O
HT2 None None O
receptors None None O
( None None O
IC50 None None O
= None None O
3.4 None None O
nM None None O
) None None O
and None None O
extremely None None O
low None None O
affinity None None O
for None None O
both None None O
dopamine None None O
D2 None None O
receptors None None O
( None None O
IC50 None None O
= None None O
6900 None None O
nM None None O
) None None O
and None None O
alpha None None O
1 None None O
adrenoceptors None None O
( None None O
IC50 None None O
= None None O
2300 None None O
nM None None O
) None None O
. None None O


The None None O
dopaminergic None None O
receptor None None O
profile None None O
of None None O
a None None O
series None None O
of None None O
trans None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylcyclopropyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
arylpiperazines None None I-IUPAC
was None None O
examined None None O
. None None O

Aromatic None None O
substitution None None O
patterns None None O
were None None O
varied None None O
with None None O
the None None O
goal None None O
of None None O
identifying None None O
a None None O
compound None None O
having None None O
affinities None None O
for None None O
the None None O
D None None O
( None None O
2 None None O
) None None O
and None None O
D None None O
( None None O
4 None None O
) None None O
receptors None None O
in None None O
a None None O
ratio None None O
similar None None O
to None None O
that None None O
observed None None O
for None None O
the None None O
atypical None None O
neuroleptic None None O
clozapine None None O
. None None O

The None None O
compounds None None O
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
2S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylcyclopropyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
piperazine None None I-IUPAC
( None None O
5m None None O
) None None O
and None None O
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
2S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylcyclopropyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
dimethylphenyl None None I-IUPAC
) None None I-IUPAC
piperazine None None I-IUPAC
( None None O
5t None None O
) None None O
were None None O
selected None None O
for None None O
functional None None O
antagonists None None O
at None None O
D None None O
( None None O
2 None None O
) None None O
and None None O
D None None O
( None None O
4 None None O
) None None O
receptors None None O
and None None O
had None None O
a None None O
D None None O
( None None O
2 None None O
) None None O
/ None None O
D None None O
( None None O
4 None None O
) None None O
ratio None None O
approximating None None O
that None None O
of None None O
clozapine None None O
; None None O
they None None O
proved None None O
inactive None None O
in None None O
behavioral None None O
tests None None O
of None None O
antipsychotic None None O
activity None None O
. None None O


A None None O
series None None O
of None None O
eight None None O
previously None None O
undescribed None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diaminothieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
analogues None None I-MODIFIER
of None None O
the None None O
potent None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
inhibitors None None O
trimetrexate None None O
( None None O
TMQ None None O
) None None O
and None None O
piritrexim None None O
( None None O
PTX None None O
) None None O
were None None O
synthesized None None O
as None None O
potential None None O
drugs None None O
against None None O
Pneumocystis None None O
carinii None None O
and None None O
Toxoplasma None None O
gondii None None O
, None None O
which None None O
are None None O
major None None O
causes None None O
of None None O
severe None None O
opportunistic None None O
infections None None O
in None None O
AIDS None None O
patients None None O
. None None O

2,4 None None I-IUPAC
- None None I-IUPAC
Diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aryl None None I-IUPAC
/ None None I-IUPAC
aralkyl None None I-IUPAC
) None None I-IUPAC
thieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
with None None O
3,4,5 None None I-IUPAC
- None None I-IUPAC
trimethoxy None None I-IUPAC
or None None O
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
substitution None None I-MODIFIER
in None None O
the None None O
aryl None None O
/ None None O
aralkyl None None O
moiety None None O
and None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aryl None None I-IUPAC
/ None None I-IUPAC
aralkyl None None I-IUPAC
) None None I-IUPAC
thieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
with None None O
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
substitution None None I-MODIFIER
in None None O
the None None O
aryl None None O
/ None None O
aralkyl None None O
moiety None None O
were None None O
obtained None None O
by None None O
reaction None None O
of None None O
the None None O
corresponding None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyanothiophenes None None I-IUPAC
with None None O
chloroformamidine None None O
hydrochloride None None O
. None None O

The None None O
aryl None None O
group None None O
in None None O
the None None O
5,6 None None O
- None None O
disubstituted None None O
analogues None None O
was None None O
either None None O
attached None None O
directly None None O
to None None O
the None None O
hetero None None O
ring None None O
or None None O
was None None O
separated None None O
from None None O
it None None O
by None None O
one None None O
or None None O
two None None O
carbons None None O
, None None O
whereas None None O
the None None O
aryl None None O
group None None O
in None None O
the None None O
5 None None O
- None None O
monosubstituted None None O
analogues None None O
was None None O
separated None None O
from None None O
the None None O
hetero None None O
ring None None O
by None None O
two None None O
or None None O
three None None O
carbons None None O
. None None O

2 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aryl None None I-IUPAC
/ None None I-IUPAC
alkyl None None I-IUPAC
) None None I-IUPAC
thiophene None None I-IUPAC
intermediates None None O
for None None O
the None None O
preparation None None O
of None None O
the None None O
5,6 None None O
- None None O
disubstituted None None O
analogues None None O
were None None O
prepared None None O
from None None O
omega None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
alkylidene None None I-IUPAC
- None None I-IUPAC
malononitriles None None I-IUPAC
and None None O
sulfur None None O
in None None O
the None None O
presence None None O
of None None O
a None None O
secondary None None O
amine None None O
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aryl None None I-IUPAC
/ None None I-IUPAC
aralkyl None None I-IUPAC
) None None I-IUPAC
thiophene None None I-IUPAC
intermediates None None I-MODIFIER
for None None O
the None None O
preparation None None O
of None None O
the None None O
5 None None O
- None None O
monosubstituted None None O
analogues None None O
were None None O
obtained None None O
from None None O
omega None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
alkylidenemalononitriles None None I-IUPAC
and None None O
sodium None None O
hydrosulfide None None O
. None None O

Synthetic None None O
routes None None O
to None None O
the None None O
heretofore None None O
unknown None None O
ylidenemalononitriles None None O
, None None O
and None None O
the None None O
ketone None None O
precursors None None O
thereof None None O
, None None O
were None None O
developed None None O
. None None O

The None None O
final None None O
products None None O
were None None O
tested None None O
in None None O
vitro None None O
as None None O
inhibitors None None O
of None None O
DHFR None None O
from None None O
Pneumocystis None None O
carinii None None O
, None None O
Toxoplasma None None O
gondii None None O
, None None O
rat None None O
liver None None O
, None None O
beef None None O
liver None None O
, None None O
and None None O
Lactobacillus None None O
casei None None O
. None None O

A None None O
selected None None O
number None None O
of None None O
previously None None O
known None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diaminothieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
lacking None None O
the None None O
3,4,5 None None I-IUPAC
- None None I-IUPAC
trimethoxyphenyl None None I-IUPAC
and None None O
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxyphenyl None None I-IUPAC
substitution None None I-MODIFIER
pattern None None I-MODIFIER
of None None O
TMQ None None O
and None None O
PTX None None O
, None None O
respectively None None O
, None None O
were None None O
also None None O
tested None None O
for None None O
comparison None None O
. None None O

None None None O
of None None O
the None None O
compounds None None O
was None None O
as None None O
potent None None O
as None None O
TMQ None None O
or None None O
PTX None None O
, None None O
and None None O
while None None O
some None None O
of None None O
them None None O
showed None None O
some None None O
selectivity None None O
in None None O
their None None O
binding None None O
to None None O
Pneumocystis None None O
carinii None None O
and None None O
Toxoplasma None None O
gondii None None O
versus None None O
rat None None O
liver None None O
DHFR None None O
, None None O
this None None O
effect None None O
was None None O
not None None O
deemed None None O
large None None O
enough None None O
to None None O
warrant None None O
further None None O
preclinical None None O
evaluation None None O
. None None O


Extensive None None O
evidence None None O
gathered None None O
from None None O
structure None None O
- None None O
activity None None O
relationship None None O
analysis None None O
has None None O
identified None None O
and None None O
confirmed None None O
specific None None O
positions None None O
in None None O
the None None O
glucagon None None O
sequence None None O
that None None O
are None None O
important None None O
either None None O
for None None O
binding None None O
to None None O
its None None O
receptor None None O
or None None O
for None None O
signal None None O
transduction None None O
. None None O

Fifteen None None O
glucagon None None O
analogues None None O
have None None O
been None None O
designed None None O
and None None O
synthesized None None O
by None None O
incorporating None None O
structural None None O
changes None None O
in None None O
the None None O
N None None O
- None None O
terminal None None O
region None None O
of None None O
glucagon None None O
, None None O
in None None O
particular None None O
histidine None None O
- None None O
1 None None O
, None None O
phenylalanine None None O
- None None O
6 None None O
, None None O
and None None O
aspartic None None O
acid None None O
- None None O
9 None None O
. None None O

This None None O
investigation None None O
was None None O
conducted None None O
to None None O
study None None O
the None None O
role None None O
of None None O
phenylalanine None None O
at None None O
position None None O
6 None None O
on None None O
the None None O
glucagon None None O
mechanism None None O
of None None O
action None None O
. None None O

These None None O
glucagon None None O
analogues None None O
have None None O
been None None O
made None None O
by None None O
either None None O
deleting None None O
or None None O
substituting None None O
hydrophobic None None O
groups None None O
, None None O
hydrophilic None None O
groups None None O
, None None O
aromatic None None O
amino None None O
acids None None O
, None None O
or None None O
a None None O
D None None O
- None None O
phenylalanine None None O
residue None None O
at None None O
this None None O
position None None O
. None None O

The None None O
structures None None O
of None None O
the None None O
new None None O
analogues None None O
are None None O
as None None O
follows None None O
: None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
des None None O
- None None O
Phe6 None None O
, None None O
Glu9 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
1 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
Ala6 None None O
, None None O
Glu9 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
2 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
Tyr6 None None O
, None None O
Glu9 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
3 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
Trp6 None None O
, None None O
Glu9 None None O
] None None O
- None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
4 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
D None None O
- None None O
Phe6 None None O
, None None O
Glu9 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
5 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
Nle6 None None O
, None None O
Glu9 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
6 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
Asp6 None None O
, None None O
Glu9 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
7 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
des None None O
- None None O
Gly4 None None O
, None None O
Glu9 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
8 None None O
) None None O
; None None O
[ None None O
desPhe6 None None O
, None None O
- None None O
Glu9 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
9 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
Phe6 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
10 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
des None None O
- None None O
Phe6 None None O
] None None O
glucagon None None O
- None None O
NH2 None None O
( None None O
11 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
des None None O
- None None O
Phe6 None None O
, None None O
Glu9 None None O
] None None O
glucagon None None O
( None None O
12 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
Phe6 None None O
, None None O
Glu9 None None O
] None None O
glucagon None None O
( None None O
13 None None O
) None None O
; None None O
[ None None O
des None None O
- None None O
Phe6 None None O
] None None O
glucagon None None O
( None None O
14 None None O
) None None O
; None None O
and None None O
[ None None O
des None None O
- None None O
His1 None None O
, None None O
des None None O
- None None O
Phe6 None None O
] None None O
glucagon None None O
( None None O
15 None None O
) None None O
. None None O

The None None O
receptor None None O
binding None None O
potencies None None O
IC50 None None O
values None None O
are None None O
48 None None O
( None None O
1 None None O
) None None O
, None None O
126 None None O
( None None O
2 None None O
) None None O
, None None O
40 None None O
( None None O
3 None None O
) None None O
, None None O
19 None None O
( None None O
4 None None O
) None None O
, None None O
100 None None O
( None None O
5 None None O
) None None O
, None None O
48 None None O
( None None O
6 None None O
) None None O
, None None O
2000 None None O
( None None O
7 None None O
) None None O
, None None O
52 None None O
( None None O
8 None None O
) None None O
, None None O
113 None None O
( None None O
9 None None O
) None None O
, None None O
512 None None O
( None None O
10 None None O
) None None O
, None None O
128 None None O
( None None O
11 None None O
) None None O
, None None O
1000 None None O
( None None O
12 None None O
) None None O
, None None O
2000 None None O
( None None O
13 None None O
) None None O
, None None O
500 None None O
( None None O
14 None None O
) None None O
, None None O
and None None O
200 None None O
nM None None O
( None None O
15 None None O
) None None O
. None None O

All None None O
analogues None None O
were None None O
found None None O
to None None O
be None None O
antagonists None None O
unable None None O
to None None O
activate None None O
the None None O
adenylate None None O
cyclase None None O
system None None O
even None None O
at None None O
concentrations None None O
as None None O
high None None O
as None None O
10 None None O
( None None O
- None None O
5 None None O
) None None O
M None None O
except None None O
for None None O
analogues None None O
6 None None O
and None None O
8 None None O
, None None O
which None None O
were None None O
found None None O
to None None O
be None None O
weak None None O
partial None None O
agonists None None O
/ None None O
partial None None O
antagonists None None O
with None None O
maximum None None O
stimulation None None O
between None None O
6-12% None None O
. None None O

In None None O
competitive None None O
inhibition None None O
experiments None None O
, None None O
all None None O
the None None O
analogues None None O
caused None None O
a None None O
right None None O
shift None None O
of None None O
the None None O
glucagon None None O
- None None O
stimulated None None O
adenylate None None O
cyclase None None O
dose None None O
- None None O
response None None O
curve None None O
. None None O

The None None O
pA2 None None O
values None None O
were None None O
8.20 None None O
( None None O
1 None None O
) None None O
, None None O
6.40 None None O
( None None O
2 None None O
) None None O
, None None O
6.20 None None O
( None None O
3 None None O
) None None O
, None None O
6.25 None None O
( None None O
4 None None O
) None None O
, None None O
6.30 None None O
( None None O
5 None None O
) None None O
, None None O
6.30 None None O
( None None O
7 None None O
) None None O
, None None O
6.05 None None O
( None None O
8 None None O
) None None O
, None None O
6.20 None None O
( None None O
9 None None O
) None None O
, None None O
6.30 None None O
( None None O
10 None None O
) None None O
, None None O
6.25 None None O
( None None O
11 None None O
) None None O
, None None O
6.10 None None O
( None None O
12 None None O
) None None O
, None None O
6.20 None None O
( None None O
13 None None O
) None None O
, None None O
6.20 None None O
( None None O
14 None None O
) None None O
, None None O
and None None O
6.35 None None O
( None None O
15 None None O
) None None O
. None None O


A None None O
convenient None None O
synthesis None None O
of None None O
8 None None O
- None None O
azapurine None None O
ribonucleosides None None O
substituted None None O
at None None O
the None None O
6 None None O
position None None O
with None None O
thio None None I-IUPAC
, None None O
alkylthio None None I-IUPAC
, None None O
alkoxy None None I-IUPAC
, None None O
amino None None I-IUPAC
, None None O
and None None O
alkylamino None None I-IUPAC
groups None None B-MODIFIER
is None None O
described None None O
. None None O

The None None O
reaction None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
azapurine None None I-IUPAC
( None None O
1 None None O
) None None O
with None None O
2,3,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
chloride None None I-IUPAC
in None None O
the None None O
presence None None O
of None None O
Linde None None O
AW None None O
- None None O
500 None None O
molecular None None O
sieve None None O
gave None None O
a None None O
2 None None O
: None None O
1 None None O
mixture None None O
of None None O
2 None None O
and None None O
3 None None O
, None None O
respectively None None O
. None None O

This None None O
mixture None None O
was None None O
rearranged None None O
by None None O
heating None None O
with None None O
molecular None None O
sieve None None O
in None None O
refluxing None None O
toluene None None O
to None None O
give None None O
a None None O
6 None None O
: None None O
1 None None O
mixture None None O
of None None O
2 None None O
and None None O
3 None None O
. None None O

Treatment None None O
of None None O
2 None None O
or None None O
3 None None O
with None None O
the None None O
appropriate None None O
nucleophiles None None O
at None None O
room None None O
temperature None None O
gave None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
8 None None I-IUPAC
- None None I-IUPAC
azapurine None None I-IUPAC
ribonucleosides None None I-IUPAC
( None None O
7 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
3 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
1,2,3 None None I-IUPAC
- None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
) None None O
4-13 None None O
. None None O

The None None O
thione None None O
11 None None O
rearranges None None O
to None None O
N None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
[ None None I-IUPAC
1,2,3 None None I-IUPAC
] None None I-IUPAC
thiadiazolo None None I-IUPAC
[ None None I-IUPAC
5,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
amine None None I-IUPAC
( None None O
14 None None O
) None None O
in None None O
the None None O
solid None None O
state None None O
or None None O
in None None O
solution None None O
. None None O

All None None O
of None None O
these None None O
compounds None None O
were None None O
cytotoxic None None O
to None None O
H None None O
. None None O

Ep None None O
. None None O

No None None O
. None None O

2 None None O
cells None None O
in None None O
culture None None O
except None None O
the None None O
parent None None O
base None None O
, None None O
8 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
purine None None I-IUPAC
( None None O
1 None None O
) None None O
and None None O
the None None O
8 None None O
- None None O
isomers None None O
( None None O
3,12 None None O
, None None O
and None None O
13 None None O
) None None O
. None None O

Three None None O
of None None O
these None None O
compounds None None O
- None None O
8azaadenosine None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
8 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
purine None None I-IUPAC
ribonucleoside None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
and None None O
8 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methoxy None None I-IUPAC
) None None I-IUPAC
purine None None I-IUPAC
ribonucleoside None None I-IUPAC
( None None O
7 None None O
) None None O
- None None O
showed None None O
borderline None None O
activity None None O
in None None O
the None None O
leukemia None None O
L1210 None None O
system None None O
. None None O

The None None O
thiadiazolopyrimidine None None O
( None None O
14 None None O
) None None O
showed None None O
activity None None O
at None None O
three None None O
dose None None O
levels None None O
. None None O


The None None O
synthesis None None O
and None None O
pharmacological None None O
properties None None O
of None None O
several None None O
racemic None None I-MODIFIER
6,7,8,9 None None B-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzazepine None None I-IUPAC
- None None I-IUPAC
2,5 None None I-IUPAC
- None None I-IUPAC
diones None None I-IUPAC
( None None O
THHBADs None None O
) None None O
are None None O
described None None O
. None None O

Synthesis None None O
was None None O
accomplished None None O
via None None O
a None None O
Schmidt None None O
reaction None None O
with None None O
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxynaphthalene None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
diones None None I-IUPAC
( None None O
THMNDs None None O
) None None O
followed None None O
by None None O
demethylation None None O
. None None O

THMNDs None None O
were None None O
prepared None None O
via None None O
a None None O
Diels None None O
- None None O
Alder None None O
reaction None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
methoxybenzoquinone None None I-IUPAC
( None None O
5 None None O
) None None O
or None None O
2 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methoxybenzoquinone None None I-IUPAC
( None None O
14 None None O
) None None O
and None None O
substituted None None I-MODIFIER
1,3 None None B-IUPAC
- None None I-IUPAC
butadienes None None I-IUPAC
. None None O

The None None O
pharmacology None None O
of None None O
THHBADs None None O
was None None O
characterized None None O
by None None O
electrical None None O
recordings None None O
in None None O
Xenopus None None O
oocytes None None O
expressing None None O
rat None None O
brain None None O
NMDA None None O
and None None O
AMPA None None O
receptors None None O
. None None O

THHBADs None None O
are None None O
antagonists None None O
of None None O
NMDA None None O
and None None O
AMPA None None O
receptors None None O
with None None O
functional None None O
potency None None O
being None None O
dependent None None O
upon None None O
the None None O
substitution None None O
pattern None None O
on None None O
the None None O
tetrahydrobenzene None None O
moiety None None O
. None None O

The None None O
7,8 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
( None None O
18a None None O
) None None O
and None None O
7,8 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
( None None O
18b None None O
) None None O
analogs None None I-MODIFIER
are None None O
the None None O
most None None O
potent None None O
THHBADs None None O
prepared None None O
and None None O
have None None O
apparent None None O
antagonist None None O
dissociation None None O
constants None None O
( None None O
Kb None None O
values None None O
) None None O
of None None O
0.0041 None None O
and None None O
0.0028 None None O
microM None None O
, None None O
respectively None None O
, None None O
for None None O
NMDA None None O
receptors None None O
and None None O
0.51 None None O
and None None O
0.72 None None O
microM None None O
, None None O
respectively None None O
, None None O
for None None O
AMPA None None O
receptors None None O
. None None O


Several None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
arylalkylpolyamines None None I-IUPAC
containing None None O
various None None O
aromatic None None O
ring None None O
systems None None O
were None None O
synthesized None None O
as None None O
their None None O
respective None None O
HCl None None O
salts None None O
. None None O

The None None O
N None None O
( None None O
1 None None O
) None None O
- None None O
substituents None None O
evaluated None None O
ranged None None O
in None None O
size None None O
from None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
, None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
naphthalen None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
, None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
naphthalen None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
, None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
naphthalen None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
, None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
anthracen None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
, None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
anthracen None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
, None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
anthracen None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
, None None O
and None None O
pyren None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
. None None O

The None None O
polyamine None None O
architecture None None O
was None None O
also None None O
altered None None O
and None None O
ranged None None O
from None None O
diamine None None O
to None None O
triamine None None O
and None None O
tetraamine None None O
systems None None O
. None None O

Biological None None O
activities None None O
in None None O
L1210 None None O
( None None O
murine None None O
leukemia None None O
) None None O
, None None O
Chinese None None O
hamster None None O
ovary None None O
( None None O
CHO None None O
) None None O
, None None O
and None None O
CHO None None O
's None None O
polyamine None None O
transport None None O
- None None O
deficient None None O
mutant None None O
( None None O
CHO None None O
- None None O
MG None None O
) None None O
cell None None O
lines None None O
were None None O
investigated None None O
via None None O
IC None None O
( None None O
50 None None O
) None None O
cytotoxicity None None O
determinations None None O
. None None O

K None None O
( None None O
i None None O
) None None O
values None None O
for None None O
spermidine None None O
uptake None None O
were None None O
also None None O
determined None None O
in None None O
L1210 None None O
cells None None O
. None None O

The None None O
size None None O
of None None O
the None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
arylalkyl None None I-IUPAC
substituent None None I-MODIFIER
as None None O
well None None O
as None None O
the None None O
polyamine None None O
sequence None None O
used None None O
had None None O
direct None None O
bearing None None O
on None None O
the None None O
observed None None O
cytotoxicity None None O
profiles None None O
. None None O

N None None O
( None None O
1 None None O
) None None O
- None None O
Tethers None None O
longer None None O
than None None O
ethylene None None O
showed None None O
dramatic None None O
loss None None O
of None None O
selectivity None None O
for None None O
the None None O
polyamine None None O
transporter None None O
( None None O
PAT None None O
) None None O
as None None O
shown None None O
in None None O
a None None O
CHO None None O
/ None None O
CHO None None O
- None None O
MG None None O
cytotoxicity None None O
screen None None O
. None None O

In None None O
summary None None O
, None None O
there None None O
are None None O
clear None None O
limits None None O
to None None O
the None None O
size None None O
of None None O
N None None O
( None None O
1 None None O
) None None O
- None None O
substituents None None O
, None None O
which None None O
can None None O
be None None O
accommodated None None O
by None None O
the None None O
polyamine None None O
transporter None None O
. None None O

A None None O
direct None None O
correlation None None O
was None None O
observed None None O
between None None O
polyamine None None O
- None None O
conjugate None None O
uptake None None O
and None None O
cytotoxicity None None O
. None None O

In None None O
this None None O
regard None None O
, None None O
a None None O
cytotoxicity None None O
model None None O
was None None O
proposed None None O
, None None O
which None None O
describes None None O
a None None O
hydrophobic None None O
pocket None None O
of None None O
set None None O
dimensions None None O
adjacent None None O
to None None O
the None None O
putative None None O
PAT None None O
polyamine None None O
- None None O
binding None None O
site None None O
. None None O


A None None O
variety None None O
of None None O
amine None None O
complexes None None O
with None None O
1 None None I-IUPAC
- None None I-IUPAC
boraadamatane None None I-IUPAC
were None None O
synthesized None None O
and None None O
subsequently None None O
evaluated None None O
for None None O
an None None O
antiproliferative None None O
effect None None O
on None None O
CD81 None None O
- None None O
enriched None None O
cell None None O
lines None None O
to None None O
provide None None O
evidence None None O
for None None O
binding None None O
and None None O
activation None None O
of None None O
CD81 None None O
. None None O

CD81 None None O
is None None O
a None None O
member None None O
of None None O
the None None O
tetraspanin None None O
family None None O
of None None O
membrane None None O
proteins None None O
found None None O
in None None O
all None None O
cell None None O
lineages None None O
in None None O
the None None O
liver None None O
. None None O

CD81 None None O
signals None None O
for None None O
antiproliferation None None O
when None None O
bound None None O
by None None O
antibodies None None O
. None None O

It None None O
is None None O
known None None O
that None None O
the None None O
HCV None None O
- None None O
E2 None None O
envelope None None O
glycoprotein None None O
binds None None O
to None None O
the None None O
CD81 None None O
protein None None O
. None None O

While None None O
it None None O
is None None O
unclear None None O
whether None None O
virus None None O
entry None None O
into None None O
host None None O
cells None None O
is None None O
directly None None O
linked None None O
to None None O
virus None None O
attachment None None O
via None None O
CD81 None None O
for None None O
HCV None None O
, None None O
this None None O
step None None O
in None None O
the None None O
viral None None O
life None None O
cycle None None O
has None None O
recently None None O
proven None None O
to None None O
be None None O
an None None O
effective None None O
point None None O
of None None O
attack None None O
for None None O
other None None O
viruses None None O
including None None O
HIV None None O
and None None O
rhinoviruses None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
current None None O
study None None O
concerns None None O
the None None O
synthesis None None O
of None None O
amantidine None None O
analogues None None O
by None None O
appending None None O
primary None None O
amines None None O
to None None O
1 None None I-IUPAC
- None None I-IUPAC
boraadamantane None None I-IUPAC
to None None O
evaluate None None O
such None None O
compounds None None O
for None None O
CD81 None None O
- None None O
dependent None None O
antiproliferation None None O
of None None O
CD81 None None O
- None None O
enriched None None O
cell None None O
lines None None O
( None None O
astrocyte None None O
) None None O
vs None None O
CD81 None None O
- None None O
deficient None None O
cell None None O
lines None None O
( None None O
C6 None None O
glioma None None O
) None None O
. None None O

If None None O
the None None O
antiproliferative None None O
effect None None O
of None None O
these None None O
amantidine None None O
analogues None None O
proves None None O
to None None O
be None None O
an None None O
effect None None O
of None None O
binding None None O
and None None O
activating None None O
CD81 None None O
, None None O
then None None O
these None None O
compounds None None O
may None None O
have None None O
the None None O
potential None None O
to None None O
prevent None None O
or None None O
treat None None O
HCV None None O
infections None None O
. None None O

Each None None O
compound None None O
's None None O
potential None None O
for None None O
preventive None None O
and None None O
therapeutic None None O
activity None None O
stems None None O
from None None O
the None None O
compound None None O
's None None O
potential None None O
to None None O
block None None O
viral None None O
attachment None None O
, None None O
virus None None O
- None None O
cell None None O
fusion None None O
, None None O
or None None O
virus None None O
entry None None O
into None None O
host None None O
cells None None O
or None None O
to None None O
counter None None O
potential None None O
mechanisms None None O
of None None O
HCV None None O
immune None None O
evasion None None O
. None None O

Out None None O
of None None O
a None None O
library None None O
of None None O
over None None O
500 None None O
compounds None None O
, None None O
including None None O
randomly None None O
selected None None O
small None None O
molecules None None O
and None None O
rationally None None O
designed None None O
small None None O
molecules None None O
, None None O
only None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
boraadamantaneamine None None I-IUPAC
compounds None None I-MODIFIER
and None None O
structurally None None O
similar None None O
analogues None None O
display None None O
a None None O
significant None None O
antiproliferative None None O
effect None None O
on None None O
the None None O
CD81 None None O
- None None O
enriched None None O
astrocytes None None O
relative None None O
to None None O
the None None O
CD81 None None O
- None None O
deficient None None O
cell None None O
lines None None O
. None None O

In None None O
fact None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
boraadamantane None None I-IUPAC
. None None I-IUPAC

l None None I-IUPAC
- None None I-IUPAC
phenylalanine None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
complex None None I-MODIFIER
( None None O
5 None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
boraadamantane None None I-IUPAC
. None None I-IUPAC

ethanolamine None None I-IUPAC
complex None None I-MODIFIER
( None None O
8 None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
adamantane None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylpropionic None None I-IUPAC
acid None None I-IUPAC
( None None O
15 None None O
) None None O
show None None O
a None None O
dose None None O
- None None O
dependent None None O
, None None O
astrocyte None None O
- None None O
selective None None O
antiproliferative None None O
activity None None O
in None None O
the None None O
concentration None None O
range None None O
0.1-10 None None O
microM None None O
. None None O

This None None O
is None None O
consistent None None O
with None None O
the None None O
binding None None O
and None None O
activation None None O
of None None O
CD81 None None O
and None None O
represents None None O
a None None O
2 None None O
- None None O
fold None None O
improvement None None O
compared None None O
to None None O
the None None O
clinically None None O
prescribed None None O
anti None None O
- None None O
HCV None None O
agent None None O
, None None O
amantidine None None O
, None None O
in None None O
the None None O
same None None O
concentration None None O
range None None O
. None None O

Consequently None None O
, None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
boraadamantaneamine None None I-IUPAC
derivatives None None I-MODIFIER
present None None O
a None None O
promising None None O
lead None None O
in None None O
the None None O
development None None O
of None None O
small None None O
molecules None None O
with None None O
potential None None O
to None None O
bind None None O
to None None O
CD81 None None O
and None None O
treat None None O
HCV None None O
infections None None O
. None None O


A None None O
broad None None O
structure None None O
- None None O
activity None None O
program None None O
was None None O
undertaken None None O
in None None O
search None None O
of None None O
effective None None O
surrogates None None O
for None None O
the None None O
key None None O
benzothiazole None None O
side None None O
chain None None O
of None None O
the None None O
potent None None O
aldose None None O
reductase None None O
inhibitor None None O
, None None O
zopolrestat None None O
( None None O
1 None None O
) None None O
. None None O

A None None O
structure None None O
- None None O
driven None None O
approach None None O
was None None O
pursued None None O
, None None O
which None None O
spanned None None O
exploration None None O
of None None O
three None None O
areas None None O
: None None O
( None None O
1 None None O
) None None O
5/6 None None O
fused None None O
heterocycles None None O
such None None O
as None None O
benzoxazole None None O
, None None O
benzothiophene None None O
, None None O
benzofuran None None O
, None None O
and None None O
imidazopyridine None None O
; None None O
( None None O
2 None None O
) None None O
5 None None O
- None None O
membered None None O
heterocycles None None O
, None None O
including None None O
oxadiazole None None O
, None None O
oxazole None None O
, None None O
thiazole None None O
, None None O
and None None O
thiadiazole None None O
, None None O
with None None O
pendant None None O
aryl None None O
groups None None O
, None None O
and None None O
( None None O
3 None None O
) None None O
thioanilide None None O
as None None O
a None None O
formal None None O
equivalent None None O
of None None O
benzothiazole None None O
. None None O

Several None None O
benzoxazole None None I-IUPAC
- None None O
and None None O
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
- None None O
derived None None O
analogues None None I-MODIFIER
were None None O
found None None O
to None None O
be None None O
potent None None O
inhibitors None None O
of None None O
aldose None None O
reductase None None O
from None None O
human None None O
placenta None None O
and None None O
were None None O
orally None None O
active None None O
in None None O
preventing None None O
sorbitol None None O
accumulation None None O
in None None O
rat None None O
sciatic None None O
nerve None None O
, None None O
in None None O
an None None O
acute None None O
test None None O
of None None O
diabetic None None O
complications None None O
. None None O

3,4 None None I-IUPAC
- None None I-IUPAC
Dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
5,7 None None I-IUPAC
- None None I-IUPAC
difluoro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzoxazolyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phthalazineacetic None None I-IUPAC
acid None None I-IUPAC
( None None O
124 None None O
) None None O
was None None O
the None None O
best None None O
of None None O
the None None O
benzoxazole None None O
series None None O
( None None O
IC50 None None O
= None None O
3.2 None None O
x None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
M None None O
) None None O
; None None O
it None None O
suppressed None None O
accumulation None None O
of None None O
sorbitol None None O
in None None O
rat None None O
sciatic None None O
nerve None None O
by None None O
78% None None O
at None None O
an None None O
oral None None O
dose None None O
of None None O
10 None None O
mg None None O
/ None None O
kg None None O
. None None O

Compound None None O
139 None None O
, None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phthalazineacetic None None I-IUPAC
acid None None I-IUPAC
, None None O
with None None O
IC50 None None O
less None None O
than None None O
1.0 None None O
x None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
, None None O
caused None None O
a None None O
69% None None O
reduction None None O
in None None O
sorbitol None None O
accumulation None None O
in None None O
rat None None O
sciatic None None O
nerve None None O
at None None O
an None None O
oral None None O
dose None None O
of None None O
25 None None O
mg None None O
/ None None O
kg None None O
. None None O

The None None O
thioanilide None None O
side None None O
chain None None O
featured None None O
in None None O
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thioxoethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phthalazineacetic None None I-IUPAC
acid None None I-IUPAC
( None None O
195 None None O
) None None O
proved None None O
to None None O
be None None O
an None None O
effective None None O
surrogate None None O
for None None O
benzothiazole None None O
. None None O

Compound None None O
195 None None O
was None None O
highly None None O
potent None None O
in None None O
vitro None None O
( None None O
IC50 None None O
= None None O
5.2 None None O
x None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
) None None O
but None None O
did None None O
not None None O
show None None O
oral None None O
activity None None O
when None None O
tested None None O
at None None O
100 None None O
mg None None O
/ None None O
kg None None O
. None None O

Additional None None O
structure None None O
- None None O
activity None None O
relationships None None O
encompassing None None O
a None None O
variety None None O
of None None O
heterocyclic None None O
side None None O
chains None None O
are None None O
discussed None None O
. None None O


9,11 None None O
- None None O
Secoestradiol None None O
( None None O
9 None None O
) None None O
and None None O
11 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
9,11 None None I-IUPAC
- None None I-IUPAC
secoestradiol None None I-IUPAC
( None None O
12 None None O
) None None O
have None None O
been None None O
synthesized None None O
starting None None O
from None None O
17 None None I-IUPAC
- None None I-IUPAC
acetoxyestradiol None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
ether None None I-IUPAC
( None None O
1 None None O
) None None O
and None None O
found None None O
to None None O
possess None None O
significant None None O
antifertility None None O
activity None None O
in None None O
rats None None O
. None None O

3 None None I-IUPAC
- None None I-IUPAC
Methoxy None None I-IUPAC
- None None I-IUPAC
9,11 None None I-IUPAC
- None None I-IUPAC
seco None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
17beta None None I-IUPAC
- None None I-IUPAC
acetoxyestra None None I-IUPAC
- None None I-IUPAC
1,3,5 None None I-IUPAC
( None None I-IUPAC
10 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trien None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
oic None None I-IUPAC
acid None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
prepared None None O
by None None O
CrO3 None None O
oxidation None None O
of None None O
1 None None O
, None None O
on None None O
hydrogenolysis None None O
gave None None O
methyl None None I-IUPAC
17beta None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
9,11 None None I-IUPAC
- None None I-IUPAC
secoestra None None I-IUPAC
- None None I-IUPAC
1,3,5 None None I-IUPAC
( None None I-IUPAC
10 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
triene None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
3 None None O
) None None O
. None None O

The None None O
17 None None O
- None None O
O None None O
- None None O
THP None None O
derivative None None O
of None None O
3 None None O
was None None O
treated None None O
with None None O
LiAlH4 None None O
to None None O
give None None O
17beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
tetrahydropyranyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
9,11 None None I-IUPAC
- None None I-IUPAC
secoestra None None I-IUPAC
- None None I-IUPAC
1,3,5 None None I-IUPAC
( None None I-IUPAC
10 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
triene None None I-IUPAC
( None None O
5 None None O
) None None O
. None None O

The None None O
11 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
mesylate None None I-IUPAC
of None None O
5 None None O
on None None O
LiAlH4 None None O
reduction None None O
followed None None O
by None None O
mild None None O
acid None None O
treatment None None O
and None None O
demethylation None None O
under None None O
alkaline None None O
conditions None None O
gave None None O
9 None None O
. None None O

LiAlH4 None None O
reduction None None O
of None None O
3 None None O
gave None None O
9,11 None None I-IUPAC
- None None I-IUPAC
seco None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
hydroxyestradiol None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
ether None None I-IUPAC
( None None O
11 None None O
) None None O
which None None O
on None None O
demethylation None None O
gave None None O
9,11 None None I-IUPAC
- None None I-IUPAC
seco None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
hydroxyestradiol None None I-IUPAC
( None None O
12 None None O
) None None O
. None None O


Previously None None O
we None None O
have None None O
reported None None O
the None None O
discovery None None O
of None None O
ABT None None O
- None None O
627 None None O
( None None O
1 None None O
, None None O
A None None O
- None None O
147627 None None O
, None None O
active None None O
enantiomer None None O
of None None O
A None None O
- None None O
127722 None None O
) None None O
, None None O
a None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diaryl None None I-IUPAC
substituted None None I-MODIFIER
pyrrolidine None None B-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
based None None O
endothelin None None O
receptor None None O
- None None O
A None None O
antagonist None None O
. None None O

This None None O
compound None None O
binds None None O
to None None O
the None None O
ETA None None O
receptor None None O
with None None O
an None None O
affinity None None O
( None None O
Ki None None O
) None None O
of None None O
0 None None O
. None None O

034 None None O
nM None None O
and None None O
with None None O
a None None O
2000 None None O
- None None O
fold None None O
selectivity None None O
for None None O
the None None O
ETA None None O
receptor None None O
versus None None O
the None None O
ETB None None O
receptor None None O
. None None O

We None None O
have None None O
expanded None None O
our None None O
structure None None O
- None None O
activity None None O
studies None None O
in None None O
this None None O
series None None O
, None None O
in None None O
an None None O
attempt None None O
to None None O
further None None O
increase None None O
the None None O
ETA None None O
selectivity None None O
. None None O

When None None O
the None None O
p None None O
- None None O
anisyl None None O
group None None O
of None None O
1 None None O
was None None O
replaced None None O
by None None O
an None None O
n None None O
- None None O
pentyl None None O
group None None O
, None None O
the None None O
resultant None None O
antagonist None None O
3 None None O
exhibited None None O
substantially None None O
increased None None O
ETB None None O
/ None None O
ETA None None O
activity None None O
ratio None None O
, None None O
but None None O
a None None O
decreased None None O
ETA None None O
affinity None None O
. None None O

Structure None None O
- None None O
activity None None O
studies None None O
revealed None None O
that None None O
substitution None None O
and None None O
geometry None None O
of None None O
this None None O
alkyl None None O
group None None O
, None None O
and None None O
substitution None None O
on None None O
the None None O
benzodioxolyl None None O
ring None None O
, None None O
are None None O
important None None O
in None None O
optimizing None None O
this None None O
series None None O
of None None O
highly None None O
ETA None None O
selective None None O
antagonists None None O
. None None O

In None None O
particular None None O
, None None O
the None None O
combination None None O
of None None O
a None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pentenyl None None I-IUPAC
group None None I-MODIFIER
and None None O
a None None O
7 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
benzodioxol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
group None None I-MODIFIER
provided None None O
hydrophobic None None O
compound None None O
10b None None O
with None None O
subnanomolar None None O
affinity None None O
for None None O
human None None O
ETA None None O
receptor None None O
subtype None None O
and None None O
with None None O
an None None O
ETB None None O
/ None None O
ETA None None O
activity None None O
ratio None None O
of None None O
over None None O
130000 None None O
. None None O

Meanwhile None None O
, None None O
synthetic None None O
efforts None None O
en None None O
route None None O
to None None O
olefinic None None O
compounds None None O
led None None O
to None None O
the None None O
discovery None None O
that None None O
2 None None I-IUPAC
- None None I-IUPAC
pyridylethyl None None I-IUPAC
( None None O
9o None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxopyrrolidinyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
( None None O
9u None None O
) None None O
replacement None None I-MODIFIER
of None None O
the None None O
p None None O
- None None O
anisyl None None O
group None None O
of None None O
1yielded None None O
very None None O
hydrophilic None None O
ETA None None O
antagonists None None O
with None None O
potency None None O
and None None O
selectivity None None O
equal None None O
to None None O
those None None O
of None None O
10b None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
overall None None O
superior None None O
affinity None None O
, None None O
high None None O
selectivity None None O
for None None O
the None None O
ETA None None O
receptor None None O
( None None O
Ki None None O
, None None O
0.46 None None O
nM None None O
for None None O
ETA None None O
and None None O
13000 None None O
nM None None O
for None None O
ETB None None O
) None None O
, None None O
and None None O
good None None O
oral None None O
bioavailability None None O
( None None O
48% None None O
in None None O
rats None None O
) None None O
, None None O
A None None O
- None None O
216546 None None O
( None None O
10a None None O
) None None O
was None None O
selected None None O
as None None O
a None None O
potential None None O
clinical None None O
backup None None O
for None None O
1 None None O
. None None O


The None None O
stereochemical None None O
diversity None None O
- None None O
oriented None None O
conformational None None O
restriction None None O
strategy None None O
can None None O
be None None O
an None None O
efficient None None O
method None None O
for None None O
developing None None O
specific None None O
ligands None None O
for None None O
drug None None O
target None None O
proteins None None O
, None None O
especially None None O
in None None O
cases None None O
where None None O
neither None None O
the None None O
bioactive None None O
conformation None None O
nor None None O
the None None O
pharmacophore None None O
is None None O
known None None O
. None None O

To None None O
develop None None O
potent None None O
H3 None None O
and None None O
H4 None None O
receptor None None O
antagonists None None O
, None None O
a None None O
series None None O
of None None O
conformationally None None O
restricted None None O
analogues None None O
of None None O
histamine None None O
with None None O
a None None O
chiral None None I-MODIFIER
cis None None B-PARTIUPAC
- None None I-PARTIUPAC
or None None O
trans None None I-IUPAC
- None None I-IUPAC
cyclopropane None None I-IUPAC
structure None None I-MODIFIER
were None None O
designed None None O
on None None O
the None None O
basis None None O
of None None O
this None None O
strategy None None O
. None None O

These None None O
target None None O
compounds None None O
with None None O
stereochemical None None O
diversity None None O
were None None O
synthesized None None O
from None None O
the None None O
versatile None None O
chiral None None O
cyclopropane None None O
units None None O
( None None I-PARTIUPAC
1S None None I-PARTIUPAC
, None None I-PARTIUPAC
2R None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
1R None None I-IUPAC
, None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyldiphenylsilyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
formylcyclopropane None None I-IUPAC
( None None O
6 None None O
and None None O
7 None None O
, None None O
respectively None None O
) None None O
or None None O
their None None O
enantiomers None None O
ent None None O
- None None O
6 None None O
and None None O
ent None None O
- None None O
7 None None O
. None None O

Pharmacological None None O
profiles None None O
of None None O
these None None O
conformationally None None O
restricted None None O
analogues None None O
were None None O
shown None None O
to None None O
be None None O
different None None O
depending None None O
on None None O
the None None O
cyclopropane None None O
backbones None None O
. None None O

Among None None O
the None None O
analogues None None I-MODIFIER
, None None O
( None None I-IUPAC
1R None None I-IUPAC
, None None I-IUPAC
2S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorobenzylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
cyclopropane None None I-IUPAC
( None None O
11a None None O
) None None O
with None None O
the None None O
( None None I-IUPAC
1R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
cyclopropane None None I-IUPAC
structure None None I-MODIFIER
has None None O
remarkable None None O
antagonistic None None O
activity None None O
to None None O
both None None O
the None None O
H3 None None O
( None None O
Ki None None O
= None None O
8.4 None None O
nM None None O
) None None O
and None None O
H4 None None O
( None None O
Ki None None O
= None None O
7.6 None None O
nM None None O
) None None O
receptors None None O
. None None O

The None None O
enantiomer None None O
of None None O
11a None None O
, None None O
i.e. None None O
, None None O
ent None None O
- None None O
11a None None O
, None None O
with None None O
the None None O
( None None I-IUPAC
1S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
cyclopropane None None I-IUPAC
structure None None I-MODIFIER
turned None None O
out None None O
to None None O
be None None O
a None None O
highly None None O
potent None None O
and None None O
selective None None O
H3 None None O
receptor None None O
antagonist None None O
with None None O
a None None O
Ki None None O
of None None O
3.6 None None O
nM None None O
. None None O

Conversely None None O
, None None O
( None None I-IUPAC
1R None None I-IUPAC
, None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorobenzylamino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
cyclopropane None None I-IUPAC
( None None O
10a None None O
) None None O
with None None O
the None None O
( None None O
1R None None O
) None None O
- None None O
trans None None O
structure None None O
was None None O
selective None None O
for None None O
the None None O
H4 None None O
receptor None None O
( None None O
Ki None None O
= None None O
118 None None O
nM None None O
) None None O
compared None None O
to None None O
the None None O
H3 None None O
receptor None None O
( None None O
Ki None None O
& None None O
gt None None O
; None None O
10 None None O
( None None O
3 None None O
) None None O
nM None None O
) None None O
. None None O

Thus None None O
, None None O
a None None O
variety None None O
of None None O
compounds None None O
with None None O
different None None O
pharmacological None None O
profiles None None O
have None None O
been None None O
developed None None O
. None None O

These None None O
results None None O
show None None O
that None None O
when None None O
the None None O
structure None None O
of None None O
the None None O
target None None O
protein None None O
is None None O
unknown None None O
, None None O
the None None O
stereochemical None None O
diversity None None O
- None None O
oriented None None O
approach None None O
can None None O
be None None O
a None None O
powerful None None O
strategy None None O
in None None O
medicinal None None O
chemical None None O
studies None None O
. None None O


A None None O
series None None O
of None None O
dioxolane None None O
analogues None None I-MODIFIER
based None None O
on None None O
dexoxadrol None None O
( None None O
( None None I-IUPAC
4S None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,2 None None I-IUPAC
- None None I-IUPAC
diphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
piperidyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dioxolane None None I-IUPAC
) None None O
and None None O
etoxadrol None None O
( None None O
( None None I-IUPAC
2S None None I-IUPAC
, None None I-IUPAC
4S None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
piperidyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dioxolane None None I-IUPAC
) None None O
were None None O
prepared None None O
and None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
displace None None O
[ None None O
3H None None O
] None None O
TCP None None O
( None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
cyclohexyl None None I-IUPAC
] None None I-IUPAC
piperidine None None I-IUPAC
) None None O
from None None O
PCP None None O
( None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenylcyclohexyl None None I-IUPAC
) None None I-IUPAC
piperidine None None I-IUPAC
) None None O
binding None None O
sites None None O
in None None O
rat None None O
brain None None O
tissue None None O
homogenates None None O
. None None O

Qualitative None None O
structure None None O
- None None O
activity None None O
relationships None None O
within None None O
this None None O
series None None O
were None None O
explored None None O
through None None O
modifications None None O
of None None O
the None None O
three None None O
major None None O
structural None None O
units None None O
of None None O
dexoxadrol None None O
, None None O
the None None O
piperidine None None O
, None None O
1,3 None None I-IUPAC
- None None I-IUPAC
dioxolane None None I-IUPAC
, None None O
and None None O
aromatic None None O
rings None None O
of None None O
the None None O
molecule None None O
. None None O

N None None O
- None None O
Alkyl None None O
derivatives None None O
of None None O
dexoxadrol None None O
were None None O
found None None O
to None None O
be None None O
inactive None None O
, None None O
as None None O
were None None O
those None None O
analogues None None O
where None None O
the None None O
dioxolane None None O
ring None None O
was None None O
modified None None O
. None None O

Phenyl None None O
- None None O
substituted None None O
etoxadrol None None O
analogues None None O
were None None O
compared None None O
to None None O
similarly None None O
substituted None None O
PCP None None O
analogues None None O
and None None O
distinct None None O
differences None None O
were None None O
found None None O
in None None O
their None None O
structure None None O
- None None O
activity None None O
relationships None None O
suggesting None None O
that None None O
the None None O
aromatic None None O
rings None None O
in None None O
these None None O
two None None O
drug None None O
classes None None O
interact None None O
differently None None O
with None None O
the None None O
PCP None None O
binding None None O
sites None None O
. None None O

The None None O
replacement None None O
of None None O
the None None O
phenyl None None O
ring None None O
in None None O
etoxadrol None None O
by None None O
either None None O
a None None O
2 None None O
- None None O
or None None O
3 None None O
- None None O
thienyl None None O
ring None None O
led None None O
to None None O
compounds None None O
with None None O
affinity None None O
comparable None None O
to None None O
etoxadrol None None O
, None None O
and None None O
the None None O
replacement None None O
of None None O
the None None O
ethyl None None O
moiety None None O
on None None O
etoxadrol None None O
's None None O
dioxolane None None O
ring None None O
with None None O
propyl None None O
( None None O
7 None None O
) None None O
or None None O
isopropyl None None O
( None None O
8 None None O
) None None O
led None None O
to None None O
compounds None None O
which None None O
were None None O
more None None O
potent None None O
than None None O
etoxadrol None None O
or None None O
PCP None None O
. None None O

The None None O
most None None O
potent None None O
compound None None O
was None None O
( None None I-IUPAC
2S None None I-IUPAC
, None None I-IUPAC
4S None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
piperidyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dioxolane None None I-IUPAC
( None None O
11 None None O
) None None O
, None None O
where None None O
a None None O
chlorine None None O
moiety None None O
was None None O
placed None None O
in None None O
the None None O
ortho None None O
position None None O
in None None O
the None None O
aromatic None None O
ring None None O
of None None O
etoxadrol None None O
. None None O

Its None None O
potency None None O
was None None O
comparable None None O
with None None O
TCP None None O
in None None O
vitro None None O
. None None O


A None None O
new None None O
metabolic None None O
pathway None None O
of None None O
terminal None None O
hydroxylation None None O
( None None O
omega None None O
- None None O
hydroxylation None None O
) None None O
of None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
group None None I-MODIFIER
of None None O
propranolol None None O
( None None O
1 None None O
) None None O
was None None O
established None None O
. None None O

Selected None None O
ion None None O
- None None O
monitoring None None O
GC None None O
- None None O
MS None None O
analysis None None O
, None None O
based None None O
on None None O
use None None O
of None None O
the None None O
synthesized None None O
mixture None None O
of None None O
diastereoisomers None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthoxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propanol None None I-IUPAC
( None None O
2 None None O
) None None O
as None None O
a None None O
standard None None O
, None None O
established None None O
formation None None O
of None None O
both None None O
diastereoisomers None None O
of None None O
2 None None O
as None None O
metabolites None None O
of None None O
1 None None O
. None None O

These None None O
diastereoisomers None None O
were None None O
formed None None O
in None None O
unequal None None O
amounts None None O
when None None O
1 None None O
, None None O
its None None O
hexadeuterated None None O
analogue None None O
8 None None O
or None None O
heptadeuterated None None O
analogue None None O
9 None None O
, None None O
were None None O
incubated None None O
in None None O
the None None O
presence None None O
of None None O
the None None O
rat None None O
liver None None O
microsomal None None O
fraction None None O
. None None O

Authentic None None O
( None None O
2R None None O
, None None O
2 None None O
" None None O
S None None O
) None None O
- None None O
2 None None O
, None None O
obtained None None O
from None None O
the None None O
amide None None O
formed None None O
from None None O
( None None I-IUPAC
2S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthoxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxypropionic None None I-IUPAC
acid None None I-IUPAC
[ None None O
( None None O
2S None None O
) None None O
- None None O
5 None None O
] None None O
and None None O
( None None I-IUPAC
2S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alaninol None None I-IUPAC
by None None O
diborane None None O
reduction None None O
, None None O
facilitated None None O
examination None None O
of None None O
stereochemical None None O
aspects None None O
of None None O
this None None O
process None None O
. None None O

From None None O
incubations None None O
of None None O
the None None O
enantiomers None None O
of None None O
1 None None O
and None None O
pseudoracemic None None O
propranolol None None O
[ None None O
equimolar None None O
( None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
propranolol None None I-IUPAC
- None None I-IUPAC
3,3 None None I-IUPAC
- None None I-IUPAC
d2 None None I-IUPAC
and None None O
( None None I-IUPAC
2S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
propranolol None None I-IUPAC
- None None I-IUPAC
d0 None None I-IUPAC
] None None O
in None None O
the None None O
presence None None O
of None None O
the None None O
rat None None O
liver None None O
microsomal None None O
fraction None None O
, None None O
we None None O
established None None O
that None None O
the None None O
diastereomeric None None O
products None None O
were None None O
formed None None O
in None None O
the None None O
order None None O
( None None O
2S None None O
, None None O
2 None None O
" None None O
S None None O
) None None O
- None None O
2 None None O
approximately None None O
equal None None O
to None None O
( None None O
2S None None O
, None None O
2 None None O
" None None O
R None None O
) None None O
- None None O
2 None None O
greater None None O
than None None O
( None None O
2R None None O
, None None O
2 None None O
" None None O
R None None O
) None None O
- None None O
2 None None O
greater None None O
than None None O
( None None O
2R None None O
, None None O
2 None None O
" None None O
S None None O
) None None O
- None None O
2 None None O
. None None O

( None None O
2S None None O
) None None O
- None None O
1 None None O
, None None O
which None None O
was None None O
metabolized None None O
to None None O
2 None None O
to None None O
a None None O
greater None None O
extent None None O
than None None O
( None None O
2R None None O
) None None O
- None None O
1 None None O
, None None O
showed None None O
no None None O
stereoselectivity None None O
, None None O
affording None None O
about None None O
equal None None O
amounts None None O
of None None O
( None None O
2S None None O
, None None O
2 None None O
" None None O
S None None O
) None None O
- None None O
2 None None O
and None None O
( None None O
2S None None O
, None None O
2 None None O
" None None O
R None None O
) None None O
- None None O
2 None None O
. None None O

( None None O
2R None None O
) None None O
- None None O
1 None None O
, None None O
which None None O
was None None O
metabolized None None O
to None None O
2 None None O
to None None O
a None None O
lesser None None O
extent None None O
, None None O
afforded None None O
considerably None None O
more None None O
( None None O
2R None None O
, None None O
2 None None O
" None None O
R None None O
) None None O
- None None O
2 None None O
than None None O
( None None O
2R None None O
, None None O
2 None None O
" None None O
S None None O
) None None O
- None None O
2 None None O
. None None O

omega None None O
- None None O
Hydroxylation None None O
was None None O
a None None O
minor None None O
metabolic None None O
pathway None None O
in None None O
the None None O
microsomal None None O
incubation None None O
. None None O

About None None O
2000X None None O
less None None O
2 None None O
than None None O
1 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthoxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propanol None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
the None None O
product None None O
of None None O
N None None O
- None None O
dealkylation None None O
of None None O
1 None None O
, None None O
was None None O
formed None None O
. None None O


A None None O
detailed None None O
structure None None O
- None None O
activity None None O
analysis None None O
was None None O
carried None None O
out None None O
using None None O
eight None None O
1 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
( None None I-IUPAC
aralkyl None None I-IUPAC
) None None I-IUPAC
nipecotamides None None I-IUPAC
( None None O
type None None O
5 None None O
) None None O
, None None O
33 None None O
bis None None I-IUPAC
- None None I-IUPAC
nipecotamidoalkanes None None I-IUPAC
and None None O
aralkanes None None I-IUPAC
( None None O
type None None O
6 None None O
) None None O
, None None O
and None None O
7 None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
nipecotoyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
piperazines None None I-IUPAC
( None None O
type None None O
7 None None O
) None None O
as None None O
inhibitors None None O
of None None O
human None None O
platelet None None O
aggregation None None O
. None None O

Steric None None O
factors None None O
played None None O
an None None O
important None None O
role None None O
in None None O
determining None None O
the None None O
activity None None O
of None None O
type None None O
5 None None O
compounds None None O
possessing None None O
an None None O
an None None O
appropriate None None O
degree None None O
of None None O
hydrophobic None None O
character None None O
. None None O

Types None None O
6 None None O
and None None O
7 None None O
compounds None None O
were None None O
more None None O
potent None None O
than None None O
the None None O
corresponding None None O
type None None O
5 None None O
molecules None None O
. None None O

Hydrophobic None None O
character None None O
appeared None None O
to None None O
influence None None O
the None None O
activity None None O
of None None O
type None None O
6 None None O
compounds None None O
. None None O

A None None O
3 None None O
- None None O
substituent None None O
on None None O
the None None O
piperidine None None O
ring None None O
was None None O
necessary None None O
for None None O
antiplatelet None None O
activity None None O
; None None O
the None None O
substituent None None O
should None None O
be None None O
preferably None None O
an None None O
amide None None O
with None None O
its None None O
C None None O
attached None None O
directly None None O
to None None O
the None None O
ring None None O
. None None O

3,5 None None O
- None None O
Disubstitution None None O
and None None O
2 None None O
- None None O
substitution None None O
led None None O
to None None O
a None None O
decline None None O
in None None O
activity None None O
. None None O

Optimal None None O
activity None None O
was None None O
attained None None O
when None None O
the None None O
two None None O
nipecotoyl None None O
ring None None O
N None None O
atoms None None O
were None None O
connected None None O
by None None O
an None None O
aralkyl None None I-IUPAC
group None None B-MODIFIER
, None None O
and None None O
separated None None O
by None None O
approximately None None O
7 None None O
A None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
van None None O
der None None O
Waals None None O
forces None None O
and None None O
pi None None O
interactions None None O
may None None O
govern None None O
the None None O
inhibitor None None O
- None None O
platelet None None O
interaction None None O
. None None O

The None None O
most None None O
potent None None O
type None None O
6 None None O
inhibitor None None O
was None None O
alpha None None I-IUPAC
, None None I-IUPAC
alpha None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
butylcarbamoyl None None I-IUPAC
) None None I-IUPAC
piperidino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
xylene None None I-IUPAC
( None None O
6i None None O
) None None O
. None None O

The None None O
most None None O
potent None None O
type None None O
5 None None O
compound None None O
was None None O
1 None None I-IUPAC
- None None I-IUPAC
decyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
diethylcarbamoyl None None I-IUPAC
) None None I-IUPAC
piperidine None None I-IUPAC
( None None O
5a None None O
) None None O
. None None O

Any None None O
substitution None None O
on None None O
the None None O
piperazine None None O
ring None None O
of None None O
type None None O
7 None None O
compounds None None O
led None None O
to None None O
a None None O
decline None None O
in None None O
activity None None O
, None None O
the None None O
most None None O
active None None O
analog None None I-MODIFIER
being None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
decylnipecotoyl None None I-IUPAC
) None None I-IUPAC
piperazine None None I-IUPAC
( None None O
7a None None O
) None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
nipecotamides None None O
interact None None O
with None None O
anionic None None O
platelet None None O
sites None None O
located None None O
7 None None O
A None None O
from None None O
each None None O
other None None O
and None None O
connected None None O
by None None O
a None None O
hydrophobic None None O
well None None O
. None None O


Synthesis None None O
of None None O
various None None O
substituted None None I-MODIFIER
5 None None B-IUPAC
- None None I-IUPAC
thio None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylic None None I-IUPAC
acids None None I-IUPAC
and None None O
their None None O
derivatives None None O
is None None O
described None None O
by None None O
three None None O
methods None None O
, None None O
i.e. None None O
, None None O
displacement None None O
of None None O
nitrite None None O
from None None O
methyl None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylate None None I-IUPAC
( None None O
10 None None O
) None None O
by None None O
a None None O
thiol None None O
anion None None O
, None None O
alkylation None None O
of None None O
methyl None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
thio None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylate None None I-IUPAC
derived None None O
from None None O
reaction None None O
of None None O
the None None O
diazotized None None I-MODIFIER
methyl None None B-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylate None None I-IUPAC
( None None O
5 None None O
) None None O
with None None O
thiocyanate None None O
followed None None O
by None None O
borohydride None None O
reduction None None O
of None None O
the None None O
product None None O
, None None O
and None None O
alkylation None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
thio None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarbonitrile None None I-IUPAC
followed None None O
by None None O
hydrolysis None None O
. None None O

5 None None I-IUPAC
- None None I-IUPAC
Thio None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarbonitrile None None I-IUPAC
was None None O
obtained None None O
from None None O
butyl None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
sulfoxide None None I-IUPAC
( None None O
2 None None O
) None None O
by None None O
nitrosation None None O
and None None O
dehydration None None O
of None None O
the None None O
oxime None None O
. None None O

Many None None O
of None None O
these None None O
5 None None I-IUPAC
- None None I-IUPAC
thio None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylic None None I-IUPAC
acid None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
orally None None O
active None None O
antihypertensive None None O
agents None None O
in None None O
the None None O
spontaneously None None O
hypertensive None None O
rat None None O
. None None O

Optimization None None O
of None None O
the None None O
structural None None O
parameters None None O
for None None O
this None None O
activity None None O
yiedled None None O
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
trifluorobenzyl None None I-IUPAC
) None None I-IUPAC
thio None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridinecarboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
41 None None O
) None None O
and None None O
its None None O
sulfoxide None None O
, None None O
42 None None O
. None None O

Further None None O
biological None None O
studies None None O
with None None O
these None None O
compounds None None O
are None None O
described None None O
. None None O


A None None O
series None None O
of None None O
gallium None None O
( None None O
III None None O
) None None O
and None None O
iron None None O
( None None O
III None None O
) None None O
complexes None None O
with None None O
five None None O
different None None O
4N None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
alpha None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
heterocyclic None None I-IUPAC
thiosemicarbazones None None I-IUPAC
, None None O
viz None None O
. None None O

, None None O
2 None None I-IUPAC
- None None I-IUPAC
acetylpyridine None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylthiosemicarbazone None None I-IUPAC
( None None O
1 None None O
) None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
acetylpyridine None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
pyrrolidinylthiosemicarbazone None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
acetylpyrazine None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylthiosemicarbazone None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
acetylpyrazine None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
pyrrolidinylthiosemicarbazone None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
and None None O
acetylpyrazine None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
piperidinylthiosemicarbazone None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
with None None O
the None None O
general None None O
formula None None O
[ None None O
GaLCl2 None None O
] None None O
( None None O
HL None None O
= None None O
1 None None O
and None None O
2 None None O
) None None O
and None None O
[ None None O
ML2 None None O
] None None O
[ None None O
Y None None O
] None None O
( None None O
M None None O
= None None O
Ga None None O
, None None O
HL None None O
= None None O
1-5 None None O
, None None O
Y None None O
= None None O
PF6 None None O
; None None O
M None None O
= None None O
Fe None None O
, None None O
HL None None O
= None None O
1-5 None None O
, None None O
Y None None O
= None None O
FeCl4 None None O
and None None O
PF6 None None O
) None None O
were None None O
synthesized None None O
and None None O
characterized None None O
by None None O
elemental None None O
analysis None None O
, None None O
a None None O
number None None O
of None None O
spectroscopic None None O
methods None None O
( None None O
NMR None None O
, None None O
IR None None O
, None None O
UV None None O
- None None O
vis None None O
) None None O
, None None O
mass None None O
spectrometry None None O
, None None O
and None None O
X None None O
- None None O
ray None None O
crystallography None None O
. None None O

The None None O
in None None O
vitro None None O
antitumor None None O
potency None None O
was None None O
studied None None O
in None None O
two None None O
human None None O
cancer None None O
cell None None O
lines None None O
( None None O
41M None None O
and None None O
SK None None O
- None None O
BR None None O
- None None O
3 None None O
) None None O
. None None O

The None None O
central None None O
metal None None O
ions None None O
exert None None O
pronounced None None O
effects None None O
in None None O
a None None O
divergent None None O
manner None None O
: None None O
gallium None None O
( None None O
III None None O
) None None O
enhances None None O
, None None O
whereas None None O
iron None None O
( None None O
III None None O
) None None O
weakens None None O
the None None O
cytotoxicity None None O
of None None O
the None None O
ligands None None O
. None None O

The None None O
capacity None None O
of None None O
ligand None None O
1 None None O
and None None O
its None None O
Ga None None O
( None None O
III None None O
) None None O
and None None O
Fe None None O
( None None O
III None None O
) None None O
complexes None None O
to None None O
destroy None None O
the None None O
tyrosyl None None O
radical None None O
of None None O
the None None O
presumed None None O
target None None O
ribonucleotide None None O
reductase None None O
is None None O
reported None None O
. None None O


The None None O
synthesis None None O
of None None O
11 None None I-IUPAC
- None None I-IUPAC
thiohomofolic None None I-IUPAC
acid None None I-IUPAC
( None None O
2 None None O
) None None O
has None None O
been None None O
accomplished None None O
by None None O
an None None O
unambiguous None None O
procedure None None O
. None None O

Reaction None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carbomethoxy None None I-IUPAC
) None None I-IUPAC
thiophenoxy None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
butanone None None I-IUPAC
( None None O
10 None None O
) None None O
with None None O
hydroxylamine None None O
under None None O
carefully None None O
controlled None None O
conditions None None O
gave None None O
the None None O
corresponding None None O
oxime None None O
33 None None O
. None None O

Conversion None None O
of None None O
this None None O
oxime None None O
to None None O
1 None None I-IUPAC
- None None I-IUPAC
phthalimido None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carbomethoxy None None I-IUPAC
) None None I-IUPAC
thiophenoxy None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
butanone None None I-IUPAC
oxime None None I-IUPAC
( None None O
4 None None O
) None None O
was None None O
carried None None O
out None None O
by None None O
its None None O
reaction None None O
with None None O
potassium None None O
phthalimide None None O
using None None O
crown None None O
18 None None O
ether None None O
as None None O
a None None O
catalyst None None O
. None None O

Hydrazinolysis None None O
of None None O
compound None None O
4 None None O
gave None None O
1 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carbomethoxy None None I-IUPAC
) None None I-IUPAC
thiophenoxy None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
butanone None None I-IUPAC
oxime None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
which None None O
was None None O
used None None O
for None None O
the None None O
construction None None O
of None None O
the None None O
title None None O
compound None None O
2 None None O
by None None O
modification None None O
of None None O
the None None O
Boon None None O
and None None O
Leigh None None O
procedure None None O
. None None O

An None None O
alternate None None O
synthesis None None O
utilizing None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carbomethoxy None None I-IUPAC
) None None I-IUPAC
thiophenoxy None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
butanone None None I-IUPAC
( None None O
11 None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2,5,6 None None I-IUPAC
- None None I-IUPAC
triaminopyrimidine None None I-IUPAC
has None None O
also None None O
been None None O
carried None None O
out None None O
. None None O

Compound None None O
2 None None O
did None None O
not None None O
exhibit None None O
any None None O
antifolate None None O
activity None None O
against None None O
Lactobacillus None None O
casei None None O
or None None O
Streptococcus None None O
faecium None None O
. None None O

The None None O
dithionite None None O
reduction None None O
product None None O
, None None O
7,8 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
thiohomofolic None None I-IUPAC
acid None None I-IUPAC
, None None O
was None None O
able None None O
to None None O
function None None O
as None None O
a None None O
substrate None None O
of None None O
L None None O
. None None O

casei None None O
dihydrofolate None None O
reductase None None O
. None None O

The None None O
catalytic None None O
reduction None None O
product None None O
of None None O
2 None None O
, None None O
consisting None None O
of None None O
a None None O
mixture None None O
of None None O
diastereomers None None O
, None None O
exhibited None None O
powerful None None O
antifolate None None O
activity None None O
against None None O
both None None O
these None None O
organisms None None O
. None None O


Preference None None O
for None None O
the None None O
Northern None None O
( None None O
N None None O
) None None O
ring None None O
conformation None None O
of None None O
the None None O
ribose None None O
moiety None None O
of None None O
nucleotide None None O
5' None None O
- None None O
triphosphate None None O
agonists None None O
at None None O
P2Y None None O
( None None O
1 None None O
) None None O
, None None O
P2Y None None O
( None None O
2 None None O
) None None O
, None None O
P2Y None None O
( None None O
4 None None O
) None None O
, None None O
and None None O
P2Y None None O
( None None O
11 None None O
) None None O
receptors None None O
, None None O
but None None O
not None None O
P2Y None None O
( None None O
6 None None O
) None None O
receptors None None O
, None None O
was None None O
established None None O
using None None O
a None None O
ring None None O
- None None O
constrained None None O
methanocarba None None O
( None None O
a None None O
3.1.0 None None O
- None None O
bicyclohexane None None O
) None None O
ring None None O
as None None O
a None None O
ribose None None O
substitute None None O
( None None O
Kim None None O
et None None O
al. None None O
J None None O
. None None O

Med. None None O
Chem. None None O
2002 None None O
, None None O
45 None None O
, None None O
208-218 None None O
. None None O

) None None O
. None None O

We None None O
have None None O
now None None O
combined None None O
the None None O
ring None None O
- None None O
constrained None None O
( None None O
N None None O
) None None O
- None None O
methanocarba None None O
modification None None O
of None None O
adenine None None O
nucleotides None None O
with None None O
other None None O
functionalities None None O
known None None O
to None None O
enhance None None O
potency None None O
at None None O
P2 None None O
receptors None None O
. None None O

The None None O
potency None None O
of None None O
the None None O
newly None None O
synthesized None None O
analogues None None O
was None None O
determined None None O
in None None O
the None None O
stimulation None None O
of None None O
phospholipase None None O
C None None O
through None None O
activation None None O
of None None O
turkey None None O
erythrocyte None None O
P2Y None None O
( None None O
1 None None O
) None None O
or None None O
human None None O
P2Y None None O
( None None O
1 None None O
) None None O
and None None O
P2Y None None O
( None None O
2 None None O
) None None O
receptors None None O
stably None None O
expressed None None O
in None None O
astrocytoma None None O
cells None None O
. None None O

An None None O
( None None I-IUPAC
N None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methanocarba None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylthio None None I-IUPAC
- None None I-IUPAC
ADP None None I-IUPAC
analogue None None I-MODIFIER
displayed None None O
an None None O
EC None None O
( None None O
50 None None O
) None None O
at None None O
the None None O
hP2Y None None O
( None None O
1 None None O
) None None O
receptor None None O
of None None O
0.40 None None O
nM None None O
and None None O
was None None O
55 None None O
- None None O
fold None None O
more None None O
potent None None O
than None None O
the None None O
corresponding None None O
triphosphate None None O
and None None O
16 None None O
- None None O
fold None None O
more None None O
potent None None O
than None None O
the None None O
riboside None None O
5' None None I-IUPAC
- None None I-IUPAC
diphosphate None None I-IUPAC
. None None O

2 None None I-IUPAC
- None None I-IUPAC
Cl None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methanocarba None None I-IUPAC
- None None I-IUPAC
ATP None None I-IUPAC
and None None O
its None None O
N None None O
( None None O
6 None None O
) None None O
- None None O
Me None None O
analogue None None O
were None None O
also None None O
highly None None O
selective None None O
, None None O
full None None O
agonists None None O
at None None O
P2Y None None O
( None None O
1 None None O
) None None O
receptors None None O
. None None O

The None None O
( None None I-IUPAC
N None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methanocarba None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylthio None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
chloromonophosphate None None I-IUPAC
analogues None None I-MODIFIER
were None None O
full None None O
agonists None None O
exhibiting None None O
micromolar None None O
potency None None O
at None None O
P2Y None None O
( None None O
1 None None O
) None None O
receptors None None O
, None None O
while None None O
the None None O
corresponding None None O
ribosides None None O
were None None O
inactive None None O
. None None O

Although None None O
beta None None I-IUPAC
, None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
methylene None None I-IUPAC
- None None I-IUPAC
ATP None None I-IUPAC
was None None O
inactive None None O
at None None O
P2Y None None O
receptors None None O
, None None O
beta None None I-IUPAC
, None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
methylene None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methanocarba None None I-IUPAC
- None None I-IUPAC
ATP None None I-IUPAC
was None None O
a None None O
potent None None O
hP2Y None None O
( None None O
1 None None O
) None None O
receptor None None O
agonist None None O
with None None O
an None None O
EC None None O
( None None O
50 None None O
) None None O
of None None O
160 None None O
nM None None O
and None None O
was None None O
selective None None O
versus None None O
hP2Y None None O
( None None O
2 None None O
) None None O
and None None O
hP2Y None None O
( None None O
4 None None O
) None None O
receptors None None O
. None None O

The None None O
rates None None O
of None None O
hydrolysis None None O
of None None O
Northern None None O
( None None O
N None None O
) None None O
and None None O
Southern None None O
( None None O
S None None O
) None None O
methanocarba None None O
analogues None None O
of None None O
AMP None None O
by None None O
rat None None O
5' None None O
- None None O
ectonucleotidase None None O
were None None O
negligible None None O
. None None O

The None None O
rates None None O
of None None O
hydrolysis None None O
of None None O
the None None O
corresponding None None O
triphosphates None None O
by None None O
recombinant None None O
rat None None O
NTPDase1 None None O
and None None O
2 None None O
were None None O
studied None None O
. None None O

Both None None O
isomers None None O
were None None O
hydrolyzed None None O
by None None O
NTPDase None None O
1 None None O
at None None O
about None None O
half None None O
the None None O
rate None None O
of None None O
ATP None None O
hydrolysis None None O
. None None O

The None None O
( None None O
N None None O
) None None O
isomer None None O
was None None O
hardly None None O
hydrolyzed None None O
by None None O
NTPDase None None O
2 None None O
, None None O
while None None O
the None None O
( None None O
S None None O
) None None O
isomer None None O
was None None O
hydrolyzed None None O
at None None O
one None None O
- None None O
third None None O
of None None O
the None None O
rate None None O
of None None O
ATP None None O
hydrolysis None None O
. None None O

This None None O
suggests None None O
that None None O
new None None O
, None None O
more None None O
stable None None O
and None None O
selective None None O
nucleotide None None O
agonists None None O
may None None O
be None None O
designed None None O
on None None O
the None None O
basis None None O
of None None O
the None None O
( None None O
N None None O
) None None O
- None None O
conformation None None O
, None None O
which None None O
greatly None None O
enhanced None None O
potency None None O
at None None O
P2Y None None O
( None None O
1 None None O
) None None O
receptors None None O
. None None O


The None None O
conformationally None None O
restricted None None O
, None None O
cyclic None None O
disulfide None None O
- None None O
containing None None O
delta None None O
opioid None None O
receptor None None O
selective None None O
enkephalin None None O
analogue None None O
[ None None O
D None None O
- None None O
Pen2 None None O
, None None O
D None None O
- None None O
Pen5 None None O
] None None O
enkephalin None None O
( None None O
1 None None O
, None None O
DPDPE None None O
) None None O
was None None O
systematically None None O
modified None None O
topographically None None O
by None None O
addition None None O
of None None O
a None None O
methyl None None I-IUPAC
group None None B-MODIFIER
at None None O
either None None O
the None None O
pro None None O
- None None O
S None None O
or None None O
pro None None O
- None None O
R None None O
position None None O
of None None O
the None None O
beta None None O
carbon None None O
of None None O
an None None O
L None None O
- None None O
Phe4 None None O
or None None O
D None None O
- None None O
Phe4 None None O
residue None None O
to None None O
give None None O
[ None None O
( None None O
2S None None O
, None None O
3S None None O
) None None O
- None None O
beta None None O
- None None O
MePhe4 None None O
] None None O
DPDPE None None O
( None None O
2 None None O
) None None O
, None None O
[ None None O
( None None O
2R None None O
, None None O
3R None None O
) None None O
- None None O
beta None None O
- None None O
MePhe4 None None O
] None None O
DPDPE None None O
( None None O
3 None None O
) None None O
, None None O
[ None None O
( None None O
2S None None O
, None None O
3R None None O
) None None O
- None None O
beta None None O
- None None O
MePhe4 None None O
] None None O
DPDPE None None O
( None None O
4 None None O
) None None O
, None None O
and None None O
[ None None O
( None None O
2R None None O
, None None O
3S None None O
) None None O
- None None O
beta None None O
- None None O
MePhe4 None None O
] None None O
DPDPE None None O
( None None O
5 None None O
) None None O
. None None O

The None None O
four None None O
corresponding None None O
isomers None None O
were None None O
prepared None None O
in None None O
which None None O
the None None O
beta None None I-IUPAC
- None None I-IUPAC
methylphenylalanine None None I-IUPAC
residue None None I-MODIFIER
was None None O
p None None O
- None None O
nitro None None O
substituted None None O
, None None O
that None None O
is None None O
with None None O
a None None O
beta None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
nitrophenylalanine None None I-IUPAC
( None None O
beta None None O
- None None O
Me None None O
- None None O
p None None O
- None None O
NO2Phe None None O
) None None O
residue None None O
, None None O
to None None O
give None None O
[ None None O
( None None O
2S None None O
, None None O
3S None None O
) None None O
- None None O
beta None None O
- None None O
Me None None O
- None None O
p None None O
- None None O
NO2Phe4 None None O
] None None O
DPDPE None None O
( None None O
6 None None O
) None None O
, None None O
[ None None O
( None None O
2R None None O
, None None O
3R None None O
) None None O
- None None O
beta None None O
- None None O
Me None None O
- None None O
p None None O
- None None O
NO2Phe4 None None O
] None None O
DPDPE None None O
( None None O
7 None None O
) None None O
, None None O
[ None None O
( None None O
2S None None O
, None None O
3R None None O
) None None O
- None None O
beta None None O
- None None O
Me None None O
- None None O
p None None O
- None None O
NO2Phe4 None None O
] None None O
DPDPE None None O
( None None O
8 None None O
) None None O
, None None O
and None None O
[ None None O
( None None O
2R None None O
, None None O
3S None None O
) None None O
- None None O
beta None None O
- None None O
Me None None O
- None None O
p None None O
- None None O
NO2Phe4 None None O
] None None O
DPDPE None None O
( None None O
9 None None O
) None None O
, None None O
respectively None None O
. None None O

The None None O
potency None None O
and None None O
selectivity None None O
( None None O
delta None None O
vs None None O
mu None None O
opioid None None O
receptor None None O
) None None O
were None None O
evaluated None None O
by None None O
radioreceptor None None O
binding None None O
assays None None O
in None None O
the None None O
rat None None O
brain None None O
using None None O
[ None None O
3H None None O
] None None O
CTOP None None O
( None None O
mu None None O
ligand None None O
) None None O
and None None O
[ None None O
3H None None O
] None None O
DPDPE None None O
( None None O
delta None None O
ligand None None O
) None None O
and None None O
by None None O
bioassay None None O
with None None O
mouse None None O
vas None None O
deferens None None O
( None None O
MVD None None O
, None None O
delta None None O
receptor None None O
assay None None O
) None None O
and None None O
guinea None None O
pig None None O
ileum None None O
( None None O
GPI None None O
, None None O
mu None None O
receptor None None O
assay None None O
) None None O
. None None O

The None None O
eight None None O
analogues None None O
of None None O
DPDPE None None O
showed None None O
highly None None O
variable None None O
binding None None O
and None None O
bioassay None None O
activities None None O
particularly None None O
at None None O
the None None O
delta None None O
opioid None None O
receptor None None O
( None None O
4 None None O
orders None None O
of None None O
magnitude None None O
) None None O
, None None O
but None None O
also None None O
at None None O
the None None O
mu None None O
opioid None None O
receptor None None O
, None None O
which None None O
led None None O
to None None O
large None None O
differences None None O
( None None O
3 None None O
orders None None O
of None None O
magnitude None None O
) None None O
in None None O
receptor None None O
selectivity None None O
. None None O

For None None O
example None None O
, None None O
[ None None O
( None None O
2S None None O
, None None O
3S None None O
) None None O
- None None O
beta None None O
- None None O
MePhe4 None None O
] None None O
DPDPE None None O
( None None O
2 None None O
) None None O
is None None O
1800 None None O
- None None O
fold None None O
selective None None O
in None None O
binding None None O
to None None O
the None None O
delta None None O
vs None None O
mu None None O
receptor None None O
, None None O
making None None O
it None None O
one None None O
of None None O
the None None O
most None None O
selective None None O
delta None None O
opioid None None O
receptor None None O
ligands None None O
in None None O
the None None O
enkephalin None None O
series None None O
as None None O
assessed None None O
by None None O
the None None O
rat None None O
brain None None O
binding None None O
assay None None O
, None None O
whereas None None O
the None None O
corresponding None None O
( None None O
2R None None O
, None None O
3R None None O
) None None O
- None None O
beta None None O
- None None O
Me None None O
- None None O
p None None O
- None None O
NO2Phe None None O
- None None O
containing None None O
analogue None None O
9 None None O
is None None O
only None None O
4.5 None None O
- None None O
fold None None O
selective None None O
( None None O
nonselective None None O
) None None O
in None None O
this None None O
same None None O
assay None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
in None None O
the None None O
bioassay None None O
systems None None O
, None None O
[ None None O
( None None O
2S None None O
, None None O
3S None None O
) None None O
- None None O
beta None None O
- None None O
Me None None O
- None None O
p None None O
- None None O
NO2Phe4 None None O
] None None O
DPDPE None None O
( None None O
5 None None O
) None None O
is None None O
more None None O
potent None None O
than None None O
DPDPE None None O
and None None O
8800 None None O
- None None O
fold None None O
selective None None O
for None None O
the None None O
MVD None None O
( None None O
delta None None O
receptor None None O
) None None O
vs None None O
the None None O
GPI None None O
( None None O
mu None None O
receptor None None O
) None None O
, None None O
making None None O
it None None O
the None None O
most None None O
highly None None O
selective None None O
ligand None None O
in None None O
this None None O
series None None O
for None None O
the None None O
delta None None O
opioid None None O
receptor None None O
on None None O
the None None O
basis None None O
of None None O
these None None O
bioassays None None O
. None None O

In None None O
these None None O
assay None None O
systems None None O
, None None O
the None None O
( None None O
2R None None O
, None None O
3S None None O
) None None O
- None None O
beta None None O
- None None O
MePhe4 None None O
- None None O
containing None None O
analogue None None O
5 None None O
had None None O
very None None O
weak None None O
potency None None O
and None None O
virtually None None O
no None None O
receptor None None O
selectivity None None O
( None None O
4.4 None None O
- None None O
fold None None O
) None None O
. None None O

These None None O
results None None O
demonstrate None None O
that None None O
topographical None None O
modification None None O
alone None None O
in None None O
a None None O
conformationally None None O
restricted None None O
peptide None None O
ligand None None O
can None None O
significantly None None O
modulate None None O
both None None O
potency None None O
and None None O
receptor None None O
selectivity None None O
of None None O
peptide None None O
ligands None None O
that None None O
have None None O
multiple None None O
sites None None O
of None None O
biological None None O
activity None None O
and None None O
suggest None None O
that None None O
this None None O
approach None None O
may None None O
have None None O
general None None O
application None None O
to None None O
peptide None None O
ligand None None O
design None None O
. None None O


A None None O
series None None O
of None None O
2 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimidazole None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acids None None I-IUPAC
was None None O
prepared None None O
from None None O
the None None O
key None None O
intermediate None None O
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
6a None None O
- None None O
c None None O
) None None O
in None None O
order None None O
to None None O
clarify None None O
the None None O
structure None None O
- None None O
activity None None O
relationships None None O
of None None O
various None None O
analogues None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
ben None None I-IUPAC
zimidazole None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
CV None None O
- None None O
11194 None None O
) None None O
, None None O
a None None O
potent None None O
and None None O
long None None O
acting None None O
angiotensin None None O
II None None O
( None None O
AII None None O
) None None O
receptor None None O
antagonist None None O
. None None O

The None None O
AII None None O
antagonistic None None O
activity None None O
of None None O
the None None O
benzimidazoles None None O
was None None O
investigated None None O
by None None O
in None None O
vitro None None O
assays None None O
, None None O
which None None O
included None None O
an None None O
AII None None O
receptor None None O
binding None None O
assay None None O
and None None O
AII None None O
- None None O
induced None None O
vasocontraction None None O
assay None None O
, None None O
as None None O
well None None O
as None None O
by None None O
in None None O
vivo None None O
assays None None O
such None None O
as None None O
an None None O
AII None None O
- None None O
induced None None O
pressor None None O
response None None O
in None None O
rats None None O
. None None O

Most None None O
of None None O
the None None O
benzimidazoles None None O
showed None None O
high None None O
affinity None None O
for None None O
the None None O
AII None None O
receptor None None O
( None None O
IC50 None None O
value None None O
, None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
- None None O
10 None None O
( None None O
- None None O
7 None None O
) None None O
M None None O
) None None O
and None None O
inhibited None None O
the None None O
AII None None O
- None None O
induced None None O
pressor None None O
response None None O
at None None O
1 None None O
or None None O
3 None None O
mg None None O
/ None None O
kg None None O
po None None O
, None None O
and None None O
the None None O
effects None None O
were None None O
more None None O
potent None None O
than None None O
those None None O
of None None O
CV None None O
- None None O
11194 None None O
and None None O
DuP None None O
753 None None O
. None None O

The None None O
structure None None O
- None None O
activity None None O
relationship None None O
studies None None O
on None None O
the None None O
binding None None O
affinity None None O
and None None O
the None None O
inhibition None None O
of None None O
AII None None O
- None None O
induced None None O
pressor None None O
response None None O
suggested None None O
that None None O
straight None None O
chains None None O
of None None O
a None None O
certain None None O
length None None O
( None None O
e.g. None None O
, None None O
ethoxy None None O
groups None None O
, None None O
ethyl None None O
groups None None O
) None None O
were None None O
the None None O
best None None O
as None None O
substituents None None O
at None None O
the None None O
2 None None O
- None None O
position None None O
and None None O
that None None O
their None None O
steric None None O
factors None None O
, None None O
lipophilicity None None O
, None None O
and None None O
electronic None None O
effects None None O
affected None None O
the None None O
potency None None O
of None None O
the None None O
AII None None O
antagonistic None None O
action None None O
. None None O

Both None None O
a None None O
carboxyl None None O
group None None O
at None None O
the None None O
7 None None O
- None None O
position None None O
and None None O
a None None O
tetrazole None None O
ring None None O
at None None O
the None None O
2' None None O
- None None O
position None None O
were None None O
particularly None None O
important None None O
for None None O
potent None None O
and None None O
orally None None O
active None None O
AII None None O
antagonistic None None O
activity None None O
and None None O
a None None O
long None None O
- None None O
acting None None O
hypotensive None None O
effect None None O
. None None O

The None None O
representative None None O
compound None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimidazole None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
26b None None O
, None None O
CV None None O
- None None O
11974 None None O
) None None O
, None None O
inhibited None None O
the None None O
specific None None O
binding None None O
of None None O
[ None None O
125I None None O
] None None O
AII None None O
to None None O
bovine None None O
adrenal None None O
cortical None None O
membrane None None O
with None None O
an None None O
IC50 None None O
value None None O
of None None O
1.1 None None O
x None None O
10 None None O
( None None O
- None None O
7 None None O
) None None O
M None None O
. None None O

The None None O
AII None None O
- None None O
induced None None O
contraction None None O
of None None O
rabbit None None O
aortic None None O
strips None None O
was None None O
antagonized None None O
by None None O
CV None None O
- None None O
11974 None None O
( None None O
IC50 None None O
value None None O
, None None O
3.0 None None O
x None None O
10 None None O
( None None O
- None None O
10 None None O
) None None O
M None None O
) None None O
. None None O

Oral None None O
administration None None O
of None None O
CV None None O
- None None O
11974 None None O
to None None O
conscious None None O
normotensive None None O
rats None None O
at None None O
1 None None O
mg None None O
/ None None O
kg None None O
resulted None None O
in None None O
long None None O
- None None O
lasting None None O
inhibition None None O
of None None O
the None None O
AII None None O
- None None O
induced None None O
pressor None None O
response None None O
. None None O

CV None None O
- None None O
11974 None None O
at None None O
0.1-1 None None O
mg None None O
/ None None O
kg None None O
iv None None O
reduced None None O
blood None None O
pressure None None O
dose None None O
- None None O
dependently None None O
in None None O
spontaneously None None O
hypertensive None None O
rats None None O
. None None O


3 None None O
- None None O
Deoxy None None O
- None None O
2,5 None None O
- None None O
di None None O
- None None O
O None None O
- None None O
p None None O
- None None O
nitrobenzoyl None None O
- None None O
alpha None None O
- None None O
D None None O
- None None O
threo None None O
- None None O
entofuranosyl None None O
bromide None None O
( None None O
1 None None O
) None None O
reacted None None O
with None None O
mercuric None None O
cyanide None None O
to None None O
give None None O
2,5 None None I-IUPAC
- None None I-IUPAC
anhydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
lyxo None None I-IUPAC
- None None I-IUPAC
hexononitrile None None I-IUPAC
( None None O
2 None None O
) None None O
which None None O
upon None None O
acid None None O
hydrolysis None None O
of None None O
the None None O
CN None None O
group None None O
gave None None O
acid None None O
3 None None O
. None None O

Saponification None None O
of None None O
the None None O
protecting None None O
groups None None O
gave None None O
2,5 None None I-IUPAC
- None None I-IUPAC
anhydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
lyxo None None I-IUPAC
- None None I-IUPAC
hexonic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None O
) None None O
which None None O
reacted None None O
with None None O
4,5,6 None None I-IUPAC
- None None I-IUPAC
triaminopyrimidine None None I-IUPAC
forming None None O
an None None O
amide None None O
( None None O
5 None None O
) None None O
that None None O
was None None O
pyrolized None None O
to None None O
give None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
threo None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
( None None O
6 None None O
) None None O
. None None O

Reaction None None O
of None None O
bromide None None O
1 None None O
with None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzamido None None I-IUPAC
) None None I-IUPAC
chloromercuriopurine None None I-IUPAC
followed None None O
by None None O
saponification None None O
yielded None None O
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
threo None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
( None None O
8 None None O
) None None O
. None None O

8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
Ribofuranosyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
, None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabinofuranosyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
, None None O
and None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
, None None O
as None None O
well None None O
as None None O
compound None None O
6 None None O
, None None O
showed None None O
no None None O
antimalarial None None O
activity None None O
. None None O


The None None O
effect None None O
of None None O
substitution None None O
in None None O
the None None O
acyclic None None O
structure None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
thymine None None I-IUPAC
( None None O
HEPT None None O
) None None O
on None None O
anti None None O
- None None O
HIV None None O
- None None O
1 None None O
activity None None O
was None None O
investigated None None O
by None None O
synthesizing None None O
a None None O
series None None O
of None None O
deoxy None None I-IUPAC
analogs None None B-MODIFIER
and None None O
related None None O
compounds None None O
. None None O

Preparation None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
alkyloxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
( None None O
2-4 None None O
) None None O
derivatives None None I-MODIFIER
was None None O
carried None None O
out None None O
based None None O
on None None O
alkylation None None O
of None None O
HEPT None None O
with None None O
primary None None O
alkyl None None O
halides None None O
. None None O

Preparation None None O
of None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
alkyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
( None None O
26-31 None None O
) None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
alkyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thiouracil None None I-IUPAC
( None None O
32-45 None None O
) None None O
derivatives None None I-MODIFIER
was None None O
carried None None O
out None None O
on None None O
the None None O
basis None None O
of None None O
LDA None None O
lithiation None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
alkyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
thymine None None I-IUPAC
( None None O
9-14 None None O
) None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
alkyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thiouracil None None I-IUPAC
( None None O
15-25 None None O
) None None O
followed None None O
by None None O
reaction None None O
with None None O
diaryl None None O
disulfides None None O
. None None O

The None None O
oxidative None None O
hydrolysis None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
thiouracil None None I-IUPAC
derivatives None None I-MODIFIER
gave None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
alkyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylthio None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
46-57 None None O
) None None O
. None None O

1 None None I-IUPAC
- None None I-IUPAC
Alkyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
( None None O
59-61 None None O
) None None O
derivatives None None I-MODIFIER
were None None O
prepared None None O
on None None O
the None None O
basis None None O
of None None O
alkylation None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
( None None O
58 None None O
) None None O
. None None O

Methylation None None O
of None None O
the None None O
hydroxyl None None I-IUPAC
group None None B-MODIFIER
of None None O
HEPT None None O
did None None O
not None None O
affect None None O
the None None O
anti None None O
- None None O
HIV None None O
- None None O
1 None None O
activity None None O
of None None O
HEPT None None O
. None None O

Substitution None None O
of None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
by None None O
ethyl None None I-IUPAC
, None None O
butyl None None I-IUPAC
, None None O
methoxymethyl None None I-IUPAC
, None None O
( None None I-IUPAC
propyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
, None None O
and None None O
( None None I-IUPAC
butyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
groups None None I-MODIFIER
somewhat None None O
improved None None O
the None None O
original None None O
anti None None O
- None None O
HIV None None O
- None None O
1 None None O
activity None None O
of None None O
HEPT None None O
. None None O

Substitution None None O
with None None O
ethoxymethyl None None I-IUPAC
and None None O
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
groups None None I-MODIFIER
further None None O
potentiated None None O
the None None O
activity None None O
[ None None O
EC50 None None O
: None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
( None None O
27 None None O
) None None O
, None None O
0.33 None None O
microM None None O
; None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
( None None O
31 None None O
) None None O
, None None O
0.088 None None O
microM None None O
] None None O
. None None O

When None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
of None None O
27 None None O
and None None O
31 None None O
was None None O
replaced None None O
by None None O
an None None O
ethyl None None I-IUPAC
or None None O
an None None O
isopropyl None None I-IUPAC
group None None B-MODIFIER
, None None O
the None None O
anti None None O
- None None O
HIV None None O
- None None O
1 None None O
activity None None O
was None None O
improved None None O
remarkably None None O
[ None None O
EC50 None None O
: None None O
5 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
uracil None None I-IUPAC
( None None O
46 None None O
) None None O
, None None O
0.019 None None O
microM None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
52 None None O
) None None O
, None None O
0.0059 None None O
microM None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
55 None None O
) None None O
, None None O
0.012 None None O
microM None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
56 None None O
) None None O
, None None O
0.0027 None None O
microM None None O
] None None O
. None None O

Introduction None None O
of None None O
two None None O
m None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
groups None None I-MODIFIER
into None None O
the None None O
phenylthio None None I-IUPAC
ring None None B-MODIFIER
also None None O
potentiated None None O
the None None O
activity None None O
. None None O


alpha None None O
- None None O
Fluoromethyl None None O
amino None None O
acids None None O
are None None O
enzyme None None O
- None None O
activated None None O
irreversible None None O
inhibitors None None O
of None None O
amino None None O
acid None None O
decarboxylases None None O
. None None O

Aromatic None None O
L None None O
- None None O
amino None None O
acid None None O
decarboxylase None None O
( None None O
AADC None None O
) None None O
is None None O
the None None O
enzyme None None O
responsible None None O
for None None O
the None None O
final None None O
step None None O
in None None O
the None None O
biosynthesis None None O
of None None O
both None None O
dopamine None None O
and None None O
serotonin None None O
via None None O
decarboxylation None None O
of None None O
L None None I-IUPAC
- None None I-IUPAC
dopa None None I-IUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tryptophan None None I-IUPAC
, None None O
respectively None None O
. None None O

Our None None O
goal None None O
is None None O
to None None O
utilize None None O
antagonists None None O
of None None O
the None None O
serotonin None None O
- None None O
producing None None O
enzymes None None O
( None None O
tryptophan None None O
hydroxylase None None O
and None None O
AADC None None O
) None None O
as None None O
the None None O
basis None None O
for None None O
a None None O
chemotherapeutic None None O
approach None None O
to None None O
the None None O
treatment None None O
of None None O
carcinoid None None O
tumors None None O
, None None O
a None None O
rare None None O
tumor None None O
type None None O
characterized None None O
by None None O
the None None O
overproduction None None O
of None None O
serotonin None None O
. None None O

We None None O
report None None O
here None None O
an None None O
enantiospecific None None O
synthesis None None O
of None None O
alpha None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoromethyl None None I-IUPAC
) None None I-IUPAC
tryptophan None None I-IUPAC
[ None None O
( None None O
S None None O
) None None O
- None None O
11a None None O
] None None O
and None None O
alpha None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoromethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxytryptophan None None I-IUPAC
[ None None O
( None None O
S None None O
) None None O
- None None O
11b None None O
] None None O
, None None O
as None None O
well None None O
as None None O
the None None O
( None None O
R None None O
) None None O
- None None O
enantiomers None None O
, None None O
based None None O
upon None None O
recent None None O
methodology None None O
involving None None O
the None None O
face None None O
- None None O
selective None None O
alkylation None None O
of None None O
cyclic None None O
tryptophan None None O
tautomers None None O
. None None O

Our None None O
synthetic None None O
route None None O
provided None None O
both None None O
enantiomers None None O
of None None O
11a None None O
and None None O
11b None None O
with None None O
greater None None O
than None None O
97% None None O
enantiomeric None None O
purity None None O
based None None O
upon None None O
evaluation None None O
of None None O
the None None O
NMR None None O
spectra None None O
of None None O
their None None O
Mosher None None O
's None None O
acid None None O
derivatives None None O
. None None O

( None None O
S None None O
) None None O
- None None O
11a None None O
was None None O
evaluated None None O
as None None O
a None None O
substrate None None O
for None None O
P815 None None O
tryptophan None None O
hydroxylase None None O
and None None O
determined None None O
to None None O
have None None O
an None None O
apparent None None O
Km None None O
of None None O
4.31 None None O
+ None None O
/ None None O
- None None O
1.07 None None O
mM None None O
, None None O
essentially None None O
half None None O
the None None O
value None None O
previously None None O
reported None None O
for None None O
the None None O
racemic None None O
mixture None None O
of None None O
11a None None O
with None None O
rat None None O
brain None None O
stem None None O
tryptophan None None O
hydroxylase None None O
. None None O

( None None O
R None None O
) None None O
- None None O
11a None None O
was None None O
not None None O
a None None O
substrate None None O
for None None O
P815 None None O
tryptophan None None O
hydroxylase None None O
. None None O

( None None O
S None None O
) None None O
- None None O
11b None None O
was None None O
evaluated None None O
as None None O
an None None O
enzyme None None O
- None None O
activated None None O
irreversible None None O
inhibitor None None O
of None None O
murine None None O
liver None None O
AADC None None O
and None None O
determined None None O
to None None O
have None None O
a None None O
KI None None O
of None None O
24.3 None None O
+ None None O
/ None None O
- None None O
3.01 None None O
microM None None O
and None None O
a None None O
k2 None None O
of None None O
2.26 None None O
+ None None O
/ None None O
- None None O
0.44 None None O
min None None O
- None None O
1 None None O
. None None O

( None None O
R None None O
) None None O
- None None O
11b None None O
was None None O
not None None O
an None None O
inhibitor None None O
of None None O
murine None None O
liver None None O
AADC None None O
. None None O


Dextromethorphan None None O
( None None O
1 None None O
, None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
- None None I-IUPAC
methylmorphinan None None I-IUPAC
) None None O
demonstrates None None O
anticonvulsant None None O
activity None None O
in None None O
a None None O
variety None None O
of None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
models None None O
of None None O
convulsive None None O
action None None O
. None None O

It None None O
is None None O
well None None O
known None None O
that None None O
1 None None O
is None None O
metabolized None None O
to None None O
its None None O
phenolic None None O
derivative None None O
dextrorphan None None O
( None None O
2 None None O
) None None O
and None None O
this None None O
metabolite None None O
is None None O
also None None O
a None None O
potent None None O
anticonvulsant None None O
. None None O

A None None O
series None None O
of None None O
( None None I-MODIFIER
+ None None I-MODIFIER
) None None I-MODIFIER
- None None I-MODIFIER
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
17 None None I-IUPAC
- None None I-IUPAC
methylmorphinans None None I-IUPAC
, None None O
which None None O
are None None O
structurally None None O
similar None None O
to None None O
1 None None O
but None None O
are None None O
either None None O
not None None O
expected None None O
to None None O
be None None O
metabolized None None O
to None None O
2 None None O
or None None O
might None None O
do None None O
so None None O
at None None O
a None None O
reduced None None O
rate None None O
, None None O
as None None O
compared None None O
to None None O
1 None None O
, None None O
were None None O
prepared None None O
. None None O

Three None None O
analogs None None O
, None None O
5 None None O
( None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
- None None I-IUPAC
methylmorphinan None None I-IUPAC
) None None O
, None None O
14 None None O
( None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
- None None I-IUPAC
methylmorphinan None None I-IUPAC
) None None O
, None None O
and None None O
15 None None O
( None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propoxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
- None None I-IUPAC
methylmorphinan None None I-IUPAC
) None None O
were None None O
found None None O
to None None O
possess None None O
potent None None O
anticonvulsant None None O
activity None None O
with None None O
full None None O
efficacy None None O
( None None O
ED50 None None O
25 None None O
, None None O
5.6 None None O
, None None O
and None None O
3.9 None None O
mg None None O
/ None None O
kg None None O
, None None O
sc None None O
, None None O
respectively None None O
) None None O
in None None O
the None None O
rat None None O
supramaximal None None O
electroshock None None O
( None None O
MES None None O
) None None O
test None None O
. None None O

Binding None None O
potencies None None O
of None None O
these None None O
compounds None None O
to None None O
receptor None None O
sites None None O
labeled None None O
with None None O
[ None None O
3H None None O
] None None O
dextromethorphan None None O
( None None O
[ None None O
3H None None O
] None None O
1 None None O
) None None O
, None None O
in None None O
rat None None O
brain None None O
and None None O
guinea None None O
pig None None O
brain None None O
subcellular None None O
fractions None None O
, None None O
and None None O
[ None None O
3H None None O
] None None O
thienylcyclohexylpiperidine None None O
( None None O
TCP None None O
) None None O
and None None O
[ None None O
3H None None O
] None None O
glycine None None O
in None None O
rat None None O
brain None None O
, None None O
were None None O
determined None None O
. None None O

Most None None O
of None None O
the None None O
analogs None None O
displaced None None O
[ None None O
3H None None O
] None None O
1 None None O
from None None O
its None None O
binding None None O
sites None None O
, None None O
with None None O
compounds None None O
14 None None O
( None None O
IC50 None None O
0.42 None None O
microM None None O
) None None O
and None None O
15 None None O
( None None O
IC50 None None O
0.88 None None O
microM None None O
) None None O
having None None O
equivalent None None O
potencies None None O
to None None O
1 None None O
( None None O
IC50 None None O
0.59 None None O
microM None None O
) None None O
, None None O
in None None O
rat None None O
brain None None O
, None None O
and None None O
no None None O
appreciable None None O
activity None None O
at None None O
the None None O
[ None None O
3H None None O
] None None O
TCP None None O
or None None O
[ None None O
3H None None O
] None None O
glycine None None O
- None None O
labeled None None O
sites None None O
. None None O

Compound None None O
5 None None O
did None None O
not None None O
bind None None O
with None None O
appreciable None None O
activity None None O
to None None O
the None None O
[ None None O
3H None None O
] None None O
1 None None O
site None None O
, None None O
in None None O
rat None None O
brain None None O
, None None O
but None None O
did None None O
bind None None O
to None None O
the None None O
[ None None O
3H None None O
] None None O
TCP None None O
site None None O
with None None O
lower None None O
potency None None O
than None None O
the None None O
parent None None O
1 None None O
( None None O
IC50 None None O
7.8 None None O
and None None O
2.0 None None O
microM None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
mechanism None None O
of None None O
anticonvulsant None None O
action None None O
of None None O
these None None O
agents None None O
is None None O
not None None O
clear None None O
although None None O
it None None O
appears None None O
that None None O
interaction None None O
at None None O
the None None O
[ None None O
3H None None O
] None None O
1 None None O
sites None None O
may None None O
be None None O
involved None None O
. None None O


Clinical None None O
studies None None O
concerning None None O
the None None O
role None None O
of None None O
poly None None O
( None None O
ADP None None O
- None None O
ribose None None O
) None None O
polymerase None None O
( None None O
PARP None None O
) None None O
in None None O
the None None O
repair None None O
of None None O
drug None None O
- None None O
and None None O
radiation None None O
- None None O
induced None None O
DNA None None O
damage None None O
have None None O
been None None O
impeded None None O
by None None O
the None None O
poor None None O
solubility None None O
, None None O
lack None None O
of None None O
potency None None O
, None None O
and None None O
limited None None O
specificity None None O
of None None O
currently None None O
available None None O
inhibitors None None O
. None None O

A None None O
series None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
8 None None B-PARTIUPAC
- None None I-PARTIUPAC
hydroxy None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
8 None None I-IUPAC
- None None I-IUPAC
methylquinazolin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
has None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
PARP None None O
inhibitory None None O
activity None None O
in None None O
permeabilized None None O
L1210 None None O
murine None None O
leukemia None None O
cells None None O
. None None O

8 None None I-PARTIUPAC
- None None I-PARTIUPAC
Methoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
8 None None I-IUPAC
- None None I-IUPAC
methylquinazolinones None None I-IUPAC
( None None O
14-34 None None O
) None None O
were None None O
readily None None O
prepared None None O
by None None O
acylation None None O
of None None O
3 None None O
- None None O
substituted None None O
anthranilamides None None O
with None None O
the None None O
appropriate None None O
acid None None O
chloride None None O
, None None O
followed None None O
by None None O
base None None O
- None None O
catalyzed None None O
cyclization None None O
. None None O

The None None O
requisite None None O
8 None None I-IUPAC
- None None I-IUPAC
hydroxyquinazolinones None None I-IUPAC
( None None O
6 None None O
, None None O
35-39 None None O
) None None O
were None None O
synthesized None None O
by None None O
demethylation None None O
of None None O
the None None O
corresponding None None O
8 None None I-IUPAC
- None None I-IUPAC
methoxyquinazolinones None None I-IUPAC
with None None O
BBr3 None None O
. None None O

N None None O
- None None O
Methylation None None O
of None None O
8 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylquinazolinone None None I-IUPAC
( None None O
15 None None O
) None None O
with None None O
MeI None None O
, None None O
followed None None O
by None None O
O None None O
- None None O
demethylation None None O
by None None O
BBr3 None None O
, None None O
afforded None None O
the None None O
control None None O
N3 None None I-IUPAC
- None None I-IUPAC
methylquinazolinones None None I-IUPAC
42 None None O
and None None O
43 None None O
, None None O
respectively None None O
. None None O

In None None O
general None None O
, None None O
an None None O
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
or None None O
8 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
substituent None None I-MODIFIER
enhanced None None O
inhibitory None None O
activity None None O
in None None O
comparison None None O
with None None O
an None None O
8 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
group None None I-MODIFIER
. None None O

2 None None I-IUPAC
- None None I-IUPAC
Phenylquinazolinones None None I-IUPAC
were None None O
marginally None None O
less None None O
potent None None O
than None None O
the None None O
corresponding None None O
2 None None I-IUPAC
- None None I-IUPAC
methylquinazolinones None None I-IUPAC
, None None O
but None None O
the None None O
introduction None None O
of None None O
an None None O
electron None None O
- None None O
withdrawing None None O
or None None O
electron None None O
- None None O
donating None None O
4' None None O
- None None O
substituent None None O
on None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
ring None None I-MODIFIER
invariably None None O
increased None None O
potency None None O
. None None O

This None None O
was None None O
particularly None None O
evident None None O
in None None O
the None None O
8 None None I-IUPAC
- None None I-IUPAC
methylquinazolinone None None I-IUPAC
series None None I-MODIFIER
( None None O
IC50 None None O
values None None O
0.13-0.27 None None O
microM None None O
) None None O
, None None O
which None None O
are None None O
among None None O
the None None O
most None None O
potent None None O
PARP None None O
inhibitors None None O
reported None None O
to None None O
date None None O
. None None O

N3 None None I-IUPAC
- None None I-IUPAC
Methylquinazolinones None None I-IUPAC
42 None None O
and None None O
43 None None O
were None None O
essentially None None O
devoid None None O
of None None O
activity None None O
( None None O
IC50 None None O
values None None O
& None None O
gt None None O
; None None O
100 None None O
microM None None O
) None None O
. None None O

In None None O
studies None None O
with None None O
L1210 None None O
cells None None O
in None None O
vitro None None O
, None None O
a None None O
concentration None None O
of None None O
200 None None O
microM None None O
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylquinazolinone None None I-IUPAC
( None None O
6 None None O
, None None O
NU1025 None None O
) None None O
( None None O
IC50 None None O
value None None O
0.40 None None O
microM None None O
) None None O
potentiated None None O
the None None O
cytotoxicity None None O
of None None O
the None None O
monomethylating None None O
agent None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyltriazen None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
imidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
and None None O
gamma None None O
- None None O
radiation None None O
3.5 None None O
- None None O
and None None O
1.4 None None O
- None None O
fold None None O
, None None O
respectively None None O
, None None O
at None None O
the None None O
10% None None O
survival None None O
level None None O
. None None O


A None None O
number None None O
of None None O
nucleoside None None O
and None None O
nucleotide None None O
derivatives None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosylpyrazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
pyrazofurin None None O
, None None O
1 None None O
) None None O
were None None O
prepared None None O
and None None O
tested None None O
for None None O
their None None O
antiviral None None O
and None None O
cytostatic None None O
activity None None O
in None None O
cell None None O
culture None None O
. None None O

Treatment None None O
of None None O
1 None None O
with None None O
benzyl None None I-IUPAC
bromide None None I-IUPAC
gave None None O
4 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzylpyrazofurin None None I-IUPAC
( None None O
4 None None O
) None None O
. None None O

Methylation None None O
of None None O
4 None None O
with None None O
CH2N2 None None O
and None None O
subsequent None None O
removal None None O
of None None O
the None None O
benzyl None None I-IUPAC
group None None B-MODIFIER
by None None O
catalytic None None O
hydrogenation None None O
provided None None O
1 None None I-IUPAC
- None None I-IUPAC
methylpyrazofurin None None I-IUPAC
( None None O
8 None None O
) None None O
. None None O

Direct None None O
methylation None None O
of None None O
1 None None O
with None None O
CH3I None None O
furnished None None O
4 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methylpyrazofurin None None I-IUPAC
( None None O
6 None None O
) None None O
. None None O

Dehydration None None O
of None None O
the None None O
pentaacetylpyrazofurin None None O
( None None O
9 None None O
) None None O
with None None O
phosgene None None O
furnished None None O
4 None None I-IUPAC
- None None I-IUPAC
acetoxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
acetylpyrazol None None I-IUPAC
e None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carbonitrile None None I-IUPAC
( None None O
10 None None O
) None None O
. None None O

A None None O
similar None None O
dehydration None None O
of None None O
the None None O
precursor None None O
tetraacetyl None None I-IUPAC
derivative None None B-MODIFIER
of None None O
4 None None O
gave None None O
the None None O
corresponding None None O
carbonitrile None None O
, None None O
which None None O
on None None O
deprotection None None O
and None None O
subsequent None None O
treatment None None O
with None None O
hydroxylamine None None O
furnished None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosylpyrazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxamidoxime None None I-IUPAC
( None None O
13 None None O
) None None O
. None None O

Treatment None None O
of None None O
the None None O
tetraacetyl None None I-IUPAC
derivative None None B-MODIFIER
of None None O
4 None None O
with None None O
Lawesson None None O
's None None O
reagent None None O
and None None O
subsequent None None O
deacetylation None None O
furnished None None O
a None None O
mixture None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosylpyrazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
thiocarboxamide None None I-IUPAC
( None None O
15 None None O
) None None O
and None None O
the None None O
corresponding None None O
nitrile None None I-IUPAC
derivative None None B-MODIFIER
( None None O
16 None None O
) None None O
. None None O

Phosphorylation None None O
of None None O
unprotected None None O
4 None None O
with None None O
POCl3 None None O
and None None O
subsequent None None O
debenzylation None None O
of None None O
the None None O
intermediate None None O
17 None None O
gave None None O
pyrazofurin None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
phosphate None None I-IUPAC
( None None O
18 None None O
) None None O
, None None O
which None None O
provided None None O
the None None O
first None None O
chemical None None O
synthesis None None O
of None None O
18 None None O
. None None O

Similar None None O
phosphorylation None None O
of None None O
4 None None O
with None None O
POCl3 None None O
and None None O
quenching None None O
the None None O
reaction None None O
mixture None None O
with None None O
either None None O
EtOH None None O
or None None O
MeOH None None O
, None None O
followed None None O
by None None O
debenzylation None None O
, None None O
furnished None None O
the None None O
5' None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethyl None None I-IUPAC
phosphate None None I-IUPAC
) None None I-IUPAC
( None None O
19b None None O
) None None O
and None None O
5' None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethyl None None I-IUPAC
phosphate None None I-IUPAC
) None None I-IUPAC
( None None O
20b None None O
) None None O
derivatives None None O
of None None O
pyrazofurin None None O
. None None O

DCC None None O
- None None O
mediated None None O
cyclization None None O
of None None O
17 None None O
, None None O
followed None None O
by None None O
debenzylation None None O
, None None O
gave None None O
pyrazofurin None None O
3' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
cyclic None None I-IUPAC
) None None I-IUPAC
phosphate None None I-IUPAC
( None None O
21b None None O
) None None O
. None None O

The None None O
NAD None None O
analogue None None O
23b None None O
was None None O
also None None O
prepared None None O
by None None O
the None None O
treatment None None O
of None None O
17 None None O
with None None O
an None None O
activated None None O
form None None O
of None None O
AMP None None O
in None None O
the None None O
presence None None O
of None None O
AgNO3 None None O
. None None O

The None None O
structural None None O
assignment None None O
of None None O
7,8 None None O
, None None O
and None None O
20a None None O
were None None O
made None None O
by None None O
single None None O
- None None O
crystal None None O
X None None O
- None None O
ray None None O
analysis None None O
, None None O
and None None O
along None None O
with None None O
pyrazofurin None None O
, None None O
their None None O
intramolecular None None O
hydrogen None None O
bond None None O
characteristics None None O
have None None O
been None None O
studied None None O
. None None O

All None None O
of None None O
these None None O
compounds None None O
were None None O
tested None None O
in None None O
Vero None None O
cell None None O
cultures None None O
against None None O
a None None O
spectrum None None O
of None None O
viruses None None O
. None None O

Compounds None None O
18 None None O
and None None O
23b None None O
were None None O
active None None O
at None None O
concentrations None None O
very None None O
similar None None O
to None None O
pyrazofurin None None O
but None None O
are None None O
less None None O
toxic None None O
to None None O
the None None O
cells None None O
than None None O
pyrazofurin None None O
. None None O

Compounds None None O
19b None None O
, None None O
20b None None O
, None None O
and None None O
the None None O
3' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
cyclic None None I-IUPAC
) None None I-IUPAC
phosphate None None I-IUPAC
21b None None O
are None None O
less None None O
active None None O
than None None O
1 None None O
. None None O

Compounds None None O
18 None None O
, None None O
19b None None O
, None None O
20b None None O
, None None O
and None None O
23b None None O
also None None O
exhibited None None O
significant None None O
inhibitory None None O
effects None None O
on None None O
the None None O
growth None None O
of None None O
L1210 None None O
and None None O
P388 None None O
leukemias None None O
and None None O
Lewis None None O
lung None None O
carcinoma None None O
cells None None O
in None None O
vitro None None O
, None None O
whereas None None O
B16 None None O
melanoma None None O
cells None None O
were None None O
less None None O
sensitive None None O
to None None O
growth None None O
inhibition None None O
by None None O
these None None O
compounds None None O
. None None O

Pyrazofurin None None O
derivatives None None O
modified None None O
at None None O
the None None O
1 None None O
- None None O
, None None O
4 None None O
- None None O
, None None O
or None None O
5 None None O
- None None O
position None None O
showed None None O
neither None None O
antiviral None None O
nor None None O
cytostatic None None O
activity None None O
in None None O
cell None None O
culture None None O
. None None O


A None None O
series None None O
of None None O
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2,3 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
- None None O
1 None None I-IUPAC
- None None I-IUPAC
azetidinyl None None I-IUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
1,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
dihydro None None I-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
fluoro None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
oxoquinoline None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
1,8 None None I-PARTIUPAC
- None None I-PARTIUPAC
naphthyridine None None I-PARTIUPAC
- None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
carboxylic None None I-PARTIUPAC
acids None None I-PARTIUPAC
, None None O
with None None O
varied None None O
substituents None None O
at None None O
the None None O
1 None None O
- None None O
, None None O
5 None None O
- None None O
, None None O
and None None O
8 None None O
- None None O
positions None None O
, None None O
was None None O
prepared None None O
to None None O
study None None O
the None None O
effects None None O
on None None O
potency None None O
and None None O
physicochemical None None O
properties None None O
of None None O
the None None O
substituent None None O
at None None O
position None None O
2 None None O
of None None O
the None None O
azetidine None None O
moiety None None O
. None None O

The None None O
activity None None O
of None None O
the None None O
title None None O
compounds None None O
was None None O
determined None None O
in None None O
vitro None None O
against None None O
Gram None None O
- None None O
positive None None O
and None None O
Gram None None O
- None None O
negative None None O
bacteria None None O
, None None O
and None None O
the None None O
in None None O
vivo None None O
efficacy None None O
of None None O
selected None None O
derivatives None None O
was None None O
determined None None O
using None None O
a None None O
mouse None None O
infection None None O
model None None O
. None None O

The None None O
X None None O
- None None O
ray None None O
crystal None None O
structures None None O
of None None O
6b None None O
, None None O
6c None None O
, None None O
and None None O
6d None None O
were None None O
found None None O
to None None O
be None None O
in None None O
reasonable None None O
agreement None None O
with None None O
the None None O
corresponding None None O
AM1 None None O
calculated None None O
geometries None None O
. None None O

Correlations None None O
between None None O
antibacterial None None O
potency None None O
of None None O
all None None O
the None None O
synthesized None None O
7 None None I-IUPAC
- None None I-IUPAC
azetidinylquinolones None None I-IUPAC
and None None O
naphthyridines None None O
and None None O
their None None O
calculated None None O
electronic None None O
properties None None O
and None None O
experimental None None O
capacity None None O
factors None None O
were None None O
established None None O
. None None O

Antibacterial None None O
efficacy None None O
and None None O
pharmacokinetic None None O
and None None O
physicochemical None None O
properties None None O
of None None O
selected None None O
derivatives None None O
were None None O
compared None None O
to None None O
the None None O
relevant None None O
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azetidinyl None None I-IUPAC
) None None I-IUPAC
and None None O
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azetidinyl None None I-IUPAC
) None None I-IUPAC
analogues None None I-MODIFIER
( None None O
for None None O
Part None None O
1 None None O
, None None O
see None None O
: None None O
J None None O
. None None O

Med. None None O
Chem. None None O
1993 None None O
, None None O
36 None None O
, None None O
801-810 None None O
) None None O
. None None O

A None None O
combination None None O
of None None O
a None None O
cyclopropyl None None O
or None None O
a None None O
substituted None None O
phenyl None None I-IUPAC
group None None B-MODIFIER
at None None O
N None None O
- None None O
1 None None O
and None None O
a None None O
trans None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azetidinyl None None I-IUPAC
group None None I-MODIFIER
at None None O
C None None O
- None None O
7 None None O
conferred None None O
the None None O
best None None O
overall None None O
antibacterial None None O
, None None O
pharmacokinetic None None O
, None None O
and None None O
physicochemical None None O
properties None None O
to None None O
the None None O
azetidinylquinolones None None O
studied None None O
. None None O


Synthetic None None O
procedures None None O
for None None O
the None None O
preparation None None O
of None None O
various None None O
3 None None I-MODIFIER
- None None I-MODIFIER
unsubstituted None None I-MODIFIER
xanthines None None I-IUPAC
, None None O
including None None O
paraxanthine None None O
analogs None None O
( None None O
1,7 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
xanthines None None I-IUPAC
) None None O
and None None O
1,8 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
xanthines None None I-IUPAC
, None None O
were None None O
developed None None O
. None None O

Silylation None None O
of None None O
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
xanthines None None I-IUPAC
followed None None O
by None None O
alkylation None None O
at None None O
the None None O
7 None None O
- None None O
position None None O
provides None None O
a None None O
facile None None O
route None None O
to None None O
paraxanthine None None O
analogs None None O
. None None O

Regioselective None None O
alkylation None None O
of None None O
tris None None I-IUPAC
( None None I-IUPAC
trimethylsilyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
aminouracil None None I-IUPAC
provides None None O
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
6 None None I-IUPAC
- None None I-IUPAC
aminouracils None None I-IUPAC
, None None O
which None None O
are None None O
converted None None O
to None None O
1,8 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
xanthines None None I-IUPAC
by None None O
standard None None O
procedures None None O
. None None O

The None None O
ring None None O
closure None None O
of None None O
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
cyclopentanecarboxamido None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzoylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
aminouracils None None I-IUPAC
requires None None O
drastic None None O
reaction None None O
conditions None None O
. None None O

Affinity None None O
for None None O
brain None None O
A1 None None O
and None None O
A2 None None O
adenosine None None O
receptors None None O
was None None O
determined None None O
in None None O
binding None None O
assays None None O
for None None O
these None None O
and None None O
other None None O
xanthines None None O
with None None O
substituents None None O
in None None O
1 None None O
- None None O
, None None O
3 None None O
- None None O
, None None O
7 None None O
- None None O
, None None O
8 None None O
- None None O
, None None O
and None None O
9 None None O
- None None O
positions None None O
. None None O

Substitution None None O
at None None O
the None None O
1 None None O
- None None O
position None None O
was None None O
necessary None None O
for None None O
high None None O
affinity None None O
at None None O
adenosine None None O
receptors None None O
. None None O

1,3 None None I-MODIFIER
- None None I-MODIFIER
Disubstituted None None I-MODIFIER
xanthines None None I-IUPAC
generally None None O
had None None O
higher None None O
affinity None None O
than None None O
1,7 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
xanthines None None I-IUPAC
. None None O

1,8 None None I-MODIFIER
- None None I-MODIFIER
Disubstituted None None I-MODIFIER
xanthines None None I-IUPAC
had None None O
high None None O
affinity None None O
for None None O
adenosine None None O
receptors None None O
; None None O
some None None O
were None None O
highly None None O
selective None None O
for None None O
A1 None None O
receptors None None O
. None None O


[ None None O
1 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylisoleucine None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
threonine None None I-IUPAC
] None None O
- None None O
( None None O
I None None O
) None None O
, None None O
[ None None O
1 None None I-IUPAC
- None None I-IUPAC
dimethylglycine None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
threonine None None I-IUPAC
] None None O
- None None O
( None None O
II None None O
) None None O
, None None O
[ None None O
1 None None I-IUPAC
- None None I-IUPAC
guanidineacetic None None I-IUPAC
acid None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
threonine None None I-IUPAC
] None None O
- None None O
( None None O
III None None O
) None None O
, None None O
des None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
aspartic None None I-IUPAC
acid None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
threonine None None I-IUPAC
] None None I-IUPAC
- None None O
( None None O
IV None None O
) None None O
, None None O
and None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
sarcosine None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methylserine None None I-IUPAC
] None None I-IUPAC
angiotensin None None I-IUPAC
II None None I-IUPAC
( None None O
V None None O
) None None O
were None None O
synthesized None None O
by None None O
Merrifield None None O
's None None O
solid None None O
- None None O
phase None None O
procedure None None O
to None None O
study None None O
the None None O
effect None None O
of None None O
( None None O
a None None O
) None None O
substituents None None O
in None None O
position None None O
1 None None O
on None None O
the None None O
antagonistic None None O
activity None None O
of None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
sarcosine None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
threonine None None I-IUPAC
] None None I-IUPAC
angiotensin None None I-IUPAC
II None None I-IUPAC
, None None O
and None None O
( None None O
b None None O
) None None O
a None None O
change None None O
in None None O
size None None O
and None None O
branching None None O
in None None O
position None None O
8 None None O
of None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
sarcosine None None I-IUPAC
, None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methylthreonine None None I-IUPAC
] None None I-IUPAC
angiotensin None None I-IUPAC
II None None I-IUPAC
. None None O

The None None O
analogues None None O
I None None O
- None None O
V None None O
caused None None O
an None None O
initial None None O
rise None None O
in None None O
blood None None O
pressure None None O
( None None O
30 None None O
min None None O
of None None O
infusion None None O
, None None O
250 None None O
ng None None O
/ None None O
kg None None O
/ None None O
min None None O
in None None O
vagotomized None None O
ganglion None None O
- None None O
blocked None None O
rats None None O
) None None O
of None None O
8.05 None None O
, None None O
11.7 None None O
, None None O
3.50 None None O
, None None O
4.5 None None O
, None None O
and None None O
11.16 None None O
mmHg None None O
. None None O

The None None O
pA2 None None O
values None None O
( None None O
rabbit None None O
aortic None None O
strips None None O
) None None O
obtained None None O
were None None O
7.68 None None O
, None None O
7.53 None None O
, None None O
7.23 None None O
, None None O
7.53 None None O
, None None O
and None None O
9.66 None None O
, None None O
and None None O
the None None O
dose None None O
ratios None None O
( None None O
in None None O
vagotomized None None O
ganglion None None O
- None None O
blocked None None O
rats None None O
infused None None O
at None None O
250 None None O
ng None None O
/ None None O
kg None None O
/ None None O
min None None O
) None None O
obtained None None O
were None None O
2.37 None None O
, None None O
4.49 None None O
, None None O
1.02 None None O
, None None O
1.47 None None O
, None None O
and None None O
24.04 None None O
, None None O
respectively None None O
. None None O

The None None O
results None None O
obtained None None O
indicate None None O
that None None O
( None None O
a None None O
) None None O
the None None O
nature None None O
of None None O
the None None O
substituent None None O
in None None O
position None None O
1 None None O
has None None O
an None None O
important None None O
influence None None O
on None None O
the None None O
biological None None O
activity None None O
of None None O
these None None O
peptides None None O
, None None O
and None None O
( None None O
b None None O
) None None O
the None None O
potency None None O
of None None O
antagonists None None O
I None None O
- None None O
IV None None O
( None None O
all None None O
less None None O
potent None None O
antagonists None None O
than None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
sarcosine None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
threonine None None I-IUPAC
] None None I-IUPAC
angiotensin None None I-IUPAC
II None None I-IUPAC
) None None O
is None None O
very None None O
much None None O
influenced None None O
by None None O
the None None O
length None None O
and None None O
branching None None O
of None None O
the None None O
side None None O
chain None None O
in None None O
position None None O
8 None None O
. None None O

The None None O
in None None O
vivo None None O
antagonistic None None O
activity None None O
of None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
sarcosine None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methylthreonine None None I-IUPAC
] None None I-IUPAC
angiotensin None None I-IUPAC
II None None I-IUPAC
is None None O
reduced None None O
considerably None None O
by None None O
shortening None None O
the None None O
chain None None O
length None None O
by None None O
one None None O
carbon None None O
atom None None O
as None None O
is None None O
in None None O
V None None O
. None None O


In None None O
furtherance None None O
of None None O
our None None O
SAR None None O
study None None O
on None None O
the None None O
chemistry None None O
and None None O
antitumor None None O
activity None None O
of None None O
fused None None O
nitrogen None None O
heteroaromatic None None O
compounds None None O
, None None O
a None None O
series None None O
of None None O
linear None None O
, None None O
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
derivatives None None B-MODIFIER
of None None O
5H None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
6H None None I-IUPAC
- None None I-IUPAC
indolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
quinolines None None I-IUPAC
were None None O
synthesized None None O
according None None O
to None None O
the None None O
modified None None O
Graebe None None O
- None None O
Ullmann None None O
reaction None None O
. None None O

To None None O
establish None None O
the None None O
relationship None None O
between None None O
the None None O
physicochemical None None O
and None None O
biological None None O
activities None None O
of None None O
indolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
quinolines None None I-IUPAC
, None None O
their None None O
lipophilic None None O
properties None None O
, None None O
cytotoxic None None O
and None None O
antimicrobial None None O
activity None None O
, None None O
and None None O
ability None None O
to None None O
induce None None O
topoisomerase None None O
II None None O
dependent None None O
pSP65 None None O
DNA None None O
cleavage None None O
in None None O
vitro None None O
were None None O
investigated None None O
. None None O

We None None O
found None None O
that None None O
the None None O
antimicrobial None None O
and None None O
cytotoxic None None O
activity None None O
of None None O
indolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
quinolines None None I-IUPAC
was None None O
strongly None None O
influenced None None O
by None None O
the None None O
position None None O
, None None O
and None None O
the None None O
number None None O
of None None O
methyl None None I-IUPAC
substituents None None B-MODIFIER
and None None O
the None None O
presence None None O
of None None O
methyl None None I-IUPAC
group None None B-MODIFIER
at None None O
pyridine None None O
nitrogen None None O
was None None O
essential None None O
for None None O
the None None O
cytotoxicity None None O
of None None O
these None None O
compounds None None O
. None None O

All None None O
indolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
quinolines None None I-IUPAC
belonging None None O
to None None O
the None None O
5H None None O
series None None O
, None None O
i.e. None None O
, None None O
bearing None None O
a None None O
methyl None None I-IUPAC
group None None B-MODIFIER
on None None O
the None None O
pyridine None None O
nitrogen None None O
, None None O
showed None None O
significant None None O
activity None None O
against None None O
procaryotic None None O
and None None O
eucaryotic None None O
organisms None None O
. None None O

They None None O
inhibited None None O
the None None O
growth None None O
of None None O
Gram None None O
- None None O
positive None None O
bacteria None None O
and None None O
pathogenic None None O
fungi None None O
at None None O
MIC None None O
range None None O
3 None None O
x None None O
10 None None O
( None None O
- None None O
2 None None O
) None None O
to None None O
2.5 None None O
x None None O
10 None None O
( None None O
- None None O
1 None None O
) None None O
mumol None None O
/ None None O
mL None None O
, None None O
displayed None None O
cytotoxicity None None O
against None None O
KB None None O
cells None None O
ID50 None None O
in None None O
the None None O
range None None O
2 None None O
x None None O
10 None None O
( None None O
- None None O
3 None None O
) None None O
to None None O
9 None None O
x None None O
10 None None O
( None None O
- None None O
3 None None O
) None None O
mumol None None O
/ None None O
mL None None O
, None None O
and None None O
stimulated None None O
the None None O
formation None None O
of None None O
calf None None O
thymus None None O
topoisomerase None None O
II None None O
mediated None None O
DNA None None O
cleavage None None O
at None None O
concentration None None O
between None None O
0.4 None None O
and None None O
10 None None O
microM None None O
. None None O

None None None O
of None None O
the None None O
indolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
quinolines None None I-IUPAC
belonging None None O
to None None O
the None None O
6H None None O
series None None O
, None None O
i.e. None None O
, None None O
lacking None None O
a None None O
methyl None None I-IUPAC
group None None B-MODIFIER
on None None O
the None None O
pyridine None None O
nitrogen None None O
, None None O
was None None O
active None None O
in None None O
analogous None None O
tests None None O
. None None O

Of None None O
the None None O
investigated None None O
compounds None None O
, None None O
the None None O
most None None O
active None None O
was None None O
2,5,9,11 None None I-IUPAC
- None None I-IUPAC
tetramethyl None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
indolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
quinoline None None I-IUPAC
, None None O
a None None O
compound None None O
bearing None None O
the None None O
highest None None O
number None None O
of None None O
symmetrically None None O
distributed None None O
methyl None None I-IUPAC
groups None None B-MODIFIER
. None None O

The None None O
interaction None None O
of None None O
indolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
quinolines None None I-IUPAC
with None None O
DNA None None O
was None None O
studied None None O
by None None O
measuring None None O
the None None O
increase None None O
of None None O
calf None None O
thymus None None O
DNA None None O
denaturating None None O
temperature None None O
( None None O
Tm None None O
) None None O
. None None O

The None None O
delta None None O
Tm None None O
values None None O
for None None O
the None None O
5H None None O
series None None O
were None None O
found None None O
to None None O
be None None O
about None None O
10 None None O
times None None O
as None None O
high None None O
as None None O
those None None O
for None None O
the None None O
6H None None O
compounds None None O
. None None O

Indolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
quinolines None None I-IUPAC
with None None O
the None None O
highest None None O
number None None O
of None None O
methyl None None I-IUPAC
groups None None B-MODIFIER
had None None O
the None None O
greatest None None O
contribution None None O
to None None O
the None None O
increase None None O
in None None O
the None None O
Tm None None O
of None None O
calf None None O
thymus None None O
DNA None None O
. None None O

The None None O
values None None O
of None None O
delta None None O
Tm None None O
reached None None O
19 None None O
degrees None None O
C None None O
and None None O
1.6 None None O
degrees None None O
C None None O
for None None O
the None None O
most None None O
substituted None None O
compounds None None O
of None None O
both None None O
series None None O
. None None O


The None None O
dedifferentiation None None O
agent None None O
" None None O
reversine None None O
" None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
morpholinoanilino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyclohexyladenine None None I-IUPAC
2 None None I-IUPAC
] None None O
was None None O
found None None O
to None None O
be None None O
a None None O
moderately None None O
potent None None O
antagonist None None O
for None None O
the None None O
human None None O
A None None O
( None None O
3 None None O
) None None O
adenosine None None O
receptor None None O
( None None O
AR None None O
) None None O
with None None O
a None None O
K None None O
( None None O
i None None O
) None None O
value None None O
of None None O
0.66 None None O
microM None None O
. None None O

This None None O
result None None O
prompted None None O
an None None O
exploration None None O
of None None O
the None None O
structure None None O
- None None O
activity None None O
relationship None None O
of None None O
related None None O
derivatives None None O
, None None O
synthesized None None O
via None None O
sequential None None O
substitution None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
fluoropurine None None I-IUPAC
with None None O
selected None None O
nucleophiles None None O
. None None O

Optimization None None O
of None None O
substituents None None O
at None None O
these None None O
two None None O
positions None None O
identified None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyclohexyladenine None None I-IUPAC
( None None O
12 None None O
) None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cycloheptyladenine None None I-IUPAC
( None None O
19 None None O
) None None O
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
phenylamino None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
endo None None I-IUPAC
- None None I-IUPAC
norbornyladenine None None I-IUPAC
( None None O
21 None None O
) None None O
as None None O
potent None None O
A None None O
( None None O
3 None None O
) None None O
AR None None O
ligands None None O
with None None O
K None None O
( None None O
i None None O
) None None O
values None None O
of None None O
51 None None O
, None None O
42 None None O
, None None O
and None None O
37 None None O
nM None None O
, None None O
respectively None None O
, None None O
with None None O
30-200 None None O
- None None O
fold None None O
selectivity None None O
in None None O
comparison None None O
to None None O
A None None O
( None None O
1 None None O
) None None O
and None None O
A None None O
( None None O
2A None None O
) None None O
ARs None None O
. None None O

The None None O
most None None O
selective None None O
A None None O
( None None O
3 None None O
) None None O
AR None None O
antagonist None None O
( None None O
& None None O
gt None None O
; None None O
200 None None O
- None None O
fold None None O
) None None O
was None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyclohexyladenine None None I-IUPAC
( None None O
22 None None O
) None None O
. None None O

9 None None O
- None None O
Methylation None None O
of None None O
12 None None O
, None None O
but None None O
not None None O
19 None None O
, None None O
was None None O
well None None O
- None None O
tolerated None None O
in None None O
A None None O
( None None O
3 None None O
) None None O
AR None None O
binding None None O
. None None O

Extension None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
phenylamino None None I-IUPAC
group None None I-MODIFIER
to None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
benzyl None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethylamino None None I-IUPAC
) None None I-IUPAC
reduced None None O
affinity None None O
. None None O

In None None O
the None None O
series None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylamino None None I-IUPAC
) None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenyloxy None None I-IUPAC
) None None I-IUPAC
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
substitutions None None I-MODIFIER
, None None O
the None None O
order None None O
of None None O
affinity None None O
at None None O
the None None O
A None None O
( None None O
3 None None O
) None None O
AR None None O
was None None O
oxy None None O
& None None O
gt None None O
; None None O
or None None O
= None None O
amino None None O
& None None O
gt None None O
; None None O
thio None None O
. None None O

Selected None None O
derivatives None None O
, None None O
including None None O
reversine None None O
( None None O
K None None O
( None None O
B None None O
) None None O
value None None O
of None None O
466 None None O
nM None None O
via None None O
Schild None None O
analysis None None O
) None None O
, None None O
competitively None None O
antagonized None None O
the None None O
functional None None O
effects None None O
of None None O
a None None O
selective None None O
A None None O
( None None O
3 None None O
) None None O
AR None None O
agonist None None O
, None None O
i.e. None None O
, None None O
inhibition None None O
of None None O
forskolin None None O
- None None O
stimulated None None O
cAMP None None O
production None None O
in None None O
stably None None O
transfected None None O
Chinese None None O
hamster None None O
ovary None None O
( None None O
CHO None None O
) None None O
cells None None O
. None None O

These None None O
results None None O
are None None O
in None None O
agreement None None O
with None None O
other None None O
studies None None O
suggesting None None O
the None None O
presence None None O
of None None O
a None None O
lipophilic None None O
pocket None None O
in None None O
the None None O
AR None None O
binding None None O
site None None O
that None None O
is None None O
filled None None O
by None None O
moderately None None O
sized None None O
cycloalkyl None None O
rings None None O
at None None O
the None None O
N None None O
( None None O
6 None None O
) None None O
position None None O
of None None O
both None None O
adenine None None O
and None None O
adenosine None None O
derivatives None None O
. None None O

Thus None None O
, None None O
the None None O
compound None None O
series None None O
reported None None O
herein None None O
comprise None None O
an None None O
important None None O
new None None O
series None None O
of None None O
selective None None O
A None None O
( None None O
3 None None O
) None None O
AR None None O
antagonists None None O
. None None O

We None None O
were None None O
unable None None O
to None None O
reproduce None None O
the None None O
dedifferentiation None None O
effect None None O
of None None O
reversine None None O
, None None O
previously None None O
reported None None O
, None None O
or None None O
to None None O
demonstrate None None O
any None None O
connection None None O
between None None O
A None None O
( None None O
3 None None O
) None None O
AR None None O
antagonist None None O
effects None None O
and None None O
dedifferentiation None None O
. None None O


In None None O
order None None O
to None None O
investigate None None O
the None None O
structural None None O
requirements None None O
for None None O
gastroprotective None None O
activity None None O
in None None O
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylbutyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ammoniohexanoate None None I-IUPAC
[ None None O
AI None None O
- None None O
77 None None O
- None None O
B None None O
, None None O
1 None None O
] None None O
, None None O
a None None O
product None None O
of None None O
Bacillus None None O
pumilus None None O
AI None None O
- None None O
77 None None O
, None None O
nine None None O
derivatives None None O
were None None O
prepared None None O
and None None O
then None None O
tested None None O
for None None O
protective None None O
activity None None O
against None None O
stress None None O
- None None O
induced None None O
ulcers None None O
in None None O
rats None None O
. None None O

Neither None None O
the None None O
chromophore None None O
, None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylbutyl None None I-IUPAC
] None None I-IUPAC
ammonium None None I-IUPAC
chloride None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
nor None None O
the None None O
side None None O
- None None O
chain None None O
moiety None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydroxyhexanedioic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
as None None O
separate None None O
fragments None None O
alone None None O
showed None None O
any None None O
significant None None O
activity None None O
. None None O

Hydrolysis None None O
of None None O
the None None O
lactone None None O
ring None None O
of None None O
the None None O
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
skeleton None None I-MODIFIER
, None None O
to None None O
give None None O
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylhex None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ammoniohexanoate None None I-IUPAC
( None None O
5 None None O
) None None O
, None None O
led None None O
to None None O
a None None O
considerable None None O
decrease None None O
in None None O
activity None None O
. None None O

The None None O
formation None None O
of None None O
a None None O
gamma None None O
- None None O
lactone None None O
ring None None O
in None None O
the None None O
side None None O
chain None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylbutyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoethyl None None I-IUPAC
] None None I-IUPAC
butan None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
olid None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
ammonium None None I-IUPAC
chloride None None I-IUPAC
( None None O
6 None None O
) None None O
, None None O
resulted None None O
in None None O
a None None O
small None None O
decrease None None O
in None None O
activity None None O
. None None O

Selective None None O
acetylation None None O
at None None O
the None None O
primary None None O
amine None None O
position None None O
of None None O
6 None None O
, None None O
to None None O
give None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylbutyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
acetylamino None None I-IUPAC
) None None I-IUPAC
butan None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
olide None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
led None None O
to None None O
a None None O
considerable None None O
decrease None None O
in None None O
activity None None O
. None None O

Both None None O
di None None O
- None None O
and None None O
triacetylated None None O
derivatives None None O
of None None O
6 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
acetoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylbutyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
acetylamino None None I-IUPAC
) None None I-IUPAC
butan None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
olide None None I-IUPAC
( None None O
8 None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
acetoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
acetoxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylbutyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
acetylamino None None I-IUPAC
) None None I-IUPAC
butan None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
olide None None I-IUPAC
( None None O
9 None None O
) None None O
, None None O
were None None O
inactive None None O
. None None O

Selective None None O
methylation None None O
of None None O
the None None O
phenolic None None I-MODIFIER
hydroxyl None None B-IUPAC
group None None B-MODIFIER
of None None O
to None None O
give None None O
1 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylbutyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ammoniohexanoate None None I-IUPAC
( None None O
15 None None O
) None None O
, None None O
resulted None None O
in None None O
a None None O
small None None O
decrease None None O
in None None O
activity None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
conversion None None O
of None None O
the None None O
carboxyl None None I-IUPAC
group None None B-MODIFIER
of None None O
the None None O
side None None O
chain None None O
to None None O
an None None O
amide None None O
, None None O
to None None O
give None None O
[ None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylbutyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hexanamido None None I-IUPAC
] None None I-IUPAC
ammonium None None I-IUPAC
chloride None None I-IUPAC
( None None O
10 None None O
) None None O
, None None O
caused None None O
a None None O
considerable None None O
increase None None O
in None None O
both None None O
activity None None O
and None None O
toxicity None None O
. None None O

The None None O
findings None None O
showed None None O
that None None O
modifications None None O
at None None O
the None None O
position None None O
of None None O
the None None O
amino None None O
acid None None O
moiety None None O
of None None O
1 None None O
significantly None None O
influenced None None O
the None None O
activity None None O
and None None O
that None None O
the None None O
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
skeleton None None I-MODIFIER
was None None O
also None None O
required None None O
for None None O
activity None None O
to None None O
occur None None O
. None None O


The None None O
binding None None O
of None None O
selective None None O
muscarinic None None O
receptor None None O
antagonists None None O
to None None O
regions None None O
of None None O
rat None None O
brain None None O
was None None O
examined None None O
through None None O
quantitative None None O
autoradiographic None None O
techniques None None O
. None None O

5,11 None None I-IUPAC
- None None I-IUPAC
Dihydro None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperazinyl None None I-IUPAC
) None None I-IUPAC
acetyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
benzodiazepin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
[ None None O
pirenzepine None None O
( None None O
compound None None O
I None None O
) None None O
] None None O
and None None O
11 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
] None None I-IUPAC
acetyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5,11 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
6H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
benzodiazepin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
[ None None O
AF None None O
- None None O
DX None None O
116 None None O
( None None O
compound None None O
II None None O
) None None O
] None None O
were None None O
chosen None None O
on None None O
the None None O
basis None None O
of None None O
their None None O
selectivity None None O
for None None O
M1 None None O
and None None O
M2 None None O
muscarinic None None O
receptors None None O
, None None O
respectively None None O
, None None O
and None None O
similarities None None O
in None None O
chemical None None O
structure None None O
. None None O

Pirenzepine None None O
displayed None None O
a None None O
higher None None O
potency None None O
than None None O
II None None O
for None None O
inhibition None None O
of None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
l None None I-IUPAC
- None None I-IUPAC
quinuclidinyl None None I-IUPAC
benzilate None None I-IUPAC
( None None O
[ None None O
3H None None O
] None None O
- None None O
l None None O
- None None O
QNB None None O
) None None O
binding None None O
to None None O
rat None None O
brain None None O
sections None None O
. None None O

Scatchard None None O
analyses None None O
of None None O
binding None None O
to None None O
brain None None O
sections None None O
revealed None None O
heterogeneous None None O
binding None None O
profiles None None O
for None None O
both None None O
antagonists None None O
, None None O
suggesting None None O
the None None O
presence None None O
of None None O
multiple None None O
receptor None None O
binding None None O
sites None None O
. None None O

Quantitative None None O
autoradiographic None None O
techniques None None O
were None None O
utilized None None O
in None None O
regional None None O
analyses None None O
of None None O
antagonist None None O
binding None None O
. None None O

Pirenzepine None None O
displayed None None O
the None None O
highest None None O
affinity None None O
for None None O
hippocampal None None O
, None None O
striatal None None O
, None None O
and None None O
amygdaloid None None O
muscarinic None None O
receptors None None O
( None None O
IC50 None None O
values None None O
less None None O
than None None O
0.4 None None O
microM None None O
) None None O
, None None O
with None None O
a None None O
slightly None None O
lower None None O
affinity None None O
for None None O
cortical None None O
receptors None None O
( None None O
IC50 None None O
values None None O
between None None O
0.4 None None O
and None None O
0.8 None None O
microM None None O
) None None O
. None None O

Pirenzepine None None O
displayed None None O
the None None O
lowest None None O
affinity None None O
for None None O
thalamic None None O
and None None O
brainstem None None O
regions None None O
with None None O
IC50 None None O
values None None O
generally None None O
greater None None O
than None None O
1.0 None None O
microM None None O
. None None O

In None None O
contrast None None O
, None None O
II None None O
bound None None O
with None None O
higher None None O
affinity None None O
to None None O
muscarinic None None O
receptors None None O
in None None O
brainstem None None O
, None None O
cerebellar None None O
, None None O
and None None O
hypothalamic None None O
nuclei None None O
( None None O
IC50 None None O
values None None O
less None None O
than None None O
0.5 None None O
microM None None O
) None None O
than None None O
to None None O
receptors None None O
in None None O
thalamic None None O
nuclei None None O
( None None O
IC50 None None O
values None None O
between None None O
0.5 None None O
and None None O
2.0 None None O
microM None None O
) None None O
. None None O

Binding None None O
sites None None O
with None None O
the None None O
lowest None None O
affinity None None O
for None None O
II None None O
were None None O
found None None O
in None None O
cortical None None O
, None None O
striatal None None O
, None None O
and None None O
hippocampal None None O
regions None None O
( None None O
IC50 None None O
values None None O
greater None None O
than None None O
2.0 None None O
microM None None O
) None None O
. None None O

The None None O
binding None None O
profiles None None O
of None None O
the None None O
two None None O
selective None None O
muscarinic None None O
antagonists None None O
reveal None None O
the None None O
complexity None None O
and None None O
diversity None None O
of None None O
muscarinic None None O
receptor None None O
subtypes None None O
throughout None None O
the None None O
brain None None O
. None None O

The None None O
data None None O
provide None None O
a None None O
basis None None O
for None None O
identifying None None O
muscarinic None None O
receptor None None O
subtypes None None O
( None None O
as None None O
defined None None O
through None None O
cloning None None O
procedures None None O
) None None O
with None None O
selective None None O
ligands None None O
. None None O

Minimum None None O
- None None O
energy None None O
conformations None None O
of None None O
pirenzepine None None O
and None None O
II None None O
were None None O
calculated None None O
by None None O
using None None O
the None None O
program None None O
MacroModel None None O
( None None O
version None None O
2.0 None None O
) None None O
. None None O

Pirenzepine None None O
displayed None None O
three None None O
energy None None O
minima None None O
, None None O
differing None None O
in None None O
the None None O
relative None None O
position None None O
of None None O
the None None O
piperazine None None O
ring None None O
with None None O
respect None None O
to None None O
the None None O
tricyclic None None O
system None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
substituent None None I-MODIFIER
on None None O
the None None O
piperidine None None O
ring None None O
conferred None None O
a None None O
much None None O
larger None None O
set None None O
of None None O
minimum None None O
- None None O
energy None None O
conformations None None O
on None None O
II None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
the None None O
greater None None O
conformational None None O
flexibility None None O
of None None O
the None None O
side None None O
chain None None O
allows None None O
II None None O
to None None O
achieve None None O
a None None O
conformation None None O
inaccessible None None O
to None None O
pirenzepine None None O
, None None O
which None None O
allows None None O
it None None O
to None None O
bind None None O
preferentially None None O
to None None O
M2 None None O
receptors None None O
. None None O


2 None None O
- None None O
[ None None O
5 None None O
- None None O
( None None O
4 None None O
- None None O
Amidinophenyl None None O
) None None O
- None None O
furan None None O
- None None O
2 None None O
- None None O
yl None None O
] None None O
- None None O
5,6,7,8 None None O
- None None O
tetrahydro None None O
- None None O
imidazo None None O
[ None None O
1,2 None None O
- None None O
a None None O
] None None O
pyridine None None O
- None None O
6 None None O
- None None O
carboxamidine None None O
acetate None None O
salt None None O
( None None O
7 None None O
) None None O
was None None O
synthesized None None O
from None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
cyanophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
furan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carbonitrile None None I-IUPAC
( None None O
4a None None O
) None None O
, None None O
through None None O
the None None O
bis None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetoxyamidoxime None None I-IUPAC
followed None None O
by None None O
hydrogenation None None O
in None None O
glacial None None O
acetic None None O
acid None None O
. None None O

Compound None None O
4a None None O
was None None O
obtained None None O
in None None O
four None None O
steps None None O
starting None None O
with None None O
two None None O
successive None None O
brominations None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
acetylfuran None None I-IUPAC
first None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
bromosuccinimide None None I-IUPAC
, None None O
and None None O
second None None O
with None None O
bromine None None O
to None None O
form None None O
alpha None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
bromofuran None None I-IUPAC
( None None O
2 None None O
) None None O
in None None O
a None None O
moderate None None O
yield None None O
. None None O

The None None O
product None None O
( None None O
3a None None O
) None None O
, None None O
of None None O
the None None O
condensation None None O
reaction None None O
between None None O
6 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
nicotinonitrile None None I-IUPAC
and None None O
2 None None O
, None None O
undergoes None None O
Suzuki None None O
coupling None None O
with None None O
4 None None I-IUPAC
- None None I-IUPAC
cyanophenylboronic None None I-IUPAC
acid None None I-IUPAC
to None None O
furnish None None O
4a None None O
in None None O
good None None O
yield None None O
. None None O

Acetate None None O
salt None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amidinophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
furan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxamidine None None I-IUPAC
( None None O
8a None None O
) None None O
was None None O
obtained None None O
from None None O
4a None None O
, None None O
through None None O
the None None O
bis None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetoxyamidoxime None None I-IUPAC
followed None None O
by None None O
hydrogenation None None O
in None None O
a None None O
mixture None None O
of None None O
ethanol None None O
/ None None O
ethyl None None O
acetate None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
Methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methoxyamidino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
furan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxamidine None None I-IUPAC
( None None O
6 None None O
) None None O
was None None O
prepared None None O
via None None O
methylation None None O
of None None O
the None None O
respective None None O
diamidoxime None None O
5a None None O
with None None O
dimethyl None None O
sulfate None None O
. None None O

By None None O
these None None O
approaches None None O
eight None None O
new None None O
diamidines None None O
and None None O
four None None O
potential None None O
prodrugs None None O
were None None O
prepared None None O
. None None O

All None None O
of None None O
the None None O
diamidines None None O
showed None None O
strong None None O
DNA None None O
affinities None None O
as None None O
judged None None O
by None None O
high None None O
DeltaT None None O
( None None O
m None None O
) None None O
values None None O
. None None O

Six None None O
of None None O
the None None O
eight None None O
diamidines None None O
gave None None O
in None None O
vitro None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
of None None O
63 None None O
nM None None O
or None None O
less None None O
vs None None O
T None None O
. None None O

b None None O
. None None O

rhodesiense None None O
with None None O
two None None O
exhibiting None None O
values None None O
of None None O
6 None None O
nM None None O
and None None O
1 None None O
nM None None O
. None None O

Also None None O
, None None O
six None None O
of None None O
the None None O
eight None None O
diamidines None None O
gave None None O
in None None O
vitro None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
of None None O
88 None None O
nM None None O
or None None O
less None None O
vs None None O
P None None O
. None None O

falciparum None None O
with None None O
two None None O
exhibiting None None O
values None None O
of None None O
14 None None O
nM None None O
. None None O

Excellent None None O
in None None O
vivo None None O
activity None None O
in None None O
the None None O
trypanosomal None None O
STIB900 None None O
mouse None None O
model None None O
was None None O
found None None O
for None None O
five None None O
of None None O
the None None O
diamidines None None O
on None None O
ip None None O
dosage None None O
; None None O
these None None O
compounds None None O
gave None None O
4/4 None None O
cures None None O
in None None O
this None None O
model None None O
. None None O

The None None O
oral None None O
activity None None O
of None None O
the None None O
prodrugs None None O
was None None O
modest None None O
with None None O
only None None O
one None None O
showing None None O
2/4 None None O
cures None None O
in None None O
the None None O
same None None O
mouse None None O
model None None O
. None None O


Condensation None None O
of None None O
cyanothioacetamide None None O
( None None O
4 None None O
) None None O
with None None O
ethyl None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxymethylene None None I-IUPAC
) None None I-IUPAC
acetoacetate None None I-IUPAC
( None None O
5b None None O
) None None O
, None None O
ethyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxymethylene None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxobutanoate None None I-IUPAC
( None None O
5c None None O
) None None O
, None None O
ethyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxymethylene None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenylpropanoate None None I-IUPAC
( None None O
5d None None O
) None None O
afforded None None O
exclusively None None O
the None None O
corresponding None None O
6 None None O
- None None O
substituted None None O
pyridines None None O
( None None O
6b None None O
- None None O
d None None O
) None None O
. None None O

Cyclization None None O
of None None O
4 None None O
with None None O
3 None None I-IUPAC
- None None I-IUPAC
carbethoxybutane None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
( None None O
5e None None O
) None None O
gave None None O
3 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4,6 None None I-IUPAC
- None None I-IUPAC
dimethylpyridine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
thione None None I-IUPAC
( None None O
6e None None O
) None None O
, None None O
whereas None None O
reaction None None O
of None None O
4 None None O
with None None O
3 None None I-IUPAC
- None None I-IUPAC
carbethoxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenylpropane None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
( None None O
5f None None O
) None None O
yielded None None O
two None None O
products None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
phenylpyridine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
thione None None I-IUPAC
( None None O
6f None None O
) None None O
and None None O
the None None O
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
isomer None None I-MODIFIER
6g None None O
. None None O

The None None O
structural None None O
assignments None None O
for None None O
6f None None O
and None None O
6g None None O
are None None O
made None None O
on None None O
the None None O
basis None None O
of None None O
1H None None O
and None None O
13C None None O
NMR None None O
spectral None None O
analyses None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
nicotinates None None I-IUPAC
( None None O
7f None None O
, None None O
g None None O
) None None O
prepared None None O
from None None O
6f None None O
and None None O
6g None None O
by None None O
treatment None None O
with None None O
MeI None None O
/ None None O
K2CO3 None None O
. None None O

Nicotinates None None O
7b None None O
, None None O
d None None O
- None None O
g None None O
were None None O
converted None None O
into None None O
their None None O
corresponding None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diaminopyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
12b None None O
, None None O
d None None O
- None None O
g None None O
in None None O
five None None O
steps None None O
, None None O
via None None O
reduction None None O
, None None O
protection None None O
, None None O
oxidation None None O
, None None O
condensation None None O
with None None O
guanidine None None O
, None None O
and None None O
deprotection None None O
. None None O

The None None O
7 None None I-MODIFIER
- None None I-MODIFIER
mono None None I-MODIFIER
- None None I-MODIFIER
and None None O
5,7 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
- None None O
5 None None I-IUPAC
- None None I-IUPAC
deazaaminopterins None None I-IUPAC
( None None O
1b None None O
, None None O
d None None O
- None None O
g None None O
) None None O
were None None O
prepared None None O
from None None O
the None None O
respective None None O
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
12b None None O
, None None O
d None None O
- None None O
g None None O
. None None O

Preliminary None None O
biological None None O
studies None None O
showed None None O
that None None O
7 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
and None None O
5,7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
analogues None None I-MODIFIER
( None None O
1b None None O
and None None O
1e None None O
) None None O
were None None O
less None None O
active None None O
than None None O
methotrexate None None O
against None None O
human None None O
leukemic None None O
HL None None O
- None None O
60 None None O
and None None O
murine None None O
L None None O
- None None O
1210 None None O
cells None None O
in None None O
tissue None None O
culture None None O
. None None O

Compound None None O
1e None None O
produced None None O
an None None O
ILS None None O
of None None O
71% None None O
at None None O
100 None None O
mg None None O
/ None None O
kg None None O
per None None O
day None None O
X None None O
5 None None O
( None None O
ip None None O
) None None O
in None None O
BDF None None O
mice None None O
inoculated None None O
ip None None O
with None None O
10 None None O
( None None O
6 None None O
) None None O
L None None O
- None None O
1210 None None O
cells None None O
. None None O


In None None O
a None None O
sequence None None O
of None None O
reactions None None O
, None None O
methyl None None O
mesopyropheophorbide None None O
a None None O
, None None O
mesochlorin None None I-IUPAC
e None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
trimethyl None None I-IUPAC
ester None None I-IUPAC
, None None O
mesochlorin None None I-IUPAC
p None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
trimethyl None None I-IUPAC
ester None None I-IUPAC
, None None O
mesopurpurin None None I-IUPAC
- None None I-IUPAC
18 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
hexylimide None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
, None None O
and None None O
mesopurpurin None None I-IUPAC
- None None I-IUPAC
18 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
benzylimide None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
were None None O
synthesized None None O
from None None O
chlorophyll None None O
- None None O
a None None O
. None None O

These None None O
chlorins None None O
on None None O
reacting None None O
with None None O
osmium None None O
tetraoxide None None O
produced None None O
the None None O
corresponding None None O
vic None None O
- None None O
dihydroxybacteriochlorins None None O
. None None O

The None None O
8 None None I-IUPAC
- None None I-IUPAC
vinylchlorins None None I-IUPAC
obtained None None O
by None None O
refluxing None None O
the None None O
related None None O
vic None None O
- None None O
dihydroxybacteriochlorins None None O
in None None O
o None None I-IUPAC
- None None I-IUPAC
dichlorobenzene None None I-IUPAC
were None None O
individually None None O
treated None None O
with None None O
dimethylacetylenedicarboxylate None None I-IUPAC
( None None O
DMAD None None O
) None None O
under None None O
Diels None None O
- None None O
Alder None None O
reaction None None O
conditions None None O
. None None O

The None None O
intermediate None None O
adducts None None O
on None None O
1,8 None None I-IUPAC
- None None I-IUPAC
diazabicyclo None None I-IUPAC
[ None None I-IUPAC
5.4.0 None None I-IUPAC
] None None I-IUPAC
undec None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
ene None None I-IUPAC
( None None O
DBU None None O
) None None O
treatment None None O
rearranged None None O
to None None O
the None None O
corresponding None None O
stable None None O
benzobacteriochlorins None None O
, None None O
exhibiting None None O
the None None O
longest None None O
wavelength None None O
absorption None None O
in None None O
the None None O
range None None O
of None None O
737 None None O
to None None O
805 None None O
nm None None O
. None None O

In None None O
preliminary None None O
in None None O
vitro None None O
( None None O
RIF None None O
tumor None None O
cells None None O
) None None O
and None None O
in None None O
vivo None None O
screening None None O
( None None O
C3H None None O
/ None None O
HeJ None None O
mice None None O
bearing None None O
RIF None None O
tumors None None O
) None None O
, None None O
some None None O
of None None O
these None None O
compounds None None O
were None None O
found None None O
to None None O
be None None O
quite None None O
effective None None O
. None None O

Under None None O
similar None None O
treatment None None O
conditions None None O
( None None O
drug None None O
dose None None O
: None None O
5.0 None None O
micromol None None O
/ None None O
kg None None O
; None None O
light None None O
dose None None O
: None None O
135 None None O
J None None O
/ None None O
cm None None O
( None None O
2 None None O
) None None O
, None None O
tumors None None O
were None None O
exposed None None O
to None None O
light None None O
for None None O
30 None None O
min None None O
at None None O
24 None None O
h None None O
postinjection None None O
) None None O
, None None O
the None None O
benzobacteriochlorins None None O
containing None None O
N None None O
- None None O
substituted None None O
- None None O
imide None None O
ring None None O
system None None O
produced None None O
enhanced None None O
photosensitizing None None O
efficacy None None O
with None None O
limited None None O
skin None None O
phototoxicity None None O
. None None O

These None None O
compounds None None O
were None None O
also None None O
found None None O
to None None O
bind None None O
to None None O
site None None O
II None None O
of None None O
human None None O
serum None None O
albumin None None O
( None None O
HSA None None O
) None None O
. None None O

However None None O
, None None O
no None None O
correlation None None O
between None None O
the None None O
binding None None O
constant None None O
values None None O
and None None O
photosensitizing None None O
efficacy None None O
was None None O
observed None None O
. None None O

A None None O
competitive None None O
intracellular None None O
localization None None O
study None None O
of None None O
these None None O
novel None None O
structures None None O
with None None O
Rhodamine None None O
- None None O
123 None None O
( None None O
a None None O
mitochondrial None None O
probe None None O
) None None O
indicated None None O
their None None O
preferential None None O
localization None None O
in None None O
mitochondria None None O
, None None O
without None None O
producing None None O
any None None O
specific None None O
displacement None None O
of None None O
( None None O
3 None None O
) None None O
H None None O
- None None O
PK11195 None None O
( None None O
PBR None None O
probe None None O
, None None O
( None None I-MODIFIER
3 None None I-MODIFIER
) None None I-MODIFIER
H None None I-MODIFIER
- None None I-MODIFIER
labeled None None I-MODIFIER
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methylpropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
isoquinoline None None I-IUPAC
carboxamide None None I-IUPAC
) None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
mitochondrial None None O
peripheral None None O
benzodiazepine None None O
receptor None None O
( None None O
PBR None None O
) None None O
is None None O
not None None O
the None None O
cellular None None O
binding None None O
site None None O
for None None O
this None None O
class None None O
of None None O
compounds None None O
. None None O


7 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,6 None None I-IUPAC
- None None I-IUPAC
naphthyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
are None None O
potent None None O
inhibitors None None O
of None None O
protein None None O
tyrosine None None O
kinases None None O
, None None O
with None None O
some None None O
selectivity None None O
for None None O
c None None O
- None None O
Src None None O
. None None O

The None None O
compounds None None O
were None None O
prepared None None O
by None None O
condensing None None O
4 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
diaminonicotinaldehyde None None I-IUPAC
with None None O
2,6 None None I-IUPAC
- None None I-IUPAC
dichlorophenylacetonitrile None None I-IUPAC
and None None O
selectively None None O
converting None None O
the None None O
2 None None O
- None None O
and None None O
7 None None O
- None None O
amino None None O
groups None None O
of None None O
the None None O
product None None O
to None None O
hydroxy None None O
and None None O
fluoro None None O
groups None None O
, None None O
respectively None None O
, None None O
by None None O
prolonged None None O
diazotization None None O
in None None O
50% None None O
aqueous None None O
fluoboric None None O
acid None None O
. None None O

N None None O
- None None O
Methylation None None O
, None None O
followed None None O
by None None O
treatment None None O
with None None O
aliphatic None None O
diamines None None O
, None None O
aromatic None None O
amines None None O
, None None O
or None None O
their None None O
derived None None O
lithium None None O
anions None None O
, None None O
gave None None O
the None None O
desired None None O
compounds None None O
. None None O

Selected None None O
isomeric None None O
1 None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
naphthyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
were None None O
also None None O
prepared None None O
in None None O
order None None O
to None None O
evaluate None None O
the None None O
relative None None O
contributions None None O
of None None O
both None None O
ring None None O
A None None O
aza None None O
atoms None None O
of None None O
the None None O
related None None O
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
( None None I-IUPAC
8H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
to None None O
the None None O
inhibitory None None O
activity None None O
. None None O

The None None O
compounds None None O
were None None O
evaluated None None O
for None None O
their None None O
ability None None O
to None None O
prevent None None O
phosphorylation None None O
of None None O
a None None O
model None None O
substrate None None O
by None None O
c None None O
- None None O
Src None None O
, None None O
FGF None None O
- None None O
1 None None O
receptor None None O
, None None O
and None None O
PDGF None None O
- None None O
beta None None O
receptor None None O
enzymes None None O
. None None O

Overall None None O
, None None O
there None None O
was None None O
a None None O
high None None O
degree None None O
of None None O
correlation None None O
of None None O
the None None O
activities None None O
against None None O
the None None O
different None None O
kinases None None O
, None None O
with None None O
c None None O
- None None O
Src None None O
being None None O
generally None None O
the None None O
most None None O
sensitive None None O
to None None O
structural None None O
changes None None O
. None None O

1 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
Naphthyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
analogues None None I-MODIFIER
bearing None None O
basic None None O
aliphatic None None O
side None None O
chains None None O
[ None None O
7 None None O
- None None O
NH None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
n None None O
) None None O
( None None O
) None None O
NRR None None O
, None None O
7 None None O
- None None O
NHPhO None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
n None None O
) None None O
( None None O
) None None O
NRR None None O
, None None O
or None None O
7 None None O
- None None O
NHPhN None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
4 None None O
) None None O
NMe None None O
] None None O
were None None O
the None None O
most None None O
potent None None O
against None None O
c None None O
- None None O
Src None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
s None None O
of None None O
10-80 None None O
nM None None O
) None None O
, None None O
showing None None O
good None None O
selectivity None None O
with None None O
respect None None O
to None None O
PDGFR None None O
( None None O
10-300 None None O
- None None O
fold None None O
) None None O
but None None O
less None None O
with None None O
respect None None O
to None None O
FGFR None None O
. None None O

The None None O
1 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
naphthyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
showed None None O
broadly None None O
similar None None O
activity None None O
to None None O
the None None O
analogous None None I-MODIFIER
pyrido None None B-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
( None None I-IUPAC
8H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
whereas None None O
the None None O
1 None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
naphthyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
were None None O
at None None O
least None None O
10 None None O
( None None O
3 None None O
) None None O
- None None O
fold None None O
less None None O
potent None None O
. None None O

These None None O
results None None O
, None None O
indicating None None O
that None None O
the None None O
3 None None O
- None None O
aza None None O
atom None None O
in None None O
the None None O
pyrido None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
( None None I-IUPAC
8H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
is None None O
mandatory None None O
, None None O
whereas None None O
the None None O
1 None None O
- None None O
aza None None O
atom None None O
is None None O
not None None O
, None None O
support None None O
the None None O
published None None O
binding None None O
model None None O
for None None O
these None None O
compounds None None O
to None None O
c None None O
- None None O
Src None None O
( None None O
J None None O
. None None O

Med. None None O
Chem. None None O
1998 None None O
, None None O
41 None None O
, None None O
1752 None None O
) None None O
, None None O
where None None O
the None None O
3 None None O
- None None O
aza None None O
and None None O
2 None None O
- None None O
NH None None O
atoms None None O
form None None O
a None None O
bidentate None None O
H None None O
- None None O
bond None None O
donor None None O
- None None O
acceptor None None O
motif None None O
that None None O
interacts None None O
with None None O
Met341 None None O
and None None O
the None None O
1 None None O
- None None O
aza None None O
atom None None O
is None None O
not None None O
involved None None O
in None None O
specific None None O
binding None None O
interactions None None O
. None None O


beta None None O
- None None O
( None None O
1 None None O
- None None O
Chloro None None O
- None None O
2 None None O
- None None O
naphthyl None None O
) None None O
alanine None None O
and None None O
beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
were None None O
synthesized None None O
by None None O
ammonolysis None None O
of None None O
the None None O
corresponding None None O
alpha None None I-IUPAC
, None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
dihalo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthalenepropanoic None None I-IUPAC
acids None None I-IUPAC
derived None None O
from None None O
1 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthylamine None None I-IUPAC
by None None O
diazotization None None O
and None None O
condensation None None O
with None None O
acrylic None None O
acid None None O
in None None O
the None None O
presence None None O
of None None O
cuprous None None O
halides None None O
. None None O

The None None O
two None None O
analogs None None O
as None None O
well None None O
as None None O
the None None O
previously None None O
reported None None O
beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
and None None O
beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
were None None O
studied None None O
as None None O
growth None None O
inhibitors None None O
of None None O
Escherichia None None O
coli None None O
9723 None None O
, None None O
Leuconostoc None None O
dextranicum None None O
8086 None None O
, None None O
and None None O
Lactobacillus None None O
plantarum None None O
8014 None None O
. None None O

In None None O
general None None O
, None None O
the None None O
chloro None None O
and None None O
bromo None None O
analogs None None O
were None None O
more None None O
effective None None O
than None None O
the None None O
unsubstituted None None O
naphthylalanines None None O
as None None O
growth None None O
inhibitors None None O
of None None O
the None None O
three None None O
microorganisms None None O
studied None None O
. None None O


Several None None O
6 None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
analogs None None I-MODIFIER
of None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
( None None O
1 None None O
; None None O
HEPT None None O
) None None O
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
their None None O
anti None None O
- None None O
HIV None None O
- None None O
1 None None O
activity None None O
. None None O

LDA None None O
( None None O
lithium None None O
diisopropylamide None None O
) None None O
lithiation None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
ethyluracil None None I-IUPAC
derivatives None None I-MODIFIER
7 None None O
and None None O
8 None None O
and None None O
subsequent None None O
reaction None None O
with None None O
an None None O
aryl None None O
aldehyde None None O
gave None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylhydroxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ethyluracil None None I-IUPAC
derivatives None None I-MODIFIER
9-12 None None O
. None None O

6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Arylhydroxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
isopropyluracil None None I-IUPAC
derivatives None None I-MODIFIER
15-18 None None O
were None None O
prepared None None O
from None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thiouracil None None I-IUPAC
derivatives None None I-MODIFIER
13 None None O
and None None O
14 None None O
by None None O
the None None O
above None None O
procedure None None O
following None None O
oxidative None None O
hydrolysis None None O
of None None O
the None None O
thione None None O
. None None O

Preparation None None O
of None None O
the None None O
target None None O
5 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alkoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
benzyluracil None None I-IUPAC
derivatives None None I-MODIFIER
27-34 None None O
was None None O
carried None None O
out None None O
by None None O
acetylation None None O
of None None O
9-14 None None O
followed None None O
by None None O
Pd None None O
- None None O
catalyzed None None O
hydrogenolysis None None O
. None None O

The None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
butyl None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
37 None None O
and None None O
39 None None O
) None None O
and None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
38 None None O
and None None O
40 None None O
) None None O
5 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
benzyluracils None None I-IUPAC
were None None O
synthesized None None O
by None None O
1 None None O
- None None O
alkylation None None O
of None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
phenacyl None None I-IUPAC
derivatives None None I-MODIFIER
35 None None O
and None None O
36 None None O
with None None O
alkyl None None O
halides None None O
followed None None O
by None None O
deprotection None None O
of None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
phenacyl None None I-IUPAC
group None None I-MODIFIER
. None None O

Compounds None None O
synthesized None None O
in None None O
this None None O
study None None O
inhibited None None O
HIV None None O
- None None O
1 None None O
replication None None O
in None None O
MT None None O
- None None O
4 None None O
cells None None O
in None None O
the None None O
submicromolar None None O
to None None O
namomolar None None O
concentration None None O
range None None O
. None None O

From None None O
this None None O
series None None O
of None None O
compounds None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
isopropyluracil None None I-IUPAC
( None None O
33 None None O
) None None O
was None None O
selected None None O
for None None O
clinical None None O
evaluation None None O
. None None O


The None None O
novel None None O
semirigid None None O
derivatives None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bicyclo None None I-IUPAC
[ None None I-IUPAC
3.1.0 None None I-IUPAC
] None None I-IUPAC
hexyl None None I-IUPAC
] None None I-IUPAC
piperidine None None I-IUPAC
[ None None O
( None None O
+ None None O
) None None O
- None None O
8 None None O
] None None O
, None None O
its None None O
enantiomer None None O
( None None I-PARTIUPAC
- None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
8 None None I-PARTIUPAC
, None None O
and None None O
( None None I-IUPAC
+ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bicyclo None None I-IUPAC
[ None None I-IUPAC
3.1.0 None None I-IUPAC
] None None I-IUPAC
hexyl None None I-IUPAC
] None None I-IUPAC
piperidine None None I-IUPAC
[ None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
9 None None O
] None None O
were None None O
synthesized None None O
as None None O
probes None None O
to None None O
investigate None None O
the None None O
mode None None O
of None None O
interaction None None O
of None None O
phencyclidine None None O
( None None O
PCP None None O
) None None O
with None None O
its None None O
binding None None O
site None None O
on None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
aspartate None None I-IUPAC
receptor None None O
complex None None O
. None None O

Each None None O
target None None O
compound None None O
was None None O
obtained None None O
in None None O
five None None O
steps None None O
starting None None O
from None None O
cyclopent None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
enone None None I-IUPAC
. None None O

( None None O
+ None None O
) None None O
- None None O
and None None O
( None None O
- None None O
) None None O
- None None O
8 None None O
were None None O
obtained None None O
in None None O
greater None None O
than None None O
98% None None O
optical None None O
purity None None O
through None None O
three None None O
recrystallizations None None O
from None None O
ethanol None None O
of None None O
the None None O
( None None I-PARTIUPAC
S None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
+ None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
mandelate None None I-IUPAC
salts None None I-IUPAC
of None None O
intermediate None None O
( None None I-IUPAC
+ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bicyclo None None I-IUPAC
[ None None I-IUPAC
3.1.0 None None I-IUPAC
] None None I-IUPAC
hexylamine None None I-IUPAC
( None None O
[ None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
16 None None O
] None None O
. None None O

Crystallization None None O
of None None O
the None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
mandelate None None I-IUPAC
salt None None I-IUPAC
afforded None None O
( None None O
1R None None O
, None None O
2R None None O
, None None O
5S None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
16 None None O
, None None O
whereas None None O
the None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
mandelate None None I-IUPAC
salt None None I-IUPAC
afforded None None O
( None None O
1S None None O
, None None O
2S None None O
, None None O
5R None None O
) None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
16 None None O
; None None O
the None None O
absolute None None O
configuration None None O
was None None O
determined None None O
by None None O
single None None O
- None None O
crystal None None O
X None None O
- None None O
ray None None O
analysis None None O
of None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
16 None None I-IUPAC
. None None I-IUPAC

( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
mandelate None None I-IUPAC
. None None O

Single None None O
- None None O
crystal None None O
X None None O
- None None O
ray None None O
analysis None None O
of None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
picrate None None I-IUPAC
confirmed None None O
its None None O
trans None None O
configuration None None O
and None None O
provided None None O
conformational None None O
data None None O
. None None O

( None None O
+ None None O
) None None O
- None None O
and None None O
( None None O
- None None O
) None None O
- None None O
8 None None O
and None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
9 None None O
were None None O
examined None None O
for None None O
their None None O
ability None None O
to None None O
interact None None O
with None None O
PCP None None O
and None None O
sigma None None O
binding None None O
sites None None O
in None None O
vitro None None O
using None None O
[ None None O
3H None None O
] None None O
TCP None None O
and None None O
[ None None O
3H None None O
] None None O
pentazocine None None O
as None None O
radioligands None None O
. None None O

The None None O
binding None None O
was None None O
compared None None O
with None None O
that None None O
of None None O
PCP None None O
and None None O
contrasted None None O
with None None O
the None None O
rigid None None O
symmetrical None None O
phencyclidine None None O
derivatives None None O
cis None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
bicyclo None None I-IUPAC
[ None None I-IUPAC
3.1.0 None None I-IUPAC
] None None I-IUPAC
hexyl None None I-IUPAC
] None None I-IUPAC
piperidines None None I-IUPAC
( None None O
6 None None O
and None None O
7 None None O
) None None O
. None None O

The None None O
results None None O
of None None O
the None None O
study None None O
indicated None None O
that None None O
the None None O
conformations None None O
of None None O
PCP None None O
represented None None O
by None None O
6-9 None None O
are None None O
not None None O
optimal None None O
for None None O
potent None None O
interaction None None O
at None None O
either None None O
of None None O
these None None O
sites None None O
. None None O

Affinities None None O
ranged None None O
from None None O
582 None None O
nM None None O
[ None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
9 None None O
] None None O
to None None O
29,000 None None O
nM None None O
[ None None O
( None None O
+ None None O
) None None O
- None None O
8 None None O
] None None O
at None None O
PCP None None O
binding None None O
sites None None O
and None None O
from None None O
1130 None None O
nM None None O
[ None None O
( None None O
- None None O
) None None O
- None None O
8 None None O
] None None O
to None None O
16,300 None None O
nM None None O
( None None O
7 None None O
) None None O
at None None O
sigma None None O
sites None None O
. None None O

In None None O
this None None O
assay None None O
, None None O
PCP None None O
exhibited None None O
affinities None None O
of None None O
64.5 None None O
nM None None O
at None None O
PCP None None O
and None None O
1090 None None O
nM None None O
at None None O
sigma None None O
sites None None O
. None None O

Qualitative None None O
correlation None None O
between None None O
the None None O
sigma None None O
and None None O
PCP None None O
binding None None O
data None None O
suggests None None O
some None None O
similarities None None O
between None None O
these None None O
binding None None O
sites None None O
. None None O

An None None O
axial None None O
phenyl None None I-MODIFIER
and None None O
equatorial None None I-MODIFIER
piperidine None None B-IUPAC
ring None None B-MODIFIER
with None None O
the None None O
nitrogen None None O
lone None None O
pair None None O
of None None O
electrons None None O
antiperiplanar None None O
to None None O
the None None O
phenyl None None I-IUPAC
ring None None B-MODIFIER
has None None O
been None None O
postulated None None O
as None None O
the None None O
receptor None None O
- None None O
active None None O
conformation None None O
of None None O
PCP None None O
- None None O
like None None O
ligands None None O
at None None O
the None None O
PCP None None O
binding None None O
site None None O
. None None O

Comparison None None O
of None None O
the None None O
binding None None O
data None None O
of None None O
7-9 None None O
with None None O
that None None O
of None None O
the None None O
previously None None O
described None None O
methylcyclohexyl None None O
- None None O
PCP None None O
derivatives None None O
allowed None None O
its None None O
rationalization None None O
in None None O
terms None None O
of None None O
this None None O
model None None O
. None None O

It None None O
is None None O
likely None None O
that None None O
the None None O
lowered None None O
affinity None None O
in None None O
this None None O
bicyclo None None I-IUPAC
[ None None I-IUPAC
3.1.0 None None I-IUPAC
] None None I-IUPAC
hexane None None I-IUPAC
series None None I-MODIFIER
is None None O
a None None O
consequence None None O
of None None O
nonoptimal None None O
geometry None None O
( None None O
pseudoequatorial None None O
phenyl None None O
or None None O
pseudoboat None None O
) None None O
for None None O
binding None None O
as None None O
opposed None None O
to None None O
the None None O
presence None None O
of None None O
steric None None O
bulk None None O
which None None O
proved None None O
deleterious None None O
in None None O
the None None O
methylcyclohexyl None None O
- None None O
PCP None None O
derivatives None None O
. None None O


N10 None None I-IUPAC
- None None I-IUPAC
Propargylfolic None None I-IUPAC
acid None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
which None None O
is None None O
the None None O
closest None None O
pteridine None None O
analogue None None O
of None None O
the None None O
thymidylate None None O
synthase None None O
inhibitor None None O
N10 None None I-IUPAC
- None None I-IUPAC
propargyl None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dideazafolic None None I-IUPAC
acid None None I-IUPAC
( None None O
PDDF None None O
) None None O
, None None O
was None None O
synthesized None None O
starting None None O
from None None O
diethyl None None I-IUPAC
[ None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
propargylamino None None I-IUPAC
) None None I-IUPAC
benzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
( None None O
5 None None O
) None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxopropyl None None I-IUPAC
) None None I-IUPAC
phthalimide None None I-IUPAC
( None None O
8 None None O
) None None O
. None None O

The None None O
7,8 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
derivative None None I-MODIFIER
of None None O
propargylfolic None None O
acid None None O
served None None O
as None None O
a None None O
synthetic None None O
substrate None None O
of None None O
Lactobacillus None None O
casei None None O
dihydrofolate None None O
reductase None None O
. None None O

Propargylfolic None None O
acid None None O
and None None O
its None None O
reduced None None O
derivatives None None O
were None None O
weak None None O
inhibitors None None O
of None None O
L None None O
. None None O

casei None None O
thymidylate None None O
synthase None None O
compared None None O
to None None O
PDDF None None O
. None None O

All None None O
derivatives None None O
of None None O
propargylfolate None None O
were None None O
active None None O
against None None O
the None None O
growth None None O
of None None O
Streptococcus None None O
faecium None None O
, None None O
but None None O
with None None O
the None None O
exception None None O
of None None O
7,8 None None I-IUPAC
- None None I-IUPAC
dihydropropargylfolic None None I-IUPAC
acid None None I-IUPAC
, None None O
all None None O
were None None O
inactive None None O
against None None O
L None None O
. None None O

casei None None O
. None None O

Although None None O
less None None O
potent None None O
than None None O
PDDF None None O
, None None O
marked None None O
inhibition None None O
of None None O
thymidylate None None O
synthase None None O
by None None O
2 None None O
was None None O
observed None None O
in None None O
permeabilized None None O
L1210 None None O
cells None None O
. None None O


Xanthine None None O
derivatives None None O
with None None O
several None None O
functional None None O
groups None None O
at None None O
the None None O
1 None None O
- None None O
or None None O
7 None None O
- None None O
position None None O
were None None O
synthesized None None O
, None None O
and None None O
their None None O
pharmacological None None O
activities None None O
in None None O
guinea None None O
pigs None None O
were None None O
studied None None O
. None None O

In None None O
general None None O
, None None O
the None None O
in None None O
vitro None None O
tracheal None None O
relaxant None None O
action None None O
and None None O
positive None None O
chronotropic None None O
action None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
propylxanthines None None I-IUPAC
were None None O
increased None None O
by None None O
substitutions None None O
with None None O
nonpolar None None O
functional None None O
groups None None O
at None None O
the None None O
1 None None O
- None None O
position None None O
, None None O
but None None O
decreased None None O
by None None O
any None None O
substitution None None O
at None None O
the None None O
7 None None O
- None None O
position None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
because None None O
positive None None O
chronotropic None None O
actions None None O
of None None O
substituents None None I-MODIFIER
with None None O
allyl None None I-IUPAC
, None None O
aminoalkyl None None I-IUPAC
, None None O
alkoxyalkyl None None I-IUPAC
, None None O
and None None O
normal None None O
alkyl None None I-IUPAC
groups None None B-MODIFIER
were None None O
much None None O
less None None O
than None None O
tracheal None None O
muscle None None O
became None None O
very None None O
high None None O
with None None O
substitutions None None I-MODIFIER
of None None O
3' None None I-IUPAC
- None None I-IUPAC
butenyl None None I-IUPAC
, None None O
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
, None None O
2' None None I-IUPAC
- None None I-IUPAC
ethoxyethyl None None I-IUPAC
, None None O
3' None None I-IUPAC
- None None I-IUPAC
methoxypropyl None None I-IUPAC
, None None O
and None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
groups None None I-MODIFIER
at None None O
the None None O
1 None None O
- None None O
position None None O
and None None O
of None None O
2' None None I-IUPAC
- None None I-IUPAC
ethoxyethyl None None I-IUPAC
, None None O
2' None None I-IUPAC
- None None I-IUPAC
oxopropyl None None I-IUPAC
, None None O
and None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
groups None None I-MODIFIER
at None None O
the None None O
7 None None O
- None None O
position None None O
, None None O
compared None None O
with None None O
theophylline None None O
and None None O
the None None O
corresponding None None O
unsubstituted None None O
xanthines None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
propylxanthine None None I-IUPAC
and None None O
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
propylxanthine None None I-IUPAC
. None None O

When None None O
compounds None None O
were None None O
intraduodenally None None O
administered None None O
to None None O
the None None O
guinea None None O
pig None None O
, None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2' None None I-PARTIUPAC
- None None I-PARTIUPAC
ethoxyethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3' None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxypropyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3' None None I-PARTIUPAC
- None None I-PARTIUPAC
butenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
propylxanthines None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
oxopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
propylxanthine None None I-IUPAC
, None None O
and None None O
denbufylline None None O
( None None O
1,3 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
oxopropyl None None I-IUPAC
) None None I-IUPAC
xanthine None None I-IUPAC
) None None O
effectively None None O
inhibited None None O
the None None O
acetylcholine None None O
- None None O
induced None None O
bronchospasm None None O
without None None O
heart None None O
stimulation None None O
or None None O
central None None O
nervous None None O
system None None O
- None None O
stimulation None None O
at None None O
the None None O
effective None None O
dosage None None O
range None None O
. None None O

Particularly None None O
, None None O
the None None O
bronchodilatory None None O
effect None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
ethoxyethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
propylxanthine None None I-IUPAC
was None None O
much None None O
stronger None None O
and None None O
more None None O
continuous None None O
than None None O
those None None O
of None None O
theophylline None None O
and None None O
pentoxifylline None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
there None None O
were None None O
certain None None O
relationships None None O
among None None O
the None None O
in None None O
vitro None None O
tracheal None None O
relaxant None None O
activities None None O
of None None O
these None None O
compounds None None O
, None None O
their None None O
affinities None None O
for None None O
adenosine None None O
( None None O
A1 None None O
) None None O
receptors None None O
in None None O
the None None O
brain None None O
membrane None None O
, None None O
and None None O
their None None O
inhibition None None O
of None None O
cyclic None None O
AMP None None O
- None None O
phosphodiesterase None None O
( None None O
PDE None None O
) None None O
in None None O
the None None O
tracheal None None O
muscle None None O
. None None O

The None None O
affinity None None O
for None None O
A2 None None O
receptors None None O
of None None O
these None None O
compounds None None O
was None None O
very None None O
low None None O
or None None O
negligible None None O
. None None O

This None None O
suggests None None O
that None None O
both None None O
the None None O
action None None O
on None None O
A1 None None O
receptors None None O
or None None O
interaction None None O
with None None O
adenosine None None O
and None None O
the None None O
cyclic None None O
AMP None None O
- None None O
PDE None None O
inhibitory None None O
activity None None O
contribute None None O
to None None O
the None None O
bronchodilator None None O
action None None O
of None None O
1 None None O
- None None O
and None None O
7 None None O
- None None O
substituted None None O
xanthines None None O
. None None O

This None None O
study None None O
indicates None None O
that None None O
the None None O
substitutions None None O
with None None O
none None None O
or None None O
low None None O
polar None None O
functional None None O
groups None None O
at None None O
the None None O
1 None None O
- None None O
position None None O
could None None O
improve None None O
the None None O
selectivity None None O
and None None O
duration None None O
of None None O
the None None O
bronchodilator None None O
effects None None O
of None None O
xanthines None None O
. None None O


The None None O
synthesis None None O
of None None O
5,11 None None I-IUPAC
- None None I-IUPAC
methenyltetrahydrohomofolate None None I-IUPAC
was None None O
accomplished None None O
by None None O
treatment None None O
of None None O
tetrahydrohomofolate None None O
( None None O
H4homofolate None None O
) None None O
with None None O
triethyl None None O
orthoformate None None O
in None None O
glacial None None O
acetic None None O
acid None None O
. None None O

This None None O
compound None None O
is None None O
a None None O
homofolate None None O
analogue None None O
of None None O
5,10 None None I-IUPAC
- None None I-IUPAC
methenyltetrahydrofolate None None I-IUPAC
which None None O
serves None None O
as None None O
one None None O
precursor None None O
to None None O
the None None O
10 None None O
- None None O
formyl None None O
one None None O
- None None O
carbon None None O
donor None None O
for None None O
the None None O
first None None O
transformylation None None O
in None None O
de None None O
novo None None O
purine None None O
biosynthesis None None O
, None None O
namely None None O
, None None O
the None None O
conversion None None O
of None None O
glycinamide None None O
ribonucleotide None None O
( None None O
GAR None None O
) None None O
to None None O
N None None I-IUPAC
- None None I-IUPAC
formylglycinamide None None I-IUPAC
ribonucleotide None None I-IUPAC
( None None O
FGAR None None O
) None None O
, None None O
catalyzed None None O
by None None O
the None None O
enzyme None None O
glycinamide None None O
ribonucleotide None None O
transformylase None None O
( None None O
EC None None O
2.1.2.2 None None O
) None None O
. None None O

The None None O
analogue None None O
proved None None O
to None None O
retard None None O
the None None O
rate None None O
of None None O
formation None None O
of None None O
formylglycinamide None None O
ribonucleotide None None O
apparently None None O
by None None O
inhibiting None None O
the None None O
rate None None O
of None None O
synthesis None None O
of None None O
10 None None I-IUPAC
- None None I-IUPAC
formyltetrahydrofolate None None I-IUPAC
, None None O
the None None O
actual None None O
cofactor None None O
for None None O
the None None O
transformylase None None O
enzyme None None O
, None None O
from None None O
5,10 None None I-IUPAC
- None None I-IUPAC
methenyltetrahydrofolate None None I-IUPAC
. None None O

Its None None O
inhibition None None O
of None None O
the None None O
enzyme None None O
, None None O
5,10 None None I-IUPAC
- None None I-IUPAC
methenyltetrahydrofolate None None I-IUPAC
cyclohydrolase None None O
( None None O
EC None None O
3.5.4.9 None None O
) None None O
, None None O
was None None O
competitive None None O
against None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
5,10 None None I-IUPAC
- None None I-IUPAC
methenyltetrahydrofolate None None I-IUPAC
, None None O
with None None O
a None None O
Ki None None O
= None None O
41 None None O
micro None None O
M None None O
. None None O

This None None O
derivative None None O
of None None O
homofolate None None O
may None None O
be None None O
responsible None None O
for None None O
its None None O
inhibition None None O
of None None O
purine None None O
biosynthesis None None O
in None None O
Sarcoma None None O
180 None None O
cells None None O
. None None O


The None None O
anticonvulsant None None O
activity None None O
of None None O
diphenylhydantoin None None O
( None None O
DPH None None O
or None None O
phenytoin None None O
) None None O
is None None O
consistent None None O
with None None O
its None None O
actions None None O
on None None O
the None None O
neuronal None None O
voltage None None O
- None None O
dependent None None O
sodium None None O
channel None None O
. None None O

To None None O
further None None O
elucidate None None O
the None None O
binding None None O
requirements None None O
for None None O
this None None O
site None None O
, None None O
we None None O
synthesized None None O
several None None O
hydantoin None None O
analogs None None O
and None None O
evaluated None None O
these None None O
in None None O
in None None O
vitro None None O
sodium None None O
channel None None O
- None None O
binding None None O
and None None O
/ None None O
or None None O
in None None O
vivo None None O
whole None None O
animal None None O
anticonvulsant None None O
assays None None O
. None None O

5 None None I-IUPAC
- None None I-IUPAC
Pentyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenylhydantoin None None I-IUPAC
( None None O
8 None None O
) None None O
, None None O
the None None O
most None None O
potent None None O
binder None None O
to None None O
the None None O
sodium None None O
channel None None O
in None None O
this None None O
study None None O
, None None O
had None None O
the None None O
same None None O
affinity None None O
as None None O
DPH None None O
( None None O
IC50 None None O
= None None O
40 None None O
microM None None O
) None None O
, None None O
revealing None None O
that None None O
one None None O
phenyl None None O
ring None None O
is None None O
sufficient None None O
for None None O
good None None O
interactions None None O
. None None O

Since None None O
our None None O
previous None None O
studies None None O
with None None O
monophenyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
bicyclic None None B-MODIFIER
2,4 None None B-IUPAC
- None None I-IUPAC
oxazolidinediones None None I-IUPAC
suggested None None O
that None None O
N3 None None O
- None None O
alkylation None None O
and None None O
the None None O
conformational None None O
constraint None None O
of None None O
a None None O
5 None None O
- None None O
alkyl None None O
substituent None None O
over None None O
one None None O
face None None O
of None None O
the None None O
oxazolidinedione None None O
ring None None O
improved None None O
activity None None O
, None None O
we None None O
synthesized None None O
two None None O
examples None None O
of None None O
analogous None None O
bicyclic None None O
hydantoins None None O
. None None O

However None None O
, None None O
the None None O
bicyclic None None O
hydantoins None None O
were None None O
much None None O
less None None O
potent None None O
binders None None O
to None None O
the None None O
neuronal None None O
voltage None None O
- None None O
dependent None None O
sodium None None O
channel None None O
than None None O
their None None O
monocyclic None None O
counterparts None None O
. None None O

The None None O
binding None None O
activity None None O
for None None O
the None None O
more None None O
potent None None O
bicyclic None None O
hydantoin None None O
, None None O
1,8 None None I-IUPAC
- None None I-IUPAC
diaza None None I-IUPAC
- None None I-IUPAC
9,10 None None I-IUPAC
- None None I-IUPAC
dioxo None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
phenylbicyclo None None I-IUPAC
[ None None I-IUPAC
5.2.1 None None I-IUPAC
] None None I-IUPAC
decane None None I-IUPAC
( None None O
4 None None O
) None None O
( None None O
IC50 None None O
= None None O
427 None None O
microM None None O
) None None O
, None None O
was None None O
comparable None None O
to None None O
that None None O
of None None O
the None None O
ring None None O
- None None O
opened None None O
, None None O
N3 None None O
- None None O
methylated None None O
monocyclic None None O
hydantoin None None O
model None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenylhydantoin None None I-IUPAC
( None None O
9 None None O
) None None O
( None None O
IC50 None None O
= None None O
285 None None O
microM None None O
) None None O
, None None O
and None None O
these None None O
were None None O
8-11 None None O
times None None O
less None None O
potent None None O
than None None O
the None None O
monocyclic None None O
model None None O
8 None None O
, None None O
which None None O
contains None None O
a None None O
free None None O
imide None None O
NH None None O
. None None O

Furthermore None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenylhydantoin None None I-IUPAC
( None None O
7 None None O
; None None O
IC50 None None O
= None None O
103 None None O
microM None None O
) None None O
was None None O
less None None O
potent None None O
than None None O
8 None None O
, None None O
suggesting None None O
that None None O
increased None None O
log None None O
P None None O
may None None O
enhance None None O
binding None None O
. None None O

Thus None None O
, None None O
unlike None None O
2,4 None None I-IUPAC
- None None I-IUPAC
oxazolidinediones None None I-IUPAC
, None None O
N3 None None O
- None None O
alkylation None None O
of None None O
hydantoins None None O
dramatically None None O
decreases None None O
sodium None None O
channel None None O
- None None O
binding None None O
activity None None O
. None None O

Bicyclic None None O
hydantoin None None O
4 None None O
was None None O
nevertheless None None O
a None None O
good None None O
anti None None O
- None None O
MES None None O
anticonvulsant None None O
in None None O
mice None None O
( None None O
ED50 None None O
= None None O
86 None None O
mg None None O
/ None None O
kg None None O
) None None O
, None None O
although None None O
this None None O
activity None None O
likely None None O
results None None O
from None None O
mechanisms None None O
other None None O
than None None O
interactions None None O
at None None O
the None None O
neuronal None None O
voltage None None O
- None None O
dependent None None O
sodium None None O
channel None None O
. None None O

Compound None None O
4 None None O
was None None O
also None None O
relatively None None O
neurotoxic None None O
( None None O
TD50 None None O
= None None O
124 None None O
mg None None O
/ None None O
kg None None O
) None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
binding None None O
of None None O
hydantoins None None O
to None None O
the None None O
sodium None None O
channel None None O
may None None O
be None None O
enhanced None None O
by None None O
( None None O
a None None O
) None None O
a None None O
free None None O
imide None None O
NH None None O
group None None O
and None None O
( None None O
b None None O
) None None O
an None None O
increased None None O
log None None O
P None None O
. None None O

Furthermore None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
oxazolidinediones None None I-IUPAC
and None None O
hydantoins None None O
must None None O
either None None O
orient None None O
differently None None O
in None None O
the None None O
same None None O
binding None None O
site None None O
or None None O
interact None None O
with None None O
different None None O
sites None None O
on None None O
the None None O
neuronal None None O
voltage None None O
- None None O
dependent None None O
sodium None None O
channel None None O
. None None O


Evidence None None O
incicating None None O
that None None O
effective None None O
in None None O
vivo None None O
inhibition None None O
of None None O
hypoxanthine None None O
- None None O
guanine None None O
phosphoribosyltransferase None None O
( None None O
HGPRT None None O
, None None O
EC None None O
2.4.2.8 None None O
) None None O
should None None O
produce None None O
antiprotozoal None None O
activity None None O
without None None O
significant None None O
toxic None None O
effects None None O
on None None O
mammalian None None O
hosts None None O
prompted None None O
syntheses None None O
of None None O
1 None None O
- None None O
substituted None None O
hypoxanthines None None O
bearing None None O
functionalized None None O
side None None O
chains None None O
whose None None O
groupings None None O
might None None O
interact None None O
with None None O
appropriate None None O
groupings None None O
of None None O
HGPRT None None O
to None None O
form None None O
covalent None None O
bonds None None O
or None None O
strong None None O
hydrophobic None None O
bonds None None O
. None None O

3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Fluorosulfonyl None None I-IUPAC
) None None I-IUPAC
benzoyl None None I-IUPAC
, None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluorosulfonyl None None I-IUPAC
) None None I-IUPAC
benzoyl None None I-IUPAC
, None None O
4 None None I-IUPAC
- None None I-IUPAC
chlorobenzoyl None None I-IUPAC
, None None O
and None None O
bromacetyl None None I-IUPAC
derivatives None None B-MODIFIER
of None None O
two None None O
parent None None O
amines None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
hypoxanthine None None I-IUPAC
and None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminobenzyl None None I-IUPAC
) None None I-IUPAC
hypoxanthine None None I-IUPAC
, None None O
were None None O
synthesized None None O
for None None O
evaluation None None O
in None None O
this None None O
connection None None O
. None None O

None None None O
of None None O
these None None O
compounds None None O
extended None None O
the None None O
life None None O
span None None O
of None None O
Plasmodium None None O
berghei None None O
infected None None O
mice None None O
or None None O
showed None None O
significant None None O
in None None O
vitro None None O
inhibition None None O
of None None O
HGPRT None None O
from None None O
H None None O
. None None O

Ep None None O
. None None O

- None None O
2 None None O
cells None None O
, None None O
but None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromoacetamido None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
hypoxanthine None None I-IUPAC
displayed None None O
in None None O
vivo None None O
activity None None O
against None None O
Trypanosoma None None O
rhodesiense None None O
. None None O


Glucuronic None None O
acid None None O
linked None None O
prodrugs None None O
of None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzylguanine None None I-IUPAC
and None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyguanosine None None I-IUPAC
were None None O
synthesized None None O
. None None O

The None None O
prodrugs None None O
were None None O
found None None O
to None None O
be None None O
quite None None O
stable None None O
at None None O
physiological None None O
pH None None O
and None None O
were None None O
more None None O
than None None O
200 None None O
- None None O
fold None None O
less None None O
active None None O
as None None O
inactivators None None O
of None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alkylguanine None None I-IUPAC
- None None O
DNA None None O
alkyltransferase None None O
( None None O
alkyltransferase None None O
) None None O
than None None O
either None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzylguanine None None I-IUPAC
or None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyguanosine None None I-IUPAC
. None None O

Beta None None O
- None None O
glucuronidase None None O
from None None O
both None None O
Escherichia None None O
coli None None O
and None None O
bovine None None O
liver None None O
cleaved None None O
the None None O
prodrugs None None O
efficiently None None O
to None None O
release None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzylguanine None None I-IUPAC
and None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyguanosine None None I-IUPAC
, None None O
respectively None None O
. None None O

In None None O
combination None None O
with None None O
1,3 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
nitrosourea None None I-IUPAC
( None None O
BCNU None None O
) None None O
, None None O
the None None O
prodrugs None None O
were None None O
not None None O
effective None None O
adjuvants None None O
for None None O
HT29 None None O
cell None None O
killing None None O
. None None O

However None None O
, None None O
as None None O
expected None None O
, None None O
incubation None None O
of None None O
these None None O
prodrugs None None O
with None None O
beta None None O
- None None O
glucuronidase None None O
in None None O
the None None O
culture None None O
medium None None O
led None None O
to None None O
much None None O
more None None O
efficient None None O
cell None None O
killing None None O
by None None O
BCNU None None O
as None None O
a None None O
result None None O
of None None O
the None None O
liberation None None O
of None None O
the None None O
more None None O
potent None None O
inactivators None None O
, None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzylguanine None None I-IUPAC
and None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyguanosine None None I-IUPAC
. None None O

These None None O
prodrugs None None O
may None None O
be None None O
useful None None O
for None None O
prodrug None None O
monotherapy None None O
of None None O
necrotic None None O
tumors None None O
that None None O
liberate None None O
beta None None O
- None None O
glucuronidase None None O
or None None O
for None None O
antibody None None O
- None None O
directed None None O
enzyme None None O
prodrug None None O
therapy None None O
with None None O
antibodies None None O
that None None O
can None None O
deliver None None O
beta None None O
- None None O
glucuronidase None None O
to None None O
target None None O
tumor None None O
cells None None O
. None None O


5,5 None None I-IUPAC
- None None I-IUPAC
Bis None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanone None None I-IUPAC
and None None O
its None None O
isomer None None O
4,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanone None None I-IUPAC
were None None O
investigated None None O
as None None O
possible None None O
templates None None O
for None None O
the None None O
construction None None O
of None None O
conformationally None None O
constrained None None O
analogues None None O
of None None O
the None None O
biologically None None O
important None None O
second None None O
messenger None None O
, None None O
diacylglycerol None None O
( None None O
DAG None None O
) None None O
. None None O

The None None O
former None None O
lactone None None O
contains None None O
embedded None None O
within None None O
its None None O
structure None None O
an None None O
exact None None O
glycerol None None O
moiety None None O
, None None O
while None None O
in None None O
the None None O
latter None None O
the None None O
ring None None O
oxygen None None O
has None None O
been None None O
transposed None None O
to None None O
the None None O
other None None O
side None None O
of None None O
the None None O
carbonyl None None O
group None None O
. None None O

All None None O
target None None O
compounds None None O
were None None O
synthesized None None O
as None None O
racemates None None O
from None None O
1,3 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propanone None None I-IUPAC
. None None O

The None None O
5,5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanone None None I-IUPAC
proved None None O
to None None O
be None None O
the None None O
better None None O
template None None O
for None None O
the None None O
construction None None O
of None None O
DAG None None O
surrogates None None O
that None None O
were None None O
demonstrated None None O
to None None O
have None None O
high None None O
binding None None O
affinities None None O
for None None O
the None None O
biological None None O
target None None O
, None None O
protein None None O
kinase None None O
C None None O
( None None O
PK None None O
- None None O
C None None O
) None None O
. None None O

The None None O
simplest None None O
target None None O
compounds None None O
derived None None O
from None None O
this None None O
template None None O
( None None O
3e None None O
and None None O
3f None None O
) None None O
have None None O
one None None O
of None None O
the None None O
hydroxyl None None I-IUPAC
moieties None None B-MODIFIER
functionalized None None O
either None None O
as None None O
a None None O
myristate None None O
or None None O
as None None O
an None None O
oleate None None O
ester None None O
. None None O

The None None O
simplest None None O
target None None O
compound None None O
( None None O
9c None None O
) None None O
derived None None O
from None None O
the None None O
ineffective None None O
4,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanone None None I-IUPAC
template None None O
was None None O
investigated None None O
only None None O
with None None O
a None None O
myristoyl None None O
acyl None None O
chain None None O
. None None O

Reducing None None O
the None None O
long None None O
acyl None None O
chain None None O
to None None O
an None None O
acetyl None None O
moiety None None O
and None None O
attaching None None O
a None None O
compensating None None O
lipophilic None None O
chain None None O
to None None O
the None None O
lactone None None O
ring None None O
as None None O
an None None O
alpha None None I-IUPAC
- None None I-IUPAC
alkylidene None None I-IUPAC
moiety None None I-MODIFIER
produced None None O
compounds None None O
10e None None O
and None None O
10f None None O
( None None O
Z None None O
- None None O
isomers None None O
) None None O
and None None O
11e None None O
and None None O
11f None None O
( None None O
E None None O
- None None O
isomers None None O
) None None O
, None None O
which None None O
were None None O
constructed None None O
on None None O
the None None O
more None None O
effective None None O
5,5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanone None None I-IUPAC
template None None O
. None None O

Targets None None O
14c None None O
( None None O
Z None None O
- None None O
isomer None None O
) None None O
and None None O
15c None None O
( None None O
E None None O
- None None O
isomer None None O
) None None O
were None None O
derived None None O
, None None O
in None None O
turn None None O
, None None O
from None None O
4,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanone None None I-IUPAC
. None None O

The None None O
affinities None None O
of None None O
these None None O
ligands None None O
for None None O
PK None None O
- None None O
C None None O
were None None O
assessed None None O
in None None O
terms None None O
of None None O
their None None O
ability None None O
to None None O
displace None None O
bound None None O
[ None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
20 None None I-IUPAC
] None None I-IUPAC
phorbol None None I-IUPAC
12,13 None None I-IUPAC
- None None I-IUPAC
dibutyrate None None I-IUPAC
( None None O
PDBU None None O
) None None O
from None None O
the None None O
single None None O
isozyme None None O
PK None None O
- None None O
C None None O
alpha None None O
. None None O

The None None O
biological None None O
data None None O
support None None O
the None None O
hypothesis None None O
that None None O
the None None O
increase None None O
in None None O
binding None None O
affinity None None O
for None None O
PK None None O
- None None O
C None None O
shown None None O
by None None O
some None None O
of None None O
these None None O
constrained None None O
DAG None None O
mimetics None None O
appears None None O
to None None O
be None None O
entropic None None O
in None None O
nature None None O
. None None O

Two None None O
of None None O
the None None O
designed None None O
ligands None None O
( None None O
10e None None O
and None None O
10f None None O
) None None O
showed None None O
the None None O
highest None None O
affinities None None O
( None None O
34 None None O
and None None O
24 None None O
nM None None O
, None None O
respectively None None O
) None None O
reported None None O
so None None O
far None None O
for None None O
a None None O
DAG None None O
analogue None None O
. None None O

Assuming None None O
that None None O
the None None O
interaction None None O
between None None O
these None None O
racemic None None O
compounds None None O
and None None O
PK None None O
- None None O
C None None O
is None None O
stereospecific None None O
, None None O
the None None O
potency None None O
of None None O
the None None O
active None None O
enantiomer None None O
is None None O
anticipated None None O
to None None O
double None None O
. None None O


In None None O
this None None O
study None None O
, None None O
13 None None O
heteroarotinoids None None O
were None None O
synthesized None None O
. None None O

The None None O
key None None O
step None None O
in None None O
each None None O
preparation None None O
was None None O
the None None O
condensation None None O
of None None O
the None None O
appropriate None None O
chroman None None I-IUPAC
- None None O
, None None O
thiochroman None None I-IUPAC
- None None I-IUPAC
, None None O
or None None O
benzothienyl None None I-IUPAC
- None None I-IUPAC
substituted None None I-MODIFIER
phosphorus None None B-IUPAC
ylide None None I-IUPAC
, None None O
obtained None None O
from None None O
the None None O
independent None None O
synthesis None None O
of None None O
the None None O
corresponding None None O
phosphonium None None O
salts None None O
, None None O
with None None O
selected None None O
polyene None None I-IUPAC
- None None O
substituted None None I-MODIFIER
aldehyde None None B-IUPAC
esters None None I-IUPAC
. None None O

Nine None None O
of None None O
these None None O
heterocycles None None O
contained None None O
a None None O
thiochroman None None O
group None None O
, None None O
two None None O
had None None O
a None None O
chroman None None O
group None None O
, None None O
and None None O
two None None O
others None None O
had None None O
a None None O
benzothienyl None None O
system None None O
. None None O

Screening None None O
of None None O
the None None O
compounds None None O
was None None O
with None None O
one None None O
of None None O
two None None O
assays None None O
. None None O

One None None O
assay None None O
measured None None O
the None None O
ability None None O
of None None O
a None None O
retinoid None None O
to None None O
inhibit None None O
the None None O
phorbol None None O
ester None None O
induced None None O
increase None None O
of None None O
mouse None None O
epidermal None None O
ornithine None None O
decarboxylase None None O
( None None O
ODC None None O
) None None O
activity None None O
. None None O

The None None O
other None None O
assay None None O
measured None None O
retinoid None None O
- None None O
induced None None O
differentiation None None O
of None None O
the None None O
human None None O
myoloid None None O
leukemia None None O
cell None None O
line None None O
HL None None O
- None None O
60 None None O
. None None O

In None None O
the None None O
ODC None None O
assay None None O
, None None O
all None None O
thirteen None None O
compounds None None O
were None None O
screened None None O
. None None O

The None None O
most None None O
active None None O
heteroarotinoids None None O
were None None O
ester None None O
10 None None O
[ None None O
methyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,2,4,4 None None I-IUPAC
- None None I-IUPAC
tetramethylthiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
] None None O
and None None O
acid None None O
11 None None O
[ None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,2,4,4 None None I-IUPAC
- None None I-IUPAC
tetramethyl None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzothiopyran None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
] None None O
. None None O

Both None None O
of None None O
these None None O
retinoids None None O
had None None O
ID50 None None O
values None None O
( None None O
dose None None O
required None None O
for None None O
half None None O
- None None O
maximal None None O
inhibition None None O
of None None O
phorbol None None O
ester None None O
induced None None O
ODC None None O
activity None None O
) None None O
of None None O
about None None O
0.3 None None O
nmol None None O
. None None O

In None None O
comparison None None O
, None None O
the None None O
ID50 None None O
value None None O
for None None O
trans None None O
- None None O
retinoic None None O
acid None None O
( None None O
1 None None O
) None None O
was None None O
0.12 None None O
nmol None None O
while None None O
the None None O
ID50 None None O
values None None O
for None None O
acids None None O
7 None None O
and None None O
9 None None O
, None None O
namely None None O
( None None I-IUPAC
2Z None None I-IUPAC
, None None I-IUPAC
4E None None I-IUPAC
, None None I-IUPAC
6E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
thiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4,6 None None I-IUPAC
- None None I-IUPAC
heptatrienoic None None I-IUPAC
acid None None I-IUPAC
and None None O
( None None I-IUPAC
2E None None I-IUPAC
, None None I-IUPAC
4E None None I-IUPAC
, None None I-IUPAC
6E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,2,4,4 None None I-IUPAC
- None None I-IUPAC
tetramethylthiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4,6 None None I-IUPAC
- None None I-IUPAC
heptatrienoic None None I-IUPAC
acid None None I-IUPAC
, None None O
respectively None None O
, None None O
were None None O
about None None O
3.5 None None O
nmol None None O
. None None O

Heteroarotinoids None None O
8 None None O
and None None O
12-17 None None O
had None None O
ID50 None None O
values None None O
of None None O
35 None None O
nmol None None O
or None None O
greater None None O
. None None O

With None None O
a None None O
thiochroman None None O
unit None None O
, None None O
the None None O
most None None O
active None None O
acids None None O
in None None O
decreasing None None O
order None None O
of None None O
activity None None O
in None None O
the None None O
ODC None None O
assay None None O
were None None O
7 None None O
greater None None O
than None None O
9 None None O
greater None None O
than None None O
8 None None O
. None None O

Thus None None O
, None None O
simple None None O
replacement None None O
of None None O
the None None O
terminal None None O
propenyl None None I-IUPAC
system None None B-MODIFIER
[ None None O
C None None O
( None None O
16,17,18 None None O
) None None O
] None None O
in None None O
7 None None O
with None None O
a None None O
cyclopropyl None None I-IUPAC
group None None B-MODIFIER
produced None None O
acid None None O
8 None None O
[ None None O
( None None I-IUPAC
2E None None I-IUPAC
, None None I-IUPAC
4E None None I-IUPAC
, None None I-IUPAC
6E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylthiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
methylene None None I-IUPAC
- None None I-IUPAC
4,6 None None I-IUPAC
- None None I-IUPAC
heptadienoic None None I-IUPAC
acid None None I-IUPAC
with None None O
markedly None None O
reduced None None O
activity None None O
. None None O

With None None O
a None None O
benzoic None None O
acid None None O
group None None O
as None None O
part None None O
of None None O
the None None O
structure None None O
attached None None O
to None None O
the None None O
thiochroman None None O
unit None None O
, None None O
the None None O
ODC None None O
activity None None O
was None None O
enhanced None None O
as None None O
shown None None O
in None None O
10 None None O
and None None O
11 None None O
. None None O

The None None O
combination None None O
of None None O
the None None O
2,2,4,4 None None I-IUPAC
- None None I-IUPAC
tetramethylthiochroman None None I-IUPAC
group None None I-MODIFIER
and None None O
the None None O
benzoic None None O
acid None None O
( None None O
or None None O
ester None None O
) None None O
terminal None None O
group None None O
seemed None None O
to None None O
enhance None None O
the None None O
biological None None O
action None None O
which None None O
resembles None None O
that None None O
found None None O
with None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
5,5,8,8 None None I-IUPAC
- None None I-IUPAC
tetramethyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthalenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
TTNPB None None O
, None None O
6b None None O
) None None O
, None None O
a None None O
well None None O
- None None O
known None None O
model None None O
system None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

To None None O
develop None None O
a None None O
novel None None O
cerebroprotective None None O
agent None None O
with None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
stimulating None None O
activity None None O
, None None O
a None None O
series None None I-MODIFIER
of None None O
1 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
hydroxyindan None None I-IUPAC
derivatives None None I-MODIFIER
was None None O
synthesized None None O
, None None O
and None None O
their None None O
effects None None O
on None None O
the None None O
survival None None O
time None None O
of None None O
mice None None O
under None None O
hypoxic None None O
conditions None None O
were None None O
tested None None O
. None None O

CNS None None O
- None None O
stimulating None None O
activity None None O
was None None O
also None None O
evaluated None None O
by None None O
examining None None O
the None None O
promotional None None O
effect None None O
on None None O
the None None O
recovery None None O
from None None O
cerebral None None O
concussion None None O
induced None None O
coma None None O
in None None O
mice None None O
. None None O

Several None None O
compounds None None O
prolonged None None O
the None None O
survival None None O
time None None O
of None None O
mice None None O
in None None O
hypoxic None None O
conditions None None O
at None None O
a None None O
dose None None O
of None None O
30 None None O
mg None None O
/ None None O
kg None None O
( None None O
sc None None O
or None None O
ip None None O
) None None O
and None None O
100 None None O
mg None None O
/ None None O
kg None None O
( None None O
po None None O
) None None O
. None None O

They None None O
also None None O
exhibited None None O
the None None O
promotional None None O
effects None None O
on None None O
recovery None None O
from None None O
coma None None O
at None None O
a None None O
dose None None O
of None None O
100 None None O
mg None None O
/ None None O
kg None None O
po None None O
. None None O

The None None O
three None None O
most None None O
potent None None O
compounds None None O
in None None O
both None None O
tests None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methylpropyl None None I-IUPAC
) None None I-IUPAC
indan None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylindan None None I-IUPAC
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2,2,4,6 None None I-IUPAC
- None None I-IUPAC
tetramethylindan None None I-IUPAC
were None None O
selected None None O
for None None O
further None None O
investigations None None O
. None None O

Structure None None O
- None None O
activity None None O
relationships None None O
were None None O
also None None O
discussed None None O
. None None O


Prazosin None None O
- None None O
related None None O
quinazolines None None O
4-20 None None O
were None None O
synthesized None None O
, None None O
and None None O
their None None O
biological None None O
profiles None None O
at None None O
alpha1 None None O
- None None O
adrenoreceptor None None O
subtypes None None O
were None None O
assessed None None O
by None None O
functional None None O
experiments None None O
in None None O
isolated None None O
rat None None O
vas None None O
deferens None None O
( None None O
alpha1A None None O
) None None O
, None None O
spleen None None O
( None None O
alpha1B None None O
) None None O
, None None O
and None None O
aorta None None O
( None None O
alpha1D None None O
) None None O
and None None O
by None None O
binding None None O
assays None None O
in None None O
CHO None None O
cells None None O
expressing None None O
human None None O
cloned None None O
alpha1 None None O
- None None O
adrenoreceptor None None O
subtypes None None O
. None None O

The None None O
replacement None None O
of None None O
piperazine None None O
and None None O
furan None None O
units None None O
of None None O
prazosin None None O
( None None O
1 None None O
) None None O
by None None O
1 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hexanediamine None None I-IUPAC
and None None O
phenyl None None I-IUPAC
moieties None None B-MODIFIER
, None None O
respectively None None O
, None None O
affording None None O
3-20 None None O
, None None O
markedly None None O
affected None None O
both None None O
affinity None None O
and None None O
selectivity None None O
for None None O
alpha1 None None O
- None None O
adrenoreceptor None None O
subtypes None None O
in None None O
functional None None O
experiments None None O
. None None O

Cystazosin None None O
( None None O
3 None None O
) None None O
, None None O
bearing None None O
a None None O
cystamine None None O
moiety None None O
, None None O
was None None O
a None None O
selective None None O
alpha1D None None O
- None None O
adrenoreceptor None None O
antagonist None None O
being None None O
1 None None O
order None None O
of None None O
magnitude None None O
more None None O
potent None None O
at None None O
alpha1D None None O
- None None O
adrenoreceptors None None O
( None None O
pA2 None None O
, None None O
8.54 None None O
+ None None O
/ None None O
- None None O
0.02 None None O
) None None O
than None None O
at None None O
the None None O
alpha1A None None O
- None None O
( None None O
pA2 None None O
, None None O
7.53 None None O
+ None None O
/ None None O
- None None O
0.01 None None O
) None None O
and None None O
alpha1B None None O
- None None O
subtypes None None O
( None None O
pA2 None None O
, None None O
7.49 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O

01 None None O
) None None O
. None None O

The None None O
insertion None None O
of None None O
substituents None None O
on None None O
the None None O
furan None None O
ring None None O
of None None O
3 None None O
, None None O
as None None O
in None None O
compounds None None O
4 None None O
and None None O
5 None None O
, None None O
did None None O
not None None O
improve None None O
the None None O
selectivity None None O
profile None None O
. None None O

The None None O
simultaneous None None O
replacement None None O
of None None O
both None None O
piperazine None None O
and None None O
furan None None O
rings None None O
of None None O
1 None None O
gave None None O
8 None None O
which None None O
resulted None None O
in None None O
a None None O
potent None None O
, None None O
selective None None O
alpha1B None None O
- None None O
adrenoreceptor None None O
antagonist None None O
( None None O
85 None None O
- None None O
and None None O
15 None None O
- None None O
fold None None O
more None None O
potent None None O
than None None O
at None None O
alpha1A None None O
- None None O
and None None O
alpha1D None None O
- None None O
subtypes None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
insertion None None O
of None None O
substituents None None O
on None None O
the None None O
benzene None None O
ring None None O
of None None O
8 None None O
affected None None O
, None None O
according None None O
to None None O
the None None O
type None None O
and None None O
the None None O
position None None O
of None None O
the None None O
substituent None None O
, None None O
affinity None None O
and None None O
selectivity None None O
for None None O
alpha1 None None O
- None None O
adrenoreceptors None None O
. None None O

Consequently None None O
, None None O
the None None O
insertion None None O
of None None O
appropriate None None O
substituents None None O
in None None O
the None None O
phenyl None None O
ring None None O
of None None O
8 None None O
may None None O
represent None None O
the None None O
basis None None O
of None None O
designing None None O
new None None O
selective None None O
ligands None None O
for None None O
alpha1 None None O
- None None O
adrenoreceptor None None O
subtypes None None O
. None None O

Interestingly None None O
, None None O
the None None O
finding None None O
that None None O
polyamines None None O
11 None None O
, None None O
16 None None O
, None None O
and None None O
20 None None O
, None None O
bearing None None O
a None None O
1,6 None None I-IUPAC
- None None I-IUPAC
hexanediamine None None I-IUPAC
moiety None None I-MODIFIER
, None None O
retained None None O
high None None O
affinity None None O
for None None O
alpha1 None None O
- None None O
adrenoreceptor None None O
subtypes None None O
suggests None None O
that None None O
the None None O
substituent None None O
did None None O
not None None O
give None None O
rise None None O
to None None O
negative None None O
interactions None None O
with None None O
the None None O
receptor None None O
. None None O

Finally None None O
, None None O
binding None None O
assays None None O
performed None None O
with None None O
selected None None O
quinazolines None None O
( None None O
2 None None O
, None None O
3 None None O
, None None O
and None None O
14 None None O
) None None O
produced None None O
affinity None None O
results None None O
, None None O
which None None O
were None None O
not None None O
in None None O
agreement None None O
with None None O
the None None O
selectivity None None O
profiles None None O
obtained None None O
from None None O
functional None None O
experiments None None O
. None None O

This None None O
rather None None O
surprising None None O
and None None O
unexpected None None O
finding None None O
may None None O
be None None O
explained None None O
by None None O
considering None None O
neutral None None O
and None None O
negative None None O
antagonism None None O
. None None O


New None None O
nucleoside None None O
analogues None None O
14-17 None None O
based None None O
on None None O
a None None O
methylenecyclopropane None None O
structure None None O
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
antiviral None None O
activity None None O
. None None O

Reaction None None O
of None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dibromopropene None None I-IUPAC
( None None O
19 None None O
) None None O
with None None O
adenine None None O
( None None O
18 None None O
) None None O
led None None O
to None None O
bromoalkene None None O
20 None None O
, None None O
which None None O
was None None O
benzoylated None None O
to None None O
give None None O
N6 None None I-IUPAC
, None None I-IUPAC
N6 None None I-IUPAC
- None None I-IUPAC
dibenzoyl None None I-IUPAC
derivative None None I-MODIFIER
23 None None O
. None None O

Attempts None None O
to None None O
convert None None O
20 None None O
or None None O
23 None None O
to None None O
bromocyclopropanes None None O
21 None None O
and None None O
22 None None O
by None None O
reaction None None O
with None None O
ethyl None None O
diazoacetate None None O
catalyzed None None O
by None None O
Rh2 None None O
( None None O
OAc None None O
) None None O
4 None None O
were None None O
futile None None O
. None None O

By None None O
contrast None None O
, None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dibromopropene None None I-IUPAC
( None None O
19 None None O
) None None O
afforded None None O
smoothly None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
and None None O
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dibromocyclopropane None None I-IUPAC
carboxylic None None I-IUPAC
esters None None I-IUPAC
24 None None O
+ None None O
25 None None O
. None None O

Alkylation None None O
of None None O
adenine None None O
( None None O
18 None None O
) None None O
with None None O
24 None None O
+ None None O
25 None None O
gave None None O
( None None O
E None None O
) None None O
- None None O
and None None O
( None None O
Z None None O
) None None O
- None None O
bromo None None O
derivatives None None O
21 None None O
+ None None O
22 None None O
. None None O

Base None None O
- None None O
catalyzed None None O
elimination None None O
of None None O
HBr None None O
resulted None None O
in None None O
the None None O
formation None None O
of None None O
( None None I-PARTIUPAC
Z None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methylenecyclopropanecarboxylic None None I-IUPAC
esters None None I-IUPAC
26 None None O
+ None None O
27 None None O
. None None O

More None None O
convenient None None O
one None None O
- None None O
pot None None O
alkylation None None O
- None None O
elimination None None O
of None None O
adenine None None O
( None None O
18 None None O
) None None O
or None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
( None None O
30 None None O
) None None O
with None None O
24 None None O
+ None None O
25 None None O
afforded None None O
( None None I-PARTIUPAC
Z None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methylenecyclopropane None None I-IUPAC
derivatives None None I-MODIFIER
26 None None O
+ None None O
27 None None O
and None None O
31 None None O
+ None None O
32 None None O
. None None O

The None None O
Z None None O
- None None O
isomers None None O
were None None O
always None None O
predominant None None O
in None None O
these None None O
mixtures None None O
( None None O
Z None None O
/ None None O
E None None O
approximately None None O
2/1 None None O
) None None O
. None None O

Reduction None None O
of None None O
26 None None O
+ None None O
27 None None O
and None None O
31 None None O
+ None None O
32 None None O
with None None O
DIBALH None None O
afforded None None O
( None None I-PARTIUPAC
Z None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methylenecyclopropane None None I-IUPAC
alcohols None None I-IUPAC
14 None None O
+ None None O
16 None None O
and None None O
33 None None O
+ None None O
34 None None O
. None None O

The None None O
latter None None O
were None None O
resolved None None O
directly None None O
by None None O
chromatography None None O
. None None O

Compounds None None O
14 None None O
+ None None O
16 None None O
were None None O
converted None None O
to None None O
N6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
methylene None None I-IUPAC
derivatives None None I-MODIFIER
28 None None O
and None None O
29 None None O
which None None O
were None None O
separated None None O
and None None O
deprotected None None O
to None None O
give None None O
14 None None O
and None None O
16 None None O
. None None O

Reaction None None O
of None None O
33 None None O
and None None O
34 None None O
with None None O
HCO2H None None O
led None None O
to None None O
guanine None None O
analogues None None O
15 None None O
and None None O
17 None None O
. None None O

The None None O
1H None None O
NMR None None O
spectra None None O
of None None O
the None None O
Z None None O
- None None O
analogues None None O
14 None None O
and None None O
15 None None O
are None None O
consistent None None O
with None None O
an None None O
anti None None O
- None None O
like None None O
conformation None None O
of None None O
the None None O
nucleobases None None O
. None None O

By None None O
contrast None None O
, None None O
1H None None O
NMR None None O
and None None O
IR None None O
spectra None None O
of None None O
bromo None None O
ester None None O
21 None None O
are None None O
indicative None None O
of None None O
syn None None O
- None None O
conformation None None O
of None None O
adenine None None O
. None None O

Several None None O
Z None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
methylenecyclopropanes None None I-IUPAC
exhibited None None O
in None None O
vitro None None O
antiviral None None O
activity None None O
in None None O
micromolar None None O
or None None O
submicromolar None None O
range None None O
against None None O
human None None O
and None None O
murine None None O
cytomegalovirus None None O
( None None O
HCMV None None O
and None None O
MCMV None None O
) None None O
, None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
, None None O
human None None O
herpes None None O
virus None None O
6 None None O
( None None O
HHV None None O
- None None O
6 None None O
) None None O
, None None O
varicella None None O
zoster None None O
virus None None O
( None None O
VZV None None O
) None None O
, None None O
and None None O
hepatitis None None O
B None None O
virus None None O
( None None O
HBV None None O
) None None O
. None None O

Analogues None None O
14 None None O
, None None O
15 None None O
, None None O
and None None O
33 None None O
were None None O
the None None O
most None None O
effective None None O
agents None None O
against None None O
HCMV None None O
( None None O
IC50 None None O
1-2.1 None None O
, None None O
0.04-2.1 None None O
, None None O
and None None O
0.8-5.6 None None O
microM None None O
) None None O
, None None O
MCMV None None O
( None None O
IC50 None None O
2.1 None None O
, None None O
0.3 None None O
, None None O
and None None O
0.3 None None O
microM None None O
) None None O
and None None O
EBV None None O
in None None O
H None None O
- None None O
1 None None O
( None None O
IC50 None None O
0.2 None None O
, None None O
0.3 None None O
, None None O
and None None O
0.7 None None O
microM None None O
) None None O
and None None O
Daudi None None O
cells None None O
( None None O
IC50 None None O
3.2 None None O
, None None O
5.6 None None O
, None None O
and None None O
1.2 None None O
microM None None O
) None None O
. None None O

Adenine None None O
analogue None None O
14 None None O
was None None O
active None None O
against None None O
HBV None None O
( None None O
IC50 None None O
2 None None O
microM None None O
) None None O
, None None O
VZV None None O
( None None O
IC50 None None O
2.5 None None O
microM None None O
) None None O
, None None O
and None None O
HHV None None O
- None None O
6 None None O
( None None O
IC50 None None O
14 None None O
microM None None O
) None None O
. None None O

Synadenol None None O
( None None O
14 None None O
) None None O
and None None O
the None None O
E None None O
- None None O
isomer None None O
( None None O
16 None None O
) None None O
were None None O
substrates None None O
of None None O
moderate None None O
efficiency None None O
for None None O
adenosine None None O
deaminase None None O
from None None O
calf None None O
intestine None None O
. None None O

The None None O
E None None O
- None None O
isomer None None O
16 None None O
was None None O
more None None O
reactive None None O
than None None O
Z None None O
- None None O
isomer None None O
14 None None O
. None None O

The None None O
deamination None None O
of None None O
14 None None O
effectively None None O
stopped None None O
at None None O
50% None None O
conversion None None O
. None None O

Synadenol None None O
( None None O
14 None None O
) None None O
was None None O
also None None O
deaminated None None O
by None None O
AMP None None O
deaminase None None O
from None None O
aspergillus None None O
sp None None O
. None None O


We None None O
have None None O
previously None None O
reported None None O
that None None O
a None None O
series None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
( None None I-IUPAC
thio None None I-IUPAC
) None None I-IUPAC
carbamoyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperazinyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
dimethoxyquinazoline None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
potent None None O
and None None O
selective None None O
inhibitors None None O
of None None O
platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
receptor None None O
( None None O
PDGFR None None O
) None None O
phosphorylation None None O
and None None O
demonstrated None None O
several None None O
biological None None O
effects None None O
such None None O
as None None O
suppression None None O
of None None O
neointima None None O
formation None None O
following None None O
balloon None None O
injury None None O
in None None O
rat None None O
carotid None None O
artery None None O
by None None O
oral None None O
administration None None O
. None None O

Here None None O
, None None O
we None None O
investigated None None O
structure None None O
- None None O
activity None None O
relationships None None O
of None None O
the None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dimethoxyquinazolinyl None None I-IUPAC
moiety None None I-MODIFIER
. None None O

In None None O
regard None None O
to None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
groups None None I-MODIFIER
, None None O
ethoxy None None O
analogues None None O
showed None None O
potent None None O
activity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
16b None None O
is None None O
0.04 None None O
microM None None O
; None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
17a None None O
is None None O
0.01 None None O
microM None None O
) None None O
and None None O
further None None O
extension None None O
of None None O
the None None O
alkyl None None O
group None None O
reduced None None O
activity None None O
. None None O

Interestingly None None O
, None None O
methoxyethoxy None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
16j None None O
is None None O
0.02 None None O
microM None None O
; None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
17h None None O
is None None O
0.01 None None O
microM None None O
) None None O
and None None O
ethoxyethoxy None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
17j None None O
is None None O
0.02 None None O
micro None None O
M None None O
) None None O
analogues None None O
showed None None O
the None None O
most None None O
potent None None O
activity None None O
, None None O
suggesting None None O
that None None O
the None None O
inserted None None O
oxygen None None O
atom None None O
significantly None None O
interacts None None O
with None None O
beta None None O
- None None O
PDGFR None None O
. None None O

Among None None O
tricyclic None None O
quinazoline None None O
derivatives None None O
, None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
oxoimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
quinazoline None None I-IUPAC
derivative None None I-MODIFIER
21a None None O
showed None None O
potent None None O
activity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.10 None None O
microM None None O
) None None O
. None None O

Regarding None None O
replacements None None O
of None None O
quinazoline None None O
by None None O
other None None O
heterocyclic None None O
rings None None O
, None None O
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
39a None None O
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.17 None None O
microM None None O
) None None O
and None None O
quinoline None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
40a None None O
is None None O
0.18 None None O
microM None None O
; None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
40b None None O
is None None O
0.09 None None O
microM None None O
) None None O
derivatives None None O
showed None None O
potent None None O
activity None None O
. None None O

Isoquinoline None None O
and None None O
some None None O
pyridopyrimidine None None O
derivatives None None O
were None None O
completely None None O
inactive None None O
; None None O
therefore None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
has None None O
an None None O
important None None O
role None None O
. None None O

Also None None O
7 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
and None None O
8 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
substitution None None I-MODIFIER
on None None O
the None None O
parent None None O
quinazoline None None O
ring None None O
has None None O
a None None O
detrimental None None O
effect None None O
on None None O
the None None O
interaction None None O
with None None O
beta None None O
- None None O
PDGFR None None O
. None None O

We None None O
also None None O
demonstrated None None O
that None None O
the None None O
substituents None None O
on None None O
the None None O
quinazoline None None O
ring None None O
possess None None O
major None None O
consequences None None O
for None None O
metabolic None None O
polymorphism None None O
. None None O

Although None None O
there None None O
existed None None O
extensive None None O
metabolizers None None O
and None None O
poor None None O
metabolizers None None O
in None None O
Sprague None None O
- None None O
Dawley None None O
rats None None O
administrated None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dimethoxyquinazoline None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
1b None None O
and None None O
1c None None O
) None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
) None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
methoxyquinazoline None None I-IUPAC
analogue None None I-MODIFIER
16k None None O
showed None None O
no None None O
metabolic None None O
polymorphism None None O
. None None O


The None None O
structure None None O
- None None O
activity None None O
relationships None None O
of None None O
two None None O
series None None O
of None None O
novel None None O
retinoids None None O
( None None O
2 None None I-IUPAC
- None None I-IUPAC
pyrazinylcarboxamidobenzoates None None I-IUPAC
and None None O
beta None None I-IUPAC
- None None I-IUPAC
ionylideneacetamidobenzoates None None I-IUPAC
) None None O
have None None O
been None None O
investigated None None O
by None None O
evaluating None None O
their None None O
ability None None O
to None None O
induce None None O
differentiation None None O
in None None O
both None None O
human None None O
promyelocytic None None O
leukemia None None O
( None None O
HL60 None None O
) None None O
cells None None O
and None None O
mouse None None O
embryonal None None O
carcinoma None None O
( None None O
P19 None None O
) None None O
cells None None O
. None None O

The None None O
most None None O
active None None O
compound None None O
( None None O
ED50 None None O
= None None O
8.3 None None O
x None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
M None None O
) None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
pyrazinylcarboxamidobenzoates None None I-IUPAC
is None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
5,5,8 None None I-IUPAC
, None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
tetramethylquinoxalyl None None I-IUPAC
) None None I-IUPAC
carboxamido None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
9u None None O
) None None O
, None None O
while None None O
the None None O
most None None O
active None None O
analogue None None O
of None None O
the None None O
beta None None O
- None None O
ionylideneacetamidobenzoates None None O
is None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
trimethyl None None I-IUPAC
- None None I-IUPAC
1' None None I-IUPAC
- None None I-IUPAC
cyclohexen None None I-IUPAC
- None None I-IUPAC
1' None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2E None None I-IUPAC
, None None I-IUPAC
4E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pentadienamido None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
10a None None O
, None None O
ED50 None None O
= None None O
3.2 None None O
x None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
) None None O
. None None O

Our None None O
studies None None O
identify None None O
an None None O
absolute None None O
requirement None None O
for None None O
the None None O
carboxylic None None O
acid None None O
moiety None None O
on None None O
the None None O
aromatic None None O
ring None None O
to None None O
be None None O
para None None O
relative None None O
to None None O
the None None O
amide None None O
linkage None None O
for None None O
activity None None O
. None None O

Benzoate None None O
substitutions None None O
in None None O
the None None O
ortho None None O
position None None O
relative None None O
to None None O
the None None O
terminal None None O
carboxylate None None O
( None None O
9d None None O
, None None O
k None None O
, None None O
r None None O
) None None O
are None None O
well None None O
- None None O
tolerated None None O
; None None O
however None None O
, None None O
a None None O
methoxy None None O
substituent None None O
meta None None O
relative None None O
to None None O
the None None O
terminal None None O
carboxylate None None O
gives None None O
rise None None O
to None None O
only None None O
weakly None None O
active None None O
analogues None None O
( None None O
9x None None O
) None None O
. None None O

Conformational None None O
studies None None O
( None None O
NMR None None O
, None None O
X None None O
- None None O
ray None None O
crystallography None None O
) None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
pyrazinylcarboxamidobenzoates None None I-IUPAC
indicate None None O
that None None O
the None None O
preferred None None O
conformation None None O
exhibits None None O
a None None O
trans None None O
- None None O
amide None None O
bond None None O
and None None O
an None None O
internal None None O
hydrogen None None O
bond None None O
between None None O
the None None O
quinoxaline None None O
N1 None None O
and None None O
HN None None O
amide None None O
which None None O
locks None None O
the None None O
torsional None None O
angle None None O
between None None O
C2 None None O
and None None O
CO None None O
in None None O
the None None O
s None None O
- None None O
trans None None O
conformation None None O
. None None O

N None None O
- None None O
Methylation None None O
( None None O
9y None None O
) None None O
results None None O
in None None O
loss None None O
of None None O
activity None None O
. None None O

Studies None None O
indicate None None O
that None None O
there None None O
is None None O
now None None O
a None None O
cis None None O
- None None O
amide None None O
bond None None O
present None None O
which None None O
redirects None None O
the None None O
carboxylate None None O
toward None None O
the None None O
pharmacophoric None None O
gem None None O
- None None O
dimethyl None None O
groups None None O
. None None O

The None None O
distance None None O
between None None O
the None None O
gem None None O
- None None O
dimethyl None None O
group None None O
and None None O
the None None O
terminal None None O
carboxylate None None O
appears None None O
to None None O
be None None O
too None None O
short None None O
to None None O
activate None None O
the None None O
retinoid None None O
receptor None None O
. None None O

N None None O
- None None O
Methylation None None O
in None None O
the None None O
beta None None I-IUPAC
- None None I-IUPAC
ionylideneacetamidobenzoate None None I-IUPAC
series None None I-MODIFIER
( None None O
10c None None O
) None None O
also None None O
results None None O
in None None O
the None None O
formation None None O
of None None O
a None None O
cis None None O
- None None O
amide None None O
bond None None O
and None None O
loss None None O
of None None O
activity None None O
. None None O


Examination None None O
of None None O
the None None O
PTP1B None None O
inhibitory None None O
potency None None O
of None None O
an None None O
extensive None None O
series None None O
of None None O
phosphotyrosyl None None I-IUPAC
( None None O
pTyr None None O
) None None O
mimetics None None I-MODIFIER
( None None O
Xxx None None O
) None None O
expressed None None O
in None None O
the None None O
EGFr None None O
- None None O
derived None None O
hexapeptide None None O
platform None None O
Ac None None O
- None None O
Asp None None O
- None None O
Ala None None O
- None None O
Asp None None O
- None None O
Xxx None None O
- None None O
Leu None None O
- None None O
amide None None O
previously None None O
led None None O
to None None O
the None None O
finding None None O
of None None O
high None None O
inhibitory None None O
potency None None O
when None None O
Xxx None None O
= None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonodifluoromethyl None None I-IUPAC
) None None I-IUPAC
phenylalanyl None None I-IUPAC
( None None O
F2Pmp None None O
) None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
0.2 None None O
microM None None O
) None None O
and None None O
when None None O
Xxx None None O
= None None O
3 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxymethyloxyphenylalanyl None None I-IUPAC
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
3.6 None None O
microM None None O
) None None O
. None None O

In None None O
the None None O
first None None O
instance None None O
, None None O
further None None O
work None None O
led None None O
from None None O
the None None O
F2Pmp None None O
- None None O
containing None None O
peptide None None O
to None None O
monomeric None None O
inhibitor None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonodifluoromethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
22 None None O
microM None None O
) None None O
, None None O
and None None O
to None None O
the None None O
pseudo None None O
- None None O
dipeptide None None O
mimetic None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonodifluoromethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
12 None None O
microM None None O
) None None O
. None None O

In None None O
the None None O
current None None O
study None None O
, None None O
a None None O
similar None None O
approach None None O
was None None O
applied None None O
to None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxymethyloxyphenylalanyl None None I-IUPAC
- None None O
containing None None O
peptide None None O
, None None O
which None None O
led None None O
to None None O
the None None O
preparation None None O
of None None O
monomeric None None O
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxymethyloxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
900 None None O
microM None None O
) None None O
. None None O

However None None O
, None None O
contrary None None O
to None None O
expectations None None O
based None None O
on None None O
the None None O
aforementioned None None O
F2Pmp None None O
work None None O
, None None O
incorporation None None O
of None None O
this None None O
putative None None O
pTyr None None O
mimetic None None O
into None None O
the None None O
pseudo None None O
- None None O
dipeptide None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxymethyloxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
, None None O
resulted None None O
in None None O
a None None O
substantial None None O
loss None None O
of None None O
binding None None O
affinity None None O
. None None O

A None None O
reevaluation None None O
of None None O
binding None None O
orientation None None O
for None None O
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxymethyloxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
was None None O
therefore None None O
undertaken None None O
, None None O
which None None O
indicated None None O
a None None O
180 None None O
degrees None None O
reversal None None O
of None None O
the None None O
binding None None O
orientation None None O
within None None O
the None None O
PTP1B None None O
catalytic None None O
site None None O
. None None O

In None None O
the None None O
new None None O
orientation None None O
, None None O
the None None O
naphthyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxyl None None I-IUPAC
group None None I-MODIFIER
, None None O
and None None O
not None None O
the None None O
o None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
carboxymethyloxy None None I-IUPAC
groups None None I-MODIFIER
, None None O
mimics None None O
a None None O
phosphoryl None None O
group None None O
. None None O

Indeed None None O
, None None O
when None None O
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
itself None None O
was None None O
examined None None O
at None None O
neutral None None O
pH None None O
for None None O
inhibitory None None O
potency None None O
, None None O
it None None O
was None None O
found None None O
to None None O
have None None O
K None None O
( None None O
i None None O
) None None O
= None None O
31 None None O
+ None None O
/ None None O
- None None O
7 None None O
microM None None O
, None None O
which None None O
is None None O
lower None None O
than None None O
parent None None O
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxymethyloxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
. None None O

In None None O
this None None O
fashion None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
( None None O
or None None O
more None None O
appropriately None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthoic None None I-IUPAC
acid None None I-IUPAC
) None None O
has None None O
been None None O
identified None None O
as None None O
a None None O
novel None None O
PTP1B None None O
binding None None O
motif None None O
. None None O


Novel None None O
derivatives None None O
of None None O
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
quinolones None None I-IUPAC
3a None None O
- None None O
j None None O
were None None O
synthesized None None O
in None None O
a None None O
multistep None None O
synthesis None None O
starting None None O
from None None O
substituted None None I-MODIFIER
benzo None None B-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiophene None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
chlorides None None I-IUPAC
, None None O
to None None O
their None None O
corresponding None None O
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiophene None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxamides None None I-IUPAC
, None None O
which None None O
were None None O
photochemically None None O
dehydrohalogenated None None O
to None None O
their None None O
corresponding None None O
substituted None None O
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
quinolones None None I-IUPAC
. None None O

Compound None None O
4 None None O
was None None O
prepared None None O
from None None O
3i None None O
by None None O
alkylation None None O
with None None O
3 None None I-IUPAC
- None None I-IUPAC
dimethylaminopropyl None None I-IUPAC
chloride None None I-IUPAC
in None None O
the None None O
presence None None O
of None None O
NaH None None O
. None None O

Compounds None None O
7a None None O
, None None O
b None None O
were None None O
prepared None None O
from None None O
3g None None O
in None None O
the None None O
multistep None None O
synthesis None None O
from None None O
compounds None None O
5 None None O
and None None O
6 None None O
. None None O

Compounds None None O
3b None None O
, None None O
3c None None O
- None None O
f None None O
, None None O
3h None None O
, None None O
7a None None O
, None None O
and None None O
7b None None O
were None None O
found None None O
to None None O
exert None None O
cytostatic None None O
activity None None O
against None None O
malignant None None O
cell None None O
lines None None O
: None None O
pancreatic None None O
carcinoma None None O
( None None O
MiaPaCa2 None None O
) None None O
, None None O
breast None None O
carcinoma None None O
( None None O
MCF7 None None O
) None None O
, None None O
cervical None None O
carcinoma None None O
( None None O
HeLa None None O
) None None O
, None None O
laryngeal None None O
carcinoma None None O
( None None O
Hep2 None None O
) None None O
, None None O
colon None None O
carcinoma None None O
( None None O
CaCo None None O
- None None O
2 None None O
) None None O
, None None O
melanoma None None O
( None None O
HBL None None O
) None None O
, None None O
human None None O
fibroblast None None O
cell None None O
lines None None O
( None None O
WI None None O
- None None O
38 None None O
) None None O
. None None O

The None None O
compounds None None O
that None None O
bear None None O
a None None O
3 None None I-IUPAC
- None None I-IUPAC
dimethylaminopropyl None None I-IUPAC
substituent None None I-MODIFIER
on None None O
the None None O
quinolone None None O
nitrogen None None O
( None None O
3b None None O
, None None O
3c None None O
- None None O
f None None O
, None None O
3h None None O
) None None O
showed None None O
higher None None O
antitumor None None O
activity None None O
than None None O
compounds None None O
bearing None None O
the None None O
same None None O
substituent None None O
on None None O
the None None O
amidic None None O
nitrogen None None O
( None None O
7a None None O
and None None O
7b None None O
) None None O
. None None O

The None None O
compound None None O
3h None None O
, None None O
which None None O
has None None O
a None None O
3 None None I-IUPAC
- None None I-IUPAC
dimethylaminopropyl None None I-IUPAC
substituent None None I-MODIFIER
on None None O
the None None O
quinolone None None O
nitrogen None None O
and None None O
a None None O
methoxycarbonyl None None I-IUPAC
substituent None None B-MODIFIER
at None None O
position None None O
9 None None O
, None None O
had None None O
marked None None O
antitumor None None O
activity None None O
. None None O

Because None None O
of None None O
strong None None O
cytotoxic None None O
effect None None O
of None None O
compound None None O
4 None None O
on None None O
melanoma None None O
cells None None O
( None None O
HBL None None O
, None None O
ME None None O
67.3 None None O
, None None O
and None None O
ME None None O
67.1 None None O
) None None O
, None None O
a None None O
potential None None O
mechanism None None O
of None None O
action None None O
was None None O
examined None None O
. None None O

Analysis None None O
of None None O
DNA None None O
and None None O
Annexin None None O
- None None O
V None None O
- None None O
FLUOS None None O
staining None None O
indicated None None O
that None None O
compound None None O
4 None None O
causes None None O
cell None None O
death None None O
by None None O
apoptosis None None O
. None None O


A None None O
series None None O
of None None O
aza None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
[ None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
phenanthridin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
were None None O
synthesized None None O
and None None O
evaluated None None O
as None None O
inhibitors None None O
of None None O
poly None None O
ADP None None O
- None None O
ribose None None O
polymerase None None O
- None None O
1 None None O
( None None O
PARP None None O
- None None O
1 None None O
) None None O
. None None O

Inhibitory None None O
potency None None O
of None None O
the None None O
unsubstituted None None I-MODIFIER
aza None None B-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
[ None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
phenanthridin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
( None None O
i.e. None None O
, None None O
benzonaphthyridones None None O
) None None O
was None None O
dependent None None O
on None None O
the None None O
position None None O
of None None O
the None None O
nitrogen None None O
atom None None O
within None None O
the None None O
core None None O
structure None None O
. None None O

The None None O
A None None O
ring None None O
nitrogen None None O
analogues None None O
( None None O
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
10 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
[ None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
phenanthridin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
) None None O
were None None O
an None None O
order None None O
of None None O
magnitude None None O
less None None O
potent None None O
than None None O
C None None O
ring None None O
nitrogen None None O
analogues None None O
( None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
[ None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
phenanthridin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
) None None O
. None None O

Preliminary None None O
stroke None None O
results None None O
from None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
[ None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
phenanthridin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
prompted None None O
structure None None O
- None None O
activity None None O
relationships None None O
to None None O
be None None O
established None None O
for None None O
several None None O
2 None None I-MODIFIER
- None None I-MODIFIER
and None None O
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
1 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
[ None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
phenanthridin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
. None None O

The None None O
2 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
1 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
[ None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
phenanthridin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
were None None O
designed None None O
to None None O
improve None None O
the None None O
solubility None None O
and None None O
pharmacokinetic None None O
profiles None None O
for None None O
this None None O
series None None O
of None None O
PARP None None O
- None None O
1 None None O
inhibitors None None O
. None None O

Most None None O
importantly None None O
, None None O
three None None O
compounds None None O
from None None O
this None None O
series None None O
demonstrated None None O
statistically None None O
significant None None O
protective None None O
effects None None O
in None None O
rat None None O
models None None O
of None None O
stroke None None O
and None None O
heart None None O
ischemia None None O
. None None O


Following None None O
the None None O
discovery None None O
of None None O
moderately None None O
potent None None O
antagonist None None O
activity None None O
platelet None None O
- None None O
activating None None O
factor None None O
( None None O
PAF None None O
) None None O
in None None O
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
( None None O
2 None None O
) None None O
( None None O
IC50 None None O
= None None O
840 None None O
nM None None O
) None None O
, None None O
19 None None O
derivatives None None O
( None None O
3-21 None None O
) None None O
were None None O
prepared None None O
which None None O
incorporated None None O
various None None O
lipophilic None None O
groups None None O
attached None None O
to None None O
the None None O
phenyl None None O
4 None None O
- None None O
position None None O
. None None O

Structure None None O
- None None O
activity None None O
relationships None None O
were None None O
evaluated None None O
where None None O
PAF None None O
antagonist None None O
activity None None O
was None None O
measured None None O
in None None O
vitro None None O
by None None O
determining None None O
the None None O
concentration None None O
of None None O
compound None None O
( None None O
IC50 None None O
) None None O
required None None O
to None None O
inhibit None None O
the None None O
PAF None None O
- None None O
induced None None O
aggregation None None O
of None None O
rabbit None None O
washed None None O
platelets None None O
and None None O
in None None O
vivo None None O
by None None O
determining None None O
the None None O
oral None None O
dose None None O
( None None O
ED50 None None O
) None None O
which None None O
protected None None O
mice None None O
from None None O
a None None O
lethal None None O
injection None None O
of None None O
PAF None None O
. None None O

[ None None I-IUPAC
1,5 None None I-IUPAC
] None None I-IUPAC
Benzodiazepines None None I-IUPAC
, None None O
e.g. None None O
, None None O
14 None None O
( None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyrid None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
] None None I-IUPAC
benzodiazepin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
) None None O
( None None O
IC50 None None O
= None None O
4.9 None None O
nM None None O
, None None O
Ed50 None None O
= None None O
0.03 None None O
mg None None O
/ None None O
kg None None O
po None None O
) None None O
, None None O
were None None O
found None None O
to None None O
possess None None O
equivalent None None O
or None None O
superior None None O
potency None None O
to None None O
the None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyridine None None I-IUPAC
PAF None None O
antagonist None None O
UK None None O
- None None O
74,505 None None O
( None None O
1,4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyrid None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
carbamoyl None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
) None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

Furthermore None None O
, None None O
a None None O
potent None None O
benzazepine None None O
, None None O
21 None None O
( None None O
7,8 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyrid None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,3,4,5 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzazepin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
) None None O
( None None O
IC50 None None O
= None None O
0.5 None None O
nM None None O
, None None O
ED50 None None O
= None None O
0.03 None None O
mg None None O
/ None None O
kg None None O
po None None O
) None None O
, None None O
was None None O
discovered None None O
. None None O

These None None O
investigations None None O
prompted None None O
the None None O
synthesis None None O
and None None O
evaluation None None O
of None None O
additional None None O
diazepine None None O
derivatives None None O
, None None O
which None None O
are None None O
described None None O
in None None O
the None None O
following None None O
paper None None O
. None None O

The None None O
relationship None None O
between None None O
the None None O
key None None O
PAF None None O
antagonist None None O
pharmacophores None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
, None None O
a None None O
triazolothienodiazepine None None O
( None None O
WEB2170 None None O
) None None O
, None None O
and None None O
a None None O
pyrrolothiazolidine None None O
( None None O
RP None None O
- None None O
52,770 None None O
) None None O
is None None O
discussed None None O
. None None O


Various None None O
substituted None None O
isoquinoline None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxaldehyde None None I-IUPAC
thiosemicarbazones None None I-IUPAC
( None None O
12 None None O
compounds None None O
) None None O
have None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
antineoplastic None None O
activity None None O
in None None O
mice None None O
bearing None None O
the None None O
L1210 None None O
leukemia None None O
. None None O

Condensation None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methylisoquinoline None None I-IUPAC
( None None O
4 None None O
) None None O
with None None O
ammonium None None O
hydroxide None None O
, None None O
methylamine None None O
, None None O
ethylamine None None O
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
acetylethylenediamine None None I-IUPAC
gave None None O
the None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
, None None O
4 None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
, None None O
4 None None I-IUPAC
- None None I-IUPAC
ethylamino None None I-IUPAC
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
acetylethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
which None None O
were None None O
then None None O
converted None None O
to None None O
amides None None O
and None None O
subsequently None None O
oxidized None None O
to None None O
aldehydes None None O
followed None None O
by None None O
condensation None None O
with None None O
thiosemicarbazide None None O
to None None O
yield None None O
thiosemicarbazones None None O
8a None None O
- None None O
c None None O
, None None O
9a None None O
- None None O
c None None O
, None None O
and None None O
16 None None O
. None None O

Nitration None None O
of None None O
4 None None O
, None None O
followed None None O
by None None O
oxidation None None O
with None None O
selenium None None O
dioxide None None O
, None None O
produced None None O
aldehyde None None O
18 None None O
, None None O
which None None O
was None None O
then None None O
converted None None O
to None None O
the None None O
cyclic None None O
ethylene None None O
acetal None None O
19 None None O
. None None O

Condensation None None O
of None None O
19 None None O
with None None O
morpholine None None O
followed None None O
by None None O
catalytic None None O
reduction None None O
of None None O
the None None O
nitro None None O
group None None O
and None None O
treatment None None O
with None None O
thiosemicarbazide None None O
afforded None None O
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
morpholinoisoquinoline None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxaldehyde None None I-IUPAC
thiosemicarbazone None None I-IUPAC
( None None O
22 None None O
) None None O
. None None O

N None None O
- None None O
Oxidation None None O
of None None O
1,5 None None I-IUPAC
- None None I-IUPAC
dimethylisoquinoline None None I-IUPAC
, None None O
followed None None O
by None None O
rearrangement None None O
with None None O
acetic None None O
anhydride None None O
, None None O
gave None None O
, None None O
after None None O
acid None None O
hydrolysis None None O
, None None O
1,5 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyisoquinoline None None I-IUPAC
, None None O
which None None O
was None None O
converted None None O
to None None O
its None None O
acetate None None O
and None None O
then None None O
oxidized None None O
to None None O
yield None None O
4 None None I-IUPAC
- None None I-IUPAC
acetoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoquinoline None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxaldehyde None None I-IUPAC
( None None O
32 None None O
) None None O
. None None O

Sulfonation None None O
of None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dimethylisoquinoline None None I-IUPAC
, None None O
followed None None O
by None None O
reaction None None O
with None None O
potassium None None O
hydroxide None None O
, None None O
acetylation None None O
, None None O
and None None O
oxidation None None O
, None None O
gave None None O
5 None None I-IUPAC
- None None I-IUPAC
acetoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylisoquinoline None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxaldehyde None None I-IUPAC
( None None O
40 None None O
) None None O
. None None O

Condensation None None O
of None None O
compounds None None O
32 None None O
and None None O
39 None None O
with None None O
thiosemicarbazide None None O
afforded None None O
the None None O
respective None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
acetoxy None None I-PARTIUPAC
( None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
) None None I-PARTIUPAC
thiosemicarbazones None None I-PARTIUPAC
33 None None O
and None None O
40 None None O
, None None O
which None None O
were None None O
then None None O
converted None None O
to None None O
their None None O
respective None None O
4 None None O
- None None O
and None None O
5 None None O
- None None O
hydroxy None None O
derivatives None None O
34 None None O
and None None O
41 None None O
by None None O
acid None None O
hydrolysis None None O
. None None O

The None None O
most None None O
active None None O
compounds None None O
synthesized None None O
were None None O
4 None None I-IUPAC
- None None I-IUPAC
aminoisoquinoline None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxaldehyde None None I-IUPAC
thiosemicarbazone None None I-IUPAC
( None None O
9a None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylamino None None I-IUPAC
) None None I-IUPAC
isoquinoline None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxaldehyde None None I-IUPAC
thiosemicarbazone None None I-IUPAC
( None None O
9b None None O
) None None O
, None None O
which None None O
both None None O
produced None None O
optimum None None O
% None None O
T None None O
/ None None O
C None None O
values None None O
of None None O
177 None None O
against None None O
the None None O
L1210 None None O
leukemia None None O
in None None O
mice None None O
when None None O
used None None O
at None None O
a None None O
daily None None O
dosage None None O
of None None O
40 None None O
mg None None O
/ None None O
kg None None O
for None None O
6 None None O
consecutive None None O
days None None O
. None None O

Furthermore None None O
, None None O
when None None O
9a None None O
was None None O
given None None O
twice None None O
daily None None O
at None None O
a None None O
dosage None None O
of None None O
40 None None O
mg None None O
/ None None O
kg None None O
for None None O
6 None None O
consecutive None None O
days None None O
, None None O
a None None O
T None None O
/ None None O
C None None O
value None None O
of None None O
165 None None O
was None None O
obtained None None O
and None None O
60% None None O
of None None O
the None None O
mice None None O
were None None O
60 None None O
- None None O
day None None O
long None None O
- None None O
term None None O
survivors None None O
. None None O


An None None O
enzymatically None None O
activated None None O
liposome None None O
- None None O
based None None O
drug None None O
- None None O
delivery None None O
concept None None O
involving None None O
masked None None O
antitumor None None O
ether None None O
lipids None None O
( None None O
AELs None None O
) None None O
has None None O
been None None O
investigated None None O
. None None O

This None None O
concept None None O
takes None None O
advantage None None O
of None None O
the None None O
cytotoxic None None O
properties None None O
of None None O
AEL None None O
drugs None None O
as None None O
well None None O
as None None O
the None None O
membrane None None O
permeability None None O
enhancing None None O
properties None None O
of None None O
these None None O
molecules None None O
, None None O
which None None O
can None None O
lead None None O
to None None O
enhanced None None O
drug None None O
diffusion None None O
into None None O
cells None None O
. None None O

Three None None O
prodrugs None None O
of None None O
AELs None None O
( None None O
proAELs None None O
) None None O
have None None O
been None None O
synthesized None None O
and None None O
four None None O
liposome None None O
systems None None O
, None None O
consisting None None O
of None None O
these None None O
proAELs None None O
, None None O
were None None O
investigated None None O
for None None O
enzymatic None None O
degradation None None O
by None None O
secretory None None O
phospholipase None None O
A None None O
( None None O
2 None None O
) None None O
( None None O
sPLA None None O
( None None O
2 None None O
) None None O
) None None O
, None None O
resulting None None O
in None None O
the None None O
release None None O
of None None O
AELs None None O
. None None O

The None None O
three None None O
synthesized None None O
proAELs None None O
were None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
hexadecyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
palmitoyl None None I-IUPAC
- None None I-IUPAC
sn None None I-IUPAC
- None None I-IUPAC
glycero None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phosphocholine None None I-IUPAC
( None None O
1 None None O
- None None O
O None None O
- None None O
DPPC None None O
) None None O
, None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
hexadecyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
palmitoyl None None I-IUPAC
- None None I-IUPAC
sn None None I-IUPAC
- None None I-IUPAC
glycero None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phosphoethanolamine None None I-IUPAC
poly None None I-IUPAC
( None None I-IUPAC
ethylene None None I-IUPAC
glycol None None I-IUPAC
) None None I-IUPAC
( None None O
350 None None O
) None None O
( None None O
1 None None O
- None None O
O None None O
- None None O
DPPE None None O
- None None O
PEG None None O
( None None O
350 None None O
) None None O
) None None O
, None None O
and None None O
1 None None O
- None None O
O None None O
- None None O
DPPE None None O
- None None O
PEG None None O
( None None O
2000 None None O
) None None O
of None None O
which None None O
1 None None O
- None None O
O None None O
- None None O
DPPC None None O
was None None O
the None None O
main None None O
liposome None None O
component None None O
. None None O

All None None O
three None None O
phospholipids None None O
were None None O
synthesized None None O
from None None O
the None None O
versatile None None O
starting None None O
material None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
glycidol None None I-IUPAC
. None None O

A None None O
phosphorylation None None O
method None None O
, None None O
employing None None O
methyl None None O
dichlorophosphate None None O
, None None O
was None None O
developed None None O
and None None O
applied None None O
in None None O
the None None O
synthesis None None O
of None None O
two None None O
analogues None None O
of None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
hexadecyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
palmitoyl None None I-IUPAC
- None None I-IUPAC
sn None None I-IUPAC
- None None I-IUPAC
glycero None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phosphoethanolamine None None I-IUPAC
poly None None I-IUPAC
( None None I-IUPAC
ethylene None None I-IUPAC
glycol None None I-IUPAC
) None None I-IUPAC
. None None O

Differential None None O
scanning None None O
calorimetry None None O
has None None O
been None None O
used None None O
to None None O
investigate None None O
the None None O
phase None None O
behavior None None O
of None None O
the None None O
lipid None None O
bilayers None None O
. None None O

A None None O
release None None O
study None None O
, None None O
employing None None O
calcein None None O
encapsulated None None O
in None None O
non None None O
- None None O
hydrolyzable None None O
1,2 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
octadecyl None None I-IUPAC
- None None I-IUPAC
sn None None I-IUPAC
- None None I-IUPAC
glycero None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phosphocholine None None I-IUPAC
( None None O
D None None O
- None None O
O None None O
- None None O
SPC None None O
) None None O
liposomes None None O
, None None O
showed None None O
that None None O
proAELs None None O
, None None O
activated None None O
by None None O
sPLA None None O
( None None O
2 None None O
) None None O
, None None O
perturb None None O
membranes None None O
because None None O
of None None O
the None None O
detergent None None O
- None None O
like None None O
properties None None O
of None None O
the None None O
released None None O
hydrolysis None None O
products None None O
. None None O

A None None O
hemolysis None None O
investigation None None O
was None None O
conducted None None O
on None None O
human None None O
red None None O
blood None None O
cells None None O
, None None O
and None None O
the None None O
results None None O
demonstrate None None O
that None None O
proAEL None None O
liposomes None None O
display None None O
a None None O
very None None O
low None None O
hemotoxicity None None O
, None None O
which None None O
has None None O
been None None O
a None None O
major None None O
obstacle None None O
for None None O
using None None O
AELs None None O
in None None O
cancer None None O
therapy None None O
. None None O

The None None O
results None None O
suggest None None O
a None None O
possible None None O
way None None O
of None None O
combining None None O
a None None O
drug None None O
- None None O
delivery None None O
and None None O
prodrug None None O
concept None None O
in None None O
a None None O
single None None O
liposome None None O
system None None O
. None None O

Our None None O
investigation None None O
of None None O
the None None O
permeability None None O
- None None O
enhancing None None O
properties None None O
of None None O
the None None O
AEL None None O
molecules None None O
imply None None O
that None None O
by None None O
encapsulating None None O
conventional None None O
chemotherapeutic None None O
drugs None None O
, None None O
such None None O
as None None O
doxorubicin None None O
, None None O
in None None O
liposomes None None O
consisting None None O
of None None O
proAELs None None O
, None None O
an None None O
increased None None O
effect None None O
of None None O
the None None O
encapsulated None None O
drug None None O
might None None O
be None None O
achievable None None O
due None None O
to None None O
an None None O
enhanced None None O
transmembrane None None O
drug None None O
diffusion None None O
. None None O


As None None O
a None None O
continuation None None O
of None None O
our None None O
earlier None None O
study None None O
( None None O
J None None O
. None None O

Med. None None O
Chem. None None O
1992 None None O
, None None O
35 None None O
, None None O
4334-4343 None None O
) None None O
we None None O
conformationally None None O
restricted None None O
the None None O
sigma None None O
- None None O
receptor None None O
ligand None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylethylamine None None I-IUPAC
( None None O
1 None None O
) None None O
by None None O
incorporating None None O
it None None O
into None None O
a None None O
series None None O
of None None O
homologous None None O
piperazines None None O
3-9 None None O
and None None O
homopiperazines None None O
10 None None O
and None None O
11 None None O
, None None O
diazabicyclononanes None None O
and None None O
decanes None None O
, None None O
bridgehead None None O
bicyclooctanes None None O
and None None O
nonanes None None O
as None None O
well None None O
as None None O
other None None O
miscellaneous None None O
compounds None None O
. None None O

sigma None None O
- None None O
Receptor None None O
binding None None O
affinities None None O
were None None O
obtained None None O
using None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pentazocine None None I-IUPAC
in None None O
guinea None None O
pig None None O
brain None None O
membrane None None O
sigma None None O
1 None None O
sites None None O
. None None O

The None None O
studies None None O
suggest None None O
that None None O
the None None O
nitrogen None None O
lone None None O
pair None None O
orientation None None O
found None None O
in None None O
the None None O
piperazines None None O
affords None None O
the None None O
strongest None None O
binding None None O
interaction None None O
. None None O

Other None None O
nitrogen None None O
lone None None O
pair None None O
orientations None None O
or None None O
compounds None None O
representing None None O
unlikely None None O
staggered None None O
conformations None None O
of None None O
1 None None O
[ None None O
as None None O
in None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
diazabicyclo None None I-IUPAC
[ None None I-IUPAC
3.2.2 None None I-IUPAC
] None None I-IUPAC
nonane None None I-IUPAC
( None None O
16 None None O
) None None O
] None None O
show None None O
very None None O
weak None None O
sigma None None O
interaction None None O
. None None O

Comparison None None O
of None None O
the None None O
binding None None O
data None None O
of None None O
different None None O
N None None O
- None None O
substituted None None O
homologues None None O
of None None O
1 None None O
with None None O
those None None O
of None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
alkylpiperazines None None I-IUPAC
suggests None None O
that None None O
the None None O
two None None O
nitrogen None None O
atoms None None O
of None None O
1 None None O
are None None O
working None None O
in None None O
opposition None None O
to None None O
one None None O
another None None O
in None None O
terms None None O
of None None O
their None None O
sensitivity None None O
to None None O
steric None None O
bulk None None O
. None None O

The None None O
high None None O
binding None None O
affinity None None O
of None None O
the None None O
1,4 None None I-IUPAC
- None None I-IUPAC
diazabicyclo None None I-IUPAC
[ None None O
4.3.0 None None O
] None None O
nonanes None None I-IUPAC
12 None None O
suggests None None O
that None None O
these None None O
may None None O
approximate None None O
the None None O
methyl None None O
and None None O
pyrrolidine None None O
ring None None O
conformations None None O
found None None O
in None None O
1 None None O
when None None O
it None None O
is None None O
bound None None O
to None None O
the None None O
sigma None None O
receptor None None O
. None None O

Compound None None O
12 None None O
exhibited None None O
a None None O
4 None None O
- None None O
fold None None O
enantioselectivity None None O
favoring None None O
( None None O
+ None None O
) None None O
- None None O
12 None None O
. None None O

The None None O
synthesis None None O
of None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
tetralin None None I-IUPAC
( None None O
19 None None O
) None None O
and None None O
its None None O
desmethyl None None I-IUPAC
derivative None None I-IUPAC
20 None None O
permitted None None O
constraint None None O
of None None O
the None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
moieties None None I-MODIFIER
of None None O
1 None None O
into None None O
a None None O
gauche None None O
orientation None None O
. None None O

The None None O
binding None None O
data None None O
suggests None None O
that None None O
this None None O
conformation None None O
in None None O
1 None None O
favors None None O
strong None None O
binding None None O
interaction None None O
at None None O
sigma None None O
- None None O
receptors None None O
. None None O

sigma None None O
- None None O
Receptor None None O
Ki None None O
's None None O
ranged None None O
from None None O
0.55 None None O
nM None None O
for None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butylpiperazine None None I-IUPAC
( None None O
7 None None O
) None None O
to None None O
654 None None O
nM None None O
for None None O
16 None None O
. None None O

Overall None None O
comparison None None O
of None None O
the None None O
results None None O
indicate None None O
that None None O
1 None None O
is None None O
subject None None O
to None None O
considerable None None O
conformational None None O
freedom None None O
and None None O
suggests None None O
that None None O
the None None O
sigma None None O
receptor None None O
is None None O
not None None O
subject None None O
to None None O
rigid None None O
stereochemical None None O
restraints None None O
with None None O
1 None None O
. None None O

These None None O
results None None O
add None None O
to None None O
our None None O
earlier None None O
study None None O
where None None O
we None None O
restrained None None O
1 None None O
using None None O
simple None None O
monocyclic None None O
heterocycles None None O
. None None O


A None None O
number None None O
of None None O
7 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
aminopyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carbonitrile None None I-IUPAC
, None None O
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
, None None O
and None None O
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
thiocarboxamide None None I-IUPAC
derivatives None None I-MODIFIER
related None None O
to None None O
the None None O
nucleoside None None O
antibiotics None None O
toyocamycin None None O
and None None O
sangivamycin None None O
were None None O
prepared None None O
and None None O
tested None None O
for None None O
their None None O
activity None None O
against None None O
human None None O
cytomegalovirus None None O
( None None O
HCMV None None O
) None None O
and None None O
herpes None None O
simplex None None O
virus None None O
type None None O
- None None O
1 None None O
( None None O
HSV None None O
- None None O
1 None None O
) None None O
. None None O

Treatment None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dicyanopyrrole None None I-IUPAC
( None None O
1 None None O
) None None O
with None None O
triethyl None None O
orthoformate None None O
followed None None O
by None None O
alkylation None None O
via None None O
the None None O
sodium None None O
salt None None O
method None None O
with None None O
a None None O
variety None None O
of None None O
alkylating None None O
agents None None O
furnished None None O
the None None O
corresponding None None O
1 None None O
- None None O
substituted None None O
pyrroles None None O
2a None None O
- None None O
k None None O
. None None O

Ring None None O
annulation None None O
was None None O
achieved None None O
with None None O
methanolic None None O
ammonia None None O
affording None None O
the None None O
7 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
bromopyrrolo+ None None I-IUPAC
+ None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carbonitrile None None I-IUPAC
derivatives None None I-MODIFIER
3a None None O
- None None O
k None None O
. None None O

Debromination None None O
of None None O
3a None None O
- None None O
k None None O
, None None O
via None None O
catalytic None None O
hydrogenation None None O
, None None O
gave None None O
the None None O
corresponding None None O
7 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
aminopyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carbonitrile None None I-IUPAC
analogs None None I-MODIFIER
4a None None O
- None None O
j None None O
, None None O
l None None O
. None None O

A None None O
selective None None O
reduction None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
allylpyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carbon None None I-IUPAC
ril None None I-IUPAC
e None None I-IUPAC
( None None O
3k None None O
) None None O
in None None O
zinc None None O
and None None O
acetic None None O
acid None None O
furnished None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
allylpyrrolo None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carbonitrile None None I-IUPAC
( None None O
4k None None O
) None None O
. None None O

Conventional None None O
functional None None O
group None None O
transformations None None O
involving None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
group None None I-MODIFIER
of None None O
4 None None O
furnished None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
derivatives None None I-MODIFIER
5a None None O
- None None O
1 None None O
and None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
thio None None I-IUPAC
- None None I-IUPAC
amide None None I-IUPAC
analogs None None I-MODIFIER
6a None None O
- None None O
l None None O
. None None O

A None None O
similar None None O
transformation None None O
of None None O
the None None O
aglycone None None O
of None None O
toyocamycin None None O
( None None O
4m None None O
) None None O
furnished None None O
the None None O
corresponding None None O
aglycone None None O
of None None O
thiosangivamycin None None O
( None None O
6m None None O
) None None O
. None None O

Several None None O
of None None O
the None None O
new None None O
compounds None None O
( None None O
4-6 None None O
a None None O
- None None O
ej None None O
- None None O
l None None O
) None None O
were None None O
evaluated None None O
for None None O
their None None O
ability None None O
to None None O
inhibit None None O
the None None O
growth None None O
of None None O
L1210 None None O
murine None None O
leukemic None None O
cells None None O
. None None O

Whereas None None O
a None None O
number None None O
of None None O
the None None O
carboxamide None None O
( None None O
5 None None O
) None None O
and None None O
thioamide None None O
( None None O
6 None None O
) None None O
derivatives None None O
had None None O
modest None None O
activity None None O
, None None O
the None None O
corresponding None None O
nitrile None None I-IUPAC
analogs None None B-MODIFIER
( None None O
4 None None O
) None None O
were None None O
all None None O
inactive None None O
. None None O

All None None O
compounds None None O
were None None O
tested None None O
for None None O
activity None None O
against None None O
HCMV None None O
and None None O
HSV None None O
- None None O
1 None None O
. None None O

The None None O
non None None O
- None None O
nucleoside None None O
nitrile None None O
analogs None None O
4a None None O
- None None O
m None None O
and None None O
carboxamide None None I-IUPAC
derivatives None None B-MODIFIER
5a None None O
- None None O
l None None O
were None None O
, None None O
with None None O
a None None O
few None None O
exceptions None None O
, None None O
essentially None None O
inactive None None O
against None None O
HCMV None None O
and None None O
HSV None None O
- None None O
1 None None O
and None None O
relatively None None O
nontoxic None None O
. None None O

In None None O
direct None None O
contrast None None O
, None None O
nearly None None O
all None None O
of None None O
the None None O
thioamide None None I-IUPAC
derivates None None B-MODIFIER
6a None None O
- None None O
1 None None O
, None None O
including None None O
the None None O
aglycone None None O
of None None O
thiosangivamycin None None O
( None None O
6m None None O
) None None O
, None None O
were None None O
good None None O
inhibitors None None O
of None None O
HCMV None None O
and None None O
HSV None None O
- None None O
1 None None O
. None None O

Most None None O
were None None O
noncytotoxic None None O
in None None O
their None None O
antiviral None None O
concentration None None O
range None None O
. None None O

Cytotoxicity None None O
which None None O
was None None O
observed None None O
appeared None None O
to None None O
be None None O
a None None O
consequence None None O
of None None O
DNA None None O
synthesis None None O
inhibition None None O
. None None O

Several None None O
of None None O
these None None O
compounds None None O
, None None O
such None None O
as None None O
6b None None O
, None None O
e None None O
, None None O
were None None O
particularly None None O
interesting None None O
inhibitors None None O
of None None O
HCMV None None O
with None None O
IC None None O
( None None O
50 None None O
) None None O
's None None O
ranging None None O
from None None O
0.1 None None O
to None None O
1.3 None None O
muM None None O
. None None O

The None None O
antiviral None None O
activity None None O
of None None O
both None None O
compounds None None O
was None None O
well None None O
separated None None O
from None None O
cytotoxicity None None O
in None None O
KB None None O
, None None O
HFF None None O
, None None O
and None None O
L1210 None None O
cells None None O
. None None O


The None None O
antitumor None None O
activity None None O
of None None O
various None None O
platinum None None O
( None None O
II None None O
) None None O
complexes None None O
of None None O
1,2 None None I-IUPAC
- None None I-IUPAC
cyclohexanediamine None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
cyclohexylamine None None I-IUPAC
isomers None None O
against None None O
leukemia None None O
P388 None None O
was None None O
evaluated None None O
by None None O
means None None O
of None None O
the None None O
platinum None None O
analogue None None O
study None None O
protocol None None O
recommended None None O
by None None O
the None None O
National None None O
Cancer None None O
Institute None None O
. None None O

For None None O
the None None O
former None None O
complexes None None O
, None None O
trans None None O
isomers None None O
are None None O
more None None O
efficacious None None O
than None None O
the None None O
corresponding None None O
cis None None O
isomers None None O
. None None O

For None None O
the None None O
latter None None O
complexes None None O
, None None O
cis None None O
isomers None None O
seem None None O
to None None O
be None None O
somewhat None None O
more None None O
active None None O
than None None O
trans None None O
isomers None None O
. None None O

2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Aminomethyl None None I-IUPAC
) None None I-IUPAC
cyclohexylamine None None I-IUPAC
platinum None None I-IUPAC
complexes None None I-MODIFIER
exhibited None None O
higher None None O
activity None None O
than None None O
1,2 None None I-IUPAC
- None None I-IUPAC
cyclohexanediamine None None I-IUPAC
complexes None None I-MODIFIER
in None None O
this None None O
tumor None None O
system None None O
. None None O

These None None O
findings None None O
encouraged None None O
us None None O
to None None O
determine None None O
the None None O
structural None None O
differences None None O
between None None O
1,2 None None I-IUPAC
- None None I-IUPAC
cyclohexanediamine None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
cyclohexylamine None None I-IUPAC
complexes None None I-MODIFIER
. None None O

Their None None O
structures None None O
of None None O
platinum None None O
complexes None None O
were None None O
elucidated None None O
from None None O
circular None None O
dichroism None None O
and None None O
13C None None O
NMR None None O
spectral None None O
analyses None None O
, None None O
and None None O
it None None O
has None None O
been None None O
concluded None None O
that None None O
the None None O
cyclohexane None None O
ring None None O
of None None O
cis None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
cyclohexanediamine None None I-IUPAC
is None None O
nearly None None O
perpendicular None None O
to None None O
the None None O
chelate None None O
ring None None O
, None None O
while None None O
both None None O
rings None None O
of None None O
trans None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
cyclohexanediamine None None I-IUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
cyclohexylamine None None I-IUPAC
complexes None None I-MODIFIER
lie None None O
in None None O
a None None O
common None None O
plane None None O
. None None O

The None None O
structure None None O
of None None O
cis None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
cyclohexylamine None None I-IUPAC
complexes None None I-MODIFIER
is None None O
flexible None None O
, None None O
and None None O
the None None O
cyclohexane None None O
ring None None O
is None None O
not None None O
perpendicular None None O
to None None O
the None None O
chelate None None O
ring None None O
. None None O

The None None O
coplanarity None None O
of None None O
trans None None O
isomers None None O
and None None O
the None None O
flexibility None None O
of None None O
cis None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
cyclohexylamine None None I-IUPAC
complexes None None I-MODIFIER
allow None None O
them None None O
easy None None O
approach None None O
to None None O
the None None O
target None None O
DNA None None O
. None None O

However None None O
, None None O
the None None O
perpendicular None None O
ring None None O
of None None O
cis None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
cyclohexanediamine None None I-IUPAC
complexes None None I-MODIFIER
would None None O
prevent None None O
their None None O
interactions None None O
with None None O
dna None None O
molecules None None O
due None None O
to None None O
the None None O
steric None None O
hindrance None None O
. None None O


Two None None O
novel None None O
classical None None O
antifolates None None O
N None None I-IUPAC
- None None I-IUPAC
{ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4,7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
thio None None I-IUPAC
] None None I-IUPAC
benzoyl None None I-IUPAC
} None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
3 None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
{ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4,7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
thio None None I-IUPAC
] None None I-IUPAC
benzoyl None None I-IUPAC
} None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
4 None None O
were None None O
designed None None O
, None None O
synthesized None None O
, None None O
and None None O
evaluated None None O
as None None O
antitumor None None O
agents None None O
. None None O

Compounds None None O
3 None None O
and None None O
4 None None O
were None None O
obtained None None O
from None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylpyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
7 None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylpyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
12 None None O
, None None O
respectively None None O
, None None O
in None None O
a None None O
concise None None O
three None None O
- None None O
step None None O
sequence None None O
. None None O

Compound None None O
3 None None O
is None None O
the None None O
first None None O
example None None O
, None None O
to None None O
our None None O
knowledge None None O
, None None O
of None None O
a None None O
2,4 None None O
- None None O
diamino None None O
classical None None O
antifolate None None O
that None None O
has None None O
potent None None O
inhibitory None None O
activity None None O
against None None O
both None None O
human None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
and None None O
human None None O
thymidylate None None O
synthase None None O
( None None O
TS None None O
) None None O
. None None O

Compound None None O
4 None None O
was None None O
a None None O
dual None None O
DHFR None None O
- None None O
TS None None O
inhibitor None None O
against None None O
the None None O
bifunctional None None O
enzyme None None O
derived None None O
from None None O
Toxoplasma None None O
gondii None None O
( None None O
tg None None O
) None None O
. None None O

Further None None O
evaluation None None O
of None None O
the None None O
mechanism None None O
of None None O
action None None O
of None None O
3 None None O
implicated None None O
DHFR None None O
as None None O
its None None O
primary None None O
intracellular None None O
target None None O
. None None O

Both None None O
3 None None O
and None None O
4 None None O
were None None O
folylpolyglutamate None None O
synthetase None None O
( None None O
FPGS None None O
) None None O
substrates None None O
. None None O

Compound None None O
3 None None O
also None None O
inhibited None None O
the None None O
growth None None O
of None None O
several None None O
human None None O
tumor None None O
cell None None O
lines None None O
in None None O
culture None None O
with None None O
GI50 None None O
& None None O
lt None None O
; None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
. None None O

This None None O
study None None O
shows None None O
that None None O
the None None O
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
scaffold None None I-MODIFIER
is None None O
conducive None None O
to None None O
dual None None O
DHFR None None O
- None None O
TS None None O
and None None O
tumor None None O
inhibitory None None O
activity None None O
, None None O
and None None O
the None None O
potency None None O
is None None O
determined None None O
by None None O
the None None O
4 None None O
- None None O
position None None O
substituent None None O
. None None O


A None None O
diverse None None O
range None None O
of None None O
chromen None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
, None None O
chromen None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
and None None O
pyrimidoisoquinolin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
derivatives None None I-MODIFIER
was None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
inhibitory None None O
activity None None O
against None None O
the None None O
DNA None None O
repair None None O
enzyme None None O
DNA None None O
- None None O
dependent None None O
protein None None O
kinase None None O
( None None O
DNA None None O
- None None O
PK None None O
) None None O
, None None O
with None None O
a None None O
view None None O
to None None O
elucidating None None O
structure None None O
- None None O
activity None None O
relationships None None O
for None None O
potency None None O
and None None O
kinase None None O
selectivity None None O
. None None O

DNA None None O
- None None O
PK None None O
inhibitory None None O
activity None None O
varied None None O
widely None None O
over None None O
the None None O
series None None O
of None None O
compounds None None O
evaluated None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
ranged None None O
from None None O
0.19 None None O
to None None O
& None None O
gt None None O
; None None O
10 None None O
microM None None O
) None None O
, None None O
with None None O
excellent None None O
activity None None O
being None None O
observed None None O
for None None O
the None None O
7,8 None None I-IUPAC
- None None I-IUPAC
benzochromen None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
and None None O
pyrimido None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
isoquinolin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
templates None None O
. None None O

By None None O
contrast None None O
, None None O
inhibitors None None O
based None None O
on None None O
the None None O
benzochromen None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
coumarin None None O
) None None O
or None None O
2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
benzochromen None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
flavone None None O
) None None O
scaffolds None None I-MODIFIER
were None None O
less None None O
potent None None O
. None None O

Crucially None None O
, None None O
these None None O
studies None None O
revealed None None O
a None None O
very None None O
constrained None None O
structure None None O
- None None O
activity None None O
relationship None None O
at None None O
the None None O
2 None None O
- None None O
position None None O
of None None O
the None None O
benzopyranone None None O
and None None O
pyrimido None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
isoquinolin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
pharmacophore None None I-MODIFIER
, None None O
with None None O
only None None O
a None None O
2 None None I-IUPAC
- None None I-IUPAC
morpholino None None I-IUPAC
or None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
methylmorpholino None None I-IUPAC
) None None I-IUPAC
group None None I-MODIFIER
being None None O
tolerated None None O
at None None O
this None None O
position None None O
. None None O

More None None O
detailed None None O
biological None None O
studies None None O
conducted None None O
with None None O
the None None O
most None None O
potent None None O
inhibitor None None O
NU7163 None None O
( None None O
48 None None O
; None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.19 None None O
microM None None O
) None None O
demonstrated None None O
ATP None None O
- None None O
competitive None None O
DNA None None O
- None None O
PK None None O
inhibition None None O
, None None O
with None None O
a None None O
K None None O
( None None O
i None None O
) None None O
value None None O
of None None O
24 None None O
nM None None O
, None None O
and None None O
48 None None O
exhibited None None O
selectivity None None O
for None None O
DNA None None O
- None None O
PK None None O
compared None None O
with None None O
the None None O
related None None O
enzymes None None O
ATM None None O
, None None O
ATR None None O
, None None O
mTOR None None O
, None None O
and None None O
PI None None O
3 None None O
- None None O
K None None O
( None None O
p110alpha None None O
) None None O
. None None O

Compound None None O
48 None None O
sensitized None None O
the None None O
HeLa None None O
human None None O
tumor None None O
cell None None O
line None None O
to None None O
the None None O
cytotoxic None None O
effects None None O
of None None O
ionizing None None O
radiation None None O
in None None O
vitro None None O
, None None O
a None None O
dose None None O
modification None None O
factor None None O
of None None O
2.3 None None O
at None None O
10% None None O
survival None None O
being None None O
observed None None O
with None None O
an None None O
inhibitor None None O
concentration None None O
of None None O
5 None None O
microM None None O
. None None O

This None None O
study None None O
identified None None O
these None None O
structural None None O
classes None None O
as None None O
novel None None O
DNA None None O
- None None O
PK None None O
inhibitors None None O
and None None O
delineated None None O
initial None None O
structure None None O
- None None O
activity None None O
relationships None None O
against None None O
DNA None None O
- None None O
PK None None O
. None None O


A None None O
series None None O
of None None O
analogues None None O
and None None O
homologues None None O
of None None O
N1 None None I-IUPAC
, None None I-IUPAC
N12 None None I-IUPAC
- None None I-IUPAC
diethylspermine None None I-IUPAC
( None None O
DESPM None None O
) None None O
was None None O
synthesized None None O
, None None O
and None None O
their None None O
biological None None O
properties None None O
were None None O
evaluated None None O
. None None O

These None None O
tetraamines None None O
include None None O
a None None O
simple None None O
linear None None O
analogue None None O
of None None O
DESPM None None O
, None None O
N1 None None I-IUPAC
, None None I-IUPAC
N12 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2,2,2 None None I-IUPAC
- None None I-IUPAC
trifluoroethyl None None I-IUPAC
) None None I-IUPAC
spermine None None I-IUPAC
( None None O
FDESPM None None O
) None None O
, None None O
the None None O
cyclic None None O
analogues None None O
of None None O
DESPM None None O
, None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidinylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
diaminobutane None None I-IUPAC
[ None None O
PIP None None O
( None None O
4,4,4 None None O
) None None O
] None None O
and None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
diaminobutane None None I-IUPAC
[ None None O
PIP None None O
( None None O
5,4,5 None None O
) None None O
] None None O
, None None O
and None None O
their None None O
aromatic None None O
counterparts None None O
, None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
diaminobutane None None I-IUPAC
[ None None O
PYR None None O
( None None O
4,4,4 None None O
) None None O
] None None O
and None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
diaminobutane None None I-IUPAC
[ None None O
PYR None None O
( None None O
5,4,5 None None O
) None None O
] None None O
. None None O

The None None O
analogues None None O
FDESPM None None O
, None None O
PIP None None O
( None None O
4,4,4 None None O
) None None O
, None None O
and None None O
PYR None None O
( None None O
4,4,4 None None O
) None None O
have None None O
distances None None O
between None None O
their None None O
nitrogen None None O
atoms None None O
almost None None O
identical None None O
to None None O
those None None O
of None None O
DESPM None None O
. None None O

The None None O
longer None None O
analogues None None O
PIP None None O
( None None O
5,4,5 None None O
) None None O
and None None O
PYR None None O
( None None O
5,4,5 None None O
) None None O
are None None O
very None None O
similar None None O
in None None O
the None None O
spacing None None O
of None None O
their None None O
amino None None O
groups None None O
. None None O

However None None O
, None None O
the None None O
pKa None None O
of None None O
the None None O
nitrogens None None O
in None None O
the None None O
groups None None O
differ None None O
; None None O
thus None None O
, None None O
the None None O
extent None None O
of None None O
protonation None None O
and None None O
the None None O
charge None None O
characteristics None None O
among None None O
the None None O
members None None O
of None None O
the None None O
groups None None O
differ None None O
. None None O

A None None O
comparison None None O
of None None O
the None None O
biological None None O
properties None None O
of None None O
these None None O
compounds None None O
clearly None None O
demonstrates None None O
that None None O
the None None O
tetraamines None None O
must None None O
be None None O
charged None None O
to None None O
be None None O
" None None O
recognized None None O
" None None O
by None None O
the None None O
cell None None O
. None None O

Analogues None None O
with None None O
low None None O
nitrogen None None O
pKa None None O
's None None O
such None None O
that None None O
the None None O
nitrogens None None O
are None None O
poorly None None O
protonated None None O
at None None O
physiological None None O
pH None None O
do None None O
not None None O
compete None None O
well None None O
with None None O
spermidine None None O
for None None O
uptake None None O
and None None O
, None None O
as None None O
expected None None O
, None None O
have None None O
high None None O
96 None None O
h None None O
IC50 None None O
values None None O
and None None O
have None None O
little None None O
effect None None O
on None None O
S None None I-IUPAC
- None None I-IUPAC
adenosylmethionine None None I-IUPAC
decarboxylase None None O
, None None O
ornithine None None O
decarboxylase None None O
, None None O
and None None O
spermidine None None O
/ None None O
spermine None None O
N1 None None O
- None None O
acetyltransferase None None O
activities None None O
and None None O
on None None O
intracellular None None O
polyamine None None O
pools None None O
. None None O


WB None None O
4101 None None O
( None None O
1 None None O
) None None O
- None None O
related None None O
benzodioxanes None None O
were None None O
synthesized None None O
by None None O
replacing None None O
the None None O
ethylene None None O
chain None None O
separating None None O
the None None O
amine None None O
and None None O
the None None O
phenoxy None None O
units None None O
of None None O
1 None None O
with None None O
a None None O
cyclopentanol None None I-IUPAC
moiety None None I-IUPAC
, None None O
a None None O
feature None None O
of None None O
6 None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
cis None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenoxycyclopentyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
meth None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylbenzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiophen None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
5H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
that None None O
was None None O
reported None None O
to None None O
display None None O
an None None O
intriguing None None O
selectivity None None O
profile None None O
at None None O
alpha None None O
( None None O
1 None None O
) None None O
- None None O
adrenoreceptors None None O
. None None O

This None None O
synthesis None None O
strategy None None O
led None None O
to None None O
4 None None O
out None None O
of None None O
16 None None O
possible None None O
stereoisomers None None O
, None None O
which None None O
were None None O
isolated None None O
in None None O
the None None O
case None None O
of None None O
( None None O
- None None O
) None None O
- None None O
3 None None O
, None None O
( None None O
+ None None O
) None None O
- None None O
3 None None O
, None None O
( None None O
- None None O
) None None O
- None None O
4 None None O
, None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
4 None None O
and None None O
whose None None O
absolute None None O
configuration None None O
was None None O
assigned None None O
using None None O
a None None O
chiral None None O
building None None O
block None None O
for None None O
the None None O
synthesis None None O
of None None O
( None None O
- None None O
) None None O
- None None O
3 None None O
starting None None O
from None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
benzodioxine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
( None None O
+ None None O
) None None O
- None None O
9 None None O
) None None O
and None None O
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
2S None None I-IUPAC
, None None I-IUPAC
5S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenoxycyclopentan None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
( None None O
( None None O
+ None None O
) None None O
- None None O
10 None None O
) None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
project None None O
was None None O
to None None O
further None None O
investigate None None O
whether None None O
it None None O
is None None O
possible None None O
to None None O
differentiate None None O
between None None O
these None None O
compounds None None O
with None None O
respect None None O
to None None O
their None None O
affinity None None O
for None None O
alpha None None O
( None None O
1 None None O
) None None O
- None None O
adrenoreceptor None None O
subtypes None None O
and None None O
the None None O
affinity None None O
for None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
receptors None None O
, None None O
as None None O
1 None None O
binds None None O
with None None O
high None None O
affinity None None O
at None None O
both None None O
receptor None None O
systems None None O
. None None O

The None None O
biological None None O
profiles None None O
of None None O
reported None None O
compounds None None O
at None None O
alpha None None O
( None None O
1 None None O
) None None O
- None None O
adrenoreceptor None None O
subtypes None None O
were None None O
assessed None None O
by None None O
functional None None O
experiments None None O
in None None O
isolated None None O
rat None None O
vas None None O
deferens None None O
( None None O
alpha None None O
( None None O
1A None None O
) None None O
) None None O
, None None O
spleen None None O
( None None O
alpha None None O
( None None O
1B None None O
) None None O
) None None O
, None None O
and None None O
aorta None None O
( None None O
alpha None None O
( None None O
1D None None O
) None None O
) None None O
and None None O
by None None O
binding None None O
assays None None O
in None None O
CHO None None O
and None None O
HeLa None None O
cells None None O
membranes None None O
expressing None None O
the None None O
human None None O
cloned None None O
alpha None None O
( None None O
1 None None O
) None None O
- None None O
adrenoreceptor None None O
subtypes None None O
and None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
receptors None None O
, None None O
respectively None None O
. None None O

Furthermore None None O
, None None O
the None None O
functional None None O
activity None None O
of None None O
( None None O
- None None O
) None None O
- None None O
3 None None O
, None None O
( None None O
+ None None O
) None None O
- None None O
3 None None O
, None None O
( None None O
- None None O
) None None O
- None None O
4 None None O
, None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
4 None None O
toward None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
receptors None None O
was None None O
evaluated None None O
by None None O
determining None None O
the None None O
induced None None O
stimulation None None O
of None None O
[ None None O
( None None O
35 None None O
) None None O
S None None O
] None None O
GTPgammaS None None O
binding None None O
in None None O
cell None None O
membranes None None O
from None None O
HeLa None None O
cells None None O
transfected None None O
with None None O
human None None O
cloned None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
receptors None None O
. None None O

The None None O
configuration None None O
of None None O
the None None O
cyclopentane None None O
unit None None O
determined None None O
the None None O
affinity None None O
profile None None O
: None None O
a None None O
1R None None O
configuration None None O
, None None O
as None None O
in None None O
( None None O
+ None None O
) None None O
- None None O
3 None None O
and None None O
( None None O
- None None O
) None None O
- None None O
4 None None O
, None None O
conferred None None O
higher None None O
affinity None None O
at None None O
alpha None None O
( None None O
1 None None O
) None None O
- None None O
adrenoreceptors None None O
, None None O
whereas None None O
a None None O
1S None None O
configuration None None O
, None None O
as None None O
in None None O
( None None O
- None None O
) None None O
- None None O
3 None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
4 None None O
, None None O
produced None None O
higher None None O
affinity None None O
for None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
receptors None None O
. None None O

For None None O
the None None O
enantiomers None None O
( None None O
+ None None O
) None None O
- None None O
4 None None O
and None None O
( None None O
- None None O
) None None O
- None None O
4 None None O
also None None O
a None None O
remarkable None None O
selectivity None None O
was None None O
achieved None None O
. None None O

Functionally None None O
, None None O
the None None O
stereoisomers None None O
displayed None None O
a None None O
similar None None O
alpha None None O
( None None O
1 None None O
) None None O
- None None O
selectivity None None O
profile None None O
, None None O
that None None O
is None None O
alpha None None O
( None None O
1D None None O
) None None O
& None None O
gt None None O
; None None O
alpha None None O
( None None O
1B None None O
) None None O
& None None O
gt None None O
; None None O
alpha None None O
( None None O
1A None None O
) None None O
, None None O
which None None O
is None None O
different None None O
from None None O
that None None O
exhibited None None O
by None None O
the None None O
reference None None O
compound None None O
1 None None O
. None None O

The None None O
epimers None None O
( None None O
- None None O
) None None O
- None None O
3 None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
4 None None O
proved None None O
to None None O
be None None O
agonists None None O
at None None O
the None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
receptors None None O
, None None O
with None None O
a None None O
potency None None O
comparable None None O
to None None O
that None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
hydroxytryptamine None None I-IUPAC
. None None O


The None None O
development None None O
of None None O
99mTc None None O
- None None O
labeled None None O
fatty None None O
acid None None O
analogues None None O
metabolized None None O
by None None O
beta None None O
- None None O
oxidation None None O
in None None O
the None None O
myocardium None None O
constitutes None None O
an None None O
unsolved None None O
challenge None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
our None None O
recent None None O
findings None None O
that None None O
[ None None I-IUPAC
188Re None None I-IUPAC
] None None I-IUPAC
tricarbonyl None None I-IUPAC
( None None I-IUPAC
cyclopentadienylcarbonate None None I-IUPAC
) None None I-IUPAC
rhenium None None I-IUPAC
( None None O
[ None None O
188Re None None O
] None None O
CpTR None None O
- None None O
COOH None None O
) None None O
was None None O
recognized None None O
as None None O
an None None O
aromatic None None O
compound None None O
and None None O
was None None O
metabolized None None O
as None None O
such None None O
in None None O
the None None O
body None None O
, None None O
[ None None O
99mTc None None O
] None None O
cyclopentadienyltricarbonyltechnetium None None O
( None None O
[ None None O
99mTc None None O
] None None O
CpTT None None O
) None None O
was None None O
conjugated None None O
at None None O
the None None O
omega None None O
- None None O
position None None O
of None None O
pentadecanoic None None O
acid None None O
to None None O
prepare None None O
[ None None O
99mTc None None O
] None None O
CpTT None None O
- None None O
PA None None O
. None None O

When None None O
injected None None O
into None None O
rats None None O
, None None O
[ None None O
99mTc None None O
] None None O
CpTT None None O
- None None O
PA None None O
exhibited None None O
the None None O
maximum None None O
myocardial None None O
accumulation None None O
and None None O
heart None None O
- None None O
to None None O
- None None O
blood None None O
ratio None None O
of None None O
3.85 None None O
% None None O
ID None None O
/ None None O
g None None O
at None None O
1 None None O
min None None O
and None None O
4.60 None None O
at None None O
10 None None O
min None None O
postinjection None None O
, None None O
respectively None None O
. None None O

The None None O
metabolic None None O
study None None O
using None None O
isolated None None O
Langendorff None None O
perfused None None O
rat None None O
hearts None None O
demonstrated None None O
that None None O
approximately None None O
67% None None O
of None None O
perfused None None O
[ None None O
99mTc None None O
] None None O
CpTT None None O
- None None O
PA None None O
was None None O
incorporated None None O
and None None O
[ None None O
99mTc None None O
] None None O
CpTT None None O
- None None O
propionic None None O
acid None None O
, None None O
the None None O
metabolite None None O
after None None O
six None None O
cycles None None O
of None None O
beta None None O
- None None O
oxidation None None O
of None None O
[ None None O
99mTc None None O
] None None O
CpTT None None O
- None None O
PA None None O
, None None O
was None None O
detected None None O
as None None O
the None None O
major None None O
radiometabolite None None O
in None None O
the None None O
perfusate None None O
and None None O
myocardium None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
[ None None O
99mTc None None O
] None None O
CpTT None None O
- None None O
PA None None O
was None None O
recognized None None O
, None None O
transported None None O
, None None O
and None None O
metabolized None None O
as None None O
a None None O
long None None O
chain None None O
fatty None None O
acid None None O
analogue None None O
for None None O
energy None None O
production None None O
in None None O
the None None O
myocardium None None O
. None None O


This None None O
paper None None O
outlines None None O
the None None O
synthesis None None O
of None None O
selected None None O
acid None None O
mimics None None O
of None None O
the None None O
non None None O
- None None O
peptide None None O
CCK None None O
- None None O
B None None O
selective None None O
antagonist None None O
CI None None O
- None None O
988 None None O
, None None O
1 None None O
. None None O

CCK None None O
- None None O
B None None O
and None None O
CCK None None O
- None None O
A None None O
binding None None O
affinities None None O
of None None O
these None None O
analogues None None O
are None None O
described None None O
and None None O
their None None O
CCK None None O
- None None O
B None None O
affinity None None O
and None None O
selectivity None None O
rationalized None None O
by None None O
consideration None None O
of None None O
the None None O
pK None None O
( None None O
a None None O
) None None O
values None None O
, None None O
charge None None O
distribution None None O
, None None O
and None None O
geometry None None O
of None None O
the None None O
respective None None O
acid None None O
mimics None None O
. None None O

Several None None O
of None None O
the None None O
compounds None None O
have None None O
CCK None None O
- None None O
B None None O
binding None None O
affinities None None O
similar None None O
to None None O
the None None O
parent None None O
carboxylic None None O
acid None None O
1 None None O
( None None O
CCK None None O
- None None O
B None None O
, None None O
IC50 None None O
= None None O
1.7 None None O
nM None None O
; None None O
pK None None O
( None None O
a None None O
) None None O
= None None O
5.6 None None O
) None None O
and None None O
span None None O
a None None O
pK None None O
( None None O
a None None O
) None None O
range None None O
of None None O
less None None O
than None None O
1 None None O
( None None O
sulfonic None None O
acid None None O
27 None None O
) None None O
to None None O
greater None None O
than None None O
9.5 None None O
( None None O
5 None None I-IUPAC
- None None I-IUPAC
thio None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazole None None I-IUPAC
24 None None O
) None None O
. None None O

Among None None O
the None None O
more None None O
active None None O
compounds None None O
synthesized None None O
are None None O
tricyclo None None I-IUPAC
[ None None I-IUPAC
3.3.1.1 None None I-IUPAC
( None None I-IUPAC
3,7 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
dec None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
[ None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
* None None I-IUPAC
, None None I-IUPAC
R None None I-IUPAC
* None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
isoxazolyl None None I-IUPAC
) None None I-IUPAC
acetyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoethyl+ None None I-IUPAC
+ None None I-IUPAC
+ None None I-IUPAC
] None None I-IUPAC
carbamate None None I-IUPAC
( None None O
15 None None O
) None None O
, None None O
tricyclo None None I-IUPAC
[ None None I-IUPAC
3.3.1.1 None None I-IUPAC
( None None I-IUPAC
3,7 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
dec None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
[ None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
* None None I-IUPAC
, None None I-IUPAC
R None None I-IUPAC
* None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
sulfopropyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
carbamate None None I-IUPAC
, None None O
monosodium None None O
salt None None O
( None None O
27 None None O
) None None O
, None None O
and None None O
tricyclo None None I-IUPAC
[ None None I-IUPAC
3.3.1.1 None None I-IUPAC
( None None I-IUPAC
3,7 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
dec None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
[ None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
* None None I-IUPAC
, None None I-IUPAC
R None None I-IUPAC
* None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylsulfinyl None None I-IUPAC
) None None I-IUPAC
acetyl None None I-IUPAC
] None None I-IUPAC
a None None I-IUPAC
mino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
carbamic None None I-IUPAC
acid None None I-IUPAC
( None None O
34 None None O
) None None O
which None None O
have None None O
CCK None None O
- None None O
B None None O
binding None None O
affinities None None O
of None None O
IC50 None None O
= None None O
2.6 None None O
, None None O
1.3 None None O
, None None O
and None None O
1.7 None None O
nM None None O
, None None O
CCK None None O
- None None O
A None None O
/ None None O
- None None O
B None None O
ratios None None O
of None None O
650 None None O
, None None O
780 None None O
, None None O
and None None O
550 None None O
and None None O
pK None None O
( None None O
a None None O
) None None O
values None None O
of None None O
6.5 None None O
, None None O
less None None O
than None None O
1 None None O
, None None O
and None None O
7.0 None None O
, None None O
respectively None None O
. None None O


Synthesis None None O
and None None O
antitetrabenazine None None O
activity None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylmethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
piperidines None None I-IUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenylpiperidines None None I-IUPAC
, None None O
prepared None None O
as None None O
simplified None None O
and None None O
possibly None None O
more None None O
readily None None O
synthesized None None O
analogues None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
phenylspiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
, None None O
are None None O
reported None None O
. None None O

Several None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylmethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
piperidines None None I-IUPAC
display None None O
antitetrabenazine None None O
activity None None O
comparable None None O
to None None O
imipramine None None O
or None None O
amitriptyline None None O
but None None O
are None None O
two None None O
- None None O
to None None O
fourfold None None O
less None None O
active None None O
than None None O
analogous None None O
3 None None I-IUPAC
- None None I-IUPAC
arylspiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidines None None I-IUPAC
] None None I-IUPAC
. None None O

Structure None None O
- None None O
- None None O
activity None None O
relationships None None O
for None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2p None None I-IUPAC
( None None I-IUPAC
arylmethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
piperidines None None I-IUPAC
are None None O
generally None None O
similar None None O
to None None O
the None None O
profile None None O
established None None O
for None None O
3 None None I-IUPAC
- None None I-IUPAC
arylspiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidines None None I-IUPAC
] None None I-IUPAC
. None None O

Significant None None O
antitetrabenazine None None O
activity None None O
is None None O
associated None None O
only None None O
with None None O
derivatives None None O
where None None O
the None None O
arylmethyl None None O
group None None O
is None None O
ortho None None O
to None None O
the None None O
piperidine None None O
ring None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Benzyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenylpiperidines None None I-IUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylmethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidinols None None I-IUPAC
and None None O
the None None O
corresponding None None O
methyl None None O
ethers None None O
and None None O
esters None None O
display None None O
weak None None O
to None None O
modest None None O
antitetrabenazine None None O
activity None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Arylmethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydropyridine None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
at None None O
best None None O
, None None O
exhibit None None O
modest None None O
antitetrabenazine None None O
activity None None O
, None None O
with None None O
the None None O
exception None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylmethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydropyridine None None I-IUPAC
which None None O
is None None O
approximately None None O
equipotent None None O
with None None O
amitriptyline None None O
. None None O

The None None O
results None None O
of None None O
these None None O
investigations None None O
allow None None O
certain None None O
speculations None None O
to None None O
be None None O
made None None O
with None None O
respect None None O
to None None O
the None None O
role None None O
of None None O
the None None O
furan None None O
ring None None O
in None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
arylspiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidines None None I-IUPAC
] None None I-IUPAC
and None None O
antitetrabenazine None None O
activity None None O
. None None O


The None None O
adenosine None None O
antagonist None None O
9 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
quinazolin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
amine None None I-IUPAC
( None None O
CGS None None O
15943 None None O
) None None O
binds None None O
nonselectively None None O
to None None O
human None None O
A1 None None O
, None None O
A2A None None O
, None None O
and None None O
A3 None None O
receptors None None O
with None None O
high None None O
affinity None None O
. None None O

Acylated None None O
derivatives None None O
and None None O
one None None O
alkyl None None O
derivative None None O
of None None O
the None None O
5 None None O
- None None O
amino None None O
group None None O
and None None O
other None None O
modifications None None O
were None None O
prepared None None O
in None None O
an None None O
effort None None O
to None None O
enhance None None O
A2B None None O
or None None O
A3 None None O
subtype None None O
potency None None O
. None None O

In None None O
general None None O
, None None O
distal None None O
modifications None None O
of None None O
the None None O
N5 None None O
- None None O
substituent None None O
were None None O
highly None None O
modulatory None None O
to None None O
potency None None O
and None None O
selectivity None None O
at None None O
adenosine None None O
receptors None None O
, None None O
as None None O
determined None None O
in None None O
radioligand None None O
binding None None O
assays None None O
at None None O
rat None None O
brain None None O
A1 None None O
and None None O
A2A None None O
receptors None None O
and None None O
at None None O
recombinant None None O
human None None O
A3 None None O
receptors None None O
. None None O

In None None O
Chinese None None O
hamster None None O
ovary None None O
cells None None O
stably None None O
transfected None None O
with None None O
human None None O
A2B None None O
receptor None None O
cDNA None None O
, None None O
inhibition None None O
of None None O
agonist None None O
- None None O
induced None None O
cyclic None None O
AMP None None O
production None None O
was None None O
measured None None O
. None None O

An None None O
N5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodophenyl None None I-IUPAC
) None None I-IUPAC
acetyl None None I-IUPAC
derivative None None I-MODIFIER
was None None O
highly None None O
selective None None O
for None None O
A2A None None O
receptors None None O
. None None O

An None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N5 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
( None None I-IUPAC
phenylacetyl None None I-IUPAC
) None None I-IUPAC
derivative None None I-MODIFIER
was None None O
the None None O
most None None O
potent None None O
derivative None None O
at None None O
A3 None None O
receptors None None O
, None None O
with None None O
a None None O
Ki None None O
value None None O
of None None O
0.36 None None O
nM None None O
. None None O

A None None O
bulky None None O
N5 None None I-IUPAC
- None None I-IUPAC
diphenylacetyl None None I-IUPAC
derivative None None I-MODIFIER
, None None O
13 None None O
, None None O
displayed None None O
a None None O
Ki None None O
value None None O
of None None O
0 None None O
. None None O

59 None None O
nM None None O
at None None O
human None None O
A3 None None O
receptors None None O
and None None O
was None None O
moderately None None O
selective None None O
for None None O
that None None O
subtype None None O
. None None O

Thus None None O
, None None O
a None None O
large None None O
, None None O
nondiscriminating None None O
hydrophobic None None O
region None None O
occurs None None O
in None None O
the None None O
A3 None None O
receptor None None O
in None None O
proximity None None O
to None None O
the None None O
N5 None None O
- None None O
substituent None None O
. None None O

A None None O
series None None O
of None None O
straight None None O
- None None O
chain None None O
N5 None None I-IUPAC
- None None I-IUPAC
aminoalkylacyl None None I-IUPAC
derivatives None None I-MODIFIER
demonstrated None None O
that None None O
for None None O
A2B None None O
receptors None None O
the None None O
optimal None None O
chain None None O
length None None O
occurs None None O
with None None O
three None None O
methylene None None O
groups None None O
, None None O
i.e. None None O
, None None O
the None None O
N5 None None I-IUPAC
- None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
aminobutyryl None None I-IUPAC
derivative None None I-MODIFIER
27 None None O
which None None O
had None None O
a None None O
pA2 None None O
value None None O
of None None O
8.0 None None O
but None None O
was None None O
not None None O
selective None None O
for None None O
A2B None None O
receptors None None O
. None None O

At None None O
A1 None None O
, None None O
A2A None None O
, None None O
and None None O
A3 None None O
receptors None None O
however None None O
the None None O
optimum None None O
occurs None None O
with None None O
four None None O
methylene None None O
groups None None O
. None None O

An None None O
N5 None None I-IUPAC
- None None I-IUPAC
pivaloyl None None I-IUPAC
derivative None None I-MODIFIER
, None None O
which None None O
was None None O
less None None O
potent None None O
than None None O
27 None None O
at None None O
A1 None None O
, None None O
A2A None None O
, None None O
and None None O
A3 None None O
receptors None None O
, None None O
retained None None O
moderate None None O
potency None None O
at None None O
A2B None None O
receptors None None O
. None None O

A None None O
molecular None None O
model None None O
of None None O
the None None O
27 None None O
- None None O
A2B None None O
receptor None None O
complex None None O
based None None O
on None None O
the None None O
structure None None O
of None None O
rhodopsin None None O
utilizing None None O
a None None O
" None None O
cross None None O
- None None O
docking None None O
" None None O
procedure None None O
was None None O
developed None None O
in None None O
order None None O
to None None O
visualize None None O
the None None O
environment None None O
of None None O
the None None O
ligand None None O
binding None None O
site None None O
. None None O


By None None O
the None None O
use None None O
of None None O
space None None O
- None None O
filling None None O
models None None O
, None None O
a None None O
novel None None O
compound None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
carbamylmethyl None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
H None None I-IUPAC
- None None I-IUPAC
cyclopenta None None I-IUPAC
[ None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
isoquinolin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
was None None O
devised None None O
which None None O
would None None O
be None None O
expected None None O
to None None O
hydrogen None None O
bond None None O
specifically None None O
to None None O
GC None None O
pairs None None O
in None None O
the None None O
major None None O
groove None None O
of None None O
the None None O
double None None O
helix None None O
such None None O
that None None O
( None None O
i None None O
) None None O
the None None O
amino None None I-IUPAC
group None None B-MODIFIER
of None None O
the None None O
cytosine None None O
molecule None None O
donates None None O
a None None O
hydrogen None None O
bond None None O
to None None O
the None None O
C None None O
- None None O
3 None None O
carbonyl None None O
of None None O
the None None O
isoquinoline None None O
moiety None None O
and None None O
( None None O
ii None None O
) None None O
the None None O
amide None None O
proton None None O
of None None O
the None None O
side None None O
chain None None O
donates None None O
a None None O
hydrogen None None O
bond None None O
to None None O
the None None O
N None None O
- None None O
7 None None O
of None None O
guanine None None O
. None None O

3 None None I-IUPAC
- None None I-IUPAC
Ethoxy None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
H None None I-IUPAC
- None None I-IUPAC
cyclopenta None None I-IUPAC
[ None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
isoquinoline None None I-IUPAC
( None None O
4 None None O
) None None O
which None None O
constitutes None None O
the None None O
basic None None O
ring None None O
system None None O
of None None O
1 None None O
was None None O
synthesized None None O
in None None O
a None None O
multistep None None O
procedure None None O
starting None None O
from None None O
m None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
acetylbenzylamine None None I-IUPAC
( None None O
5 None None O
) None None O
. None None O

Friedel None None O
- None None O
Crafts None None O
reaction None None O
of None None O
5 None None O
led None None O
to None None O
2,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
chloromethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
acetylbenzylamine None None I-IUPAC
( None None O
6 None None O
) None None O
which None None O
on None None O
treatment None None O
with None None O
KCN None None O
, None None O
hydrolysis None None O
of None None O
the None None O
resultant None None O
nitrile None None O
, None None O
and None None O
subsequent None None O
esterification None None O
afforded None None O
6 None None I-IUPAC
- None None I-IUPAC
carbethoxymethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinolin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
9 None None O
) None None O
. None None O

Treatment None None O
of None None O
9 None None O
with None None O
triethyloxonium None None O
fluoborate None None O
followed None None O
by None None O
dehydrogenation None None O
of None None O
the None None O
product None None O
gave None None O
6 None None I-IUPAC
- None None I-IUPAC
carbethoxy None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
methylisoquinoline None None I-IUPAC
( None None O
14 None None O
) None None O
. None None O

Chain None None O
extension None None O
of None None O
14 None None O
followed None None O
by None None O
cyclization None None O
led None None O
to None None O
3 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5,6 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
7H None None I-IUPAC
- None None I-IUPAC
cyclopenta None None I-IUPAC
[ None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
isoquinolin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
19 None None O
) None None O
which None None O
on None None O
reduction None None O
and None None O
subsequent None None O
dehydration None None O
yielded None None O
3 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
H None None I-IUPAC
- None None I-IUPAC
cyclopenta None None I-IUPAC
[ None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
isoquinoline None None I-IUPAC
( None None O
4 None None O
) None None O
. None None O


Reaction None None O
of None None O
hydroxyl None None O
- None None O
protected None None O
derivatives None None O
of None None O
hydroxyalkoxyamines None None O
( None None O
3a None None O
, None None O
b None None O
, None None O
c None None O
) None None O
with None None O
either None None O
4,6 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
2,5 None None I-IUPAC
- None None I-IUPAC
diformamidopyrimidine None None I-IUPAC
( None None O
5 None None O
) None None O
or None None O
4,6 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
formamidopyrimidine None None I-IUPAC
( None None O
31 None None O
) None None O
and None None O
subsequent None None O
cyclization None None O
of None None O
the None None O
resultant None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alkoxyamino None None I-IUPAC
) None None I-IUPAC
pyrimidines None None I-IUPAC
( None None O
6 None None O
, None None O
17 None None O
, None None O
32 None None O
, None None O
35 None None O
) None None O
by None None O
heating None None O
with None None O
diethoxymethyl None None O
acetate None None O
afforded None None O
9 None None I-IUPAC
- None None I-IUPAC
alkoxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropurines None None I-IUPAC
( None None O
7 None None O
, None None O
18 None None O
, None None O
33 None None O
, None None O
36 None None O
) None None O
, None None O
which None None O
were None None O
converted None None O
subsequently None None O
to None None O
9 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxypropoxy None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
propoxy None None I-IUPAC
] None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
guanine None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
alkoxypurines None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
aminopurine None None I-IUPAC
, None None O
2,6 None None I-IUPAC
- None None I-IUPAC
diaminopurine None None I-IUPAC
, None None O
adenine None None O
, None None O
hypoxanthine None None O
, None None O
and None None O
6 None None I-IUPAC
- None None I-IUPAC
methoxypurine None None I-IUPAC
( None None O
8 None None O
, None None O
12 None None O
, None None O
13 None None O
, None None O
19-21 None None O
, None None O
23-26 None None O
, None None O
34 None None O
, None None O
37-39 None None O
) None None O
. None None O

Carboxylic None None O
acid None None O
esters None None O
( None None O
9-11 None None O
, None None O
14-16 None None O
, None None O
27-29 None None O
) None None O
and None None O
a None None O
cyclic None None O
phosphate None None O
derivative None None O
( None None O
22 None None O
) None None O
of None None O
the None None O
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyalkoxy None None I-IUPAC
) None None I-IUPAC
guanines None None I-IUPAC
( None None O
8 None None O
, None None O
21 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyalkoxy None None I-IUPAC
) None None I-IUPAC
purines None None I-IUPAC
( None None O
13 None None O
, None None O
26 None None O
) None None O
were None None O
also None None O
prepared None None O
. None None O

The None None O
guanine None None O
derivatives None None O
( None None O
8 None None O
, None None O
21 None None O
) None None O
showed None None O
potent None None O
and None None O
selective None None O
activity None None O
against None None O
herpes None None O
simplex None None O
virus None None O
types None None O
1 None None O
and None None O
2 None None O
and None None O
varicella None None O
zoster None None O
virus None None O
in None None O
cell None None O
cultures None None O
and None None O
8 None None O
is None None O
more None None O
active None None O
than None None O
acyclovir None None O
. None None O

Although None None O
without None None O
significant None None O
antiviral None None O
activity None None O
in None None O
cell None None O
cultures None None O
, None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
aminopurines None None I-IUPAC
( None None O
13 None None O
, None None O
14-16 None None O
, None None O
26-29 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
alkoxypurines None None I-IUPAC
( None None O
12 None None O
, None None O
23-25 None None O
) None None O
are None None O
well None None O
absorbed None None O
after None None O
oral None None O
administration None None O
to None None O
mice None None O
and None None O
are None None O
converted None None O
efficiently None None O
to None None O
the None None O
antiviral None None O
guanine None None O
derivatives None None O
( None None O
8 None None O
, None None O
21 None None O
) None None O
in None None O
vivo None None O
. None None O


Variation None None O
of None None O
the None None O
bridge None None O
linking None None O
the None None O
heterocyclic None None O
ring None None O
and None None O
p None None I-IUPAC
- None None I-IUPAC
aminobenzoyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
portions None None I-MODIFIER
of None None O
our None None O
previously None None O
described None None O
classical None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diaminofuro None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
1 None None O
and None None O
2 None None O
are None None O
reported None None O
as None None O
inhibitors None None O
of None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
and None None O
thymidylate None None O
synthase None None O
( None None O
TS None None O
) None None O
and None None O
as None None O
antitumor None None O
agents None None O
. None None O

Specifically None None O
- None None O
CH2CH2 None None O
- None None O
and None None O
- None None O
CH2NHCH2 None None O
- None None O
bridged None None O
analogues None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diaminofuro None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
benzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
( None None O
3 None None O
) None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diaminofuro None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
benzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
respectively None None O
, None None O
were None None O
synthesized None None O
. None None O

Compound None None O
3 None None O
was None None O
obtained None None O
via None None O
a None None O
Wittig None None O
reaction None None O
of None None O
the None None O
tributylphosphonium None None O
salt None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloromethyl None None I-IUPAC
) None None I-IUPAC
furo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
5 None None O
) None None O
and None None O
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
formylbenzoate None None I-IUPAC
( None None O
6 None None O
) None None O
followed None None O
by None None O
reduction None None O
and None None O
coupling None None O
with None None O
the None None O
diethyl None None O
ester None None O
of None None O
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
. None None O

Compound None None O
4 None None O
was None None O
synthesized None None O
by None None O
the None None O
nucleophilic None None O
displacement None None O
of None None O
5 None None O
with None None O
diethyl None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
benzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
( None None O
15 None None O
) None None O
and None None O
saponification None None O
. None None O

Both None None O
analogues None None O
were None None O
evaluated None None O
in None None O
vitro None None O
as None None O
inhibitors None None O
of None None O
DHFRs None None O
from None None O
( None None O
recombinant None None O
) None None O
human None None O
, None None O
human None None O
CCRF None None O
- None None O
CEM None None O
cells None None O
, None None O
and None None O
Lactobacillus None None O
casei None None O
. None None O

Compound None None O
3 None None O
showed None None O
moderate None None O
activity None None O
( None None O
IC50 None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
- None None O
10 None None O
( None None O
- None None O
7 None None O
) None None O
M None None O
) None None O
. None None O

Compound None None O
4 None None O
was None None O
essentially None None O
inactive None None O
( None None O
IC50 None None O
10 None None O
( None None O
- None None O
5 None None O
) None None O
M None None O
, None None O
CCRF None None O
- None None O
CEM None None O
) None None O
. None None O

The None None O
compounds None None O
were None None O
also None None O
evaluated None None O
against None None O
TS None None O
from None None O
( None None O
recombinant None None O
) None None O
human None None O
and None None O
L None None O
. None None O

casei None None O
and None None O
were None None O
of None None O
low None None O
activity None None O
( None None O
IC50 None None O
10 None None O
( None None O
- None None O
5 None None O
) None None O
M None None O
) None None O
. None None O

The None None O
three None None O
- None None O
atom None None O
- None None O
bridged None None O
analogue None None O
4 None None O
was None None O
somewhat None None O
more None None O
inhibitory None None O
to None None O
human None None O
TS None None O
than None None O
methotrexate None None O
( None None O
MTX None None O
) None None O
. None None O

Compound None None O
3 None None O
inhibited None None O
the None None O
growth None None O
of None None O
tumor None None O
cells None None O
in None None O
culture None None O
( None None O
IC50 None None O
10 None None O
( None None O
- None None O
7 None None O
) None None O
M None None O
) None None O
while None None O
4 None None O
showed None None O
a None None O
low None None O
level None None O
of None None O
growth None None O
inhibitory None None O
activity None None O
. None None O

The None None O
inhibition None None O
of None None O
the None None O
growth None None O
of None None O
leukemia None None O
CCRF None None O
- None None O
CEM None None O
cells None None O
by None None O
both None None O
compounds None None O
parallels None None O
their None None O
inhibition None None O
of None None O
CCRF None None O
- None None O
CEM None None O
DHFR None None O
. None None O

Analogue None None O
3 None None O
was None None O
a None None O
good None None O
substrate None None O
for None None O
human None None O
folylpolyglutamate None None O
synthetase None None O
( None None O
FPGS None None O
) None None O
derived None None O
from None None O
CCRF None None O
- None None O
CEM None None O
cells None None O
( None None O
Km None None O
8.5 None None O
microM None None O
) None None O
. None None O

Further None None O
evaluation None None O
of None None O
the None None O
growth None None O
inhibitory None None O
activity None None O
of None None O
3 None None O
against None None O
the None None O
MTX None None O
- None None O
resistant None None O
subline None None O
of None None O
CCRF None None O
- None None O
CEM None None O
cells None None O
( None None O
R30dm None None O
) None None O
with None None O
decreased None None O
FPGS None None O
indicated None None O
that None None O
poly None None O
- None None O
gamma None None O
- None None O
glutamylation None None O
was None None O
important None None O
for None None O
its None None O
action None None O
. None None O

Protection None None O
studies None None O
with None None O
3 None None O
in None None O
the None None O
FaDu None None O
squamous None None O
cell None None O
carcinoma None None O
cell None None O
line None None O
indicated None None O
that None None O
inhibition None None O
was None None O
completely None None O
reversed None None O
by None None O
leucovorin None None O
[ None None O
( None None O
6R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
formyltetrahydrofolate None None I-IUPAC
] None None O
or None None O
by None None O
a None None O
combination None None O
of None None O
thymidine None None O
and None None O
hypoxanthine None None O
, None None O
suggesting None None O
an None None O
antifolate None None O
effect None None O
directed None None O
at None None O
DHFR None None O
. None None O


Various None None O
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
aryl None None I-PARTIUPAC
and None None O
aralkyl None None I-PARTIUPAC
) None None I-PARTIUPAC
amino None None I-PARTIUPAC
] None None I-PARTIUPAC
methyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
2,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
pteridinediamines None None I-PARTIUPAC
and None None O
their None None O
8 None None I-IUPAC
- None None I-IUPAC
oxides None None I-IUPAC
have None None O
been None None O
synthesized None None O
for None None O
antimalarial None None O
evaluation None None O
. None None O

Condensation None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyrazinecarbonitrile None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
V None None O
) None None O
with None None O
the None None O
appropriately None None O
substituted None None O
amine None None O
afforded None None O
a None None O
series None None O
of None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
amino None None I-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
aryl None None I-PARTIUPAC
and None None O
aralkyl None None I-PARTIUPAC
) None None I-PARTIUPAC
amino None None I-PARTIUPAC
] None None I-PARTIUPAC
methyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
pyrazinecarbonitrile None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
oxides None None I-PARTIUPAC
VI None None O
. None None O

Deoxygenation None None O
gave None None O
the None None O
corresponding None None O
pyrazines None None O
VII None None O
. None None O

Cyclization None None O
of None None O
VI None None O
and None None O
VII None None O
with None None O
guanidine None None O
then None None O
produced None None O
the None None O
desired None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
pteridinediamine None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxides None None I-IUPAC
VIII None None O
and None None O
teridinediamines None None O
IX None None O
, None None O
respectively None None O
. None None O

Formylation None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
pteridinediamine None None I-IUPAC
gave None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
pteridinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
formamide None None I-IUPAC
. None None O

The None None O
N None None I-IUPAC
- None None I-IUPAC
oxides None None I-IUPAC
VIII None None O
did None None O
not None None O
exhibit None None O
significant None None O
activity None None O
against None None O
Plasmodium None None O
berghei None None O
infections None None O
in None None O
mice None None O
. None None O

Activity None None O
among None None O
the None None O
2,4 None None I-IUPAC
- None None I-IUPAC
pteridinediamines None None I-IUPAC
IX None None O
was None None O
generally None None O
poor None None O
with None None O
the None None O
exception None None O
of None None O
the None None O
3,4,5 None None I-IUPAC
- None None I-IUPAC
trimethoxyphenyl None None I-IUPAC
and None None O
1 None None I-IUPAC
- None None I-IUPAC
naphthalenyl None None I-IUPAC
analogues None None I-MODIFIER
which None None O
showed None None O
strong None None O
suppressive None None O
activity None None O
at None None O
doses None None O
ranging None None O
from None None O
80 None None O
to None None O
640 None None O
mg None None O
/ None None O
kg None None O
. None None O

Furthermore None None O
, None None O
several None None O
of None None O
the None None O
2,4 None None I-IUPAC
- None None I-IUPAC
pteridinediamines None None I-IUPAC
exhibited None None O
potent None None O
prophylactic None None O
activity None None O
against None None O
Plasmodium None None O
gallinaceum None None O
infections None None O
in None None O
the None None O
chick None None O
and None None O
also None None O
showed None None O
strong None None O
antibacterial None None O
action None None O
against None None O
Streptococcus None None O
faecalis None None O
and None None O
Staphylococcus None None O
aureus None None O
. None None O


The None None O
aim None None O
of None None O
this None None O
work None None O
was None None O
to None None O
improve None None O
the None None O
oral None None O
bioavailability None None O
of None None O
a None None O
recently None None O
discovered None None O
, None None O
novel None None O
structural None None O
class None None O
of None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
agonists None None O
: None None O
aryl None None I-IUPAC
- None None I-IUPAC
{ None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
} None None I-IUPAC
- None None I-IUPAC
piperidin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
metha None None I-IUPAC
none None None I-IUPAC
. None None O

Incorporation None None O
of None None O
a None None O
fluorine None None O
atom None None O
in None None O
the None None O
beta None None O
- None None O
position None None O
to None None O
the None None O
amino None None O
function None None O
in None None O
the None None O
side None None O
chain None None O
led None None O
to None None O
analogues None None O
that None None O
exhibited None None O
, None None O
in None None O
general None None O
, None None O
enhanced None None O
and None None O
long None None O
- None None O
lasting None None O
5 None None O
- None None O
HT1A None None O
agonist None None O
activity None None O
in None None O
rats None None O
after None None O
oral None None O
administration None None O
. None None O

Location None None O
of None None O
the None None O
fluorine None None O
atom None None O
at None None O
the None None O
C None None O
- None None O
4 None None O
position None None O
of None None O
the None None O
piperidine None None O
ring None None O
was None None O
the None None O
most None None O
favorable None None O
, None None O
and None None O
among None None O
the None None O
various None None O
substituents None None O
tested None None O
, None None O
the None None O
ability None None O
of None None O
the None None O
fluorine None None O
was None None O
unique None None O
in None None O
improving None None O
the None None O
oral None None O
activity None None O
of None None O
this None None O
family None None O
of None None O
ligands None None O
. None None O

Thus None None O
, None None O
the None None O
derivatives None None O
39 None None O
, None None O
46 None None O
, None None O
and None None O
61 None None O
bound None None O
with None None O
higher None None O
affinity None None O
and None None O
selectivity None None O
to None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
( None None O
versus None None O
dopaminergic None None O
D2 None None O
and None None O
adrenergic None None O
alpha1 None None O
receptors None None O
) None None O
and None None O
displayed None None O
more None None O
potent None None O
5 None None O
- None None O
HT1A None None O
agonist None None O
activity None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
than None None O
their None None O
C None None O
- None None O
4 None None O
desfluoro None None O
analogues None None O
. None None O

To None None O
examine None None O
the None None O
relationship None None O
between None None O
the None None O
conformation None None O
of None None O
the None None O
pharmacophore None None O
and None None O
the None None O
level None None O
of None None O
agonistic None None O
activity None None O
of None None O
this None None O
type None None O
of None None O
ligand None None O
, None None O
we None None O
synthesized None None O
a None None O
series None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
{ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
H None None I-IUPAC
or None None I-IUPAC
CH3 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
} None None I-IUPAC
- None None I-IUPAC
piperidin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
+ None None I-IUPAC
+ None None I-IUPAC
+ None None I-IUPAC
methanone None None I-IUPAC
derivatives None None I-MODIFIER
and None None O
found None None O
that None None O
the None None O
combination None None O
of None None O
a None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
and None None O
a None None O
6 None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
substituent None None I-MODIFIER
on None None O
the None None O
pyridine None None O
ring None None O
synergistically None None O
affected None None O
their None None O
5 None None O
- None None O
HT1A None None O
agonist None None O
properties None None O
. None None O

Thus None None O
, None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
{ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
- None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
} None None I-IUPAC
- None None I-IUPAC
piperidin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
methanone None None I-IUPAC
40 None None O
behaved None None O
as None None O
a None None O
more None None O
potent None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
agonist None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
than None None O
its None None O
5 None None O
- None None O
unsubstituted None None O
analogue None None O
38 None None O
. None None O

The None None O
antidepressant None None O
potential None None O
of None None O
the None None O
lead None None O
compounds None None O
40 None None O
, None None O
45 None None O
, None None O
and None None O
54 None None O
was None None O
examined None None O
by None None O
means None None O
of None None O
the None None O
forced None None O
swimming None None O
test None None O
( None None O
FST None None O
) None None O
in None None O
rats None None O
. None None O

The None None O
results None None O
indicated None None O
that None None O
, None None O
after None None O
a None None O
single None None O
oral None None O
administration None None O
, None None O
these None None O
compounds None None O
inhibited None None O
immobility None None O
in None None O
the None None O
FST None None O
more None None O
potently None None O
and None None O
more None None O
extensively None None O
than None None O
the None None O
clinically None None O
used None None O
antidepressant None None O
imipramine None None O
. None None O

Thus None None O
, None None O
40 None None O
, None None O
45 None None O
, None None O
and None None O
54 None None O
are None None O
potent None None O
, None None O
orally None None O
active None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
agonists None None O
with None None O
marked None None O
antidepressant None None O
potential None None O
. None None O


A None None O
series None None O
of None None O
4 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2 None None I-IUPAC
- None None I-IUPAC
formylpyridine None None I-IUPAC
thiosemicarbazones None None I-IUPAC
has None None O
been None None O
synthesized None None O
which None None O
contain None None O
a None None O
tertiary None None O
N None None O
at None None O
the None None O
4 None None O
position None None O
. None None O

These None None O
materials None None O
were None None O
obtained None None O
by None None O
reacting None None O
4 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
picoline None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
, None None O
either None None O
directly None None O
or None None O
after None None O
conversion None None O
to None None O
the None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
derivative None None I-MODIFIER
, None None O
with None None O
a None None O
variety None None O
of None None O
secondary None None O
amines None None O
. None None O

Rearrangement None None O
of None None O
the None None O
4 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2 None None I-IUPAC
- None None I-IUPAC
picoline None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxides None None I-IUPAC
with None None O
Ac2O None None O
yielded None None O
respective None None O
methyl None None O
acetates None None O
, None None O
which None None O
upon None None O
acid None None O
hydrolysis None None O
, None None O
MnO2 None None O
oxidation None None O
, None None O
and None None O
reaction None None O
with None None O
thiosemicarbazide None None O
resulted None None O
in None None O
the None None O
desired None None O
compounds None None O
. None None O

An None None O
alternate None None O
procedure None None O
which None None O
consisted None None O
of None None O
reacting None None O
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
formylpyridine None None I-IUPAC
ethylene None None I-IUPAC
acetal None None I-IUPAC
with None None O
various None None O
amines None None O
, None None O
followed None None O
by None None O
hydrolysis None None O
and None None O
reaction None None O
with None None O
thiosemicarbazide None None O
, None None O
was None None O
also None None O
employed None None O
. None None O

Introduction None None O
of None None O
an None None O
alkyl None None O
group None None O
at None None O
the None None O
3 None None O
position None None O
of None None O
the None None O
pyridine None None O
ring None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
morpholino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
formylpyridine None None I-IUPAC
thiosemicarbazone None None I-IUPAC
was None None O
achieved None None O
by None None O
utilizing None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitropyridine None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
; None None O
this None None O
material None None O
was None None O
converted None None O
to None None O
the None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
derivative None None I-MODIFIER
which None None O
was None None O
then None None O
subjected None None O
to None None O
nucleophilic None None O
substitution None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Morpholino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
formylpyridine None None I-IUPAC
thiosemicarbazone None None I-IUPAC
was None None O
the None None O
most None None O
active None None O
antineoplastic None None O
agent None None O
of None None O
this None None O
series None None O
in None None O
mice None None O
bearing None None O
Sarcoma None None O
180 None None O
ascites None None O
cells None None O
and None None O
was None None O
significantly None None O
superior None None O
to None None O
5 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
formylpyridine None None I-IUPAC
thiosemicarbazone None None I-IUPAC
in None None O
this None None O
test None None O
system None None O
. None None O


Syntheses None None O
and None None O
biological None None O
activities None None O
of None None O
26 None None O
N4 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
aminopyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
as None None O
analogs None None O
of None None O
naturally None None O
occurring None None O
modified None None O
nucleic None None O
acid None None O
bases None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
purin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
ylcarbamoyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
threonine None None I-IUPAC
and None None O
N6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
delta2 None None I-IUPAC
- None None I-IUPAC
isopentenyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
, None None O
are None None O
described None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Aminopyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
was None None O
converted None None O
into None None O
the None None O
desired None None O
intermediate None None O
, None None O
ethyl None None I-IUPAC
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carbamate None None I-IUPAC
( None None O
2 None None O
) None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Ureidopyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
( None None O
6-26 None None O
) None None O
were None None O
prepared None None O
by None None O
displacement None None O
of None None O
the None None O
ethoxy None None O
group None None O
of None None O
the None None O
carbamate None None O
2 None None O
by None None O
amino None None O
acids None None O
and None None O
a None None O
variety None None O
of None None O
amines None None O
and None None O
by None None O
a None None O
reaction None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
aminopyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
1 None None O
) None None O
with None None O
isocyanates None None O
. None None O

N4 None None I-IUPAC
- None None I-IUPAC
Alkylaminopyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
were None None O
generally None None O
prepared None None O
by None None O
displacement None None O
of None None O
the None None O
chlorine None None O
from None None O
4 None None I-IUPAC
- None None I-IUPAC
chloropyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
with None None O
various None None O
amines None None O
. None None O

Several None None O
analogs None None O
exhibited None None O
moderate None None O
to None None O
very None None O
good None None O
growth None None O
inhibitory None None O
activities None None O
against None None O
cultured None None O
L1210 None None O
leukemia None None O
and None None O
6410 None None O
human None None O
leukemic None None O
myeloblasts None None O
. None None O


In None None O
pursuit None None O
of None None O
radiolabeled None None O
monoclonal None None O
antibodies None None O
( None None O
mAbs None None O
) None None O
with None None O
rapid None None O
urinary None None O
excretion None None O
of None None O
radioactivity None None O
from None None O
nontarget None None O
tissues None None O
, None None O
radioiodinated None None O
mAbs None None O
releasing None None O
a None None O
m None None I-IUPAC
- None None I-IUPAC
iodohippuric None None I-IUPAC
acid None None I-IUPAC
from None None O
the None None O
mAbs None None O
in None None O
nontarget None None O
tissues None None O
were None None O
designed None None O
. None None O

A None None O
novel None None O
reagent None None O
, None None O
maleimidoethyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butylstannyl None None I-IUPAC
) None None I-IUPAC
hippurate None None I-IUPAC
( None None O
MIH None None O
) None None O
, None None O
was None None O
synthesized None None O
by None None O
reacting None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyethyl None None I-IUPAC
) None None I-IUPAC
maleimide None None I-IUPAC
with None None O
N None None I-IUPAC
- None None I-IUPAC
Boc None None I-IUPAC
- None None I-IUPAC
glycine None None I-IUPAC
before None None O
coupling None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
succinimidyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butylstannyl None None I-IUPAC
) None None I-IUPAC
benzoate None None I-IUPAC
( None None O
ATE None None O
) None None O
. None None O

MIH None None O
possessed None None O
a None None O
maleimide None None O
group None None O
for None None O
mAb None None O
conjugation None None O
and None None O
a None None O
butylstannyl None None O
moiety None None O
for None None O
high None None O
- None None O
yield None None O
and None None O
site None None O
- None None O
specific None None O
radioiodination None None O
, None None O
and None None O
the None None O
two None None O
functional None None O
groups None None O
were None None O
linked None None O
via None None O
an None None O
ester None None O
bond None None O
to None None O
release None None O
m None None I-IUPAC
- None None I-IUPAC
iodohippuric None None I-IUPAC
acid None None I-IUPAC
. None None O

To None None O
investigate None None O
the None None O
fate None None O
of None None O
radiolabels None None O
after None None O
lysosomal None None O
proteolysis None None O
, None None O
hepatic None None O
parenchymal None None O
cells None None O
were None None O
used None None O
as None None O
a None None O
model None None O
nontarget None None O
tissue None None O
and None None O
131I None None O
- None None O
labeled None None O
MIH None None O
was None None O
conjugated None None O
with None None O
galactosyl None None O
- None None O
neoglycoalbumin None None O
( None None O
NGA None None O
) None None O
. None None O

Further None None O
conjugation None None O
of None None O
[ None None O
131I None None O
] None None O
MIH None None O
with None None O
a None None O
mAb None None O
against None None O
osteogenic None None O
sarcoma None None O
( None None O
OST7 None None O
) None None O
after None None O
reduction None None O
of None None O
its None None O
disulfide None None O
bonds None None O
was None None O
followed None None O
up None None O
. None None O

In None None O
murine None None O
biodistribution None None O
studies None None O
, None None O
[ None None O
131I None None O
] None None O
MIH None None O
- None None O
NGA None None O
exhibited None None O
rapid None None O
accumulation None None O
in None None O
the None None O
liver None None O
followed None None O
by None None O
radioactivity None None O
elimination None None O
from None None O
the None None O
liver None None O
at None None O
a None None O
rate None None O
that None None O
was None None O
identical None None O
to None None O
and None None O
faster None None O
than None None O
those None None O
of None None O
131I None None O
- None None O
labeled None None O
NGA None None O
via None None O
direct None None O
iodination None None O
( None None O
[ None None O
131I None None O
] None None O
NGA None None O
) None None O
and None None O
[ None None O
131I None None O
] None None O
ATE None None O
- None None O
labeled None None O
NGA None None O
, None None O
respectively None None O
. None None O

While None None O
[ None None O
131I None None O
] None None O
NGA None None O
indicated None None O
high None None O
radioactivity None None O
levels None None O
in None None O
the None None O
murine None None O
neck None None O
, None None O
stomach None None O
, None None O
and None None O
blood None None O
, None None O
such None None O
increases None None O
in None None O
the None None O
radioactivity None None O
count None None O
were None None O
not None None O
detectable None None O
by None None O
the None None O
administration None None O
of None None O
either None None O
[ None None O
131I None None O
] None None O
MIH None None O
- None None O
NGA None None O
or None None O
[ None None O
131I None None O
] None None O
ATE None None O
- None None O
NGA None None O
. None None O

At None None O
6 None None O
h None None O
postinjection None None O
of None None O
[ None None O
131I None None O
] None None O
MIH None None O
- None None O
NGA None None O
, None None O
80% None None O
of None None O
the None None O
injected None None O
radioactivity None None O
was None None O
recovered None None O
in None None O
the None None O
urine None None O
. None None O

Analyses None None O
of None None O
urine None None O
samples None None O
indicated None None O
that None None O
m None None O
- None None O
iodohippuric None None O
acid None None O
was None None O
the None None O
sole None None O
radiolabeled None None O
metabolite None None O
. None None O

In None None O
biodistribution None None O
studies None None O
using None None O
[ None None O
131I None None O
] None None O
- None None O
MIH None None O
- None None O
OST7 None None O
and None None O
[ None None O
131I None None O
] None None O
ATE None None O
- None None O
OST7 None None O
, None None O
while None None O
both None None O
131I None None O
- None None O
labeled None None O
OST7s None None O
registered None None O
almost None None O
identical None None O
radioactivity None None O
levels None None O
in None None O
the None None O
blood None None O
up None None O
to None None O
6 None None O
h None None O
postinjection None None O
, None None O
the None None O
former None None O
demonstrated None None O
a None None O
lower None None O
radioactivity None None O
level None None O
than None None O
[ None None O
131I None None O
] None None O
ATE None None O
- None None O
OST7 None None O
in None None O
nontarget None None O
tissues None None O
throughout None None O
the None None O
experiment None None O
. None None O

Such None None O
chemical None None O
and None None O
biological None None O
characteristics None None O
of None None O
MIH None None O
would None None O
enable None None O
high None None O
target None None O
/ None None O
nontarget None None O
ratios None None O
in None None O
diagnostic None None O
and None None O
therapeutic None None O
nuclear None None O
medicine None None O
using None None O
mAbs None None O
and None None O
other None None O
polypeptides None None O
. None None O


In None None O
order None None O
to None None O
assess None None O
steric None None O
, None None O
lipophilic None None O
, None None O
and None None O
electronic None None O
influences None None O
on None None O
opioid None None O
binding None None O
affinity None None O
, None None O
analogs None None O
of None None O
the None None O
delta None None O
receptor None None O
selective None None O
peptide None None O
deltorphin None None O
I None None O
( None None O
Tyr None None O
- None None O
D None None O
- None None O
Ala None None O
- None None O
Phe None None O
- None None O
Asp None None O
- None None O
Val None None O
- None None O
Val None None O
- None None O
GlyNH2 None None O
) None None O
were None None O
prepared None None O
in None None O
which None None O
the None None O
residue None None O
3 None None O
phenylalanine None None O
was None None O
replaced None None O
with None None O
lipophilic None None O
fluoro None None I-IUPAC
- None None O
and None None O
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
phenylalanines None None B-IUPAC
or None None O
with None None O
the None None O
heterocyclic None None O
aromatic None None O
amino None None O
acids None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
thiazolyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
, None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
, None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
, None None O
histidine None None O
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
thiazolyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
. None None O

mu None None O
binding None None O
was None None O
variable None None O
, None None O
with None None O
KiS None None O
in None None O
excess None None O
of None None O
10,000 None None O
nM None None O
for None None O
most None None O
analogs None None O
, None None O
and None None O
all None None O
of None None O
the None None O
analogs None None O
bound None None O
poorly None None O
to None None O
k None None O
receptors None None O
. None None O

Among None None O
the None None O
phenyl None None O
ring None None O
- None None O
substituted None None O
analogs None None O
, None None O
those None None O
containing None None O
the None None O
smaller None None O
and None None O
electron None None O
- None None O
withdrawing None None O
halogens None None O
were None None O
favored None None O
over None None O
those None None O
with None None O
larger None None O
, None None O
electron None None O
- None None O
releasing None None O
methyl None None O
groups None None O
, None None O
although None None O
delta None None O
opioid None None O
binding None None O
affinity None None O
was None None O
reduced None None O
in None None O
all None None O
cases None None O
. None None O

The None None O
m None None O
- None None O
fluorophenylalanine None None O
analog None None O
demonstrated None None O
the None None O
best None None O
delta None None O
binding None None O
of None None O
the None None O
group None None O
, None None O
with None None O
a None None O
Ki None None O
of None None O
4.79 None None O
nM None None O
. None None O

Within None None O
the None None O
group None None O
of None None O
heterocyclic None None O
analogs None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
proved None None O
to None None O
be None None O
the None None O
best None None O
modification None None O
, None None O
displaying None None O
a None None O
delta None None O
receptor None None O
Ki None None O
of None None O
1.38 None None O
nM None None O
, None None O
while None None O
the None None O
polar None None O
histidine None None O
analog None None O
suffered None None O
the None None O
greatest None None O
loss None None O
in None None O
delta None None O
binding None None O
( None None O
Ki None None O
= None None O
317 None None O
) None None O
. None None O

Compounds None None O
containing None None O
pyridylalanine None None O
and None None O
thiazolylalanine None None O
were None None O
intermediate None None O
in None None O
binding None None O
affinity None None O
, None None O
with None None O
delta None None O
KiS None None O
ranging None None O
from None None O
39.5 None None O
to None None O
62.4 None None O
nM None None O
. None None O

The None None O
major None None O
factor None None O
influencing None None O
the None None O
opioid None None O
binding None None O
of None None O
the None None O
similar None None O
- None None O
sized None None O
heterocyclic None None O
compounds None None O
was None None O
relative None None O
lipophilicity None None O
, None None O
which None None O
outweighed None None O
electronic None None O
character None None O
. None None O


Six None None O
new None None O
B None None O
- None None O
ring None None O
analogues None None O
of None None O
the None None O
nonpolyglutamatable None None O
antifolate None None O
Nalpha None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxypteroyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
Ndelta None None I-IUPAC
- None None I-IUPAC
hemiphthaloy None None I-IUPAC
l None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
ornithine None None I-IUPAC
( None None O
PT523 None None O
, None None O
3 None None O
) None None O
were None None O
synthesized None None O
with None None O
a None None O
view None None O
to None None O
determining None None O
the None None O
effect None None O
of None None O
modifications None None O
at None None O
the None None O
5 None None O
- None None O
and None None O
/ None None O
or None None O
8 None None O
- None None O
position None None O
on None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
binding None None O
and None None O
tumor None None O
cell None None O
growth None None O
inhibition None None O
. None None O

The None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
8 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
analogues None None I-MODIFIER
were None None O
prepared None None O
from None None O
methyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phthalimidopentanoate None None I-IUPAC
and None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
amino None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
deoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
N10 None None I-PARTIUPAC
- None None I-PARTIUPAC
formyl None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
deaza None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
deazapteroic None None I-PARTIUPAC
acid None None I-PARTIUPAC
, None None O
respectively None None O
. None None O

The None None O
5,8 None None I-IUPAC
- None None I-IUPAC
dideaza None None I-IUPAC
analogues None None I-MODIFIER
were None None O
prepared None None O
from None None O
methyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminobenzoyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phthalimidopentanoate None None I-IUPAC
and None None O
2 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
diaminoquinazoline None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carbonitriles None None I-IUPAC
. None None O

The None None O
Ki None None O
for None None O
inhibition None None O
of None None O
human None None O
DHFR None None O
by None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
analogues None None I-MODIFIER
was None None O
about None None O
the None None O
same None None O
as None None O
that None None O
of None None O
3 None None O
( None None O
0.35 None None O
pM None None O
) None None O
, None None O
11 None None O
- None None O
fold None None O
lower None None O
than None None O
that None None O
of None None O
aminopterin None None O
( None None O
AMT None None O
, None None O
1 None None O
) None None O
, None None O
and None None O
15 None None O
- None None O
fold None None O
lower None None O
than None None O
that None None O
of None None O
methotrexate None None O
( None None O
MTX None None O
, None None O
2 None None O
) None None O
. None None O

However None None O
the None None O
Ki None None O
of None None O
the None None O
8 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
analogue None None I-MODIFIER
was None None O
27 None None O
- None None O
fold None None O
lower None None O
than None None O
that None None O
of None None O
1 None None O
, None None O
and None None O
that None None O
of None None O
the None None O
5,8 None None I-IUPAC
- None None I-IUPAC
dideaza None None I-IUPAC
, None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dideaza None None I-IUPAC
, None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dideaza None None I-IUPAC
analogues None None I-MODIFIER
was None None O
approximately None None O
50 None None O
- None None O
fold None None O
lower None None O
. None None O

This None None O
trend None None O
was None None O
consistent None None O
with None None O
the None None O
published None None O
literature None None O
on None None O
the None None O
corresponding None None O
DHFR None None O
inhibitors None None O
with None None O
a None None O
glutamate None None O
side None None O
chain None None O
. None None O

In None None O
colony None None O
formation None None O
assays None None O
against None None O
the None None O
human None None O
head None None O
and None None O
neck None None O
squamous None None O
carcinoma None None O
cell None None O
line None None O
SCC25 None None O
after None None O
72 None None O
h None None O
of None None O
treatment None None O
, None None O
the None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
8 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
analogues None None I-MODIFIER
were None None O
approximately None None O
as None None O
potent None None O
as None None O
3 None None O
, None None O
whereas None None O
the None None O
5,8 None None I-IUPAC
- None None I-IUPAC
dideaza None None I-IUPAC
analogue None None I-MODIFIER
was None None O
3 None None O
times None None O
more None None O
potent None None O
. None None O

5 None None I-IUPAC
- None None I-IUPAC
Methyl None None I-IUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
substitution None None I-MODIFIER
was None None O
also None None O
favorable None None O
, None None O
with None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
analogue None None I-MODIFIER
being None None O
2 None None O
. None None O

5 None None O
- None None O
fold None None O
more None None O
potent None None O
than None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
analogue None None I-MODIFIER
. None None O

However None None O
the None None O
effect None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
substitution None None I-MODIFIER
was None None O
less None None O
pronounced None None O
in None None O
the None None O
5,8 None None I-IUPAC
- None None I-IUPAC
dideaza None None I-IUPAC
analogues None None I-MODIFIER
than None None O
in None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
analogues None None I-MODIFIER
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dideaza None None I-IUPAC
analogue None None I-MODIFIER
of None None O
3 None None O
was None None O
the None None O
most None None O
active None None O
member None None O
of None None O
the None None O
series None None O
, None None O
with None None O
an None None O
IC50 None None O
= None None O
0.33 None None O
nM None None O
versus None None O
1.8 None None O
nM None None O
for None None O
3 None None O
and None None O
15 None None O
nM None None O
for None None O
MTX None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
analogue None None I-MODIFIER
of None None O
3 None None O
was None None O
also None None O
tested None None O
at None None O
the None None O
National None None O
Cancer None None O
Institute None None O
against None None O
a None None O
panel None None O
of None None O
50 None None O
human None None O
tumor None None O
cell None None O
lines None None O
in None None O
culture None None O
and None None O
was None None O
consistently None None O
more None None O
potent None None O
than None None O
3 None None O
, None None O
with None None O
IC50 None None O
values None None O
in None None O
the None None O
low None None O
- None None O
nanomolar None None O
to None None O
subnanomolar None None O
range None None O
against None None O
most None None O
of None None O
the None None O
tumors None None O
. None None O

Leukemia None None O
and None None O
colorectal None None O
carcinoma None None O
cell None None O
lines None None O
were None None O
generally None None O
most None None O
sensitive None None O
, None None O
though None None O
good None None O
activity None None O
was None None O
also None None O
observed None None O
against None None O
CNS None None O
tumors None None O
and None None O
carcinomas None None O
of None None O
the None None O
breast None None O
and None None O
prostate None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
demonstrate None None O
that None None O
B None None O
- None None O
ring None None O
analogues None None O
of None None O
3 None None O
inhibit None None O
DHFR None None O
activity None None O
and None None O
tumor None None O
cell None None O
colony None None O
formation None None O
as None None O
well None None O
as None None O
, None None O
or None None O
better None None O
than None None O
, None None O
the None None O
parent None None O
compound None None O
. None None O

In None None O
view None None O
of None None O
the None None O
fact None None O
that None None O
3 None None O
and None None O
its None None O
B None None O
- None None O
ring None None O
analogues None None O
cannot None None O
form None None O
polyglutamates None None O
, None None O
their None None O
high None None O
cytotoxicity None None O
relative None None O
to None None O
the None None O
corresponding None None O
B None None O
- None None O
ring None None O
analogues None None O
of None None O
AMT None None O
is None None O
noteworthy None None O
. None None O


[ None None O
1 None None O
- None None O
Beta None None O
- None None O
mercapto None None O
- None None O
beta None None O
, None None O
beta None None O
- None None O
pentamethylenepropionic None None O
acid None None O
] None None O
oxytocin None None O
was None None O
prepared None None O
from None None O
beta None None O
- None None O
Mpa None None O
( None None O
beta None None O
- None None O
( None None O
CH2 None None O
) None None O
5 None None O
) None None O
( None None O
Bzl None None O
) None None O
- None None O
Tyr None None O
( None None O
Bzl None None O
) None None O
- None None O
Ile None None O
- None None O
Gln None None O
- None None O
Asn None None O
- None None O
Cys None None O
( None None O
Bzl None None O
) None None O
- None None O
Pro None None O
- None None O
Leu None None O
- None None O
Gly None None O
- None None O
NH2 None None O
by None None O
removal None None O
of None None O
the None None O
Bzl None None O
- None None O
protecting None None O
groups None None O
with None None O
Na None None O
- None None O
NH3 None None O
followed None None O
by None None O
cyclization None None O
of None None O
the None None O
resulting None None O
disulfhydryl None None O
compound None None O
with None None O
K3Fe None None O
( None None O
CN None None O
) None None O
6 None None O
. None None O

The None None O
analog None None O
was None None O
purified None None O
by None None O
desalting None None O
on None None O
Sephadex None None O
G None None O
- None None O
15 None None O
in None None O
50% None None O
HOAc None None O
and None None O
gel None None O
filtration None None O
on None None O
Sephadex None None O
G None None O
- None None O
25 None None O
and None None O
LH None None O
- None None O
20 None None O
. None None O

The None None O
protected None None O
intermediate None None O
above None None O
was None None O
synthesized None None O
from None None O
Z None None O
- None None O
Cys None None O
( None None O
Bzl None None O
) None None O
- None None O
Pro None None O
- None None O
Leu None None O
- None None O
Gly None None O
- None None O
NH2 None None O
by None None O
the None None O
stepwose None None O
p None None O
- None None O
nitrophenyl None None O
ester None None O
method None None O
using None None O
Nalpha None None O
- None None O
Boc None None O
protection None None O
at None None O
the None None O
penta None None O
- None None O
, None None O
hexa None None O
- None None O
, None None O
and None None O
octapeptide None None O
stages None None O
. None None O

The None None O
analog None None O
was None None O
found None None O
to None None O
be None None O
a None None O
potent None None O
inhibitor None None O
of None None O
the None None O
oxytocic None None O
and None None O
avian None None O
vasodepressor None None O
effects None None O
of None None O
oxytocin None None O
( None None O
pA2 None None O
values None None O
of None None O
7.43 None None O
and None None O
8.30 None None O
, None None O
respectively None None O
) None None O
but None None O
was None None O
only None None O
a None None O
weak None None O
inhibitor None None O
of None None O
the None None O
rat None None O
pressor None None O
effect None None O
of None None O
8 None None I-IUPAC
- None None I-IUPAC
lysine None None I-IUPAC
- None None I-IUPAC
vasopressin None None I-IUPAC
. None None O

The None None O
rat None None O
antipressor None None O
potency None None O
of None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
deaminopenicillamine None None I-IUPAC
] None None I-IUPAC
oxytocin None None I-IUPAC
was None None O
also None None O
determined None None O
in None None O
this None None O
study None None O
: None None O
pA2 None None O
= None None O
6.27 None None O
. None None O

Of None None O
the None None O
alkyl None None O
- None None O
substituted None None O
1 None None O
- None None O
position None None O
analogs None None O
of None None O
oxytocin None None O
studied None None O
so None None O
far None None O
, None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
mercapto None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
, None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
pentamethylenepropionic None None I-IUPAC
acid None None I-IUPAC
] None None I-IUPAC
oxytocin None None I-IUPAC
is None None O
the None None O
most None None O
potent None None O
antioxytocic None None O
agent None None O
. None None O


A None None O
series None None O
of None None O
thieno None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
oxazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
and None None O
thieno None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
thiazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
were None None O
synthesized None None O
and None None O
investigated None None O
as None None O
inhibitors None None O
of None None O
the None None O
alpha None None O
/ None None O
beta None None O
hydrolases None None O
cholesterol None None O
esterase None None O
( None None O
CEase None None O
) None None O
and None None O
acetylcholinesterase None None O
( None None O
AChE None None O
) None None O
. None None O

The None None O
introduction None None O
of None None O
a None None O
cycloaliphatic None None O
five None None O
- None None O
or None None O
six None None O
- None None O
membered None None O
ring None None O
fused None None O
at None None O
the None None O
thiophene None None O
was None None O
favorable None None O
for None None O
CEase None None O
inhibition None None O
. None None O

Such None None O
compounds None None O
were None None O
analyzed None None O
as None None O
true None None O
alternate None None O
substrate None None O
inhibitors None None O
. None None O

6,7 None None I-IUPAC
- None None I-IUPAC
Dihydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
, None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
cyclopenta None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
] None None I-IUPAC
thieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
oxazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
33 None None O
) None None O
exhibited None None O
a None None O
K None None O
( None None O
i None None O
) None None O
value None None O
of None None O
630 None None O
nM None None O
and None None O
excelled None None O
in None None O
its None None O
low None None O
susceptibility None None O
to None None O
CEase None None O
- None None O
catalyzed None None O
degradation None None O
. None None O

Compound None None O
33 None None O
and None None O
its None None O
analogues None None O
did None None O
not None None O
inhibit None None O
AChE None None O
. None None O

The None None O
introduction None None O
of None None O
a None None O
tetrahydropyrido None None O
ring None None O
with None None O
bulky None None O
hydrophobic None None O
substituents None None O
at None None O
the None None O
basic None None O
nitrogen None None O
provided None None O
inhibitors None None O
of None None O
AChE None None O
which None None O
were None None O
completely None None O
inactive None None O
toward None None O
CEase None None O
. None None O

7 None None I-IUPAC
- None None I-IUPAC
Benzyl None None I-IUPAC
- None None I-IUPAC
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
4' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
: None None I-IUPAC
4,5 None None I-IUPAC
] None None I-IUPAC
thieno None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
oxazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
21 None None O
) None None O
had None None O
the None None O
IC None None O
( None None O
50 None None O
) None None O
value None None O
of None None O
330 None None O
nM None None O
for None None O
AChE None None O
inhibition None None O
. None None O

A None None O
residual None None O
enzymatic None None O
activity None None O
at None None O
an None None O
infinite None None O
inhibitor None None O
concentration None None O
and None None O
thus None None O
a None None O
catalytically None None O
active None None O
ternary None None O
enzyme None None O
- None None O
substrate None None O
- None None O
inhibitor None None O
complex None None O
was None None O
concluded None None O
. None None O

To None None O
specify None None O
kinetic None None O
parameters None None O
of None None O
inhibition None None O
, None None O
a None None O
new None None O
method None None O
was None None O
derived None None O
to None None O
characterize None None O
selected None None O
thieno None None I-IUPAC
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
oxazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
as None None O
hyperbolic None None O
mixed None None O
- None None O
type None None O
inhibitors None None O
of None None O
AChE None None O
. None None O


Series None None O
of None None O
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
9,10 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
3,4,6,7 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
pyrimido None None I-IUPAC
[ None None I-IUPAC
6,1 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
isoquinoline None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diones None None I-IUPAC
and None None O
2 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
9,10 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
pyrimido None None I-IUPAC
[ None None I-IUPAC
6,1 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
isoquinolin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
were None None O
synthesized None None O
and None None O
tested None None O
for None None O
blood None None O
pressure None None O
lowering None None O
properties None None O
in None None O
anesthetized None None O
normotensive None None O
cats None None O
and None None O
conscious None None O
spontaneously None None O
hypertensive None None O
rats None None O
. None None O

Several None None O
compounds None None O
in None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9,10 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
pyrimido None None I-IUPAC
[ None None I-IUPAC
6,1 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
isoquinolin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
series None None I-MODIFIER
display None None O
a None None O
high None None O
order None None O
of None None O
activity None None O
. None None O

The None None O
most None None O
active None None O
compounds None None O
are None None O
the None None O
alkyl None None O
derivatives None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
mesitylamino None None I-IUPAC
/ None None O
2 None None I-IUPAC
- None None I-IUPAC
mesitylimino None None I-IUPAC
tautomeric None None I-MODIFIER
forms None None I-MODIFIER
. None None O

The None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
mesitylimino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
analogue None None I-MODIFIER
trequinsin None None O
is None None O
a None None O
potent None None O
antihypertensive None None O
agent None None O
and None None O
displays None None O
a None None O
hemodynamic None None O
profile None None O
characteristic None None O
of None None O
an None None O
arteriolar None None O
dilator None None O
. None None O

It None None O
is None None O
also None None O
a None None O
potent None None O
inhibitor None None O
of None None O
both None None O
cAMP None None O
phosphodiesterase None None O
and None None O
platelet None None O
aggregation None None O
. None None O


Cyclic None None O
depsipeptide None None O
cyclo None None O
- None None O
[ None None O
D None None O
- None None O
Hmp None None O
( None None O
1 None None O
) None None O
- None None O
L None None O
- None None O
MeVal None None O
( None None O
2 None None O
) None None O
- None None O
L None None O
- None None O
Phe None None O
( None None O
3 None None O
) None None O
- None None O
L None None O
- None None O
MePhe None None O
( None None O
4 None None O
) None None O
- None None O
L None None O
- None None O
Pro None None O
( None None O
5 None None O
) None None O
- None None O
L None None O
- None None O
aIle+ None None O
+ None None O
+ None None O
( None None O
6 None None O
) None None O
- None None O
L None None O
- None None O
MeVal None None O
( None None O
7 None None O
) None None O
- None None O
L None None O
- None None O
Leu None None O
( None None O
8 None None O
) None None O
- None None O
L None None O
- None None O
betaHOMeVal None None O
( None None O
9 None None O
) None None O
] None None O
, None None O
the None None O
antifungal None None O
antibiotic None None O
aureobasidin None None O
A None None O
( None None O
AbA None None O
) None None O
, None None O
was None None O
reported None None O
to None None O
interfere None None O
with None None O
ATP None None O
- None None O
binding None None O
cassette None None O
( None None O
ABC None None O
) None None O
transporters None None O
in None None O
yeast None None O
and None None O
mammalian None None O
cells None None O
, None None O
particularly None None O
the None None O
MDR1 None None O
P None None O
- None None O
glycoprotein None None O
( None None O
Pgp None None O
) None None O
, None None O
a None None O
transmembrane None None O
phospholipid None None O
flippase None None O
or None None O
" None None O
hydrophobic None None O
vacuum None None O
cleaner None None O
" None None O
that None None O
mediates None None O
multidrug None None O
resistance None None O
( None None O
MDR None None O
) None None O
of None None O
cancer None None O
cells None None O
. None None O

In None None O
a None None O
standardized None None O
assay None None O
that None None O
measures None None O
Pgp None None O
function None None O
by None None O
the None None O
Pgp None None O
- None None O
mediated None None O
efflux None None O
of None None O
the None None O
calcein None None O
- None None O
AM None None O
Pgp None None O
substrate None None O
and None None O
uses None None O
human None None O
lymphoblastoid None None O
MDR None None O
- None None O
CEM None None O
( None None O
VBL None None O
( None None O
100 None None O
) None None O
) None None O
cells None None O
as None None O
highly None None O
resistant None None O
Pgp None None O
- None None O
expressing None None O
cells None None O
and None None O
the None None O
cyclic None None O
undecapeptide None None O
cyclosporin None None O
A None None O
( None None O
CsA None None O
) None None O
as None None O
a None None O
reference None None O
MDR None None O
- None None O
reversing None None O
agent None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
3.4 None None O
microM None None O
) None None O
, None None O
AbA None None O
was None None O
found None None O
to None None O
be None None O
a None None O
more None None O
active None None O
Pgp None None O
inhibitor None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
2.3 None None O
microM None None O
) None None O
. None None O

Out None None O
of None None O
seven None None O
natural None None O
analogues None None O
and None None O
18 None None O
chemical None None O
derivatives None None O
of None None O
AbA None None O
, None None O
several None None O
were None None O
shown None None O
to None None O
display None None O
even None None O
more None None O
potent None None O
Pgp None None O
- None None O
inhibitory None None O
activity None None O
. None None O

The None None O
Pgp None None O
- None None O
inhibitory None None O
activity None None O
was None None O
increased None None O
about None None O
2 None None O
- None None O
fold None None O
by None None O
some None None O
minor None None O
modifications None None O
such None None O
as None None O
those None None O
found None None O
in None None O
the None None O
naturally None None O
occurring None None O
aureobasidins None None O
AbB None None O
( None None O
[ None None O
D None None O
- None None O
Hiv None None O
( None None O
1 None None O
) None None O
] None None O
- None None O
AbA None None O
) None None O
, None None O
AbC None None O
( None None O
[ None None O
Val None None O
( None None O
6 None None O
) None None O
] None None O
- None None O
AbA None None O
) None None O
, None None O
and None None O
AbD None None O
[ None None O
gammaHOMeVal None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
AbA None None O
) None None O
. None None O

The None None O
replacement None None O
of None None O
the None None O
[ None None O
Phe None None O
( None None O
3 None None O
) None None O
- None None O
MePhe None None O
( None None O
4 None None O
) None None O
- None None O
Pro None None O
( None None O
5 None None O
) None None O
] None None O
tripeptide None None O
by None None O
an None None O
8 None None I-IUPAC
- None None I-IUPAC
aminocaprylic None None I-IUPAC
acid None None I-IUPAC
or None None O
the None None O
N None None O
( None None O
7 None None O
) None None O
( None None O
) None None O
- None None O
desmethylation None None O
of None None O
MeVal None None O
( None None O
7 None None O
) None None O
led None None O
to None None O
only None None O
a None None O
3.3 None None O
- None None O
fold None None O
decreased None None O
capacity None None O
to None None O
inhibit None None O
Pgp None None O
function None None O
, None None O
suggesting None None O
that None None O
the None None O
Pgp None None O
inhibitory None None O
potential None None O
of None None O
aureobasidins None None O
, None None O
though None None O
favored None None O
by None None O
the None None O
establishment None None O
of None None O
an None None O
antiparallel None None O
beta None None O
- None None O
sheet None None O
between None None O
the None None O
[ None None O
D None None O
- None None O
Hmp None None O
( None None O
1 None None O
) None None O
- None None O
L None None O
- None None O
MeVal None None O
( None None O
2 None None O
) None None O
- None None O
L None None O
- None None O
Phe None None O
( None None O
3 None None O
) None None O
] None None O
and None None O
[ None None O
L None None O
- None None O
aIle None None O
( None None O
6 None None O
) None None O
- None None O
L None None O
- None None O
MeVal None None O
( None None O
7 None None O
) None None O
- None None O
L None None O
- None None O
Leu None None O
( None None O
8 None None O
) None None O
- None None O
] None None O
tripeptides None None O
, None None O
does None None O
not None None O
critically None None O
depend None None O
on None None O
the None None O
occurrence None None O
of None None O
the None None O
[ None None O
L None None O
- None None O
Phe None None O
( None None O
3 None None O
) None None O
- None None O
L None None O
- None None O
MePhe None None O
( None None O
4 None None O
) None None O
- None None O
L None None O
- None None O
Pro None None O
( None None O
5 None None O
) None None O
- None None O
L None None O
- None None O
aIle None None O
( None None O
6 None None O
) None None O
] None None O
type None None O
II None None O
' None None O
beta None None O
- None None O
turn None None O
secondary None None O
structure None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
most None None O
potent None None O
Pgp None None O
inhibitors None None O
were None None O
found None None O
among None None O
AbA None None O
analogues None None O
with None None O
[ None None O
betaHO None None O
- None None O
MeVal None None O
( None None O
9 None None O
) None None O
] None None O
residue None None O
alterations None None O
, None None O
with None None O
some None None O
data None None O
suggesting None None O
a None None O
negative None None O
impact None None O
of None None O
the None None O
[ None None O
L None None O
- None None O
Leu None None O
( None None O
8 None None O
) None None O
- None None O
L None None O
- None None O
betaHOMeVal None None O
( None None O
9 None None O
) None None O
- None None O
D None None O
- None None O
Hmp None None O
( None None O
1 None None O
) None None O
] None None O
gamma None None O
- None None O
turn None None O
secondary None None O
structure None None O
on None None O
Pgp None None O
inhibitory None None O
potential None None O
. None None O

The None None O
[ None None O
2,3 None None O
- None None O
dehydro None None O
- None None O
MeVal None None O
( None None O
9 None None O
) None None O
] None None O
- None None O
AbA None None O
was None None O
the None None O
most None None O
potent None None O
Pgp None None O
inhibitory None None O
aureobasidin None None O
, None None O
being None None O
13 None None O
- None None O
fold None None O
more None None O
potent None None O
than None None O
AbA None None O
and None None O
19 None None O
- None None O
fold None None O
more None None O
potent None None O
( None None O
on None None O
a None None O
molar None None O
basis None None O
) None None O
than None None O
CsA None None O
. None None O

Finally None None O
, None None O
there None None O
was None None O
no None None O
correlation None None O
between None None O
the None None O
SAR None None O
for None None O
the None None O
human None None O
MDR1 None None O
Pgp None None O
inhibition None None O
and None None O
the None None O
SAR None None O
for None None O
Saccharomyces None None O
cerevisiae None None O
antifungal None None O
activity None None O
, None None O
which None None O
is None None O
mediated None None O
by None None O
an None None O
inositol None None O
phosphoceramide None None O
synthase None None O
activity None None O
. None None O


5 None None O
- None None O
( None None O
4 None None O
- None None O
Piperidyl None None O
) None None O
isoxazol None None O
- None None O
3 None None O
- None None O
ol None None O
( None None O
4 None None O
- None None O
PIOL None None O
, None None O
10 None None O
) None None O
, None None O
a None None O
structural None None O
analog None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
aminobutanoic None None I-IUPAC
acid None None I-IUPAC
( None None O
GABA None None O
, None None O
1 None None O
) None None O
and None None O
the None None O
GABAA None None O
agonist None None O
4,5,6,7 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoxazolo None None I-IUPAC
[ None None I-IUPAC
5,4 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
( None None O
THIP None None O
, None None O
5 None None O
) None None O
, None None O
is None None O
a None None O
low None None O
- None None O
efficacy None None O
partial None None O
GABAA None None O
agonist None None O
. None None O

A None None O
number None None O
of None None O
compounds None None O
bioisosterically None None O
derived None None O
from None None O
10 None None O
, None None O
including None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidyl None None I-IUPAC
) None None I-IUPAC
isothiazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
( None None O
11 None None O
) None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidyl None None I-IUPAC
) None None I-IUPAC
isoxazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
( None None O
12 None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydropyrid None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
isoxazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
( None None O
13 None None O
) None None O
, None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,3,6 None None I-IUPAC
- None None I-IUPAC
tetrahydropyrid None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
isothiazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
( None None O
14 None None O
) None None O
, None None O
were None None O
synthesized None None O
and None None O
tested None None O
as None None O
GABAA None None O
receptor None None O
ligands None None O
. None None O

Whereas None None O
none None None O
of None None O
these None None O
compounds None None O
significantly None None O
affected None None O
GABAB None None O
receptor None None O
binding None None O
or None None O
GABA None None O
uptake None None O
, None None O
they None None O
showed None None O
affinities None None O
for None None O
GABAA None None O
receptor None None O
sites None None O
in None None O
the None None O
low None None O
- None None O
micromolar None None O
range None None O
. None None O

Using None None O
cultured None None O
cerebral None None O
cortical None None O
neurons None None O
and None None O
whole None None O
- None None O
cell None None O
patch None None O
- None None O
clamp None None O
techniques None None O
, None None O
the None None O
efficacies None None O
of None None O
these None None O
compounds None None O
relative None None O
to None None O
that None None O
of None None O
the None None O
full None None O
GABAA None None O
agonist None None O
, None None O
isoguvacine None None O
( None None O
8 None None O
) None None O
( None None O
20 None None O
microM None None O
) None None O
, None None O
were None None O
determined None None O
. None None O

The None None O
relative None None O
efficacy None None O
of None None O
11 None None O
, None None O
which None None O
has None None O
a None None O
higher None None O
receptor None None O
affinity None None O
( None None O
IC50 None None O
= None None O
1.3 None None O
+ None None O
/ None None O
- None None O
0.3 None None O
microM None None O
) None None O
than None None O
10 None None O
( None None O
IC50 None None O
= None None O
9.3 None None O
+ None None O
/ None None O
- None None O
2.6 None None O
microM None None O
) None None O
, None None O
was None None O
comparable None None O
with None None O
that None None O
of None None O
10 None None O
( None None O
30-35% None None O
) None None O
. None None O

The None None O
tetrahydropyridine None None O
analog None None O
of None None O
10 None None O
, None None O
compound None None O
13 None None O
, None None O
showed None None O
a None None O
markedly None None O
lower None None O
receptor None None O
affinity None None O
( None None O
IC50 None None O
= None None O
32 None None O
+ None None O
/ None None O
- None None O
10 None None O
microM None None O
) None None O
and None None O
apparently None None O
a None None O
lower None None O
relative None None O
efficacy None None O
than None None O
10 None None O
. None None O

The None None O
corresponding None None O
unsaturated None None O
analog None None O
of None None O
11 None None O
, None None O
compound None None O
14 None None O
, None None O
showed None None O
a None None O
slightly None None O
weaker None None O
receptor None None O
affinity None None O
( None None O
IC50 None None O
= None None O
4.0 None None O
+ None None O
/ None None O
- None None O
2.0 None None O
microM None None O
) None None O
but None None O
a None None O
significantly None None O
higher None None O
relative None None O
efficacy None None O
( None None O
50-55% None None O
) None None O
than None None O
11 None None O
. None None O

The None None O
5 None None O
- None None O
isoxazolol None None O
isomer None None O
of None None O
10 None None O
, None None O
compound None None O
12 None None O
, None None O
showed None None O
a None None O
reduced None None O
receptor None None O
affinity None None O
( None None O
IC50 None None O
= None None O
26 None None O
+ None None O
/ None None O
- None None O
7 None None O
microM None None O
) None None O
and None None O
a None None O
very None None O
low None None O
relative None None O
efficacy None None O
. None None O

Substitution None None O
of None None O
propanoic None None O
or None None O
propenoic None None O
acid None None O
moieties None None O
for None None O
the None None O
acidic None None O
heterocyclic None None O
units None None O
of None None O
these None None O
compounds None None O
gave None None O
the None None O
monocyclic None None O
amino None None O
acids None None O
15-18 None None O
, None None O
which None None O
have None None O
very None None O
little None None O
or None None O
no None None O
affinity None None O
for None None O
GABAA None None O
receptor None None O
sites None None O
. None None O


Continuing None None O
studies None None O
on None None O
the None None O
chemical None None O
modification None None O
of None None O
the None None O
previously None None O
reported None None O
novel None None O
tripeptide None None O
SP None None O
antagonist None None O
, None None O
N None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyloxycarbonyl None None I-IUPAC
) None None I-IUPAC
glutaminyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N1 None None I-IUPAC
- None None I-IUPAC
formyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
tryptophyl None None I-IUPAC
] None None I-IUPAC
phenylalanine None None I-IUPAC
benzyl None None I-IUPAC
ester None None I-IUPAC
[ None None O
Boc None None O
- None None O
Gln None None O
- None None O
D None None O
- None None O
Trp None None O
- None None O
( None None O
CHO None None O
) None None O
- None None O
Phe None None O
- None None O
OBzl None None O
( None None O
1 None None O
) None None O
] None None O
, None None O
are None None O
described None None O
herein None None O
. None None O

We None None O
initially None None O
investigated None None O
the None None O
stability None None O
of None None O
1 None None O
in None None O
guinea None None O
pig None None O
plasma None None O
and None None O
liver None None O
homogenate None None O
to None None O
elucidate None None O
the None None O
most None None O
labile None None O
part None None O
in None None O
the None None O
structure None None O
. None None O

It None None O
was None None O
consequently None None O
revealed None None O
that None None O
the None None O
benzyl None None O
ester None None O
part None None O
was None None O
easily None None O
hydrolyzed None None O
to None None O
produce None None O
the None None O
inactive None None O
acid None None O
analog None None O
. None None O

Thus None None O
we None None O
searched None None O
for None None O
a None None O
benzyl None None O
ester None None O
surrogate None None O
that None None O
would None None O
be None None O
more None None O
resistant None None O
to None None O
hydrolytic None None O
enzymes None None O
. None None O

This None None O
approach None None O
found None None O
an None None O
isosteric None None O
amide None None O
structure None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylmethyl None None I-IUPAC
) None None I-IUPAC
amide None None I-IUPAC
, None None O
suitable None None O
in None None O
terms None None O
of None None O
potency None None O
and None None O
stability None None O
. None None O

Subsequent None None O
modification None None O
of None None O
the None None O
amino None None O
terminal None None O
into None None O
N None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
threonine None None I-IUPAC
led None None O
to None None O
the None None O
most None None O
potent None None O
compound None None O
, None None O
N None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
threonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N1 None None I-IUPAC
- None None I-IUPAC
formyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
tryptophyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
phenylalaninamide None None I-IUPAC
[ None None O
Ac None None O
- None None O
Thr None None O
- None None O
D None None O
- None None O
Trp None None O
( None None O
CHO None None O
) None None O
- None None O
Phe None None O
- None None O
NMeBzl None None O
( None None O
5a None None O
, None None O
FR113680 None None O
) None None O
] None None O
. None None O

This None None O
compound None None O
5a None None O
potently None None O
blocked None None O
3H None None O
- None None O
SP None None O
binding None None O
to None None O
guinea None None O
pig None None O
lung None None O
membranes None None O
with None None O
IC50 None None O
of None None O
( None None O
5.8 None None O
+ None None O
/ None None O
- None None O
0.78 None None O
) None None O
x None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
M None None O
. None None O

In None None O
vitro None None O
, None None O
5a None None O
inhibited None None O
SP None None O
- None None O
induced None None O
contraction None None O
of None None O
isolated None None O
guinea None None O
pig None None O
trachea None None O
strips None None O
with None None O
IC50 None None O
of None None O
2.3 None None O
x None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
M None None O
and None None O
caused None None O
no None None O
contraction None None O
when None None O
used None None O
alone None None O
in None None O
this None None O
preparation None None O
up None None O
to None None O
3.2 None None O
x None None O
10 None None O
( None None O
- None None O
5 None None O
) None None O
M None None O
. None None O

In None None O
addition None None O
5a None None O
exhibited None None O
no None None O
effect None None O
on None None O
the None None O
contraction None None O
induced None None O
by None None O
histamine None None O
or None None O
acetylcholine None None O
. None None O

Intriguingly None None O
, None None O
it None None O
was None None O
demonstrated None None O
in None None O
vivo None None O
that None None O
5a None None O
suppressed None None O
the None None O
SP None None O
- None None O
induced None None O
bronchoconstriction None None O
and None None O
airway None None O
edema None None O
in None None O
guinea None None O
pigs None None O
with None None O
ED50 None None O
of None None O
0.42 None None O
mg None None O
/ None None O
kg None None O
and None None O
0.66 None None O
mg None None O
/ None None O
kg None None O
, None None O
respectively None None O
, None None O
when None None O
administered None None O
intravenously None None O
. None None O


Piperidine None None O
and None None O
cyclohexyl None None O
ring None None O
homologues None None O
of None None O
the None None O
high None None O
- None None O
affinity None None O
dopamine None None O
( None None O
DA None None O
) None None O
uptake None None O
inhibitor None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
cyclohexyl None None I-IUPAC
] None None I-IUPAC
piperidine None None I-IUPAC
( None None O
BTCP None None O
, None None O
3 None None O
) None None O
were None None O
each None None O
prepared None None O
in None None O
four None None O
steps None None O
from None None O
the None None O
appropriate None None O
cycloalkanones None None O
. None None O

These None None O
compounds None None O
were None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
displace None None O
[ None None O
3H None None O
] None None O
BTCP None None O
and None None O
[ None None O
3H None None O
] None None O
cocaine None None O
and None None O
to None None O
inhibit None None O
[ None None O
3H None None O
] None None O
DA None None O
uptake None None O
in None None O
rat None None O
striatal None None O
homogenates None None O
. None None O

The None None O
ratios None None O
IC50 None None O
( None None O
[ None None O
3H None None O
] None None O
cocaine None None O
) None None O
/ None None O
IC50 None None O
( None None O
[ None None O
3H None None O
] None None O
BTCP None None O
) None None O
ranged None None O
from None None O
62 None None O
for None None O
BTCP None None O
to None None O
1.5 None None O
for None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyclopentylamine None None I-IUPAC
( None None O
17 None None O
) None None O
; None None O
cocaine None None O
gave None None O
a None None O
ratio None None O
of None None O
0.6 None None O
. None None O

This None None O
indicates None None O
that None None O
BTCP None None O
is None None O
the None None O
most None None O
selective None None O
of None None O
all None None O
the None None O
compounds None None O
tested None None O
for None None O
sites None None O
labeled None None O
by None None O
[ None None O
3H None None O
] None None O
BTCP None None O
whereas None None O
cocaine None None O
is None None O
most None None O
selective None None O
for None None O
sites None None O
labeled None None O
by None None O
[ None None O
3H None None O
] None None O
cocaine None None O
. None None O

The None None O
wide None None O
differences None None O
in None None O
the None None O
relative None None O
abilities None None O
of None None O
these None None O
compounds None None O
to None None O
displace None None O
[ None None O
3H None None O
] None None O
BTCP None None O
and None None O
[ None None O
3H None None O
] None None O
cocaine None None O
suggests None None O
that None None O
these None None O
two None None O
radioligands None None O
are None None O
labeling None None O
different None None O
sites None None O
on None None O
the None None O
transporter None None O
. None None O

In None None O
general None None O
, None None O
the None None O
compounds None None O
structurally None None O
related None None O
to None None O
BTCP None None O
exhibited None None O
greater None None O
selectivity None None O
for None None O
sites None None O
labeled None None O
by None None O
[ None None O
3H None None O
] None None O
BTCP None None O
. None None O

However None None O
, None None O
several None None O
of None None O
the None None O
BTCP None None O
- None None O
related None None O
derivatives None None O
showed None None O
greater None None O
( None None O
compared None None O
with None None O
BTCP None None O
and None None O
cocaine None None O
) None None O
ability None None O
to None None O
displace None None O
[ None None O
3H None None O
] None None O
cocaine None None O
. None None O

Most None None O
notably None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
cyclohexyl None None I-IUPAC
] None None I-IUPAC
pyrrolidine None None I-IUPAC
( None None O
7 None None O
) None None O
exhibited None None O
a None None O
3.4 None None O
- None None O
fold None None O
greater None None O
affinity None None O
for None None O
these None None O
sites None None O
compared None None O
with None None O
BTCP None None O
and None None O
a None None O
9 None None O
- None None O
fold None None O
greater None None O
affinity None None O
at None None O
these None None O
sites None None O
than None None O
cocaine None None O
. None None O

Most None None O
of None None O
the None None O
BTCP None None O
homologues None None O
displayed None None O
greater None None O
ability None None O
to None None O
inhibit None None O
[ None None O
3H None None O
] None None O
DA None None O
uptake None None O
in None None O
rat None None O
forebrain None None O
synaptosomes None None O
than None None O
cocaine None None O
. None None O

BTCP None None O
and None None O
7 None None O
were None None O
the None None O
most None None O
potent None None O
of None None O
all None None O
the None None O
compounds None None O
tested None None O
in None None O
terms None None O
of None None O
their None None O
ability None None O
to None None O
inhibit None None O
uptake None None O
of None None O
[ None None O
3H None None O
] None None O
DA None None O
. None None O

IC50 None None O
ratios None None O
for None None O
[ None None O
3H None None O
] None None O
cocaine None None O
binding None None O
/ None None O
[ None None O
3H None None O
] None None O
DA None None O
uptake None None O
ranged None None O
from None None O
0.47 None None O
for None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
cyclopentyl None None I-IUPAC
] None None I-IUPAC
homopiperidine None None I-IUPAC
( None None O
11 None None O
) None None O
to None None O
8.8 None None O
for None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
cyclohexylamine None None I-IUPAC
( None None O
4 None None O
) None None O
. None None O

The None None O
importance None None O
of None None O
this None None O
ratio None None O
remains None None O
unclear None None O
in None None O
terms None None O
of None None O
identification None None O
of None None O
potential None None O
cocaine None None O
antagonists None None O
. None None O

As None None O
for None None O
BTCP None None O
, None None O
all None None O
of None None O
the None None O
compounds None None O
tested None None O
showed None None O
Ki None None O
values None None O
& None None O
gt None None O
; None None O
10,000 None None O
nM None None O
for None None O
displacement None None O
of None None O
[ None None O
3H None None O
] None None O
TCP None None O
from None None O
rat None None O
brain None None O
homogenates None None O
. None None O

These None None O
compounds None None O
were None None O
able None None O
to None None O
displace None None O
the None None O
highly None None O
selective None None O
sigma None None O
receptor None None O
probe None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pentazocine None None I-IUPAC
from None None O
guinea None None O
pig None None O
brain None None O
homogenates None None O
with None None O
Ki None None O
values None None O
ranging None None O
from None None O
125 None None O
to None None O
9170 None None O
nM None None O
. None None O

The None None O
significance None None O
of None None O
their None None O
sigma None None O
- None None O
binding None None O
activity None None O
in None None O
light None None O
of None None O
their None None O
dopaminergic None None O
properties None None O
is None None O
unclear None None O
. None None O

The None None O
diverse None None O
binding None None O
properties None None O
of None None O
these None None O
compounds None None O
at None None O
the None None O
DA None None O
- None None O
uptake None None O
site None None O
and None None O
their None None O
spectrum None None O
of None None O
inhibitory None None O
activities None None O
for None None O
[ None None O
3H None None O
] None None O
DA None None O
uptake None None O
identifies None None O
them None None O
as None None O
a None None O
useful None None O
base None None O
for None None O
the None None O
development None None O
of None None O
subtype None None O
selective None None O
probes None None O
at None None O
this None None O
site None None O
. None None O

These None None O
compounds None None O
will None None O
allow None None O
further None None O
study None None O
of None None O
the None None O
structure None None O
and None None O
function None None O
of None None O
the None None O
" None None O
cocaine None None O
" None None O
receptor None None O
as None None O
well None None O
as None None O
the None None O
development None None O
of None None O
potential None None O
cocaine None None O
antagonists None None O
. None None O


A None None O
series None None O
of None None O
new None None O
enantiomerically None None O
pure None None O
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyrans None None I-IUPAC
( None None O
3 None None I-IUPAC
- None None I-IUPAC
aminochromans None None I-IUPAC
) None None O
has None None O
been None None O
synthesized None None O
from None None O
( None None I-PARTIUPAC
R None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
. None None O

The None None O
absolute None None O
configuration None None O
of None None O
the None None O
respective None None O
( None None O
R None None O
) None None O
- None None O
and None None O
( None None O
S None None O
) None None O
- None None O
enantiomers None None O
was None None O
deduced None None O
from None None O
X None None O
- None None O
ray None None O
crystallography None None O
of None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
isopropylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
, None None O
( None None O
R None None O
) None None O
- None None O
9a None None O
. None None O

Various None None O
5 None None O
- None None O
substituents None None O
were None None O
introduced None None O
via None None O
palladium None None O
- None None O
catalyzed None None O
carbonylation None None O
of None None O
N None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
trifluoromethanesulfonyloxy None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
. None None O

The None None O
effect None None O
of None None O
N None None O
- None None O
and None None O
5 None None O
- None None O
substitution None None O
on None None O
affinity None None O
for None None O
the None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
was None None O
evaluated None None O
in None None O
competition None None O
experiments None None O
using None None O
rat None None O
hippocampal None None O
membranes None None O
and None None O
[ None None O
3H None None O
] None None O
8 None None O
- None None O
OH None None O
- None None O
DPAT None None O
as None None O
radioligand None None O
. None None O

Selected None None O
compounds None None O
were None None O
also None None O
tested None None O
for None None O
their None None O
affinity None None O
to None None O
the None None O
D1 None None O
( None None O
rat None None O
striatum None None O
) None None O
, None None O
D2 None None O
( None None O
rat None None O
striatum None None O
) None None O
, None None O
D2A None None O
( None None O
human None None O
cloned None None O
) None None O
, None None O
and None None O
5 None None O
- None None O
HT2A None None O
( None None O
rat None None O
cortex None None O
) None None O
receptors None None O
. None None O

The None None O
intrinsic None None O
activity None None O
of None None O
the None None O
compounds None None O
was None None O
evaluated None None O
by None None O
measuring None None O
their None None O
effect None None O
on None None O
VIP None None O
- None None O
stimulated None None O
cAMP None None O
production None None O
in None None O
GH4ZD10 None None O
cells None None O
stably None None O
transfected None None O
with None None O
the None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
. None None O

High None None O
- None None O
affinity None None O
compounds None None O
with None None O
high None None O
selectivity None None O
for None None O
the None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
were None None O
found None None O
among None None O
structures None None O
substituted None None O
with None None O
carboxylate None None O
esters None None O
, None None O
amides None None O
, None None O
and None None O
ketones None None O
in None None O
the None None O
5 None None O
- None None O
position None None O
. None None O

Primary None None O
and None None O
secondary None None O
amines None None O
bound None None O
with None None O
lower None None O
affinity None None O
than None None O
tertiary None None O
amines None None O
. None None O

Larger None None O
substituents None None O
were None None O
well None None O
- None None O
tolerated None None O
by None None O
the None None O
receptor None None O
, None None O
but None None O
the None None O
smaller None None O
N None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
bound None None I-MODIFIER
with None None O
lower None None O
affinity None None O
. None None O

Generally None None O
, None None O
the None None O
( None None O
R None None O
) None None O
- None None O
enantiomers None None O
displayed None None O
higher None None O
affinity None None O
for None None O
the None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
than None None O
the None None O
corresponding None None O
( None None O
S None None O
) None None O
- None None O
enantiomers None None O
. None None O

In None None O
the None None O
present None None O
series None None O
of None None O
compounds None None O
, None None O
both None None O
full None None O
and None None O
partial None None O
agonists None None O
were None None O
found None None O
. None None O


3 None None I-IUPAC
- None None I-IUPAC
Ethylaminomethyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
quinolone None None I-IUPAC
( None None O
1a None None O
) None None O
and None None O
its None None O
6 None None O
- None None O
CH3 None None O
, None None O
6 None None O
- None None O
OCH3 None None O
, None None O
and None None O
7 None None O
- None None O
Cl None None O
derivatives None None O
were None None O
prepared None None O
by None None O
means None None O
of None None O
the None None O
Mannich None None O
reaction None None O
. None None O

Conversion None None O
to None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
derivatives None None I-MODIFIER
and None None O
condensation None None O
with None None O
3 None None I-IUPAC
- None None I-IUPAC
chloroaniline None None I-IUPAC
gave None None O
the None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chloroanilino None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
. None None O

Cyclization None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chloroanilino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
aminomethylquinoline None None I-IUPAC
( None None O
3a None None O
) None None O
and None None O
its None None O
6 None None O
- None None O
OCH3 None None O
derivative None None O
with None None O
paraformaldehyde None None O
gave None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,9 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethyltetrahydropyrimido None None I-IUPAC
[ None None I-IUPAC
5,4 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
quinoline None None I-IUPAC
( None None O
4a None None O
) None None O
and None None O
the None None O
9 None None O
- None None O
OCH3 None None O
derivative None None O
4b None None O
. None None O

Treatment None None O
of None None O
4b None None O
with None None O
benzaldehyde None None I-IUPAC
gave None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
styryltetrahydropyrimido None None I-IUPAC
[ None None I-IUPAC
5,4 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
quinoline None None I-IUPAC
( None None O
5 None None O
) None None O
. None None O

3 None None I-IUPAC
- None None I-IUPAC
Benzylaminomethyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
quinolone None None I-IUPAC
( None None O
1e None None O
) None None O
and None None O
3,3 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
benzyliminodimethylene None None I-IUPAC
) None None I-IUPAC
di None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
quinolone None None I-IUPAC
] None None I-IUPAC
( None None O
6b None None O
) None None O
were None None O
also None None O
synthesized None None O
. None None O

The None None O
compounds None None O
were None None O
inactive None None O
as None None O
antimalarials None None O
. None None O


A None None O
series None None O
of None None O
1,1 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
2,2,3 None None I-IUPAC
- None None I-IUPAC
triarylcyclopropanes None None I-IUPAC
( None None O
DTACs None None O
) None None O
was None None O
synthesized None None O
and None None O
evaluated None None O
as None None O
pure None None O
antiestrogens None None O
. None None O

Addition None None O
of None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
Grignard None None O
reagents None None O
to None None O
p None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
, None None O
p None None I-IUPAC
- None None I-IUPAC
benzyloxy None None I-IUPAC
, None None O
or None None O
unsubstituted None None O
deoxybenzoins None None O
, None None O
followed None None O
by None None O
dehydration None None O
of None None O
the None None O
resulting None None O
carbinols None None O
produced None None O
a None None O
mixture None None O
of None None O
E None None O
and None None O
Z None None O
olefins None None O
, None None O
which None None O
were None None O
reacted None None O
with None None O
dichlorocarbene None None O
to None None O
give None None O
O None None O
- None None O
protected None None O
DTACs None None O
. None None O

The None None O
E None None O
and None None O
Z None None O
isomers None None O
were None None O
separated None None O
by None None O
fractional None None O
crystallization None None O
and None None O
the None None O
central None None O
or None None O
geminal None None O
phenyl None None O
ring None None O
was None None O
deprotected None None O
to None None O
provide None None O
phenolic None None O
DTACs None None O
. None None O

Alkylation None None O
with None None O
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
chloride None None I-IUPAC
yielded None None O
basic None None O
cyclopropanes None None O
. None None O

Two None None O
chlorodiarylindenes None None O
were None None O
isolated None None O
as None None O
thermolysis None None O
products None None O
of None None O
the None None O
DTACs None None O
, None None O
and None None O
one None None O
was None None O
converted None None O
to None None O
a None None O
phenol None None O
by None None O
hydrogenolysis None None O
. None None O

All None None O
DTACs None None O
and None None O
indenes None None O
were None None O
competitive None None O
inhibitors None None O
of None None O
[ None None O
3H None None O
] None None O
estradiol None None O
binding None None O
in None None O
the None None O
immature None None O
rat None None O
uterine None None O
cytosol None None O
receptor None None O
assay None None O
, None None O
with None None O
relative None None O
binding None None O
affinities None None O
of None None O
0.1-3.6% None None O
of None None O
estradiol None None O
. None None O

None None None O
of None None O
the None None O
new None None O
compounds None None O
were None None O
estrogenic None None O
in None None O
the None None O
3 None None O
- None None O
day None None O
immature None None O
mouse None None O
uterotrophic None None O
assay None None O
at None None O
doses None None O
up None None O
to None None O
750 None None O
micrograms None None O
. None None O

In None None O
the None None O
3 None None O
- None None O
day None None O
immature None None O
mouse None None O
antiuterotrophic None None O
assay None None O
, None None O
five None None O
DTACs None None O
with None None O
either None None O
a None None O
methoxy None None I-IUPAC
( None None O
5a None None O
) None None O
, None None O
benzyloxy None None I-IUPAC
( None None O
4d None None O
, None None O
5c None None O
) None None O
, None None O
or None None O
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
ethoxy None None I-IUPAC
( None None O
7a None None O
, None None O
7b None None O
) None None O
central None None O
ring None None O
side None None O
chain None None O
produced None None O
significant None None O
decreases None None O
in None None O
uterine None None O
weight None None O
at None None O
doses None None O
up None None O
to None None O
750 None None O
micrograms None None O
. None None O

One None None O
compound None None O
, None None O
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
ethoxy None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylcyclopropane None None I-IUPAC
( None None O
7b None None O
) None None O
, None None O
elicited None None O
a None None O
dose None None O
- None None O
dependent None None O
decrease None None O
in None None O
vivo None None O
comparable None None O
to None None O
MER None None O
25 None None O
. None None O

These None None O
same None None O
five None None O
compounds None None O
, None None O
as None None O
well None None O
as None None O
the None None O
lead None None O
compound None None O
Analog None None O
II None None O
, None None O
were None None O
active None None O
in None None O
vitro None None O
against None None O
the None None O
estrogen None None O
- None None O
dependent None None O
MCF None None O
- None None O
7 None None O
human None None O
breast None None O
tumor None None O
cell None None O
line None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
fashion None None O
. None None O


To None None O
develop None None O
potential None None O
antitumor None None O
agents None None O
directed None None O
toward None None O
HER2 None None O
/ None None O
ErbB2 None None O
overexpression None None O
in None None O
cancer None None O
, None None O
we None None O
have None None O
designed None None O
inhibitors None None O
of None None O
the None None O
recognition None None O
between None None O
the None None O
phosphotyrosine None None O
of None None O
the None None O
receptor None None O
and None None O
the None None O
SH2 None None O
domain None None O
of None None O
the None None O
adaptor None None O
protein None None O
Grb2 None None O
. None None O

In None None O
the None None O
first None None O
part None None O
of None None O
the None None O
paper None None O
, None None O
we None None O
report None None O
the None None O
synthesis None None O
of None None O
mimetics None None O
of None None O
the None None O
constrained None None O
( None None O
alpha None None O
- None None O
Me None None O
) None None O
phosphotyrosine None None O
residue None None O
such None None O
as None None O
( None None I-MODIFIER
alpha None None I-MODIFIER
- None None I-MODIFIER
Me None None I-MODIFIER
) None None I-MODIFIER
- None None O
4 None None I-IUPAC
- None None I-IUPAC
phosphonomethylphenylalanine None None I-IUPAC
( None None O
- None None O
CH2PO3H2 None None O
) None None O
, None None O
( None None I-MODIFIER
alpha None None I-MODIFIER
- None None I-MODIFIER
Me None None I-MODIFIER
) None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
phosphonodifluoromethylphenylalanine None None I-IUPAC
( None None O
- None None O
CF2PO3H2 None None O
) None None O
, None None O
and None None O
( None None I-MODIFIER
alpha None None I-MODIFIER
- None None I-MODIFIER
Me None None I-MODIFIER
) None None I-MODIFIER
- None None O
4 None None I-IUPAC
- None None I-IUPAC
phosphonophenylalanine None None I-IUPAC
( None None O
- None None O
PO3H2 None None O
) None None O
. None None O

The None None O
incorporation None None O
of None None O
these None None O
residues None None O
in None None O
the None None O
mAZ None None O
- None None O
pTyr None None O
- None None O
Xaa None None O
- None None O
Asn None None O
- None None O
NH2 None None O
series None None O
provided None None O
compounds None None O
with None None O
very None None O
high None None O
affinity None None O
for None None O
the None None O
Grb2 None None O
SH2 None None O
domain None None O
, None None O
in None None O
the None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
- None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
range None None O
of None None O
Kd None None O
values None None O
. None None O

These None None O
compounds None None O
behave None None O
as None None O
potent None None O
antagonists None None O
of None None O
the None None O
Grb2 None None O
- None None O
Shc None None O
interaction None None O
. None None O

Our None None O
results None None O
highlight None None O
the None None O
importance None None O
of None None O
the None None O
doubly None None O
negative None None O
charge None None O
borne None None O
by None None O
the None None O
pY None None O
+ None None O
1 None None O
amino None None O
acid None None O
in None None O
accordance None None O
with None None O
the None None O
interactions None None O
observed None None O
in None None O
the None None O
complex None None O
crystallized None None O
between None None O
mAZ None None O
- None None O
pTyr None None O
- None None O
( None None O
alphaMe None None O
) None None O
pTyr None None O
- None None O
Asn None None O
- None None O
NH2 None None O
and None None O
the None None O
Grb2 None None O
SH2 None None O
domain None None O
. None None O

mAZ None None O
- None None O
pTyr None None O
- None None O
( None None O
alphaMe None None O
) None None O
pTyr None None O
- None None O
Asn None None O
- None None O
NH2 None None O
was None None O
derivatized None None O
as None None O
the None None O
S None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
thioester None None I-IUPAC
( None None O
SATE None None O
) None None O
of None None O
the None None O
phosphotyrosine None None O
residues None None O
, None None O
and None None O
its None None O
surrogates None None O
provided None None O
prodrugs None None O
with None None O
very None None O
potent None None O
antiproliferative None None O
activity None None O
on None None O
cells None None O
overexpressing None None O
HER2 None None O
/ None None O
ErbB2 None None O
, None None O
with None None O
ED50 None None O
values None None O
amounting None None O
to None None O
0.1 None None O
microM None None O
. None None O

Finally None None O
a None None O
new None None O
prodrug None None O
is None None O
put None None O
forth None None O
under None None O
the None None O
form None None O
of None None O
a None None O
monobenzyl None None O
ester None None O
of None None O
phosphate None None O
group None None O
that None None O
is None None O
as None None O
active None None O
as None None O
and None None O
much None None O
easier None None O
to None None O
synthesize None None O
than None None O
SATE None None O
prodrugs None None O
. None None O

These None None O
compounds None None O
show None None O
promising None None O
activity None None O
for None None O
further None None O
testing None None O
on None None O
in None None O
vivo None None O
models None None O
. None None O


Analogs None None O
of None None O
CVFM None None O
( None None O
a None None O
known None None O
nonsubstrate None None O
farnesyltransferase None None O
( None None O
FT None None O
) None None O
inhibitor None None O
derived None None O
from None None O
a None None O
CA1A2X None None O
sequence None None O
where None None O
C None None O
is None None O
cysteine None None O
, None None O
A None None O
is None None O
an None None O
aliphatic None None O
residue None None O
, None None O
and None None O
X None None O
is None None O
any None None O
residue None None O
) None None O
were None None O
prepared None None O
where None None O
phenylalanine None None O
was None None O
replaced None None O
by None None O
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dehydrophenylalanine None None I-IUPAC
, None None O
2 None None I-IUPAC
- None None I-IUPAC
aminoindan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
, None None O
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
Tic None None O
) None None O
, None None O
and None None O
indoline None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
. None None O

The None None O
greatest None None O
improvement None None O
in None None O
FT None None O
inhibitory None None O
potency None None O
was None None O
observed None None O
for None None O
the None None O
Tic None None O
derivative None None O
( None None O
IC50 None None O
= None None O
1 None None O
nM None None O
) None None O
; None None O
however None None O
, None None O
this None None O
compound None None O
was None None O
ineffective None None O
in None None O
blocking None None O
oncogenic None None O
Ras None None O
- None None O
induced None None O
transformation None None O
of None None O
NIH None None O
- None None O
3T3 None None O
fibroblast None None O
cells None None O
. None None O

A None None O
compound None None O
was None None O
prepared None None O
in None None O
which None None O
both None None O
the None None O
Cys None None O
- None None O
Val None None O
methyleneamine None None O
isostere None None O
and None None O
the None None O
Tic None None O
replacement None None O
were None None O
incorporated None None O
. None None O

This None None O
derivative None None O
inhibited None None O
FT None None O
with None None O
an None None O
IC50 None None O
of None None O
0.6 None None O
nM None None O
and None None O
inhibited None None O
anchorage None None O
- None None O
independent None None O
growth None None O
of None None O
stably None None O
transformed None None O
NIH None None O
- None None O
3T3 None None O
fibroblast None None O
cells None None O
by None None O
50% None None O
at None None O
5 None None O
microM None None O
. None None O

Replacing None None O
the None None O
A1 None None O
side None None O
chain None None O
of None None O
this None None O
derivative None None O
with None None O
a None None O
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
group None None I-MODIFIER
and None None O
replacing None None O
the None None O
X None None O
position None None O
with None None O
glutamine None None O
led None None O
to None None O
a None None O
derivative None None O
with None None O
an None None O
IC50 None None O
of None None O
2.8 None None O
nM None None O
and None None O
an None None O
EC50 None None O
of None None O
0.19 None None O
microM None None O
, None None O
a None None O
26 None None O
- None None O
fold None None O
improvement None None O
over None None O
( None None I-IUPAC
S None None I-IUPAC
* None None I-IUPAC
, None None I-IUPAC
R None None I-IUPAC
* None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
mercaptopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
valyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
isoquinolinyl None None I-IUPAC
] None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
methionine None None I-IUPAC
. None None O

This None None O
derivative None None O
, None None O
( None None I-IUPAC
S None None I-IUPAC
* None None I-IUPAC
, None None I-IUPAC
R None None I-IUPAC
* None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
mercaptopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
leucyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
isoquinolinyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamine None None I-IUPAC
, None None O
was None None O
evaluated None None O
in None None O
vivo None None O
along None None O
with None None O
( None None I-IUPAC
S None None I-IUPAC
* None None I-IUPAC
, None None I-IUPAC
R None None I-IUPAC
* None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
mercaptopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
leucyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
isoquinolinyl None None I-IUPAC
] None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
methionine None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
for None None O
antitumor None None O
activity None None O
in None None O
an None None O
athymic None None O
mouse None None O
model None None O
implanted None None O
ip None None O
with None None O
H None None O
- None None O
ras None None O
- None None O
transformed None None O
rat None None O
- None None O
1 None None O
tumor None None O
cells None None O
. None None O

When None None O
administered None None O
by None None O
injection None None O
twice None None O
a None None O
day None None O
at None None O
45 None None O
mg None None O
/ None None O
kg None None O
for None None O
11 None None O
consecutive None None O
days None None O
, None None O
both None None O
compounds None None O
showed None None O
prolonged None None O
survival None None O
time None None O
( None None O
T None None O
/ None None O
C None None O
= None None O
142-145% None None O
) None None O
, None None O
thus None None O
demonstrating None None O
efficacy None None O
against None None O
ras None None O
oncogene None None O
- None None O
containing None None O
tumors None None O
in None None O
vivo None None O
. None None O


Substituted None None I-MODIFIER
9H None None B-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indoles None None I-IUPAC
( None None O
beta None None O
- None None O
carbolines None None O
) None None O
, None None O
identified None None O
in None None O
our None None O
laboratory None None O
as None None O
potential None None O
pharmacophores None None O
for None None O
designing None None O
macrofilaricidal None None O
agents None None O
, None None O
have None None O
been None None O
explored None None O
further None None O
for None None O
identifying None None O
the None None O
pharmacophore None None O
responsible None None O
for None None O
the None None O
high None None O
order None None O
of None None O
adulticidal None None O
activity None None O
. None None O

This None None O
has None None O
led None None O
to None None O
syntheses None None O
and None None O
macrofilaricidal None None O
evaluations None None O
of None None O
a None None O
number None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
9H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
3-7 None None O
) None None O
. None None O

The None None O
macrofilaricidal None None O
activity None None O
was None None O
initially None None O
evaluated None None O
in None None O
vivo None None O
against None None O
Acanthoeilonema None None O
viteae None None O
. None None O

Among None None O
all None None O
the None None O
synthesized None None O
compounds None None O
, None None O
only None None O
12 None None O
compounds None None O
, None None O
namely None None O
3a None None O
, None None O
3c None None O
, None None O
3d None None O
, None None O
3f None None O
, None None O
4c None None O
, None None O
4d None None O
, None None O
4f None None O
, None None O
5a None None O
, None None O
6f None None O
, None None O
6h None None O
, None None O
6i None None O
, None None O
and None None O
7h None None O
, None None O
have None None O
exhibited None None O
either None None O
& None None O
gt None None O
; None None O
90% None None O
micro None None O
- None None O
or None None O
macrofilaricidal None None O
activity None None O
or None None O
sterlization None None O
of None None O
female None None O
worms None None O
. None None O

These None None O
compounds None None O
have None None O
also None None O
been None None O
screened None None O
against None None O
Litomosoides None None O
carinii None None O
, None None O
and None None O
of None None O
these None None O
only None None O
3f None None O
and None None O
5a None None O
have None None O
also None None O
been None None O
found None None O
to None None O
be None None O
active None None O
. None None O

Finally None None O
these None None O
two None None O
compounds None None O
have None None O
been None None O
evaluated None None O
against None None O
Brugia None None O
malayi None None O
. None None O

The None None O
structure None None O
- None None O
activity None None O
relationship None None O
( None None O
SAR None None O
) None None O
associated None None O
with None None O
position None None O
1 None None O
and None None O
3 None None O
substituents None None O
in None None O
beta None None O
- None None O
carbolines None None O
has None None O
been None None O
discussed None None O
. None None O

It None None O
has None None O
been None None O
observed None None O
that None None O
the None None O
presence None None O
of None None O
a None None O
carbomethoxy None None O
at None None O
position None None O
3 None None O
and None None O
an None None O
aryl None None O
substituent None None O
at None None O
position None None O
1 None None O
in None None O
beta None None O
- None None O
carbolines None None O
effectively None None O
enhances None None O
antifilarial None None O
activity None None O
particularly None None O
against None None O
A None None O
. None None O

viteae None None O
. None None O

Among None None O
the None None O
various None None O
compounds None None O
screened None None O
, None None O
methyl None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
4c None None O
) None None O
has None None O
shown None None O
the None None O
highest None None O
adulticidal None None O
activity None None O
and None None O
methyl None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
9H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
3a None None O
) None None O
has None None O
shown None None O
the None None O
highest None None O
microfilaricidal None None O
action None None O
against None None O
A None None O
. None None O

viteae None None O
at None None O
50 None None O
mg None None O
/ None None O
kg None None O
x None None O
5 None None O
days None None O
( None None O
ip None None O
) None None O
. None None O

Another None None O
derivative None None O
of None None O
this None None O
compound None None O
, None None O
namely None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
( None None O
5a None None O
) None None O
, None None O
exhibited None None O
the None None O
highest None None O
activity None None O
against None None O
L None None O
. None None O

carinii None None O
at None None O
30 None None O
mg None None O
/ None None O
kg None None O
x None None O
5 None None O
days None None O
( None None O
ip None None O
) None None O
and None None O
against None None O
B None None O
. None None O

malayiat None None O
50 None None O
mg None None O
/ None None O
kg None None O
x None None O
5 None None O
days None None O
( None None O
ip None None O
) None None O
or None None O
at None None O
200 None None O
mg None None O
/ None None O
kg None None O
x None None O
5 None None O
days None None O
( None None O
po None None O
) None None O
. None None O


Certain None None O
novel None None O
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydronaphthalenes None None I-IUPAC
( None None O
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminotetralins None None I-IUPAC
, None None O
PATs None None O
) None None O
produced None None O
stimulation None None O
( None None O
ca. None None O
30% None None O
above None None O
basal None None O
levels None None O
) None None O
of None None O
tyrosine None None O
hydroxylase None None O
( None None O
TH None None O
) None None O
activity None None O
at None None O
0.1 None None O
microM None None O
concentrations None None O
in None None O
rodent None None O
brain None None O
tissue None None O
. None None O

This None None O
effect None None O
on None None O
TH None None O
was None None O
blocked None None O
by None None O
the None None O
putative None None O
sigma None None O
- None None O
receptor None None O
antagonist None None O
BMY None None O
- None None O
14802 None None O
, None None O
suggesting None None O
involvement None None O
of None None O
a None None O
novel None None O
neuromodulatory None None O
sigma None None O
- None None O
like None None O
receptor None None O
. None None O

Within None None O
the None None O
new None None O
phenylaminotetralin None None O
series None None O
, None None O
a None None O
correlation None None O
was None None O
found None None O
between None None O
the None None O
ability None None O
to None None O
stimulate None None O
TH None None O
and None None O
the None None O
potency None None O
to None None O
compete None None O
for None None O
binding None None O
sites None None O
labeled None None O
by None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydronaphthalene None None I-IUPAC
( None None O
[ None None O
3H None None O
] None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
4 None None O
) None None O
. None None O

trans None None O
- None None O
Catechol None None O
analogs None None O
had None None O
low None None O
affinity None None O
for None None O
[ None None O
3H None None O
] None None O
4 None None O
sites None None O
, None None O
and None None O
although None None O
they None None O
inhibited None None O
TH None None O
activity None None O
, None None O
this None None O
effect None None O
was None None O
not None None O
blocked None None O
by None None O
known None None O
sigma None None O
or None None O
dopamine None None O
antagonists None None O
. None None O

Analogs None None O
with None None O
dihydroxy None None I-IUPAC
substituents None None B-MODIFIER
( None None O
catechols None None O
) None None O
, None None O
as None None O
well None None O
as None None O
nitrogen None None O
substituents None None O
larger None None O
than None None O
methyl None None O
, None None O
had None None O
little None None O
affinity None None O
for None None O
[ None None O
3H None None O
] None None O
4 None None O
binding None None O
sites None None O
and None None O
did None None O
not None None O
significantly None None O
affect None None O
TH None None O
activity None None O
. None None O

The None None O
pharmacology None None O
of None None O
the None None O
[ None None O
3H None None O
] None None O
4 None None O
binding None None O
site None None O
is None None O
unique None None O
from None None O
that None None O
of None None O
any None None O
known None None O
sigma None None O
or None None O
dopamine None None O
receptor None None O
, None None O
thus None None O
the None None O
effects None None O
appear None None O
to None None O
be None None O
mediated None None O
by None None O
a None None O
previously None None O
uncharacterized None None O
binding None None O
site None None O
/ None None O
receptor None None O
. None None O

The None None O
site None None O
has None None O
stereoselectivity None None O
for None None O
the None None O
( None None O
1R None None O
, None None O
3S None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
isomer None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydronaphthalene None None I-IUPAC
; None None O
this None None O
isomer None None O
is None None O
also None None O
more None None O
active None None O
at None None O
stimulating None None O
TH None None O
. None None O

Thus None None O
, None None O
certain None None O
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydronaphthalenes None None I-IUPAC
appear None None O
to None None O
be None None O
selective None None O
probes None None O
of None None O
a None None O
novel None None O
receptor None None O
type None None O
that None None O
mediates None None O
sigma None None O
- None None O
like None None O
neuromodulatory None None O
activity None None O
and None None O
may None None O
have None None O
pharmacotherapeutic None None O
utility None None O
in None None O
conditions None None O
in None None O
which None None O
modulation None None O
of None None O
dopamine None None O
function None None O
is None None O
important None None O
. None None O


Various None None O
4 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkylamino None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkylthio None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
sulfamoylbenzoic None None I-IUPAC
acids None None I-IUPAC
related None None O
to None None O
known None None O
aminobenzoic None None O
acid None None O
diuretics None None O
were None None O
synthesized None None O
and None None O
screened None None O
for None None O
their None None O
diuretic None None O
properties None None O
in None None O
dogs None None O
. None None O

The None None O
tabulated None None O
results None None O
from None None O
a None None O
3 None None O
- None None O
hr None None O
test None None O
period None None O
revealed None None O
that None None O
generally None None O
the None None O
diuretic None None O
profile None None O
and None None O
potency None None O
could None None O
be None None O
retained None None O
when None None O
3 None None I-IUPAC
- None None I-IUPAC
alkoxy None None I-IUPAC
, None None O
3 None None I-IUPAC
- None None I-IUPAC
alkylthio None None I-IUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
phenethyl None None I-IUPAC
were None None O
substituted None None O
for None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
alkylamino None None I-IUPAC
moiety None None I-MODIFIER
. None None O

The None None O
high None None O
potency None None O
of None None O
several None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkylthio None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
phenethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
sulfamoylbenzoic None None I-IUPAC
acids None None I-IUPAC
confirmed None None O
previous None None O
suggestions None None O
that None None O
the None None O
apparent None None O
diuretic None None O
effect None None O
of None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
alkylamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
benzisothiazole None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxides None None I-IUPAC
originates None None O
from None None O
the None None O
corresponding None None O
4 None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
sulfamoylbenzoic None None I-IUPAC
acid None None I-IUPAC
derivatives None None I-MODIFIER
due None None O
to None None O
an None None O
existing None None O
equilibrium None None O
in None None O
plasma None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Benzoyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
sulfamoyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
thenyloxy None None I-IUPAC
) None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
118 None None O
) None None O
is None None O
among None None O
the None None O
most None None O
potent None None O
benzoic None None O
acid None None O
diuretics None None O
hitherto None None O
synthesized None None O
and None None O
shows None None O
significant None None O
diuretic None None O
activity None None O
in None None O
dogs None None O
at None None O
1 None None O
mug None None O
/ None None O
kg None None O
. None None O

The None None O
results None None O
obtained None None O
with None None O
different None None O
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
sulfamoylbenzoic None None I-IUPAC
acids None None I-IUPAC
supported None None O
the None None O
earlier None None O
concept None None O
regarding None None O
the None None O
steric None None O
influence None None O
of None None O
the None None O
4 None None O
- None None O
substituent None None O
on None None O
the None None O
diuretic None None O
potency None None O
of None None O
sulfamoylbenzoic None None O
acid None None O
diuretics None None O
. None None O


A None None O
series None None O
of None None O
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2,4 None None I-IUPAC
- None None I-IUPAC
dinitroimidazole None None I-IUPAC
analogues None None I-MODIFIER
have None None O
been None None O
synthesized None None O
and None None O
tested None None O
for None None O
their None None O
radiosensitizing None None O
ability None None O
for None None O
selectively None None O
sensitizing None None O
hypoxic None None O
mammalian None None O
cells None None O
to None None O
the None None O
lethal None None O
effect None None O
of None None O
radiation None None O
. None None O

The None None O
reaction None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dinitroimidazole None None I-IUPAC
( None None O
1 None None O
) None None O
with None None O
a None None O
variety None None O
of None None O
oxiranes None None O
upon None None O
heating None None O
in None None O
absolute None None O
ethanol None None O
yielded None None O
the None None O
expected None None O
1 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2,4 None None I-IUPAC
- None None I-IUPAC
dinitroimidazoles None None I-IUPAC
( None None O
2 None None O
) None None O
and None None O
also None None O
resulted None None O
in None None O
the None None O
formation None None O
of None None O
a None None O
novel None None O
class None None O
of None None O
isomeric None None I-MODIFIER
nitroimidazo None None B-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
oxazoles None None I-IUPAC
3 None None O
and None None O
4 None None O
) None None O
by None None O
intramolecular None None O
cyclization None None O
. None None O

The None None O
results None None O
of None None O
radiosensitizing None None O
activity None None O
of None None O
these None None O
agents None None O
against None None O
hypoxic None None O
Chinese None None O
hamster None None O
cells None None O
( None None O
V None None O
- None None O
79 None None O
) None None O
indicated None None O
that None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dinitroimidazoles None None I-IUPAC
were None None O
better None None O
sensitizers None None O
than None None O
the None None O
nitroimidazo None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
oxazoles None None I-IUPAC
, None None O
suggesting None None O
the None None O
necessity None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
function None None I-MODIFIER
in None None O
the None None O
molecule None None O
. None None O

The None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxypropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dinitroimidazole None None I-IUPAC
( None None O
2d None None O
) None None O
was None None O
found None None O
to None None O
be None None O
the None None O
most None None O
effective None None O
radiosensitizer None None O
of None None O
this None None O
series None None O
. None None O


Several None None O
8 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
O6 None None I-IUPAC
- None None I-IUPAC
benzylguanines None None I-IUPAC
, None None O
2 None None I-MODIFIER
- None None I-MODIFIER
and None None O
/ None None O
or None None O
8 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
purines None None I-IUPAC
, None None O
substituted None None I-MODIFIER
6 None None B-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
pyrimidines None None I-IUPAC
, None None O
and None None O
a None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
s None None I-IUPAC
- None None I-IUPAC
triazine None None I-IUPAC
were None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
inactivate None None O
the None None O
human None None O
DNA None None O
repair None None O
protein None None O
, None None O
O6 None None I-IUPAC
- None None I-IUPAC
alkylguanine None None I-IUPAC
- None None O
DNA None None O
alkyltransferase None None O
( None None O
AGT None None O
, None None O
alkyltransferase None None O
) None None O
. None None O

Two None None O
types None None O
of None None O
compounds None None O
were None None O
identified None None O
as None None O
being None None O
significantly None None O
more None None O
effective None None O
than None None O
O6 None None I-IUPAC
- None None I-IUPAC
benzylguanine None None I-IUPAC
( None None O
the None None O
prototype None None O
low None None O
molecular None None O
weight None None O
inactivator None None O
) None None O
at None None O
inactivating None None O
AGT None None O
in None None O
human None None O
HT29 None None O
colon None None O
tumor None None O
cell None None O
extracts None None O
. None None O

These None None O
were None None O
8 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
O6 None None I-IUPAC
- None None I-IUPAC
benzylguanines None None I-IUPAC
bearing None None O
electron None None O
- None None O
withdrawing None None O
groups None None O
at None None O
the None None O
8 None None O
- None None O
position None None O
( None None O
e.g. None None O
8 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
O6 None None I-IUPAC
- None None I-IUPAC
benzylguanine None None I-IUPAC
and None None O
O6 None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
bromoguanine None None I-IUPAC
) None None O
and None None O
5 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
pyrimidines None None I-IUPAC
bearing None None O
electron None None O
- None None O
withdrawing None None O
groups None None O
at None None O
the None None O
5 None None O
- None None O
position None None O
( None None O
e.g. None None O
2,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
diamino None None I-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
benzyloxy None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
nitroso None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
nitropyrimidine None None I-IUPAC
) None None O
. None None O

The None None O
latter None None O
derivatives None None O
were None None O
also None None O
more None None O
effective None None O
than None None O
O6 None None I-IUPAC
- None None I-IUPAC
benzylguanine None None I-IUPAC
at None None O
inactivating None None O
AGT None None O
in None None O
intact None None O
HT29 None None O
colon None None O
tumor None None O
cells None None O
. None None O

Provided None None O
these None None O
types None None O
of None None O
purines None None O
and None None O
pyrimidines None None O
do None None O
not None None O
exhibit None None O
undesirable None None O
toxicity None None O
, None None O
they None None O
may None None O
be None None O
superior None None O
to None None O
O6 None None I-IUPAC
- None None I-IUPAC
benzylguanine None None I-IUPAC
as None None O
chemotherapeutic None None O
adjuvants None None O
for None None O
enhancing None None O
the None None O
effectiveness None None O
of None None O
antitumor None None O
drugs None None O
for None None O
which None None O
the None None O
mechanism None None O
of None None O
action None None O
involves None None O
modification None None O
of None None O
the None None O
O6 None None O
- None None O
position None None O
of None None O
DNA None None O
guanine None None O
residues None None O
. None None O


Structure None None O
- None None O
activity None None O
relationships None None O
for None None O
inhibition None None O
of None None O
DNA None None O
- None None O
dependent None None O
protein None None O
kinase None None O
( None None O
DNA None None O
- None None O
PK None None O
) None None O
have None None O
been None None O
defined None None O
for None None O
substituted None None I-MODIFIER
chromen None None B-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
. None None O

For None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None O
substituted None None I-MODIFIER
benzo None None B-IUPAC
[ None None I-IUPAC
h None None I-IUPAC
] None None I-IUPAC
chromen None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
a None None O
morpholine None None O
substituent None None O
at None None O
this None None O
position None None O
was None None O
essential None None O
for None None O
activity None None O
. None None O

Small None None O
libraries None None O
of None None O
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
7 None None I-IUPAC
- None None I-IUPAC
alkoxy None None I-IUPAC
- None None O
substituted None None I-MODIFIER
chromen None None B-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
showed None None O
that None None O
a None None O
number None None O
of None None O
7 None None I-IUPAC
- None None I-IUPAC
alkoxy None None I-IUPAC
- None None O
substituted None None I-MODIFIER
chromenones None None B-IUPAC
displayed None None O
improved None None O
activity None None O
. None None O

Focused None None O
libraries None None O
incorporating None None O
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
8 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
and None None O
heteroaryl None None I-IUPAC
substituents None None B-MODIFIER
were None None O
prepared None None O
. None None O

In None None O
these None None O
cases None None O
, None None O
6 None None O
- None None O
and None None O
7 None None O
- None None O
substitution None None O
was None None O
disfavored None None O
, None None O
whereas None None O
8 None None O
- None None O
substitution None None O
was None None O
largely None None O
tolerated None None O
. None None O

Surprisingly None None O
, None None O
two None None O
compounds None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
morpholino None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
dibenzofuranyl None None I-IUPAC
- None None I-IUPAC
chromen None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
NU7427 None None O
, None None O
32 None None O
{ None None O
38 None None O
} None None O
) None None O
and None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
morpholino None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
dibenzothiophenyl None None I-IUPAC
- None None I-IUPAC
chromen None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
NU7441 None None O
, None None O
32 None None O
{ None None O
26 None None O
} None None O
) None None O
were None None O
excellent None None O
inhibitors None None O
( None None O
IC50 None None O
vs None None O
DNA None None O
- None None O
PK None None O
= None None O
40 None None O
and None None O
13 None None O
nM None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
ring None None I-MODIFIER
- None None I-MODIFIER
saturated None None I-MODIFIER
analogue None None I-MODIFIER
2 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
morpholino None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
6' None None I-IUPAC
, None None I-IUPAC
7' None None I-IUPAC
, None None I-IUPAC
8' None None I-IUPAC
, None None I-IUPAC
9' None None I-IUPAC
- None None I-IUPAC
tetrahydrodibenzothiophene None None I-IUPAC
) None None I-IUPAC
chromen None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
, None None O
36 None None O
, None None O
retained None None O
potent None None O
activity None None O
( None None O
IC50 None None O
vs None None O
DNA None None O
- None None O
PK None None O
= None None O
23 None None O
nM None None O
) None None O
. None None O

The None None O
dibenzothiophene None None O
32 None None O
{ None None O
38 None None O
} None None O
sensitized None None O
HeLa None None O
cells None None O
to None None O
ionizing None None O
radiation None None O
in None None O
vitro None None O
, None None O
with None None O
dose None None O
modification None None O
factors None None O
of None None O
2.5 None None O
at None None O
10% None None O
survival None None O
being None None O
observed None None O
at None None O
0.5 None None O
microM None None O
. None None O

The None None O
cytotoxicity None None O
of None None O
the None None O
topoisomerase None None O
II None None O
inhibitor None None O
etoposide None None O
was None None O
also None None O
potentiated None None O
. None None O


4,5,6,7 None None I-IUPAC
- None None I-IUPAC
Tetrahydro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5,1 None None I-IUPAC
- None None I-IUPAC
jk None None I-IUPAC
] None None I-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
benzodiazepin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
( None None O
TIBO None None O
) None None O
, None None O
1 None None O
, None None O
have None None O
been None None O
shown None None O
to None None O
significantly None None O
inhibit None None O
HIV None None O
- None None O
1 None None O
replication None None O
in None None O
vitro None None O
by None None O
interfering None None O
with None None O
the None None O
virus None None O
's None None O
reverse None None O
transcriptase None None O
enzyme None None O
. None None O

They None None O
have None None O
also None None O
demonstrated None None O
potential None None O
clinical None None O
efficacy None None O
in None None O
combating None None O
HIV None None O
- None None O
1 None None O
, None None O
on None None O
the None None O
basis None None O
of None None O
a None None O
preliminary None None O
study None None O
. None None O

Our None None O
prior None None O
publications None None O
have None None O
discussed None None O
the None None O
discovery None None O
of None None O
this None None O
series None None O
of None None O
compounds None None O
and None None O
reported None None O
some None None O
preliminary None None O
chemical None None O
and None None O
biological None None O
studies None None O
around None None O
N None None O
- None None O
6 None None O
substitutions None None O
and None None O
5 None None O
- None None O
membered None None O
ring None None O
variations None None O
of None None O
1 None None O
. None None O

This None None O
manuscript None None O
describes None None O
our None None O
synthetic None None O
endeavors None None O
around None None O
4 None None O
, None None O
5 None None O
, None None O
and None None O
7 None None O
mono None None O
- None None O
and None None O
disubstitutions None None O
of None None O
1 None None O
and None None O
discusses None None O
related None None O
HIV None None O
- None None O
1 None None O
inhibitory None None O
structure None None O
- None None O
activity None None O
relationships None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
inhibition None None O
of None None O
HIV None None O
- None None O
1' None None O
s None None O
cytopathic None None O
effects None None O
in None None O
MT None None O
- None None O
4 None None O
cells None None O
, None None O
we None None O
found None None O
that None None O
5 None None O
- None None O
mono None None O
- None None O
Me None None O
- None None O
substituted None None O
analogues None None O
, None None O
the None None O
original None None O
substitution None None O
in None None O
the None None O
early None None O
lead None None O
compounds None None O
, None None O
and None None O
7 None None O
- None None O
mono None None O
- None None O
Me None None O
- None None O
substituted None None O
analogues None None O
of None None O
1 None None O
were None None O
comparable None None O
as None None O
being None None O
consistently None None O
the None None O
most None None O
active None None O
compounds None None O
. None None O

Although None None O
generally None None O
less None None O
active None None O
, None None O
the None None O
4,5,7 None None O
- None None O
unsubstituted None None O
, None None O
4 None None O
- None None O
mono None None O
- None None O
substituted None None O
, None None O
cis None None O
- None None O
and None None O
trans None None O
- None None O
5,7 None None O
- None None O
di None None O
- None None O
Me None None O
- None None O
substituted None None O
, None None O
and None None O
cis None None O
- None None O
4,5 None None O
- None None O
di None None O
- None None O
Me None None O
- None None O
substituted None None O
analogues None None O
of None None O
1 None None O
also None None O
exhibited None None O
some None None O
significant None None O
desired None None O
activity None None O
. None None O

The None None O
remaining None None O
trans None None O
- None None O
4,5 None None O
- None None O
di None None O
- None None O
Me None None O
- None None O
substituted None None O
, None None O
cis None None O
- None None O
and None None O
trans None None O
- None None O
4,7 None None O
- None None O
di None None O
- None None O
Me None None O
- None None O
substituted None None O
, None None O
and None None O
all None None O
4,5 None None O
- None None O
, None None O
5,6 None None O
- None None O
, None None O
6,7 None None O
- None None O
, None None O
and None None O
7,8 None None O
- None None O
fused None None O
disubstituted None None O
analogues None None O
of None None O
1 None None O
possessed None None O
no None None O
noticeable None None O
desired None None O
activity None None O
. None None O


From None None O
the None None O
reaction None None O
of None None O
silylated None None I-MODIFIER
4 None None B-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
triazeno None None I-IUPAC
) None None I-IUPAC
imidazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
DTIC None None O
, None None O
5 None None O
) None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
triazeno None None I-IUPAC
) None None I-IUPAC
pyrazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
DTPC None None O
, None None O
9 None None O
) None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
chlorotetrahydrofuran None None I-IUPAC
, None None O
we None None O
have None None O
isolated None None O
in None None O
both None None O
cases None None O
a None None O
single None None O
tetrahydrofuran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
derivative None None I-MODIFIER
. None None O

However None None O
, None None O
when None None O
silylated None None O
DTPC None None O
was None None O
reacted None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
chlorotetrahydropyran None None I-IUPAC
, None None O
two None None O
tetrahydropyran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
compounds None None I-MODIFIER
were None None O
obtained None None O
, None None O
and None None O
these None None O
were None None O
shown None None O
to None None O
be None None O
positional None None O
isomers None None O
on None None O
the None None O
basis None None O
of None None O
1H None None O
NMR None None O
and None None O
UV None None O
data None None O
. None None O

These None None O
furanyl None None I-IUPAC
and None None O
pyranyl None None I-IUPAC
derivatives None None B-MODIFIER
were None None O
tested None None O
for None None O
antileukemic None None O
activity None None O
( None None O
L None None O
- None None O
1210 None None O
, None None O
in None None O
vivo None None O
) None None O
and None None O
the None None O
results None None O
were None None O
compared None None O
with None None O
the None None O
results None None O
obtained None None O
for None None O
the None None O
corresponding None None O
ribosyl None None I-IUPAC
derivatives None None B-MODIFIER
of None None O
DTIC None None O
and None None O
DTPC None None O
. None None O


Syntheses None None O
of None None O
the None None O
trans None None I-IUPAC
- None None I-IUPAC
dihydrodiol None None I-IUPAC
derivatives None None I-MODIFIER
implicated None None O
as None None O
the None None O
proximate None None O
carcinogenic None None O
metabolites None None O
of None None O
the None None O
polycyclic None None O
hydrocarbons None None O
cholanthrene None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
methylcholanthrene None None I-IUPAC
, None None O
benz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
, None None O
and None None O
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
12 None None I-IUPAC
- None None I-IUPAC
methylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
are None None O
described None None O
. None None O

These None None O
compounds None None O
are None None O
useful None None O
models None None O
for None None O
research None None O
to None None O
determine None None O
the None None O
molecular None None O
basis None None O
of None None O
the None None O
strong None None O
enhancement None None O
of None None O
carcinogenicity None None O
consequent None None O
upon None None O
methyl None None I-IUPAC
substitution None None B-MODIFIER
in None None O
nonbenzo None None O
bay None None O
molecular None None O
sites None None O
and None None O
meso None None O
regions None None O
of None None O
polycyclic None None O
hydrocarbons None None O
. None None O

Synthesis None None O
of None None O
the None None O
bay None None O
region None None O
anti None None O
- None None O
diol None None O
epoxide None None O
derivative None None O
of None None O
cholanthrene None None O
, None None O
its None None O
putative None None O
ultimate None None O
carcinogenic None None O
metabolite None None O
, None None O
is None None O
also None None O
described None None O
. None None O

Tumorigenicity None None O
assays None None O
indicate None None O
that None None O
the None None O
9,10 None None I-IUPAC
- None None I-IUPAC
dihydrodiol None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
cholanthrene None None O
and None None O
its None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
derivatives None None I-MODIFIER
are None None O
all None None O
potent None None O
tumor None None O
initiators None None O
on None None O
mouse None None O
skin None None O
. None None O

The None None O
most None None O
active None None O
member None None O
of None None O
the None None O
series None None O
is None None O
the None None O
dihydrodiol None None I-IUPAC
derivative None None B-MODIFIER
of None None O
6 None None I-IUPAC
- None None I-IUPAC
methylcholanthrene None None I-IUPAC
, None None O
which None None O
contains None None O
a None None O
bay None None O
region None None O
methyl None None I-IUPAC
group None None B-MODIFIER
. None None O

The None None O
ability None None O
of None None O
the None None O
dihydrodiols None None O
3a None None O
- None None O
c None None O
and None None O
the None None O
trans None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydrodiol None None I-IUPAC
of None None O
7,12 None None I-IUPAC
- None None I-IUPAC
dimethylbenz None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
anthracene None None I-IUPAC
( None None O
3d None None O
) None None O
to None None O
induce None None O
chromosomal None None O
aberrations None None O
in None None O
rat None None O
bone None None O
marrow None None O
cells None None O
was None None O
also None None O
examined None None O
. None None O

The None None O
observed None None O
order None None O
of None None O
activity None None O
was None None O
3d None None O
greater None None O
than None None O
3c None None O
greater None None O
than None None O
3b None None O
greater None None O
than None None O
3a None None O
. None None O

These None None O
findings None None O
are None None O
consistent None None O
with None None O
the None None O
hypothesis None None O
that None None O
the None None O
diol None None O
epoxide None None O
metabolites None None O
of None None O
these None None O
dihydrodiols None None O
are None None O
the None None O
active None None O
carcinogenic None None O
forms None None O
of None None O
the None None O
parent None None O
hydrocarbons None None O
. None None O


The None None O
syntheses None None O
of None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolepropionic None None I-IUPAC
acid None None I-IUPAC
( None None O
9 None None O
, None None O
ATPA None None O
) None None O
, None None O
( None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
RS None None I-IUPAC
, None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
isoxazolepropionic None None I-IUPAC
acid None None I-IUPAC
( None None O
8 None None O
) None None O
, None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
isoxazolebutyric None None I-IUPAC
acid None None I-IUPAC
( None None O
15a None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
isoxazolevaleric None None I-IUPAC
acid None None I-IUPAC
( None None O
15b None None O
) None None O
are None None O
described None None O
. None None O

The None None O
compounds None None O
were None None O
tested None None O
in None None O
vitro None None O
together None None O
with None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolepropionic None None I-IUPAC
acid None None I-IUPAC
( None None O
ABPA None None O
) None None O
as None None O
inhibitors None None O
of None None O
the None None O
binding None None O
of None None O
radioactive None None O
- None None O
labeled None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isoxazolepropionic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
) None None O
to None None O
rat None None O
brain None None O
synaptic None None O
membranes None None O
. None None O

These None None O
data None None O
were None None O
compared None None O
with None None O
the None None O
earlier None None O
reported None None O
effects None None O
of None None O
the None None O
compounds None None O
on None None O
single None None O
neurons None None O
in None None O
the None None O
feline None None O
spinal None None O
cord None None O
obtained None None O
by None None O
microelectrophoretic None None O
techniques None None O
. None None O

The None None O
three None None O
compounds None None O
AMPA None None O
, None None O
ATPA None None O
, None None O
and None None O
ABPA None None O
are None None O
agonists None None O
at None None O
the None None O
class None None O
of None None O
receptors None None O
assumed None None O
to None None O
represent None None O
a None None O
subtype None None O
of None None O
physiological None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
( None None O
Glu None None O
) None None O
receptors None None O
. None None O

Inhibition None None O
of None None O
[ None None O
3H None None O
] None None O
AMPA None None O
binding None None O
by None None O
ATPA None None O
was None None O
1 None None O
order None None O
of None None O
magnitude None None O
weaker None None O
than None None O
that None None O
of None None O
AMPA None None O
, None None O
in None None O
agreement None None O
with None None O
the None None O
relative None None O
potency None None O
of None None O
these None None O
compounds None None O
in None None O
vivo None None O
. None None O

ABPA None None O
proved None None O
to None None O
be None None O
equipotent None None O
with None None O
AMPA None None O
both None None O
as None None O
an None None O
inhibitor None None O
of None None O
AMPA None None O
binding None None O
and None None O
as None None O
a None None O
neuronal None None O
excitant None None O
. None None O

The None None O
compounds None None O
8 None None O
, None None O
15a None None O
, None None O
and None None O
15b None None O
have None None O
no None None O
effect None None O
as None None O
inhibitors None None O
of None None O
AMPA None None O
binding None None O
, None None O
in None None O
agreement None None O
with None None O
in None None O
vivo None None O
studies None None O
that None None O
have None None O
shown None None O
that None None O
8 None None O
does None None O
not None None O
affect None None O
the None None O
firing None None O
of None None O
central None None O
neurons None None O
whereas None None O
15a None None O
and None None O
15b None None O
are None None O
antagonists None None O
at None None O
NMDA None None O
receptors None None O
, None None O
a None None O
subpopulation None None O
of None None O
excitatory None None O
receptors None None O
not None None O
affected None None O
by None None O
AMPA None None O
. None None O

Molecular None None O
mechanical None None O
calculations None None O
on None None O
AMPA None None O
, None None O
ATPA None None O
, None None O
and None None O
ABPA None None O
using None None O
the None None O
program None None O
MM2 None None O
showed None None O
that None None O
conformations None None O
of None None O
AMPA None None O
, None None O
ABPA None None O
, None None O
and None None O
especially None None O
ATPA None None O
by None None O
rotation None None O
of None None O
the None None O
amino None None O
acid None None O
side None None O
chain None None O
have None None O
energy None None O
barriers None None O
. None None O

A None None O
possible None None O
receptor None None O
- None None O
active None None O
conformation None None O
is None None O
suggested None None O
. None None O


A None None O
number None None O
of None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
bromo None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
nitro None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
- None None I-IUPAC
5,7 None None I-IUPAC
- None None I-IUPAC
dialkylpyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
were None None O
synthesized None None O
and None None O
screened None None O
as None None O
in None None O
vitro None None O
cAMP None None O
phosphodiesterase None None O
inhibitors None None O
. None None O

The None None O
condensation None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
aminopyrazole None None I-IUPAC
with None None O
symmetrical None None O
beta None None O
- None None O
diketones None None O
( None None O
acetylacetone None None O
, None None O
heptane None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
, None None O
etc None None O
. None None O

) None None O
afforded None None O
symmetrical None None O
dialkylpyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
( None None O
5 None None O
) None None O
. None None O

The None None O
reaction None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
aminopyrazole None None I-IUPAC
with None None O
unsymmetrical None None O
beta None None O
- None None O
diketones None None O
( None None O
hexane None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
, None None O
heptane None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
, None None O
etc None None O
. None None O

) None None O
gave None None O
a None None O
mixture None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
alkylpyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
3 None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
methylpyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
( None None O
4 None None O
) None None O
. None None O

The None None O
technique None None O
for None None O
the None None O
separation None None O
of None None O
3 None None O
from None None O
4 None None O
is None None O
described None None O
. None None O

The None None O
inhibition None None O
constants None None O
, None None O
alpha None None O
( None None O
the None None O
ratio None None O
of None None O
the None None O
molar None None O
I50 None None O
of None None O
theophylline None None O
to None None O
the None None O
molar None None O
I50 None None O
of None None O
the None None O
test None None O
compounds None None O
) None None O
, None None O
were None None O
subjected None None O
to None None O
a None None O
Hansch None None O
correlation None None O
analysis None None O
. None None O

The None None O
results None None O
indicated None None O
that None None O
PDE None None O
isolated None None O
from None None O
beef None None O
heart None None O
tissue None None O
was None None O
most None None O
sensitive None None O
to None None O
changes None None O
in None None O
the None None O
length None None O
of None None O
the None None O
alkyl None None O
group None None O
in None None O
the None None O
5 None None O
position None None O
of None None O
the None None O
pyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
ring None None I-MODIFIER
, None None O
whereas None None O
the None None O
PDE None None O
isolated None None O
from None None O
rabbit None None O
lung None None O
tissue None None O
was None None O
more None None O
sensitive None None O
to None None O
changes None None O
in None None O
the None None O
length None None O
of None None O
the None None O
7 None None O
- None None O
alkyl None None O
group None None O
. None None O

Experimentally None None O
and None None O
theoretically None None O
, None None O
the None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
group None None I-MODIFIER
was None None O
found None None O
to None None O
approximate None None O
the None None O
ideal None None O
size None None O
for None None O
the None None O
alkyl None None O
group None None O
in None None O
both None None O
the None None O
5 None None O
and None None O
7 None None O
positions None None O
; None None O
5,7 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethoxycarbonylpyrazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
5e None None O
) None None O
was None None O
the None None O
most None None O
potent None None O
inhibitor None None O
of None None O
both None None O
lung None None O
and None None O
heart None None O
PDE None None O
. None None O


In None None O
order None None O
to None None O
improve None None O
the None None O
oral None None O
bioavailability None None O
( None None O
BA None None O
) None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimid None None I-IUPAC
azole None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
3 None None O
: None None O
CV None None O
- None None O
11194 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimidazole None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None O
: None None O
CV None None O
- None None O
11974 None None O
) None None O
, None None O
novel None None O
angiotensin None None O
II None None O
( None None O
AII None None O
) None None O
receptor None None O
antagonists None None O
, None None O
chemical None None O
modification None None O
to None None O
yield None None O
prodrugs None None O
has None None O
been None None O
examined None None O
. None None O

After None None O
selective None None O
tritylation None None O
of None None O
the None None O
tetrazole None None O
rings None None O
in None None O
3 None None O
and None None O
4 None None O
, None None O
treatment None None O
of None None O
N None None I-MODIFIER
- None None I-MODIFIER
tritylated None None I-MODIFIER
benzimidazole None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acids None None I-IUPAC
( None None O
6 None None O
, None None O
7 None None O
) None None O
with None None O
a None None O
variety None None O
of None None O
alkyl None None O
halides None None O
, None None O
followed None None O
by None None O
deprotection None None O
with None None O
hydrochloric None None O
acid None None O
, None None O
afforded None None O
esters None None O
of None None O
3 None None O
and None None O
4 None None O
. None None O

Mainly None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
acyloxy None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
esters None None I-IUPAC
and None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
alkoxycarbonyl None None I-IUPAC
) None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
alkyl None None I-IUPAC
esters None None I-IUPAC
, None None O
double None None O
ester None None O
derivatives None None O
, None None O
were None None O
synthesized None None O
. None None O

Their None None O
inhibitory None None O
effect None None O
on None None O
AII None None O
- None None O
induced None None O
pressor None None O
response None None O
in None None O
rats None None O
and None None O
oral None None O
BA None None O
were None None O
investigated None None O
. None None O

( None None I-PARTIUPAC
Pivaloyloxy None None I-PARTIUPAC
) None None I-PARTIUPAC
methyl None None I-PARTIUPAC
and None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
cyclohexyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
ethyl None None I-IUPAC
esters None None I-IUPAC
of None None O
3 None None O
and None None O
4 None None O
showed None None O
marked None None O
increases None None O
in None None O
oral None None O
bioavailability None None O
which None None O
significantly None None O
potentiated None None O
the None None O
inhibitory None None O
effect None None O
of None None O
the None None O
parent None None O
compounds None None O
on None None O
AII None None O
- None None O
induced None None O
pressor None None O
response None None O
. None None O

Among None None O
them None None O
, None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
cyclohexyloxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
ethyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimida None None I-IUPAC
zole None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
10s None None O
, None None O
TCV None None O
- None None O
116 None None O
) None None O
was None None O
selected None None O
as None None O
a None None O
candidate None None O
for None None O
clinical None None O
evaluation None None O
. None None O


In None None O
this None None O
report None None O
, None None O
we None None O
describe None None O
structure None None O
- None None O
activity None None O
studies None None O
of None None O
the None None O
bicyclic None None O
oxytocin None None O
antagonist None None O
[ None None O
Mpa1 None None O
, None None O
cyclo None None O
( None None O
Glu4 None None O
, None None O
Lys8 None None O
) None None O
] None None O
oxytocin None None O
. None None O

The None None O
monocylic None None O
analogue None None O
[ None None O
dPen1 None None O
, None None O
( None None O
Glu4 None None O
, None None O
Lys8 None None O
) None None O
] None None O
oxytocin None None O
was None None O
a None None O
weak None None O
oxytocin None None O
antagonist None None O
with None None O
a None None O
pA2 None None O
value None None O
of None None O
5.8 None None O
in None None O
the None None O
uterotonic None None O
assay None None O
. None None O

Bicyclization None None O
of None None O
this None None O
analogue None None O
yielded None None O
[ None None O
dPen1 None None O
, None None O
cyclo None None O
( None None O
Glu4 None None O
, None None O
Lys8 None None O
) None None O
] None None O
oxytocin None None O
, None None O
a None None O
potent None None O
antagonist None None O
of None None O
oxytocin None None O
in None None O
the None None O
uterotonic None None O
assay None None O
( None None O
pA2 None None O
8.74 None None O
) None None O
with None None O
a None None O
potency None None O
3 None None O
times None None O
greater None None O
than None None O
that None None O
of None None O
[ None None O
Mpa1 None None O
, None None O
cyclo None None O
( None None O
Glu4 None None O
, None None O
Lys8 None None O
) None None O
] None None O
oxytocin None None O
. None None O

[ None None O
dPen1 None None O
, None None O
cyclo None None O
( None None O
Glu4 None None O
, None None O
Lys8 None None O
) None None O
] None None O
oxytocin None None O
also None None O
was None None O
a None None O
weak None None O
antagonist None None O
in None None O
the None None O
pressor None None O
assay None None O
with None None O
a None None O
pA2 None None O
of None None O
6.3 None None O
. None None O

To None None O
establish None None O
if None None O
the None None O
potent None None O
antagonistic None None O
effects None None O
of None None O
these None None O
bicyclic None None O
compounds None None O
was None None O
because None None O
of None None O
the None None O
lactam None None O
ring None None O
or None None O
merely None None O
the None None O
result None None O
of None None O
obtaining None None O
an None None O
optimal None None O
degree None None O
of None None O
lipophilicity None None O
of None None O
the None None O
side None None O
chains None None O
in None None O
positions None None O
4 None None O
and None None O
8 None None O
, None None O
we None None O
synthesized None None O
a None None O
series None None O
of None None O
analogues None None O
containing None None O
neutral None None O
and None None O
/ None None O
or None None O
charged None None O
groups None None O
on None None O
these None None O
side None None O
chains None None O
. None None O

Monocyclic None None O
derivatives None None O
of None None O
[ None None O
Mpa1 None None O
, None None O
Gln4 None None O
, None None O
Lys None None O
( None None O
CHO None None O
) None None O
8 None None O
] None None O
oxytocin None None O
were None None O
moderate None None O
to None None O
weak None None O
agonists None None O
of None None O
oxytocin None None O
all None None O
following None None O
classical None None O
structure None None O
- None None O
activity None None O
profiles None None O
of None None O
oxytocin None None O
. None None O

The None None O
monocyclic None None O
derivatives None None O
of None None O
[ None None O
dPen1 None None O
, None None O
Gln4 None None O
, None None O
Lys None None O
( None None O
CHO None None O
) None None O
8 None None O
] None None O
oxytocin None None O
were None None O
antagonists None None O
of None None O
oxytocin None None O
which None None O
was None None O
attributed None None O
to None None O
the None None O
dPen1 None None O
substitution None None O
. None None O

However None None O
, None None O
the None None O
potency None None O
of None None O
all None None O
of None None O
these None None O
latter None None O
derivatives None None O
was None None O
at None None O
least None None O
1 None None O
order None None O
of None None O
magnitude None None O
less None None O
than None None O
[ None None O
dPen1 None None O
, None None O
cyclo None None O
( None None O
Glu4 None None O
, None None O
Lys8 None None O
) None None O
] None None O
oxytocin None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
potent None None O
antagonistic None None O
properties None None O
of None None O
the None None O
bicyclic None None O
analogues None None O
[ None None O
Mpa1 None None O
, None None O
cyclo None None O
( None None O
Glu4 None None O
, None None O
Lys8 None None O
) None None O
] None None O
oxytocin None None O
and None None O
[ None None O
dPen1 None None O
, None None O
cyclo None None O
( None None O
Glu4 None None O
, None None O
Lys8 None None O
) None None O
] None None O
oxytocin None None O
can None None O
be None None O
attributed None None O
to None None O
the None None O
effect None None O
of None None O
the None None O
lactam None None O
bridge None None O
on None None O
the None None O
conformational None None O
flexibility None None O
and None None O
topographical None None O
properties None None O
of None None O
the None None O
analogues None None O
, None None O
rendering None None O
them None None O
more None None O
favorable None None O
for None None O
binding None None O
to None None O
the None None O
receptor None None O
in None None O
such None None O
a None None O
manner None None O
as None None O
to None None O
prevent None None O
transduction None None O
of None None O
a None None O
biological None None O
response None None O
. None None O


A None None O
series None None I-MODIFIER
of None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylthio None None I-IUPAC
) None None I-IUPAC
furoxans None None I-IUPAC
were None None O
synthesized None None O
by None None O
oxidation None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylglyoxymes None None I-IUPAC
with None None O
dinitrogen None None O
tetroxide None None O
. None None O

Reduction None None O
with None None O
trimethyl None None O
phosphite None None O
of None None O
the None None O
furoxan None None O
derivatives None None O
afforded None None O
the None None O
corresponding None None O
furazans None None O
, None None O
while None None O
oxidation None None O
with None None O
an None None O
equimolar None None O
amount None None O
of None None O
30% None None O
hydrogen None None O
peroxide None None O
in None None O
acetic None None O
acid None None O
or None None O
with None None O
an None None O
excess None None O
of None None O
81% None None O
hydrogen None None O
peroxide None None O
in None None O
trifluoroacetic None None O
acid None None O
afforded None None O
the None None O
corresponding None None O
arylsulfinyl None None I-IUPAC
and None None O
arylsulfonyl None None I-IUPAC
analogues None None B-MODIFIER
, None None O
respectively None None O
. None None O

All None None O
the None None O
furoxan None None O
and None None O
furazan None None O
derivatives None None O
showed None None O
activity None None O
as None None O
inhibitors None None O
of None None O
platelet None None O
aggregation None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylsulfonyl None None I-IUPAC
) None None I-IUPAC
furoxans None None I-IUPAC
were None None O
the None None O
most None None O
potent None None O
derivatives None None O
of None None O
the None None O
series None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylsulfonyl None None I-IUPAC
) None None I-IUPAC
furoxan None None I-IUPAC
( None None O
10a None None O
) None None O
, None None O
one None None O
of None None O
the None None O
most None None O
active None None O
derivatives None None O
, None None O
inhibits None None O
the None None O
AA None None O
- None None O
induced None None O
increase None None O
of None None O
cytosolic None None O
free None None O
Ca2+ None None O
and None None O
production None None O
of None None O
malondialdehyde None None O
. None None O

A None None O
primary None None O
action None None O
of None None O
the None None O
compound None None O
on None None O
cyclooxygenase None None O
is None None O
excluded None None O
, None None O
as None None O
a None None O
stable None None O
epoxymethano None None O
analogue None None O
of None None O
prostaglandin None None O
H2 None None O
does None None O
not None None O
reverse None None O
the None None O
inhibitory None None O
effect None None O
of None None O
10a None None O
. None None O

This None None O
compound None None O
produces None None O
a None None O
significant None None O
increase None None O
in None None O
cGMP None None O
which None None O
is None None O
likely None None O
to None None O
cause None None O
inhibition None None O
at None None O
an None None O
early None None O
stage None None O
of None None O
the None None O
platelet None None O
activation None None O
pathway None None O
. None None O


A None None O
series None None O
of None None O
aldehydo None None O
sugars None None O
was None None O
subjected None None O
to None None O
condensation None None O
reactions None None O
with None None O
active None None O
methylene None None O
compounds None None O
. None None O

Acetylacetone None None O
was None None O
condensed None None O
with None None O
2,4 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzylidene None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
dibenzoyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribose None None I-IUPAC
( None None O
1 None None O
) None None O
, None None O
2,4 None None I-IUPAC
: None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
dibenzylidene None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribose None None I-IUPAC
( None None O
6 None None O
) None None O
, None None O
2,3,4,5 None None I-IUPAC
- None None I-IUPAC
tetraacetyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribose None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
and None None O
2,3,4,5,6 None None I-IUPAC
- None None I-IUPAC
pentaacetyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
glucose None None I-IUPAC
( None None O
9 None None O
) None None O
to None None O
yield None None O
3 None None I-IUPAC
- None None I-IUPAC
ylidene None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
pentanedione None None I-IUPAC
derivatives None None I-MODIFIER
2 None None O
, None None O
11 None None O
, None None O
12 None None O
, None None O
and None None O
13 None None O
, None None O
respectively None None O
. None None O

Sugar None None O
derivatives None None O
1 None None O
and None None O
6 None None O
were None None O
also None None O
condensed None None O
with None None O
benzoylacetone None None O
to None None O
give None None O
14 None None O
and None None O
18 None None O
, None None O
with None None O
acetoacetanilide None None O
to None None O
give None None O
16 None None O
and None None O
19 None None O
, None None O
with None None O
malononitrile None None O
to None None O
give None None O
17 None None O
and None None O
20 None None O
, None None O
and None None O
with None None O
alpha None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
butyrolactonylidene None None I-IUPAC
) None None I-IUPAC
triphenylphosphorane None None I-IUPAC
to None None O
give None None O
21 None None O
and None None O
22 None None O
, None None O
respectively None None O
. None None O

Condensation None None O
of None None O
1 None None O
with None None O
dibenzoylmethane None None I-IUPAC
gave None None O
15 None None O
. None None O

The None None O
double None None O
bond None None O
in None None O
compounds None None O
2 None None O
and None None O
11 None None O
was None None O
saturated None None O
by None None O
hydrogenation None None O
to None None O
give None None O
23 None None O
and None None O
24 None None O
. None None O

All None None O
alpha None None O
, None None O
beta None None O
- None None O
unsaturated None None O
carbonyl None None O
compounds None None O
obtained None None O
exhibited None None O
antiviral None None O
activity None None O
and None None O
cytotoxicity None None O
. None None O

Compound None None O
11 None None O
was None None O
found None None O
to None None O
have None None O
the None None O
most None None O
significant None None O
and None None O
selective None None O
antiviral None None O
activity None None O
against None None O
herpes None None O
simplex None None O
virus None None O
. None None O


New None None O
boron None None O
- None None O
containing None None O
polyamine None None O
have None None O
been None None O
synthesized None None O
: None None O
( None None I-IUPAC
aminoalkylamine None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminoalkyl None None I-IUPAC
) None None I-IUPAC
azanonaborane None None I-IUPAC
( None None O
11 None None O
) None None O
derivatives None None I-MODIFIER
[ None None O
H None None O
( None None O
2 None None O
) None None O
N None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
n None None O
) None None O
H None None O
( None None O
2 None None O
) None None O
NB None None O
( None None O
8 None None O
) None None O
H None None O
( None None O
11 None None O
) None None O
NH None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
n None None O
) None None O
NH None None O
( None None O
2 None None O
) None None O
] None None O
, None None O
where None None O
n None None O
= None None O
4-6 None None O
and None None O
12 None None O
, None None O
and None None O
[ None None O
H None None O
( None None O
2 None None O
) None None O
N None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
3 None None O
) None None O
H None None O
( None None O
2 None None O
) None None O
NB None None O
( None None O
8 None None O
) None None O
H None None O
( None None O
11 None None O
) None None O
NH None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
4 None None O
) None None O
NH None None O
( None None O
2 None None O
) None None O
] None None O
. None None O

( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
Aminobutylamine None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminobutyl None None I-IUPAC
) None None I-IUPAC
azanonaborane None None I-IUPAC
and None None O
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminopropylamine None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminobutyl None None I-IUPAC
) None None I-IUPAC
azanonaborane None None I-IUPAC
were None None O
less None None O
toxic None None O
in None None O
vitro None None O
( None None O
LD None None O
( None None O
50 None None O
) None None O
of None None O
approximately None None O
700 None None O
and None None O
approximately None None O
1100 None None O
microM None None O
, None None O
respectively None None O
) None None O
than None None O
spermine None None O
, None None O
while None None O
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminobutylamine None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
isopropylazanonaborane None None I-IUPAC
with None None O
its None None O
hydrophobic None None O
isopropyl None None I-IUPAC
group None None B-MODIFIER
and None None O
those None None O
with None None O
n None None O
= None None O
5 None None O
, None None O
6 None None O
, None None O
and None None O
12 None None O
were None None O
already None None O
toxic None None O
under None None O
similar None None O
conditions None None O
( None None O
LD None None O
( None None O
50 None None O
) None None O
& None None O
lt None None O
; None None O
& None None O
lt None None O
; None None O
500 None None O
microM None None O
) None None O
. None None O

These None None O
compounds None None O
may None None O
be None None O
useful None None O
as None None O
delivery None None O
agents None None O
for None None O
boron None None O
neutron None None O
capture None None O
therapy None None O
. None None O


A None None O
series None None O
of None None O
squalestatins None None O
modified None None O
at None None O
the None None O
C3 None None O
- None None O
position None None O
with None None O
a None None O
heterocyclic None None O
functionality None None O
was None None O
prepared None None O
and None None O
evaluated None None O
in None None O
vitro None None O
as None None O
inhibitors None None O
of None None O
squalene None None O
synthase None None O
( None None O
SQS None None O
) None None O
. None None O

Structure None None O
- None None O
activity None None O
relationships None None O
for None None O
compounds None None O
with None None O
the None None O
4,6 None None I-IUPAC
- None None I-IUPAC
dimethyloctenoate None None I-IUPAC
at None None O
C6 None None O
( None None O
S1 None None O
analogues None None O
) None None O
were None None O
different None None O
from None None O
those None None O
for None None O
analogues None None O
lacking None None O
the None None O
C6 None None O
ester None None O
( None None O
H1 None None O
analogues None None O
) None None O
, None None O
with None None O
a None None O
greater None None O
dependence None None O
on None None O
the None None O
nature None None O
of None None O
the None None O
C3 None None O
- None None O
substituent None None O
for None None O
the None None O
H1 None None O
series None None O
. None None O

Potent None None O
SQS None None O
inhibitory None None O
activity None None O
equivalent None None O
to None None O
that None None O
of None None O
H1 None None O
is None None O
retained None None O
by None None O
a None None O
C3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
analogue None None I-MODIFIER
, None None O
i.e. None None O
, None None O
a None None O
carboxylic None None O
acid None None O
mimetic None None O
. None None O

The None None O
C3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
derivative None None I-MODIFIER
is None None O
10 None None O
- None None O
fold None None O
less None None O
active None None O
than None None O
H1 None None O
, None None O
and None None O
SQS None None O
inhibitory None None O
activity None None O
similar None None O
to None None O
that None None O
of None None O
the None None O
methyl None None O
ester None None O
was None None O
retained None None O
only None None O
in None None O
those None None O
C3 None None O
- None None O
heterocycle None None O
- None None O
substituted None None O
H1 None None O
analogues None None O
for None None O
which None None O
electrostatic None None O
potential None None O
maps None None O
of None None O
the None None O
C3 None None O
- None None O
substituent None None O
were None None O
closely None None O
similar None None O
to None None O
that None None O
of None None O
a None None O
methyl None None O
ester None None O
. None None O


The None None O
present None None O
work None None O
explored None None O
3 None None I-IUPAC
- None None I-IUPAC
alkylamino None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
benzothiadiazine None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxides None None I-IUPAC
diversely None None O
substituted None None O
in None None O
the None None O
7 None None O
- None None O
position None None O
. None None O

Those None None O
compounds None None O
, None None O
structurally None None O
related None None O
to None None O
previously None None O
described None None O
potassium None None O
channel None None O
openers None None O
such None None O
as None None O
the None None O
benzothiadiazine None None O
dioxide None None O
BPDZ None None O
73 None None O
, None None O
were None None O
tested None None O
as None None O
putative None None O
K None None O
( None None O
ATP None None O
) None None O
channel None None O
activators None None O
on None None O
the None None O
pancreatic None None O
endocrine None None O
tissue None None O
and None None O
on None None O
the None None O
vascular None None O
smooth None None O
muscle None None O
tissue None None O
. None None O

The None None O
nature None None O
of None None O
the None None O
substituent None None O
introduced None None O
in None None O
the None None O
7 None None O
- None None O
position None None O
as None None O
well None None O
as None None O
the None None O
nature None None O
of None None O
the None None O
alkylamino None None O
side None None O
chain None None O
in None None O
the None None O
3 None None O
- None None O
position None None O
strongly None None O
affected None None O
both None None O
potency None None O
and None None O
tissue None None O
selectivity None None O
of None None O
4H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
benzothiadiazine None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxides None None I-IUPAC
. None None O

Thus None None O
, None None O
compounds None None O
bearing None None O
in None None O
the None None O
7 None None O
- None None O
position None None O
a None None O
methyl None None O
or None None O
a None None O
methoxy None None O
group None None O
or None None O
devoid None None O
of None None O
a None None O
substituent None None O
in None None O
this None None O
position None None O
, None None O
and None None O
bearing None None O
an None None O
ethyl None None O
, None None O
an None None O
isopropyl None None O
, None None O
or None None O
a None None O
cyclobutylamino None None O
group None None O
in None None O
the None None O
3 None None O
- None None O
position None None O
were None None O
found None None O
to None None O
be None None O
potent None None O
and None None O
selective None None O
inhibitors None None O
of None None O
insulin None None O
release None None O
from None None O
rat None None O
pancreatic None None O
B None None O
- None None O
cells None None O
( None None O
i.e. None None O
10a None None O
, None None O
10b None None O
, None None O
12b None None O
, None None O
12d None None O
, None None O
22c None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkylamino None None I-PARTIUPAC
- None None I-PARTIUPAC
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
trifluoromethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
20a None None O
- None None O
c None None O
) None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
alkylamino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
pentyl None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
benzothiadiazine None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxides None None I-IUPAC
( None None O
11a None None O
, None None O
b None None O
) None None O
expressed None None O
a None None O
marked None None O
myorelaxant None None O
activity None None O
on None None O
rat None None O
aorta None None O
ring None None O
. None None O

Among None None O
the None None O
latter None None O
compounds None None O
, None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
alkylamino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
pentyl None None I-IUPAC
derivative None None I-MODIFIER
( None None O
11a None None O
) None None O
showed None None O
a None None O
clear None None O
selectivity None None O
for None None O
the None None O
vascular None None O
smooth None None O
muscle None None O
tissue None None O
. None None O

The None None O
present None None O
work None None O
gives None None O
new None None O
insights None None O
into None None O
the None None O
role None None O
of None None O
the None None O
substituent None None O
in None None O
both None None O
the None None O
7 None None O
- None None O
and None None O
the None None O
3 None None O
- None None O
position None None O
for None None O
the None None O
design None None O
of None None O
4H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
benzothiadiazine None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
potassium None None O
channel None None O
openers None None O
exhibiting None None O
different None None O
tissue None None O
selectivity None None O
profiles None None O
. None None O


In None None O
order None None O
to None None O
study None None O
the None None O
structure None None O
- None None O
activity None None O
relationships None None O
of None None O
L None None I-IUPAC
- None None I-IUPAC
oxathiolanyl None None I-IUPAC
nucleosides None None I-MODIFIER
as None None O
potential None None O
anti None None O
- None None O
HIV None None O
agents None None O
, None None O
a None None O
series None None O
of None None O
enantiomerically None None O
pure None None O
L None None I-IUPAC
- None None I-IUPAC
oxathiolanyl None None I-IUPAC
pyrimidine None None I-IUPAC
and None None O
purine None None O
nucleosides None None O
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
anti None None O
- None None O
HIV None None O
- None None O
1 None None O
activity None None O
in None None O
human None None O
peripheral None None O
blood None None O
mononuclear None None O
( None None O
PBM None None O
) None None O
cells None None O
. None None O

The None None O
key None None O
intermediate None None O
8 None None O
was None None O
synthesized None None O
starting None None O
from None None O
L None None O
- None None O
gulose None None O
via None None O
1,6 None None I-IUPAC
- None None I-IUPAC
thioanhydro None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
gulopyranose None None I-IUPAC
. None None O

The None None O
acetate None None O
8 None None O
was None None O
condensed None None O
with None None O
thymine None None O
, None None O
5 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
uracils None None I-IUPAC
and None None O
cytosines None None I-IUPAC
, None None O
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
, None None O
and None None O
6 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
fluoropurine None None I-IUPAC
to None None O
give None None O
pyrimidine None None O
and None None O
purine None None O
nucleosides None None O
. None None O

Upon None None O
evaluation None None O
of None None O
these None None O
final None None O
nucleosides None None O
, None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
derivative None None I-MODIFIER
51 None None O
was None None O
found None None O
to None None O
be None None O
the None None O
most None None O
potent None None O
compound None None O
among None None O
those None None O
tested None None O
. None None O

In None None O
the None None O
case None None O
of None None O
5 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
cytosine None None I-IUPAC
analogues None None B-MODIFIER
, None None O
the None None O
antiviral None None O
potency None None O
was None None O
found None None O
to None None O
be None None O
in None None O
the None None O
following None None O
decreasing None None O
order None None O
: None None O
cytosine None None O
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
iodocytosine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
methylcytosine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
methylcytosine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
bromocytosine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
chlorocytosine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
. None None O

Among None None O
the None None O
thymine None None O
, None None O
uracil None None O
, None None O
and None None O
5 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
uracil None None I-IUPAC
derivatives None None B-MODIFIER
, None None O
thymine None None O
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
and None None O
uracil None None O
( None None O
beta None None O
- None None O
isomer None None O
) None None O
derivatives None None O
exhibited None None O
moderate None None O
anti None None O
- None None O
HIV None None O
activity None None O
. None None O

In None None O
the None None O
purine None None O
series None None O
, None None O
the None None O
antiviral None None O
potency None None O
is None None O
found None None O
to None None O
be None None O
in None None O
the None None O
following None None O
decreasing None None O
order None None O
: None None O
adenine None None O
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
2 None None O
- None None O
NH2 None None O
- None None O
6 None None O
- None None O
Cl None None O
- None None O
purine None None O
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
guanine None None O
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
N6 None None I-IUPAC
- None None I-IUPAC
methyladenine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
N6 None None I-IUPAC
- None None I-IUPAC
methyladenine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
. None None O

The None None O
cytotoxicity None None O
was None None O
also None None O
determined None None O
in None None O
human None None O
PBM None None O
cells None None O
as None None O
well None None O
as None None O
Vero None None O
cells None None O
. None None O

None None None O
of None None O
the None None O
synthesized None None O
nucleosides None None O
was None None O
toxic None None O
up None None O
to None None O
100 None None O
microM None None O
in None None O
PBM None None O
cells None None O
. None None O


The None None O
3 None None I-IUPAC
- None None I-IUPAC
isoxazolol None None I-IUPAC
amino None None I-IUPAC
acid None None I-IUPAC
( None None B-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
, None None O
2 None None O
) None None O
and None None O
the None None O
isomeric None None O
compound None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None I-IUPAC
- None None I-IUPAC
methylhomoibotenic None None I-IUPAC
acid None None I-IUPAC
, None None O
4a None None O
) None None O
are None None O
potent None None O
agonists None None O
at None None O
the None None O
AMPA None None O
subtype None None O
of None None O
central None None O
excitatory None None O
amino None None O
acid None None O
receptors None None O
. None None O

Using None None O
4a None None O
as None None O
a None None O
lead None None O
structure None None O
, None None O
the None None O
amino None None O
acids None None O
4c None None O
- None None O
e None None O
, None None O
in None None O
which None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
of None None O
4a None None O
is None None O
replaced None None O
by None None O
substituents None None O
of None None O
different None None O
size None None O
and None None O
polarity None None O
, None None O
were None None O
synthesized None None O
. None None O

Attempts None None O
to None None O
synthesize None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
homoibotenic None None I-IUPAC
acid None None I-IUPAC
( None None O
4f None None O
) None None O
, None None O
a None None O
potential None None O
receptor None None O
alkylating None None O
agent None None O
, None None O
were None None O
unsuccessful None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Butylhomoibotenic None None I-IUPAC
acid None None I-IUPAC
( None None O
4c None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
) None None I-IUPAC
homoibotenic None None I-IUPAC
acid None None I-IUPAC
( None None O
4e None None O
) None None O
were None None O
equipotent None None O
as None None O
inhibitors None None O
of None None O
[ None None O
3H None None O
] None None O
AMPA None None O
binding None None O
( None None O
IC50 None None O
= None None O
2 None None O
microM None None O
) None None O
and None None O
showed None None O
similar None None O
excitatory None None O
activity None None O
in None None O
the None None O
rat None None O
cortical None None O
slice None None O
preparation None None O
. None None O

4d None None O
did None None O
not None None O
show None None O
significant None None O
affinity None None O
for None None O
AMPA None None O
receptor None None O
sites None None O
, None None O
but None None O
turned None None O
out None None O
to None None O
be None None O
a None None O
weak None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
aspartic None None I-IUPAC
acid None None I-IUPAC
( None None O
NMDA None None O
) None None O
receptor None None O
antagonist None None O
. None None O

However None None O
, None None O
like None None O
4c None None O
, None None O
e None None O
, None None O
4d None None O
did None None O
not None None O
significantly None None O
affect None None O
the None None O
binding None None O
of None None O
the None None O
competitive None None O
NMDA None None O
antagonist None None O
, None None O
[ None None O
3H None None O
] None None O
CPP None None O
, None None O
or None None O
the None None O
noncompetitive None None O
NMDA None None O
antagonist None None O
, None None O
[ None None O
3H None None O
] None None O
MK None None O
- None None O
801 None None O
. None None O

None None None O
of None None O
the None None O
amino None None O
acids None None O
4c None None O
- None None O
e None None O
showed None None O
detectable None None O
affinity None None O
for None None O
[ None None O
3H None None O
] None None O
kainic None None O
acid None None O
binding None None O
sites None None O
. None None O

Like None None O
the None None O
parent None None O
compound None None O
4a None None O
( None None O
IC50 None None O
= None None O
0.18 None None O
microM None None O
) None None O
, None None O
4c None None O
( None None O
IC50 None None O
= None None O
0.18 None None O
microM None None O
) None None O
, None None O
4e None None O
( None None O
IC50 None None O
= None None O
0.14 None None O
microM None None O
) None None O
, None None O
and None None O
in None None O
particular None None O
4d None None O
( None None O
IC50 None None O
= None None O
0.02 None None O
microM None None O
) None None O
were None None O
effective None None O
inhibitors None None O
of None None O
calcium None None O
chloride None None O
- None None O
dependent None None O
[ None None O
3H None None O
] None None O
glutamic None None O
acid None None O
binding None None O
, None None O
whereas None None O
AMPA None None O
is None None O
inactive None None O
( None None O
IC50 None None O
greater None None O
than None None O
100 None None O
microM None None O
) None None O
in None None O
this None None O
binding None None O
assay None None O
. None None O

Thus None None O
, None None O
4d None None O
is None None O
an None None O
effective None None O
and None None O
highly None None O
selective None None O
inhibitor None None O
of None None O
calcium None None O
chloride None None O
- None None O
dependent None None O
[ None None O
3H None None O
] None None O
glutamic None None O
acid None None O
binding None None O
and None None O
may None None O
be None None O
a None None O
useful None None O
tool None None O
for None None O
studies None None O
of None None O
the None None O
physiological None None O
relevance None None O
and None None O
pharmacological None None O
importance None None O
of None None O
this None None O
binding None None O
affinity None None O
. None None O


New None None O
water None None O
- None None O
soluble None None O
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylazopyridine None None I-IUPAC
) None None I-IUPAC
ruthenium None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
complexes None None I-MODIFIER
, None None O
all None None O
derivatives None None O
of None None O
the None None O
highly None None O
cytotoxic None None O
alpha None None O
- None None O
[ None None O
Ru None None O
( None None O
azpy None None O
) None None O
( None None O
2 None None O
) None None O
Cl None None O
( None None O
2 None None O
) None None O
] None None O
( None None O
alpha None None O
denoting None None O
the None None O
coordinating None None O
pairs None None O
Cl None None O
, None None O
N None None O
( None None O
py None None O
) None None O
, None None O
and None None O
N None None O
( None None O
azo None None O
) None None O
as None None O
cis None None O
, None None O
trans None None O
, None None O
cis None None O
, None None O
respectively None None O
) None None O
have None None O
been None None O
developed None None O
. None None O

The None None O
compounds None None O
1,1 None None I-IUPAC
- None None I-IUPAC
cyclobutanedicarboxylatobis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylazopyridine None None I-IUPAC
) None None I-IUPAC
ruthenium None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
, None None O
alpha None None O
- None None O
[ None None O
Ru None None O
( None None O
azpy None None O
) None None O
( None None O
2 None None O
) None None O
( None None O
cbdca None None O
- None None O
O None None O
, None None O
O' None None O
) None None O
] None None O
( None None O
1 None None O
) None None O
, None None O
oxalatobis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylazopyridine None None I-IUPAC
) None None I-IUPAC
ruthenium None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
, None None O
alpha None None O
- None None O
[ None None O
Ru None None O
( None None O
azpy None None O
) None None O
( None None O
2 None None O
) None None O
( None None O
ox None None O
) None None O
] None None O
( None None O
2 None None O
) None None O
, None None O
and None None O
malonatobis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylazopyridine None None I-IUPAC
) None None I-IUPAC
ruthenium None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
, None None O
alpha None None O
- None None O
[ None None O
Ru None None O
( None None O
azpy None None O
) None None O
( None None O
2 None None O
) None None O
( None None O
mal None None O
) None None O
] None None O
( None None O
3 None None O
) None None O
, None None O
have None None O
been None None O
synthesized None None O
and None None O
fully None None O
characterized None None O
. None None O

X None None O
- None None O
ray None None O
analyses None None O
of None None O
1 None None O
and None None O
2 None None O
are None None O
reported None None O
, None None O
and None None O
compound None None O
1 None None O
is None None O
the None None O
first None None O
example None None O
in None None O
which None None O
the None None O
cbdca None None O
ligand None None O
is None None O
coordinated None None O
to None None O
a None None O
ruthenium None None O
center None None O
. None None O

The None None O
cytotoxicity None None O
of None None O
this None None O
series None None O
of None None O
water None None O
- None None O
soluble None None O
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylazopyridine None None I-IUPAC
) None None I-IUPAC
complexes None None I-MODIFIER
has None None O
been None None O
determined None None O
in None None O
A2780 None None O
human None None O
ovarian None None O
carcinoma None None O
and None None O
A2780cisR None None O
, None None O
the None None O
corresponding None None O
cisplatin None None O
- None None O
resistant None None O
cell None None O
line None None O
. None None O

For None None O
comparison None None O
reasons None None O
, None None O
the None None O
cytotoxicity None None O
of None None O
the None None O
complexes None None O
alpha None None O
- None None O
[ None None O
Ru None None O
( None None O
azpy None None O
) None None O
( None None O
2 None None O
) None None O
Cl None None O
( None None O
2 None None O
) None None O
] None None O
, None None O
alpha None None O
- None None O
[ None None O
Ru None None O
( None None O
azpy None None O
) None None O
( None None O
2 None None O
) None None O
( None None O
NO None None O
( None None O
3 None None O
) None None O
) None None O
( None None O
2 None None O
) None None O
] None None O
, None None O
beta None None O
- None None O
[ None None O
Ru None None O
( None None O
azpy None None O
) None None O
( None None O
2 None None O
) None None O
Cl None None O
( None None O
2 None None O
) None None O
] None None O
( None None O
beta None None O
indicating None None O
the None None O
coordinating None None O
pairs None None O
Cl None None O
, None None O
N None None O
( None None O
py None None O
) None None O
, None None O
and None None O
N None None O
( None None O
azo None None O
) None None O
as None None O
cis None None O
, None None O
cis None None O
, None None O
cis None None O
, None None O
respectively None None O
) None None O
, None None O
and None None O
beta None None O
- None None O
[ None None O
Ru None None O
( None None O
azpy None None O
) None None O
( None None O
2 None None O
) None None O
( None None O
NO None None O
( None None O
3 None None O
) None None O
) None None O
( None None O
2 None None O
) None None O
] None None O
have None None O
been None None O
determined None None O
in None None O
this None None O
cell None None O
line None None O
. None None O

All None None O
the None None O
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylazopyridine None None I-IUPAC
) None None I-IUPAC
ruthenium None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
compounds None None I-MODIFIER
display None None O
a None None O
promising None None O
cytotoxicity None None O
in None None O
the None None O
A2780 None None O
cell None None O
line None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.9-10 None None O
microM None None O
) None None O
, None None O
with None None O
an None None O
activity None None O
comparable None None O
to None None O
that None None O
of None None O
cisplatin None None O
and None None O
even None None O
higher None None O
than None None O
the None None O
activity None None O
of None None O
carboplatin None None O
. None None O

Interestingly None None O
, None None O
the None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
of None None O
this None None O
series None None O
of None None O
ruthenium None None O
compounds None None O
( None None O
except None None O
the None None O
beta None None O
isomeric None None O
compounds None None O
) None None O
are None None O
similar None None O
in None None O
the None None O
cisplatin None None O
- None None O
resistant None None O
A2780cisR None None O
cell None None O
line None None O
compared None None O
to None None O
the None None O
normal None None O
cell None None O
line None None O
A2780 None None O
, None None O
suggesting None None O
that None None O
the None None O
activity None None O
of None None O
these None None O
compounds None None O
might None None O
not None None O
be None None O
influenced None None O
by None None O
the None None O
multifactorial None None O
resistance None None O
mechanism None None O
that None None O
affect None None O
platinum None None O
anticancer None None O
agents None None O
. None None O


Water None None O
- None None O
soluble None None O
prodrugs None None O
of None None O
potent None None O
, None None O
A None None O
( None None O
2A None None O
) None None O
- None None O
selective None None O
adenosine None None O
receptor None None O
( None None O
AR None None O
) None None O
antagonists None None O
were None None O
prepared None None O
. None None O

8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
Bromostyryl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propargylxanthine None None I-IUPAC
( None None O
BS None None O
- None None O
DMPX None None O
, None None O
11 None None O
) None None O
and None None O
the None None O
analogous None None I-MODIFIER
8 None None B-IUPAC
- None None I-IUPAC
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
methoxystyryl None None I-IUPAC
) None None I-IUPAC
xanthine None None I-IUPAC
derivative None None I-MODIFIER
( None None O
MS None None O
- None None O
DMPX None None O
, None None O
5b None None O
) None None O
were None None O
used None None O
as None None O
starting None None O
points None None O
. None None O

It None None O
was None None O
found None None O
that None None O
polar None None O
functional None None O
groups None None O
suitable None None O
for None None O
the None None O
attachment None None O
of None None O
a None None O
prodrug None None O
moiety None None O
were None None O
tolerated None None O
on None None O
the None None O
styryl None None O
ring None None O
and None None O
even None None O
better None None O
on None None O
the None None O
3 None None O
- None None O
substituent None None O
. None None O

8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
Hydroxystyryl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
DMPX None None I-IUPAC
( None None O
7 None None O
) None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
methoxystyryl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propargylxanthine None None I-IUPAC
( None None O
5e None None O
, None None O
MSX None None O
- None None O
2 None None O
) None None O
were None None O
the None None O
most None None O
potent None None O
and None None O
A None None O
( None None O
2A None None O
) None None O
- None None O
selective None None O
compounds None None O
and None None O
were None None O
selected None None O
for None None O
prodrug None None O
formation None None O
. None None O

For None None O
the None None O
preparation None None O
of None None O
5e None None O
a None None O
new None None O
ring None None O
- None None O
closure None None O
method None None O
was None None O
applied None None O
. None None O

Treatment None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
methoxycinnamoylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
propa None None I-IUPAC
rgylur None None I-IUPAC
acil None None I-IUPAC
with None None O
hexamethyldisilazane None None O
at None None O
high None None O
temperature None None O
resulted None None O
in None None O
higher None None O
yields None None O
of None None O
the None None O
target None None O
xanthine None None O
than None None O
the None None O
standard None None O
ring None None O
- None None O
closure None None O
procedure None None O
using None None O
sodium None None O
hydroxide None None O
. None None O

Phosphate None None O
prodrugs None None O
were None None O
prepared None None O
by None None O
classical None None O
phosphorylation None None O
using None None O
phosphorus None None O
oxychloride None None O
and None None O
alternatively None None O
by None None O
using None None O
a None None O
phosphoramidite None None O
method None None O
. None None O

Phosphates None None O
of None None O
the None None O
aliphatic None None O
alcohol None None O
5e None None O
could None None O
be None None O
obtained None None O
by None None O
both None None O
methods None None O
in None None O
similar None None O
yields None None O
. None None O

The None None O
phenolic None None O
compound None None O
7 None None O
, None None O
however None None O
, None None O
could None None O
be None None O
phosphorylated None None O
only None None O
by None None O
using None None O
the None None O
phosphoramidite None None O
method None None O
. None None O

The None None O
disodium None None O
salts None None O
of None None O
the None None O
phosphate None None O
prodrugs None None O
exhibited None None O
high None None O
water None None O
solubility None None O
( None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
methoxystyryl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
phosphatylpropyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propargylxan None None I-IUPAC
thine None None I-IUPAC
disodium None None I-IUPAC
salt None None I-IUPAC
, None None O
9b None None O
: None None O
17 None None O
mM None None O
, None None O
9 None None O
mg None None O
/ None None O
mL None None O
) None None O
. None None O

Prodrug None None O
9b None None O
was None None O
found None None O
to None None O
be None None O
stable None None O
in None None O
aqueous None None O
solution None None O
( None None O
pH None None O
7 None None O
) None None O
but None None O
readily None None O
cleaved None None O
by None None O
phosphatases None None O
to None None O
liberate None None O
5e None None O
( None None O
MSX None None O
- None None O
2 None None O
) None None O
. None None O

Compound None None O
5e None None O
showed None None O
high None None O
affinity None None O
for None None O
rat None None O
A None None O
( None None O
2A None None O
) None None O
AR None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
8 None None O
nM None None O
) None None O
, None None O
human None None O
recombinant None None O
A None None O
( None None O
2A None None O
) None None O
AR None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
5 None None O
nM None None O
) None None O
, None None O
and None None O
human None None O
native None None O
A None None O
( None None O
2A None None O
) None None O
AR None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
15 None None O
nM None None O
) None None O
and None None O
was None None O
highly None None O
selective None None O
versus None None O
rat None None O
A None None O
( None None O
1 None None O
) None None O
AR None None O
( None None O
110 None None O
- None None O
fold None None O
) None None O
, None None O
human None None O
recombinant None None O
A None None O
( None None O
2A None None O
) None None O
AR None None O
( None None O
500 None None O
- None None O
fold None None O
) None None O
, None None O
human None None O
A None None O
( None None O
2B None None O
) None None O
AR None None O
( None None O
& None None O
gt None None O
; None None O
2000 None None O
- None None O
fold None None O
) None None O
, None None O
and None None O
human None None O
A None None O
( None None O
3 None None O
) None None O
AR None None O
( None None O
& None None O
gt None None O
; None None O
2000 None None O
- None None O
fold None None O
) None None O
. None None O


The None None O
adenosine None None O
antagonist None None O
9 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
[ None None I-IUPAC
1,2,4 None None I-IUPAC
] None None I-IUPAC
triazolo None None I-IUPAC
[ None None I-IUPAC
1,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
quinazolin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
amine None None I-IUPAC
( None None O
CGS15943 None None O
) None None O
binds None None O
to None None O
human None None O
A3 None None O
receptors None None O
with None None O
high None None O
affinity None None O
( None None O
Ki None None O
= None None O
14 None None O
nM None None O
) None None O
, None None O
while None None O
it None None O
lacks None None O
affinity None None O
at None None O
rat None None O
A3 None None O
receptors None None O
. None None O

Acylated None None O
derivatives None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
group None None I-MODIFIER
and None None O
other None None O
modifications None None O
were None None O
prepared None None O
in None None O
an None None O
effort None None O
to None None O
provide None None O
A3 None None O
subtype None None O
selectivity None None O
. None None O

Affinity None None O
was None None O
determined None None O
in None None O
radioligand None None O
binding None None O
assays None None O
at None None O
rat None None O
brain None None O
A1 None None O
and None None O
A2A None None O
receptors None None O
using None None O
[ None None O
3H None None O
] None None O
- None None O
( None None O
R None None O
) None None O
- None None O
PIA None None O
( None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylisopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
adenosine None None I-IUPAC
) None None O
and None None O
[ None None O
3H None None O
] None None O
CGS None None O
21680 None None O
( None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
ethyl None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
ethylaminol None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
carbamoyl None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
) None None O
, None None O
respectively None None O
. None None O

Affinity None None O
was None None O
determined None None O
at None None O
cloned None None O
human None None O
A3 None None O
receptors None None O
using None None O
[ None None O
125I None None O
] None None O
AB None None O
- None None O
MECA None None O
( None None O
N6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
iodobenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylcarbamoyl None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
) None None O
. None None O

A None None O
series None None O
of None None O
straight None None O
chain None None O
alkyl None None O
amides None None O
demonstrated None None O
that None None O
the None None O
optimal None None O
chain None None O
length None None O
occurs None None O
with None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
propionyl None None I-IUPAC
derivative None None I-MODIFIER
, None None O
3 None None O
, None None O
which None None O
had None None O
a None None O
Ki None None O
value None None O
of None None O
7.7 None None O
nM None None O
at None None O
human None None O
A3 None None O
receptors None None O
, None None O
and None None O
was None None O
40 None None O
- None None O
and None None O
14 None None O
- None None O
fold None None O
selective None None O
vs None None O
rat None None O
A1 None None O
and None None O
A2A None None O
receptors None None O
, None None O
respectively None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
derivative None None I-MODIFIER
, None None O
10 None None O
, None None O
displayed None None O
Ki None None O
values None None O
of None None O
680 None None O
and None None O
273 None None O
nM None None O
at None None O
rat None None O
A1 None None O
and None None O
A2A None None O
receptors None None O
, None None O
respectively None None O
, None None O
and None None O
3.0 None None O
nM None None O
at None None O
human None None O
A3 None None O
receptors None None O
. None None O

A None None O
5 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
phenylacetyl None None I-IUPAC
derivative None None I-MODIFIER
, None None O
12 None None O
, None None O
was None None O
470 None None O
- None None O
fold None None O
selective None None O
for None None O
human None None O
A3 None None O
vs None None O
rat None None O
A1 None None O
receptors None None O
with None None O
a None None O
Ki None None O
value None None O
of None None O
0.65 None None O
nM None None O
. None None O

A None None O
conjugate None None O
of None None O
Boc None None O
- None None O
gamma None None O
- None None O
aminobutyric None None O
acid None None O
was None None O
also None None O
prepared None None O
but None None O
was None None O
nonselective None None O
. None None O

Conversion None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
group None None I-MODIFIER
of None None O
CGS15943 None None O
to None None O
an None None O
oxo None None O
function None None O
resulted None None O
in None None O
lower None None O
affinity None None O
but None None O
15 None None O
- None None O
fold None None O
selectivity None None O
for None None O
human None None O
A3 None None O
receptors None None O
. None None O


Treatment None None O
of None None O
the None None O
5' None None I-IUPAC
- None None I-IUPAC
carboxaldehyde None None I-IUPAC
derived None None O
by None None O
Moffatt None None O
oxidation None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
isopropylideneadenosine None None I-IUPAC
( None None O
1 None None O
) None None O
with None None O
the None None O
" None None O
( None None I-IUPAC
bromofluoromethylene None None I-IUPAC
) None None I-IUPAC
triphenylphosphorane None None I-IUPAC
" None None O
reagent None None O
and None None O
deprotection None None O
gave None None O
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
- None None I-IUPAC
ribo None None I-IUPAC
- None None I-IUPAC
hex None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
enofuranosyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
( None None O
4 None None O
) None None O
. None None O

Parallel None None O
treatment None None O
with None None O
a None None O
" None None O
dibromomethylene None None O
Wittig None None O
reagent None None O
" None None O
and None None O
deprotection None None O
gave None None O
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
6,6 None None I-IUPAC
- None None I-IUPAC
dibromo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
- None None I-IUPAC
ribo None None I-IUPAC
- None None I-IUPAC
hex None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
enofuranosyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
which None None O
also None None O
was None None O
prepared None None O
by None None O
successive None None O
bromination None None O
and None None O
dehydrobromination None None O
of None None O
the None None O
6' None None I-IUPAC
- None None I-IUPAC
bromohomovinyl None None I-IUPAC
nucleoside None None I-IUPAC
8 None None O
. None None O

Bromination None None O
- None None O
dehydrobromination None None O
of None None O
the None None O
5' None None I-IUPAC
- None None I-IUPAC
bromohomovinyl None None I-IUPAC
analogue None None I-MODIFIER
11 None None O
and None None O
deprotection None None O
gave None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
dibromo None None I-IUPAC
- None None I-IUPAC
5,6 None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
- None None I-IUPAC
ribo None None I-IUPAC
- None None I-IUPAC
hex None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
enofuranosyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
( None None O
15 None None O
) None None O
. None None O

Compounds None None O
4 None None O
, None None O
7 None None O
, None None O
and None None O
15 None None O
were None None O
designed None None O
as None None O
putative None None O
substrates None None O
of None None O
the None None O
" None None O
hydrolytic None None O
activity None None O
" None None O
of None None O
S None None I-IUPAC
- None None I-IUPAC
adenosyl None None I-IUPAC
- None None I-IUPAC
l None None I-IUPAC
- None None I-IUPAC
homocysteine None None I-IUPAC
( None None O
AdoHcy None None O
) None None O
hydrolase None None O
. None None O

Enzyme None None O
- None None O
mediated None None O
addition None None O
of None None O
water None None O
across None None O
the None None O
5,6 None None O
- None None O
double None None O
bond None None O
could None None O
generate None None O
electrophilic None None O
acyl None None O
halide None None O
or None None O
alpha None None I-IUPAC
- None None I-IUPAC
halo None None I-IUPAC
ketone None None I-IUPAC
species None None O
that None None O
could None None O
undergo None None O
nucleophilic None None O
attack None None O
by None None O
proximal None None O
groups None None O
on None None O
the None None O
enzyme None None O
. None None O

Such None None O
type None None O
II None None O
( None None O
covalent None None O
) None None O
mechanism None None O
- None None O
based None None O
inactivation None None O
is None None O
supported None None O
by None None O
protein None None O
labeling None None O
with None None O
8 None None O
- None None O
[ None None O
3H None None O
] None None O
- None None O
4 None None O
and None None O
concomitant None None O
release None None O
of None None O
bromide None None O
and None None O
fluoride None None O
ions None None O
. None None O

Incubation None None O
of None None O
AdoHcy None None O
hydrolase None None O
with None None O
7 None None O
or None None O
15 None None O
resulted None None O
in None None O
irreversible None None O
inactivation None None O
and None None O
release None None O
of None None O
bromide None None O
ion None None O
. None None O

In None None O
contrast None None O
with None None O
type None None O
I None None O
mechanism None None O
- None None O
based None None O
inactivation None None O
, None None O
reduction None None O
of None None O
enzyme None None O
- None None O
bound None None O
NAD+ None None O
to None None O
NADH None None O
was None None O
not None None O
observed None None O
. None None O

Compounds None None O
4 None None O
, None None O
7 None None O
, None None O
and None None O
15 None None O
were None None O
not None None O
inhibitory None None O
to None None O
a None None O
variety None None O
of None None O
viruses None None O
in None None O
cell None None O
culture None None O
, None None O
and None None O
weak None None O
cytotoxicity None None O
was None None O
observed None None O
only None None O
for None None O
CEM None None O
cells None None O
. None None O


New None None O
1 None None I-IUPAC
- None None I-IUPAC
benzhydryl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylurea None None I-IUPAC
derivatives None None I-MODIFIER
and None None O
their None None O
1 None None I-IUPAC
- None None I-IUPAC
benzhydryl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylthiourea None None I-IUPAC
isosteres None None I-MODIFIER
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
their None None O
human None None O
CB1 None None O
and None None O
CB2 None None O
cannabinoid None None O
receptor None None O
affinity None None O
. None None O

These None None O
compounds None None O
proved None None O
to None None O
be None None O
selective None None O
CB1 None None O
cannabinoid None None O
receptor None None O
ligands None None O
, None None O
acting None None O
as None None O
inverse None None O
agonists None None O
in None None O
a None None O
[ None None O
35S None None O
] None None O
- None None O
GTPgammaS None None O
assay None None O
. None None O

The None None O
affinity None None O
of None None O
3,5,5 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
triphenylimidazolidine None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
and None None O
3,5,5 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
triphenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thioxoimidazolidin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
possessing None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
benzhydryl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylurea None None I-IUPAC
and None None O
1 None None I-IUPAC
- None None I-IUPAC
benzhydryl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylthiourea None None I-IUPAC
moiety None None I-MODIFIER
, None None O
respectively None None O
, None None O
was None None O
also None None O
evaluated None None O
. None None O

In None None O
conclusion None None O
, None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
benzhydryl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylurea None None I-IUPAC
scaffold None None I-MODIFIER
seems None None O
to None None O
be None None O
a None None O
new None None O
interesting None None O
template None None O
of None None O
CB1 None None O
cannabinoid None None O
receptor None None O
inverse None None O
agonists None None O
. None None O


2 None None O
- None None O
( None None O
4 None None O
- None None O
Chloro None None O
- None None O
3 None None O
- None None O
hydroxyphenyl None None O
) None None O
ethylamine None None O
( None None O
4 None None O
) None None O
and None None O
some None None O
derivatives None None O
were None None O
synthesized None None O
as None None O
dopamine None None O
( None None O
DA None None O
) None None O
receptor None None O
ligands None None O
. None None O

Amine None None O
4 None None O
retains None None O
the None None O
dopaminergic None None O
pharmacophore None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ethylamine None None I-IUPAC
, None None O
and None None O
the None None O
chlorine None None O
atom None None O
replaces None None O
the None None O
" None None O
para None None O
" None None O
hydroxyl None None I-IUPAC
group None None B-MODIFIER
of None None O
DA None None O
. None None O

The None None O
derivatives None None O
18a None None O
- None None O
e None None O
were None None O
obtained None None O
by None None O
introducing None None O
on None None O
the None None O
nitrogen None None O
of None None O
amine None None O
4 None None O
the None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
or None None O
3 None None I-IUPAC
- None None I-IUPAC
phenylpropyl None None I-IUPAC
groups None None I-MODIFIER
which None None O
can None None O
be None None O
accommodated None None O
by None None O
the None None O
D None None O
- None None O
2 None None O
receptor None None O
lipophilic None None O
sites None None O
3C None None O
and None None O
pi None None O
3 None None O
, None None O
respectively None None O
. None None O

The None None O
affinity None None O
and None None O
selectivity None None O
of None None O
these None None O
compounds None None O
for None None O
D None None O
- None None O
1 None None O
and None None O
D None None O
- None None O
2 None None O
subtypes None None O
was None None O
determined None None O
in None None O
radioligand None None O
competition None None O
assays None None O
for None None O
the None None O
DA None None O
receptors None None O
of None None O
rat None None O
striatum None None O
membranes None None O
using None None O
[ None None O
3H None None O
] None None O
SCH None None O
23390 None None O
( None None O
D None None O
- None None O
1 None None O
selective None None O
) None None O
and None None O
[ None None O
3H None None O
] None None O
spiperone None None O
( None None O
D None None O
- None None O
2 None None O
selective None None O
) None None O
as None None O
radioligands None None O
. None None O

The None None O
amine None None O
4 None None O
shows None None O
about None None O
7 None None O
- None None O
fold None None O
lower None None O
affinity None None O
than None None O
DA None None O
for None None O
both None None O
sites None None O
and None None O
is None None O
not None None O
able None None O
to None None O
discriminate None None O
between None None O
the None None O
two None None O
subtypes None None O
of None None O
DA None None O
receptors None None O
. None None O

The None None O
introduction None None O
of None None O
two None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
groups None None I-MODIFIER
( None None O
18a None None O
) None None O
on None None O
the None None O
nitrogen None None O
atom None None O
reduces None None O
by None None O
one None None O
- None None O
half None None O
and None None O
doubles None None O
the None None O
affinity None None O
for None None O
D None None O
- None None O
1 None None O
and None None O
D None None O
- None None O
2 None None O
binding None None O
sites None None O
, None None O
respectively None None O
. None None O

The None None O
substitution None None O
of None None O
an None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
group None None I-MODIFIER
with None None O
different None None O
alkylphenyl None None O
groups None None O
, None None O
to None None O
give None None O
compounds None None O
18b None None O
- None None O
e None None O
, None None O
increases None None O
the None None O
affinity None None O
for None None O
the None None O
D None None O
- None None O
2 None None O
subtype None None O
from None None O
19 None None O
- None None O
fold None None O
to None None O
36 None None O
- None None O
fold None None O
. None None O

These None None O
compounds None None O
have None None O
the None None O
same None None O
affinity None None O
at None None O
the None None O
D None None O
- None None O
2 None None O
site None None O
as None None O
the None None O
DA None None O
agonist None None O
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ethylamine None None I-IUPAC
( None None O
2a None None O
) None None O
and None None O
are None None O
about None None O
20 None None O
times None None O
more None None O
selective None None O
than None None O
DA None None O
for None None O
this None None O
binding None None O
site None None O
. None None O

In None None O
the None None O
assay None None O
for None None O
D None None O
- None None O
2 None None O
receptor None None O
mediated None None O
inhibition None None O
of None None O
adenylate None None O
cyclase None None O
activity None None O
, None None O
all None None O
the None None O
tested None None O
compounds None None O
behaved None None O
as None None O
D None None O
- None None O
2 None None O
agonists None None O
; None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
n None None I-PARTIUPAC
- None None I-PARTIUPAC
propyl None None I-PARTIUPAC
- None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
2 None None I-PARTIUPAC
( None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxyphenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
ethyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
18d None None O
) None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
ethylamine None None I-IUPAC
( None None O
18b None None O
) None None O
were None None O
more None None O
effective None None O
than None None O
DA None None O
or None None O
2a None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
all None None O
compounds None None O
were None None O
less None None O
effective None None O
than None None O
DA None None O
in None None O
stimulation None None O
of None None O
adenylate None None O
cyclase None None O
activity None None O
in None None O
rat None None O
striatal None None O
homogenates None None O
, None None O
a None None O
kind None None O
of None None O
effect None None O
which None None O
is None None O
mediated None None O
by None None O
the None None O
D None None O
- None None O
1 None None O
subtype None None O
of None None O
DA None None O
receptors None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
nitrogen None None O
substitution None None O
enhances None None O
the None None O
affinity None None O
and None None O
selectivity None None O
for None None O
the None None O
D None None O
- None None O
2 None None O
receptor None None O
. None None O

In None None O
the None None O
adenylate None None O
cyclase None None O
assay None None O
, None None O
the None None O
compounds None None O
behave None None O
as None None O
potent None None O
D None None O
- None None O
2 None None O
agonists None None O
. None None O


The None None O
nuclear None None O
enzyme None None O
poly None None O
( None None O
ADP None None O
- None None O
ribose None None O
) None None O
polymerase None None O
( None None O
PARP None None O
) None None O
facilitates None None O
the None None O
repair None None O
of None None O
DNA None None O
strand None None O
breaks None None O
and None None O
is None None O
implicated None None O
in None None O
the None None O
resistance None None O
of None None O
cancer None None O
cells None None O
to None None O
certain None None O
DNA None None O
- None None O
damaging None None O
agents None None O
. None None O

Inhibitors None None O
of None None O
PARP None None O
have None None O
clinical None None O
potential None None O
as None None O
resistance None None O
- None None O
modifying None None O
agents None None O
capable None None O
of None None O
potentiating None None O
radiotherapy None None O
and None None O
the None None O
cytotoxicity None None O
of None None O
some None None O
forms None None O
of None None O
cancer None None O
chemotherapy None None O
. None None O

The None None O
preclinical None None O
development None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamides None None I-IUPAC
as None None O
resistance None None O
- None None O
modifying None None O
agents None None O
in None None O
cancer None None O
chemotherapy None None O
is None None O
described None None O
. None None O

1H None None I-IUPAC
- None None I-IUPAC
Benzimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamides None None I-IUPAC
, None None O
particularly None None O
2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
are None None O
identified None None O
as None None O
a None None O
class None None O
of None None O
potent None None O
PARP None None O
inhibitors None None O
. None None O

Derivatives None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
23 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
15 None None O
nM None None O
) None None O
, None None O
in None None O
which None None O
the None None O
phenyl None None O
ring None None O
contains None None O
substituents None None O
, None None O
have None None O
been None None O
synthesized None None O
. None None O

Many None None O
of None None O
these None None O
derivatives None None O
exhibit None None O
K None None O
( None None O
i None None O
) None None O
values None None O
for None None O
PARP None None O
inhibition None None O
& None None O
lt None None O
; None None O
10 None None O
nM None None O
, None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxymethylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
78 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
1.6 None None O
nM None None O
) None None O
being None None O
one None None O
of None None O
the None None O
most None None O
potent None None O
. None None O

Insight None None O
into None None O
structure None None O
- None None O
activity None None O
relationships None None O
( None None O
SAR None None O
) None None O
for None None O
2 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamides None None I-IUPAC
has None None O
been None None O
enhanced None None O
by None None O
studying None None O
the None None O
complex None None O
formed None None O
between None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
44 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
6 None None O
nM None None O
) None None O
and None None O
the None None O
catalytic None None O
domain None None O
of None None O
chicken None None O
PARP None None O
. None None O

Important None None O
hydrogen None None O
- None None O
bonding None None O
and None None O
hydrophobic None None O
interactions None None O
with None None O
the None None O
protein None None O
have None None O
been None None O
identified None None O
for None None O
this None None O
inhibitor None None O
. None None O

2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
Hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benzimidazole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
45 None None O
, None None O
K None None O
( None None O
i None None O
) None None O
= None None O
6 None None O
nM None None O
) None None O
potentiates None None O
the None None O
cytotoxicity None None O
of None None O
both None None O
temozolomide None None O
and None None O
topotecan None None O
against None None O
A2780 None None O
cells None None O
in None None O
vitro None None O
( None None O
by None None O
2.8 None None O
- None None O
and None None O
2.9 None None O
- None None O
fold None None O
, None None O
respectively None None O
) None None O
. None None O


The None None O
synthesis None None O
and None None O
biological None None O
evaluation None None O
of None None O
new None None O
histamine None None O
H3 None None O
receptor None None O
antagonists None None O
with None None O
an None None O
iodinated None None O
aryl None None O
partial None None O
structure None None O
are None None O
described None None O
as None None O
part None None O
of None None O
an None None O
extensive None None O
research None None O
program None None O
to None None O
find None None O
model None None O
compounds None None O
for None None O
the None None O
development None None O
of None None O
a None None O
new None None O
radioligand None None O
with None None O
high None None O
H3 None None O
receptor None None O
affinity None None O
and None None O
specific None None O
activity None None O
. None None O

All None None O
compounds None None O
were None None O
tested None None O
for None None O
their None None O
H3 None None O
receptor None None O
antagonist None None O
activity None None O
in None None O
a None None O
[ None None O
3H None None O
] None None O
- None None O
histamine None None O
- None None O
release None None O
assay None None O
with None None O
synaptosomes None None O
from None None O
rat None None O
cerebral None None O
cortex None None O
. None None O

The None None O
new None None O
leads None None O
with None None O
potent None None O
H3 None None O
receptor None None O
antagonist None None O
activity None None O
belong None None O
to None None O
a None None O
series None None O
of None None O
derivatives None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propanol None None I-IUPAC
with None None O
carbamate None None O
( None None O
4-7 None None O
) None None O
, None None O
ester None None O
( None None O
8-16 None None O
) None None O
, None None O
and None None O
ether None None O
( None None O
17-22 None None O
) None None O
as None None O
functional None None O
groups None None O
. None None O

Structure None None O
- None None O
activity None None O
relationships None None O
are None None O
discussed None None O
. None None O

The None None O
most None None O
active None None O
compound None None O
in None None O
the None None O
functional None None O
test None None O
( None None O
- None None O
log None None O
Ki None None O
= None None O
8.3 None None O
) None None O
and None None O
in None None O
binding None None O
studies None None O
with None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
methylhistamine None None I-IUPAC
on None None O
rat None None O
cerebral None None O
cortex None None O
( None None O
- None None O
log None None O
Ki None None O
= None None O
9.0 None None O
) None None O
in None None O
vitro None None O
was None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
iodophenyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
ether None None I-IUPAC
( None None O
iodoproxyfan None None O
, None None O
19 None None O
) None None O
exhibiting None None O
no None None O
central None None O
H3 None None O
receptor None None O
antagonist None None O
activity None None O
in None None O
vivo None None O
. None None O

The None None O
potency None None O
of None None O
iodoproxyfan None None O
is None None O
more None None O
than None None O
300 None None O
times None None O
lower None None O
at None None O
H1 None None O
, None None O
H2 None None O
, None None O
alpha1 None None O
, None None O
alpha2 None None O
, None None O
beta1 None None O
, None None O
5 None None O
- None None O
HT2A None None O
, None None O
5 None None O
- None None O
HT3 None None O
, None None O
and None None O
M3 None None O
receptors None None O
than None None O
at None None O
histamine None None O
H3 None None O
receptors None None O
. None None O

Because None None O
of None None O
the None None O
high None None O
potency None None O
and None None O
selectivity None None O
of None None O
19 None None O
, None None O
this None None O
compound None None O
has None None O
also None None O
been None None O
prepared None None O
in None None O
the None None O
[ None None O
125I None None O
] None None O
- None None O
iodinated None None O
form None None O
by None None O
a None None O
nucleophilic None None O
halogen None None O
exchange None None O
reaction None None O
using None None O
the None None O
corresponding None None O
bromo None None O
derivative None None O
22 None None O
as None None O
a None None O
precursor None None O
. None None O

The None None O
newly None None O
prepared None None O
[ None None O
125I None None O
] None None O
iodoproxyfan None None O
( None None O
23 None None O
) None None O
possesses None None O
advantageous None None O
pharmacological None None O
properties None None O
and None None O
fulfills None None O
all None None O
criteria None None O
of None None O
a None None O
useful None None O
radioligand None None O
. None None O


Thrombin None None O
is None None O
a None None O
serine None None O
protease None None O
responsible None None O
for None None O
blood None None O
coagulation None None O
. None None O

Since None None O
thrombin None None O
inhibitors None None O
appear None None O
to None None O
be None None O
effective None None O
in None None O
the None None O
treatment None None O
and None None O
prevention None None O
of None None O
thrombotic None None O
and None None O
embolic None None O
disorders None None O
, None None O
considerable None None O
attention None None O
has None None O
been None None O
focused None None O
on None None O
the None None O
structure None None O
and None None O
interactions None None O
of None None O
this None None O
enzyme None None O
. None None O

In None None O
this None None O
work None None O
, None None O
to None None O
evaluate None None O
the None None O
relative None None O
free None None O
energies None None O
of None None O
hydration None None O
and None None O
binding None None O
to None None O
thrombin None None O
for None None O
some None None O
benzamidine None None O
derivatives None None O
, None None O
we None None O
used None None O
the None None O
finite None None O
difference None None O
thermodynamic None None O
integration None None O
( None None O
FDTI None None O
) None None O
algorithm None None O
within None None O
the None None O
Discover None None O
program None None O
of None None O
MSI None None O
. None None O

By None None O
this None None O
method None None O
, None None O
two None None O
possible None None O
orders None None O
of None None O
hydration None None O
for None None O
the None None O
candidates None None O
were None None O
obtained None None O
: None None O
p None None I-IUPAC
- None None I-IUPAC
amidinophenylpyruvate None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
benzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
methylbenzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
ethylbenzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
benzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
benzamidine None None I-IUPAC
and None None O
p None None I-IUPAC
- None None I-IUPAC
amidinophenylpyruvate None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
benzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
methylbenzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
ethylbenzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
benzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
benzamidine None None I-IUPAC
. None None O

We None None O
also None None O
obtained None None O
the None None O
following None None O
order None None O
for None None O
thrombin None None O
binding None None O
: None None O
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
benzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
ethylbenzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
benzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
methylbenzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
benzamidine None None I-IUPAC
& None None O
gt None None O
; None None O
p None None I-IUPAC
- None None I-IUPAC
amidinophenylpyruvate None None I-IUPAC
. None None O


In None None O
this None None O
paper None None O
, None None O
we None None O
describe None None O
the None None O
synthesis None None O
of None None O
a None None O
series None None O
of None None O
novel None None O
substituted None None I-MODIFIER
4 None None B-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
methylenedioxyphthalazin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
2H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
. None None O

The None None O
anticonvulsant None None O
activity None None O
of None None O
these None None O
compounds None None O
against None None O
audiogenic None None O
seizures None None O
was None None O
evaluated None None O
in None None O
DBA None None O
/ None None O
2 None None O
mice None None O
after None None O
intraperitoneal None None O
( None None O
ip None None O
) None None O
injection None None O
. None None O

Most None None O
of None None O
these None None O
derivatives None None O
are None None O
more None None O
active None None O
than None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
methylenedioxy None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
benzodiazepine None None I-IUPAC
( None None O
1 None None O
, None None O
GYKI None None O
52466 None None O
) None None O
, None None O
a None None O
well None None O
- None None O
known None None O
noncompetitive None None O
AMPA None None O
receptor None None O
antagonist None None O
. None None O

As None None O
deduced None None O
by None None O
the None None O
rotarod None None O
test None None O
, None None O
all None None O
the None None O
compounds None None O
exhibit None None O
a None None O
toxicity None None O
lower None None O
than None None O
that None None O
of None None O
1 None None O
. None None O

Within None None O
the None None O
series None None O
of None None O
derivatives None None O
submitted None None O
to None None O
investigation None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
butylcarbamoyl None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
methylenedioxyphthalazin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
2H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
21 None None O
) None None O
proved None None O
to None None O
be None None O
the None None O
most None None O
active None None O
compound None None O
and None None O
is None None O
11 None None O
- None None O
fold None None O
more None None O
potent None None O
than None None O
1 None None O
( None None O
i.e. None None O
, None None O
ED50 None None O
3.25 None None O
micromol None None O
/ None None O
kg None None O
for None None O
21 None None O
versus None None O
ED50 None None O
35.8 None None O
micromol None None O
/ None None O
kg None None O
for None None O
1 None None O
) None None O
. None None O

When None None O
compared None None O
to None None O
1 None None O
, None None O
compound None None O
21 None None O
as None None O
well None None O
as None None O
its None None O
analogue None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
methylenedioxyphthalazin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
2H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
16 None None O
) None None O
show None None O
a None None O
longer None None O
lasting None None O
anticonvulsant None None O
activity None None O
. None None O

Compound None None O
21 None None O
also None None O
effectively None None O
suppresses None None O
seizures None None O
induced None None O
in None None O
Swiss None None O
mice None None O
by None None O
maximal None None O
electroshock None None O
( None None O
MES None None O
) None None O
and None None O
pentylenetetrazole None None O
( None None O
PTZ None None O
) None None O
. None None O

Furthermore None None O
, None None O
it None None O
antagonizes None None O
in None None O
vivo None None O
seizures None None O
induced None None O
by None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None O
) None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
isoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
ATPA None None O
) None None O
, None None O
and None None O
kainate None None O
( None None O
KA None None O
) None None O
, None None O
and None None O
its None None O
anticonvulsant None None O
activity None None O
is None None O
reversed None None O
by None None O
pretreatment None None O
with None None O
aniracetam None None O
. None None O

Using None None O
the None None O
patch None None O
- None None O
clamp None None O
technique None None O
, None None O
the None None O
capability None None O
of None None O
derivatives None None O
16 None None O
and None None O
21 None None O
to None None O
antagonize None None O
KA None None O
- None None O
evoked None None O
currents None None O
in None None O
primary None None O
cultures None None O
of None None O
granule None None O
neurons None None O
was None None O
tested None None O
. None None O

They None None O
behaved None None O
as None None O
antagonists None None O
, None None O
but None None O
they None None O
proved None None O
to None None O
be None None O
less None None O
effective None None O
than None None O
1 None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylcarbamoyl None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
met None None I-IUPAC
hylenedioxy None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
benzodiazepine None None I-IUPAC
( None None O
2 None None O
, None None O
GYKI None None O
53655 None None O
) None None O
to None None O
reduce None None O
the None None O
KA None None O
- None None O
evoked None None O
currents None None O
. None None O


The None None O
synthesis None None O
of None None O
ethyl None None I-IUPAC
or None None O
methyl None None I-IUPAC
4 None None B-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
or None None O
unsubstituted None None I-MODIFIER
2 None None B-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
pyrimidinecarboxylates None None I-IUPAC
10-20 None None O
, None None O
which None None O
is None None O
mainly None None O
carried None None O
out None None O
by None None O
reaction None None O
of None None O
ethyl None None I-IUPAC
or None None O
methyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
methylene None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxoalkanoates None None I-IUPAC
with None None O
1,1 None None I-IUPAC
- None None I-IUPAC
dimethylguanidine None None I-IUPAC
, None None O
is None None O
described None None O
. None None O

The None None O
above None None O
esters None None O
were None None O
hydrolyzed None None O
to None None O
the None None O
relative None None O
carboxylic None None O
acids None None O
21-30 None None O
, None None O
which None None O
were None None O
decarboxylated None None O
to None None O
the None None O
corresponding None None O
2,4 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
pyrimidines None None I-IUPAC
31-40 None None O
. None None O

All None None O
the None None O
new None None O
synthesized None None O
pyrimidines None None O
were None None O
evaluated None None O
in None None O
spontaneously None None O
beating None None O
and None None O
electrically None None O
driven None None O
atria None None O
from None None O
reserpine None None O
- None None O
treated None None O
guinea None None O
pigs None None O
. None None O

Their None None O
effects None None O
were None None O
compared None None O
to None None O
those None None O
induced None None O
by None None O
milrinone None None O
in None None O
both None None O
atria None None O
preparations None None O
. None None O

Compound None None O
28 None None O
( None None O
4 None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
pyrimidinecarboxylic None None I-IUPAC
acid None None I-IUPAC
) None None O
was None None O
the None None O
most None None O
effective None None O
positive None None O
inotropic None None O
agent None None O
, None None O
while None None O
the None None O
corresponding None None O
methyl None None O
ester None None O
17 None None O
reduced None None O
both None None O
the None None O
contractile None None O
force None None O
and None None O
the None None O
frequency None None O
of None None O
guinea None None O
pig None None O
atria None None O
. None None O

An None None O
antagonism None None O
toward None None O
the None None O
negative None None O
influence None None O
exerted None None O
by None None O
endogenous None None O
adenosine None None O
on None None O
the None None O
heart None None O
seems None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
contractile None None O
activity None None O
of None None O
compound None None O
28 None None O
. None None O

By None None O
contrast None None O
, None None O
compound None None O
17 None None O
might None None O
be None None O
partial None None O
agonist None None O
at None None O
the None None O
purinergic None None O
inhibitory None None O
( None None O
A1 None None O
) None None O
receptor None None O
. None None O

X None None O
- None None O
ray None None O
analysis None None O
carried None None O
out None None O
on None None O
17 None None O
and None None O
28 None None O
and None None O
molecular None None O
modeling None None O
investigations None None O
extended None None O
also None None O
to None None O
related None None O
derivatives None None O
allowed None None O
a None None O
possible None None O
rationalization None None O
between None None O
structure None None O
and None None O
inotropic None None O
activity None None O
for None None O
this None None O
series None None O
of None None O
compounds None None O
. None None O


A None None O
series None None O
of None None O
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
) None None I-IUPAC
indolones None None I-IUPAC
and None None O
related None None O
compounds None None O
was None None O
synthesized None None O
and None None O
evaluated None None O
in None None O
vitro None None O
as None None O
peripheral None None O
prejunctional None None O
dopaminergic None None O
agonists None None O
in None None O
the None None O
field None None O
- None None O
stimulated None None O
isolated None None O
perfused None None O
rabbit None None O
ear None None O
artery None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
indolone None None I-IUPAC
was None None O
the None None O
most None None O
potent None None O
compound None None O
( None None O
ED50 None None O
= None None O
2 None None O
+ None None O
/ None None O
- None None O
0.3 None None O
nM None None O
) None None O
tested None None O
, None None O
while None None O
the None None O
related None None O
secondary None None O
amine None None O
24 None None O
and None None O
the None None O
des None None O
- None None O
OH None None O
derivatives None None O
28 None None O
and None None O
34 None None O
were None None O
only None None O
slightly None None O
less None None O
potent None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Methoxybenzeneethanamine None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
nitrophenylacetic None None I-IUPAC
acid None None I-IUPAC
were None None O
employed None None O
as None None O
starting None None O
materials None None O
for None None O
for None None O
the None None O
synthesis None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
) None None I-IUPAC
indolones None None I-IUPAC
. None None O

The None None O
ring None None O
- None None O
opened None None O
3 None None I-IUPAC
- None None I-IUPAC
acylamino None None I-IUPAC
analogues None None I-MODIFIER
46 None None O
and None None O
47 None None O
were None None O
prepared None None O
via None None O
nitration None None O
of None None O
the None None O
phenethylamine None None O
43 None None O
derived None None O
from None None O
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenylacetic None None I-IUPAC
acid None None I-IUPAC
. None None O

The None None O
inactive None None O
isomeric None None O
indolones None None O
38 None None O
, None None O
39 None None O
, None None O
and None None O
41 None None O
were None None O
derived None None O
from None None O
4 None None I-IUPAC
- None None I-IUPAC
nitrobenzeneethanamine None None I-IUPAC
and None None O
from None None O
indolone None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
acetic None None I-IUPAC
acid None None I-IUPAC
. None None O


Synthesis None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
benzoxazaphosphorin None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
which None None O
is None None O
a None None O
benzo None None O
annulated None None O
analog None None O
of None None O
cyclophosphamide None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
aminotetrahydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
oxazaphosphorin None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
1 None None O
) None None O
] None None O
, None None O
was None None O
carried None None O
out None None O
in None None O
order None None O
to None None O
test None None O
for None None O
possible None None O
increased None None O
antitumor None None O
activity None None O
relative None None O
to None None O
1 None None O
due None None O
to None None O
the None None O
presence None None O
of None None O
an None None O
oxidatively None None O
reactive None None O
C None None O
- None None O
4 None None O
benzylic None None O
site None None O
in None None O
2 None None O
. None None O

A None None O
structural None None O
isomer None None O
of None None O
2 None None I-IUPAC
, None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
3,1,2 None None I-IUPAC
- None None I-IUPAC
benzoxazaphosphorin None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
and None None O
cognate None None O
systems None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
benzodiazaphosphorin None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
4 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
benzodioxaphosphorin None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
5 None None O
) None None O
were None None O
also None None O
prepared None None O
for None None O
comparative None None O
purposes None None O
. None None O

In None None O
vivo None None O
antitumor None None O
evaluation None None O
in None None O
mice None None O
against None None O
L1210 None None O
lymphoid None None O
leukemia None None O
indicated None None O
no None None O
significant None None O
activity None None O
for None None O
compound None None O
2 None None O
. None None O

Compounds None None O
3 None None O
and None None O
4 None None O
were None None O
likewise None None O
found None None O
to None None O
be None None O
inactive None None O
and None None O
only None None O
marginal None None O
activity None None O
was None None O
exhibited None None O
by None None O
5 None None O
. None None O


Replacement None None O
of None None O
the None None O
polar None None O
head None None O
of None None O
our None None O
previous None None O
series None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
acyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyanomethyl None None I-IUPAC
] None None I-IUPAC
piperazines None None I-IUPAC
with None None O
a None None O
2 None None I-IUPAC
- None None I-IUPAC
methylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
group None None I-MODIFIER
has None None O
led None None O
to None None O
the None None O
identification None None O
of None None O
a None None O
new None None O
series None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
acyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
c None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
derivatives None None I-MODIFIER
as None None O
potent None None O
, None None O
orally None None O
active None None O
platelet None None O
- None None O
activating None None O
factor None None O
( None None O
PAF None None O
) None None O
antagonists None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
the None None O
general None None O
structure None None O
- None None O
- None None O
activity None None O
relationship None None O
trends None None O
found None None O
for None None O
the None None O
acyl None None I-IUPAC
substituent None None B-MODIFIER
in None None O
our None None O
earlier None None O
series None None O
, None None O
five None None O
groups None None O
of None None O
compounds None None O
were None None O
tested None None O
, None None O
diaryl None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
alkylarylpropanoyl None None I-IUPAC
derivatives None None B-MODIFIER
, None None O
their None None O
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None O
substituted None None I-MODIFIER
analogues None None I-MODIFIER
, None None O
and None None O
urea None None O
, None None O
carbamate None None O
and None None O
amino None None O
acid None None O
derivatives None None O
. None None O

The None None O
optimal None None O
compound None None O
19 None None O
UR None None O
- None None O
12670 None None O
) None None O
, None None O
bearing None None O
the None None O
3,3 None None I-IUPAC
- None None I-IUPAC
diphenylpropanoyl None None I-IUPAC
moiety None None I-MODIFIER
, None None O
exhibited None None O
very None None O
high None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
potency None None O
IC50 None None O
= None None O
0.0076 None None O
microM None None O
for None None O
the None None O
in None None O
vitro None None O
PAF None None O
- None None O
induced None None O
platelet None None O
aggregation None None O
assay None None O
, None None O
ID50 None None O
= None None O
0.0086 None None O
mg None None O
/ None None O
kg None None O
for None None O
the None None O
in None None O
vivo None None O
PAF None None O
- None None O
induced None None O
hypotension None None O
test None None O
in None None O
normotensive None None O
rats None None O
, None None O
and None None O
ID50 None None O
= None None O
0.092 None None O
mg None None O
/ None None O
kg None None O
po None None O
and None None O
0.0008 None None O
mg None None O
/ None None O
kg None None O
i None None O
. None None O

v None None O
. None None O

for None None O
the None None O
PAF None None O
- None None O
induced None None O
mortality None None O
test None None O
in None None O
mice None None O
) None None O
. None None O

Compound None None O
19 None None O
also None None O
showed None None O
long None None O
duration None None O
of None None O
activity None None O
. None None O

It None None O
gave None None O
100% None None O
protection None None O
against None None O
PAF None None O
- None None O
induced None None O
mortality None None O
in None None O
mice None None O
7 None None O
h None None O
after None None O
i None None O
. None None O

v None None O
. None None O

administration None None O
of None None O
a None None O
single None None O
dose None None O
of None None O
1 None None O
mg None None O
/ None None O
kg None None O
and None None O
also None None O
provided None None O
100% None None O
inhibition None None O
of None None O
PAF None None O
- None None O
induced None None O
aggregation None None O
in None None O
dog None None O
whole None None O
blood None None O
6 None None O
h None None O
after None None O
i None None O
. None None O

v None None O
. None None O

administration None None O
of None None O
the None None O
same None None O
dose None None O
. None None O

The None None O
lead None None O
structure None None O
19 None None O
has None None O
been None None O
selected None None O
for None None O
in None None O
- None None O
depth None None O
pharmacological None None O
evaluation None None O
. None None O


On None None O
the None None O
basis None None O
of None None O
the None None O
SAR None None O
of None None O
a None None O
series None None O
of None None O
known None None O
gamma None None O
- None None O
aminobutyric None None O
acid None None O
( None None O
GABA None None O
) None None O
uptake None None O
inhibitors None None O
, None None O
including None None O
4 None None O
( None None O
SKF None None O
89976 None None O
) None None O
, None None O
new None None O
tricyclic None None O
analogues None None O
have None None O
been None None O
prepared None None O
. None None O

These None None O
novel None None O
compounds None None O
are None None O
derivatives None None O
of None None O
nipecotic None None O
acid None None O
, None None O
guvacine None None O
, None None O
and None None O
homo None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
proline None None I-IUPAC
, None None O
substituted None None O
at None None O
the None None O
nitrogen None None O
of None None O
these None None O
amino None None O
acids None None O
by None None O
various None None O
lipophilic None None O
moieties None None O
such None None O
as None None O
( None None I-IUPAC
10,11 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
dibenz None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
, None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
azepin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
alkoxyalkyl None None I-IUPAC
or None None O
( None None I-IUPAC
10,11 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
dibenzo None None I-IUPAC
[ None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
cyclohepten None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylidene None None I-IUPAC
) None None I-IUPAC
alkoxyalkyl None None I-IUPAC
. None None O

The None None O
in None None O
vitro None None O
values None None O
for None None O
inhibition None None O
of None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
- None None O
GABA None None O
uptake None None O
in None None O
rat None None O
synaptosomes None None O
was None None O
determined None None O
for None None O
each None None O
compound None None O
in None None O
this None None O
new None None O
series None None O
, None None O
and None None O
it None None O
was None None O
found None None O
that None None O
several None None O
of None None O
the None None O
novel None None O
compounds None None O
showed None None O
a None None O
high None None O
potency None None O
comparable None None O
with None None O
that None None O
of None None O
the None None O
reference None None O
compounds None None O
4 None None O
, None None O
5 None None O
( None None O
tiagabine None None O
) None None O
, None None O
and None None O
6 None None O
( None None O
CI None None O
- None None O
966 None None O
) None None O
. None None O

Several None None O
of None None O
the None None O
novel None None O
compounds None None O
were None None O
also None None O
evaluated None None O
for None None O
their None None O
ability None None O
in None None O
vivo None None O
to None None O
inhibit None None O
clonic None None O
seizures None None O
induced None None O
by None None O
a None None O
15 None None O
mg None None O
/ None None O
kg None None O
( None None O
ip None None O
) None None O
dose None None O
of None None O
methyl None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
carboline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
DMCM None None O
) None None O
. None None O

One None None O
compound None None O
, None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
10,11 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
dibenz None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
, None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
azepin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
ethoxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
piperidinecarboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
23 None None O
) None None O
, None None O
was None None O
selected None None O
for None None O
further None None O
biological None None O
investigations None None O
and None None O
showed None None O
a None None O
protective None None O
index None None O
comparable None None O
to None None O
or None None O
slightly None None O
better None None O
than None None O
that None None O
of None None O
the None None O
recently None None O
launched None None O
anticonvulsant None None O
product None None O
5 None None O
( None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thienyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
butenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
piperidinecarboxylic None None I-IUPAC
acid None None I-IUPAC
) None None O
. None None O


In None None O
order None None O
to None None O
study None None O
the None None O
structure None None O
- None None O
activity None None O
relationships None None O
of None None O
L None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2S None None I-PARTIUPAC
, None None I-PARTIUPAC
4S None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
L None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2S None None I-IUPAC
, None None I-IUPAC
4R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dioxolanyl None None I-IUPAC
nucleoside None None I-IUPAC
as None None O
potential None None O
anti None None O
- None None O
HIV None None O
agents None None O
, None None O
various None None O
enantiomerically None None O
pure None None O
L None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2S None None I-PARTIUPAC
, None None I-PARTIUPAC
4S None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
2S None None I-IUPAC
, None None I-IUPAC
4R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dioxolanylpyrimidine None None I-IUPAC
and None None O
- None None I-PARTIUPAC
purine None None I-PARTIUPAC
nucleosides None None I-PARTIUPAC
have None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
against None None O
HIV None None O
- None None O
1 None None O
in None None O
human None None O
peripheral None None O
blood None None O
mononuclear None None O
( None None O
PBM None None O
) None None O
cells None None O
. None None O

The None None O
enantiomerically None None O
pure None None O
key None None O
intermediate None None O
8 None None O
has None None O
been None None O
synthesized None None O
in None None O
six None None O
steps None None O
from None None O
1,6 None None I-IUPAC
- None None I-IUPAC
anhydro None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
gulose None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
and None None O
compound None None O
8 None None O
was None None O
condensed None None O
with None None O
5 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
pyrimidines None None I-IUPAC
, None None O
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
, None None O
and None None O
2,6 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
purine None None I-IUPAC
to None None O
obtain None None O
various None None O
dioxolanylpyrimidine None None I-IUPAC
and None None O
- None None I-PARTIUPAC
purine None None I-PARTIUPAC
nucleosides None None I-PARTIUPAC
, None None O
respectively None None O
. None None O

Among None None O
the None None O
compound None None O
synthesized None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
derivative None None I-MODIFIER
29 None None O
was None None O
found None None O
to None None O
exhibit None None O
the None None O
most None None O
potent None None O
anti None None O
- None None O
HIV None None O
activity None None O
( None None O
EC50 None None O
= None None O
0.0012 None None O
microM None None O
) None None O
although None None O
it None None O
was None None O
toxic None None O
( None None O
IC50 None None O
= None None O
10.0 None None O
microM None None O
) None None O
. None None O

The None None O
order None None O
of None None O
anti None None O
- None None O
HIV None None O
potency None None O
of None None O
pyrimidine None None O
analogues None None O
was None None O
as None None O
follows None None O
: None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
cytosine None None O
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
iodocytosine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
cytosine None None O
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
bromocytosine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
thymine None None O
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
methylcytosine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
iodocytosine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
5 None None I-IUPAC
- None None I-IUPAC
chlorocytosine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
. None None O

The None None O
anti None None O
- None None O
HIV None None O
potency None None O
of None None O
purine None None O
analogues None None O
was None None O
found None None O
to None None O
be None None O
in None None O
the None None O
following None None O
decreasing None None O
order None None O
: None None O
2,6 None None I-IUPAC
- None None I-IUPAC
diaminopurine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
2 None None I-IUPAC
- None None I-IUPAC
chloroadenine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
2 None None I-IUPAC
- None None I-IUPAC
fluoroadenine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
adenine None None O
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
guanine None None O
( None None O
beta None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
2 None None I-IUPAC
- None None I-IUPAC
fluoroadenine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
adenine None None O
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
2,6 None None I-IUPAC
- None None I-IUPAC
diaminopurine None None I-IUPAC
( None None O
alpha None None O
- None None O
isomer None None O
) None None O
& None None O
gt None None O
; None None O
N6 None None I-IUPAC
- None None I-IUPAC
methyladenine None None I-IUPAC
( None None O
beta None None O
- None None O
isomer None None O
) None None O
. None None O

It None None O
is None None O
interesting None None O
to None None O
note None None O
that None None O
the None None O
alpha None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorocytosine None None I-IUPAC
analogue None None I-MODIFIER
exhibited None None O
an None None O
excellent None None O
anti None None O
- None None O
HIV None None O
activity None None O
( None None O
EC50 None None O
= None None O
0.063 None None O
microM None None O
) None None O
without None None O
cytotoxicity None None O
up None None O
to None None O
100 None None O
microM None None O
in None None O
PBM None None O
cell None None O
. None None O


As None None O
shown None None O
by None None O
structure None None O
- None None O
activity None None O
relationship None None O
studies None None O
in None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
substituted None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinolines None None I-IUPAC
, None None O
the None None O
most None None O
important None None O
structural None None O
requirement None None O
for None None O
a None None O
marked None None O
antidepressant None None O
action None None O
is None None O
the None None O
presence None None O
of None None O
an None None O
ureido None None I-IUPAC
, None None O
( None None I-IUPAC
alkoxycarbonyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
, None None O
or None None O
[ None None I-IUPAC
( None None I-IUPAC
alkylamino None None I-IUPAC
) None None I-IUPAC
acyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
group None None I-MODIFIER
attached None None O
to None None O
the None None O
isoquinoline None None O
skeleton None None O
in None None O
position None None O
8 None None O
. None None O

In None None O
one None None O
of None None O
the None None O
biological None None O
tests None None O
a None None O
significant None None O
difference None None O
was None None O
found None None O
between None None O
8 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
( None None O
nomifensine None None O
) None None O
and None None O
the None None O
new None None O
compounds None None O
synthesized None None O
. None None O

Nearly None None O
all None None O
compounds None None O
substituted None None O
in None None O
the None None O
amino None None O
group None None O
either None None O
decrease None None O
the None None O
spontaneous None None O
motility None None O
in None None O
mice None None O
or None None O
exert None None O
no None None O
effect None None O
on None None O
it None None O
. None None O

Two None None O
syntheses None None O
have None None O
been None None O
elaborated None None O
for None None O
the None None O
preparation None None O
of None None O
the None None O
compounds None None O
represented None None O
by None None O
the None None O
general None None O
formulas None None O
II None None O
- None None O
V None None O
where None None O
R1 None None O
= None None O
hydrogen None None O
, None None O
halogen None None O
, None None O
or None None O
methyl None None I-IUPAC
; None None O
Y None None O
= None None O
CONHR None None O
, None None O
OCOR None None O
, None None O
or None None O
CO None None O
( None None O
CH2 None None O
) None None O
nNHR None None O
, None None O
in None None O
which None None O
R None None O
= None None O
alkyl None None O
or None None O
aralkyl None None O
or None None O
NHR None None O
= None None O
cyclic None None O
amine None None O
and None None O
n None None O
= None None O
1-2 None None O
. None None O

The None None O
syntheses None None O
start None None O
either None None O
from None None O
the None None O
corresponding None None O
8 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinolines None None I-IUPAC
or None None O
from None None O
the None None O
corresponding None None O
noncyclized None None O
amino None None O
alcohols None None O
. None None O

Of None None O
the None None O
compounds None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
carbonyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
was None None O
found None None O
to None None O
possess None None O
the None None O
highest None None O
activity None None O
. None None O


As None None O
part None None O
of None None O
an None None O
effort None None O
to None None O
develop None None O
a None None O
new None None O
class None None O
of None None O
subtype None None O
selective None None O
nicotine None None O
agonists None None O
, None None O
we None None O
have None None O
synthesized None None O
and None None O
tested None None O
a None None O
group None None O
of None None O
12 None None O
hydroxylated None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
piperidyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyrrolidyl None None I-IUPAC
) None None I-IUPAC
chromans None None I-IUPAC
. None None O

In None None O
rat None None O
brain None None O
membranes None None O
, None None O
all None None O
12 None None O
compounds None None O
displayed None None O
poor None None O
affinity None None O
for None None O
[ None None O
( None None O
125 None None O
) None None O
I None None O
] None None O
- None None O
alpha None None O
- None None O
bunagarotoxin None None O
binding None None O
sites None None O
. None None O

In None None O
contrast None None O
, None None O
three None None O
compounds None None O
, None None O
17c None None O
, None None O
24 None None O
, None None O
and None None O
26 None None O
, None None O
displayed None None O
moderate None None O
to None None O
high None None O
affinity None None O
for None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
cytisine None None O
binding None None O
sites None None O
, None None O
while None None O
three None None O
( None None O
17b None None O
, None None O
18b None None O
, None None O
c None None O
) None None O
and None None O
six None None O
( None None O
17a None None O
, None None O
d None None O
, None None O
e None None O
and None None O
18a None None O
, None None O
d None None O
, None None O
e None None O
) None None O
compounds None None O
showed None None O
weak None None O
and None None O
poor None None O
affinity None None O
, None None O
respectively None None O
, None None O
for None None O
these None None O
same None None O
sites None None O
. None None O

In None None O
subsequent None None O
studies None None O
, None None O
compounds None None O
17a None None O
and None None O
17c None None O
were None None O
found None None O
to None None O
stimulate None None O
the None None O
efflux None None O
of None None O
( None None O
86 None None O
) None None O
Rb None None O
( None None O
+ None None O
) None None O
from None None O
rat None None O
cortical None None O
synaptosomes None None O
, None None O
an None None O
indication None None O
of None None O
agonist None None O
activity None None O
. None None O

Further None None O
, None None O
both None None O
17c None None O
and None None O
26 None None O
displayed None None O
high None None O
intrinsic None None O
activity None None O
in None None O
stimulating None None O
the None None O
release None None O
of None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
dopamine None None O
from None None O
striatal None None O
synaptosomes None None O
; None None O
however None None O
, None None O
only None None O
17c None None O
was None None O
effective None None O
at None None O
stimulating None None O
the None None O
release None None O
of None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
acetylcholine None None O
from None None O
cortical None None O
synaptosomes None None O
, None None O
suggesting None None O
differential None None O
selectivity None None O
. None None O

In None None O
cloned None None O
human None None O
nicotinic None None O
acetylcholine None None O
receptors None None O
( None None O
nAChR None None O
) None None O
expressed None None O
in None None O
Xenopus None None O
oocytes None None O
, None None O
both None None O
17c None None O
and None None O
26 None None O
activated None None O
alpha7 None None O
and None None O
alpha3beta2 None None O
receptor None None O
subtypes None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
, None None O
but None None O
26 None None O
was None None O
clearly None None O
the None None O
more None None O
potent None None O
agonist None None O
. None None O

Last None None O
, None None O
neither None None O
compound None None O
displayed None None O
dose None None O
- None None O
dependent None None O
activation None None O
of None None O
alpha4beta2 None None O
nAChRs None None O
. None None O

We None None O
conclude None None O
that None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
azacyclic None None I-IUPAC
) None None I-IUPAC
chromans None None I-IUPAC
appear None None O
to None None O
be None None O
a None None O
promising None None O
new None None O
class None None O
of None None O
nicotine None None O
agonists None None O
. None None O


In None None O
this None None O
paper None None O
, None None O
it None None O
is None None O
hypothesized None None O
that None None O
the None None O
distinction None None O
between None None O
certain None None O
active None None O
and None None O
inactive None None O
cannabinoids None None O
is None None O
that None None O
the None None O
inactive None None O
analogs None None O
possess None None O
extra None None O
volume None None O
associated None None O
with None None O
their None None O
carbocyclic None None O
rings None None O
that None None O
may None None O
be None None O
responsible None None O
for None None O
an None None O
unfavorable None None O
interaction None None O
at None None O
the None None O
cannabinoid None None O
receptor None None O
. None None O

Using None None O
the None None O
active None None O
analog None None O
approach None None O
, None None O
a None None O
model None None O
is None None O
developed None None O
of None None O
a None None O
region None None O
of None None O
steric None None O
interference None None O
at None None O
this None None O
receptor None None O
using None None O
the None None O
active None None O
cannabinoids None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
delta None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
tetrahydrocannabinol None None I-IUPAC
, None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
delta None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
tetrahydrocannabinol None None I-IUPAC
, None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
hexahydrocannabinol None None I-IUPAC
, None None O
and None None O
a None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
delta None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
tetrahydrocannabinol None None I-IUPAC
dimethylheptyl None None I-IUPAC
derivative None None I-MODIFIER
and None None O
the None None O
inactive None None O
cannabinoids None None O
( None None I-IUPAC
9S None None I-IUPAC
, None None I-IUPAC
6aR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
delta None None I-IUPAC
10,10 None None I-IUPAC
a None None I-IUPAC
- None None I-IUPAC
tetrahydrocannabinol None None I-IUPAC
and None None O
a None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
delta None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
tetrahydrocannabinol None None I-IUPAC
dimethylheptyl None None I-IUPAC
derivative None None I-MODIFIER
. None None O

Each None None O
of None None O
these None None O
molecules None None O
satisfy None None O
the None None O
cannabinoid None None O
pharmacophoric None None O
requirements None None O
, None None O
i.e. None None O
, None None O
a None None O
phenolic None None O
oxygen None None O
at None None O
C1 None None O
and None None O
a None None O
side None None O
chain None None O
of None None O
acceptable None None O
length None None O
at None None O
C3 None None O
. None None O

Accessible None None O
conformers None None O
of None None O
each None None O
molecule None None O
were None None O
identified None None O
by None None O
using None None O
the None None O
method None None O
of None None O
molecular None None O
mechanics None None O
as None None O
encoded None None O
in None None O
the None None O
MMP2 None None O
( None None O
85 None None O
) None None O
program None None O
. None None O

The None None O
MAP None None O
facility None None O
within None None O
the None None O
Chem None None O
- None None O
X None None O
molecular None None O
modeling None None O
program None None O
was None None O
then None None O
used None None O
to None None O
calculate None None O
the None None O
region None None O
of None None O
steric None None O
interference None None O
( None None O
termed None None O
the None None O
receptor None None O
essential None None O
volume None None O
, None None O
REV None None O
) None None O
from None None O
these None None O
accessible None None O
conformers None None O
. None None O

The None None O
calculations None None O
revealed None None O
an None None O
REV None None O
region None None O
located None None O
near None None O
the None None O
top None None O
of None None O
the None None O
carbocyclic None None O
ring None None O
in None None O
the None None O
bottom None None O
face None None O
of None None O
the None None O
molecule None None O
. None None O

In None None O
order None None O
to None None O
explore None None O
the None None O
use None None O
of None None O
this None None O
REV None None O
to None None O
account None None O
for None None O
the None None O
activities None None O
of None None O
other None None O
cannabinoids None None O
, None None O
the None None O
minimally None None O
active None None O
classical None None O
cannabinoid None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
hexahydrocannabinol None None I-IUPAC
, None None O
an None None O
active None None O
benzofuran None None O
cannabinoid None None O
, None None O
and None None O
the None None O
active None None O
nonclassical None None O
cannabinoid None None O
CP None None O
- None None O
47,497 None None O
were None None O
then None None O
studied None None O
. None None O

In None None O
each None None O
case None None O
, None None O
the None None O
activity None None O
or None None O
minimal None None O
activity None None O
of None None O
each None None O
compound None None O
can None None O
be None None O
explained None None O
on None None O
the None None O
basis None None O
of None None O
the None None O
ability None None O
of None None O
one None None O
or None None O
more None None O
accessible None None O
conformer None None O
of None None O
each None None O
molecule None None O
to None None O
clear None None O
the None None O
REV None None O
calculated None None O
here None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
provide None None O
an None None O
explanation None None O
at None None O
the None None O
molecular None None O
level None None O
for None None O
observed None None O
activity None None O
differences None None O
between None None O
cannabinoids None None O
that None None O
exhibit None None O
shape None None O
differences None None O
associated None None O
with None None O
their None None O
carbocyclic None None O
rings None None O
. None None O


A None None O
series None None O
of None None O
functionalized None None O
congeners None None O
of None None O
1,3 None None I-IUPAC
- None None I-IUPAC
dialkylxanthines None None I-IUPAC
has None None O
been None None O
prepared None None O
as None None O
adenosine None None O
receptor None None O
antagonists None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
the None None O
high None None O
potency None None O
of None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dialkylxanthines None None I-IUPAC
, None None O
the None None O
parent None None O
compounds None None O
were None None O
8 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
carboxymethyl None None I-IUPAC
) None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
theophylline None None O
and None None O
1,3 None None I-IUPAC
- None None I-IUPAC
dipropylxanthine None None I-IUPAC
. None None O

A None None O
series None None O
of None None O
analogues None None O
including None None O
esters None None O
of None None O
ethanol None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxysuccinimide None None I-IUPAC
, None None O
amides None None O
, None None O
a None None O
hydrazide None None O
, None None O
an None None O
acylurea None None O
, None None O
and None None O
anilides None None O
were None None O
prepared None None O
. None None O

The None None O
potency None None O
in None None O
blocking None None O
A1 None None O
- None None O
adenosine None None O
receptors None None O
( None None O
inhibition None None O
of None None O
binding None None O
of None None O
N6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
cyclohexyladenosine None None I-IUPAC
to None None O
brain None None O
membranes None None O
) None None O
and None None O
A2 None None O
- None None O
adenosine None None O
receptors None None O
( None None O
inhibition None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
chloroadenosine None None I-IUPAC
- None None O
elicited None None O
accumulations None None O
of None None O
cyclic None None O
AMP None None O
in None None O
brain None None O
slices None None O
) None None O
was None None O
markedly None None O
affected None None O
by None None O
structural None None O
changes None None O
distal None None O
to None None O
the None None O
primary None None O
pharmacophore None None O
( None None O
8 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dialkylxanthine None None I-IUPAC
) None None O
. None None O

Potencies None None O
in None None O
the None None O
dipropyl None None I-IUPAC
series None None B-MODIFIER
at None None O
the None None O
A1 None None O
receptor None None O
ranged None None O
from None None O
Ki None None O
values None None O
of None None O
1.2 None None O
nM None None O
for None None O
a None None O
congener None None O
with None None O
a None None O
terminal None None O
amidoethyleneamine None None I-IUPAC
moiety None None B-MODIFIER
to None None O
a None None O
Ki None None O
value None None O
of None None O
58 None None O
nM None None O
for None None O
the None None O
parent None None O
carboxylic None None O
acid None None O
to None None O
a None None O
Ki None None O
of None None O
96 None None O
nM None None O
for None None O
the None None O
bulky None None O
ureido None None O
congener None None O
. None None O

Certain None None O
congeners None None O
were None None O
up None None O
to None None O
145 None None O
- None None O
fold None None O
more None None O
active None None O
at None None O
A1 None None O
receptors None None O
than None None O
at None None O
A2 None None O
receptors None None O
. None None O

Various None None O
derivatives None None O
of None None O
the None None O
congeners None None O
should None None O
be None None O
useful None None O
as None None O
receptor None None O
probes None None O
and None None O
for None None O
radioiodination None None O
, None None O
avidin None None O
binding None None O
, None None O
and None None O
preparation None None O
of None None O
affinity None None O
columns None None O
. None None O


In None None O
general None None O
, None None O
3alpha None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diphenylmethoxy None None I-IUPAC
) None None I-IUPAC
tropane None None I-IUPAC
( None None O
benztropine None None O
) None None O
- None None O
based None None O
dopamine None None O
uptake None None O
inhibitors None None O
do None None O
not None None O
demonstrate None None O
cocaine None None O
- None None O
like None None O
pharmacological None None O
activity None None O
in None None O
models None None O
of None None O
psychostimulant None None O
abuse None None O
and None None O
have None None O
been None None O
proposed None None O
as None None O
potential None None O
medications None None O
for None None O
the None None O
treatment None None O
of None None O
cocaine None None O
addiction None None O
. None None O

However None None O
, None None O
several None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboalkoxy None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
- None None I-IUPAC
3alpha None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
methoxy None None I-IUPAC
] None None I-IUPAC
tropane None None I-IUPAC
analogues None None I-MODIFIER
were None None O
discovered None None O
to None None O
stimulate None None O
locomotor None None O
activity None None O
and None None O
substitute None None O
in None None O
subjects None None O
trained None None O
to None None O
discriminate None None O
cocaine None None O
, None None O
suggesting None None O
a None None O
role None None O
of None None O
the None None O
2 None None O
- None None O
position None None O
substituent None None O
in None None O
mediating None None O
these None None O
cocaine None None O
- None None O
like None None O
actions None None O
. None None O

Herein None None O
, None None O
we None None O
describe None None O
the None None O
synthesis None None O
of None None O
a None None O
series None None O
of None None O
novel None None O
N None None I-MODIFIER
- None None I-MODIFIER
and None None O
2 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
3alpha None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
bis None None I-PARTIUPAC
( None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
fluoro None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
4 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
methoxy None None I-IUPAC
] None None I-IUPAC
tropane None None I-IUPAC
analogues None None I-MODIFIER
. None None O

Most None None O
of None None O
these None None O
analogues None None O
demonstrated None None O
high None None O
affinity None None O
binding None None O
to None None O
the None None O
dopamine None None O
transporter None None O
( None None O
DAT None None O
; None None O
K None None O
( None None O
i None None O
) None None O
= None None O
1.8-40 None None O
nM None None O
) None None O
, None None O
and None None O
selectivity None None O
over None None O
the None None O
other None None O
monoamine None None O
transporters None None O
and None None O
muscarinic None None O
M None None O
( None None O
1 None None O
) None None O
receptors None None O
. None None O

When None None O
the None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboalkoxy None None I-IUPAC
substituent None None I-MODIFIER
was None None O
replaced None None O
with None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ethenyl None None I-IUPAC
, None None O
the None None O
resulting None None O
analogue None None O
11 None None O
demonstrated None None O
the None None O
highest None None O
DAT None None O
binding None None O
affinity None None O
in None None O
the None None O
series None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
1.81 None None O
nM None None O
) None None O
with None None O
DAT None None O
selectivity None None O
over None None O
serotonin None None O
transporters None None O
( None None O
SERT None None O
; None None O
989 None None O
- None None O
fold None None O
) None None O
, None None O
norepinephrine None None O
transporters None None O
( None None O
NET None None O
; None None O
261 None None O
- None None O
fold None None O
) None None O
and None None O
muscarinic None None O
receptors None None O
( None None O
90 None None O
- None None O
fold None None O
) None None O
. None None O

When None None O
the None None O
4' None None O
- None None O
F None None O
groups None None O
of None None O
compounds None None O
5 None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
2.94 None None O
nM None None O
) None None O
and None None O
8 None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
6.87 None None O
nM None None O
) None None O
were None None O
replaced None None O
with None None O
4' None None O
- None None O
Cl None None O
in None None O
the None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboalkoxy None None I-IUPAC
series None None I-MODIFIER
, None None O
DAT None None O
binding None None O
affinities None None O
were None None O
slightly None None O
reduced None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
12.6 None None O
and None None O
14.6 None None O
nM None None O
for None None O
6 None None O
and None None O
7 None None O
, None None O
respectively None None O
) None None O
, None None O
yet None None O
inhibition None None O
of None None O
dopamine None None O
uptake None None O
potency None None O
remained None None O
comparably None None O
high None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
range None None O
= None None O
1.5-2.5 None None O
nM None None O
) None None O
. None None O

Interestingly None None O
, None None O
the None None O
4' None None O
- None None O
Cl None None O
analogue None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
6 None None O
substituted None None O
less None None O
in None None O
rats None None O
trained None None O
to None None O
discriminate None None O
cocaine None None O
than None None O
the None None O
4' None None O
- None None O
F None None O
analogue None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
5 None None O
. None None O

These None None O
studies None None O
demonstrate None None O
that None None O
manipulation None None O
of None None O
the None None O
2 None None I-MODIFIER
- None None I-MODIFIER
, None None O
N None None I-MODIFIER
- None None I-MODIFIER
, None None O
and None None O
3 None None I-MODIFIER
- None None I-MODIFIER
position None None I-MODIFIER
substituents None None I-MODIFIER
in None None O
the None None O
3alpha None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diphenylmethoxy None None I-IUPAC
) None None I-IUPAC
tropane None None I-IUPAC
class None None I-MODIFIER
of None None O
dopamine None None O
uptake None None O
inhibitors None None O
can None None O
result None None O
in None None O
ligands None None O
with None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
the None None O
DAT None None O
, None None O
and None None O
distinctive None None O
in None None O
vivo None None O
pharmacological None None O
profiles None None O
that None None O
cannot None None O
be None None O
predicted None None O
by None None O
their None None O
effects None None O
in None None O
vitro None None O
. None None O


The None None O
nonapeptide None None O
[ None None O
des None None O
- None None O
Asp1 None None O
] None None O
angiotensin None None O
I None None O
( None None O
IV None None O
) None None O
, None None O
synthesized None None O
by None None O
Merrifield None None O
's None None O
solid None None O
- None None O
phase None None O
procedure None None O
, None None O
was None None O
tested None None O
as None None O
a None None O
possible None None O
substrate None None O
for None None O
the None None O
converting None None O
enzymes None None O
from None None O
porcine None None O
lung None None O
and None None O
plasma None None O
. None None O

IV None None O
, None None O
[ None None O
des None None O
- None None O
Asp1 None None O
] None None O
angiotensin None None O
II None None O
( None None O
III None None O
) None None O
, None None O
[ None None O
des None None O
- None None O
( None None O
Asp1 None None O
, None None O
Arg2 None None O
) None None O
] None None O
angiotensin None None O
II None None O
( None None O
V None None O
) None None O
, None None O
[ None None O
des None None O
- None None O
( None None O
Asp1 None None O
, None None O
Arg2 None None O
, None None O
Val3 None None O
) None None O
] None None O
angiotensin None None O
II None None O
( None None O
VI None None O
) None None O
, None None O
[ None None O
Sar1 None None O
, None None O
Ile8 None None O
] None None O
angiotensin None None O
II None None O
( None None O
VII None None O
) None None O
, None None O
and None None O
[ None None O
des None None O
- None None O
Asp1 None None O
, None None O
Ile8 None None O
] None None O
angiotensin None None O
II None None O
( None None O
VIII None None O
) None None O
possessed None None O
0.5 None None O
, None None O
20 None None O
, None None O
2 None None O
, None None O
0 None None O
less None None O
than None None O
0.1 None None O
, None None O
and None None O
less None None O
than None None O
0.01% None None O
of None None O
the None None O
inotropic None None O
activity None None O
( None None O
rabbit None None O
atria None None O
) None None O
, None None O
1 None None O
, None None O
15 None None O
, None None O
5 None None O
, None None O
0 None None O
, None None O
3 None None O
, None None O
and None None O
0% None None O
secretory None None O
activity None None O
of None None O
the None None O
cat None None O
adrenal None None O
medulla None None O
, None None O
and None None O
0.0 None None O
, None None O
150 None None O
, None None O
0.5 None None O
, None None O
3 None None O
, None None O
and None None O
10% None None O
of None None O
the None None O
adrenal None None O
steroidogenic None None O
activity None None O
of None None O
angiotensin None None O
II None None O
, None None O
respectively None None O
. None None O

When None None O
tested None None O
for None None O
their None None O
antagonistic None None O
activity None None O
in None None O
the None None O
above None None O
tissues None None O
, None None O
only None None O
VII None None O
and None None O
VIII None None O
were None None O
found None None O
to None None O
inhibit None None O
responses None None O
to None None O
angiotensin None None O
II None None O
. None None O

The None None O
pA2 None None O
values None None O
for None None O
VII None None O
and None None O
VIII None None O
were None None O
8.31 None None O
and None None O
10.0 None None O
in None None O
the None None O
adrenal None None O
cortex None None O
and None None O
9.31 None None O
and None None O
9.16 None None O
in None None O
the None None O
adrenal None None O
medulla None None O
, None None O
respectively None None O
. None None O

All None None O
these None None O
peptides None None O
were None None O
also None None O
tested None None O
as None None O
product None None O
inhibitors None None O
for None None O
the None None O
plasma None None O
and None None O
lung None None O
converting None None O
enzymes None None O
. None None O

With None None O
the None None O
plasma None None O
enzyme None None O
, None None O
the None None O
ID50 None None O
values None None O
were None None O
II None None O
, None None O
1.6 None None O
X None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
; None None O
III None None O
, None None O
5 None None O
X None None O
10 None None O
( None None O
- None None O
5 None None O
) None None O
M None None O
; None None O
V None None O
, None None O
1.2 None None O
X None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
; None None O
VI None None O
5 None None O
X None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
; None None O
VII None None O
5 None None O
X None None O
10 None None O
( None None O
- None None O
5 None None O
) None None O
M None None O
; None None O
VIII None None O
, None None O
5 None None O
X None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
. None None O

Thus None None O
, None None O
IV None None O
is None None O
a None None O
good None None O
substrate None None O
for None None O
converting None None O
enzymes None None O
from None None O
lung None None O
and None None O
plasma None None O
while None None O
all None None O
other None None O
compounds None None O
were None None O
inhibitors None None O
of None None O
these None None O
enzymes None None O
. None None O

The None None O
most None None O
potent None None O
inhibitors None None O
of None None O
converting None None O
enzyme None None O
were None None O
III None None O
followed None None O
by None None O
VII None None O
and None None O
VIII None None O
. None None O

With None None O
the None None O
exception None None O
of None None O
II None None O
and None None O
III None None O
, None None O
all None None O
the None None O
other None None O
analogs None None O
had None None O
very None None O
low None None O
intrinsic None None O
activities None None O
, None None O
per None None O
se None None O
. None None O

These None None O
results None None O
suggest None None O
( None None O
a None None O
) None None O
an None None O
alternate None None O
pathway None None O
for None None O
the None None O
formation None None O
of None None O
heptapeptide None None O
III None None O
, None None O
viz None None O
. None None O

, None None O
by None None O
the None None O
action None None O
of None None O
converting None None O
enzyme None None O
on None None O
the None None O
nonapeptide None None O
IV None None O
, None None O
and None None O
( None None O
b None None O
) None None O
that None None O
III None None O
may None None O
also None None O
be None None O
acting None None O
as None None O
inhibitor None None O
of None None O
the None None O
converting None None O
enzyme None None O
by None None O
the None None O
feedback None None O
mechanism None None O
. None None O


The None None O
sugar None None O
moiety None None O
of None None O
nucleosides None None O
in None None O
solution None None O
is None None O
known None None O
to None None O
exist None None O
in None None O
a None None O
rapid None None O
dynamic None None O
equilibrium None None O
between None None O
extreme None None O
Northern None None O
and None None O
Southern None None O
conformations None None O
as None None O
defined None None O
in None None O
the None None O
pseudorotational None None O
cycle None None O
. None None O

In None None O
the None None O
present None None O
work None None O
, None None O
we None None O
describe None None O
how None None O
the None None O
bicyclo None None I-IUPAC
[ None None I-IUPAC
3.1.0 None None I-IUPAC
] None None I-IUPAC
hexane None None I-IUPAC
template None None O
fixes None None O
the None None O
ring None None O
pucker None None O
of None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
methanocarba None None I-IUPAC
- None None I-IUPAC
nucleosides None None I-IUPAC
1-5 None None O
and None None O
12 None None O
to None None O
values None None O
corresponding None None O
to None None O
either None None O
one None None O
of None None O
these None None O
two None None O
extreme None None O
conformations None None O
that None None O
are None None O
typical None None O
of None None O
nucleosides None None O
. None None O

The None None O
syntheses None None O
of None None O
the None None O
fixed None None O
Northern None None O
conformers None None O
1-5 None None O
were None None O
performed None None O
by None None O
Mitsunobu None None O
coupling None None O
of None None O
the None None O
heterocyclic None None O
bases None None O
with None None O
the None None O
chiral None None O
carbocyclic None None O
alcohol None None O
6 None None O
[ None None O
( None None I-IUPAC
1R None None I-IUPAC
, None None I-IUPAC
2S None None I-IUPAC
, None None I-IUPAC
4R None None I-IUPAC
, None None I-IUPAC
5S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
benzyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydrox None None I-IUPAC
ybicyclo None None I-IUPAC
[ None None I-IUPAC
3.1.0 None None I-IUPAC
] None None I-IUPAC
hexane None None I-IUPAC
] None None O
, None None O
while None None O
the None None O
synthesis None None O
of None None O
the None None O
Southern None None O
conformer None None O
, None None O
( None None O
S None None O
) None None O
- None None O
methanocarba None None O
- None None O
T None None O
( None None O
12 None None O
) None None O
, None None O
was None None O
reported None None O
earlier None None O
. None None O

Carbocyclic None None O
thymidine None None O
( None None O
carba None None O
- None None O
T None None O
, None None O
13 None None O
) None None O
was None None O
used None None O
as None None O
a None None O
reference None None O
, None None O
flexible None None O
carbocyclic None None O
nucleoside None None O
. None None O

Antiviral None None O
evaluation None None O
of None None O
these None None O
compounds None None O
revealed None None O
a None None O
very None None O
potent None None O
antiherpetic None None O
activity None None O
associated None None O
with None None O
the None None O
Northern None None O
thymidine None None O
analogue None None O
2 None None O
, None None O
which None None O
was None None O
more None None O
powerful None None O
than None None O
the None None O
reference None None O
standard None None O
acyclovir None None O
against None None O
both None None O
HSV None None O
- None None O
1 None None O
and None None O
HSV None None O
- None None O
2 None None O
. None None O

( None None O
N None None O
) None None O
- None None O
Methanocarba None None O
- None None O
T None None O
( None None O
2 None None O
) None None O
was None None O
further None None O
evaluated None None O
as None None O
a None None O
component None None O
of None None O
a None None O
short None None O
oligodeoxynucleotide None None O
( None None O
ODN None None O
) None None O
phosphorothioate None None O
( None None O
5' None None O
- None None O
CTTCATTTTTTCTTC None None O
- None None O
3' None None O
) None None O
where None None O
all None None O
thymidines None None O
were None None O
replaced None None O
by None None O
2 None None O
. None None O

The None None O
expected None None O
thermodynamic None None O
stability None None O
resulting None None O
from None None O
the None None O
preorganization None None O
of None None O
the None None O
pseudosugar None None O
rings None None O
into None None O
a None None O
Northern None None O
conformation None None O
, None None O
typical None None O
of None None O
A None None O
- None None O
DNA None None O
, None None O
was None None O
evident None None O
by None None O
the None None O
increase None None O
in None None O
Tm None None O
of None None O
the None None O
corresponding None None O
DNA None None O
/ None None O
RNA None None O
heteroduplex None None O
. None None O

However None None O
, None None O
the None None O
rigid None None O
A None None O
- None None O
tract None None O
ODN None None O
caused None None O
loss None None O
of None None O
RNase None None O
H None None O
recruitment None None O
. None None O

A None None O
detailed None None O
conformational None None O
analysis None None O
of None None O
( None None O
N None None O
) None None O
- None None O
methanocarba None None O
- None None O
T None None O
( None None O
2 None None O
) None None O
and None None O
( None None O
S None None O
) None None O
- None None O
methanocarba None None O
- None None O
T None None O
( None None O
12 None None O
) None None O
, None None O
as None None O
representative None None O
examples None None O
of None None O
conformationally None None O
rigid None None O
pseudorotational None None O
antipodes None None O
, None None O
revealed None None O
that None None O
in None None O
addition None None O
to None None O
their None None O
different None None O
forms None None O
of None None O
ring None None O
pucker None None O
, None None O
( None None O
S None None O
) None None O
- None None O
methanocarba None None O
- None None O
T None None O
appears None None O
to None None O
be None None O
a None None O
rather None None O
stiff None None O
molecule None None O
with None None O
fewer None None O
low None None O
- None None O
energy None None O
conformational None None O
states None None O
available None None O
compared None None O
to None None O
( None None O
N None None O
) None None O
- None None O
methanocarba None None O
- None None O
T None None O
. None None O

The None None O
syn None None O
/ None None O
anti None None O
- None None O
energy None None O
barrier None None O
for None None O
these None None O
nucleoside None None O
analogues None None O
is None None O
5-6 None None O
kcal None None O
/ None None O
mol None None O
higher None None O
than None None O
for None None O
common None None O
nucleosides None None O
. None None O


31P None None O
NMR None None O
spectroscopy None None O
was None None O
used None None O
to None None O
study None None O
the None None O
products None None O
of None None O
the None None O
decomposition None None O
of None None O
the None None O
antitumor None None O
drug None None O
ifosfamide None None O
( None None O
IF None None O
, None None O
1d None None O
) None None O
and None None O
its None None O
N None None I-IUPAC
- None None I-IUPAC
dechloroethylated None None I-IUPAC
metabolites None None I-MODIFIER
, None None O
namely None None O
, None None O
2,3 None None I-IUPAC
- None None I-IUPAC
didechloroethylIF None None I-IUPAC
( None None O
1a None None O
) None None O
and None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
1b None None O
) None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
dechloroethylIF None None I-IUPAC
( None None O
1c None None O
) None None O
, None None O
in None None O
buffered None None O
solutions None None O
at None None O
acidic None None O
pH None None O
. None None O

The None None O
first None None O
stage None None O
of None None O
acid None None O
hydrolysis None None O
of None None O
these None None O
four None None O
oxazaphosphorines None None O
is None None O
a None None O
P None None O
- None None O
N None None O
bond None None O
cleavage None None O
of None None O
the None None O
six None None O
- None None O
membered None None O
ring None None O
leading None None O
to None None O
the None None O
phosphoramidic None None O
acid None None O
monoesters None None O
( None None O
2a None None O
- None None O
d None None O
) None None O
of None None O
type None None O
R' None None O
HN None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
3 None None O
) None None O
OP None None O
( None None O
O None None O
) None None O
( None None O
OH None None O
) None None O
NHR None None O
, None None O
with None None O
R None None O
and None None O
/ None None O
or None None O
R' None None O
= None None O
H None None O
or None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
2 None None O
) None None O
Cl None None O
. None None O

The None None O
electron None None O
- None None O
withdrawing None None O
chloroethyl None None I-IUPAC
group None None B-MODIFIER
at None None O
the None None O
endocyclic None None O
and None None O
/ None None O
or None None O
exocyclic None None O
nitrogens None None O
counteracts None None O
the None None O
endocyclic None None O
P None None O
- None None O
N None None O
bond None None O
hydrolysis None None O
. None None O

This None None O
effect None None O
is None None O
even None None O
more None None O
marked None None O
when None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
group None None I-MODIFIER
is None None O
in None None O
the None None O
exocyclic None None O
position None None O
since None None O
the None None O
order None None O
of None None O
stability None None O
is None None O
1d None None O
& None None O
gt None None O
; None None O
1c None None O
& None None O
gt None None O
; None None O
1b None None O
& None None O
gt None None O
; None None O
1a None None O
. None None O

In None None O
the None None O
second None None O
stage None None O
of None None O
hydrolysis None None O
, None None O
the None None O
remaining None None O
P None None O
- None None O
N None None O
bond None None O
is None None O
cleaved None None O
together None None O
with None None O
an None None O
intramolecular None None O
attack None None O
at None None O
the None None O
phosphorus None None O
atom None None O
by None None O
the None None O
non None None O
- None None O
P None None O
- None None O
linked None None O
nitrogen None None O
of None None O
the None None O
compounds None None O
2a None None O
- None None O
d None None O
. None None O

This None None O
leads None None O
to None None O
the None None O
formation None None O
of None None O
a None None O
2 None None I-IUPAC
- None None I-IUPAC
hydroxyoxazaphosphorine None None I-IUPAC
ring None None O
with None None O
R None None O
= None None O
H None None O
( None None O
3a None None O
coming None None O
from None None O
compounds None None O
2a None None O
, None None O
c None None O
) None None O
or None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
2 None None O
) None None O
Cl None None O
( None None O
3b None None O
coming None None O
from None None O
compounds None None O
2b None None O
, None None O
d None None O
) None None O
and None None O
to None None O
the None None O
release None None O
of None None O
ammonia None None O
or None None O
chloroethylamine None None O
. None None O

The None None O
third None None O
step None None O
is None None O
the None None O
P None None O
- None None O
N None None O
ring None None O
opening None None O
of None None O
the None None O
oxazaphosphorines None None O
3a None None O
, None None O
b None None O
leading None None O
to None None O
the None None O
phosphoric None None O
acid None None O
monoesters None None O
, None None O
H None None O
( None None O
2 None None O
) None None O
N None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
3 None None O
) None None O
OP None None O
( None None O
O None None O
) None None O
( None None O
OH None None O
) None None O
( None None O
2 None None O
) None None O
( None None O
4a None None O
) None None O
and None None O
Cl None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
2 None None O
) None None O
HN None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
3 None None O
) None None O
OP None None O
( None None O
O None None O
) None None O
( None None O
OH None None O
) None None O
( None None O
2 None None O
) None None O
( None None O
4b None None O
- None None O
1 None None O
) None None O
, None None O
respectively None None O
. None None O

For None None O
the None None O
latter None None O
compound None None O
, None None O
the None None O
chloroethyl None None O
group None None O
is None None O
partially None None O
( None None O
at None None O
pH None None O
5.5 None None O
) None None O
or None None O
totally None None O
( None None O
at None None O
pH None None O
7.0 None None O
) None None O
cyclized None None O
into None None O
aziridine None None O
( None None O
4b None None O
- None None O
2 None None O
) None None O
, None None O
which None None O
is None None O
then None None O
progressively None None O
hydrolyzed None None O
into None None O
an None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
group None None I-MODIFIER
( None None O
4b None None O
- None None O
3 None None O
) None None O
. None None O

Compounds None None O
3a None None O
, None None O
b None None O
are None None O
transient None None O
intermediates None None O
, None None O
which None None O
in None None O
strongly None None O
acidic None None O
medium None None O
are None None O
not None None O
observed None None O
with None None O
( None None O
31 None None O
) None None O
P None None O
NMR None None O
. None None O

In None None O
this None None O
case None None O
, None None O
cleavage None None O
of None None O
the None None O
P None None O
- None None O
N None None O
bond None None O
of None None O
the None None O
type None None O
2 None None O
phosphoramidic None None O
acid None None O
monoesters None None O
leads None None O
directly None None O
to None None O
the None None O
type None None O
4 None None O
phosphoric None None O
acid None None O
monoesters None None O
. None None O

The None None O
phosphate None None O
anion None None O
, None None O
derived None None O
from None None O
P None None O
- None None O
O None None O
bond None None O
cleavage None None O
of None None O
these None None O
latter None None O
compounds None None O
, None None O
is None None O
only None None O
observed None None O
at None None O
low None None O
levels None None O
after None None O
a None None O
long None None O
period None None O
of None None O
hydrolysis None None O
. None None O

Compounds None None O
1a None None O
- None None O
c None None O
and None None O
some None None O
of None None O
their None None O
hydrolytic None None O
degradation None None O
products None None O
( None None O
4b None None O
- None None O
1 None None O
, None None O
4b None None O
- None None O
2 None None O
, None None O
diphosphoric None None O
diester None None O
[ None None O
Cl None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
2 None None O
) None None O
NH None None O
( None None O
CH None None O
( None None O
2 None None O
) None None O
) None None O
( None None O
3 None None O
) None None O
OP None None O
( None None O
O None None O
) None None O
( None None O
OH None None O
) None None O
] None None O
( None None O
2 None None O
) None None O
O None None O
( None None O
5 None None O
) None None O
, None None O
and None None O
chloroethylamine None None O
) None None O
did None None O
not None None O
exhibit None None O
, None None O
as None None O
expected None None O
, None None O
any None None O
antitumor None None O
efficacy None None O
in None None O
vivo None None O
against None None O
P388 None None O
leukemia None None O
. None None O

( None None O
31 None None O
) None None O
P None None O
NMR None None O
determination None None O
of None None O
the None None O
N None None O
- None None O
dechloroethylated None None O
metabolites None None O
of None None O
IF None None O
or None None O
its None None O
structural None None O
isomer None None O
, None None O
cyclophosphamide None None O
( None None O
CP None None O
) None None O
, None None O
and None None O
their None None O
degradation None None O
compounds None None O
could None None O
provide None None O
an None None O
indirect None None O
and None None O
accurate None None O
estimation None None O
of None None O
chloroacetaldehyde None None O
amounts None None O
formed None None O
from None None O
CP None None O
or None None O
IF None None O
. None None O


The None None O
high None None O
antiradiation None None O
activity None None O
and None None O
low None None O
toxicity None None O
of None None O
sodium None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxypropyl None None I-IUPAC
hydrogen None None I-IUPAC
phosphorothioate None None I-IUPAC
( None None O
1 None None O
) None None O
suggested None None O
the None None O
introduction None None O
of None None O
hydroxyl None None I-IUPAC
groups None None B-MODIFIER
into None None O
other None None O
types None None O
of None None O
radioprotective None None O
phosphorothioates None None O
. None None O

A None None O
number None None O
of None None O
such None None O
compounds None None O
were None None O
synthesized None None O
, None None O
including None None O
S None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminopropylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxypropyl None None I-IUPAC
dihydrogen None None I-IUPAC
phosphorothioate None None I-IUPAC
( None None O
11 None None O
, None None O
n None None O
equals None None O
3 None None O
) None None O
, None None O
S None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxypropylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
dihydrogen None None I-IUPAC
phosphorothioate None None I-IUPAC
( None None O
20 None None O
) None None O
and None None O
its None None O
propyl None None I-IUPAC
homolog None None B-MODIFIER
26 None None O
, None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxytrimethylene None None I-IUPAC
) None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
dihydrogen None None I-IUPAC
phosphorothioate None None I-IUPAC
) None None I-IUPAC
( None None O
40 None None O
) None None O
, None None O
S None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethylamino None None I-IUPAC
) None None I-IUPAC
propylaminoi1ethyl None None I-IUPAC
dihydrogen None None I-IUPAC
phosphorothioate None None I-IUPAC
( None None O
44 None None O
) None None O
, None None O
and None None O
sodium None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypropyl None None I-IUPAC
hydrogen None None I-IUPAC
phosphorothioate None None I-IUPAC
( None None O
49 None None O
) None None O
. None None O

Compounds None None O
11 None None O
( None None O
n None None O
equals None None O
3 None None O
) None None O
, None None O
20 None None O
, None None O
26 None None O
, None None O
and None None O
49 None None O
were None None O
highly None None O
protective None None O
when None None O
administered None None O
intraperitoneally None None O
but None None O
were None None O
generally None None O
ineffective None None O
when None None O
given None None O
perorally None None O
, None None O
as None None O
were None None O
the None None O
other None None O
hydroxylated None None O
phosphorothioates None None O
prepared None None O
. None None O

The None None O
introduction None None O
of None None O
hydroxyl None None I-IUPAC
groups None None B-MODIFIER
significantly None None O
enhanced None None O
the None None O
radioprotective None None O
properties None None O
of None None O
nonhydroxylated None None O
parent None None O
compounds None None O
, None None O
however None None O
, None None O
only None None O
in None None O
the None None O
case None None O
of None None O
intraperitoneally None None O
administered None None O
. None None O


We None None O
have None None O
designed None None O
and None None O
synthesized None None O
16 None None O
new None None O
olean None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
urs None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
triterpenoids None None I-IUPAC
with None None O
various None None O
modified None None O
rings None None O
C None None O
as None None O
potential None None O
antiinflammatory None None O
and None None O
cancer None None O
chemopreventive None None O
agents None None O
and None None O
evaluated None None O
their None None O
inhibitory None None O
activities None None O
against None None O
production None None O
of None None O
nitric None None O
oxide None None O
induced None None O
by None None O
interferon None None O
- None None O
gamma None None O
in None None O
mouse None None O
macrophages None None O
. None None O

This None None O
investigation None None O
revealed None None O
that None None O
9 None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
and None None O
12 None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
functionalities None None O
in None None O
ring None None O
C None None O
increase None None O
the None None O
potency None None O
by None None O
about None None O
2-10 None None O
times None None O
compared None None O
with None None O
the None None O
original None None O
12 None None I-IUPAC
- None None I-IUPAC
ene None None I-IUPAC
. None None O

Subsequently None None O
, None None O
we None None O
have None None O
designed None None O
and None None O
synthesized None None O
novel None None O
olean None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
urs None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
derivatives None None I-MODIFIER
with None None O
nitrile None None I-IUPAC
and None None O
carboxyl None None I-IUPAC
groups None None B-MODIFIER
at None None O
C None None O
- None None O
2 None None O
in None None O
ring None None O
A None None O
and None None O
with None None O
9 None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
and None None O
12 None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
functionalities None None I-MODIFIER
in None None O
ring None None O
C None None O
. None None O

Among None None O
them None None O
, None None O
we None None O
have None None O
found None None O
that None None O
methyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
, None None I-IUPAC
12 None None I-IUPAC
- None None I-IUPAC
dioxooleana None None I-IUPAC
- None None I-IUPAC
1,9 None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dien None None I-IUPAC
- None None I-IUPAC
28 None None I-IUPAC
- None None I-IUPAC
oate None None I-IUPAC
( None None O
25 None None O
) None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
3,12 None None I-IUPAC
- None None I-IUPAC
dioxooleana None None I-IUPAC
- None None I-IUPAC
1,9 None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dien None None I-IUPAC
- None None I-IUPAC
28 None None I-IUPAC
- None None I-IUPAC
oic None None I-IUPAC
acid None None I-IUPAC
( None None O
CDDO None None O
) None None O
( None None O
26 None None O
) None None O
, None None O
and None None O
methyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
3,12 None None I-IUPAC
- None None I-IUPAC
dioxooleana None None I-IUPAC
- None None I-IUPAC
1,9 None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
dien None None I-IUPAC
- None None I-IUPAC
28 None None I-IUPAC
- None None I-IUPAC
oate None None I-IUPAC
( None None O
29 None None O
) None None O
have None None O
extremely None None O
high None None O
potency None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.1 None None O
nM None None O
level None None O
) None None O
. None None O

Their None None O
potency None None O
is None None O
similar None None O
to None None O
that None None O
of None None O
dexamethasone None None O
although None None O
they None None O
do None None O
not None None O
act None None O
through None None O
the None None O
glucocorticoid None None O
receptor None None O
. None None O

Overall None None O
, None None O
the None None O
combination None None O
of None None O
modified None None O
rings None None O
A None None O
and None None O
C None None O
increases None None O
the None None O
potency None None O
by None None O
about None None O
10 None None O
000 None None O
times None None O
compared None None O
with None None O
the None None O
lead None None O
compound None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
oxooleana None None I-IUPAC
- None None I-IUPAC
1,12 None None I-IUPAC
- None None I-IUPAC
dien None None I-IUPAC
- None None I-IUPAC
28 None None I-IUPAC
- None None I-IUPAC
oic None None I-IUPAC
acid None None I-IUPAC
( None None O
8 None None O
) None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1 None None O
microM None None O
level None None O
) None None O
. None None O

The None None O
selected None None O
oleanane None None O
triterpenoid None None O
, None None O
CDDO None None O
( None None O
26 None None O
) None None O
, None None O
was None None O
found None None O
to None None O
be None None O
a None None O
potent None None O
, None None O
multifunctional None None O
agent None None O
in None None O
various None None O
in None None O
vitro None None O
assays None None O
and None None O
to None None O
show None None O
antiinflammatory None None O
activity None None O
against None None O
thioglycollate None None O
- None None O
interferon None None O
- None None O
gamma None None O
- None None O
induced None None O
mouse None None O
peritonitis None None O
. None None O


A None None O
series None None O
of None None O
new None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
alkylamides None None I-IUPAC
44-84 None None O
has None None O
been None None O
prepared None None O
in None None O
the None None O
search None None O
of None None O
novel None None O
antiallergic None None O
compounds None None O
. None None O

Synthesis None None O
of None None O
the None None O
desired None None O
ethyl None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyindol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
acetates None None I-IUPAC
1-4 None None O
was None None O
achieved None None O
by None None O
indolization None None O
under None None O
Fischer None None O
conditions None None O
; None None O
Japp None None O
- None None O
Klingemann None None O
method None None O
followed None None O
by None None O
2 None None O
- None None O
decarboxylation None None O
afforded None None O
the None None O
ethyl None None I-IUPAC
( None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
alkanoates None None I-IUPAC
17-25 None None O
. None None O

Amidification None None O
was None None O
successfully None None O
carried None None O
out None None O
by None None O
condensation None None O
of None None O
the None None O
corresponding None None O
acids None None O
or None None O
their None None O
N None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
( None None I-IUPAC
methyl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
with None None O
4 None None I-IUPAC
- None None I-IUPAC
aminopyridine None None I-IUPAC
promoted None None O
by None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methylpyridinium None None I-IUPAC
iodide None None I-IUPAC
. None None O

Efforts None None O
to None None O
improve None None O
the None None O
antiallergic None None O
potency None None O
of None None O
the None None O
title None None O
series None None O
by None None O
variation None None O
of None None O
the None None O
indole None None O
substituents None None O
( None None O
R1 None None O
, None None O
R2 None None O
, None None O
R None None O
) None None O
and None None O
the None None O
length None None O
of None None O
the None None O
alkanoic None None O
chain None None O
( None None O
n None None O
= None None O
1 None None O
, None None O
2 None None O
, None None O
3 None None O
) None None O
led None None O
to None None O
the None None O
selection None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorobenzyl None None I-IUPAC
) None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
acetamide None None I-IUPAC
45 None None O
, None None O
out None None O
of None None O
41 None None O
compounds None None O
. None None O

This None None O
amide None None O
was None None O
406 None None O
- None None O
fold None None O
more None None O
potent None None O
than None None O
astemizole None None O
in None None O
the None None O
ovalbumin None None O
- None None O
induced None None O
histamine None None O
release None None O
assay None None O
, None None O
using None None O
guinea None None O
pig None None O
peritoneal None None O
mast None None O
cells None None O
, None None O
with None None O
an None None O
IC50 None None O
= None None O
0.016 None None O
microM None None O
. None None O

Its None None O
inhibitory None None O
activity None None O
in None None O
IL None None O
- None None O
4 None None O
production None None O
test None None O
from None None O
Th None None O
- None None O
2 None None O
cells None None O
was None None O
identical None None O
to None None O
that None None O
of None None O
the None None O
reference None None O
histamine None None O
antagonist None None O
( None None O
IC50 None None O
= None None O
8.0 None None O
microM None None O
) None None O
and None None O
twice None None O
higher None None O
in None None O
IL None None O
- None None O
5 None None O
assay None None O
: None None O
IC50 None None O
= None None O
1.5 None None O
and None None O
3.3 None None O
microM None None O
, None None O
respectively None None O
. None None O

In None None O
vivo None None O
antiallergic None None O
activity None None O
evaluation None None O
confirmed None None O
efficiency None None O
of None None O
45 None None O
in None None O
sensitized None None O
guinea None None O
pig None None O
late None None O
phase None None O
eosinophilia None None O
inhibition None None O
, None None O
after None None O
parenteral None None O
and None None O
oral None None O
administration None None O
at None None O
5 None None O
and None None O
30 None None O
mg None None O
/ None None O
kg None None O
, None None O
respectively None None O
. None None O

Its None None O
efficiency None None O
in None None O
inhibition None None O
of None None O
microvascular None None O
permeability None None O
was None None O
assessed None None O
in None None O
two None None O
rhinitis None None O
models None None O
; None None O
ovalbumin None None O
and None None O
capsaicin None None O
- None None O
induced None None O
rhinorrhea None None O
could None None O
be None None O
prevented None None O
after None None O
topical None None O
application None None O
of None None O
submicromolar None None O
concentrations None None O
of None None O
45 None None O
( None None O
IC50 None None O
= None None O
0.25 None None O
and None None O
0.30 None None O
microM None None O
) None None O
; None None O
and None None O
it None None O
also None None O
exerted None None O
significant None None O
inhibitory None None O
effect None None O
in None None O
the None None O
first None None O
test None None O
after None None O
iv None None O
and None None O
oral None None O
administration None None O
, None None O
with None None O
ID50 None None O
= None None O
0.005 None None O
and None None O
0.46 None None O
mg None None O
/ None None O
kg None None O
. None None O


5 None None O
- None None O
Alkyl None None O
- None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
arylalkyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylenedihydrofuran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
13a None None O
- None None O
e None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
alkylidenedihydrofuran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
18a None None O
- None None O
c None None O
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
methylenepyrrolidin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
16a None None O
- None None O
e None None O
were None None O
synthesized None None O
utilizing None None O
ethyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
diethoxyphosphoryl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitroalkanoates None None I-IUPAC
9a None None O
- None None O
e None None O
as None None O
common None None O
intermediates None None O
. None None O

All None None O
obtained None None O
compounds None None O
were None None O
tested None None O
against None None O
L None None O
- None None O
1210 None None O
, None None O
HL None None O
- None None O
60 None None O
, None None O
and None None O
NALM None None O
- None None O
6 None None O
leukemia None None O
cells None None O
. None None O

The None None O
highest None None O
cytotoxic None None O
activity None None O
was None None O
observed None None O
for None None O
3 None None I-IUPAC
- None None I-IUPAC
methylenefuranones None None I-IUPAC
13d None None O
, None None O
e None None O
bearing None None O
benzyl None None I-IUPAC
or None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dimethoxyphenylmethyl None None I-IUPAC
substituents None None I-MODIFIER
at None None O
position None None O
5 None None O
, None None O
with None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
of None None O
5.4 None None O
and None None O
6.0 None None O
microM None None O
, None None O
respectively None None O
. None None O

Contrary None None O
to None None O
the None None O
literature None None O
reports None None O
, None None O
no None None O
enhancement None None O
in None None O
activity None None O
due None None O
to None None O
the None None O
presence None None O
of None None O
a None None O
hydroxy None None O
group None None O
was None None O
found None None O
when None None O
the None None O
cytotoxicity None None O
of None None O
furanones None None O
13a None None O
, None None O
b None None O
, None None O
d None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1' None None I-IUPAC
- None None I-IUPAC
hydroxyalkyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylenedihydrofuran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
6a None None O
, None None O
b None None O
, None None O
d None None O
was None None O
compared None None O
. None None O

The None None O
anticancer None None O
activity None None O
of None None O
pyrrolidinones None None O
16a None None O
- None None O
e None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
alkylidenefuranones None None I-IUPAC
18a None None O
- None None O
c None None O
was None None O
much None None O
weaker None None O
than None None O
that None None O
of None None O
furanones None None O
13a None None O
- None None O
e None None O
. None None O


Several None None O
derivatives None None O
of None None O
4,5 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
imidazole None None I-IUPAC
, None None O
2,4,5 None None I-MODIFIER
- None None I-MODIFIER
trisubstituted None None I-MODIFIER
pyrimidine None None I-IUPAC
, None None O
2 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
purine None None I-IUPAC
, None None O
thiazolo None None I-IUPAC
[ None None I-IUPAC
3,2 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
] None None I-IUPAC
purine None None I-IUPAC
, None None O
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
thiazino None None I-IUPAC
[ None None I-IUPAC
3,2 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
] None None I-IUPAC
purine None None I-IUPAC
, None None O
thiazolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
i None None I-IUPAC
] None None I-IUPAC
purine None None I-IUPAC
, None None O
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
thiazino None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
i None None I-IUPAC
] None None I-IUPAC
purine None None I-IUPAC
, None None O
and None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
pyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
were None None O
synthesized None None O
and None None O
tested None None O
as None None O
inhibitors None None O
of None None O
the None None O
xanthine None None O
oxidase None None O
enzyme None None O
. None None O

Of None None O
those None None O
, None None O
some None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
acylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carbamoylimidazoles None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
thioalkyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
purines None None B-IUPAC
exhibited None None O
very None None O
good None None O
inhibitory None None O
activity None None O
, None None O
being None None O
at None None O
least None None O
500 None None O
times None None O
more None None O
effective None None O
than None None O
allopurinol None None O
. None None O

The None None O
ineffectiveness None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
alkylpyrazolo None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
is None None O
imputable None None O
to None None O
the None None O
alkyl None None O
chain None None O
which None None O
could None None O
hinder None None O
the None None O
coordination None None O
with None None O
molybdenum None None O
according None None O
to None None O
the None None O
known None None O
mechanism None None O
for None None O
the None None O
binding None None O
of None None O
the None None O
inhibitor None None O
allopurinol None None O
; None None O
the None None O
effectiveness None None O
of None None O
imidazole None None O
derivatives None None O
, None None O
by None None O
contrast None None O
with None None O
the None None O
ineffectiveness None None O
of None None O
4,5 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
thioalkyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hydroxypyrimidines None None I-IUPAC
, None None O
indicates None None O
the None None O
relative None None O
importance None None O
of None None O
the None None O
five None None O
- None None O
membered None None O
ring None None O
in None None O
the None None O
interaction None None O
with None None O
the None None O
enzyme None None O
. None None O

Moreover None None O
, None None O
the None None O
marked None None O
effectiveness None None O
of None None O
the None None O
angularly None None O
- None None O
cyclized None None O
[ None None I-IUPAC
1,3 None None I-IUPAC
] None None I-IUPAC
thiazino None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
i None None I-IUPAC
] None None I-IUPAC
purinones None None I-IUPAC
, None None O
which None None O
constitute None None O
an None None O
interesting None None O
new None None O
class None None O
of None None O
inhibitors None None O
, None None O
together None None O
with None None O
the None None O
weak None None O
activity None None O
of None None O
linearly None None O
- None None O
cyclized None None O
derivatives None None O
, None None O
allowed None None O
us None None O
to None None O
characterize None None O
more None None O
precisely None None O
the None None O
lipophilic None None O
region None None O
of None None O
the None None O
enzyme None None O
facing None None O
the None None O
N None None O
( None None O
1 None None O
) None None O
- None None O
C None None O
( None None O
2 None None O
) None None O
positions None None O
of None None O
the None None O
substrate None None O
hypoxanthine None None O
. None None O


A None None O
synthesis None None O
scheme None None O
for None None O
3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxynucleosides None None I-IUPAC
and None None O
3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methylidene None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyluridine None None I-IUPAC
has None None O
been None None O
proposed None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxyribose None None I-IUPAC
as None None O
the None None O
starting None None O
material None None O
. None None O

Methyl None None O
5 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxyribofuranose None None I-IUPAC
was None None O
oxidized None None O
and None None O
the None None O
mixture None None O
of None None O
the None None O
3' None None I-IUPAC
- None None I-IUPAC
keto None None I-IUPAC
derivatives None None I-MODIFIER
was None None O
separated None None O
into None None O
the None None O
alpha None None O
- None None O
and None None O
beta None None O
- None None O
anomers None None O
. None None O

The None None O
beta None None O
- None None O
keto None None O
derivative None None O
was None None O
converted None None O
by None None O
reaction None None O
with None None O
MeMgBr None None O
, None None O
and None None O
after None None O
reaction None None O
with None None O
thymine None None O
and None None O
subsequent None None O
deprotection None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
threo None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
and None None O
its None None O
beta None None O
- None None O
anomer None None O
were None None O
obtained None None O
. None None O

The None None O
same None None O
reactions None None O
with None None O
the None None O
alpha None None O
- None None O
keto None None O
sugar None None O
gave None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
and None None O
its None None O
beta None None O
- None None O
anomer None None O
. None None O

1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
Benzoyl None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
threo None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
thymine None None I-IUPAC
was None None O
converted None None O
to None None O
a None None O
mixture None None O
of None None O
3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methylidene None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyluridine None None I-IUPAC
and None None O
3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
didehydro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyluridine None None I-IUPAC
, None None O
which None None O
were None None O
separated None None O
. None None O

The None None O
stereoselectivity None None O
of None None O
the None None O
Grignard None None O
reagent None None O
's None None O
attachment None None O
to None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxyfuranose None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ulosides None None I-IUPAC
has None None O
been None None O
ruled None None O
by None None O
the None None O
substitute None None O
configuration None None O
at None None O
Cl None None O
. None None O

Also None None O
, None None O
the None None O
effect None None O
of None None O
the None None O
hydroxyl None None I-IUPAC
or None None O
OBz None None O
group None None O
configuration None None O
at None None O
C3 None None O
on None None O
the None None O
condensation None None O
stereoselectivity None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxyfuranosides None None I-IUPAC
with None None O
silylated None None O
thymine None None O
has None None O
been None None O
studied None None O
. None None O

The None None O
structure None None O
of None None O
the None None O
obtained None None O
compounds None None O
was None None O
proved None None O
by None None O
1H None None O
NMR None None O
UV None None O
, None None O
13C None None O
NMR None None O
, None None O
and None None O
CD None None O
spectroscopy None None O
, None None O
as None None O
well None None O
as None None O
elemental None None O
( None None O
C None None O
, None None O
H None None O
, None None O
N None None O
) None None O
analysis None None O
. None None O

The None None O
C2 None None O
' None None O
- None None O
endo None None O
- None None O
C1 None None O
' None None O
- None None O
exo None None O
conformation None None O
, None None O
the None None O
anti None None O
conformation None None O
of None None O
thymine None None O
in None None O
relation None None O
to None None O
the None None O
glycosidic None None O
bond None None O
, None None O
and None None O
the None None O
gauche+ None None O
conformation None None O
in None None O
relation None None O
to None None O
the None None O
C4 None None O
' None None O
- None None O
C5 None None O
' None None O
bond None None O
are None None O
characteristic None None O
for None None O
the None None O
3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxythymidine None None I-IUPAC
structure None None O
in None None O
the None None O
crystals None None O
. None None O

3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
Methyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxythymidine None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
triphosphate None None I-IUPAC
was None None O
synthesized None None O
and None None O
proved None None O
to None None O
be None None O
a None None O
competitive None None O
inhibitor None None O
, None None O
with None None O
respect None None O
to None None O
dTTP None None O
, None None O
of None None O
a None None O
number None None O
of None None O
DNA None None O
polymerases None None O
, None None O
including None None O
the None None O
reverse None None O
transcriptases None None O
of None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
( None None O
HIV None None O
- None None O
1 None None O
) None None O
and None None O
avian None None O
myeloblastosis None None O
virus None None O
( None None O
AMV None None O
) None None O
. None None O

None None None O
of None None O
the None None O
DNA None None O
polymerases None None O
examined None None O
were None None O
able None None O
to None None O
incorporate None None O
this None None O
compound None None O
into None None O
the None None O
growing None None O
DNA None None O
chain None None O
. None None O

In None None O
contrast None None O
, None None O
3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
methylidene None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyluridine None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
triphosphate None None I-IUPAC
was None None O
found None None O
to None None O
be None None O
incorporated None None O
at None None O
the None None O
3' None None O
- None None O
end None None O
of None None O
the None None O
DNA None None O
chain None None O
by None None O
HIV None None O
- None None O
1 None None O
reverse None None O
transcriptase None None O
, None None O
albeit None None O
with None None O
very None None O
low None None O
efficiency None None O
. None None O

3' None None I-IUPAC
- None None I-IUPAC
C None None I-IUPAC
- None None I-IUPAC
Methyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyluridine None None I-IUPAC
did None None O
not None None O
suppress None None O
HIV None None O
- None None O
1 None None O
replication None None O
in None None O
MT None None O
- None None O
4 None None O
cells None None O
at None None O
500 None None O
microM None None O
while None None O
its None None O
5' None None I-IUPAC
- None None I-IUPAC
phosphite None None I-IUPAC
derivative None None I-MODIFIER
exhibited None None O
modest None None O
anti None None O
- None None O
HIV None None O
- None None O
1 None None O
activity None None O
. None None O


Treatment None None O
of None None O
3' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromovinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
2 None None O
) None None O
with None None O
p None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
phosphorodichloridate None None I-IUPAC
and None None O
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazole None None I-IUPAC
gave None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
br None None I-IUPAC
o None None I-IUPAC
movinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
3 None None O
) None None O
. None None O

Reaction None None O
of None None O
3 None None O
with None None O
ammonia None None O
gave None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromovinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxycytidine None None I-IUPAC
( None None O
1 None None O
) None None O
, None None O
the None None O
overall None None O
yield None None O
from None None O
2 None None O
being None None O
60% None None O
. None None O

A None None O
similar None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
derivative None None I-MODIFIER
( None None O
4 None None O
) None None O
was None None O
obtained None None O
from None None O
3' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
thymidine None None I-IUPAC
by None None O
the None None O
use None None O
of None None O
phosphoryl None None O
chloride None None O
as None None O
the None None O
condensing None None O
agent None None O
. None None O

Treatment None None O
of None None O
thymidine None None O
with None None O
trimethylsilyl None None O
chloride None None O
and None None O
then None None O
with None None O
phosphoryl None None O
chloride None None O
and None None O
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazole None None I-IUPAC
gave None None O
upon None None O
workup None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
5 None None O
) None None O
. None None O

( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
Bromovinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
BVDU None None O
) None None O
when None None O
similarly None None O
treated None None O
gave None None O
the None None O
corresponding None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromovinyl None None I-IUPAC
) None None I-IUPAC
compound None None I-MODIFIER
7 None None O
. None None O

A None None O
minor None None O
product None None O
formed None None O
in None None O
both None None O
cases None None O
was None None O
a None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
derivative None None I-MODIFIER
in None None O
which None None O
the None None O
nucleoside None None O
5' None None I-IUPAC
- None None I-IUPAC
hydroxyl None None I-IUPAC
group None None I-MODIFIER
had None None O
been None None O
replaced None None O
by None None O
chlorine None None O
( None None O
6 None None O
and None None O
8 None None O
) None None O
. None None O

Whereas None None O
compounds None None O
4-6 None None O
and None None O
8 None None O
did None None O
not None None O
exhibit None None O
a None None O
selective None None O
antiviral None None O
effect None None O
, None None O
compounds None None O
1-3 None None O
and None None O
7 None None O
proved None None O
almost None None O
as None None O
active None None O
as None None O
the None None O
reference None None O
compound None None O
BVDU None None O
. None None O

In None None O
particular None None O
, None None O
compound None None O
7 None None O
, None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
triazolyl None None I-IUPAC
derivative None None I-MODIFIER
of None None O
BVDU None None O
, None None O
would None None O
seem None None O
worth None None O
pursuing None None O
for None None O
its None None O
potential None None O
as None None O
an None None O
inhibitor None None O
of None None O
herpes None None O
simplex None None O
virus None None O
type None None O
1 None None O
and None None O
varicella None None O
- None None O
zoster None None O
virus None None O
. None None O


Certain None None O
derivatives None None O
containing None None O
the None None O
1,2 None None I-IUPAC
- None None I-IUPAC
dihydropyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyrazine None None I-IUPAC
( None None O
1 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
dihydropteridine None None I-IUPAC
) None None O
ring None None I-MODIFIER
system None None I-MODIFIER
are None None O
active None None O
against None None O
experimental None None O
neoplasms None None O
in None None O
mice None None O
. None None O

The None None O
mechanism None None O
of None None O
action None None O
of None None O
these None None O
agents None None O
has None None O
been None None O
attributed None None O
to None None O
the None None O
accumulation None None O
of None None O
cells None None O
at None None O
mitosis None None O
. None None O

Identification None None O
of None None O
the None None O
structural None None O
features None None O
that None None O
are None None O
necessary None None O
for None None O
activity None None O
was None None O
accomplished None None O
by None None O
evaluation None None O
of None None O
modified None None O
1 None None I-IUPAC
- None None I-IUPAC
deazapteridines None None I-IUPAC
and None None O
ring None None O
and None None O
ring None None O
- None None O
opened None None O
analogues None None O
. None None O

Relative None None O
to None None O
ethyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylanilino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
pteridine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamate None None I-IUPAC
( None None O
11 None None O
) None None O
and None None O
the None None O
corresponding None None O
6 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
compound None None I-MODIFIER
( None None O
12 None None O
) None None O
, None None O
no None None O
antitumor None None O
activity None None O
was None None O
observed None None O
with None None O
7,8 None None I-IUPAC
- None None I-IUPAC
dihydropteridines None None I-IUPAC
, None None O
3 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
dihydropteridines None None I-IUPAC
, None None O
and None None O
the None None O
corresponding None None O
heteroaromatic None None O
compounds None None O
. None None O

Also None None O
, None None O
activity None None O
was None None O
diminished None None O
or None None O
destroyed None None O
when None None O
1 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
dihydropteridines None None I-IUPAC
were None None O
oxidized None None O
to None None O
1 None None I-IUPAC
- None None I-IUPAC
deazapteridines None None I-IUPAC
or None None O
reduced None None O
to None None O
1 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
- None None I-IUPAC
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydropteridines None None I-IUPAC
. None None O

In None None O
addition None None O
, None None O
replacement None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
group None None I-MODIFIER
with None None O
other None None O
substituents None None O
destroyed None None O
activity None None O
. None None O

The None None O
presence None None O
of None None O
a None None O
6 None None O
- None None O
substituent None None O
containing None None O
an None None O
aryl None None O
group None None O
appeared None None O
to None None O
be None None O
necessary None None O
for None None O
activity None None O
, None None O
which None None O
was None None O
increased None None O
when None None O
a None None O
methyl None None I-IUPAC
group None None I-IUPAC
was None None O
substituted None None I-MODIFIER
at None None O
the None None O
7 None None O
- None None O
position None None O
. None None O


2 None None O
- None None O
( None None O
Aminomethyl None None O
) None None O
- None None O
4 None None O
- None None O
aminobutyric None None O
acid None None O
( None None O
isoornithine None None O
) None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
methylisoornithine None None I-IUPAC
, None None O
and None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dimethylisoornithine None None I-IUPAC
were None None O
not None None O
decarboxylated None None O
by None None O
liver None None O
ornithine None None O
decarboxylase None None O
( None None O
ODC None None O
, None None O
EC None None O
4.1.1.17 None None O
) None None O
of None None O
thioacetamide None None O
- None None O
treated None None O
rats None None O
but None None O
were None None O
good None None O
competitive None None O
inhibitors None None O
of None None O
the None None O
enzyme None None O
( None None O
Ki None None O
ranged None None O
from None None O
0.72 None None O
to None None O
1.79 None None O
mM None None O
) None None O
. None None O

When None None O
assayed None None O
in None None O
vivo None None O
in None None O
the None None O
treated None None O
rats None None O
, None None O
the None None O
above None None O
mentioned None None O
isoornithines None None O
were None None O
also None None O
found None None O
to None None O
inhibit None None O
liver None None O
ODC None None O
when None None O
administered None None O
1 None None O
h None None O
before None None O
sacrifice None None O
. None None O

When None None O
the None None O
methylputrescines None None O
formally None None O
derived None None O
from None None O
the None None O
decarboxylation None None O
of None None O
several None None O
isoornithines None None O
were None None O
assayed None None O
on None None O
rat None None O
liver None None O
ODC None None O
, None None O
it None None O
was None None O
found None None O
that None None O
only None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dimethylputrescine None None I-IUPAC
decreased None None O
the None None O
enzymatic None None O
activity None None O
. None None O

When None None O
assayed None None O
in None None O
vivo None None O
, None None O
it None None O
was None None O
found None None O
to None None O
decrease None None O
ODC None None O
activity None None O
by None None O
60% None None O
, None None O
when None None O
the None None O
latter None None O
was None None O
measured None None O
1 None None O
h None None O
after None None O
administration None None O
. None None O

The None None O
effect None None O
was None None O
reverted None None O
4 None None O
h None None O
after None None O
administration None None O
of None None O
the None None O
drug None None O
. None None O

Isoornithines None None O
were None None O
not None None O
taken None None O
up None None O
by None None O
H None None O
- None None O
35 None None O
hepatoma None None O
cells None None O
; None None O
hence None None O
they None None O
did None None O
not None None O
affect None None O
their None None O
ODC None None O
activity None None O
. None None O

2,3 None None I-IUPAC
- None None I-IUPAC
Dimethylputrescine None None I-IUPAC
however None None O
, None None O
was None None O
transported None None O
into None None O
the None None O
cells None None O
and None None O
significantly None None O
decreased None None O
its None None O
ODC None None O
activity None None O
. None None O


Eleven None None O
new None None O
12 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6,7,10,11 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
, None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
methanocycloocta None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
quinoline None None I-IUPAC
derivatives None None I-MODIFIER
[ None None O
tacrine None None O
( None None O
THA None None O
) None None O
- None None O
huperzine None None O
A None None O
hybrids None None O
, None None O
rac None None O
- None None O
21-31 None None O
] None None O
have None None O
been None None O
synthesized None None O
as None None O
racemic None None O
mixtures None None O
and None None O
tested None None O
as None None O
acetylcholinesterase None None O
( None None O
AChE None None O
) None None O
inhibitors None None O
. None None O

For None None O
derivatives None None O
unsubstituted None None O
at None None O
the None None O
benzene None None O
ring None None O
, None None O
the None None O
highest None None O
activity None None O
was None None O
obtained None None O
for None None O
the None None O
9 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
derivative None None I-MODIFIER
rac None None O
- None None O
20 None None O
, None None O
previously None None O
prepared None None O
by None None O
our None None O
group None None O
. None None O

More None None O
bulky None None O
substituents None None O
at None None O
position None None O
9 None None O
led None None O
to None None O
less None None O
active None None O
compounds None None O
, None None O
although None None O
some None None O
of None None O
them None None O
[ None None O
9 None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
( None None O
rac None None O
- None None O
22 None None O
) None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
( None None O
rac None None O
- None None O
23 None None O
) None None O
, None None O
and None None O
9 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
( None None O
rac None None O
- None None O
26 None None O
) None None O
] None None O
show None None O
activities None None O
similar None None O
to None None O
that None None O
of None None O
THA None None O
. None None O

Substitution None None O
at None None O
position None None O
1 None None O
or None None O
3 None None O
with None None O
methyl None None O
or None None O
fluorine None None O
atoms None None O
always None None O
led None None O
to None None O
more None None O
active None None O
compounds None None O
. None None O

Among None None O
them None None O
, None None O
the None None O
highest None None O
activity None None O
was None None O
observed None None O
for None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
derivative None None I-MODIFIER
rac None None O
- None None O
28 None None O
[ None None O
about None None O
15 None None O
- None None O
fold None None O
more None None O
active None None O
than None None O
THA None None O
and None None O
about None None O
9 None None O
- None None O
fold None None O
more None None O
active None None O
than None None O
( None None O
- None None O
) None None O
- None None O
huperzine None None O
A None None O
] None None O
. None None O

The None None O
activity None None O
of None None O
some None None O
THA None None O
- None None O
huperzine None None O
A None None O
hybrids None None O
( None None O
rac None None O
- None None O
19 None None O
, None None O
rac None None O
- None None O
20 None None O
, None None O
rac None None O
- None None O
28 None None O
, None None O
and None None O
rac None None O
- None None O
30 None None O
) None None O
, None None O
which None None O
were None None O
separated None None O
into None None O
their None None O
enantiomers None None O
by None None O
chiral None None O
medium None None O
- None None O
pressure None None O
liquid None None O
chromatography None None O
( None None O
chiral None None O
MPLC None None O
) None None O
, None None O
using None None O
microcrystalline None None O
cellulose None None O
triacetate None None O
as None None O
the None None O
chiral None None O
stationary None None O
phase None None O
, None None O
showed None None O
the None None O
eutomer None None O
to None None O
be None None O
always None None O
the None None O
levorotatory None None O
enantiomer None None O
, None None O
their None None O
activity None None O
being None None O
roughly None None O
double None None O
that None None O
of None None O
the None None O
corresponding None None O
racemic None None O
mixture None None O
, None None O
the None None O
distomer None None O
being None None O
much None None O
less None None O
active None None O
. None None O

Also None None O
, None None O
the None None O
activity None None O
of None None O
some None None O
of None None O
these None None O
compounds None None O
inhibiting None None O
butyrylcholinesterase None None I-IUPAC
( None None O
BChE None None O
) None None O
was None None O
tested None None O
. None None O

Most None None O
of None None O
them None None O
[ None None O
rac None None O
- None None O
27-31 None None O
, None None O
( None None O
- None None O
) None None O
- None None O
28 None None O
, None None O
and None None O
( None None O
- None None O
) None None O
- None None O
30 None None O
] None None O
, None None O
which None None O
are None None O
more None None O
active None None O
than None None O
( None None O
- None None O
) None None O
- None None O
huperzine None None O
A None None O
as None None O
AChE None None O
inhibitors None None O
, None None O
turned None None O
out None None O
to None None O
be None None O
quite None None O
selective None None O
for None None O
AChE None None O
, None None O
although None None O
not None None O
so None None O
selective None None O
as None None O
( None None O
- None None O
) None None O
- None None O
huperzine None None O
A None None O
. None None O

Most None None O
of None None O
the None None O
tested None None O
compounds None None O
19-31 None None O
proved None None O
to None None O
be None None O
much None None O
more None None O
active None None O
than None None O
THA None None O
in None None O
reversing None None O
the None None O
neuromuscular None None O
blockade None None O
induced None None O
by None None O
d None None O
- None None O
tubocurarine None None O
. None None O

Molecular None None O
modeling None None O
of None None O
the None None O
interaction None None O
of None None O
these None None O
compounds None None O
with None None O
AChE None None O
from None None O
Torpedo None None O
californica None None O
showed None None O
them None None O
to None None O
interact None None O
as None None O
truly None None O
THA None None O
- None None O
huperzine None None O
A None None O
hybrids None None O
: None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
aminoquinoline None None I-IUPAC
subunit None None I-MODIFIER
of None None O
( None None O
- None None O
) None None O
- None None O
19 None None O
occupies None None O
the None None O
same None None O
position None None O
of None None O
the None None O
corresponding None None O
subunit None None O
in None None O
THA None None O
, None None O
while None None O
its None None O
bicyclo None None O
[ None None O
3.3.1 None None O
] None None O
nonadiene None None O
substructure None None O
roughly None None O
occupies None None O
the None None O
same None None O
position None None O
of None None O
the None None O
corresponding None None O
substructure None None O
in None None O
( None None O
- None None O
) None None O
- None None O
huperzine None None O
A None None O
, None None O
in None None O
agreement None None O
with None None O
the None None O
absolute None None O
configurations None None O
of None None O
( None None O
- None None O
) None None O
- None None O
19 None None O
and None None O
( None None O
- None None O
) None None O
- None None O
huperzine None None O
A None None O
. None None O


The None None O
linear None None O
octadentate None None O
ligand None None O
3,4,3 None None O
- None None O
LIHOPO None None O
, None None O
which None None O
contains None None O
four None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
1,2 None None O
- None None O
HOPO None None O
) None None O
groups None None O
, None None O
is None None O
the None None O
most None None O
effective None None O
agent None None O
for None None O
in None None O
vivo None None O
chelation None None O
of None None O
Pu None None O
( None None O
IV None None O
) None None O
yet None None O
prepared None None O
. None None O

However None None O
, None None O
its None None O
clinical None None O
potential None None O
is None None O
limited None None O
by None None O
acute None None O
toxicity None None O
of None None O
the None None O
free None None O
ligand None None O
( None None O
but None None O
not None None O
Fe3+ None None O
complex None None O
) None None O
at None None O
high None None O
dosage None None O
. None None O

The None None O
high None None O
acidity None None O
of None None O
HOPO None None O
ligands None None O
and None None O
the None None O
much None None O
lower None None O
acidity None None O
of None None O
catechol None None O
( None None O
CAM None None O
) None None O
ligands None None O
suggested None None O
that None None O
mixed None None O
octadentate None None O
( None None O
CAM None None O
- None None O
HOPO None None O
) None None O
ligands None None O
containing None None O
one None None O
or None None O
two None None O
1,2 None None O
- None None O
HOPO None None O
and None None O
three None None O
( None None O
or None None O
two None None O
) None None O
catechol None None O
( None None O
CAM None None O
) None None O
groups None None O
might None None O
be None None O
as None None O
effective None None O
for None None O
Pu None None O
removal None None O
[ None None O
fully None None O
eight None None O
- None None O
coordinated None None O
Pu None None O
( None None O
IV None None O
) None None O
complexes None None O
formed None None O
at None None O
pH None None O
& None None O
gt None None O
; None None O
or None None O
= None None O
6 None None O
] None None O
and None None O
less None None O
toxic None None O
than None None O
3,4,3 None None O
- None None O
LIHOPO None None O
. None None O

Treatment None None O
of None None O
spermine None None O
with None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzoyl None None I-IUPAC
) None None I-IUPAC
thiazol None None I-IUPAC
- None None I-IUPAC
idine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thione None None I-IUPAC
( None None O
1 None None O
) None None O
( None None O
molar None None O
ratio None None O
2 None None O
: None None O
1 None None O
) None None O
gave None None O
1,14 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzoyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,5,10,14 None None I-IUPAC
- None None I-IUPAC
tetraazatetradecane None None I-IUPAC
( None None O
2 None None O
, None None O
DiCAM None None O
- None None O
spermine None None O
) None None O
in None None O
80% None None O
yield None None O
. None None O

Addition None None O
of None None O
2 None None O
to None None O
a None None O
2 None None O
- None None O
fold None None O
excess None None O
of None None O
the None None O
reaction None None O
product None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridone None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
HOPO None None O
- None None O
C None None O
) None None O
and None None O
1,1 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
carbonyldiimidazole None None I-IUPAC
( None None O
CDI None None O
) None None O
in None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylformamide None None I-IUPAC
( None None O
DMF None None O
) None None O
and None None O
deprotection None None O
with None None O
BBr3 None None O
gave None None O
1,14 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydroxybenzoyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5,10 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridon None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
oyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,5,10,14 None None I-IUPAC
- None None I-IUPAC
tetraaza None None I-IUPAC
- None None I-IUPAC
tetradecane None None I-IUPAC
[ None None O
3 None None O
, None None O
3,4,3 None None O
- None None O
LI None None O
( None None O
diCAM None None O
- None None O
diHOPO None None O
) None None O
] None None O
in None None O
5% None None O
yield None None O
. None None O

Addition None None O
of None None O
2 None None O
to None None O
an None None O
equimolar None None O
amount None None O
of None None O
the None None O
reaction None None O
product None None O
of None None O
HOPO None None O
- None None O
C None None O
and None None O
CDI None None O
in None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylacetamide None None I-IUPAC
( None None O
DMAA None None O
) None None O
, None None O
purification None None O
of None None O
the None None O
hexadentate None None O
intermediate None None O
, None None O
subsequent None None O
treatment None None O
with None None O
an None None O
equimolar None None O
amount None None O
of None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzoyl None None I-IUPAC
chloride None None I-IUPAC
( None None O
DMB None None O
) None None O
, None None O
and None None O
deprotection None None O
with None None O
BBr3 None None O
gave None None O
1,5,14 None None I-IUPAC
- None None I-IUPAC
tris None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydroxybenzoyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridon None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
oyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
5,10,14 None None I-IUPAC
- None None I-IUPAC
tetraazatetradecane None None I-IUPAC
[ None None O
4 None None O
, None None O
3,4,3 None None O
- None None O
LI None None O
( None None O
triCAM None None O
- None None O
HOPO None None O
) None None O
] None None O
in None None O
5% None None O
yield None None O
. None None O

Ligands None None O
were None None O
administered None None O
to None None O
mice None None O
[ None None O
30 None None O
mumol None None O
kg None None O
- None None O
1 None None O
ip None None O
at None None O
1 None None O
h None None O
or None None O
orally None None O
at None None O
3 None None O
min None None O
after None None O
iv None None O
injection None None O
of None None O
plutonium None None O
( None None O
IV None None O
) None None O
- None None O
238 None None O
citrate None None O
, None None O
kill None None O
at None None O
24 None None O
h None None O
] None None O
. None None O

Plutonium None None O
excretion None None O
after None None O
injection None None O
of None None O
either None None O
CAM None None O
- None None O
HOPO None None O
ligand None None O
was None None O
700% None None O
of None None O
that None None O
for None None O
24 None None O
- None None O
h None None O
Pu None None O
- None None O
injected None None O
controls None None O
, None None O
140% None None O
of None None O
that None None O
for None None O
mice None None O
given None None O
the None None O
tetracatecholate None None O
analogue None None O
3,4,3 None None O
- None None O
LICAM None None O
( None None O
significantly None None O
more None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
but None None O
only None None O
80% None None O
of None None O
that None None O
promoted None None O
by None None O
3,4,3 None None O
- None None O
LIHOPO None None O
( None None O
significantly None None O
less None None O
) None None O
. None None O

Orally None None O
administered None None O
3,4,3 None None O
- None None O
LI None None O
- None None O
( None None O
diCAM None None O
- None None O
diHOPO None None O
) None None O
promoted None None O
significantly None None O
more None None O
Pu None None O
excretion None None O
than None None O
an None None O
equimolar None None O
amount None None O
of None None O
CaNa3DTPA None None O
. None None O

Potency None None O
of None None O
the None None O
CAM None None O
- None None O
HOPO None None O
ligands None None O
for None None O
in None None O
vivo None None O
chelation None None O
of None None O
Pu None None O
( None None O
IV None None O
) None None O
resembled None None O
that None None O
of None None O
structurally None None O
hexadentate None None I-IUPAC
tris None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxypyridinonate None None I-IUPAC
) None None I-IUPAC
and None None O
tris None None I-IUPAC
( None None I-IUPAC
sulfocatecholate None None I-IUPAC
) None None I-IUPAC
ligands None None O
and None None O
functionally None None O
hexadentate None None O
tetrakis None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
sulfocatecholate None None I-IUPAC
) None None I-IUPAC
and None None O
tetrakis None None I-IUPAC
( None None I-IUPAC
carboxycatecholate None None I-IUPAC
) None None I-IUPAC
ligands None None O
. None None O

The None None O
Pu None None O
complexes None None O
of None None O
the None None O
CAM None None O
- None None O
HOPO None None O
ligands None None O
are None None O
to None None O
some None None O
degree None None O
unstable None None O
at None None O
pH None None O
& None None O
lt None None O
; None None O
7.4 None None O
, None None O
as None None O
judged None None O
by None None O
Pu None None O
residues None None O
in None None O
kidneys None None O
in None None O
excess None None O
of None None O
24 None None O
- None None O
h None None O
Pu None None O
- None None O
injected None None O
controls None None O
. None None O

Synthetic None None O
yields None None O
were None None O
insufficient None None O
for None None O
chemical None None O
investigations None None O
or None None O
evaluation None None O
of None None O
acute None None O
toxicity None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

A None None O
series None None O
of None None O
2,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dihydroxyphenyl None None I-IUPAC
alkyl None None I-IUPAC
ketones None None I-IUPAC
has None None O
been None None O
investigated None None O
as None None O
inhibitors None None O
of None None O
hepatic None None O
microsomal None None O
aniline None None O
hydroxylase None None O
and None None O
aminopyrine None None O
demethylase None None O
activities None None O
. None None O

Structural None None O
alterations None None O
in None None O
both None None O
series None None O
did None None O
little None None O
to None None O
enhance None None O
the None None O
inhibitory None None O
activity None None O
of None None O
the None None O
parent None None O
compounds None None O
2,6 None None I-IUPAC
- None None I-IUPAC
dihydroxyacetophenone None None I-IUPAC
( None None O
3 None None O
) None None O
and None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dihydroxyacetophenone None None I-IUPAC
( None None O
27 None None O
) None None O
. None None O

In None None O
the None None O
2,6 None None O
series None None O
activity None None O
against None None O
both None None O
microsomal None None O
systems None None O
varied None None O
only None None O
over None None O
a None None O
relatively None None O
narrow None None O
range None None O
, None None O
6 None None I-IUPAC
- None None I-IUPAC
allyloxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyacetophenone None None I-IUPAC
( None None O
19 None None O
) None None O
being None None O
the None None O
most None None O
potent None None O
inhibitor None None O
. None None O

In None None O
the None None O
2,4 None None O
series None None O
, None None O
activity None None O
against None None O
aniline None None O
hydroxylase None None O
was None None O
poor None None O
or None None O
absent None None O
in None None O
most None None O
cases None None O
. None None O

tthe None None O
most None None O
potent None None O
inhibitor None None O
was None None O
5 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dihydroxyacetophenone None None I-IUPAC
( None None O
31 None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
high None None O
activity None None O
against None None O
aminopyrine None None O
demethylase None None O
was None None O
frequently None None O
displayed None None O
in None None O
this None None O
series None None O
, None None O
3,5 None None I-IUPAC
- None None I-IUPAC
dibromo None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dihydroxypropiophenone None None I-IUPAC
( None None O
36 None None O
) None None O
showing None None O
greatest None None O
inhibitory None None O
potency None None O
. None None O

The None None O
effects None None O
of None None O
some None None O
compounds None None O
on None None O
hexobarbital None None O
sleeping None None O
times None None O
and None None O
zoxazolamine None None O
paralysis None None O
times None None O
in None None O
mice None None O
were None None O
also None None O
examined None None O
. None None O


A None None O
series None None O
of None None O
aporphine None None O
nitrogen None None O
mustards None None O
and None None O
their None None O
congeners None None O
( None None O
1b None None O
- None None O
g None None O
) None None O
has None None O
been None None O
prepared None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
Bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,11 None None I-IUPAC
- None None I-IUPAC
dihyroxy None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
methoxynoraporphine None None I-IUPAC
( None None O
1b None None O
) None None O
and None None O
its None None O
mono None None O
- None None O
and None None O
diacetyl None None O
ester None None O
derivatives None None O
( None None O
1c None None O
- None None O
d None None O
) None None O
were None None O
prepared None None O
from None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,11 None None I-IUPAC
- None None I-IUPAC
diacetoxy None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
methoxynoraporphine None None I-IUPAC
( None None O
2 None None O
) None None O
. None None O

Reaction None None O
of None None O
2 None None O
with None None O
diethanolamine None None O
under None None O
various None None O
conditions None None O
and None None O
different None None O
solvents None None O
resulted None None O
in None None O
the None None O
corresponding None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
acetyl None None I-IUPAC
] None None I-IUPAC
precursors None None O
, None None O
which None None O
were None None O
subsequently None None O
treated None None O
with None None O
SOCl2 None None O
to None None O
yield None None O
the None None O
target None None O
compounds None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
Choroethyl None None I-IUPAC
) None None I-IUPAC
norapocodeine None None I-IUPAC
( None None O
1e None None O
) None None O
was None None O
obtained None None O
from None None O
the None None O
chlorination None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
) None None I-IUPAC
norapocodeine None None I-IUPAC
( None None O
9 None None O
) None None O
with None None O
SOCl2 None None O
. None None O

Prolonging None None O
such None None O
treatment None None O
was None None O
found None None O
to None None O
result None None O
in None None O
the None None O
formation None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloroethoxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
norapocodeine None None I-IUPAC
( None None O
1f None None O
) None None O
at None None O
the None None O
expense None None O
of None None O
1e None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
Chloroethyl None None I-IUPAC
) None None I-IUPAC
carbamyl None None I-IUPAC
] None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
norapocodeine None None I-IUPAC
( None None O
1g None None O
) None None O
and None None O
its None None O
11 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
carbamyl None None I-IUPAC
derivative None None I-MODIFIER
( None None O
1h None None O
) None None O
were None None O
also None None O
prepared None None O
. None None O

All None None O
the None None O
double None None O
- None None O
armed None None O
aporphine None None O
amide None None O
nitrogen None None O
mustards None None O
( None None O
ab None None O
- None None O
d None None O
) None None O
were None None O
found None None O
to None None O
have None None O
antitumor None None O
activity None None O
. None None O

The None None O
single None None O
- None None O
armed None None O
aporphine None None O
nitrogen None None O
mustard None None O
( None None O
1e None None O
) None None O
was None None O
also None None O
active None None O
in None None O
P388 None None O
but None None O
the None None O
activity None None O
was None None O
less None None O
than None None O
that None None O
observed None None O
with None None O
1b None None O
- None None O
d None None O
. None None O

The None None O
lead None None O
compound None None O
1a None None O
was None None O
inactive None None O
in None None O
the None None O
LE1210 None None O
and None None O
P388 None None O
systems None None O
at None None O
the None None O
doses None None O
tested None None O
. None None O

Similarly None None O
, None None O
the None None O
two None None O
aporphine None None O
mustard None None O
congeners None None O
( None None O
1f None None O
, None None O
g None None O
) None None O
were None None O
also None None O
inactive None None O
in None None O
the None None O
P388 None None O
system None None O
. None None O

All None None O
the None None O
activity None None O
was None None O
observed None None O
in None None O
the None None O
intraperitoneally None None O
innoculated None None O
tumor None None O
systems None None O
. None None O


7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Aminosulfonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
( None None O
SK None None O
& None None O
amp None None O
; None None O
F None None O
29661 None None O
, None None O
1 None None O
) None None O
is None None O
a None None O
potent None None O
inhibitor None None O
of None None O
the None None O
enzyme None None O
phenylethanolamine None None O
N None None O
- None None O
methyltransferase None None O
( None None O
PNMT None None O
, None None O
EC None None O
2.1.1.28 None None O
) None None O
. None None O

In None None O
contrast None None O
to None None O
other None None O
inhibitors None None O
of None None O
PNMT None None O
, None None O
it None None O
is None None O
also None None O
highly None None O
selective None None O
toward None None O
PNMT None None O
in None None O
comparison None None O
with None None O
its None None O
affinity None None O
toward None None O
the None None O
alpha None None O
2 None None O
- None None O
adrenoceptor None None O
( None None O
PNMT None None O
Ki None None O
= None None O
0.55 None None O
microM None None O
, None None O
alpha None None O
2 None None O
Ki None None O
= None None O
100 None None O
microM None None O
, None None O
selectivity None None O
[ None None O
alpha None None O
2 None None O
Ki None None O
/ None None O
PNMT None None O
Ki None None O
] None None O
= None None O
180 None None O
) None None O
. None None O

A None None O
diverse None None O
set None None O
of None None O
compounds None None O
was None None O
synthesized None None O
and None None O
evaluated None None O
to None None O
probe None None O
the None None O
role None None O
of None None O
the None None O
acidic None None O
hydrogen None None O
of None None O
the None None O
aminosulfonyl None None I-IUPAC
group None None B-MODIFIER
of None None O
1 None None O
in None None O
imparting None None O
this None None O
selectivity None None O
. None None O

Compounds None None O
were None None O
designed None None O
to None None O
investigate None None O
the None None O
effect None None O
on None None O
selectivity None None O
of None None O
the None None O
acidity None None O
of None None O
the None None O
NH None None O
group None None O
[ None None O
the None None O
7 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
( None None O
compound None None O
5 None None O
) None None O
and None None O
7 None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
( None None O
compound None None O
4 None None O
) None None O
derivatives None None I-MODIFIER
of None None O
1 None None O
] None None O
, None None O
the None None O
relative None None O
spatial None None O
position None None O
of None None O
the None None O
acidic None None O
hydrogen None None I-IUPAC
[ None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylsulfonyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
( None None O
6 None None O
) None None O
and None None O
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylsulfonyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
( None None O
8 None None O
) None None O
] None None O
, None None O
or None None O
the None None O
effect None None O
of None None O
the None None O
substitution None None O
of None None O
an None None O
acidic None None O
phenolic None None O
group None None O
for None None O
the None None O
aminosulfonyl None None I-IUPAC
moiety None None B-MODIFIER
[ None None B-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hydroxynaphthalene None None I-IUPAC
( None None O
23 None None O
) None None O
and None None O
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydrobenz None None I-IUPAC
[ None None I-IUPAC
h None None I-IUPAC
] None None I-IUPAC
isoquinoline None None I-IUPAC
( None None O
9 None None O
) None None O
] None None O
. None None O

All None None O
of None None O
the None None O
compounds None None O
studied None None O
displayed None None O
lower None None O
affinity None None O
for None None O
PNMT None None O
than None None O
1 None None O
, None None O
and None None O
nine None None O
of None None O
the None None O
eleven None None O
compounds None None O
studied None None O
showed None None O
increased None None O
, None None O
rather None None O
than None None O
the None None O
desired None None O
decreased None None O
, None None O
affinity None None O
for None None O
the None None O
alpha None None O
2 None None O
- None None O
adrenoceptor None None O
. None None O

Specifically None None O
, None None O
compound None None O
4 None None O
, None None O
in None None O
which None None O
the None None O
aminosulfonyl None None O
NH None None O
group None None O
is None None O
more None None O
acidic None None O
than None None O
that None None O
in None None O
1 None None O
, None None O
showed None None O
greatly None None O
reduced None None O
selectivity None None O
on None None O
account None None O
of None None O
increased None None O
alpha None None O
2 None None O
- None None O
adrenoceptor None None O
affinity None None O
as None None O
compared None None O
to None None O
1 None None O
( None None O
PNMT None None O
Ki None None O
= None None O
2.6 None None O
microM None None O
, None None O
alpha None None O
2 None None O
Ki None None O
= None None O
6.3 None None O
microM None None O
, None None O
selectivity None None O
= None None O
2.4 None None O
) None None O
. None None O

Compound None None O
8 None None O
, None None O
in None None O
which None None O
the None None O
acidic None None O
NH None None O
group None None O
is None None O
in None None O
the None None O
same None None O
region None None O
of None None O
space None None O
as None None O
that None None O
in None None O
1 None None O
, None None O
although None None O
the None None O
aminosulfonyl None None I-IUPAC
group None None B-MODIFIER
is None None O
reversed None None O
with None None O
respect None None O
to None None O
the None None O
aromatic None None O
ring None None O
, None None O
showed None None O
poor None None O
PNMT None None O
affinity None None O
and None None O
modest None None O
alpha None None O
2 None None O
- None None O
adrenoceptor None None O
affinity None None O
( None None O
PNMT None None O
Ki None None O
= None None O
330 None None O
microM None None O
, None None O
alpha None None O
2 None None O
Ki None None O
= None None O
18 None None O
microM None None O
, None None O
selectivity None None O
= None None O
0.055 None None O
) None None O
. None None O

Compound None None O
9 None None O
, None None O
in None None O
which None None O
a None None O
phenolic None None O
group None None O
is None None O
in None None O
the None None O
same None None O
region None None O
of None None O
space None None O
as None None O
the None None O
acidic None None O
NH None None O
of None None O
1 None None O
, None None O
exhibited None None O
the None None O
best None None O
alpha None None O
2 None None O
- None None O
adrenoceptor None None O
affinity None None O
of None None O
any None None O
of None None O
the None None O
compounds None None O
studied None None O
( None None O
PNMT None None O
Ki None None O
= None None O
0.98 None None O
microM None None O
, None None O
alpha None None O
2 None None O
Ki None None O
= None None O
0.078 None None O
microM None None O
, None None O
selectivity None None O
= None None O
0.080 None None O
) None None O
. None None O

Results None None O
from None None O
this None None O
study None None O
suggest None None O
that None None O
the None None O
selectivity None None O
of None None O
1 None None O
is None None O
not None None O
solely None None O
due None None O
to None None O
the None None O
presence None None O
of None None O
an None None O
acidic None None O
hydrogen None None O
on None None O
the None None O
7 None None I-IUPAC
- None None I-IUPAC
aminosulfonyl None None I-IUPAC
group None None I-MODIFIER
of None None O
1 None None O
but None None O
is None None O
likely None None O
also None None O
dependent None None O
on None None O
some None None O
other None None O
property None None O
( None None O
e.g. None None O
electron None None O
- None None O
withdrawing None None O
character None None O
) None None O
of None None O
the None None O
aminosulfonyl None None I-IUPAC
group None None B-MODIFIER
. None None O


Synthetic None None O
routes None None O
to None None O
a None None O
series None None O
of None None O
mono None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
difluorinated None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None O
substituted None None I-MODIFIER
- None None O
phenyl None None I-IUPAC
) None None I-IUPAC
benzothiazoles None None I-IUPAC
have None None O
been None None O
devised None None O
. None None O

Whereas None None O
mixtures None None O
of None None O
regioisomeric None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
7 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
benzothiazoles None None I-IUPAC
were None None O
formed None None O
from None None O
the None None O
established None None O
Jacobsen None None O
cyclization None None O
of None None O
precursor None None O
3 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
thiobenzanilides None None I-IUPAC
, None None O
two None None O
modifications None None O
to None None O
this None None O
general None None O
process None None O
have None None O
allowed None None O
the None None O
synthesis None None O
of None None O
pure None None O
samples None None O
of None None O
these None None O
target None None O
compounds None None O
. None None O

Fluorinated None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
) None None I-IUPAC
benzothiazoles None None I-IUPAC
were None None O
potently None None O
cytotoxic None None O
( None None O
GI None None O
( None None O
50 None None O
) None None O
& None None O
lt None None O
; None None O
1 None None O
nM None None O
) None None O
in None None O
vitro None None O
in None None O
sensitive None None O
human None None O
breast None None O
MCF None None O
- None None O
7 None None O
( None None O
ER+ None None O
) None None O
and None None O
MDA None None O
468 None None O
( None None O
ER None None O
- None None O
) None None O
cell None None O
lines None None O
but None None O
inactive None None O
( None None O
GI None None O
( None None O
50 None None O
) None None O
& None None O
gt None None O
; None None O
10 None None O
microM None None O
) None None O
against None None O
PC None None O
3 None None O
prostate None None O
, None None O
nonmalignant None None O
HBL None None O
100 None None O
breast None None O
, None None O
and None None O
HCT None None O
116 None None O
colon None None O
cells None None O
. None None O

The None None O
biphasic None None O
dose None None O
- None None O
response None None O
relationship None None O
characteristically None None O
shown None None O
by None None O
the None None O
benzothiazole None None O
series None None O
against None None O
sensitive None None O
cell None None O
lines None None O
was None None O
exhibited None None O
by None None O
the None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
benzothiazoles None None I-IUPAC
( None None O
10b None None O
, None None O
d None None O
) None None O
but None None O
not None None O
by None None O
the None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
7 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
benzothiazoles None None I-IUPAC
( None None O
10h None None O
, None None O
i None None O
) None None O
. None None O

The None None O
most None None O
potent None None O
broad None None O
spectrum None None O
agent None None O
in None None O
the None None O
NCI None None O
cell None None O
panel None None O
was None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorobenzothiazole None None I-IUPAC
( None None O
10h None None O
) None None O
which None None O
, None None O
unlike None None O
the None None O
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
isomer None None I-MODIFIER
( None None O
10d None None O
) None None O
, None None O
produces None None O
no None None O
exportable None None O
metabolites None None O
in None None O
the None None O
presence None None O
of None None O
sensitive None None O
MCF None None O
- None None O
7 None None O
cells None None O
. None None O

Induction None None O
of None None O
cytochrome None None O
P450 None None O
CYP1A1 None None O
, None None O
a None None O
crucial None None O
event None None O
in None None O
determining None None O
the None None O
antitumor None None O
specificity None None O
of None None O
this None None O
series None None O
of None None O
benzothiazoles None None O
, None None O
was None None O
not None None O
compromised None None O
. None None O

10h None None O
is None None O
currently None None O
the None None O
focus None None O
of None None O
pharmaceutical None None O
and None None O
preclinical None None O
development None None O
. None None O


With None None O
a None None O
novel None None O
assay None None O
using None None O
isolated None None O
ferret None None O
detrusor None None O
to None None O
estimate None None O
beta None None O
( None None O
3 None None O
) None None O
- None None O
adrenoceptor None None O
agonistic None None O
activity None None O
, None None O
we None None O
found None None O
that None None O
a None None O
series None None O
of None None O
glycine None None O
derivatives None None O
of None None O
ritodrine None None O
, None None O
a None None O
beta None None O
( None None O
2 None None O
) None None O
- None None O
adrenoceptor None None O
agonist None None O
, None None O
are None None O
potent None None O
beta None None O
( None None O
3 None None O
) None None O
- None None O
adrenoceptor None None O
agonists None None O
, None None O
with None None O
excellent None None O
selectivity None None O
versus None None O
beta None None O
( None None O
1 None None O
) None None O
and None None O
beta None None O
( None None O
2 None None O
) None None O
subtypes None None O
. None None O

Substitution None None O
of None None O
halogens None None O
in None None O
the None None O
phenyl None None I-IUPAC
ring None None B-MODIFIER
increased None None O
potency None None O
and None None O
selectivity None None O
for None None O
the None None O
beta None None O
( None None O
3 None None O
) None None O
- None None O
adrenoceptor None None O
, None None O
and None None O
this None None O
was None None O
dependent None None O
upon None None O
the None None O
position None None O
of None None O
the None None O
halogens None None O
. None None O

The None None O
chlorine None None O
- None None O
substituted None None O
derivatives None None O
3f None None O
- None None O
i None None O
exhibited None None O
potent None None O
beta None None O
( None None O
3 None None O
) None None O
- None None O
adrenoceptor None None O
- None None O
mediated None None O
relaxation None None O
of None None O
ferret None None O
detrusor None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
0.93 None None O
, None None O
11 None None O
, None None O
14 None None O
, None None O
and None None O
160 None None O
nM None None O
) None None O
and None None O
higher None None O
potency None None O
at None None O
beta None None O
( None None O
3 None None O
) None None O
- None None O
adrenoceptors None None O
than None None O
at None None O
beta None None O
( None None O
1 None None O
) None None O
or None None O
beta None None O
( None None O
2 None None O
) None None O
. None None O

The None None O
intravenous None None O
administration None None O
of None None O
3h None None O
significantly None None O
reduced None None O
the None None O
urinary None None O
bladder None None O
pressure None None O
in None None O
anesthetized None None O
male None None O
rats None None O
( None None O
ED None None O
( None None O
50 None None O
) None None O
= None None O
48 None None O
microg None None O
/ None None O
kg None None O
) None None O
without None None O
cardiovascular None None O
side None None O
effects None None O
. None None O

This None None O
article None None O
is None None O
the None None O
first None None O
report None None O
of None None O
structure None None O
- None None O
activity None None O
relationships None None O
( None None O
SAR None None O
) None None O
concerning None None O
beta None None O
( None None O
3 None None O
) None None O
- None None O
adrenoceptor None None O
agonists None None O
as None None O
agents None None O
for None None O
the None None O
treatment None None O
of None None O
urinary None None O
frequency None None O
and None None O
incontinence None None O
. None None O


Sugar None None O
- None None O
modified None None O
analogs None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyridazin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
1 None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyridazin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
3 None None O
) None None O
were None None O
prepared None None O
in None None O
an None None O
effort None None O
to None None O
obtain None None O
selective None None O
antiviral None None O
agents None None O
. None None O

Treatment None None O
of None None O
ethyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabinofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrrole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
6 None None O
) None None O
with None None O
hydrazine None None O
afforded None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabinofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyridazin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
7 None None O
) None None O
. None None O

Treatment None None O
of None None O
7 None None O
with None None O
bromine None None O
afforded None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3,5 None None I-IUPAC
- None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabinofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyridazin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
hydrobromide None None I-IUPAC
( None None O
9 None None O
) None None O
. None None O

The None None O
benzyl None None I-IUPAC
ether None None I-IUPAC
functions None None I-MODIFIER
of None None O
7 None None O
and None None O
9 None None O
were None None O
removed None None O
with None None O
boron None None O
trichloride None None O
to None None O
afford None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
arabinofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyridazin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
8 None None O
) None None O
and None None O
its None None O
3 None None O
- None None O
bromo None None O
analog None None O
10 None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrida None None I-IUPAC
zin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
13 None None O
) None None O
was None None O
prepared None None O
by None None O
the None None O
sodium None None O
salt None None O
condensation None None O
of None None O
ethyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyanopyrrole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
5 None None O
) None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoyl None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
chloride None None I-IUPAC
( None None O
11 None None O
) None None O
followed None None O
by None None O
ring None None O
annulation None None O
with None None O
hydrazine None None O
. None None O

Deprotection None None O
of None None O
ethyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoyl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrr None None I-IUPAC
ole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
12 None None O
) None None O
using None None O
sodium None None O
ethoxide None None O
furnished None None O
ethyl None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
erythro None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyanopyrrole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
late None None I-IUPAC
( None None O
14 None None O
) None None O
which None None O
served None None O
as None None O
the None None O
starting None None O
material None None O
for None None O
the None None O
preparation None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
glycero None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
) None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyridazin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
20 None None O
) None None O
. None None O

Selective None None O
protection None None O
of None None O
the None None O
5' None None I-IUPAC
- None None I-IUPAC
hydroxyl None None I-IUPAC
group None None I-MODIFIER
of None None O
14 None None O
with None None O
tert None None I-IUPAC
- None None I-IUPAC
butyldimethylsilyl None None I-IUPAC
chloride None None I-IUPAC
followed None None O
by None None O
a None None O
Barton None None O
type None None O
deoxygenation None None O
sequence None None O
of None None O
the None None O
3' None None I-IUPAC
- None None I-IUPAC
hydroxyl None None I-IUPAC
groups None None I-MODIFIER
afforded None None O
ethyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyldimethylsilyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
glycero None None I-IUPAC
- None None I-IUPAC
pentofuranosyl None None I-IUPAC
] None None I-IUPAC
pyrrole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
( None None O
18 None None O
) None None O
. None None O

Deprotection None None O
of None None O
18 None None O
with None None O
tetra None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butylammonium None None I-IUPAC
fluoride None None I-IUPAC
and None None O
ring None None O
annulation None None O
with None None O
hydrazine None None O
afforded None None O
20 None None O
. None None O

The None None O
acyclic None None I-MODIFIER
analog None None I-MODIFIER
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyridazin None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
24 None None O
) None None O
was None None O
prepared None None O
via None None O
the None None O
sodium None None O
salt None None O
glycosylation None None O
of None None O
5 None None O
with None None O
( None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
bromide None None I-IUPAC
( None None O
22 None None O
) None None O
followed None None O
by None None O
a None None O
ring None None O
annulation None None O
with None None O
hydrazine None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
Bromosuccinimide None None I-IUPAC
treatment None None O
of None None O
13 None None O
, None None O
20 None None O
, None None O
and None None O
25 None None O
afforded None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
derivatives None None I-MODIFIER
15 None None O
, None None O
21 None None O
, None None O
and None None O
25 None None O
. None None O

Evaluation None None O
of None None O
these None None O
compounds None None O
in None None O
L1210 None None O
, None None O
HFF None None O
, None None O
and None None O
KB None None O
cells None None O
showed None None O
that None None O
the None None O
sugar None None O
- None None O
modified None None O
analogs None None O
all None None O
were None None O
less None None O
cytotoxic None None O
than None None O
their None None O
corresponding None None O
ribonucleoside None None O
analogs None None O
. None None O

The None None O
compounds None None O
also None None O
were None None O
less None None O
active None None O
against None None O
human None None O
cytomegalovirus None None O
( None None O
HCMV None None O
) None None O
and None None O
herpes None None O
simplex None None O
virus None None O
type None None O
1 None None O
( None None O
HSV None None O
- None None O
1 None None O
) None None O
. None None O

The None None O
3 None None O
- None None O
bromo None None O
derivatives None None O
were None None O
much None None O
more None None O
active None None O
than None None O
the None None O
3 None None O
- None None O
unsubstituted None None O
analogs None None O
in None None O
both None None O
the None None O
cytotoxicity None None O
, None None O
and None None O
antiviral None None O
assays None None O
. None None O

However None None O
, None None O
there None None O
was None None O
only None None O
modest None None O
separation None None O
between None None O
activity None None O
against None None O
HCMV None None O
and None None O
cytotoxicity None None O
and None None O
there None None O
was None None O
virtually None None O
no None None O
selectivity None None O
for None None O
activity None None O
against None None O
HSV None None O
- None None O
1 None None O
. None None O


The None None O
conformationally None None O
restricted None None O
linear None None O
tricyclic None None O
analogs None None O
of None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
tetralins None None I-IUPAC
were None None O
investigated None None O
for None None O
their None None O
serotonergic None None O
and None None O
dopaminergic None None O
properties None None O
. None None O

These None None O
cis None None O
and None None O
trans None None O
analogs None None O
of None None O
2,3,3 None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
4,9,9 None None I-IUPAC
a None None I-IUPAC
- None None I-IUPAC
hexahydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
benz None None I-IUPAC
[ None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
where None None O
a None None O
five None None O
- None None O
membered None None O
ring None None O
is None None O
fused None None O
between None None O
the None None O
nitrogen None None O
and None None O
C None None O
- None None O
3 None None O
carbon None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
aminotetralin None None I-IUPAC
, None None O
were None None O
synthesized None None O
from None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
8 None None I-IUPAC
- None None I-IUPAC
methoxytetralones None None I-IUPAC
. None None O

The None None O
enantiomers None None O
of None None O
trans None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
and None None O
- None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
allyl None None I-PARTIUPAC
analogs None None I-MODIFIER
were None None O
obtained None None O
via None None O
fractional None None O
recrystallization None None O
of None None O
their None None O
di None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
( None None O
or None None O
D None None I-PARTIUPAC
) None None O
tartaric None None I-IUPAC
acid None None I-IUPAC
salts None None I-IUPAC
. None None O

All None None O
analogs None None O
were None None O
evaluated None None O
in None None O
the None None O
in None None O
vitro None None O
5 None None O
- None None O
HT1A None None O
and None None O
D2 None None O
binding None None O
assays None None O
and None None O
selected None None O
analogs None None O
were None None O
investigated None None O
further None None O
in None None O
biochemical None None O
and None None O
behavioral None None O
tests None None O
. None None O

In None None O
the None None O
5 None None O
- None None O
substituted None None O
series None None O
( None None O
R1 None None O
in None None O
3 None None O
) None None O
, None None O
the None None O
trans None None O
isomers None None O
were None None O
found None None O
to None None O
possess None None O
higher None None O
levels None None O
of None None O
pharmacological None None O
activity None None O
then None None O
the None None O
corresponding None None O
cis None None O
isomers None None O
. None None O

The None None O
trans None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
analogs None None I-MODIFIER
showed None None O
selective None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
activity None None O
in None None O
vitro None None O
but None None O
displayed None None O
mixed None None O
5 None None O
- None None O
HT1A None None O
and None None O
D2 None None O
agonist None None O
properties None None O
in None None O
vivo None None O
. None None O

The None None O
corresponding None None O
trans None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
analogs None None I-MODIFIER
were None None O
found None None O
to None None O
be None None O
potent None None O
D2 None None O
agonists None None O
with None None O
full None None O
intrinsic None None O
activity None None O
. None None O

An None None O
examination None None O
of None None O
nitrogen None None O
substitution None None O
( None None O
R2 None None O
in None None O
3 None None O
) None None O
revealed None None O
that None None O
analogs None None O
with None None O
either None None O
an None None O
allyl None None O
or None None O
an None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
group None None I-MODIFIER
displayed None None O
equipotent None None O
activities None None O
. None None O

Substitution None None O
with None None O
a None None O
cyclopropylmethyl None None O
or None None O
benzyl None None O
group None None O
resulted None None O
in None None O
reduced None None O
activity None None O
. None None O

Among None None O
the None None O
resolved None None O
analogs None None O
tested None None O
, None None O
the None None O
activity None None O
was None None O
found None None O
to None None O
reside None None O
exclusively None None O
in None None O
the None None O
( None None O
3aS None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
enantiomers None None O
. None None O

In None None O
the None None O
8 None None O
- None None O
substituted None None O
series None None O
( None None O
R1 None None O
in None None O
3 None None O
) None None O
, None None O
only None None O
8 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
analogs None None I-MODIFIER
were None None O
synthesized None None O
and None None O
evaluated None None O
. None None O

In None None O
this None None O
case None None O
, None None O
both None None O
cis None None O
and None None O
trans None None O
isomers None None O
showed None None O
equally None None O
weak None None O
in None None O
vitro None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
agonist None None O
activity None None O
devoid None None O
of None None O
dopaminergic None None O
effects None None O
. None None O

The None None O
presence None None O
of None None O
an None None O
additional None None O
methyl None None O
group None None O
at None None O
the None None O
C None None O
- None None O
2 None None O
position None None O
( None None O
R3 None None O
in None None O
3 None None O
) None None O
of None None O
the None None O
cis None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
analog None None I-MODIFIER
resulted None None O
in None None O
enhancement None None O
of None None O
in None None O
vitro None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
binding None None O
affinity None None O
, None None O
with None None O
the None None O
( None None O
2 None None O
beta None None O
, None None O
3a None None O
alpha None None O
, None None O
9a None None O
alpha None None O
) None None O
- None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
isomer None None O
displaying None None O
potency None None O
35 None None O
times None None O
greater None None O
than None None O
the None None O
( None None O
2 None None O
alpha None None O
, None None O
3a None None O
alpha None None O
, None None O
9a None None O
alpha None None O
) None None O
- None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
- None None O
isomer None None O
. None None O


N None None I-IUPAC
- None None I-IUPAC
Acetyl None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
benzoquinone None None I-IUPAC
imine None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
benzoquinone None None I-IUPAC
imine None None I-IUPAC
were None None O
prepared None None O
from None None O
2,6 None None I-IUPAC
- None None I-IUPAC
dimethylacetaminophen None None I-IUPAC
and None None O
3,5 None None I-IUPAC
- None None I-IUPAC
dimethylacetaminophen None None I-IUPAC
by None None O
oxidation None None O
with None None O
lead None None O
tetraacetate None None O
. None None O

Reaction None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
benzoquinone None None I-IUPAC
imine None None I-IUPAC
with None None O
hydrochloric None None O
acid None None O
gave None None O
3' None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
hydroxyacetanilide None None I-IUPAC
, None None O
whereas None None O
ethanethiol None None O
, None None O
aniline None None O
, None None O
and None None O
ethanol None None O
gave None None O
tetrahedral None None O
adducts None None O
resulting None None O
from None None O
addition None None O
to None None O
the None None O
imine None None O
carbon None None O
. None None O

Water None None O
gave None None O
2,6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
benzoquinone None None I-IUPAC
. None None O

With None None O
N None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
benzoquinone None None I-IUPAC
imine None None I-IUPAC
, None None O
water None None O
and None None O
aniline None None O
gave None None O
substitution None None O
on None None O
the None None O
imine None None O
carbon None None O
, None None O
yielding None None O
2,6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
benzoquinone None None I-IUPAC
and None None O
3,5 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
benzoquinone None None I-IUPAC
imine None None I-IUPAC
, None None O
respectively None None O
. None None O

Ethanethiol None None O
gave None None O
3' None None I-IUPAC
.5 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
hydroxyacetanilide None None I-IUPAC
. None None O

The None None O
toxicity None None O
of None None O
2,6 None None I-IUPAC
- None None I-IUPAC
dimethylacetaminophen None None I-IUPAC
and None None O
3,5 None None I-IUPAC
- None None I-IUPAC
dimethylacetaminophen None None I-IUPAC
was None None O
examined None None O
histologically None None O
in None None O
mice None None O
and None None O
rats None None O
. None None O

3,5 None None I-IUPAC
- None None I-IUPAC
Dimethylacetaminophen None None I-IUPAC
was None None O
slightly None None O
more None None O
nephrotoxic None None O
but None None O
showed None None O
a None None O
similar None None O
hepatotoxicity None None O
to None None O
acetaminophen None None O
. None None O

2,6 None None I-IUPAC
- None None I-IUPAC
Dimethylacetaminophen None None I-IUPAC
, None None O
like None None O
N None None I-IUPAC
- None None I-IUPAC
methylacetaminophen None None I-IUPAC
, None None O
showed None None O
very None None O
little None None O
tissue None None O
damage None None O
. None None O


The None None O
in None None O
vitro None None O
pharmacological None None O
properties None None O
and None None O
conformational None None O
features None None O
of None None O
analogs None None O
of None None O
the None None O
delta None None O
opioid None None O
receptor None None O
selective None None O
tetrapeptide None None O
Tyr None None O
- None None O
c None None O
[ None None O
D None None O
- None None O
Cys None None O
- None None O
Phe None None O
- None None O
D None None O
- None None O
Pen None None O
] None None O
OH None None O
( None None O
JOM None None O
- None None O
13 None None O
) None None O
in None None O
which None None O
the None None O
Phe3 None None O
residue None None O
was None None O
replaced None None O
by None None O
each None None O
of None None O
the None None O
four None None O
stereoisomers None None O
of None None O
beta None None I-IUPAC
- None None I-IUPAC
methylphenylalanine None None I-IUPAC
( None None O
beta None None O
- None None O
MePhe None None O
) None None O
were None None O
investigated None None O
. None None O

Both None None O
analogs None None O
in None None O
which None None O
the None None O
alpha None None O
carbon None None O
of None None O
the None None O
Phe3 None None O
replacement None None O
has None None O
L None None O
- None None O
stereochemistry None None O
display None None O
high None None O
affinity None None O
for None None O
delta None None O
receptors None None O
with None None O
the None None O
( None None O
2S None None O
, None None O
3S None None O
) None None O
- None None O
MePhe3 None None O
analog None None O
exhibiting None None O
approximately None None O
8 None None O
- None None O
fold None None O
higher None None O
affinity None None O
than None None O
the None None O
( None None O
2S None None O
, None None O
3R None None O
) None None O
- None None O
MePhe3 None None O
diastereomer None None O
. None None O

Surprisingly None None O
, None None O
one None None O
analog None None O
with None None O
D None None O
- None None O
stereochemistry None None O
in None None O
residue None None O
3 None None O
, None None O
the None None O
( None None O
2R None None O
, None None O
3R None None O
) None None O
- None None O
MePhe3 None None O
analog None None O
, None None O
also None None O
displays None None O
high None None O
affinity None None O
for None None O
the None None O
delta None None O
receptor None None O
and None None O
is None None O
extraordinarily None None O
selective None None O
for None None O
this None None O
receptor None None O
. None None O

All None None O
analogs None None O
were None None O
agonists None None O
in None None O
the None None O
mouse None None O
vas None None O
deferens None None O
( None None O
MVD None None O
) None None O
and None None O
guinea None None O
pig None None O
ileum None None O
( None None O
GPI None None O
) None None O
smooth None None O
muscle None None O
bioassays None None O
, None None O
displaying None None O
MVD None None O
and None None O
GPI None None O
potencies None None O
consistent None None O
with None None O
their None None O
delta None None O
and None None O
mu None None O
opioid None None O
receptor None None O
affinities None None O
, None None O
respectively None None O
. None None O

The None None O
use None None O
of None None O
beta None None O
- None None O
MePhe None None O
as None None O
a None None O
replacement None None O
for None None O
Phe3 None None O
was None None O
based None None O
upon None None O
the None None O
desire None None O
to None None O
reduce None None O
the None None O
conformational None None O
flexibility None None O
of None None O
the None None O
Phe3 None None O
side None None O
chain None None O
by None None O
imposing None None O
a None None O
steric None None O
rotational None None O
constraint None None O
in None None O
the None None O
form None None O
of None None O
the None None O
beta None None O
- None None O
methyl None None O
substituent None None O
and None None O
to None None O
thus None None O
deduce None None O
the None None O
residue None None O
3 None None O
side None None O
chain None None O
orientation None None O
in None None O
the None None O
delta None None O
receptor None None O
- None None O
bound None None O
conformation None None O
from None None O
the None None O
correlation None None O
between None None O
delta None None O
receptor None None O
binding None None O
affinities None None O
and None None O
conformational None None O
preferences None None O
. None None O

Molecular None None O
mechanics None None O
computations None None O
revealed None None O
, None None O
however None None O
, None None O
that None None O
the None None O
conformational None None O
constraints None None O
imposed None None O
by None None O
the None None O
beta None None O
- None None O
methyl None None O
group None None O
in None None O
the None None O
( None None O
2S None None O
, None None O
3S None None O
) None None O
- None None O
MePhe3 None None O
and None None O
( None None O
2S None None O
, None None O
3R None None O
) None None O
- None None O
MePhe3 None None O
analogs None None O
were None None O
too None None O
modest None None O
to None None O
allow None None O
unequivocal None None O
determination None None O
of None None O
delta None None O
receptor None None O
- None None O
bound None None O
residue None None O
3 None None O
side None None O
chain None None O
conformation None None O
. None None O

However None None O
, None None O
analysis None None O
of None None O
the None None O
high None None O
- None None O
affinity None None O
( None None O
2R None None O
, None None O
3R None None O
) None None O
- None None O
MePhe3 None None O
analog None None O
revealed None None O
a None None O
strong None None O
preference None None O
for None None O
a None None O
single None None O
side None None O
chain None None O
conformer None None O
( None None O
chi None None O
1 None None O
approximately None None O
60 None None O
degrees None None O
) None None O
. None None O

Low None None O
- None None O
energy None None O
conformers None None O
of None None O
this None None O
analog None None O
could None None O
only None None O
be None None O
effectively None None O
superimposed None None O
with None None O
low None None O
- None None O
energy None None O
conformers None None O
of None None O
the None None O
parent None None O
peptide None None O
in None None O
which None None O
the None None O
Phe3 None None O
side None None O
chain None None O
conformation None None O
was None None O
limited None None O
to None None O
chi None None O
1 None None O
approximately None None O
- None None O
60 None None O
degrees None None O
. None None O

This None None O
observation None None O
eliminates None None O
the None None O
last None None O
remaining None None O
uncertainty None None O
regarding None None O
conformational None None O
features None None O
of None None O
the None None O
pharmacophore None None O
elements None None O
in None None O
the None None O
delta None None O
receptor None None O
- None None O
bound None None O
state None None O
, None None O
allowing None None O
the None None O
proposal None None O
of None None O
a None None O
complete None None O
model None None O
. None None O


Aromatic None None O
carboxylic None None O
esters None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidinol None None I-IUPAC
were None None O
prepared None None O
and None None O
evaluated None None O
for None None O
analgesic None None O
activity None None O
. None None O

In None None O
addition None None O
, None None O
aralkyl None None I-IUPAC
, None None O
alkyl None None I-IUPAC
, None None O
and None None O
cycloalkyl None None I-IUPAC
carboxylates None None B-IUPAC
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
piperidinol None None I-IUPAC
system None None I-MODIFIER
and None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzoates None None I-IUPAC
of None None O
isomeric None None O
piperidinols None None O
( None None O
24-26 None None O
) None None O
were None None O
synthesized None None O
. None None O

The None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzoate None None I-IUPAC
23 None None O
was None None O
nearly None None O
twice None None O
as None None O
active None None O
as None None O
codeine None None O
in None None O
the None None O
mouse None None O
hot None None O
- None None O
plate None None O
assay None None O
. None None O

In None None O
monkeys None None O
, None None O
23 None None O
showed None None O
no None None O
morphine None None O
- None None O
like None None O
physical None None O
dependence None None O
liability None None O
, None None O
cis None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidinol None None I-IUPAC
esters None None I-IUPAC
24 None None O
and None None O
25 None None O
showed None None O
no None None O
binding None None O
to None None O
the None None O
opiate None None O
receptor None None O
in None None O
rat None None O
brain None None O
homogenates None None O
. None None O

The None None O
3 None None O
- None None O
and None None O
4 None None O
- None None O
monosubstituted None None O
and None None O
the None None O
3,4 None None O
- None None O
disubstituted None None O
benzoate None None O
esters None None O
were None None O
examined None None O
for None None O
qualitative None None O
structure None None O
- None None O
activity None None O
relationships None None O
with None None O
respect None None O
to None None O
parameters None None O
Esc None None O
and None None O
pi None None O
. None None O

Various None None O
structural None None O
features None None O
of None None O
this None None O
series None None O
of None None O
compounds None None O
that None None O
may None None O
have None None O
an None None O
affinity None None O
for None None O
receptor None None O
binding None None O
sites None None O
are None None O
discussed None None O
. None None O


Convenient None None O
and None None O
efficient None None O
methods None None O
were None None O
developed None None O
for None None O
preparing None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorouracil None None I-IUPAC
( None None O
Thf None None O
- None None O
FU None None O
, None None O
3 None None O
) None None O
[ None None O
trade None None O
name None None O
, None None O
Futraful None None O
( None None O
Ftorafur None None O
) None None O
or None None O
FT None None O
- None None O
207 None None O
] None None O
, None None O
which None None O
is None None O
used None None O
clinically None None O
as None None O
an None None O
antitumor None None O
agent None None O
, None None O
and None None O
1,3 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorouracil None None I-IUPAC
( None None O
Thf2 None None O
- None None O
FU None None O
, None None O
4 None None O
) None None O
. None None O

For None None O
the None None O
syntheses None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
trimethylsily None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorouracil None None I-IUPAC
( None None O
Me3Si None None O
- None None O
FU None None O
, None None O
1 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
acetoxytetrahydrofuran None None I-IUPAC
( None None O
Thf None None O
- None None O
OAc None None O
, None None O
2 None None O
) None None O
were None None O
condensed None None O
in None None O
the None None O
presence None None O
of None None O
Friedel None None O
- None None O
Crafts None None O
catalysts None None O
, None None O
such None None O
as None None O
SnCl4 None None O
and None None O
BF3 None None O
- None None O
Et2O None None O
in None None O
dichloromethane None None O
, None None O
or None None O
in None None O
the None None O
presence None None O
of None None O
NaI None None O
in None None O
acetonitrile None None O
to None None O
give None None O
Thf None None O
- None None O
Fu None None O
or None None O
Thf2 None None O
- None None O
FU None None O
depending None None O
on None None O
the None None O
reaction None None O
conditions None None O
and None None O
workup None None O
procedure None None O
. None None O

A None None O
trace None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorouracil None None I-IUPAC
( None None O
3 None None O
- None None O
Thf None None O
- None None O
FU None None O
, None None O
5 None None O
) None None O
was None None O
formed None None O
in None None O
these None None O
reactions None None O
. None None O

Thf2 None None O
- None None O
FU None None O
was None None O
easily None None O
hydrolyzed None None O
to None None O
Thf None None O
- None None O
FU None None O
. None None O

2 None None I-IUPAC
- None None I-IUPAC
Methoxytetrahydrofuran None None I-IUPAC
can None None O
be None None O
used None None O
instead None None O
of None None O
Thf None None O
- None None O
OAc None None O
for None None O
preparation None None O
of None None O
Thf None None O
- None None O
FU None None O
under None None O
similar None None O
conditions None None O
. None None O

The None None O
optimal None None O
ratios None None O
of None None O
Me3Si None None O
- None None O
FU None None O
, None None O
Thf None None O
- None None O
OAc None None O
, None None O
and None None O
SnCl4 None None O
or None None O
NaI None None O
for None None O
preparation None None O
of None None O
Thf None None O
- None None O
FU None None O
and None None O
Thf2 None None O
- None None O
FU None None O
were None None O
determined None None O
. None None O

In None None O
all None None O
cases None None O
, None None O
2-2.5 None None O
equiv None None O
of None None O
Thf None None O
- None None O
OAc None None O
with None None O
respect None None O
to None None O
Me3Si None None O
- None None O
FU None None O
gave None None O
the None None O
best None None O
results None None O
. None None O

The None None O
yields None None O
of None None O
Thf None None O
- None None O
FU None None O
and None None O
more None None O
especially None None O
of None None O
Thf2 None None O
- None None O
FU None None O
were None None O
greatly None None O
dependent None None O
on None None O
the None None O
relative None None O
amount None None O
of None None O
SnCl4 None None O
, None None O
and None None O
0.01-0.1 None None O
equiv None None O
of None None O
the None None O
catalyst None None O
with None None O
respect None None O
to None None O
Me3Si None None O
- None None O
FU None None O
gave None None O
the None None O
best None None O
results None None O
. None None O

Thf2 None None O
- None None O
FU None None O
was None None O
found None None O
to None None O
be None None O
effective None None O
against None None O
murine None None O
solid None None O
tumors None None O
and None None O
it None None O
was None None O
less None None O
toxic None None O
than None None O
Thf None None O
- None None O
FU None None O
when None None O
given None None O
orally None None O
. None None O

The None None O
antitumor None None O
activity None None O
of None None O
3 None None O
- None None O
Thf None None O
- None None O
FU None None O
is None None O
also None None O
reported None None O
. None None O


Previous None None O
findings None None O
suggesting None None O
that None None O
5,10 None None I-IUPAC
- None None I-IUPAC
dialkyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
derivatives None None I-MODIFIER
of None None O
5,10 None None I-IUPAC
- None None I-IUPAC
dideazaaminopterin None None I-IUPAC
warranted None None O
study None None O
as None None O
potential None None O
antifolates None None O
prompted None None O
synthesis None None O
of None None O
10 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5,10 None None I-IUPAC
- None None I-IUPAC
dideazaaminopterin None None I-IUPAC
( None None O
12a None None O
) None None O
. None None O

The None None O
key None None O
step None None O
in None None O
the None None O
synthetic None None O
route None None O
to None None O
12a None None O
was None None O
Wittig None None O
condensation None None O
of None None O
the None None O
tributylphosphorane None None O
derived None None O
from None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylpyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
7a None None O
) None None O
with None None O
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
propionylbenzoate None None I-IUPAC
. None None O

Reaction None None O
conditions None None O
for None None O
the None None O
Wittig None None O
condensation None None O
were None None O
developed None None O
using None None O
the None None O
tributylphosphorane None None O
prepared None None O
from None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
pteridinediamine None None I-IUPAC
( None None O
7b None None O
) None None O
as None None O
a None None O
model None None O
. None None O

Each None None O
of None None O
the None None O
respective None None O
Wittig None None O
products None None O
8a None None O
and None None O
8b None None O
was None None O
obtained None None O
in None None O
75-80% None None O
yield None None O
. None None O

Hydrogenation None None O
of None None O
8a None None O
and None None O
8b None None O
at None None O
their None None O
9,10 None None O
- None None O
double None None O
bond None None O
afforded None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5,10 None None I-IUPAC
- None None I-IUPAC
dideazapteroic None None I-IUPAC
acid None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
( None None O
9a None None O
) None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
deazapteroic None None I-IUPAC
acid None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
( None None O
9b None None O
) None None O
. None None O

This None None O
route None None O
to None None O
9b None None O
intersects None None O
reported None None O
synthetic None None O
approaches None None O
leading None None O
to None None O
10 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
deazaaminopterin None None I-IUPAC
( None None O
10 None None O
- None None O
EDAM None None O
, None None O
edatrexate None None O
) None None O
, None None O
an None None O
agent None None O
now None None O
in None None O
advanced None None O
clinical None None O
trials None None O
. None None O

Thus None None O
the None None O
Wittig None None O
approach None None O
affords None None O
an None None O
alternative None None O
synthetic None None O
route None None O
to None None O
10 None None O
- None None O
EDAM None None O
. None None O

Remaining None None O
steps None None O
were None None O
ester None None O
hydrolysis None None O
of None None O
9a None None O
, None None O
b None None O
to None None O
give None None O
carboxylic None None O
acids None None O
10a None None O
, None None O
b None None O
followed None None O
by None None O
standard None None O
peptide None None O
coupling None None O
with None None O
diethyl None None O
L None None O
- None None O
glutamate None None O
to None None O
produce None None O
diethyl None None O
esters None None O
11a None None O
, None None O
b None None O
, None None O
which None None O
on None None O
hydrolysis None None O
gave None None O
12a None None O
and None None O
10 None None O
- None None O
EDAM None None O
( None None O
12b None None O
) None None O
, None None O
respectively None None O
. None None O

The None None O
relative None None O
influx None None O
of None None O
12a None None O
was None None O
enhanced None None O
about None None O
3.2 None None O
- None None O
fold None None O
over None None O
MTX None None O
, None None O
but None None O
as None None O
an None None O
inhibitor None None O
of None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
from None None O
L1210 None None O
cells None None O
and None None O
in None None O
the None None O
inhibition None None O
of None None O
L1210 None None O
cell None None O
growth None None O
in None None O
vitro None None O
, None None O
this None None O
compound None None O
was None None O
approximately None None O
20 None None O
- None None O
fold None None O
less None None O
effective None None O
than None None O
MTX None None O
( None None O
DHFR None None O
inhibition None None O
, None None O
Ki None None O
= None None O
4.82 None None O
+ None None O
/ None None O
- None None O
0.60 None None O
pM None None O
for None None O
MTX None None O
, None None O
100 None None O
pM None None O
for None None O
12a None None O
; None None O
cell None None O
growth None None O
, None None O
IC50 None None O
= None None O
3.4 None None O
+ None None O
/ None None O
- None None O
1.0 None None O
nM None None O
for None None O
MTX None None O
, None None O
65 None None O
+ None None O
/ None None O
- None None O
18 None None O
nM None None O
for None None O
12a None None O
) None None O
. None None O


The None None O
lead None None O
compound None None O
of None None O
a None None O
new None None O
series None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
ethers None None I-IUPAC
, None None O
the None None O
azetidine None None O
derivative None None O
A None None O
- None None O
85380 None None O
( None None O
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
azetidinylmethoxy None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
) None None O
, None None O
is None None O
a None None O
potent None None O
and None None O
selective None None O
ligand None None O
for None None O
the None None O
human None None O
alpha4beta2 None None O
nicotinic None None O
acetylcholine None None O
receptor None None O
( None None O
nAChR None None O
) None None O
subtype None None O
. None None O

In None None O
vitro None None O
, None None O
the None None O
fluoro None None O
derivative None None O
of None None O
A None None O
- None None O
85380 None None O
( None None O
2 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
azetidinylmethoxy None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
or None None O
F None None O
- None None O
A None None O
- None None O
85380 None None O
) None None O
competitively None None O
displaced None None O
[ None None O
3H None None O
] None None O
cytisine None None O
or None None O
[ None None O
3H None None O
] None None O
epibatidine None None O
with None None O
Ki None None O
values None None O
of None None O
48 None None O
and None None O
46 None None O
pM None None O
, None None O
respectively None None O
. None None O

F None None O
- None None O
A None None O
- None None O
85380 None None O
has None None O
been None None O
labeled None None O
with None None O
the None None O
positron None None O
emitter None None O
fluorine None None O
- None None O
18 None None O
( None None O
t1/2 None None O
( None None O
half None None O
- None None O
life None None O
) None None O
= None None O
110 None None O
min None None O
) None None O
by None None O
no None None O
- None None O
carrier None None O
- None None O
added None None O
nucleophilic None None O
aromatic None None O
substitution None None O
by None None O
K None None O
[ None None O
18F None None O
] None None O
F None None O
- None None O
K222 None None O
complex None None O
with None None O
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
azetidinylmethoxy None None I-IUPAC
] None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
tri None None I-IUPAC
methylammonium None None I-IUPAC
trifluoromethanesulfonate None None I-IUPAC
as None None O
a None None O
highly None None O
efficient None None O
labeling None None O
precursor None None O
, None None O
followed None None O
by None None O
TFA None None O
removal None None O
of None None O
the None None O
Boc None None O
protective None None O
group None None O
. None None O

The None None O
total None None O
synthesis None None O
time None None O
was None None O
50-53 None None O
min None None O
from None None O
the None None O
end None None O
of None None O
cyclotron None None O
fluorine None None O
- None None O
18 None None O
production None None O
( None None O
EOB None None O
) None None O
. None None O

Radiochemical None None O
yields None None O
, None None O
with None None O
respect None None O
to None None O
initial None None O
[ None None O
18F None None O
] None None O
fluoride None None O
ion None None O
radioactivity None None O
, None None O
were None None O
68-72% None None O
( None None O
decay None None O
- None None O
corrected None None O
) None None O
and None None O
49-52% None None O
( None None O
non None None O
- None None O
decay None None O
- None None O
corrected None None O
) None None O
, None None O
and None None O
the None None O
specific None None O
radioactivities None None O
at None None O
EOB None None O
were None None O
4-7 None None O
Ci None None O
/ None None O
micromol None None O
( None None O
148-259 None None O
GBq None None O
/ None None O
micromol None None O
) None None O
. None None O

In None None O
vivo None None O
characterization None None O
of None None O
[ None None O
18F None None O
] None None O
F None None O
- None None O
A None None O
- None None O
85380 None None O
showed None None O
promising None None O
properties None None O
for None None O
PET None None O
imaging None None O
of None None O
central None None O
nAChRs None None O
. None None O

This None None O
compound None None O
does None None O
not None None O
bind None None O
in None None O
vivo None None O
to None None O
alpha7 None None O
nicotinic None None O
or None None O
5HT3 None None O
receptors None None O
. None None O

Moreover None None O
, None None O
its None None O
cerebral None None O
uptake None None O
can None None O
be None None O
modulated None None O
by None None O
the None None O
synaptic None None O
concentration None None O
of None None O
the None None O
endogenous None None O
ligand None None O
acetylcholine None None O
. None None O

The None None O
preliminary None None O
PET None None O
experiments None None O
in None None O
baboons None None O
with None None O
[ None None O
18F None None O
] None None O
F None None O
- None None O
A None None O
- None None O
85380 None None O
show None None O
an None None O
accumulation None None O
of None None O
the None None O
radiotracer None None O
in None None O
the None None O
brain None None O
within None None O
60 None None O
min None None O
. None None O

In None None O
the None None O
thalamus None None O
, None None O
a None None O
nAChR None None O
- None None O
rich None None O
area None None O
, None None O
uptake None None O
of None None O
radioactivity None None O
reached None None O
a None None O
maximum None None O
at None None O
60 None None O
min None None O
( None None O
4% None None O
I None None O
. None None O

D None None O
. None None O

/ None None O
100 None None O
mL None None O
of None None O
tissue None None O
) None None O
. None None O

[ None None O
18F None None O
] None None O
F None None O
- None None O
A None None O
- None None O
85380 None None O
appears None None O
to None None O
be None None O
a None None O
suitable None None O
radioligand None None O
for None None O
brain None None O
imaging None None O
nAChRs None None O
with None None O
PET None None O
. None None O


A None None O
series None None O
of None None O
28 None None O
new None None O
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amines None None I-IUPAC
, None None O
pyrimido None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amines None None I-IUPAC
, None None O
and None None O
tetrahydropyrimido None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amines None None I-IUPAC
was None None O
synthesized None None O
and None None O
their None None O
adenosine None None O
receptor None None O
affinity None None O
determined None None O
in None None O
radioligand None None O
binding None None O
assays None None O
at None None O
rat None None O
A None None O
( None None O
1 None None O
) None None O
and None None O
A None None O
( None None O
2A None None O
) None None O
adenosine None None O
receptors None None O
( None None O
ARs None None O
) None None O
. None None O

Selected None None O
compounds None None O
were None None O
additionally None None O
investigated None None O
in None None O
binding None None O
assays None None O
at None None O
recombinant None None O
A None None O
( None None O
3 None None O
) None None O
ARs None None O
. None None O

The None None O
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
residue None None I-MODIFIER
in None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methylbenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenylpyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amine None None I-IUPAC
( None None O
ADPEP None None O
, None None O
1 None None O
) None None O
and None None O
in None None O
the None None O
corresponding None None O
pyrimido None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
( None None O
APEPI None None O
, None None O
3 None None O
) None None O
could None None O
be None None O
bioisosterically None None O
replaced None None O
by None None O
heterocyclic None None O
rings None None O
, None None O
such None None O
as None None O
2 None None I-IUPAC
- None None I-IUPAC
thienyl None None I-IUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
. None None O

The None None O
resulting None None O
compounds None None O
retained None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
A None None O
( None None O
1 None None O
) None None O
ARs None None O
. None None O

Judging None None O
from None None O
the None None O
investigation None None O
of None None O
selected None None O
compounds None None O
, None None O
it None None O
appears None None O
that None None O
they None None O
are None None O
also None None O
potent None None O
at None None O
human None None O
A None None O
( None None O
1 None None O
) None None O
ARs None None O
and None None O
selective None None O
not None None O
only None None O
versus None None O
A None None O
( None None O
2A None None O
) None None O
ARs None None O
but None None O
also None None O
highly None None O
selective None None O
versus None None O
A None None O
( None None O
2B None None O
) None None O
and None None O
A None None O
( None None O
3 None None O
) None None O
ARs None None O
. None None O

The None None O
p None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
derivatives None None B-MODIFIER
11 None None O
and None None O
27 None None O
( None None O
APPPI None None O
) None None O
may None None O
be None None O
interesting None None O
pharmacological None None O
tools None None O
due None None O
to None None O
their None None O
fluorescent None None O
properties None None O
. None None O

Pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amine None None I-IUPAC
derivatives None None I-MODIFIER
which None None O
were None None O
simultaneously None None O
substituted None None O
at None None O
N7 None None O
and None None O
N None None O
( None None O
4 None None O
) None None O
, None None O
combining None None O
the None None O
substitution None None O
pattern None None O
of None None O
ADPEP None None O
( None None O
1 None None O
) None None O
and None None O
DPEAP None None O
( None None O
2 None None O
) None None O
, None None O
showed None None O
very None None O
low None None O
affinity None None O
for None None O
A None None O
( None None O
1 None None O
) None None O
ARs None None O
. None None O

This None None O
finding None None O
supports None None O
our None None O
previously None None O
published None None O
hypothesis None None O
of None None O
different None None O
binding None None O
modes None None O
for None None O
pyrrolopyrimidines None None O
, None None O
such None None O
as None None O
ADPEP None None O
( None None O
1 None None O
) None None O
and None None O
DPEAP None None O
( None None O
2 None None O
) None None O
. None None O

DPEAP None None O
( None None O
2 None None O
) None None O
, None None O
a None None O
pyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amine None None I-IUPAC
substituted None None O
at None None O
the None None O
amino None None O
group None None O
( None None O
N None None O
( None None O
4 None None O
) None None O
) None None O
, None None O
was None None O
found None None O
to None None O
exhibit None None O
high None None O
affinity None None O
for None None O
human None None O
A None None O
( None None O
3 None None O
) None None O
ARs None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
28 None None O
nM None None O
) None None O
, None None O
whereas None None O
N None None O
( None None O
4 None None O
) None None O
- None None O
unsubstituted None None O
analogues None None O
were None None O
inactive None None O
. None None O

DPEAP None None O
( None None O
2 None None O
) None None O
and None None O
related None None O
compounds None None O
provide None None O
new None None O
leads None None O
for None None O
the None None O
development None None O
of None None O
antagonists None None O
for None None O
the None None O
human None None O
A None None O
( None None O
3 None None O
) None None O
AR None None O
. None None O


N None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
omega None None I-PARTIUPAC
- None None I-PARTIUPAC
Aminoalkyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
2,2,5,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
tetramethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
pyrroline None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
- None None I-PARTIUPAC
pyrrolidine None None I-PARTIUPAC
- None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
carboxamides None None I-PARTIUPAC
were None None O
acylated None None O
on None None O
the None None O
primary None None O
amino None None O
group None None O
of None None O
the None None O
side None None O
chain None None O
by None None O
means None None O
of None None O
reactive None None O
acid None None O
derivatives None None O
( None None O
acid None None O
chlorides None None O
, None None O
activated None None O
esters None None O
, None None O
phthalic None None O
anhydrides None None O
, None None O
phthalimide None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
3,1 None None I-IUPAC
- None None I-IUPAC
benzoxazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
) None None O
or None None O
they None None O
were None None O
alkylated None None O
by None None O
forming None None O
the None None O
Schiff None None O
bases None None O
and None None O
subsequent None None O
sodium None None O
borohydride None None O
reduction None None O
. None None O

Other None None O
tetramethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyrrolinecarboxamide None None I-IUPAC
compounds None None I-MODIFIER
were None None O
synthesized None None O
by None None O
acylating None None O
the None None O
aminoalkyl None None I-IUPAC
compounds None None B-MODIFIER
with None None O
2,2,6,6 None None I-IUPAC
- None None I-IUPAC
tetramethyl None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dibromo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
piperidinone None None I-IUPAC
in None None O
a None None O
reaction None None O
involving None None O
Favorskii None None O
rearrangement None None O
. None None O

Saturation None None O
of None None O
the None None O
double None None O
bond None None O
of None None O
some None None O
pyrroline None None I-IUPAC
derivatives None None B-MODIFIER
furnished None None O
the None None O
pyrrolidinecarboxamides None None O
. None None O

The None None O
new None None O
compounds None None O
of None None O
each None None O
type None None O
were None None O
active None None O
against None None O
aconitine None None O
- None None O
induced None None O
arrhythmia None None O
and None None O
several None None O
of None None O
them None None O
had None None O
higher None None O
activity None None O
and None None O
better None None O
chemotherapeutic None None O
index None None O
than None None O
quinidine None None O
. None None O

A None None O
few None None O
selected None None O
examples None None O
from None None O
each None None O
type None None O
of None None O
the None None O
active None None O
new None None O
compounds None None O
showed None None O
strong None None O
activity None None O
against None None O
ouabain None None O
- None None O
induced None None O
arrhythmia None None O
; None None O
for None None O
comparison None None O
known None None O
drugs None None O
such None None O
as None None O
lidocaine None None O
, None None O
mexiletine None None O
, None None O
and None None O
tocainide None None O
were None None O
selected None None O
. None None O

The None None O
most None None O
potent None None O
compounds None None O
were None None O
oxidized None None O
to None None O
the None None O
paramagnetic None None O
nitroxides None None O
and None None O
the None None O
latter None None O
were None None O
reduced None None O
to None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
derivatives None None I-MODIFIER
; None None O
these None None O
products None None O
had None None O
no None None O
or None None O
only None None O
decreased None None O
antiarrhythmic None None O
effect None None O
. None None O


New None None O
1H None None I-IUPAC
, None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
pyrimido None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
purine None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
arylpiperazine None None O
( None None O
11-22 None None O
) None None O
were None None O
prepared None None O
and None None O
evaluated None None O
in None None O
vitro None None O
for None None O
their None None O
affinity None None O
for None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
, None None O
5 None None O
- None None O
HT None None O
( None None O
2A None None O
) None None O
, None None O
alpha None None O
( None None O
1 None None O
) None None O
, None None O
and None None O
D None None O
( None None O
2 None None O
) None None O
receptors None None O
. None None O

The None None O
tested None None O
compounds None None O
showed None None O
high None None O
affinity None None O
for None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
and None None O
alpha None None O
( None None O
1 None None O
) None None O
receptors None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
1.1-87 None None O
and None None O
10-62 None None O
nM None None O
, None None O
respectively None None O
) None None O
and None None O
moderate None None O
to None None O
low None None O
affinity None None O
for None None O
5 None None O
- None None O
HT None None O
( None None O
2A None None O
) None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
56-881 None None O
nM None None O
) None None O
and None None O
D None None O
( None None O
2 None None O
) None None O
receptors None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
94-1245 None None O
nM None None O
) None None O
. None None O

Compounds None None O
14 None None O
, None None O
15 None None O
, None None O
18 None None O
, None None O
19 None None O
, None None O
and None None O
21 None None O
, None None O
mostly None None O
3' None None I-IUPAC
- None None I-IUPAC
chlorophenylpiperazine None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
can None None O
be None None O
classified None None O
as None None O
mixed None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
/ None None O
5 None None O
- None None O
HT None None O
( None None O
2A None None O
) None None O
/ None None O
alpha None None O
( None None O
1 None None O
) None None O
ligands None None O
. None None O

Compound None None O
13 None None O
, None None O
which None None O
showed None None O
the None None O
highest None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
receptor None None O
affinity None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
1.1 None None O
nM None None O
) None None O
, None None O
was None None O
50 None None O
- None None O
fold None None O
selective None None O
in None None O
relation None None O
to None None O
alpha None None O
( None None O
1 None None O
) None None O
adrenoceptors None None O
and None None O
at None None O
least None None O
250 None None O
- None None O
fold None None O
over None None O
5 None None O
- None None O
HT None None O
( None None O
2A None None O
) None None O
and None None O
D None None O
( None None O
2 None None O
) None None O
sites None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
in None None O
vivo None None O
functional None None O
tests None None O
, None None O
8 None None I-IUPAC
- None None I-IUPAC
phenylpiperazinoethylamino None None I-IUPAC
( None None O
11 None None O
) None None O
, None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
methoxyphenylpiperazino None None I-IUPAC
) None None I-IUPAC
ethylamino None None I-IUPAC
( None None O
13 None None O
) None None O
, None None O
and None None O
8 None None I-IUPAC
- None None I-IUPAC
phenylpiperazinopropylamino None None I-IUPAC
( None None O
14 None None O
) None None O
derivatives None None I-MODIFIER
of None None O
1,3 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
, None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
pyrimido None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
purine None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
were None None O
identified None None O
as None None O
potent None None O
pre None None O
- None None O
and None None O
postsynaptic None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
receptor None None O
antagonists None None O
. None None O

1,3 None None I-IUPAC
- None None I-IUPAC
Dimethyl None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylpiperazinopropylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
, None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
pyrimido None None I-IUPAC
[ None None I-IUPAC
2,1 None None I-IUPAC
- None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
purine None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
( None None O
20 None None O
) None None O
behaved None None O
like None None O
an None None O
agonist None None O
of None None O
presynaptic None None O
and None None O
as None None O
a None None O
partial None None O
agonist None None O
of None None O
postsynaptic None None O
5 None None O
- None None O
HT None None O
( None None O
1A None None O
) None None O
receptors None None O
and None None O
resembled None None O
ipsapirone None None O
in None None O
terms None None O
of None None O
functional None None O
intrinsic None None O
activity None None O
. None None O

It None None O
revealed None None O
marked None None O
anxiolytic None None O
- None None O
like None None O
activity None None O
in None None O
the None None O
Vogel None None O
test None None O
in None None O
rats None None O
, None None O
comparable None None O
to None None O
that None None O
of None None O
the None None O
reference None None O
drug None None O
diazepam None None O
, None None O
and None None O
exhibited None None O
antidepressant None None O
- None None O
like None None O
activity None None O
in None None O
the None None O
Porsolt None None O
test None None O
in None None O
rats None None O
. None None O

The None None O
sedative None None O
effect None None O
of None None O
20 None None O
, None None O
evaluated None None O
in None None O
the None None O
open None None O
field None None O
test None None O
in None None O
rats None None O
, None None O
appeared None None O
at None None O
doses None None O
twice None None O
as None None O
high None None O
as None None O
those None None O
inducing None None O
a None None O
minimal None None O
anxiolytic None None O
- None None O
like None None O
effect None None O
and None None O
was None None O
similar None None O
to None None O
the None None O
effects None None O
of None None O
diazepam None None O
. None None O


N None None I-IUPAC
- None None I-IUPAC
Methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
phenethylphenylacetamide None None I-IUPAC
has None None O
been None None O
reported None None O
to None None O
be None None O
a None None O
key None None O
binding None None O
domain None None O
to None None O
LTB4 None None O
receptors None None O
. None None O

Here None None O
we None None O
describe None None O
the None None O
synthesis None None O
and None None O
structure None None O
- None None O
activity None None O
relationship None None O
( None None O
SAR None None O
) None None O
studies None None O
of None None O
two None None O
new None None O
series None None O
of None None O
LTB4 None None O
receptor None None O
antagonists None None O
in None None O
which None None O
the None None O
phenyl None None O
ring None None O
of None None O
this None None O
receptor None None O
binding None None O
domain None None O
is None None O
replaced None None O
with None None O
indole None None O
and None None O
naphthalene None None O
, None None O
respectively None None O
. None None O

Results None None O
of None None O
these None None O
studies None None O
indicate None None O
that None None O
, None None O
in None None O
addition None None O
to None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
methyl None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoethyl None None I-IUPAC
moiety None None I-MODIFIER
, None None O
the None None O
presence None None O
of None None O
an None None O
acid None None O
group None None O
and None None O
a None None O
lipophilic None None O
side None None O
chain None None O
, None None O
as None None O
well None None O
as None None O
the None None O
spatial None None O
relationship None None O
of None None O
these None None O
three None None O
functions None None O
, None None O
is None None O
crucial None None O
for None None O
high None None O
binding None None O
affinity None None O
with None None O
LTB4 None None O
receptors None None O
. None None O

Our None None O
SAR None None O
studies None None O
also None None O
reveal None None O
that None None O
an None None O
arenecarboxylic None None O
acid None None O
, None None O
or None None O
an None None O
enoic None None O
acid None None O
in None None O
which None None O
the None None O
carboxyl None None I-IUPAC
group None None B-MODIFIER
is None None O
conjugated None None O
with None None O
the None None O
central None None O
ring None None O
, None None O
is None None O
the None None O
preferred None None O
polar None None O
group None None O
. None None O

The None None O
lipophilic None None O
side None None O
chain None None O
of None None O
the None None O
naphthyl None None I-IUPAC
series None None B-MODIFIER
was None None O
found None None O
to None None O
tolerate None None O
minor None None O
variations None None O
, None None O
ranging None None O
from None None O
a None None O
phenylmethoxy None None I-IUPAC
group None None B-MODIFIER
to None None O
phenyl None None I-IUPAC
and None None O
alkyloxy None None I-IUPAC
groups None None B-MODIFIER
. None None O

The None None O
most None None O
active None None O
compounds None None O
are None None O
2 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
methyl None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylmethoxy None None I-IUPAC
) None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
propenoic+ None None I-IUPAC
+ None None I-IUPAC
+ None None I-IUPAC
acid None None I-IUPAC
( None None O
4g None None O
) None None O
of None None O
the None None O
indolyl None None O
series None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
methyl None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylmethoxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthalenecarboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
2a None None O
) None None O
or None None O
the None None O
naphthyl None None I-IUPAC
series None None B-MODIFIER
, None None O
with None None O
IC50 None None O
of None None O
8 None None O
and None None O
4.7 None None O
nM None None O
respectively None None O
, None None O
in None None O
the None None O
receptor None None O
binding None None O
assay None None O
using None None O
intact None None O
human None None O
neutrophils None None O
. None None O


5 None None I-IUPAC
- None None I-IUPAC
Deaza None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
propargylfolic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
an None None O
analogue None None O
of None None O
the None None O
thymidylate None None O
synthase None None O
( None None O
TS None None O
) None None O
inhibitor None None O
10 None None I-IUPAC
- None None I-IUPAC
propargyl None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dideazafolic None None I-IUPAC
acid None None I-IUPAC
( None None O
PDDF None None O
, None None O
1 None None O
) None None O
, None None O
was None None O
prepared None None O
via None None O
alkylation None None O
of None None O
diethyl None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
propargylamino None None I-IUPAC
) None None I-IUPAC
benzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
( None None O
7 None None O
) None None O
by None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidinone None None I-IUPAC
( None None O
15 None None O
) None None O
. None None O

Bromomethyl None None O
intermediate None None O
15 None None O
was None None O
prepared None None O
from None None O
the None None O
corresponding None None O
hydroxymethyl None None I-IUPAC
precursor None None B-MODIFIER
14 None None O
by None None O
treatment None None O
with None None O
48% None None O
HBr None None O
. None None O

Hydroxymethyl None None O
compound None None O
14 None None O
was None None O
obtained None None O
by None None O
deamination None None O
of None None O
reported None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diaminopyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methanol None None I-IUPAC
( None None O
12a None None O
) None None O
in None None O
refluxing None None O
1 None None O
N None None O
NaOH None None O
. None None O

Both None None O
12a None None O
and None None O
its None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
analogue None None B-MODIFIER
12b None None O
were None None O
converted None None O
to None None O
versatile None None O
6 None None I-IUPAC
- None None I-IUPAC
bromomethyl None None I-IUPAC
intermediates None None I-MODIFIER
13a None None O
and None None O
13b None None O
from None None O
which None None O
important None None O
antifolates None None O
may None None O
be None None O
readily None None O
derived None None O
. None None O

Alkylation None None O
of None None O
7 None None O
by None None O
13a None None O
, None None O
b None None O
led None None O
to None None O
10 None None I-IUPAC
- None None I-IUPAC
propargyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deazaaminopterin None None I-IUPAC
( None None O
5 None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
propargyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deazaaminopterin None None I-IUPAC
( None None O
6 None None O
) None None O
. None None O

As None None O
an None None O
inhibitor None None O
of None None O
TS None None O
from None None O
H35F None None O
/ None None O
F None None O
cells None None O
, None None O
4 None None O
gave None None O
an None None O
IC50 None None O
value None None O
showing None None O
it None None O
to None None O
be None None O
approximately None None O
6 None None O
- None None O
fold None None O
less None None O
inhibitory None None O
than None None O
PDDF None None O
( None None O
90 None None O
nM None None O
for None None O
4 None None O
vs None None O
14 None None O
nM None None O
for None None O
PDDF None None O
) None None O
. None None O

In None None O
in None None O
vitro None None O
studies None None O
, None None O
IC50 None None O
( None None O
microM None None O
) None None O
values None None O
obtained None None O
for None None O
4 None None O
vs None None O
L1210 None None O
and None None O
S180 None None O
of None None O
1.50 None None O
and None None O
2.35 None None O
, None None O
respectively None None O
, None None O
were None None O
similar None None O
to None None O
those None None O
obtained None None O
for None None O
PDDF None None O
( None None O
2.61 None None O
and None None O
1.97 None None O
) None None O
. None None O

Against None None O
HL60 None None O
cells None None O
, None None O
4 None None O
was None None O
about None None O
7 None None O
- None None O
fold None None O
more None None O
cytotoxic None None O
than None None O
PDDF None None O
( None None O
IC50 None None O
values None None O
0.72 None None O
and None None O
5.29 None None O
microM None None O
) None None O
. None None O

Inclusion None None O
of None None O
thymidine None None O
did None None O
not None None O
establish None None O
TS None None O
as None None O
the None None O
site None None O
of None None O
cytotoxic None None O
action None None O
for None None O
either None None O
4 None None O
or None None O
PDDF None None O
in None None O
the None None O
cell None None O
lines None None O
used None None O
. None None O

In None None O
in None None O
vivo None None O
tests None None O
against None None O
L1210 None None O
in None None O
mice None None O
, None None O
4 None None O
failed None None O
to None None O
show None None O
therapeutic None None O
effect None None O
. None None O

The None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
compounds None None I-MODIFIER
5 None None O
and None None O
6 None None O
were None None O
as None None O
potent None None O
inhibitors None None O
of None None O
DHFR None None O
from None None O
L1210 None None O
cells None None O
as None None O
MTX None None O
and None None O
7 None None O
- None None O
and None None O
35 None None O
- None None O
fold None None O
, None None O
respectively None None O
, None None O
more None None O
inhibitory None None O
than None None O
MTX None None O
toward None None O
L1210 None None O
cell None None O
growth None None O
. None None O

In None None O
mediated None None O
influx None None O
into None None O
L1210 None None O
cells None None O
, None None O
5 None None O
and None None O
6 None None O
were None None O
transported None None O
2.7 None None O
- None None O
and None None O
8.5 None None O
- None None O
fold None None O
, None None O
respectively None None O
, None None O
more None None O
readily None None O
than None None O
MTX None None O
. None None O

Against None None O
the None None O
EO771 None None O
mammary None None O
adenocarcinoma None None O
in None None O
mice None None O
, None None O
6 None None O
produced None None O
greater None None O
antitumor None None O
effect None None O
than None None O
MTX None None O
. None None O

A None None O
dose None None O
of None None O
36 None None O
mg None None O
/ None None O
kg None None O
per None None O
day None None O
for None None O
5 None None O
days None None O
caused None None O
no None None O
toxic None None O
deaths None None O
while None None O
the None None O
average None None O
tumor None None O
volume None None O
among None None O
10 None None O
mice None None O
was None None O
reduced None None O
to None None O
8-9% None None O
of None None O
that None None O
of None None O
the None None O
control None None O
, None None O
and None None O
20% None None O
of None None O
the None None O
test None None O
animals None None O
were None None O
rendered None None O
tumor None None O
free None None O
. None None O


1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
Chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
imidazolidine None None I-IUPAC
( None None O
1 None None O
) None None O
, None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
desnitro None None I-IUPAC
metabolite None None I-MODIFIER
of None None O
the None None O
major None None O
insecticide None None O
imidacloprid None None O
, None None O
is None None O
known None None O
to None None O
have None None O
similar None None O
potency None None O
to None None O
that None None O
of None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nicotine None None I-IUPAC
as None None O
an None None O
inhibitor None None O
of None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nicotine None None I-IUPAC
binding None None O
at None None O
the None None O
rat None None O
recombinant None None O
alpha4beta2 None None O
neuronal None None O
nicotinic None None O
acetylcholine None None O
receptor None None O
( None None O
nAChR None None O
) None None O
; None None O
IC50 None None O
values None None O
in None None O
the None None O
present None None O
study None None O
are None None O
3.8 None None O
nM None None O
for None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nicotine None None I-IUPAC
, None None O
6.0 None None O
nM None None O
for None None O
1 None None O
, None None O
and None None O
155 None None O
nM None None O
for None None O
imidacloprid None None O
. None None O

Synthesis None None O
of None None O
new None None O
analogues None None O
of None None O
1 None None O
, None None O
modified None None O
only None None O
in None None O
the None None O
heterocyclic None None O
moiety None None O
( None None O
five None None O
- None None O
, None None O
six None None O
- None None O
, None None O
or None None O
seven None None O
- None None O
membered None None O
rings None None O
with None None O
NH None None O
, None None O
S None None O
, None None O
O None None O
, None None O
and None None O
CH2 None None O
substituents None None O
) None None O
, None None O
gave None None O
compounds None None O
varying None None O
from None None O
4 None None O
- None None O
fold None None O
higher None None O
potency None None O
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iminothiazole None None I-IUPAC
analogue None None O
10 None None O
) None None O
to None None O
& None None O
gt None None O
; None None O
6000 None None O
- None None O
fold None None O
less None None O
active None None O
than None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nicotine None None I-IUPAC
. None None O

Other None None O
potent None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
compounds None None I-MODIFIER
are None None O
those None None O
in None None O
which None None O
the None None O
heterocyclic None None O
imine None None O
is None None O
replaced None None O
with None None O
pyrrolidine None None O
( None None O
19 None None O
) None None O
( None None O
IC50 None None O
9 None None O
nM None None O
) None None O
or None None O
trimethylammonium None None O
( None None O
22 None None O
) None None O
( None None O
IC50 None None O
18 None None O
nM None None O
) None None O
. None None O

A None None O
novel None None O
conversion None None O
of None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
nicotine None None I-IUPAC
to None None O
its None None O
6 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
analogue None None I-MODIFIER
increased None None O
the None None O
potency None None O
2 None None O
- None None O
fold None None O
. None None O

These None None O
6 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
compounds None None I-MODIFIER
are None None O
of None None O
interest None None O
as None None O
novel None None O
nAChR None None O
probes None None O
and None None O
potential None None O
metabolites None None O
of None None O
candidate None None O
insecticides None None O
. None None O


Two None None O
complete None None O
and None None O
two None None O
partial None None O
structure None None O
- None None O
activity None None O
relationship None None O
scans None None O
of None None O
the None None O
active None None O
fragment None None O
of None None O
human None None O
growth None None O
hormone None None O
- None None O
releasing None None O
hormone None None O
, None None O
[ None None O
Nle27 None None O
] None None O
- None None O
hGHRH None None O
( None None O
1-29 None None O
) None None O
- None None O
NH2 None None O
, None None O
have None None O
identified None None O
potent None None O
agonists None None O
in None None O
vitro None None O
. None None O

Single None None O
- None None O
point None None O
replacement None None O
of None None O
each None None O
amino None None O
acid None None O
by None None O
alanine None None O
led None None O
to None None O
the None None O
identification None None O
of None None O
[ None None O
Ala8 None None O
] None None O
- None None O
, None None O
[ None None O
Ala9 None None O
] None None O
- None None O
, None None O
[ None None O
Ala15 None None O
] None None O
- None None O
( None None O
Felix None None O
et None None O
al. None None O
Peptides None None O
1986 None None O
1986 None None O
, None None O
481 None None O
) None None O
, None None O
[ None None O
Ala22 None None O
] None None O
- None None O
, None None O
and None None O
[ None None O
Ala28 None None O
, None None O
Nle27 None None O
] None None O
- None None O
hGHRH None None O
( None None O
1-29 None None O
) None None O
- None None O
NH2 None None O
as None None O
being None None O
2-6 None None O
times None None O
more None None O
potent None None O
than None None O
hGHRH None None O
( None None O
1-40 None None O
) None None O
- None None O
OH None None O
( None None O
standard None None O
) None None O
in None None O
vitro None None O
. None None O

Nearly None None O
complete None None O
loss None None O
of None None O
potency None None O
was None None O
seen None None O
for None None O
[ None None O
Ala1 None None O
] None None O
, None None O
[ None None O
Ala3 None None O
] None None O
, None None O
[ None None O
Ala5 None None O
] None None O
, None None O
[ None None O
Ala6 None None O
] None None O
, None None O
[ None None O
Ala10 None None O
] None None O
, None None O
[ None None O
Ala11 None None O
] None None O
, None None O
[ None None O
Ala13 None None O
] None None O
, None None O
[ None None O
Ala14 None None O
] None None O
, None None O
and None None O
[ None None O
Ala23 None None O
] None None O
, None None O
whereas None None O
[ None None O
Ala16 None None O
] None None O
, None None O
[ None None O
Ala18 None None O
] None None O
, None None O
[ None None O
Ala24 None None O
] None None O
, None None O
[ None None O
Ala25 None None O
] None None O
, None None O
[ None None O
Ala26 None None O
] None None O
, None None O
and None None O
[ None None O
Ala29 None None O
] None None O
yielded None None O
equipotent None None O
analogues None None O
and None None O
[ None None O
Ala7 None None O
] None None O
, None None O
[ None None O
Ala12 None None O
] None None O
, None None O
[ None None O
Ala17 None None O
] None None O
, None None O
[ None None O
Ala20 None None O
] None None O
, None None O
[ None None O
Ala21 None None O
] None None O
, None None O
and None None O
[ None None O
Ala27 None None O
] None None O
gave None None O
weak None None O
agonists None None O
with None None O
potencies None None O
15-40% None None O
that None None O
of None None O
the None None O
standard None None O
. None None O

The None None O
multiple None None O
- None None O
alanine None None O
- None None O
substituted None None O
peptides None None O
[ None None O
MeTyr1 None None O
, None None O
Ala15 None None O
, None None O
22 None None O
, None None O
Nle27 None None O
] None None O
- None None O
hGHRH None None O
( None None O
1-29 None None O
) None None O
- None None O
NH2 None None O
( None None O
29 None None O
) None None O
and None None O
[ None None O
MeTyr1 None None O
, None None O
Ala8 None None O
, None None O
9,15,22,28 None None O
, None None O
Nle None None O
27 None None O
] None None O
- None None O
hGHRH None None O
( None None O
1-29 None None O
) None None O
- None None O
NH2 None None O
( None None O
30 None None O
) None None O
released None None O
growth None None O
hormone None None O
26 None None O
and None None O
11 None None O
times None None O
, None None O
respectively None None O
, None None O
more None None O
effectively None None O
than None None O
the None None O
standard None None O
in None None O
vitro None None O
. None None O

Individual None None O
substitution None None O
of None None O
the None None O
nine None None O
most None None O
potent None None O
peptides None None O
identified None None O
from None None O
the None None O
Ala None None O
series None None O
with None None O
the None None O
helix None None O
promoter None None O
alpha None None I-IUPAC
- None None I-IUPAC
aminoisobutyric None None I-IUPAC
acid None None I-IUPAC
( None None O
Aib None None O
) None None O
produced None None O
similar None None O
results None None O
, None None O
except None None O
for None None O
[ None None O
Aib8 None None O
] None None O
( None None O
doubling None None O
vs None None O
[ None None O
Ala8 None None O
] None None O
) None None O
, None None O
[ None None O
Aib9 None None O
] None None O
( None None O
having None None O
vs None None O
[ None None O
Ala9 None None O
] None None O
) None None O
, None None O
and None None O
[ None None O
Aib15 None None O
] None None O
( None None O
10 None None O
- None None O
fold None None O
decrease None None O
vs None None O
[ None None O
Ala15 None None O
] None None O
) None None O
. None None O

A None None O
series None None O
of None None O
cyclic None None O
analogues None None O
was None None O
synthesized None None O
having None None O
the None None O
general None None O
formula None None O
cyclo None None O
( None None O
25-29 None None O
) None None O
[ None None O
MeTyr1 None None O
, None None O
- None None O
Ala15 None None O
, None None O
Xaa25 None None O
, None None O
Nle27 None None O
, None None O
Yaa29+ None None O
+ None None O
+ None None O
] None None O
- None None O
GHRH None None O
( None None O
1-29 None None O
) None None O
- None None O
NH2 None None O
, None None O
where None None O
Xaa None None O
and None None O
Yaa None None O
represent None None O
the None None O
bridgehead None None O
residues None None O
of None None O
a None None O
side None None O
- None None O
chain None None O
cystine None None O
or None None O
[ None None O
i None None O
- None None O
( None None O
i None None O
+ None None O
4 None None O
) None None O
] None None O
lactam None None O
ring None None O
. None None O

The None None O
ring None None O
size None None O
, None None O
bridgehead None None O
amino None None O
acid None None O
chirality None None O
, None None O
and None None O
side None None O
- None None O
chain None None O
amide None None O
bond None None O
location None None O
were None None O
varied None None O
in None None O
this None None O
partial None None O
series None None O
in None None O
an None None O
attempt None None O
to None None O
maximize None None O
potency None None O
. None None O

Application None None O
of None None O
lactam None None O
constraints None None O
in None None O
the None None O
C None None O
- None None O
terminus None None O
of None None O
GHRH None None O
( None None O
1-29 None None O
) None None O
- None None O
NH2 None None O
identified None None O
cyclo None None O
( None None O
25-29 None None O
) None None O
[ None None O
MeTyr1 None None O
, None None O
Ala15 None None O
, None None O
DAsp25 None None O
, None None O
Nle27 None None O
, None None O
Orn29+ None None O
+ None None O
+ None None O
] None None O
- None None O
hGHRH None None O
( None None O
1-29 None None O
) None None O
- None None O
NH2 None None O
( None None O
46 None None O
) None None O
as None None O
containing None None O
the None None O
optimum None None O
bridging None None O
element None None O
( None None O
19 None None O
- None None O
membered None None O
ring None None O
) None None O
in None None O
this None None O
region None None O
of None None O
the None None O
molecule None None O
. None None O

This None None O
analogue None None O
( None None O
46 None None O
) None None O
was None None O
17 None None O
times None None O
more None None O
potent None None O
than None None O
the None None O
standard None None O
. None None O

Equally None None O
effective None None O
was None None O
an None None O
[ None None O
i None None O
- None None O
( None None O
i None None O
+ None None O
3 None None O
) None None O
] None None O
constraint None None O
yielding None None O
the None None O
18 None None O
- None None O
membered None None O
ring None None O
cyclo None None O
( None None O
25-28 None None O
) None None O
[ None None O
MeTyr1 None None O
, None None O
Ala15 None None O
, None None O
Glu25 None None O
, None None O
Nle None None O
, None None O
27Lys28 None None O
] None None O
- None None O
hGHRH None None O
- None None O
( None None O
1-29 None None O
) None None O
- None None O
NH2 None None O
( None None O
51 None None O
) None None O
which None None O
was None None O
14 None None O
times None None O
more None None O
potent None None O
than None None O
the None None O
standard None None O
. None None O

A None None O
complete None None O
[ None None O
i None None O
- None None O
( None None O
i None None O
+ None None O
3 None None O
) None None O
] None None O
scan None None O
of None None O
cyclo None None O
( None None O
i None None O
, None None O
i None None O
+ None None O
3 None None O
) None None O
[ None None O
MeTyr1 None None O
, None None O
Ala15 None None O
, None None O
Glui None None O
, None None O
Lys None None O
( None None O
i None None O
+ None None O
3 None None O
) None None O
, None None O
Nle27 None None O
] None None O
- None None O
hGHRH None None O
( None None O
1-29 None None O
) None None O
- None None O
NH2 None None O
was None None O
then None None O
produced None None O
in None None O
order None None O
to None None O
test None None O
the None None O
effects None None O
of None None O
a None None O
Glu None None O
- None None O
to None None O
- None None O
Lys None None O
lactam None None O
bridge None None O
at None None O
all None None O
points None None O
in None None O
the None None O
peptide None None O
. None None O

Of None None O
the None None O
26 None None O
analogues None None O
in None None O
the None None O
series None None O
, None None O
11 None None O
had None None O
diminished None None O
potencies None None O
of None None O
less None None O
than None None O
10% None None O
that None None O
of None None O
the None None O
agonist None None O
standard None None O
, None None O
4 None None O
were None None O
weak None None O
agonists None None O
( None None O
15-40% None None O
relative None None O
potency None None O
) None None O
, None None O
and None None O
4 None None O
analogues None None O
were None None O
equipotent None None O
to None None O
the None None O
standard None None O
. None None O

The None None O
7 None None O
most None None O
potent None None O
analogues None None O
ranged None None O
in None None O
potency None None O
from None None O
3 None None O
to None None O
14 None None O
times None None O
greater None None O
than None None O
that None None O
of None None O
the None None O
standard None None O
and None None O
contained None None O
the None None O
[ None None O
i None None O
- None None O
( None None O
i None None O
+ None None O
3 None None O
) None None O
] None None O
cycles None None O
between None None O
residues None None O
4-7 None None O
, None None O
5-8 None None O
, None None O
9-12 None None O
, None None O
16-19 None None O
, None None O
21-24 None None O
, None None O
22-25 None None O
, None None O
and None None O
25-28 None None O
. None None O

The None None O
combined None None O
results None None O
from None None O
these None None O
systematic None None O
studies None None O
allowed None None O
for None None O
an None None O
analysis None None O
of None None O
structural None None O
features None None O
in None None O
the None None O
native None None O
peptide None None O
that None None O
are None None O
important None None O
for None None O
receptor None None O
activation None None O
. None None O

Reinforcement None None O
of None None O
the None None O
characteristics None None O
of None None O
amphiphilicity None None O
, None None O
helicity None None O
, None None O
and None None O
peptide None None O
dipolar None None O
effects None None O
, None None O
using None None O
recognized None None O
medicinal None None O
chemistry None None O
approaches None None O
including None None O
introduction None None O
of None None O
conformational None None O
constraints None None O
, None None O
has None None O
resulted None None O
in None None O
several None None O
potent None None O
GHRH None None O
analogues None None O
. None None O


A None None O
series None None O
of None None O
unsaturated None None O
analogues None None O
of None None O
nucleosides None None O
were None None O
prepared None None O
and None None O
their None None O
cytotoxic None None O
, None None O
antitumor None None O
, None None O
and None None O
antiviral None None O
activities None None O
were None None O
investigated None None O
. None None O

Alkylation None None O
of None None O
cytosine None None O
with None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
butene None None I-IUPAC
gave None None O
chloro None None O
derivative None None O
2f None None O
, None None O
which None None O
was None None O
hydrolyzed None None O
to None None O
alcohol None None O
2h None None O
. None None O

Cytosine None None O
, None None O
adenine None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
, None None O
thymine None None O
, None None O
and None None O
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
butene None None I-IUPAC
gave None None O
compounds None None O
4c None None O
- None None O
f None None O
, None None O
which None None O
, None None O
after None None O
hydrolysis None None O
, None None O
afforded None None O
alcohols None None O
4a None None O
, None None O
4b None None O
, None None O
4g None None O
, None None O
and None None O
4h None None O
. None None O

Alkenes None None O
4d None None O
and None None O
4e None None O
were None None O
cyclized None None O
to None None O
heterocycles None None O
12 None None O
and None None O
13 None None O
. None None O

Alkylation None None O
of None None O
2,6 None None I-IUPAC
- None None I-IUPAC
diaminopurine None None I-IUPAC
with None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
butyne None None I-IUPAC
led None None O
to None None O
chloro None None I-IUPAC
derivative None None B-MODIFIER
6a None None O
, None None O
which None None O
was None None O
hydrolyzed None None O
to None None O
alcohol None None O
6b None None O
. None None O

Allenic None None O
isomerization None None O
of None None O
6b None None O
gave None None O
compound None None O
5c None None O
. None None O

Chloro None None I-IUPAC
derivatives None None B-MODIFIER
2e None None O
- None None O
g None None O
, None None O
4c None None O
- None None O
f None None O
, None None O
5d None None O
, None None O
and None None O
6c None None O
- None None O
e None None O
as None None O
well None None O
as None None O
pyrimidine None None O
oxacyclopentenes None None O
9c None None O
and None None O
9d None None O
are None None O
slow None None O
- None None O
acting None None O
inhibitors None None O
of None None O
murine None None O
leukemia None None O
L1210 None None O
of None None O
IC50 None None O
10-100 None None O
microM None None O
. None None O

The None None O
most None None O
active None None O
were None None O
analogues None None O
4c None None O
, None None O
4d None None O
, None None O
4e None None O
, None None O
and None None O
6e None None O
( None None O
IC50 None None O
10-20 None None O
microM None None O
) None None O
. None None O

The None None O
corresponding None None O
hydroxy None None I-IUPAC
derivatives None None B-MODIFIER
were None None O
less None None O
active None None O
of None None O
inactive None None O
. None None O

Inhibition None None O
of None None O
macromolecular None None O
synthesis None None O
with None None O
compounds None None O
4c None None O
, None None O
4d None None O
, None None O
6e None None O
, None None O
9c None None O
, None None O
and None None O
9d None None O
follows None None O
the None None O
order None None O
: None None O
DNA None None O
greater None None O
than None None O
RNA None None O
greater None None O
than None None O
or None None O
equal None None O
to None None O
protein None None O
. None None O

Cytotoxic None None O
effects None None O
of None None O
4c None None O
, None None O
6e None None O
, None None O
and None None O
9d None None O
are None None O
not None None O
reversed None None O
with None None O
any None None O
of None None O
the None None O
four None None O
basic None None O
ribonucleosides None None O
or None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxyribonucleosides None None I-IUPAC
. None None O

Inhibitory None None O
activity None None O
of None None O
cytosine None None O
derivative None None O
9c None None O
is None None O
reversed None None O
with None None O
uridine None None O
and None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
but None None O
not None None O
with None None O
the None None O
corresponding None None O
cytosine None None O
nucleosides None None O
. None None O

Zone None None O
assays None None O
in None None O
several None None O
tumor None None O
cell None None O
lines None None O
show None None O
that None None O
active None None O
compounds None None O
are None None O
cytotoxic None None O
agents None None O
with None None O
little None None O
selectivity None None O
for None None O
tumor None None O
cells None None O
. None None O

Analogue None None O
6c None None O
showed None None O
16.7% None None O
ILS None None O
in None None O
leukemia None None O
P388 None None O
/ None None O
o None None O
implanted None None O
ip None None O
in None None O
mice None None O
at None None O
510 None None O
and None None O
1020 None None O
mg None None O
/ None None O
kg None None O
, None None O
respectively None None O
. None None O

Cytallene None None O
( None None O
5b None None O
) None None O
and None None O
6' None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
hydroxyaristeromycin None None I-IUPAC
( None None O
10 None None O
) None None O
exhibited None None O
significant None None O
activity None None O
against None None O
Friend None None O
and None None O
Rauscher None None O
murine None None O
leukemia None None O
viruses None None O
. None None O

The None None O
rest None None O
of None None O
the None None O
hydroxy None None O
derivatives None None O
, None None O
with None None O
the None None O
exception None None O
of None None O
4a None None O
, None None O
were None None O
moderately None None O
effective None None O
or None None O
inactive None None O
as None None O
antiviral None None O
agents None None O
. None None O

None None None O
of None None O
the None None O
chloro None None O
derivatives None None O
or None None O
oxacyclopentenes None None O
exhibited None None O
an None None O
antiviral None None O
effect None None O
at None None O
noncytotoxic None None O
concentrations None None O
. None None O

Z None None O
- None None O
Olefin None None O
4b None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
aminoadenallene None None I-IUPAC
( None None O
5c None None O
) None None O
are None None O
substrates None None O
for None None O
adenosine None None O
deaminase None None O
. None None O


A None None O
series None None O
of None None O
bis None None O
( None None O
hydroxymethyl None None O
) None None O
- None None O
substituted None None O
heterocycles None None O
were None None O
synthesized None None O
and None None O
converted None None O
to None None O
the None None O
corresponding None None O
bis None None I-IUPAC
( None None I-IUPAC
methylcarbamate None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
. None None O

The None None O
heterocyclic None None O
systems None None O
studied None None O
were None None O
based None None O
on None None O
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylfuran None None I-IUPAC
( None None O
2-4 None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
phenylpyrazole None None I-IUPAC
( None None O
5-7 None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylpyrazole None None I-IUPAC
( None None O
9-11 None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylthiophene None None I-IUPAC
( None None O
13 None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,2,3 None None I-IUPAC
- None None I-IUPAC
triazole None None I-IUPAC
( None None O
14 None None O
) None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
phenylisoxazole None None I-IUPAC
( None None O
15 None None O
) None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
phenylisothiazole None None I-IUPAC
( None None O
16 None None O
) None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
phenylthiazole None None I-IUPAC
( None None O
17 None None O
) None None O
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
phenyloxazole None None I-IUPAC
( None None O
18 None None O
) None None O
. None None O

None None None O
of None None O
the None None O
bis None None O
( None None O
carbamates None None O
) None None O
prepared None None O
was None None O
active None None O
against None None O
murine None None O
P388 None None O
lymphocytic None None O
leukemia None None O
. None None O

Pyrrole None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
carbamates None None I-IUPAC
) None None I-IUPAC
20 None None O
and None None O
21 None None O
, None None O
which None None O
exhibited None None O
antileukemic None None O
activity None None O
, None None O
also None None O
showed None None O
reactivity None None O
toward None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
nitrobenzyl None None I-IUPAC
) None None I-IUPAC
pyridine None None I-IUPAC
while None None O
the None None O
inactive None None O
bis None None I-IUPAC
( None None I-IUPAC
carbamates None None I-IUPAC
) None None I-IUPAC
were None None O
unreactive None None O
in None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
nitrobenzyl None None I-IUPAC
) None None I-IUPAC
pyridine None None I-IUPAC
assay None None O
. None None O


Urokinase None None O
- None None O
type None None O
plasminogen None None O
activator None None O
( None None O
uPA None None O
) None None O
, None None O
a None None O
trypsin None None O
- None None O
like None None O
serine None None O
protease None None O
, None None O
has None None O
been None None O
implicated None None O
in None None O
large None None O
number None None O
of None None O
malignancies None None O
, None None O
tumor None None O
cell None None O
invasion None None O
, None None O
angiogenesis None None O
and None None O
metastasis None None O
; None None O
hence None None O
, None None O
the None None O
potent None None O
and None None O
selective None None O
inhibitors None None O
of None None O
uPA None None O
may None None O
therefore None None O
be None None O
therapeutically None None O
useful None None O
drugs None None O
for None None O
treatment None None O
of None None O
various None None O
forms None None O
of None None O
cancer None None O
. None None O

A None None O
three None None O
- None None O
dimensional None None O
quantitative None None O
structure None None O
- None None O
activity None None O
relationship None None O
( None None O
3D None None O
QSAR None None O
) None None O
study None None O
was None None O
performed None None O
on None None O
five None None O
different None None O
chemical None None O
series None None O
reported None None O
as None None O
selective None None O
uPA None None O
inhibitors None None O
employing None None O
comparative None None O
molecular None None O
field None None O
analysis None None O
( None None O
CoMFA None None O
) None None O
/ None None O
comparative None None O
molecular None None O
similarity None None O
indices None None O
analysis None None O
( None None O
CoMSIA None None O
) None None O
techniques None None O
to None None O
investigate None None O
the None None O
structural None None O
requirements None None O
for None None O
substrates None None O
and None None O
derive None None O
a None None O
predictive None None O
model None None O
that None None O
may None None O
be None None O
used None None O
for None None O
the None None O
design None None O
of None None O
novel None None O
uPA None None O
inhibitors None None O
. None None O

ClogP None None O
has None None O
been None None O
used None None O
as None None O
an None None O
additional None None O
descriptor None None O
in None None O
the None None O
CoMFA None None O
analysis None None O
to None None O
study None None O
the None None O
effects None None O
of None None O
lipophilic None None O
parameters None None O
on None None O
activity None None O
. None None O

Inclusion None None O
of None None O
ClogP None None O
did None None O
not None None O
improve None None O
the None None O
models None None O
significantly None None O
and None None O
exhibited None None O
comparable None None O
correlation None None O
coefficients None None O
with None None O
CoMFA None None O
steric None None O
and None None O
electrostatic None None O
models None None O
. None None O

3D None None O
QSAR None None O
models None None O
were None None O
derived None None O
for None None O
2 None None I-IUPAC
- None None I-IUPAC
pyridinylguanidines None None I-IUPAC
( None None O
training None None O
set None None O
N None None O
= None None O
25 None None O
, None None O
test None None O
set None None O
N None None O
= None None O
8 None None O
) None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
aminoarylguanidines None None I-IUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
aminoarylbenzamidines None None I-IUPAC
( None None O
training None None O
set None None O
N None None O
= None None O
29 None None O
, None None O
test None None O
set None None O
N None None O
= None None O
8 None None O
) None None O
, None None O
thiophene None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxamindines None None I-IUPAC
( None None O
training None None O
set None None O
N None None O
= None None O
64 None None O
, None None O
test None None O
set None None O
N None None O
= None None O
19 None None O
) None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
naphthamidines None None I-IUPAC
( None None O
training None None O
set None None O
N None None O
= None None O
32 None None O
, None None O
test None None O
set None None O
N None None O
= None None O
8 None None O
) None None O
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
isoquinolinylguanidines None None I-IUPAC
( None None O
training None None O
set None None O
N None None O
= None None O
29 None None O
, None None O
test None None O
set None None O
N None None O
= None None O
7 None None O
) None None O
. None None O

The None None O
CoMFA None None O
models None None O
with None None O
steric None None O
and None None O
electrostatic None None O
fields None None O
exhibited None None O
r None None O
( None None O
2 None None O
) None None O
( None None O
cv None None O
) None None O
0.452-0.722 None None O
, None None O
r None None O
( None None O
2 None None O
) None None O
( None None O
ncv None None O
) None None O
0.812-0.986 None None O
, None None O
r None None O
( None None O
2 None None O
) None None O
( None None O
pred None None O
) None None O
0.597-0.870 None None O
, None None O
whereas None None O
CoMFA None None O
ClogP None None O
models None None O
showed None None O
r None None O
( None None O
2 None None O
) None None O
( None None O
cv None None O
) None None O
0.420-0.707 None None O
, None None O
r None None O
( None None O
2 None None O
) None None O
( None None O
ncv None None O
) None None O
0.849-0.957 None None O
, None None O
r None None O
( None None O
2 None None O
) None None O
( None None O
pred None None O
) None None O
0.600-0.870 None None O
. None None O

The None None O
CoMSIA None None O
models None None O
displayed None None O
r None None O
( None None O
2 None None O
) None None O
( None None O
cv None None O
) None None O
0.663-0.729 None None O
, None None O
r None None O
( None None O
2 None None O
) None None O
( None None O
ncv None None O
) None None O
0.909-0.998 None None O
, None None O
r None None O
( None None O
2 None None O
) None None O
( None None O
pred None None O
) None None O
0.554-0.855 None None O
. None None O

3D None None O
contour None None O
maps None None O
generated None None O
from None None O
these None None O
models None None O
were None None O
analyzed None None O
individually None None O
, None None O
which None None O
provides None None O
the None None O
regions None None O
in None None O
space None None O
where None None O
interactive None None O
fields None None O
may None None O
influence None None O
the None None O
activity None None O
. None None O

The None None O
superimposition None None O
of None None O
contour None None O
maps None None O
on None None O
the None None O
active None None O
site None None O
of None None O
serine None None O
proteases None None O
additionally None None O
helps None None O
in None None O
understanding None None O
the None None O
structural None None O
requirements None None O
of None None O
these None None O
inhibitors None None O
. None None O

Further None None O
, None None O
the None None O
predictive None None O
ability None None O
of None None O
3D None None O
QSAR None None O
models None None O
was None None O
affirmed None None O
by None None O
predicting None None O
the None None O
activity None None O
of None None O
novel None None O
2 None None I-IUPAC
- None None I-IUPAC
naphthamidines None None I-IUPAC
. None None O

3D None None O
QSAR None None O
models None None O
developed None None O
may None None O
be None None O
used None None O
in None None O
designing None None O
and None None O
predicting None None O
the None None O
uPA None None O
inhibitory None None O
activity None None O
of None None O
novel None None O
molecules None None O
. None None O


A None None O
new None None O
class None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
cyanamido None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
haloethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridines None None I-IUPAC
( None None O
4-6 None None O
) None None O
and None None O
arabinouridines None None O
( None None O
7 None None O
, None None O
8 None None O
) None None O
were None None O
synthesized None None O
by None None O
the None None O
regiospecific None None O
addition None None O
of None None O
halogenocyanamides None None O
( None None O
X None None O
- None None O
NHCN None None O
) None None O
to None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyl None None I-IUPAC
substituent None None I-MODIFIER
of None None O
the None None O
respective None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
2 None None O
) None None O
and None None O
2' None None I-IUPAC
- None None I-IUPAC
arabinouridine None None I-IUPAC
( None None O
3 None None O
) None None O
. None None O

Reaction None None O
of None None O
2 None None O
with None None O
sodium None None O
azide None None O
, None None O
ceric None None O
ammonium None None O
nitrate None None O
, None None O
and None None O
acetonitrile None None O
- None None O
methanol None None O
or None None O
water None None O
afforded None None O
the None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxy None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
azidoethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None O
10 None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
azidoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridines None None I-IUPAC
( None None O
11 None None O
) None None O
. None None O

In None None O
vitro None None O
antiviral None None O
activities None None O
against None None O
HSV None None O
- None None O
1 None None O
- None None O
TK None None O
( None None O
+ None None O
) None None O
( None None O
KOS None None O
and None None O
E None None O
- None None O
377 None None O
) None None O
, None None O
HSV None None O
- None None O
1 None None O
- None None O
TK None None O
( None None O
- None None O
) None None O
, None None O
HSV None None O
- None None O
2 None None O
, None None O
VZV None None O
, None None O
HCMV None None O
, None None O
and None None O
DHBV None None O
were None None O
determined None None O
. None None O

Of None None O
the None None O
newly None None O
synthesized None None O
compounds None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
cyanamido None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
6 None None O
) None None O
exhibited None None O
the None None O
most None None O
potent None None O
anti None None O
- None None O
HSV None None O
- None None O
1 None None O
activity None None O
, None None O
which None None O
was None None O
equipotent None None O
to None None O
acyclovir None None O
and None None O
superior None None O
to None None O
5 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
EDU None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
it None None O
was None None O
significantly None None O
inhibitory None None O
for None None O
thymidine None None O
kinase None None O
deficient None None O
strain None None O
of None None O
HSV None None O
- None None O
1 None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
2.3-15.3 None None O
microM None None O
) None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
cyanamido None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
haloethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridines None None I-IUPAC
( None None O
4-6 None None O
) None None O
all None None O
were None None O
approximately None None O
equipotent None None O
against None None O
HSV None None O
- None None O
2 None None O
and None None O
were None None O
approximately None None O
1.5 None None O
- None None O
and None None O
15 None None O
- None None O
fold None None O
less None None O
inhibitory None None O
for None None O
HSV None None O
- None None O
2 None None O
than None None O
EDU None None O
and None None O
acyclovir None None O
, None None O
respectively None None O
. None None O

Compounds None None O
4-6 None None O
were None None O
all None None O
inactive None None O
against None None O
HCMV None None O
but None None O
exhibited None None O
appreciable None None O
antiviral None None O
activity None None O
against None None O
VZV None None O
. None None O

Their None None O
anti None None O
- None None O
VZV None None O
activity None None O
was None None O
similar None None O
or None None O
higher None None O
to None None O
that None None O
of None None O
EDU None None O
and None None O
approximately None None O
5-12 None None O
- None None O
fold None None O
lower None None O
than None None O
that None None O
of None None O
acyclovir None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
cyanamido None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
haloethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
7,8 None None I-IUPAC
) None None I-IUPAC
analogues None None I-MODIFIER
of None None O
arabinouridine None None O
were None None O
moderately None None O
inhibitory None None O
for None None O
VZV None None O
and None None O
HSV None None O
- None None O
1 None None O
( None None O
strain None None O
KOS None None O
) None None O
, None None O
whereas None None O
compounds None None O
10 None None O
and None None O
11 None None O
were None None O
inactive None None O
against None None O
herpes None None O
viruses None None O
. None None O

Compounds None None O
5 None None O
and None None O
6 None None O
also None None O
demonstrated None None O
modest None None O
anti None None O
- None None O
hepatitis None None O
B None None O
virus None None O
activity None None O
against None None O
DHBV None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
19.9-23.6 None None O
microM None None O
) None None O
. None None O

Interestingly None None O
, None None O
the None None O
related None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
1n None None O
) None None O
analogue None None O
proved None None O
to None None O
be None None O
markedly None None O
inhibitory None None O
to None None O
DHBV None None O
replication None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
2.6-6.6 None None O
microM None None O
) None None O
. None None O

All None None O
compounds None None O
investigated None None O
exhibited None None O
low None None O
host None None O
cell None None O
toxicity None None O
to None None O
several None None O
stationary None None O
and None None O
proliferating None None O
host None None O
cell None None O
lines None None O
as None None O
well None None O
as None None O
mitogen None None O
- None None O
stimulated None None O
proliferating None None O
human None None O
T None None O
lymphocytes None None O
. None None O


Four None None O
isomers None None O
of None None O
[ None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
tetrahydrofuran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
trimethylammonium None None I-IUPAC
iodide None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
muscarines None None I-IUPAC
) None None I-IUPAC
were None None O
prepared None None O
in None None O
enantiomerically None None O
and None None O
diastereomerically None None O
pure None None O
form None None O
from None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
sulfoxide None None I-IUPAC
, None None O
ethyl None None O
fluoroacetate None None O
, None None O
and None None O
allyl None None O
bromide None None O
. None None O

Their None None O
absolute None None O
configurations None None O
were None None O
assigned None None O
by None None O
1H None None O
NMR None None O
analyses None None O
. None None O

The None None O
four None None O
optically None None O
pure None None O
compounds None None O
were None None O
tested None None O
in None None O
vitro None None O
on None None O
guinea None None O
pig None None O
and None None O
their None None O
muscarinic None None O
potency None None O
was None None O
evaluated None None O
at None None O
M3 None None O
( None None O
ileum None None O
and None None O
bladder None None O
) None None O
and None None O
M2 None None O
( None None O
heart None None O
) None None O
muscarinic None None O
receptor None None O
subtypes None None O
. None None O

Compound None None O
1a None None O
, None None O
the None None O
most None None O
potent None None O
isomer None None O
of None None O
the None None O
series None None O
, None None O
was None None O
also None None O
tested None None O
in None None O
vivo None None O
on None None O
pithed None None O
rat None None O
and None None O
its None None O
muscarinic None None O
activity None None O
at None None O
the None None O
M1 None None O
receptor None None O
subtype None None O
was None None O
compared None None O
with None None O
that None None O
of None None O
muscarine None None O
. None None O

Moreover None None O
, None None O
affinity None None O
and None None O
relative None None O
efficacy None None O
were None None O
calculated None None O
in None None O
vitro None None O
for None None O
this None None O
compound None None O
at None None O
M2 None None O
( None None O
heart None None O
force None None O
and None None O
rate None None O
) None None O
and None None O
M3 None None O
( None None O
ileum None None O
and None None O
bladder None None O
) None None O
receptors None None O
in None None O
order None None O
to None None O
investigate None None O
muscarinic None None O
receptor None None O
heterogeneity None None O
. None None O

The None None O
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluoromuscarines None None I-IUPAC
display None None O
a None None O
similar None None O
trend None None O
of None None O
potency None None O
as None None O
the None None O
corresponding None None O
muscarines None None O
and None None O
compound None None O
1a None None O
shows None None O
differences None None O
in None None O
the None None O
affinity None None O
constants None None O
among None None O
the None None O
studied None None O
tissues None None O
. None None O

Replacement None None O
of None None O
a None None O
hydroxyl None None I-IUPAC
group None None B-MODIFIER
for None None O
a None None O
fluorine None None O
atom None None O
in None None O
the None None O
4 None None O
position None None O
of None None O
muscarine None None O
produces None None O
1 None None O
order None None O
of None None O
magnitude None None O
increase None None O
in None None O
affinity None None O
for None None O
cardiac None None O
M2 None None O
muscarinic None None O
receptors None None O
controlling None None O
rate None None O
, None None O
while None None O
the None None O
affinity None None O
at None None O
cardiac None None O
M2 None None O
muscarinic None None O
receptors None None O
controlling None None O
force None None O
is None None O
unchanged None None O
, None None O
opening None None O
the None None O
possibility None None O
of None None O
a None None O
further None None O
classification None None O
of None None O
cardiac None None O
muscarinic None None O
receptors None None O
. None None O


N5 None None I-IUPAC
- None None I-IUPAC
Acetyl None None I-IUPAC
- None None I-IUPAC
N5 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
ornithine None None I-IUPAC
( None None O
1 None None O
) None None O
, None None O
the None None O
key None None O
constituent None None O
of None None O
several None None O
microbial None None O
siderophores None None O
, None None O
has None None O
been None None O
synthesized None None O
in None None O
23% None None O
yield None None O
overall None None O
from None None O
N None None O
- None None O
Cbz None None O
- None None O
L None None O
- None None O
glutamic None None O
acid None None O
1 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
ester None None I-IUPAC
( None None O
6 None None O
) None None O
derived None None O
from None None O
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
. None None O

Reduction None None O
of None None O
6 None None O
to None None O
7 None None O
and None None O
treatment None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
trichloroethoxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
benzylhydroxylamine None None I-IUPAC
( None None O
8 None None O
) None None O
, None None O
and None None O
diethyl None None I-IUPAC
azodicarboxylate None None I-IUPAC
and None None O
triphenylphosphine None None O
followed None None O
by None None O
deprotection None None O
produced None None O
the None None O
protected None None O
N5 None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
N5 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
ornithine None None I-IUPAC
derivatives None None I-MODIFIER
11 None None O
and None None O
12 None None O
in None None O
large None None O
quantities None None O
( None None O
10-20 None None O
g None None O
) None None O
. None None O

Following None None O
alpha None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
and None None O
alpha None None I-IUPAC
- None None I-IUPAC
carboxyl None None I-IUPAC
deprotections None None I-MODIFIER
of None None O
11 None None O
and None None O
12 None None O
, None None O
EEDQ None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
ethoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
dihydroquinoline None None I-IUPAC
] None None O
mediated None None O
peptide None None O
coupling None None O
and None None O
final None None O
deprotection None None O
provided None None O
amino None None O
acid None None O
1 None None O
and None None O
six None None O
albomycin None None O
- None None O
like None None O
peptides None None O
( None None O
20 None None O
, None None O
23 None None O
, None None O
25 None None O
, None None O
28 None None O
, None None O
35 None None O
, None None O
and None None O
36 None None O
) None None O
. None None O

The None None O
growth None None O
- None None O
promoting None None O
ability None None O
of None None O
each None None O
was None None O
evaluated None None O
with None None O
the None None O
siderophore None None O
biosynthesis None None O
mutant None None O
Shigella None None O
flexneri None None O
SA240 None None O
( None None O
SA None None O
100 None None O
iucD None None O
: None None O
Tn5 None None O
) None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
substantial None None O
modification None None O
of None None O
the None None O
framework None None O
of None None O
peptide None None O
- None None O
based None None O
siderophores None None O
can None None O
be None None O
tolerated None None O
by None None O
microbial None None O
iron None None O
- None None O
transport None None O
systems None None O
. None None O


4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Phenylethynyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyridine None None I-IUPAC
derivatives None None I-MODIFIER
are None None O
selective None None O
antagonists None None O
at None None O
human None None O
A3 None None O
adenosine None None O
receptors None None O
, None None O
with None None O
Ki None None O
values None None O
in None None O
a None None O
radioligand None None O
binding None None O
assay None None O
vs None None O
[ None None O
125I None None O
] None None O
AB None None O
- None None O
MECA None None O
( None None O
N6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
iodobenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylcarbamoyl None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
) None None O
in None None O
the None None O
submicromolar None None O
range None None O
. None None O

In None None O
this None None O
study None None O
, None None O
structure None None O
- None None O
activity None None O
relationships None None O
at None None O
various None None O
positions None None O
of None None O
the None None O
dihydropyridine None None O
ring None None O
( None None O
the None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
acyl None None I-IUPAC
substituents None None I-MODIFIER
, None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
substituent None None I-MODIFIER
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
group None None I-MODIFIER
) None None O
were None None O
probed None None O
synthetically None None O
. None None O

Using None None O
the None None O
combined None None O
protection None None O
of None None O
the None None O
1 None None I-IUPAC
- None None I-IUPAC
ethoxymethyl None None I-IUPAC
and None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trimethylsilyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
ester None None I-IUPAC
groups None None I-MODIFIER
, None None O
a None None O
free None None O
carboxylic None None O
acid None None O
was None None O
formed None None O
at None None O
the None None O
5 None None O
- None None O
position None None O
allowing None None O
various None None O
substitutions None None O
. None None O

Selectivity None None O
of None None O
the None None O
new None None O
analogues None None O
for None None O
cloned None None O
human None None O
A3 None None O
adenosine None None O
receptors None None O
was None None O
determined None None O
vs None None O
radioligand None None O
binding None None O
at None None O
rat None None O
brain None None O
A1 None None O
and None None O
A2A None None O
receptors None None O
. None None O

Structure None None O
- None None O
activity None None O
analysis None None O
at None None O
adenosine None None O
receptors None None O
indicated None None O
that None None O
pyridyl None None O
, None None O
furyl None None O
, None None O
benzofuryl None None O
, None None O
and None None O
thienyl None None O
groups None None O
at None None O
the None None O
4 None None O
- None None O
position None None O
resulted None None O
in None None O
, None None O
at None None O
most None None O
, None None O
only None None O
moderate None None O
selectivity None None O
for None None O
A3 None None O
adenosine None None O
receptors None None O
. None None O

Ring None None O
substitution None None O
( None None O
e.g. None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
) None None O
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
phenylethylnyl None None I-IUPAC
group None None I-MODIFIER
did None None O
not None None O
provide None None O
enhanced None None O
selectivity None None O
, None None O
as None None O
it None None O
did None None O
for None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
styryl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
dihydropyridines None None B-IUPAC
. None None O

At None None O
the None None O
3 None None O
- None None O
position None None O
of None None O
the None None O
dihydropyridine None None O
ring None None O
, None None O
esters None None O
were None None O
much None None O
more None None O
selective None None O
for None None O
A3 None None O
receptors None None O
than None None O
closely None None O
related None None O
thioester None None O
, None None O
amide None None O
, None None O
and None None O
ketone None None O
derivatives None None O
. None None O

A None None O
cyclic None None O
3 None None O
- None None O
keto None None O
derivative None None O
was None None O
5 None None O
- None None O
fold None None O
more None None O
potent None None O
at None None O
A3 None None O
receptors None None O
than None None O
a None None O
related None None O
open None None O
- None None O
ring None None O
analogue None None O
. None None O

At None None O
the None None O
5 None None O
- None None O
position None None O
, None None O
a None None O
homologous None None O
series None None O
of None None O
phenylalkyl None None O
esters None None O
and None None O
a None None O
series None None O
of None None O
substituted None None I-MODIFIER
benzyl None None B-IUPAC
esters None None I-IUPAC
were None None O
prepared None None O
and None None O
tested None None O
. None None O

( None None I-PARTIUPAC
Trifluoromethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
nitro None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
other None None O
benzyl None None O
esters None None O
substituted None None O
with None None O
electron None None O
- None None O
withdrawing None None O
groups None None O
were None None O
specific None None O
for None None O
A3 None None O
receptors None None O
with None None O
nanomolar None None O
Ki None None O
values None None O
and None None O
selectivity None None O
as None None O
high None None O
as None None O
37000 None None O
- None None O
fold None None O
. None None O

A None None O
functionalized None None O
congener None None O
bearing None None O
an None None O
[ None None I-IUPAC
( None None I-IUPAC
aminoethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
carbonyl None None I-IUPAC
group None None I-MODIFIER
was None None O
also None None O
prepared None None O
as None None O
an None None O
intermediate None None O
in None None O
the None None O
synthesis None None O
of None None O
biologically None None O
active None None O
conjugates None None O
. None None O


The None None O
synthesis None None O
and None None O
biological None None O
evaluation None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
1,6 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
pyrimidinyl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
( None None O
1 None None O
) None None O
( None None O
5 None None O
- None None O
DACTHF None None O
, None None O
543U76 None None O
) None None O
, None None O
an None None O
acyclic None None O
analogue None None O
of None None O
5,6,7,8 None None I-IUPAC
- None None I-IUPAC
tetrahydrofolic None None I-IUPAC
acid None None I-IUPAC
( None None O
THFA None None O
) None None O
, None None O
are None None O
described None None O
. None None O

The None None O
key None None O
intermediate None None O
, None None O
hemiaminal None None O
8 None None O
, None None O
was None None O
prepared None None O
in None None O
four None None O
stages None None O
from None None O
3 None None I-IUPAC
- None None I-IUPAC
chloropropionaldehyde None None I-IUPAC
diethyl None None I-IUPAC
acetal None None I-IUPAC
. None None O

Reaction None None O
of None None O
8 None None O
with None None O
dimethyl None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminobenzoyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
gave None None O
the None None O
2,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
acetylamino None None I-IUPAC
) None None I-IUPAC
derivative None None I-MODIFIER
11 None None O
, None None O
which None None O
was None None O
hydrolyzed None None O
with None None O
1 None None O
N None None O
sodium None None O
hydroxide None None O
to None None O
give None None O
1 None None O
; None None O
the None None O
glycine None None O
analogue None None O
16 None None O
was None None O
prepared None None O
in None None O
a None None O
similar None None O
manner None None O
. None None O

The None None O
N None None O
- None None O
methyl None None O
analogue None None O
2 None None O
and None None O
N None None O
- None None O
formyl None None O
analogue None None O
3 None None O
were None None O
prepared None None O
from None None O
11 None None O
and None None O
1 None None O
, None None O
respectively None None O
. None None O

Compounds None None O
1-3 None None O
inhibited None None O
growth None None O
of None None O
Detroit None None O
98 None None O
and None None O
L None None O
cells None None O
in None None O
cell None None O
culture None None O
, None None O
with None None O
IC50s None None O
ranging None None O
from None None O
2 None None O
to None None O
0.018 None None O
microM None None O
. None None O

Cell None None O
culture None None O
toxicity None None O
reversal None None O
studies None None O
and None None O
enzyme None None O
inhibition None None O
tests None None O
showed None None O
that None None O
1 None None O
was None None O
cytotoxic None None O
but None None O
not None None O
by None None O
the None None O
mechanism None None O
of None None O
the None None O
dihydrofolate None None O
reductase None None O
inhibitor None None O
aminopterin None None O
. None None O

Compound None None O
1 None None O
and None None O
its None None O
polyglutamylated None None O
homologues None None O
inhibited None None O
glycinamide None None O
ribonucleotide None None O
transformylase None None O
( None None O
GAR None None O
- None None O
TFase None None O
) None None O
and None None O
aminoimidazole None None O
ribonucleotide None None O
transformylase None None O
( None None O
AICAR None None O
- None None O
TFase None None O
) None None O
, None None O
the None None O
folate None None O
- None None O
dependent None None O
enzymes None None O
in None None O
de None None O
novo None None O
purine None None O
biosynthesis None None O
; None None O
and None None O
1 None None O
was None None O
an None None O
effective None None O
substrate None None O
for None None O
mammalian None None O
folyl None None O
- None None O
polyglutamate None None O
synthetase None None O
. None None O

The None None O
compound None None O
inhibited None None O
( None None O
IC50 None None O
= None None O
20 None None O
nM None None O
) None None O
the None None O
conversion None None O
of None None O
[ None None O
14C None None O
] None None O
formate None None O
to None None O
[ None None I-IUPAC
14C None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
formylglycinamide None None I-IUPAC
ribonucleotide None None I-IUPAC
by None None O
MOLT None None O
- None None O
4 None None O
cells None None O
in None None O
culture None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
the None None O
site None None O
of None None O
action None None O
of None None O
1 None None O
is None None O
inhibition None None O
of None None O
purine None None O
de None None O
novo None None O
biosynthesis None None O
. None None O

Moderate None None O
activity None None O
was None None O
observed None None O
against None None O
P388 None None O
leukemia None None O
in None None O
vivo None None O
. None None O


Crystal None None O
structure None None O
determinations None None O
have None None O
been None None O
carried None None O
out None None O
for None None O
the None None O
following None None O
seven None None O
thyrotropin None None O
releasing None None O
hormone None None O
analogues None None O
: None None O
I None None O
, None None O
( None None I-IUPAC
3R None None I-IUPAC
, None None I-IUPAC
6R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
oxothiomorpholin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylcarbonyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
histidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
proline None None I-IUPAC
amide None None I-IUPAC
; None None O
II None None O
, None None O
( None None I-IUPAC
3R None None I-IUPAC
, None None I-IUPAC
6S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
oxothiomorpholin None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylcarbonyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
histid None None I-IUPAC
inyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
proline None None I-IUPAC
amide None None I-IUPAC
; None None O
III None None O
, None None O
( None None I-IUPAC
4R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxothiazolidin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ylcarbonyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
histidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
prol None None I-IUPAC
ine None None I-IUPAC
amide None None I-IUPAC
; None None O
IV None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
ethylorotyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
histidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
proline None None I-IUPAC
amide None None I-IUPAC
; None None O
V None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylorotyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
histidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
proline None None I-IUPAC
amide None None I-IUPAC
; None None O
VI None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
bromoorotyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
histidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
proline None None I-IUPAC
amide None None I-IUPAC
; None None O
and None None O
VII None None O
, None None O
Phe2 None None O
- None None O
TRH None None O
. None None O

A None None O
surprising None None O
degree None None O
of None None O
conformational None None O
similarity None None O
has None None O
been None None O
observed None None O
for None None O
the None None O
peptide None None O
backbone None None O
. None None O

All None None O
peptide None None O
bonds None None O
are None None O
found None None O
to None None O
be None None O
trans None None O
. None None O

A None None O
composite None None O
hydrogen None None O
- None None O
bonding None None O
environment None None O
has None None O
been None None O
constructed None None O
for None None O
the None None O
TRH None None O
analogue None None O
system None None O
and None None O
examined None None O
for None None O
its None None O
inference None None O
with None None O
respect None None O
to None None O
receptor None None O
binding None None O
. None None O

A None None O
comparison None None O
of None None O
the None None O
conformations None None O
of None None O
these None None O
analogues None None O
with None None O
those None None O
displayed None None O
by None None O
Leu5 None None O
- None None O
enkephalin None None O
has None None O
also None None O
been None None O
made None None O
, None None O
and None None O
unexpected None None O
similarities None None O
have None None O
been None None O
revealed None None O
. None None O


We None None O
prepared None None O
six None None O
pairs None None O
of None None O
alpha None None I-IUPAC
- None None I-IUPAC
heteroaromatic None None I-IUPAC
aldoximes None None I-IUPAC
, None None O
RC None None O
( None None O
= None None O
NOH None None O
) None None O
H None None O
, None None O
and None None O
thiohydroximates None None O
, None None O
RC None None O
( None None O
= None None O
NOH None None O
) None None O
S None None O
- None None O
( None None O
CH2 None None O
) None None O
2N None None O
( None None O
C2H5 None None O
) None None O
2 None None O
, None None O
where None None O
R None None O
represents None None O
various None None O
oxadiazole None None O
and None None O
thiadiazole None None O
rings None None O
. None None O

Each None None O
compound None None O
was None None O
characterized None None O
with None None O
respect None None O
to None None O
the None None O
following None None O
: None None O
structure None None O
, None None O
( None None I-IUPAC
hydroxyimino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
acid None None I-IUPAC
dissociation None None O
constant None None O
, None None O
nucleophilicity None None O
toward None None O
trigonal None None O
carbon None None O
and None None O
tetrahedral None None O
phosphorus None None O
, None None O
octanol None None O
- None None O
buffer None None O
partition None None O
coefficient None None O
, None None O
reversible None None O
inhibition None None O
of None None O
eel None None O
acetylcholinesterase None None O
( None None O
AChE None None O
) None None O
, None None O
and None None O
in None None O
vitro None None O
reactivation None None O
of None None O
AChE None None O
inhibited None None O
by None None O
ethyl None None O
p None None O
- None None O
nitrophenyl None None O
methylphosphonate None None O
. None None O

Eight None None O
of None None O
the None None O
twelve None None O
compounds None None O
significantly None None O
reactivate None None O
ethyl None None O
methylphosphonyl None None O
- None None O
AChE None None O
, None None O
but None None O
inherent None None O
reactivities None None O
are None None O
moderate None None O
to None None O
low None None O
: None None O
the None None O
most None None O
potent None None O
nonquaternary None None O
reactivator None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
hydroxyimino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
, None None O
is None None O
17 None None O
times None None O
less None None O
reactive None None O
than None None O
the None None O
well None None O
- None None O
known None None O
reactivator None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
hydroxyimino None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methylpyridinium None None I-IUPAC
iodide None None I-IUPAC
( None None O
2 None None O
- None None O
PAM None None O
) None None O
. None None O

One None None O
of None None O
the None None O
nonquaternary None None O
compounds None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
thiohydroximic None None I-IUPAC
acid None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
ester None None I-IUPAC
, None None O
is None None O
a None None O
powerful None None O
reversible None None O
inhibitor None None O
of None None O
AChE None None O
( None None O
I50 None None O
= None None O
7.5 None None O
microM None None O
) None None O
. None None O

The None None O
observed None None O
relationships None None O
between None None O
nonquaternary None None O
compound None None O
structure None None O
, None None O
reactivation None None O
potency None None O
, None None O
and None None O
anti None None O
- None None O
AChE None None O
activity None None O
reveal None None O
important None None O
molecular None None O
requirements None None O
for None None O
high None None O
reactivity None None O
toward None None O
phosphonylated None None O
AChE None None O
. None None O


The None None O
structural None None O
basis None None O
of None None O
protein None None O
kinase None None O
C None None O
( None None O
PKC None None O
) None None O
binding None None O
to None None O
several None None O
classes None None O
of None None O
high None None O
- None None O
affinity None None O
ligands None None O
has None None O
been None None O
investigated None None O
through None None O
complementary None None O
computational None None O
and None None O
experimental None None O
methods None None O
. None None O

Employing None None O
a None None O
recently None None O
developed None None O
q None None O
- None None O
jumping None None O
molecular None None O
dynamics None None O
( None None O
MD None None O
) None None O
simulation None None O
method None None O
, None None O
which None None O
allows None None O
us None None O
to None None O
consider None None O
the None None O
flexibility None None O
of None None O
both None None O
the None None O
ligands None None O
and None None O
the None None O
receptor None None O
in None None O
docking None None O
studies None None O
, None None O
we None None O
predicted None None O
the None None O
binding None None O
models None None O
of None None O
phorbol None None I-IUPAC
- None None I-IUPAC
13 None None I-IUPAC
- None None I-IUPAC
acetate None None I-IUPAC
, None None O
phorbol None None I-IUPAC
- None None I-IUPAC
12,13 None None I-IUPAC
- None None I-IUPAC
dibutyrate None None I-IUPAC
( None None O
PDBu None None O
) None None O
, None None O
indolactam None None O
V None None O
( None None O
ILV None None O
) None None O
, None None O
ingenol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzoate None None I-IUPAC
, None None O
and None None O
thymeleatoxin None None O
to None None O
PKC None None O
. None None O

The None None O
" None None O
predicted None None O
" None None O
binding None None O
model None None O
for None None O
phorbol None None I-IUPAC
- None None I-IUPAC
13 None None I-IUPAC
- None None I-IUPAC
acetate None None I-IUPAC
is None None O
virtually None None O
identical None None O
to None None O
the None None O
experimentally None None O
determined None None O
binding None None O
model None None O
for None None O
this None None O
ligand None None O
. None None O

The None None O
predicted None None O
binding None None O
model None None O
for None None O
PDBU None None O
is None None O
the None None O
same None None O
as None None O
that None None O
for None None O
phorbol None None I-IUPAC
- None None I-IUPAC
13 None None I-IUPAC
- None None I-IUPAC
acetate None None I-IUPAC
in None None O
terms None None O
of None None O
the None None O
hydrogen None None O
- None None O
bonding None None O
network None None O
and None None O
hydrophobic None None O
contacts None None O
. None None O

The None None O
predicted None None O
binding None None O
model None None O
for None None O
ILV None None O
is None None O
the None None O
same None None O
as None None O
that None None O
obtained None None O
in None None O
a None None O
previous None None O
docking None None O
study None None O
using None None O
a None None O
Monte None None O
Carlo None None O
method None None O
and None None O
is None None O
consistent None None O
with None None O
the None None O
structure None None O
- None None O
activity None None O
relationships None None O
for None None O
this None None O
class None None O
of None None O
ligands None None O
. None None O

Together None None O
with None None O
the None None O
X None None O
- None None O
ray None None O
structure None None O
of None None O
phorbol None None I-IUPAC
- None None I-IUPAC
13 None None I-IUPAC
- None None I-IUPAC
acetate None None I-IUPAC
in None None O
complex None None O
with None None O
PKCdelta None None O
C1b None None O
, None None O
the None None O
predicted None None O
binding None None O
models None None O
of None None O
PDBu None None O
, None None O
ILV None None O
, None None O
ingenol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzoate None None I-IUPAC
, None None O
and None None O
thymeleatoxin None None O
in None None O
complex None None O
with None None O
PKC None None O
showed None None O
that None None O
the None None O
binding None None O
of None None O
these None None O
ligands None None O
to None None O
PKC None None O
is None None O
governed None None O
by None None O
a None None O
combination None None O
of None None O
several None None O
highly None None O
specific None None O
and None None O
optimal None None O
hydrogen None None O
bonds None None O
and None None O
hydrophobic None None O
contacts None None O
. None None O

However None None O
, None None O
the None None O
hydrogen None None O
- None None O
bonding None None O
network None None O
for None None O
each None None O
class None None O
of None None O
ligand None None O
is None None O
somewhat None None O
different None None O
and None None O
the None None O
number None None O
of None None O
hydrogen None None O
bonds None None O
formed None None O
between None None O
PKC None None O
and None None O
these None None O
ligands None None O
has None None O
no None None O
correlation None None O
with None None O
their None None O
binding None None O
affinities None None O
. None None O

To None None O
provide None None O
a None None O
direct None None O
and None None O
quantitative None None O
assessment None None O
of None None O
the None None O
contributions None None O
of None None O
several None None O
conserved None None O
residues None None O
around None None O
the None None O
binding None None O
site None None O
to None None O
PKC None None O
- None None O
ligand None None O
binding None None O
, None None O
we None None O
have None None O
made None None O
11 None None O
mutations None None O
and None None O
measured None None O
the None None O
binding None None O
affinities None None O
of None None O
the None None O
high None None O
- None None O
affinity None None O
PKC None None O
ligands None None O
to None None O
these None None O
mutants None None O
. None None O

The None None O
results None None O
obtained None None O
through None None O
site None None O
- None None O
directed None None O
mutagenic None None O
analysis None None O
support None None O
our None None O
predicted None None O
binding None None O
models None None O
for None None O
these None None O
ligands None None O
and None None O
provide None None O
new None None O
insights None None O
into None None O
PKC None None O
- None None O
ligand None None O
binding None None O
. None None O

Although None None O
all None None O
the None None O
ligands None None O
have None None O
high None None O
affinity None None O
for None None O
the None None O
wild None None O
- None None O
type None None O
PKCdelta None None O
C1b None None O
, None None O
our None None O
site None None O
- None None O
directed None None O
mutagenic None None O
results None None O
showed None None O
that None None O
ILV None None O
is None None O
the None None O
ligand None None O
most None None O
sensitive None None O
to None None O
structural None None O
perturbations None None O
of None None O
the None None O
binding None None O
site None None O
while None None O
ingenol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzoate None None I-IUPAC
is None None O
the None None O
least None None O
sensitive None None O
among None None O
the None None O
four None None O
classes None None O
of None None O
ligands None None O
examined None None O
here None None O
. None None O

Finally None None O
, None None O
we None None O
have None None O
employed None None O
conventional None None O
MD None None O
simulations None None O
to None None O
investigate None None O
the None None O
structural None None O
perturbations None None O
caused None None O
by None None O
each None None O
mutation None None O
to None None O
further None None O
examine None None O
the None None O
role None None O
played None None O
by None None O
each None None O
individual None None O
residue None None O
in None None O
PKC None None O
- None None O
ligand None None O
binding None None O
. None None O

MD None None O
simulations None None O
revealed None None O
that None None O
several None None O
mutations None None O
, None None O
including None None O
Pro11 None None O
- None None O
- None None O
& None None O
gt None None O
; None None O
Gly None None O
, None None O
Leu21 None None O
- None None O
- None None O
& None None O
gt None None O
; None None O
Gly None None O
, None None O
Leu24 None None O
- None None O
- None None O
& None None O
gt None None O
; None None O
Gly None None O
, None None O
and None None O
Gln27 None None O
- None None O
- None None O
& None None O
gt None None O
; None None O
Gly None None O
, None None O
cause None None O
a None None O
rather None None O
large None None O
conformational None None O
alteration None None O
to None None O
the None None O
PKC None None O
binding None None O
site None None O
and None None O
, None None O
in None None O
some None None O
cases None None O
, None None O
to None None O
the None None O
overall None None O
structure None None O
of None None O
the None None O
protein None None O
. None None O

The None None O
complete None None O
abolishment None None O
or None None O
the None None O
significant None None O
reduction None None O
in None None O
PKC None None O
- None None O
ligand None None O
binding None None O
observed None None O
for None None O
these None None O
mutants None None O
thus None None O
reflects None None O
the None None O
loss None None O
of None None O
certain None None O
direct None None O
contacts None None O
between None None O
the None None O
side None None O
chain None None O
of None None O
the None None O
mutated None None O
residue None None O
in None None O
PKC None None O
and None None O
ligands None None O
as None None O
well None None O
as None None O
the None None O
large None None O
conformational None None O
alteration None None O
to None None O
the None None O
binding None None O
site None None O
caused None None O
by None None O
the None None O
mutation None None O
. None None O


Five None None O
new None None O
analogues None None O
( None None O
1c None None O
- None None O
g None None O
) None None O
of None None O
the None None O
antifolate None None O
N10 None None I-IUPAC
- None None I-IUPAC
propargyl None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dideazafolic None None I-IUPAC
acid None None I-IUPAC
( None None O
1a None None O
) None None O
are None None O
described None None O
in None None O
which None None O
the None None O
benzoyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
moiety None None I-MODIFIER
was None None O
replaced None None O
by None None O
benzoic None None O
acid None None O
( None None O
desglutamyl None None I-IUPAC
- None None I-IUPAC
N10 None None I-IUPAC
- None None I-IUPAC
propargyl None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dideazafolic None None I-IUPAC
acid None None I-IUPAC
) None None O
, None None O
benzoyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
aspartate None None I-IUPAC
, None None O
4 None None I-IUPAC
- None None I-IUPAC
phenylbutyrate None None I-IUPAC
, None None O
benzoylglycine None None O
, None None O
and None None O
benzoyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
alanine None None I-IUPAC
. None None O

The None None O
esters None None O
of None None O
the None None O
appropriate None None O
4 None None I-IUPAC
- None None I-IUPAC
aminophenyl None None I-IUPAC
( None None O
benzoyl None None I-PARTIUPAC
) None None O
starting None None O
materials None None O
were None None O
sequentially None None O
alkylated None None O
upon None None O
nitrogen None None O
, None None O
first None None O
with None None O
a None None O
propargyl None None O
halide None None O
and None None O
then None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyquinazoline None None I-IUPAC
hydrobromide None None I-IUPAC
. None None O

Saponification None None O
of None None O
the None None O
antifolate None None O
esters None None O
so None None O
produced None None O
gave None None O
the None None O
desired None None O
analogues None None O
. None None O

The None None O
new None None O
derivatives None None O
( None None O
1c None None O
- None None O
g None None O
) None None O
and None None O
also None None O
the None None O
known None None O
diethyl None None O
ester None None O
of None None O
1a None None O
( None None O
1b None None O
) None None O
were None None O
tested None None O
for None None O
their None None O
inhibition None None O
of None None O
purified None None O
L1210 None None O
thymidylate None None O
synthase None None O
( None None O
TS None None O
) None None O
and None None O
for None None O
their None None O
inhibition None None O
of None None O
the None None O
growth None None O
of None None O
L1210 None None O
cells None None O
in None None O
culture None None O
. None None O

The None None O
TS None None O
inhibition None None O
of None None O
the None None O
analogues None None O
1b None None O
- None None O
g None None O
was None None O
estimated None None O
by None None O
calculating None None O
the None None O
inverse None None O
relative None None O
potency None None O
, None None O
defined None None O
as None None O
the None None O
ratio None None O
IC50 None None O
( None None O
compound None None O
) None None O
/ None None O
IC50 None None O
( None None O
1a None None O
) None None O
. None None O

The None None O
results None None O
obtained None None O
were None None O
as None None O
follows None None O
: None None O
greater None None O
than None None O
62 None None O
, None None O
84 None None O
, None None O
9 None None O
, None None O
333 None None O
, None None O
21 None None O
, None None O
and None None O
5 None None O
, None None O
respectively None None O
. None None O

All None None O
were None None O
thus None None O
less None None O
inhibitory None None O
than None None O
1a None None O
. None None O

None None None O
of None None O
the None None O
compounds None None O
improved None None O
upon None None O
1a None None O
in None None O
inhibiting None None O
the None None O
growth None None O
of None None O
L1210 None None O
cells None None O
in None None O
culture None None O
. None None O


The None None O
syntheses None None O
of None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6,7,8,9 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
, None None I-IUPAC
10H None None I-IUPAC
- None None I-IUPAC
pyrrolo None None I-IUPAC
[ None None I-IUPAC
3,2 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
carbazol None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
amine None None I-IUPAC
( None None O
8 None None O
) None None O
, None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
7,8,9,10 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
11H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
3,2 None None I-IUPAC
- None None I-IUPAC
a None None I-IUPAC
] None None I-IUPAC
carbazol None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
amine None None I-IUPAC
( None None O
9a None None O
) None None O
, None None O
and None None O
the None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
trimethyl None None I-IUPAC
analogue None None I-MODIFIER
( None None O
9b None None O
) None None O
are None None O
described None None O
. None None O

The None None O
in None None O
vitro None None O
inotropic None None O
activity None None O
of None None O
these None None O
compounds None None O
, None None O
as None None O
well None None O
as None None O
the None None O
known None None O
cardiotonics None None O
amrinone None None O
and None None O
7 None None I-IUPAC
- None None I-IUPAC
hydroxycyclindole None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
was None None O
investigated None None O
. None None O

Compound None None O
8 None None O
, None None O
a None None O
pyrrolo None None O
analogue None None O
of None None O
7 None None O
, None None O
was None None O
devoid None None O
of None None O
inotropic None None O
activity None None O
, None None O
while None None O
the None None O
pyrido None None I-IUPAC
analogues None None B-MODIFIER
9 None None O
were None None O
equiactive None None O
to None None O
7 None None O
and None None O
amrinone None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
hydroxyl None None O
group None None O
of None None O
7 None None O
functions None None O
as None None O
an None None O
H None None O
- None None O
bond None None O
acceptor None None O
, None None O
rather None None O
than None None O
a None None O
donor None None O
, None None O
and None None O
that None None O
on None None O
interaction None None O
of None None O
7 None None O
, None None O
and None None O
the None None O
pyrido None None O
analogues None None O
9 None None O
, None None O
with None None O
a None None O
common None None O
receptor None None O
, None None O
an None None O
orbital None None O
occupied None None O
by None None O
one None None O
of None None O
the None None O
oxygen None None O
lone None None O
pair None None O
electrons None None O
of None None O
7 None None O
must None None O
assume None None O
the None None O
same None None O
orientation None None O
as None None O
the None None O
orbital None None O
occupied None None O
by None None O
the None None O
pyridine None None O
nitrogen None None O
lone None None O
pair None None O
. None None O


Study None None O
of None None O
P2 None None O
- None None O
purinoceptor None None O
subtypes None None O
has None None O
been None None O
difficult None None O
due None None O
to None None O
the None None O
lack None None O
of None None O
potent None None O
and None None O
selective None None O
ligands None None O
. None None O

With None None O
the None None O
goal None None O
of None None O
developing None None O
high None None O
affinity None None O
P2 None None O
- None None O
purinoceptor None None O
- None None O
selective None None O
agonist None None O
, None None O
we None None O
have None None O
synthesized None None O
a None None O
series None None O
of None None O
analogues None None O
of None None O
adenine None None O
nucleotides None None O
modified None None O
on None None O
the None None O
purine None None O
ring None None O
as None None O
chain None None O
- None None O
extended None None O
2 None None O
- None None O
thioethers None None O
or None None O
as None None O
N6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
compounds None None O
. None None O

Chemical None None O
functionality None None O
incorporated None None O
in None None O
the None None O
thioether None None O
moiety None None O
included None None O
cyanoalkyl None None O
, None None O
nitroaromatic None None O
, None None O
amino None None I-IUPAC
, None None O
thiol None None I-IUPAC
, None None O
cycloalkyl None None O
, None None O
n None None O
- None None O
alkyl None None O
, None None O
and None None O
olefinic None None O
groups None None O
. None None O

Apparent None None O
affinity None None O
of None None O
the None None O
compounds None None O
for None None O
P2Y None None O
- None None O
purinoceptors None None O
was None None O
established None None O
by None None O
measurement None None O
of None None O
P2Y None None O
- None None O
purinoceptor None None O
- None None O
promoted None None O
phospholipase None None O
C None None O
activity None None O
in None None O
turkey None None O
erythrocyte None None O
membranes None None O
and None None O
relaxation None None O
of None None O
carbachol None None O
- None None O
contracted None None O
smooth None None O
muscle None None O
in None None O
three None None O
different None None O
preparations None None O
( None None O
guinea None None O
pig None None O
taenia None None O
coli None None O
, None None O
rabbit None None O
aorta None None O
, None None O
and None None O
rabbit None None O
mesenteric None None O
artery None None O
) None None O
. None None O

Activity None None O
at None None O
P2X None None O
- None None O
purinoceptors None None O
was None None O
established None None O
by None None O
measurement None None O
of None None O
contraction None None O
of None None O
rabbit None None O
saphenous None None O
artery None None O
and None None O
of None None O
the None None O
guinea None None O
pig None None O
vas None None O
deferens None None O
and None None O
urinary None None O
bladder None None O
. None None O

All None None O
11 None None O
of None None O
the None None O
2 None None O
- None None O
thioethers None None O
of None None O
ATP None None O
stimulated None None O
the None None O
production None None O
of None None O
inositol None None O
phosphates None None O
with None None O
K0 None None O
.5 None None O
values None None O
of None None O
1.5-770 None None O
nM None None O
, None None O
with None None O
an None None O
( None None O
aminophenyl None None O
) None None O
ethyl None None O
derivative None None O
being None None O
most None None O
potent None None O
. None None O

Two None None O
adenosine None None O
diphosphate None None O
analogues None None O
were None None O
equipotent None None O
to None None O
the None None O
corresponding None None O
ATP None None O
analogues None None O
. None None O

Adenosine None None O
monophosphate None None O
analogues None None O
were None None O
full None None O
agonists None None O
, None None O
although None None O
generally None None O
4 None None O
orders None None O
of None None O
magnitude None None O
less None None O
potent None None O
. None None O

ATP None None O
2 None None O
- None None O
thioethers None None O
displayed None None O
pD2 None None O
values None None O
in None None O
the None None O
range None None O
of None None O
6-8 None None O
in None None O
smooth None None O
muscle None None O
assay None None O
systems None None O
for None None O
activity None None O
at None None O
P2Y None None O
- None None O
receptors None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
correlation None None O
for None None O
the None None O
2 None None O
- None None O
thioether None None O
compounds None None O
between None None O
the None None O
pK0 None None O
.5 None None O
values None None O
for None None O
inositol None None O
phosphate None None O
production None None O
and None None O
the None None O
pD2 None None O
values None None O
for None None O
relaxation None None O
mediated None None O
via None None O
the None None O
P2Y None None O
- None None O
purinoceptors None None O
in None None O
the None None O
guinea None None O
pig None None O
taenia None None O
coli None None O
, None None O
but None None O
not None None O
for None None O
the None None O
vascular None None O
P2Y None None O
- None None O
receptors None None O
or None None O
for None None O
the None None O
P2X None None O
- None None O
receptors None None O
. None None O

At None None O
P2X None None O
- None None O
receptors None None O
, None None O
no None None O
activity None None O
was None None O
observed None None O
in None None O
the None None O
rabbit None None O
saphenous None None O
artery None None O
, None None O
but None None O
variable None None O
degrees None None O
of None None O
activity None None O
were None None O
observed None None O
in None None O
the None None O
guinea None None O
pig None None O
vas None None O
deferens None None O
and None None O
bladder None None O
depending None None O
on None None O
distal None None O
substituents None None O
of None None O
the None None O
thioether None None O
moiety None None O
. None None O

N6 None None O
- None None O
Methyl None None O
- None None O
ATP None None O
was None None O
inactive None None O
at None None O
P2X None None O
- None None O
receptors None None O
, None None O
and None None O
approximately None None O
equipotent None None O
to None None O
ATP None None O
at None None O
taenia None None O
coil None None O
P2Y None None O
- None None O
receptors None None O
. None None O

This None None O
suggested None None O
that None None O
hybrid None None O
N6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
thioether None None I-IUPAC
ATP None None I-IUPAC
derivatives None None I-MODIFIER
might None None O
be None None O
potent None None O
and None None O
selective None None O
for None None O
certain None None O
P2Y None None O
- None None O
receptors None None O
, None None O
as None None O
was None None O
shown None None O
for None None O
one None None O
such None None O
derivative None None O
, None None O
N6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hexenylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
ATP None None I-IUPAC
. None None O


1,3,5 None None I-MODIFIER
- None None I-MODIFIER
Substituted None None I-MODIFIER
indoles None None O
and None None O
indazoles None None O
have None None O
been None None O
studied None None O
as None None O
receptor None None O
antagonists None None O
of None None O
the None None O
peptidoleukotrienes None None O
. None None O

The None None O
best None None O
of None None O
these None None O
compounds None None O
generally None None O
had None None O
a None None O
methyl None None O
group None None O
at None None O
the None None O
N1 None None O
position None None O
, None None O
a None None O
[ None None I-IUPAC
( None None I-IUPAC
cyclopentyloxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
or None None O
2 None None I-IUPAC
- None None I-IUPAC
cyclopentylacetamido None None I-IUPAC
or None None O
N' None None I-IUPAC
- None None I-IUPAC
cyclopentylureido None None I-IUPAC
group None None I-MODIFIER
at None None O
the None None O
C None None O
- None None O
5 None None O
position None None O
, None None O
and None None O
an None None O
arylsulfonyl None None O
amide None None O
group None None O
as None None O
part None None O
of None None O
the None None O
acidic None None O
chain None None O
at None None O
the None None O
C None None O
- None None O
3 None None O
position None None O
of None None O
the None None O
ring None None O
. None None O

Such None None O
compounds None None O
had None None O
in None None O
vitro None None O
dissociation None None O
constants None None O
( None None O
KB None None O
) None None O
in None None O
the None None O
range None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
- None None O
10 None None O
( None None O
- None None O
11 None None O
) None None O
M None None O
on None None O
guinea None None O
pig None None O
trachea None None O
against None None O
LTE4 None None O
as None None O
agonist None None O
and None None O
inhibition None None O
constants None None O
( None None O
Ki None None O
) None None O
less None None O
than None None O
or None None O
equal None None O
to None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
M None None O
on None None O
guinea None None O
pig None None O
parenchymal None None O
membranes None None O
against None None O
[ None None O
3H None None O
] None None O
LTD4 None None O
. None None O

A None None O
number None None O
of None None O
compounds None None O
were None None O
orally None None O
effective None None O
at None None O
doses None None O
less None None O
than None None O
or None None O
equal None None O
to None None O
1 None None O
mg None None O
/ None None O
kg None None O
in None None O
blocking None None O
LTD4 None None O
- None None O
induced None None O
" None None O
dyspnea None None O
" None None O
in None None O
guinea None None O
pigs None None O
. None None O

Compound None None O
45 None None O
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
cyclopentyloxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methylindol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methoxybenzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylbenzenesulfonamide None None I-IUPAC
, None None O
ICI None None O
204,219 None None O
; None None O
pKB None None O
= None None O
9.67 None None O
+ None None O
/ None None O
- None None O
0.13 None None O
, None None O
Ki None None O
= None None O
0.3 None None O
+ None None O
/ None None O
- None None O
0.03 None None O
nM None None O
, None None O
po None None O
ED50 None None O
= None None O
0.3 None None O
mg None None O
/ None None O
kg None None O
] None None O
is None None O
currently None None O
under None None O
clinical None None O
investigation None None O
for None None O
asthma None None O
. None None O

In None None O
the None None O
indole None None O
series None None O
, None None O
certain None None O
alkylsulfonyl None None O
amides None None O
possessing None None O
a None None O
3 None None I-IUPAC
- None None I-IUPAC
cyanobenzyl None None I-IUPAC
substituent None None I-MODIFIER
at None None O
the None None O
N None None O
- None None O
1 None None O
position None None O
( None None O
60 None None O
, None None O
61 None None O
) None None O
were None None O
produced None None O
that None None O
had None None O
KB None None O
less None None O
than None None O
or None None O
equal None None O
to None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
M None None O
on None None O
guinea None None O
pig None None O
trachea None None O
. None None O


A None None O
series None None O
of None None O
substituted None None I-MODIFIER
dibenzo None None B-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
dioxin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxamides None None I-IUPAC
has None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
antitumor None None O
activity None None O
. None None O

The None None O
required None None O
substituted None None I-MODIFIER
dibenzo None None B-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
dioxin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acids None None I-IUPAC
were None None O
prepared None None O
by None None O
a None None O
variety None None O
of None None O
methods None None O
. None None O

No None None O
regiospecific None None O
syntheses None None O
were None None O
available None None O
for None None O
many None None O
of None None O
these None None O
, None None O
and None None O
separation None None O
of None None O
the None None O
mixtures None None O
of None None O
regioisomers None None O
obtained None None O
was None None O
sometimes None None O
difficult None None O
. None None O

The None None O
dibenzo None None I-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
dioxin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxamides None None I-IUPAC
are None None O
active None None O
against None None O
wild None None O
- None None O
type None None O
P388 None None O
leukemia None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
, None None O
with None None O
structure None None O
- None None O
activity None None O
relationships None None O
resembling None None O
those None None O
for None None O
both None None O
the None None O
acridine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
and None None O
phenazine None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
series None None I-MODIFIER
of None None O
DNA None None O
- None None O
intercalating None None O
antitumor None None O
agents None None O
. None None O

In None None O
all None None O
three None None O
series None None O
, None None O
substituents None None O
placed None None O
peri None None O
to None None O
the None None O
carboxamide None None O
sidechain None None O
( None None O
the None None O
5 None None O
- None None O
position None None O
in None None O
the None None O
acridines None None O
, None None O
and None None O
the None None O
9 None None O
- None None O
position None None O
in None None O
the None None O
phenazines None None O
and None None O
dibenzo None None I-IUPAC
[ None None I-IUPAC
1,4 None None I-IUPAC
] None None I-IUPAC
dioxins None None I-IUPAC
) None None O
enhance None None O
activity None None O
and None None O
potency None None O
. None None O

The None None O
9 None None I-IUPAC
- None None I-IUPAC
chlorodibenzodioxin None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
was None None O
also None None O
curative None None O
against None None O
the None None O
remotely None None O
sited None None O
Lewis None None O
lung None None O
carcinoma None None O
. None None O

Several None None O
of None None O
the None None O
compounds None None O
showed None None O
much None None O
lower None None O
levels None None O
of None None O
cross None None O
- None None O
resistance None None O
to None None O
the None None O
P388 None None O
/ None None O
AMSA None None O
line None None O
than None None O
classical None None O
DNA None None O
- None None O
intercalating None None O
agents None None O
, None None O
which None None O
suggests None None O
that None None O
their None None O
primary None None O
mechanism None None O
of None None O
action None None O
may None None O
not None None O
be None None O
via None None O
interference None None O
with None None O
topoisomerase None None O
II None None O
alpha None None O
. None None O

This None None O
is None None O
of None None O
interest None None O
with None None O
regard None None O
to None None O
the None None O
development None None O
of None None O
drugs None None O
to None None O
combat None None O
resistance None None O
mechanisms None None O
which None None O
arise None None O
by None None O
the None None O
expression None None O
of None None O
the None None O
topo None None O
II None None O
beta None None O
isozyme None None O
. None None O


Octreotide None None O
, None None O
an None None O
analogue None None O
of None None O
the None None O
hormone None None O
somatostatin None None O
, None None O
has None None O
applications None None O
as None None O
a None None O
therapeutic None None O
and None None O
imaging None None O
agent None None O
for None None O
somatostatin None None O
- None None O
positive None None O
tumors None None O
. None None O

We None None O
have None None O
developed None None O
a None None O
generally None None O
applicable None None O
, None None O
convenient None None O
stepwise None None O
solid None None O
- None None O
phase None None O
synthetic None None O
protocol None None O
for None None O
octreotide None None O
( None None O
D None None O
- None None O
Phe None None O
- None None O
Cys None None O
- None None O
Phe None None O
- None None O
D None None O
- None None O
Trp None None O
- None None O
Lys None None O
- None None O
Thr None None O
- None None O
Cys None None O
- None None O
threoninol None None O
) None None O
. None None O

[ None None O
Cys None None O
( None None O
Acm None None O
) None None O
2 None None O
, None None O
D None None O
- None None O
Trp None None O
( None None O
Boc None None O
) None None O
4 None None O
, None None O
Lys None None O
( None None O
Boc None None O
) None None O
5 None None O
, None None O
Thr None None O
( None None O
tBu None None O
) None None O
6 None None O
, None None O
Cys None None O
( None None O
Acm None None O
) None None O
7 None None O
, None None O
des None None I-IUPAC
( None None I-IUPAC
threoninol None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
octreotide None None I-IUPAC
was None None O
assembled None None O
by None None O
Fmoc None None O
solid None None O
- None None O
phase None None O
synthesis None None O
and None None O
the None None O
intramolecular None None O
disulfide None None O
bond None None O
formed None None O
by None None O
treatment None None O
of None None O
the None None O
resin None None O
- None None O
bound None None O
peptide None None O
with None None O
thallium None None O
trifluoroacetate None None O
[ None None O
Tl None None O
( None None O
Tfa None None O
) None None O
3 None None O
] None None O
. None None O

Side None None O
- None None O
chain None None O
protection None None O
of None None O
Trp None None O
by None None O
the None None O
Boc None None O
group None None O
was None None O
found None None O
to None None O
preserve None None O
Trp None None O
integrity None None O
during None None O
Tl None None O
( None None O
Tfa None None O
) None None O
3 None None O
treatment None None O
. None None O

The None None O
protected None None O
peptide None None O
was None None O
cleaved None None O
from None None O
the None None O
resin None None O
by None None O
aminolysis None None O
with None None O
threoninol None None O
and None None O
purified None None O
by None None O
semipreparative None None O
RP None None O
- None None O
HPLC None None O
. None None O

Isolated None None O
[ None None O
D None None O
- None None O
Trp None None O
( None None O
Boc None None O
) None None O
4 None None O
, None None O
Lys None None O
( None None O
Boc None None O
) None None O
5 None None O
, None None O
Thr None None O
( None None O
tBu None None O
) None None O
6 None None O
] None None O
octreotide None None O
had None None O
the None None O
correct None None O
molecular None None O
mass None None O
( None None O
[ None None O
M+ None None O
H None None O
] None None O
+ None None O
= None None O
1275 None None O
Da None None O
) None None O
and None None O
sequence None None O
and None None O
was None None O
obtained None None O
in None None O
14% None None O
yield None None O
at None None O
& None None O
gt None None O
; None None O
98% None None O
purity None None O
. None None O

[ None None O
D None None O
- None None O
Trp None None O
( None None O
Boc None None O
) None None O
4 None None O
, None None O
Lys None None O
( None None O
Boc None None O
) None None O
5 None None O
, None None O
Thr None None O
( None None O
tBu None None O
) None None O
6 None None O
] None None O
octreotide None None O
was None None O
utilized None None O
for None None O
the None None O
solution None None O
- None None O
phase None None O
synthesis None None O
of None None O
CPTA None None O
- None None O
D None None O
- None None O
Phe1 None None O
- None None O
octreotide None None O
, None None O
where None None O
CPTA None None O
is None None O
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1,4,8,11 None None I-IUPAC
- None None I-IUPAC
tetraazacyclotetradec None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
. None None O

Cyclic None None O
dianhydride None None O
of None None O
diethylenetriaminepentaacetic None None O
acid None None O
( None None O
DTPA None None O
) None None O
was None None O
coupled None None O
to None None O
a None None O
portion None None O
of None None O
the None None O
protected None None O
peptide None None O
- None None O
resin None None O
following None None O
disulfide None None O
bond None None O
formation None None O
. None None O

The None None O
DTPA None None O
- None None O
conjugated None None O
, None None O
side None None O
- None None O
chain None None O
- None None O
protected None None O
peptide None None O
was None None O
cleaved None None O
from None None O
the None None O
resin None None O
by None None O
aminolysis None None O
with None None O
threoninol None None O
, None None O
side None None O
- None None O
chain None None O
deprotected None None O
with None None O
trifluoroacetic None None O
acid None None O
, None None O
and None None O
purified None None O
by None None O
semipreparative None None O
RP None None O
- None None O
HPLC None None O
. None None O

The None None O
isolated None None O
DTPA None None O
- None None O
D None None O
- None None O
Phe1 None None O
- None None O
octreotide None None O
had None None O
the None None O
correct None None O
molecular None None O
mass None None O
( None None O
[ None None O
M+ None None O
H None None O
] None None O
+ None None O
= None None O
1395 None None O
Da None None O
) None None O
and None None O
was None None O
obtained None None O
in None None O
5% None None O
yield None None O
at None None O
& None None O
gt None None O
; None None O
90% None None O
purity None None O
. None None O

The None None O
efficiency None None O
of None None O
aminolysis None None O
was None None O
partially None None O
dependent None None O
upon None None O
the None None O
linkage None None O
between None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
phenoxy None None I-IUPAC
( None None O
HMP None None O
) None None O
handles None None I-MODIFIER
and None None O
the None None O
resin None None O
and None None O
/ None None O
or None None O
resin None None O
particle None None O
size None None O
. None None O

The None None O
somatostatin None None O
receptor None None O
binding None None O
affinities None None O
of None None O
synthetic None None O
DTPA None None O
- None None O
D None None O
- None None O
Phe1 None None O
- None None O
octreotide None None O
and None None O
CPTA None None O
- None None O
D None None O
- None None O
Phe1 None None O
- None None O
octreotide None None O
to None None O
AtT None None O
- None None O
20 None None O
mouse None None O
pituitary None None O
carcinoma None None O
cell None None O
membranes None None O
were None None O
examined None None O
by None None O
labeling None None O
with None None O
111In None None O
and None None O
64Cu None None O
, None None O
respectively None None O
, None None O
and None None O
performing None None O
Scatchard None None O
analyses None None O
. None None O

The None None O
dissociation None None O
constant None None O
( None None O
Kd None None O
) None None O
for None None O
our None None O
synthetic None None O
[ None None O
111In None None O
] None None O
DTPA None None O
- None None O
D None None O
- None None O
Phe1 None None O
- None None O
octreotide None None O
was None None O
4.31 None None O
nM None None O
, None None O
which None None O
is None None O
comparable None None O
to None None O
a None None O
Kd None None O
= None None O
5.57 None None O
nM None None O
obtained None None O
with None None O
commercially None None O
available None None O
DTPA None None O
- None None O
D None None O
- None None O
Phe1 None None O
- None None O
octreotide None None O
. None None O

The None None O
Kd None None O
for None None O
[ None None O
64Cu None None O
] None None O
CPTA None None O
- None None O
D None None O
- None None O
Phe1 None None O
- None None O
octreotide None None O
was None None O
78.5 None None O
pM None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
the None None O
criteria None None O
of None None O
molecular None None O
mass None None O
, None None O
RP None None O
- None None O
HPLC None None O
elution None None O
time None None O
, None None O
sequence None None O
analysis None None O
, None None O
and None None O
somatostatin None None O
receptor None None O
binding None None O
affinity None None O
, None None O
our None None O
synthetic None None O
octreotide None None O
is None None O
identical None None O
to None None O
commercially None None O
available None None O
octreotide None None O
. None None O

The None None O
aminolysis None None O
protocol None None O
used None None O
here None None O
has None None O
distinct None None O
advantages None None O
over None None O
either None None O
reductive None None O
cleavage None None O
or None None O
preformed None None O
linker None None O
methods None None O
described None None O
previously None None O
for None None O
the None None O
preparation None None O
of None None O
octreotide None None O
. None None O


The None None O
antimicrobial None None O
and None None O
cytotoxic None None O
properties None None O
of None None O
a None None O
series None None O
of None None O
9,10 None None I-IUPAC
- None None I-IUPAC
dihydrophenanthrenes None None I-IUPAC
structurally None None O
related None None O
to None None O
juncusol None None O
( None None O
1a None None O
) None None O
, None None O
a None None O
postulated None None O
phytoalexin None None O
with None None O
confirmed None None O
cytotoxic None None O
properties None None O
, None None O
are None None O
detailed None None O
. None None O

Two None None O
simple None None O
9,10 None None I-IUPAC
- None None I-IUPAC
dihydrophenanthrenes None None I-IUPAC
, None None O
2,7 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
3,8 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
9,10 None None I-IUPAC
- None None I-IUPAC
dihydrophenanthrene None None I-IUPAC
( None None O
2h None None O
, None None O
desvinyljuncusol None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
9,10 None None I-IUPAC
- None None I-IUPAC
dihydrophenanthrene None None I-IUPAC
( None None O
3h None None O
) None None O
, None None O
were None None O
found None None O
to None None O
possess None None O
in None None O
vitro None None O
antimicrobial None None O
activity None None O
comparable None None O
with None None O
that None None O
of None None O
the None None O
natural None None O
product None None O
. None None O

Two None None O
9,10 None None I-IUPAC
- None None I-IUPAC
dihydrophenanthrenes None None I-IUPAC
substituted None None O
with None None O
quaternary None None O
ammonium None None O
salts None None O
, None None O
2d None None O
and None None O
3d None None O
, None None O
each None None O
containing None None O
a None None O
reactive None None O
benzylic None None I-MODIFIER
dimethyl None None B-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
ammonio None None I-IUPAC
group None None I-MODIFIER
, None None O
were None None O
found None None O
to None None O
be None None O
10-20 None None O
times None None O
more None None O
potent None None O
than None None O
juncusol None None O
( None None O
1a None None O
) None None O
. None None O

Confirmed None None O
in None None O
vitro None None O
cytotoxic None None O
activity None None O
that None None O
parallels None None O
antimicrobial None None O
activity None None O
was None None O
found None None O
for None None O
juncusol None None O
( None None O
1a None None O
) None None O
, None None O
desvinyljuncusol None None O
( None None O
2h None None O
) None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
9,10 None None I-IUPAC
- None None I-IUPAC
dihydrophenanthrene None None I-IUPAC
( None None O
3h None None O
) None None O
, None None O
and None None O
the None None O
quaternary None None I-MODIFIER
dimethyl None None B-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
ammonium None None I-IUPAC
salts None None I-MODIFIER
2d None None O
and None None O
3d None None O
in None None O
a None None O
human None None O
lymphoblastic None None O
leukemia None None O
cell None None O
culture None None O
( None None O
CCRF None None O
- None None O
CEM None None O
, None None O
IC50 None None O
= None None O
nt None None O
, None None O
9.3 None None O
, None None O
nt None None O
, None None O
0.9 None None O
and None None O
1.4 None None O
microgram None None O
/ None None O
mL None None O
, None None O
respectively None None O
) None None O
, None None O
B None None O
- None None O
16 None None O
mouse None None O
melanoma None None O
cell None None O
culture None None O
( None None O
IC50 None None O
= None None O
12.5 None None O
, None None O
17.5 None None O
, None None O
27.7 None None O
, None None O
0.3 None None O
, None None O
and None None O
0.5 None None O
microgram None None O
/ None None O
mL None None O
, None None O
respectively None None O
) None None O
, None None O
and None None O
L None None O
- None None O
1210 None None O
mouse None None O
lymphocytic None None O
leukemia None None O
cell None None O
culture None None O
( None None O
IC50 None None O
= None None O
13.8 None None O
, None None O
10.2 None None O
, None None O
24.5 None None O
, None None O
1.3 None None O
, None None O
and None None O
3.7 None None O
micrograms None None O
/ None None O
mL None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
comparable None None O
potency None None O
and None None O
spectrum None None O
of None None O
activity None None O
of None None O
juncusol None None O
( None None O
1a None None O
) None None O
, None None O
desvinyljuncusol None None O
( None None O
2h None None O
) None None O
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
9,10 None None I-IUPAC
- None None I-IUPAC
dihydrophenanthrene None None I-IUPAC
( None None O
3h None None O
) None None O
suggest None None O
that None None O
the None None O
agents None None O
are None None O
acting None None O
as None None O
simple None None O
phenols None None O
in None None O
exerting None None O
their None None O
antimicrobial None None O
and None None O
cytotoxic None None O
effects None None O
. None None O


A None None O
number None None O
of None None O
17 None None I-PARTIUPAC
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
alkyl None None I-PARTIUPAC
/ None None I-PARTIUPAC
arylformamido None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
17 None None I-PARTIUPAC
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
alkyl None None I-PARTIUPAC
/ None None I-PARTIUPAC
aryl None None I-PARTIUPAC
) None None I-PARTIUPAC
alkyl None None I-PARTIUPAC
/ None None I-PARTIUPAC
arylamido None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
oxo None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
aza None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
alpha None None I-PARTIUPAC
- None None O
steroids None None I-MODIFIER
were None None O
prepared None None O
from None None O
17 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
azasteroids None None I-IUPAC
and None None O
evaluated None None O
as None None O
inhibitors None None O
of None None O
human None None O
5 None None O
alpha None None O
- None None O
reductase None None O
and None None O
antagonists None None O
of None None O
the None None O
androgen None None O
receptor None None O
. None None O

Jones None None O
' None None O
oxidation None None O
of None None O
17 None None I-PARTIUPAC
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxy None None I-PARTIUPAC
compounds None None I-MODIFIER
gave None None O
the None None O
17 None None I-IUPAC
- None None I-IUPAC
keto None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
azasteroids None None I-IUPAC
, None None O
which None None O
were None None O
treated None None O
with None None O
amines None None O
and None None O
NaBH None None O
( None None O
OAc None None O
) None None O
3 None None O
/ None None O
NaBH3CN None None O
to None None O
give None None O
17 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
/ None None I-IUPAC
arylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
azasteroids None None I-IUPAC
10-27 None None O
. None None O

Alternatively None None O
, None None O
the None None O
above None None O
- None None O
indicated None None O
compounds None None O
were None None O
prepared None None O
from None None O
amines None None O
and None None O
17 None None I-IUPAC
- None None I-IUPAC
keto None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
azasteroids None None I-IUPAC
to None None O
form None None O
imines None None O
, None None O
which None None O
were None None O
then None None O
reduced None None O
with None None O
NaBH4 None None O
. None None O

Formylation None None O
of None None O
amines None None O
10-27 None None O
gave None None O
17 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
alkylformamides None None I-IUPAC
) None None I-IUPAC
28-41 None None O
; None None O
however None None O
, None None O
acylation None None O
afforded None None O
17 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
/ None None I-IUPAC
aryl None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
/ None None I-IUPAC
arylamides None None I-IUPAC
] None None I-IUPAC
42-53 None None O
. None None O

In None None O
comparison None None O
to None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
diethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
androstane None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
4 None None O
- None None O
MA None None O
; None None O
IC50 None None O
= None None O
4.15 None None O
nM None None O
) None None O
, None None O
17 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
alkylformamido None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
azasteroids None None I-IUPAC
were None None O
potent None None O
inhibitors None None O
of None None O
human None None O
type None None O
I None None O
5 None None O
alpha None None O
- None None O
reductase None None O
, None None O
IC50 None None O
values None None O
of None None O
compounds None None O
29 None None O
, None None O
30 None None O
, None None O
36 None None O
, None None O
and None None O
37 None None O
being None None O
measured None None O
as None None O
3.05 None None O
, None None O
0.91 None None O
, None None O
2.19 None None O
, None None O
and None None O
2.35 None None O
nM None None O
, None None O
respectively None None O
. None None O

The None None O
structure None None O
- None None O
activity None None O
relationships None None O
suggest None None O
that None None O
the None None O
type None None O
I None None O
enzyme None None O
has None None O
preference None None O
for None None O
N None None O
- None None O
substituted None None O
straight None None O
alkyl None None O
side None None O
chains None None O
of None None O
four None None O
to None None O
five None None O
carbon None None O
atoms None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
formamides None None O
32 None None O
( None None O
N None None I-IUPAC
- None None I-IUPAC
heptyl None None I-IUPAC
) None None O
and None None O
33 None None O
( None None O
N None None I-IUPAC
- None None I-IUPAC
octyl None None I-IUPAC
) None None O
, None None O
in None None O
addition None None O
to None None O
inhibiting None None O
the None None O
type None None O
I None None O
enzyme None None O
( None None O
IC50s None None O
= None None O
9.57 None None O
and None None O
16.9 None None O
nM None None O
, None None O
respectively None None O
) None None O
, None None O
showed None None O
also None None O
strong None None O
inhibitory None None O
activity None None O
( None None O
IC50s None None O
= None None O
14.0 None None O
and None None O
18.4 None None O
nM None None O
, None None O
respectively None None O
) None None O
for None None O
human None None O
type None None O
II None None O
5 None None O
alpha None None O
- None None O
reductase None None O
, None None O
in None None O
comparison None None O
to None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1' None None I-IUPAC
, None None I-IUPAC
1' None None I-IUPAC
- None None I-IUPAC
dimethylethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
androst None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ene None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
MK None None O
- None None O
906 None None O
; None None O
IC50 None None O
= None None O
4.53 None None O
nM None None O
) None None O
. None None O

Other None None O
compounds None None O
in None None O
this None None O
series None None O
showed None None O
moderate None None O
activities None None O
( None None O
IC50 None None O
& None None O
gt None None O
; None None O
100 None None O
nM None None O
) None None O
on None None O
the None None O
type None None O
II None None O
enzyme None None O
. None None O

17 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
Alkyl None None I-IUPAC
/ None None I-IUPAC
aryl None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
/ None None I-IUPAC
arylamides None None I-IUPAC
] None None I-IUPAC
45 None None O
, None None O
46 None None O
, None None O
48 None None O
, None None O
and None None O
51 None None O
exhibited None None O
highly None None O
potent None None O
inhibitory None None O
activity None None O
for None None O
human None None O
type None None O
I None None O
5 None None O
alpha None None O
- None None O
reductase None None O
with None None O
IC50s None None O
of None None O
1.77 None None O
, None None O
2.42 None None O
, None None O
2.93 None None O
, None None O
and None None O
5.44 None None O
nM None None O
, None None O
respectively None None O
, None None O
while None None O
moderate None None O
to None None O
no None None O
effect None None O
was None None O
observed None None O
on None None O
the None None O
type None None O
II None None O
enzyme None None O
( None None O
100 None None O
& None None O
lt None None O
; None None O
IC50s None None O
& None None O
lt None None O
; None None O
1000 None None O
nM None None O
) None None O
, None None O
except None None O
for None None O
compound None None O
48 None None O
( None None O
IC50 None None O
= None None O
3.75 None None O
nM None None O
) None None O
. None None O

In None None O
another None None O
substitution None None O
pattern None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
/ None None O
alkylamides None None I-IUPAC
were None None O
studied None None O
; None None O
an None None O
electron None None O
- None None O
donating None None O
group None None O
increased None None O
the None None O
potency None None O
of None None O
compound None None O
51 None None O
, None None O
whereas None None O
an None None O
electron None None O
- None None O
withdrawing None None O
group None None O
decreased None None O
the None None O
potency None None O
of None None O
compounds None None O
52 None None O
and None None O
53 None None O
compared None None O
to None None O
parent None None O
compound None None O
50 None None O
. None None O

In None None O
addition None None O
to None None O
their None None O
5 None None O
alpha None None O
- None None O
reductase None None O
activities None None O
, None None O
17 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
alkylformamides None None I-IUPAC
) None None I-IUPAC
were None None O
also None None O
studied None None O
for None None O
their None None O
inhibitory None None O
activities None None O
on None None O
dihydrotestosterone None None O
( None None O
DHT None None O
) None None O
- None None O
stimulated None None O
proliferation None None O
of None None O
androgen None None O
- None None O
sensitive None None O
Shionogi None None O
mouse None None O
mammary None None O
carcinoma None None O
cells None None O
( None None O
clone None None O
SEM None None O
- None None O
107 None None O
) None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

A None None O
series None None O
of None None O
analogues None None O
of None None O
the None None O
conformationally None None O
restricted None None O
delta None None O
opioid None None O
receptor None None O
selective None None O
tetrapeptide None None O
Tyr None None O
- None None O
c None None O
[ None None O
D None None O
- None None O
Cys None None O
- None None O
Phe None None O
- None None O
D None None O
- None None O
Pen None None O
] None None O
OH None None O
( None None O
JOM None None O
13 None None O
) None None O
was None None O
prepared None None O
in None None O
which None None O
the None None O
conformationally None None O
labile None None O
Tyr None None O
residue None None O
was None None O
replaced None None O
with None None O
several None None O
less None None O
flexible None None O
tyrosine None None O
analogues None None O
. None None O

Among None None O
these None None O
tyrosine None None O
analogues None None O
were None None O
the None None O
bicyclic None None O
structures None None O
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
hydroxyisoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
HO None None O
- None None O
Tic None None O
) None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hydroxytetralin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
Hat None None O
) None None O
, None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxyindan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
Hai None None O
) None None O
in None None O
which None None O
rotations None None O
about None None O
the None None O
C None None O
alpha None None O
- None None O
C None None O
beta None None O
and None None O
C None None O
beta None None O
- None None O
C None None O
gamma None None O
bonds None None O
are None None O
restricted None None O
due None None O
to None None O
cyclization None None O
of None None O
the None None O
side None None O
chain None None O
to None None O
the None None O
backbone None None O
. None None O

Also None None O
examined None None O
were None None O
analogues None None O
in None None O
which None None O
tyrosine None None O
was None None O
replaced None None O
with None None O
either None None O
trans None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
proline None None I-IUPAC
( None None O
t None None O
- None None O
Hpp None None O
) None None O
or None None O
cis None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
proline None None I-IUPAC
( None None O
c None None O
- None None O
Hpp None None O
) None None O
, None None O
residues None None O
in None None O
which None None O
rotations None None O
about None None O
C None None O
alpha None None O
- None None O
C None None O
beta None None O
, None None O
but None None O
not None None O
C None None O
beta None None O
- None None O
C None None O
gamma None None O
, None None O
are None None O
restricted None None O
. None None O

Both None None O
the None None O
t None None O
- None None O
Hpp1 None None O
and None None O
c None None O
- None None O
Hpp1 None None O
analogues None None O
displayed None None O
delta None None O
receptor None None O
binding None None O
affinity None None O
similar None None O
to None None O
the None None O
parent None None O
Tyr1 None None O
- None None O
containing None None O
peptide None None O
, None None O
while None None O
the None None O
D None None O
- None None O
Hat1 None None O
, None None O
L None None O
- None None O
Hat1 None None O
, None None O
and None None O
L None None O
- None None O
Hai1 None None O
analogues None None O
exhibited None None O
somewhat None None O
lower None None O
affinity None None O
. None None O

The None None O
results None None O
observed None None O
for None None O
the None None O
t None None O
- None None O
Hpp1 None None O
and None None O
c None None O
- None None O
Hpp1 None None O
analogues None None O
are None None O
particularly None None O
significant None None O
since None None O
these None None O
two None None O
residues None None O
have None None O
little None None O
accessible None None O
conformational None None O
space None None O
in None None O
common None None O
. None None O

Since None None O
the None None O
binding None None O
conformation None None O
of None None O
residue None None O
1 None None O
must None None O
be None None O
included None None O
in None None O
this None None O
limited None None O
conformational None None O
intersection None None O
, None None O
its None None O
elucidation None None O
is None None O
facilitated None None O
. None None O

Bioassay None None O
results None None O
from None None O
guinea None None O
pig None None O
ileum None None O
and None None O
mouse None None O
vas None None O
deferens None None O
preparations None None O
are None None O
in None None O
general None None O
agreement None None O
with None None O
the None None O
binding None None O
results None None O
; None None O
however None None O
some None None O
potency None None O
discrepancies None None O
are None None O
observed None None O
. None None O

These None None O
discrepancies None None O
may None None O
reflect None None O
different None None O
selectivities None None O
among None None O
delta None None O
receptor None None O
subtypes None None O
for None None O
the None None O
analogues None None O
or None None O
may None None O
represent None None O
differing None None O
efficacies None None O
among None None O
these None None O
conformationally None None O
restricted None None O
peptides None None O
. None None O

The None None O
conformational None None O
properties None None O
of None None O
the None None O
parent None None O
tetrapeptide None None O
and None None O
the None None O
residue None None O
1 None None O
- None None O
modified None None O
analogues None None O
were None None O
studied None None O
by None None O
molecular None None O
mechanics None None O
computations None None O
. None None O

All None None O
these None None O
peptides None None O
share None None O
a None None O
common None None O
rigid None None O
tripeptide None None O
cycle None None O
with None None O
a None None O
single None None O
energetically None None O
preferred None None O
backbone None None O
conformation None None O
and None None O
three None None O
different None None O
conformers None None O
of None None O
the None None O
D None None O
- None None O
Cys None None O
, None None O
D None None O
- None None O
Pen None None O
disulfide None None O
bridge None None O
, None None O
two None None O
of None None O
which None None O
are None None O
observed None None O
in None None O
the None None O
solid None None O
state None None O
and None None O
in None None O
aqueous None None O
solution None None O
, None None O
as None None O
previously None None O
determined None None O
from None None O
X None None O
- None None O
ray None None O
crystallography None None O
and None None O
1H None None O
NMR None None O
spectroscopy None None O
data None None O
( None None O
Lomize None None O
, None None O
A None None O
; None None O
et None None O
al. None None O
J None None O
. None None O

Am. None None O
Chem. None None O
Soc None None O
. None None O

1994 None None O
, None None O
116 None None O
, None None O
429-436 None None O
) None None O
. None None O

All None None O
the None None O
peptides None None O
have None None O
similar None None O
sets None None O
of None None O
low None None O
- None None O
energy None None O
conformations None None O
of None None O
their None None O
common None None O
flexible None None O
elements None None O
, None None O
the None None O
Phe3 None None O
side None None O
chain None None O
and None None O
the None None O
peptide None None O
group None None O
between None None O
the None None O
first None None O
residue None None O
and None None O
the None None O
rigid None None O
tripeptide None None O
cycle None None O
. None None O

However None None O
, None None O
possible None None O
conformations None None O
of None None O
the None None O
first None None O
residue None None O
differ None None O
and None None O
depend None None O
on None None O
the None None O
covalent None None O
constraints None None O
incorporated None None O
into None None O
the None None O
side None None O
chain None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

The None None O
synthesis None None O
and None None O
sigma None None O
receptor None None O
affinity None None O
of None None O
a None None O
series None None O
of None None O
conformationally None None O
restricted None None O
derivatives None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylethylenedi None None I-IUPAC
amine None None I-IUPAC
( None None O
1 None None O
) None None O
is None None O
described None None O
. None None O

The None None O
pyrrolidinyl None None I-IUPAC
( None None O
or None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dialkyl None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
ethylenediamine None None I-IUPAC
, None None O
N None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
, None None O
and None None O
phenylethyl None None I-IUPAC
portions None None B-MODIFIER
of None None O
this None None O
sigma None None O
receptor None None O
pharmacophore None None O
were None None O
restricted None None O
by None None O
its None None O
incorporation None None O
into None None O
1,2 None None I-IUPAC
- None None I-IUPAC
cyclohexanediamine None None I-IUPAC
- None None O
, None None O
pyrrolidine None None I-IUPAC
- None None O
, None None O
piperidine None None I-PARTIUPAC
- None None O
, None None O
homopiperidine None None I-PARTIUPAC
- None None O
, None None O
and None None O
tetrahydroisoquinoline None None I-IUPAC
- None None O
containing None None I-MODIFIER
ligands None None I-MODIFIER
. None None O

The None None O
sigma None None O
receptor None None O
binding None None O
affinities None None O
of None None O
these None None O
compounds None None O
were None None O
determined None None O
using None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pentazocine None None I-IUPAC
in None None O
guinea None None O
pig None None O
brain None None O
homogenates None None O
. None None O

The None None O
synthesis None None O
of None None O
all None None O
but None None O
one None None O
class None None O
was None None O
achieved None None O
by None None O
acylation None None O
and None None O
alane None None O
reduction None None O
of None None O
the None None O
appropriate None None O
diamine None None O
precursors None None O
whose None None O
synthesis None None O
is None None O
also None None O
reported None None O
. None None O

sigma None None O
receptor None None O
affinities None None O
ranged None None O
from None None O
1.34 None None O
nM None None O
for None None O
6,7 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
( None None O
12 None None O
) None None O
to None None O
455 None None O
nM None None O
for None None O
( None None I-IUPAC
1R None None I-IUPAC
, None None I-IUPAC
2R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dichlorophenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
cyclohexylamine None None I-IUPAC
[ None None O
( None None O
- None None O
) None None O
- None None O
4 None None O
] None None O
. None None O

In None None O
this None None O
displacement None None O
assay None None O
, None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pentazocine None None I-IUPAC
exhibited None None O
a None None O
Ki None None O
of None None O
3.1 None None O
nM None None O
while None None O
DTG None None O
and None None O
haloperidol None None O
showed None None O
Ki None None O
values None None O
of None None O
27.7 None None O
and None None O
3.7 None None O
nM None None O
, None None O
respectively None None O
. None None O

The None None O
conformationally None None O
free None None O
parent None None O
compound None None O
1 None None O
exhibited None None O
a None None O
Ki None None O
value None None O
of None None O
2.1 None None O
nM None None O
. None None O

Comparison None None O
of None None O
both None None O
the None None O
sigma None None O
receptor None None O
affinities None None O
and None None O
nitrogen None None O
atom None None O
geometry None None O
of None None O
the None None O
compounds None None O
revealed None None O
that None None O
a None None O
gauche None None O
relation None None O
of None None O
the None None O
nitrogen None None O
atoms None None O
of None None O
cis None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
cyclohexanediamines None None I-IUPAC
is None None O
not None None O
imperative None None O
for None None O
high None None O
affinity None None O
as None None O
we None None O
had None None O
previously None None O
thought None None O
. None None O

It None None O
is None None O
highly None None O
likely None None O
that None None O
nitrogen None None O
lone None None O
pair None None O
orientations None None O
and None None O
steric None None O
factors None None O
on None None O
the None None O
aliphatic None None O
portions None None O
of None None O
these None None O
ligands None None O
play None None O
a None None O
major None None O
role None None O
in None None O
the None None O
sigma None None O
receptor None None O
binding None None O
of None None O
this None None O
pharmacophore None None O
. None None O


The None None O
design None None O
of None None O
analogues None None O
of None None O
7,8 None None I-IUPAC
- None None I-IUPAC
dihydroretinoic None None I-IUPAC
acid None None I-IUPAC
( None None O
7,8 None None O
- None None O
dihydro None None O
- None None O
RA None None O
) None None O
was None None O
based None None O
on None None O
reported None None O
biological None None O
activities None None O
of None None O
this None None O
retinoid None None O
and None None O
its None None O
dihydro None None O
- None None O
TMMP None None O
( None None O
1 None None O
) None None O
analogue None None O
and None None O
on None None O
structural None None O
hypotheses None None O
. None None O

7 None None I-IUPAC
- None None I-IUPAC
Oxa None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
dihydroretinoids None None I-IUPAC
( None None O
5 None None O
, None None O
6 None None O
) None None O
were None None O
prepared None None O
by None None O
O None None O
- None None O
alkylation None None O
of None None O
phenoxides None None O
by None None O
methyl None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
3,7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
2,4,6 None None I-IUPAC
- None None I-IUPAC
octatrienoate None None I-IUPAC
. None None O

In None None O
some None None O
cases None None O
, None None O
C None None O
- None None O
alkylation None None O
also None None O
occurred None None O
. None None O

7 None None I-IUPAC
- None None I-IUPAC
Aza None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
dihydroretinoids None None I-IUPAC
( None None O
12 None None O
, None None O
13 None None O
) None None O
were None None O
synthesized None None O
from None None O
benzeneamines None None O
and None None O
the None None O
acyl None None I-IUPAC
cyano None None I-IUPAC
or None None O
bromo None None I-IUPAC
derivative None None B-MODIFIER
of None None O
the None None O
monomethyl None None O
ester None None O
of None None O
3,7 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
2,4,6 None None I-IUPAC
- None None I-IUPAC
octatriene None None I-IUPAC
- None None I-IUPAC
1,8 None None I-IUPAC
- None None I-IUPAC
dioic None None I-IUPAC
acid None None I-IUPAC
. None None O

These None None O
monomethyl None None O
ester None None O
precursors None None O
were None None O
synthesized None None O
from None None O
the None None O
known None None O
analogous None None O
aldehyde None None O
via None None O
an None None O
O None None I-IUPAC
- None None I-IUPAC
trimethylsilyl None None I-IUPAC
cyanohydrin None None I-IUPAC
. None None O

7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3,5 None None I-IUPAC
- None None I-IUPAC
Trimethylphenoxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
2,4,6 None None I-IUPAC
- None None I-IUPAC
octatrienoic None None I-IUPAC
acid None None I-IUPAC
( None None O
6b None None O
) None None O
was None None O
the None None O
most None None O
active None None O
of None None O
the None None O
7 None None O
- None None O
oxa None None O
- None None O
7,8 None None O
- None None O
dihydro None None O
- None None O
RAs None None O
in None None O
inhibiting None None O
DMBA None None O
- None None O
initiated None None O
and None None O
TPA None None O
- None None O
promoted None None O
mouse None None O
- None None O
skin None None O
papillomas None None O
. None None O

The None None O
ED None None O
( None None O
50 None None O
) None None O
was None None O
about None None O
4 None None O
- None None O
fold None None O
that None None O
of None None O
etretinate None None O
. None None O

Two None None O
additional None None O
7 None None O
- None None O
oxa None None O
- None None O
7,8 None None O
- None None O
dihydro None None O
- None None O
RAs None None O
exhibited None None O
modest None None O
activity None None O
in None None O
the None None O
papilloma None None O
assay None None O
. None None O

Some None None O
of None None O
the None None O
7 None None O
- None None O
oxa None None O
- None None O
7,8 None None O
- None None O
dihydro None None O
- None None O
RAs None None O
bind None None O
to None None O
CRABP None None O
and None None O
RARalpha None None O
. None None O


Anthelmintic None None O
efficacies None None O
of None None O
a None None O
series None None O
of None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
methyl None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamates None None I-IUPAC
were None None O
compared None None O
to None None O
similarly None None O
substituted None None I-MODIFIER
benzimidazole None None B-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamates None None I-IUPAC
. None None O

With None None O
only None None O
one None None O
exception None None O
, None None O
methyl None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
benzoylimidazo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamate None None I-IUPAC
, None None O
both None None O
classes None None O
of None None O
compounds None None O
exhibited None None O
similar None None O
activity None None O
vs. None None O
Nematospiroides None None O
dubius None None O
in None None O
mice None None O
. None None O

Preliminary None None O
screening None None O
indicated None None O
methyl None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1,2,2 None None I-IUPAC
- None None I-IUPAC
trichloroethenyl None None I-IUPAC
) None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamate None None I-IUPAC
to None None O
be None None O
the None None O
most None None O
potent None None O
derivative None None O
in None None O
the None None O
series None None O
. None None O

However None None O
, None None O
evaluation None None O
in None None O
sheep None None O
indicated None None O
that None None O
its None None O
anthelmintic None None O
spectrum None None O
was None None O
inferior None None O
to None None O
methyl None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylsulfinyl None None I-IUPAC
) None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbamate None None I-IUPAC
. None None O


Methods None None O
have None None O
been None None O
developed None None O
for None None O
the None None O
preparation None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodothiophenes None None I-IUPAC
. None None O

The None None O
syntheses None None O
and None None O
physical None None O
properties None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodothiophene None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodothiophene None None I-IUPAC
are None None O
described None None O
. None None O

The None None O
radioiodinated None None O
agents None None O
are None None O
of None None O
interest None None O
because None None O
of None None O
the None None O
high None None O
expected None None O
uptake None None O
and None None O
prolonged None None O
brain None None O
retention None None O
that None None O
may None None O
result None None O
from None None O
binding None None O
to None None O
high None None O
- None None O
capacity None None O
, None None O
relatively None None O
nonspecific None None O
amine None None O
binding None None O
sites None None O
. None None O

Radioiodine None None O
was None None O
introduced None None O
into None None O
the None None O
5 None None O
- None None O
position None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodothiophene None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodothiophene None None I-IUPAC
by None None O
radioiodination None None O
of None None O
the None None O
corresponding None None O
5 None None I-IUPAC
- None None I-IUPAC
boronic None None I-IUPAC
acid None None I-IUPAC
or None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trimethylstannyl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
. None None O

Tissue None None O
distribution None None O
studies None None O
in None None O
rats None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
125I None None I-IUPAC
] None None I-IUPAC
iodothiophene None None I-IUPAC
showed None None O
high None None O
brain None None O
uptake None None O
( None None O
5 None None O
min None None O
, None None O
2.77% None None O
dose None None O
/ None None O
g None None O
; None None O
30 None None O
min None None O
, None None O
2.51% None None O
dose None None O
/ None None O
g None None O
) None None O
and None None O
good None None O
brain None None O
/ None None O
blood None None O
( None None O
B None None O
/ None None O
B None None O
) None None O
ratios None None O
( None None O
5 None None O
min None None O
, None None O
6/1 None None O
; None None O
30 None None O
min None None O
3.8/1 None None O
. None None O

A None None O
comparison None None O
of None None O
the None None O
brain None None O
uptake None None O
of None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
isopropyl None None I-IUPAC
derivative None None I-MODIFIER
with None None O
the None None O
2 None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
analogue None None I-MODIFIER
demonstrated None None O
higher None None O
initial None None O
brain None None O
uptake None None O
and None None O
brain None None O
to None None O
blood None None O
ratios None None O
( None None O
5 None None O
min None None O
, None None O
3.2% None None O
dose None None O
/ None None O
g None None O
; None None O
10.3/1 None None O
) None None O
but None None O
more None None O
rapid None None O
washout None None O
( None None O
30 None None O
min None None O
, None None O
1.37% None None O
dose None None O
; None None O
2.8/1 None None O
) None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
radiolabeled None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodothiophenes None None I-IUPAC
are None None O
potentially None None O
useful None None O
agents None None O
for None None O
cerebral None None O
perfusion None None O
imaging None None O
by None None O
single None None O
- None None O
photon None None O
- None None O
emission None None O
computerized None None O
tomography None None O
( None None O
SPECT None None O
) None None O
. None None O


N None None O
- None None O
Substituted None None O
analogues None None O
of None None O
trans None None I-PARTIUPAC
- None None I-PARTIUPAC
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
trans None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1,2,3,4,4 None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
5,6,10 None None I-IUPAC
b None None I-IUPAC
- None None I-IUPAC
octahydrobenzo None None I-IUPAC
[ None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
quinoline None None I-IUPAC
( None None O
trans None None O
- None None O
7 None None O
- None None O
and None None O
trans None None O
- None None O
9 None None O
- None None O
OH None None O
- None None O
OHBQ None None O
) None None O
were None None O
tested None None O
for None None O
dopamine None None O
( None None O
DA None None O
) None None O
D2 None None O
receptor None None O
affinity None None O
by None None O
using None None O
in None None O
vitro None None O
[ None None O
3H None None O
] None None O
spiperone None None O
and None None O
in None None O
vivo None None O
5,6 None None O
- None None O
di None None O
- None None O
n None None O
- None None O
Pr None None O
- None None O
ADTN None None O
binding None None O
assays None None O
. None None O

Potencies None None O
at None None O
central None None O
pre None None O
- None None O
( None None O
auto None None O
- None None O
) None None O
and None None O
postsynaptic None None O
DA None None O
receptors None None O
were None None O
determined None None O
by None None O
a None None O
biochemical None None O
and None None O
a None None O
behavioral None None O
method None None O
, None None O
respectively None None O
. None None O

Corresponding None None O
data None None O
were None None O
included None None O
for None None O
analogous None None O
, None None O
resolved None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
piperidines None None I-IUPAC
and None None O
a None None O
few None None O
other None None O
substituted None None O
, None None O
racemic None None I-MODIFIER
3 None None B-IUPAC
- None None I-IUPAC
phenylpiperidines None None I-IUPAC
. None None O

Beside None None O
the None None O
central None None O
dopaminergic None None O
effects None None O
of None None O
these None None O
compounds None None O
, None None O
previously None None O
reported None None O
sigma None None O
receptor None None O
affinity None None O
data None None O
[ None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylpiperidine None None I-IUPAC
; None None O
[ None None O
3H None None O
] None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
3 None None O
- None None O
PPP None None O
] None None O
were None None O
also None None O
taken None None O
into None None O
account None None O
for None None O
a None None O
comparison None None O
of None None O
the None None O
structure None None O
- None None O
activity None None O
/ None None O
affinity None None O
relationships None None O
of None None O
these None None O
compounds None None O
at None None O
these None None O
two None None O
receptor None None O
types None None O
. None None O

Larger None None O
N None None O
- None None O
substituents None None O
in None None O
both None None O
phenylpiperidines None None O
and None None O
OHBQs None None O
increase None None O
both None None O
pre None None O
- None None O
and None None O
postsynaptic None None O
dopaminergic None None O
activity None None O
. None None O

An None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
group None None I-MODIFIER
gives None None O
high None None O
dopaminergic None None O
efficacy None None O
at None None O
both None None O
receptor None None O
sites None None O
( None None O
pre None None O
- None None O
and None None O
postsynaptic None None O
) None None O
in None None O
all None None O
series None None O
. None None O

However None None O
, None None O
even None None O
higher None None O
dopaminergic None None O
potency None None O
is None None O
observed None None O
for None None O
trans None None O
- None None O
7 None None O
- None None O
OH None None O
- None None O
OHBQs None None O
and None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
piperidines None None I-IUPAC
with None None O
N None None O
- None None O
substituents None None O
larger None None O
than None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
. None None O

In None None O
contrast None None O
, None None O
trans None None O
- None None O
4 None None O
- None None O
n None None O
- None None O
Bu None None O
- None None O
9 None None O
- None None O
OH None None O
- None None O
OHBQ None None O
is None None O
inactive None None O
, None None O
and None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butylpiperidine None None I-IUPAC
is None None O
less None None O
active None None O
at None None O
central None None O
DA None None O
receptors None None O
than None None O
its None None O
corresponding None None O
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
analogue None None I-MODIFIER
. None None O

This None None O
implies None None O
interesting None None O
differences None None O
in None None O
N None None O
- None None O
substituent None None O
sensitivity None None O
for None None O
the None None O
different None None O
classes None None O
of None None O
compounds None None O
with None None O
respect None None O
to None None O
the None None O
direction None None O
of None None O
their None None O
respective None None O
N None None O
- None None O
substituents None None O
at None None O
the None None O
drug None None O
- None None O
receptor None None O
interaction None None O
. None None O

The None None O
stereochemical None None O
and None None O
steric None None O
demands None None O
for None None O
sigma None None O
receptor None None O
affinity None None O
are None None O
much None None O
less None None O
stringent None None O
. None None O

The None None O
general None None O
trend None None O
is None None O
that None None O
, None None O
up None None O
to None None O
a None None O
certain None None O
size None None O
, None None O
the None None O
more None None O
lipophilic None None O
the None None O
N None None O
- None None O
substituent None None O
, None None O
the None None O
higher None None O
the None None O
affinity None None O
for None None O
sigma None None O
receptor None None O
sites None None O
. None None O


A None None O
series None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
propenyl None None I-IUPAC
carboxamide None None I-IUPAC
derivatives None None I-MODIFIER
bearing None None O
an None None O
unsaturated None None O
bicyclic None None O
moiety None None O
in None None O
the None None O
3 None None O
- None None O
position None None O
was None None O
prepared None None O
and None None O
evaluated None None O
for None None O
PAF None None O
( None None O
platelet None None O
activating None None O
factor None None O
) None None O
antagonist None None O
activity None None O
. None None O

These None None O
compounds None None O
represent None None O
conformationally None None O
constrained None None O
direct None None O
analogues None None O
of None None O
the None None O
corresponding None None O
potent None None O
5 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
pentadienecarboxamides None None I-IUPAC
( None None O
5 None None O
) None None O
. None None O

Most None None O
of None None O
the None None O
new None None O
compounds None None O
were None None O
active None None O
in None None O
a None None O
PAF None None O
- None None O
binding None None O
assay None None O
employing None None O
whole None None O
, None None O
washed None None O
dog None None O
platelets None None O
as None None O
the None None O
receptor None None O
source None None O
and None None O
inhibited None None O
PAF None None O
- None None O
induced None None O
bronchoconstriction None None O
in None None O
guinea None None O
pigs None None O
after None None O
intravenous None None O
administration None None O
. None None O

However None None O
, None None O
oral None None O
activity None None O
in None None O
the None None O
PAF None None O
- None None O
induced None None O
bronchoconstriction None None O
model None None O
was None None O
highly None None O
sensitive None None O
to None None O
the None None O
nature None None O
and None None O
substitution None None O
of None None O
the None None O
bicyclic None None O
ring None None O
system None None O
. None None O

The None None O
most None None O
interesting None None O
compounds None None O
included None None O
[ None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
naphthyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propenamide None None I-IUPAC
( None None O
4b None None O
) None None O
, None None O
[ None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiophene None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propenamide None None I-IUPAC
( None None O
4k None None O
) None None O
, None None O
and None None O
[ None None I-IUPAC
R None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
indoly None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
pyridinyl None None I-IUPAC
) None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propenamide None None I-IUPAC
( None None O
4l None None O
) None None O
which None None O
inhibited None None O
PAF None None O
- None None O
induced None None O
broncho None None O
- None None O
constriction None None O
in None None O
guinea None None O
pigs None None O
with None None O
IC50s None None O
of None None O
3.0-5.4 None None O
mg None None O
/ None None O
kg None None O
, None None O
when None None O
the None None O
animals None None O
were None None O
challenged None None O
2 None None O
h None None O
after None None O
drug None None O
treatment None None O
. None None O

They None None O
were None None O
also None None O
highly None None O
effective None None O
6 None None O
h None None O
after None None O
a None None O
50 None None O
mg None None O
/ None None O
kg None None O
oral None None O
dose None None O
. None None O

This None None O
study None None O
supports None None O
the None None O
notion None None O
that None None O
the None None O
key None None O
remote None None O
aromatic None None O
ring None None O
present None None O
in None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
arylpentadienecarboxamides None None I-IUPAC
( None None O
5 None None O
) None None O
is None None O
preferentially None None O
coplanar None None O
with None None O
the None None O
diene None None O
system None None O
for None None O
good None None O
PAF None None O
antagonist None None O
activity None None O
. None None O


A None None O
series None None O
of None None O
secondary None None O
and None None O
tertiary None None O
N None None O
- None None O
alkyl None None O
derivatives None None O
of None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorotetralin None None I-IUPAC
have None None O
been None None O
prepared None None O
. None None O

The None None O
affinities None None O
of None None O
the None None O
compounds None None O
for None None O
[ None None O
3H None None O
] None None O
raclopride None None O
- None None O
labeled None None O
cloned None None O
human None None O
dopamine None None O
( None None O
DA None None O
) None None O
D2 None None O
and None None O
D3 None None O
receptors None None O
as None None O
well None None O
as None None O
[ None None O
3H None None O
] None None O
- None None O
8 None None O
- None None O
OH None None O
- None None O
DPAT None None O
- None None O
labeled None None O
rat None None O
hippocampal None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
were None None O
determined None None O
. None None O

In None None O
order None None O
to None None O
selectively None None O
determine None None O
affinities None None O
for None None O
the None None O
high None None O
- None None O
affinity None None O
agonist None None O
binding None None O
site None None O
at None None O
DA None None O
D2 None None O
receptors None None O
, None None O
the None None O
agonist None None O
[ None None O
3H None None O
] None None O
quinpirole None None O
was None None O
used None None O
. None None O

The None None O
intrinsic None None O
activities None None O
of None None O
the None None O
compounds None None O
at None None O
DA None None O
D2 None None O
and None None O
D3 None None O
receptors None None O
were None None O
evaluated None None O
in None None O
a None None O
[ None None O
35S None None O
] None None O
GTP None None O
gamma None None O
S None None O
binding None None O
assay None None O
. None None O

The None None O
novel None None O
compounds None None O
were None None O
characterized None None O
as None None O
dopaminergic None None O
antagonists None None O
or None None O
inverse None None O
agonists None None O
. None None O

The None None O
antagonist None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
butylpropylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorotetralin None None I-IUPAC
( None None O
16 None None O
) None None O
bound None None O
with None None O
high None None O
affinity None None O
( None None O
Ki None None O
= None None O
4.4 None None O
nM None None O
) None None O
to None None O
the None None O
DA None None O
D3 None None O
receptor None None O
and None None O
was None None O
the None None O
most None None O
D3 None None O
- None None O
selective None None O
compound None None O
( None None O
10 None None O
- None None O
fold None None O
) None None O
. None None O

( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
Aza None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
, None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
dioxospiro None None I-IUPAC
[ None None I-IUPAC
4.5 None None I-IUPAC
] None None I-IUPAC
decan None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
propylamino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorote None None I-IUPAC
tralin None None I-IUPAC
( None None O
18 None None O
) None None O
bound None None O
with None None O
very None None O
high None None O
affinity None None O
to None None O
both None None O
DA None None O
D3 None None O
and None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
( None None O
Ki None None O
= None None O
0.2 None None O
nM None None O
) None None O
and None None O
was None None O
also None None O
characterized None None O
as None None O
a None None O
dopaminergic None None O
antagonist None None O
. None None O

( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Benzylpropylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorotetralin None None I-IUPAC
( None None O
10 None None O
) None None O
behaved None None O
as None None O
an None None O
inverse None None O
agonist None None O
at None None O
both None None O
DA None None O
D2 None None O
and None None O
D3 None None O
receptors None None O
. None None O

It None None O
decreased None None O
the None None O
basal None None O
[ None None O
35S None None O
] None None O
GTP None None O
gamma None None O
S None None O
binding None None O
and None None O
potently None None O
inhibited None None O
the None None O
DA None None O
- None None O
stimulated None None O
[ None None O
35S None None O
] None None O
GTP None None O
gamma None None O
S None None O
binding None None O
. None None O

It None None O
is None None O
apparent None None O
that None None O
the None None O
intrinsic None None O
activity None None O
of None None O
a None None O
2 None None I-IUPAC
- None None I-IUPAC
aminotetralin None None I-IUPAC
derivative None None I-MODIFIER
may None None O
be None None O
modified None None O
by None None O
varying None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
substituents None None I-MODIFIER
. None None O


A None None O
series None None O
of None None O
dialkyl None None I-MODIFIER
N None None B-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
phenylene None None I-IUPAC
) None None I-IUPAC
dioxamates None None I-IUPAC
was None None O
synthesized None None O
by None None O
treatment None None O
of None None O
the None None O
requisite None None O
m None None I-IUPAC
- None None I-IUPAC
phenylenediamines None None I-IUPAC
with None None O
an None None O
alkyloxalyl None None O
chloride None None O
in None None O
the None None O
presence None None O
of None None O
triethylamine None None O
. None None O

Hydrolysis None None O
with None None O
sodium None None O
hydroxide None None O
solution None None O
gave None None O
the None None O
corresponding None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
phenylene None None I-IUPAC
) None None I-IUPAC
dioxamic None None I-IUPAC
acids None None I-IUPAC
. None None O

Several None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
phenylene None None I-IUPAC
) None None I-IUPAC
dioxamic None None I-IUPAC
acids None None I-IUPAC
were None None O
synthesized None None O
also None None O
in None None O
the None None O
same None None O
manner None None O
starting None None O
with None None O
the None None O
requisite None None O
p None None I-IUPAC
- None None I-IUPAC
phenylenediamines None None I-IUPAC
. None None O

These None None O
compounds None None O
were None None O
tested None None O
in None None O
the None None O
rat None None O
passive None None O
cutaneous None None O
anaphylaxis None None O
( None None O
PCA None None O
) None None O
assay None None O
. None None O

When None None O
tested None None O
iv None None O
, None None O
activity None None O
was None None O
found None None O
in None None O
the None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
phenylene None None I-IUPAC
) None None I-IUPAC
dioxamic None None I-IUPAC
acids None None I-IUPAC
up None None O
to None None O
2500 None None O
times None None O
that None None O
shown None None O
by None None O
disodium None None O
cromoglycate None None O
[ None None O
50% None None O
inhibition None None O
at None None O
0.001 None None O
mg None None O
/ None None O
kg None None O
for None None O
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
phenylene None None I-IUPAC
) None None I-IUPAC
dioxamic None None I-IUPAC
acid None None I-IUPAC
( None None O
compound None None O
61 None None O
) None None O
] None None O
. None None O

Oral None None O
activity None None O
was None None O
seen None None O
in None None O
this None None O
series None None O
of None None O
compounds None None O
with None None O
duration None None O
of None None O
activity None None O
up None None O
to None None O
120 None None O
min None None O
. None None O

Oral None None O
activity None None O
was None None O
detected None None O
in None None O
diethyl None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
cyano None None I-IUPAC
- None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
phenylene None None I-IUPAC
) None None I-IUPAC
dioxamate None None I-IUPAC
( None None O
compound None None O
38 None None O
) None None O
at None None O
levels None None O
of None None O
drug None None O
as None None O
low None None O
as None None O
0.1 None None O
mg None None O
/ None None O
kg None None O
. None None O


Tumor None None O
cell None None O
migration None None O
and None None O
metastasis None None O
in None None O
cancer None None O
are None None O
facilitated None None O
by None None O
interaction None None O
of None None O
the None None O
serine None None O
protease None None O
urokinase None None O
type None None O
plasminogen None None O
activator None None O
( None None O
uPA None None O
) None None O
with None None O
its None None O
receptor None None O
uPAR None None O
( None None O
CD None None O
87 None None O
) None None O
. None None O

Overexpression None None O
of None None O
uPA None None O
and None None O
uPAR None None O
in None None O
cancer None None O
tissues None None O
is None None O
associated None None O
with None None O
a None None O
high None None O
incidence None None O
of None None O
disease None None O
recurrence None None O
and None None O
early None None O
death None None O
. None None O

In None None O
agreement None None O
with None None O
these None None O
findings None None O
, None None O
disruption None None O
of None None O
the None None O
protein None None O
- None None O
protein None None O
interaction None None O
between None None O
uPAR None None O
present None None O
on None None O
tumor None None O
cells None None O
and None None O
its None None O
ligand None None O
uPA None None O
evolved None None O
as None None O
an None None O
attractive None None O
intervention None None O
strategy None None O
to None None O
impair None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
. None None O

For None None O
this None None O
, None None O
the None None O
uPAR None None O
antagonist None None O
cyclo None None O
[ None None O
19,31 None None O
] None None O
[ None None O
D None None O
- None None O
Cys None None O
( None None O
19 None None O
) None None O
] None None O
- None None O
uPA None None O
( None None O
19 None None O
) None None O
( None None O
- None None O
) None None O
( None None O
31 None None O
) None None O
was None None O
optimized None None O
to None None O
efficiently None None O
interrupt None None O
binding None None O
of None None O
uPA None None O
to None None O
cellular None None O
uPAR None None O
. None None O

First None None O
, None None O
the None None O
disulfide None None O
bridge None None O
of None None O
this None None O
lead None None O
compound None None O
was None None O
shifted None None O
and None None O
then None None O
the None None O
modified None None O
peptide None None O
was None None O
shortened None None O
from None None O
the None None O
amino None None O
and None None O
carboxy None None O
terminus None None O
to None None O
generate None None O
cyclo None None O
[ None None O
21,29 None None O
] None None O
[ None None O
Cys None None O
( None None O
21,29 None None O
) None None O
] None None O
- None None O
uPA None None O
( None None O
21 None None O
) None None O
( None None O
- None None O
) None None O
( None None O
30 None None O
) None None O
. None None O

Next None None O
, None None O
cyclo None None O
[ None None O
21,29 None None O
] None None O
[ None None O
D None None O
- None None O
Cys None None O
( None None O
21 None None O
) None None O
Cys None None O
( None None O
29 None None O
) None None O
] None None O
- None None O
uPA None None O
( None None O
21 None None O
) None None O
( None None O
- None None O
) None None O
( None None O
30 None None O
) None None O
was None None O
yielded None None O
by None None O
changing None None O
the None None O
chirality None None O
of None None O
Cys None None O
( None None O
21 None None O
) None None O
to None None O
D None None O
- None None O
Cys None None O
( None None O
21 None None O
) None None O
. None None O

For None None O
analysis None None O
of None None O
uPAR None None O
binding None None O
activity None None O
, None None O
we None None O
employed None None O
competitive None None O
flow None None O
cytofluorometric None None O
receptor None None O
binding None None O
assays None None O
, None None O
using None None O
FITC None None O
- None None O
uPA None None O
as None None O
the None None O
ligand None None O
and None None O
U937 None None O
promyeloid None None O
leukemia None None O
cells None None O
as None None O
the None None O
cellular None None O
source None None O
of None None O
uPAR None None O
. None None O

As None None O
demonstrated None None O
for None None O
cyclo None None O
[ None None O
21,29 None None O
] None None O
[ None None O
D None None O
- None None O
Cys None None O
( None None O
21 None None O
) None None O
Cys None None O
( None None O
29 None None O
) None None O
] None None O
- None None O
uPA None None O
( None None O
21 None None O
) None None O
( None None O
- None None O
) None None O
( None None O
30 None None O
) None None O
, None None O
the None None O
achieved None None O
peptide None None O
modifications None None O
maintained None None O
receptor None None O
binding None None O
activity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.04 None None O
microM None None O
) None None O
, None None O
which None None O
is None None O
close None None O
in None None O
order None None O
to None None O
that None None O
of None None O
the None None O
parent None None O
protein None None O
ligand None None O
, None None O
uPA None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.01 None None O
microM None None O
) None None O
. None None O

A None None O
detailed None None O
NMR None None O
analysis None None O
with None None O
restrained None None O
and None None O
free None None O
molecular None None O
dynamics None None O
calculations None None O
in None None O
explicit None None O
H None None O
( None None O
2 None None O
) None None O
O None None O
exhibits None None O
a None None O
well None None O
- None None O
defined None None O
structure None None O
with None None O
characteristic None None O
features None None O
such None None O
as None None O
an None None O
omega None None O
- None None O
loop None None O
with None None O
two None None O
betaI None None O
- None None O
turns None None O
about None None O
Lys None None O
( None None O
3 None None O
) None None O
, None None O
Tyr None None O
( None None O
4 None None O
) None None O
, None None O
Ser None None O
( None None O
6 None None O
) None None O
, None None O
and None None O
Asn None None O
( None None O
7 None None O
) None None O
. None None O

Hydrophobic None None O
clustering None None O
of None None O
the None None O
side None None O
chains None None O
of None None O
Tyr None None O
( None None O
4 None None O
) None None O
, None None O
Phe None None O
( None None O
5 None None O
) None None O
, None None O
Ile None None O
( None None O
8 None None O
) None None O
, None None O
and None None O
Trp None None O
( None None O
10 None None O
) None None O
is None None O
observed None None O
. None None O

Side None None O
chain None None O
mobility None None O
is None None O
analyzed None None O
with None None O
time None None O
- None None O
dependent None None O
distance None None O
restraints None None O
. None None O

The None None O
NMR None None O
structure None None O
of None None O
cyclo None None O
[ None None O
21,29 None None O
] None None O
[ None None O
D None None O
- None None O
Cys None None O
( None None O
21 None None O
) None None O
Cys None None O
( None None O
29 None None O
) None None O
] None None O
- None None O
uPA None None O
( None None O
21 None None O
) None None O
( None None O
- None None O
) None None O
( None None O
30 None None O
) None None O
is None None O
very None None O
similar None None O
to None None O
the None None O
previously None None O
reported None None O
structure None None O
of None None O
the None None O
amino None None O
terminal None None O
fragment None None O
of None None O
uPA None None O
. None None O

Systematic None None O
point None None O
mutations None None O
led None None O
to None None O
cyclo None None O
[ None None O
21,29 None None O
] None None O
[ None None O
D None None O
- None None O
Cys None None O
( None None O
21 None None O
) None None O
Nle None None O
( None None O
23 None None O
) None None O
Cys None None O
( None None O
29 None None O
) None None O
] None None O
- None None O
uPA None None O
( None None O
21 None None O
) None None O
( None None O
- None None O
) None None O
( None None O
30 None None O
) None None O
, None None O
which None None O
still None None O
binds None None O
to None None O
uPAR None None O
but None None O
is None None O
resistant None None O
to None None O
proteolytic None None O
cleavage None None O
, None None O
e.g. None None O
, None None O
by None None O
the None None O
tumor None None O
- None None O
associated None None O
serine None None O
proteases None None O
uPA None None O
and None None O
plasmin None None O
, None None O
and None None O
is None None O
stable None None O
in None None O
blood None None O
serum None None O
or None None O
plasma None None O
. None None O

In None None O
conclusion None None O
, None None O
small None None O
cyclic None None O
peptides None None O
were None None O
created None None O
, None None O
which None None O
mimic None None O
the None None O
structure None None O
and None None O
activity None None O
of None None O
the None None O
binding None None O
epitope None None O
of None None O
uPA None None O
to None None O
uPAR None None O
and None None O
which None None O
may None None O
serve None None O
as None None O
novel None None O
therapeutic None None O
agents None None O
in None None O
cancer None None O
metastasis None None O
. None None O


A None None O
series None None O
of None None O
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
isothiazole None None I-IUPAC
nucleosides None None I-MODIFIER
related None None O
to None None O
the None None O
antibiotic None None O
nebularine None None O
and None None O
the None None O
highly None None O
cytotoxic None None O
6 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosylpurine None None I-IUPAC
have None None O
been None None O
synthesized None None O
from None None O
the None None O
corresponding None None O
heterocycles None None O
. None None O

The None None O
sodium None None O
salt None None O
glycosylation None None O
of None None O
the None None O
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
isothiazoles None None I-IUPAC
proceeded None None O
smoothly None None O
, None None O
giving None None O
mixtures None None O
of None None O
N None None O
- None None O
4 None None O
and None None O
N None None O
- None None O
6 None None O
regioisomers None None O
in None None O
generally None None O
good None None O
yields None None O
. None None O

The None None O
protected None None O
derivatives None None O
were None None O
deblocked None None O
using None None O
standard None None O
conditions None None O
to None None O
afford None None O
the None None O
desired None None O
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
isothiazole None None I-IUPAC
nucleosides None None I-MODIFIER
, None None O
usually None None O
as None None O
crystalline None None O
solids None None O
. None None O

None None None O
of None None O
the None None O
new None None O
nucleosides None None O
or None None O
heterocycles None None O
displayed None None O
selective None None O
activity None None O
against None None O
human None None O
cytomegalovirus None None O
( None None O
HCMV None None O
) None None O
or None None O
herpes None None O
simplex None None O
virus None None O
type None None O
1 None None O
( None None O
HSV None None O
- None None O
1 None None O
) None None O
. None None O

The None None O
N None None I-MODIFIER
- None None I-MODIFIER
6 None None I-MODIFIER
glycosylated None None I-MODIFIER
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
isothiazoles None None I-IUPAC
were None None O
completely None None O
inactive None None O
up None None O
to None None O
the None None O
highest None None O
concentration None None O
tested None None O
. None None O

The None None O
N None None I-MODIFIER
- None None I-MODIFIER
6 None None I-MODIFIER
glycosylated None None I-MODIFIER
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
isothiazoles None None I-IUPAC
also None None O
were None None O
inactive None None O
in None None O
antiproliferative None None O
and None None O
cytotoxicity None None O
assays None None O
, None None O
except None None O
for None None O
3 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosylimidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
isothiazole None None I-IUPAC
( None None O
15a None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
benzylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
) None None I-IUPAC
imidazo None None I-IUPAC
[ None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
isothiaz None None I-IUPAC
ole None None I-IUPAC
( None None O
5e None None O
) None None O
, None None O
which None None O
showed None None O
moderate None None O
inhibition None None O
of None None O
L1210 None None O
cell None None O
growth None None O
. None None O

However None None O
, None None O
the None None O
heterocycles None None O
and None None O
several None None O
of None None O
the None None O
N None None O
- None None O
4 None None O
glycosylated None None O
derivatives None None O
were None None O
toxic None None O
to None None O
HFF None None O
, None None O
KB None None O
and None None O
L1210 None None O
cells None None O
; None None O
compounds None None O
with None None O
5 None None I-IUPAC
- None None I-IUPAC
benzylthio None None I-IUPAC
substituents None None I-MODIFIER
were None None O
the None None O
most None None O
cytotoxic None None O
agents None None O
in None None O
this None None O
series None None O
. None None O


In None None O
order None None O
to None None O
obtain None None O
agents None None O
with None None O
therapeutic None None O
indices None None O
superior None None O
to None None O
those None None O
of None None O
AZT None None O
, None None O
FLT None None O
, None None O
or None None O
D4T None None O
, None None O
several None None O
analogues None None O
of None None O
anti None None O
- None None O
HIV None None O
- None None O
1 None None O
nucleosides None None O
were None None O
synthesized None None O
. None None O

These None None O
include None None O
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
difluoro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyluridine None None I-IUPAC
( None None O
13 None None O
) None None O
, None None O
its None None O
arabino None None O
analogue None None O
19 None None O
, None None O
arabino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylcytosine None None I-IUPAC
analogue None None O
21 None None O
, None None O
3' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
didehydro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
fluorothymidine None None I-IUPAC
( None None O
25 None None O
) None None O
, None None O
3' None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyluridine None None I-IUPAC
( None None O
29 None None O
) None None O
, None None O
2' None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyluridine None None I-IUPAC
( None None O
31 None None O
) None None O
, None None O
and None None O
2' None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyluridine None None I-IUPAC
( None None O
37 None None O
) None None O
. None None O

These None None O
new None None O
nucleosides None None O
were None None O
screened None None O
for None None O
their None None O
activity None None O
against None None O
HIV None None O
and None None O
feline None None O
TLV None None O
in None None O
vitro None None O
. None None O

None None None O
of None None O
the None None O
compounds None None O
showed None None O
significant None None O
activity None None O
. None None O

It None None O
is None None O
interesting None None O
to None None O
note None None O
that None None O
such None None O
a None None O
small None None O
modification None None O
in None None O
the None None O
sugar None None O
moiety None None O
of None None O
active None None O
anti None None O
- None None O
HIV None None O
nucleosides None None O
( None None O
i.e. None None O
, None None O
displacement None None O
of None None O
hydrogen None None O
by None None O
fluorine None None O
) None None O
almost None None O
completely None None O
inactivate None None O
the None None O
agents None None O
. None None O


In None None O
this None None O
study None None O
we None None O
designed None None O
, None None O
prepared None None O
, None None O
and None None O
analyzed None None O
a None None O
water None None O
- None None O
soluble None None O
, None None O
long None None O
- None None O
acting None None O
insulin None None O
derivative None None O
whose None None O
protracted None None O
action None None O
in None None O
vivo None None O
is None None O
based None None O
on None None O
a None None O
new None None O
principle None None O
rather None None O
than None None O
on None None O
slower None None O
absorption None None O
rates None None O
of None None O
suspended None None O
insulin None None O
formulations None None O
. None None O

To None None O
this None None O
end None None O
, None None O
we None None O
have None None O
prepared None None O
( None None O
9 None None O
- None None O
fluorenylmethoxycarbonyl None None O
- None None O
SO None None O
( None None O
3 None None O
) None None O
H None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
insulin None None O
( None None O
( None None O
FMS None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
insulin None None O
) None None O
, None None O
a None None O
derivative None None O
having None None O
three None None O
9 None None O
- None None O
fluorenylmethoxycarbonyl None None O
- None None O
SO None None O
( None None O
3 None None O
) None None O
H None None O
( None None O
FMS None None O
) None None O
moieties None None O
covalently None None O
linked None None O
to None None O
the None None O
three None None O
amino None None O
side None None O
chains None None O
of None None O
insulin None None O
. None None O

( None None O
FMS None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
insulin None None O
is None None O
soluble None None O
in None None O
aqueous None None O
buffers None None O
at None None O
neutral None None O
pH None None O
, None None O
at None None O
a None None O
concentration None None O
range None None O
of None None O
0.15-0.60 None None O
mM None None O
, None None O
and None None O
has None None O
about None None O
1% None None O
of None None O
both None None O
the None None O
biological None None O
potency None None O
and None None O
the None None O
receptor None None O
- None None O
binding None None O
affinity None None O
of None None O
the None None O
native None None O
hormone None None O
. None None O

Upon None None O
incubation None None O
at None None O
pH None None O
7.4 None None O
and None None O
37 None None O
degrees None None O
C None None O
, None None O
it None None O
undergoes None None O
a None None O
slow None None O
hydrolysis None None O
with None None O
linear None None O
regeneration None None O
of None None O
insulin None None O
possessing None None O
full None None O
biological None None O
potency None None O
. None None O

A None None O
single None None O
subcutaneous None None O
administration None None O
of None None O
( None None O
FMS None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
insulin None None O
to None None O
streptozocin None None O
- None None O
treated None None O
rats None None O
lowered None None O
circulating None None O
glucose None None O
levels None None O
for None None O
a None None O
prolonged None None O
period None None O
( None None O
t None None O
( None None O
1/2 None None O
) None None O
= None None O
30 None None O
h None None O
) None None O
. None None O

Similarly None None O
, None None O
intraperitoneal None None O
administration None None O
of None None O
( None None O
FMS None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
insulin None None O
to None None O
healthy None None O
rats None None O
had None None O
a None None O
prolonged None None O
glucose None None O
- None None O
lowering None None O
effect None None O
. None None O

In None None O
this None None O
experimental None None O
system None None O
, None None O
recovery None None O
from None None O
hypoglycemia None None O
proceeded None None O
with None None O
a None None O
t None None O
( None None O
1/2 None None O
) None None O
value None None O
of None None O
14 None None O
+ None None O
/ None None O
- None None O
1 None None O
h None None O
, None None O
as None None O
compared None None O
with None None O
t None None O
( None None O
1/2 None None O
) None None O
= None None O
8.0 None None O
+ None None O
/ None None O
- None None O
1 None None O
h None None O
for None None O
native None None O
insulin None None O
and None None O
t None None O
( None None O
1/2 None None O
) None None O
= None None O
10.0 None None O
+ None None O
/ None None O
- None None O
1 None None O
h None None O
for None None O
NPH None None O
- None None O
insulin None None O
. None None O

( None None O
FMS None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
insulin None None O
is None None O
more None None O
resistant None None O
to None None O
proteolysis None None O
and None None O
appears None None O
to None None O
be None None O
nonimmunogenic None None O
. None None O

On None None O
the None None O
whole None None O
, None None O
( None None O
FMS None None O
) None None O
( None None O
3 None None O
) None None O
( None None O
- None None O
) None None O
insulin None None O
represents None None O
a None None O
prototype None None O
version None None O
of None None O
a None None O
water None None O
- None None O
soluble None None O
, None None O
long None None O
- None None O
acting None None O
preparation None None O
of None None O
insulin None None O
. None None O

It None None O
is None None O
nearly None None O
inactive None None O
at None None O
the None None O
time None None O
of None None O
administration None None O
, None None O
and None None O
therefore None None O
can None None O
be None None O
administered None None O
, None None O
at None None O
high None None O
dose None None O
, None None O
with None None O
no None None O
concern None None O
for None None O
hypoglycemia None None O
. None None O

Because None None O
of None None O
its None None O
decreased None None O
receptor None None O
- None None O
binding None None O
affinity None None O
, None None O
( None None O
FMS None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
insulin None None O
evades None None O
receptor None None O
- None None O
mediated None None O
endocytosis None None O
and None None O
degradation None None O
and None None O
, None None O
hence None None O
, None None O
persists None None O
for None None O
a None None O
long None None O
period None None O
in None None O
the None None O
circulation None None O
. None None O

The None None O
insulin None None O
constituent None None O
of None None O
the None None O
( None None O
FMS None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
insulin None None O
conjugate None None O
undergoes None None O
a None None O
slow None None O
, None None O
spontaneous None None O
activation None None O
in None None O
the None None O
circulatory None None O
system None None O
, None None O
manifesting None None O
a None None O
prolonged None None O
glucose None None O
- None None O
lowering None None O
action None None O
in None None O
vivo None None O
. None None O

According None None O
to None None O
the None None O
data None None O
presented None None O
here None None O
, None None O
( None None O
FMS None None O
) None None O
( None None O
3 None None O
) None None O
- None None O
insulin None None O
represents None None O
a None None O
typical None None O
prodrug None None O
: None None O
a None None O
compound None None O
which None None O
by None None O
itself None None O
shows None None O
only None None O
marginal None None O
activity None None O
but None None O
over None None O
time None None O
it None None O
is None None O
chemically None None O
hydrolyzed None None O
to None None O
the None None O
fully None None O
active None None O
hormone None None O
. None None O


As None None O
part None None O
of None None O
our None None O
investigation None None O
into None None O
the None None O
structure None None O
- None None O
activity None None O
relationship None None O
of None None O
a None None O
novel None None O
class None None O
of None None O
aromatase None None O
inhibitors None None O
, None None O
C None None O
( None None O
19 None None O
) None None O
steroids None None O
having None None O
no None None O
oxygen None None O
function None None O
at None None O
C None None O
- None None O
3 None None O
, None None O
we None None O
tested None None O
aromatase None None O
inhibition None None O
activity None None O
of None None O
polar None None O
diol None None O
compounds None None O
4,19 None None I-IUPAC
- None None I-IUPAC
dihydroxyandrost None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
( None None O
25 None None O
and None None O
27 None None O
) None None O
and None None O
6,19 None None I-IUPAC
- None None I-IUPAC
dihydroxyandrost None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
( None None O
36 None None O
and None None O
37 None None O
) None None O
. None None O

4alpha None None I-IUPAC
, None None I-IUPAC
19 None None I-IUPAC
- None None I-IUPAC
Diol None None I-IUPAC
25 None None O
was None None O
synthesized None None O
from None None O
tert None None I-IUPAC
- None None I-IUPAC
butyldimethylsilyoxyandrost None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ene None None I-IUPAC
steroid None None I-MODIFIER
( None None O
9 None None O
) None None O
through None None O
its None None O
OsO None None O
( None None O
4 None None O
) None None O
oxidation None None O
, None None O
giving None None O
the None None O
4alpha None None I-IUPAC
, None None I-IUPAC
5alpha None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
derivative None None I-MODIFIER
12 None None O
, None None O
as None None O
a None None O
key None None O
reaction None None O
. None None O

Acetylation None None O
of None None O
5beta None None I-IUPAC
, None None I-IUPAC
6alpha None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
19 None None I-IUPAC
- None None I-IUPAC
acetate None None I-IUPAC
30 None None O
and None None O
its None None O
5alpha None None I-IUPAC
, None None I-IUPAC
6beta None None I-IUPAC
- None None I-IUPAC
analogue None None I-IUPAC
31 None None O
followed None None O
by None None O
dehydration None None O
with None None O
SOCl None None O
( None None O
2 None None O
) None None O
and None None O
alkaline None None O
hydroxysis None None O
gave None None O
6alpha None None O
, None None O
19 None None O
- None None O
diol None None O
36 None None O
and None None O
its None None O
6beta None None O
- None None O
isomer None None O
37 None None O
, None None O
respectively None None O
. None None O

The None None O
stereochemistry None None O
of None None O
a None None O
hydroxy None None O
group None None O
at None None O
C None None O
- None None O
4 None None O
of None None O
compound None None O
25 None None O
and None None O
that None None O
at None None O
C None None O
- None None O
6 None None O
of None None O
compounds None None O
36 None None O
and None None O
37 None None O
were None None O
determined None None O
on None None O
the None None O
basis None None O
of None None O
( None None O
1 None None O
) None None O
H None None O
NMR None None O
spectroscopy None None O
in None None O
each None None O
case None None O
. None None O

4beta None None I-IUPAC
, None None I-IUPAC
19 None None I-IUPAC
- None None I-IUPAC
Diol None None I-IUPAC
27 None None O
, None None O
previously None None O
synthesized None None O
, None None O
was None None O
identified None None O
as None None O
an None None O
extremely None None O
powerful None None O
competitive None None O
inhibitor None None O
of None None O
aromatase None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
3.4 None None O
nM None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
its None None O
4alpha None None I-IUPAC
, None None I-IUPAC
19 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
isomer None None I-MODIFIER
25 None None O
and None None O
other None None O
series None None O
of None None O
diol None None O
compounds None None O
, None None O
6,19 None None I-IUPAC
- None None I-IUPAC
dihydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
en None None I-IUPAC
- None None I-IUPAC
17 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
steroids None None I-MODIFIER
, None None O
were None None O
moderate None None O
to None None O
poor None None O
competitive None None O
inhibitors None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
110-800 None None O
nM None None O
) None None O
. None None O

Through None None O
this None None O
series None None O
of None None O
analyses None None O
, None None O
it None None O
was None None O
concluded None None O
that None None O
hydrophilic None None O
interaction None None O
of None None O
a None None O
4beta None None I-IUPAC
, None None I-IUPAC
19 None None I-IUPAC
- None None I-IUPAC
diol None None I-IUPAC
function None None I-MODIFIER
with None None O
the None None O
active None None O
site None None O
of None None O
aromatase None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
the None None O
tight None None O
binding None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ene None None I-IUPAC
steroids None None I-MODIFIER
. None None O


6 None None O
- None None O
[ None None O
5 None None O
- None None O
( None None O
4 None None O
- None None O
Amidinophenyl None None O
) None None O
furan None None O
- None None O
2 None None O
- None None O
yl None None O
] None None O
nicotinamidine None None O
( None None O
8a None None O
) None None O
was None None O
synthesized None None O
from None None O
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
cyanophenyl None None I-IUPAC
) None None I-IUPAC
furan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
nicotinonitrile None None I-IUPAC
( None None O
4a None None O
) None None O
, None None O
through None None O
the None None O
bis None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetoxyamidoxime None None I-IUPAC
followed None None O
by None None O
hydrogenation None None O
. None None O

Compound None None O
4a None None O
was None None O
prepared None None O
via None None O
selective None None O
bromination None None O
of None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
furan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
nicotinonitrile None None I-IUPAC
( None None O
2a None None O
) None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
bromosuccinimide None None I-IUPAC
, None None O
followed None None O
by None None O
Suzuki None None O
coupling None None O
with None None O
4 None None I-IUPAC
- None None I-IUPAC
cyanophenylboronic None None I-IUPAC
acid None None I-IUPAC
. None None O

In None None O
a None None O
similar None None O
way None None O
, None None O
diamidines None None O
8b None None O
and None None O
8c None None O
were None None O
prepared None None O
from None None O
the None None O
dicyano None None I-IUPAC
derivatives None None B-MODIFIER
4c None None O
and None None O
4d None None O
, None None O
respectively None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
Methoxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methoxyamidino None None I-IUPAC
) None None I-IUPAC
phenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
furan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
nicotinamidine None None I-IUPAC
( None None O
6a None None O
) None None O
was None None O
prepared None None O
via None None O
methylation None None O
of None None O
the None None O
respective None None O
diamidoxime None None O
5a None None O
with None None O
dimethylsulfate None None O
. None None O

Prodrugs None None O
6b None None O
and None None O
6c None None O
were None None O
also None None O
prepared None None O
by None None O
methylation None None O
of None None O
the None None O
respective None None O
diamidoximes None None O
5b None None O
and None None O
5d None None O
. None None O

The None None O
symmetrical None None O
diamidines None None O
14a None None O
, None None O
b None None O
were None None O
synthesized None None O
through None None O
the None None O
corresponding None None O
bis None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetoxyamidoxime None None I-IUPAC
followed None None O
by None None O
hydrogenation None None O
. None None O

The None None O
key None None O
compounds None None O
11a None None O
, None None O
b None None O
were None None O
conveniently None None O
obtained None None O
by None None O
Stille None None O
coupling None None O
between None None O
2,5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
tri None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butylstannyl None None I-IUPAC
) None None I-IUPAC
furan None None I-IUPAC
and None None O
the None None O
corresponding None None O
heteroaryl None None O
halides None None O
. None None O

These None None O
compounds None None O
have None None O
been None None O
evaluated None None O
in None None O
vitro None None O
for None None O
activity None None O
against None None O
Trypanosoma None None O
b None None O
. None None O

rhodesiense None None O
( None None O
T None None O
. None None O

b None None O
. None None O

r None None O
. None None O

) None None O
and None None O
P None None O
. None None O

falciparum None None O
( None None O
P None None O
. None None O

f None None O
. None None O

) None None O
. None None O

The None None O
diamidines None None O
8a None None O
, None None O
8c None None O
, None None O
and None None O
14b None None O
gave None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
versus None None O
T None None O
. None None O

b None None O
. None None O

r None None O
. None None O

of None None O
less None None O
than None None O
10 None None O
nM None None O
. None None O

Against None None O
P None None O
. None None O

f None None O
. None None O

8a None None O
, None None O
8b None None O
, None None O
and None None O
14b None None O
exhibited None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
less None None O
than None None O
10 None None O
nM None None O
. None None O

In None None O
an None None O
in None None O
vivo None None O
mouse None None O
model None None O
for None None O
T None None O
. None None O

b None None O
. None None O

r None None O
. None None O

four None None O
compounds None None O
6a None None O
, None None O
6c None None O
, None None O
6d None None O
, None None O
and None None O
8a None None O
were None None O
curative None None O
. None None O

Compound None None O
6a None None O
produced None None O
cures None None O
at None None O
an None None O
oral None None O
dosage None None O
of None None O
5 None None O
mg None None O
/ None None O
kg None None O
. None None O


8,9 None None O
- None None O
Dioxo None None O
- None None O
6 None None O
- None None O
phenyl None None O
- None None O
1 None None O
- None None O
aza None None O
- None None O
7 None None O
- None None O
oxabicyclo None None O
[ None None O
4.2.1 None None O
] None None O
nonane None None O
( None None O
1 None None O
) None None O
and None None O
9,10 None None I-IUPAC
- None None I-IUPAC
dioxo None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
aza None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
oxabicyclo None None I-IUPAC
[ None None I-IUPAC
5.2.1 None None I-IUPAC
] None None I-IUPAC
decane None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
examples None None O
of None None O
anti None None O
- None None O
Bredt None None O
bicyclic None None O
2,4 None None I-IUPAC
- None None I-IUPAC
oxazolidinediones None None I-IUPAC
, None None O
were None None O
investigated None None O
as None None O
anticonvulsants None None O
in None None O
mice None None O
. None None O

Compound None None O
2 None None O
was None None O
the None None O
more None None O
potent None None O
( None None O
anti None None O
- None None O
MES None None O
ED50 None None O
= None None O
66 None None O
mg None None O
/ None None O
kg None None O
) None None O
, None None O
and None None O
its None None O
in None None O
vivo None None O
anti None None O
- None None O
MES None None O
effect None None O
was None None O
consistent None None O
with None None O
its None None O
in None None O
vitro None None O
potency None None O
of None None O
binding None None O
to None None O
the None None O
voltage None None O
- None None O
sensitive None None O
sodium None None O
channel None None O
( None None O
IC50 None None O
= None None O
160 None None O
microM None None O
for None None O
the None None O
inhibition None None O
of None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
BTX None None O
- None None O
B None None O
) None None O
, None None O
suggesting None None O
that None None O
2 None None O
may None None O
be None None O
a None None O
new None None O
class None None O
I None None O
anticonvulsant None None O
. None None O

Several None None O
partial None None O
structures None None O
of None None O
2 None None O
, None None O
either None None O
monocyclic None None O
lactams None None O
or None None O
monocyclic None None O
2,4 None None I-IUPAC
- None None I-IUPAC
oxazolidinediones None None I-IUPAC
, None None O
were None None O
also None None O
evaluated None None O
in None None O
these None None O
assays None None O
, None None O
but None None O
no None None O
correlation None None O
was None None O
observed None None O
between None None O
sodium None None O
channel None None O
binding None None O
and None None O
anti None None O
- None None O
MES None None O
effects None None O
. None None O

A None None O
significant None None O
finding None None O
was None None O
that None None O
monocyclic None None O
5 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
oxazolidinediones None None I-IUPAC
provided None None O
relatively None None O
potent None None O
, None None O
nontoxic None None O
, None None O
broad None None O
- None None O
spectrum None None O
anticonvulsants None None O
. None None O


The None None O
peripheral None None O
benzodiazepine None None O
receptor None None O
( None None O
PBR None None O
) None None O
is None None O
widely None None O
expressed None None O
in None None O
peripheral None None O
tissues None None O
, None None O
blood None None O
cells None None O
, None None O
and None None O
in None None O
glia None None O
cells None None O
in None None O
the None None O
brain None None O
. None None O

We None None O
have None None O
previously None None O
developed None None O
two None None O
positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
ligands None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
] None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
dimethoxybenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenoxyphenyl None None I-IUPAC
) None None I-IUPAC
acetamide None None I-IUPAC
( None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
2 None None O
) None None O
and None None O
its None None O
[ None None I-IUPAC
( None None I-IUPAC
18 None None I-IUPAC
) None None I-IUPAC
F None None I-IUPAC
] None None I-IUPAC
fluoroethyl None None I-IUPAC
analogue None None I-MODIFIER
( None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
6 None None O
) None None O
, None None O
for None None O
the None None O
current None None O
investigation None None O
of None None O
PBR None None O
in None None O
the None None O
human None None O
brain None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
label None None O
the None None O
potent None None O
PBR None None O
agonist None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenoxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
isopropoxybenzyl None None I-IUPAC
) None None I-IUPAC
acetamide None None I-IUPAC
( None None O
3 None None O
) None None O
and None None O
its None None O
ethyl None None I-IUPAC
( None None O
7 None None O
) None None O
and None None O
methyl None None I-IUPAC
( None None O
8 None None O
) None None O
homologues None None I-MODIFIER
with None None O
( None None O
11 None None O
) None None O
C None None O
and None None O
to None None O
evaluate None None O
them None None O
as None None O
PET None None O
ligands None None O
for None None O
PBR None None O
with None None O
mice None None O
, None None O
rats None None O
, None None O
and None None O
monkeys None None O
. None None O

Ligands None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
3 None None O
, None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
7 None None O
, None None O
and None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
8 None None O
were None None O
synthesized None None O
by None None O
alkylation None None O
of None None O
phenol None None O
precursor None None O
9 None None O
with None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
] None None I-IUPAC
iodopropane None None I-IUPAC
( None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
10 None None O
) None None O
, None None O
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
] None None I-IUPAC
iodoethane None None I-IUPAC
( None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
11 None None O
) None None O
, None None O
and None None O
[ None None I-IUPAC
( None None I-IUPAC
11 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
] None None I-IUPAC
iodomethane None None I-IUPAC
( None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
12 None None O
) None None O
, None None O
respectively None None O
. None None O

The None None O
alkylating None None O
agent None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
10 None None O
or None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
11 None None O
was None None O
prepared None None O
by None None O
reacting None None O
CH None None O
( None None O
3 None None O
) None None O
MgBr None None O
with None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
CO None None O
( None None O
2 None None O
) None None O
, None None O
followed None None O
by None None O
reduction None None O
with None None O
LiAlH None None O
( None None O
4 None None O
) None None O
and None None O
iodination None None O
with None None O
HI None None O
. None None O

In None None O
vitro None None O
quantitative None None O
autoradiography None None O
determined None None O
that None None O
3 None None O
, None None O
7 None None O
, None None O
and None None O
8 None None O
had None None O
potent None None O
binding None None O
affinities None None O
( None None O
K None None O
( None None O
i None None O
) None None O
= None None O
0.07-0.19 None None O
nM None None O
) None None O
for None None O
PBR None None O
in None None O
the None None O
rat None None O
brain None None O
. None None O

These None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
ligands None None O
could None None O
pass None None O
across None None O
the None None O
blood None None O
- None None O
brain None None O
barrier None None O
and None None O
enter None None O
the None None O
rat None None O
brain None None O
( None None O
0.17-0.32% None None O
of None None O
injected None None O
dose None None O
per None None O
gram None None O
wet None None O
tissue None None O
) None None O
. None None O

Ex None None O
vivo None None O
autoradiography None None O
showed None None O
that None None O
the None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
ligands None None O
preferably None None O
distributed None None O
in None None O
the None None O
olfactory None None O
bulb None None O
and None None O
cerebellum None None O
, None None O
two None None O
regions None None O
with None None O
richer None None O
PBR None None O
density None None O
in None None O
the None None O
rat None None O
brain None None O
. None None O

The None None O
co None None O
- None None O
injection None None O
of None None O
PBR None None O
- None None O
selective None None O
2 None None O
reduced None None O
the None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
ligand None None O
binding None None O
in None None O
the None None O
two None None O
regions None None O
, None None O
suggesting None None O
that None None O
binding None None O
in None None O
the None None O
rat None None O
brain None None O
was None None O
specific None None O
to None None O
PBR None None O
. None None O

PET None None O
study None None O
determined None None O
that None None O
the None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
ligands None None O
preferably None None O
accumulate None None O
in None None O
the None None O
occipital None None O
cortex None None O
of None None O
the None None O
monkey None None O
brain None None O
, None None O
a None None O
region None None O
with None None O
a None None O
high None None O
density None None O
of None None O
PBR None None O
in None None O
the None None O
primate None None O
brain None None O
. None None O

Moreover None None O
, None None O
in None None O
vivo None None O
binding None None O
of None None O
the None None O
methyl None None O
homologue None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
8 None None O
in None None O
the None None O
monkey None None O
brain None None O
could None None O
be None None O
inhibited None None O
by None None O
PBR None None O
- None None O
selective None None O
2 None None O
or None None O
1 None None O
, None None O
indicating None None O
that None None O
some None None O
of None None O
the None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
8 None None O
binding None None O
was None None O
due None None O
to None None O
PBR None None O
. None None O

Metabolite None None O
analysis None None O
demonstrated None None O
that None None O
these None None O
[ None None O
( None None O
11 None None O
) None None O
C None None O
] None None O
ligands None None O
were None None O
metabolized None None O
by None None O
debenzylation None None O
to None None O
polar None None O
products None None O
mainly None None O
in None None O
the None None O
plasma None None O
. None None O


Vasotocin None None O
( None None O
AVT None None O
) None None O
analogues None None O
with None None O
tyrosine None None O
or None None O
phenylalanine None None O
in None None O
position None None O
9 None None O
, None None O
i.e. None None O
, None None O
[ None None O
9 None None I-IUPAC
- None None I-IUPAC
tyrosine None None I-IUPAC
] None None O
AVT None None O
, None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
phenylalanine None None I-IUPAC
, None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
tyrosine None None I-IUPAC
] None None O
AVT None None O
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
desamino None None I-IUPAC
[ None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
aminophenylalanine None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
AVT None None O
, None None O
were None None O
synthesized None None O
by None None O
the None None O
solid None None O
- None None O
phase None None O
method None None O
. None None O

These None None O
compounds None None O
showed None None O
a None None O
high None None O
biological None None O
activity None None O
in None None O
the None None O
hydroosmotic None None O
toad None None O
bladder None None O
assay None None O
. None None O

Using None None O
the None None O
chemically None None O
reactive None None O
functional None None O
groups None None O
on None None O
tyrosine None None O
and None None O
p None None O
- None None O
aminophenylalanine None None O
in None None O
position None None O
9 None None O
, None None O
we None None O
prepared None None O
iodinated None None O
, None None O
photoreactive None None O
, None None O
and None None O
affinity None None O
ligands None None O
, None None O
i.e. None None O
, None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
phenylalanine None None I-IUPAC
, None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
iodotyrosine None None I-IUPAC
) None None I-IUPAC
] None None O
AVT None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
desamino None None I-IUPAC
[ None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
azidophenylalanine None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
AVT None None O
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
desamino None None I-IUPAC
[ None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
biotinylphenylalanine None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
AVT None None O
, None None O
respectively None None O
. None None O

Half None None O
- None None O
maximal None None O
hydroosmotic None None O
responses None None O
( None None O
ED None None O
- None None O
50 None None O
values None None O
) None None O
were None None O
obtained None None O
with None None O
2.5 None None O
X None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
M None None O
for None None O
the None None O
iodinated None None O
analogue None None O
, None None O
with None None O
0.9 None None O
X None None O
10 None None O
( None None O
- None None O
10 None None O
) None None O
M None None O
for None None O
the None None O
photoaffinity None None O
analogue None None O
, None None O
and None None O
with None None O
1.2 None None O
X None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
for None None O
the None None O
biotinyl None None O
analogue None None O
. None None O

The None None O
hydroosmotic None None O
activity None None O
of None None O
the None None O
biotinyl None None O
analogue None None O
was None None O
reversed None None O
following None None O
addition None None O
of None None O
avidin None None O
, None None O
whereas None None O
the None None O
photoaffinity None None O
analogue None None O
induced None None O
a None None O
persistent None None O
response None None O
following None None O
UV None None O
irradiation None None O
that None None O
was None None O
not None None O
reversed None None O
upon None None O
repeated None None O
and None None O
prolonged None None O
periods None None O
of None None O
washout None None O
. None None O

These None None O
analogues None None O
of None None O
vasotocin None None O
are None None O
the None None O
most None None O
potent None None O
that None None O
have None None O
been None None O
synthesized None None O
to None None O
date None None O
, None None O
and None None O
they None None O
should None None O
serve None None O
as None None O
useful None None O
probes None None O
in None None O
the None None O
isolation None None O
and None None O
characterization None None O
of None None O
vasotocin None None O
receptors None None O
in None None O
toad None None O
bladders None None O
and None None O
tissues None None O
from None None O
other None None O
species None None O
that None None O
use None None O
vasotocin None None O
as None None O
an None None O
antidiuretic None None O
/ None None O
pressor None None O
principle None None O
. None None O

The None None O
photoaffinity None None O
and None None O
biotinyl None None O
analogues None None O
had None None O
a None None O
rat None None O
antidiuretic None None O
activity None None O
of None None O
66 None None O
and None None O
40 None None O
units None None O
/ None None O
mg None None O
, None None O
respectively None None O
. None None O

These None None O
compounds None None O
are None None O
, None None O
therefore None None O
, None None O
also None None O
suitable None None O
for None None O
the None None O
isolation None None O
of None None O
V None None O
- None None O
2 None None O
vasopressin None None O
receptors None None O
from None None O
mammalian None None O
tissues None None O
. None None O


trans None None O
- None None O
2 None None O
- None None O
Carboxy None None O
- None None O
5,7 None None O
- None None O
dichloro None None O
- None None O
4 None None O
- None None O
amidotetrahydroquinolines None None O
, None None O
evolved None None O
from None None O
the None None O
lead None None O
5,7 None None I-IUPAC
- None None I-IUPAC
dichlorokynurenic None None I-IUPAC
acid None None I-IUPAC
, None None O
have None None O
been None None O
synthesized None None O
and None None O
tested None None O
for None None O
in None None O
vitro None None O
antagonist None None O
activity None None O
at None None O
the None None O
glycine None None O
site None None O
on None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
aspartate None None I-IUPAC
( None None O
NMDA None None O
) None None O
receptor None None O
. None None O

Optimization None None O
of None None O
the None None O
4 None None O
- None None O
substituent None None O
has None None O
provided None None O
antagonists None None O
having None None O
nanomolar None None O
affinity None None O
, None None O
including None None O
the None None O
urea None None O
trans None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
5,7 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
phenylamino None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,3 None None I-IUPAC
, None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
tetrahydroquinoline None None I-IUPAC
( None None O
35 None None O
; None None O
IC50 None None O
= None None O
7.4 None None O
nM None None O
vs None None O
[ None None O
3H None None O
] None None O
glycine None None O
binding None None O
; None None O
Kb None None O
= None None O
130 None None O
nM None None O
for None None O
block None None O
of None None O
NMDA None None O
responses None None O
in None None O
the None None O
rat None None O
cortical None None O
slice None None O
) None None O
, None None O
which None None O
is None None O
one None None O
of None None O
the None None O
most None None O
potent None None O
NMDA None None O
antagonists None None O
yet None None O
found None None O
. None None O

The None None O
absolute None None O
stereochemical None None O
requirements None None O
for None None O
binding None None O
were None None O
found None None O
to None None O
be None None O
2S None None O
, None None O
4R None None O
, None None O
showing None None O
that None None O
, None None O
in None None O
common None None O
with None None O
other None None O
glycine None None O
- None None O
site None None O
NMDA None None O
receptor None None O
ligands None None O
, None None O
the None None O
unnatural None None O
configuration None None O
at None None O
the None None O
alpha None None O
- None None O
amino None None O
acid None None O
center None None O
is None None O
required None None O
. None None O

The None None O
preferred None None O
conformation None None O
of None None O
the None None O
trans None None I-MODIFIER
- None None I-MODIFIER
2,4 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
tetrahydroquinoline None None I-IUPAC
system None None O
, None None O
as None None O
shown None None O
by None None O
X None None O
- None None O
ray None None O
crystallography None None O
and None None O
1H None None O
NMR None None O
studies None None O
, None None O
places None None O
the None None O
2 None None O
- None None O
carboxyl None None O
pseudoequatorial None None O
and None None O
the None None O
4 None None O
- None None O
substituent None None O
pseudoaxial None None O
. None None O

Modifications None None O
of None None O
the None None O
4 None None O
- None None O
amide None None O
show None None O
that None None O
bulky None None O
substituents None None O
are None None O
tolerated None None O
and None None O
reveal None None O
the None None O
critical None None O
importance None None O
for None None O
activity None None O
of None None O
correct None None O
positioning None None O
of None None O
the None None O
carbonyl None None O
group None None O
. None None O

The None None O
high None None O
affinity None None O
of None None O
trans None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
5,7 None None I-IUPAC
- None None I-IUPAC
dichloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxoimidazolidinyl None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroquinoline None None I-IUPAC
( None None O
55 None None O
; None None O
IC50 None None O
= None None O
6 None None O
nM None None O
) None None O
suggests None None O
that None None O
the None None O
Z None None O
, None None O
Z None None O
conformer None None O
of None None O
the None None O
phenyl None None O
urea None None O
moiety None None O
in None None O
35 None None O
is None None O
recognized None None O
by None None O
the None None O
receptor None None O
. None None O

Molecular None None O
modeling None None O
studies None None O
show None None O
that None None O
the None None O
4 None None O
- None None O
carbonyl None None O
groups None None O
of None None O
the None None O
kynurenic None None O
acids None None O
, None None O
the None None O
tetrahydroquinolines None None O
, None None O
and None None O
related None None O
antagonists None None O
based None None O
on None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
glycine None None I-IUPAC
, None None O
can None None O
interact None None O
with None None O
a None None O
single None None O
putative None None O
H None None O
- None None O
bond None None O
donor None None O
on None None O
the None None O
receptor None None O
. None None O

The None None O
results None None O
allow None None O
the None None O
establishment None None O
of None None O
a None None O
three None None O
- None None O
dimensional None None O
pharmacophore None None O
of None None O
the None None O
glycine None None O
receptor None None O
antagonist None None O
site None None O
, None None O
incorporating None None O
a None None O
newly None None O
defined None None O
bulk None None O
tolerance None None O
/ None None O
hydrophobic None None O
region None None O
. None None O


The None None O
synthesis None None O
and None None O
sigma None None O
1 None None O
and None None O
sigma None None O
2 None None O
binding None None O
properties None None O
of None None O
several None None O
( None None I-PARTIUPAC
+ None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-PARTIUPAC
- None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
benzyl None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
dimethylallyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
- None None I-IUPAC
5,9 None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
benzomorphans None None I-IUPAC
( None None O
3 None None O
and None None O
4 None None O
) None None O
are None None O
presented None None O
. None None O

In None None O
agreement None None O
with None None O
previously None None O
reported None None O
binding None None O
data None None O
for None None O
2 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
5,9 None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
benzomorphans None None I-IUPAC
( None None O
N None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
N None None I-IUPAC
- None None I-IUPAC
normetazocine None None I-IUPAC
) None None O
, None None O
all None None O
( None None O
1S None None O
, None None O
5S None None O
, None None O
9S None None O
) None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
isomers None None O
showed None None O
higher None None O
affinity None None O
for None None O
the None None O
sigma None None O
1 None None O
site None None O
than None None O
the None None O
corresponding None None O
( None None O
1R None None O
, None None O
5R None None O
, None None O
9R None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
isomers None None O
. None None O

Replacement None None O
of None None O
the None None O
2' None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
group None None I-MODIFIER
of None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
5,9 None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
benzomorphan None None I-IUPAC
[ None None O
( None None O
+ None None O
) None None O
- None None O
1f None None O
] None None O
with None None O
a None None O
2' None None O
- None None O
NH2 None None O
and None None O
2' None None O
- None None O
N None None O
( None None O
CH3 None None O
) None None O
2 None None O
[ None None O
( None None O
+ None None O
) None None O
- None None O
3b None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
3c None None O
, None None O
respectively None None O
] None None O
had None None O
only None None O
a None None O
small None None O
effect None None O
on None None O
the None None O
sigma None None O
1 None None O
Ki None None O
values None None O
. None None O

Changing None None O
the None None O
2' None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
group None None I-MODIFIER
of None None O
( None None O
+ None None O
) None None O
- None None O
1f None None O
to None None O
an None None O
H None None O
, None None O
F None None O
, None None O
Cl None None O
, None None O
Br None None O
, None None O
I None None O
, None None O
NHAc None None O
, None None O
or None None O
NHSO2CH3 None None O
resulted None None O
in None None O
a None None O
5 None None O
- None None O
fold None None O
or None None O
greater None None O
loss None None O
in None None O
potency None None O
. None None O

In None None O
contrast None None O
, None None O
replacement None None O
of None None O
the None None O
2' None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
group None None I-MODIFIER
of None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylallyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5,9 None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
benzomorphan None None I-IUPAC
[ None None O
( None None O
+ None None O
) None None O
- None None O
1b None None O
, None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pentazocine None None I-IUPAC
] None None O
with None None O
a None None O
2' None None O
- None None O
H None None O
or None None O
2' None None O
- None None O
F None None O
group None None O
resulted None None O
in None None O
a None None O
2 None None O
- None None O
fold None None O
increase None None O
in None None O
potency None None O
. None None O

Conversion None None O
of None None O
( None None O
+ None None O
) None None O
- None None O
1f None None O
to None None O
its None None O
2' None None I-IUPAC
- None None I-IUPAC
desoxy None None I-IUPAC
analogue None None I-MODIFIER
( None None O
+ None None O
) None None O
- None None O
2d None None O
resulted None None O
in None None O
a None None O
27.5 None None O
- None None O
fold None None O
loss None None O
in None None O
affinity None None O
. None None O

This None None O
suggests None None O
that None None O
( None None O
+ None None O
) None None O
- None None O
1f None None O
and None None O
other None None O
N None None O
- None None O
substituted None None O
benzomorphan None None O
analogues None None O
may None None O
be None None O
binding None None O
to None None O
single None None O
sigma None None O
1 None None O
receptors None None O
in None None O
a None None O
different None None O
way None None O
or None None O
to None None O
different None None O
sigma None None O
1 None None O
receptors None None O
. None None O

( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
Pentazocine None None I-IUPAC
[ None None O
( None None O
- None None O
) None None O
- None None O
1b None None O
] None None O
and None None O
its None None O
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
analogue None None I-MODIFIER
, None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylallyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5,9 None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
benzomorphan None None I-IUPAC
[ None None O
( None None O
- None None O
) None None O
- None None O
4a None None O
] None None O
showed None None O
the None None O
highest None None O
potency None None O
for None None O
the None None O
sigma None None O
2 None None O
binding None None O
site None None O
. None None O


The None None O
synthesis None None O
and None None O
biological None None O
activities None None O
of None None O
14 None None O
6 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
2,4 None None I-IUPAC
- None None I-IUPAC
diaminoquinazolines None None I-IUPAC
are None None O
reported None None O
. None None O

These None None O
compounds None None O
were None None O
designed None None O
to None None O
improve None None O
the None None O
cell None None O
penetration None None O
of None None O
a None None O
previously None None O
reported None None O
series None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None O
substituted None None I-MODIFIER
- None None O
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
which None None O
had None None O
shown None None O
significant None None O
potency None None O
and None None O
remarkable None None O
selectivity None None O
for None None O
Toxoplasma None None O
gondii None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
, None None O
but None None O
had None None O
much None None O
lower None None O
inhibitory None None O
effects None None O
on None None O
the None None O
growth None None O
of None None O
T None None O
. None None O

gondii None None O
cells None None O
in None None O
culture None None O
. None None O

The None None O
target None None O
N9 None None O
- None None O
H None None O
analogues None None O
were None None O
obtained None None O
via None None O
regiospecific None None O
reductive None None O
amination None None O
of None None O
the None None O
appropriate None None O
benzaldehydes None None O
with None None O
2,4,6 None None I-IUPAC
- None None I-IUPAC
triaminoquinazoline None None I-IUPAC
, None None O
which None None O
, None None O
in None None O
turn None None O
, None None O
was None None O
synthesized None None O
from None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
nitroquinazoline None None I-IUPAC
. None None O

The None None O
N9 None None O
- None None O
CH3 None None O
analogues None None O
were None None O
synthesized None None O
via None None O
a None None O
regiospecific None None O
reductive None None O
methylation None None O
of None None O
the None None O
corresponding None None O
N9 None None O
- None None O
H None None O
precursors None None O
. None None O

The None None O
compounds None None O
were None None O
evaluated None None O
as None None O
inhibitors None None O
of None None O
DHFR None None O
from None None O
human None None O
, None None O
Pneumocystis None None O
carinii None None O
, None None O
T None None O
. None None O

gondii None None O
, None None O
rat None None O
liver None None O
, None None O
Lactobacillus None None O
casei None None O
, None None O
and None None O
Escherichia None None O
coli None None O
, None None O
and None None O
selected None None O
analogues None None O
were None None O
evaluated None None O
as None None O
inhibitors None None O
of None None O
the None None O
growth None None O
of None None O
tumor None None O
cells None None O
in None None O
culture None None O
. None None O

These None None O
analogues None None O
displayed None None O
potent None None O
T None None O
. None None O

gondii None None O
DHFR None None O
inhibition None None O
as None None O
well None None O
as None None O
inhibition None None O
of None None O
the None None O
growth None None O
of None None O
T None None O
. None None O

gondii None None O
cells None None O
in None None O
culture None None O
. None None O

Further None None O
, None None O
selected None None O
analogues None None O
were None None O
potent None None O
inhibitors None None O
of None None O
the None None O
growth None None O
of None None O
tumor None None O
cells None None O
in None None O
culture None None O
in None None O
the None None O
in None None O
vitro None None O
screening None None O
program None None O
of None None O
the None None O
National None None O
Cancer None None O
Institute None None O
with None None O
GI50s None None O
in None None O
the None None O
nanomolar None None O
and None None O
subnanomolar None None O
range None None O
. None None O

Crystallographic None None O
data None None O
for None None O
the None None O
ternary None None O
complex None None O
of None None O
hDHFR None None O
- None None O
NADPH None None O
and None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
dimethoxybenzyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
] None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
, None None O
1c None None O
, None None O
reveal None None O
the None None O
first None None O
structural None None O
details None None O
for None None O
a None None O
reversed None None O
N9 None None O
- None None O
C10 None None O
folate None None O
bridge None None O
geometry None None O
as None None O
well None None O
as None None O
the None None O
first None None O
conformational None None O
details None None O
of None None O
a None None O
hybrid None None O
piritrexim None None O
- None None O
trimetrexate None None O
analogue None None O
. None None O


A None None O
novel None None O
series None None O
of None None O
10 None None I-IUPAC
- None None I-IUPAC
benzylidene None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
( None None I-IUPAC
10H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
anthracenones None None I-IUPAC
and None None O
10 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylmethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
( None None I-IUPAC
10H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
anthracenones None None I-IUPAC
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
antiproliferative None None O
activity None None O
in None None O
an None None O
assay None None O
based None None O
on None None O
K562 None None O
leukemia None None O
cells None None O
. None None O

The None None O
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxybenzylidene None None I-IUPAC
analogue None None I-MODIFIER
9h None None O
was None None O
found None None O
to None None O
be None None O
the None None O
most None None O
active None None O
compound None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
K562 None None O
: None None O
20 None None O
nM None None O
) None None O
. None None O

Structure None None O
- None None O
activity None None O
relationships None None O
are None None O
also None None O
considered None None O
. None None O

The None None O
highly None None O
active None None O
compound None None O
9h None None O
and None None O
the None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxybenzylidene None None I-IUPAC
analogue None None I-MODIFIER
9l None None O
were None None O
tested None None O
against None None O
five None None O
tumor None None O
cell None None O
lines None None O
using None None O
the None None O
XTT None None O
assay None None O
, None None O
including None None O
multidrug None None O
resistant None None O
phenotypes None None O
. None None O

Induction None None O
of None None O
cell None None O
death None None O
in None None O
a None None O
variety None None O
of None None O
tumor None None O
cell None None O
lines None None O
was None None O
determined None None O
in None None O
a None None O
monolayer None None O
assay None None O
using None None O
propidium None None O
iodide None None O
. None None O

Noteworthy None None O
, None None O
all None None O
compounds None None O
within None None O
the None None O
series None None O
induced None None O
elongations None None O
in None None O
K562 None None O
cells None None O
similar None None O
to None None O
vinblastine None None O
- None None O
treated None None O
cells None None O
. None None O

The None None O
effect None None O
of None None O
the None None O
lead None None O
compound None None O
9h None None O
on None None O
K562 None None O
cell None None O
growth None None O
was None None O
associated None None O
with None None O
cell None None O
cycle None None O
arrest None None O
in None None O
G2 None None O
/ None None O
M None None O
. None None O

Concentrations None None O
for None None O
50% None None O
KB None None O
/ None None O
HeLa None None O
cells None None O
arrested None None O
in None None O
G2 None None O
/ None None O
M None None O
after None None O
treatment None None O
with None None O
9h None None O
and None None O
9l None None O
were None None O
determined None None O
and None None O
found None None O
to None None O
be None None O
in None None O
the None None O
range None None O
of None None O
0.2 None None O
microM None None O
. None None O

Additionally None None O
, None None O
we None None O
monitored None None O
the None None O
dose None None O
dependent None None O
caspase None None O
- None None O
3 None None O
- None None O
like None None O
protease None None O
activity None None O
in None None O
K562 None None O
cells None None O
and None None O
MCF None None O
- None None O
7 None None O
/ None None O
Casp None None O
- None None O
3 None None O
cells None None O
treated None None O
with None None O
9h None None O
, None None O
indicating None None O
induction None None O
of None None O
apoptosis None None O
. None None O

Western None None O
blotting None None O
analysis None None O
demonstrated None None O
that None None O
9h None None O
caused None None O
a None None O
shift None None O
in None None O
tubulin None None O
concentration None None O
from None None O
the None None O
polymerized None None O
state None None O
found None None O
in None None O
the None None O
cell None None O
pellet None None O
to None None O
the None None O
unpolymerized None None O
state None None O
found None None O
in None None O
the None None O
cell None None O
supernatant None None O
. None None O

Seven None None O
compounds None None O
strongly None None O
inhibited None None O
tubulin None None O
polymerization None None O
with None None O
activities None None O
higher None None O
or None None O
comparable None None O
to None None O
those None None O
of None None O
the None None O
reference None None O
compounds None None O
such None None O
as None None O
colchicine None None O
, None None O
podophyllotoxin None None O
, None None O
and None None O
nocodazole None None O
. None None O

In None None O
general None None O
, None None O
the None None O
antiproliferative None None O
activity None None O
correlated None None O
with None None O
inhibition None None O
of None None O
tubulin None None O
polymerization None None O
. None None O

The None None O
most None None O
active None None O
compounds None None O
strongly None None O
displaced None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
colchicine None None O
from None None O
its None None O
binding None None O
site None None O
in None None O
the None None O
tubulin None None O
, None None O
yielding None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
3 None None O
- None None O
to None None O
4 None None O
- None None O
fold None None O
lower None None O
than None None O
that None None O
of None None O
colchicine None None O
. None None O

The None None O
novel None None O
benzylidene None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
( None None I-IUPAC
10H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
anthracenones None None I-IUPAC
described None None O
in None None O
the None None O
present None None O
study None None O
constitute None None O
an None None O
interesting None None O
group None None O
of None None O
highly None None O
active None None O
and None None O
easily None None O
accessible None None O
antimitotic None None O
agents None None O
that None None O
inhibit None None O
tubulin None None O
polymerization None None O
. None None O


The None None O
synthesis None None O
, None None O
physical None None O
properties None None O
, None None O
antitumor None None O
activity None None O
, None None O
structure None None O
- None None O
activity None None O
relationships None None O
, None None O
and None None O
nephrotoxicity None None O
of None None O
a None None O
series None None O
of None None O
[ None None O
2 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
4,5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dioxolane None None I-IUPAC
] None None I-IUPAC
platinum None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
complexes None None I-MODIFIER
are None None O
described None None O
. None None O

The None None O
42 None None O
platinum None None O
( None None O
II None None O
) None None O
complexes None None O
having None None O
a None None O
seven None None O
- None None O
membered None None O
ring None None O
structure None None O
in None None O
this None None O
series None None O
have None None O
been None None O
prepared None None O
and None None O
characterized None None O
by None None O
1H None None O
NMR None None O
, None None O
13C None None O
NMR None None O
, None None O
IR None None O
, None None O
FAB None None O
- None None O
MS None None O
, None None O
and None None O
elemental None None O
analysis None None O
. None None O

All None None O
members None None O
of None None O
the None None O
series None None O
were None None O
designed None None O
to None None O
have None None O
a None None O
1,3 None None O
- None None O
dioxolane None None O
ring None None O
moiety None None O
in None None O
their None None O
carrier None None O
ligands None None O
to None None O
increase None None O
water None None O
solubility None None O
. None None O

The None None O
solubility None None O
of None None O
platinum None None O
complexes None None O
was None None O
related None None O
to None None O
the None None O
nature None None O
of None None O
leaving None None O
ligands None None O
and None None O
2 None None O
- None None O
substituents None None O
in None None O
the None None O
4,5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dioxolane None None I-IUPAC
carrier None None O
ligands None None O
. None None O

In None None O
general None None O
, None None O
compounds None None O
having None None O
two None None O
different None None O
R1 None None O
and None None O
R2 None None O
substituents None None O
in None None O
the None None O
4,5 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
dioxolane None None I-IUPAC
moiety None None I-MODIFIER
were None None O
more None None O
water None None O
- None None O
soluble None None O
than None None O
those None None O
having None None O
the None None O
same None None O
substituents None None O
. None None O

Most None None O
members None None O
of None None O
this None None O
series None None O
showed None None O
the None None O
excellent None None O
antitumor None None O
activity None None O
against None None O
murine None None O
L1210 None None O
leukemia None None O
cells None None O
transplanted None None O
in None None O
mice None None O
and None None O
were None None O
superior None None O
to None None O
cisplatin None None O
and None None O
carboplatin None None O
. None None O

The None None O
( None None O
4R None None O
, None None O
5R None None O
) None None O
- None None O
stereoisomer None None O
1a None None O
- None None O
h None None O
exhibited None None O
the None None O
higher None None O
antitumor None None O
activity None None O
than None None O
the None None O
corresponding None None O
( None None O
4S None None O
, None None O
5S None None O
) None None O
- None None O
stereoisomer None None O
2a None None O
- None None O
h None None O
in None None O
the None None O
( None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
cyclobutanedicarboxylato None None I-IUPAC
) None None I-IUPAC
platinum None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
complexes None None I-MODIFIER
. None None O

The None None O
( None None I-IUPAC
glycolato None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
platinum None None I-IUPAC
( None None I-IUPAC
II None None I-IUPAC
) None None I-IUPAC
complexes None None I-MODIFIER
were None None O
highly None None O
cytotoxic None None O
toward None None O
four None None O
human None None O
stomach None None O
cancer None None O
cell None None O
lines None None O
, None None O
SNU None None O
- None None O
1 None None O
, None None O
SNU None None O
- None None O
5 None None O
, None None O
SNU None None O
- None None O
16 None None O
, None None O
and None None O
NCI None None O
- None None O
N87 None None O
, None None O
and None None O
among None None O
them None None O
, None None O
complexes None None O
3d None None O
- None None O
g None None O
were None None O
even None None O
more None None O
cytotoxic None None O
than None None O
cisplatin None None O
. None None O

The None None O
( None None O
malonato None None O
) None None O
platinum None None O
( None None O
II None None O
) None None O
complex None None O
1m None None O
and None None O
the None None O
( None None O
glycolato None None O
) None None O
platinum None None O
( None None O
II None None O
) None None O
complexes None None O
3d None None O
- None None O
g None None O
were None None O
selected None None O
for None None O
further None None O
studies None None O
based None None O
on None None O
the None None O
greater None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
antitumor None None O
activity None None O
and None None O
desirable None None O
physical None None O
properties None None O
. None None O

The None None O
complexes None None O
3e None None O
- None None O
g None None O
were None None O
almost None None O
equally None None O
cytotoxic None None O
to None None O
cisplatin None None O
toward None None O
human None None O
stomach None None O
cancer None None O
cell None None O
lines None None O
, None None O
KATO None None O
- None None O
III None None O
and None None O
MKN None None O
- None None O
45 None None O
, None None O
and None None O
a None None O
human None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
cell None None O
line None None O
, None None O
PC14 None None O
. None None O

In None None O
contrast None None O
with None None O
cisplatin None None O
and None None O
carboplatin None None O
, None None O
five None None O
complexes None None O
selected None None O
significantly None None O
increased None None O
in None None O
life None None O
span None None O
in None None O
mice None None O
transplanted None None O
with None None O
cisplatin None None O
- None None O
resistant None None O
L1210 None None O
cells None None O
. None None O

Nephrotoxicity None None O
studies None None O
in None None O
ICR None None O
mice None None O
indicated None None O
that None None O
serum None None O
BUN None None O
and None None O
creatinine None None O
levels None None O
were None None O
not None None O
elevated None None O
when None None O
five None None O
complexes None None O
were None None O
given None None O
at None None O
a None None O
dose None None O
equal None None O
to None None O
1.5 None None O
times None None O
the None None O
optimal None None O
dose None None O
determined None None O
in None None O
the None None O
in None None O
vivo None None O
L1210 None None O
screening None None O
system None None O
. None None O


5 None None O
- None None O
( None None O
2 None None O
- None None O
Acylethynyl None None O
) None None O
- None None O
2,4 None None O
- None None O
dimethoxypyrimidines None None O
( None None O
3-6 None None O
) None None O
were None None O
synthesized None None O
in None None O
excellent None None O
yields None None O
from None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trimethylsilyl None None I-IUPAC
) None None I-IUPAC
ethynyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
2 None None O
) None None O
by None None O
treatment None None O
with None None O
acid None None O
chlorides None None O
in None None O
the None None O
presence None None O
of None None O
anhydrous None None O
aluminum None None O
chloride None None O
. None None O

Compounds None None O
3-6 None None O
were None None O
deblocked None None O
with None None O
chlorotrimethylsilane None None I-IUPAC
and None None O
sodium None None O
iodide None None O
in None None O
acetonitrile None None O
to None None O
the None None O
corresponding None None O
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
) None None I-IUPAC
vinyl None None I-IUPAC
] None None I-IUPAC
uracils None None I-IUPAC
( None None O
7-10 None None O
) None None O
, None None O
which None None O
on None None O
treatment None None O
with None None O
potassium None None O
hydroxide None None O
in None None O
dioxane None None O
yielded None None O
the None None O
corresponding None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acylethynyl None None I-IUPAC
) None None I-IUPAC
uracils None None I-IUPAC
( None None O
11-14 None None O
) None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acylethynyl None None I-IUPAC
) None None I-IUPAC
uracils None None I-IUPAC
were None None O
found None None O
to None None O
be None None O
active None None O
against None None O
Ehrlich None None O
ascites None None O
carcinoma None None O
( None None O
EAC None None O
) None None O
cells None None O
in None None O
vivo None None O
, None None O
the None None O
most None None O
active None None O
compounds None None O
being None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzoylethynyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
11 None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoylethynyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
12 None None O
) None None O
. None None O

The None None O
T None None O
/ None None O
C None None O
values None None O
of None None O
281 None None O
and None None O
300 None None O
were None None O
obtained None None O
for None None O
compounds None None O
11 None None O
and None None O
12 None None O
, None None O
respectively None None O
, None None O
in None None O
the None None O
case None None O
of None None O
mice None None O
bearing None None O
EAC None None O
cells None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
acylethynyl None None I-IUPAC
) None None I-IUPAC
uracils None None I-IUPAC
have None None O
also None None O
shown None None O
in None None O
vitro None None O
activity None None O
against None None O
CCRF None None O
- None None O
CEM None None O
and None None O
L1210/0 None None O
tumor None None O
cell None None O
lines None None O
. None None O

The None None O
lead None None O
compound None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluoylethynyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
effectively None None O
inhibited None None O
thymidylate None None O
synthetase None None O
. None None O


Chemical None None O
and None None O
biological None None O
similarities None None O
of None None O
plutonium None None O
( None None O
IV None None O
) None None O
and None None O
iron None None O
( None None O
III None None O
) None None O
suggested None None O
that None None O
octadentate None None O
ligands None None O
containing None None O
hydroxamate None None O
or None None O
catecholate None None O
functional None None O
groups None None O
, None None O
which None None O
are None None O
found None None O
in None None O
microbial None None O
iron None None O
chelating None None O
agents None None O
( None None O
siderophores None None O
) None None O
, None None O
would None None O
be None None O
effective None None O
and None None O
relatively None None O
selective None None O
complexing None None O
agents None None O
for None None O
actinide None None O
( None None O
IV None None O
) None None O
ions None None O
. None None O

However None None O
, None None O
their None None O
usefulness None None O
for None None O
in None None O
vivo None None O
chelation None None O
of None None O
actinide None None O
( None None O
IV None None O
) None None O
is None None O
limited None None O
, None None O
because None None O
catechol None None O
and None None O
hydroxamate None None O
are None None O
such None None O
weak None None O
acids None None O
that None None O
the None None O
potential None None O
for None None O
octadentate None None O
binding None None O
of None None O
actinide None None O
( None None O
IV None None O
) None None O
cannot None None O
be None None O
achieved None None O
at None None O
physiological None None O
pH None None O
. None None O

The None None O
structurally None None O
similar None None O
monoprotic None None O
and None None O
more None None O
acidic None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinone None None I-IUPAC
( None None O
1,2 None None O
- None None O
HOPO None None O
) None None O
group None None O
was None None O
, None None O
therefore None None O
, None None O
incorporated None None O
into None None O
multidentate None None O
ligands None None O
. None None O

Treatment None None O
of None None O
1,2 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxopyridine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
5 None None O
) None None O
with None None O
phosgene None None O
in None None O
THF None None O
solution None None O
gives None None O
the None None O
active None None O
ester None None O
poly None None I-IUPAC
[ None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
dioxopyridine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
] None None I-IUPAC
, None None O
which None None O
upon None None O
treatment None None O
with None None O
excess None None O
anhydrous None None O
dimethylamine None None O
gave None None O
a None None O
60% None None O
yield None None O
of None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxopyridine None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
( None None O
6 None None O
) None None O
. None None O

A None None O
similarly None None O
reactive None None O
intermediate None None O
was None None O
prepared None None O
from None None O
5 None None O
and None None O
an None None O
equimolar None None O
amount None None O
of None None O
phosgene None None O
in None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylacetamide None None I-IUPAC
. None None O

Combined None None O
in None None O
situ None None O
with None None O
1,3 None None I-IUPAC
- None None I-IUPAC
propanediamine None None I-IUPAC
, None None O
benzylamine None None O
, None None O
spermine None None O
, None None O
spermidine None None O
, None None O
1,3,5 None None I-IUPAC
- None None I-IUPAC
tris None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
benzene None None I-IUPAC
, None None O
or None None O
desferrioxamine None None O
B None None O
and None None O
excess None None O
triethylamine None None O
, None None O
the None None O
latter None None O
intermediate None None O
gave None None O
the None None O
corresponding None None O
amides None None O
in None None O
isolated None None O
yields None None O
ranging None None O
from None None O
16% None None O
to None None O
60% None None O
. None None O

The None None O
free None None O
ligands None None O
, None None O
their None None O
Zn None None O
( None None O
II None None O
) None None O
complexes None None O
, None None O
and None None O
the None None O
ferric None None O
complex None None O
of None None O
3,4,3 None None O
- None None O
LIHOPO None None O
were None None O
administered None None O
to None None O
mice None None O
[ None None O
30 None None O
mumol None None O
/ None None O
kg None None O
intraperitoneally None None O
1 None None O
h None None O
after None None O
Pu None None O
( None None O
IV None None O
) None None O
- None None O
238 None None O
citrate None None O
, None None O
kill None None O
at None None O
24 None None O
h None None O
] None None O
. None None O

Net None None O
Pu None None O
removal None None O
[ None None O
Pu None None O
excretion None None O
( None None O
treated None None O
) None None O
- None None O
PU None None O
excretion None None O
( None None O
control None None O
) None None O
] None None O
, None None O
expressed None None O
as None None O
percent None None O
of None None O
injected None None O
Pu None None O
, None None O
was None None O
as None None O
follows None None O
: None None O
Na None None O
salts None None O
and None None O
Zn None None O
( None None O
II None None O
) None None O
complexes None None O
, None None O
respectively None None O
, None None O
of None None O
3 None None O
- None None O
LIHOPO None None O
( None None O
54 None None O
, None None O
56 None None O
) None None O
, None None O
3,4 None None O
- None None O
LIHOPO None None O
( None None O
58 None None O
, None None O
60 None None O
) None None O
, None None O
3,4,3 None None O
- None None O
LIHOPO None None O
( None None O
73 None None O
, None None O
76 None None O
) None None O
; None None O
Na None None O
salts None None O
of None None O
MEHOPO None None O
( None None O
46 None None O
) None None O
, None None O
DFO None None O
- None None O
HOPO None None O
( None None O
78 None None O
) None None O
; None None O
Fe None None O
( None None O
III None None O
) None None O
complex None None O
of None None O
3,4,3 None None O
- None None O
LIHOPO None None O
( None None O
79 None None O
) None None O
. None None O

DFO None None O
- None None O
HOPO None None O
and None None O
3,4,3 None None O
- None None O
LIHOPO None None O
and None None O
its None None O
Zn None None O
( None None O
II None None O
) None None O
and None None O
Fe None None O
( None None O
III None None O
) None None O
complexes None None O
promoted None None O
significantly None None O
more None None O
Pu None None O
excretion None None O
than None None O
CaNa3 None None O
- None None O
DTPA None None O
( None None O
61% None None O
of None None O
injected None None O
Pu None None O
) None None O
. None None O

Preliminary None None O
findings None None O
on None None O
the None None O
acute None None O
toxicity None None O
of None None O
the None None O
poly None None O
( None None O
HOPO None None O
) None None O
ligands None None O
and None None O
HOPO None None O
monomers None None O
are None None O
presented None None O
in None None O
an None None O
appendix None None O
. None None O

The None None O
biological None None O
data None None O
indicate None None O
strongly None None O
that None None O
the None None O
aqueous None None O
solubility None None O
and None None O
relatively None None O
high None None O
acidity None None O
of None None O
the None None O
octadentate None None O
HOPO None None O
ligands None None O
, None None O
3,4,3 None None O
- None None O
LIHOPO None None O
and None None O
DFO None None O
- None None O
HOPO None None O
allow None None O
them None None O
to None None O
form None None O
complete None None O
eight None None O
- None None O
coordinate None None O
complexes None None O
with None None O
Pu None None O
( None None O
IV None None O
) None None O
ion None None O
. None None O


A None None O
series None None O
of None None O
N None None O
- None None O
substituted None None O
imidazolines None None O
and None None O
ethylenediamines None None O
were None None O
synthesized None None O
and None None O
examined None None O
for None None O
their None None O
activity None None O
in None None O
alpha None None O
- None None O
and None None O
beta None None O
- None None O
adrenergic None None O
systems None None O
. None None O

The None None O
length None None O
of None None O
the None None O
intermediate None None O
side None None O
chain None None O
between None None O
the None None O
catechol None None O
and None None O
imidazoline None None O
ring None None O
or None None O
the None None O
amine None None O
of None None O
the None None O
ethylenediamine None None O
segment None None O
was None None O
shown None None O
to None None O
affect None None O
the None None O
adrenergic None None O
activity None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
Dihydroxyphenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
imidazoline None None I-IUPAC
hydrochloride None None I-IUPAC
( None None O
2 None None O
) None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydroxyphenyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
ethylenediamine None None I-IUPAC
dihydrochloride None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
both None None O
with None None O
two None None O
methylene None None O
groups None None O
between None None O
the None None O
catechol None None O
and None None O
amine None None O
segment None None O
, None None O
were None None O
found None None O
to None None O
be None None O
somewhat None None O
selective None None O
for None None O
alpha None None O
2 None None O
- None None O
adrenergic None None O
receptors None None O
while None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydroxybenzyl None None I-IUPAC
) None None I-IUPAC
imidazoline None None I-IUPAC
hydrochloride None None I-IUPAC
( None None O
1 None None O
) None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydroxybenzyl None None I-IUPAC
) None None I-IUPAC
ethylenediamine None None I-IUPAC
dihydrochloride None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
both None None O
with None None O
one None None O
methylene None None I-IUPAC
group None None B-MODIFIER
between None None O
the None None O
catechol None None O
and None None O
amine None None O
segment None None O
, None None O
were None None O
more None None O
selective None None O
for None None O
alpha1 None None O
- None None O
adrenergic None None O
receptors None None O
in None None O
a None None O
pithed None None O
rat None None O
model None None O
. None None O

Of None None O
the None None O
four None None O
compounds None None O
examined None None O
, None None O
only None None O
compound None None O
2 None None O
showed None None O
significant None None O
direct None None O
activity None None O
on None None O
beta1 None None O
- None None O
and None None O
beta2 None None O
- None None O
adrenergic None None O
receptors None None O
. None None O


O None None O
( None None O
6 None None O
) None None O
- None None O
Substituted None None O
guanine None None I-IUPAC
derivatives None None B-MODIFIER
are None None O
powerful None None O
agents None None O
used None None O
for None None O
tumor None None O
cell None None O
sensitization None None O
by None None O
inhibition None None O
of None None O
the None None O
DNA None None O
repair None None O
enzyme None None O
O None None O
( None None O
6 None None O
) None None O
- None None O
methylguanine None None O
- None None O
DNA None None O
methyltransferase None None O
( None None O
MGMT None None O
) None None O
. None None O

To None None O
provide None None O
targeted None None O
accumulation None None O
of None None O
MGMT None None O
inhibitors None None O
in None None O
tumor None None O
tissue None None O
as None None O
well None None O
as None None O
tools None None O
for None None O
in None None O
vivo None None O
imaging None None O
, None None O
we None None O
synthesized None None O
iodinated None None O
C None None O
( None None O
8 None None O
) None None O
- None None O
alkyl None None O
- None None O
linked None None O
glucose None None O
conjugates None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodothenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9H None None I-IUPAC
- None None I-IUPAC
purine None None I-IUPAC
( None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodothenyl None None I-IUPAC
) None None I-IUPAC
guanine None None I-IUPAC
, None None O
ITG None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
iodobenzyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9H None None I-IUPAC
- None None I-IUPAC
purine None None I-IUPAC
( None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodobenzyl None None I-IUPAC
) None None I-IUPAC
guanine None None I-IUPAC
, None None O
IBG None None O
) None None O
. None None O

These None None O
compounds None None O
have None None O
MGMT None None O
inhibitor None None O
constants None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
) None None O
of None None O
0.8 None None O
and None None O
0.45 None None O
microM None None O
for None None O
ITGG None None O
and None None O
IBGG None None O
, None None O
respectively None None O
, None None O
as None None O
determined None None O
in None None O
HeLa None None O
S3 None None O
cells None None O
after None None O
2 None None O
- None None O
h None None O
incubation None None O
with None None O
inhibitor None None O
. None None O

To None None O
substantiate None None O
that None None O
the None None O
( None None I-IUPAC
131 None None I-IUPAC
) None None I-IUPAC
I None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hetero None None I-IUPAC
) None None I-IUPAC
arylmethylene None None I-IUPAC
group None None I-MODIFIER
at None None O
the None None O
O None None O
( None None O
6 None None O
) None None O
- None None O
position None None O
of None None O
guanine None None O
is None None O
transferred None None O
to None None O
MGMT None None O
, None None O
both None None O
the None None O
glucose None None O
conjugated None None O
inhibitors None None O
ITGG None None O
and None None O
IBGG None None O
and None None O
the None None O
corresponding None None O
nonglucose None None O
conjugated None None O
compounds None None O
ITG None None O
and None None O
IBG None None O
were None None O
labeled None None O
with None None O
iodine None None O
- None None O
131 None None O
. None None O

The None None O
radioiodinations None None O
of None None O
all None None O
compounds None None O
with None None O
[ None None O
( None None O
131 None None O
) None None O
I None None O
] None None O
I None None O
( None None O
- None None O
) None None O
were None None O
performed None None O
with None None O
radiochemical None None O
yields None None O
of None None O
& None None O
gt None None O
; None None O
70% None None O
for None None O
the None None O
destannylation None None O
of None None O
the None None O
corresponding None None O
tri None None O
- None None O
n None None O
- None None O
butylstannylated None None O
precursors None None O
. None None O

The None None O
binding None None O
ability None None O
of None None O
[ None None O
( None None O
131 None None O
) None None O
I None None O
] None None O
ITGG None None O
, None None O
[ None None O
( None None O
131 None None O
) None None O
] None None O
IBGG None None O
, None None O
[ None None O
( None None O
131 None None O
) None None O
I None None O
] None None O
ITG None None O
, None None O
and None None O
[ None None O
( None None O
131 None None O
) None None O
I None None O
] None None O
IBG None None O
to None None O
purified None None O
MGMT None None O
was None None O
tested None None O
. None None O

All None None O
radioactive None None O
compounds None None O
were None None O
substrates None None O
for None None O
MGMT None None O
, None None O
as None None O
demonstrated None None O
using None None O
a None None O
competitive None None O
repair None None O
assay None None O
. None None O

The None None O
newly None None O
synthesized None None O
radioactive None None O
inhibitors None None O
were None None O
utilized None None O
to None None O
study None None O
ex None None O
vivo None None O
biodistribution None None O
in None None O
mice None None O
, None None O
and None None O
the None None O
tumor None None O
- None None O
to None None O
- None None O
blood None None O
ratio None None O
of None None O
tissue None None O
uptake None None O
of None None O
[ None None O
( None None O
131 None None O
) None None O
I None None O
] None None O
IBG None None O
and None None O
[ None None O
( None None O
131 None None O
) None None O
I None None O
] None None O
IBGG None None O
was None None O
determined None None O
to None None O
be None None O
0.24 None None O
and None None O
0.76 None None O
after None None O
0.5 None None O
h None None O
, None None O
respectively None None O
. None None O


4,5 None None O
- None None O
Diphenyl None None O
- None None O
2 None None O
- None None O
oxazolenonanoic None None O
acid None None O
( None None O
2 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
diphenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxazolyl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
phenoxy None None I-IUPAC
] None None I-IUPAC
acetic None None I-IUPAC
acid None None I-IUPAC
( None None O
3 None None O
) None None O
were None None O
previously None None O
identified None None O
as None None O
nonprostanoid None None O
prostacyclin None None O
( None None O
PGI2 None None O
) None None O
mimetics None None O
that None None O
inhibit None None O
ADP None None O
- None None O
induced None None O
aggregation None None O
of None None O
human None None O
platelets None None O
in None None O
vitro None None O
. None None O

The None None O
effects None None O
on None None O
biological None None O
activity None None O
of None None O
substitution None None O
and None None O
structural None None O
modification None None O
of None None O
the None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
rings None None I-MODIFIER
of None None O
3 None None O
was None None O
examined None None O
. None None O

Potency None None O
showed None None O
a None None O
marked None None O
sensitivity None None O
to None None O
the None None O
introduction None None O
of None None O
substituents None None O
to None None O
these None None O
aromatic None None O
rings None None O
and None None O
only None None O
the None None O
bis None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
derivative None None I-MODIFIER
9j None None O
, None None O
IC50 None None O
= None None O
0.34 None None O
microM None None O
, None None O
demonstrated None None O
enhanced None None O
potency None None O
compared None None O
to None None O
the None None O
parent None None O
structure None None O
3 None None O
, None None O
IC50 None None O
= None None O
1.2 None None O
microM None None O
. None None O

Substitution None None O
at None None O
the None None O
ortho None None O
or None None O
meta None None O
positions None None O
of None None O
the None None O
phenyl None None O
rings None None O
, None None O
replacement None None O
by None None O
thiopheneyl None None O
or None None O
cyclohexyl None None O
moieties None None O
, None None O
or None None O
constraining None None O
in None None O
a None None O
planar None None O
phenanthrene None None O
system None None O
resulted None None O
in None None O
compounds None None O
that None None O
were None None O
less None None O
effective None None O
inhibitors None None O
of None None O
ADP None None O
- None None O
induced None None O
platelet None None O
aggregation None None O
. None None O

In None None O
contrast None None O
, None None O
variation None None O
of None None O
the None None O
heterocycle None None O
moiety None None O
revealed None None O
a None None O
much None None O
less None None O
stringent None None O
SAR None None O
and None None O
many None None O
5 None None O
- None None O
and None None O
6 None None O
- None None O
membered None None O
heterocycles None None O
were None None O
found None None O
to None None O
effectively None None O
substitute None None O
for None None O
the None None O
oxazole None None O
ring None None O
of None None O
2 None None O
and None None O
3 None None O
. None None O

The None None O
diphenylmethyl None None O
moiety None None O
functioned None None O
as None None O
an None None O
effective None None O
isostere None None O
for None None O
4,5 None None O
- None None O
diphenylated None None O
heterocycles None None O
since None None O
13aad None None O
showed None None O
similar None None O
platelet None None O
inhibitory None None O
activity None None O
to None None O
3 None None O
. None None O

With None None O
the None None O
exception None None O
of None None O
the None None O
3,4,5 None None I-IUPAC
- None None I-IUPAC
triphenylpyrazole None None I-IUPAC
derivative None None I-MODIFIER
13g None None O
, None None O
compounds None None O
presenting None None O
the None None O
( None None I-IUPAC
m None None I-IUPAC
- None None I-IUPAC
ethylphenoxy None None I-IUPAC
) None None I-IUPAC
acetic None None I-IUPAC
acid None None I-IUPAC
side None None I-MODIFIER
chain None None I-MODIFIER
discovered None None O
with None None O
3 None None O
demonstrated None None O
enhanced None None O
potency None None O
compared None None O
to None None O
the None None O
analogously None None O
substituted None None O
alkanoic None None O
acid None None O
derivative None None O
. None None O

The None None O
structure None None O
- None None O
activity None None O
findings None None O
led None None O
to None None O
a None None O
refinement None None O
of None None O
a None None O
model None None O
of None None O
the None None O
nonprostanoid None None O
PGI2 None None O
mimetic None None O
pharmacophore None None O
. None None O


5' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Pivaloyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
dioxaphosphorinan None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorouridine None None I-IUPAC
( None None O
1c None None O
) None None O
was None None O
designed None None O
as None None O
a None None O
potential None None O
membrane None None O
- None None O
permeable None None O
prodrug None None O
of None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorouridine None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
monophosphate None None I-IUPAC
( None None O
FdUMP None None O
) None None O
, None None O
a None None O
putative None None O
active None None O
metabolite None None O
of None None O
the None None O
antitumor None None O
drug None None O
5 None None I-IUPAC
- None None I-IUPAC
fluorouracil None None I-IUPAC
( None None O
FU None None O
) None None O
. None None O

It None None O
was None None O
anticipated None None O
that None None O
1c None None O
would None None O
be None None O
hydrolyzed None None O
in None None O
vivo None None O
by None None O
carboxylate None None O
esterase None None O
( None None O
E None None O
. None None O

C None None O
. None None O

3.1.1.1 None None O
) None None O
to None None O
the None None O
labile None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
analogue None None I-MODIFIER
2a None None O
, None None O
which None None O
should None None O
penetrate None None O
cells None None O
by None None O
passive None None O
diffusion None None O
and None None O
ring None None O
open None None O
to None None O
the None None O
aldehyde None None O
3a None None O
. None None O

Spontaneous None None O
elimination None None O
of None None O
acrolein None None O
from None None O
3a None None O
would None None O
then None None O
generate None None O
the None None O
free None None O
nucleotide None None O
, None None O
FdUMP None None O
. None None O

1c None None O
might None None O
also None None O
penetrate None None O
cells None None O
directly None None O
and None None O
undergo None None O
the None None O
same None None O
degradation None None O
sequence None None O
after None None O
hydrolysis None None O
by None None O
cellular None None O
esterases None None O
. None None O

1c None None O
was None None O
prepared None None O
by None None O
condensing None None O
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
pivaloyloxy None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
dioxaphosphorinane None None I-IUPAC
with None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
fluorouridine None None I-IUPAC
( None None O
FUdR None None O
) None None O
in None None O
the None None O
presence None None O
of None None O
triphenylphosphine None None O
and None None O
diethyl None None O
azodicarboxylate None None O
. None None O

1c None None O
was None None O
moderately None None O
stable None None O
in None None O
aqueous None None O
buffers None None O
over None None O
the None None O
pH None None O
range None None O
1-7.4 None None O
( None None O
T1/2 None None O
& None None O
gt None None O
; None None O
30 None None O
h None None O
) None None O
. None None O

In None None O
the None None O
presence None None O
of None None O
carboxylate None None O
esterase None None O
, None None O
however None None O
, None None O
it None None O
was None None O
degraded None None O
, None None O
in None None O
a None None O
concentration None None O
- None None O
dependent None None O
manner None None O
, None None O
to None None O
FdUMP None None O
. None None O

No None None O
intermediates None None O
were None None O
detected None None O
in None None O
the None None O
incubation None None O
mixture None None O
. None None O

In None None O
mouse None None O
plasma None None O
, None None O
1c None None O
was None None O
degraded None None O
first None None O
to None None O
FdUMP None None O
and None None O
then None None O
to None None O
FUdR None None O
. None None O

The None None O
latter None None O
is None None O
presumably None None O
formed None None O
by None None O
dephosphorylation None None O
of None None O
FdUMP None None O
by None None O
plasma None None O
5' None None O
- None None O
nucleotidases None None O
or None None O
phosphatases None None O
. None None O

1c None None O
and None None O
FU None None O
inhibited None None O
the None None O
growth None None O
of None None O
Chinese None None O
hamster None None O
ovary None None O
( None None O
CHO None None O
) None None O
cells None None O
in None None O
culture None None O
at None None O
a None None O
concentration None None O
of None None O
5 None None O
x None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
M None None O
. None None O

1c None None O
was None None O
equally None None O
potent None None O
against None None O
a None None O
CHO None None O
variant None None O
that None None O
was None None O
20 None None O
- None None O
fold None None O
resistant None None O
to None None O
FU None None O
. None None O

Administered None None O
intraperitoneally None None O
for None None O
5 None None O
consecutive None None O
days None None O
, None None O
1c None None O
was None None O
as None None O
effective None None O
as None None O
FU None None O
at None None O
prolonging None None O
the None None O
life None None O
span None None O
of None None O
mice None None O
bearing None None O
P None None O
- None None O
388 None None O
leukemia None None O
. None None O

In None None O
the None None O
presence None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
mercaptoehtanesulfonic None None I-IUPAC
acid None None I-IUPAC
, None None O
an None None O
acrolein None None O
scavenger None None O
, None None O
1c None None O
was None None O
equally None None O
effective None None O
against None None O
a None None O
P None None O
- None None O
388 None None O
mutant None None O
cell None None O
line None None O
that None None O
was None None O
resistant None None O
to None None O
FU None None O
. None None O

Collectively None None O
, None None O
these None None O
data None None O
suggest None None O
that None None O
1c None None O
acts None None O
as None None O
a None None O
membrane None None O
- None None O
permeable None None O
prodrug None None O
of None None O
FdUMP None None O
. None None O

This None None O
prodrug None None O
strategy None None O
may None None O
be None None O
generally None None O
useful None None O
for None None O
introducing None None O
dianionic None None O
phosphates None None O
and None None O
phosphonates None None O
into None None O
cells None None O
. None None O


The None None O
hydrogen None None O
- None None O
bond None None O
- None None O
acceptor None None O
properties None None O
of None None O
the None None O
carbonyl None None I-IUPAC
moiety None None B-MODIFIER
in None None O
the None None O
17beta None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
group None None I-MODIFIER
on None None O
the None None O
D None None O
- None None O
ring None None O
of None None O
the None None O
anesthetic None None O
steroids None None O
( None None I-PARTIUPAC
3alpha None None I-PARTIUPAC
, None None I-PARTIUPAC
5alpha None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
3alpha None None I-IUPAC
, None None I-IUPAC
5beta None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypregan None None I-IUPAC
- None None I-IUPAC
20 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
form None None O
an None None O
important None None O
part None None O
of None None O
the None None O
anesthetic None None O
steroid None None O
pharmacophore None None O
. None None O

13,24 None None I-IUPAC
- None None I-IUPAC
Cyclo None None I-IUPAC
- None None I-IUPAC
18,21 None None I-IUPAC
- None None I-IUPAC
dinorcholanes None None I-IUPAC
containing None None O
a None None O
ketone None None O
or None None O
conjugated None None O
ketone None None O
group None None O
at None None O
C None None O
- None None O
20 None None O
, None None O
C None None O
- None None O
22 None None O
, None None O
C None None O
- None None O
23 None None O
, None None O
or None None O
C None None O
- None None O
24 None None O
were None None O
prepared None None O
as None None O
conformationally None None O
constrained None None O
analogues None None O
of None None O
these None None O
anesthetic None None O
steroids None None O
and None None O
were None None O
used None None O
to None None O
probe None None O
for None None O
alternate None None O
locations None None O
for None None O
the None None O
D None None O
- None None O
ring None None O
hydrogen None None O
- None None O
bond None None O
- None None O
accepting None None O
carbonyl None None I-IUPAC
group None None B-MODIFIER
. None None O

The None None O
analogues None None O
were None None O
evaluated None None O
( None None O
1 None None O
) None None O
. None None O

in None None O
[ None None I-IUPAC
( None None I-IUPAC
35 None None I-IUPAC
) None None I-IUPAC
S None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butylbicyclophosphorothionate None None I-IUPAC
binding None None O
experiments None None O
, None None O
( None None O
2 None None O
) None None O
. None None O

in None None O
electrophysiological None None O
experiments None None O
using None None O
rat None None O
alpha None None O
( None None O
1 None None O
) None None O
beta None None O
( None None O
2 None None O
) None None O
gamma None None O
( None None O
2L None None O
) None None O
GABA None None O
( None None O
A None None O
) None None O
receptors None None O
expressed None None O
in None None O
Xenopus None None O
laevis None None O
oocytes None None O
, None None O
and None None O
( None None O
3 None None O
) None None O
. None None O

as None None O
tadpole None None O
anesthetics None None O
. None None O

In None None O
the None None O
binding None None O
assay None None O
, None None O
the None None O
relative None None O
order None None O
of None None O
potencies None None O
for None None O
the None None O
analogues None None O
in None None O
the None None O
5alpha None None O
- None None O
and None None O
5beta None None O
- None None O
series None None O
is None None O
identical None None O
. None None O

For None None O
the None None O
ketones None None O
, None None O
the None None O
order None None O
is None None O
24 None None O
- None None O
one None None O
& None None O
gt None None O
; None None O
or None None O
= None None O
23 None None O
- None None O
one None None O
& None None O
gt None None O
; None None O
20 None None O
- None None O
one None None O
& None None O
gt None None O
; None None O
22 None None O
- None None O
one None None O
. None None O

Likewise None None O
, None None O
for None None O
the None None O
enones None None O
, None None O
the None None O
order None None O
is None None O
delta None None O
( None None O
22 None None O
) None None O
- None None O
24 None None O
- None None O
one None None O
& None None O
gt None None O
; None None O
delta None None O
( None None O
20 None None O
( None None O
22 None None O
) None None O
) None None O
- None None O
23 None None O
- None None O
one None None O
& None None O
gt None None O
; None None O
delta None None O
( None None O
22 None None O
) None None O
- None None O
20 None None O
- None None O
one None None O
& None None O
gt None None O
; None None O
delta None None O
( None None O
23 None None O
) None None O
- None None O
22 None None O
- None None O
one None None O
. None None O

Similar None None O
relative None None O
orders None None O
of None None O
potencies None None O
are None None O
also None None O
found None None O
in None None O
the None None O
other None None O
two None None O
bioassays None None O
. None None O

The None None O
activities None None O
of None None O
the None None O
24 None None O
- None None O
one None None O
and None None O
delta None None O
( None None O
22 None None O
) None None O
- None None O
24 None None O
- None None O
one None None O
compounds None None O
were None None O
expected None None O
to None None O
be None None O
very None None O
low None None O
, None None O
because None None O
the None None O
carbonyl None None I-IUPAC
group None None B-MODIFIER
in None None O
these None None O
compounds None None O
is None None O
located None None O
over None None O
the None None O
steroid None None O
C None None O
- None None O
ring None None O
and None None O
oriented None None O
toward None None O
C None None O
- None None O
8 None None O
. None None O

Instead None None O
, None None O
these None None O
compounds None None O
have None None O
the None None O
highest None None O
activities None None O
in None None O
their None None O
respective None None O
series None None O
, None None O
with None None O
the None None O
delta None None O
( None None O
22 None None O
) None None O
- None None O
24 None None O
- None None O
one None None O
compounds None None O
having None None O
activities None None O
comparable None None O
to None None O
those None None O
of None None O
the None None O
reference None None O
anesthetic None None O
steroids None None O
. None None O

The None None O
electrophysiology None None O
results None None O
obtained None None O
with None None O
the None None O
24 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
cyclosteroids None None I-IUPAC
suggest None None O
that None None O
rat None None O
alpha None None O
( None None O
1 None None O
) None None O
beta None None O
( None None O
2 None None O
) None None O
gamma None None O
( None None O
2L None None O
) None None O
GABA None None O
( None None O
A None None O
) None None O
receptors None None O
contain None None O
more None None O
than None None O
one None None O
donor None None O
for None None O
the None None O
hydrogen None None O
- None None O
bond None None O
- None None O
acceptor None None O
group None None O
of None None O
anesthetic None None O
steroids None None O
. None None O

The None None O
family None None O
of None None O
cyclosteroids None None O
should None None O
be None None O
useful None None O
for None None O
future None None O
structure None None O
- None None O
activity None None O
relationship None None O
studies None None O
of None None O
steroid None None O
modulation None None O
of None None O
other None None O
GABA None None O
( None None O
A None None O
) None None O
receptor None None O
subtypes None None O
. None None O


Syntheses None None O
of None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,3,3 None None I-IUPAC
- None None I-IUPAC
trifluoro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
TFPe None None O
- None None O
dUrd None None O
) None None O
( None None O
1 None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,3,3 None None I-IUPAC
- None None I-IUPAC
trifluoro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
11 None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,3,3 None None I-IUPAC
- None None I-IUPAC
trifluoro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
8 None None O
) None None O
, None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,3,3 None None I-IUPAC
- None None I-IUPAC
trifluoro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
10 None None O
) None None O
from None None O
5 None None I-IUPAC
- None None I-IUPAC
chloromercuri None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
are None None O
described None None O
. None None O

The None None O
antiviral None None O
activity None None O
of None None O
TFPe None None O
- None None O
dUrd None None O
was None None O
determined None None O
in None None O
cell None None O
culture None None O
against None None O
herpes None None O
simplex None None O
virus None None O
type None None O
1 None None O
( None None O
HSV None None O
- None None O
1 None None O
) None None O
, None None O
herpes None None O
simplex None None O
virus None None O
type None None O
2 None None O
( None None O
HSV None None O
- None None O
2 None None O
) None None O
, None None O
and None None O
vaccinia None None O
virus None None O
and None None O
compared None None O
concurrently None None O
with None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromovinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
, None None O
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
, None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
. None None O

TFPe None None O
- None None O
dUrd None None O
demonstrated None None O
a None None O
potent None None O
and None None O
unusually None None O
selective None None O
activity None None O
against None None O
HSV None None O
- None None O
1 None None O
, None None O
with None None O
a None None O
2 None None O
- None None O
log None None O
reduction None None O
in None None O
virus None None O
yield None None O
at None None O
0.03 None None O
micrograms None None O
/ None None O
mL None None O
( None None O
0.09 None None O
microM None None O
) None None O
; None None O
L None None O
- None None O
1210 None None O
cell None None O
growth None None O
was None None O
inhibited None None O
by None None O
50% None None O
only None None O
at None None O
290 None None O
micrograms None None O
/ None None O
mL None None O
. None None O

Isopycnic None None O
centrifugation None None O
of None None O
32P None None O
- None None O
labeled None None O
DNA None None O
indicated None None O
that None None O
if None None O
0.5 None None O
or None None O
2 None None O
microM None None O
TFPe None None O
- None None O
dUrd None None O
was None None O
present None None O
for None None O
0-6 None None O
h None None O
postinfection None None O
, None None O
viral None None O
DNA None None O
synthesis None None O
was None None O
reduced None None O
by None None O
ca. None None O
50 None None O
and None None O
85% None None O
, None None O
respectively None None O
; None None O
concomitantly None None O
, None None O
a None None O
new None None O
DNA None None O
band None None O
appeared None None O
at None None O
lower None None O
density None None O
than None None O
normal None None O
cellular None None O
or None None O
viral None None O
DNA None None O
. None None O


This None None O
paper None None O
describes None None O
the None None O
synthesis None None O
and None None O
kappa None None O
and None None O
mu None None O
opioid None None O
receptor None None O
binding None None O
affinity None None O
of None None O
some None None O
conformationally None None O
restrained None None O
derivatives None None O
of None None O
the None None O
arylacetamide None None O
group None None O
in None None O
the None None O
selective None None O
kappa None None O
opioid None None O
receptor None None O
agonist None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
cyclohexyl None None I-IUPAC
] None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiophene None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
acetamide None None I-IUPAC
monohydrochloride None None I-IUPAC
( None None O
1 None None O
, None None O
PD117302 None None O
) None None O
, None None O
which None None O
is None None O
an None None O
analogue None None O
of None None O
U None None O
- None None O
50 None None O
, None None O
488 None None O
. None None O

The None None O
methyl None None I-IUPAC
- None None O
substituted None None I-MODIFIER
derivatives None None B-MODIFIER
( None None B-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
cyclohexyl None None I-IUPAC
] None None I-IUPAC
benzo None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
thiophene None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
acetamide None None I-IUPAC
monohydrochloride None None I-IUPAC
( None None O
6a None None O
, None None O
b None None O
) None None O
possess None None O
significantly None None O
weaker None None O
affinity None None O
than None None O
1 None None O
for None None O
the None None O
kappa None None O
opioid None None O
receptor None None O
( None None O
Ki None None O
= None None O
172 None None O
and None None O
3.7 None None O
nM None None O
, None None O
respectively None None O
) None None O
. None None O

It None None O
is None None O
proposed None None O
that None None O
this None None O
is None None O
due None None O
to None None O
the None None O
conformational None None O
restriction None None O
imposed None None O
by None None O
the None None O
methyl None None I-IUPAC
group None None B-MODIFIER
of None None O
6 None None O
. None None O

In None None O
order None None O
to None None O
test None None O
this None None O
proposal None None O
the None None O
acenaphthene None None O
derivative None None O
and None None O
the None None O
4,5 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
naphtho None None I-IUPAC
[ None None I-IUPAC
1,8 None None I-IUPAC
- None None I-IUPAC
bc None None I-IUPAC
] None None I-IUPAC
thiophene None None I-IUPAC
derivative None None I-MODIFIER
were None None O
prepared None None O
. None None O

The None None O
acenaphthene None None I-IUPAC
derivative None None B-MODIFIER
( None None B-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxaspiro None None I-IUPAC
[ None None I-IUPAC
4.5 None None I-IUPAC
] None None I-IUPAC
dec None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
acenaphthenecarboxamide None None I-IUPAC
monohydrochloride None None I-IUPAC
( None None O
9 None None O
) None None O
was None None O
found None None O
to None None O
have None None O
high None None O
kappa None None O
opioid None None O
receptor None None O
affinity None None O
and None None O
selectivity None None O
( None None O
kappa None None O
Ki None None O
= None None O
0.37 None None O
+ None None O
/ None None O
- None None O
0.05 None None O
nM None None O
, None None O
mu None None O
/ None None O
kappa None None O
= None None O
659 None None O
, None None O
delta None None O
/ None None O
kappa None None O
= None None O
1562 None None O
) None None O
and None None O
is None None O
100 None None O
times None None O
more None None O
potent None None O
than None None O
morphine None None O
as None None O
an None None O
analgesic None None O
in None None O
the None None O
rat None None O
paw None None O
pressure None None O
test None None O
for None None O
analgesia None None O
after None None O
intravenous None None O
administration None None O
( None None O
MPE50 None None O
= None None O
0.014 None None O
and None None O
1.4 None None O
mg None None O
/ None None O
kg None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
4,5 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
naphtho None None I-IUPAC
[ None None I-IUPAC
1,8 None None I-IUPAC
- None None I-IUPAC
bc None None I-IUPAC
] None None I-IUPAC
thiophene None None I-IUPAC
derivative None None I-MODIFIER
( None None B-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pyrrolidinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxaspiro None None I-IUPAC
[ None None I-IUPAC
4.5 None None I-IUPAC
] None None I-IUPAC
dec None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
naphthol None None I-IUPAC
[ None None I-IUPAC
1,8 None None I-IUPAC
- None None I-IUPAC
bc None None I-IUPAC
] None None I-IUPAC
thiophene None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxamide None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
toluenesulfonate None None I-IUPAC
( None None O
17 None None O
) None None O
also None None O
has None None O
high None None O
kappa None None O
opioid None None O
receptor None None O
affinity None None O
and None None O
selectivity None None O
( None None O
kappa None None O
Ki None None O
= None None O
4.65 None None O
nM None None O
, None None O
mu None None O
/ None None O
kappa None None O
= None None O
109 None None O
) None None O
. None None O


4 None None I-MODIFIER
- None None I-MODIFIER
N None None I-MODIFIER
- None None I-MODIFIER
Substituted None None B-MODIFIER
and None None O
- None None I-MODIFIER
unsubstituted None None I-MODIFIER
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
alkyl None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alkylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
thiadiazine None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxides None None I-IUPAC
were None None O
synthesized None None O
and None None O
tested None None O
vs None None O
diazoxide None None O
and None None O
selected None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
alykl None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alkylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
benzothiadiazine None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxides None None I-IUPAC
as None None O
potassium None None O
channel None None O
openers None None O
on None None O
pancreatic None None O
and None None O
vascular None None O
tissues None None O
. None None O

Several None None O
4 None None I-MODIFIER
- None None I-MODIFIER
N None None I-MODIFIER
- None None I-MODIFIER
unsubstituted None None I-MODIFIER
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alkylamino None None I-IUPAC
) None None I-IUPAC
pyridothiadiazines None None I-IUPAC
and None None O
some None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alkylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
chlorobenzothiadiazines None None I-IUPAC
were None None O
found None None O
to None None O
be None None O
more None None O
potent None None O
than None None O
diazoxide None None O
for None None O
the None None O
inhibition None None O
of None None O
the None None O
insulin None None O
- None None O
releasing None None O
process None None O
. None None O

Moreover None None O
, None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alkylamino None None I-IUPAC
) None None I-IUPAC
pyridothiadiazines None None I-IUPAC
appeared None None O
to None None O
be None None O
more None None O
selective None None O
for None None O
the None None O
pancreatic None None O
than None None O
for None None O
the None None O
vascular None None O
tissue None None O
. None None O

By None None O
means None None O
of None None O
the None None O
pharmacological None None O
results None None O
obtained None None O
on None None O
pancreatic None None O
B None None O
- None None O
cells None None O
, None None O
structure None None O
- None None O
- None None O
activity None None O
relationships None None O
were None None O
deduced None None O
and None None O
a None None O
pharmacophoric None None O
model None None O
for None None O
the None None O
interaction None None O
of None None O
these None None O
drugs None None O
with None None O
their None None O
receptor None None O
site None None O
associated None None O
to None None O
the None None O
pancreatic None None O
K None None O
( None None O
ATP None None O
) None None O
channel None None O
was None None O
proposed None None O
. None None O

According None None O
to None None O
their None None O
selectivity None None O
for None None O
the None None O
B None None O
- None None O
cell None None O
( None None O
endocrine None None O
tissue None None O
) None None O
vs None None O
the None None O
vascular None None O
( None None O
smooth None None O
muscle None None O
tissue None None O
) None None O
ionic None None O
channel None None O
, None None O
selected None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alkylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
, None None I-IUPAC
- None None I-IUPAC
thiadiazine None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxides None None I-IUPAC
may None None O
serve None None O
as None None O
pharmacological None None O
tools None None O
in None None O
studying None None O
the None None O
K None None O
( None None O
ATP None None O
) None None O
channels None None O
( None None O
" None None O
pancreatic None None O
- None None O
like None None O
" None None O
K None None O
( None None O
ATP None None O
) None None O
channels None None O
) None None O
in None None O
other None None O
tissues None None O
. None None O


A None None O
series None None O
of None None O
2,3 None None I-IUPAC
- None None I-IUPAC
diaryl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
analogues None None I-MODIFIER
substituted None None B-MODIFIER
at None None O
position None None O
4 None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
with None None O
a None None O
hydroxy None None I-IUPAC
or None None O
pyrrolidinoethoxy None None I-IUPAC
residue None None B-MODIFIER
were None None O
synthesized None None O
as None None O
models None None O
for None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
triarylpropenones None None I-IUPAC
constrained None None O
in None None O
the None None O
s None None O
- None None O
trans None None O
conformation None None O
. None None O

The None None O
prototypes None None O
, None None O
belonging None None O
to None None O
five None None O
chemical None None O
series None None O
, None None O
were None None O
evaluated None None O
for None None O
their None None O
estrogen None None O
receptor None None O
affinity None None O
and None None O
for None None O
estrogen None None O
agonist None None O
- None None O
antagonist None None O
activities None None O
. None None O

The None None O
4H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
, None None O
the None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
, None None O
the None None O
4H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
, None None O
and None None O
the None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
found None None O
to None None O
be None None O
inactive None None O
or None None O
only None None O
marginally None None O
activate None None O
as None None O
receptor None None O
ligands None None O
or None None O
estrogen None None O
agonists None None O
- None None O
antagonists None None O
. None None O

In None None O
the None None O
2H None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
category None None O
the None None O
parent None None O
phenol None None O
was None None O
also None None O
inactive None None O
whereas None None O
the None None O
basic None None O
ethers None None O
16 None None O
and None None O
26 None None O
were None None O
modest None None O
receptor None None O
ligands None None O
while None None O
being None None O
quite None None O
active None None O
as None None O
antiestrogens None None O
. None None O

In None None O
a None None O
comparative None None O
study None None O
the None None O
benzopyran None None O
16 None None O
was None None O
found None None O
to None None O
be None None O
more None None O
effective None None O
antiestrogen None None O
than None None O
tamoxifen None None O
while None None O
being None None O
as None None O
effective None None O
as None None O
LY None None O
- None None O
117018 None None O
. None None O

The None None O
benzopyrans None None O
have None None O
thus None None O
emerged None None O
as None None O
a None None O
new None None O
class None None O
of None None O
potent None None O
antiestrogens None None O
. None None O


A None None O
series None None O
of None None O
synthetic None None O
estrogens None None O
containing None None O
hydroxyalkyl None None O
side None None O
chains None None O
at None None O
the None None O
C None None O
- None None O
4 None None O
position None None O
of None None O
the None None O
A None None O
ring None None O
were None None O
designed None None O
as None None O
metabolically None None O
stable None None O
analogs None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxyestradiol None None I-IUPAC
, None None O
a None None O
catechol None None O
estrogen None None O
. None None O

These None None O
synthetic None None O
steroids None None O
would None None O
facilitate None None O
investigations None None O
on None None O
the None None O
potential None None O
biological None None O
role None None O
of None None O
catechol None None O
estrogens None None O
and None None O
also None None O
enable None None O
further None None O
examination None None O
of None None O
the None None O
structural None None O
and None None O
electronic None None O
constraints None None O
on None None O
the None None O
A None None O
ring None None O
in None None O
the None None O
interaction None None O
of None None O
estrogens None None O
with None None O
the None None O
estrogen None None O
receptor None None O
. None None O

Catechol None None O
estrogens None None O
are None None O
implicated None None O
as None None O
possible None None O
causative None None O
agents None None O
in None None O
estrogen None None O
- None None O
induced None None O
tumorigenesis None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Hydroxyestradiol None None I-IUPAC
has None None O
weaker None None O
affinity None None O
for None None O
the None None O
estrogen None None O
receptor None None O
and None None O
exhibits None None O
lower None None O
estrogenic None None O
activity None None O
in None None O
vivo None None O
; None None O
on None None O
the None None O
other None None O
hand None None O
, None None O
the None None O
catechol None None O
estrogens None None O
are None None O
prone None None O
to None None O
further None None O
oxidative None None O
metabolism None None O
and None None O
can None None O
form None None O
reactive None None O
intermediates None None O
. None None O

This None None O
report None None O
describes None None O
the None None O
synthesis None None O
and None None O
initial None None O
biochemical None None O
evaluation None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyalkyl None None I-IUPAC
) None None I-IUPAC
estrogens None None I-IUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminoalkyl None None I-IUPAC
) None None I-IUPAC
estradiols None None I-IUPAC
. None None O

The None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyalkyl None None I-IUPAC
) None None I-IUPAC
estrogens None None I-IUPAC
were None None O
prepared None None O
by None None O
oxidative None None O
hydroboration None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
alkenylestradiols None None I-IUPAC
. None None O

The None None O
alkenylestradiols None None O
were None None O
obtained None None O
via None None O
a None None O
Stille None None O
cross None None O
- None None O
coupling None None O
between None None O
a None None O
MOM None None O
- None None O
protected None None O
4 None None I-IUPAC
- None None I-IUPAC
bromoestradiol None None I-IUPAC
and None None O
an None None O
alkenylstannane None None O
. None None O

The None None O
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminoalkyl None None I-IUPAC
) None None I-IUPAC
estrogens None None I-IUPAC
were None None O
prepared None None O
from None None O
the None None O
hydroxyalkyl None None O
derivatives None None O
with None None O
phthalimide None None O
under None None O
Mitsunobu None None O
conditions None None O
. None None O

The None None O
substituted None None O
estradiols None None O
were None None O
evaluated None None O
for None None O
estrogen None None O
receptor None None O
binding None None O
activity None None O
in None None O
MCF None None O
- None None O
7 None None O
human None None O
mammary None None O
carcinoma None None O
cells None None O
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
estradiol None None I-IUPAC
1 None None O
exhibited None None O
the None None O
highest None None O
affinity None None O
with None None O
an None None O
apparent None None O
EC50 None None O
value None None O
of None None O
364 None None O
nM None None O
. None None O

The None None O
relative None None O
activities None None O
for None None O
mRNA None None O
induction None None O
of None None O
the None None O
pS2 None None O
gene None None O
in None None O
MCF None None O
- None None O
7 None None O
cell None None O
cultures None None O
by None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyalkyl None None I-IUPAC
) None None I-IUPAC
estrogens None None I-IUPAC
closely None None O
parallel None None O
the None None O
relative None None O
binding None None O
affinities None None O
. None None O

4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Hydroxymethyl None None I-IUPAC
) None None I-IUPAC
estradiol None None I-IUPAC
1 None None O
did None None O
not None None O
stimulate None None O
the None None O
growth None None O
of None None O
MCF None None O
- None None O
7 None None O
cells None None O
at None None O
concentrations None None O
up None None O
to None None O
1 None None O
microM None None O
. None None O

Thus None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
estradiol None None I-IUPAC
1 None None O
exhibited None None O
similar None None O
estrogen None None O
receptor None None O
affinity None None O
as None None O
the None None O
catechol None None O
estrogen None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxyestradiol None None I-IUPAC
, None None O
and None None O
may None None O
prove None None O
useful None None O
in None None O
the None None O
examination None None O
of None None O
the None None O
biological None None O
effects None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
hydroxyestrogens None None I-IUPAC
. None None O


A None None O
library None None O
of None None O
compounds None None O
were None None O
prepared None None O
by None None O
reacting None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzisothiazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
( None None I-IUPAC
2H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
( None None O
5 None None O
) None None O
with None None O
commercially None None O
available None None O
carboxylic None None O
acids None None O
in None None O
the None None O
presence None None O
of None None O
potassium None None O
carbonate None None O
or None None O
a None None O
tertiary None None O
amine None None O
base None None O
. None None O

From None None O
this None None O
library None None O
, None None O
( None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxido None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzisothiazol None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
phenylmethoxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
alanate None None I-IUPAC
( None None O
7b None None O
) None None O
emerged None None O
as None None O
a None None O
potent None None O
inhibitor None None O
of None None O
human None None O
mast None None O
cell None None O
tryptase None None O
( None None O
IC50 None None O
= None None O
0.85 None None O
microM None None O
) None None O
. None None O

Extension None None O
of None None O
the None None O
side None None O
chain None None O
of None None O
7b None None O
by None None O
two None None O
carbons None None O
gave None None O
( None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
1 None None B-IUPAC
- None None I-IUPAC
dioxido None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
benzisothiazol None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
phenylmethoxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
pentanoate None None I-IUPAC
( None None O
7d None None O
) None None O
which None None O
was None None O
an None None O
8 None None O
- None None O
fold None None O
more None None O
potent None None O
inhibitor None None O
( None None O
IC50 None None O
= None None O
0.1 None None O
microM None None O
) None None O
. None None O

Further None None O
modification None None O
of None None O
this None None O
series None None O
produced None None O
benzoic None None O
acid None None O
derivative None None O
( None None I-IUPAC
1 None None I-IUPAC
, None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
dioxido None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
oxo None None I-IUPAC
- None None I-IUPAC
1,2 None None I-IUPAC
- None None I-IUPAC
benzisothiazol None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
phenylmethoxy None None I-IUPAC
) None None I-IUPAC
carbonyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
7n None None O
) None None O
which None None O
is None None O
the None None O
most None None O
potent None None O
inhibitor None None O
identified None None O
in None None O
this None None O
series None None O
( None None O
IC50 None None O
= None None O
0.064 None None O
microM None None O
) None None O
. None None O

These None None O
compounds None None O
exhibit None None O
time None None O
- None None O
dependent None None O
inhibition None None O
consistent None None O
with None None O
mechanism None None O
- None None O
based None None O
inhibition None None O
. None None O

For None None O
7b None None O
, None None O
the None None O
initial None None O
enzyme None None O
velocity None None O
is None None O
not None None O
a None None O
saturable None None O
function None None O
of None None O
the None None O
inhibitor None None O
concentration None None O
and None None O
the None None O
initial None None O
Ki None None O
could None None O
not None None O
be None None O
determined None None O
( None None O
Ki None None O
& None None O
gt None None O
; None None O
10 None None O
microM None None O
) None None O
. None None O

The None None O
steady None None O
- None None O
state None None O
rate None None O
constant None None O
, None None O
Ki None None O
, None None O
was None None O
determined None None O
to None None O
be None None O
396 None None O
nM None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
compounds None None O
7d None None O
and None None O
7n None None O
are None None O
time None None O
- None None O
dependent None None O
inhibitors None None O
with None None O
a None None O
saturable None None O
initial None None O
complex None None O
. None None O

From None None O
these None None O
studies None None O
, None None O
an None None O
initial None None O
rate None None O
constant None None O
, None None O
Ki None None O
, None None O
for None None O
7d None None O
and None None O
7n None None O
was None None O
found None None O
to None None O
be None None O
345 None None O
and None None O
465 None None O
nM None None O
, None None O
respectively None None O
. None None O

The None None O
steady None None O
- None None O
state None None O
inhibition None None O
constants None None O
, None None O
Ki None None O
, None None O
for None None O
7d None None O
and None None O
7n None None O
were None None O
calculated None None O
to None None O
be None None O
60 None None O
and None None O
52 None None O
nM None None O
, None None O
respectively None None O
. None None O

Compound None None O
7n None None O
is None None O
a None None O
13 None None O
- None None O
fold None None O
more None None O
potent None None O
inhibitor None None O
than None None O
7b None None O
, None None O
and None None O
these None None O
kinetic None None O
studies None None O
indicate None None O
that None None O
the None None O
increase None None O
in None None O
inhibitory None None O
activity None None O
is None None O
due None None O
to None None O
an None None O
increase None None O
in None None O
initial None None O
affinity None None O
toward None None O
the None None O
enzyme None None O
and None None O
not None None O
an None None O
increase None None O
in None None O
chemical None None O
reactivity None None O
. None None O

These None None O
inhibitors None None O
generally None None O
show None None O
high None None O
selectivity None None O
for None None O
tryptase None None O
, None None O
being None None O
40 None None O
- None None O
fold None None O
weaker None None O
inhibitors None None O
of None None O
elastase None None O
, None None O
being None None O
100 None None O
- None None O
fold None None O
weaker None None O
against None None O
trypsin None None O
, None None O
and None None O
showing None None O
no None None O
inhibition None None O
against None None O
thrombin None None O
. None None O

These None None O
compounds None None O
are None None O
not None None O
inhibitors None None O
of None None O
thrombin None None O
, None None O
plasmin None None O
t None None O
- None None O
PA None None O
, None None O
urokinase None None O
, None None O
and None None O
factor None None O
Xa None None O
( None None O
IC50 None None O
& None None O
gt None None O
; None None O
33 None None O
microM None None O
) None None O
. None None O

In None None O
the None None O
delayed None None O
- None None O
type None None O
hypersensitivity None None O
( None None O
DTH None None O
) None None O
mouse None None O
model None None O
, None None O
a None None O
model None None O
of None None O
skin None None O
inflammation None None O
, None None O
a None None O
5% None None O
solution None None O
of None None O
7d None None O
reduced None None O
edema None None O
by None None O
69% None None O
compared None None O
to None None O
control None None O
animals None None O
. None None O


A None None O
series None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
arylalkyl None None I-IUPAC
) None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylglyoxylylamides None None I-IUPAC
( None None O
4-8 None None O
) None None O
was None None O
synthesized None None O
as None None O
ligands None None O
of None None O
the None None O
benzodiazepine None None O
receptor None None O
( None None O
BzR None None O
) None None O
and None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
displace None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
flumazenil None None O
from None None O
bovine None None O
brain None None O
membranes None None O
. None None O

The None None O
new None None O
compounds None None O
, None None O
bearing None None O
a None None O
branched None None O
( None None O
4 None None O
) None None O
or None None O
a None None O
geometrically None None O
constrained None None O
benzyl None None I-IUPAC
/ None None O
phenylethyl None None I-IUPAC
amide None None I-IUPAC
side None None I-MODIFIER
chain None None I-MODIFIER
( None None O
5-8 None None O
) None None O
, None None O
represent None None O
the None None O
continuation None None O
of None None O
our None None O
research None None O
on None None O
N None None I-IUPAC
- None None I-IUPAC
benzylindol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylglyoxylylamides None None I-IUPAC
1 None None O
( None None O
Da None None O
Settimo None None O
et None None O
al. None None O
, None None O
1996 None None O
) None None O
, None None O
N' None None I-IUPAC
- None None I-IUPAC
phenylindol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylglyoxylohydrazides None None I-IUPAC
2 None None O
( None None O
Da None None O
Settimo None None O
et None None O
al. None None O
, None None O
1998 None None O
) None None O
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ylglyoxylyl None None I-IUPAC
) None None I-IUPAC
alanine None None I-IUPAC
derivatives None None I-MODIFIER
3 None None O
( None None O
Primofiore None None O
et None None O
al. None None O
, None None O
1989 None None O
) None None O
. None None O

A None None O
few None None O
indoles None None O
belonging None None O
to None None O
the None None O
previously None None O
investigated None None O
benzylamides None None O
1 None None O
and None None O
phenylhydrazides None None O
2 None None O
were None None O
synthesized None None O
and None None O
tested None None O
to None None O
enrich None None O
the None None O
SARs None None O
in None None O
these None None O
two None None O
series None None O
. None None O

The None None O
affinities None None O
and None None O
the None None O
GABA None None O
ratios None None O
of None None O
selected None None O
compounds None None O
for None None O
clonal None None O
mammalian None None O
alpha None None O
( None None O
1 None None O
) None None O
beta None None O
( None None O
2 None None O
) None None O
gamma None None O
( None None O
2 None None O
) None None O
, None None O
alpha None None O
( None None O
3 None None O
) None None O
beta None None O
( None None O
2 None None O
) None None O
gamma None None O
( None None O
2 None None O
) None None O
, None None O
and None None O
alpha None None O
( None None O
5 None None O
) None None O
beta None None O
( None None O
3 None None O
) None None O
gamma None None O
( None None O
2 None None O
) None None O
BzR None None O
subtypes None None O
were None None O
also None None O
determined None None O
. None None O

It None None O
was None None O
hypothesized None None O
that None None O
the None None O
reduced None None O
flexibility None None O
of None None O
indoles None None O
4-8 None None O
would None None O
both None None O
facilitate None None O
the None None O
mapping None None O
of None None O
the None None O
BzR None None O
binding None None O
cleft None None O
and None None O
increase None None O
the None None O
chances None None O
of None None O
conferring None None O
selectivity None None O
for None None O
the None None O
considered None None O
receptor None None O
subtypes None None O
. None None O

In None None O
the None None O
series None None O
of None None O
indoles None None O
4 None None O
, None None O
the None None O
introduction None None O
of None None O
a None None O
methyl None None I-IUPAC
group None None B-MODIFIER
on None None O
the None None O
benzylic None None O
carbon None None O
with None None O
the None None O
R None None O
configuration None None O
improved None None O
affinity None None O
of None None O
the None None O
5 None None O
- None None O
substituted None None O
( None None O
5 None None O
- None None O
Cl None None O
and None None O
5 None None O
- None None O
NO None None O
( None None O
2 None None O
) None None O
) None None O
derivatives None None O
, None None O
whereas None None O
it None None O
was None None O
detrimental None None O
for None None O
their None None O
5 None None O
- None None O
unsubtituted None None O
( None None O
5 None None O
- None None O
H None None O
) None None O
counterparts None None O
. None None O

All None None O
S None None O
enantiomers None None O
were None None O
less None None O
potent None None O
than None None O
the None None O
R None None O
ones None None O
. None None O

Replacement None None O
of None None O
the None None O
methyl None None O
with None None O
hydrophilic None None O
substituents None None O
on None None O
the None None O
benzylic None None O
carbon None None O
lowered None None O
affinity None None O
. None None O

The None None O
isoindolinylamide None None I-IUPAC
side None None B-MODIFIER
chain None None I-MODIFIER
was None None O
tolerated None None O
if None None O
the None None O
5 None None O
- None None O
position None None O
was None None O
unsubstituted None None O
( None None O
K None None O
( None None O
i None None O
) None None O
of None None O
5a None None O
= None None O
123 None None O
nM None None O
) None None O
, None None O
otherwise None None O
affinity None None O
was None None O
abolished None None O
( None None O
5b None None O
, None None O
c None None O
) None None O
. None None O

All None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
indanylamides None None I-IUPAC
6 None None O
and None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
indanylamides None None I-IUPAC
8 None None O
were None None O
devoid None None O
of None None O
any None None O
appreciable None None O
affinity None None O
. None None O

The None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
Cl None None I-PARTIUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
NO None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
) None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
indanylamides None None I-IUPAC
7b None None O
( None None O
K None None O
( None None O
i None None O
) None None O
80 None None O
nM None None O
) None None O
and None None O
7c None None O
( None None O
K None None O
( None None O
i None None O
) None None O
28 None None O
nM None None O
) None None O
were None None O
the None None O
most None None O
potent None None O
among None None O
the None None O
indoles None None O
5-8 None None O
geometrically None None O
constrained None None O
about None None O
the None None O
side None None O
chain None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
H None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
indanylamide None None I-IUPAC
7a None None O
displayed None None O
a None None O
lower None None O
affinity None None O
( None None O
K None None O
( None None O
i None None O
) None None O
675 None None O
nM None None O
) None None O
. None None O

The None None O
SARs None None O
developed None None O
from None None O
the None None O
new None None O
compounds None None O
, None None O
together None None O
with None None O
those None None O
collected None None O
from None None O
our None None O
previous None None O
studies None None O
, None None O
confirmed None None O
the None None O
hypothesis None None O
of None None O
different None None O
binding None None O
modes None None O
for None None O
5 None None O
- None None O
substituted None None O
and None None O
5 None None O
- None None O
unsubstituted None None O
indoles None None O
, None None O
suggesting None None O
that None None O
the None None O
shape None None O
of None None O
the None None O
lipophilic None None O
pocket None None O
L None None O
( None None O
1 None None O
) None None O
( None None O
notation None None O
in None None O
accordance None None O
with None None O
Cook None None O
's None None O
BzR None None O
topological None None O
model None None O
) None None O
is None None O
asymmetric None None O
and None None O
highlighted None None O
the None None O
stereoelectronic None None O
and None None O
conformational None None O
properties None None O
of None None O
the None None O
amide None None O
side None None O
chain None None O
required None None O
for None None O
high None None O
potency None None O
. None None O

Several None None O
of None None O
the None None O
new None None O
indoles None None O
showed None None O
selectivity None None O
for None None O
the None None O
alpha None None O
( None None O
1 None None O
) None None O
beta None None O
( None None O
2 None None O
) None None O
gamma None None O
( None None O
2 None None O
) None None O
subtype None None O
compared None None O
with None None O
the None None O
alpha None None O
( None None O
3 None None O
) None None O
beta None None O
( None None O
2 None None O
) None None O
gamma None None O
( None None O
2 None None O
) None None O
and None None O
alpha None None O
( None None O
5 None None O
) None None O
beta None None O
( None None O
3 None None O
) None None O
gamma None None O
( None None O
2 None None O
) None None O
subtypes None None O
( None None O
e.g. None None O
: None None O
4t None None O
and None None O
7c None None O
bind None None O
to None None O
these None None O
three None None O
BzR None None O
isoforms None None O
with None None O
K None None O
( None None O
i None None O
) None None O
values None None O
of None None O
14 None None O
nM None None O
, None None O
283 None None O
nM None None O
, None None O
239 None None O
nM None None O
, None None O
and None None O
9 None None O
nM None None O
, None None O
1960 None None O
nM None None O
, None None O
95 None None O
nM None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
GABA None None O
ratios None None O
close None None O
to None None O
unity None None O
exhibited None None O
by None None O
all None None O
the None None O
tested None None O
compounds None None O
on None None O
each None None O
BzR None None O
subtype None None O
were None None O
predictive None None O
of None None O
an None None O
efficacy None None O
profile None None O
typical None None O
of None None O
antagonists None None O
. None None O


A None None O
series None None O
of None None O
new None None O
S None None I-IUPAC
- None None I-IUPAC
adenosyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
homocysteine None None I-IUPAC
( None None O
AdoHcy None None O
) None None O
analogues None None I-MODIFIER
with None None O
modifications None None O
to None None O
amino None None O
acid None None O
and None None O
nucleoside None None O
moieties None None O
was None None O
prepared None None O
via None None O
condensation None None O
of None None O
appropriate None None O
nucleoside None None O
precursors None None O
and None None O
suitably None None O
protected None None O
L None None O
- None None O
homocystine None None O
derivatives None None O
. None None O

The None None O
AdoHcy None None O
derivatives None None O
as None None O
well None None O
as None None O
the None None O
nucleoside None None O
precursors None None O
were None None O
evaluated None None O
for None None O
their None None O
antiviral None None O
activity None None O
. None None O

Some None None O
of None None O
the None None O
compounds None None O
, None None O
in None None O
particular None None O
S None None I-IUPAC
- None None I-IUPAC
tubercidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
homocysteine None None I-IUPAC
propyl None None I-IUPAC
ester None None I-IUPAC
( None None O
36 None None O
) None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
tubercidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
homocysteine None None I-IUPAC
isopropyl None None I-IUPAC
ester None None I-IUPAC
( None None O
27 None None O
) None None O
, None None O
S None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
deoxytubercidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
homocysteine None None I-IUPAC
( None None O
58 None None O
) None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoracetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
tubercidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
homocysteine None None I-IUPAC
propyl None None I-IUPAC
ester None None I-IUPAC
( None None O
26 None None O
) None None O
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methoxyacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
tubercidinyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
homocysteine None None I-IUPAC
ethyl None None I-IUPAC
ester None None I-IUPAC
( None None O
31 None None O
) None None O
showed None None O
potent None None O
and None None O
selective None None O
activity None None O
against None None O
HSV None None O
, None None O
VV None None O
, None None O
and None None O
VSV None None O
. None None O

It None None O
is None None O
likely None None O
that None None O
they None None O
exert None None O
their None None O
antiviral None None O
effect None None O
via None None O
selective None None O
inhibition None None O
of None None O
the None None O
methyltransferases None None O
which None None O
are None None O
required None None O
for None None O
the None None O
maturation None None O
of None None O
viral None None O
mRNAs None None O
. None None O


As None None O
part None None O
of None None O
a None None O
search None None O
for None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
inhibitors None None O
combining None None O
the None None O
high None None O
potency None None O
of None None O
piritrexim None None O
( None None O
PTX None None O
) None None O
with None None O
the None None O
high None None O
antiparasitic None None O
vs None None O
mammalian None None O
selectivity None None O
of None None O
trimethoprim None None O
( None None O
TMP None None O
) None None O
, None None O
the None None O
heretofore None None O
undescribed None None O
2,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
diamino None None I-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
2' None None I-MODIFIER
, None None I-MODIFIER
5' None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
benzyl None None I-PARTIUPAC
) None None I-PARTIUPAC
pyrido None None I-PARTIUPAC
[ None None I-PARTIUPAC
2,3 None None I-PARTIUPAC
- None None I-PARTIUPAC
d None None I-PARTIUPAC
] None None I-PARTIUPAC
pyrimidines None None I-PARTIUPAC
6-14 None None O
with None None O
O None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
omega None None I-IUPAC
- None None I-IUPAC
carboxyalkyl None None I-IUPAC
) None None I-IUPAC
or None None O
omega None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
alkynyl None None I-IUPAC
groups None None I-MODIFIER
on None None O
the None None O
benzyl None None I-IUPAC
moiety None None B-MODIFIER
were None None O
synthesized None None O
and None None O
tested None None O
against None None O
Pneumocystis None None O
carinii None None O
, None None O
Toxoplasma None None O
gondii None None O
, None None O
and None None O
Mycobacterium None None O
avium None None O
DHFR None None O
vs None None O
rat None None O
DHFR None None O
. None None O

Three None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diaminopteridin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
omega None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
alkynyl None None I-IUPAC
) None None I-IUPAC
dibenz None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
, None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
azepines None None I-IUPAC
( None None O
19-21 None None O
) None None O
were None None O
also None None O
synthesized None None O
and None None O
tested None None O
. None None O

The None None O
pyridopyrimidine None None O
with None None O
the None None O
best None None O
combination None None O
of None None O
potency None None O
and None None O
selectivity None None O
was None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butynyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
] None None I-IUPAC
benzyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
13 None None O
) None None O
, None None O
with None None O
an None None O
IC None None O
( None None O
50 None None O
) None None O
value None None O
of None None O
0.65 None None O
nM None None O
against None None O
P None None O
. None None O

carinii None None O
DHFR None None O
, None None O
0.57 None None O
nM None None O
against None None O
M None None O
. None None O

avium None None O
DHFR None None O
, None None O
and None None O
55 None None O
nM None None O
against None None O
rat None None O
DHFR None None O
. None None O

The None None O
potency None None O
of None None O
13 None None O
against None None O
P None None O
. None None O

carinii None None O
DHFR None None O
was None None O
20 None None O
- None None O
fold None None O
greater None None O
than None None O
that None None O
of None None O
PTX None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
13 None None O
nM None None O
) None None O
, None None O
and None None O
its None None O
selectivity None None O
index None None O
( None None O
SI None None O
) None None O
relative None None O
to None None O
rat None None O
DHFR None None O
was None None O
85 None None O
, None None O
whereas None None O
PTX None None O
was None None O
nonselective None None O
. None None O

The None None O
activity None None O
of None None O
13 None None O
against None None O
P None None O
. None None O

carinii None None O
DHFR None None O
was None None O
20 None None O
000 None None O
times None None O
greater None None O
than None None O
that None None O
of None None O
TMP None None O
, None None O
with None None O
an None None O
SI None None O
of None None O
96 None None O
, None None O
whereas None None O
that None None O
of None None O
TMP None None O
was None None O
only None None O
14 None None O
. None None O

However None None O
13 None None O
was None None O
no None None O
more None None O
potent None None O
than None None O
PTX None None O
against None None O
M None None O
. None None O

avium None None O
DHFR None None O
, None None O
and None None O
its None None O
SI None None O
was None None O
no None None O
better None None O
than None None O
that None None O
of None None O
TMP None None O
. None None O

Molecular None None O
modeling None None O
dynamics None None O
studies None None O
using None None O
compounds None None O
10 None None O
and None None O
13 None None O
indicated None None O
a None None O
slight None None O
binding None None O
preference None None O
for None None O
the None None O
latter None None O
, None None O
in None None O
qualitative None None O
agreement None None O
with None None O
the None None O
IC None None O
( None None O
50 None None O
) None None O
data None None O
. None None O

Among None None O
the None None O
pteridines None None O
, None None O
the None None O
most None None O
potent None None O
against None None O
P None None O
. None None O

carinii None None O
DHFR None None O
and None None O
M None None O
. None None O

avium None None O
DHFR None None O
was None None O
the None None O
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butynyl None None I-IUPAC
) None None I-IUPAC
dibenz None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
, None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
azepinyl None None I-IUPAC
derivative None None I-MODIFIER
20 None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
2.9 None None O
nM None None O
) None None O
, None None O
whereas None None O
the None None O
most None None O
selective None None O
was None None O
the None None O
2' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
pentynyl None None I-IUPAC
) None None I-IUPAC
analogue None None I-MODIFIER
21 None None O
, None None O
with None None O
SI None None O
values None None O
of None None O
& None None O
gt None None O
; None None O
100 None None O
against None None O
both None None O
P None None O
. None None O

carinii None None O
and None None O
M None None O
. None None O

avium None None O
DHFR None None O
relative None None O
to None None O
rat None None O
DHFR None None O
. None None O

The None None O
final None None O
compound None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butynyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
22 None None O
) None None O
, None None O
was None None O
both None None O
potent None None O
and None None O
selective None None O
against None None O
M None None O
. None None O

avium None None O
DHFR None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0.47 None None O
nM None None O
, None None O
SI None None O
= None None O
1300 None None O
) None None O
but None None O
was None None O
not None None O
potent None None O
or None None O
selective None None O
against None None O
either None None O
P None None O
. None None O

carinii None None O
or None None O
T None None O
. None None O

gondii None None O
DHFR None None O
. None None O


6 None None I-IUPAC
- None None I-IUPAC
Hydroxypyrimidines None None I-IUPAC
substituted None None I-MODIFIER
at None None O
positions None None O
2 None None O
and None None O
4 None None O
by None None O
hydrogen None None O
, None None O
methyl None None O
, None None O
amino None None O
, None None O
cyclopropylamino None None O
, None None O
dimethylamino None None O
, None None O
methylsulfanyl None None O
, None None O
or None None O
hydroxyl None None O
group None None O
afford None None O
by None None O
the None None O
reaction None None O
with None None O
diisopropyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloroethoxy None None I-IUPAC
) None None I-IUPAC
methylphosphonate None None I-IUPAC
in None None O
the None None O
presence None None O
of None None O
NaH None None O
, None None O
Cs None None O
( None None O
2 None None O
) None None O
CO None None O
( None None O
3 None None O
) None None O
, None None O
or None None O
DBU None None O
a None None O
mixture None None O
of None None O
N None None I-PARTIUPAC
( None None I-PARTIUPAC
1 None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
O None None I-IUPAC
( None None I-IUPAC
6 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diisopropylphosphorylmethoxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
isomers None None I-MODIFIER
which None None O
were None None O
converted None None O
to None None O
the None None O
free None None O
phosphonic None None O
acids None None O
by None None O
treatment None None O
with None None O
bromotrimethylsilane None None O
followed None None O
by None None O
hydrolysis None None O
. None None O

Analogously None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hydroxypyrimidine None None I-IUPAC
gave None None O
on None None O
reaction None None O
with None None O
[ None None O
( None None I-PARTIUPAC
R None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diisopropylphosphorylmethoxy None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None O
tosylate None None I-MODIFIER
, None None O
followed None None O
by None None O
deprotection None None O
, None None O
the None None O
enantiomeric None None O
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethoxy None None I-IUPAC
) None None I-IUPAC
propoxy None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
. None None O

2,4 None None I-IUPAC
- None None I-IUPAC
Diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
sulfanylpyrimidine None None I-IUPAC
gave None None O
, None None O
on None None O
treatment None None O
with None None O
diisopropyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
chloroethoxy None None I-IUPAC
) None None I-IUPAC
methylphosphonate None None I-IUPAC
in None None O
the None None O
presence None None O
of None None O
NaH None None O
and None None O
subsequent None None O
deprotection None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethoxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
sulfanyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
. None None O

2 None None I-IUPAC
- None None I-IUPAC
Amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethoxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
was None None O
obtained None None O
from None None O
the None None O
appropriate None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chloropyrimidine None None I-IUPAC
derivative None None I-MODIFIER
by None None O
alkaline None None O
hydrolysis None None O
and None None O
ester None None O
cleavage None None O
. None None O

Direct None None O
alkylation None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4,6 None None I-IUPAC
- None None I-IUPAC
dihydroxypyrimidine None None I-IUPAC
afforded None None O
a None None O
mixture None None O
of None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
amino None None I-PARTIUPAC
- None None I-PARTIUPAC
4,6 None None I-PARTIUPAC
- None None I-PARTIUPAC
bis None None I-PARTIUPAC
[ None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
phosphonomethoxy None None I-PARTIUPAC
) None None I-PARTIUPAC
ethyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
bis None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethoxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
. None None O

None None None O
of None None O
the None None O
N None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethoxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
isomers None None I-MODIFIER
exhibited None None O
any None None O
antiviral None None O
activity None None O
against None None O
DNA None None O
viruses None None O
or None None O
RNA None None O
viruses None None O
tested None None O
in None None O
vitro None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
the None None O
O None None O
( None None O
6 None None O
) None None O
- None None O
isomers None None O
, None None O
namely None None O
the None None O
compounds None None O
derived None None O
from None None O
2,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
diamino None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
amino None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxy None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
or None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethoxy None None I-IUPAC
) None None I-IUPAC
ethoxy None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hydroxypyrimidine None None I-IUPAC
, None None O
inhibited None None O
the None None O
replication None None O
of None None O
herpes None None O
viruses None None O
[ None None O
herpes None None O
simplex None None O
type None None O
1 None None O
( None None O
HSV None None O
- None None O
1 None None O
) None None O
and None None O
type None None O
2 None None O
( None None O
HSV None None O
- None None O
2 None None O
) None None O
, None None O
varicella None None O
- None None O
zoster None None O
virus None None O
( None None O
VZV None None O
) None None O
, None None O
and None None O
cytomegalovirus None None O
( None None O
CMV None None O
) None None O
] None None O
and None None O
retroviruses None None O
[ None None O
Moloney None None O
sarcoma None None O
virus None None O
( None None O
MSV None None O
) None None O
and None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
( None None O
HIV None None O
- None None O
1 None None O
) None None O
and None None O
type None None O
2 None None O
( None None O
HIV None None O
- None None O
2 None None O
) None None O
] None None O
, None None O
their None None O
activity None None O
being None None O
most None None O
pronounced None None O
against None None O
the None None O
latter None None O
. None None O

The None None O
antiviral None None O
activity None None O
was None None O
lower None None O
if None None O
the None None O
oxygen None None O
at None None O
the None None O
position None None O
6 None None O
was None None O
replaced None None O
by None None O
a None None O
sulfur None None O
atom None None O
, None None O
as None None O
in None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethoxy None None I-IUPAC
) None None I-IUPAC
ethylsulfanyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
. None None O

In None None O
analogy None None O
to None None O
N None None I-IUPAC
( None None I-IUPAC
9 None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethoxy None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
diaminopurine None None I-IUPAC
( None None O
PMPDAP None None O
) None None O
, None None O
solely None None O
the None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phosphonomethoxy None None I-IUPAC
) None None I-IUPAC
propoxy None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
exerted None None O
antiviral None None O
activity None None O
, None None O
whereas None None O
its None None O
( None None O
S None None O
) None None O
- None None O
enantiomer None None O
was None None O
essentially None None O
inactive None None O
. None None O


Twenty None None O
- None None O
six None None O
compounds None None O
derived None None O
from None None O
the None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
deaza None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
5,10 None None I-IUPAC
- None None I-IUPAC
dideazaaminopterin None None I-IUPAC
series None None I-MODIFIER
of None None O
aminopterin None None O
analogues None None O
were None None O
evaluated None None O
for None None O
antiarthritic None None O
activity None None O
in None None O
the None None O
mouse None None O
type None None O
II None None O
collagen None None O
model None None O
. None None O

New None None O
compounds None None O
in None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
series None None I-MODIFIER
were None None O
prepared None None O
by None None O
alkylation None None O
of None None O
an None None O
appropriate None None O
N None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminobenzoyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamic None None I-IUPAC
acid None None I-IUPAC
dialkyl None None I-IUPAC
ester None None I-IUPAC
or None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
thenoyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
diester None None I-IUPAC
with None None O
a None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
alkyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deazapteridine None None I-IUPAC
. None None O

The None None O
resultant None None O
5 None None I-IUPAC
- None None I-IUPAC
deazaaminopterin None None I-IUPAC
diesters None None I-IUPAC
were None None O
saponified None None O
to None None O
provide None None O
the None None O
target None None O
5 None None I-IUPAC
- None None I-IUPAC
deaza None None I-IUPAC
analogues None None I-MODIFIER
. None None O

5,10 None None I-IUPAC
- None None I-IUPAC
Dideazaaminopterins None None I-IUPAC
were None None O
synthesized None None O
by None None O
similar None None O
alkylation None None O
of None None O
the None None O
carbanions None None O
of None None O
appropriate None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
carboxyphenylacetic None None I-PARTIUPAC
, None None O
( None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
carboxy None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
thienyl None None I-PARTIUPAC
) None None I-PARTIUPAC
acetic None None I-PARTIUPAC
, None None O
or None None O
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
) None None I-IUPAC
acetic None None I-IUPAC
acid None None I-IUPAC
dimethyl None None I-IUPAC
esters None None I-IUPAC
. None None O

The None None O
diesters None None O
of None None O
the None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
carboxy None None I-IUPAC
- None None I-IUPAC
5,10 None None I-IUPAC
- None None I-IUPAC
dideazapteroic None None I-IUPAC
acid None None I-IUPAC
types None None O
so None None O
obtained None None O
were None None O
saponified None None O
and None None O
then None None O
readily None None O
decarboxylated None None O
by None None O
heating None None O
in None None O
Me2SO None None O
solution None None O
to None None O
provide None None O
the None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5,10 None None I-IUPAC
- None None I-IUPAC
dideazapteroic None None I-IUPAC
acid None None I-IUPAC
- None None O
type None None O
intermediates None None O
. None None O

Peptide None None O
coupling None None O
with None None O
diethyl None None O
L None None O
- None None O
glutamate None None O
followed None None O
by None None O
ester None None O
hydrolysis None None O
at None None O
room None None O
temperature None None O
afforded None None O
the None None O
new None None O
5,10 None None I-IUPAC
- None None I-IUPAC
dideazaaminopterin None None I-IUPAC
analogues None None I-MODIFIER
. None None O

5 None None I-IUPAC
- None None I-IUPAC
Deazaaminopterins None None I-IUPAC
bearing None None O
an None None O
alkyl None None O
substituent None None O
at None None O
the None None O
5 None None O
- None None O
position None None O
were None None O
generally None None O
quite None None O
effective None None O
as None None O
antiinflammatory None None O
agents None None O
. None None O

Thus None None O
5 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deazaaminopterin None None I-IUPAC
, None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
propargyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deazaaminopterin None None I-IUPAC
, None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deazaaminopterin None None I-IUPAC
, None None O
5 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deazamethotrexate None None I-IUPAC
, None None O
and None None O
2,5 None None I-MODIFIER
- None None I-MODIFIER
disubstituted None None I-MODIFIER
thiophene None None I-IUPAC
analogue None None B-MODIFIER
of None None O
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
deazaaminopterin None None I-IUPAC
showed None None O
potencies None None O
greater None None O
than None None O
methotrexate None None O
by None None O
intraperitoneal None None O
or None None O
oral None None O
administration None None O
and None None O
were None None O
active None None O
over None None O
a None None O
considerably None None O
broader None None O
dose None None O
range None None O
. None None O

Useful None None O
activity None None O
in None None O
the None None O
5,10 None None I-IUPAC
- None None I-IUPAC
dideaza None None I-IUPAC
series None None I-MODIFIER
was None None O
only None None O
observed None None O
for None None O
5,10 None None I-IUPAC
- None None I-IUPAC
dideazaaminopterin None None I-IUPAC
and None None O
its None None O
10 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
analogue None None I-MODIFIER
. None None O

Alkyl None None O
substitution None None O
at None None O
C None None O
- None None O
5 None None O
or None None O
C None None O
- None None O
10 None None O
was None None O
generally None None O
detrimental None None O
to None None O
antiinflammatory None None O
activity None None O
in None None O
this None None O
series None None O
. None None O


The None None O
synthesis None None O
and None None O
pharmacological None None O
activities None None O
of None None O
the None None O
four None None O
stereoisomers None None O
of None None O
methyl None None I-IUPAC
tetrahydrofuran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydropyridine None None I-IUPAC
- None None I-IUPAC
3,5 None None I-IUPAC
- None None I-IUPAC
dicarboxylate None None I-IUPAC
( None None I-IUPAC
furnidipine None None I-IUPAC
) None None I-IUPAC
are None None O
reported None None O
. None None O

The None None O
four None None O
isomers None None O
were None None O
synthesized None None O
by None None O
a None None O
modified None None O
Hantzsch None None O
synthesis None None O
by None None O
reaction None None O
of None None O
( None None I-PARTIUPAC
- None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
tetrahydrofuran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminocrotonate None None I-IUPAC
and None None O
methyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
methylene None None I-IUPAC
] None None I-IUPAC
acetoacetate None None I-IUPAC
or None None O
, None None O
alternatively None None O
, None None O
by None None O
reaction None None O
of None None O
( None None I-PARTIUPAC
- None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
tetrahydrofuran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
methylene None None I-IUPAC
] None None I-IUPAC
acetoacetate None None I-IUPAC
and None None O
methyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminocrotonate None None I-IUPAC
. None None O

The None None O
1 None None O
: None None O
1 None None O
diastereomeric None None O
mixtures None None O
thus None None O
obtained None None O
were None None O
separated None None O
by None None O
chromatography None None O
, None None O
using None None O
poly None None O
( None None O
D None None O
- None None O
phenylglycine None None O
) None None O
as None None O
the None None O
chiral None None O
stationary None None O
phase None None O
. None None O

The None None O
enantiomeric None None O
purity None None O
of None None O
the None None O
stereoisomers None None O
was None None O
determined None None O
by None None O
a None None O
high None None O
- None None O
performance None None O
liquid None None O
chromatography None None O
- None None O
chiral None None O
stationary None None O
phase None None O
technique None None O
( None None O
HPLC None None O
- None None O
CSP None None O
) None None O
. None None O

Attempts None None O
to None None O
obtain None None O
crystals None None O
of None None O
a None None O
single None None O
stereoisomer None None O
failed None None O
in None None O
different None None O
solvents None None O
, None None O
while None None O
methanol None None O
crystallization None None O
of None None O
the None None O
product None None O
obtained None None O
from None None O
( None None I-IUPAC
+ None None I-IUPAC
/ None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
tetrahydrofuran None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ylmethyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
methylene None None I-IUPAC
] None None I-IUPAC
acetoacetate None None I-IUPAC
and None None O
methyl None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
aminocrotonate None None I-IUPAC
yielded None None O
good None None O
- None None O
quality None None O
crystals None None O
of None None O
the None None O
most None None O
insoluble None None O
racemate None None O
which None None O
proved None None O
to None None O
be None None O
a None None O
mixture None None O
of None None O
the None None O
( None None O
SS None None O
) None None O
/ None None O
( None None O
RR None None O
) None None O
enantiomers None None O
by None None O
X None None O
- None None O
ray None None O
crystallography None None O
. None None O

Conformational None None O
analysis None None O
of None None O
the None None O
stereoisomers None None O
, None None O
assuming None None O
rotation None None O
of None None O
the None None O
aryl None None O
substituent None None O
and None None O
ester None None O
groups None None O
, None None O
shows None None O
small None None O
energy None None O
differences None None O
( None None O
about None None O
4 None None O
kcal None None O
. None None O

mol None None O
- None None O
1 None None O
) None None O
between None None O
the None None O
most None None O
and None None O
the None None O
least None None O
favorable None None O
conformations None None O
. None None O

Binding None None O
studies None None O
were None None O
performed None None O
using None None O
[ None None O
3H None None O
] None None O
isradipine None None O
as None None O
a None None O
reference None None O
ligand None None O
. None None O

The None None O
results None None O
showed None None O
stereospecificity None None O
of None None O
the None None O
furnidipine None None O
isomers None None O
in None None O
brain None None O
, None None O
ileum None None O
, None None O
and None None O
cardiac None None O
tissues None None O
, None None O
the None None O
( None None O
SS None None O
) None None O
- None None O
and None None O
( None None O
SR None None O
) None None O
- None None O
isomers None None O
clearly None None O
being None None O
more None None O
potent None None O
than None None O
their None None O
( None None O
RR None None O
) None None O
- None None O
and None None O
( None None O
RS None None O
) None None O
- None None O
enantiomers None None O
. None None O

The None None O
( None None O
SS None None O
) None None O
- None None O
and None None O
( None None O
SR None None O
) None None O
- None None O
isomers None None O
were None None O
also None None O
more None None O
selective None None O
on None None O
cerebral None None O
tissue None None O
when None None O
compared None None O
with None None O
ileal None None O
and None None O
cardiac None None O
preparations None None O
. None None O


Synthesis None None O
and None None O
biological None None O
activities None None O
of None None O
12 None None O
analogs None None O
of None None O
N6 None None I-IUPAC
- None None I-IUPAC
benzyladenosine None None I-IUPAC
are None None O
described None None O
. None None O

The None None O
compounds None None O
were None None O
prepared None None O
by None None O
two None None O
methods None None O
: None None O
( None None O
1 None None O
) None None O
direct None None O
alkylation None None O
of None None O
adenosine None None O
with None None O
an None None O
appropriately None None O
substituted None None O
benzyl None None O
bromide None None O
to None None O
give None None O
the None None O
N1 None None O
- None None O
substituted None None O
derivative None None O
which None None O
was None None O
then None None O
rearranged None None O
in None None O
base None None O
to None None O
give None None O
the None None O
N6 None None O
- None None O
substituted None None O
compound None None O
, None None O
and None None O
( None None O
2 None None O
) None None O
by None None O
nucleophilic None None O
displacement None None O
of None None O
chlorine None None O
in None None O
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
ribonucleoside None None I-MODIFIER
, None None O
6 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminopurine None None I-IUPAC
ribonucleoside None None I-MODIFIER
, None None O
and None None O
6 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminopurine None None I-IUPAC
with None None O
an None None O
amine None None O
. None None O

These None None O
analogs None None O
were None None O
examined None None O
for None None O
their None None O
growth None None O
inhibitory None None O
effect None None O
in None None O
cultured None None O
leukemic None None O
cells None None O
and None None O
also None None O
for None None O
their None None O
effect None None O
on None None O
adenosine None None O
aminohydrolase None None O
activity None None O
. None None O

N6 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
Nitrobenzyladenosine None None I-IUPAC
and None None O
its None None O
2' None None O
- None None O
deoxy None None O
analog None None O
were None None O
competitive None None O
inhibitors None None O
( None None O
K1 None None O
65 None None O
, None None O
22 None None O
MUM None None O
) None None O
. None None O

The None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
N6 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
nitrobenzyladenine None None I-IUPAC
and None None O
its None None O
ribonucleoside None None O
were None None O
found None None O
to None None O
be None None O
noncompetitive None None O
inhibitors None None O
of None None O
adenosine None None O
aminohydrolase None None O
. None None O

In None None O
cultured None None O
L1210 None None O
leukemia None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
nitrobenzylaminopurine None None I-IUPAC
and None None O
the None None O
corresponding None None O
ribonucleoside None None O
were None None O
better None None O
growth None None O
inhibitors None None O
than None None O
N6 None None I-IUPAC
- None None I-IUPAC
benzyladenosine None None I-IUPAC
, None None O
while None None O
N6 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
nitrobenzyladenosine None None I-IUPAC
, None None O
its None None O
2' None None O
- None None O
deoxy None None O
analog None None O
, None None O
and None None O
N6 None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
fluorobenzyladenosine None None I-IUPAC
were None None O
as None None O
active None None O
as None None O
N6 None None I-IUPAC
- None None I-IUPAC
benzyladenosine None None I-IUPAC
. None None O


Numerous None None O
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylanilino None None I-IUPAC
) None None I-IUPAC
uracils None None I-IUPAC
( None None O
EMAU None None O
) None None O
have None None O
been None None O
synthesized None None O
and None None O
screened None None O
for None None O
their None None O
capacity None None O
to None None O
inhibit None None O
the None None O
replication None None O
- None None O
specific None None O
bacterial None None O
DNA None None O
polymerase None None O
IIIC None None O
( None None O
pol None None O
IIIC None None O
) None None O
and None None O
the None None O
growth None None O
of None None O
Gram+ None None O
bacteria None None O
in None None O
culture None None O
. None None O

Direct None None O
alkylation None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
pyrimidone None None I-IUPAC
produced None None O
the None None O
N3 None None O
- None None O
substituted None None O
derivatives None None O
, None None O
which None None O
were None None O
separated None None O
from None None O
the None None O
byproduct None None O
4 None None I-IUPAC
- None None I-IUPAC
alkoxy None None I-IUPAC
analogues None None I-MODIFIER
. None None O

The None None O
N3 None None O
- None None O
substituted None None O
derivatives None None O
were None None O
heated None None O
with None None O
a None None O
mixture None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methylaniline None None I-IUPAC
and None None O
its None None O
hydrochloride None None O
to None None O
effect None None O
displacement None None O
of None None O
the None None O
6 None None O
- None None O
amino None None O
group None None O
and None None O
simultaneous None None O
demethylation None None O
of None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
group None None I-MODIFIER
to None None O
yield None None O
target None None O
compounds None None O
in None None O
good None None O
yields None None O
. None None O

Certain None None O
intermediates None None O
, None None O
e.g. None None O
the None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
iodoalkyl None None I-IUPAC
) None None I-IUPAC
compounds None None I-MODIFIER
, None None O
were None None O
converted None None O
to None None O
a None None O
variety None None O
of None None O
( None None O
3 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
- None None O
alkyl None None I-IUPAC
) None None O
- None None O
EMAUs None None O
by None None O
displacement None None O
. None None O

Most None None O
compounds None None O
were None None O
potent None None O
competitive None None O
inhibitors None None O
of None None O
pol None None O
IIIC None None O
( None None O
K None None O
( None None O
i None None O
) None None O
s None None O
0.02-0.5 None None O
microM None None O
) None None O
, None None O
and None None O
those None None O
with None None O
neutral None None O
, None None O
moderately None None O
polar None None O
3 None None O
- None None O
substituents None None O
had None None O
potent None None O
antibacterial None None O
activity None None O
against None None O
Gram+ None None O
organisms None None O
in None None O
culture None None O
( None None O
MICs None None O
0.125-10 None None O
microg None None O
/ None None O
mL None None O
) None None O
. None None O

Several None None O
compounds None None O
protected None None O
mice None None O
from None None O
lethal None None O
intraperitoneal None None O
( None None O
ip None None O
) None None O
infections None None O
with None None O
S None None O
. None None O

aureus None None O
( None None O
Smith None None O
) None None O
when None None O
given None None O
by None None O
the None None O
ip None None O
route None None O
. None None O

A None None O
water None None O
soluble None None O
derivative None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
morpholinylbutyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
EMAU None None I-IUPAC
hydrochloride None None I-IUPAC
, None None O
given None None O
subcutaneously None None O
, None None O
prolonged None None O
the None None O
life None None O
of None None O
infected None None O
mice None None O
in None None O
a None None O
dose None None O
dependent None None O
manner None None O
. None None O


The None None O
synthesis None None O
and None None O
structure None None O
- None None O
activity None None O
relationship None None O
of None None O
a None None O
series None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxobut None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
enoic None None I-IUPAC
acids None None I-IUPAC
and None None O
esters None None I-PARTIUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxobut None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
enoic None None I-IUPAC
acids None None I-IUPAC
and None None O
esters None None I-PARTIUPAC
as None None O
potent None None O
inhibitors None None O
of None None O
kynurenine None None O
- None None O
3 None None O
- None None O
hydroxylase None None O
are None None O
described None None O
. None None O

These None None O
compounds None None O
are None None O
the None None O
most None None O
potent None None O
inhibitors None None O
of None None O
the None None O
kynurenine None None O
- None None O
3 None None O
- None None O
hydroxylase None None O
enzyme None None O
so None None O
far None None O
disclosed None None O
. None None O

Additionally None None O
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxobut None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
enoate None None I-IUPAC
( None None O
2d None None O
) None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chlorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxobut None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
enoic None None I-IUPAC
acid None None I-IUPAC
( None None O
3d None None O
) None None O
, None None O
methyl None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxobut None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
enoate None None I-IUPAC
( None None O
2f None None O
) None None O
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxobut None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
enoic None None I-IUPAC
acid None None I-IUPAC
( None None O
3f None None O
) None None O
prevent None None O
the None None O
increase None None O
in None None O
the None None O
interferon None None O
- None None O
gamma None None O
- None None O
induced None None O
synthesis None None O
of None None O
quinolinic None None O
acid None None O
in None None O
primary None None O
cultures None None O
of None None O
cultured None None O
human None None O
peripheral None None O
blood None None O
monocyte None None O
- None None O
derived None None O
macrophages None None O
. None None O


The None None O
present None None O
work None None O
reports None None O
the None None O
synthesis None None O
of None None O
enantiomeric None None O
pairs None None O
of None None O
the None None O
trans None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indene None None I-IUPAC
[ None None O
( None None O
+ None None O
) None None O
- None None O
14a None None O
, None None O
( None None O
- None None O
) None None O
- None None O
14a None None O
] None None O
and None None O
trans None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
H None None I-IUPAC
- None None I-IUPAC
indene None None I-IUPAC
[ None None O
( None None O
+ None None O
) None None O
- None None O
14b None None O
, None None O
( None None O
- None None O
) None None O
- None None O
14b None None O
] None None O
and None None O
their None None O
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
[ None None O
( None None O
+ None None O
) None None O
- None None O
and None None O
( None None O
- None None O
) None None O
- None None O
15a None None O
, None None O
b None None O
] None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
allyl None None I-IUPAC
[ None None O
( None None O
+ None None O
) None None O
- None None O
and None None O
( None None O
- None None O
) None None O
- None None O
16a None None O
, None None O
b None None O
] None None O
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
[ None None O
( None None O
+ None None O
) None None O
and None None O
( None None O
- None None O
) None None O
- None None O
17a None None O
, None None O
b None None O
] None None O
derivatives None None I-MODIFIER
obtained None None O
by None None O
a None None O
combination None None O
of None None O
stereospecific None None O
reactions None None O
and None None O
optical None None O
resolution None None O
. None None O

The None None O
new None None O
compounds None None O
were None None O
evaluated None None O
for None None O
their None None O
affinity None None O
at None None O
the None None O
dopamine None None O
D1 None None O
and None None O
D2 None None O
receptors None None O
. None None O

The None None O
amines None None O
( None None O
+ None None O
) None None O
- None None O
and None None O
( None None O
- None None O
) None None O
- None None O
14a None None O
, None None O
incorporating None None O
the None None O
D1 None None O
pharmacophore None None O
2 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
ethylamine None None I-IUPAC
in None None O
a None None O
trans None None O
extended None None O
conformation None None O
, None None O
and None None O
their None None O
derivatives None None O
displayed None None O
D1 None None O
and None None O
D2 None None O
affinity None None O
in None None O
the None None O
nanomolar None None O
range None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
the None None O
enantiomers None None O
( None None O
+ None None O
) None None O
- None None O
and None None O
( None None O
- None None O
) None None O
- None None O
14b None None O
, None None O
( None None O
+ None None O
) None None O
- None None O
and None None O
( None None O
- None None O
) None None O
- None None O
15b None None O
displayed None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
the None None O
D1 None None O
receptor None None O
. None None O

In None None O
a None None O
preliminary None None O
behavioral None None O
study None None O
on None None O
rats None None O
( None None O
+ None None O
) None None O
- None None O
14b None None O
, None None O
and None None O
to None None O
a None None O
greater None None O
extent None None O
( None None O
+ None None O
) None None O
- None None O
15b None None O
, None None O
promoted None None O
episodes None None O
of None None O
intense None None O
grooming None None O
, None None O
thus None None O
indicating None None O
that None None O
they None None O
act None None O
as None None O
central None None O
D1 None None O
agonists None None O
. None None O

The None None O
trans None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indenes None None I-IUPAC
( None None O
+ None None O
) None None O
- None None O
14b None None O
and None None O
( None None O
+ None None O
) None None O
- None None O
15b None None O
represent None None O
selective None None O
D1 None None O
agonists None None O
lacking None None O
a None None O
catechol None None O
group None None O
, None None O
which None None O
should None None O
meet None None O
the None None O
prerequisites None None O
for None None O
a None None O
central None None O
nervous None None O
system None None O
penetration None None O
. None None O


A None None O
series None None O
of None None O
4 None None I-IUPAC
- None None I-IUPAC
phenylisoquinolone None None I-IUPAC
derivatives None None I-MODIFIER
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
NK1 None None O
( None None O
substance None None O
P None None O
) None None O
antagonist None None O
activity None None O
. None None O

Highly None None O
potent None None O
antagonists None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
isoquinolone None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
benzylcarboxamides None None I-IUPAC
( None None O
11 None None O
) None None O
, None None O
were None None O
discovered None None O
from None None O
the None None O
structure None None O
- None None O
activity None None O
relationship None None O
studies None None O
on None None O
the None None O
isoquinolone None None O
- None None O
urea None None O
lead None None O
1a None None O
. None None O

Optimization None None O
of None None O
the None None O
activity None None O
in None None O
this None None O
series None None O
resulted None None O
in None None O
the None None O
development None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
pyridine None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
benzylcarboxamides None None I-IUPAC
( None None O
30 None None O
) None None O
which None None O
are None None O
highly None None O
potent None None O
orally None None O
active None None O
NK1 None None O
antagonists None None O
. None None O

Among None None O
the None None O
compounds None None O
synthesized None None O
, None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
3,5 None None I-PARTIUPAC
- None None I-PARTIUPAC
bis None None I-PARTIUPAC
( None None I-PARTIUPAC
trifluoromethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
benzyl None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
7,8 None None I-PARTIUPAC
- None None I-PARTIUPAC
dihydro None None I-PARTIUPAC
- None None I-PARTIUPAC
N None None I-PARTIUPAC
, None None I-PARTIUPAC
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
dimethyl None None I-PARTIUPAC
- None None I-PARTIUPAC
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
oxo None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
substituted None None I-MODIFIER
phenyl None None B-IUPAC
) None None B-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
pyrido None None I-PARTIUPAC
[ None None I-PARTIUPAC
3,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
b None None I-PARTIUPAC
] None None I-PARTIUPAC
pyridinecarboxamides None None I-PARTIUPAC
( None None O
30a None None O
, None None O
f None None O
, None None O
g None None O
) None None O
showed None None O
excellent None None O
antagonist None None O
activities None None O
with None None O
IC50 None None O
values None None O
( None None O
in None None O
vitro None None O
inhibition None None O
of None None O
[ None None O
125I None None O
] None None O
- None None O
BH None None O
- None None O
SP None None O
binding None None O
in None None O
human None None O
IM None None O
- None None O
9 None None O
cells None None O
) None None O
of None None O
0.21-0.34 None None O
nM None None O
and None None O
ED50 None None O
values None None O
( None None O
in None None O
vivo None None O
inhibition None None O
of None None O
capsaicin None None O
- None None O
induced None None O
plasma None None O
extravasation None None O
in None None O
guinea None None O
- None None O
pig None None O
trachea None None O
, None None O
iv None None O
) None None O
of None None O
0.017-0.030 None None O
mg None None O
/ None None O
kg None None O
. None None O

These None None O
compounds None None O
exhibited None None O
significantly None None O
potent None None O
activity None None O
upon None None O
oral None None O
administration None None O
with None None O
ED50 None None O
values None None O
of None None O
0.068-0.17 None None O
mg None None O
/ None None O
kg None None O
. None None O

Conformational None None O
studies None None O
on None None O
30g None None O
indicated None None O
that None None O
the None None O
two None None O
stable None None O
conformers None None O
of None None O
30g None None O
are None None O
quite None None O
similar None None O
to None None O
those None None O
of None None O
CP None None O
- None None O
99,994 None None O
. None None O


A None None O
series None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
aryl None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
was None None O
evaluated None None O
for None None O
anticonvulsant None None O
activity None None O
. None None O

In None None O
general None None O
the None None O
members None None O
of None None O
this None None O
series None None O
were None None O
prepared None None O
by None None O
the None None O
alkaline None None O
cyclization None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
aroyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
alkylsemicarbazides None None I-IUPAC
. None None O

The None None O
resulting None None O
2 None None I-MODIFIER
- None None I-MODIFIER
unsubstituted None None I-MODIFIER
3H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
were None None O
then None None O
alkylated None None O
, None None O
yielding None None O
2,4 None None I-IUPAC
- None None I-IUPAC
dialkyl None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
. None None O

Approximately None None O
one None None O
- None None O
third None None O
of None None O
the None None O
compounds None None O
examined None None O
exhibited None None O
activity None None O
against None None O
both None None O
maximal None None O
electroshock None None O
- None None O
and None None O
pentylenetetrazole None None O
- None None O
induced None None O
seizures None None O
in None None O
mice None None O
. None None O

Receptor None None O
- None None O
binding None None O
studies None None O
suggest None None O
that None None O
this None None O
activity None None O
was None None O
not None None O
a None None O
consequence None None O
of None None O
activity None None O
at None None O
either None None O
benzodiazepine None None O
or None None O
NMDA None None O
- None None O
type None None O
glutamate None None O
receptors None None O
. None None O

From None None O
this None None O
series None None O
, None None O
compound None None O
45 None None O
was None None O
selected None None O
for None None O
further None None O
evaluation None None O
where None None O
it None None O
was None None O
also None None O
found None None O
to None None O
be None None O
active None None O
against None None O
3 None None I-IUPAC
- None None I-IUPAC
mercaptopropionic None None I-IUPAC
acid None None I-IUPAC
, None None O
bicuculline None None O
, None None O
and None None O
quinolinic None None O
acid None None O
induced None None O
seizures None None O
in None None O
mice None None O
. None None O

In None None O
addition None None O
, None None O
45 None None O
also None None O
protected None None O
gerbils None None O
from None None O
hippocampal None None O
neuronal None None O
degeneration None None O
produced None None O
by None None O
either None None O
hypoxia None None O
or None None O
intrastriatal None None O
quinolinic None None O
acid None None O
injection None None O
. None None O


In None None O
order None None O
to None None O
determine None None O
the None None O
active None None O
site None None O
binding None None O
orientation None None O
of None None O
norepinephrine None None O
, None None O
a None None O
series None None O
of None None O
conformationally None None O
defined None None O
analogues None None O
of None None O
the None None O
tyramines None None O
, None None O
in None None O
which None None O
the None None O
ethylamine None None O
side None None O
chain None None O
is None None O
held None None O
fixed None None O
by None None O
incorporation None None O
into None None O
a None None O
benzonorbornene None None O
skeleton None None O
, None None O
were None None O
prepared None None O
and None None O
evaluated None None O
for None None O
phenylethanolamine None None O
N None None O
- None None O
methyltransferase None None O
( None None O
PNMT None None O
) None None O
activity None None O
. None None O

While None None O
exo None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
amino None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
exo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
hydroxybenzonorbornene None None I-IUPAC
( None None O
7 None None O
and None None O
10 None None O
, None None O
respectively None None O
) None None O
were None None O
prepared None None O
from None None O
5 None None I-IUPAC
- None None I-IUPAC
methoxybenzonorbornadiene None None I-IUPAC
by None None O
azidomercuration None None O
/ None None O
demercuration None None O
and None None O
reduction None None O
, None None O
it None None O
was None None O
necessary None None O
to None None O
employ None None O
both None None O
normal None None O
( None None O
inversion None None O
of None None O
configuration None None O
) None None O
and None None O
abnormal None None O
( None None O
retention None None O
of None None O
configuration None None O
) None None O
Mitsunobu None None O
reactions None None O
to None None O
prepare None None O
, None None O
stereoselectively None None O
, None None O
exo None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
amino None None I-PARTIUPAC
- None None I-PARTIUPAC
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
exo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
hydroxybenzonorbornene None None I-IUPAC
( None None O
8 None None O
and None None O
9 None None O
, None None O
respectively None None O
) None None O
from None None O
6 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
7 None None I-IUPAC
- None None I-IUPAC
methoxybenzonorbornen None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
. None None O

None None None O
of None None O
the None None O
six None None O
analogues None None O
were None None O
substrates None None O
. None None O

However None None O
, None None O
exo None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hydroxybenzonorbornene None None I-IUPAC
( None None O
8 None None O
) None None O
and None None O
anti None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
hydroxybenzonorbornene None None I-IUPAC
( None None O
12 None None O
) None None O
displayed None None O
significant None None O
activity None None O
as None None O
inhibitors None None O
toward None None O
PNMT None None O
. None None O

The None None O
greater None None O
potency None None O
of None None O
8 None None O
and None None O
12 None None O
, None None O
as None None O
compared None None O
to None None O
the None None O
parent None None O
unsubstituted None None O
analogues None None O
exo None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
amino None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
anti None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
benzonorbornene None None I-IUPAC
( None None O
4 None None O
and None None O
5 None None O
, None None O
respectively None None O
) None None O
, None None O
indicates None None O
the None None O
presence None None O
of None None O
a None None O
spatially None None O
compact None None O
hydrophilic None None O
pocket None None O
within None None O
the None None O
aromatic None None O
ring None None O
binding None None O
region None None O
of None None O
the None None O
active None None O
site None None O
of None None O
the None None O
enzyme None None O
. None None O

Furthermore None None O
, None None O
the None None O
greater None None O
activity None None O
of None None O
12 None None O
, None None O
relative None None O
to None None O
8 None None O
, None None O
is None None O
consistent None None O
with None None O
an None None O
active None None O
site None None O
binding None None O
preference None None O
for None None O
molecules None None O
in None None O
which None None O
a None None O
more None None O
coplanar None None O
relationship None None O
exists None None O
between None None O
the None None O
aromatic None None O
ring None None O
and None None O
the None None O
amine None None O
nitrogen None None O
. None None O

From None None O
the None None O
findings None None O
of None None O
this None None O
study None None O
, None None O
it None None O
appears None None O
that None None O
norepinephrine None None O
has None None O
a None None O
different None None O
active None None O
site None None O
binding None None O
orientation None None O
than None None O
most None None O
known None None O
substrates None None O
and None None O
competitive None None O
inhibitors None None O
of None None O
PNMT None None O
. None None O


To None None O
provide None None O
potential None None O
new None None O
leads None None O
for None None O
the None None O
treatment None None O
of None None O
orthopoxvirus None None O
infections None None O
, None None O
the None None O
5 None None O
- None None O
position None None O
of None None O
the None None O
pyrimidine None None O
nucleosides None None O
have None None O
been None None O
modified None None O
with None None O
a None None O
gem None None O
diether None None O
moiety None None O
to None None O
yield None None O
the None None O
following None None O
new None None O
nucleosides None None O
: None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
2b None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
3b None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
formyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
ethylene None None I-IUPAC
acetal None None I-IUPAC
( None None O
4b None None O
) None None O
, None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
formyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
propylene None None I-IUPAC
acetal None None I-IUPAC
( None None O
5b None None O
) None None O
. None None O

These None None O
were None None O
evaluated None None O
in None None O
human None None O
foreskin None None O
fibroblast None None O
cells None None O
challenged None None O
with None None O
the None None O
vaccinia None None O
virus None None O
or None None O
cowpox None None O
virus None None O
. None None O

Of None None O
the None None O
four None None O
gem None None O
diether None None O
nucleosides None None O
, None None O
only None None O
the None None O
dimethyl None None O
gem None None O
diether None None O
congener None None O
showed None None O
significant None None O
antiviral None None O
activity None None O
against None None O
both None None O
viruses None None O
. None None O

This None None O
antiviral None None O
activity None None O
did None None O
not None None O
appear None None O
to None None O
be None None O
related None None O
to None None O
the None None O
decomposition None None O
to None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
formyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
, None None O
which None None O
was None None O
itself None None O
devoid None None O
of None None O
anti None None O
- None None O
orthopoxvirus None None O
activity None None O
in None None O
these None None O
assays None None O
. None None O

Moreover None None O
, None None O
at None None O
the None None O
pH None None O
of None None O
the None None O
in None None O
vitro None None O
assays None None O
, None None O
2b None None O
was None None O
very None None O
stable None None O
with None None O
a None None O
decomposition None None O
( None None O
to None None O
aldehyde None None O
) None None O
half None None O
- None None O
life None None O
of None None O
& None None O
gt None None O
; None None O
15 None None O
d None None O
. None None O

The None None O
anti None None O
- None None O
orthopoxvirus None None O
activity None None O
of None None O
pyrimidine None None O
may None None O
be None None O
favored None None O
by None None O
the None None O
introduction None None O
of None None O
hydrophilic None None O
moieties None None O
to None None O
the None None O
5 None None O
- None None O
position None None O
side None None O
chain None None O
. None None O


New None None O
acylated None None O
bis None None I-IUPAC
- None None I-IUPAC
catecholates None None I-IUPAC
and None None O
1,3 None None I-IUPAC
- None None I-IUPAC
benzoxazine None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
derivatives None None I-MODIFIER
based None None O
on None None O
secondary None None O
diamino None None O
acids None None O
( None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminoalkyl None None I-IUPAC
) None None I-IUPAC
glycines None None I-IUPAC
, None None O
N None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
- None None I-IUPAC
alanine None None I-IUPAC
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
aminopropyl None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
aminovaleric None None I-IUPAC
acid None None I-IUPAC
) None None O
, None None O
on None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminoalkyl None None I-IUPAC
) None None I-IUPAC
aminomethyl None None I-IUPAC
benzoic None None I-IUPAC
acids None None I-IUPAC
, None None O
on None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminoalkyl None None I-IUPAC
) None None I-IUPAC
aminomethyl None None I-IUPAC
phenoxyacetic None None I-IUPAC
acids None None I-IUPAC
, None None O
or None None O
on None None O
3,5 None None I-IUPAC
- None None I-IUPAC
diaminobenzoic None None I-IUPAC
acid None None I-IUPAC
were None None O
synthesized None None O
as None None O
artificial None None O
siderophores None None O
. None None O

The None None O
corresponding None None O
diamino None None O
acids None None O
were None None O
obtained None None O
from None None O
the None None O
diamines None None O
and None None O
oxocarboxylic None None O
acids None None O
by None None O
catalytic None None O
hydrogenation None None O
. None None O

The None None O
acylated None None O
bis None None I-IUPAC
- None None I-IUPAC
catecholates None None I-IUPAC
and None None O
1,3 None None I-IUPAC
- None None I-IUPAC
benzoxazine None None I-IUPAC
- None None I-IUPAC
2,4 None None I-IUPAC
- None None I-IUPAC
diones None None I-IUPAC
were None None O
coupled None None O
with None None O
ampicillin None None O
or None None O
amoxicillin None None O
to None None O
new None None O
siderophore None None O
aminoacylpenicillin None None O
conjugates None None O
. None None O

These None None O
conjugates None None O
exhibited None None O
very None None O
strong None None O
antibacterial None None O
activity None None O
in None None O
vitro None None O
against None None O
Gram None None O
- None None O
negative None None O
bacterial None None O
pathogens None None O
including None None O
Pseudomonas None None O
aeruginosa None None O
, None None O
Stenotrophomonas None None O
maltophilia None None O
, None None O
Escherichia None None O
coli None None O
, None None O
Klebsiella None None O
pneumoniae None None O
, None None O
and None None O
Serratia None None O
marcescens None None O
. None None O

The None None O
ampicillin None None O
derivative None None O
7b None None O
( None None O
HKI None None O
9924154 None None O
) None None O
and None None O
the None None O
corresponding None None O
amoxicillin None None O
derivative None None O
8 None None O
( None None O
HKI None None O
9924155 None None O
) None None O
represent None None O
the None None O
most None None O
active None None O
compounds None None O
. None None O

The None None O
conjugates None None O
can None None O
use None None O
bacterial None None O
iron None None O
siderophore None None O
uptake None None O
routes None None O
to None None O
penetrate None None O
the None None O
Gram None None O
- None None O
negative None None O
outer None None O
membrane None None O
permeability None None O
barrier None None O
. None None O

This None None O
was None None O
demonstrated None None O
by None None O
assays None None O
with None None O
mutants None None O
deficient None None O
in None None O
components None None O
of None None O
the None None O
iron None None O
transport None None O
systems None None O
. None None O

New None None O
siderophore None None O
penicillin None None O
V None None O
conjugates None None O
with None None O
the None None O
siderophore None None O
component None None O
attached None None O
to None None O
the None None O
phenyl None None O
ring None None O
of None None O
penicillin None None O
V None None O
are None None O
inactive None None O
against None None O
these None None O
Gram None None O
- None None O
negative None None O
bacteria None None O
. None None O


A None None O
series None None O
of None None O
O' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
epoxyalkyl None None I-IUPAC
) None None I-IUPAC
tyrosines None None I-IUPAC
and None None O
a None None O
carboxy None None O
terminal None None O
( None None I-IUPAC
epoxyalkyl None None I-IUPAC
) None None I-IUPAC
tyrosine None None I-IUPAC
and None None O
- None None I-PARTIUPAC
phenylalanine None None I-PARTIUPAC
were None None O
synthesized None None O
as None None O
potential None None O
serine None None O
protease None None O
inhibitors None None O
. None None O

N None None I-IUPAC
- None None I-IUPAC
Acetyl None None I-IUPAC
derivatives None None I-MODIFIER
showed None None O
irreversible None None O
inactivation None None O
vis None None O
- None None O
a None None O
- None None O
vis None None O
subtilisin None None O
, None None O
while None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
ones None None I-IUPAC
were None None O
specific None None O
toward None None O
chymotrypsin None None O
. None None O

The None None O
most None None O
potent None None O
inactivation None None O
of None None O
chymotrypsin None None O
was None None O
achieved None None O
by None None O
a None None O
O' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
epoxybutyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tyrosine None None I-IUPAC
derivative None None I-MODIFIER
. None None O

The None None O
inactivation None None O
was None None O
shown None None O
to None None O
be None None O
stereospecific None None O
since None None O
a None None O
D None None O
derivative None None O
led None None O
to None None O
no None None O
irreversible None None O
inactivation None None O
. None None O

Placement None None O
of None None O
the None None O
epoxyalkyl None None O
group None None O
at None None O
the None None O
carboxy None None O
terminus None None O
led None None O
to None None O
potent None None O
rapid None None O
inactivation None None O
. None None O

Under None None O
these None None O
conditions None None O
some None None O
of None None O
the None None O
activity None None O
was None None O
later None None O
recovered None None O
. None None O

The None None O
two None None O
classes None None O
of None None O
inactivators None None O
( None None O
O' None None I-IUPAC
- None None I-IUPAC
epoxyalkyl None None I-IUPAC
and None None O
carboxy None None I-IUPAC
- None None I-IUPAC
epoxyalkyl None None I-IUPAC
) None None O
appear None None O
to None None O
operate None None O
by None None O
different None None O
mechanisms None None O
. None None O

Most None None O
importantly None None O
, None None O
it None None O
was None None O
found None None O
that None None O
irreversible None None O
inactivation None None O
by None None O
O' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
epoxyalkyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tyrosine None None I-IUPAC
only None None O
resulted None None O
if None None O
the None None O
carboxy None None O
terminus None None O
was None None O
a None None O
substrate None None O
( None None O
i.e. None None O
a None None O
compound None None O
with None None O
free None None O
carboxy None None O
terminus None None O
did None None O
not None None O
lead None None O
to None None O
inactivation None None O
) None None O
. None None O

The None None O
ultimate None None O
activity None None O
kinetic None None O
assay None None O
( None None O
Daniels None None O
, None None O
S None None O
. None None O

B None None O
. None None O

; None None O
et None None O
al. None None O
J None None O
. None None O

Biol. None None O
Chem. None None O
1983 None None O
, None None O
258 None None O
, None None O
15046-15053 None None O
. None None O

) None None O
indicated None None O
that None None O
the None None O
epoxyalkyl None None O
group None None O
on None None O
the None None O
phenolic None None O
oxygen None None O
had None None O
an None None O
optimal None None O
length None None O
of None None O
four None None O
carbons None None O
with None None O
respect None None O
to None None O
the None None O
turnover None None O
ratio None None O
( None None O
the None None O
ratio None None O
of None None O
molecules None None O
undergoing None None O
turnover None None O
compared None None O
to None None O
those None None O
that None None O
inactivate None None O
the None None O
enzyme None None O
) None None O
for None None O
chymotrypsin None None O
. None None O

A None None O
different None None O
kinetic None None O
assay None None O
( None None O
Ashani None None O
, None None O
Y None None O
. None None O

; None None O
Wins None None O
, None None O
P None None O
. None None O

; None None O
Wilson None None O
, None None O
I None None O
. None None O

B None None O
. None None O

Biochim None None O
. None None O

Biophys None None O
. None None O

Acta None None O
1972 None None O
, None None O
284 None None O
, None None O
427-434 None None O
. None None O

) None None O
demonstrated None None O
that None None O
substratelike None None O
turnover None None O
was None None O
proceeding None None O
at None None O
considerably None None O
slower None None O
rates None None O
than None None O
for None None O
the None None O
corresponding None None O
true None None O
substrates None None O
and None None O
with None None O
rate None None O
- None None O
limiting None None O
deacylation None None O
of None None O
the None None O
acyl None None O
- None None O
enzyme None None O
. None None O

Amino None None O
acid None None O
analysis None None O
subsequent None None O
to None None O
acid None None O
hydrolysis None None O
demonstrated None None O
that None None O
Met None None O
had None None O
been None None O
selectively None None O
alkylated None None O
by None None O
the None None O
O' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
epoxyalkyl None None I-IUPAC
) None None I-IUPAC
tyrosine None None I-IUPAC
derivative None None I-MODIFIER
. None None O

By None None O
contrast None None O
, None None O
alpha None None O
- None None O
chymotrypsin None None O
inactivated None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
benzoyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
Phe None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
epoxypropyl None None I-IUPAC
ester None None I-IUPAC
then None None O
subjected None None O
to None None O
amino None None O
acid None None O
analysis None None O
showed None None O
no None None O
change None None O
in None None O
the None None O
content None None O
of None None O
any None None O
amino None None O
acid None None O
that None None O
would None None O
serve None None O
as None None O
a None None O
potential None None O
nucleophile None None O
to None None O
the None None O
inhibitor None None O
. None None O

Yet None None O
, None None O
the None None O
L None None O
- None None O
Phe None None O
content None None O
increased None None O
, None None O
indicating None None O
that None None O
a None None O
covalent None None O
bond None None O
had None None O
been None None O
formed None None O
between None None O
the None None O
inhibitor None None O
and None None O
the None None O
enzyme None None O
. None None O

Either None None O
the None None O
bond None None O
between None None O
the None None O
inhibitor None None O
and None None O
the None None O
enzyme None None O
did None None O
not None None O
withstand None None O
the None None O
hydrolytic None None O
conditions None None O
and None None O
/ None None O
or None None O
there None None O
was None None O
less None None O
than None None O
10% None None O
decrease None None O
in None None O
the None None O
amino None None O
acids None None O
with None None O
nucleophilic None None O
side None None O
chains None None O
upon None None O
inactivation None None O
. None None O

Finally None None O
, None None O
two None None O
tripeptides None None O
containing None None O
O' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
epoxyalkyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tryosines None None I-IUPAC
were None None O
synthesized None None O
[ None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butoxycarbonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
alanyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
alanyl None None I-IUPAC
- None None I-IUPAC
O' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
epoxypropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tyrosi None None I-IUPAC
ne None None I-IUPAC
ethyl None None I-IUPAC
ester None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
valyl None None I-IUPAC
- None None I-IUPAC
O' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
epoxypropyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
tyrosyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
valine None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
] None None O
as None None O
potential None None O
elastase None None O
inhibitors None None O
and None None O
were None None O
found None None O
to None None O
reversibly None None O
and None None O
competitively None None O
inhibit None None O
porcine None None O
pancreatic None None O
elastase None None O
. None None O


A None None O
series None None O
of None None O
erythro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
nonyl None None I-IUPAC
) None None I-IUPAC
azole None None I-IUPAC
derivatives None None I-MODIFIER
have None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
adenosine None None O
deaminase None None O
( None None O
ADA None None O
) None None O
inhibitory None None O
activity None None O
, None None O
in None None O
order None None O
to None None O
introduce None None O
simplifications None None O
in None None O
the None None O
ADA None None O
inhibitor None None O
erythro None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
nonyl None None I-IUPAC
) None None I-IUPAC
adenine None None I-IUPAC
( None None O
EHNA None None O
, None None O
1a None None O
) None None O
. None None O

The None None O
synthesis None None O
of None None O
most None None O
of None None O
the None None O
reported None None O
compounds None None O
was None None O
achieved None None O
by None None O
reaction None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
bromo None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
nonanone None None I-IUPAC
with None None O
the None None O
suitable None None O
azole None None O
followed None None O
by None None O
reduction None None O
of None None O
the None None O
carbonyl None None I-IUPAC
group None None B-MODIFIER
to None None O
give None None O
a None None O
diastereoisomeric None None O
mixture None None O
of None None O
N None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
nonyl None None I-IUPAC
) None None I-IUPAC
azoles None None I-IUPAC
. None None O

Separation None None O
of None None O
diastereoisomers None None O
was None None O
achieved None None O
by None None O
HPLC None None O
or None None O
by None None O
preparative None None O
TLC None None O
plates None None O
. None None O

The None None O
results None None O
of None None O
the None None O
enzymatic None None O
test None None O
indicate None None O
that None None O
the None None O
nitrogen None None O
in None None O
the None None O
3 None None O
- None None O
position None None O
, None None O
and None None O
secondly None None O
, None None O
the None None O
nitrogen None None O
in None None O
the None None O
5 None None O
- None None O
position None None O
are None None O
very None None O
important None None O
for None None O
the None None O
interaction None None O
of None None O
the None None O
azole None None O
ring None None O
with None None O
the None None O
inhibitory None None O
site None None O
on None None O
the None None O
enzyme None None O
. None None O

In None None O
fact None None O
, None None O
the None None O
pyrazole None None O
and None None O
the None None O
2 None None I-MODIFIER
- None None I-MODIFIER
substituted None None I-MODIFIER
1,2,3 None None I-IUPAC
- None None I-IUPAC
triazole None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
10 None None O
and None None O
15 None None O
, None None O
respectively None None O
) None None O
are None None O
nearly None None O
inactive None None O
, None None O
whereas None None O
the None None O
erythro None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
nonyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
triazole None None I-IUPAC
( None None O
18e None None O
) None None O
was None None O
the None None O
most None None O
potent None None O
ADA None None O
inhibitor None None O
in None None O
the None None O
series None None O
with None None O
Ki None None O
= None None O
0.3 None None O
microM None None O
. None None O


